{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "oscars paper clustering by NLP.ipynb",
      "provenance": [],
      "collapsed_sections": [],
      "authorship_tag": "ABX9TyNdgwTyibVsGEnZmc7FPO1e",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/ojcharles/snippets/blob/main/oscars_paper_clustering_by_NLP.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Scientific Article Literature Clustering by NLP"
      ],
      "metadata": {
        "id": "2sgPmlxLjD8-"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "Oscar Charles 2021\n",
        "\n",
        "This is a notebook that clusters journals, and can help you find similar papers to those you already know are important.\n",
        "\n",
        "What you need:\n",
        "\n",
        "\n",
        "*   A pubmed query. Example included\n",
        "*   A list of DOI's for papers you already care about. Example included\n",
        "\n",
        "\n",
        "\n",
        "Question: Can we use Natural Language processing to take a set of abstracts (strings) -> tokens -> vectorisation -> clustering of abstracts by similarity? We have a set of papers we want to cluster close together, can we get them too such that we can find similar papers we may have missed?\n",
        "\n"
      ],
      "metadata": {
        "id": "tiC3y-Hlb0dv"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# install all the python stuff I need\n",
        "# get the requirements file\n",
        "!wget https://raw.githubusercontent.com/ojcharles/snippets/main/nlp_lit_clustering_requirements.txt\n",
        "\n",
        "# install the packages\n",
        "!pip install -r nlp_lit_clustering_requirements.txt\n",
        "\n",
        "# install the spacy model\n",
        "# A full spaCy pipeline for biomedical data with a larger vocabulary and 50k word vectors.\n",
        "! python -m pip install https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.5.0/en_core_sci_md-0.5.0.tar.gz"
      ],
      "metadata": {
        "id": "xku-ZsHYc1Rr"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# also install EDirect for pubmed APi calls\n",
        "!  yes | sh -c \"$(curl -fsSL ftp://ftp.ncbi.nlm.nih.gov/entrez/entrezdirect/install-edirect.sh)\""
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "k2oCkhY6jjxR",
        "outputId": "30b805fe-6ad4-4d36-fed1-3f0ae0cdbcd9"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "Entrez Direct has been successfully downloaded and installed.\n",
            "\n",
            "\n",
            "To activate EDirect for this terminal session, please execute the following:\n",
            "\n",
            "export PATH=${PATH}:${HOME}/edirect\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Getting paper data from Pubmed and parseing the json"
      ],
      "metadata": {
        "id": "ivvImRzTi6iZ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np # linear algebra\n",
        "import pandas as pd # data processing, CSV file I/O (e.g. pd.read_csv)\n",
        "import xml.etree.ElementTree as ET\n",
        "import bokeh"
      ],
      "metadata": {
        "id": "kXIpz_I5i6tq"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# pubmed has all papers, epmc only those that are openly accessible.\n",
        "\n",
        "# Conduct a PubMed search and retrieve the results as a list of PMIDs\n",
        "! ${HOME}/edirect/esearch -db pubmed -query \"((resistance)) AND ((ribavirin) OR (favipiravir) OR (remdesivir) OR (EIDD-2801) OR (molnupiravir)) \"   | ${HOME}/edirect/efetch -format uid > pubmed.txt\n",
        "\n",
        "# how many entries?\n",
        "! wc -l pubmed.txt \n",
        "\n",
        "# take those identified pubmed ids of interest and \n",
        "! ${HOME}/edirect/efetch -db pubmed -input pubmed.txt -format xml > pubmed.xml\n",
        "\n",
        "# sanity check\n",
        "! head -5 pubmed.xml"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "huJ1CUBWi5Et",
        "outputId": "96fe113e-e56c-4f7d-cd13-37f4d19dc775"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "1807 pubmed.txt\n",
            "<?xml version=\"1.0\" encoding=\"UTF-8\" ?>\n",
            "<!DOCTYPE PubmedArticleSet>\n",
            "<PubmedArticleSet>\n",
            "  <PubmedArticle>\n",
            "    <MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\">\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# parse xml\n",
        "dict_ = {'doi': [], 'title': [], 'abstract':[]}\n",
        "\n",
        "tree = ET.parse('pubmed.xml') # download from a search in epmc\n",
        "root = tree.getroot()\n",
        "\n",
        "search_doi = 'PubmedData/ArticleIdList/ArticleId[@IdType=\"doi\"]'\n",
        "search_title = 'MedlineCitation/Article/ArticleTitle'\n",
        "search_abstract = 'MedlineCitation/Article/Abstract/AbstractText'\n",
        "\n",
        "for entry in root.iter('PubmedArticle'):\n",
        "    if entry.find(search_doi) is None:\n",
        "        continue\n",
        "    else:\n",
        "        doi = entry.find(search_doi).text\n",
        "        \n",
        "    if entry.find(search_title) is None:\n",
        "        continue\n",
        "    else:\n",
        "        title = entry.find(search_title).text\n",
        "        \n",
        "    if entry.find(search_abstract) is None:\n",
        "        continue\n",
        "    else:\n",
        "        abstractText = entry.find(search_abstract).text\n",
        "    #print(doi, title)\n",
        "    dict_['doi'].append(doi)\n",
        "    dict_['title'].append(title)\n",
        "    dict_['abstract'].append(abstractText)\n"
      ],
      "metadata": {
        "id": "bHEg2y7UlOdx"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# format the dict to a table\n",
        "df = pd.DataFrame(dict_, columns=['doi', 'title','abstract'])\n",
        "df.head()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 337
        },
        "id": "jXU22MWdlQE5",
        "outputId": "dcfe7cee-e2cc-4dcf-9d9a-95b07d6f3d95"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                          doi  \\\n",
              "0         10.2147/IDR.S353605   \n",
              "1                       16230   \n",
              "2                         527   \n",
              "3  10.1038/s41467-022-29104-y   \n",
              "4       S0166-3542(22)00042-0   \n",
              "\n",
              "                                               title  \\\n",
              "0  Identification of NS5B Resistance-Associated M...   \n",
              "1  Management of SARS-CoV-2 infection: recommenda...   \n",
              "2  Genetic Diversity Does Not Contribute to Atten...   \n",
              "3  De novo emergence of a remdesivir resistance m...   \n",
              "4  High dose sofosbuvir and sofosbuvir-plus-ribav...   \n",
              "\n",
              "                                            abstract  \n",
              "0  Treatment of HCV infection with peginterferon ...  \n",
              "1  The first Polish recommendations regarding the...  \n",
              "2  The disease yellow fever was prevented by two ...  \n",
              "3  SARS-CoV-2 remdesivir resistance mutations hav...  \n",
              "4  Hepatitis E virus (HEV) is an important cause ...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-b4c5e1f1-4a32-4112-ae90-88b3e4b754ab\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>doi</th>\n",
              "      <th>title</th>\n",
              "      <th>abstract</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.2147/IDR.S353605</td>\n",
              "      <td>Identification of NS5B Resistance-Associated M...</td>\n",
              "      <td>Treatment of HCV infection with peginterferon ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>16230</td>\n",
              "      <td>Management of SARS-CoV-2 infection: recommenda...</td>\n",
              "      <td>The first Polish recommendations regarding the...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>527</td>\n",
              "      <td>Genetic Diversity Does Not Contribute to Atten...</td>\n",
              "      <td>The disease yellow fever was prevented by two ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1038/s41467-022-29104-y</td>\n",
              "      <td>De novo emergence of a remdesivir resistance m...</td>\n",
              "      <td>SARS-CoV-2 remdesivir resistance mutations hav...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>S0166-3542(22)00042-0</td>\n",
              "      <td>High dose sofosbuvir and sofosbuvir-plus-ribav...</td>\n",
              "      <td>Hepatitis E virus (HEV) is an important cause ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-b4c5e1f1-4a32-4112-ae90-88b3e4b754ab')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-b4c5e1f1-4a32-4112-ae90-88b3e4b754ab button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-b4c5e1f1-4a32-4112-ae90-88b3e4b754ab');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 54
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# how many papers are left with al the required info?\n",
        "len(df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "70fEvRJylR_g",
        "outputId": "8fdd3951-7e8d-417b-dfc4-02ae8b03e44f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "1301"
            ]
          },
          "metadata": {},
          "execution_count": 56
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Paper Encoding\n",
        "\n",
        "Here we take the text and identify each token \"word\" and use the spacy model to find the relationships etc."
      ],
      "metadata": {
        "id": "KOf6H35ylTs6"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "#NLP \n",
        "import spacy\n",
        "from spacy.lang.en.stop_words import STOP_WORDS\n",
        "from spacy.lang.en import English\n",
        "# spacy.prefer_gpu() # if you have a GPU do this its so much faster\n",
        "\n",
        "# using scispacy we can add support for scientific abbreviations\n",
        "from scispacy.abbreviation import AbbreviationDetector\n",
        "\n",
        "parser = spacy.load(\"en_core_sci_md\") # scispacy model\n",
        "# Add the abbreviation pipe to the spacy pipeline.\n",
        "parser.add_pipe(\"abbreviation_detector\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mlURjzvBlVUs",
        "outputId": "f282311f-d7f8-4e99-e3c7-7a79ad6d4a04"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/spacy/util.py:833: UserWarning: [W095] Model 'en_core_sci_md' (0.5.0) was trained with spaCy v3.2 and may not be 100% compatible with the current version (3.2.1). If you see errors or degraded performance, download a newer compatible model or retrain your custom model with the current spaCy version. For more details and available updates, run: python -m spacy validate\n",
            "  warnings.warn(warn_msg)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<scispacy.abbreviation.AbbreviationDetector at 0x7f4db944dcd0>"
            ]
          },
          "metadata": {},
          "execution_count": 57
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import string\n",
        "\n",
        "punctuations = string.punctuation\n",
        "stopwords = list(STOP_WORDS)\n",
        "stopwords[:10]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "M3OXPnShmG5H",
        "outputId": "b401952e-fcf2-401e-c97c-1d757c7aab82"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['besides',\n",
              " 'did',\n",
              " 'there',\n",
              " 'first',\n",
              " 'some',\n",
              " 'nobody',\n",
              " 'whole',\n",
              " 'front',\n",
              " 'their',\n",
              " 'â€˜ll']"
            ]
          },
          "metadata": {},
          "execution_count": 58
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# stop words are words that are removed.\n",
        "# as We don't want a cluster per virus, per drug etc but generally paper with novel rna resmuts we add these extra stopwords.\n",
        "custom_stop_words = [\n",
        "    'doi', 'preprint', 'copyright', 'peer', 'reviewed', 'org', 'https', 'et', 'al', 'author', 'figure', \n",
        "    'rights', 'reserved', 'permission', 'used', 'using', 'biorxiv', 'medrxiv', 'license', 'fig', 'fig.', \n",
        "    'al.', 'Elsevier', 'PMC', 'CZI', 'www',\n",
        "    \"Hepatitis C\", \"Herpes\", \"Simplex 1\", \"Simplex 2\", \"Cytomegalovirus\", \"Coronavirus\", \"HCMV\", \"CMV\", \"HSV1\", \"HSV2\", \n",
        "    \"influenza A\", \"(H1N1)\", \"HIV-1\", \"HIV\", \"Hepatitis B\", \"HCV\", \"HBV\",\n",
        "    \"SARS-COV-2\", \"COVID-19\", \"COVID\", \"human immunodeficiency virus\", \"HIV-RNA\", \"subtype\", \"genotype\", \"subtype\",\n",
        "    \"avian influenza\", \"syncytial\", \"polio\", \"poliovirus\", \"chikungunya\"\n",
        "    \n",
        "]\n",
        "\n",
        "for w in custom_stop_words:\n",
        "    if w not in stopwords:\n",
        "        stopwords.append(w)"
      ],
      "metadata": {
        "id": "fST2REdyoXeB"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Parser\n",
        "\n",
        "parser.max_length = 7000000\n",
        "\n",
        "def call_tokenizer(df):\n",
        "    df[\"processed_abstract\"] = df[\"abstract\"].apply(spacy_tokenizer)\n",
        "    return df\n",
        "\n",
        "def spacy_tokenizer(sentence):\n",
        "    mytokens = parser(sentence)\n",
        "    mytokens = [ word.lemma_.lower().strip() if word.lemma_ != \"-PRON-\" else word.lower_ for word in mytokens ]\n",
        "    mytokens = [ word for word in mytokens if word not in stopwords and word not in punctuations ]\n",
        "    mytokens = \" \".join([i for i in mytokens])\n",
        "    return mytokens"
      ],
      "metadata": {
        "id": "asuLDvrZoZ69"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from multiprocessing import  Pool\n",
        "\n",
        "def parallelize_dataframe(df, func, n_cores=4):\n",
        "    df_split = np.array_split(df, n_cores)\n",
        "    pool = Pool(n_cores)\n",
        "    df = pd.concat(pool.map(func, df_split))\n",
        "    pool.close()\n",
        "    pool.join()\n",
        "    return df"
      ],
      "metadata": {
        "id": "BxZsbVRJobQE"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "%%capture --no-stdout\n",
        "# scispacy abbreviation complains each time a abstract has no abbreviations it knows.... stop that warning.\n",
        "# tokenise\n",
        "# single core - single gpu\n",
        "df[\"processed_abstract\"] = df[\"abstract\"].apply(spacy_tokenizer)\n",
        "# many cpu\n",
        "#%time df = parallelize_dataframe(df=df, func=call_tokenizer, n_cores=16)"
      ],
      "metadata": {
        "id": "hdMuOBOoocoP"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### save\n"
      ],
      "metadata": {
        "id": "h6HBAxmpojVt"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import pickle\n",
        "pickle.dump(df, open(\"tokenised_df.p\", \"wb\" ))"
      ],
      "metadata": {
        "id": "8UeA5J9eokYU"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## paper vectoriser\n"
      ],
      "metadata": {
        "id": "byTecMWholrf"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df = pickle.load(open(\"tokenised_df.p\", \"rb\"))\n",
        "#df = df.sample(600000)"
      ],
      "metadata": {
        "id": "F5dVfBf8oqWS"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from sklearn.feature_extraction.text import TfidfVectorizer\n",
        "def vectorize(text, maxx_features):\n",
        "    \n",
        "    vectorizer = TfidfVectorizer(max_features=maxx_features)\n",
        "    X = vectorizer.fit_transform(text)\n",
        "    return X"
      ],
      "metadata": {
        "id": "MpGoI8J4oriI"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "text = df['processed_abstract'].values\n",
        "%time X = vectorize(text, 2 ** 12)\n",
        "X.shape"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7pRhw_tsosUe",
        "outputId": "89d29408-46fc-4b4b-9b3d-d6eddb49cf2c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 122 ms, sys: 0 ns, total: 122 ms\n",
            "Wall time: 123 ms\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(1301, 4096)"
            ]
          },
          "metadata": {},
          "execution_count": 67
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "##Cluster"
      ],
      "metadata": {
        "id": "PfH-jWGBouNR"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# as well as x and y space, lets colour each paper by Kmeans clustering\n",
        "from sklearn.cluster import KMeans\n",
        "k = 20\n",
        "kmeans = KMeans(n_clusters=k, random_state=42)\n",
        "%time y_pred = kmeans.fit_predict(X)\n",
        "df['y'] = y_pred"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "pCryx3W0owvy",
        "outputId": "6e72f325-74c1-46d0-c89d-d240b9e38e91"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 1.49 s, sys: 105 ms, total: 1.6 s\n",
            "Wall time: 1.78 s\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Plotting"
      ],
      "metadata": {
        "id": "FVrgmd65o03r"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# reduce dimensions\n",
        "%matplotlib inline\n",
        "from matplotlib import pyplot as plt\n",
        "import seaborn as sns\n",
        "from sklearn.decomposition import PCA\n",
        "\n",
        "pca = PCA(n_components=30, random_state=42)\n",
        "%time X_embedded_pca= pca.fit_transform(X.toarray())\n",
        "X_embedded_pca.shape"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "JcczXPYMo2ZV",
        "outputId": "dccfc9b8-e9ca-4ed7-f435-4aec1cf1a26b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 903 ms, sys: 122 ms, total: 1.02 s\n",
            "Wall time: 557 ms\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(1301, 30)"
            ]
          },
          "metadata": {},
          "execution_count": 75
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# t-sne\n",
        "from sklearn.manifold import TSNE\n",
        "X_embedded_tsne = TSNE(n_components=2, learning_rate='auto',init='random').fit_transform(X_embedded_pca)\n",
        "df['x_tsne'] = X_embedded_tsne[:,0] \n",
        "df['y_tsne'] = X_embedded_tsne[:,1]\n",
        "\n",
        "#from tsnecuda import TSNE\n",
        "#%time X_embedded_tsne = TSNE(n_components=2, learning_rate=30, n_iter=500000, verbose=1).fit_transform(X_embedded_pca)"
      ],
      "metadata": {
        "id": "bjTDR2WZo68G"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# identify which papers we know are of interest, then make them squares. maybe we need to hide the virus name from the model?\n",
        "key_doi=[\"10.1371/journal.ppat.1009929\",\n",
        "\"10.1128/mBio.00221-18\",\n",
        "\"10.1128/JVI.01965-17\",\n",
        "\"10.1073/pnas.1811345115\",\n",
        "\"10.1093/jac/dku209\",\n",
        "\"10.1128/AAC.01073-16\",\n",
        "\"10.1073/pnas.1232294100\",\n",
        "\"10.1128/JVI.02139-12\",\n",
        "\"10.1016/j.antiviral.2013.07.008\",\n",
        "\"10.1371/journal.ppat.1001163\",\n",
        "\"10.1128/JVI.00289-14\",\n",
        "\"10.1073/pnas.1111650108\",\n",
        "\"10.1128/JVI.79.4.2346-2355.2005\",\n",
        "\"10.1128/JVI.03594-13\",\n",
        "\"10.1128/JVI.01297-08\",\n",
        "\"10.1371/journal.ppat.1003877\",\n",
        "\"10.1128/JVI.01528-14\",\n",
        "        \"10.1128/JVI.00367-19\",\n",
        "        \"10.1128/JVI.00078-16\",\n",
        "        \"10.1016/j.jmii.2017.03.004\",\n",
        "        \"10.1038/ncomms5794\",\n",
        "        \"10.1074/jbc.C112.401471\",\n",
        "        \"10.1099/jgv.0.000316\",\n",
        "        \"10.3791/2953\",\n",
        "        \"10.1099/jgv.0.000682\",\n",
        "        \"10.1371/journal.ppat.1001163\",\n",
        "        \"10.1016/j.bbrc.2013.12.071\",\n",
        "        \"10.1038/nm1726\",\n",
        "        \"10.1371/journal.ppat.1005010\"]\n",
        "df['key'] = df['doi'].isin(key_doi)\n",
        "df[df['doi'].isin(key_doi)]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "bSHIBYoIpEGE",
        "outputId": "70f2d5b9-a297-45e5-ff1b-2813aade2823"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                 doi  \\\n",
              "35      10.1371/journal.ppat.1009929   \n",
              "229          10.1073/pnas.1811345115   \n",
              "384             10.1099/jgv.0.000682   \n",
              "443             10.1128/JVI.00078-16   \n",
              "449             10.1128/AAC.01073-16   \n",
              "539             10.1099/jgv.0.000316   \n",
              "676               10.1038/ncomms5794   \n",
              "702               10.1093/jac/dku209   \n",
              "743             10.1128/JVI.00289-14   \n",
              "758             10.1128/JVI.03594-13   \n",
              "771       10.1016/j.bbrc.2013.12.071   \n",
              "822  10.1016/j.antiviral.2013.07.008   \n",
              "905             10.1128/JVI.02139-12   \n",
              "\n",
              "                                                 title  \\\n",
              "35   In vitro selection of Remdesivir resistance su...   \n",
              "229  The mechanism of resistance to favipiravir in ...   \n",
              "384  Mutagen resistance and mutation restriction of...   \n",
              "443  Poliovirus Polymerase Leu420 Facilitates RNA R...   \n",
              "449  In Vitro Assessment of Combinations of Enterov...   \n",
              "539  Amino acid residues Ala283 and His421 in the R...   \n",
              "676  Generation and characterization of influenza A...   \n",
              "702  Mutations in the chikungunya virus non-structu...   \n",
              "743  Attenuation of human enterovirus 71 high-repli...   \n",
              "758  Ribavirin-resistant variants of foot-and-mouth...   \n",
              "771  Involvement of the N-terminal portion of influ...   \n",
              "822  An increased replication fidelity mutant of fo...   \n",
              "905  Ribavirin-resistant mutants of human enterovir...   \n",
              "\n",
              "                                              abstract  \\\n",
              "35   Remdesivir (RDV), a broadly acting nucleoside ...   \n",
              "229  Favipiravir is a broad-spectrum antiviral that...   \n",
              "384  The error rate of the RNA-dependent RNA polyme...   \n",
              "443  RNA recombination is important in the formatio...   \n",
              "449  Enterovirus 71 (EV-A71) is a major causative p...   \n",
              "539  The quasispecies diversity of RNA viruses is m...   \n",
              "676  Genetic diversity of influenza A viruses (IAV)...   \n",
              "702  T-705, also known as favipiravir, is a small-m...   \n",
              "743  In a screen for ribavirin resistance, a novel ...   \n",
              "758  Mutagenic nucleoside analogues can be used to ...   \n",
              "771  The influenza virus PB1 protein functions as a...   \n",
              "822  In a screen for RNA mutagen-resistant foot-and...   \n",
              "905  It has been shown in animal models that ribavi...   \n",
              "\n",
              "                                    processed_abstract   y     x_tsne  \\\n",
              "35   remdesivir rdv broadly act nucleoside analogue...   6 -11.084248   \n",
              "229  favipiravir broad-spectrum antiviral promise t...  18 -35.909420   \n",
              "384  error rate rna-dependent rna polymerase rdrp r...   8 -17.598848   \n",
              "443  rna recombination important formation picornav...   8 -15.428197   \n",
              "449  enterovirus 71 ev-a71 major causative pathogen...   8 -12.135286   \n",
              "539  quasispecie diversity rna virus mainly determi...   8 -16.780453   \n",
              "676  genetic diversity influenza virus iav acquire ...   8 -18.304201   \n",
              "702  t-705 know favipiravir small-molecule inhibito...  18 -38.347027   \n",
              "743  screen ribavirin resistance novel high-fidelit...   8 -17.242252   \n",
              "758  mutagenic nucleoside analogue use isolate rna ...   8 -18.198774   \n",
              "771  influenza virus pb1 protein function catalytic...   8 -15.679549   \n",
              "822  screen rna mutagen-resistant foot-and-mouth di...   8 -18.620758   \n",
              "905  animal model ribavirin-resistant g64s mutation...   8 -16.639713   \n",
              "\n",
              "        y_tsne   key  \n",
              "35   45.179966  True  \n",
              "229  21.598940  True  \n",
              "384  25.597475  True  \n",
              "443  24.191156  True  \n",
              "449  18.616566  True  \n",
              "539  25.325102  True  \n",
              "676  23.493374  True  \n",
              "702  22.072716  True  \n",
              "743  24.193941  True  \n",
              "758  26.157326  True  \n",
              "771  25.631859  True  \n",
              "822  25.958916  True  \n",
              "905  22.971025  True  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-b76d777d-cb69-4ae7-9a9d-df281de5f56b\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>doi</th>\n",
              "      <th>title</th>\n",
              "      <th>abstract</th>\n",
              "      <th>processed_abstract</th>\n",
              "      <th>y</th>\n",
              "      <th>x_tsne</th>\n",
              "      <th>y_tsne</th>\n",
              "      <th>key</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>35</th>\n",
              "      <td>10.1371/journal.ppat.1009929</td>\n",
              "      <td>In vitro selection of Remdesivir resistance su...</td>\n",
              "      <td>Remdesivir (RDV), a broadly acting nucleoside ...</td>\n",
              "      <td>remdesivir rdv broadly act nucleoside analogue...</td>\n",
              "      <td>6</td>\n",
              "      <td>-11.084248</td>\n",
              "      <td>45.179966</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>229</th>\n",
              "      <td>10.1073/pnas.1811345115</td>\n",
              "      <td>The mechanism of resistance to favipiravir in ...</td>\n",
              "      <td>Favipiravir is a broad-spectrum antiviral that...</td>\n",
              "      <td>favipiravir broad-spectrum antiviral promise t...</td>\n",
              "      <td>18</td>\n",
              "      <td>-35.909420</td>\n",
              "      <td>21.598940</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>384</th>\n",
              "      <td>10.1099/jgv.0.000682</td>\n",
              "      <td>Mutagen resistance and mutation restriction of...</td>\n",
              "      <td>The error rate of the RNA-dependent RNA polyme...</td>\n",
              "      <td>error rate rna-dependent rna polymerase rdrp r...</td>\n",
              "      <td>8</td>\n",
              "      <td>-17.598848</td>\n",
              "      <td>25.597475</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>443</th>\n",
              "      <td>10.1128/JVI.00078-16</td>\n",
              "      <td>Poliovirus Polymerase Leu420 Facilitates RNA R...</td>\n",
              "      <td>RNA recombination is important in the formatio...</td>\n",
              "      <td>rna recombination important formation picornav...</td>\n",
              "      <td>8</td>\n",
              "      <td>-15.428197</td>\n",
              "      <td>24.191156</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>449</th>\n",
              "      <td>10.1128/AAC.01073-16</td>\n",
              "      <td>In Vitro Assessment of Combinations of Enterov...</td>\n",
              "      <td>Enterovirus 71 (EV-A71) is a major causative p...</td>\n",
              "      <td>enterovirus 71 ev-a71 major causative pathogen...</td>\n",
              "      <td>8</td>\n",
              "      <td>-12.135286</td>\n",
              "      <td>18.616566</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>539</th>\n",
              "      <td>10.1099/jgv.0.000316</td>\n",
              "      <td>Amino acid residues Ala283 and His421 in the R...</td>\n",
              "      <td>The quasispecies diversity of RNA viruses is m...</td>\n",
              "      <td>quasispecie diversity rna virus mainly determi...</td>\n",
              "      <td>8</td>\n",
              "      <td>-16.780453</td>\n",
              "      <td>25.325102</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>676</th>\n",
              "      <td>10.1038/ncomms5794</td>\n",
              "      <td>Generation and characterization of influenza A...</td>\n",
              "      <td>Genetic diversity of influenza A viruses (IAV)...</td>\n",
              "      <td>genetic diversity influenza virus iav acquire ...</td>\n",
              "      <td>8</td>\n",
              "      <td>-18.304201</td>\n",
              "      <td>23.493374</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>702</th>\n",
              "      <td>10.1093/jac/dku209</td>\n",
              "      <td>Mutations in the chikungunya virus non-structu...</td>\n",
              "      <td>T-705, also known as favipiravir, is a small-m...</td>\n",
              "      <td>t-705 know favipiravir small-molecule inhibito...</td>\n",
              "      <td>18</td>\n",
              "      <td>-38.347027</td>\n",
              "      <td>22.072716</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>743</th>\n",
              "      <td>10.1128/JVI.00289-14</td>\n",
              "      <td>Attenuation of human enterovirus 71 high-repli...</td>\n",
              "      <td>In a screen for ribavirin resistance, a novel ...</td>\n",
              "      <td>screen ribavirin resistance novel high-fidelit...</td>\n",
              "      <td>8</td>\n",
              "      <td>-17.242252</td>\n",
              "      <td>24.193941</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>758</th>\n",
              "      <td>10.1128/JVI.03594-13</td>\n",
              "      <td>Ribavirin-resistant variants of foot-and-mouth...</td>\n",
              "      <td>Mutagenic nucleoside analogues can be used to ...</td>\n",
              "      <td>mutagenic nucleoside analogue use isolate rna ...</td>\n",
              "      <td>8</td>\n",
              "      <td>-18.198774</td>\n",
              "      <td>26.157326</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>771</th>\n",
              "      <td>10.1016/j.bbrc.2013.12.071</td>\n",
              "      <td>Involvement of the N-terminal portion of influ...</td>\n",
              "      <td>The influenza virus PB1 protein functions as a...</td>\n",
              "      <td>influenza virus pb1 protein function catalytic...</td>\n",
              "      <td>8</td>\n",
              "      <td>-15.679549</td>\n",
              "      <td>25.631859</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>822</th>\n",
              "      <td>10.1016/j.antiviral.2013.07.008</td>\n",
              "      <td>An increased replication fidelity mutant of fo...</td>\n",
              "      <td>In a screen for RNA mutagen-resistant foot-and...</td>\n",
              "      <td>screen rna mutagen-resistant foot-and-mouth di...</td>\n",
              "      <td>8</td>\n",
              "      <td>-18.620758</td>\n",
              "      <td>25.958916</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>905</th>\n",
              "      <td>10.1128/JVI.02139-12</td>\n",
              "      <td>Ribavirin-resistant mutants of human enterovir...</td>\n",
              "      <td>It has been shown in animal models that ribavi...</td>\n",
              "      <td>animal model ribavirin-resistant g64s mutation...</td>\n",
              "      <td>8</td>\n",
              "      <td>-16.639713</td>\n",
              "      <td>22.971025</td>\n",
              "      <td>True</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-b76d777d-cb69-4ae7-9a9d-df281de5f56b')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-b76d777d-cb69-4ae7-9a9d-df281de5f56b button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-b76d777d-cb69-4ae7-9a9d-df281de5f56b');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 77
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# we want bokeh to treat y (cluster) as discrete not continuous \n",
        "df['y'] = df['y'].apply(str)\n",
        "df.dtypes"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "h_ol41opvd_6",
        "outputId": "36a41f96-2fb8-4784-f2c5-f890f6724101"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "doi                    object\n",
              "title                  object\n",
              "abstract               object\n",
              "processed_abstract     object\n",
              "y                      object\n",
              "x_tsne                float32\n",
              "y_tsne                float32\n",
              "key                      bool\n",
              "dtype: object"
            ]
          },
          "metadata": {},
          "execution_count": 82
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# make a pretty plot\n",
        "from bokeh.plotting import ColumnDataSource, figure, output_notebook, show, output_file, save\n",
        "from bokeh.palettes import d3\n",
        "import bokeh.models as bmo\n",
        "#output_file(\"toolbar.html\")\n",
        "output_notebook()\n",
        "\n",
        "TOOLTIPS = [\n",
        "    (\"index\", \"$index\"),\n",
        "    (\"(x,y)\", \"($x, $y)\"),\n",
        "    (\"doi\", \"@doi\"),\n",
        "    (\"title\", \"@title\"),\n",
        "]\n",
        "\n",
        "# use whatever palette you want...\n",
        "palette = d3['Category20'][len(df['y'].unique())]\n",
        "color_map = bmo.CategoricalColorMapper(factors=df['y'].unique(),\n",
        "                                   palette=palette)\n",
        "\n",
        "p = figure(width=800, height=800, tooltips=TOOLTIPS,\n",
        "           title=\"Mouse over the dots\")\n",
        "p.scatter('x_tsne', 'y_tsne', size=5, source=df[df['key'] == False], color={'field': 'y', 'transform': color_map})\n",
        "p.scatter('x_tsne', 'y_tsne', size=8, source=df[df['key'] == True], color=\"black\", marker=\"square\")\n",
        "show(p)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 817
        },
        "id": "ocDSSng-pGBL",
        "outputId": "d1cd1b42-2dcd-4b6c-9821-6bc57cf6657f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "application/javascript": [
              "\n",
              "(function(root) {\n",
              "  function now() {\n",
              "    return new Date();\n",
              "  }\n",
              "\n",
              "  var force = true;\n",
              "\n",
              "  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n",
              "    root._bokeh_onload_callbacks = [];\n",
              "    root._bokeh_is_loading = undefined;\n",
              "  }\n",
              "\n",
              "  var JS_MIME_TYPE = 'application/javascript';\n",
              "  var HTML_MIME_TYPE = 'text/html';\n",
              "  var EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n",
              "  var CLASS_NAME = 'output_bokeh rendered_html';\n",
              "\n",
              "  /**\n",
              "   * Render data to the DOM node\n",
              "   */\n",
              "  function render(props, node) {\n",
              "    var script = document.createElement(\"script\");\n",
              "    node.appendChild(script);\n",
              "  }\n",
              "\n",
              "  /**\n",
              "   * Handle when an output is cleared or removed\n",
              "   */\n",
              "  function handleClearOutput(event, handle) {\n",
              "    var cell = handle.cell;\n",
              "\n",
              "    var id = cell.output_area._bokeh_element_id;\n",
              "    var server_id = cell.output_area._bokeh_server_id;\n",
              "    // Clean up Bokeh references\n",
              "    if (id != null && id in Bokeh.index) {\n",
              "      Bokeh.index[id].model.document.clear();\n",
              "      delete Bokeh.index[id];\n",
              "    }\n",
              "\n",
              "    if (server_id !== undefined) {\n",
              "      // Clean up Bokeh references\n",
              "      var cmd = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n",
              "      cell.notebook.kernel.execute(cmd, {\n",
              "        iopub: {\n",
              "          output: function(msg) {\n",
              "            var id = msg.content.text.trim();\n",
              "            if (id in Bokeh.index) {\n",
              "              Bokeh.index[id].model.document.clear();\n",
              "              delete Bokeh.index[id];\n",
              "            }\n",
              "          }\n",
              "        }\n",
              "      });\n",
              "      // Destroy server and session\n",
              "      var cmd = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n",
              "      cell.notebook.kernel.execute(cmd);\n",
              "    }\n",
              "  }\n",
              "\n",
              "  /**\n",
              "   * Handle when a new output is added\n",
              "   */\n",
              "  function handleAddOutput(event, handle) {\n",
              "    var output_area = handle.output_area;\n",
              "    var output = handle.output;\n",
              "\n",
              "    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n",
              "    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n",
              "      return\n",
              "    }\n",
              "\n",
              "    var toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n",
              "\n",
              "    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n",
              "      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n",
              "      // store reference to embed id on output_area\n",
              "      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n",
              "    }\n",
              "    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n",
              "      var bk_div = document.createElement(\"div\");\n",
              "      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n",
              "      var script_attrs = bk_div.children[0].attributes;\n",
              "      for (var i = 0; i < script_attrs.length; i++) {\n",
              "        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n",
              "        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n",
              "      }\n",
              "      // store reference to server id on output_area\n",
              "      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n",
              "    }\n",
              "  }\n",
              "\n",
              "  function register_renderer(events, OutputArea) {\n",
              "\n",
              "    function append_mime(data, metadata, element) {\n",
              "      // create a DOM node to render to\n",
              "      var toinsert = this.create_output_subarea(\n",
              "        metadata,\n",
              "        CLASS_NAME,\n",
              "        EXEC_MIME_TYPE\n",
              "      );\n",
              "      this.keyboard_manager.register_events(toinsert);\n",
              "      // Render to node\n",
              "      var props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n",
              "      render(props, toinsert[toinsert.length - 1]);\n",
              "      element.append(toinsert);\n",
              "      return toinsert\n",
              "    }\n",
              "\n",
              "    /* Handle when an output is cleared or removed */\n",
              "    events.on('clear_output.CodeCell', handleClearOutput);\n",
              "    events.on('delete.Cell', handleClearOutput);\n",
              "\n",
              "    /* Handle when a new output is added */\n",
              "    events.on('output_added.OutputArea', handleAddOutput);\n",
              "\n",
              "    /**\n",
              "     * Register the mime type and append_mime function with output_area\n",
              "     */\n",
              "    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n",
              "      /* Is output safe? */\n",
              "      safe: true,\n",
              "      /* Index of renderer in `output_area.display_order` */\n",
              "      index: 0\n",
              "    });\n",
              "  }\n",
              "\n",
              "  // register the mime type if in Jupyter Notebook environment and previously unregistered\n",
              "  if (root.Jupyter !== undefined) {\n",
              "    var events = require('base/js/events');\n",
              "    var OutputArea = require('notebook/js/outputarea').OutputArea;\n",
              "\n",
              "    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n",
              "      register_renderer(events, OutputArea);\n",
              "    }\n",
              "  }\n",
              "\n",
              "  \n",
              "  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n",
              "    root._bokeh_timeout = Date.now() + 5000;\n",
              "    root._bokeh_failed_load = false;\n",
              "  }\n",
              "\n",
              "  var NB_LOAD_WARNING = {'data': {'text/html':\n",
              "     \"<div style='background-color: #fdd'>\\n\"+\n",
              "     \"<p>\\n\"+\n",
              "     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n",
              "     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n",
              "     \"</p>\\n\"+\n",
              "     \"<ul>\\n\"+\n",
              "     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n",
              "     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n",
              "     \"</ul>\\n\"+\n",
              "     \"<code>\\n\"+\n",
              "     \"from bokeh.resources import INLINE\\n\"+\n",
              "     \"output_notebook(resources=INLINE)\\n\"+\n",
              "     \"</code>\\n\"+\n",
              "     \"</div>\"}};\n",
              "\n",
              "  function display_loaded() {\n",
              "    var el = document.getElementById(null);\n",
              "    if (el != null) {\n",
              "      el.textContent = \"BokehJS is loading...\";\n",
              "    }\n",
              "    if (root.Bokeh !== undefined) {\n",
              "      if (el != null) {\n",
              "        el.textContent = \"BokehJS \" + root.Bokeh.version + \" successfully loaded.\";\n",
              "      }\n",
              "    } else if (Date.now() < root._bokeh_timeout) {\n",
              "      setTimeout(display_loaded, 100)\n",
              "    }\n",
              "  }\n",
              "\n",
              "\n",
              "  function run_callbacks() {\n",
              "    try {\n",
              "      root._bokeh_onload_callbacks.forEach(function(callback) {\n",
              "        if (callback != null)\n",
              "          callback();\n",
              "      });\n",
              "    } finally {\n",
              "      delete root._bokeh_onload_callbacks\n",
              "    }\n",
              "    console.debug(\"Bokeh: all callbacks have finished\");\n",
              "  }\n",
              "\n",
              "  function load_libs(css_urls, js_urls, callback) {\n",
              "    if (css_urls == null) css_urls = [];\n",
              "    if (js_urls == null) js_urls = [];\n",
              "\n",
              "    root._bokeh_onload_callbacks.push(callback);\n",
              "    if (root._bokeh_is_loading > 0) {\n",
              "      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n",
              "      return null;\n",
              "    }\n",
              "    if (js_urls == null || js_urls.length === 0) {\n",
              "      run_callbacks();\n",
              "      return null;\n",
              "    }\n",
              "    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n",
              "    root._bokeh_is_loading = css_urls.length + js_urls.length;\n",
              "\n",
              "    function on_load() {\n",
              "      root._bokeh_is_loading--;\n",
              "      if (root._bokeh_is_loading === 0) {\n",
              "        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n",
              "        run_callbacks()\n",
              "      }\n",
              "    }\n",
              "\n",
              "    function on_error(url) {\n",
              "      console.error(\"failed to load \" + url);\n",
              "    }\n",
              "\n",
              "    for (let i = 0; i < css_urls.length; i++) {\n",
              "      const url = css_urls[i];\n",
              "      const element = document.createElement(\"link\");\n",
              "      element.onload = on_load;\n",
              "      element.onerror = on_error.bind(null, url);\n",
              "      element.rel = \"stylesheet\";\n",
              "      element.type = \"text/css\";\n",
              "      element.href = url;\n",
              "      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n",
              "      document.body.appendChild(element);\n",
              "    }\n",
              "\n",
              "    const hashes = {\"https://cdn.bokeh.org/bokeh/release/bokeh-2.3.3.min.js\": \"dM3QQsP+wXdHg42wTqW85BjZQdLNNIXqlPw/BgKoExPmTG7ZLML4EGqLMfqHT6ON\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-2.3.3.min.js\": \"8x57I4YuIfu8XyZfFo0XVr2WAT8EK4rh/uDe3wF7YuW2FNUSNEpJbsPaB1nJ2fz2\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-2.3.3.min.js\": \"3QTqdz9LyAm2i0sG5XTePsHec3UHWwVsrOL68SYRoAXsafvfAyqtQ+h440+qIBhS\"};\n",
              "\n",
              "    for (let i = 0; i < js_urls.length; i++) {\n",
              "      const url = js_urls[i];\n",
              "      const element = document.createElement('script');\n",
              "      element.onload = on_load;\n",
              "      element.onerror = on_error.bind(null, url);\n",
              "      element.async = false;\n",
              "      element.src = url;\n",
              "      if (url in hashes) {\n",
              "        element.crossOrigin = \"anonymous\";\n",
              "        element.integrity = \"sha384-\" + hashes[url];\n",
              "      }\n",
              "      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n",
              "      document.head.appendChild(element);\n",
              "    }\n",
              "  };\n",
              "\n",
              "  function inject_raw_css(css) {\n",
              "    const element = document.createElement(\"style\");\n",
              "    element.appendChild(document.createTextNode(css));\n",
              "    document.body.appendChild(element);\n",
              "  }\n",
              "\n",
              "  \n",
              "  var js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-2.3.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-2.3.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-2.3.3.min.js\"];\n",
              "  var css_urls = [];\n",
              "  \n",
              "\n",
              "  var inline_js = [\n",
              "    function(Bokeh) {\n",
              "      Bokeh.set_log_level(\"info\");\n",
              "    },\n",
              "    function(Bokeh) {\n",
              "    \n",
              "    \n",
              "    }\n",
              "  ];\n",
              "\n",
              "  function run_inline_js() {\n",
              "    \n",
              "    if (root.Bokeh !== undefined || force === true) {\n",
              "      \n",
              "    for (var i = 0; i < inline_js.length; i++) {\n",
              "      inline_js[i].call(root, root.Bokeh);\n",
              "    }\n",
              "    } else if (Date.now() < root._bokeh_timeout) {\n",
              "      setTimeout(run_inline_js, 100);\n",
              "    } else if (!root._bokeh_failed_load) {\n",
              "      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n",
              "      root._bokeh_failed_load = true;\n",
              "    } else if (force !== true) {\n",
              "      var cell = $(document.getElementById(null)).parents('.cell').data().cell;\n",
              "      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n",
              "    }\n",
              "\n",
              "  }\n",
              "\n",
              "  if (root._bokeh_is_loading === 0) {\n",
              "    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n",
              "    run_inline_js();\n",
              "  } else {\n",
              "    load_libs(css_urls, js_urls, function() {\n",
              "      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n",
              "      run_inline_js();\n",
              "    });\n",
              "  }\n",
              "}(window));"
            ],
            "application/vnd.bokehjs_load.v0+json": "\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  var force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\n  \n\n  \n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  var NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded() {\n    var el = document.getElementById(null);\n    if (el != null) {\n      el.textContent = \"BokehJS is loading...\";\n    }\n    if (root.Bokeh !== undefined) {\n      if (el != null) {\n        el.textContent = \"BokehJS \" + root.Bokeh.version + \" successfully loaded.\";\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(display_loaded, 100)\n    }\n  }\n\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    const hashes = {\"https://cdn.bokeh.org/bokeh/release/bokeh-2.3.3.min.js\": \"dM3QQsP+wXdHg42wTqW85BjZQdLNNIXqlPw/BgKoExPmTG7ZLML4EGqLMfqHT6ON\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-2.3.3.min.js\": \"8x57I4YuIfu8XyZfFo0XVr2WAT8EK4rh/uDe3wF7YuW2FNUSNEpJbsPaB1nJ2fz2\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-2.3.3.min.js\": \"3QTqdz9LyAm2i0sG5XTePsHec3UHWwVsrOL68SYRoAXsafvfAyqtQ+h440+qIBhS\"};\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      if (url in hashes) {\n        element.crossOrigin = \"anonymous\";\n        element.integrity = \"sha384-\" + hashes[url];\n      }\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  \n  var js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-2.3.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-2.3.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-2.3.3.min.js\"];\n  var css_urls = [];\n  \n\n  var inline_js = [\n    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\n    function(Bokeh) {\n    \n    \n    }\n  ];\n\n  function run_inline_js() {\n    \n    if (root.Bokeh !== undefined || force === true) {\n      \n    for (var i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      var cell = $(document.getElementById(null)).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));"
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/html": [
              "\n",
              "\n",
              "\n",
              "\n",
              "\n",
              "\n",
              "  <div class=\"bk-root\" id=\"068d5fcc-7369-453e-ae06-ad9afba151fd\" data-root-id=\"1261\"></div>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "application/javascript": [
              "(function(root) {\n",
              "  function embed_document(root) {\n",
              "    \n",
              "  var docs_json = {\"bca35dff-5df1-469f-a99f-210fee959c98\":{\"defs\":[],\"roots\":{\"references\":[{\"attributes\":{\"below\":[{\"id\":\"1272\"}],\"center\":[{\"id\":\"1275\"},{\"id\":\"1279\"}],\"height\":800,\"left\":[{\"id\":\"1276\"}],\"renderers\":[{\"id\":\"1300\"},{\"id\":\"1306\"}],\"title\":{\"id\":\"1262\"},\"toolbar\":{\"id\":\"1288\"},\"width\":800,\"x_range\":{\"id\":\"1264\"},\"x_scale\":{\"id\":\"1268\"},\"y_range\":{\"id\":\"1266\"},\"y_scale\":{\"id\":\"1270\"}},\"id\":\"1261\",\"subtype\":\"Figure\",\"type\":\"Plot\"},{\"attributes\":{\"formatter\":{\"id\":\"1338\"},\"major_label_policy\":{\"id\":\"1336\"},\"ticker\":{\"id\":\"1277\"}},\"id\":\"1276\",\"type\":\"LinearAxis\"},{\"attributes\":{},\"id\":\"1333\",\"type\":\"AllLabels\"},{\"attributes\":{},\"id\":\"1340\",\"type\":\"Selection\"},{\"attributes\":{},\"id\":\"1264\",\"type\":\"DataRange1d\"},{\"attributes\":{},\"id\":\"1268\",\"type\":\"LinearScale\"},{\"attributes\":{\"overlay\":{\"id\":\"1286\"}},\"id\":\"1282\",\"type\":\"BoxZoomTool\"},{\"attributes\":{},\"id\":\"1273\",\"type\":\"BasicTicker\"},{\"attributes\":{},\"id\":\"1266\",\"type\":\"DataRange1d\"},{\"attributes\":{\"source\":{\"id\":\"1296\"}},\"id\":\"1301\",\"type\":\"CDSView\"},{\"attributes\":{\"active_multi\":null,\"tools\":[{\"id\":\"1280\"},{\"id\":\"1281\"},{\"id\":\"1282\"},{\"id\":\"1283\"},{\"id\":\"1284\"},{\"id\":\"1285\"},{\"id\":\"1287\"}]},\"id\":\"1288\",\"type\":\"Toolbar\"},{\"attributes\":{\"data\":{\"abstract\":[\"Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports identifying SARS-CoV-2 RDV resistance in patients, animal models or in vitro. Here, we selected drug-resistant viral populations by serially passaging SARS-CoV-2 in vitro in the presence of RDV. Using high throughput sequencing, we identified a single mutation in RNA-dependent RNA polymerase (NSP12) at a residue conserved among all coronaviruses in two independently evolved populations displaying decreased RDV sensitivity. Introduction of the NSP12 E802D mutation into our SARS-CoV-2 reverse genetics backbone confirmed its role in decreasing RDV sensitivity in vitro. Substitution of E802 did not affect viral replication or activity of an alternate nucleoside analogue (EIDD2801) but did affect virus fitness in a competition assay. Analysis of the globally circulating SARS-CoV-2 variants (>800,000 sequences) showed no evidence of widespread transmission of RDV-resistant mutants. Surprisingly, we observed an excess of substitutions in spike at corresponding sites identified in the emerging SARS-CoV-2 variants of concern (i.e., H69, E484, N501, H655) indicating that they can arise in vitro in the absence of immune selection. The identification and characterisation of a drug resistant signature within the SARS-CoV-2 genome has implications for clinical management and virus surveillance.\",\"Favipiravir is a broad-spectrum antiviral that has shown promise in treatment of influenza virus infections. While emergence of resistance has been observed for many antiinfluenza drugs, to date, clinical trials and laboratory studies of favipiravir have not yielded resistant viruses. Here we show evolution of resistance to favipiravir in the pandemic H1N1 influenza A virus in a laboratory setting. We found that two mutations were required for robust resistance to favipiravir. We demonstrate that a K229R mutation in motif F of the PB1 subunit of the influenza virus RNA-dependent RNA polymerase (RdRP) confers resistance to favipiravir in vitro and in cell culture. This mutation has a cost to viral fitness, but fitness can be restored by a P653L mutation in the PA subunit of the polymerase. K229R also conferred favipiravir resistance to RNA polymerases of other influenza A virus strains, and its location within a highly conserved structural feature of the RdRP suggests that other RNA viruses might also acquire resistance through mutations in motif F. The mutations identified here could be used to screen influenza virus-infected patients treated with favipiravir for the emergence of resistance.\",\"The error rate of the RNA-dependent RNA polymerase (RdRp) of RNA viruses is important in maintaining genetic diversity for viral adaptation and fitness. Numerous studies have shown that mutagen-resistant RNA virus variants display amino acid mutations in the RdRp and other replicase subunits, which in turn exhibit an altered fidelity phenotype affecting viral fitness, adaptability and pathogenicity. St. Louis encephalitis virus (SLEV), like its close relative West Nile virus, is a mosquito-borne flavivirus that has the ability to cause neuroinvasive disease in humans. Here, we describe the successful generation of multiple ribavirin-resistant populations containing a shared amino acid mutation in the SLEV RdRp (E416K). These E416K mutants also displayed resistance to the antiviral T-1106, an RNA mutagen similar to ribavirin. Structural modelling of the E416K polymerase mutation indicated its location in the pinky finger domain of the RdRp, distant from the active site. Deep sequencing of the E416K mutant revealed lower genetic diversity than wild-type SLEV after growth in both vertebrate and invertebrate cells. Phenotypic characterization showed that E416K mutants displayed similar or increased replication in mammalian cells, as well as modest attenuation in mosquito cells, consistent with previous work with West Nile virus high-fidelity variants. In addition, attenuation was limited to mosquito cells with a functional RNA interference response, suggesting an impaired capacity to escape RNA interference could contribute to attenuation of high-fidelity variants. Our results provide increased evidence that RNA mutagen resistance arises through modulation of the RdRp and give further insight into the consequences of altered fidelity of flaviviruses.\",\"RNA recombination is important in the formation of picornavirus species groups and the ongoing evolution of viruses within species groups. In this study, we examined the structure and function of poliovirus polymerase, 3D(pol), as it relates to RNA recombination. Recombination occurs when nascent RNA products exchange one viral RNA template for another during RNA replication. Because recombination is a natural aspect of picornavirus replication, we hypothesized that some features of 3D(pol) may exist, in part, to facilitate RNA recombination. Furthermore, we reasoned that alanine substitution mutations that disrupt 3D(pol)-RNA interactions within the polymerase elongation complex might increase and/or decrease the magnitudes of recombination. We found that an L420A mutation in 3D(pol) decreased the frequency of RNA recombination, whereas alanine substitutions at other sites in 3D(pol) increased the frequency of recombination. The 3D(pol) Leu420 side chain interacts with a ribose in the nascent RNA product 3 nucleotides from the active site of the polymerase. Notably, the L420A mutation that reduced recombination also rendered the virus more susceptible to inhibition by ribavirin, coincident with the accumulation of ribavirin-induced G\\u2192A and C\\u2192U mutations in viral RNA. We conclude that 3D(pol) Leu420 is critically important for RNA recombination and that RNA recombination contributes to ribavirin resistance.\",\"Enterovirus 71 (EV-A71) is a major causative pathogen of hand, foot, and mouth disease (HFMD) epidemics. No antiviral therapies are currently available for treating EV-A71 infections. Here, we selected five reported enterovirus inhibitors (suramin, itraconazole [ITZ], GW5074, rupintrivir, and favipiravir) with different mechanisms of action to test their abilities to inhibit EV-A71 replication alone and in combination. All selected compounds have anti-EV-A71 activities in cell culture. The combination of rupintrivir and ITZ or favipiravir was synergistic, while the combination of rupintrivir and suramin was additive. The combination of suramin and favipiravir exerted a strong synergistic antiviral effect. The observed synergy was not due to cytotoxicity, as there was no significant increase in cytotoxicity when compounds were used in combinations at the tested doses. To investigate the potential inhibitory mechanism of favipiravir against enterovirus, two favipiravir-resistant EV-A71 variants were independently selected, and both of them carried an S121N mutation in the finger subdomain of the 3D polymerase. Reverse engineering of this 3D S121N mutation into an infectious clone of EV-A71 confirmed the resistant phenotype. Moreover, viruses resistant to ITZ or favipiravir remained susceptible to other inhibitors. Most notably, combined with ITZ, rupintrivir prevented the development of ITZ-resistant variants. Taken together, these results provide a rational basis for the design of combination regimens for use in the treatment of EV-A71 infections.\",\"The quasispecies diversity of RNA viruses is mainly determined by the fidelity of RNA-dependent RNA polymerase (RdRp) during viral RNA replication. Certain amino acid residues play an important role in determining the fidelity, and such residues can be substituted with other amino acids to produce virus strains with higher fidelity. In this study, two amino acid substitutions (A283T and H421Y) in the RdRp of porcine reproductive and respiratory syndrome virus (PRRSV) were identified under the selection of ribavirin. Preliminary data showed that two substitutions were involved in conferring PRRSV with the properties of increased ribavirin resistance and restricted quasispecies diversity. The results indicated that these two amino acid residues (Ala283 and His421) play a crucial role in PRRSV replication by affecting the fidelity of its RdRp. The results have important implications for understanding the molecular mechanism of PRRSV evolution and pathogenicity, and developing a safer modified live-attenuated vaccine (MLV) against PRRSV.\",\"Genetic diversity of influenza A viruses (IAV) acquired through the error-prone RNA-dependent RNA polymerase (RdRP) or through genetic reassortment enables perpetuation of IAV in humans through epidemics or pandemics. Here, to assess the biological significance of genetic diversity acquired through RdRP, we characterize an IAV fidelity variant derived from passaging a seasonal H3N2 virus in the presence of ribavirin, a purine analogue that increases guanosine-to-adenosine mutations. We demonstrate that a single PB1-V43I mutation increases selectivity to guanosine in A/Wuhan/359/95 (H3N2) and A/Vietnam/1203/04 (H5N1) viruses. The H5N1 PB1-V43I-recombinant virus replicates to comparable titres as the wild-type virus in vitro or in the mouse lungs. However, a decrease in viral population diversity at day 3 post inoculation is associated with a tenfold reduced lethality and neurotropism in mice. Applying a fidelity variant with reduced mutational frequency, we provide direct experimental evidence for the role of genetic diversity in IAV pathogenesis.\",\"T-705, also known as favipiravir, is a small-molecule inhibitor that is currently in clinical development for the treatment of influenza virus infections. This molecule also inhibits the replication of a broad spectrum of other RNA viruses. The objective of this study was to investigate the antiviral effect of favipiravir on chikungunya virus (CHIKV) replication and to contribute to unravelling the molecular mechanism of action against this virus.\",\"In a screen for ribavirin resistance, a novel high-fidelity variant of human enterovirus 71 (EV71) with the single amino acid change L123F in its RNA-dependent RNA polymerase (RdRp or 3D) was identified. Based on the crystal structure of EV71 RdRp, L123 locates at the entrance of the RNA template binding channel, which might form a fidelity checkpoint. EV71 RdRp-L123F variants generated less progeny in a guanidine resistance assay and virus populations with lower mutation frequencies in cell culture passage due to their higher replication fidelity. However, compared with wild-type viruses, they did not show growth defects. In vivo infections further revealed that high-fidelity mutations L123F and G64R (previously reported) negatively impacted EV71 fitness and greatly reduced viral pathogenicity alone or together in AG129 mice. Interestingly, a variant with double mutations, RG/B4-G64R/L123F (where RG/B4 is an EV71 genotype B4 virus constructed by reverse genetics [RG])showed higher fidelity in vitro and less virulence in vivo than any one of the above two single mutants. The 50% lethal dose (LD50) of the double mutant increased more than 500 times compared with the LD50 of wild-type RG/B4 in mice. The results indicated that these high-fidelity variants exhibited an attenuated pathogenic phenotype in vivo and offer promise as a live attenuated EV71 vaccine.\",\"Mutagenic nucleoside analogues can be used to isolate RNA virus high-fidelity RNA-dependent RNA polymerase (RdRp) variants, the majority of which are attenuated in vivo. However, attenuated foot-and-mouth disease virus (FMDV) high-fidelity RdRp variants have not been isolated, and the correlations between RdRp fidelity and virulence remain unclear. Here, the mutagen ribavirin was used to select a ribavirin-resistant population of FMDV, and 4 amino acid substitutions (D5N, A38V, M194I, and M296V) were identified in the RdRp-coding region of the population. Through single or combined mutagenesis using a reverse genetics system, we generated direct experimental evidence that the rescued D5N, A38V, and DAMM mutants but not the M194I and M296V mutants are high-fidelity RdRp variants. Mutagen resistance assays revealed that the higher replication fidelity was associated with higher-level resistance to ribavirin. In addition, significantly attenuated fitness and virulence phenotypes were observed for the D5N, A38V, and DAMM mutants. Based on a systematic quantitative analysis of fidelity and virulence, we concluded that higher replication fidelity is associated with a more attenuated virus. These data suggest that the resulting restricted quasispecies diversity compromises the adaptability and virulence of an RNA virus population. The modulation of replication fidelity to attenuate virulence may represent a general strategy for the rational design of new types of live, attenuated vaccine strains.\",\"The influenza virus PB1 protein functions as a catalytic subunit of the viral RNA-dependent RNA polymerase and contains the highly conserved motifs of RNA-dependent RNA polymerases together with putative nucleotide-binding sites. PB1 also binds to viral genomic RNAs and its replicative intermediates through the promoter regions. The detail function and interplay between functional domains are not clarified although a part of structures and functions of PB1 have been clarified. In this study, we analyzed the function of PB1 subunit in the sense of nucleotide recognition using ribavirin, which is a nucleoside analog and inhibits viral RNA synthesis of many RNA viruses including influenza virus. We screened ribavirin-resistant PB1 mutants from randomly mutated PB1 cDNA library using a mini-replicon assay, and we identified a single mutation at the amino acid position 27 of PB1 as an important residue for the nucleotide recognition.\",\"In a screen for RNA mutagen-resistant foot-and-mouth disease virus (FMDV) strains, we isolated an FMDV mutant with RNA-dependent RNA polymerase (RdRp) R84H substitution. This mutant, selected under the mutagenic pressure of 5-fluorouracil (5-FU), is resistant not only to 5-FU but also to other two RNA mutagens, 5-azacytidine and ribavirin, suggesting that the RdRp R84H mutant is a high fidelity variant. Subsequently, the increased fidelity of this mutant was verified through analysis of mutation frequency, which revealed a 1.4-fold enhancement in RdRp fidelity compared with the wild-type virus. Further studies indicated that the R84H mutant exhibited slightly increased fitness in vitro, and its virulence was not reduced in suckling mice. These results indicated that an increase in RdRp fidelity does not always correlate with reduced virus fitness and virus attenuation. Thus, this isolated R84H mutant provides a new platform to examine the evolutionary dynamics of fidelity-changing RNA viruses, such as mutagen resistance, fitness and virulence.\",\"It has been shown in animal models that ribavirin-resistant poliovirus with a G64S mutation in its 3D polymerase has high replication fidelity coupled with attenuated virulence. Here, we describe the effects of mutagenesis in the human enterovirus 71 (HEV71) 3D polymerase on ribavirin resistance and replication fidelity. Seven substitutions were introduced at amino acid position 3D-G64 of a HEV71 full-length infectious cDNA clone (26M). Viable clone-derived virus populations were rescued from the G64N, G64R, and G64T mutant cDNA clones. The clone-derived G64R and G64T mutant virus populations were resistant to growth inhibition in the presence of 1,600 \\u03bcM ribavirin, whereas the growth of parental 26M and the G64N mutant viruses were inhibited in the presence of 800 \\u03bcM ribavirin. Nucleotide sequencing of the 2C and 3D coding regions revealed that the rate of random mutagenesis after 13 passages in the presence of 400 \\u03bcM ribavirin was nearly 10 times higher in the 26M genome than in the mutant G64R virus genome. Furthermore, random mutations acquired in the 2C coding regions of 26M and G64N conferred resistance to growth inhibition in the presence of 0.5 mM guanidine, whereas the G64R and G64T mutant virus populations remained susceptible to growth inhibition by 0.5 mM guanidine. Interestingly, a S264L mutation identified in the 3D coding region of 26M after ribavirin selection was also associated with both ribavirin-resistant and high replication fidelity phenotypes. These findings are consistent with the hypothesis that the 3D-G64R, 3D-G64T, and 3D-S264L mutations confer resistance upon HEV71 to the antiviral mutagen ribavirin, coupled with a high replication fidelity phenotype during growth in cell culture.\"],\"doi\":[\"10.1371/journal.ppat.1009929\",\"10.1073/pnas.1811345115\",\"10.1099/jgv.0.000682\",\"10.1128/JVI.00078-16\",\"10.1128/AAC.01073-16\",\"10.1099/jgv.0.000316\",\"10.1038/ncomms5794\",\"10.1093/jac/dku209\",\"10.1128/JVI.00289-14\",\"10.1128/JVI.03594-13\",\"10.1016/j.bbrc.2013.12.071\",\"10.1016/j.antiviral.2013.07.008\",\"10.1128/JVI.02139-12\"],\"index\":[35,229,384,443,449,539,676,702,743,758,771,822,905],\"key\":[true,true,true,true,true,true,true,true,true,true,true,true,true],\"processed_abstract\":[\"remdesivir rdv broadly act nucleoside analogue fda approve small molecule antiviral treatment covid-19 patient date report identify sars-cov-2 rdv resistance patient animal model vitro select drug-resistant viral population serially passage sars-cov-2 vitro presence rdv use high throughput sequencing identify single mutation rna-dependent rna polymerase nsp12 residue conserve coronaviruse independently evolve population display decrease rdv sensitivity introduction nsp12 e802d mutation sars-cov-2 reverse genetic backbone confirm role decrease rdv sensitivity vitro substitution e802 affect viral replication activity alternate nucleoside analogue eidd2801 affect virus fitness competition assay analysis globally circulate sars-cov-2 variant 800,000 sequence evidence widespread transmission rdv-resistant mutant surprisingly observe excess substitution spike correspond site identify emerge sars-cov-2 variant concern i.e. h69 e484 n501 h655 indicate arise vitro absence immune selection identification characterisation drug resistant signature sars-cov-2 genome implication clinical management virus surveillance\",\"favipiravir broad-spectrum antiviral promise treatment influenza virus infection emergence resistance observe antiinfluenza drug date clinical trial laboratory study favipiravir yield resistant virus evolution resistance favipiravir pandemic h1n1 influenza virus laboratory setting find mutation require robust resistance favipiravir demonstrate k229r mutation motif f pb1 subunit influenza virus rna-dependent rna polymerase rdrp confer resistance favipiravir vitro cell culture mutation cost viral fitness fitness restore p653l mutation pa subunit polymerase k229r confer favipiravir resistance rna polymerase influenza virus strain location highly conserve structural feature rdrp suggest rna virus acquire resistance mutation motif f. mutation identify use screen influenza virus-infected patient treat favipiravir emergence resistance\",\"error rate rna-dependent rna polymerase rdrp rna virus important maintain genetic diversity viral adaptation fitness numerous study mutagen-resistant rna virus variant display amino acid mutation rdrp replicase subunit turn exhibit altered fidelity phenotype affect viral fitness adaptability pathogenicity st. louis encephalitis virus slev like close relative west nile virus mosquito-borne flavivirus ability cause neuroinvasive disease human describe successful generation multiple ribavirin-resistant population contain share amino acid mutation slev rdrp e416 k e416 k mutant display resistance antiviral t-1106 rna mutagen similar ribavirin structural modelling e416 k polymerase mutation indicate location pinky finger domain rdrp distant active site deep sequencing e416 k mutant reveal low genetic diversity wild-type slev growth vertebrate invertebrate cell phenotypic characterization e416 k mutant display similar increase replication mammalian cell modest attenuation mosquito cell consistent previous work west nile virus high-fidelity variant addition attenuation limited mosquito cell functional rna interference response suggest impaired capacity escape rna interference contribute attenuation high-fidelity variant result provide increase evidence rna mutagen resistance arise modulation rdrp insight consequence altered fidelity flavivirus\",\"rna recombination important formation picornavirus specie group ongoing evolution virus specie group study examine structure function polymerase 3d(pol relate rna recombination recombination occur nascent rna product exchange viral rna template rna replication recombination natural aspect picornavirus replication hypothesize feature 3d(pol exist facilitate rna recombination furthermore reason alanine substitution mutation disrupt 3d(pol)-rna interaction polymerase elongation complex increase and/or decrease magnitude recombination find l420a mutation 3d(pol decrease frequency rna recombination alanine substitution site 3d(pol increase frequency recombination 3d(pol leu420 chain interact ribose nascent rna product 3 nucleotide active site polymerase notably l420a mutation reduce recombination render virus susceptible inhibition ribavirin coincident accumulation ribavirin-induced g\\u2192a c\\u2192u mutation viral rna conclude 3d(pol leu420 critically important rna recombination rna recombination contribute ribavirin resistance\",\"enterovirus 71 ev-a71 major causative pathogen hand foot mouth disease hfmd epidemic antiviral therapy currently available treat ev-a71 infection select report enterovirus inhibitor suramin itraconazole itz gw5074 rupintrivir favipiravir different mechanism action test ability inhibit ev-a71 replication combination select compound anti-ev-a71 activity cell culture combination rupintrivir itz favipiravir synergistic combination rupintrivir suramin additive combination suramin favipiravir exert strong synergistic antiviral effect observe synergy cytotoxicity significant increase cytotoxicity compound use combination test dose investigate potential inhibitory mechanism favipiravir enterovirus favipiravir-resistant ev-a71 variant independently select carry s121n mutation finger subdomain 3d polymerase reverse engineering 3d s121n mutation infectious clone ev-a71 confirm resistant phenotype virus resistant itz favipiravir remain susceptible inhibitor notably combine itz rupintrivir prevent development itz-resistant variant result provide rational basis design combination regimen use treatment ev-a71 infection\",\"quasispecie diversity rna virus mainly determine fidelity rna-dependent rna polymerase rdrp viral rna replication certain amino acid residue play important role determine fidelity residue substitute amino acid produce virus strain high fidelity study amino acid substitution a283 t h421y rdrp porcine reproductive respiratory syndrome virus prrsv identify selection ribavirin preliminary datum substitution involve confer prrsv property increase ribavirin resistance restricted quasispecie diversity result indicate amino acid residue ala283 his421 play crucial role prrsv replication affect fidelity rdrp result important implication understand molecular mechanism prrsv evolution pathogenicity develop safer modify live-attenuated vaccine mlv prrsv\",\"genetic diversity influenza virus iav acquire error-prone rna-dependent rna polymerase rdrp genetic reassortment enable perpetuation iav human epidemic pandemic assess biological significance genetic diversity acquire rdrp characterize iav fidelity variant derive passage seasonal h3n2 virus presence ribavirin purine analogue increase guanosine-to-adenosine mutation demonstrate single pb1-v43i mutation increase selectivity guanosine a/wuhan/359/95 h3n2 a/vietnam/1203/04 h5n1 virus h5n1 pb1-v43i-recombinant virus replicate comparable titre wild-type virus vitro mouse lung decrease viral population diversity day 3 post inoculation associate tenfold reduce lethality neurotropism mouse apply fidelity variant reduce mutational frequency provide direct experimental evidence role genetic diversity iav pathogenesis\",\"t-705 know favipiravir small-molecule inhibitor currently clinical development treatment influenza virus infection molecule inhibit replication broad spectrum rna virus objective study investigate antiviral effect favipiravir virus chikv replication contribute unravel molecular mechanism action virus\",\"screen ribavirin resistance novel high-fidelity variant human enterovirus 71 ev71 single amino acid change l123f rna-dependent rna polymerase rdrp 3d identify base crystal structure ev71 rdrp l123 locate entrance rna template binding channel form fidelity checkpoint ev71 rdrp-l123f variant generate progeny guanidine resistance assay virus population low mutation frequency cell culture passage high replication fidelity compare wild-type virus growth defect vivo infection far reveal high-fidelity mutation l123f g64r previously report negatively impact ev71 fitness greatly reduce viral pathogenicity ag129 mouse interestingly variant double mutation rg/b4-g64r/l123f rg/b4 ev71 b4 virus construct reverse genetic [rg])showed high fidelity vitro virulence vivo single mutant 50 lethal dose ld50 double mutant increase 500 time compare ld50 wild-type rg/b4 mouse result indicate high-fidelity variant exhibit attenuate pathogenic phenotype vivo offer promise live attenuate ev71 vaccine\",\"mutagenic nucleoside analogue use isolate rna virus high-fidelity rna-dependent rna polymerase rdrp variant majority attenuate vivo attenuate foot-and-mouth disease virus fmdv high-fidelity rdrp variant isolate correlation rdrp fidelity virulence remain unclear mutagen ribavirin use select ribavirin-resistant population fmdv 4 amino acid substitution d5n a38v m194i m296v identify rdrp-coding region population single combined mutagenesis use reverse genetic system generate direct experimental evidence rescue d5n a38v damm mutant m194i m296v mutant high-fidelity rdrp variant mutagen resistance assay reveal high replication fidelity associate higher-level resistance ribavirin addition significantly attenuate fitness virulence phenotype observe d5n a38v damm mutant base systematic quantitative analysis fidelity virulence conclude high replication fidelity associate attenuate virus datum suggest result restricted quasispecie diversity compromise adaptability virulence rna virus population modulation replication fidelity attenuate virulence represent general strategy rational design new type live attenuate vaccine strain\",\"influenza virus pb1 protein function catalytic subunit viral rna-dependent rna polymerase contain highly conserve motif rna-dependent rna polymerase putative nucleotide-binding site pb1 bind viral genomic rna replicative intermediate promoter region detail function interplay functional domain clarify structure function pb1 clarify study analyze function pb1 subunit sense nucleotide recognition use ribavirin nucleoside analog inhibit viral rna synthesis rna virus include influenza virus screen ribavirin-resistant pb1 mutant randomly mutate pb1 cdna library use mini-replicon assay identify single mutation amino acid position 27 pb1 important residue nucleotide recognition\",\"screen rna mutagen-resistant foot-and-mouth disease virus fmdv strain isolate fmdv mutant rna-dependent rna polymerase rdrp r84h substitution mutant select mutagenic pressure 5-fluorouracil 5-fu resistant 5-fu rna mutagen 5-azacytidine ribavirin suggest rdrp r84h mutant high fidelity variant subsequently increase fidelity mutant verify analysis mutation frequency reveal 1.4-fold enhancement rdrp fidelity compare wild-type virus study indicate r84h mutant exhibit slightly increase fitness vitro virulence reduce suckle mouse result indicate increase rdrp fidelity correlate reduce virus fitness virus attenuation isolate r84h mutant provide new platform examine evolutionary dynamic fidelity-changing rna virus mutagen resistance fitness virulence\",\"animal model ribavirin-resistant g64s mutation 3d polymerase high replication fidelity couple attenuate virulence describe effect mutagenesis human enterovirus 71 hev71 3d polymerase ribavirin resistance replication fidelity seven substitution introduce amino acid position 3d-g64 hev71 full-length infectious cdna clone 26 m viable clone-derived virus population rescue g64n g64r g64 t mutant cdna clone clone-derived g64r g64 t mutant virus population resistant growth inhibition presence 1,600 \\u03bcm ribavirin growth parental 26 m g64n mutant virus inhibit presence 800 \\u03bcm ribavirin nucleotide sequencing 2c 3d coding region reveal rate random mutagenesis 13 passage presence 400 \\u03bcm ribavirin nearly 10 time high 26 m genome mutant g64r virus genome furthermore random mutation acquire 2c coding region 26 m g64n confer resistance growth inhibition presence 0.5 mm guanidine g64r g64 t mutant virus population remain susceptible growth inhibition 0.5 mm guanidine interestingly s264l mutation identify 3d coding region 26 m ribavirin selection associate ribavirin-resistant high replication fidelity phenotype finding consistent hypothesis 3d-g64r 3d-g64 t 3d-s264l mutation confer resistance hev71 antiviral mutagen ribavirin couple high replication fidelity phenotype growth cell culture\"],\"title\":[\"In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.\",\"The mechanism of resistance to favipiravir in influenza.\",\"Mutagen resistance and mutation restriction of St. Louis encephalitis virus.\",\"Poliovirus Polymerase Leu420 Facilitates RNA Recombination and Ribavirin Resistance.\",\"In Vitro Assessment of Combinations of Enterovirus Inhibitors against Enterovirus 71.\",\"Amino acid residues Ala283 and His421 in the RNA-dependent RNA polymerase of porcine reproductive and respiratory syndrome virus play important roles in viral ribavirin sensitivity and quasispecies diversity.\",\"Generation and characterization of influenza A viruses with altered polymerase fidelity.\",\"Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.\",\"Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice.\",\"Ribavirin-resistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence.\",\"Involvement of the N-terminal portion of influenza virus RNA polymerase subunit PB1 in nucleotide recognition.\",\"An increased replication fidelity mutant of foot-and-mouth disease virus retains fitness in vitro and virulence in vivo.\",\"Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture.\"],\"x_tsne\":{\"__ndarray__\":\"FFkxwT+jD8JxyozB5dl2wSIqQsFePobBAW+SwVtjGcIi8InBF5eRwW/fesFQ95TBIh6FwQ==\",\"dtype\":\"float32\",\"order\":\"little\",\"shape\":[13]},\"y\":[\"6\",\"18\",\"8\",\"8\",\"8\",\"8\",\"8\",\"18\",\"8\",\"8\",\"8\",\"8\",\"8\"],\"y_tsne\":{\"__ndarray__\":\"Sbg0QqHKrEGhx8xBfYfBQbrulEHPmcpBbvK7QeyUsEExjcFBNELRQQwOzUHcq89BqcS3QQ==\",\"dtype\":\"float32\",\"order\":\"little\",\"shape\":[13]}},\"selected\":{\"id\":\"1342\"},\"selection_policy\":{\"id\":\"1341\"}},\"id\":\"1302\",\"type\":\"ColumnDataSource\"},{\"attributes\":{\"data\":{\"abstract\":[\"Treatment of HCV infection with peginterferon and ribavirin results in a low sustained virologic response rate, but has a number of undesirable adverse effects. Direct-acting antivirals (DAAs) offer a high efficacy, low risk, and a short treatment time. However, the existence of resistance-associated mutations, particularly in the NS5B polymerase, can attenuate the efficacy of DAAs. The objective of this study was to identify amino acid changes in the NS5B gene linked to DAA resistance in treatment-naive Vietnamese chronic hepatitis C patients.\",\"The first Polish recommendations regarding the management of patients with COVID-19 were published by the Polish Society of Epidemiologists and Infectiologists (PTEiLChZ) on March 31, 2020, and the last annex was dated November 12, 2021. The ongoing state of pandemic, the emergence of new variants of the virus, and the availability of new drugs necessitate their updating. Changes introduced in the current version of recommendations for the management of COVID-19 comprised the possibility of using remedesivir in an outpatient setting, previously reserved for inpatient treatment, as well as other antiviral drugs-molnupiravir and nirmatrelvir / ritonavir. We revised the possibility of using monoclonal antibodies due to the resistance of the currently dominant Omicron variant. Anakinra, an antagonist of interleukin 1 receptors, has been added as a treatment option in advanced stages of the disease, and the recommended daily dose of glucocorticosteroids used in the most severe forms of COVID-19 has been increased. Information on vaccination and pre-exposure prophylaxis in specific populations has also been updated.\",\"The disease yellow fever was prevented by two live attenuated vaccines, strains 17D and French neurotropic vaccine (FNV), derived by serial passage of wild-type (WT) strains Asibi and French Viscerotropic virus (FVV), respectively. Both 17D and FNV displayed decreased genetic diversity and resistance to the antiviral Ribavirin compared to their WT parental strains, which are thought to contribute to their attenuated phenotypes. Subsequent studies found that only a few passages of WT strain FVV in HeLa cells resulted in an attenuated virus. In the current study, the genome sequence of FVV following five passages in HeLa cells (FVV HeLa p5) was determined through Next Generation Sequencing (NGS) with the aim to investigate the molecular basis of viral attenuation. It was found that WT FVV and FVV HeLa p5 virus differed by five amino acid substitutions: E-D155A, E-K331R, E-I412V, NS2A-T105A, and NS4B-V98I. Surprisingly, the genetic diversity and Ribavirin resistance of the FVV HeLa p5 virus were not statistically different to WT parent FVV. These findings suggest that while FVV HeLa p5 is attenuated, this is not dependent on a high-fidelity replication complex, characterized by reduced genetic diversity or increased Ribavirin stability, as seen with FNV and 17D vaccines.\",\"SARS-CoV-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. We present a case of an immunocompromised patient with acquired B-cell deficiency who developed an indolent, protracted course of SARS-CoV-2 infection. Remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. Whole genome sequencing identified a mutation, E802D, in the nsp12 RNA-dependent RNA polymerase, which was not present in pre-treatment specimens. In vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir IC50 but resulted in a fitness cost in the absence of remdesivir. Sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. Although the fitness cost observed in vitro may limit the risk posed by E802D, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with SARS-CoV-2 infection.\",\"Hepatitis E virus (HEV) is an important cause of viral hepatitis worldwide and there is currently no FDA-approved anti-HEV drug. The commonly used drug ribavirin (RBV) could not achieve viral clearance in all patients and can induce drug resistance. Recent studies showed sofosbuvir (SOF) can inhibit HEV replication in vitro and has add-on effect when combined with RBV, but the clinical effect of SOF against HEV infection remains controversial and the dosage of SOF warrants further exploration. In this study, a rabbit model for acute HEV infection was used to evaluate the effect of SOF at different doses against HEV genotype 3 and 4, and to compare the antiviral effect of SOF-plus-RBV therapy with RBV monotherapy. Virological parameters on fecal, serological and intrahepatic level were tested by real-time PCR and ELISA. Liver function tests and histopathological assays were performed. Both 200 mg/d and 300 mg/d SOF treatment inhibits HEV replication with relieved liver inflammation and declined levels of fecal HEV RNA and antigenemia. 300 mg/d SOF eliminated HEV replication while a short viral rebound was observed after 200 mg/d SOF treatment. The SOF-plus-RBV therapy also showed stronger anti-HEV effect than RBV monotherapy. Our study suggests that high dose of SOF showed anti-HEV effect in the rabbit model. Moreover, the de novo SOF-plus-RBV therapy which eliminated acute HEV infection more efficiently than RBV monotherapy may serve as an alternative treatment strategy but warrants further preclinical and clinical study.\",\"Hepatitis C viral (HCV) infection is a major clinical burden globally. Pegylated IFN-\\u03b1-2a (PEG-IFN-\\u03b1-2a) with ribavirin (RIB) therapy induces an array of cellular antiviral responses including dsRNA kinases (PKR), chemokines and cytokines to tackle the HCV infection. However, many HCV patients develop resistance to PEG-IFN/RIB therapy rendering the theray ineffective.\",\"The antiviral efficacy of remdesivir in COVID-19 hospitalized patients remains controversial.\",\"Combinations of direct-acting antivirals are needed to minimize drug resistance mutations and stably suppress replication of RNA viruses. Currently, there are limited therapeutic options against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and testing of a number of drug regimens has led to conflicting results. Here, we show that cobicistat, which is an FDA-approved drug booster that blocks the activity of the drug-metabolizing proteins cytochrome P450-3As (CYP3As) and P-glycoprotein (P-gp), inhibits SARS-CoV-2 replication. Two independent cell-to-cell membrane fusion assays showed that the antiviral effect of cobicistat is exerted through inhibition of spike protein-mediated membrane fusion. In line with this, incubation with low-micromolar concentrations of cobicistat decreased viral replication in three different cell lines including cells of lung and gut origin. When cobicistat was used in combination with remdesivir, a synergistic effect on the inhibition of viral replication was observed in cell lines and in a primary human colon organoid. This was consistent with the effects of cobicistat on two of its known targets, CYP3A4 and P-gp, the silencing of which boosted the in vitro antiviral activity of remdesivir in a cobicistat-like manner. When administered in vivo to Syrian hamsters at a high dose, cobicistat decreased viral load and mitigated clinical progression. These data highlight cobicistat as a therapeutic candidate for treating SARS-CoV-2 infection and as a potential building block of combination therapies for COVID-19. IMPORTANCE The lack of effective antiviral treatments against SARS-CoV-2 is a significant limitation in the fight against the COVID-19 pandemic. Single-drug regimens have so far yielded limited results, indicating that combinations of antivirals might be required, as previously seen for other RNA viruses. Our work introduces the drug booster cobicistat, which is approved by the FDA and typically used to potentiate the effect of anti-HIV protease inhibitors, as a candidate inhibitor of SARS-CoV-2 replication. Beyond its direct activity as an antiviral, we show that cobicistat can enhance the effect of remdesivir, which was one of the first drugs proposed for treatment of SARS-CoV-2. Overall, the dual action of cobicistat as a direct antiviral and a drug booster can provide a new approach to design combination therapies and rescue the activity of compounds that are only partially effective in monotherapy.\",\"The COVID-19 pandemic continues to threaten healthcare systems worldwide due to the limited access to vaccines, suboptimal treatment options, and the continuous emergence of new and more transmissible SARS-CoV-2 variants. Reverse-genetics studies of viral genes and mutations have proven highly valuable in advancing basic virus research, leading to the development of therapeutics. We developed a functional and highly versatile full-length SARS-CoV-2 infectious system by cloning the sequence of a COVID-19 associated virus isolate (DK-AHH1) into a bacterial artificial chromosome (BAC). Viruses recovered after RNA-transfection of in vitro transcripts into Vero E6 cells showed growth kinetics and remdesivir susceptibility similar to the DK-AHH1 virus isolate. Insertion of reporter genes, green fluorescent protein, and nanoluciferase into the ORF7 genomic region led to high levels of reporter activity, which facilitated high throughput treatment experiments. We found that putative coronavirus remdesivir resistance-associated substitutions F480L and V570L-and naturally found polymorphisms A97V, P323L, and N491S, all in nsp12-did not decrease SARS-CoV-2 susceptibility to remdesivir. A nanoluciferase reporter clone with deletion of spike (S), envelope (E), and membrane (M) proteins exhibited high levels of transient replication, was inhibited by remdesivir, and therefore could function as an efficient non-infectious subgenomic replicon system. The developed SARS-CoV-2 reverse-genetics systems, including recombinants to modify infectious viruses and non-infectious subgenomic replicons with autonomous genomic RNA replication, will permit high-throughput cell culture studies-providing fundamental understanding of basic biology of this coronavirus. We have proven the utility of the systems in rapidly introducing mutations in nsp12 and studying their effect on the efficacy of remdesivir, which is used worldwide for the treatment of COVID-19. Our system provides a platform to effectively test the antiviral activity of drugs and the phenotype of SARS-CoV-2 mutants.\",\"Here, we report six cases of spontaneous pneumothorax and pneumomediastinitis in patients with COVID-19 in Iran, which were treated with different drugs such as hydroxychloroquine, sofosbuvir, atazanavir, and remdesivir as antiviral agents. Despite the differences in the type of drugs, pneumothorax occurred in all patients.\",\"Coronavirus disease 2019 (COVID-19) represents an unmet clinical need, due to a high mortality rate, rapid mutation rate in the virus, increased chances of reinfection, lack of effectiveness of repurposed drugs and economic damage. COVID-19 pandemic has created an urgent need for effective molecules. Clinically proven efficacy and safety profiles have made favipiravir (FVP) and remdesivir (RDV) promising therapeutic options for use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Even though both are prodrug molecules with an antiviral role based on a similar mechanism of action, differences in pharmacological, pharmacokinetic and pharmacotoxicological mechanisms have been identified. The present study aims to provide a comprehensive comparative assessment of FVP and RDV against SARS-CoV-2 infections, by centralizing medical data provided by significant literature and authorized clinical trials, focusing on the importance of a better understanding of the interactions between drug molecules and infectious agents in order to improve the global management of COVID-19 patients and to reduce the risk of antiviral resistance.\",\"According to pivotal clinical trials, cure rates for sofosbuvir-based antiviral therapy exceed 96%. Treatment failure is usually assumed to be because of virological resistance-associated substitutions or clinical risk factors, yet the role of patient-specific genetic factors has not been well explored. We determined if patient-specific genetic factors help predict patients likely to fail sofosbuvir treatment in real-world treatment situations.\",\"A key element for the prevention and management of coronavirus disease 2019 is the development of effective therapeutics. Drug combination strategies offer several advantages over monotherapies. They have the potential to achieve greater efficacy, to increase the therapeutic index of drugs and to reduce the emergence of drug resistance. We assessed the in vitro synergistic interaction between remdesivir and ivermectin, both approved by the US Food and Drug Administration, and demonstrated enhanced antiviral activity against severe acute respiratory syndrome coronavirus-2. Whilst the in vitro synergistic activity reported here does not support the clinical application of this combination treatment strategy due to insufficient exposure of ivermectin in vivo, the data do warrant further investigation. Efforts to define the mechanisms underpinning the observed synergistic action could lead to the development of novel treatment strategies.\",\"Modified nucleosides show therapeutic promise for antiviral therapies. However, issues including the emergence of drug resistance, toxicity, and coinfections have posed new challenges for nucleoside-based antiviral drug discovery, particularly in the era of the coronavirus disease 2019 (COVID-19) pandemic. Chemical manipulation could impact the antiviral potency, safety, and drug resistance of nucleosides. Generally, modified nucleosides are difficult to recognize by intracellular important enzymes as substrates and thus exhibit low toxicity. 4'-Modified nucleosides represent an important subclass of modified nucleosides for antiviral therapies. To prevent the occurrence of drug resistance, 4'-modified nucleosides should have 3'-OH, which should also be chemically unreactive for proviral DNA biosynthesis. The absence of 3'-OH may explain the occurrence of drug resistance for censavudine. The introduction of 4'-substituents improves enzymatic and acidic stability and makes the nucleosides more lipophilic, thus improving cell permeability and bioavailability. Steric hindrance between the 4'-substituent and 3'-OH changes the furanose conformation to the 3'-endo type, in which the oxygen lone pair on the furanose ring could not form an oxocarbonium ion for glycolysis. Currently, seven 4'-modified nucleoside drug candidates such as azvudine (also known as FNC), islatravir, censavudine, balapiravir, lumicitabine, AL-335, and 4-azidothymidine have progressed into clinical stages for treating viral infections. Of note, FNC was officially approved by NMPA in July 2021 for use in adult patients with high HIV-1 virus loads (nos. H20210035 and H20210036), providing an alternative therapeutic for patients with HIV-1. The long-term cellular retention of FNC suggests its potential as a long-lasting pre-exposure prophylaxis (PrEP) agent for preventing HIV-1 infection. Mechanistically, FNC not only inhibited HIV-1 reverse transcription and replication but also restored A3G expression in peripheral blood CD4[+] T cells in HIV-1 patients receiving FNC. The 4'-azido group in azvudine stabilizes the 3'-C-endo (north) conformation by steric effects and the formation of an intramolecular hydrogen bond with the 3'-OH group, thus decreasing the nucleophilicity of 3'-OH. The north conformation may also enhance the phosphorylation efficiency of FNC by cellular kinases. Encouragingly, FNC, islatravir, and balapiravir show promise for the treatment of coronaviruses, of which FNC has advanced to phase 3 clinical trials in different countries to treat patients with COVID-19 (clinical trial numbers: NCT04668235 and NCT04425772). FNC cured the COVID-19 disease in almost all patients and showed better therapeutic efficacy than remdesivir. In this Account, we provide an overview of 4'-modified nucleoside analogs in clinical stages for antiviral therapies, highlighting the drug discovery strategies, structure-activity relationship studies, and preclinical/clinical studies and also give our perspectives on nucleoside-based antiviral drug discovery.\",\"Hepatotropic viruses naturally have narrow host and tissue tropisms, challenging the development of robust experimental models. The advent of organoid technology provides a unique opportunity for moving the field forward. Here, we demonstrate that three-dimensional cultured organoids from fetal and adult human liver with cholangiocyte or hepatocyte phenotype support hepatitis E virus (HEV) replication. Inoculation with infectious HEV particles demonstrates that human liver\\u2013derived organoids support the full life cycle of HEV infection. By directing organoids toward polarized monolayers in a transwell system, we observed predominantly apical secretion of HEV particles. Genome-wide transcriptomic and tRNAome analyses revealed robust host responses triggered by viral replication. Drug screening in organoids identified brequinar and homoharringtonine as potent HEV inhibitors, which are also effective against the ribavirin resistance variant harboring G1634R mutation. Thus, successful recapitulation of HEV infection in liver-derived organoids shall facilitate the study of virus-host interactions and development of antiviral therapies.\",\"Massive usage of antiviral compounds during a pandemic creates an ideal ground for emergence of resistant strains. Remdesivir, a broad-spectrum inhibitor of the viral RNA-dependent RNA polymerase (RdRp), was extensively prescribed under emergency use authorization during the first 18 months of the COVID19 pandemic, before randomized controlled trials showed poor efficacy in hospitalized patients. RdRp mutations conferring resistance to remdesivir are well known from in vitro studies, and the huge SARS-CoV-2 sequencing effort during the ongoing COVID19 pandemic represents an unprecedented opportunity to assess emergence and fitness of antiviral resistance in vivo. We mined the GISAID database to extrapolate the frequency of remdesivir escape mutations. Our analysis reveals very low levels of remdesivir resistance worldwide despite massive usage.\",\"Circulation of avian influenza A viruses in poultry is a public health concern because these viruses may cause severe disease in humans and have the potential to become more transmissible among humans. Monitoring the susceptibility of these viruses to antivirals is important for influenza pandemic preparedness. However, information about their antiviral susceptibility is limited. Here, we determined the susceptibilities of avian influenza A(H5N1), A(H5N2), A(H5N8), A(H7N7), A(H7N9), A(H9N1), and A(H9N2) viruses isolated in Japan to the antivirals approved for use there: the M2 inhibitor amantadine; the neuraminidase inhibitors oseltamivir, peramivir, zanamivir, and laninamivir; and the RNA polymerase inhibitors baloxavir and favipiravir. Genotypic methods that detect amino acid substitutions associated with antiviral resistance and phenotypic methods that assess viral susceptibility to drugs revealed that these avian influenza A viruses are susceptible to neuraminidase inhibitors and RNA polymerase inhibitors. These results suggest that the neuraminidase inhibitors and the RNA polymerase inhibitors currently approved in Japan could be a treatment option against influenza A virus infections in humans.\",\"Since its discovery in 1989, the road to a cure for hepatitis C virus (HCV) has been slow, but most patients can now expect to achieve a sustained virological response (SVR). With direct-acting antiviral (DAA) combination therapies such as glecaprevir/pibrentasvir and velpatasvir/sofosbuvir, 98% of patients successfully eradicate the virus, even if previous treatments failed or if resistance-associated substitutions (RASs) are present. Adverse events are rare or mild, and patients with compensated cirrhosis and other co-morbidities are often eligible for treatment. However, a small number of patients fail to eradicate the virus even after retreatment. The cause of failure is mainly due to emergence of NS5A P32 deletion mutants after initial DAA therapy in genotype 1b patients, although the reason is unknown for some patients. Alternative therapies that do not rely on NS5A inhibitors, such as sofosbuvir plus ribavirin, can be attempted in these patients. While scaled-up treatment efforts present a challenge, another problem is that many carriers are unaware of their infection. Long-term damage to the liver becomes irreversible, and patients who are not diagnosed in time can develop liver cancer or liver failure even after eliminating the virus. The long-term costs of treatment of advanced liver disease in undiagnosed patients relative to the immediate costs of DAA therapy should be considered. As no vaccine is yet available, eventual elimination of the virus requires identifying and treating undiagnosed cases and screening of high-risk populations such as injection drug users and men who have sex with men and female sex workers.\",\"The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global crisis. Clinical candidates with high efficacy, ready availability, and that do not develop resistance are in urgent need. Despite that screening to repurpose clinically approved drugs has provided a variety of hits shown to be effective against SARS-CoV-2 infection in cell culture, there are few confirmed antiviral candidates in vivo. In this study, 94 compounds showing high antiviral activity against SARS-CoV-2 in Vero E6 cells were identified from 2,580 FDA-approved small-molecule drugs. Among them, 24 compounds with low cytotoxicity were selected, and of these, 17 compounds also effectively suppressed SARS-CoV-2 infection in HeLa cells transduced with human ACE2. Six compounds disturb multiple processes of the SARS-CoV-2 life cycle. Their prophylactic efficacies were determined in vivo using Syrian hamsters challenged with SARS-CoV-2 infection. Seven compounds reduced weight loss and promoted weight regain of hamsters infected not only with the original strain but also the D614G variant. Except for cisatracurium, six compounds reduced hamster pulmonary viral load, and IL-6 and TNF-\\u03b1 mRNA when assayed at 4 d postinfection. In particular, sertraline, salinomycin, and gilteritinib showed similar protective effects as remdesivir in vivo and did not induce antiviral drug resistance after 10 serial passages of SARS-CoV-2 in vitro, suggesting promising application for COVID-19 treatment.\",\"Frequent mumps outbreaks in vaccinated populations and the occurrence of neurological complications (e.g., aseptic meningitis or encephalitis) in patients with mumps indicate the need for the development of more efficient vaccines as well as specific antiviral therapies. RNA viruses are genetically highly heterogeneous populations that exist on the edge of an error threshold, such that additional increases in mutational burden can lead to extinction of the virus population. Deliberate modulation of their natural mutation rate is being exploited as an antiviral strategy and a possibility for rational vaccine design. The aim of this study was to examine the ability of ribavirin, a broad-spectrum antiviral agent, to introduce mutations in the mumps virus (MuV) genome and to investigate if resistance develops during long-term in vitro exposure to ribavirin. An increase in MuV population heterogeneity in the presence of ribavirin has been observed after one passage in cell culture, as well as a bias toward C-to-U and G-to-A transitions, which have previously been defined as ribavirin-related. At higher ribavirin concentration, MuV loses its infectivity during serial passaging and does not recover. At low ribavirin concentration, serial passaging leads to a more significant increase in population diversity and a stronger bias towards ribavirin-related transitions, independently of viral strain or cell culture. In these conditions, the virus retains its initial growth capacity, without development of resistance at a whole-virus population level.\",\"Several clinical trials started during the COVID-19 pandemic to discover effective therapeutics led to identify a few candidates from the major clinical trials. However, in the past several months, quite a few SARS-CoV-2 variants have emerged with significant mutations. Major mutations in the S-glycoprotein and other parts of the genome have led to the antibody's escape to small molecule-based therapeutic resistance. The mutations in S-glycoprotein trigger the antibody escape/resistance, and mutations in RdRp might cause remdesivir resistance. The article illustrates emerging mutations that have resulted in antibody escape to therapeutics resistance. In this direction, the article illustrates presently developed neutralizing antibodies (with their preclinical, clinical stages) and antibody escapes and associated mutations. Finally, owing to the RdRp mutations, the antiviral small molecules resistance is illustrated.\",\"SARS-CoV-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. We present a case of an immunocompromised patient with acquired B-cell deficiency who developed an indolent, protracted course of SARS-CoV-2 infection. Remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. Whole genome sequencing identified a mutation, E802D, in the nsp12 RNA-dependent RNA polymerase, which was not present in pre-treatment specimens. In vitro experiments demonstrated that the mutation conferred a \\u223c6-fold increase in remdesivir IC50 but resulted in a fitness cost in the absence of remdesivir. Sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. Although the fitness cost observed in vitro may limit the risk posed by E802D, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with SARS-CoV-2 infection.\",\"Human coronavirus NL63 (HCoV-NL63) mainly affects young children and immunocompromised patients, causing morbidity and mortality in a subset of patients. Since no specific treatment is available, this study aims to explore the anti-SARS-CoV-2 agents including favipiravir and remdesivir for treating HCoV-NL63 infection. We first successfully modelled the 3D structure of HCoV-NL63 RNA-dependent RNA polymerase (RdRp) based on the experimentally solved SARS-CoV-2 RdRp structure. Molecular docking indicated that favipiravir has similar binding affinities to SARS-CoV-2 and HCoV-NL63 RdRp with LibDock scores of 75 and 74, respectively. The LibDock scores of remdesivir to SARS-CoV-2 and HCoV-NL63 were 135 and 151, suggesting that remdesivir may have a higher affinity to HCoV-NL63 compared to SARS-CoV-2 RdRp. In cell culture models infected with HCoV-NL63, both favipiravir and remdesivir significantly inhibited viral replication and production of infectious viruses. Overall, remdesivir compared to favipiravir is more potent in inhibiting HCoV-NL63 in cell culture. Importantly, there is no evidence of resistance development upon long-term exposure to remdesivir. Furthermore, combining favipiravir or remdesivir with the clinically used antiviral cytokine interferon-alpha resulted in synergistic effects. These findings provided a proof-of-concept that anti-SARS-CoV-2 drugs, in particular remdesivir, have the potential to be repurposed for treating HCoV-NL63 infection.\",\"The emergence of fast-spreading SARS-CoV-2 mutants has sparked a new phase of COVID-19 pandemic. There is a dire necessity for antivirals targeting highly conserved genomic domains on SARS-CoV-2 that are less prone to mutation. The nsp12, also known as the RNA-dependent RNA-polymerase (RdRp), the core component of 'SARS-CoV-2 replication-transcription complex', is a potential well-conserved druggable antiviral target. Several FDA-approved RdRp 'nucleotide analog inhibitors (NAIs)' such as remdesivir, have been repurposed to treat COVID-19 infections. The NAIs target RdRp protein translation and competitively block the nucleotide insertion into the RNA chain, resulting in the inhibition of viral replication. However, the replication proofreading function of nsp14-ExoN could provide resistance to SARS-CoV-2 against many NAIs. Conversely, the 'non-nucleoside analog inhibitors (NNAIs)' bind to allosteric sites on viral polymerase surface, change the redox state; thereby, exert antiviral activity by altering interactions between the enzyme substrate and active core catalytic site of the RdRp. NNAIs neither require metabolic activation (unlike NAIs) nor compete with intracellular pool of nucleotide triphosphates (NTPs) for anti-RdRp activity. The NNAIs from phytonutrient origin are potential antiviral candidates compared to their synthetic counterparts. Several in-silico studies reported the antiviral spectrum of natural phytonutrient-NNAIs such as Suramin, Silibinin (flavonolignan), Theaflavin (tea polyphenol), Baicalein (5,6,7-trihydroxyflavone), Corilagin (gallotannin), Hesperidin (citrus bioflavonoid), Lycorine (pyrrolidine alkaloid), with superior redox characteristics (free binding energy, hydrogen-bonds, etc.) than antiviral drugs (i.e. remdesivir, favipiravir). These phytonutrient-NNAIs also exert anti-inflammatory, antioxidant, immunomodulatory and cardioprotective functions, with multifunctional therapeutic benefits in the clinical management of COVID-19.\",\"Considering the threat of the COVID-19 pandemic, caused by SARS-CoV-2, there is an urgent need to develop effective treatments. At present, neutralizing antibodies and small-molecule drugs such as remdesivir, the most promising compound to treat this infection, have attracted considerable attention. However, some potential problems need to be concerned including viral resistance to antibody-mediated neutralization caused by selective pressure from a single antibody treatment, the unexpected antibody-dependent enhancement (ADE) effect, and the toxic effect of small-molecule drugs.\",\"The genomic reshuffling, mutagenicity, and high transmission rate of the SARS-CoV-2 pathogen highlights an urgent need for effective antiviral interventions for COVID-19 control. Targeting the highly conserved viral genes and/or gene-encoded viral proteins such as main proteinase (M[pro]), RNA-dependent RNA polymerase (RdRp) and helicases are plausible antiviral approaches to prevent replication and propagation of the SARS-CoV-2 infection. Coronaviruses (CoVs) are prone to extensive mutagenesis; however, any genetic alteration to its highly conserved M[pro] enzyme is often detrimental to the viral pathogen. Therefore, inhibitors that target the M[pro] enzyme could reduce the risk of mutation-mediated drug resistance and provide effective antiviral protection. Several existing antiviral drugs and dietary bioactives are currently repurposed to treat COVID-19. Dietary bioactives from three ayurvedic medicinal herbs, 18 \\u03b2-glycyrrhetinic acid (\\u0394G = 8.86 kcal/mol), Solanocapsine (\\u0394G = 8.59 kcal/mol), and Vasicoline (\\u0394G = 7.34 kcal/mol), showed high-affinity binding to M[pro] enzyme than the native N3 inhibitor (\\u0394G = 5.41 kcal/mol). Flavonoids strongly inhibited SARS-CoV-2 M[pro] with comparable or higher potency than the antiviral drug, remdesivir. Several tannin hydrolysates avidly bound to the receptor-binding domain and catalytic dyad (His41 and Cys145) of SARS-CoV-2 M[pro] through H-bonding forces. Quercetin binding to M[pro] altered the thermostability of the viral protein through redox-based mechanism and inhibited the viral enzymatic activity. Interaction of quercetin-derivatives with the M[pro] seem to be influenced by the 7-OH group and the acetoxylation of sugar moiety on the ligand molecule. Based on pharmacokinetic and ADMET profiles, several phytonutrients could serve as a promising redox nutraceutical for COVID-19 management.\",\"Influenza A virus, the main flu agent, affects billions of people worldwide. Conventional treatments still present limitations related to drug-resistance and severe side effects. As a result, natural product-derived molecules have been increasingly investigated as prospect drug candidates. Therefore, the aim of this study was to investigate the possible anti-flu activity and to evaluate the toxicity and pharmacokinetic parameters, by in silico approaches, of the Schinopsis brasiliensis Engl. phytochemical compounds. Nine phytocompounds and six antiviral drugs (Amantadine, Umifenovir, Favipiravir, Nitazoxanide, Oseltamivir, Zanamivir) were selected for the analyses against four Influenza A proteins: neuraminidase, polymerase basic protein 2, hemagglutinin and M2 ion channel protein. The molecular docking, the predicted antiviral activity, the predicted toxicity and the pharmacokinetics investigations were conducted. The obtained results demonstrated that Syringaresinol and Cycloartenone display promising in silico antiviral activity (binding energy < 5.0 and \\u2265 9.0 kcal/mol) and safety (low toxicity than commercial anti-flu drugs). Overall, this study corroborated the hypothesis that S. brasiliensis barks extract has a biological activity against Influenza A virus. Additionally, Syringaresinol and Cycloartenone have multiple targets in Influenza A virus and showed themselves as the most promising phytocompounds to be isolated and considered for the therapeutic arsenal against the flu.\",\"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of Coronavirus Disease 2019 (COVID-19) pandemic. Despite intensive and global efforts to discover and develop novel antiviral therapies, only Remdesivir has been approved as a treatment for COVID-19. Therefore, effective antiviral therapeutics are still urgently needed to combat and halt the pandemic. Viral RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 demonstrates high potential as a reliable target for the development of antivirals. We previously developed a cell-based assay to assess the efficiency of compounds that target SARS-CoV-2 RdRp, as well as their tolerance to viral exoribonuclease-mediated proof-reading. In our previous study, we discovered that 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides specifically targets the RdRp of both respiratory syncytial virus (RSV) and influenza A virus. Thus, we hypothesize that 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides may also have the ability to inhibit SARS-CoV-2 replication by targeting its RdRp activity. In this research, we test a compound library containing 103 of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides against SARS-CoV-2 RdRp, using our cell-based assay. Among these compounds, the top five candidates strongly inhibit SARS-CoV-2 RdRp activity while exhibiting low cytotoxicity and resistance to viral exoribonuclease. Compound 6-72-2a is the most promising candidate with the lowest EC50 value of 1.41 \\u03bcM and highest selectivity index (CC50/EC50) (above 70.92). Furthermore, our data suggests that 4-46b and 6-72-2a also inhibit the replication of HCoV-OC43 and HCoV-NL63 virus in a dose-dependent manner. Compounds 4-46b and 6-72-2a exhibit EC50 values of 1.13 \\u03bcM and 0.94 \\u03bcM, respectively, on HCoV-OC43 viral replication. However, higher concentrations of these compounds are needed to effectively block HCoV-NL63 replication. Together, our findings successfully identified 4-46b and 6-72-2a as promising inhibitors against SARS-CoV-2 RdRp.\",\"Plant elicitors are a class of plant protection agents that can stimulate plant immunity against phytopathogen without a potential resistance problem. In searching for novel plant elicitor candidates, a series of novel N-(2-phenyl-3-pyridyl) thiadiazole/isothiazole carboxamide analogs were designed and synthesized.\",\"Hepatitis C virus (HCV) was first discovered in 1989, and patients infected with HCV were initially treated with interferon (IFN) monotherapy. In the 2000s, pegylated IFN combined with ribavirin was the mainstay of therapy for infected patients, but the sustained virologic response (SVR) rate was less than 50% for patients with HCV genotype 1. To further improve the therapeutic effect, direct-acting antiviral (DAA) was developed, and combination therapy with DAA and IFN has been available since 2011. In addition, IFN-free DAA therapy became available in 2014, and SVR was achieved in more than 95% of patients with chronic hepatitis and compensated cirrhosis. Thus, in just 30 years since the discovery of HCV, we aim to eliminate HCV in almost all patients. However, there are remaining issues to be addressed. Many of the patients who achieved SVR with DAA therapy had advanced liver fibrosis, and it is necessary to verify to what extent DAA therapy improves their prognosis in terms of liver function, hepatocellular carcinoma occurrence, and mortality. Resistance-associated substitutions can cause failure of DAA therapy, and the search for an effective therapy for high-level resistant viruses such as P32 deletion is particularly important. DAA therapy was approved for use in patients with decompensated cirrhosis in Japan in 2019, which is an unmet need so far. It is also important to verify the efficacy and safety in real-world settings. The World Health Organization aims to eliminate HCV by 2030, and Japan must tackle its remaining issues to achieve this goal.\",\"This study aimed to assess the correlation between the genotyping of interleukin-10 (IL-10 polymorphism rs 1800871) and the incidence hepatocellular carcinoma (HCC) among patients with hepatitis C virus (HCV) treated with direct acting antivirals (DAAs).\",\"The therapeutic targeting of the nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp) of the Hepatitis C Virus (HCV) with nucleotide analogs led to a deep understanding of this enzymes structure, function and substrate specificity. Unlike previously studied DNA polymerases including the reverse transcriptase of Human Immunodeficiency Virus, development of biochemical assays for HCV RdRp proved challenging due to low solubility of the full-length protein and inefficient acceptance of exogenous primer/templates. Despite the poor apparent specific activity, HCV RdRp was found to support rapid and processive transcription once elongation is initiated in vitro consistent with its high level of viral replication in the livers of patients. Understanding of the substrate specificity of HCV RdRp led to the discovery of the active triphosphate of sofosbuvir as a nonobligate chain-terminator of viral RNA transcripts. The ternary crystal structure of HCV RdRp, primer/template, and incoming nucleotide showed the interaction between the nucleotide analog and the 2'-hydroxyl binding pocket and how an unfit mutation of serine 282 to threonine results in resistance by interacting with the uracil base and modified 2'-position of the analog. Host polymerases mediate off-target toxicity of nucleotide analogs and the active metabolite of sofosbuvir was found to not be efficiently incorporated by host polymerases including the mitochondrial RNA polymerase (POLRMT). Knowledge from studying inhibitors of HCV RdRp serves to advance antiviral drug discovery for other emerging RNA viruses including the discovery of remdesivir as an inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), the virus that causes COVID-19.\",\"A massive vaccination campaign against the global COVID-19 pandemic caused by SARS-CoV-2 virus began worldwide in January 2021. However, studies continue to investigate the most effective and safe drug therapies to manage the various stages of viral infection. It is critical in the therapeutic management of the patient, with ongoing COVID-19 infection, to reduce viral load and replication, and to regulate the generalized hyperinflammatory state caused by the cytokine storm that occurs in the most severe phases. Probably the right drug therapy is represented by the use of different drugs acting in different modalities and on different targets, to avoid also viral drug resistance. In this article, we describe an interesting scientific pharmacological hypothesis arising from the evidence in the literature; we believe that the association of baricitinib/remdesivir/rhACE2, administered at the right time and dose, represents an important pharmacological synergism that can be therapeutically more effective for the treatment of COVID-19 infection than the single administration of drugs and avoid the phenomenon of drug resistance caused by the virus.\",\"Hepatitis C virus (HCV) is one of the major causes of chronic liver disease, as it holds a significant role in developing liver cirrhosis and hepatocellular carcinoma. Combination therapy with Pegaferon and Ribavirin leads to viral clearance of only 50% of patients. During the host antiviral response, protein kinase R (PKR) interacts with eukaryotic translation initiation factor 2 alpha (eIF2\\u03b1), that leads to the inhibition of viral protein synthesis. The viral NS5A protein appears to interfere with this antiviral action, evading the host immune response. However, mutations in the NS5A gene have been observed to render HCV more susceptible to treatment. The aim of this study was to determine the mutations present in the IFN Sensitivity Determining Region (ISDR) and NS5A-PKRbinding domain regions in chronic HCV infected patients before and after therapy.\",\"The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial. We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with standard of care alone in patients admitted to hospital with COVID-19, with indication of oxygen or ventilator support.\",\"The unprecedented 2013-2016 West Africa Ebola outbreak accelerated several medical countermeasures (MCMs) against Ebola virus disease (EVD). Several investigational products (IPs) were used throughout the outbreak but were not conclusive for efficacy results. Only the Randomized Controlled Trial (RCT) on ZMapp was promising but inconclusive. More recently, during the second-largest Ebola outbreak in North Kivu and Ituri provinces, Democratic Republic of the Congo (DRC), four IPs, including one small molecule (Remdesivir), two monoclonal antibody (mAb) cocktails (ZMapp and REGN-EB3) and a single mAb (mAb114), were evaluated in an RCT, the Pamoja Tulinde Maisha (PALM) study. Two products (REGN-EB3 and mAb114) demonstrated efficacy as compared to the control arm, ZMapp. There were remarkably few side effects recorded in the trial. The FDA approved both medications in this scientifically sound study, marking a watershed moment in the field of EVD therapy. These products can be produced relatively inexpensively and can be stockpiled. The administration of mAbs in EVD patients appears to be safe and effective, while several critical knowledge gaps remain; the impact of early administration of Ebola-specific mAbs on developing a robust immune response for future Ebola virus exposure is unknown. The viral mutation escape, leading to resistance, presents a potential limitation for single mAb therapy; further improvements need to be explored. Understanding the contribution of Fc-mediated antibody functions such as antibody-dependent cellular cytotoxicity (ADCC) of those approved mAbs is still critical. The potential merit of combination therapy and post-exposure prophylaxis (PEP) need to be demonstrated. Furthermore, the PALM trial has accounted for 30% of mortality despite the administration of specific treatments. The putative role of EBOV soluble Glycoprotein (sGP) as a decoy to the immune system, the virus persistence, and relapses might be investigated for treatment failure. The development of pan-filovirus or pan-species mAbs remains essential for protection. The interaction between FDA-approved mAbs and vaccines remains unclear and needs to be investigated. In this review, we summarize the efficacy and safety results of the PALM study and review current research questions for the further development of mAbs in pre-exposure or emergency post-exposure use.\",\"Transporters in the human liver play a major role in the clearance of endo- and xenobiotics. Apical (canalicular) transporters extrude compounds to the bile, while basolateral hepatocyte transporters promote the uptake of, or expel, various compounds from/into the venous blood stream. In the present work we have examined the in vitro interactions of some key repurposed drugs advocated to treat COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir), with the key drug transporters of hepatocytes. These transporters included ABCB11/BSEP, ABCC2/MRP2, and SLC47A1/MATE1 in the canalicular membrane, as well as ABCC3/MRP3, ABCC4/MRP4, SLC22A1/OCT1, SLCO1B1/OATP1B1, SLCO1B3/OATP1B3, and SLC10A1/NTCP, residing in the basolateral membrane. Lopinavir and ritonavir in low micromolar concentrations inhibited BSEP and MATE1 exporters, as well as OATP1B1/1B3 uptake transporters. Ritonavir had a similar inhibitory pattern, also inhibiting OCT1. Remdesivir strongly inhibited MRP4, OATP1B1/1B3, MATE1 and OCT1. Favipiravir had no significant effect on any of these transporters. Since both general drug metabolism and drug-induced liver toxicity are strongly dependent on the functioning of these transporters, the various interactions reported here may have important clinical relevance in the drug treatment of this viral disease and the existing co-morbidities.\",\"The antiviral remdesivir has been approved by regulatory bodies such as the European Medicines Agency (EMA) and the US Food and Drug administration (FDA) for the treatment of COVID-19. However, its efficacy is debated and toxicity concerns might limit the therapeutic range of this drug. Computational models that aid in balancing efficacy and toxicity would be of great help. Parametrizing models is difficult because the prodrug remdesivir is metabolized to its active form (RDV-TP) upon cell entry, which complicates dose-activity relationships. Here, we employ a computational model that allows drug efficacy predictions based on the binding affinity of RDV-TP for its target polymerase in SARS-CoV-2. We identify an optimal infusion rate to maximize remdesivir efficacy. We also assess drug efficacy in suppressing both wild-type and resistant strains, and thereby describe a drug regimen that may select for resistance. Our results differ from predictions using prodrug dose-response curves (pseudo-EC50s). We expect that reaching 90% inhibition (EC90) is insufficient to suppress SARS-CoV-2 in the lungs. While standard dosing mildly inhibits viral polymerase and therefore likely reduces morbidity, we also expect selection for resistant mutants for most realistic parameter ranges. To increase efficacy and safeguard against resistance, we recommend more clinical trials with dosing regimens that substantially increase the levels of RDV-TP and/or pair remdesivir with companion antivirals.\",\"With the increasing severity of plant diseases and the emergence of pathogen resistance, there is an urgent need for the development of new efficient and environment-friendly pesticides. Marine natural product (MNP) resources are rich and diverse. Structural simplification based on MNPs is an important strategy to find novel pesticide candidates. In this work, the marine natural product 6\\u2033-debromohamacanthin A (1a) was efficiently prepared and selected as the parent structure. A series of hamacanthin derivatives were designed, synthesized, and studied on the antiviral and antifungal activities. Most of these compounds displayed higher antiviral activities than ribavirin. The antiviral activities of compounds 1a and 13e-13h are similar to or higher than that of ningnanmycin (perhaps the most efficient anti-plant-virus agent). Compound 13h was selected for further antiviral mechanism research via transmission electron microscopy, molecular docking, and fluorescence titration. The results showed that compound 13h could bind to TMV CP and interfere with the assembly process of TMV CP and RNA. In addition, these hamacanthin derivatives also exhibited broad-spectrum inhibitory effects against eight common agricultural pathogens. Compounds 1a, 12b, and 12f with excellent fungicidal activities can be considered as new fungicidal candidates for further research. These results provide a basis for the application of hamacanthin alkaloids in crop protection.\",\"Detailed information on intrahost viral evolution in SARS-CoV-2 with and without treatment is limited. Sequential viral loads and deep sequencing of SARS-CoV-2 from the upper respiratory tract of nine hospitalized children, three of whom were treated with remdesivir, revealed that remdesivir treatment suppressed viral load in one patient but not in a second infected with an identical strain without any evidence of drug resistance found. Reduced levels of subgenomic RNA during treatment of the second patient, suggest an additional effect of remdesivir on viral replication. Haplotype reconstruction uncovered persistent SARS-CoV-2 variant genotypes in four patients. These likely arose from within-host evolution, although superinfection cannot be excluded in one case. Although our dataset is small, observed sample-to-sample heterogeneity in variant frequencies across four of nine patients suggests the presence of discrete viral populations in the lung with incomplete population sampling in diagnostic swabs. Such compartmentalization could compromise the penetration of remdesivir into the lung, limiting the drugs in vivo efficacy, as has been observed in other lung infections.\",\"Favipiravir is a broad-spectrum inhibitor of viral RNA-dependent RNA polymerase (RdRp) currently being used to manage COVID-19. Accumulation of mutations in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RdRp may facilitate antigenic drift, generating favipiravir resistance. Focussing on the chain-termination mechanism utilized by favipiravir, we used high-throughput interface-based protein design to generate > 100 000 designs of the favipiravir-binding site of RdRp and identify mutational hotspots. We identified several single-point mutants and designs having a sequence identity of 97%-98% with wild-type RdRp, suggesting that SARS-CoV-2 can develop favipiravir resistance with few mutations. Out of 134 mutations documented in the CoV-GLUE database, 63 specific mutations were already predicted as resistant in our calculations, thus attaining \\u02dc 47% correlation with the sequencing data. These findings improve our understanding of the potential signatures of adaptation in SARS-CoV-2 against favipiravir.\",\"Background: The World Health Organization (WHO) has identified the need for a better understanding of which patients with hepatitis C virus (HCV) can be cured with ultrashort course HCV therapy. Methods: A total of 202 individuals with chronic HCV were randomised to fixed-duration shortened therapy (8 weeks) vs variable-duration ultrashort strategies (VUS1/2). Participants not cured following first-line treatment were retreated with 12 weeks' sofosbuvir/ledipasvir/ribavirin. The primary outcome was sustained virological response 12 weeks (SVR12) after first-line treatment and retreatment. Participants were factorially randomised to receive ribavirin with first-line treatment. Results: All evaluable participants achieved SVR12 overall (197/197, 100% [95% CI 98-100]) demonstrating non-inferiority between fixed-duration and variable-duration strategies (difference 0% [95% CI -3.8%, +3.7%], 4% pre-specified non-inferiority margin). First-line SVR12 was 91% [86%-97%] (92/101) for fixed-duration vs 48% [39%-57%] (47/98) for variable-duration, but was significantly higher for VUS2 (72% [56%-87%] (23/32)) than VUS1 (36% [25%-48%] (24/66)). Overall, first-line SVR12 was 72% [65%-78%] (70/101) without ribavirin and 68% [61%-76%] (69/98) with ribavirin (p=0.48). At treatment failure, the emergence of viral resistance was lower with ribavirin (12% [2%-30%] (3/26)) than without (38% [21%-58%] (11/29), p=0.01). Conclusions: Unsuccessful first-line short-course therapy did not compromise retreatment with sofosbuvir/ledipasvir/ribavirin (100% SVR12). SVR12 rates were significantly increased when ultrashort treatment varied between 4-7 weeks rather than 4-6 weeks. Ribavirin significantly reduced resistance emergence in those failing first-line therapy. ISRCTN Registration: 37915093 (11/04/2016).\",\"Members of the genus Ebolavirus cause lethal disease in humans, with Zaire ebolavirus (EBOV) being the most pathogenic (up to 90% morality) and Bundibugyo ebolavirus (BDBV) the least pathogenic (\\u223c37% mortality). Historically, there has been a lack of research on BDBV, and there is no means to study BDBV outside of a high-containment laboratory. Here, we describe a minigenome replication system to study BDBV transcription and compare the efficacy of small-molecule inhibitors between EBOV and BDBV. Using this system, we examined the ability of the polymerase complex proteins from EBOV and BDBV to interact and form a functional unit as well as the impact of the genomic untranslated ends, known to contain important signals for transcription (3'-untranslated region) and replication (5'-untranslated region). Various levels of compatibility were observed between proteins of the polymerase complex from each ebolavirus, resulting in differences in genome transcription efficiency. Most pronounced was the effect of the nucleoprotein and the 3'-untranslated region. These data suggest that there are intrinsic specificities in the polymerase complex and untranslated signaling regions that could offer insight regarding observed pathogenic differences. Further adding to the differences in the polymerase complexes, posttransfection/infection treatment with the compound remdesivir (GS-5734) showed a greater inhibitory effect against BDBV than EBOV. The delayed growth kinetics of BDBV and the greater susceptibility to polymerase inhibitors indicate that disruption of the polymerase complex is a viable target for therapeutics. IMPORTANCE Ebolavirus disease is a viral infection and is fatal in 25 to 90% of cases, depending on the viral species and the amount of supportive care available. Two species have caused outbreaks in the Democratic Republic of the Congo, Zaire ebolavirus (EBOV) and Bundibugyo ebolavirus (BDBV). Pathogenesis and clinical outcome differ between these two species, but there is still limited information regarding the viral mechanism for these differences. Previous studies suggested that BDBV replicates slower than EBOV, but it is unknown if this is due to differences in the polymerase complex and its role in transcription and replication. This study details the construction of a minigenome replication system that can be used in a biosafety level 2 laboratory. This system will be important for studying the polymerase complex of BDBV and comparing it with other filoviruses and can be used as a tool for screening inhibitors of viral growth.\",\"At present, global vaccination for the SARS-CoV2 virus 2019 (COVID-19) is 95% effective. Generally, viral infections are arduous to cure due to the mutating nature of viral genomes, with the consequent quick development of resistance, posing significant fatalities or hazards. The novel corona viral strains are increasingly lethal than earlier variants, as those evolve faster than imagined. Despite the emergence of several present innovative treatment options, the vaccines, and available drugs, the latter still are the needs of the time. Therefore, repurposing the approved pharmaceutical drugs of a well-known safety profile would be ascertained to provide faster antiviral approaches for the newer strains of COVID-19. Recently, a combination of remdesivir, which has a competitively inhibitory effect on the nucleotide uptake in the virus, and the merimepodibs, an inhibitor of the enzyme inosine monophosphate dehydrogenase, which has a role in the synthesis of nucleotides of guanine bases, is in use in phase 2 clinical trials. However, new investigations suggest that using remdesivir, there is no statistically significant difference with uncertain clinical importance for moderate COVID-19 patients. Herein, an intellectual selection of approved drugs based on the safety profile is described, to target any essential enzymes that are required for the virus-receptor contact, fusion, and/or different stages of the life cycle of this virus, should help to screen drugs against newer strains of COVID-19.Graphical abstract.\",\"During the current SARS-CoV-2 pandemic, the identification of effective antiviral drugs is crucial. Unfortunately, no specific treatment or vaccine is available to date.\",\"Antiviral drugs (AvDs) are the primary resource in the global battle against viruses, including the recent fight against corona virus disease 2019 (COVID-19). Most AvDs require multiple medications, and their use frequently leads to drug resistance, since they have poor oral bioavailability and low efficacy due to their low solubility/low permeability. Characterizing the in vivo metabolism and pharmacokinetic characteristics of AvDs may help to solve the problems associated with AvDs and enhance their efficacy. In this review of AvDs, we systematically investigated their structure-based metabolic reactions and related enzymes, their cellular pharmacology, and the effects of metabolism on AvD pharmacodynamics and pharmacokinetics. We further assessed how delivery systems achieve better metabolism and pharmacology of AvDs. This review suggests that suitable nanosystems may help to achieve better pharmacological activity and pharmacokinetic behavior of AvDs by altering drug metabolism through the utilization of advanced nanotechnology and appropriate administration routes. Notably, such AvDs as ribavirin, remdesivir, favipiravir, chloroquine, lopinavir and ritonavir have been confirmed to bind to the severe acute respiratory syndrome-like coronavirus (SARS-CoV-2) receptor and thus may represent anti-COVID-19 treatments. Elucidating the metabolic and pharmacokinetic characteristics of AvDs may help pharmacologists to identify new formulations with high bioavailability and efficacy and help physicians to better treat virus-related diseases, including COVID-19.\",\"During chronic viral infections, CD8 T cells rapidly lose antiviral and immune-stimulatory functions in a sustained program termed exhaustion. In addition to this loss of function, CD8 T cells with the highest affinity for viral antigen can be physically deleted. Consequently, treatments designed to restore function to exhausted cells and control chronic viral replication are limited from the onset by the decreased breadth of the antiviral T cell response. Yet, it remains unclear why certain populations of CD8 T cells are deleted while others are preserved in an exhausted state. We report that CD8 T cell deletion during chronic viral infection can be prevented by therapeutically lowering viral replication early after infection. The initial resistance to deletion enabled long-term maintenance of antiviral cytolytic activity of the otherwise deleted high-affinity CD8 T cells. In combination with decreased virus titers, CD4 T cell help and prolonged interactions with costimulatory molecules B7-1/B7-2 were required to prevent CD8 T cell deletion. Thus, therapeutic strategies to decrease early virus replication could enhance virus-specific CD8 T cell diversity and function during chronic infection.\",\"Several clinical studies have reported the efficacy of favipiravir in reducing viral load and shortening the duration of symptoms. However, the viability of SARS-CoV-2 in the context of favipiravir therapy and the potential for resistance development is unclear.\",\"Due to complex interplay between host and viral factors, pathogenesis of chronic hepatitis C (CHC) is considered a challenging issue. Infection with hepatitis C virus (HCV) is not confined only to liver but can induce disturbances in many other organs and systems. Our primary aim for this study was to evaluate biological response rates and sustained virological response (SVR) in patients diagnosed with CHC, treated with Interferon-alpha (IFN-\\u03b1), Pegylated (PEG)-IFN-\\u03b12a or -\\u03b12b plus Ribavirin. The second aim of the study was the identification of predictive factors for a favorable response to antiviral therapy in patients diagnosed with CHC. We enrolled in this study 210 patients diagnosed with CHC who have accomplished all inclusion and exclusion criteria, treated with PEG-IFN plus Ribavirin. Patients' recovery progress has been evaluated by determining: age, gender; biochemical tests: alanine aminotransferase (ALT), aspartate aminotransferase (AST); serological assays - detect anti-HCV antibody and molecular assays - detect, quantify and/or characterize hepatitis C viral load (ribonucleic acid) (HCV-RNA); liver histopathological (HP) examination. According to their response to treatment, they were classified into responders (n=145) and non-responders (n=65). Liver biopsies were histopathologically evaluated for necroinflammatory grade and fibrosis stage according to the modified Ishak and Metavir scoring systems for chronic hepatitis. Demographic, laboratory, and HP results were introduced in statistical analysis. These parameters were included in area under curve (AUC) analysis in order to estimate their degree of influence on getting early virological response (EVR) and SVR. Our study demonstrates that factors connected to treatment failure in CHC are linked to older age, high hepatitis C viral load, and impaired glucose tolerance at beginning of treatment [high fasting glucose and insulin, high homeostatic model assessment of insulin resistance (HOMA-IR) index] and also to liver histology features (high fibrosis score, liver steatosis, iron infiltration, and more or less high necroinflammatory activity). Analyzing results of our study shows that HOMA-IR index, serum insulin levels, baseline HCV-RNA, baseline mean blood glucose and HP score like Ishak fibrosis score, steatosis score and liver iron score may have a predictive value for obtaining an EVR in patients diagnosed with CHC.\",\"The abuse of ribavirin, an antiviral drug, in poultry breeding can cause quality degradation and drug resistance. So it is of great importance to establish a simple and effective method for detecting ribavirin in foods. In this work, aptamers that could especially bind to ribavirin with high affinity were obtained by the Capture-SELEX method. After 15 rounds of enrichment, ssDNA library pool was enriched and then analyzed by high-throughput sequencing. The seven most enriched sequences were selected as candidate aptamers for affinity and specificity characterization. Among the candidate aptamers, APT-1 was proved to be the optimal aptamer. The dissociation constant (Kd) values of APT-1 obtained by the two methods of colorimetric and fluorescence were 34.34 \\u00b1 6.038 nmol L[-1], 61.19 \\u00b1 21.48 nmol L[-1], respectively. To study the binding mechanism of the selected aptamer, molecular docking was conducted and results indicated that hydrogen bonds were formed at binding sites located at G37, T38, A40, T53 and A54. Furthermore, to confirm the practicability of the selected aptamer, a fluorescence assay was designed, showing the liner range within 1.0-50 ng mL[-1] and the low detection limit of 0.67 ng mL[-1]. Besides, the aptamer was applied for the detection of ribavirin in chicken samples and the recoveries ranged from 87.26% to 105.57%, which showed great application potential in food safety.\",\"Shortening the treatment duration for chronic hepatitis C may increase feasibility and reduce the cost of cure. The aims of this study were to compare 4 weeks of glecaprevir/pibrentasvir (GLE/PIB) treatment with and without ribavirin for patients with chronic hepatitis C and favourable baseline characteristics and to monitor the development of resistance-associated substitutions (RAS) and re-treatment outcomes if treatment failed.\",\"Interactive networks of transcription factors (TFs) have critical roles in epigenetic and gene regulation for cancer progression. It is required to clarify underlying mechanisms for transcriptional activation through concerted efforts of TFs. Here, we show the essential role of disease phase-specific TF collaboration changes in advanced prostate cancer (PC). Investigation of the transcriptome in castration-resistant PC (CRPC) revealed OCT4 as a key TF in the disease pathology. OCT4 confers epigenetic changes by promoting complex formation with FOXA1 and androgen receptor (AR), the central signals for the progression to CRPC. Meanwhile, OCT4 facilitates a distinctive complex formation with nuclear respiratory factor 1 (NRF1) to gain chemo-resistance in the absence of AR. Mechanistically, we reveal that OCT4 increases large droplet formations with AR/FOXA1 as well as NRF1 in vitro. Disruption of TF collaborations using a nucleoside analogue, ribavirin, inhibited treatment-resistant PC tumor growth. Thus, our findings highlight the formation of TF collaborations as a potent therapeutic target in advanced cancer.\",\"A variety of antiviral treatments for COVID-19 have been investigated, involving many repurposed drugs. Currently, the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp, encoded by nsp12-nsp7-nsp8) has been targeted by numerous inhibitors, e.g., remdesivir, the only provisionally approved treatment to-date, although the clinical impact of these interventions remains inconclusive. However, the potential emergence of antiviral resistance poses a threat to the efficacy of any successful therapies on a wide scale. Here, we propose a framework to monitor the emergence of antiviral resistance, and as a proof of concept, we address the interaction between RdRp and remdesivir. We show that SARS-CoV-2 RdRp is under purifying selection, that potential escape mutations are rare in circulating lineages, and that those mutations, where present, do not destabilise RdRp. In more than 56,000 viral genomes from 105 countries from the first pandemic wave, we found negative selective pressure affecting nsp12 (Tajima's D = -2.62), with potential antiviral escape mutations in only 0.3% of sequenced genomes. Potential escape mutations included known key residues, such as Nsp12:Val473 and Nsp12:Arg555. Of the potential escape mutations involved globally, in silico structural models found that they were unlikely to be associated with loss of stability in RdRp. No potential escape mutation was found in a local cohort of remdesivir treated patients. Collectively, these findings indicate that RdRp is a suitable drug target, and that remdesivir does not seem to exert high selective pressure. We anticipate our framework to be the starting point of a larger effort for a global monitoring of drug resistance throughout the COVID-19 pandemic.\",\"Favipiravir is a nucleoside analogue which has been licensed to treat influenza in the event of a new pandemic. We previously described a favipiravir resistant influenza A virus generated by in vitro passage in presence of drug with two mutations: K229R in PB1, which conferred resistance at a cost to polymerase activity, and P653L in PA, which compensated for the cost of polymerase activity. However, the clinical relevance of these mutations is unclear as the mutations have not been found in natural isolates and it is unknown whether viruses harbouring these mutations would replicate or transmit in vivo. Here, we infected ferrets with a mix of wild type p(H1N1) 2009 and corresponding favipiravir-resistant virus and tested for replication and transmission in the absence of drug. Favipiravir-resistant virus successfully infected ferrets and was transmitted by both contact transmission and respiratory droplet routes. However, sequencing revealed the mutation that conferred resistance, K229R, decreased in frequency over time within ferrets. Modelling revealed that due to a fitness advantage for the PA P653L mutant, reassortment with the wild-type virus to gain wild-type PB1 segment in vivo resulted in the loss of the PB1 resistance mutation K229R. We demonstrated that this fitness advantage of PA P653L in the background of our starting virus A/England/195/2009 was due to a maladapted PA in first wave isolates from the 2009 pandemic. We show there is no fitness advantage of P653L in more recent pH1N1 influenza A viruses. Therefore, whilst favipiravir-resistant virus can transmit in vivo, the likelihood that the resistance mutation is retained in the absence of drug pressure may vary depending on the genetic background of the starting viral strain.\",\"We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-\\u03b2-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in coronavirus 2019 disease (COVID-19) inpatients requiring oxygen and/or ventilatory support.\",\"Retreatment with glecaprevir/pibrentasvir (G/P) resulted in a rate of sustained virologic response 12 weeks after treatment completion (SVR12) of >90% in HCV genotype 1 (GT1) patients who previously failed a regimen of sofosbuvir plus an NS5A inhibitor (NS5Ai). This study investigated the prevalence and impact of baseline NS3 and NS5A resistance-associated substitutions (RASs) on the efficacy of G/P in prior GT1 sofosbuvir+NS5Ai failures and the persistence of treatment-emergent RASs.\",\"The COVID-19 pandemic has severely destructed human life worldwide, with no suitable treatment until now. SARS-CoV-2 virus is unprecedented, resistance against number of therapeutics and spreading rapidly with high mortality, which warrants the need to discover new effective drugs to combat this situation. This current study is undertaken to explore the antiviral potential of marine algal compounds to inhibit the viral entry and its multiplication using computational analysis. Among the proven drug discovery targets of SARS-CoV-2, spike glycoprotein and 3-chymotrypsin-like protease are responsible for the virus attachment and viral genome replication in the host cell. In this study, the above-mentioned drug targets were docked with marine algal compounds (sulfated polysaccharides, polysaccharide derivatives and polyphenols) using molecular docking tools (AutoDockTools). The obtained results indicate that \\u03ba-carrageenan, laminarin, eckol, trifucol and \\u03b2-D-galactose are the top-ranking compounds showing better docking scores with SARS-CoV-2 targets, than the current experimental COVID-19 antiviral drugs like dexamethasone, remdesivir, favipiravir and MIV-150. Further, molecular dynamic simulation, ADMET and density functional theory calculations were evaluated to substantiate the findings. To the best of our knowledge, this is the first report on in silico analysis of aforesaid algal metabolites against SARS-CoV-2 targets. This study concludes that these metabolites can be curative for COVID-19 in the hour of need after further validations in in vitro and in vivo testings.Communicated by Ramaswamy H. Sarma.\",\"The current recommendation for treating hepatitis C virus (HCV) in HIV patients includes the combination of sofosbuvir (SOF) and daclatasvir (DCV). DCV should be used at different doses to compensate for interactions with antiretroviral therapy (ART). Up to three pills a day might be required which will significantly add to the pill burden of these patients. In this study, we have used a single-tablet approach to treating HCV-HIV coinfection.\",\"Replication of RNA viruses is characterized by exploration of sequence space which facilitates their adaptation to changing environments. It is generally accepted that such exploration takes place mainly in response to positive selection, and that further diversification is boosted by modifications of virus population size, particularly bottleneck events. Our recent results with hepatitis C virus (HCV) have shown that the expansion in sequence space of a viral clone continues despite prolonged replication in a stable cell culture environment. Diagnosis of the expansion was based on the quantification of diversity indices, the occurrence of intra-population mutational waves (variations in mutant frequencies), and greater individual residue variations in mutant spectra than those anticipated from sequence alignments in data banks. In the present report, we review our previous results, and show additionally that mutational waves in amplicons from the NS5A-NS5B-coding region are equally prominent during HCV passage in the absence or presence of the mutagenic nucleotide analogues favipiravir or ribavirin. In addition, by extending our previous analysis to amplicons of the NS3- and NS5A-coding region, we provide further evidence of the incongruence between amino acid conservation scores in mutant spectra from infected patients and in the Los Alamos National Laboratory HCV data banks. We hypothesize that these observations have as a common origin a permanent state of HCV population disequilibrium even upon extensive viral replication in the absence of external selective constraints or changes in population size. Such a persistent disequilibrium-revealed by the changing composition of the mutant spectrum-may facilitate finding alternative mutational pathways for HCV antiviral resistance. The possible significance of our model for other genetically variable viruses is discussed.\",\"Direct-Acting agents (DAAs) target and inhibit essential viral replication proteins. They have revolutionized the treatment of Hepatitis C virus (HCV) infection reaching high levels of sustained virologic response. However, the detection of basal resistance-associated substitutions (RASs) to DAAs in na\\u00efve patients could be important in predicting the treatment outcome in some patients exhibiting failures to DAA-based therapies. Therefore, the aim of this work was to evaluate the presence of RASs as minority variants within intra-host viral populations, and assess their relationship to response to therapy on a multiple times relapser patient infected chronically with HCV.\",\"The number of confirmed COVID-19 cases is rapidly increasing with no direct treatment for the disease. Few repurposed drugs, such as Remdesivir, Chloroquine, Hydroxychloroquine, Lopinavir, and Ritonavir, are being tested against SARS-CoV-2. Remdesivir is the drug of choice for Ebola virus disease and has been authorized for emergency use. This drug acts against SARS-CoV-2 by inhibiting the RNA-dependent-RNA-polymerase (RdRp) of SARS-CoV-2. RdRp of viruses is prone to mutations that confer drug resistance. A recent study by Pachetti et al. in 2020 identified the P323L mutation in the RdRp protein of SARS-CoV-2. In this study, we aimed to determine the potency of lead compounds similar to Remdesivir, which can be used as an alternative when variants of SARS-CoV-2 develop resistance due to RdRp mutations. The initial screening yielded 704 compounds that were 90% similar to the control drug, Remdesivir. On further evaluation through drugability and antiviral inhibition percentage analyses, we shortlisted 32 and seven compounds, respectively. These seven compounds were further analyzed for their molecular interactions, which revealed that all seven compounds interacted with RdRp with higher affinity than Remdesivir under native conditions. However, three compounds failed to interact with the mutant protein with higher affinity than Remdesivir. Dynamic cross-correlation matrix (DCCM) and vector field collective motions analyses were performed to identify the precise movements of docked complexes' residues. Furthermore, the compound SCHEMBL20144212 showed a high affinity for native and mutant proteins and might provide an alternative against SARS-CoV-2 variants that might confer resistance to Remdesivir. Further validations by in vitro and in vivo studies are needed to confirm the efficacy of our lead compounds for their inhibition against SARS-CoV-2.\",\"Antiviral therapeutics is one effective avenue to control and end this devastating COVID-19 pandemic. The viral RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 has been recognized as a valuable target of antivirals. However, the cell-free SARS-CoV-2 RdRp biochemical assay requires the conversion of nucleotide prodrugs into the active triphosphate forms, which regularly occurs in cells yet is a complicated multiple-step chemical process in vitro, and thus hinders the utility of this cell-free assay in the rapid discovery of RdRp inhibitors. In addition, SARS-CoV-2 exoribonuclease provides the proof-reading capacity to viral RdRp, thus creates relatively high resistance threshold of viral RdRp to nucleotide analog inhibitors, which must be examined and evaluated in the development of this class of antivirals. Here, we report a cell-based assay to evaluate the efficacy of nucleotide analog compounds against SARS-CoV-2 RdRp and assess their tolerance to viral exoribonuclease-mediated proof-reading. By testing seven commonly used nucleotide analog viral polymerase inhibitors, Remdesivir, Molnupiravir, Ribavirin, Favipiravir, Penciclovir, Entecavir and Tenofovir, we found that both Molnupiravir and Remdesivir showed the strong inhibition of SARS-CoV-2 RdRp, with EC50 value of 0.22 \\u03bcM and 0.67 \\u03bcM, respectively. Moreover, our results suggested that exoribonuclease nsp14 increases resistance of SARS-CoV-2 RdRp to nucleotide analog inhibitors. We also determined that Remdesivir presented the highest resistance to viral exoribonuclease activity in cells. Therefore, we have developed a cell-based SARS-CoV-2 RdRp assay which can be deployed to discover SARS-CoV-2 RdRp inhibitors that are urgently needed to treat COVID-19 patients.\",\"Limited literature on the prevalence of baseline resistance associated substitutions (BL-RAS) among HCV-HIV co-infected patients and their association with treatment outcomes is available especially from India. Hence, the present study aimed to study naturally occurring RAS among non-cirrhotic HCV-HIV co-infected patients and their impact on the response to anti-HCV therapy.\",\"NS5B polymerase inhibitors represent the cornerstone of the present treatment of Hepatitis C virus infection (HCV). Naturally occurring substitution mutations to NS5B inhibitors have been recorded. The current study intended to demonstrate possible natural direct acting antiviral (DAA)-mutations of the HCV NS5B region in HCV patients in Minia governorate, Egypt.\",\"The SARS-CoV-2 replication and transcription complex (RTC) comprising nonstructural protein (nsp) 2-16 plays crucial roles in viral replication, reducing the efficacy of broad-spectrum nucleoside analog drugs such as remdesivir and evading innate immune responses. Most studies target a specific viral component of the RTC such as the main protease or the RNA-dependent RNA polymerase. In contrast, our strategy is to target multiple conserved domains of the RTC to prevent SARS-CoV-2 genome replication and to create a high barrier to viral resistance and/or evasion of antiviral drugs. We show that the clinically safe Zn-ejector drugs disulfiram and ebselen can target conserved Zn[2+] sites in SARS-CoV-2 nsp13 and nsp14 and inhibit nsp13 ATPase and nsp14 exoribonuclease activities. As the SARS-CoV-2 nsp14 domain targeted by disulfiram/ebselen is involved in RNA fidelity control, our strategy allows coupling of the Zn-ejector drug with a broad-spectrum nucleoside analog that would otherwise be excised by the nsp14 proofreading domain. As proof-of-concept, we show that disulfiram/ebselen, when combined with remdesivir, can synergistically inhibit SARS-CoV-2 replication in Vero E6 cells. We present a mechanism of action and the advantages of our multitargeting strategy, which can be applied to any type of coronavirus with conserved Zn[2+] sites.\",\"RNA viruses demonstrate a vast range of variants, called quasispecies, due to error-prone replication by viral RNA-dependent RNA polymerase. Although live attenuated vaccines are effective in preventing RNA virus infection, there is a risk of reversal to virulence after their administration. To test the hypothesis that high-fidelity viral polymerase reduces the diversity of influenza virus quasispecies, resulting in inhibition of reversal of the attenuated phenotype, we first screened for a high-fidelity viral polymerase using serial virus passages under selection with a guanosine analog ribavirin. Consequently, we identified a Leu66-to-Val single amino acid mutation in polymerase basic protein 1 (PB1). The high-fidelity phenotype of PB1-L66V was confirmed using next-generation sequencing analysis and biochemical assays with the purified influenza viral polymerase. As expected, PB1-L66V showed at least two-times-lower mutation rates and decreased misincorporation rates, compared to the wild type (WT). Therefore, we next generated an attenuated PB1-L66V virus with a temperature-sensitive (ts) phenotype based on FluMist, a live attenuated influenza vaccine (LAIV) that can restrict virus propagation by ts mutations, and examined the genetic stability of the attenuated PB1-L66V virus using serial virus passages. The PB1-L66V mutation prevented reversion of the ts phenotype to the WT phenotype, suggesting that the high-fidelity viral polymerase could contribute to generating an LAIV with high genetic stability, which would not revert to the pathogenic virus.IMPORTANCE The LAIV currently in use is prescribed for actively immunizing individuals aged 2 to 49 years. However, it is not approved for infants and elderly individuals, who actually need it the most, because it might prolong virus propagation and cause an apparent infection in these individuals, due to their weak immune systems. Recently, reversion of the ts phenotype of the LAIV strain currently in use to a pathogenic virus was demonstrated in cultured cells. Thus, the generation of mutations associated with enhanced virulence in LAIV should be considered. In this study, we isolated a novel influenza virus strain with a Leu66-to-Val single amino acid mutation in PB1 that displayed a significantly higher fidelity than the WT. We generated a novel LAIV candidate strain harboring this mutation. This strain showed higher genetic stability and no ts phenotype reversion. Thus, our high-fidelity strain might be useful for the development of a safer LAIV.\",\"The treatment of coronavirus disease 2019 (COVID-19) has been a challenge. The efficacy of several drugs has been evaluated and variability in drug response has been observed. Pharmacogenetics could explain this variation and improve patients' outcomes with this complex disease; nevertheless, several disease-related issues must be carefully reviewed in the pharmacogenetic study of COVID-19 treatment. We aimed to describe the pharmacogenetic variants reported for drugs used for COVID-19 treatment (remdesivir, oseltamivir, lopinavir, ritonavir, azithromycin, chloroquine, hydroxychloroquine, ivermectin, and dexamethasone). In addition, other factors relevant to the design of pharmacogenetic studies were mentioned. Variants in CYP3A4, CYP3A5, CYP2C8, CY2D6, ABCB1, ABCC2, and SLCO1B1, among other variants, could be included in pharmacogenetic studies of COVID-19 treatment. Besides, nongenetic factors such as drug-drug interactions and inflammation should be considered in the search for personalized therapy of COVID-19.\",\"Direct-acting antiviral (DAA) drugs are associated with high (>95%) sustained virological response at 12 weeks (SVR12) in chronic hepatitis C (CHC) patients. There is a paucity of data regarding the characteristics and re-treatment outcomes of DAA treatment failure patients. In a retrospective analysis of the prospectively collected database, we assessed the outcomes of re-treatment among patients with previous DAA failure. Patients' characteristics, viral characteristics, including resistance-associated substitutions (RAS) in a subgroup of patients, SVR12, and clinical outcomes were studied. Of 40 patients with DAA failure, among whom 36 were retreated, mean age was 45.7 years, 63.9% (n = 23) were male, 63.9% (n = 23) had a genotype-3 infection and 63.9% (n = 23) were cirrhotic. The re-treatment regimens included a combination of pan-genotypic DAA, mainly sofosbuvir and velpatasvir with or without ribavirin. Three patients who declined retreatment and one who was still on treatment was excluded. For patients who completed re-treatment, SVR12 was 100% irrespective of genotypes. SVR12 among genotype 3 was 75% (15 of 20) when lost to follow-up was considered a treatment failure. Six patients died due to liver-related causes, including five (83.3%) with hepatocellular carcinoma. RAS analysis in 17 randomly selected patients did not reveal any dominant substitutions in NS5A or NS5B region affecting SVR12, though several novel mutations were observed. In conclusion, re-treatment of CHC patients with prior DAA failure using pan-genotypic DAA is associated with high SVR12 rates irrespective of genotype or the presence of RAS.\",\"Molecular surveillance by whole-genome sequencing was used to monitor the susceptibility of circulating influenza A viruses to three polymerase complex inhibitors. A total of 12 resistance substitutions were found among 285 genomes analyzed, but none were associated with high levels of resistance. Natural resistance to these influenza A antivirals is currently uncommon.\",\"Backtracking, the reverse motion of the transcriptase enzyme on the nucleic acid template, is a universal regulatory feature of transcription in cellular organisms but its role in viruses is not established. Here we present evidence that backtracking extends into the viral realm, where backtracking by the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) may aid viral transcription and replication. Structures of SARS-CoV-2 RdRp bound to the essential nsp13 helicase and RNA suggested the helicase facilitates backtracking. We use cryo-electron microscopy, RNA-protein crosslinking, and unbiased molecular dynamics simulations to characterize SARS-CoV-2 RdRp backtracking. The results establish that the single-stranded 3'-segment of the product-RNA generated by backtracking extrudes through the RdRp NTP-entry tunnel, that a mismatched nucleotide at the product-RNA 3'-end frays and enters the NTP-entry tunnel to initiate backtracking, and that nsp13 stimulates RdRp backtracking. Backtracking may aid proofreading, a crucial process for SARS-CoV-2 resistance against antivirals.\",\"Despite strict control measures implemented worldwide, the COVID-19 pandemic continues to rage. Several drugs, including lopinavir/ritonavir, hydroxychloroquine, dexamethasone, and remdesivir, have been evaluated for the treatment of COVID-19 during the past year. While most of the drugs failed to display efficacy in treating COVID-19, scientists have encouraged herd immunity to control the pandemic. Immunity generated after natural infection with SARS-CoV-2 is precarious, as indicated by real-world evidence in the form of epidemiological data from Manaus, Brazil. Vaccines using different platforms are therefore the most promising approach to help us return to normality. Although several vaccines have been authorized for emergency use, there are still many concerns regarding their accessibility, the vaccination rate, and most importantly, their efficacy in preventing infection with emerging virus variants. Continued virus surveillance and rapid redesign of new vaccines to counter new variants are crucial to fighting COVID-19. Rapid production and extensive vaccination are also essential to preventing the emergence of new variants. Nevertheless, antivirals including monoclonal antibodies and oral medicines need to be developed in light of uncertainties with regard to vaccination. In the battle between humans and SARS-CoV-2, the speed with which we fight the virus, and especially its emerging variants, is the key to winning.\",\"We examined the safety and efficacy of a treatment protocol containing Favipiravir for the treatment of SARS-CoV-2.\",\"Viral resistance is a major reason for virological failure in patients being treated with direct-acting antivirals (DAAs) for chronic HCV infection. However, the importance of viral resistance mainly depends on the DAA regimen and HCV genotype. For first-line therapy with glecaprevir/pibrentasvir (G/P) or velpatasvir/sofosbuvir (VEL/SOF) no general baseline resistance analysis is required because of the high antiviral activity and high barrier to resistance. If available, resistance testing may help to optimise therapy in certain subgroups of patients with HCV genotype 3 and other rare HCV geno/subtypes. Voxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is the first choice for the second-line treatment of patients following a previous DAA failure, with rates of viral eradication above 90% irrespective of the presence of resistance-associated substitutions (RASs). However, in resource-limited settings, only first-generation DAAs may be available for second-line therapy. Here, RASs selected during initial antiviral therapy should be considered if testing is available and rescue treatment should include a switch to a regimen with a new DAA class to optimise treatment response. Patients with HCV genotype 3 are overrepresented in the group who experience DAA treatment failure. Limited data are available for third-line therapies, but promising results have been achieved with G/P plus SOF or VOX/VEL/SOF with or without ribavirin for 12 to 24 weeks; these regimens should be administered irrespective of a patient's RAS profile.\",\"The use of direct-acting antiviral agents (DAAs) in patients with chronic HCV genotype (GT) 1 infection results in sustained virologic response (SVR) rates of 95%-97%, but 3%-5% of patients experience virologic failure. We observed 41 patients infected with HCV subtype 1b who failed previous treatment with DAAs, including 37 subjects (90.2%) with liver cirrhosis. In total, 30 (73.2%) subjects previously received NS5A inhibitors of the first generation (ledipasvir, daclatasvir, or ombitasvir) and 11 subjects (26.8%) received NS5A inhibitors of the second generation (velpatasvir). All patients received retreatment with a combination of ombitasvir/paritaprevir/ritonavir and dasabuvir (3D) with sofosbuvir (SOF) and ribavirin (RBV). We compared SVR12 rates depending on fibrosis stage, presence of just single or double NS5A mutation (L31M/V/I and/or Y93H), and the generation of previously used NS5A inhibitors. Observed SVR12 rates were as follows: 97.6% (40/41 patients) overall; 100% in patients without cirrhosis (n = 4) versus 97.3% in those with cirrhosis (n = 37); 100% with single L31M/V/I or Y93H mutation (n = 22) versus 94.4% with double mutations (n = 18); 100% in patients who failed previous treatment with first-generation (n = 30) versus 90.9% in those who failed previous treatment with second-generation NS5A inhibitors (n = 11). Retreatment with 3D + SOF + RBV was highly effective and safe in patients with chronic HCV GT1b infection, including those with liver cirrhosis, who failed previous treatment with DAA containing NS5A inhibitors. Fibrosis stage and single or simultaneous presence of NS5A RASs L31M/V/I and Y93H at the baseline, as well as the generation of previously used NS5A inhibitors, did not impact SVR12 rates.\",\"The objective of this trial is to assess whether early antiviral therapy in outpatients with COVID-19 with either favipiravir plus lopinavir/ritonavir, lopinavir/ritonavir alone, or favipiravir alone, is associated with a decrease in viral load of SARS-CoV-2 compared with placebo.\",\"Despite the current highly effective therapies with direct-acting antiviral agents (DAAs), some patients with chronic hepatitis C virus (HCV) infection still do not achieve sustained virological response (SVR) and require retreatment. Sofosbuvir/velpatasvir/voxilaprevir (SVV) is recommended as the first-line retreatment option for most patients. The aim of this study was to evaluate the efficacy of SVV as salvage therapy after at least one course of DAA.\",\"SARS-CoV-2 is a positive-sense RNA virus that requires an RNA-dependent RNA polymerase (RdRp) for replication of its viral genome. Nucleoside analogs such as Remdesivir and \\u03b2-d-N[4]-hydroxycytidine are antiviral candidates and may function as chain terminators or induce viral mutations, thus impairing RdRp function. Recently disclosed Cryo-EM structures of apo, RNA-bound, and inhibitor-bound SARS-CoV-2 RdRp provided insight into the inhibitor-bound structure by capturing the enzyme with its reaction product: Remdesivir covalently bound to the RNA primer strand. To gain a structural understanding of the binding of this and several other nucleoside analogs in the precatalytic state, molecular models were developed that predict the noncovalent interactions to a complex of SARS-CoV-2 RdRp, RNA, and catalytic metal cations. MM-GBSA evaluation of these interactions is consistent with resistance-conferring mutations and existing structure-activity relationship (SAR) data. Therefore, this approach may yield insights into antiviral mechanisms and guide the development of experimental drugs for COVID-19 treatment.\",\"Antiviral drugs have been used to treat the ever-growing number of coronavirus disease, 2019 (COVID-19) patients. Consequently, unprecedented amounts of such drug residues discharging into ambient waters raise concerns on the potential ecotoxicological effects to aquatic lives, as well as development of antiviral drug-resistance in wildlife. Here, we estimated the occurrence, fate and ecotoxicological risk of 11 therapeutic agents suggested as drugs for COVID-19 treatment and their 13 metabolites in wastewater and environmental waters, based on drug consumption, physical-chemical property, and ecotoxicological and pharmacological data for the drugs, with the aid of quantitative structure-activity relationship (QSAR) modelling. Our results suggest that the removal efficiencies at conventional wastewater treatment plants will remain low (<20%) for half of the substances, and consequently, high drug residues (e.g. 7402 ng/L ribavirin, 4231 ng/L favipiravir, 730 ng/L lopinavir, 319 ng/L remdesivir; each combined for both unchanged forms and metabolites; and when each drug is administered to 100 patients out of 100,000 populations on a day) can be present in secondary effluents and persist in the environmental waters. Ecotoxicological risk in receiving river waters can be high (risk quotient >1) by a use of favipiravir, lopinavir, umifenovir and ritonavir, and medium (risk quotient >0.1) by a use of chloroquine, hydroxychloroquine, remdesivir, and ribavirin, while the risk will remain low (risk quotient <0.1) for dexamethasone and oseltamivir. The potential of wild animals acquiring antiviral drug resistance was estimated to be low. Our prediction suggests a pressing need for proper usage and waste management of antiviral drugs as well as for improving removal efficiencies of drug residues in wastewater.\",\"Severe coronavirus disease 2019 (COVID-19) may lead to the cytokine storm syndrome which may cause acute respiratory failure syndrome and death. Our aim was to investigate the therapeutic effects of infliximab, intravenous gammaglobulin (IVIg) or combination therapy in patients with severe COVID-19 disease admitted to the intensive care unit (ICU).\",\"Rift Valley fever virus (RVFV) is a mosquito-borne bunyavirus that causes Rift Valley fever (RVF), a zoonotic disease of wild and domestic ruminants, causing serious economic losses and a threat to human health that could be controlled by vaccination. Though RVF vaccines are available for livestock, no RVF vaccines have been licensed for veterinary use in non-endemic countries nor for human populations in RVF risk areas. In a recent work, we showed that favipiravir, a promising drug with antiviral activity against a number of RNA viruses, led to the extinction of RVFV from infected cell cultures. Nevertheless, certain drug concentrations allowed the recovery of a virus variant showing increased resistance to favipiravir. In this work, we characterized this novel resistant variant both at genomic and phenotypic level in vitro and in vivo. Interestingly, the resistant virus displayed reduced growth rates in C6/36 insect cells but not in mammalian cell lines, and was highly attenuated but still immunogenic in vivo. Some amino acid substitutions were identified in the viral RNA-dependent RNA-polymerase (RdRp) gene and in the virus encoded type I-interferon (IFN-I) antagonist NSs gene, in catalytic core motifs and nuclear localization associated positions, respectively. These data may help to characterize novel potential virulence markers, offering additional strategies for further safety improvements of RVF live attenuated vaccine candidates.\",\"HCV genotype 4 dominates the HCV epidemic in Egypt. Drug resistance was the most serious side effect that reflects bad clinical outcome. Several studies had demonstrated that baseline serum interferon-\\u03b3-inducible-protein 10 (IP-10) levels and interleukin 28B polymorphisms were associated with the resistance to the standard of care pegylated interferon alpha and ribavirin (PEG-IFN\\u03b1/RBV) therapy and development of post-treatment relapse. Our purpose was to assess the predictive value of combining IP-10 levels and IL28B genotypes to PEG-IFN\\u03b1/RBV therapy response in Egyptian chronic HCV infection patients with genotype 4. Ninety Egyptian patients chronically infected by HCV genotype-4 treated with pegylated interferon alpha and ribavirin (PEG-IFN\\u03b1/RBV) therapy were enrolled. Serum IP-10 levels were determined by enzyme linked immunosorbent assay pre- and post- treatment. IL-28B (rs12979860 and rs8099917) polymorphisms were performed by PCR-RFLP in all patients. Overall, 38 patients (42.2%) achieved sustained virologic response (SVR) and 52 (57.8%) patients have non-viral response (NVR). Pretreatment serum IP-10 mean levels were significantly lower in patients who achieved SVR than in NVR (P<0.05). CC genotype in IL28B polymorphism (rs12979860) was the favorable genotype as 65.8% achieved SVR, while TT genotype in IL-28B polymorphism (rs8099917) was the favorable genotype as 81.5% achieved SVR. Baseline IP-10 was significantly correlated to genotypes CC in rs12979860 and TT in rs8099917. Combined use of serum baseline IP-10 levels with IL-28B polymorphisms could improve the prediction of SVR to PEG-IFN\\u03b1/RBV therapy in Egyptian chronic HCV infection patients with genotype 4.\",\"The Egyptian National Committee of Viral Hepatitis program is the leading national hepatitis C virus (HCV) management program globally. However, limited data is available about the effect of the new directly acting antiviral agents on the cardiovascular system.\",\"Remdesivir (RDV) exhibits potent antiviral activity against SARS-CoV-2 and is currently the only drug approved for the treatment of COVID-19. However, little is currently known about the potential for pre-existing resistance to RDV and the possibility of SARS-CoV-2 genetic diversification that might impact RDV efficacy as the virus continue to spread globally. In this study, >90,000 SARS-CoV-2 sequences from globally circulating clinical isolates, including sequences from recently emerged United Kingdom and South Africa variants, and >300 from mink isolates were analyzed for genetic diversity in the RNA replication complex (nsp7, nsp8, nsp10, nsp12, nsp13, and nsp14) with a focus on the RNA-dependent RNA polymerase (nsp12), the molecular target of RDV. Overall, low genetic variation was observed with only 12 amino acid substitutions present in the entire RNA replication complex in \\u22650.5% of analyzed sequences with the highest overall frequency (82.2%) observed for nsp12 P323L that consistently increased over time. Low sequence variation in the RNA replication complex was also observed among the mink isolates. Importantly, the coronavirus Nsp12 mutations previously selected in vitro in the presence of RDV were identified in only 2 isolates (0.002%) within all the analyzed sequences. In addition, among the sequence variants observed in \\u22650.5% clinical isolates, including P323L, none were located near the established polymerase active site or sites critical for the RDV mechanism of inhibition. In summary, the low diversity and high genetic stability of the RNA replication complex observed over time and in the recently emerged SARS-CoV-2 variants suggests a minimal global risk of pre-existing SARS-CoV-2 resistance to RDV.\",\"The outbreak of Coronavirus disease 2019 (COVID-19) has evolved into an emergent global pandemic. Many drugs without established efficacy are being used to treat COVID-19 patients either as an offlabel/compassionate use or as a clinical trial. Although drug repurposing is an attractive approach with reduced time and cost, there is a need to make predictions on success before the start of therapy. For the optimum use of these repurposed drugs, many factors should be considered such as drug-gene or dug-drug interactions, drug toxicity, and patient co-morbidity. There is limited data on the pharmacogenomics of these agents and this may constitute an obstacle for successful COVID-19 therapy. This article reviewed the available human genome interactions with some promising repurposed drugs for COVID-19 management. These drugs include chloroquine (CQ), hydroxychloroquine (HCQ), azithromycin, lopinavir/ritonavir (LPV/r), atazanavir (ATV), favipiravir (FVP), nevirapine (NVP), efavirenz (EFV), oseltamivir, remdesivir, anakinra, tocilizumab (TCZ), eculizumab, heme oxygenase 1 (HO-1) regulators, renin-angiotensin-aldosterone system (RAAS) inhibitors, ivermectin, and nitazoxanide. Drug-gene variant pairs that may alter the therapeutic outcomes in COVID-19 patients are presented. The major drug variant pairs that associated with variations in clinical efficacy include CQ/HCQ (CYP2C8, CYP2D6, ACE2, and HO-1); azithromycin (ABCB1); LPV/r (SLCO1B1, ABCB1, ABCC2 and CYP3A); NVP (ABCC10); oseltamivir (CES1 and ABCB1); remdesivir (CYP2C8, CYP2D6, CYP3A4, and OATP1B1); anakinra (IL-1a); and TCZ (IL6R and FCGR3A). The major drug variant pairs that associated with variations in adverse effects include CQ/HCQ (G6PD; hemolysis and ABCA4; retinopathy), ATV (MDR1 and UGT1A1*28; hyperbilirubinemia; and APOA5; dyslipidemia), NVP (HLA-DRB1*01, HLA-B*3505 and CYP2B6; skin rash and MDR1; hepatotoxicity), and EFV (CYP2B6; depression and suicidal tendencies).\",\"Hepatitis C virus (HCV) accounts for hepatitis, liver cirrhosis, hepatocellular carcinoma, and liver transplantation. This virus is a single-stranded RNA virus that belongs to the Flaviviridae family. According to the WHO, about 71 million people have chronic HCV infections around the globe in 2020, and hence, it is a plague of humankind. The credit of discovery of HCV goes to Michael Houghton, Harvey Alter, and Charles Rice for which they are awarded 2020 Nobel Prize in Medicine. Their contribution has given better hope to mankind to cure HCV for the first time in the history. With the use of pegylated interferon and ribavirin jointly, higher SVR has been found comparatively, even in patients with chronic liver diseases. However, due to excessive pain tolerated by patients, interferon (IFN)-based therapy is rapidly being replaced with IFN-free DAA regimens. With the onset of resistance to DAA drugs, CRISPR-Cas system can be used to modify the viral genome to impair their ability to develop resistance. How to cite this article: Laugi H. Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine. Euroasian J Hepato-Gastroenterol 2020;10(2): 105-108.\",\"Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths worldwide and massive societal and economic burden. Recently, a new variant of SARS-CoV-2, known as B.1.1.7, was first detected in the United Kingdom and is spreading in several other countries, heightening public health concern and raising questions as to the resulting effectiveness of vaccines and therapeutic interventions. We and others previously identified host-directed therapies with antiviral efficacy against SARS-CoV-2 infection. Less prone to the development of therapy resistance, host-directed drugs represent promising therapeutic options to combat emerging viral variants as host genes possess a lower propensity to mutate compared to viral genes. Here, in the first study of the full-length B.1.1.7 variant virus , we find two host-directed drugs, plitidepsin (aplidin; inhibits translation elongation factor eEF1A) and ralimetinib (inhibits p38 MAP kinase cascade), as well as remdesivir, to possess similar antiviral activity against both the early-lineage SARS-CoV-2 and the B.1.1.7 variant, evaluated in both human gastrointestinal and lung epithelial cell lines. We find that plitidepsin is over an order of magnitude more potent than remdesivir against both viruses. These results highlight the importance of continued development of host-directed therapeutics to combat current and future coronavirus variant outbreaks.\",\"This study aimed to investigate the role of resistance-associated substitutions (RASs) to direct-acting-antivirals (DAAs) in HCV genotype 3 (GT3).\",\"The use of remdesivir to treat COVID-19 will likely continue before clinical trials are completed. Due to the lengthening pandemic and evolving nature of the virus, predicting potential residues prone to mutation is crucial for the management of remdesivir resistance. Using a rational ligand-based interface design complemented with mutational mapping, we generated a total of 100,000 mutations and provided insight into the functional outcomes of mutations in the remdesivir-binding site in nsp12 subunit of RdRp. After designing 46 residues in the remdesivir-binding site of nsp12, the designs retained 97%-98% sequence identity, suggesting that very few mutations in nsp12 are required for SARS-CoV-2 to attain remdesivir resistance. Several mutants displayed decreased binding affinity to remdesivir, suggesting drug resistance. These hotspot residues had a higher probability of undergoing selective mutation and thus conferring remdesivir resistance. Identifying the potential residues prone to mutation improves our understanding of SARS-CoV-2 drug resistance and COVID-19 pathogenesis.\",\"ABMA and its analogue DABMA are two molecules of the adamantane family known to perturbate the endosomal pathway and to inhibit cell infection of several RNA and DNA viruses. Their activity against Rabies Virus (RABV) infection has already been demonstrated in vitro. (Wu et al., 2017, 2019). Here, we describe in more details their mechanism of action by comparison to Arbidol (umifenovir) and Ribavirin, two broad spectrum antivirals against emerging viruses such as Lassa, Ebola, influenza and Hantaan viruses. ABMA and DABMA, delivered 2 h pre-infection, inhibit RABV infection in vitro with an EC50 of 7.8 \\u03bcM and 14 \\u03bcM, respectively. They act at post-entry, by causing RABV accumulation within the endosomal compartment and DABMA specifically diminishes the expression of the GTPase Rab7a controlling the fusion of early endosomes to late endosomes or lysosomes. This may suggest that ABMA and DABMA act at different stages of the late endosomal pathway as supported by their different profile of synergy/antagonism with the fusion inhibitor Arbidol. This difference is further confirmed by the RABV mutants induced by successive passages under increasing selective pressure showing a particular involvement of the viral G protein in the DABMA inhibition while ABMA inhibition induces less mutations dispersed in the M, G and L viral proteins. These results suggest new therapeutic perspectives against rabies.\",\"At this time, there is no specific therapeutic or vaccine for treatment of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, available drugs for treatment of other viral infections may be useful to treat COVID-19.\",\"The prolonged treatment of immunosuppressed (IS) individuals with anti-influenza monotherapies may lead to the emergence of drug-resistant variants. Herein, we evaluated oseltamivir and polymerase inhibitors combinations against influenza A/H3N2 infections in an IS mouse model. Mice were IS with cyclophosphamide and infected with 3 \\u00d7 10[3] PFU of a mouse-adapted A/Switzerland/9715293/2013 (H3N2) virus. Forty-eight hours post-infection, the animals started oseltamivir, favipiravir or baloxavir marboxil (BXM) as single or combined therapies for 10 days. Weight losses, survival rates and lung viral titers (LVTs) were determined. The neuraminidase (NA) and polymerase genes from lung viral samples were sequenced. All untreated animals died. Oseltamivir and favipiravir monotherapies only delayed mortality (the mean day to death (MDD) of 21.4 and 24 compared to 11.4 days for those untreated) while a synergistic improvement in survival (80%) and LVT reduction was observed in the oseltamivir/favipiravir group compared to the oseltamivir group. BXM alone or in double/triple combination provided a complete protection and significantly reduced LVTs. Oseltamivir and BXM monotherapies induced the E119V (NA) and I38T (PA) substitutions, respectively, while no resistance mutation was detected with combinations. We found that the multiple dose regimen of BXM alone provided superior benefits compared to oseltamivir and favipiravir monotherapies. Moreover, we suggest the potential for drug combinations to reduce the incidence of resistance.\",\"The response to the coronavirus disease 2019 (COVID-19) pandemic has been hampered by lack of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral therapy. Here we report the use of remdesivir in a patient with COVID-19 and the prototypic genetic antibody deficiency X-linked agammaglobulinaemia (XLA). Despite evidence of complement activation and a robust T cell response, the patient developed persistent SARS-CoV-2 pneumonitis, without progressing to multi-organ involvement. This unusual clinical course is consistent with a contribution of antibodies to both viral clearance and progression to severe disease. In the absence of these confounders, we take an experimental medicine approach to examine the in vivo utility of remdesivir. Over two independent courses of treatment, we observe a temporally correlated clinical and virological response, leading to clinical resolution and viral clearance, with no evidence of acquired drug resistance. We therefore provide evidence for the antiviral efficacy of remdesivir in vivo, and its potential benefit in selected patients.\",\"Identification and characterization of developed antiviral drug resistance mutations are key to the success of antiviral therapies against hepatitis C virus (HCV), which remains a worldwide highly prevalent pathogenic disease. Although most studies focus on HCV genotypes 1, 2 or 3, the investigation of drug resistance in HCV genotype 4, predominant in North Africa, is especially significant in Egypt.\",\"There are limited data on patients with chronic HCV infection in whom combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus, we aimed to assess treatment failure and rescue treatment options in these patients.\",\"Introduction: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is well known as a novel member of the coronavirus family which caused a sudden outbreak of Coronavirus disease-2019 (COVID-19) in China that quickly developed into a global pandemic. No effective approaches are found as yet for the therapy and epidemiological control of this new virus. We searched the literature in PubMed, Scopus, Web of Knowledge, Google Scholar, and MeSH, for articles and abstracts describing SARS-CoV-2, COVID-19, pneumonia, clinical trials, drug, treatment, and medicine.Areas covered: The present study aimed to comprehensively overview the current literature on effective anti-SARS-CoV-2 drugs.Expert opinion: Since the beginning of this pandemic disease, many studies have been conducted to find effective drugs to prevent COVID-19, because there are no specific drugs for the treatment of this disease. Most of these drugs with the antiviral potential effect toward COVID-19 are already used as the treatment of other infectious diseases. Some drugs that show the promising therapeutic potential in the initial clinical studies include remdesivir as an inhibitor of RNA-dependent RNA polymerase and favipiravir as an inhibitor of virus replication. Currently, remdesivir received the FDA authorizes to use as an experimental drug for emergency use in COVID-19 patients.\",\"The GETAFIX trial will test the hypothesis that favipiravir is a more effective treatment for COVID-19 infection in patients who have early stage disease, compared to current standard of care. This study will also provide an important opportunity to investigate the safety and tolerability of favipiravir, the pharmacokinetic and pharmacodynamic profile of this drug and mechanisms of resistance in the context of COVID-19 infection, as well as the effect of favipiravir on hospitalisation duration and the post COVID-19 health and psycho-social wellbeing of patients recruited to the study.\",\"Patients with inherited blood disorders (IBLD) have a high risk of hepatitis C virus (HCV) infection. The aim of this work was to assess the efficacy and safety of HCV direct-acting antiviral (DAA)-based treatment in patients with IBLD and chronic HCV infection.\",\"The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented challenge to global public health. At the time of this review, COVID-19 has been diagnosed in over 40 million cases and associated with 1.1 million deaths worldwide. Current management strategies for COVID-19 are largely supportive, and while there are more than 2000 interventional clinical trials registered with the U.S. National Library of Medicine (clinicaltrials.gov), results that can clarify benefits and risks of candidate therapies are only gradually becoming available. We herein describe recent advances in understanding SARS-CoV-2 pathobiology and potential therapeutic targets that are involved in viral entry into host cells, viral spread in the body, and the subsequent COVID-19 progression. We highlight two major lines of therapeutic strategies for COVID-19 treatment: 1) repurposing the existing drugs for use in COVID-19 patients, such as antiviral medications (e.g., remdesivir) and immunomodulators (e.g., dexamethasone) which were previously approved for other disease conditions, and 2) novel biological products that are designed to target specific molecules that are involved in SARS-CoV-2 viral entry, including neutralizing antibodies against the spike protein of SARS-CoV-2, such as REGN-COV2 (an antibody cocktail), as well as recombinant human soluble ACE2 protein to counteract SARS-CoV-2 binding to the transmembrane ACE2 receptor in target cells. Finally, we discuss potential drug resistance mechanisms and provide thoughts regarding clinical trial design to address the diversity in COVID-19 clinical manifestation. Of note, preventive vaccines, cell and gene therapies are not within the scope of the current review.\",\"Multidrug resistance in microbes poses a major health crisis and demands for the discovery of novel antimicrobial agents. The recent pandemic of SARS-CoV-2 has raised a public health emergency in almost all the countries of the world. Unlike viruses, a bacterium plays a significant role in various environmental issues such as bioremediation. Furthermore, biosurfactants produced by various bacterial species have an edge over traditionally produced chemical surfactants for its biodegradability, low toxicity and better interfacial activity with various applications in agriculture and industry. This special issue focuses on the global perspective of drug discovery for various antimicrobial, antiviral, and antifungal agents for infectious diseases. The issue also emphasizes the ongoing developments and the role of microbes in environmental remediation. We wish the articles published in this issue will enhance the current understanding in microbiology among the readers, and serve as the \\\"seed of an idea\\\" for drug development for ongoing COVID-19 pandemic.\",\"Coronaviridae is a peculiar viral family, with a very large RNA genome and characteristic appearance, endowed with remarkable tendency to transfer from animals to humans. Since the beginning of the 21st century, three highly transmissible and pathogenic coronaviruses have crossed the species barrier and caused deadly pneumonia, inflicting severe outbreaks and causing human health emergencies of inconceivable magnitude. Indeed, in the past two decades, two human coronaviruses emerged causing serious respiratory illness: severe acute respiratory syndrome coronavirus (SARS-CoV-1) and Middle Eastern respiratory syndrome coronavirus (MERS-CoV), causing more than 10,000 cumulative cases, with mortality rates of 10 % for SARS-CoV-1 and 34.4 % for MERS-CoV. More recently, the severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) has emerged in China and has been identified as the etiological agent of the recent COVID-19 pandemic outbreak. It has rapidly spread throughout the world, causing nearly 22 million cases and \\u223c 770,000 deaths worldwide, with an estimated mortality rate of \\u223c3.6 %, hence posing serious challenges for adequate and effective prevention and treatment. Currently, with the exception of the nucleotide analogue prodrug remdesivir, and despite several efforts, there is no known specific, proven, pharmacological treatment capable of efficiently and rapidly inducing viral containment and clearance of SARS-CoV-2 infection as well as no broad-spectrum drug for other human pathogenic coronaviruses. Another confounding factor is the paucity of molecular information regarding the tendency of coronaviruses to acquire drug resistance, a gap that should be filled in order to optimize the efficacy of antiviral drugs. In this light, the present review provides a systematic update on the current knowledge of the marked global efforts towards the development of antiviral strategies aimed at coping with the infection sustained by SARS-CoV-2 and other human pathogenic coronaviruses, displaying drug resistance profiles. The attention has been focused on antiviral drugs mainly targeting viral protease, RNA polymerase and spike glycoprotein, that have been tested in vitro and/or in clinical trials as well as on promising compounds proven to be active against coronaviruses by an in silico drug repurposing approach. In this respect, novel insights on compounds, identified by structure-based virtual screening on the DrugBank database endowed by multi-targeting profile, are also reported. We specifically identified 14 promising compounds characterized by a good in silico binding affinity towards, at least, two of the four studied targets (viral and host proteins). Among which, ceftolozane and NADH showed the best multi-targeting profile, thus potentially reducing the emergence of resistant virus strains. We also focused on potentially novel pharmacological targets for the development of compounds with anti-pan coronavirus activity. Through the analysis of a large set of viral genomic sequences, the current review provides a comprehensive and specific map of conserved regions across human coronavirus proteins which are essential for virus replication and thus with no or very limited tendency to mutate. Hence, these represent key druggable targets for novel compounds against this virus family. In this respect, the identification of highly effective and innovative pharmacological strategies is of paramount importance for the treatment and/or prophylaxis of the current pandemic but potentially also for future and unavoidable outbreaks of human pathogenic coronaviruses.\",\"To affect the COVID-19 pandemic, lifesaving antiviral therapies must be identified. The number of clinical trials that can be performed is limited. We developed mathematical models to project multiple therapeutic approaches. Our models recapitulate off-treatment viral dynamics and predict a three-phase immune response. Simulated treatment with remdesivir, selinexor, neutralizing antibodies, or cellular immunotherapy demonstrates that rapid viral elimination is possible if in vivo potency is sufficiently high. Therapies dosed soon after peak viral load when symptoms develop may decrease shedding duration and immune response intensity but have little effect on viral area under the curve (AUC), which is driven by high early viral loads. Potent therapy dosed before viral peak during presymptomatic infection could lower AUC. Drug resistance may emerge with a moderately potent agent dosed before viral peak. Our results support early treatment for COVID-19 if shedding duration, not AUC, is most predictive of clinical severity.\",\"Intestinal permeability is a critical factor for orally administered drugs. It can be facilitated by uptake transporters or limited by efflux transporters and metabolic enzymes in the intestine. The present study aimed to characterize the Ussing chamber system incorporating human intestinal tissue as an in vitro model for investigating the impact of intestinal uptake/efflux transporters on the intestinal absorption of substrate drugs in humans. We confirmed the functions of major intestinal uptake/efflux drug transporters in freshly isolated human jejunum sections by demonstrating a significant decrease in the mucosal uptake of cefadroxil (peptide transporter 1) and methotrexate (proton-coupled folate transporter), mucosal-to-serosal permeability of ribavirin (concentrative nucleoside transporters/equilibrative nucleoside transporters), and serosal-to-mucosal permeability of P-glycoprotein and breast cancer resistance protein substrates in the presence of their typical inhibitors. The mucosal-to-serosal apparent permeability coefficients (Papp) of 19 drugs, including substrates of drug transporters and cytochrome P450 3A, ranged from 0.60 \\u00d7 10[-6] to 29 \\u00d7 10[-6] cm/s and showed a good correlation with reported fraction of an oral dose that enters the gut wall and passes into the portal circulation with escaping intestinal metabolism (FaFg) values in humans. Furthermore, the Papp values for cefadroxil, methotrexate, and ribavirin in the presence of the corresponding transporter inhibitors underestimated the FaFg of these drugs, which clearly showed that intestinal uptake transporters facilitate their intestinal absorption in humans. In conclusion, the functions of major intestinal uptake/efflux drug transporters could be maintained in freshly isolated human jejunum sections. The Ussing chamber system incorporating human intestinal tissue would be useful for evaluating the impact of intestinal uptake/efflux transporters on the intestinal absorption of various types of drugs in humans. SIGNIFICANCE STATEMENT: Although previous studies have predicted the intestinal absorption of drugs in humans using the Ussing chamber system incorporating human intestinal tissue, there is little systematic information about drug transport mediated by multiple transporters in this system. We confirmed the functions of major intestinal uptake/efflux transporters in freshly isolated human jejunum sections and demonstrated that the mucosal-to-serosal apparent permeability coefficient of various types of drugs showed a good correlation with reported human FaFg values.\",\"To assess the efficacy of several repurposed drugs to prevent hospitalisation or death in patients aged 65 or more with recent symptomatic SARS-CoV-2 infection (COVID-19) and no criteria for hospitalisation.\",\"Two antiviral classes, the neuraminidase inhibitors (NAIs) and polymerase inhibitors (baloxavir marboxil and favipiravir) can be used to prevent and treat influenza infections during seasonal epidemics and pandemics. However, prolonged treatment may lead to the emergence of drug resistance. Therapeutic combinations constitute an alternative to prevent resistance and reduce antiviral doses. Therefore, we evaluated in vitro combinations of baloxavir acid (BXA) and other approved drugs against influenza A(H1N1)pdm09 and A(H3N2) subtypes. The determination of an effective concentration inhibiting virus cytopathic effects by 50% (EC50) for each drug and combination indexes (CIs) were based on cell viability. CompuSyn software was used to determine synergism, additivity or antagonism between drugs. Combinations of BXA and NAIs or favipiravir had synergistic effects on cell viability against the two influenza A subtypes. Those effects were confirmed using a physiological and predictive ex vivo reconstructed human airway epithelium model. On the other hand, the combination of BXA and ribavirin showed mixed results. Overall, BXA stands as a good candidate for combination with several existing drugs, notably oseltamivir and favipiravir, to improve in vitro antiviral activity. These results should be considered for further animal and clinical evaluations.\",\"Honeysuckle has been used in the treatment of influenza virus infection for thousands of years in China. However, its main active components and the functional mechanisms remain to be elucidated. Here, four honeysuckle extracts, including acids extract, flavonoids extract, total extract and acids-flavonoids mixture, were prepared to clarify the main active antiviral components. The cytopathic effect reduction assay showed that all the four extracts inhibited the replication of influenza viruses H1N1, H3N2 and the oseltamivir-resistant mutant strain H1N1-H275Y. The acids-flavonoids mixture had the strongest inhibitory effects in vitro with EC50 values of 3.8, 4.1, and > 20 \\u03bcg/mL against H1N1, H3N2 and H1N1-H275Y, respectively, showing competitive antiviral activity with oseltamivir and ribavirin. Honeysuckle acids extract also showed the most significant antiviral activity in vivo. Oral administration of the acids extract at a dosage of 600 mg/kg/d effectively alleviated viral pneumonia, maintained body weight and improved the survival rate to 30% of the mice infected with a lethal dose of H1N1. The results of time-of-drug addition experiment and neuraminidase (NA) inhibition assay showed that honeysuckle extracts had a broad-spectrum inhibitory effect against influenza virus NAs. The flavonoid extract showed the strongest inhibitory effect on the NA of influenza virus H7N9 with an IC50 of 24.7 \\u03bcg/mL. These results suggested that these extracts might exert their antiviral activity by suppressing the release of influenza viruses. Briefly, our findings demonstrate that acids and flavonoids extracts of honeysuckle are the major antiviral active components, and the acids extract has the potential to be developed into an antiviral agent against influenza virus, especially for oseltamivir-resistant viruses.\",\"Remdesivir is a broad-spectrum antiviral nucleotide prodrug that has been clinically evaluated in Ebola virus patients and recently received emergency use authorization (EUA) for treatment of COVID-19. With approvals from the Federal Select Agent Program and the Centers for Disease Control and Prevention's Institutional Biosecurity Board, we characterized the resistance profile of remdesivir by serially passaging Ebola virus under remdesivir selection; we generated lineages with low-level reduced susceptibility to remdesivir after 35 passages. We found that a single amino acid substitution, F548S, in the Ebola virus polymerase conferred low-level reduced susceptibility to remdesivir. The F548 residue is highly conserved in filoviruses but should be subject to specific surveillance among novel filoviruses, in newly emerging variants in ongoing outbreaks, and also in Ebola virus patients undergoing remdesivir therapy. Homology modeling suggests that the Ebola virus polymerase F548 residue lies in the F-motif of the polymerase active site, a region that was previously identified as susceptible to resistance mutations in coronaviruses. Our data suggest that molecular surveillance of this region of the polymerase in remdesivir-treated COVID-19 patients is also warranted.\",\"Chronic hepatitis C still figures as an important cause of morbidity among the Brazilian population, and is closely associated with metabolic disturbances, including insulin resistance (IR), which can be evaluated by the Homeostatic Model Assessment (HOMA-IR). IR may entail lower sustained virologic response (SVR) on certain therapeutic regimens and faster progression to advanced hepatic fibrosis. With the arrival of the direct acting agents (DAA) in hepatitis C treatment, there is an increased need in observing the impact in patients' IR profile while using such therapies.\",\"SARS-CoV-2 is responsible for COVID-19, resulting in the largest pandemic in over a hundred years. After examining the molecular structures and activities of hepatitis C viral inhibitors and comparing hepatitis C virus and coronavirus replication, we previously postulated that the FDA-approved hepatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) might inhibit SARS-CoV-2. We subsequently demonstrated that Sofosbuvir triphosphate is incorporated by the relatively low fidelity SARS-CoV and SARS-CoV-2 RNA-dependent RNA polymerases (RdRps), serving as an immediate polymerase reaction terminator, but not by a host-like high fidelity DNA polymerase. Other investigators have since demonstrated the ability of Sofosbuvir to inhibit SARS-CoV-2 replication in lung and brain cells; additionally, COVID-19 clinical trials with EPCLUSA and with Sofosbuvir plus Daclatasvir have been initiated in several countries. SARS-CoV-2 has an exonuclease-based proofreader to maintain the viral genome integrity. Any effective antiviral targeting the SARS-CoV-2 RdRp must display a certain level of resistance to this proofreading activity. We report here that Sofosbuvir terminated RNA resists removal by the exonuclease to a substantially higher extent than RNA terminated by Remdesivir, another drug being used as a COVID-19 therapeutic. These results offer a molecular basis supporting the current use of Sofosbuvir in combination with other drugs in COVID-19 clinical trials.\",\"With the global threat of SARS-CoV-2, much effort has been focused on treatment and disease control. However, how coronaviruses react to the treatments and whether the surviving viruses have altered their characteristics are also unanswered questions with medical importance. To this end, bovine coronavirus (BCoV), which is in the same genus as SARS-CoV-2, was used as a test model and the findings were as follows. With the treatment of antiviral remdesivir, the selected BCoV variant with an altered genome structure developed resistance, but its pathogenicity was not increased in comparison to that of wild type (wt) BCoV. Under the selection pressure of innate immunity, the genome structure was also altered; however, neither resistance developed nor pathogenicity increased for the selected BCoV variant. Furthermore, both selected BCoV variants showed a better efficiency in adapting to alternative host cells than wt BCoV. In addition, the previously unidentified feature that the spike protein was a common target for mutations under different antiviral treatments might pose a problem for vaccine development because spike protein is a common target for antibody and vaccine designs. The findings derived from this fundamental research may contribute to the disease control and treatments against coronaviruses, including SARS-CoV-2.\",\"Remdesivir (RDV) is a direct-acting antiviral agent that is used to treat patients with severe coronavirus disease 2019 (COVID-19). RDV targets the viral RNA-dependent RNA polymerase (RdRp) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We have previously shown that incorporation of the active triphosphate form of RDV (RDV-TP) at position i causes delayed chain termination at position i + 3. Here we demonstrate that the S861G mutation in RdRp eliminates chain termination, which confirms the existence of a steric clash between Ser-861 and the incorporated RDV-TP. With WT RdRp, increasing concentrations of NTP pools cause a gradual decrease in termination and the resulting read-through increases full-length product formation. Hence, RDV residues could be embedded in copies of the first RNA strand that is later used as a template. We show that the efficiency of incorporation of the complementary UTP opposite template RDV is compromised, providing a second opportunity to inhibit replication. A structural model suggests that RDV, when serving as the template for the incoming UTP, is not properly positioned because of a significant clash with Ala-558. The adjacent Val-557 is in direct contact with the template base, and the V557L mutation is implicated in low-level resistance to RDV. We further show that the V557L mutation in RdRp lowers the nucleotide concentration required to bypass this template-dependent inhibition. The collective data provide strong evidence to show that template-dependent inhibition of SARS-CoV-2 RdRp by RDV is biologically relevant.\",\"Plant diseases are seriously endangering agricultural production. The emergence of drug resistance has brought great challenges to the prevention and control of plant diseases. There is an urgent need for the emergence of new drug candidates. In this work, we achieved the efficient synthesis of pulmonarins A and B in 64% and 59% overall yield, respectively. Pulmonarins A and B were found to have good antiviral activities against tobacco mosaic virus (TMV) for the first time. A series of pulmonarin derivatives were designed, synthesized, and evaluated for their antiviral and fungicidal activities systematically. Most compounds displayed higher anti-TMV activities than commercial ribavirin. Compounds 6a, 6c, and 6n with better inactivation effects than ningnanmycin emerged as new antiviral candidates. We selected 6c for further antiviral mechanism research, which revealed that it could inhibit virus assembly by interacting with TMV coat protein (CP). The molecular docking results further confirmed that these compounds could interact with CP through hydrogen bonding. These compounds also displayed broad spectrum fungicidal activities. Especially compound 6u with prominent antifungal activity emerged as a new fungicidal candidate for further research. The current work provides a reference for understanding the application of pulmonarin alkaloids in plant protection.\",\"To evaluate the impact of baseline resistance-associated substitutions (RASs) on direct-acting antiviral (DAA) treatment response among pegylated interferon in combination with ribavirin (PR) failing patients in a real-life setting.\",\"Ribavirin has been used for 25 years to treat patients with chronic hepatitis C virus (HCV) infection; however, its antiviral mechanism of action remains unclear. Here, we studied virus evolution in a subset of samples from a randomized 24-week trial of ribavirin monotherapy versus placebo in chronic HCV patients, as well as the viral resistance mechanisms of the observed ribavirin-associated mutations in cell culture. Thus, we performed next-generation sequencing of the full-length coding sequences of HCV recovered from patients at weeks 0, 12, 20, 32 and 40 and analyzed novel single nucleotide polymorphisms (SNPs), diversity, and mutation-linkage. At week 20, increased genetic diversity was observed in 5 ribavirin-treated compared to 4 placebo-treated HCV patients due to new synonymous SNPs, particularly G-to-A and C-to-U ribavirin-associated transitions. Moreover, emergence of 14 nonsynonymous SNPs in HCV nonstructural 5B (NS5B) occurred in treated patients, but not in placebo controls. Most substitutions located close to the NS5B polymerase nucleotide entry site. Linkage analysis showed that putative resistance mutations were found in the majority of genomes in ribavirin-treated patients. Identified NS5B mutations from genotype 3a patients were further introduced into the genotype 3a cell-culture-adapted DBN strain for studies in Huh7.5 cells. Specific NS5B substitutions, including DBN-D148N+I363V, DBN-A150V+I363V, and DBN-T227S+S183P, conferred resistance to ribavirin in long-term cell culture treatment, possibly by reducing the HCV polymerase error rate. In conclusion, prolonged exposure of HCV to ribavirin in chronic hepatitis C patients induces NS5B resistance mutations leading to increased polymerase fidelity, which could be one mechanism for ribavirin resistance.\",\"Induction of highly pathogenic hepatitis C virus (HCV) causes chronic hepatitis round the world. This virus is easily prone to developing resistance against antiviral drugs because of two viral polymerases that do not possess the proofreading and overlapping reading frame abilities. There is more than one explanation for how this virus builds up resistance against antiviral drug treatments. Assays are now available to detect HCV-resistant variants, based on phenotypic and genotypic assays, and next generation sequencing. But these assays are of a little value at baseline, because they are not influential enough for making therapeutic decisions in HCV patients. Moreover, HCV monitoring is now an essential part of clinical practice. Special patients, such as those with thalassemia, renal transplant due to renal failure, and the patients undergoing hemodialysis, are at higher risk for acquiring this infection. Management of HCV infection in these patient groups is complicated by multiple side effects, including flu-like symptoms, neutropenia, fever, and neuropsychiatric disorders, thus limiting the use of ribavirin and coexisting iron overload. In HCV patients suffering from depression, the treatment may be discontinued because of some defects in neurochemical pathways caused by interferon, which can enhance the level of depression in these patients. In addition, obesity has been found to be a marker of failure of HCV treatment. There will be many resistance tolerant HCV treatment options available in the near future.\",\"Obese patients who often present metabolic dysfunction-associated fatty liver disease (MAFLD) are at risk of severe presentation of coronavirus disease 2019 (COVID-19). These patients are more likely to be hospitalized and receive antiviral agents and other drugs required to treat acute respiratory distress syndrome and systemic inflammation, combat bacterial and fungal superinfections and reverse multi-organ failure. Among these pharmaceuticals, antiretrovirals such as lopinavir/ritonavir and remdesivir, antibiotics and antifungal agents can induce drug-induced liver injury (DILI), whose mechanisms are not always understood. In the present article, we hypothesize that obese COVID-19 patients with MAFLD might be at higher risk for DILI than non-infected healthy individuals or MAFLD patients. These patients present several concomitant factors, which individually can favour DILI: polypharmacy, systemic inflammation at risk of cytokine storm, fatty liver and sometimes nonalcoholic steatohepatitis (NASH) as well as insulin resistance and other diseases linked to obesity. Hence, in obese COVID-19 patients, some drugs might cause more severe (and/or more frequent) DILI, while others might trigger the transition of fatty liver to NASH, or worsen pre-existing steatosis, necroinflammation and fibrosis. We also present the main mechanisms whereby drugs can be more hepatotoxic in MAFLD including impaired activity of xenobiotic-metabolizing enzymes, mitochondrial dysfunction, altered lipid homeostasis and oxidative stress. Although comprehensive investigations are needed to confirm our hypothesis, we believe that the current epidemic of obesity and related metabolic diseases has extensively contributed to increase the number of cases of DILI in COVID-19 patients, which may have participated in presentation severity and death.\",\"This is the ninth version (eighth update) of the living guideline, replacing earlier versions, available as data supplements. New recommendations will be published as updates to this guideline.\",\"Influenza A(H1N1)pdm09 viruses carrying a dual neuraminidase (NA) substitution were isolated from immunocompromised patients after administration of one or more NA inhibitors. These mutant viruses possessed an H275Y/I223R, H275Y/I223K, or H275Y/G147R substitution in their NA and showed enhanced cross-resistance to oseltamivir and peramivir and reduced susceptibility to zanamivir compared to single H275Y mutant viruses. Baloxavir could be a treatment option against the multidrug-resistant viruses because these dual H275Y mutant viruses showed susceptibility to this drug. The G147R substitution appears to stabilize the NA structure, with the fitness of the H275Y/G147R mutant virus being similar or somewhat better than that of the wild-type virus. Since the multidrug-resistant viruses may be able to transmit between humans, surveillance of these viruses must continue to improve clinical management and to protect public health.\",\"Oxidative stress (OS) and insulin resistance (IR) induced by hepatitis C virus (HCV) infection, are involved in the development of chronic hepatitis C (CHC) complications and progression to hepatocellular carcinoma. The aim of this study was to investigate the effect of pegylated interferon alpha (IFN\\u03b1) + ribavirin (PegIFN\\u03b1+RVB) or sofosbuvir + NS5A inhibitor (SOF+InNS5A) on IR and the components of OS. HCV was genotyped in 20 CHC patients grouped by treatment with either PegIFN\\u03b1+RVB (n = 10) or SOF+InNS5A (n = 10). The treatment's effect on OS-induced damage to lipids (HNE-HDL), proteins (advanced glycation end products [AGEs]), and DNA (8-OHdG) as well as the concentrations of proinflammatory cytokines (IL-2, TNF\\u03b1, IFN\\u03b3), ALT, AST, GSH and platelets was determined. Superoxide dismutase (SOD) and catalase activity as well as IR, determined by the HOMA1-IR index, was evaluated. The HCV genotypes (GT) found were GT1b (45%), GT1a (30%), GT2b (20%), and GT2a (5%). Viral RNA became undetectable by week 12 with SOF+InNS5A in 100% of the cases and with PegIFN\\u03b1+RVB in 70% of the cases. After viral RNA became undetectable, regardless of treatment and GT, a significant increase in the platelet concentration and SOD activity was observed, whereas ALT, insulin, and IR decreased (p < 0.05). However, only for the SOF+InNS5A treated group was there an increase in oxidative damage to lipids (p < 0.017) and proteins (p < 0.05). None of the other parameters demonstrated any differences. These data confirm that OS persisted after treatment with either SOF+InNS5A or PegIFN\\u03b1+RVB. IR could be considered a response biomarker to treatment with direct-acting antivirals.\",\"The aim of our study was to evaluate the association between insulin resistance and the response to IFN-alpha and ribavirin in pediatric patients with chronic hepatitis C.\",\"We aimed to clarify the features of resistance-associated substitutions (RASs) after failure of multiple interferon (IFN)-free regimens in HCV genotype 1b infections.\",\"New therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate treatment opportunity. We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19.\",\"To evaluate the effect of generic sofosbuvir and daclatasvir (SOF/DCV) treatment on the glycemic state and insulin resistance as well as lipid profiles of those who achieved sustained virological response (SVR) in diabetic chronic hepatitis C virus (CHC) patients.\",\"On June 8, 2018, an NS3/4A protease inhibitor called danoprevir was approved in China to treat the infections of HCV genotype (GT) 1b - the most common HCV genotype worldwide. Based on phase 2 and 3 clinical trials, the 12-week regimen of ritonavir-boosted danoprevir (danoprevir/r) plus peginterferon alpha-2a and ribavirin offered 97.1% (200/206) of sustained virologic response at post-treatment week 12 (SVR12) in treatment-na\\u00efve non-cirrhotic patients infected with HCV genotype 1b. Adverse events such as anemia, fatigue, fever, and headache were associated with the inclusion of peginterferon alpha-2a and ribavirin in the danoprevir-based regimen. Moreover, drug resistance to danoprevir could be traced to amino acid substitutions (Q80K/R, R155K, D168A/E/H/N/T/V) near the drug-binding pocket of HCV NS3 protease. Despite its approval, the clinical use of danoprevir is currently limited to its combination with peginterferon alpha-2a and ribavirin, thereby driving its development towards interferon-free, ribavirin-free regimens with improved tolerability and adherence. In the foreseeable future, pan-genotypic direct-acting antivirals with better clinical efficacy and less adverse events will be available to treat HCV infections worldwide.\",\"Alphaviruses are arthropod-borne viruses of public health concern. To date no efficient vaccine nor antivirals are available for safe human use. During viral replication the nonstructural protein 1 (nsP1) catalyzes capping of genomic and subgenomic RNAs. The capping reaction is unique to the Alphavirus genus. The whole three-step process follows a particular order: (i) transfer of a methyl group from S-adenosyl methionine (SAM) onto a GTP forming [m7]GTP; (ii) guanylylation of the enzyme to form a [m7]GMP-nsP1adduct; (iii) transfer of [m7]GMP onto 5'-diphosphate RNA to yield capped RNA. Specificities of these reactions designate nsP1 as a promising target for antiviral drug development. In the current study we performed a mutational analysis on two nsP1 positions associated with Sindbis virus (SINV) ribavirin resistance in the Venezuelan equine encephalitis virus (VEEV) context through reverse genetics correlated to enzyme assays using purified recombinant VEEV nsP1 proteins. The results demonstrate that the targeted positions are strongly associated to the regulation of the capping reaction by increasing the affinity between GTP and nsP1. Data also show that in VEEV the S21A substitution, naturally occurring in Chikungunya virus (CHIKV), is a hallmark of ribavirin susceptibility. These findings uncover the specific mechanistic contributions of these residues to nsp1-mediated methyl-transfer and guanylylation reactions.\",\"Viral diversity is an important feature of hepatitis C virus (HCV) infection and an important predictor of disease progression and treatment response. HIV/HCV co-infection is associated with enhanced HCV replication, increased fibrosis, and the development of liver disease. HIV also increases quasispecies diversity of HCV structural genes, although limited data are available regarding the impact of HIV on non-structural genes of HCV, particularly in the absence of direct-acting therapies. The genetic diversity and presence of drug resistance mutations within the RNA-dependent RNA polymerase (NS5B) gene were examined in 3 groups of women with HCV genotype 1a infection, including those with HCV mono-infection, antiretroviral (ART)-na\\u00efve women with HIV/HCV co-infection and CD4 cell count <350 cells/mm3, and ART-na\\u00efve women with HIV/HCV co-infection and CD4 cell count \\u2265350 cells/mm3. None had ever been treated for HCV infection. There was evidence of significant diversity across the entire NS5B gene in all women. There were several nucleotides and amino acids with distinct distributions across the three study groups, although no obvious clustering of NS5B sequences was observed based on HIV co-infection or CD4 cell count. Polymorphisms at amino acid positions associated with resistance to dasabuvir and sofosbuvir were limited, although the Q309R variant associated with ribavirin resistance was present in 12 individuals with HCV mono-infection, 8 HIV/HCV co-infected individuals with CD4 <350 cells/mm3, and 12 HIV/HCV co-infected individuals with CD4 \\u2265350 cells/mm3. Previously reported fitness altering mutations were rare. CD8+ T cell responses against the human leukocyte antigen (HLA) B57-restricted epitopes NS5B2629-2637 and NS5B2936-2944 are critical for HCV control and were completely conserved in 44 (51.8%) and 70 (82.4%) study participants. These data demonstrate extensive variation across the NS5B gene. Genotypic variation may have a profound impact on HCV replication and pathogenesis and deserves careful evaluation.\",\"Hepatitis E virus (HEV) may be resistant to immunosuppression reduction and ribavirin treatment in kidney transplant recipients because of mutant strains and severe side effects of ribavirin which conduct to dose reduction. Sofosbuvir efficacy is controversial. Peg-interferon 2 alpha (PEG-IFN) is currently contraindicated due to a high risk of acute humoral and cellular rejection. The present study assessed, for the first time, the effect of PEG-IFN in a kidney transplant recipient infected with HEV.\",\"The hepatitis C virus (HCV) NS5A-P32 deletion (P32del) confers potent resistance to NS5A inhibitors. Chronic hepatitis C patients in whom NS5A-P32del variants had emerged during prior direct-acting antiviral (DAA) therapy with an NS5A inhibitor show poor response to DAA retreatment. Here, we report three patients with HCV NS5A-P32del infection who were treated with sofosbuvir, velpatasvir plus ribavirin (SOF/VEL + RBV) in a real-world setting. The patients developed HCV NS5A-P32del, L31F + P32del, or L31V + P32del variants following failure of daclatasvir plus asunaprevir (DCV/ASV) therapy. One of the patients failed to respond to subsequent DCV/ASV and beclabuvir therapy, and the remaining two patients failed to respond to subsequent glecaprevir and pibrentasvir therapy. All three patients completed 24-week SOF/VEL + RBV therapy. Serum HCV RNA became negative at the end of the therapy in all three patients. Two patients with NS5A-P32del and NS5A-L31F + P32del achieved sustained virological response 12 weeks after completion of treatment (SVR12), but HCV relapsed in the remaining NS5A-L13V + P32del patient. Direct sequence analysis detected no additional variants within either the NS5A or NS5B regions at the time of relapse. In conclusion, three patients with prior NS5A-P32del-associated DAA treatment failure received 24 weeks of SOF/VEL + RBV therapy, and two of the patients achieved SVR12.\",\"Plant diseases caused by plant viruses and pathogens seriously affect the production and storage of food crops. With the emergence of drug resistance, it is very difficult to control. Natural products are the source of new drug discovery. Here, the natural product streptindole was found to have good antiviral activity against tobacco mosaic virus (TMV) and fungicidal activities against 14 kinds of phytopathogenic fungi. A series of derivatives of streptindole were designed, synthesized, and evaluated for their antiviral and fungicidal activities. Compounds 4, 5, 11, 12c, 12d, 13d, and 13i-13l showed higher anti-TMV activities than ribavirin (inhibitory rate: 38, 37, and 40% at 500 \\u03bcg/mL for inactivation, curative, and protection activity in vivo, respectively), among which compound 12d (inhibitory rate: 57, 55, and 53% at 500 \\u03bcg/mL for inactivation, curative, and protection activity in vivo, respectively) with excellent antiviral activity was further evaluated for the mode of action. The mechanism research revealed that 12d can break the three-dimensional structure of TMV coat protein (CP) through hydrogen bonds, thus inhibiting the assembly of virus particles. The molecular docking result showed that compound 12d did exhibit strong interaction with TMV CP. The derivatives of streptindole also displayed broad-spectrum fungicidal activities. The current study provided valuable insights into the antiviral and fungicidal activities of streptindole derivatives.\",\"The combination of ledipasvir and sofosbuvir (LDV/SOF) has been approved for the treatment of various hepatitis C virus (HCV) genotypes across many countries. This article presents an integrated analysis of three prospective phase II/III trials in the Asia-Pacific region to evaluate the efficacy and safety of 12 weeks of LDV/SOF in HCV genotype 2 patients without cirrhosis or with compensated cirrhosis.\",\"During the last decade multiple mumps outbreaks have occurred in the U.S. despite high two dose MMR coverage with most cases detected among two dose MMR vaccine recipients. Waning immunity, the evolution of wild-type virus strains, and settings with intense exposure have contributed to the resurgence of mumps. Typically, mumps virus infections resolve without serious clinical sequelae; however, serious complications may occur among unvaccinated or severely immunocompromised individuals. Favipiravir (T-705) has been shown to have in vitro anti-viral activity against a broad range of positive and negative strand RNA viruses. Here, we demonstrate that T-705 inhibits the growth of wildtype and vaccine strains of mumps virus in vitro at low micro-molar concentrations (EC50 8-10\\u03bcM). We did not observe the development of resistance after five subsequent passages at low concentrations of drug. Both viral RNA and protein synthesis were selectively reduced compared to host mRNA and protein synthesis. Antiviral treatment options for mumps virus infection may be valuable, especially for areas with a high disease burden or for cases with severe complications. These results presented here suggest that further studies are warranted.\",\"Picornaviruses have both asexual and sexual RNA replication mechanisms. Asexual RNA replication mechanisms involve one parental template, whereas sexual RNA replication mechanisms involve two or more parental templates. Because sexual RNA replication mechanisms counteract ribavirin-induced error catastrophe, we selected for ribavirin-resistant poliovirus to identify polymerase residues that facilitate sexual RNA replication mechanisms. We used serial passage in ribavirin, beginning with a variety of ribavirin-sensitive and ribavirin-resistant parental viruses. Ribavirin-sensitive virus contained an L420A polymerase mutation, while ribavirin-resistant virus contained a G64S polymerase mutation. A G64 codon mutation (G64[Fix]) was used to inhibit emergence of G64S-mediated ribavirin resistance. Revertants (L420) or pseudorevertants (L420V and L420I) were selected from all independent lineages of L420A, G64[Fix] L420A, and G64S L420A parental viruses. Ribavirin resistance G64S mutations were selected in two independent lineages, and novel ribavirin resistance mutations were selected in the polymerase in other lineages (M299I, M323I, M392V, and T353I). The structural orientation of M392, immediately adjacent to L420 and the polymerase primer grip region, led us to engineer additional polymerase mutations into poliovirus (M392A, M392L, M392V, K375R, and R376K). L420A revertants and pseudorevertants (L420V and L420I) restored efficient viral RNA recombination, confirming that ribavirin-induced error catastrophe coincides with defects in sexual RNA replication mechanisms. Viruses containing M392 mutations (M392A, M392L, and M392V) and primer grip mutations (K375R and R376K) exhibited divergent RNA recombination, ribavirin sensitivity, and biochemical phenotypes, consistent with changes in the fidelity of RNA synthesis. We conclude that an extended primer grip of the polymerase, including L420, M392, K375, and R376, contributes to the fidelity of RNA synthesis and to efficient sexual RNA replication mechanisms.IMPORTANCE Picornaviruses have both asexual and sexual RNA replication mechanisms. Sexual RNA replication shapes picornavirus species groups, contributes to the emergence of vaccine-derived polioviruses, and counteracts error catastrophe. Can viruses distinguish between homologous and nonhomologous partners during sexual RNA replication? We implicate an extended primer grip of the viral polymerase in sexual RNA replication mechanisms. By sensing RNA sequence complementarity near the active site, the extended primer grip of the polymerase has the potential to distinguish between homologous and nonhomologous RNA templates during sexual RNA replication.\",\"Starting from late 2019, the coronavirus disease 2019 (COVID-19) has emerged as a once-in-a-century pandemic with deadly consequences, which urgently calls for new treatments, cures, and supporting apparatuses. Recently, because of its positive results in clinical trials, remdesivir was approved by the Food and Drug Administration to treat COVID-19 through Emergency Use Authorization. Here, we used molecular dynamics simulations and free energy perturbation methods to study the inhibition mechanism of remdesivir to its target SARS-CoV-2 virus RNA-dependent RNA polymerase (RdRp). We first constructed the homology model of this polymerase based on a previously available structure of SARS-CoV NSP12 RdRp (with a sequence identity of 95.8%). We then built a putative preinsertion binding structure by aligning the remdesivir + RdRp complex to the ATP bound poliovirus RdRp without the RNA template. The putative binding structure was further optimized with molecular dynamics simulations. The resulting stable preinsertion state of remdesivir appeared to form hydrogen bonds with the RNA template when aligned with the newly solved cryo-EM structure of SARS-CoV-2 RdRp. The relative binding free energy between remdesivir and ATP was calculated to be -2.80 \\u00b1 0.84 kcal/mol, where remdesivir bound much stronger to SARS-CoV-2 RdRp than the natural substrate ATP. The \\u223c100-fold improvement in the Kd from remdesivir over ATP indicates an effective replacement of ATP in blocking of the RdRp preinsertion site. Key residues D618, S549, and R555 are found to be the contributors to the binding affinity of remdesivir. These findings suggest that remdesivir can potentially act as a SARS-CoV-2 RNA-chain terminator, effectively stopping its RNA replication, with key residues also identified for future lead optimization and/or drug resistance studies.\",\"In previous studies that investigated the impact of direct-acting antiviral (DAA) treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients have been compared to baseline values with either end of treatment or post-treatment values. The results are inconsistent. We evaluated patients throughout the treatment and after treatment.\",\"COVID-19, the illness caused by infection with the novel coronavirus SARS-CoV-2, is a rapidly spreading global pandemic in urgent need of effective treatments. Here we present a comprehensive examination of the host- and virus-targeted functions of the flavonolignan silibinin, a potential drug candidate against COVID-19/SARS-CoV-2. As a direct inhibitor of STAT3-a master checkpoint regulator of inflammatory cytokine signaling and immune response-silibinin might be expected to phenotypically integrate the mechanisms of action of IL-6-targeted monoclonal antibodies and pan-JAK1/2 inhibitors to limit the cytokine storm and T-cell lymphopenia in the clinical setting of severe COVID-19. As a computationally predicted, remdesivir-like inhibitor of RNA-dependent RNA polymerase (RdRp)-the central component of the replication/transcription machinery of SARS-CoV-2-silibinin is expected to reduce viral load and impede delayed interferon responses. The dual ability of silibinin to target both the host cytokine storm and the virus replication machinery provides a strong rationale for the clinical testing of silibinin against the COVID-19 global public health emergency. A randomized, open-label, phase II multicentric clinical trial (SIL-COVID19) will evaluate the therapeutic efficacy of silibinin in the prevention of acute respiratory distress syndrome in moderate-to-severe COVID-19-positive onco-hematological patients at the Catalan Institute of Oncology in Catalonia, Spain.\",\"Effective therapies to treat coronavirus disease 2019 (COVID-19) are urgently needed. While many investigational, approved, and repurposed drugs have been suggested as potential treatments, preclinical data from animal models can guide the search for effective treatments by ruling out those that lack efficacy in vivo. Remdesivir (GS-5734) is a nucleotide analogue prodrug with broad antiviral activity[1,2] that is currently being investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration[3,4]. In animal models, remdesivir was effective against infection with Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV)[2,5,6]. In vitro, remdesivir inhibited replication of SARS-CoV-2[7,8]. Here we investigate the efficacy of remdesivir in a rhesus macaque model of SARS-CoV-2 infection[9]. Unlike vehicle-treated animals, macaques treated with remdesivir did not show signs of respiratory disease; they also showed reduced pulmonary infiltrates on radiographs and reduced virus titres in bronchoalveolar lavages twelve hours after the first dose. Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment. At necropsy, remdesivir-treated animals had lower lung viral loads and reduced lung damage. Thus, treatment with remdesivir initiated early during infection had a clinical benefit in rhesus macaques infected with SARS-CoV-2. Although the rhesus macaque model does not represent the severe disease observed in some patients with COVID-19, our data support the early initiation of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia.\",\"No information exists regarding direct-acting antivirals (DAAs) salvage therapy for Hepatitis C (HCV)-infected patients with any type of cancer. We prospectively evaluated the safety and efficacy (SVR12) of salvage therapy in these patients.\",\"Coronavirus disease 19 (COVID-19) is a severe acute respiratory syndrome caused by SARS-CoV-2 (2019-nCoV). While no drugs have yet been approved to treat this disease, small molecules effective against other viral infections are under clinical evaluation for therapeutic abatement of SARS-CoV-2 infections. Ongoing clinical trials include Kaletra (a combination of two protease inhibitors approved for HIV treatment), remdesivir (an investigational drug targeting RNA-dependent RNA polymerase [RdRP] of SARS-CoV-2), and hydroxychloroquine (an approved anti-malarial and immuno-modulatory drug). Since SARS-CoV-2 replication depends on three virally encoded proteins (RdRP, papain-like proteinase, and helicase), we screened 54 FDA-approved antiviral drugs and ~3300 investigational drugs for binding to these proteins using targeted and unbiased docking simulations and computational modeling. Elbasvir, a drug approved for treating hepatitis C, is predicted to bind stably and preferentially to all three proteins. At the therapeutic dosage, elbasvir has low toxicity (liver enzymes transiently elevated in 1% of subjects) and well-characterized drug-drug interactions. We predict that treatment with elbasvir, alone or in combination with other drugs such as grazoprevir, could efficiently block SARS-CoV-2 replication. The concerted action of elbasvir on at least three targets essential for viral replication renders viral mutation to drug resistance extremely unlikely.\",\"Highly effective direct-acting antivirals (DAAs) for Hepatitis C treatment are largely inaccessible in sub-Saharan Africa. Data on treatment feasibility and outcomes in clinical settings are limited. We assessed the feasibility of achieving a high (\\u226590%) cure rate with DAAs in six gastroenterology clinics in Cameroon.\",\"Background: In the United States, the number of new cases of hepatitis C virus infection has risen in recent years, driven largely by transmission among young white adults in their 20s and 30s. Herein, we report an integrated analysis of participants with hepatitis C virus infection aged \\u226435 years from 12 phase II/III clinical trials of elbasvir/grazoprevir.Methods: Treatment-naive and -experienced adults with hepatitis C virus genotype 1 or 4 infection received elbasvir (50 mg/day)/grazoprevir (100 mg/day) for 12 weeks without ribavirin. Analyses were stratified according to participant age (\\u226435 years vs >35 years). The primary endpoint was sustained virologic response (hepatitis C virus RNA < lower limit of quantitation at 12 weeks after completion of therapy).Results: Sustained virologic response was achieved by 98.9% (271/274) of participants aged \\u226435 years and by 96.9% (2093/2160) aged >35 years. Three participants aged \\u226435 years with genotype 1b infection relapsed. Eight participants with genotype 1a infection and baseline non-structural protein 5 A resistance-associated substitutions achieved sustained virologic response. Similarly, all 85 participants aged \\u226435 years with genotype 1a infection and no baseline non-structural protein 5 A resistance-associated substitutions achieved sustained virologic response. Safety was favorable, with the incidence of drug-related adverse events similar in younger and older participants (30.1% vs 30.6%). One participant (0.4%) aged \\u226435 years and 15 participants (0.7%) aged >35 years discontinued treatment owing to adverse events.Conclusions: Elbasvir/grazoprevir for 12 weeks was safe and highly effective in participants aged \\u226435 years with hepatitis C virus genotype 1 or 4 infection.\",\"Background: Despite the outstanding results of direct-acting antiviral therapies (DAAs) of Hepatitis C infection (HCV), non-responders had to be more defined. Aim: assess the outcome of DAAs in linkage with Interferon lambda 3 (IFNL3) in HCV patients. Methods: This case-control-study was conducted on 495 chronic-HCV (genotype-4a), previously treated Egyptians by either DAAs (responders 195, 120 relapsers) or interferon/ribavirin (IFN/RBV) (140 responders, 60 relapsers), and 98 healthy controls. IFNL3 distribution, clinical and laboratory data were assessed. Results: CT was the most predominant genotype in Egyptians (51%). All genotypes were sensitive to DAAs mainly CT genotype (60%), even TT genotype (resistant to IFN/RBV 40%) had 29.2% sensitivity. CT genotype was predominant in sofosbuvir/Daclatasvir responders (67.6%) (OR = 0.66), while non-CT prevailed in relapsers (56.7%). TT genotype may respond to SOF/Ledi better than other regimens (66.7%). In IFN/RBV relapsers; CT genotype was commoner (50%) than others, while CC genotype predominated in responders (54.3%). The c allele was the commonest in responders to IFN/RBV (71.4%), while the T allele was resistant to treatment (65% in relapsers). Addition of RBV to SOF/DCV reported higher resistance with CT genotype (42.2%-50%) and TT genotype (17.8%-27.8%). Conclusion: This study recommended IFNL3 genotyping to be a prerequisite before stratifying treatment for HCV-4a Egyptians.\",\"Relapses after therapy with direct-acting antiviral agents (DAA) in chronic hepatitis C virus (HCV) infections are rare due to high efficacy of interferon-free therapy regimens. The presence of resistance-associated substitutions (RAS) in proteins targeted by therapy can lead to lower rates of sustained virological response (SVR) in patients receiving DAA-therapy, and little evidence exists as to how to treat these patients.\",\"Many studies have been performed to develop an antiviral therapy against the hepatitis C virus (HCV) infections. The usual treatment for HCV infection is a combination of PEGylated interferon and ribavirin which offer restricted efficiency and major side effects. Thus, recent development in molecular biology of HCV and its life cycle led to the design of many drugs that target viral proteins and host factors required for viral replication. These drugs were named as direct-acting antivirals (DAAs) that were specifically designed for inhibition of viral life cycle, promising tolerability, short duration of treatment, higher barrier to resistance, and fewer drug interactions. The use of DAAs for the treatment of HCV infection resulted in high virological cure rates in patients. However, the use of combined DAA regimens may present drug interactions especially in patients under treatment for other co-morbidities. On the other hand, drug resistance against virus infection determines the success of long-term therapy. High genetic diversity among HCV virions due to error-prone polymerase activity led to the reduced susceptibility to DAA-therapy. Therefore, preclinical and clinical analysis of HCV resistance to novel drugs is needed. In this review, we describe pharmaceutical approaches for HCV treatment, structural and functional properties of DAAs, the principles of HCV drug-drug interaction, and finally HCV resistance to DAAs.\",\"Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing treatment duration can improve adherence, reduce drug exposure and cost. Accordingly, we evaluated the efficacy of 8 weeks fixed-dose combination of grazoprevir-elbasvir in treatment-na\\u00efve patients, with non-severe fibrosis.\",\"For treatment of genotype 1a (GT1a) infection with elbasvir/grazoprevir, the German guidelines recommend a differentiated approach depending on baseline viral load (BVL). For low BVL \\u2264800 000 IU/mL, treatment with 12 weeks elbasvir/grazoprevir should be considered, whereas for high BVL >800 000 IU/mL, this regimen is only recommended in nonstructural protein 5A (NS5A) resistance-associated substitutions (RAS) absence. With present NS5A RAS or when RAS-testing is not available, 16 weeks elbasvir/grazoprevir + ribavirin is preferred. Here, we investigated the adherence to these recommendations and the effectiveness of elbasvir/grazoprevir in a large German Hepatitis C-Registry GT1a cohort.\",\"The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target of choice for the prophylactic or curative treatment of several viral diseases, due to high sequence and structural conservation. To date, the most promising broad-spectrum class of viral RdRp inhibitors are nucleoside analogues (NAs), with over 25 approved for the treatment of several medically important viral diseases. However, Coronaviruses stand out as a particularly challenging case for NA drug design due to the presence of an exonuclease (ExoN) domain capable of excising incorporated NAs and thus providing resistance to many of these available antivirals. Here we use the available structures of the SARS-CoV RdRp and ExoN proteins, as well as Lassa virus N exonuclease to derive models of catalytically competent SARS-CoV-2 enzymes. We then map a promising NA candidate, GS-441524 (the active metabolite of Remdesivir) to the nucleoside active site of both proteins, identifying the residues important for nucleotide recognition, discrimination, and excision. Interestingly, GS-441524 addresses both enzyme active sites in a manner consistent with significant incorporation, delayed chain termination, and altered excision due to the ribose 1'-CN group, which may account for the increased antiviral effect compared to other available analogues. Additionally, we propose structural and function implications of two previously identified RdRp resistance mutations in relation to resistance against Remdesivir. This study highlights the importance of considering the balance between incorporation and excision properties of NAs between the RdRp and ExoN.\",\"Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of COVID-19. Here, we show that the ribonucleoside analog \\u03b2-d-N[4]-hydroxycytidine (NHC; EIDD-1931) has broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c bat-CoVs, as well as increased potency against a CoV bearing resistance mutations to the nucleoside analog inhibitor remdesivir. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC prodrug (\\u03b2-d-N[4]-hydroxycytidine-5'-isopropyl ester), improved pulmonary function and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral, but not host cell RNA, supporting a mechanism of lethal mutagenesis in CoV. The potency of NHC/EIDD-2801 against multiple CoVs and oral bioavailability highlights its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic CoVs.\",\"Introduction: Chikungunya virus (CHIKV), a reemerging human arthropod borne virus, can causes global epidemic outbreaks and has become a serious health concern due to the unavailability of any antiviral therapy/vaccine. Extensive research has been conducted to target different proteins from CHIKV to curtail the spread of virus.Areas covered: This review provides an overview of the granted patents including the current status of antiviral strategies targeting CHIKV.Expert opinion: Under the current scenario, potential molecules and different approaches have been utilized to suppress CHIKV infection. MV-CHIKV and VRC-CHKVLP059-00-VP vaccine candidates have successfully completed phase I clinical trials and ribavirin (inhibitor) has shown significant inhibition of CHIKV replication and could be the most promising candidates. The drug resistance and toxicity can be modulated by using the inhibitors/drugs in combination. Moreover, nanoparticle formulations can improve the efficacy and bioavailability of drugs.\",\"Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and hepatocellular carcinoma. Treatment with first generation protease inhibitors (PI) + peg-interferon (pegIFN) and ribavirin (RBV) achieved sustained virologic response (SVR) rates of 65-75% but was associated with multiple side effects. The aim of this study was to evaluate safety and efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir (3D) \\u00b1 RBV in HCV genotype 1 patients that failed previous treatment with first generation PIs.\",\"High-fat diet (HFD) is a predisposing factor for metabolic syndrome-related systemic inflammation and non-alcoholic fatty liver disease (NAFLD). However, there is still no effective therapeutic treatment for NAFLD. Here, we showed that remdesivir (RDV, GS-5734), as a broad-spectrum antiviral nucleotide prodrug with anti-inflammatory effects, was effective for attenuating HFD-induced metabolic disorder and insulin resistance. Results revealed that the liver weight, hepatic dysfunction and lipid accumulation were markedly increased compared with that of the Control group, while that of the RDV group exhibited significant reduction, accompanied by the improved signaling pathway regulating fatty acid metabolism. In agreement with reduced lipid deposition, RDV supplementation suppressed the systematic and hepatic inflammation, as evidenced by reduction of inflammatory cytokines and the blockage of nuclear factor \\u03baB (NF-\\u03baB) signaling. In addition, stimulator of interferon genes (STING) and its down-streaming factor interferon regulatory factor 3 (IRF3) were greatly increased in livers of HFD-fed mice, which were considerably restrained by RDV treatment. The in vitro analysis suggested that RDV functioned as an inhibitor of STING, contributing to the suppression of dyslipidemia and inflammation induced by palmitate (PA). However, PA-triggered lipid deposition and inflammatory response was further accelerated in hepatocytes with STING over-expression. Notably, RDV-attenuated lipid disorder and inflammation were significantly abrogated by the over-expression of STING in PA-stimulated hepatocytes. Taken together, these findings indicated that RDV exhibited protective effects against NAFLD development mainly through repressing STING signaling, and thus could be considered as a potential therapeutic strategy.\",\"The emergence of resistant mutants to the wildly used neuraminidase inhibitors (NAIs) makes the development of novel drugs necessary. Favipiravir (T-705) is one of the RNA-dependent RNA polymerase (RdRp) inhibitors developed in recent years. To examine the efficacy of T-705 against influenza B virus infections in vivo, C57BL/6 mice infected with wild-type or oseltamivir-resistant influenza B/Memphis/20/96 viruses were treated with T-705. Starting 2 h post inoculation (hpi), T-705 was orally administered to mice BID at dosages of 50, 150, or 300 mg/kg/day for 5 days. Oseltamivir was used as control. Here, we showed that T-705 protected mice from lethal infection in a dose-dependent manner. T-705 administration also significantly reduced viral loads and suppressed pulmonary pathology. In addition, phenotypic assays demonstrated that no T-705-resistant viruses emerged after T-705 treatment. In conclusion, T-705 can be effective to protect mice from lethal infection with both wild-type and oseltamivir-resistant influenza B viruses.\",\"The influenza virus RNA-dependent RNA polymerase is highly conserved among influenza A, B, C, and D viruses. It comprises three subunits: polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2), and polymerase acidic protein (PA) in influenza A and B viruses or polymerase 3 protein (P3) in influenza C and D viruses. Because this polymerase is essential for influenza virus replication, it has been considered as a target for antiviral agents. Recently, several polymerase inhibitors that target each subunit have been developed. This review discusses the mechanism of action, antiviral activity, and emergence of resistance to three inhibitors approved for the treatment of influenza or in late-phase clinical trials: the PB1 inhibitor favipiravir, the PB2 inhibitor pimodivir, and the PA inhibitor baloxavir marboxil.\",\"Influenza viruses are a major threat to human health globally. In addition to further improving vaccine prophylaxis, disease management through antiviral therapeutics constitutes an important component of the current intervention strategy to prevent advance to complicated disease and reduce case-fatality rates. Standard-of-care is treatment with neuraminidase inhibitors that prevent viral dissemination. In 2018, the first mechanistically new influenza drug class for the treatment of uncomplicated seasonal influenza in 2 decades was approved for human use. Targeting the PA endonuclease subunit of the viral polymerase complex, this class suppresses viral replication. However, the genetic barrier against viral resistance to both drug classes is low, pre-existing resistance is observed in circulating strains, and resistant viruses are pathogenic and transmit efficiently. Addressing the resistance problem has emerged as an important objective for the development of next-generation influenza virus therapeutics. This review will discuss the status of influenza therapeutics including the endonuclease inhibitor baloxavir marboxil after its first year of clinical use and evaluate a subset of direct-acting antiviral candidates in different stages of preclinical and clinical development.\",\"Influenza affects approximately 1 billion individuals each year resulting in between 290,000 and 650,000 deaths. Young children and immunocompromised individuals are at a particularly high risk of severe illness attributable to influenza and these are also the groups of individuals in which reduced susceptibility to neuraminidase inhibitors is most frequently seen. High levels of resistance emerged with previous adamantane therapy for influenza A and despite no longer being used to treat influenza and therefore lack of selection pressure, high levels of adamantane resistance continue to persist in currently circulating influenza A strains. Resistance to neuraminidase inhibitors has remained at low levels to date and the majority of resistance is seen in influenza A H1N1 pdm09 infected immunocompromised individuals receiving oseltamivir but is also seen less frequently with influenza A H3N2 and B. Rarely, resistance is also seen in the immunocompetent. There is evidence to suggest that these resistant strains (particularly H1N1 pdm09) are able to maintain their replicative fitness and transmissibility, although there is no clear evidence that being infected with a resistant strain is associated with a worse clinical outcome. Should neuraminidase inhibitor resistance become more problematic in the future, there are a small number of alternative novel agents within the anti-influenza armoury with different mechanisms of action to neuraminidase inhibitors and therefore potentially effective against neuraminidase inhibitor resistant strains. Limited data from use of novel agents such as baloxavir marboxil and favipiravir, does however show that resistance variants can also emerge in the presence of these drugs.\",\"The interleukin 28B (IL28B) genotype is associated with changes of lipid metabolism in patients infected with hepatitis C virus (HCV). The association of steatosis with serum levels of adiponectin in chronic hepatitis C (CHC) patients has also been documented. This study aimed for the evaluation of serum levels of IL28B and adiponectin as well as the association of IL28B SNPs with different clinicopathological parameters in HCV-infected patients.\",\"Presatovir is an oral respiratory syncytial virus (RSV) fusion inhibitor targeting RSV F protein. In a double-blind, placebo-controlled study in healthy adults experimentally infected with RSV (Memphis-37b), presatovir significantly reduced viral load and clinical disease severity in a dose-dependent manner.\",\"Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with \\u223c71 million chronically infected individuals worldwide. Treatment of patients with HCV-related liver disease has advanced considerably thanks to the development of new direct-acting antiviral drugs that are now administered as highly potent, safe, and well-tolerated combinations with a high barrier to resistance. International organizations, such as the European Association for the Study of the Liver, the American Association for the Study of Liver Diseases jointly with the Infectious Diseases Society of America, or the World Health Organization have published detailed treatment guidelines. With these therapies becoming more and more widely available, elimination of hepatitis C as a public health threat by 2030 can now be envisaged in several countries. In other regions, better screening, diagnosis, and linkage to care will be necessary to achieve this ambitious goal.\",\"Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is usually characterized by a self-limited course. However, there is an increased risk of HEV persistence in immunocompromised risk populations, comprising patients following solid organ transplantation or hematological malignancies. Recently, chronic HEV infection following rituximab-containing treatment regimens has been described. Here we report five patients with chronic hepatitis E after prior rituximab therapy for various indications. We determined the immunological characteristics of these patients and analyzed the development of ribavirin (RBV) treatment failure-associated mutations in the HEV genome. One patient became chronically HEV-infected 110 months after administration of rituximab (RTX). Immunological characterization revealed that all patients exhibited significant hypogammaglobulinemia and CD4+ T cell lymphopenia. One patient permanently cleared HEV following weight-based ribavirin treatment while three patients failed to reach a sustained virological response. In depth mutational analysis confirmed the presence of specific mutations associated with RBV treatment failure in these patients. Our cases indicate that rituximab-containing treatment regimens might imply a relevant risk for persistent HEV infection even years after the last rituximab application. Moreover, we provide further evidence to prior observations suggesting that chronically HEV infected patients following RTX-containing treatment regimens might be difficult to treat.\",\"Seasonal influenza viruses cause major morbidity and mortality worldwide, threatening in particular older adults and the immunocompromised. Two classes of influenza therapeutics dominate current disease management, but both are compromised by pre-existing or rapidly emerging viral resistance. We have recently reported a novel ribonucleoside analog clinical candidate, EIDD-2801, that combines potent antiviral efficacy in ferrets and human airway epithelium cultures with a high barrier against viral escape. In this study, we established fundamental EIDD-2801 efficacy paradigms against pandemic and seasonal influenza A virus (IAV) strains in ferrets that can be used to inform exposure targets and treatment regimens. Based on reduction of shed virus titers, alleviation of clinical signs, and lowered virus burden in upper and lower respiratory tract tissues, lowest efficacious oral dose concentrations of EIDD-2801, given twice daily, were 2.3 and 7 mg/kg of body weight against seasonal and pandemic IAVs, respectively. The latest opportunity for initiation of efficacious treatment was 36 hours after infection of ferrets. Administered in 12-hour intervals, three 7 mg/kg doses of EIDD-2801 were sufficient for maximal therapeutic benefit against a pandemic IAV and significantly shortened the time to resolution of clinical signs. Ferrets infected with pandemic IAV and treated following the minimally efficacious EIDD-2801 regimen demonstrated significantly less shed virus and inflammatory cellular infiltrates in nasal lavages, but mounted a robust humoral antiviral response after recovery that was indistinguishable from that of vehicle-treated animals. These results provide an experimental basis in a human disease-relevant influenza animal model for clinical testing of EIDD-2801.\",\"Sofosbuvir, a licensed nucleotide analog targeting hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp), has been recently evaluated as a broad anti-Flavivirus lead candidate revealing activity against Zika and Dengue viruses both in vitro and in animal models. In this study, the in vitro antiviral activity of sofosbuvir against West Nile virus (WNV) was determined by plaque assay (PA) and Immunodetection Assay (IA) in human cell lines and by enzymatic RdRp assay. By PA, the sofosbuvir half-maximal inhibitory concentration (IC50) was 1.2 \\u00b1 0.3 \\u03bcM in Huh-7, 5.3 \\u00b1 0.9 \\u03bcM in U87, 7.8 \\u00b1 2.5 \\u03bcM in LN-18 and 63.4 \\u00b1 14.1 \\u03bcM in A549 cells. By IA, anti-WNV activity was confirmed in both hepatic (Huh-7, 1.7 \\u00b1 0.5 \\u03bcM) and neuronal (U87, 7.3 \\u00b1 2.0 \\u03bcM) cell types. Sofosbuvir was confirmed to inhibit the purified WNV RdRp (IC50 11.1 \\u00b1 4.6 \\u03bcM). In vitro resistance selection experiments were performed by propagating WNV in the Huh-7 cell line with two-fold increasing concentrations of sofosbuvir. At 80 \\u03bcM, a significantly longer time for viral breakthrough was observed compared with lower concentrations (18 vs. 7-9 days post infection; p = 0.029), along with the detection of the S604T mutation, corresponding to the well-known S282T substitution in the motif B of HCV NS5B, which confers resistance to sofosbuvir. Molecular docking experiments confirmed that the S604T mutation within the catalytic site of RdRp affected the binding mode of sofosbuvir. To our knowledge, this is the first report of the antiviral activity of sofosbuvir against WNV as well as of selection of mutants in vitro.\",\"Presatovir significantly reduced nasal viral load, signs, and symptoms of respiratory syncytial virus (RSV) infection in a human challenge study. We evaluated presatovir in hematopoietic-cell transplant (HCT) recipients with RSV lower respiratory tract infection (LRTI).\",\"The current Ebolavirus disease (EVD) outbreak in the provinces of North Kivu and Ituri is the tenth outbreak affecting the Democratic Republic of Congo (DRC); the first outbreak occurring in a war context, and the second most deadly Ebolavirus outbreak on record following the 2014 outbreak in West Africa. The DRC government's response consisted of applying a package of interventions including detection and rapid isolation of cases, contact tracing, population mapping, and identification of high-risk areas to inform a coordinated effort. The coordinated effort was to screen, ring vaccinate, and conduct laboratory diagnoses using GeneXpert (Cepheid) polymerase chain reaction. The effort also included ensuring safe and dignified burials and promoting risk communication, community engagement, and social mobilization. Following the adoption of the \\\"Monitored Emergency Use of Unregistered Products Protocol,\\\" a randomized controlled trial of four investigational treatments (mAb114, ZMapp, and REGN-EB3 and Remdesivir) was carried out with all consenting patients with laboratory-confirmed EVD. REGN-EB3 and mAb114 showed promise as treatments for EVD. In addition, one investigational vaccine (rVSV-ZEBOV-GP) was used first, followed by a second prophylactic vaccine (Ad26.ZEBOV/MVA-BN-Filo) to reinforce the prevention. Although the provision of clinical supportive care remains the cornerstone of EVD outbreak management, the DRC response faced daunting challenges including general insecurity, violence and community resistance, appalling poverty, and entrenched distrust of authority. Ebolavirus remains a public health threat. A fully curative treatment is unlikely to be a game-changer given the settings of transmission, zoonotic nature, limits of effectiveness of any therapeutic intervention, and timing of presentation.\",\"The use of direct-acting antiviral agents (DAAs) in patients with chronic HCV genotype 1 infection results in sustained virologic response (SVR) rates of 95%-97%, but 3%-5% of patients experience virologic failure. We observed 17 patients infected with HCV subtype 1b who failed previous treatment with DAA, including 13 subjects (76.5%) with liver cirrhosis. Twelve subjects (70.6%) previously received NS5A inhibitors of the first generation (ledipasvir or daclatasvir) and five subjects (29.4%) - the second generation (velpatasvir). All patients were retreated with a combination of ombitasvir/paritaprevir/ritonavir and dasabuvir (3D) with sofosbuvir (SOF) and ribavirin (RBV). We compared SVR12 rates depending on fibrosis stage, presence of just single or double NS5A mutations (L31M/V/I and/or Y93H), and on the generation of previously used NS5A inhibitor. Observed SVR12 rates were as follows: 94.1% (16/17 patients) overall; 100% in patients without cirrhosis (n = 4) vs 92.3% in those with cirrhosis (n = 13); 100% with single L31M/V/I or Y93H mutation (n = 7) vs 88.9% with double mutations (n = 9); 100% in patients who previously failed first generation (n = 12) vs 80.0% in those failed second-generation NS5A inhibitors (n = 5). Retreatment with 3D + 0SOF + RBV was highly effective and safe in patients with chronic HCV GT1b infection who failed previous use of NS5A inhibitors. Fibrosis stage, baseline presence of NS5A RAS mutations and the generation of previously used NS5A inhibitors may impact the probability of achieving SVR12 , but statistical significance was not demonstrated in our small retrospective cohort. Further studies in a larger population are needed to confirm or not the predictive value of these baseline factors.\",\"NS5A-P32 deletion (P32del) is a resistance-associated amino acid change that has recently gained popularity in direct-acting antiviral treatment for chronic hepatitis C. Although not yet detected in naive patients, it appears in 5 to 10% of hepatitis C genotype 1b patients who fail to respond to daclatasvir/asunaprevir and sofosbuvir/ledipasvir treatments. In contrast to signature resistance-associated substitutions, such as substitutions at the NS5A-L31 and NS5A-Y93 positions, it shows complete resistance to all NS5A inhibitors in replicon and cell culture. Studies of humanized liver mice suggest that P32del retains good replication fitness and requires two classes of antivirals, except NS5A inhibitors, to be suppressed effectively. Patients with the P32del virus do not respond to glecaprevir/pibrentasvir but do respond to sofosbuvir/velpatasvir/voxilaprevir, presumably to sofosbuvir + glecaprevir/pibrentasvir, and at least partially to sofosbuvir/velpatasvir + ribavirin. Attention should be given to P32del in patients who experience failure with any NS5A inhibitor, especially those with genotype 1b infection.\",\"A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was to characterize the resistance profile of a large cohort of patients failing DAA-based treatments, and investigate the relationship between HCV subtype and failure, as an aid to optimizing management of these patients. A new, standardized HCV-RAS testing protocol based on deep sequencing was designed and applied to 220 previously subtyped samples from patients failing DAA treatment, collected in 39 Spanish hospitals. The majority had received DAA-based interferon (IFN) \\u03b1-free regimens; 79% had failed sofosbuvir-containing therapy. Genomic regions encoding the nonstructural protein (NS) 3, NS5A, and NS5B (DAA target regions) were analyzed using subtype-specific primers. Viral subtype distribution was as follows: genotype (G) 1, 62.7%; G3a, 21.4%; G4d, 12.3%; G2, 1.8%; and mixed infections 1.8%. Overall, 88.6% of patients carried at least 1 RAS, and 19% carried RAS at frequencies below 20% in the mutant spectrum. There were no differences in RAS selection between treatments with and without ribavirin. Regardless of the treatment received, each HCV subtype showed specific types of RAS. Of note, no RAS were detected in the target proteins of 18.6% of patients failing treatment, and 30.4% of patients had RAS in proteins that were not targets of the inhibitors they received. HCV patients failing DAA therapy showed a high diversity of RAS. Ribavirin use did not influence the type or number of RAS at failure. The subtype-specific pattern of RAS emergence underscores the importance of accurate HCV subtyping. The frequency of \\\"extra-target\\\" RAS suggests the need for RAS screening in all three DAA target regions.\",\"Ribavirin remains relevant for successful treatment of chronic hepatitis C virus (HCV) infections in low-income settings, as well as for therapy of difficult-to-treat HCV patients. We studied the effect of ribavirin against cell-culture adapted HCV of genotypes 1, 2 and 3, representing ~80% of global infections. TNcc(1a) was the most sensitive to ribavirin, while J6/JFH1(2a) was the most resistant. EC50s ranged from 21 \\u03bcM (95%CI: 20-22 \\u03bcM) to 189 \\u03bcM (95%CI: 173-207 \\u03bcM). Substitutions at position 415 of NS5B resulted in little or no change to ribavirin sensitivity (0.7-0.9 fold) but conferred moderate drug resistance during extended treatment of genotype 1 (1.8-fold). NS5A and NS5B sequences could alter ribavirin sensitivity 2-4-fold, although their contribution was not simply additive. Finally, we detected limited accumulation of mutations associated with ribavirin treatment. Our findings show that the antiviral effect of ribavirin on HCV is strain-dependent and is influenced by the specific sequence of multiple HCV nonstructural proteins.\",\"A series of compounds with potential activity to induce plant resistance was synthesized from indole and thiol compounds and methodically evaluated for antiviral activity. The results indicated that some of the synthesized compounds had high antipotato virus Y (PVY), anticucumber mosaic virus, and antitobacco mosaic virus activities. Notably, compound D21 exhibited the best activity against PVY among these compounds in vivo, and the 50% effective concentrations (EC50) of protection activity is 122 \\u03bcg/mL, which was distinctively better than the corresponding values for ribavirin (653 \\u03bcg/mL), Ningnanmycin (464 \\u03bcg/mL), and Xiangcaoliusuobingmi (279 \\u03bcg/mL). Interestingly, we found that the protection activity of D21 was associated with improvement of chlorophyll content and defense-related enzyme activities. Moreover, D21 could trigger the malate dehydrogenase (MDH) signaling pathway, as further confirmed by the MDH activity evaluation. Hence, D21 can protect plants against viral activity and has potential as a novel activator for plant resistance induction.\",\"Influenza viruses constitute a major health threat and economic burden globally, frequently exacerbated by preexisting or rapidly emerging resistance to antiviral therapeutics. To address the unmet need of improved influenza therapy, we have created EIDD-2801, an isopropylester prodrug of the ribonucleoside analog N [4]-hydroxycytidine (NHC, EIDD-1931) that has shown broad anti-influenza virus activity in cultured cells and mice. Pharmacokinetic profiling demonstrated that EIDD-2801 was orally bioavailable in ferrets and nonhuman primates. Therapeutic oral dosing of influenza virus-infected ferrets reduced group pandemic 1 and group 2 seasonal influenza A shed virus load by multiple orders of magnitude and alleviated fever, airway epithelium histopathology, and inflammation, whereas postexposure prophylactic dosing was sterilizing. Deep sequencing highlighted lethal viral mutagenesis as the underlying mechanism of activity and revealed a prohibitive barrier to the development of viral resistance. Inhibitory concentrations were low nanomolar against influenza A and B viruses in disease-relevant well-differentiated human air-liquid interface airway epithelia. Correlating antiviral efficacy and cytotoxicity thresholds with pharmacokinetic profiles in human airway epithelium models revealed a therapeutic window >1713 and established dosing parameters required for efficacious human therapy. These data recommend EIDD-2801 as a clinical candidate with high potential for monotherapy of seasonal and pandemic influenza virus infections. Our results inform EIDD-2801 clinical trial design and drug exposure targets.\",\"There is an established correlation between the PNPLA3 rs738409 C > G single nucleotide polymorphism (SNP) and hepatic steatosis and fibrosis in hepatitis C virus (HCV) infected patients. However not all data is convergent regarding the exact impact of this SNP on the pattern of disease progression in different clinical settings. In this study, we aimed to further bridge the knowledge gap on this topic by investigating the role of the G allele in promoting steatosis, fibrosis and disease progression in relation to other metabolic and anthropometric host factors. Two hundred and fifty consecutive patients, previously diagnosed with chronic hepatitis C (CHC) underwent liver biopsy. Histology was assessed using the Metavir scoring system. Transient elastography was used for follow-up. Ninety-eight patients were genotyped for PNPLA3 rs738409 and followed up for fibrosis progression. PNPLA3 rs738409[G] allele was significantly correlated with severe steatosis (P = 0.04), severe fibrosis at the time of enrollment (P = 0.0005) and fibrosis progression with an OR of 10.31 (95% CI 1.06 - 99.59, P = 0.04), after a mean follow-up time of 62.85 (95%CI: 52.21 - 76.15) months. Severe steatosis at the time of enrollment had an OR of 11.02 (95% CI 1.48 - 82.09, P = 0.01) for the association with fibrosis progression. The HOMA-IR index was also positively correlated with severe fibrosis (P = 0.03) and fibrosis progression on univariate analysis (P = 0.02). PNPLA3 rs738409[G] allele is a reliable predictor for steatosis and fibrosis in CHC. The presence of G allele, along with severe steatosis and insulin resistance are significant predictors for fibrosis progression.\",\"Hepatitis C virus (HCV) infection is a major cause of chronic liver disease globally. Direct acting antivirals (DAAs) have proven effective in curing HCV. However, the current standard of care (SOC) in Botswana remains PEGylated interferon-\\u03b1 (IFN-\\u03b1) with ribavirin. Several mutations have been reported to confer resistance to interferon-based treatments. Therefore, there is a need to determine HCV genotypes in Botswana, as these data will guide new treatment guidelines and understanding of HCV epidemiology in Botswana.\",\"Background and Aims: Ravidasvir (RDV) is a new generation pangenotypic hepatitis C virus (HCV) NS5A inhibitor, with high barrier to baseline resistance-associated species. This is the first phase 2/3 study conducted in Mainland China confirming the efficacy and safety of RDV + ritonavir-boosted danoprevir + ribavirin for 12 weeks in treatment-na\\u00efve noncirrhotic patients with genotype 1 infection in a large population. Methods: In this multicenter, randomized, double-blinded, placebo-controlled phase 2/3 trial (NCT03362814), we enrolled 424 treatment-na\\u00efve, noncirrhotic adult HCV genotype 1 patients. All patients were randomized at 3:1 ratio to receive a combination of RDV 200mg once daily plus ritonavir-boosted danoprevir 100mg/100mg twice daily and oral ribavirin 1000/1200mg/day (body weight <75/\\u226575 kg) (n = 318) or placebo (n = 106) for 12 weeks. The primary end-point was the rate of sustained virologic response 12 weeks after the end of treatment, and the safety was evaluated and compared between treatment and placebo groups. Results: The overall rate of sustained virological response at 12 weeks after treatment is 99% (306/309, 95%, CI: 97%-100%) under per protocol set analysis. All patients harboring baseline NS5A resistance-associated species in the treatment group (76/76, per protocol set) achieved sustained virological response at 12 weeks after treatment. No treatment-related serious adverse events were reported. Laboratory abnormalities showed mild or moderate severity (grade 1 and grade 2) in liver function tests. Conclusions: In treatment-na\\u00efve, noncirrhotic HCV Chinese patients infected with HCV genotype 1, all-oral regimen of RDV + ritonavir-boosted danoprevir + ribavirin for 12 weeks was highly efficacious, safe, and well tolerated.\",\"The incidence of fungal infections has increased continuously in recent years, and drug resistance, especially resistance to fluconazole (FLC), has emerged. To overcome this challenge, research on the antifungal activities of non-antifungal agents has gained more attention. In this study, we determined the anti-Candida activity of ribavirin (RBV), an antiviral drug commonly used in the clinic, and found that RBV displayed potent antifungal activity when used alone or in combination with FLC in vitro and in vivo. In vitro, the MIC80 values of RBV were 2-4 \\u00b5g/mL for FLC-susceptible Candida albicans and 8 \\u00b5g/mL for FLC-resistant C. albicans. When RBV at a dose of 1 \\u00b5g/mL was combined with FLC, significant synergistic effects were exhibited against FLC-resistant C. albicans, and the MICs of FLC decreased from >512 \\u00b5g/mL to 0.25-1 \\u00b5g/mL. Synergism was also exhibited against C. albicans biofilms. In vivo, RBV plus FLC significantly improved the survival of infected Galleria mellonella larvae compared with the FLC-treated group over a 4-day period and attenuated the damage of FLC-resistant C. albicans to G. mellonella larvae tissue. Furthermore, mechanistic studies indicated that the antifungal effects of RBV used alone or in combination with FLC might be associated with inhibition of biofilm formation, reduced extracellular phospholipase activity and inhibition of hyphal growth, but is not related to promotion of FLC uptake and inhibition of FLC efflux. These results provide a promising direction for overcoming drug resistance and for expanding the clinical application of existing drugs.\",\"Sustained virological response (SVR) in hepatitis C virus (HCV) patients treated with pegylated interferon \\u03b1-2a and ribavirin is associated with reduced insulin resistance (IR), measured as a reduction of homeostasis model assessment (HOMA) scores after 24 weeks of therapy, and reduced fasting serum insulin and serum glucose levels. The present meta-analysis aimed to evaluate the effect of HCV treatment response on IR in HCV patients who achieved SVR and those who did not (non-SVR) after receiving interferon (IFN)-based therapy. The PubMed, Cochrane and Embase databases were searched using combinations of the following search terms: 'HCV', 'hepatitis C', 'interferon', 'antiviral', 'treatment response' and 'insulin resistance'. The incidence of IR, HOMA-IR and HOMA-\\u03b2, as well as fasting glucose and fasting insulin levels, were summarized in terms of basal values and values after the end of treatment for each study. A total of 8 studies were included in the final analysis. There was no significant difference in the reduction in IR between the SVR and non-SVR groups (odds ratio, 0.995; 95% CI=0.613-1.616; P=0.984). However, the SVR group had a significantly higher mean reduction in HOMA-IR (difference in means=-0.485; 95%CI=-0.713 to -0.256; P<0.001) and HOMA-\\u03b2 (difference in means=-15.448; 95%CI=-23.326 to -7.570; P<0.001) compared to the non-SVR group. In conclusion, HCV patients who achieved SVR after IFN-based therapy exhibited improvement in HOMA-IR and HOMA-\\u03b2. The present results suggest that clinical management of IR and serum glucose levels may be an important way to impact the therapeutic response in HCV patients.\",\"Ribavirin (RBV) induces nucleotide (nt) substitutions in hepatitis C virus (HCV) genome nonstructural (NS) regions. Although emergence of drug resistance-associated variants is associated with direct-acting antiviral treatment failure, the effect of RBV on genome substitutions in such patients is unknown. Genotype 1b HCV subgenomic replicon cells were treated with RBV for 120 hours. Six patients with chronic genotype 1b with HCV-infected patients who failed to respond to prior daclatasvir plus asunaprevir (DCV/ASV) therapy were treated with 12 weeks of sofosbuvir and ledipasvir plus RBV after 4 weeks of RBV monotherapy. RBV-induced genome mutations in the HCV NS region (nt3493-9301) in replicon cells and in patients during 4 weeks of RBV monotherapy were analyzed by deep sequencing. RBV-associated G-to-A and C-to-U transitions increased in a dose-dependent manner in HCV replicon cells after the RBV treatment. In patients with prior DCV/ASV treatment failures, the median serum HCV RNA level was 6.25 \\u00b1 0.31 log IU/mL at the start of RBV therapy and decreased significantly to 5.95 \\u00b1 0.4 log IU/mL (P = .03) after 4 weeks of RBV monotherapy. Although predominant HCV genome substitutions rates were similar between nontreatment and RBV-treatment periods (0.042 and 0.031 per base pair, respectively; P = .248), the frequencies of G-to-A and C-to-U transitions significantly increased after RBV monotherapy. These transitions were enriched, particularly within the HCV NS3 region in all patients. RBV treatment induces G-to-A and C-to-U transitions in the HCV genome even in chronic patients with hepatitis C with prior DCV/ASV treatment failures.\",\"Coronaviruses (CoVs) have emerged from animal reservoirs to cause severe and lethal disease in humans, but there are currently no FDA-approved antivirals to treat the infections. One class of antiviral compounds, nucleoside analogues, mimics naturally occurring nucleosides to inhibit viral replication. While these compounds have been successful therapeutics for several viral infections, mutagenic nucleoside analogues, such as ribavirin and 5-fluorouracil, have been ineffective at inhibiting CoVs. This has been attributed to the proofreading activity of the viral 3'-5' exoribonuclease (ExoN). \\u03b2-d-N [4]-Hydroxycytidine (NHC) (EIDD-1931; Emory Institute for Drug Development) has recently been reported to inhibit multiple viruses. Here, we demonstrate that NHC inhibits both murine hepatitis virus (MHV) (50% effective concentration [EC50] = 0.17 \\u03bcM) and Middle East respiratory syndrome CoV (MERS-CoV) (EC50 = 0.56 \\u03bcM) with minimal cytotoxicity. NHC inhibited MHV lacking ExoN proofreading activity similarly to wild-type (WT) MHV, suggesting an ability to evade or overcome ExoN activity. NHC inhibited MHV only when added early during infection, decreased viral specific infectivity, and increased the number and proportion of G:A and C:U transition mutations present after a single infection. Low-level NHC resistance was difficult to achieve and was associated with multiple transition mutations across the genome in both MHV and MERS-CoV. These results point to a virus-mutagenic mechanism of NHC inhibition in CoVs and indicate a high genetic barrier to NHC resistance. Together, the data support further development of NHC for treatment of CoVs and suggest a novel mechanism of NHC interaction with the CoV replication complex that may shed light on critical aspects of replication.IMPORTANCE The emergence of coronaviruses (CoVs) into human populations from animal reservoirs has demonstrated their epidemic capability, pandemic potential, and ability to cause severe disease. However, no antivirals have been approved to treat these infections. Here, we demonstrate the potent antiviral activity of a broad-spectrum ribonucleoside analogue, \\u03b2-d-N [4]-hydroxycytidine (NHC), against two divergent CoVs. Viral proofreading activity does not markedly impact sensitivity to NHC inhibition, suggesting a novel interaction between a nucleoside analogue inhibitor and the CoV replicase. Further, passage in the presence of NHC generates only low-level resistance, likely due to the accumulation of multiple potentially deleterious transition mutations. Together, these data support a mutagenic mechanism of inhibition by NHC and further support the development of NHC for treatment of CoV infections.\",\"To study resistance-associated substitutions using next-generation sequencing in Egyptian hepatitis C virus-infected patients failing direct-acting antiviral treatment.\",\"The World Health Organization estimates that 1% of the world population (71 million) is infected with hepatitis C virus (HCV). In 2015, three direct-acting antivirals (DAAs), simeprevir (SMV), sofosbuvir (SOF) and daclatasvir (DCV) were included in the Brazilian protocol for the treatment of chronic hepatitis C. Despite the fact that the use of these drugs is associated with higher treatment response rates and with lower incidence of side effects, studies have shown the association between the presence of viral resistance mutations and the failure of pharmacological treatment.\",\"New direct-acting antiviral agents (DAAs) approved for the treatment of patients infected by Hepatitis C virus (HCV) are well tolerated and increase sustained virological response (SVR) rate. We summarize current evidence on the efficacy and safety from comparative randomized controlled trials (RCTs) of DAAs.\",\"As antiviral drug resistance develops and new viruses emerge there is a pressing need to develop strategies to rapidly develop antiviral therapeutics. Here we use phospho-specific flow cytometry to assess perturbations of many different cellular signaling pathways during treatment with drug combinations that are highly effective in blocking Herpes simplex virus type 1 (HSV-1) infection. We discovered two antiviral drug combinations act on distinct signaling pathways, either STAT1 or S6 phosphorylation, to block HSV-1 infection. We focused on upregulation of S6 phosphorylation by HSV-1 infection, and our subsequent finding that ribavirin antagonizes this upregulation of S6 phosphorylation. We go on to show that the S6 kinase inhibitor SL0101 blocks HSV-1 replication in vitro and in an in vivo animal model of HSV-1 infection. Overall, we have used an unbiased analysis of cellular signaling pathways during treatment by antiviral drug combinations to discover a novel antiviral drug target against HSV-1 infection. The outcomes of the approach we present highlight the importance of analyzing how antiviral drugs modulate cellular and pathogen-induced signaling as a method to discover new drug therapy targets.\",\"Treatment guidelines differ in their recommendation to determine baseline resistance associated substitutions (RAS) before starting a first-line treatment with direct-acting antivirals (DAAs). Here we analyze the efficacy of DAA treatment with baseline RAS information. We conducted a prospective study involving 23 centers collaborating in the GEHEP-004 DAA resistance cohort. Baseline NS5A and NS3 RASs were studied by Sanger sequencing. After issuing a comprehensive resistance report, the treating physician decided the therapy, duration and ribavirin use. Sustained virological response (SVR12) data are available in 275 patients. Baseline NS5A RAS prevalence was between 4.3% and 26.8% according to genotype, and NS3 RASs prevalence (GT1a) was 6.3%. Overall, SVR12 was 97.8%. Amongst HCV-GT1a patients, 75.0% had >800,000 IU/ml and most of those that started grazoprevir/elbasvir were treated for 12 weeks. In genotype 3, NS5A Y93H was detected in 9 patients. 42.8% of the HCV-GT3 patients that started sofosbuvir/velpatasvir included ribavirin, although only 14.7% carried Y93H. The efficacy of baseline resistance-guided treatment in our cohort has been high across the most prevalent HCV genotypes in Spain. The duration of the grazoprevir/elbasvir treatment adhered mostly to AASLD/IDSA recommendations. In cirrhotic patients infected with GT-3 there has been a high use of ribavirin.\",\"Sofosbuvir/velpatasivr/voxilaprevir (SOF/VEL/VOX) is approved for retreatment of patients with HCV and a previous failure on direct-acting antivirals (DAAs), however real-life data are limited. The aim of this study was to assess the effectiveness and safety of SOF/VEL/VOX in a real-life setting.\",\"Background: The NS5A resistance-associated substitution (RAS) Y93H is found quite frequently (5-10%) at baseline in direct-acting antiviral agents (DAA) treatment-na\\u00efve genotype (GT) 3a patients when studied by the population-sequencing method (cut-off 20%). This RAS may impair HCV DAA treatment response, since it possesses a high fold in vitro resistance to daclatasvir (DCV) and velpatasvir (VEL) in GT 3. We investigated the effect of baseline Y93H in patients with GT 3a infection on treatment outcome, with or without resistance-based DAA-treatment during 2014-2017. Patients/Methods: Treatment in the intervention group (n = 130) was tailored to baseline resistance-findings by population-sequencing method. Detection of baseline Y93H above 20% prompted a prolonged treatment duration of NS5A-inhibitor and sofosbuvir (SOF) and/or addition of ribavirin (RBV). Patients without baseline Y93H in the intervention group and all patients in the control group (n = 78) received recommended standard DAA-treatment. Results: A higher sustained virologic response rate (SVR) in the intervention group was shown compared to the control group at 95.4% (124/130) and 88.5% (69/78), respectively (p = .06). All five patients with baseline Y93H in the intervention group achieved SVR with personalised treatment based on results from resistance testing; either with the addition of RBV or prolonged treatment duration (24w). In the control group, 2/4 patients with Y93H at baseline treated with ledipasvir/SOF/RBV or DCV/SOF without RBV, failed treatment. Conclusion: The results from this real-life study are in accordance with the findings of the randomised controlled trials in 2015 and the EASL-guidelines of 2016, thus, baseline Y93H impacts on DCV and VEL treatment outcome.\",\"Treatment options are limited for patients with hepatitis C (HCV) infection with treatment failure after sofosbuvir plus an NS5A inhibitor. There are some data for the efficacy of glecaprevir/pibrentasvir (G/P) in these patients. We performed a randomized trial of the safety and efficacy of 12 and 16 weeks of G/P, with or without ribavirin, in patients with HCV genotype 1 infection with treatment failure after sofosbuvir and an NS5A inhibitor.\",\"The human respiratory syncytial virus (RSV) is one of the most common viral pathogens that affects the lower respiratory tract and could be a reason of bronchiolitis and/or pneumonia. Currently, there are no available effective ways of treating the RSV infection. Attempts to develop preventive vaccine have been unsuccessful. The only therapeutic agent used for RSV treatment is virazole (ribavirin); however, it induces adverse effects. Medications based on neutralizing monoclonal antibodies, such as IGIV (Respigam), palivizumab (Synagis), and MEDI-524 (Numab), are under clinical trials; however, their use will be limited by their high cost. One of the promising approaches for antiviral therapy is the use of natural peptides (defensins and cathelicidins), or their synthetic analogs. The majority of currently described antiviral peptides are developed against the human immunodeficiency virus, the herpes simplex virus, and the influenza virus. At the same time, a body of experimental data evidencing anti-RSV activity of peptides has been accumulated. The main advantages of peptide drugs are their wide spectrum of antiviral activity and low toxicity. However, there are obstacles in implementing peptide-based drugs in clinical practice. Due to their low resistance to the action of serum proteases, most authors consider peptides promising only for local application. Given that RSV affects the epithelium of the respiratory tract, where the protease activity is lower than in the systemic circulation, it is possible to develop locally active peptide drugs, for example, as inhalation forms. Their stability could also be increased by the synthesis of dendrimer peptides and by the development of recombinant peptides as precursor proteins. Anti-RSV peptides can be divided into several groups: (1) attachment and/or fusion blockers; (2) peptides displaying direct virucidal activity, disrupting the viral envelope. Such peptides, which suppress early stages of the viral life cycle, are considered prophylactic agents. However, for several peptides, their immunoregulatory properties have been described, which opens the possibility for therapeutic use. This review summarizes the information on the antiviral properties of such peptides and mechanisms of their action and describes the prospects of the future development of antiviral peptides.\",\"Direct-acting antiviral agent (DAA)-based therapies have been the 1st choice of antiviral agents for chronic hepatitis C throughout the world. The treatment period of DAA-based therapy has been greatly shortened by the improvement of their efficiency. Thus, glecaprevir (GLE)/pibrentasvir (PIB) therapy has enabled the therapeutic period to be reduced from 12 to 8 weeks in cases of genotype 1 or 2 chronic hepatitis C without liver cirrhosis. Currently, there is no established rescue therapy for patients who experience treatment failure on GLE/PIB therapy; however, some patients have been rescued by other regimens, including sofosbuvir (SOF)/velpatasvir (VEL) plus ribavirin (RBV) therapy and GLE/PIB, SOF, and RBV therapy. We experienced the case of a DAA-na\\u00efve non-cirrhotic patient with genotype 2a who showed virologic relapse at post-treatment week 13 following 8-week GLE/PIB therapy. After we confirmed that he did not have resistance-associated substitutions against GLE or PIB, we tried to rescue the patient using prolonged (12-week) GLE/PIB therapy. Fortunately, a sustained virologic response was achieved without any adverse events. Although this was a single-case report and is assumed to be rare, the same regimen might be effective for treatment failure with 8-week GLE/PIB therapy.\",\"Human innate immune plays an essential role in the spontaneous clearance of acute infection and therapy of HCV. We investigated whether the SNPs in retinoic acid-inducible gene I-like receptor family were associated with HCV spontaneous clearance and response to treatment. To evaluate the clinical value of DDX58 rs3824456, rs10813831 and rs10738889 genotypes on HCV spontaneous clearance and treatment response in Chinese Han population, we genotyped 1001 HCV persistent infectors, 599 participants with HCV natural clearance and 354 patients with PEGylated interferon-\\u03b1 and ribavirin (PEG IFN-\\u03b1/RBV) treatment. People carrying rs10813831-G allele genotype were more liable to achieve spontaneous clearance than the carriage of the T allele (dominant model: adjusted OR 1.35, 95% CI 1.08-1.71, P = 0.008). In rs10738889, the rate of persistent infection was significantly lower in patients with the TC genotype compared to those with TT genotype (dominant model: adjusted OR 1.36, 95% CI 1.06-1.74, P = 0.015). Multivariate stepwise analysis indicated that rs10738889, age, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were independent predictors for HCV spontaneous clearance. However, there were no significant differences in the three selection SNPs between the non-SVR group and the SVR group. These results suggest the DDX58 rs10813831 and rs10738889 are associated with spontaneous clearance of HCV, which may be identified as a predictive marker in the Chinese Han population of HCV.\",\"Despite highly effective direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection, some patients experience virological relapse. Salvage regimens should include multiple agents to suppress emergence of resistance-associated substitutions (RAS) and minimise treatment failure. The combination of sofosbuvir (SOF) and elbasvir/grazoprevir (ELB/GZR) \\u00b1ribavirin (RBV) is an effective retreatment strategy for HCV genotype (GT)1 and 4 infection. We hypothesised that SOF and ELB/GZR (\\u00b1RBV) would also be an effective salvage regimen for DAA-experienced GT3 patients.\",\"The use of antifungal agents in clinical settings is limited by the appearance of drug resistance and adverse side effects. There is, therefore, an urgent need to develop new drugs to strengthen the treatment of invasive fungal diseases. The aim of this study is to describe the potential repurposing of ribavirin as an adjunct therapy against Candida spp. Primary screening of a Prestwick Chemical library against Candida albicans ATCC 90028 and fluconazole-resistant Candida albicans strains was performed. Subsequently, we evaluated the responses of 100 Candida sp. strains to ribavirin, an antiviral agent, using the broth microdilution method as recommended by CLSI. We checked the involvement of efflux pump activity in the development of ribavirin resistance. We studied time-kill curves and performed a checkerboard assay for a ribavirin-antifungal combination study. Twenty-one nonstandard antifungal compounds were identified, including ribavirin. Ribavirin had antifungal activity in vitro against 63 Candida strains, including strains of C. albicans, C. parapsilosis, and C. tropicalis, with MICs ranging from 0.37 to 3.02 \\u03bcg/ml, while MICs for C. krusei, C. glabrata, C. lusitaniae, and some C. albicans strains remained high (\\u226524.16 \\u03bcg/ml). No relation was observed between efflux pump activity and ribavirin resistance. Ribavirin exhibited fungistatic activity against multidrug-resistant (MDR) C. albicans and fungicidal activity against a C. parapsilosis strain. In addition, ribavirin acted synergistically with azoles against Candida strains for which ribavirin MICs were <24.4 \\u03bcg/ml. This study highlights the potential clinical application of ribavirin, alone or in association with other antifungal agents, as an adjunct anti-Candida drug.\",\"Most hepatitis C virus (HCV)-infected patients failing NS5A inhibitors develop resistance-associated substitutions (RASs). Here we report the use of resistance-guided retreatment of patients who failed prior NS5A inhibitor-containing regimens in the GEHEP-004 cohort. This is the largest direct-acting antiviral (DAA)-resistance cohort study conducted in Spain. We aim to provide indications on how to use resistance information in settings where sofosbuvir/velpatasvir/voxilaprevir may not be available.\",\"We examined treatment the efficacy and data on long-term outcomes in real-world Japanese patients infected with hepatitis C virus (HCV) genotype 2 treated with 12-week sofosbuvir/ribavirin combination therapy.\",\"Development of direct-acting antivirals (DAAs) has made antihepatitis C virus (HCV) treatment highly safe and effective. However, the emergence of resistant-associated variants (RAVs) after failure of DAA therapy affects retreatment outcomes. In particular, genotype 1 HCV with P32 deletion has been reported to be highly resistant to all approved non-structural protein (NS)5A inhibitors. However, analysis of RAVs in genotype 2 HCV has been limited. Accordingly, in this study, we evaluated the roles of genotype 2 HCV variants in antiviral drug efficacy.\",\"Current influenza antivirals have limitations with regard to their effectiveness and the potential emergence of resistance. Encouragingly, several new compounds which inhibit the polymerase of influenza viruses have recently been shown to have enhanced pre-clinical and clinical effectiveness compared to the neuraminidase inhibitors, the mainstay of influenza antiviral therapy over the last two decades. In this review we focus on four compounds which inhibit polymerase function, baloxavir marboxil, favipiravir, pimodivir and AL-794 and discuss their clinical and virological effectiveness, their propensity to select for resistance and their potential for future combination therapy with the most commonly used neuraminidase inhibitor, oseltamivir.\",\"The genetically diverse Orthocoronavirinae (CoV) family is prone to cross species transmission and disease emergence in both humans and livestock. Viruses similar to known epidemic strains circulating in wild and domestic animals further increase the probability of emergence in the future. Currently, there are no approved therapeutics for any human CoV presenting a clear unmet medical need. Remdesivir (RDV, GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp). We developed multiple assays to further define the breadth of RDV antiviral activity against the CoV family. Here, we show potent antiviral activity of RDV against endemic human CoVs OC43 (HCoV-OC43) and 229E (HCoV-229E) with submicromolar EC50 values. Of known CoVs, the members of the deltacoronavirus genus have the most divergent RdRp as compared to SARS- and MERS-CoV and both avian and porcine members harbor a native residue in the RdRp that confers resistance in beta-CoVs. Nevertheless, RDV is highly efficacious against porcine deltacoronavirus (PDCoV). These data further extend the known breadth and antiviral activity of RDV to include both contemporary human and highly divergent zoonotic CoV and potentially enhance our ability to fight future emerging CoV.\",\"Chronic viral disease constitutes a major global health problem, with several hundred million people affected and an associated elevated number of deaths. An increasing number of disorders caused by human flaviviruses are related to their capacity to establish a persistent infection. Here we show that Usutu virus (USUV), an emerging zoonotic flavivirus linked to sporadic neurologic disease in humans, can establish a persistent infection in cell culture. Two independent lineages of Vero cells surviving USUV lytic infection were cultured over 82 days (41 cell transfers) without any apparent cytopathology crisis associated. We found elevated titers in the supernatant of these cells, with modest fluctuations during passages but no overall tendency towards increased or decreased infectivity. In addition to full-length genomes, viral RNA isolated from these cells at passage 40 revealed the presence of defective genomes, containing different deletions at the 5' end. These truncated transcripts were all predicted to encode shorter polyprotein products lacking membrane and envelope structural proteins, and most of non-structural protein 1. Treatment with different broad-range antiviral nucleosides revealed that USUV is sensitive to these compounds in the context of a persistent infection, in agreement with previous observations during lytic infections. The exposure of infected cells to prolonged treatment (10 days) with favipiravir and/or ribavirin resulted in the complete clearance of infectivity in the cellular supernatants (decrease of ~5 log10 in virus titers and RNA levels), although modest changes in intracellular viral RNA levels were recorded (<2 log10 decrease). Drug withdrawal after treatment day 10 resulted in a relapse in virus titers. These results encourage the use of persistently-infected cultures as a surrogate system in the identification of improved antivirals against flaviviral chronic disease.\",\"Chronic hepatitis C virus infection represents a more frequent cause of liver cirrhosis and hepatocellular carcinoma. Statins, inhibit HCV replication in vitro, enhance the antiviral effect of the already known antiviral drugs and reduce their resistance.\",\"Hepatitis C virus (HCV) infection is commonly associated with a disturbance of glucose metabolism. However, there have been conflicting reports on whether the clearance of the HCV may be followed by changes of serum blood glucose and insulin resistance. The aim of the present study was to evaluate the impact of HCV and antiviral treatment on serum glucose levels and other glucose metabolism parameters.\",\"We investigated the HCV-RNA amount, variability and prevalence of resistance-associated substitutions (RASs), in plasma, hepatic tumoral and non-tumoral tissue samples in patients undergoing liver-transplant/hepatic-resection (LT/HR), because of hepatocellular carcinoma and/or cirrhosis.\",\"Hepatitis C virus (HCV) infection is associated with insulin resistance, which may lead to type 2 diabetes and its complications. Although HCV infects mainly hepatocytes, it may impair insulin sensitivity at the level of uninfected extrahepatic tissues (muscles and adipose tissue). The aim of this study was to assess whether an interferon-free, antiviral therapy may improve HCV-associated hepatic vs. peripheral insulin sensitivity.\",\"The hepatitis C virus (HCV) NS5A inhibitor ABT-267 (ombitasvir, OBV), the HCV NS4/4A protease inhibitor ABT-450 (paritaprevir, PTV), the CYP3A inhibitor ritonavir (r) and the non-nucleoside NS5B polymerase inhibitor ABT-333 (dasabuvir, DSV) (OBV/PTV/r + DSV) with or without ribavirin (RBV) is a direct-acting antiviral regimen approved in the United States and other major countries for the treatment of HCV in genotype 1 (GT1) infected patients. Patients with HCV who are considered \\\"hard-to-cure\\\" have generally been excluded from registration trials due to rigorous study inclusion criteria, presence of comorbidities and previous treatment failures.\",\"The effectiveness of sofosbuvir/ribavirin (SOF/RBV) combination therapy, which is one of the 1[st]-choice therapeutic options for patients with hepatitis C virus (HCV) genotype 2 (HCV-G2) in Japan according to the most recent version of the Japan Society of Hepatology guideline, for patients who experienced failure of the ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r+RBV) combination therapy, which was another option for patients with HCV-G2, is unknown.\",\"Sofosbuvir is a frequently used pan-genotype inhibitor of hepatitis C virus (HCV) polymerase. This drug eliminates most chronic HCV infections, and resistance-associated substitutions in the polymerase are rare. However, HCV genotype 3 responds slightly less well to sofosbuvir-based therapies than other genotypes. We collected data from England's National Health Service Early Access Program to search for virus factors associated with sofosbuvir treatment failure.\",\"Despite the high efficacy of direct acting antivirals (DAAs) not all patients successfully clear hepatitis C virus infection, in fact, approximately 1-3% fail to reach a sustained virological response 12 weeks after end of treatment. DAA failures are characterized by advanced liver disease, specific genotypes/subtypes and resistance associated substitutions to the DAA class they have been treated with. Current European Association for the Study of the Liver guidelines recommend three therapeutic options for such patients. The first is a 12 week course of sofosbuvir (SOF), velpatasvir (VEL) and voxilaprevir (VOX), which has shown to be effective in 90-99% of patients and was granted A1 level recommendation. The second option, reserved for patients who have predictors of failure consists in 12 weeks regimen with glecaprevir (GLE) and pibrentasvir (PIB), effective in 90-97%. Finally, although not supported by published data, for especially difficult to treat patients there should theoretically be a benefit in prolonged combinations of SOF+GLE/PIB or SOF/VEL/VOX\\u00b1ribavirin. This review presents the latest evidence from both clinical trials and real-life on such therapeutic strategies.\",\"The treatment of chronic hepatitis C virus (HCV) infection has considerably evolved with the development of safe and well-tolerated combinations of direct-acting antiviral (DAA) drugs yielding high rates of infection cure. However, some patients fail to achieve a sustained virological response while receiving the most recent DAA combinations. Several waves of treatment failures have occurred concomitantly to the use of different drug combinations. The outcome of their retreatment strongly depends on the DAA(s) received and the retreatment regimen(s) available. This article discusses virological failure rates with the successive waves of HCV combination regimens, the reasons for failure, the role of HCV resistance, and current retreatment options. The triple combination of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks is the first-line retreatment strategy in patients previously exposed to DAAs. Difficult-to-retreat patients may benefit from the combination of sofosbuvir plus glecaprevir/pibrentasvir and/or the addition of ribavirin and/or longer retreatment duration.\",\"Cirrhotic patients with hepatitis C virus genotype 3 infection show unsatisfactory outcomes after 12 weeks' treatment with direct antiviral agents. The National Italian Drug Agency allows 24 weeks of therapy in difficult-to-treat patients, including genotype 3 cirrhotics. Aim of this study was to evaluate efficacy and safety of a 24-week course of sofosbuvir plus daclatasvir\\u00b1ribavirin in this population.\",\"Although overexpression of eukaryotic translation initiation factor 4E (eIF4E) is associated with enhanced growth and poor prognosis in nasopharyngeal carcinoma (NPC), the function of eIF4E in NPC response to chemotherapy has not been revealed. In this work, we demonstrate that eIF4E inhibition using both ribavirin and siRNA targets NPC cells and enhances the efficacy of 5-fluorouracil (5-FU). Mechanism studies indicate that 5-FU treatment increases phosphorylation of eIF4E in NPC cells, and this is dependent on ERK activation. eIF4E inhibition thus significantly sensitizes NPC cell response to 5-FU. Of note, ribavirin is a clinically available anti-viral drug. We show that ribavirin exhibits preferential toxicity to NPC with normal nasopharyngeal epithelial cells largely unaffected. Ribavirin acts on NPC cells via inhibiting eIF4E/Akt signaling, and the suppression of eIF4E by ribavirin are not the consequence of inhibition of eIF4E upstream signaling: Mnk and mTOR. In two independent NPC xenograft mouse models, ribavirin at well-tolerated dose that significantly inhibited NPC growth as single drug alone and its combination with 5-FU completely arrests tumor growth throughout the whole duration of treatment, without causing toxicity in mice. Our findings provide the better understanding on the role of eIF4E in NPC in response to 5-FU and preclinical rationale to explore ribavirin as a sensitizing strategy to treat NPC, particularly in those who develop 5-FU resistance.\",\"Senecavirus A (SVA) is a reemerging virus, and recent evidence has emphasized the importance of SVA recombination in vivo on virus evolution. In this study, we report the development of an infectious cDNA clone for the SVA/HLJ/CHA/2016 strain. We used this strain to develop a reporter virus expressing enhanced green fluorescent protein (eGFP), which we then used to screen for a recombination-deficient SVA by an eGFP retention assay. Sequencing of the virus that retained the eGFP following passage allowed us to identify the nonsynonymous mutations (S460L alone and I212V-S460L in combination) in the RNA-dependent RNA polymerase (RdRp) region of the genome. We developed a Senecavirus-specific cell culture-based recombination assay, which we used to elucidate the role of RdRp in SVA recombination. Our results demonstrate that these two polymerase variants (S460L and I212/S460L) have reduced recombination capacity. These results indicate that the RdRp plays a central role in SVA replicative recombination. Notably, our results showed that the two recombination-deficient variants have higher replication fidelity than the wild type (WT) and display decreased ribavirin sensitivity compared to the WT. In addition, these two mutants exhibited significantly increased fitness in vitro compared to the WT. These results demonstrate that recombination and mutation rates are intimately linked. Our results have important implications for understanding the crucial role of the RdRp in virus recombination and fitness, especially in the molecular mechanisms of SVA evolution and pathogenicity.IMPORTANCE Recent evidence has emphasized the importance of SVA recombination on virus evolution in vivo We describe the first assays to study Senecavirus A recombination. The results show that the RNA-dependent RNA polymerase plays a crucial role in recombination and that recombination can impact the fitness of SVA in cell culture. Further, SVA polymerase fidelity is closely related to recombination efficiency. The results provide key insights into the role of recombination in positive-strand RNA viruses.\",\"Resistance-associated substitutions (RASs) of hepatitis C virus (HCV) in the NS5A region impair the efficacy of NS5A inhibitors. In this study, we evaluated the characteristics of the novel RASs observed in treatment-failure patients, A92K and a deletion at P32 (P32del), and the susceptibility of viruses with these RASs to various anti-HCV reagents by using JFH-1 based recombinant HCV with NS5A from a genotype 1b Con1 strain (JFH1/5ACon1). We introduced A92K or P32del solely or in combination with Q24K, L28M, R30Q or L31F into the NS5A of JFH1/5ACon1. Viruses harboring R30Q/A92K showed high extracellular core antigens and infectivity titers, whereas the other viruses with RASs showed low replication levels and infectivity titers. All the viruses with A92K or P32del were markedly resistant to ledipasvir, velpatasvir and elbasvir. Interestingly, viruses with R30Q/A92K were more susceptible to grazoprevir than viruses without RAS. All the viruses had a similar susceptibility to ribavirin and sofosbuvir. In conclusion, combination RASs R30Q/A92K enhanced virus production whereas other RASs impaired virus replication. Both A92K and P32del conferred severe resistance even to second generation NS5A inhibitors. However, these viruses were susceptible to grazoprevir, ribavirin and sofosbuvir. Thus, combination regimens with these reagents may eradicate viruses harboring A92K or P32del.\",\"Resistance to adjuvant chemotherapy remains therapeutic challenge in nasopharyngeal carcinoma (NPC). In this work, we demonstrate that targeting eukaryotic translation initiation factor 4E (eIF4E) is a potential sensitizing strategy to overcome chemoresistance in NPC. We observe the aberrant activation of eIF4E and translational upregulation of eIF4E-regulated oncogenes in NPC cell after pro-longed exposure of cisplatin. Functional analysis demonstrates that eIF4E depletion effectively inhibits proliferation and induces apoptosis in cisplatin-resistant NPC cells. Consistently, eIF4E knockdown significantly enhances cisplatin efficacy in cisplatin-sensitive cells. We identify eIF4E as a therapeutically actionable targets by showing that ribavirin, an anti-viral drug, phenocopies the effects of eIF4E knockdown in NPC. We further demonstrate that ribavirin acts on chemoresistant NPC cells through suppressing eIF4E activity and oncogenic protein translation. Using two independent NPC xenograft mouse models, we show that ribavirin not only is effective in inhibiting chemoresistant NPC growth but also significantly augments the inhibitory effects of cisplatin efficacy in vivo without causing significant toxicity in mice. Taken together, our work shows an activation of eIF4E-mediated growth and survival mechanisms in response to chemotherapy and suggests that inhibition of eIF4E activity represents an attractive sensitizing strategy for NPC treatment. Our findings also suggest that ribavirin is a useful addition to the treatment armamentarium for NPC.\",\"Chronic hepatitis C (HCV) infection perturbs lipid and glucose metabolism. The influenceof direct acting antiviral (DAA) treatment and ribavirin on these measures was evaluated.Furthermore, the effect of HCV cure on these parameters was assessed. Participants were allocatedto one of three 12-week treatment groups: non-cirrhotic genotype 1aparitaprevir/ritonavir/ombitasvir/dasabuvir (PrOD) plus ribavirin; non-cirrhotic 1b-PrOD;compensated cirrhotic 1a or 1b-PrOD plus ribavirin. Fasting insulin, glucose, lipid andapolipoprotein measures were assessed at baseline, Treatment Weeks 4 and 12, and 12 and 24 weekspost-dosing. Twenty-three of 24 participants achieved SVR (PP= 23/24, 96% SVR). Overall, totalcholesterol, low-density lipoprotein cholesterol (LDL-C), and triglyceride levels all increased intreatment and post-dosing. However, LDL-C levels decreased during treatment in ribavirinrecipients. Fasting glucose, insulin, and HOMA-IR were unchanged during treatment and 12 weekspost-treatment. By 12 weeks post-treatment, controlled attenuation parameter (CAP) scores, ameasure of steatosis, increased from baseline (mean 30.3 \\u00b1 63.5, p = 0.05). This regimen was safe andhighly effective and did not influence glucose metabolism. Ribavirin exposure may mitigate someon-treatment lipid changes. Further mechanistic studies are needed to understand how ribavirinimpacts lipid pathways, as there could be therapeutic implications. The metabolic pathophysiologyof increased CAP score with HCV treatment requires explanation.\",\"Preexistence and appearance of resistance-associated substitutions limit the efficacy of direct-acting antivirals in treatment of hepatitis C. This is the first case report of an adolescent with chronic hepatitis C virus genotype 4 infection and cirrhosis who failed treatment with ombitasvir/paritaprevir/ritonavir and ribavirin. Resistance analysis showed baseline resistance-associated substitutions M28V and Y93C and emergent D168H.\",\"These updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of viral hepatitis in the pre- and post-transplant period. The current guidelines reflect the declining need for hepatitis B immunoglobulin following liver transplant, now replaced with nucleos(t)ide analogues that effectively suppress viral replication for the long term with minimal risk for drug resistance. It describes the limitations of pegylated interferon alpha in the treatment for chronic hepatitis D. The guidelines feature the paradigm shift in the treatment arena of chronic hepatitis C, now consisting of highly effective direct-acting antiviral (DAA) medications that effect a cure almost universally. Its safety profile and easy tolerance have permitted its use in patients with decompensated cirrhosis and/or end-stage renal disease. The high potency of the DAA's has fueled the rapidly expanding utilization of hepatitis C-exposed grafts in non-hepatitis C-infected liver, heart, or kidney recipients within structured protocols, followed by viral eradication with DAA therapy in the peri- or post-transplant period. Chronic hepatitis E has become more recognized in the solid-organ transplant recipients, and the therapeutic approach has been streamlined to start with reduction of immunosuppression, and if indicated afterward, ribavirin monotherapy.\",\"Cancer therapies are plagued by resistance. Previously, we discovered a novel form of cancer drug resistance where the Glioma-associated protein 1 (GLI1) elevates UGT1A glucuronidation enzymes, thereby glucuronidating cytarabine and ribavirin, leading to resistance in leukemia patients. Here, we demonstrate that GLI1 imparts resistance to \\u223c40 compounds, including FDA-approved drugs with disparate chemotypes (e.g., methotrexate and venetoclax). GLI1 indirectly elevates UGT1As via the chaperone calreticulin, which is required for resistance. Further, we demonstrate that resistant cells are more sensitive to ATP inhibitors, suggesting an Achilles' heel, which could be exploited in the future. In all, we identify GLI1-inducible glucuronidation as a broad-spectrum multidrug resistance pathway.\",\"Ribavirin is a broad-spectrum nucleoside-derived antiviral drug used in combination pharmacotherapy treatment of hepatitis C virus infection. Current evidence indicates that ribavirin-associated teratogenicity is not significant in humans, but more information about the developmental toxicity and mechanisms involved in ribavirin placental kinetics is required to assure its safe use in pregnancy. Thus, we have investigated potential roles of equilibrative nucleoside transporters (ENTs, SLC29A), Na[+]-dependent influx-mediating concentrative nucleoside transporters (CNTs, SLC28A), and ATP-binding cassette (ABC) efflux pumps, in ribavirin placental pharmacokinetics. Our data indicate that ENT1 participates in uptake of ribavirin by BeWo cells, fresh human placental villous fragments and microvillous plasma membrane (MVM) vesicles while activity of CNTs (probably CNT2) was only observed in BeWo cells. In situ dual perfusion experiments with rat term placenta in an open circuit setup showed that ENT inhibition significantly decreases total ribavirin maternal-to-foetal and foetal-to-maternal clearances. In contrast, no contribution of ABC transporters, p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2), or multidrug resistance-associated protein (ABCC2) was detected in assays with MDCKII cells overexpressing them, or in closed circuit dual perfusion experiments with rat term placenta. In summary, our data show that ribavirin placental pharmacokinetics are largely controlled by ENT1 activity and independent of ABCB1, ABCG2, and ABCC2 efflux pumps.\",\"Hepatitis C virus (HCV) affects approx. 3% of the world's population and accounts for ca 300 000 deaths per year. 80% of individuals with HCV develop chronic symptoms which, when untreated, may cause cirrhosis (27%) or hepatocellular carcinoma (25%). The hepatitis C virus is a (+)ssRNA enveloped virus of the family Flaviviridae. Seven major HCV genotypes and their subtypes (a, b) have been identified. In the 1990s, interferons alpha-2 were used in the treatment of HCV and in the next decade HCV therapy was based on pegylated interferon alpha-2 in combination with ribavirin. Since 2011, interferons alpha, DNA and RNA polymerase inhibitors, NS3/4A RNA protease inhibitors, NS5 RNA serine protease inhibitors, NS5B RNA polymerase inhibitors have been approved for clinical use. Monotherapy is avoided in medication due to rapidly developing viral resistance. A total of 113 papers were included comprising original publications and reviews. The paper reviews the molecular targets and chemical structures of drugs used in HCV treatment. Indications and contraindications for anti-HCV drugs are also discussed together with application regimens.\",\"The emergence of a deletion mutant at hepatitis C virus (HCV) NS5A-P32 (P32del) has recently been reported in a subset of chronic hepatitis C patients who experience virologic failure after direct-acting antiviral drug (DAA) treatment. This mutation confers extremely high resistance to NS5A inhibitors. No effective treatment has been established for cases with this mutation.\",\"Chronic hepatitis C (CHC) virus infection and associated hepatic diseases are still challenging, and the disease burden remains significant around the world. Overall treatment rates for the chronically infected patients have been \\\"dismally poor\\\" and that treatment completion of dual-therapy- pegylated interferon (PEG-IFN) and ribavirin (RBV) is suboptimal in the real-world clinical settings. The approval of first, second and next-generation direct-acting antivirals (DAAs) represents a major breakthrough in hepatitis C virus (HCV) therapeutics to treat CHC infected individuals. Such therapeutic regimens in a fixed dose combination (FDC) or along with RBV have proven their clinical efficacy against different HCV genotypes, and harder-to-treat special populations. We continue to see the development of novel pan-genotypic anti-HCV regimens with very high sustained virologic response (SVR; undetectable viral load at week 12 or at the end of therapy) rates, high barrier to drug resistance, low frequency of adverse events, and fewer drug-drug interactions as compared to some older RBV based triple DAA therapies. Oral interferon-free DAAs seem highly successful strategic treatment approaches against hepatitis C and impulse health policy makers to establish the treatment priorties and policies to reduce the rate of hepatitis C-related morbidity and mortality. This review article comprehensively overviews interferon-free anti-HCV regimens, which have totally shifted the treatment paradigms for hepatitis C with some additional benefits to galvanize our efforts to achieve the global goal of HCV elimination in near future.\",\"Approximately 650,000 people in Brazil have chronic hepatitis C virus (HCV) infection. We evaluated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) plus dasabuvir (DSV) with/without ribavirin (RBV) in an openlabel multicenter phase 3b trial in treatment-naive or interferon (IFN) treatment-experienced Brazilian patients with advanced hepatic fibrosis (METAVIR F3/4) and HCV genotype (GT) 1 infection.\",\"Intergenotypic recombinant hepatitis C virus (HCV) strains emerge rarely during coinfection of the same individual with two HCV genotypes. Few recombinant HCV strains have been identified to date and only one, CRF01 2k/1b, has become a worldwide concern. This study reevaluated the genotyping of three HCV genotype 2 strains from a group of patients with an unusually low rate of sustained virological response after pegylated interferon/ribavirin treatment. In addition, genetic determinants of host interferon resistance were evaluated.\",\"To describe factors associated with treatment failure and frequency of resistance-associated substitutions (RAS).\",\"Treatment with daclatasvir plus asunaprevir (DCV + ASV) for 24 weeks provided a sustained virologic response (SVR) rate of over 90% in hepatitis C virus genotype 1b (HCV-1b) infected patients without non-structural 5A (NS5A) resistance-associated substitutions (RASs) at the L31 and Y93 sites. In this study, we investigated whether adding ribavirin to the DCV + ASV combination could shorten the original treatment regimen to 12 weeks without compromising the treatment efficacy for HCV-1b patients without NS5A RASs.\",\"The aim of this study was to evaluate the efficacy and safety of community-based ombitasvir/paritaprevir/ritonavir plus ribavirin therapy for non-cirrhotic patients with hepatitis C virus (HCV) genotype 2a infection in a real-world setting.\",\"The poor outcomes in infant acute lymphoblastic leukemia (ALL) necessitate new treatments. Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E inhibition, as a potential treatment. We find that ribavirin treatment of actively dividing infant ALL cells on bone marrow stromal cells (BMSCs) at clinically achievable concentrations causes robust proliferation inhibition in proportion with EIF4E expression. Further, we find that ribavirin treatment of KMT2A-rearranged (KMT2A-R) infant ALL cells and the KMT2A-AFF1 cell line RS4:11 inhibits EIF4E, leading to decreases in oncogenic EIF4E-regulated cell growth and survival proteins. In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin-treated RS4:11 cells exhibit impaired EIF4E-dependent nuclear to cytoplasmic export and/or translation of the corresponding mRNAs, as well as reduced phosphorylation of the p-AKT1, p-EIF4EBP1, p-RPS6 and p-EIF4E signaling proteins. This leads to an S-phase cell cycle arrest in RS4:11 cells corresponding to the decreased proliferation. Ribavirin causes nuclear EIF4E to re-localize to the cytoplasm in KMT2A-AFF1 infant ALL and RS4:11 cells, providing further evidence for EIF4E inhibition. Ribavirin slows increases in peripheral blasts in KMT2A-R infant ALL xenograft-bearing mice. Ribavirin cooperates with chemotherapy, particularly L-asparaginase, in reducing live KMT2A-AFF1 infant ALL cells in BMSC co-cultures. This work establishes that EIF4E is broadly elevated across infant ALL and that clinically relevant ribavirin exposures have preclinical activity and effectively inhibit EIF4E in KMT2A-R cases, suggesting promise in EIF4E targeting using ribavirin as a means of treatment.\",\"Direct-acting antiviral agents (DAAs) permit the use of interferon (IFN)-free regimens to treat hepatitis C (HCV) in patients with chronic kidney disease (CKD) on hemo-dialysis (HD) or renal transplant (RTx) recipients, with excellent response rates and safety. However, the occurrence of basal or therapy-induced resistance-associated substitutions (RASs) to DAAs can result in treatment failure. The aim of this study was to estimate the prevalence of RASs to NS3A, NS5A and NS5B inhibitors, and particularly the Q80K polymorphism, in CKD patients on HD and RTx recipients infected with HCV.\",\"According to the EASL and AASLD guidelines, the recommended treatment for patients who failed to achieve a sustained virologic response (SVR) on prior interferon-based triple therapy with protease inhibitors (PI), is a combination of sofosbuvir and NS5A inhibitors. Polish national recommendations also allow the use of paritaprevir/ritonavir/ombitasvir+dasasbuvir\\u00b1ribavirin (PrODR) in this group of patients. The aim of the study was to evaluate the efficacy and safety of PrODR vs. ledipasvir/sofosbuvir\\u00b1RBV (LSR) in PI-experienced patients in real-life setting.\",\"The introduction of new multi-genotypic direct acting antivirals (DAA) in clinical practice has revolutionized HCV treatment, permitting the achievement of >95% rates of sustained virological response in many patients. However, virological failures can occur particularly if the treatments are sub optimal and/or with too short duration. Failure is often associated with development of resistance. The wide genetic variability in terms of different genotypes and subtypes, together with the natural presence and/or easy development of resistance during treatment, are intrinsic characteristics of HCV that may affect the treatment outcome and the chances of achieving a virological cure. This review explores in detail the aspects of HCV innate and treatment-induced resistance to new interferon-free DAA regimens.\",\"European treatment guidelines for hepatitis C virus (HCV) infection recommend that people with genotype (GT) 1a infection and baseline viral load \\u2264800 000 IU/mL receive elbasvir/grazoprevir (EBR/GZR) for 12 weeks, and those with baseline viral load >800 000 IU/mL receive EBR/GZR plus ribavirin for 16 weeks. This analysis was conducted to clarify whether baseline viral load can serve as an accurate, sensitive or specific stratification factor for defining EBR/GZR regimens. In this post hoc, integrated analysis, participants with GT1a infection who received EBR 50 mg/GZR 100 mg for 12 weeks were stratified according to baseline viral load. Sustained virologic response at 12 weeks post-treatment was achieved by 95.2% (911/957) of participants and was higher among participants with baseline viral load \\u2264800 000 IU/mL vs >800 000 IU/mL (98.5% vs 93.9%). The 800 000 IU/mL threshold had a positive predictive value of 98.5%, a negative predictive value of 6.1%, a specificity of 91.3%, a sensitivity of 28.4% and an overall accuracy of 31.5%. A baseline viral load cutpoint of 800 000 IU/mL had high positive predictive value and specificity but poor negative predictive value, sensitivity and accuracy in predicting treatment outcomes in this population. Baseline NS5A resistance-associated substitutions (RASs) were detected in 25% (1/4) of virologic failures with baseline viral load \\u2264800 000 IU/mL and 59.5% (25/42) of those with baseline viral load >800 000 IU/mL. Overall, these data suggest that, compared with the use of a baseline viral load cutpoint, baseline testing for NS5A RASs enables more individuals to receive the 12-week EBR/GZR regimen without compromising the opportunity for SVR.\",\"In Pakistan, the burden of the hepatitis C virus (HCV) infection is the second highest in the world with the development of chronic hepatitis. Interferon-based combination therapy with ribavirin was the only available treatment until a few years back, with severe side-effects and high failure rates against different genotypes of HCV. Interferon-free all-oral direct-acting antiviral agents (DAAs) approved by the FDA have revolutionized the HCV therapeutic landscape due to their efficiency in targeting different genotypes in different categories of patients, including treatment na\\u00efve, treatment failure and relapsing patients, as well as patients with compensated and decompensated cirrhosis. The availability and use of these DAAs is limited in the developing world. Sofosbuvir (SOF), a uridine nucleotide analogue and inhibitor of HCV encoded NS5B polymerase, is now a widely available and in-use DAA in Pakistan; whereas daclatasvir was recently added in the list. According to the documented results, there is hope that this disease can be effectively cured in Pakistan, although a few concerns still remain. The aim of this article is to review the effectiveness of DAAs and the current status of this treatment against HCV genotype 3 infection in Pakistan; various factors associated with SVR; its limitations as an effective treatment regime; and future implications.\",\"Immunosuppressed individuals can shed influenza virus for prolonged periods of time, leading to the frequent emergence of antiviral resistance. We evaluated the benefits of oseltamivir and favipiravir combination therapy compared to single antiviral agents and monitored the emergence of drug-resistant variants in a pharmacologically immunosuppressed mouse model infected with the A(H1N1) pandemic influenza virus. C57BL/6 mice were immunosuppressed with cyclophosphamide and infected with a lethal dose of pandemic influenza A(H1N1) virus. Forty-eight hours post-infection, mice were treated with oseltamivir (20 mg/kg), favipiravir (20 or 50 mg/kg) or both agents BID for 5 or 10 days. Body weight losses, survival rates, lung viral titers, cytokine levels and emergence of resistant viruses were evaluated. Treatment of immunosuppressed mice with high (50 mg/kg) but not low (20 mg/kg) doses of favipiravir in combination with oseltamivir (20 mg/kg) significantly delayed mortality and reduced lung viral titers compared to treatment with a single drug regimen with oseltamivir but did not prevent the emergence of oseltamivir-resistant H275Y neuraminidase variants. Combination therapy with oseltamivir and favipiravir should be considered for evaluation in clinical trials.\",\"Hepatitis E virus (HEV) can cause chronic infections in immunosuppressed patients with adverse clinical outcomes. Intervention strategies are limited with ribavirin (RBV) being the only main therapeutic option as off-label drug. Recent reports on RBV monotherapy failures show a coherence with the presence of certain single nucleotide variants (SNVs) and in-frame insertions in the hypervariable region of open reading frame 1 in the HEV genome. Importantly, some of the alterations were present in the viral population as minor variant before RBV administration. Individualized infection medicine by early detection of emerging viral variants in patients could improve treatment outcome and prognosis.\",\"The rapid development of direct-acting antiviral agents (DAA) for hepatitis C virus (HCV) therapy dramatically altered the treatment landscape of this disease. The DAA regimen is associated with various advantages including high sustained virological response (SVR) with minimum side effects and low pill load and specific inhibition of viral replication, which lowers dependence on the host cell. This regimen has substantially replaced conventional (interferon) therapy with high cure rates (> 90%) in most HCV populations. This review provides insight into clinical studies of NS3/4A protease inhibitors, NS5B viral polymerase inhibitor (nucleotide and non-nucleotide), and NS5A inhibitors, alone and in combination.\",\"Despite very high efficacies of direct-acting antivirals (DAAs) reported in clinical trials, treatment failure in real-life practice can occur in 5-10% of cases and is mostly associated with emergence of resistance-associated substitutions (RASs). Little is known about the efficacy of retreatment in these patients, especially in those with decompensated cirrhosis, and only a few retreatment studies have been performed so far. Here we present case reports of successful sofosbuvir-based treatment in patients with advanced class B cirrhosis with prior pegylated interferon/ribavirin and all-oral DAA failure with multiclass drug resistance. HCV resistance testing at failure was performed to guide the choice of salvage therapy.\",\"Influenza viruses (IVs) are a continual threat to global health. The high mutation rate of the IV genome makes this virus incredibly successful, genetic drift allows for annual epidemics which result in thousands of deaths and millions of hospitalizations. Moreover, the emergence of new strains through genetic shift (e.g., swine-origin influenza A) can cause devastating global outbreaks of infection. Neuraminidase inhibitors (NAIs) are currently used to treat IV infection and act directly on viral proteins to halt IV spread. However, effectivity is limited late in infection and drug resistance can develop. New therapies which target highly conserved features of IV such as antibodies to the stem region of hemagglutinin or the IV RNA polymerase inhibitor: Favipiravir are currently in clinical trials. Compared to NAIs, these treatments have a higher tolerance for resistance and a longer therapeutic window and therefore, may prove more effective. However, clinical and experimental evidence has demonstrated that it is not just viral spread, but also the host inflammatory response and damage to the lung epithelium which dictate the outcome of IV infection. Therapeutic regimens for IV infection should therefore also regulate the host inflammatory response and protect epithelial cells from unnecessary cell death. Anti-inflammatory drugs such as etanercept, statins or cyclooxygenase enzyme 2 inhibitors may temper IV induced inflammation, demonstrating the possibility of repurposing these drugs as single or adjunct therapies for IV infection. IV binds to sialic acid receptors on the host cell surface to initiate infection and productive IV replication is primarily restricted to airway epithelial cells. Accordingly, targeting therapies to the epithelium will directly inhibit IV spread while minimizing off target consequences, such as over activation of immune cells. The neuraminidase mimic Fludase cleaves sialic acid receptors from the epithelium to inhibit IV entry to cells. While type III interferons activate an antiviral gene program in epithelial cells with minimal perturbation to the IV specific immune response. This review discusses the above-mentioned candidate anti-IV therapeutics and others at the preclinical and clinical trial stage.\",\"The use of oral ribavirin (RBV) for respiratory syncytial virus (RSV) infections is not well studied. With the drastic increase in the cost of aerosolized RBV, we aimed to compare outcomes of hematopoietic cell transplant (HCT) recipients treated with oral or aerosolized RBV for RSV infections.\",\"This study aimed to describe the real-world efficacy and safety of sofosbuvir (SOF) + ribavirin (RBV) for chronic hepatitis C, genotype 2.\",\"A detailed analysis of hepatitis C virus (HCV) resistance-associated substitutions (RASs) is required to understand why people fail direct-acting antiviral therapies. This study was conducted to assess RASs in an analysis of 2 trials evaluating the second-generation NS3/4A protease inhibitor grazoprevir (GZR) in combination with peginterferon/ribavirin.\",\"Chronic hepatitis C remains a major public health concern with a prevalence of more than 1% worldwide. Of late, with the discovery of newer drugs, chronic HCV treatment has touched new dimensions. The treatment has progressed from Interferons to Pegylated interferon (Peg IFN) based therapy, with or without ribavirin to treatment with orally active Direct Acting Antivirals (DAA) with Peg IFN and ribavirin and eventually to various combinations of DAA, without IFN. Introduction of newer DAAs has transfigured the treatment of chronic HCV. Chronic HCV patients with advanced liver disease, psychiatric condition, anemia or autoimmune diseases, not eligible for Peg IFN based therapy have a ray of hope now. Amongst all DAAs, nucleoside inhibitors have been the most promising agent. Thus the present review focuses on Sofosbuvir, one of the most effective nucleoside inhibitors; in terms of potency, resistance profile, activity against all genotypes of HCV and adverse effects. FDA approved Sofobuvir for clinical use in 2013. Chemically, it is 2'-deoxy-2'-\\u03b1-fluoro-\\u03b2-Cmethyluridine- 5'-triphosphate; a phosphoramidate prodrug that is activated by enzyme present in human liver. It is a highly potent inhibitor of HCV NS5B polymerase. Efficacy of the Sofosbuvir has been established in various phase 2 and phase 3 clinical trials like PROTON, ELECTRON, FUSION, POSITRON etc. Sofosbuvir has a good safety profile with few mild to moderate adverse effects. Evidence reveals that sofosbuvir has substantial impact on the treatment of HCV.\",\"This study was performed to investigate the efficacy and safety of grazoprevir-elbasvir guided by baseline resistance-associated substitutions (RASs) in the Swiss HCVree Trial.\",\"Viral fitness quantifies the degree of virus adaptation to a given environment. How viral fitness can influence the mutant spectrum complexity of a viral quasispecies subjected to lethal mutagenesis has not been investigated. Here we document that two high fitness hepatitis C virus populations display higher resistance to the mutagenic nucleoside analogues favipiravir and ribavirin than their parental, low fitness HCV. All populations, however, exhibited a mutation transition bias indicative of active mutagenesis. Resistance to the analogues was associated with a limited expansion of mutant spectrum complexity, as evidenced by several diversity indices used to characterize mutant spectra. The results are consistent with a replicative site-drug competition mechanism that was previously proposed for HCV fitness-associated resistance to non-mutagenic inhibitors. Other alternative, non-mutually exclusive mechanisms are considered. The results introduce viral fitness as a relevant parameter to evaluate the response of viruses to lethal mutagenesis, with implications for antiviral designs.\",\"Chronic Hepatitis C virus infection (HCV) is associated with extrahepatic manifestations and an increased prevalence in cardiovascular disease. New direct acting antivirals (DAA) have revolutionized HCV treatment with high rates of sustained virological response (SVR). Recently it was demonstrated, that SVR reduces morbidity and overall mortality more than can be solely explained by hepatic effects, suggesting that treatment with DAA also affects cardiovascular disease. The aim of this pilot study was to identify possible underlying mechanisms behind the HCV-associated cardiovascular mortality reported by others.\",\"Currently, there are no interferon-free treatments available for hepatitis C virus (HCV)-infected patients younger than 12 years. We evaluated the safety and effectiveness of the all-oral regimen ledipasvir-sofosbuvir \\u00b1 ribavirin in HCV-infected children aged 6 to <12 years. In an open-label study, patients aged 6 to <12 years received ledipasvir 45 mg-sofosbuvir 200 mg as two fixed-dose combination tablets 22.5/100 mg once daily, with or without ribavirin, for 12 or 24 weeks, depending on HCV genotype and cirrhosis status. The primary efficacy endpoint was sustained virologic response 12 weeks after therapy (SVR12). Twelve patients underwent intensive pharmacokinetic sampling to confirm the appropriateness of the ledipasvir and sofosbuvir dosages. Ninety-two patients were enrolled (88 genotype 1, 2 genotype 3, and 2 genotype 4), with a median age of 9 years (range, 6-11). Most were perinatally infected (97%) and treatment-naive (78%). Two were confirmed to have cirrhosis, while the degree of fibrosis was unknown in 55 patients. The overall SVR12 rate was 99% (91/92; 95% confidence interval, 94%-100%). The single patient not reaching SVR relapsed 4 weeks after completing 12 weeks of treatment. The most common adverse events were headache and pyrexia. One patient had three serious adverse events, which were considered to be not related to study treatment: tooth abscess, abdominal pain, and gastroenteritis. The area under the concentration-time curve and maximum concentration values for sofosbuvir, its primary metabolite GS-331007, and ledipasvir were within predefined pharmacokinetic equivalence boundaries (50%-200%) compared to values in adults in phase 2/3 of the ledipasvir and sofosbuvir studies. Conclusion: Ledipasvir-sofosbuvir was well tolerated and highly effective in children 6 to <12 years old with chronic HCV.\",\"The treatment of hepatitis C virus (HCV) infection has been revolutionized by the development of all-oral combination regimens of direct-acting antiviral agents. The current analysis characterized the relationship between exposures of daclatasvir (DCV; tablets) and asunaprevir (ASV; capsules) and sustained virologic response (SVR) in Japanese patients who are HCV genotype (GT) 1b nonresponders to pegylated interferon (IFN) \\u03b1/ribavirin or IFN\\u03b2/ribavirin, and IFN-based therapy-ineligible naive/intolerant patients receiving DCV and ASV, and provided insight into patient covariates that were most closely associated with efficacy. The relationship between the probability of achieving SVR at 12 weeks after treatment (SVR12) and average steady-state plasma concentrations estimated from population pharmacokinetic models for DCV and ASV is described using a logistic regression model with data from a phase 2 and a phase 3 study in Japanese patients infected with HCV GT 1b (N=265). The functional form characterization, which describes a relationship between DCV and ASV average steady-state plasma concentrations and SVR12, as well as covariate identification (demographic, laboratory, and prognostic and treatment covariates) were investigated during model development. The presence of the signature nonstructural protein 5A Y93H mutation at baseline was the only significant parameter of SVR12 in the final exposure-response model. Model evaluation plots demonstrate that the final model was able to predict the observed SVR rates. Exposure-response analysis supports the clinical utility of the combination regimen of 60-mg once-daily DCV and 100-mg twice-daily ASV in Japanese patients infected with HCV GT 1b.\",\"Over 2,200 patients infected with hepatitis C virus (HCV) genotypes (GT) 1 to 6, with or without cirrhosis, who were treatment naive or experienced to interferon, ribavirin, and/or sofosbuvir were treated with glecaprevir/pibrentasvir for 8, 12, or 16 weeks in eight registrational phase 2 and 3 clinical studies. High rates of sustained virologic response at 12 weeks postdosing (SVR12) were achieved with a <1% virologic failure (VF) rate. The prevalence of baseline polymorphisms (BPs) in NS3 at amino acid position 155 or 168 was low (<3%) in patients infected with GT1, GT2, GT3, GT4, and GT6, while 41.9% of the GT5-infected patients had NS3-D168E; BPs were not detected at position 156 in NS3. The prevalence of NS5A-BPs was high across genotypes, driven by common polymorphisms at amino acid position 30 or 31 in GT2, 58 in GT4, and 28 in GT6. The prevalence of NS5A T/Y93 polymorphisms was 5.5% in GT1, 4.9% in GT3, and 12.5% in GT6. Consistent with the activity of glecaprevir and pibrentasvir against most amino acid polymorphisms in vitro, BPs in NS3 and/or NS5A did not have an impact on treatment outcome for patients infected with GT1 to GT6, with the exception of treatment-experienced GT3-infected patients treated for 12 weeks, for whom a 16-week regimen of glecaprevir/pibrentasvir was required to achieve SVR12 rates of \\u226595%. Among the 22 patients experiencing VF, treatment-emergent substitutions were detected in NS3 in 50% of patients and in NS5A in 82% of patients, frequently as a combination of substitutions that conferred resistance to glecaprevir and/or pibrentasvir. The glecaprevir/pibrentasvir regimen, when the recommended durations are used, allows for a pan-genotypic treatment option without the need for baseline resistance testing.\",\"Insulin resistance and diabetes mellitus are common extrahepatic manifestations of chronic hepatitis C (HCV). Insulin resistance assessed by HOMA-IR is associated with low rates of sustained virological response, especially in HCV genotype 1 positive patients treated with peginterferon/ribavirin. The effect of insulin resistance on sustained virologic response in HCV genotype 3 positive patients who were treated with peginterferon/ribavirin still remains unclear.\",\"In HCV-infected people who fail to achieve sustained virological response after receiving a direct-acting antiviral regimen, virological failure is almost always accompanied by the presence of resistance-associated substitutions (RASs) in the target protein(s). The aim of this long-term observational study was to evaluate the persistence of NS3/4A and NS5A RASs in participants with genotype (GT) 1 infection who relapsed following treatment with a grazoprevir-containing treatment regimen.\",\"In Japan, there is a growing population of patients with chronic hepatitis C virus (HCV) infection who failed a direct-acting antiviral (DAA)-based regimen. In this Phase 3 study, we evaluated sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 HCV infection who previously received DAAs.\",\"Genetic polymorphisms within the interferon \\u03bb (IFN-\\u03bb) chromosomal region, mainly rs12979860 of IFN-\\u03bb4 gene (IFNL4), are known as associated with spontaneous hepatitis C virus (HCV) resolution and sustained viral response to therapy with pegylated interferon- \\u03b1 and ribavirin. Strong linkage disequilibrium of IFNL4 rs12979860 with IFNL4 rs368234815, which is casually associated with HCV spontaneous and therapeutical eradication, at least partially explains favorable HCV outcomes attributed to major homozygosity in rs12979860. Effects of IFN-based antiviral treatment are associated with pretreatment expression of the IFN-\\u03bb1 receptor, expression of hepatic IFN-stimulated genes, production of IFN- \\u03bb4, and preactivation of the JAK-STAT signaling. Nowadays direct-acting antivirals (DAAs) became a potent tool in the treatment of hepatitis C, but IFN-\\u03bbs are still under investigation as potential antivirals and might be an option in HCV infection (DAA resistance, recurrent viremia, adverse effects). Patients with altered immunocompetence are especially prone to infections. In uremic subjects, polymorphisms within the IFN-\\u03bb chromosomal region associate with spontaneous HCV clearance, similarly like in the non-uremic population. Circulating IFN-\\u03bb3 shows a positive correlation with plasma titers of antibodies to surface antigen of hepatitis B virus (anti-HBs), which are crucial for protection against hepatitis B virus. More efficient anti-HBs production in the presence of higher IFN-\\u03bb3 levels might occur due to IFN-\\u03bb3-induced regulation of indoleamine 2,3-dioxygenase (IDO) expression. IFN-stimulated response element is a part of IDO gene promoter. It is worth further investigation whether IDO gene, circulating IDO, genetic polymorphisms within the IFN-\\u03bb region, and circulating IFN-\\u03bb3 act in concordance in immunological response to hepatotropic viruses.\",\"Insulin resistance (IR) is a common complication in chronic hepatitis C virus (HCV) patients. The impact of IR on outcome of therapy with direct antivirals has not been studied.\",\"Hepatitis C virus (HCV) exhibits great genetic diversity and is classified into 7 genotypes (GTs), with varied geographic prevalence. Until the recent development of pangenotypic direct-acting antiviral regimens, the determination of HCV GT was necessary to inform optimal treatment.\",\"Although cancer patients initially respond well to chemotherapy, they eventually develop resistance and relapse. In this work, we demonstrate that eIF4E-targeting therapy is a potential sensitizing strategy for overcoming chemoresistance and progression in cancer. We show that ribavirin, an anti-viral drug and pharmacological eIF4E inhibitor, effectively inhibits proliferation and decreases viability of paclitaxel-resistant cervical cancer and 5-FU-resistant colon cancer cells while is less toxic to human fibroblast cells. Importantly, oral administration of ribavirin significantly inhibits paclitaxel-resistant colon and 5-FU-resistant cervical cancer growth in xenograft mouse cancer model without causing significant toxicity in mice. Consistently, combination of ribavirin with paclitaxel or 5-FU sensitizes colon and cervical cancer cells to chemotherapeutic agents treatment in vitro and in vivo. We further confirm that the mechanism of the action of ribavirin in chemoresistant cancer cells is through suppressing eIF4E function. In addition, specific eIF4E knockdown via two independent siRNA mimics the effects of ribavirin in chemoresistant colon and cervical cancer cells. Cell cycle analysis indicate that ribavirin enhances the anti-proliferative effect of 5-FU by additionally arresting cells at G2/M phase via increasing cyclin B1, p-histone H3(Ser10) and Mad2 levels. Our work demonstrates that eIF4E inhibition using inhibitor or siRNA, either as single agent or in combination, could sensitize chemoresistant cancer cells to paclitaxel or 5-FU treatment and thereby improving the efficacy of chemodrug. Our findings demonstrate the therapeutic value of inhibiting eIF4E, particularly in chemoresistant cancers. Our findings also suggest ribavirin as a promising sensitizing drug for cancer treatment.\",\"In phase 3 trials and real-world settings, smaller proportions of patients with genotype 3 hepatitis C virus (HCV) infection and cirrhosis have a sustained virologic response 12 weeks after treatment (SVR12) with the combination of sofosbuvir and velpatasvir than in patients without cirrhosis. It is unclear whether adding ribavirin to this treatment regimen increases SVRs in patients with genotype 3 HCV infection and cirrhosis.\",\"Ribavirin (RBV) has been used for the last 20 years to treat patients with chronic hepatitis C virus (HCV) infection. This pluripotent drug is believed to induce mutagenesis in HCV RNA. However, for cell-cultured HCV (HCVcc) this phenomenon has only been investigated in genotype 2a recombinants. Here we studied the mutations that developed in HCVcc of genotypes 1a and 3a treated with RBV or ribavirin triphosphate (RBV-TP) compared to non-treated controls. Analysis was performed on the amplified full-length open reading frame (ORF) of recovered viruses following next-generation sequencing and clonal analyses. Compared to non-treated controls, the spread of TNcc(1a) and DBN3acc(3a) HCVcc was delayed by RBV and RBV-TP at concentrations of 40 \\u00b5M or higher. The delay in HCVcc spread was associated with increased new single-nucleotide polymorphisms (SNP). Significantly higher numbers of new SNP were observed in TNcc(1a) viruses treated with RBV or RBV-TP compared to matched non-treated controls. RBV or RBV-TP treatment led to significantly increased proportions of new G-to-A and C-to-U SNP compared to non-treated TNcc(1a). Clonal analyses confirmed a significantly increased mutation rate in RBV-treated TNcc(1a). Synonymous pairwise distances increased in both viruses across the complete ORF under RBV and RBV-TP treatment compared to controls. Consensus-shifts in single samples of RBV- or RBV-TP-treated TNcc(1a) viruses occurred in proteins E1, p7, NS3 and NS4B. No non-synonymous consensus changes were observed in DBN3acc(3a). This study supports a biased G-to-A and C-to-U mutagenic effect of RBV and RBV-TP throughout the entire ORF of HCV genotypes 1a and 3a.\",\"In hepatitis C virus (HCV), infection viral and IL28B genotype along with many clinical and biochemical factors can influence response rates to pegylated interferon plus ribavirin (Peg-IFN-a/R) therapy and progression to chronic hepatitis C (CHC).\",\"Influenza A virus (IAV) causes seasonal epidemics and occasional but devastating pandemics, which are major public health concerns. Because the effectiveness of seasonal vaccines is highly variable and the currently available drugs are limited in their efficacy because of the emergence of drug resistance, there is an urgent need to develop novel antivirals. In this study, we characterized a recombinant IAV-carrying Gaussia luciferase (Gluc) gene and determined its potential as a tool for evaluating therapeutics. We demonstrated that this recombinant IAV is replication-competent in tissue culture and pathogenic in mice, although it is slightly attenuated compared to the parental virus. Luciferase expression correlated well with virus propagation both in vitro and in vivo, providing a simple measure for viral replication in tissue culture and in mouse lungs. To demonstrate the utility of this virus, ribavirin and oseltamivir phosphate were used to treat the IAV-infected cells and mice, and we observed the dose-dependent inhibition of viral replication by a luciferase assay. Moreover, the decreased luciferase expression in the infected lungs could predict the protective efficacy of antiviral interventions as early as day 2 post virus challenge. In summary, this study provides a new and quantitative approach to evaluate antivirals against IAV.\",\"Trichomonas vaginalis infects approximately 300 million people worldwide annually. Infected individuals have a higher susceptibility to more serious conditions such as cervical and prostate cancer. The parasite has developed increasing resistance to current drug therapies, with an estimated 5% of clinical cases resulting from resistant strains, creating the need for new therapeutic strategies with novel mechanisms of action. Nucleoside salvage pathway enzymes represent novel drug targets as these pathways are essential for the parasite's survival. The guanosine/adenosine/cytidine nucleoside hydrolase (GACNH) may be particularly important as its expression is upregulated under glucose-limiting conditions mimicking those that occur during infection establishment. GACNH was screened against the NIH Clinical Collection to explore its druggability. Seven compounds were identified with IC50 values <20 \\u03bcM. Extensive overlap was found between inhibitors of GACNH and the adenosine/guanosine nucleoside hydrolase (AGNH), but no overlap was found with inhibitors of the uridine nucleoside hydrolase. The guanosine analog ribavirin was the only compound found to be specific for GACNH. Compounds that inhibit both AGNH and GACNH purine salvage pathway enzymes may prove critical given the role that GACNH appears to play in the early stages of infection.\",\"The landscape of therapeutic options for HCV infection has dramatically changed with the approval of all-oral direct-acting antiviral (DAA) regimens. DAAs target important steps in the HCV viral life cycle, resulting in higher response rates and fewer adverse events than were afforded with interferon and ribavirin, the prior standard of care. The achievement of sustained virologic response (SVR) rates in excess of 90% with use of DAA regimens has not only translated into HCV eradication for the hundreds of thousands treated but is also anticipated to decrease the incidence of major complications associated with chronic HCV infection. Additionally, the favorable side effect profile of DAAs has made HCV therapy feasible in difficult-to-treat populations, including those with previous exposure to interferon and ribavirin, cirrhosis, decompensated liver disease, HIV and HCV co-infection, and severe renal dysfunction/end stage renal disease. Given this tremendous progress, all patients infected with HCV infection should be treated.\",\"Chronic hepatitis C (CHC) has a prevalence rate of 0.43% in China and approximately 10 million chronically infected people are in urgent need of treatment. Since the beginning of 2013, pan-genotypic sofosbuvir (SOF) with its potent antiviral activity, minimal drug resistance, less drug-drug interactions and good safety has created a new era in HCV treatment. Its combination with ribavirin, in single tablet regimen with either ledipasvir or velpatasvir has been widely used in about 1.6 million patients worldwide. Furthermore, SOF-based therapy is proven to be effective and safe in serious or terminal illness such as decompensated cirrhosis, liver or kidney transplantation, HIV or HBV co-infections, bleeding disorders, intravenous drug users, adolescents, and elderly. Therefore, SOF-based regimens would fill the unmet medical needs of our patients with HCV.\",\"Search for new antiviral and anticancer agents are essential because of the emergence of drug resistance in recent years. In continuation of our efforts in identifying the new small molecule antiviral and anticancer agents, we identified chalcones as potent antiviral and anticancer agents.\",\"Hepatitis C virus (HCV) is a unique virus which interacts with cholesterol, iron and insulin metabolism. There is limited data on the effects of direct-acting antiviral agents (DAAs) on metabolic profiles. We aimed at evaluating the behavior of metabolic risk factors of chronically HCV-infected patients after sustained virologic response (SVR), comparing the outcomes with the new DAAs versus the old treatment regimen Peg-interferon \\u00b1 ribavirin.\",\"Familial Mediterranean fever is an autosomal recessive disorder characterized by periodic febrile attacks of aseptic serositis and/or arthritis. The main treatment is colchicine which prevents attacks in the majority of patients except for a group of colchicine-resistant cases. Chronic hepatitis C is a viral infection causing chronic inflammation of liver tissue (hepatitis) which ultimately progresses to fibrosis and liver cirrhosis with a high chance of hepatocellular carcinoma. However, we found no data in the literature concerning the impact of hepatitis C on the course of attacks of familial Mediterranean fever.\",\"Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people and approximately 400,000 deaths are attributed to HCV-related liver disease annually worldwide. Mainstay of treatment for over 25 years has been pegylated interferon until the advent of protease inhibitors, which has led to all-oral HCV treatment regimens that have changed the outlook of hepatitis C treatment. Grazoprevir/elbasvir provides high rates of efficacy and tolerability and is an all-oral once daily treatment option for HCV infection. Efficacy of grazoprevir/elbasvir has been proven in patients with cirrhosis, patients who have previously failed treatment with peginterferon and ribavirin (RBV), patients with end-stage renal disease and patients with HIV co-infection. Data have shown a high barrier to resistance despite the presence of resistance-associated substitutions. Grazoprevir/elbasvir represents a very promising regimen for treatment of HCV infection. This review provides a summary of pharmacology, efficacy, and safety of grazoprevir/elbasvir for the treatment of HCV infection.\",\"A series of dithioacetal derivatives bearing a strobilurin moiety were designed and synthesized on the basis of our previous work. The antiviral activities of these compounds against Potato virus Y (PVY), Cucumber mosaic virus (CMV), and Tobacco mosaic virus (TMV) were systematically evaluated. Bioassay results indicated that C14 elicited excellent curative and protective activities against PVY, CMV, and TMV. The former had 50% effective concentrations (EC50) of 125.3, 108.9, and 181.7 \\u03bcg/mL, respectively, and the latter had 148.4, 113.2, and 214.6 \\u03bcg/mL, respectively, which were significantly superior to those of lead compound 6f (297.6, 259.6, and 582.4 \\u03bcg/mL and 281.5, 244.3, and 546.3 \\u03bcg/mL, respectively), Ningnanmycin (440.5, 549.1, and 373.8 \\u03bcg/mL and 425.3, 513.3, and 242.7 \\u03bcg/mL, respectively), Chitosan oligosaccharide (553.4, 582.8, and 513.8 \\u03bcg/mL and 547.3, 570.6, and 507.9 \\u03bcg/mL, respectively), and Ribavirin (677.4, 690.3, and 686.5 \\u03bcg/mL and 652.7, 665.4, and 653.4 \\u03bcg/mL, respectively). Moreover, defensive enzyme activities and RT-qPCR analysis demonstrated that the antiviral activity was associated with the changes of SOD, CAT, and POD activities in tobacco, which was proved by the related proteins of abscisic acid signaling pathway. This work provided a basis for further design, structural modification, and development of dithioacetal derivatives as new antiviral agents.\",\"Genetic variants at the interferon lambda (IFNL) locus have been associated with several human phenotypes in both disease and health. In chronic hepatitis C virus (HCV) infections, where the IFNL variants were first identified to be associated with response to interferon-\\u03b1-ribavirin therapy, the available data clearly suggests that the causal variant could be the dinucleotide polymorphism rs368234815 that causes an open reading frame-shift in the IFNL4 gene resulting in expression of a functional IFN-\\u03bb4, a new type III IFN. In other human diseases/phenotypes where IFNL variants have been recently associated with, the causal mechanism remains unclear. In vitro evidence has shown that other IFNL variants (rs28416813, rs4803217) may regulate expression of another type III IFN, IFN-\\u03bb3. Therefore, expression of a functional IFN-\\u03bb4 and quantitative differences in IFN-\\u03bb3 expression are two potential causal mechanisms behind the observed phenotypes. Since these two potential causal mechanisms involve features of mutual exclusivity and overlapping functions, it is difficult to differentiate one from the other, in vivo, in absence of other implicating evidences. In addition, the strong linkage disequilibrium (LD) observed in many populations at the IFNL locus makes it difficult to tease out the actual functional/causal variants responsible for the phenotypes. The non-synonymous single nucleotide polymorphism rs117648444 that alters the activity of IFN-\\u03bb4 and the LD structure in the IFNL region which leads to a confounding effect of rs117648444 on other IFNL variants, provide us with additional tools in case-control studies to probe the role of IFN-\\u03bb4.\",\"Hepatitis C virus (HCV) infection induces interferon (IFN)-stimulated genes (ISGs) and downstream innate immune responses. This study investigated whether baseline and on-treatment differences in these responses predict response versus virological breakthrough during therapy with direct-acting antivirals (DAAs). Thirteen HCV genotype 1b-infected patients who had previously failed a course of pegylated IFN/ribavirin were retreated with asunaprevir/daclatasvir for 24 weeks. After pretreatment biopsy, patients were randomized to undergo a second biopsy at week 2 or 4 on therapy. Microarray and NanoString analyses were performed on paired liver biopsies and analyzed using linear mixed models. As biomarkers for peripheral IFN responses, peripheral blood natural killer cells were assessed for phosphorylated signal transducer and activator of transcription 1 (pSTAT1) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and degranulation. Nine of 13 (69%) patients achieved sustained virological response at 12 weeks off therapy (SVR12), and 4 experienced virological breakthroughs between weeks 4 and 12. Patients who achieved SVR12 displayed higher ISG expression levels in baseline liver biopsies and a higher frequency of pSTAT1 and TRAIL-expressing, degranulating natural killer cells in baseline blood samples than those who experienced virological breakthrough. Comparing gene expression levels from baseline and on-therapy biopsies, 408 genes (\\u00b11.2-fold, P < 0.01) were differentially expressed. Genes down-regulated on treatment were predominantly ISGs. Down-regulation of ISGs was rapid and correlated with HCV RNA suppression. Conclusion: An enhanced IFN signature is observed at baseline in liver and blood of patients who achieve SVR12 compared to those who experience a virological breakthrough; the findings suggest that innate immunity may contribute to clearance of HCV during DAA therapy by preventing the emergence of resistance-associated substitutions that lead to viral breakthrough during DAA therapy.\",\"Among patients with chronic hepatitis C, 20-30% develop cirrhosis and its complications within 30 years. The antiviral treatment of hepatitis C has become interferon-free, with resulting improvements in sustained virological response rates, safety and tolerability and a shorter duration of treatment.\",\"Data are limited regarding the effectiveness and safety of generic velpatasvir plus sofosbuvir (VEL/SOF) for hepatitis C virus (HCV) in patients with or without human immunodeficiency virus (HIV) coinfection.\",\"In the past few years, a growing body of clinical evidence has highlighted the risk of vitamin D deficiency in patients with chronic hepatitis C and that vitamin D levels are associated with the course of hepatitis C virus (HCV) infection, adverse effects, and treatment response to peginterferon/ribavirin. Recently, studies have found that vitamin D status is related to drug resistance and increased risk of infection in patients with liver cirrhosis. Vitamin D-related gene polymorphisms have been found to explain the interactions between vitamin D deficiency and HCV infection, offering a new perspective toward understanding the current problems such as the development of insulin resistance and racial differences in sustained virological response. Studies have been conducted to determine whether vitamin D supplementation as an adjuvant yields a better result compared with traditional HCV treatment. Here, we provide a brief review of the past and present knowledge of vitamin D in HCV infection.\",\"Curative interferon and ribavirin sparing treatments for hepatitis C virus (HCV)-infected patients require a combination of mechanistically orthogonal direct acting antivirals. A shared component of these treatments is usually an HCV NS5A inhibitor. First generation FDA approved treatments, including the component NS5A inhibitors, do not exhibit equivalent efficacy against HCV virus genotypes 1-6. In particular, these first generation NS5A inhibitors tend to select for viral drug resistance. Ombitasvir is a first generation HCV NS5A inhibitor included as a key component of Viekira Pak for the treatment of patients with HCV genotype 1 infection. Since the launch of next generation HCV treatments, functional cure for genotype 1-6 HCV infections has been achieved, as well as shortened treatment duration across a wider spectrum of genotypes. In this paper, we show how we have modified the anchor, linker, and end-cap architecture of our NS5A inhibitor design template to discover a next generation NS5A inhibitor pibrentasvir (ABT-530), which exhibits potent inhibition of the replication of wild-type genotype 1-6 HCV replicons, as well as improved activity against replicon variants demonstrating resistance against first generation NS5A inhibitors.\",\"To assess daclatasvir plus asunaprevir (DUAL) in treatment-na\\u00efve patients from mainland China, Russia and South Korea with hepatitis C virus (HCV) genotype 1b infection.\",\"The hepatitis C virus (HCV) has affected an estimated of 80 million individuals worldwide and is a strain on public health. Around 25-30% of patients in Europe and the US who are infected with HIV are coinfected with HCV. Prior to 2013, treatment modalities containing an NS3/4A protease inhibitor in combination with pegylated interferon and ribavirin improved sustained virological response (SVR) rates. However, rates of severe side effects were high. Nowadays, oral direct-acting antiviral (DAA) combination therapy offers excellent treatment efficacy, safety and tolerability.\",\"We report a real-life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D-R). He had therapy failure at week 12 after the end of treatment. We detected resistance-associated substitutions (RASs) plus polymorphisms on NS3, NS5A, and NS5B target regions by population sequencing (15% cut-off) at baseline, at relapse and during follow-up. About this, NS5A RASs generally persist longer than resistances in the other target genes and may impact treatment outcome. Therefore, to evaluate OMV drug-resistance mechanism, we studied the acquired RAS plus polymorphisms on NS5A phosphoprotein by computational studies. OMV showed a higher affinity towards baseline and 93H/108 K mutant structure (follow-up) with respect to 93H/R108 mutant structure (relapse) on phosphoprotein. By Molecular Dynamics simulations (MDs), structural information about the protein stability in presence of OMV were observed. According to our data, molecular modeling approach has proved to be a powerful method to evaluate the impact of these RASs plus specific amino acid (AA) changes on phosphoprotein.\",\"Ribavirin (RBV) is a broad-spectrum antiviral active against a wide range of RNA viruses. Despite having been used for decades in the treatment of chronic hepatitis C virus (HCV) infection, the precise mechanism of action of RBV is unknown. In other viruses, it inhibits propagation by increasing the rate of G-to-A and C-to-U transitions. Here, we utilized the J6/JFH1 HCV cell-culture system to investigate whether RBV inhibits HCV through the same mechanism. Infected Huh7.5 cells were treated with increasing concentrations of RBV or its phosphorylated forms. A fragment of the HCV NS5B-polymerase gene was amplified, cloned, and sequenced to estimate genetic distances. We confirm that the antiviral effect of all three RBV-drug forms on HCV relies on induction of specific transitions (G-to-A and C-to-U). These mutations lead to generation of non-infectious virions, reflected by decreased spread of HCV in cell culture despite relatively limited effect on virus genome titers. Moreover, treatment experiments conducted on a novel Huh7.5 cell line stably overexpressing adenosine kinase, a key enzyme for RBV activation, yielded comparable results. This study indicates that RBV action on HCV in hepatoma cell-culture is exerted through increase in mutagenesis, mediated by RBV triphosphate, and leading to production of non-infectious viruses.\",\"The clinical experience with protease-inhibitor (PI) triple regimen appears disappointing regarding effect, side effects, high work load, and costs. This real-world study evaluates baseline and emerging resistance-associated substitutions (RASs) and their significance for treatment outcome.\",\"Twelve weeks of the pangenotypic direct-acting antiviral (DAA) combination sofosbuvir/velpatasvir (SOF/VEL) was highly efficient in patients with hepatitis C virus (HCV) genotype 3 (GT3) infection in the ASTRAL-3 approval study. However, presence of resistance-associated substitutions (RASs) in the HCV nonstructural protein 5A (NS5A) was associated with lower treatment response.\",\"Favipiravir, also known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections. The drug is converted intracellularly into its active, phosphoribosylated form, which is recognized as a substrate by the viral RNA-dependent RNA polymerase. Interestingly, besides its anti-influenza virus activity, this molecule is also able to inhibit the replication of flavi-, alpha-, filo-, bunya-, arena-, noro-, and of other RNA viruses, which include neglected and (re)emerging viruses for which no antiviral therapy is currently available. We will discuss the potential of favipiravir as a broad-spectrum countermeasure against infections caused by such neglected RNA viruses. Favipiravir has already been used off-label to treat patients infected with the Ebola virus and the Lassa virus. Because of the particular set-up of the clinical trials during these outbreaks, clear conclusions on the efficacy of favipiravir could not be made. For several viruses, it was demonstrated that the barrier of resistance development against favipiravir is high. Favipiravir has been shown to be well tolerated in healthy volunteers and in influenza virus-infected patients; however, caution is needed because of the teratogenic risks of this molecule. Because of its antiviral activity against different RNA viruses and its high barrier for resistance, the potential of favipiravir as a broad-spectrum antiviral seems promising, but safety and potency issues should be overcome before this drug or similar molecules could be used to treat large patient groups.\",\"Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved therapeutics are available. The CoV nsp14 exoribonuclease (ExoN) has complicated development of antiviral nucleosides due to its proofreading activity. We recently reported that the nucleoside analogue GS-5734 (remdesivir) potently inhibits human and zoonotic CoVs in vitro and in a severe acute respiratory syndrome coronavirus (SARS-CoV) mouse model. However, studies with GS-5734 have not reported resistance associated with GS-5734, nor do we understand the action of GS-5734 in wild-type (WT) proofreading CoVs. Here, we show that GS-5734 inhibits murine hepatitis virus (MHV) with similar 50% effective concentration values (EC50) as SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Passage of WT MHV in the presence of the GS-5734 parent nucleoside selected two mutations in the nsp12 polymerase at residues conserved across all CoVs that conferred up to 5.6-fold resistance to GS-5734, as determined by EC50 The resistant viruses were unable to compete with WT in direct coinfection passage in the absence of GS-5734. Introduction of the MHV resistance mutations into SARS-CoV resulted in the same in vitro resistance phenotype and attenuated SARS-CoV pathogenesis in a mouse model. Finally, we demonstrate that an MHV mutant lacking ExoN proofreading was significantly more sensitive to GS-5734. Combined, the results indicate that GS-5734 interferes with the nsp12 polymerase even in the setting of intact ExoN proofreading activity and that resistance can be overcome with increased, nontoxic concentrations of GS-5734, further supporting the development of GS-5734 as a broad-spectrum therapeutic to protect against contemporary and emerging CoVs.IMPORTANCE Coronaviruses (CoVs) cause severe human infections, but there are no approved antivirals to treat these infections. Development of nucleoside-based therapeutics for CoV infections has been hampered by the presence of a proofreading exoribonuclease. Here, we expand the known efficacy of the nucleotide prodrug remdesivir (GS-5734) to include a group \\u03b2-2a CoV. Further, GS-5734 potently inhibits CoVs with intact proofreading. Following selection with the GS-5734 parent nucleoside, 2 amino acid substitutions in the nsp12 polymerase at residues that are identical across CoVs provide low-level resistance to GS-5734. The resistance mutations decrease viral fitness of MHV in vitro and attenuate pathogenesis in a SARS-CoV animal model of infection. Together, these studies define the target of GS-5734 activity and demonstrate that resistance is difficult to select, only partial, and impairs fitness and virulence of MHV and SARS-CoV, supporting further development of GS-5734 as a potential effective pan-CoV antiviral.\",\"Sofosbuvir is a potent nucleotide HCV NS5B polymerase inhibitor that is also a P-glycoprotein (encoded by the ABCB1 gene) and breast cancer resistance protein (encoded by the ABCG2 gene) substrate. Concerning previous anti-HCV therapies, pharmacogenetics had a significant impact, particularly considering the association of interleukin28B polymorphisms with dual-therapy (ribavirin + pegylated IFN) outcomes.\",\"The therapeutic benefit of adding ribavirin (RBV) to 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) for patients who experienced failure of a previous nonstructural protein (NS) 5A inhibitor-containing regimen is unclear.\",\"No data are available on the clinical presentation and virological pattern in the case of failure of interferon (IFN)-free regimens in patients with genotype-3h. In this paper authors identified the virological and clinical characteristics of patients with genotype-3h treated with suboptimal or not indicated IFN-free regimens for the misclassification of HCV genotype.\",\"Ombitasvir/paritaprevir-ritonavir (OBT/PTV-r) plus ribavirin (RBV) for 12 weeks in hepatitis C virus (HCV) genotype 4 patients with advanced fibrosis has been only investigated in clinical trials.\",\"Treatment of Hepatitis C Virus (HCV) with direct acting antivirals (DAAs) is able to achieve the cure of infection in almost the totality of patients, independently of the characteristics of the individual and the virus, using short treatment schedules, and without the need of ribavirin. The high cost of DAAs is the main limiting factor for universal treatment of HCV. However, there is a strong evidence that treatment of infection at the early stage of disease may be the most rewarding approach. Areas covered: This review evaluates the aspects underlying the benefit of treating chronic HCV infection at the early stage of disease. It outlines the considerations that have to be taken into account when planning treatment in patients with HCV and minimal liver disease, assessing the positive reflex of viral eradication on several HCV-associated extra-hepatic conditions such as the risk of lymphoma, insulin-resistance and glycaemic control, and renal function. Lastly, it also covers the improvement of patients' quality of life and the pharmaco-economic aspects associated with early treatment. Expert commentary: Treatment of patients with HCV and minimal liver disease is associated with a beneficial, pleiotropic effect of viral eradication that goes beyond the simplistic consideration of the improvement in liver disease-related outcomes.\",\"Following the approval of two new therapeutic combinations within the European Union in 2017, the former Swedish recommendations for the treatment of hepatitis C virus (HCV) infection from 2016 were deemed in need of updating.\",\"Background The epidemic of acute HCV infection among HIV-infected men who have sex with men (MSM) is ongoing. Transmission of drug-resistant variants (DRVs) after HCV treatment failure could pose a major threat to the effectiveness of future therapies. We determined the baseline prevalence of pre-existing DRVs in the HCV NS3 protease gene and their effects on the addition of telaprevir (TVR) to standard pegylated interferon and ribavirin (PEG-IFN/RBV) for acute HCV infection in individuals enrolled in a multicentre randomized controlled trial (2013 and 2014). Methods The HCV NS3 viral protease was analyzed using Sanger and next-generation sequencing (NGS) for DRVs at baseline (n = 31), and at viral breakthrough following TVR-based treatment (n = 3) or PEG-IFN/RBV alone (n = 2). Results Sequence analysis indicated that all individuals were infected with HCV genotype 1a. Complete (100%) concordance was seen between Sanger and NGS for high levels of mutant viral populations. The simeprevir-associated Q80K variant was present at high frequency in the German samples (7/11-64%) and infrequently in the UK samples (1/20-5%). In the three TVR-based treatment failures, V36M/l and R155K/T emerged, but not R155G which was detectable at low levels in two individuals at baseline. Failure rate at week 24 was 26.7% (with baseline DRVs) vs. 6.3% (without baseline DRVs), p = 0.17). Comparison of sequences pre- and post-therapy in 5 who failed therapy revealed the emergence of not previously described variants V193G, E176K, P189S (on TVR), and V181S in one instance each. Conclusion The presence of baseline DRVs for the NS3 protease gene of HCV genotype 1a did not appear to predict treatment failure in our patient cohort. Where detected, Q80K was present at high levels (>98%), but had no effect on outcomes and remained high after failure.\",\"Many direct-acting antiviral regimens have reduced activity in people with hepatitis C virus (HCV) genotype (GT) 3 infection and cirrhosis. The C-ISLE study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) plus sofosbuvir (SOF) with and without ribavirin (RBV) in compensated cirrhotic participants with GT3 infection. This was a phase 2, randomized, open-label study. Treatment-naive participants received EBR/GZR + SOF + RBV for 8 weeks or EBR/GZR + SOF for 12 weeks, and peginterferon/RBV treatment-experienced participants received EBR/GZR + SOF \\u00b1 RBV for 12 weeks or EBR/GZR + SOF for 16 weeks. The primary endpoint was HCV RNA <15 IU/mL 12 weeks after the end of treatment (sustained virologic response at 12 weeks [SVR12]). Among treatment-naive participants, SVR12 was 91% (21/23) in those treated with RBV for 8 weeks and 96% (23/24) in those treated for 12 weeks. Among treatment-experienced participants, SVR12 was 94% (17/18) and 100% (17/17) in the 12-week arm, with and without RBV, respectively, and 94% (17/18) in the 16-week arm. Five participants failed to achieve SVR: 2 relapsed (both in the 8-week arm), 1 discontinued due to vomiting/cellulitis (16-week arm), and 2 discontinued (consent withdrawn/lost to follow-up). SVR12 was not affected by the presence of resistance-associated substitutions (RASs). There was no consistent change in insulin resistance, and 5 participants reported serious adverse events (pneumonia, chest pain, opiate overdose, cellulitis, decreased creatinine). High efficacy was demonstrated in participants with HCV GT3 infection and cirrhosis. Treatment beyond 12 weeks was not required, and efficacy was maintained regardless of baseline RASs.\",\"Elevated liver enzymes are frequently observed in renal transplant recipients and warrant further exploration. In immunosuppressed patients, hepatitis E virus (HEV) infection may cause chronic hepatitis, cirrhosis, and extrahepatic manifestations such as renal injury.\",\"The aim of this integrated analysis was to assess the efficacy of the once-daily combination of elbasvir 50 mg and grazoprevir 100 mg, with and without ribavirin in HCV genotype 4 (GT4)-infected participants enrolled in the Phase 2/3 clinical programme with elbasvir/grazoprevir.\",\"Baseline resistance-associated substitutions (RASs) have variable impacts in clinical trials but their prevalence and impact in real-world patients remains unclear. We performed baseline resistance testing using a commercial assay (10% cutoff) for 486 patients treated with LDV/SOF or SMV/SOF, with or without ribavirin, in the multi-center, observational HCV-TARGET cohort. Linkage of RASs was evaluated in selected samples using a novel quantitative single variant sequencing assay. Our results showed that the prevalence of NS3, NS5A, NS5B RASs was 45%, 13%, and 8%, respectively, and 10% of patients harbored RASs in 2 or more drug classes. Baseline LDV RASs in GT1a, TE, and cirrhosis LDV/SOF subgroup was associated with 2-4% lower SVR12 rates. SMV RASs was associated with lower SVR12 rates in GT1a, treatment-experienced, cirrhotics SMV/SOF subgroup. Pooled analysis of all patients with baseline RASs revealed that SVR12 was 100% (19/19) in patients treated for longer than 98 days but was 87% (81/93) in patients treated for shorter than 98 days. These results demonstrate that RASs prevalence and their impact in real world practice are in general agreement with registration trials, and suggest that longer treatment duration may overcome the negative impact of baseline RASs on SVR12 rates in clinical practice.\",\"The novel available interferon (IFN)-free regimens significantly improved the sustained virological response (SVR) in patients with chronic hepatitis C (CHC), without important side effects and with shorter duration of treatment. In a subset of patients, however, the treatment failure (TF) was due to the presence of resistance-associated substitutions (RAS) that lead to virological breakthrough (BT) or relapse. We analysed in this case series the role of RAS on the TF in cirrhotic patients with genotype (GT)4, treated with a previous IFN-free regimen, and retreated with the combination of sofosbuvir (SOF)/velpatasvir (VEL) for 12 or 24 weeks, without ribavirin (RBV).\",\"Approximately 10 million people in Pakistan are infected with the hepatitis C virus (HCV). Most patients develop chronic hepatitis, with rare cases of spontaneous clearance. However, little is known about multidrug resistant viral variants in Pakistan.\",\"Direct-acting antivirals (DAAs) have transformed traditional treatment options for hepatitis C virus (HCV) infection. DAA combinations have been shown to be highly effective in reducing the burden of chronic HCV infection in clinical trials and have been recommended by the European Association for the Study of the Liver (EASL) treatment guidelines. This review examines the results of second-generation DAA combinations in real-life clinical practice in patients with genotypes 1-3 and in those co-infected with HIV (real-world data in genotypes 4-6 are rare). Second generation DAAs (sofosbuvir plus daclatasvir, sofosbuvir/ledipasvir, ombitasvir/paritaprevir/ritonavir plus dasabuvir, sofosbuvir plus velpatasvir, glecaprevir plus pibrentasvir, grazoprevir plus elbasvir) have very high SVR rates and good safety profiles, higher resistance barriers and are more convenient. Real-world data in all 3 genotypes generally support the EASL guidelines and high overall sustained virological response rates are reported with recommended regimens. However, real-world data are only available for sofosbuvir plus daclatasvir, sofosbuvir/ledipasvir, ombitasvir/paritaprevir/ritonavir plus dasabuvir. Furthermore, because of the existing level of evidence, it is difficult to define optimal regimens based on real-world data (ie, treatment duration, when to include ribavirin and options for patients with cirrhosis). The real-life challenges of managing HIV-coinfected patients are also discussed showing the additional burden of avoiding drug-drug interactions between DAAs and antiretrovirals.\",\"The presence of resistance-associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs). HCV resistance at NS5A region is mainly focused on patients with hepatitis C virus (HCV) genotypes 1a (G1a) and 3 (G3) with other factors of poor treatment response (ie cirrhosis, prior treatment-exposure, or HCV-RNA >800 000 IU/mL). Herein, we evaluated in a cohort of HCV G1a and G3 infected patients the prevalence of RASs at domain I NS5A using population-based sequencing and the impact of RASs on the optimization of current therapeutic strategies. The RASs considered as clinically relevant were: M28A/G/T, Q30D/E/H/G/K/L/R, L31M/V/F, H58D, and Y93C/H/N/S for G1a and Y93H for G3. A total of 232 patients na\\u00efve to NS5A inhibitors were included (166 G1a, 66 G3). The overall prevalence of NS5A RASs for G1a and G3 patients was low (5.5%) or null, respectively. A high proportion of patients harbored, at least, one factor of poor response (78.9% for G1a, and 75.8% for G3). Overall, the rates of patients harboring NS5A RASs in combination with any of the other factors were low and the vast majority of patients (G1a> 94% and G3 100%) could be treated with standard treatments of 12 weeks without ribavirin. In conclusion, testing NS5A RASs in specific HCV-infected populations (ie G1a & G3, cirrhosis, prior treatment experienced, HCV-RNA >800 000 IU/mL) might be useful to optimize current NS5A-based therapies avoiding ribavirin-related toxicities, and shortening treatment duration in the majority of patients.\",\"Several arenaviruses cause hemorrhagic fever (HF) disease in humans and represent important public health problems in their endemic regions. In addition, evidence indicates that the worldwide-distributed prototypic arenavirus lymphocytic choriomeningitis virus is a neglected human pathogen of clinical significance. There are no licensed arenavirus vaccines, and current antiarenavirus therapy is limited to an off-label use of ribavirin that is only partially effective. Therefore, there is an unmet need for novel therapeutics to combat human pathogenic arenaviruses, a task that will be facilitated by the identification of compounds with antiarenaviral activity that could serve as probes to identify arenavirus-host interactions suitable for targeting, as well as lead compounds to develop future antiarenaviral drugs. Screening of a combinatorial library of Kr\\u00f6nhke pyridines identified compound KP-146 [(5-(5-(2,3-dihydrobenzo[ b][1,4] dioxin-6-yl)-4'-methoxy-[1,1'-biphenyl]-3-yl)thiophene-2-carboxamide] as having strong anti-lymphocytic choriomeningitis virus (LCMV) activity in cultured cells. KP-146 did not inhibit LCMV cell entry but rather interfered with the activity of the LCMV ribonucleoprotein (vRNP) responsible for directing virus RNA replication and gene transcription, as well as with the budding process mediated by the LCMV matrix Z protein. LCMV variants with increased resistance to KP-146 did not emerge after serial passages in the presence of KP-146. Our findings support the consideration of Kr\\u00f6hnke pyridine scaffold as a valuable source to identify compounds that could serve as tools to dissect arenavirus-host interactions, as well as lead candidate structures to develop antiarenaviral drugs.\",\"S282T in NS5B is the primary amino acid substitution associated with resistance to sofosbuvir (SOF) but has rarely been detected in patients treated with a SOF-based regimen. Here, the emergence and fitness of the S282T substitution in virologic failure patients administered SOF-based regimens across the SOF and ledipasvir (LDV)/SOF phase 2 and 3 programs was evaluated. Plasma samples collected at baseline and at virologic failure were amplified and deep sequenced (1% cutoff). To date, over 12,000 patients have been treated in SOF or LDV/SOF phase 2 and 3 studies. Of these, deep sequencing was available at baseline in 8598 patients (62.4% genotype [GT] 1, 10.7% GT2, 20.9% GT3, and 6.0% GT4-6) and at virologic failure in 901 patients. In the 8598 patients, no S282T substitution was detected at baseline; at virologic failure, 10 of the 901 (1%) patients had S282T detected. The SOF-based regimen associated with treatment-emergent S282T was SOF monotherapy in two patients, retreatment with LDV/SOF in prior LDV/SOF failures in three patients, LDV/SOF for 8 weeks in 1 GT1 patient, LDV/SOF for 12 weeks in 1 patient each with GT3, GT4, and GT5, and LDV/SOF + ribavirin for 12 weeks in 1 GT6 patient. Nine of 10 patients with emergent S282T received an SOF-based retreatment regimen, eight of whom achieved sustained virologic response 12 weeks after treatment and one of whom failed retreatment. Conclusion: The emergence of S282T substitution was rare in patients who fail SOF-based regimens. Successful retreatment of prior SOF failure patients is possible in the presence of S282T substitution with SOF in combination with various direct-acting antiviral agents. (Hepatology Communications 2017;1:538-549).\",\"The incidence rate of insulin resistance (IR) in patients with chronic hepatitis C (CHC) is high. Recently, branched-chain amino acids (BCAA) have been shown to attenuate IR in CHC patients; however, their effect on patient quality of life remains unclear. Therefore, the aim of the current prospective study was to determine the effects of BCAA supplement on IR and health-related quality of life (HR-QoL) in patients with CHC. In the study, 20 non-diabetic patients with CHC, who were non-responders to peginterferon-\\u03b1 and ribavirin, were recruited. Patients took a BCAA supplement once a day (30 g, after a minimum 10-h overnight fast) for 3 months. Serum levels of glucose, insulin, albumin, triglycerides and cholesterol were measured at 0 and 3 months. Additionally, IR was measured using the Homeostasis Model Assessment-IR, HR-QoL was assessed using the 36-item Short Form Health Survey and viral load was measured by reverse transcription polymerase chain reaction using Taqman probes. The Wilcoxon signed-rank test was used to determine statistical significance. The results indicated that 70% of the subjects were positive for IR, which decreased to 50% by the end of the study; furthermore, 85% of the subjects demonstrated some level of improvement. Overall, the BCAA treatment significantly decreased IR (P=0.006) and augmented serum albumin concentration (P=0.008) compared with basal values. Additionally, by the end of the treatment, viral load and triglycerides levels had decreased, though these results were not significant (P=0.084 and P=0.080, respectively). BCAA treatment also improved HR-QoL regarding role limitations due to physical health problems (P=0.017), role limitations due to emotional problems (P=0.026) and social function (P=0.008). In conclusion, BCAA supplementation reduced IR and improved HR-QoL in patients with CHC. These findings support the application of IR therapy as a possible therapeutic strategy for hepatitis C infection.\",\"To evaluate the efficacy of direct-acting antivirals (DAAs) in Kanto Rosai Hospital.\",\"Advanced age has been a major limitation of interferon-based treatment for chronic hepatitis C virus (HCV) infection because of its poor response and tolerability. Direct-acting antiviral (DAA) drug regimens are safe and highly effective, allowing administration of treatment also in elderly. This study aims to assess the efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with ribavirin for the treatment of patients aged \\u226570 years with HCV genotype 1b compensated cirrhosis.A total of 1008 patients with HCV genotype 1b compensated cirrhosis were prospectively treated with PrOD + ribavirin for 12 weeks, between December 2015 and July 2016. Sustained virologic response 12 weeks after the end of treatment (SVR12), adverse effects (AEs), comorbidities, discontinuation, and death rates were recorded. Efficacy and safety of therapy were assessed in patients aged \\u226570 years and compared with data from patients <70 years.There were 117 patients aged \\u226570 years, preponderantly females (58.9%), mean age 73.3 \\u00b1 2.8 years (range 70-82), and 37 (31.6%) were treatment-experienced. Comorbidities were reported in 60.6% of patients \\u226570 years and in 39.8% of those <70 years (P < .001). SVR12 rates based on intention-to-treat and per-protocol analyses were 97.4% and 100%, respectively, in patients \\u226570 years, compared to 97.8% and 99.6%, respectively, in patients <70 years (P = ns and P = ns). Severe AEs were reported in 4 (3.4%) patients \\u226570 years, compared to 23 (2.6%) in those <70 years (P = ns). One death was recorded in a patient aged 79 years (0.9%) and 6 deaths (0.8%) in those <70 years (P = ns).Treatment with PrOD + ribavirin in patients 70 years of age or older with HCV genotype 1b compensated cirrhosis proved as effective, safe, and well tolerated, as it did in younger patients.\",\"Simeprevir is approved with pegylated interferon and ribavirin (PR) for chronic hepatitis C virus (HCV) genotype (GT) 1 and GT4 infection in the USA and the European Union.\",\"Since HCV infection may lead to hepatocellular carcinoma (HCC) and vitamin D (deficiency) is related to cancer, we investigated if SNPs in genes involved in vitamin D pathway could predict HCV-related HCC presence in patients treated with new anti-HCV drugs.\",\"The need for all-oral hepatitis C virus (HCV) treatments with higher response rates, improved tolerability, and lower pill burden compared with interferon-inclusive regimen has led to the development of new direct-acting antiviral agents. Ravidasvir (RDV) is a second-generation, pan-genotypic NS5A inhibitor with high barrier to resistance. The aim of this phase 2 study (EVEREST study) was to assess the efficacy and safety of interferon-free, 12-week RDV plus ritonavir-boosted danoprevir (DNVr) and ribavirin (RBV) regimen for treatment-na\\u00efve Asian HCV genotype 1 (GT1) patients without cirrhosis.\",\"Direct-acting antiviral (DAA) regimens have shown high efficacy and tolerability for patients with HCV genotype 1/1b (GT1/1b) in clinical trials. However, robust real-world evidence of interferon (IFN)-free DAA treatment for HCV GT1-infected patients in Asia is still lacking.\",\"Grazoprevir is an NS3/4A protease inhibitor (PI), while elbasvir is an NS5A inhibitor. We performed this meta-analysis to directly compare grazoprevir plus elbasvir and ribavirin regimen vs. grazoprevir and elbasvir without ribavirin in the treatment of hepatitis C virus genotype 1 infection and to precisely evaluate the efficacy of the latter regimen in cirrhotic, IL28 CC genotype patients and those coinfected with human immunodeficiency virus.\",\"Host lipid metabolism influences viral replication and lifecycle of hepatitis C virus. Our aim was to evaluate changes in glucose and lipid metabolism of patients with chronic hepatitis C after therapy with direct acting antivirals (DAA).\",\"The recent development of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) infection could lead to higher sustained virological response (SVR) rates, with shorter treatment durations and fewer adverse events compared with regimens that include interferon. However, a relatively small proportion of patients cannot achieve SVR in the first treatment, including DAAs with or without peginterferon and/or ribavirin. Although retreatment with a combination of DAAs should be conducted for these patients, it is more difficult to achieve SVR when retreating these patients because of resistance-associated substitutions (RASs) or treatment-emergent substitutions. In Japan, HCV genotype 1b (GT1b) is founded in 70% of HCV-infected individuals. In this minireview, we summarize the retreatment regimens and their SVR rates for HCV GT1b. It is important to avoid drugs that target the regions targeted by initial drugs, but next-generation combinations of DAAs, such as sofosbuvir/velpatasvir/voxilaprevir for 12 wk or glecaprevir/pibrentasvir for 12 wk, are proposed to be potential solution for the HCV GT1b-infected patients with treatment failure, mainly on a basis of targeting distinctive regions. Clinicians should follow the new information and resources for DAAs and select the proper combination of DAAs for the retreatment of HCV GT1b-infected patients with treatment failure.\",\"The hepatitis C virus (HCV), the most predominant cause of liver failure worldwide, is associated with the development of diabetes mellitus (DM) and insulin resistance (IR), both in vivo and in vitro. DM and IR aggravate the rate of fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Most studies have revealed that patients with HCV are at a greater risk of developing type 2 diabetes (T2D), compared with controls or patients with hepatitis B. In the same way, patients with T2D are highly prone to severe HCV clinical outcomes and increased progression to fibrosis and cirrhosis, ultimately leading to HCC. HCV interferes with the insulin-signaling pathway by modulating cellular gene expression such as up-regulation of inflammatory cytokine tumor necrosis factor-\\u03b1, hypophosphorylation of insulin receptor substrate-1 and -2, phosphorylation of protein kinase B (Akt), up-regulation of gluconeogenic genes, accumulation of lipids, and targeting of lipid storage organelles. Owing to the pathological association between HCV and DM, the possibility of HCV eradication, resulting in reduced morbidity and mortality rate due to T2D, cannot be ruled out. HCV diabetes-associated IR can be targeted for HCV therapy. However, few such studies have revealed that IR minimizes (interferes with) the response rate of interferon/ribavirin treatment.\",\"The 4 genotypes of hepatitis E virus (HEV) that infect humans (genotypes 1-4) vary in geographical distribution, transmission, and pathogenesis. Little is known about the properties of HEV or its hosts that contribute to these variations. Primary isolates grow poorly in cell culture; most studies have relied on variants adapted to cancer cell lines, which likely alter virus biology. We investigated the infection and replication of primary isolates of HEV in hepatocyte-like cells (HLCs) derived from human embryonic and induced pluripotent stem cells.\",\"The high rate of chronic hepatitis C (CHC) was one of the key issues of global public health concern. Interferon (IFN)-\\u03bb relevant genes were in the antiviral treatment pathway, not only influenced hepatitis C virus (HCV) spontaneous clearance, but also affected the IFN-mediated viral clearance. The aim of this study was to identify the association of interleukin 28B (IL28B), myxovirus resistance A (MxA) gene polymorphisms with HCV spontaneous clearance and therapeutic response in Chinese CHC patients. IL28B and MxA gene genotypes were detected among 231 CHC carriers, 428 subjects with HCV spontaneous clearance and 662 CHC patients with pegylated IFN-\\u03b1 and ribavirin (pegIFN-\\u03b1/RBV) treatment. Patients with MxA rs2071430 TT genotype were more likely to develop HCV infection chronicity (additive model: odds ratio (OR) 1.22, 95% confidence interval (CI) 1.01-1.48, P = 0.042). IL28B rs1298075 variant genotypes (additive model: OR 0.58, 95% CI 0.34-0.98, P = 0.040) and MxA rs17000900 variant genotypes (additive model: OR 0.54, 95% CI 0.30-0.99, P = 0.048) were less likely to achieve a sustained virological response. The life table indicated that patients with IL28B rs1298075 AG genotype were slower to achieve a viral load 106 copies/ml (all P < 0.05). This study illustrated that the carriage of IL28B rs12980275 AA had a positive effect on treatment response to pegIFN-\\u03b1/RBV among Chinese CHC patients.\",\"Since the identification of the novel reassortant avian influenza A (H7N9) virus in China in 2013, until Jun 30, 2017, the virus has caused five epidemic waves leading to a total of 1,552 human infections, with a fatality rate of about 40%. In the spring of 2017, highly pathogenic avian influenza (HPAI) H7N9 virus emerged and has caused 25 human infections. The HPAI H7N9 virus has some biological differences from the LPAI one, such as its multiple basic amino acid residues on HA leading to its independence on trypsin for replication. The pathogenicity of the HPAI H7N9 virus to experimental animals or humans is still unclear. A(H7N9) vaccine development for pandemic preparedness is ongoing, including the reassortment (H7N9/PR8) reverse genetic based vaccine, the virus like particle (VLP) vaccine, the intranasal live attenuated influenza vaccine (LAIV), the non-adjuvant Vero cell culture-derived inactivated whole-virus vaccine, the MDCK culture-derived vaccine, the H7 DNA vaccine and the recombinant replicative H7N9 virus (H7N9-53TM) vaccine. Five neuramidinase resistant sites of A(H7N9) virus isolated from patients have been reported. Some alternative drugs have been studied, such as DAS181 (Fludase), ribavirin, troglitazone and minocycline. Persistent surveillance and enhanced global control are essential to fight against human infections with A(H7N9) virus.\",\"Targeting host functions essential for viral replication has been considered as a broad spectrum and resistance-refractory antiviral approach. However, only a few host functions have, thus far, been validated as broad-spectrum antiviral targets in vivo. ER \\u03b1-glucosidases I and II have been demonstrated to be essential for the morphogenesis of many enveloped viruses, including members from four families of viruses causing hemorrhagic fever. In vivo antiviral efficacy of various iminosugar-based ER \\u03b1-glucosidase inhibitors has been reported in animals infected with Dengue, Japanese encephalitis, Ebola, Marburg and influenza viruses. Herein, we established Huh7.5-derived cell lines with ER \\u03b1-glucosidase I or II knockout using CRISPR/Cas9 and demonstrated that the replication of Dengue, Yellow fever and Zika viruses was reduced by only 1-2 logs in the knockout cell lines. The results clearly indicate that only a partial suppression of viral replication can possibly be achieved with a complete inhibition of ER-\\u03b1-glucosidases I or II by their inhibitors. We therefore explore to improve the antiviral efficacy of a lead iminosugar IHVR-19029 through combination with another broad-spectrum antiviral agent, favipiravir (T-705). Indeed, combination of IHVR-19029 and T-705 synergistically inhibited the replication of Yellow fever and Ebola viruses in cultured cells. Moreover, in a mouse model of Ebola virus infection, combination of sub-optimal doses of IHVR-19029 and T-705 significantly increased the survival rate of infected animals. We have thus proved the concept of combinational therapeutic strategy for the treatment of viral hemorrhagic fevers with broad spectrum host- and viral- targeting antiviral agents.\",\"Despite the excellent efficacy of direct acting antivirals (DAA) for hepatitis C virus (HCV), treatment failures do occur. Until recently, retreatment decisions after DAA failure were influenced by the number of available agents, concerns about HCV drug resistance, and lack of data regarding retreatment. Recommended treatment approaches previously depended on limited clinical trials and expert opinion. In this article, we review the current state of the evidence for HCV retreatment after DAA failure. Based on recent clinical trial data, most patients who fail HCV treatment with DAA agents now have excellent retreatment options. While some patients may benefit from resistance testing after DAA therapy failure to select the optimal treatment and duration, newly approved salvage therapies are not significantly impacted by common mutations and have been approved by the Food and Drug Administration for HCV retreatment without regard for the presence of resistance associated substitutions. While prior retreatment efforts were limited to longer courses of therapy, the addition of ribavirin, or novel combinations of approved therapies based on expert guidance, current DAA options make HCV retreatment in the DAA era more streamlined and evidence-based.\",\"Ultraviolet light in the UVC range is a commonly used disinfectant to control viruses in clinical settings and water treatment. However, it is currently unknown whether human viral pathogens may develop resistance to such stressor. Here, we investigate the adaptation of an enteric pathogen, human echovirus 11, to disinfection by UVC, and characterized the underlying phenotypic and genotypic changes. Repeated exposure to UVC lead to a reduction in the UVC inactivation rate of approximately 15 per cent compared to that of the wild-type and the control populations. Time-series next-generation sequencing data revealed that this adaptation to UVC was accompanied by a decrease in the virus mutation rate. The inactivation efficiency of UVC was additionally compromised by a shift from first-order to biphasic inactivation kinetics, a form of 'viral persistence' present in the UVC resistant and control populations. Importantly, populations with biphasic inactivation kinetics also exhibited resistance to ribavirin, an antiviral drug that, as UVC, interferes with the viral replication. Overall, the ability of echovirus 11 to adapt to UVC is limited, but it may have relevant consequences for disinfection in clinical settings and water treatment plants.\",\"Several highly effective, interferon-free, direct-acting antiviral (DAA)-based regimens are available for the treatment of chronic hepatitis C virus (HCV) infection. Despite impressive efficacy overall, a small proportion of patients in registrational trials experienced treatment failure, which in some cases was associated with the detection of HCV resistance-associated substitutions (RASs) at baseline. In this article, we describe methods and key findings from independent regulatory analyses investigating the impact of baseline nonstructural (NS) 3 Q80K and NS5A RASs on the efficacy of current United States Food and Drug Administration (FDA)-approved regimens for patients with HCV genotype (GT) 1 or GT3 infection. These analyses focused on clinical trials that included patients who were previously na\\u00efve to the DAA class(es) in their investigational regimen and characterized the impact of baseline RASs that were enriched in the viral population as natural or transmitted polymorphisms (i.e., not drug-selected RASs). We used a consistent approach to optimize comparability of results across different DAA regimens and patient populations, including the use of a 15% sensitivity cutoff for next-generation sequencing results and standardized lists of NS5A RASs. These analyses confirmed that detection of NS3 Q80K or NS5A baseline RASs was associated with reduced treatment efficacy for multiple DAA regimens, but their impact was often minimized with the use of an intensified treatment regimen, such as a longer treatment duration and/or addition of ribavirin. We discuss the drug resistance-related considerations that contributed to pretreatment resistance testing and treatment recommendations in drug labeling for FDA-approved DAA regimens.\",\"Glecaprevir (formerly ABT-493, pangenotypic NS3/4A protease inhibitor) and pibrentasvir (formerly ABT-530, pangenotypic NS5A inhibitor) are second generation direct acting antivirals (DAA) for the treatment of chronic Hepatitis C (HCV). It is a fixed dose ribavirin (RBV)-free regimen with activity against genotypes (GT) 1-6. In vitro the two antivirals have synergistic activity with a high barrier to resistance and potent activity against common polymorphisms. It is once daily oral dosing with minimal absorption, primary biliary excretion, and negligible renal excretion, making it safe for patients with renal impairment. This regimen is being reviewed because it is the first pangenotypic regimen suitable for those with renal impairment and prior DAA failure. Areas covered: The key phase 2 and 3 trials which investigated the efficacy and safety of glecaprevir/pibrentasvir are reviewed by methodology, primary end point, baseline demographic data, response rates, and adverse events. Literature search methodology involved reviewing key abstracts presented at the American Association for the Study of Liver Disease and European Association for the Study of Liver. Expert commentary: The advantages and limitations of glecaprevir/pibrentasvir will be reviewed in comparison to its competitor drug on the market.\",\"The hepatitis C virus (HCV) has affected an estimate of 80 million individuals worldwide and is a strain of public health. Around 25-30% of patients in Europe and the US infected with HIV are coinfected with HCV. Despite treatment modalities containing a NS3/4A protease inhibitor in combination with pegylated interferon and ribavirin prior to 2013 improved SVR rates, the amount of severe side effects was high. Nowadays, oral direct-acting antivirals (DAAs) combination therapy offers excellent treatment efficacy, safety and tolerability. This review focuses on current literature and clinical evidence and their impact regarding NS3/4A protease inhibitors. In addition, pitfalls in treatment from HIV- and HBV-coinfected patients will also be discussed. In the era of DAA treatment, the third-generation pan-genotypic NS3/4A protease inhibitors (mainly grazoprevir, glecaprevir and voxilaprevir) show a high antiviral activity and genetic resistance barrier with cure rates of over 95% when combined with an NS5A inhibitor, irrespectively of baseline resistance associated variants (RASs) being present. These new key components of DAA combination therapy are impressive options to eradicate HCV in the so called difficult-to-treat population (e.g. compensated cirrhosis, end-stage renal disease and patients who failed previous DAA treatment).\",\"Hepatitis C virus (HCV) is one of the leading causes of liver diseases and transplantation worldwide. The current available therapy for HCV infection is based on interferon-\\u03b1, ribavirin and the new direct-acting antivirals (DAAs), such as NS3 protease and NS5B polymerase inhibitors. However, the high costs of drug design, severe side effects and HCV resistance presented by the existing treatments demonstrate the need for developing more efficient anti-HCV agents. This study aimed to evaluate the antiviral effects of sorbifolin (1) and pedalitin (2), two flavonoids from Pterogyne nitens on the HCV replication cycle. These compounds were investigated for their anti-HCV activities using genotype 2a JFH-1 subgenomic replicons and infectious virus systems. Flavonoids 1 and 2 inhibited virus entry up to 45.0% and 78.7% respectively at non-cytotoxic concentrations. The mechanism of the flavonoid 2 block to virus entry was demonstrated to be by both the direct action on virus particles and the interference on the host cells. Alternatively, the flavonoid 1 activity was restricted to its virucidal effect. Additionally, no inhibitory effects on HCV replication and release were observed by treating cells with these flavonoids. These data are the first description of 1 and 2 possessing in vitro anti-HCV activity.\",\"Venezuelan equine encephalitis virus (VEEV) is a representative member of the New World alphaviruses. It is transmitted by mosquito vectors and causes highly debilitating disease in humans, equids, and other vertebrate hosts. Despite a continuous public health threat, very few compounds with anti-VEEV activity in cell culture and in mouse models have been identified to date, and rapid development of virus resistance to some of them has been recorded. In this study, we investigated the possibility of using a modified nucleoside analog, \\u03b2-d-N [4]-hydroxycytidine (NHC), as an anti-VEEV agent and defined the mechanism of its anti-VEEV activity. The results demonstrate that NHC is a very potent antiviral agent. It affects both the release of genome RNA-containing VEE virions and their infectivity. Both of these antiviral activities are determined by the NHC-induced accumulation of mutations in virus-specific RNAs. The antiviral effect is most prominent when NHC is applied early in the infectious process, during the amplification of negative- and positive-strand RNAs in infected cells. Most importantly, only a low-level resistance of VEEV to NHC can be developed, and it requires acquisition and cooperative function of more than one mutation in nsP4. These adaptive mutations are closely located in the same segment of nsP4. Our data suggest that NHC is more potent than ribavirin as an anti-VEEV agent and likely can be used to treat other alphavirus infections.IMPORTANCE Venezuelan equine encephalitis virus (VEEV) can cause widespread epidemics among humans and domestic animals. VEEV infections result in severe meningoencephalitis and long-term sequelae. No approved therapeutics exist for treatment of VEEV infections. Our study demonstrates that \\u03b2-d-N [4]-hydroxycytidine (NHC) is a very potent anti-VEEV compound, with the 50% effective concentration being below 1 \\u03bcM. The mechanism of NHC antiviral activity is based on induction of high mutation rates in the viral genome. Accordingly, NHC treatment affects both the rates of particle release and the particle infectivity. Most importantly, in contrast to most of the anti-alphavirus drugs that are under development, resistance of VEEV to NHC develops very inefficiently. Even low levels of resistance require acquisition of multiple mutations in the gene of the VEEV-specific RNA-dependent RNA polymerase nsP4.\",\"Mutations in HCV nonstructural protein 5A (NS5A) play a vital role in virus resistance. The aim of this study was to develop a correlation between NS5A mutations (genotype 3a) and virological response towards interferon alpha (IFN-\\u03b1) plus ribavirin therapy.\",\"In the era of direct-acting antivirals, hepatitis C virus (HCV) genotype (GT) 3 remains as the most difficult-to-treat HCV-GT. Currently, data on the efficacy of ledipasvir/sofosbuvir plus ribavirin (SOF/LDV+RBV) in GT3-infected patients are limited. We investigated the efficacy of this regimen in a real-life cohort from Austria.\",\"The coronavirus (CoV) RNA genome is the largest among the single-stranded positive-sense RNA viruses. CoVs encode a proofreading 3'-to-5' exoribonuclease within nonstructural protein 14 (nsp14-ExoN) that is responsible for CoV high-fidelity replication. Alanine substitution of ExoN catalytic residues [ExoN(-)] in severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and murine hepatitis virus (MHV) disrupts ExoN activity, yielding viable mutant viruses with defective replication, up to 20-fold-decreased fidelity, and increased susceptibility to nucleoside analogues. To test the stability of the ExoN(-) genotype and phenotype, we passaged MHV-ExoN(-) 250 times in cultured cells (P250), in parallel with wild-type MHV (WT-MHV). Compared to MHV-ExoN(-) P3, MHV-ExoN(-) P250 demonstrated enhanced replication and increased competitive fitness without reversion at the ExoN(-) active site. Furthermore, MHV-ExoN(-) P250 was less susceptible than MHV-ExoN(-) P3 to multiple nucleoside analogues, suggesting that MHV-ExoN(-) was under selection for increased replication fidelity. We subsequently identified novel amino acid changes within the RNA-dependent RNA polymerase and nsp14 of MHV-ExoN(-) P250 that partially accounted for the reduced susceptibility to nucleoside analogues. Our results suggest that increased replication fidelity is selected in ExoN(-) CoVs and that there may be a significant barrier to ExoN(-) reversion. These results also support the hypothesis that high-fidelity replication is linked to CoV fitness and indicate that multiple replicase proteins could compensate for ExoN functions during replication.IMPORTANCE Uniquely among RNA viruses, CoVs encode a proofreading exoribonuclease (ExoN) in nsp14 that mediates high-fidelity RNA genome replication. Proofreading-deficient CoVs with disrupted ExoN activity [ExoN(-)] either are nonviable or have significant defects in replication, RNA synthesis, fidelity, fitness, and virulence. In this study, we showed that ExoN(-) murine hepatitis virus can adapt during long-term passage for increased replication and fitness without reverting the ExoN-inactivating mutations. Passage-adapted ExoN(-) mutants also demonstrate increasing resistance to nucleoside analogues that is explained only partially by secondary mutations in nsp12 and nsp14. These data suggest that enhanced resistance to nucleoside analogues is mediated by the interplay of multiple replicase proteins and support the proposed link between CoV fidelity and fitness.\",\"Activation of eukaryotic translation initiation factor 4E (eIF4E) is a cellular survival mechanism in response to chemotherapy in cancers. In this work, we demonstrate that targeting eIF4E by ribavirin sensitizes hepatocellular carcinoma (HCC) cell response to doxorubicin. Ribavirin inhibits growth and survival of HCC cells, and to a greater extent than in normal liver cells. Its combination with doxorubicin achieves greater efficacy than single drug in vitro and in vivo. Ribavirin suppresses phosphorylation of molecules involved in Akt/mTOR/eIF4E pathway. Overexpression of the phosphomimetic form (S209D) but not the nonphosphorylatable form (S209A) eIF4E significantly reverses the inhibitory effects of ribavirin. Interestingly, doxorubicin significantly increases p-eIF4E(S209) level in a dose- and time-dependent manner, suggesting that doxorubicin induces eIF4E activation in HCC cells. In addition, eIF4E activation induced by doxorubicin in HCC cells is inhibited by ribavirin. Our work demonstrates the greater efficacy of ribavirin and doxorubicin combination and its underlying mechanisms.\",\"Although overexpression of the eukaryotic translation initiation factor 4E (eIF4E) is detected in patients with renal cell carcinoma (RCC) and associated with poor prognosis, the possible roles of eIF4E in RCC have not been revealed.\",\"Failure to achieve sustained virological response (SVR) with hepatitis C virus (HCV) direct-acting antiviral (DAA)-based regimens is commonly associated with emergence of resistance-associated substitutions (RASs). Retreatment of patients who failed prior DAAs remains challenging. The aim of this prospective and randomized study was to evaluate the efficacy (primary endpoint: SVR 12 weeks after end of treatment [SVR12]) and safety of sofosbuvir + grazoprevir/elbasvir + ribavirin for 16 or 24 weeks in patients who had failed to achieve SVR on previous NS5A- or NS3-based therapy and with evidence of RASs at failure.\",\"Almost 30 years ago, about 30% of Japanese hemophiliacs became infected with HIV-1 and hepatitis C virus (HCV) after receiving contaminated blood products. While several studies have reported the high efficacy and safety of direct acting antivirals (DAA) in HIV-1 co-infected patients, such data are limited in hemophiliacs.\",\"The availability of novel direct-acting antivirals (DAAs) represents a new era of curative hepatitis C virus (HCV) treatment, with over 95% of patients infected with HCV genotype 1 achieving sustained virological response (SVR). Nevertheless, the majority of patients globally are unable to access these treatments because of cost and infrastructure constraints and, thus, remain untreated and uncured.\",\"To evaluate the cost-utility of treatment with elbasvir/grazoprevir (EBR/GZR) regimens compared with ledipasvir/sofosbuvir (LDV/SOF), ombitasvir/paritaprevir/ritonavir + dasabuvir \\u00b1 ribavirin (3D \\u00b1 RBV), and sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C genotype (GT) 1 infection.\",\"Pretreatment evaluation of HCV-infected patients is a complex interplay between multiple clinical and viral parameters, leading to a tailored approach that may bring real-life sustained virological response (SVR) rates close to 98%-99%.\",\"Growing resistance in malarial parasites, particularly in Plasmodium falciparum needs a serious search for the discovery of novel drug targets. Inosine monophosphate dehydrogenase (IMPDH) is an important target for antimalarial drug discovery process in P. falciparum for the treatment of malaria. In the absence of x-ray crystal structure of this enzyme, homology modeling proved to be a reasonable alternate to study substrate binding mechanisms of this enzyme. In this study, a 3-D homology model for P. falciparum IMPDH was constructed taking human IMPDH (PDB code 1NF7) as template. Furthermore, an in-silico combinatorial library of ribavirin (RVP) derivatives (1347 molecules) was designed and virtually screened for ligands having selectively greater binding affinity with Plasmodium falciparum IMPDH relative to human IMPDH II. A total of five Ribavirin derivatives were identified as having greater binding affinity (-126 to -108Kcal/mol and -9.4 to -8.6Kcal/mol) with Plasmodium falciparum IMPDH. These five inhibitors should be used as selective and potent for Plasmodium falciparum IMPDH. Such type of study will provide information to synthetic medicinal chemist to enhance the potential of compounds (RVP derivatives) as chemotherapeutic agents to fight against the increasing burden of malarial infections.\",\"The chemistry, pharmacology, pharmacodynamics, pharmacokinetics, efficacy, safety, dosage, administration, and role of elbasvir-grazoprevir in the treatment of hepatitis C virus (HCV) infection are reviewed.\",\"Direct-acting antiviral (DAA) resistance-associated substitutions (RASs) can jeopardize the effectiveness of DAAs in patients with hepatitis C virus (HCV). The selection pressure by pegylated-interferon (Peg-IFN) plus ribavirin (P/R) treatment may enhance HCV genome variation. However, whether P/R treatment alters the rate of change of RASs is still unclear.\",\"Daclatasvir, asunaprevir (ASV), and beclabuvir (BCV) are direct-acting antivirals (DAAs) for patients with hepatitis C virus genotype 1 infection. This systematic review and meta-analysis investigating the efficacy and safety of this three-drug combination in HCV genotype 1 infection. Eleven electronic search engines were searched for relevant publications. Studies were screened for eligibility and data was extracted. The outcomes were pooled as event rate and risk ratio (RR). The protocol was registered in PROSPERO (CRD42017054391). Among the included six studies, five studies were included for the meta-analysis (n = 1261). The three-drug combination showed a high response rate in na\\u00efve patients with sustained virologic response at week-12 posttreatment (SVR12) rate = 95.7% (95%CI [93.8-97.1]) and no difference detected by adding ribavirin (RBV) (the pooled RR = 0.98, 95%CI [0.90-1.08], P = 0.70) or comparing with interferon-experienced patients (RR = 1.02, 95%CI [0.98-1.07], P = 0.31) regardless the genotype 1 subtypes or IL28B genotype. Treatment failure was minimal and showed no difference regarding the previous comparisons. Increasing the dose or the duration did not show a significant increase in the efficacy. In conclusion, this analysis showed high response rates in HCV genotype 1-infected patients treated with daclatasvir, ASV, and BCV irrespective of RBV use, prior interferon-based therapy, or restriction on non-cirrhotic patients, IL28B genotype, or baseline resistance-associated variants.\",\"Hepatitis C virus (HCV) infects 130-170 million people worldwide. Recently, direct-acting antivirals have been shown to eradicate HCV infection in 90-95 % of non-cirrhotic patients depending on genotype, treatment experience, and regimen used. Similar rates are achieved among compensated cirrhotics, although longer treatment duration and/or ribavirin may be required. HCV uses host lipid metabolism for its lifecycle and can cause hepatic steatosis and insulin resistance. Hepatic steatosis, defined as excessive triglyceride deposition in hepatocytes, affects approximately half of HCV-infected individuals. Genetic factors and co-morbidities can drive further steatosis, which in turn can instigate fibrosis and progression to cirrhosis and hepatocellular carcinoma. Polymorphisms in genes that modulate lipid deposition in hepatocytes such as patatin-like phospholipase domain-containing protein 3 (PNPLA3) and transmembrane six superfamily member 2 (TM6SF2) predispose people to steatosis. Metabolic syndrome, obesity, and insulin resistance are increasing worldwide and further contribute to hepatic steatosis, and alcohol has long been recognized as a cause of lipid deposition in the liver. HIV and antiretroviral drugs, but not HBV, may further drive hepatic steatosis. While many of these factors limit response to interferon-based regimens for treating HCV, responses to direct-acting antivirals appear not to be impaired. The effect of HCV eradication on hepatic steatosis and progression to fibrosis, cirrhosis, and hepatocellular carcinoma warrants further study in the era of direct-acting antivirals.\",\"Hepatitis C virus (HCV) infection induces steatosis and is accompanied by multiple metabolic alterations including hyperuricemia, reversible hypocholesterolemia and insulin resistance. Total cholesterol, low-density lipoprotein-cholesterol and triglyceride levels are increased by peginterferon and ribavirin combination therapy when a sustained virologic response (SVR) is achieved in patients with HCV. Steatosis is significantly more common in patients with HCV genotype 3 but interferon-free regimens are not always effective for treating HCV genotype 3 infections. HCV infection increases fatty acid synthase levels, resulting in the accumulation of fatty acids in hepatocytes. Of note, low-density lipoprotein receptor, scavenger receptor class B type I and Niemann-Pick C1-like 1 proteins are candidate receptors that may be involved in HCV. They are also required for the uptake of cholesterol from the external environment of hepatocytes. Among HCV-infected patients with or without human immunodeficiency virus infection, changes in serum lipid profiles are observed during interferon-free treatment and after the achievement of an SVR. It is evident that HCV affects cholesterol metabolism during interferon-free regimens. Although higher SVR rates were achieved with interferon-free treatment of HCV, special attention must also be paid to unexpected adverse events based on host metabolic changes including hyperlipidemia.\",\"The safety and efficacy of an IFN-free regimen using asunaprevir (ASV) and daclatasvir (DCV) for recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have not been evaluated in Japan. A multicenter study of LT recipients (n = 74) with recurrent HCV genotype 1b infection treated with ASV-DCV for 24 weeks was performed. Medical history was positive for pegylated interferon and ribavirin (Peg-IFN/RBV) in 40 (54.1%) patients, and for simeprevir (SMV) with Peg-IFN/RBV in 12 (16.2%) patients. Resistance-associated variants (RAVs) were positive at D168 (n = 1) in the NS3, and at L31 (n = 4), Y93 (n = 4), and L31/Y93 (n = 1) in the NS5A region of the HCV genome. Sixty-one (82.4%) patients completed the 24-week treatment protocol. Although sustained viral response (SVR) was achieved in 49 (80.3%) patients, it was achieved in only two (16.7%) patients among those with histories of receiving SMV (n = 12). Univariate analysis showed that a history of SMV (P < .01) and the presence of mutations in NS5A (P = .02) were the significant factors for no-SVR. By excluding the patients with either a history of SMV-based treatment or RAVs in NS3/NS5A, the SVR rate was 96.4%. By excluding the patients with a history of SMV and those with RAVs in NS3/NS5A, viral clearance of ASV-DCV was favorable, with a high SVR rate.\",\"Few real-life data are available on the retreatment of patients who failed direct-acting antiviral (DAA)-regimens. We reported the outcome of retreatment with approved DAA regimens in a real-life cohort of patients who previously failed an all-oral DAAs combination and we analyzed the association with resistance substitutions (RASs) performed at the time of virological failure.\",\"Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia.\",\"A 40-year-old male patient with virologic relapse after daclatasvir plus asunaprevir therapy for a serogroup 1 hepatitis C virus (HCV) infection visited our hospital for retreatment. Virologic examinations revealed that a genotype 2b HCV strain carrying both NS3-S122N / D168A and NA5A-R30Q / L31M / Q54H / Y93H mutations had relapsed. The patient received sofosbuvir plus ribavirin therapy, but virologic relapse occurred once again. Sequencing of the HCV genome clarified an intergenotypic recombination of 2b and 1b with an estimated crossover point between nucleotides 3114 and 3115, corresponding to the N-terminal end of the NS3 region (DDBJ/EMBL/GenBank databases accession no. LC273304). The NS5B-S282T mutation was not detected in the HCV strain, and resistance-association substitutions in the NS3 and NS5A regions were similar to those at baseline. Direct sequencing of the core and NS4A regions corresponding to the targeting sites of genotyping and serogrouping, respectively, is useful to determine the combination of direct-acting antivirals when a discrepancy is observed between the serogroup and genotype of HCV strains.\",\"One of the multiple factors contributing to virological response in chronic hepatitis C (CHC) is interferon-gamma-inducible protein-10 (IP-10). Its level reflects the status of interferon-stimulated genes, which in turn is associated with virological response to antiviral therapy. The aim of this study was to evaluate the role of serum IP-10 levels on sustained virological response (SVR) and the association of this parameter with insulin resistance (IR) and liver histology.\",\"Influenza virus inflicts a heavy death toll annually and resistance to existing antiviral drugs has generated interest in the development of agents with novel mechanisms of action. Favipiravir is an antiviral drug that acts by increasing the genome-wide mutation rate of influenza A virus (IAV). Potential synergistic benefits of combining oseltamivir and favipiravir have been demonstrated in animal models of influenza, but the population-level effects of combining the drugs are unknown. In order to elucidate the underlying evolutionary processes at play, we performed genome-wide sequencing of IAV experimental populations subjected to serial passaging in vitro under a combined protocol of oseltamivir and favipiravir. We describe the interplay between mutation, selection, and genetic drift that ultimately culminates in population extinction. In particular, selective sweeps around oseltamivir resistance mutations reduce genome-wide variation while deleterious mutations hitchhike to fixation given the increased mutational load generated by favipiravir. This latter effect reduces viral fitness and accelerates extinction compared with IAV populations treated with favipiravir alone, but risks spreading both established and newly emerging mutations, including possible drug resistance mutations, if transmission occurs before the viral populations are eradicated.\",\"Treatment of HCV genotype (GT) 2-infected Japanese patients with paritaprevir (NS3/4A inhibitor boosted with ritonavir) and ombitasvir (NS5A inhibitor) without ribavirin for 12 weeks in the phase 2 study M12-536, and with ribavirin for 16 weeks in phase 3 study GIFT II resulted in SVR rates of 72.2% to 91.5%. Overall, 11 out of 125 patients with GT2a and 37 out of 79 patients with GT2b infection experienced virologic failure. The prevalence of baseline polymorphisms in NS3 and NS5A and their the impact on treatment outcome, as well as the development of viral resistance in GT2-infected patients experiencing virologic failure were evaluated by HCV NS3 and NS5A population and clonal sequence analyses. Baseline polymorphisms in NS3 that confer resistance to paritaprevir were rare in both GT2a- and GT2b-infected patients, while baseline polymorphisms in NS5A that confer resistance to ombitasvir were detected in 11.2% and 14.1% of the GT2a- and GT2b-infected patients, respectively. There was no significant impact of baseline polymorphisms on treatment outcome in Japanese patients. The most common treatment-emergent substitutions at the time of virologic failure occurred at amino acid positions 168 in NS3 and 28 in NS5A in both GT2a- and GT2b-infected patients. Although there was a higher rate of virologic failure in patients with GT2b infection, the resistance analyses presented in this report support the conclusion that testing for baseline resistance-associated polymorphisms is not warranted for HCV GT2-infected patients treated with a regimen of ombitasvir/paritaprevir/ritonavir + ribavirin for 16 weeks.\",\"The efficacy and safety of an investigational combination of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) plus sofosbuvir (SOF) \\u00b1 ribavirin (RBV) in patients with HCV genotype 2 or 3 infection with or without cirrhosis was evaluated. Patients with HCV genotype 3 infection without cirrhosis were randomized to receive OBV/PTV/r + SOF \\u00b1 RBV for 12 weeks; OBV/PTV/r + SOF + RBV was administered to genotype 3-infected patients with cirrhosis for 12 weeks and to genotype 2-infected patients without cirrhosis for either 6 or 8 weeks. Efficacy was assessed by sustained virologic response [HCV RNA <25 IU/mL] 12 weeks post-treatment (SVR12). Safety was assessed in all treated patients. In patients with genotype 3 infection with or without cirrhosis treated with 12 weeks of OBV/PTV/r + SOF \\u00b1 RBV, the overall SVR12 rate was 98% (50/51), with no virologic failures. Patients with genotype 2 infection treated with OBV/PTV/r + SOF + RBV had SVR12 rates of 90% (9/10) and 44% (4/9) following 8- and 6-week treatment durations, respectively; failure to achieve SVR12 for these patients was due to relapse without baseline or treatment-emergent resistance-associated substitutions. Thus, the investigational combination of OBV/PTV/r with SOF \\u00b1 RBV was well tolerated and achieved high SVR rates with no virologic failures in patients with genotype 3 infection. Combining direct-acting antivirals with complementary mechanisms of action and different viral targets may be an effective treatment strategy that may allow for shorter durations of therapy.\",\"The study aimed to evaluate the effects of baseline hepatitis C virus (HCV) nonstructural protein 5A (NS5A) resistance-associated substitutions (RASs) on sustained virologic response to ledipasvir (LDV)-containing regimens in the absence of sofosbuvir (SOF) in patients with HCV genotype (GT) 1 infection across 6 phase 2 clinical studies. We analysed data from 1103 patients who received either LDV + vedroprevir (NS3 protease inhibitor) + tegobuvir (NS5B inhibitor) \\u00b1 ribavirin or LDV + ribavirin + pegylated interferon. Population sequencing of HCV NS5A was performed at baseline and at virologic failure from patient plasma samples. Of 1045 patients with available baseline sequences, 747 (67.7%) had GT1a, and 298 (26.9%) had GT1b infection. The overall prevalence of NS5A RASs at baseline was 9.4%; 7.6% (57/747) and 13.8% (41/298) of patients with GT1a and GT1b infection, respectively. The majority of GT1a-infected patients with NS5A RASs at baseline had a single NS5A RAS (78.9%) at NS5A positions K24R, M28T, Q30H/L, L31M and Y93H/N/C/S. The spectrum of NS5A RASs detected in GT1b patients was much less diverse compared to GT1a patients, with all patients harbouring a single NS5A RAS either L31M or Y93H/C. For patients treated with LDV-containing regimens in the absence of SOF, the presence of baseline NS5A RASs was associated with low SVR rates. In patients with virologic failure, nearly all had either pre-existing and/or emergent NS5A RASs: 287/287 (100%) and 40/42 (95.2%) patients with GT1a and GT1b infection, respectively. Three novel NS5A substitutions were identified as emergent NS5A RASs: K26E and S38F in GT1a; and L31I in GT1b. In conclusion, the presence of NS5A RASs at baseline reduced the SVR rate in patients treated with LDV in combination vedroprevir + tegobuvir \\u00b1 ribavirin or ribavirin + pegylated interferon. Virologic failure was associated with the detection of NS5A RASs in nearly all patients. These results suggest that the resistance barrier may differ depending on HCV drug combination and may be more important than that of the individual DAAs.\",\"In Japan, daclatasvir (DCV) and asunaprevir (ASV) therapy was the first IFN-free treatment to be approved, and thousands of patients have since been successfully treated, with an SVR rate of around 90%. The converse, however, is that around 10% of patients fail to achieve viral eradication and must be retreated using a different approach. This study is to evaluate treatment efficacy of ledipasvir/sofosbuvir and ribavirin in patients who failed to respond to DCV and ASV therapy.\",\"Lethal mutagenesis is a broad-spectrum antiviral strategy that employs mutagenic nucleoside analogs to exploit the high mutation rate and low mutational tolerance of many RNA viruses. Studies of mutagen-resistant viruses have identified determinants of replicative fidelity and the importance of mutation rate to viral population dynamics. We have previously demonstrated the effective lethal mutagenesis of influenza A virus using three nucleoside analogs as well as the virus's high genetic barrier to mutagen resistance. Here, we investigate the mutagen-resistant phenotypes of mutations that were enriched in drug-treated populations. We find that PB1 T123A has higher replicative fitness than the wild type, PR8, and maintains its level of genome production during 5-fluorouracil (2,4-dihydroxy-5-fluoropyrimidine) treatment. Surprisingly, this mutagen-resistant variant also has an increased baseline rate of C-to-U and G-to-A mutations. A second drug-selected mutation, PA T97I, interacts epistatically with PB1 T123A to mediate high-level mutagen resistance, predominantly by limiting the inhibitory effect of nucleosides on polymerase activity. Consistent with the importance of epistatic interactions in the influenza virus polymerase, our data suggest that nucleoside analog resistance and replication fidelity are strain dependent. Two previously identified ribavirin {1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide} resistance mutations, PB1 V43I and PB1 D27N, do not confer drug resistance in the PR8 background, and the PR8-PB1 V43I polymerase exhibits a normal baseline mutation rate. Our results highlight the genetic complexity of the influenza A virus polymerase and demonstrate that increased replicative capacity is a mechanism by which an RNA virus can counter the negative effects of elevated mutation rates. IMPORTANCE RNA viruses exist as genetically diverse populations. This standing genetic diversity gives them the potential to adapt rapidly, evolve resistance to antiviral therapeutics, and evade immune responses. Viral mutants with altered mutation rates or mutational tolerance have provided insights into how genetic diversity arises and how it affects the behavior of RNA viruses. To this end, we identified variants within the polymerase complex of influenza virus that are able to tolerate drug-mediated increases in viral mutation rates. We find that drug resistance is highly dependent on interactions among mutations in the polymerase complex. In contrast to other viruses, influenza virus counters the effect of higher mutation rates primarily by maintaining high levels of genome replication. These findings suggest the importance of maintaining large population sizes for viruses with high mutation rates and show that multiple proteins can affect both mutation rate and genome synthesis.\",\"Genetic variability in NS5A is associated with different levels of resistance to the currently licensed NS5A inhibitors. The aim of this study was to detect NS5A inhibitor resistance associated substitutions (RASs) in hepatitis C virus (HCV) genotype 1 (GT1) patients who are naive to direct-acting HCV antivirals.\",\"Norovirus is a major cause of acute gastroenteritis worldwide and has emerged as an important issue of chronic infection in transplantation patients. Since no approved antiviral is available, we evaluated the effects of different immunosuppressants and ribavirin on norovirus and explored their mechanisms of action by using a human norovirus (HuNV) replicon-harboring model and a surrogate murine norovirus (MNV) infectious model. The roles of the corresponding drug targets were investigated by gain- or loss-of-function approaches. We found that the calcineurin inhibitors cyclosporine (CsA) and tacrolimus (FK506) moderately inhibited HuNV replication. Gene silencing of their cellular targets, cyclophilin A, FKBP12, and calcineurin, significantly inhibited HuNV replication. A low concentration, therapeutically speaking, of mycophenolic acid (MPA), an uncompetitive IMP dehydrogenase (IMPDH) inhibitor, potently and rapidly inhibited norovirus replication and ultimately cleared HuNV replicons without inducible resistance following long-term drug exposure. Knockdown of the MPA cellular targets IMPDH1 and IMPDH2 suppressed HuNV replication. Consistent with the nucleotide-synthesizing function of IMPDH, exogenous guanosine counteracted the antinorovirus effects of MPA. Furthermore, the competitive IMPDH inhibitor ribavirin efficiently inhibited norovirus and resulted in an additive effect when combined with immunosuppressants. The results from this study demonstrate that calcineurin phosphatase activity and IMPDH guanine synthase activity are crucial in sustaining norovirus infection; thus, they can be therapeutically targeted. Our results suggest that MPA shall be preferentially considered immunosuppressive medication for transplantation patients at risk of norovirus infection, whereas ribavirin represents as a potential antiviral for both immunocompromised and immunocompetent patients with norovirus gastroenteritis.\",\"There are millions of chronic hepatitis C (CHC) virus-infected patients who have been treated with a combination therapy (interferon and ribavirin) and have achieved a virological response (SVR) worldwide. The aim of this study is to evaluate the risk factors for de-novo diabetes mellitus in CHC patients treated with combination therapy (interferon and ribavirin) and have achieved an SVR.\",\"To determine the number of mutations in the NS5A region of the hepatitis C virus (HCV) and its relationship to the response to antiviral therapy in patients with chronic hepatitis C genotype 1 who are non-responders to two or more treatments.\",\"Hepatitis E virus (HEV) infection is a major cause of acute hepatitis but also provokes chronic infection in immunocompromised patients. Although the pathogenesis and treatment outcome involve complex interplay between the virus and host, the nature of adaptive responses of HEV to the host immune system remain obscure at best. In this study, we used large-scale proteomic bioinformatics to profile characteristic mutations in human HEV isolates associated to ribavirin treatment failure, chronic hepatitis, hepatic failure or altered immunoreactivity. The prevalence of specific mutations was examined in a large number of protein sequences of ORF1 and ORF2 regions of the 3 major human-derived HEV genotypes (1, 3 and 4). By analyzing potential B, CD4+ and CD8+ T cell epitopes, we found that many of these mutations overlap with the predicted epitopes and are frequently present among the 3 HEV genotypes. These overlapping mutations mediate reduced antigenicity. Finally, by delineation of diversification and evolution of the underlying epitopes, we observe that most of these variants apparently evolved earlier in genotype 1 when compared with genotypes 3 and 4. These results indicate that HEV is under substantial evolutionary pressure to develop mutations enabling evasion of the host immune response and resistance to antiviral treatment. This indicates the existence of an ongoing evolutionary arms race between human immunity, antiviral medication and HEV.\",\"T-705 (favipiravir) is a potent inhibitor of RNA-dependent RNA polymerases of influenza viruses and no favipiravir-resistant virus has been isolated. Poliovirus RNA polymerase has been well characterized and isolation of resistant virus was examined in poliovirus.\",\"Chronic HCV infection has emerged as a complex multifaceted disease with manifestations extending beyond the liver. HCV plays a direct role in glucose metabolism leading to both insulin resistance and type 2 diabetes. To evaluate the changes in the glycemic state following Sofosbuvir-based treatment regimens in diabetic HCV patients. Four hundred chronic hepatitis C patients who underwent Sofosbuvir-based treatment regimens were retrospectively screened. Sixty-five diabetic HCV patients only enrolled in our analysis. Baseline demographic and laboratory data were recorded. Pretreatment Transient elastography was performed. At 24-week post EOT (SVR24), Fasting Plasma glucose, and Hemoglobin A1c were re-evaluated and compared with baseline. All enrolled diabetic patients were responders. They showed statistically significant decline in Fasting Plasma glucose and Hemoglobin A1c values at SVR24. Whatever the degree of hepatic fibrosis, the level of Fasting Plasma glucose and Hemoglobin A1c decreased at SVR24 in comparison to baseline level. Fifty-one patients showed improvement in their Hemoglobin A1c values at SVR24 and this improvement was more likely to occur among patients with low Body mass index. The reduction in Fasting Plasma glucose >20 mg/dL (>1.1 mmol/L) and Hemoglobin A1c \\u22650.5% was not associated with age, gender or hepatic fibrosis stage. Sofosbuvir-based regimens are a highly efficient antiviral therapy for diabetic chronic HCV patients resulted in improvement in Fasting Plasma glucose and Hemoglobin A1c.\",\"People with hepatitis C virus (HCV) infection who have failed treatment with an all-oral regimen represent a challenging treatment population. The present studies evaluated the safety and efficacy of grazoprevir, ruzasvir, and uprifosbuvir, with or without ribavirin, in participants who had failed an NS5A inhibitor-containing regimen. C-SURGE (PN-3682-021) and C-CREST Part C (PN-3682-011 and -012) were open-label, multicenter studies. Participants who had previously relapsed following an NS5A inhibitor-containing all-oral regimen were retreated with grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg alone for 24 weeks or with ribavirin for 16 weeks. The primary efficacy endpoint was sustained virologic response (HCV RNA below the limit of quantitation [<15 IU/mL]) 12 weeks after treatment completion (SVR12). In C-SURGE, SVR12 was achieved by 49/49 (100%) and 43/44 (98%) genotype (GT)1 participants in the 24-week no ribavirin arm and the 16-week plus ribavirin arm (lost to follow-up, n = 1), respectively. In C-CREST Part C, SVR12 was achieved by 23/24 (96%) participants treated for 16 weeks with ribavirin (GT1, 2/2 [100%]; GT2, 13/14 [93%]; GT3, 8/8 [100%]). One participant with GT2 infection discontinued study medication after a single dose of grazoprevir, ruzasvir, and uprifosbuvir plus ribavirin due to serious adverse events of vomiting and tachycardia. The presence of baseline resistance-associated substitutions had no impact on SVR12. No participant who completed treatment in either study experienced virologic failure.\",\"The pharmacology, pharmacokinetics, interaction potential, efficacy, and safety of the newest direct-acting antiviral (DAA) medication for the treatment of chronic hepatitis C are reviewed.\",\"Hepatitis E virus (HEV) infection has emerged as a global health issue, but no approved medication is available. The nucleoside analogue 2'-C-methylcytidine (2CMC), a viral polymerase inhibitor, has been shown to inhibit infection with a variety of viruses, including hepatitis C virus (HCV). Here, we report that 2CMC significantly inhibits the replication of HEV in a subgenomic replication model and in a system using a full-length infectious virus. Importantly, long-term treatment with 2CMC did not result in a loss of antiviral potency, indicating a high barrier to drug resistance development. However, the combination of 2CMC with ribavirin, an off-label treatment for HEV, exerts antagonistic effects. Our results indicate that 2CMC serves as a potential antiviral drug against HEV infection.\",\"Little is known about the epidemiology and frequency of recombinant HCV genotype 2/1 strains, which may represent a challenge for direct antiviral therapy (DAA). This study aims to identify the epidemiology and phylogeny of HCV genotype 2/1 strains and encourages genotype screening, to select the DAA-regimen that achieves the optimal sustained virologic response.\",\"Daclatasvir (DCV; non-structural [NS]5A inhibitor) plus asunaprevir (ASV; NS3 inhibitor) plus beclabuvir (BCV; non-nucleoside NS5B inhibitor) is an approved regimen for hepatitis C virus (HCV) genotype (GT)-1 treatment in Japan. A comprehensive analysis of pre-treatment and treatment-emergent HCV resistance to this regimen \\u00b1 ribavirin (RBV) was performed.\",\"The success of the antiviral treatment in patients with chronic hepatitis C depends on the factors related to the virus and the host. The aim of the study is the analysis of the antiviral therapy which is a combination of pegylated interferon and ribavirin, considering various factors that will identify the predictors of the sustained virological response.\",\"In study TMC647055HPC2001, a 3-direct-acting-antiviral (DAA) regimen combining NS3/4A protease inhibitor simeprevir (SMV), non-nucleoside NS5B inhibitor TMC647055/ritonavir (RTV) and NS5A inhibitor JNJ-56914845 resulted in high sustained virologic response 12 weeks after actual end of treatment (SVR12) in chronic hepatitis C virus (HCV) genotype 1-infected patients. SVR12 rates were generally lower in the 2-DAA regimen SMV + TMC647055/RTV with or without ribavirin. The objective of this study was to identify and characterise pre-existing and emerging resistance-associated variants (RAVs) in patients enrolled in study TMC647055HPC2001.\",\"From 2010, the landscape of hepatitis C therapeutics has been changed rapidly, and today we are standing at a cusp of a pharmacological revolution where highly effective and interferon (IFN)-free direct acting antivirals (DAAs) are already on the market. Such treatment paradigms attain 90-95% sustained virologic response (SVR; undetectable viral load at week 12 or 24 at the end of therapy) rates in treated individuals compared to 50-70% with treatment completion of dual-therapy-pegylated interferon (PEG-IFN) and ribavirin (RBV). As the major goal now for the hepatologists, clinicians, physicians, and health care workers is likely to eradicate hepatitis C infection in parallel to treatment, the demand is for a one-size-fits-all pill that could be prescribed beyond the limitations of hepatitis C genotype, viral load, previous treatment history, advanced hepatic manifestations (fibrosis, cirrhosis) and antiviral drug resistance. Although the new treatment strategies have shown high cure rates in clinical trials, such treatment paradigms are posing dilemmas too in real-world clinical practice. Therapy cost, treatment access to low and middle-income countries, treatment-emergent adverse events, lack of effective viral screening and disease progression simulation models are potential challenges in this prospect. This review article deeply overviews the challenges encountered while surmounting the burden of hepatitis C around the world.\",\"Patients chronically infected with genotype 3 hepatitis C virus (HCV) have faster disease progression and are less responsive to current direct-acting antiviral regimens than patients infected with other genotypes. We conducted an open-label trial to evaluate the safety, tolerability, and efficacy of ledipasvir and sofosbuvir plus ribavirin in patients with genotype 3 HCV infection.\",\"Foot-and-mouth disease virus (FMDV) RNA-dependent RNA polymerase (RdRp) (3D[pol]) catalyzes viral RNA synthesis. Its characteristic low fidelity and absence of proofreading activity allow FMDV to rapidly mutate and adapt to dynamic environments. In this study, we used the structure of FMDV 3D[pol] in combination with previously reported results from similar picornaviral polymerases to design point mutations that would alter replication fidelity. In particular, we targeted Trp237 within conserved polymerase motif A because of the low reversion potential inherent in the single UGG codon. Using biochemical and genetic tools, we show that the replacement of tryptophan 237 with phenylalanine imparts higher fidelity, but replacements with isoleucine and leucine resulted in lower-fidelity phenotypes. Viruses containing these W237 substitutions show in vitro growth kinetics and plaque morphologies similar to those of the wild-type (WT) A24 Cruzeiro strain in BHK cells, and both high- and low-fidelity variants retained fitness during coinfection with the wild-type virus. The higher-fidelity W237F (W237F[HF]) mutant virus was more resistant to the mutagenic nucleoside analogs ribavirin and 5-fluorouracil than the WT virus, whereas the lower-fidelity W237I (W237I[LF]) and W237L[LF] mutant viruses exhibited lower ribavirin resistance. Interestingly, the variant viruses showed heterogeneous and slightly delayed growth kinetics in primary porcine kidney cells, and they were significantly attenuated in mouse infection experiments. These data demonstrate, for a single virus, that either increased or decreased RdRp fidelity attenuates virus growth in animals, which is a desirable feature for the development of safer and genetically more stable vaccine candidates.IMPORTANCE Foot-and-mouth disease (FMD) is the most devastating disease affecting livestock worldwide. Here, using structural and biochemical analyses, we have identified FMDV 3D[pol] mutations that affect polymerase fidelity. Recombinant FMDVs containing substitutions at 3D[pol] tryptophan residue 237 were genetically stable and displayed plaque phenotypes and growth kinetics similar to those of the wild-type virus in cell culture. We further demonstrate that viruses harboring either a W237F[HF] substitution or W237I[LF] and W237L[LF] mutations were highly attenuated in animals. Our study shows that obtaining 3D[pol] fidelity variants by protein engineering based on polymerase structure and function could be exploited for the development of attenuated FMDV vaccine candidates that are safer and more stable than strains obtained by selective pressure via mutagenic nucleotides or adaptation approaches.\",\"The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct-acting antiviral-based therapies remains unclear. In this multicenter, open-label, phase 2 study, we evaluated the efficacy and safety of a fixed-dose combination of sofosbuvir-velpatasvir (400 mg/100 mg) plus weight-adjusted ribavirin administered for 24 weeks in patients who did not achieve sustained virologic response after prior treatment with direct-acting antiviral regimens that included the nucleotide analogue nonstructural protein 5B inhibitor sofosbuvir plus the nonstructural protein 5A inhibitor velpatasvir with or without the nonstructural protein 3/4A protease inhibitor voxilaprevir. The primary efficacy endpoint was the proportion of patients achieving sustained virologic response at 12 weeks after the cessation of treatment. In total, 63 of 69 (91%; 95% confidence interval, 82%-97%) patients achieved sustained virologic response at 12 weeks, including 36 of 37 (97%; 95% confidence interval, 86%-100%) patients with hepatitis C virus genotype 1 infection, 13 of 14 (93%; 95% confidence interval, 66%-100%) patients with genotype 2 infection, and 14 of 18 (78%; 95% confidence interval, 52%-94%) patients with genotype 3 infection. Most adverse events were of mild or moderate severity. The most frequently reported adverse events were fatigue, nausea, headache, insomnia, and rash. One patient (1%) with genotype 1a infection discontinued all study drugs due to an adverse event (irritability).\",\"To assess the efficacy and safety of telaprevir (TVR) when used in combination with natural human interferon-\\u03b2 (IFN-\\u03b2) and ribavirin (RBV) for genotype 1 patients with depression compared to IFN-\\u03b2/RBV therapy in Japan. We also examined the efficacy of the TVR/IFN-\\u03b2/RBV therapy in treatment failure genotype 2 patients with depression.\",\"Multiple direct-acting antiviral (DAA)-based regimens are currently approved that provide one or more interferon-free treatment options for hepatitis C virus (HCV) genotypes (G) 1-6. The choice of a DAA regimen, duration of therapy, and use of ribavirin depends on multiple viral and host factors, including HCV genotype, the detection of resistance-associated amino acid (aa) substitutions (RASs), prior treatment experience, and presence of cirrhosis. In regard to viral factors that may guide the treatment choice, the most important is the infecting genotype because a number of DAAs are genotype-designed. The potency and the genetic barrier may also impact the choice of treatment. One important and debated possible virologic factor that may negatively influence the response to DAAs is the presence of baseline RASs. Baseline resistance testing is currently not routinely considered or recommended for initiating HCV treatment, due to the overall high response rates (sustained virological response >90%) obtained. Exceptions are patients infected by HCV G1a when initiating treatment with simeprevir and elbasvir/grazoprevir or in those with cirrhosis prior to daclatasvir/sofosbuvir treatment because of natural polymorphisms demonstrated in sites of resistance. On the basis of these observations, first-line strategies should be optimized to overcome treatment failure due to HCV resistance.\",\"Pegylated interferon (PegIFN) is used in the treatment of chronic hepatitis C virus (HCV) patients especially in resource limited countries. Treatment with PegIFN stimulates the expression of a number of host genes encoding enzymes with antiviral activities, including myxovirus resistance gene-A (MxA gene). MxA gene was found to have a single nucleotide polymorphism (SNP) at position -88 in the promoter region that affects the expression of MxA gene protein and was suggested to affect the treatment outcome. The aim of the work was to assess the relation between the SNP in the MxA gene and its impact on treatment of chronic HCV patients with PegIFN and ribavirin.\",\"To review the role and utility of baseline resistance testing with currently available and pipeline genotype 1 hepatitis C virus (HCV) treatment.\",\"We have identified a series of 1-aryl-4,6-diamino-1,2-dihydrotriazines, structurally related to the antimalarial drug cycloguanil, as new inhibitors of influenza A and B virus and respiratory syncytial virus (RSV) via targeting of the host dihydrofolate reductase (DHFR) enzyme. Most analogues proved active against influenza B virus in the low micromolar range, and the best compounds (11, 13, 14 and 16) even reached the sub-micromolar potency of zanamivir (EC50 = 0.060 \\u03bcM), and markedly exceeded (up to 327 times) the antiviral efficacy of ribavirin. Activity was also observed for two influenza A strains, including a virus with the S31N mutant form of M2 proton channel, which is the most prevalent resistance mutation for amantadine. Importantly, the compounds displayed nanomolar activity against RSV and a superior selectivity index, since the ratio of cytotoxic to antiviral concentration was >10,000 for the three most active compounds 11, 14 and 16 (EC50 \\u223c0.008 \\u03bcM), far surpassing the potency and safety profile of the licensed drug ribavirin (EC50 = 5.8 \\u03bcM, SI > 43).\",\"Elbasvir (EBR; HCV NS5A inhibitor) and grazoprevir (GZR; HCV NS3/4A protease inhibitor) are approved as a fixed-dose combination to treat patients chronically infected with HCV genotypes 1 and 4. During the development programme and supported by in vitro potency, the efficacy of EBR+GZR was assessed in HCV GT3-infected patients. This study's aim was to determine the efficacy and tolerability of 12 or 18 weeks of EBR+GZR with ribavirin (RBV) in treatment-na\\u00efve, noncirrhotic HCV GT3-infected patients. Randomized patients received open-label EBR (50 mg once daily) + GZR (100 mg once daily) + RBV. The primary efficacy objective was to evaluate the sustained virologic response rates 12 weeks after the end of all study therapy (SVR12). SVR12 rates (95% confidence interval) were 45.0% (23.1, 68.5) and 57.1% (34.0, 78.2) after treatment with EBR+GZR+RBV for 12 weeks or 18 weeks, respectively. On-treatment virologic failure was observed in 41% (17 of 41) of patients. At virologic failure, resistance-associated substitutions (RASs) with a >five-fold shift in potency occurred in the NS3 region in six (35%) patients and in the NS5A region in 16 (94%) patients. The most common RAS at virologic failure was Y93H in NS5A which was identified in 13 of 17 (76%) patients. The efficacy of EBR+GZR+RBV was suboptimal in HCV GT3-infected patients due to a high rate of on-treatment virologic failure and treatment-emergent RASs which demonstrates an inadequate barrier to the development of GT3 resistance. However, rapid viral clearance demonstrated the antiviral activity of EBR+GZR+RBV in GT3-infected patients.clinicaltrials.gov: NCT01717326.\",\"Direct acting antivirals are revolutionizing the treatment of chronic hepatitis C. Specifically, the combination therapy sofosbuvir and velpatasvir offers a pangenotypic regimen with high sustained viral response (SVR). Areas covered: Reviewed here are the clinical trials that led to the FDA approval of sofosbuvir and velpatasvir combination therapy, the adverse events during registration trials, and drug-drug interactions. Sofosbuvir and velpatasvir is a fixed dose regimen that is both interferon- and ribavirin-free. It is administered for 12 weeks as a once-a-day pill, covers all genotypes of hepatitis C, and achieves SVR >95% in non-cirrhotic patients and patients with compensated cirrhosis. Addition of ribavirin is recommended for patients with decompensated cirrhosis (CTP B or C). Baseline resistance-associated substitutions do not appear to impair ability to achieve SVR with an initial course of treatment. Expert commentary: Availability of this highly efficacious, well tolerated, all oral regimen formulated as a single pill, can potentially simplify hepatitis C treatment. Its utility as a pangenotypic regimen additionally limits resource utilization.\",\"We evaluated the transition of dominant resistance-associated substitutions (RASs) in hepatitis C virus during long-term follow-up after the failure of DAAs (direct acting antivirals)-based therapy. RASs in non-structure (NS)3/4A, NS5A, NS5B, and deletions in NS5A from 20 patients who failed simeprevir/pegylated-interferon/ribavirin (SMV/PEG-IFN/RBV) and 25 patients who failed daclatasvir/asunaprevir (DCV/ASV) treatment were examined by direct sequencing. With respect to SMV/PEG-IFN/RBV treatment, RAS was detected at D168 in NS3/4A but not detected in NS5A and NS5B at treatment failure in 16 of 20 patients. During the median follow-up period of 64 weeks, the RAS at D168 became less dominant in 9 of 16 patients. Among 25 DCV/ASV failures, RASs at D168, L31, and Y93 were found in 57.1%, 72.2%, and 76.9%, respectively. NS5A deletions were detected in 3 of 10 patients treated previously with SMV/PEG-IFN/RBV. The number of RASs in the breakthrough patients exceeded that in relapsers (mean 3.9 vs. 2.7, p < 0.05). RAS at D168 in NS3/4A became less dominant in 6 of 15 patients within 80 weeks. Y93H emerged at the time of relapse, then decreased gradually by 99% at 130 weeks post-treatment. Emerged RASs were associated with the clinical course of treatment and could not be detected during longer follow-up.\",\"The aim of this study was to characterize the treatment response and serious adverse events of ledipasvir plus sofosbuvir therapies in Japanese patients infected with hepatitis C virus (HCV) genotype 1 (GT1). This retrospective study analyzed 240 Japanese HCV GT1 patients treated for 12 weeks with 90 mg of ledipasvir plus 400 mg of sofosbuvir daily. Sustained virological response at 12 weeks post-treatment (SVR12) was achieved in 236 of 240 (98.3%) patients. Among treatment-na\\u00efve patients, SVR12 was achieved in 136 of 138 (98.6%) patients, and among treatment-experienced patients, SVR12 was achieved in 100 of 102 (98.0%) patients. In patients previously treated with peginterferon plus ribavirin with various HCV NS3/4A inhibitors, 100% SVR rates (25/25) were achieved. Two relapsers had HCV NS5A resistance-associated variants (RAVs), but no HCV NS5B-S282 was observed after they relapsed. We experienced two patients with cardiac events during treatment. In conclusion, combination of ledipasvir plus sofosbuvir for 12 weeks is a potential therapy for HCV GT1 patients. Caution is needed for HCV NS5A RAVs, which were selected by HCV NS5A inhibitors and cardiac adverse events.\",\"Directly-acting antivirals (DAA) have finally allowed all patients to be potentially cured from chronic hepatitis C (HCV) infection. All-oral, Interferon (IFN)-free regimens are based upon the combination of molecules targeting different sites of the HCV replication process. Three classes of DAA exist: protease inhibitors (anti-NS3/4A), RNA-dependent polymerase inhibitors (anti-NS5B) and anti-NS5A inhibitors, which are characterized by different antiviral potency and barrier to resistance and therefore are usually combined in different treatment schedules. Treatment regimens are still largely dependent on HCV genotype and stage of liver disease, with duration ranging between 12 weeks and 24 weeks, while overall treatment efficacy has climbed to nearly 95% in most patient groups, including historically difficult-to-treat categories (HCV genotype 1, advanced liver disease). The elimination of IFN has allowed safe and efficacious treatment of patients formerly contraindicated to antiviral therapy, such as decompensated cirrhosis and solid organ transplant recipients. Availability of potent and safe antiviral drugs combined with improvement of worldwide access to treatment could finally lead to HCV elimination in the next decades.\",\"Inclusion of direct-acting antivirals into clinical practice in patients with chronic HCV (CHC) has been a milestone in medicine.\",\"Clinical studies have shown high rates of sustained virological response (hepatitis C virus [HCV] RNA <15 IU/mL) at post-treatment week 12 (SVR12) in patients with genotype 1b infection with and without cirrhosis who received coformulated ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin, for 12 weeks. In this study, we aimed to assess 8-week treatment with ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin in patients infected with HCV genotype 1b without cirrhosis.\",\"First-generation protease-inhibitors (PIs) have suboptimal efficacy in GT-1 patients with advanced liver disease, and patients experiencing treatment failure may require urgent retreatment. Our objective was to analyse the real-life efficacy of interferon (IFN)-free retreatment after PI-failure, and the role of genotypic-resistance-testing (GRT) in guiding retreatment choice.\",\"Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic, with a high barrier to resistance and short treatment duration is desirable. The efficacy and safety of 8- and 12-week treatments with glecaprevir (ABT-493; NS3/4A protease inhibitor) and pibrentasvir (ABT-530; NS5A inhibitor) were evaluated in non-cirrhotic patients with chronic HCV genotype 1-6 infection.\",\"Influenza is a highly contagious viral infection associated with excessive hospitalizations and deaths throughout the world. Continuous antigenic shift and drift is not only responsible for this devastating effect of influenza but also causes ineffectiveness of antiviral drugs and vaccines. In this study, we investigated the effectiveness of ribavirin, oseltamivir, and amantadine drugs in vitro against nine influenza A isolates collected during June 2012-August 2013 from different slums in Dhaka city. The effectiveness of these drugs was determined by measuring the inhibition of virus-induced cytopathic effect on MDCK cells through MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). Our data showed that all nine influenza isolates (6 H1N1 pdm09 and 3 H3N2 subtypes) were completely susceptible to ribavirin (The 50% effective concentrations, EC50 3.0 \\u00b5g/ml) and oseltamivir (EC50 0.35 \\u00b5g/ml). When influenza A infection was challenged with amantadine drug, eight out of nine isolates (88%) demonstrated susceptibility to amantadine drug (EC50 0.30 \\u00b5g/ml) while one H1N1 pdm09 isolate exhibited higher EC50 value (>10 \\u00b5g/ml) beyond the cell tolerance level of drug (>5 \\u00b5g/ml). Genetic analysis of transmembrane matrix protein 2 (M2), which is a target for the amantadine drug and vital for viral replication, showed a substitution of amino acid at position 31(S31 N) of that amantadine-resistant isolate indicating the possible reason of amantadine drug resistance.\",\"Interleukin-10 (IL-10) plays an important role in the immunity to hepatitis C virus (HCV). Insofar as IL-10 variants are associated with altered levels of IL-10, previous studies that examined the association of IL-10 polymorphisms with the susceptibility to and progression of chronic HCV, and response to anti-viral treatment were inconsistent. We investigated the association between common IL-10 variants in the intron and the promotor region with HCV and associated features.\",\"Favipiravir (T-705) is a broad-spectrum antiviral agent that has been approved in Japan for the treatment of influenza virus infections. T-705 also inhibits the replication of various RNA viruses, including chikungunya virus (CHIKV). We demonstrated earlier that the K291R mutation in the F1 motif of the RNA-dependent RNA polymerase (RdRp) of CHIKV is responsible for low-level resistance to T-705. Interestingly, this lysine is highly conserved in the RdRp of positive-sense single-stranded RNA (+ssRNA) viruses. To obtain insights into the unique broad-spectrum antiviral activity of T-705, we explored the role of this lysine using another +ssRNA virus, namely, coxsackievirus B3 (CVB3). Introduction of the corresponding K-to-R substitution in the CVB3 RdRp (K159R) resulted in a nonviable virus. Replication competence of the K159R variant was restored by spontaneous acquisition of an A239G substitution in the RdRp. A mutagenesis analysis at position K159 identified the K159M variant as the only other viable variant which had also acquired the A239G substitution. The K159 substitutions markedly decreased the processivity of the purified viral RdRp, which was restored by the introduction of the A239G mutation. The K159R A239G and K159M A239G variants proved, surprisingly, more susceptible than the wild-type virus to T-705 and exhibited lower fidelity in polymerase assays. Furthermore, the K159R A239G variant was found to be highly attenuated in mice. We thus demonstrate that the conserved lysine in the F1 motif of the RdRp of +ssRNA viruses is involved in the broad-spectrum antiviral activity of T-705 and that it is a key amino acid for the proper functioning of the enzyme.IMPORTANCE In this study, we report the key role of a highly conserved lysine residue of the viral polymerase in the broad-spectrum antiviral activity of favipiravir (T-705) against positive-sense single-stranded RNA viruses. Substitutions of this conserved lysine have a major negative impact on the functionality of the RdRp. Furthermore, we show that this lysine is involved in the fidelity of the RdRp and that the RdRp fidelity influences the sensitivity of the virus for the antiviral efficacy of T-705. Consequently, these results provide insights into the mechanism of the antiviral activity of T-705 and may lay the basis for the design of novel chemical scaffolds that may be endowed with a more potent broad-spectrum antiviral activity than that of T-705.\",\"The efficacy of hepatitis C virus (HCV) treatment has increased over the last 5 years to nearly 100% for many patient groups. Patients with genotype (GT) 3 HCV infection, however, and specifically cirrhotic or treatment-experienced patients, have lower sustained virologic response (SVR) rates than patients with other GTs. Because GT 3 presents more clinical challenges than other GTs, this review focuses on the evolution and efficacy of direct-acting antiviral (DAA) treatment options for HCV GT 3 infection after the historical standard of care with pegylated interferon and ribavirin. Our objective was to review the SVR rates with available and late-pipeline DAAs for HCV GT 3 infection and discuss challenges with successful GT 3 treatment. Authors performed a literature search of the PubMed/MEDLINE database (inception to March 27, 2017) and narrowed the field to clinical trials published in English. Trials that evaluated alternative treatments, non-DAA historical treatment, and DAAs not currently indicated for HCV were excluded. Trials only involving patients with human immunodeficiency virus/HCV coinfection were also excluded. Additional trials were identified from a review of the ClinicalTrials.gov database. Authors further identified references from a review of literature citations and reviewed annual meeting abstracts from the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver for pipeline and real-world GT 3 data. Phase III trial data were not available to support all GT 3 treatment recommendations found in the guidelines. The SVR rates were lower in treatment-experienced and cirrhotic patients with GT 3 than other HCV populations. Treatment failure was associated with resistance to current treatment regimens. Clinical studies included patients with various levels of advanced liver disease, but few patients with decompensated cirrhosis were represented. Recent advances in pharmacologic treatment with DAAs have greatly increased SVR rates in patients with all HCV GTs, but SVR rates for treatment-experienced cirrhotic patients with GT 3 are lower than for other GTs. Given the limited data and observed SVR rates in this patient population, the optimal therapy for patients with decompensated cirrhotic GT 3 HCV infection is not yet established. Newer agents and recommendations regarding baseline resistance are likely to evolve treatment strategies in the near future.\",\"This multinational (Taiwan, South Korea, Russia) phase 3 study evaluated the all-oral, ribavirin-free, fixed-dose combination (DCV-TRIO) of daclatasvir (NS5A inhibitor) 30 mg, asunaprevir (NS3 inhibitor) 200 mg, and beclabuvir (NS5B inhibitor) 75 mg, in patients with chronic hepatitis C virus genotype-1 infection, with or without compensated cirrhosis.\",\"We assessed the broadly used, off-label combination of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral-experienced patients, as recommended in current guidelines despite scarce data. After 24 weeks' treatment, sustained virological response 12 weeks after the end of treatment was achieved in 6 patients (60%). Two cirrhotic patients relapsed and 2 discontinued treatment due to serious adverse events.\",\"The need to test for resistance associated substitutions (RAS) has been intensively debated in the past two years. In the absence of pangenotypic combinations, it seems reasonable that, if available, RAS testing in the NS5A gene at baseline for genotypes 1a and 3 may help to avoid overtreatment in terms of ribavirin usage and/or prolonged treatment duration. When patients fail treatment, RAS testing may also be useful to guide the selection of the new regimen, especially for those that need urgent retreatment and that have failed a combination including an NS5A inhibitor. However, there are new drugs in the pipeline that in combination are pangenotypic, very potent and with a high genetic barrier to resistance. In this new scenario, RAS testing may not play such an important role.\",\"Nucleoside analogues are among the most known drugs commonly used in antiviral and anticancer chemotherapies. Among them, those featuring a five-membered ring nucleobase are of utmost interest such as the anti-cancer agent AICAR or the anti-viral drug ribavirin. Despite its low activity in vitro in different cell lines, AICAR is under clinical development for several pathologies, thanks to its original mode of action. Indeed, AICAR induced autophagy cell death and is able, following this mechanism, to circumvent resistance to apoptotic drugs including kinase inhibitors currently on the market. To improve the activity of AICAR, we report herein an efficient synthesis of new series of sulfonamide-4-substituted-1,2,3-triazolyl nucleosides using a Cu-catalyzed 1,3-dipolar cycloaddition. All these molecules have been fully characterized and evaluated against two aggressive tumor cell lines, RCC4 and MDA-MB-231. Among them, nucleoside analogue 5i belonging to the ribose series was found to be 19 to 66-fold more active than AICAR. Western blot analyses on RCC4 cells showed that 5i displayed an interesting mode of action by inducing both apoptosis and autophagy cell death, making therefore this class of molecules highly promising for further hit-to-lead optimization.\",\"Hepatitis C is a leading cause of cirrhosis and hepatocellular carcinoma responsible for almost 700,000 deaths worldwide annually. Until 2014, management of HCV infections was based on interferon alfa containing regimens, with efficacy of 40-70% and a high adverse event rate. Interferon-free therapeutic options improved sustained viral response (SVR) rate to >90% and safety profile to placebo-like levels. Areas covered: This article describes all-oral regimen consisting of three direct acting antivirals (DAA) - ombitasvir (OBV), paritaprevir (PTV) and dasabuvir (DSV), which in clinical practice is boosted with ritonavir (r) and sometimes with ribavirin (RBV). This combination is registered for treatment of patients infected with HCV genotype 1 and 4. We focused on the regimen characteristics, pharmacokinetics, risk of resistance as well as efficacy and safety in clinical trials and real world studies. Expert commentary: Combination of OBV/PTV/r\\u00b1DSV\\u00b1RBV provides SVR rate of about 95% and good safety profile even in patients with compensated liver cirrhosis and failure with previous therapy. Currently it should be of particular value in areas with a predominance of genotype 1b infections. Due to the complexity and risk of drug to drug interactions, it will probably be replaced in coming few years with pangenotypic combinations of next generation DAAs.\",\"The optimal retreatment regimen for patients with hepatitis C virus (HCV) infection who failed interferon-free, direct-acting antiviral (DAA) therapy is undetermined. In this study, we aimed to evaluate the efficacy and safety of 12-week retreatment with ledipasvir (LDV) and sofosbuvir (SOF) with add-on ribavirin (RBV) for patients who previously failed to respond to HCV-NS5A inhibitor, daclatasvir (DCV), and HCV-NS3 inhibitor, asunaprevir (ASV), therapy.\",\"Patients with genotype-1 hepatitis C virus infection who have failed to respond to standard therapy or who relapse following treatment may be considered for an interferon-free regimen incorporating a nonstructural protein 5A (NS5A) inhibitor. Sustained virologic response (SVR) with these regimens is typically >90%, but this is reduced in patients with NS5A resistance. European Association for Study of the Liver guidelines recommend simeprevir + sofosbuvir \\u00b1 ribavirin (SMV+SOF\\u00b1R) for re-treating patients failing an NS5A inhibitor-containing regimen. An alternative strategy would be to test for NS5A resistance prior to treatment, with therapy optimized based on the results. This study investigates the cost-effectiveness of this strategy.\",\"Sofosbuvir is a nucleoside analogue inhibitor of the HCV NS5B polymerase approved for treatment of HCV-infected patients in combination with ribavirin or with other antivirals. It has activity against all genotypes of HCV. Resistance to sofosbuvir in genotype-1 and -2 HCV is conferred by the S282T substitution in NS5B.\",\"Background NS3 protease inhibitors (PIs) were the first direct antiviral agents used for the treatment of hepatitis C virus. The combination of second-wave PIs with other direct antiviral agents enabled the use of interferon-free regimens for chronic kidney disease patients on dialysis and renal transplant (RTx) recipients, populations in which the use of interferon and ribavirin is limited. However, the occurrence of PI resistance-associated variants (RAVs), both baseline and induced by therapy, has resulted in the failure of many treatment strategies. Methods The aim of this study was to estimate the prevalence of PI RAVs and of the Q80K polymorphism in chronic kidney disease patients on hemodialysis and RTx recipients. Direct sequencing of the NS3 protease was performed in 67 patients (32 hemodialysis and 35 RTx).Results RAVs to PIs were detected in 18% of the patients: V55A (9%), V36L (1.5%), T54S (1.5%), S122N (1.5%), I170L (1.5%), and M175L (1.5%). Only 1.5% of the patients carried the Q80K polymorphism. The frequency of these mutations was more than two times higher in patients infected with GT1a (25%) than GT1b (9.7%) (P=0.1). The mutations were detected in 20% of treatment-naive patients and in 15.6% of peginterferon/ribavirin-experienced patients (P=0.64). Furthermore, no mutation that would confer high resistance to PIs was detected.Conclusion The Q80K polymorphism was rare in the population studied. The occurrence of RAVs was common, with predominance in GT1a. However, the variants observed were those associated with a low level of resistance to PIs, facilitating the use of these drugs in this special group of patients.\",\"We previously reported results of interferon (IFN)-free daclatasvir and asunaprevir for the treatment of recurrent hepatitis C virus (HCV) genotype 1 infection after liver transplantation (LT). Here we report three patients who achieved viral response with no effect on the blood concentrations of immunosuppressive agents following sofosbuvir plus ledipasvir treatment. The first patient was a 68-year-old female with HCV-related liver cirrhosis who failed to respond to pegylated-IFN and ribavirin (PEG-IFN/RBV) after living donor LT. She had been treated with 50 mg/day of cyclosporine. The second was a 63-year-old male with HCV-related liver cirrhosis and hepatocellular carcinoma who failed to respond to PEG-IFN/RBV after living donor LT. He had been treated with 50 mg/day of cyclosporine. The third was a 63-year-old female with HCV-related liver cirrhosis. She had been treated with tacrolimus. High alanine aminotransferase levels persisted after LT. Liver biopsy examination revealed active hepatitis or chronic rejection. Therefore, sofosbuvir plus ledipasvir therapy was started. However, the combination treatment was stopped at 4 weeks due to development of interstitial pneumonia. Serum HCV RNA became negative at the time treatment was discontinued and remained negative 12 weeks after cessation of therapy in all three cases. Sofosbuvir plus ledipasvir treatment showed a remarkable viral response with little effect on blood levels of immunosuppressive agents for recurrent HCV genotype 1 infection after LT.\",\"Treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. Indication of therapy in patients with no contraindication is based on demonstration of viral replication with consequent inflammation and/or fibrosis in the liver. Non-invasive methods (elastographies and biochemical methods) are preferred for liver fibrosis staging. The budget allocated for these patients is limited. Therefore, expensive novel direct acting antiviral combinations as first line treatment are reimbursed only, if the freely available, but less effective and more toxic pegylated interferon plus ribavirin dual therapy deemed to prone high chance of adverse events and/or low chance of cure. Priority is given to those with urgent need based on a pre-defined scoring system reflecting mainly the stage of the liver disease, but considering also additional factors, i.e., hepatic decompensation, other complications, activity and progression of liver disease, risk of transmission and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virological response value in different patient categories with consensus amongst treating physicians, the National Health Insurance Fund and patient's organizations. Interferon-free treatments and shorter therapy durations are preferred. Orv. Hetil., 2017, 158(Suppl. 1), 3-22.\",\"Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and decompensation. We analyzed the effects of the direct-acting antiviral agents elbasvir and grazoprevir in patients with HCV infection and compensated cirrhosis, combining data from 6 clinical trials.\",\"Relapse of hepatitis C virus (HCV) genotype 1 infection after combination therapy with sofosbuvir and ledipasvir is unusual. We report a treatment-na\\u00efve, non-cirrhotic patient in whom the relapse of genotype 1b HCV infection was accompanied by de novo cryoglobulinemic vasculitis and glomerulonephritis, requiring hemodialysis for acute renal failure. Sequence analysis revealed several resistance-associated variants in the HCV NS5a gene but not in NS3/4A. The patient's vasculitis was successfully treated with immunosuppression and plasmapheresis, followed by retreatment of HCV with a combination of sofosbuvir, simeprevir, and ribavirin. The patient achieved sustained virological response, recovered his renal function, and remains in remission from cryoglobulinemia.\",\"Favipiravir (T-705) is a new antiviral drug with strong inhibitory activity on RNA-dependent RNA polymerase of most RNA virus genome. All the influenza viruses have been shown fully sensitive to this new antiviral, including genetic strains to neuraminidase inhibitors (oseltamivir) resistance. Its mechanism of action lies in blocking viral replication and induction of lethal mutagenesis which determines the loss of infective activity of influenza viruses. Its activity is particularly intense in the respiratory tract, decreasing the viral load to non-infectious levels. Clinical trials in humans have not yet completed but have very favourable results. It seems that the best therapy would be the combination of favipiravir with oseltamivir; both antivirals are synergistic and avoid the emergence of resistance.\",\"The current medical treatment for hepatitis C virus (HCV) infection is pegylated interferon plus ribavirin, but just 50% of genotype 1 HCV patients and about 80% of HCV genotype 3 patients are treated completely. Recently, the rs12979860 C/T polymorphism, which is located 3 kb upstream of the IL28b gene that codes IFN\\u03bb3, shows a powerful association in response to the treatment in HCV patients.\",\"Among patients with chronic hepatitis C, 20-30% develop hepatic cirrhosis and its complications within 30 years. The antiviral treatment of hepatitis C, previously interferon-based, has recently become inter - feron-free, with resulting improvements in sustained virological response rates, safety, and tolerability and a shorter duration of treatment.\",\"The optimal therapy for recurrent hepatitis C virus (HCV) infection after liver transplantation has not yet been established. This study aimed to clarify the efficacy and safety of interferon-free therapy with sofosbuvir and ledipasvir without ribavirin for 12 weeks in Japanese patients with HCV genotype 1b infection after living donor liver transplantation.\",\"Although direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high rates of sustained virologic response, virologic failure may still occur, potentially leading to the emergence of viral resistance, which can decrease the effectiveness of subsequent treatment. Treatment options for patients who failed previous DAA-containing regimens, particularly those with nonstructural protein 5A inhibitors, are limited and remain an area of unmet medical need. This phase 2, open-label study (MAGELLAN-1) evaluated the efficacy and safety of glecaprevir (GLE) + pibrentasvir (PIB) \\u00b1 ribavirin (RBV) in HCV genotype 1-infected patients with prior virologic failure to HCV DAA-containing therapy. A total of 50 patients without cirrhosis were randomized to three arms: 200 mg GLE + 80 mg PIB (arm A), 300 mg GLE + 120 mg PIB with 800 mg once-daily RBV (arm B), or 300 mg GLE + 120 mg PIB without RBV (arm C). By intent-to-treat analysis, sustained virologic response at posttreatment week 12 was achieved in 100% (6/6, 95% confidence interval 61-100), 95% (21/22, 95% confidence interval 78-99), and 86% (19/22, 95% confidence interval 67-95) of patients in arms A, B, and C, respectively. Virologic failure occurred in no patients in arm A and in 1 patient each in arms B and C (two patients were lost to follow-up in arm C). The majority of adverse events were mild in severity; no serious adverse events related to study drug and no relevant laboratory abnormalities in alanine aminotransferase, total bilirubin, or hemoglobin were observed.\",\"GS-9256 is an inhibitor of HCV NS3 protease with a macrocyclic structure and novel phosphinic acid pharmacophore.\",\"Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures.\",\"Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12 weeks after the end of treatment (SVR12) across five clinical trials in subjects infected with chronic hepatitis C virus (HCV) genotype 1, including those with advanced chronic kidney disease (CKD), and GT4. Despite favorable results overall, the US Food and Drug Administration (FDA) encountered challenging regulatory issues due to the limitations of clinical trial data in certain subpopulations. In GT1a-infected subjects, baseline NS5A resistance-associated polymorphisms emerged as the strongest baseline characteristic associated with diminished SVR12 rates following 12 weeks of elbasvir/grazoprevir treatment. The decision for recommending 16 weeks of elbasvir/grazoprevir + ribavirin in this population and for extrapolating these recommendations to patients with advanced CKD was based on benefit-versus-risk analyses using the available data. Conversely, FDA had insufficient data to define a specific elbasvir/grazoprevir treatment regimen for GT1a-infected subjects with baseline NS5A resistance-associated polymorphisms who failed prior treatment with pegylated interferon + ribavirin (PR) and either boceprevir, simeprevir, or telaprevir. For GT4 PR-experienced patients, leveraging of data in related populations and additional pooled analyses were employed to support labeling for elbasvir/grazoprevir. This article describes FDA's rationale for labeling determinations in situations where limited data made these decisions challenging.\",\"Viral hepatitis, an inflammatory liver disease, is caused by various genotypes of hepatitis C viruses (HCV). Hepatitis C slowly sprouts into fibrosis, which progresses to cirrhosis. Over a prolonged period of time compensated cirrhosis can advance to decompensated cirrhosis culminating in hepatic failure and death. Conventional treatment of HCV involves the administration of interferons. However, association of interferon with the adverse drug reactions led to the development of novel anti-HCV drugs given as monotherapy or in combination with the other drugs. Advances in drug delivery systems (DDS) improved the pharmacokinetic profile and stability of drugs, ameliorated tissue damages on extravasation and increased the targeting of affected sites. Liposomes and lipid based vehicles have been employed with polyethylene glycol (PEG) so as to stabilize the formulations as PEG drug complex. Sofosbuvir, a novel anti-HCV drug, is administered as monotherapy or in combination with daclatasvir, ledipasivir, protease inhibitors, ribavirin and interferon for the treatment of HCV genotypes 1, 2 and 3. These drug combinations are highly effective in eradicating the interferon resistance, recurrent HCV infection in liver transplant, concurrent HIV infection and preventing interferon related adverse effects. Further investigations to improve drug targeting and identification of new drug targets are highly warranted due to the rapid emergence of drug resistance in HCV.\",\"Direct-acting antiviral (DAA) combinations are potent and effective drugs currently recommended for treatment of chronic HCV infection. Difficult to treat genotypes are the most important predictors of treatment failure. We report a case of DAA treatment failure in an HCV-infected patient carrying a recombinant genotype 2k/1b. This strain, first isolated from a Russian patient in 2002, has now been observed for the first time in Italy.\",\"The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). Most HCV patients treated with these drugs achieve viral elimination, but 1% to 15% fail to attain this objective. Treatment failures are usually related to relapse, and less often to on-treatment viral breakthrough. HCV drug resistant associated substitutions are detected in most patients who do not eliminate the virus. The risk of developing these variants depends on host- and virus-related factors, the properties of the drugs used, and the treatment strategies applied. Patients who carry Resistant Associated Substitutions (RASs) may not obtain benefits from treatment, and are at a risk of disease progression. Whether HCV RASs persist depends on their type: NS3-4A variants often disappear gradually after DAA therapy is stopped, whereas NS5A variants tend to persist for more than 2 years. The best way to prevent emergence of resistant variants is to eliminate the virus at the first treatment using highly potent DAAs with genetic barriers to resistance. For those who fail an NS5A inhibitor, deferral of treatment is recommended pending the availability of additional data if they do not have cirrhosis or reasons for urgent re-treatment. If re-treatment is needed, the most commonly used strategy is sofosbuvir as backbone therapy plus a drug from a class other than that previously used, for 24 weeks. Unless it is contraindicated, weight-based ribavirin should also be added. If available, nucleotide-based (eg, sofosbuvir) triple or quadruple DAA regimens may be considered. The optimal treatment for patients who fail an NS5A inhibitor and those with multidrug-resistant variants remains to be defined, and research efforts should continue to focus on treatment for these patients.\",\"Respiratory viruses (influenza, parainfluenza, respiratory syncytial virus, coronavirus, human metapneumovirus, and rhinovirus) represent the most common causes of respiratory viral infections in immunocompromised patients. Also, these infections may be more severe in immunocompromised patients than in the general population. Early diagnosis and treatment of viral infections continue to be of paramount importance in immunocompromised patients; because once viral replication and invasive infections are evident, prognosis can be grave. Areas covered: The purpose of this review is to provide an overview of the main antiviral agents used for the treatment of respiratory viral infections in immunocompromised patients and review of the new agents in the pipeline. Expert commentary: Over the past decade, important diagnostic advances, specifically, the use of rapid molecular testing has helped close the gap between clinical scenarios and pathogen identification and enhanced early diagnosis of viral infections and understanding of the role of prolonged shedding and viral loads. Advancements in novel antiviral therapeutics with high resistance thresholds and effective immunization for preventable infections in immunocompromised patients are needed.\",\"Single nucleotide polymorphisms (SNPs) within or near interferon lambda 4 (IFNL4) gene located upstream of IFNL3 are associated with response to anti-HCV therapy both in interferon (IFN)-based and IFN-free regimens. IFNL4 encodes IFN\\u03bb4, a newly discovered type III IFN, and its expression is controlled by rs368234815-TT/\\u0394G, which is in strong linkage disequilibrium (LD) with other tag SNPs within or near IFNL4 such as rs12979860 and rs8099917. Intrahepatic expression levels of IFN-stimulated genes (ISGs) affect the responsiveness to IFN\\u03b1 and are also associated with IFNL4 genotype. However, IFNL4 expressions and its role in intrinsic antiviral innate immunity remain unclear. This study evaluated the effect of IFNL4 on intrahepatic ISG expression and investigated its relationship with treatment outcomes in liver samples obtained from 49 chronic hepatitis C patients treated with pegylated (PEG)-IFN/ribavirin therapy. IFNL4 mRNA was detected in 11 of 22 patients with IFNL4-unfavorable SNPs but not in patients with favorable genotypes. IFNL4 expression was associated with non-response to PEG-IFN/ribavirin therapy. Intrahepatic expression of antiviral ISGs (ISG15 and MX1) was significantly higher in IFNL4-unfavorable patients with detectable IFNL4 mRNA than in patients with undetectable IFNL4 mRNA, whereas the expression of suppressive ISGs (RNF125, SOCS1, SOCS3, and RNF11) was lower in patients with detectable IFNL4 mRNA. In summary, intrahepatic expression of IFNL4 was associated with increased antiviral ISG expression and decreased suppressive ISG expression at baseline, resulting in poor responsiveness to IFN\\u03b1-based therapy in HCV infection.\",\"Influenza management and surveillance programs in Japan possess several unique features. The national influenza surveillance is affiliated with National Epidemiological Surveillance for Infectious Diseases (NESID) and features sentinel outpatient surveillance, virological surveillance, and reports on hospitalization, mortality, and influenza-associated encephalopathy. Of note, information on the number of student absences and class/grade/school closures due to influenza are also reported to the government and made publically available. A private online influenza surveillance portal by volunteer doctors provides a real-time information source for the Japanese clinicians and the general public. For influenza treatment, three classes of drugs are approved and covered by national medical insurance in Japan: M2 inhibitors, neuraminidase inhibitors (NAIs), and a polymerase inhibitor. Four NAIs, oseltamivir, zanamivir, laninamivir, and peramivir, are licensed in Japan and are prescribed to seven to eight million patients annually. NAIs are prescribed to any influenza outpatient rather than being limited to severe cases. The majority (80-95 %) of patients start the treatment within 48 h of onset. Laninamivir and peramivir were used almost solely in Japan, until the approval of the latter drug by the FDA. Observational studies showed that the two drugs have equal effectiveness as oseltamivir and zanamivir. The Japanese approach to influenza surveillance and management has facilitated bringing new influenza antivirals to the markets and has driven innovative research in this field. New classes of antivirals, including polymerase inhibitors and cap-dependent endonuclease inhibitor, provide novel tools for treatment of influenza in Japan and the rest of the world.\",\"Daclatasvir is a nonstructural protein 5A inhibitor with potent activity against hepatitis C virus genotypes 1-6 in vitro, and asunaprevir is a nonstructural protein 3 protease inhibitor with activity against genotypes 1, 4, 5, and 6. Despite a 90% sustained virologic response (SVR) rate, the SVR rate in patients with baseline NS5A-L31/Y93H polymorphisms decreased to around 40%. Therefore, an alternative regimen under the consideration of cost-effectiveness would be important. Whether the addition of ribavirin could improve the SVR rate among this group of patients remains unknown and hence our case series was reported.\",\"Treatment of hepatitis C virus (HCV) genotype 3 (GT3) is a medical priority. All-oral treatment of HCV GT3 with daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is recommended by several treatment guidelines. The impact of HCV minority populations at amino acid positions in NS5A and NS5B associated with drug resistance on response to DCV+SOF\\u00b1RBV was assessed in SOF-naive and SOF-experienced HCV patients.\",\"The development of direct-acting oral agents has dramatically changed the treatment strategy of hepatitis C virus (HCV) infection. Here we aimed to reveal the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) for recurrent HCV genotype 1 infection after liver transplantation (LT).\",\"Targeting bacterial virulence mechanisms without compromising bacterial growth is a promising strategy to prevent drug resistance. LysR-type transcriptional regulators (LTTRs) possess structural conservation across bacterial species and regulate virulence in numerous pathogens, making them attractive targets for antimicrobial agents. We targeted AphB, a Vibrio cholerae LTTR, which regulates the expression of genes encoding cholera toxin and toxin-co-regulated pilus for inhibitor designing. Since AphB ligand is unknown, we followed a molecular fragment-based approach for ligand designing using FDA-approved drugs and subsequent screen to identify molecules that exhibited high-affinity binding to AphB ligand-binding pocket. Among the identified compounds, ribavirin, an anti-viral drug, antagonized AphB functions. Ribavirin perturbed Vibrio cholerae pathogenesis in animal models. The inhibitory effects of the drug was limited to the bacteria expressing wild type AphB, but not its constitutively active mutant (AphBN100E), which represents the ligand-bound state, suggesting that ribavirin binds to the active site of AphB to exert its inhibitory role and there exists no AphB-independent mechanism of its action. Similarly, ribavirin suppressed the functions of Salmonella Typhi LTTR Hrg, indicating its broad spectrum efficacy. Moreover, ribavirin did not affect the bacterial viability in culture. This study cites an example of drug repurposing for anti-infective therapy.\",\"Ledipasvir/sofosbuvir combination treatment in phase III clinical trials resulted in sustained viral suppression in 94-99% of patients. This study characterized drug resistance in treatment failures, which may help to inform retreatment options.\",\"The presence of baseline NS5A resistance-associated variants (RAVs) impacted treatment response in HCV genotype 1a (GT1a)-infected patients treated with elbasvir/grazoprevir (EBR/GZR) for 12 weeks, but not patients treated with EBR/GZR and ribavirin (RBV) for 16 weeks.\",\"During the last 5 years, the availability of direct-acting antiviral (DAA) agents has revolutionized the treatment of hepatitis C virus (HCV). Compared with interferon/ribavirin-the previous standard of care-DAA combination regimens offer improved sustained virological response (SVR) rates, shorter treatment durations of 8-24 weeks, convenient once-daily single-tablet formulations and more favourable tolerability profiles. HCV treatment is complex, and the choice of therapy must consider a complex range of factors, including baseline viral load, fibrosis stage, the HCV genotype and subgenotype, and the presence of resistance-associated substitutions at baseline. Globally, HCV genotype 1 predominates, and there are extensive data and various treatment options available for this genotype. Genotypes 2-6 are prevalent and may even predominate in different geographical regions, reflecting diverse factors including human migration patterns and unsafe use of injection drugs and blood products. Such factors are themselves influenced by socio-economic factors, and poor regions often have the greatest unmet need for effective HCV therapies. The latest pan-genotypic DAA combination regimens provide the potential to eradicate HCV around the globe, regardless of genotype, hence minimizing the need for virological testing services, which often are unavailable in poorer regions. Economics inevitably remain a barrier to access, and extensive cooperation will be required between clinical organisations and pharmaceutical manufacturers to agree appropriate pricing policies, especially in poorer economic regions. This review considers key data and treatment guidelines for DAA therapies, including pan-genotypic combination regimens, in the context of regional differences in HCV genotype and socio-economic factors.\",\"Treatment of patients with chronic hepatitis C who failed the triple therapy with first generation of protease inhibitors is not still defined. The combined use of sofosbuvir (SOF) and daclatasvir (DCV) seems to be promising due to higher genetic barrier, good tolerance and effectiveness.\",\"Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney transplant recipients is limited because of the risk for allograft rejection and poor tolerability.\",\"The efficacy of direct-acting antiviral agents (DAAs) could be attenuated by the presence of resistance-associated variants (RAVs). The aim of this study was to investigate the natural prevalence of RAVs among Chinese HCV genotype 1b patients and analyze the efficacy of pegylated interferon (PegIFN)/ribavirin (RBV) therapy in patients with and without RAVs at baseline.\",\"This review paper summarizes the epidemiology of hepatitis C virus (HCV) and chronic HCV infection, including HCV virology and treatment regimens. Specifically, we focus on the evolution of past, current, and future HCV treatment options, the reasons for treatment failure, and the impact of resistance-associated variants on treatment success.\",\"The rapid evolution of drug resistance remains a critical public health concern. The treatment of influenza A virus (IAV) has proven particularly challenging, due to the ability of the virus to develop resistance against current antivirals and vaccines. Here, we evaluate a novel antiviral drug therapy, favipiravir, for which the mechanism of action in IAV involves an interaction with the viral RNA-dependent RNA polymerase resulting in an effective increase in the viral mutation rate. We used an experimental evolution framework, combined with novel population genetic method development for inference from time-sampled data, to evaluate the effectiveness of favipiravir against IAV. Evaluating whole genome polymorphism data across 15 time points under multiple drug concentrations and in controls, we present the first evidence for the ability of IAV populations to effectively adapt to low concentrations of favipiravir. In contrast, under high concentrations, we observe population extinction, indicative of mutational meltdown. We discuss the observed dynamics with respect to the evolutionary forces at play and emphasize the utility of evolutionary theory to inform drug development.\",\"Vaniprevir is a macrocyclic hepatitis C virus (HCV) non-structural (NS)3/4A protease inhibitor. The objective of these phase 3 multicenter, open-label trials was to evaluate the safety and efficacy of vaniprevir + peginterferon alfa-2b + ribavirin (PR) in Japanese patients with HCV genotype (GT)1 infection who had previously failed treatment with interferon-based regimens.\",\"Simeprevir (SMV)-based triple therapy is an effective retreatment option following failure of telaprevir (TVR)-based triple therapy. However, it is unclear whether the persistence of resistance-associated variants (RAVs) induced by TVR-based therapy may reduce the treatment effect of SMV-based therapy.\",\"Elbasvir (an NS5A inhibitor) and grazoprevir (an NS3/4A protease inhibitor) are direct-acting antiviral agents recently approved in the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infections, as a fixed-dose combination. Trials of elbasvir and grazoprevir, with or without ribavirin, demonstrated high rates of sustained virologic response 12 weeks after treatment ended (SVR12). However, 12 weeks of treatment with elbasvir and grazoprevir failed in a small proportion of patients with HCV genotype 1 infection. We summarize findings from independent US Food and Drug Administration analyses of drug resistance data from trials of elbasvir and grazoprevir, with and without ribavirin.\",\"Influenza viruses cause seasonal epidemics and pandemic outbreaks associated with significant morbidity and mortality, and a huge cost. Since resistance to the existing anti-influenza drugs is rising, innovative inhibitors with a different mode of action are urgently needed. The influenza polymerase complex is widely recognized as a key drug target, given its critical role in virus replication and high degree of conservation among influenza A (of human or zoonotic origin) and B viruses. We here review the major progress that has been made in recent years in unravelling the structure and functions of this protein complex, enabling structure-aided drug design toward the core regions of the PA endonuclease, PB1 polymerase, or cap-binding PB2 subunit. Alternatively, inhibitors may target a protein-protein interaction site, a cellular factor involved in viral RNA synthesis, the viral RNA itself, or the nucleoprotein component of the viral ribonucleoprotein. The latest advances made for these diverse pharmacological targets have yielded agents in advanced (i.e., favipiravir and VX-787) or early clinical testing, besides several experimental inhibitors in various stages of development, which are all covered here.\",\"In this Phase IIIb study, we evaluated the efficacy and safety of the oral nucleotide analogue inhibitor sofosbuvir plus ribavirin, with special attention given to viral resistance, in Russian patients with HCV genotype-1 or -3.\",\"Hepatitis E virus (HEV), an important agent of viral hepatitis worldwide, can cause severe courses of infection in pregnant women and immunosuppressed patients. To date, HEV infections can only be treated with ribavirin (RBV). Major drawbacks of this therapy are that RBV is not approved for administration to pregnant women and that the virus can acquire mutations, which render the intra-host population less sensitive or even resistant to RBV. One of the proposed modes of action of RBV is a direct mutagenic effect on viral genomes, inducing mismatches and subsequent nucleotide substitutions. These transition events can drive the already error-prone viral replication beyond an error threshold, causing viral population extinction. In contrast, the expanded heterogeneous viral population can facilitate selection of mutant viruses with enhanced replication fitness. Emergence of these mutant viruses can lead to therapeutic failure. Consequently, the onset of RBV treatment in chronically HEV-infected individuals can result in two divergent outcomes: viral extinction versus selection of fitness-enhanced viruses. Following an overview of RNA viruses treated with RBV in clinics and a summary of the different antiviral modes of action of this drug, we focus on the mutagenic effect of RBV on HEV intrahost populations, and how HEV is able to overcome lethal mutagenesis.\",\"The prevalence of anti-hepatitis C virus (HCV)antibodies is higher in hemodialysis patients than in the general population, and several studies have reported poor vital prognosis in HCV-infected dialysis patients because infection with HCV is not only the cause of cirrhosis and hepatocellular carcinoma, but also a risk factor for cardiovascular disease. Although sustained virologic response (SVR) is achievable with interferon and ribavirin in dialysis patients, SVR rates are lower, and the use of ribavirin is challenging because of the risk of hemolytic anemia. Recently, interferon-ribavirin free direct acting antivirals (DAAs) treatment has shown strong efficacy and fewer adverse events for chronic HCV infection patients without using dialysis, but there are few reports about DAAs for such patients. Thus, we conducted a study to examine the effect and safety of daclatasvir and asunaprevir in chronic hepatitis C virus genotype 1b-infected hemodialysis patients. We treated 10 patients: seven males and three females. Before treatment, we detected resistance-associated variants on the NS5A region, which is the L31M site variant, in two patients. Although two patients showed resistance-associated variant, all the patients showed quick disappearance of HCV RNA in the serum and achieved a SVR12. During this therapy, no patients displayed abnormal liver function during treatment. Two patients experienced diarrhea and another one patient complained of nausea soon after treatment but these were relieved by symptomatic therapy. We report good results of treatment for chronic hepatitis C virus genotype 1b -infected patients on hemodialysis with all oral DAAs (daclatasvir and asunaprevir).\",\"Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) have potent anti-HCV effects but may provoke resistance-associated variants (RAVs). In this study, we assessed the characteristics of these RAVs and explored efficacious anti-HCV reagents using recombinant HCV with NS5A from a genotype 1b strain. We replaced the NS5A of JFH1 with that of Con1 (JFH1/5ACon1) and introduced known NS5A inhibitor resistance mutations (L31M, L31V, L31I and Y93H) individually or in combination. Susceptibilities against anti-HCV reagents were also investigated. RAVs with Y93H exhibited high extracellular core antigen levels and infectivity titers. Variants with any single mutation showed mild to moderate resistance against NS5A inhibitors, whereas variants with double mutations at both L31 and Y93 showed severe resistance. The variants with mutations exhibited similar levels of susceptibility to interferon (IFN)-\\u03b1, IFN-\\u03bb1, IFN-\\u03bb3 and Ribavirin. Variants with the Y93H mutation were more sensitive to protease inhibitors compared with JFH1/5ACon1. In conclusion, the in vitro analysis indicated that the Y93H mutation enhanced infectious virus production, suggesting advantages in the propagation of RAVs with this mutation. However, these RAVs were susceptible to protease inhibitors. Thus, a therapeutic regimen that includes these reagents is a promising means to eradicate these RAVs.\",\"Simeprevir is a hepatitis C virus NS3/4A protease inhibitor. Hepatitis C virus baseline NS3/4A polymorphisms and emerging mutations were characterized in treatment-na\\u0457ve and treatment-experienced genotype 4-infected patients treated with simeprevir+peginterferon/ribavirin in the RESTORE study. Population sequencing of the NS3/4A region was performed and in vitro simeprevir activity against site-directed mutants or chimeric replicons with patient-derived NS3 protease sequences was assessed in a transient replicon assay. Simeprevir remained active against most (83/91 [91%]) baseline isolates tested in the chimeric replicon assay. Eight baseline isolates reduced simeprevir activity; these carried I132L or D168E substitutions reducing simeprevir median activity by 4.6- and 39-fold, respectively. Six of these eight isolates were from patients achieving sustained virologic response. Baseline NS3 Q80K polymorphism was not observed in the genotype 4-infected patients. Of the 107 simeprevir-treated patients, 37 did not achieve sustained virologic response for any reason. Of the 32 patients who failed treatment and had sequencing information, 28 (88%) had emerging mutations at NS3 positions 80, 122, 155, 156 and/or 168 at time of failure, similar to those in genotype 1. Emerging mutations were mainly D168V and D168E alone or combined with mutations at position 80. In general, isolates obtained at time of failure displayed high-level in vitro resistance to simeprevir (fold change \\u226550) in a chimeric replicon assay with a median simeprevir fold change value of 440, consistent with observed mutations. In conclusion, emerging mutations in genotype 4 patients failing simeprevir+peginterferon/ribavirin treatment were similar to those in genotype 1 and conferred high-level resistance to simeprevir.\",\"Within HIV-positive men having sex with men, the epidemic of hepatitis C virus (HCV) is ongoing. Transmission of resistant variants of HCV after failure of treatment with directly acting antivirals (DAA) could be a major threat to the effectivity of therapy. We determined whether HCV-resistant variants to DAAs were prevalent amongst patients with an acute HCV infection diagnosed in 2013 and 2014 in the Netherlands.\",\"Sofosbuvir/ledipasvir (SOF/LDV) is the first all-oral ribavirin-free treatment approved for chronic hepatitis C virus (HCV) genotype 6, offering a safe and highly efficacious treatment option. Large studies evaluating real-world outcomes of this regimen are lacking. We aim to evaluate real-world treatment outcomes for HCV genotype 6. A retrospective cohort study evaluated 65 adults (age \\u226518) with chronic HCV genotype 6 treated with SOF/LDV without ribavirin at a community gastroenterology clinic in the United States from November 2014 to May 2016. Rates of undetectable virus at week 4 on treatment, at end of treatment (EOT) and SVR12 were stratified by the presence of cirrhosis and prior treatment (treatment na\\u00efve vs treatment experienced). Among 65 patients with chronic HCV genotype 6 treated with SOF/LDV (52.3% male, mean age 66.3 years [SD 9.7], 41.5% cirrhosis and 15.4% treatment experienced), 97.3% had undetectable virus at week 4 on treatment, 96.9% had undetectable virus at EOT and 95.3% achieved SVR12. SVR12 was 100% in females vs 91.2% in males, P=.096, and 92.3% in patients with cirrhosis vs 97.4% in those without cirrhosis, P=.347. Resistance testing of treatment failures was attempted but unsuccessful due to lack of conforming primers to define the possible resistance mutations. Among the largest U.S. community-based real-world cohort of Asian chronic HCV genotype 6 patients treated with all-oral SOF/LDV without ribavirin, SVR12 was similar to SVR12 reported in clinical trials, confirming the safety and effectiveness of this regimen and validating current HCV genotype 6 treatment guideline recommendations.\",\"To gather data on the antiviral efficacy and safety of second generation direct acting antiviral (DAA) treatment with respect to sustained virological response (SVR) 12 wk after conclusion of treatment, and to determine predictors of SVR12 in this setting.\",\"Hepatitis C virus (HCV) is unique among RNA viruses in its ability to establish chronic infection in the majority of exposed adults. HCV persists in the liver despite interferon (IFN)-stimulated gene (ISG) induction; robust induction actually predicts treatment failure and viral persistence. It is unclear which forms of HCV RNA are associated with ISG induction and IFN resistance during natural infections. To thoroughly delineate HCV RNA populations, we developed conditions that fully separate the strands of long double-stranded RNA (dsRNA) and allow the released RNAs to be quantified in reverse transcription/polymerase chain reaction assays. These methods revealed that dsRNA, a pathogen-associated molecular pattern (PAMP), comprised 52% (standard deviation, 28%) of the HCV RNA in the livers of patients with chronic infection. HCV dsRNA was proportionally higher in patients with the unfavorable IL28B TT (rs12979860) genotype. Higher ratios of HCV double-stranded to single-stranded RNA (ssRNA) correlated positively with ISG induction. In Huh-7.5 cells, IFN treatment increased the total amount of HCV dsRNA through a process that required de novo viral RNA synthesis and shifted the ratio of viral dsRNA/ssRNA in favor of dsRNA. This shift was blocked by ribavirin (RBV), an antiviral drug that reduces relapse in HCV patients. Northern blotting established that HCV dsRNA contained genome-length minus strands.\",\"With the latest all-oral interferon- and ribavirin-free regimens based on direct acting antivirals against the hepatitis C virus (HCV), sustained virological response rates of >90% are achieved, which is equivalent to cure. This has become possible for all genotypes and all subgroups of patients, including many of the most difficult-to-treat populations so far. Since a prophylactic HCV vaccine is not yet available, control of HCV infection will for the time being have to rely on the use of effective and safe antiviral treatments as well as their accessibility and affordability. Different approaches may apply to different parts of the world, eradication of HCV representing a major long-term goal. Whether hepatitis C becomes the first chronic viral infection to be eradicated without a prophylactic vaccine remains to be shown. Here, we briefly summarize advances in the molecular virology of hepatitis C, highlight lessons of biological relevance that were learned through the study of HCV, and its translational and clinical implications. We have also listed selected unsolved challenges, emphasizing that HCV is a unique model and that advances in this direction may yield knowledge of broad biological significance, novel technologies and insights into related important human pathogens.\",\"Hepatitis C virus (HCV) is considered a major public health problem, with 200 million people infected worldwide. The treatment for HCV chronic infection with pegylated interferon alpha plus ribavirin inhibitors is unspecific; consequently, the treatment is effective in only 50% of patients infected. This has prompted the development of direct-acting antivirals (DAA) that target virus proteins. These DAA have demonstrated a potent effect in vitro and in vivo; however, virus mutations associated with the development of resistance have been described.\",\"The use of direct-acting antivirals (DAAs) to treat chronic hepatitis C has resulted in a significant increase in rates of sustained viral response (around 90%-95%) as compared with the standard treatment of peginterferon/ribavirin. Despite this, however, the rates of therapeutic failure in daily clinical practice range from 10%-15%. Most of these cases are due to the presence of resistant viral variants, resulting from mutations produced by substitutions of amino acids in the viral target protein that reduce viral sensitivity to DAAs, thus limiting the efficacy of these drugs. The high genetic diversity of hepatitis C virus has resulted in the existence of resistance-associated variants (RAVs), sometimes even before starting treatment with DAAs, though generally at low levels. These pre-existing RAVs do not appear to impact on the sustained viral response, whereas those that appear after DAA therapy could well be determinant in virological failure with future treatments. As well as the presence of RAVs, virological failure to treatment with DAAs is generally associated with other factors related with a poor response, such as the degree of fibrosis, the response to previous therapy, the viral load or the viral genotype. Nonetheless, viral breakthrough and relapse can still occur in the absence of detectable RAVs and after the use of highly effective DAAs, so that the true clinical impact of the presence of RAVs in therapeutic failure remains to be determined.\",\"During 2011 and 2013, 155 Hungarian hepatitis C genotype 1 infected patients, mostly with advanced liver fibrosis, who did not respond to prior peginterferon + ribavirin dual therapy, started boceprevir based triple therapy in an early access program.\",\"The resistance profile of anti-hepatitis C virus (HCV) agents used in combination is important to guide optimal treatment regimens. We evaluated baseline and treatment-emergent NS3/4A and NS5B amino-acid variants among HCV genotype (GT)-1a and -1b-infected patients treated with faldaprevir (HCV protease inhibitor), deleobuvir (HCV polymerase non-nucleoside inhibitor), and ribavirin in multiple clinical studies.\",\"Clinical trials of all-oral direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection reported high response rates in HCV/HIV coinfection, similar to those obtained in HCV monoinfection. We evaluated the safety and efficacy of these regimens in a clinical practice setting.\",\"Herein we report a previously undescribed case of treatment-emergent non-structural protein 5A (NS5A) resistance mutations, Q30H and Y93C, leading to a failure of 24-week course of sofosbuvir/ledipasvir+ribavirin therapy for the treatment of hepatitis C virus (HCV) genotype 1a in interferon-experienced, human immunodeficiency virus type 1 (HIV-1) co-infected patient with cirrhosis.\",\"Hepatitis C virus (HCV) is a major cause of global morbidity and mortality, with an estimated 130-150 million infected individuals worldwide. HCV is a leading cause of chronic liver diseases including cirrhosis and hepatocellular carcinoma. Current treatment options in developing countries involve pegylated interferon-\\u03b1 and ribavirin as dual therapy or in combination with one or more direct-acting antiviral agents (DAA). The emergence of resistance-associated variants (RAVs) after treatment reveals the great variability of this virus leading to a great difficulty in developing effective antiviral strategies. Baseline RAVs detected in DAA treatment-na\\u00efve HCV-infected patients could be of great importance for clinical management and outcome prediction. Although the frequency of naturally occurring HCV NS3 protease inhibitor mutations has been addressed in many countries, there are only a few reports on their prevalence in South America. In this study, we investigated the presence of RAVs in the HCV NS3 serine protease region by analysing a cohort of Uruguayan patients with chronic hepatitis C who had not been treated with any DAAs and compare them with the results found for other South American countries. The results of these studies revealed that naturally occurring mutations conferring resistance to NS3 inhibitors exist in a substantial proportion of Uruguayan treatment-na\\u00efve patients infected with HCV genotype 1 enrolled in these studies. The identification of these baseline RAVs could be of great importance for patients' management and outcome prediction in developing countries.\",\"Hepatitis C virus (HCV), the major etiologic agent of \\\"non-A, non-B hepatitis\\\" was discovered 26 years ago. Even before its discovery, interferon-\\u03b1 (IFN) was already being used for treatment of this infection. The next two decades saw a series of incremental improvements of the IFN therapies by extending the duration of therapy, using IFN in combination with oral ribavirin, using pegylated IFN with ribavirin, and most recently adding oral compounds that inhibit the HCV replication (directly acting antivirals - DAAs) to that regimen. DAAs target multiple steps in the HCV life cycle and are now used in combination to treat HCV infection without the need of IFN. These IFN-free, oral DAAs regimens are highly efficacious, have minimal toxicity and are given for short duration. Approved DAAs can cure more then 90% of persons with chronic HCV infection, thereby reducing the risk of death from cirrhosis and hepatocellular carcinoma. However, these drugs are very expensive, and currently their exorbitant cost significantly restricts the access to this therapy for many HCV infected patients.\",\"Hepatitis B and C viruses (HBV and HCV), both cause serious chronic infections leading to fatal liver diseases. The prototype therapy for both HBV and HCV was based on IFN-\\u03b1 with or without ribavirin. The advent of direct-acting antivirals (DAA) for both HBV and HCV has remarkably improved the standard of treatment for both infections. While HCV can be eliminated following combination DAA therapy, HBV persists even after treatment, requiring life-long therapy with DAAs. Treatment with DAAs is also associated with high cost, the development of resistance and side effects. There is ample published evidence that both HBV and HCV can be eliminated from infected host cells through non-cytolytic immune mechanisms. We need to identify the mechanisms behind this successful elimination of replicating viruses and develop them into novel immunotherapeutic regimens. Moreover, a synergy of, chemo- and immuno-therapeutic strategies will be necessary to eradicate HBV or HCV from a host.\",\"Interleukin-23 (IL-23) and its downstream factor IL-17 are the key cytokines involved in immune and inflammatory response in chronic liver diseases. This study aimed to investigate the role and molecular mechanisms of the IL-23/Th17 axis in chronic hepatitis C virus (HCV) infection, and the efficacy of IL-23/Th17 modulation in response to anti-HCV therapy. Sixty-six HCV-infected patients and 20 healthy controls were enrolled. The patients received PegIFNa-2a and ribavirin therapy for at least 48 weeks. The plasma level of IL-23 and the number of IL-17A-, IFN-\\u03b3-, and IL-21-producing peripheral blood mononuclear cells (PBMCs) at baseline and 12, 24, and 48 weeks following treatment were determined. The mRNA level of Th17 immune-associated molecules in PBMCs was evaluated by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) following treatment with IL-23 agonist or antagonist. Our data showed that, compared to healthy controls, HCV-infected patients had an increased plasma level of IL-23 and increased frequencies of IL-17A- and IFN-\\u03b3-producing PBMCs, whereas the HCV patients exhibited a reduced number of IL-21-producing PBMCs. However, the baseline frequencies of IL-21-producing PBMCs were markedly higher in HCV patients who achieved rapid virological response (RVR) than those without RVR. Additionally, the mRNA expressions of IL-21, IFN-\\u03b3, myxovirus resistance protein A (MxA), and suppressor of cytokine signaling 3 (SOCS3) were significantly upregulated in PBMCs, while FoxP3 expression was suppressed by IL-23 agonist. Thus, the IL-23/Th17 axis plays an important role in development of chronic HCV infection and antiviral response. IL-23 may enhance the antiviral activity of interferon-based therapy by modulating the expression of Th17 cells-associated molecules in HCV-infected patients.\",\"Treatment of chronic hepatitis C infection is most urgent in patients with severe liver fibrosis and cirrhosis because of the high risk of decompensation, hepatocellular carcinoma, and consecutively death. The development and approval of several direct-acting antiviral drugs (DAA) in the past years has revolutionized antiviral therapy especially for patients with liver cirrhosis.\",\"Chronic hepatitis C virus (HCV) infection is a major public health problem at a global level, causing an enormous burden of hepatic and extra-hepatic morbidity and mortality. Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. For such reason interferon-free regimens are now the treatments of choice for all patients. Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-related extra hepatic manifestations, eventually reducing both liver-related and overall mortality. Together with the rapidly accumulating data about the evolution of treatment landscape, different guidelines from national and international Liver Scientific Societies have been published until today. However, these recommendations may not be applied worldwide as, due to high treatment costs, most of them identify as priority groups only patients with advanced liver disease. Moreover some types of patients pose clinical management problems for which even the guidelines do not always provide useful answers. With the aim of treatment optimization by filling some of the gaps of the current guidelines and addressing the remaining unmet needs in practice, a group of Italian experts, experienced on treatment of HCV infection, met in Stresa in February 2016. The summary of all the considerations arising from this two-day meeting and the final statements are reported in this position paper.\",\"Effective treatment with direct-acting antiviral drugs against hepatitis C virus (HCV) is a medical need in cirrhotic HIV-HCV co-infected patients.\",\"The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy and safety of DCV and ASV for HCV in real-life practice.\",\"Daclatasvir (Daklinza\\u2122), a new oral direct-acting antiviral, is an inhibitor of hepatitis C virus NS5A protein and has recently been approved in the United States, Europe and Japan in chronic hepatitis C. It shows potent pangenotypic activity and moderately high genetic barrier to resistance improving the sustained virological response (SVR) rates. In COMMAND phase 2 trials, daclatasvir demonstrated high SVR rates in HCV genotype 1-4 chronically infected patients treated with peginterferon-a (pegIFN\\u03b1) plus ribavirin (RBV). Furthermore, it produced even higher response rates in all-oral combination with sofosbuvir, an interferon-free regimen, with or without ribavirin, in patients with advanced liver disease, HCV/HIV coinfection, liver transplantation in ALLY studies and other real-world studies. This narrative review provides information on the pharmacological properties, role, efficacy and safety of daclatasvir-containing regimens in chronic hepatitis C patients. Daclatasvir administered once-daily in combination with sofosbuvir is an effective 12-week treatment in adult patients with chronic hepatitis C and is generally safe and well tolerated.\",\"Therapies for hepatitis C (HCV) are evolving rapidly with the advent of novel direct-acting antiviral agents (DAAs). We review evidence for currently or imminently available regimens to aide clinicians in understanding current therapeutic options.\",\"Genotype 4 hepatitis C virus (HCV) was considered difficult to treat in the era of pegylated interferon-alpha (Peg-IFN-\\u03b1) and ribavirin regimens. We evaluated the efficacy and safety of therapy with the nonstructural (NS) 5A inhibitor, ledipasvir, combined with the NS5B polymerase inhibitor, sofosbuvir, in patients with HCV genotype 4. In this phase 2, open-label study, 44 patients (22 treatment na\\u00efve and 22 treatment experienced) received a fixed-dose combination tablet of 90 mg of ledipasvir and 400 mg of sofosbuvir orally once-daily for 12 weeks. The primary endpoint was the percentage of patients with HCV RNA <15 IU/mL 12 weeks after stopping therapy (SVR12). Among study participants, HCV genotype 4 subtypes were well represented (4a, n = 25; 4d, n = 10; other subtypes, n = 9). Ten patients (23%) had compensated cirrhosis. Of the 22 treatment-experienced patients, 21 (95%) had a non-CC IL-28B genotype. All 44 patients completed the full 12 weeks of dosing. The SVR12 rate was 93% (41 of 44; 95% confidence interval, 81-99). SVR12 rates were similar between treatment-na\\u00efve (95%; 21 of 22) and treatment-experienced (91%; 20 of 22) patients. All 3 patients who did not achieve SVR12 had virological relapse within 4 weeks of the end of treatment; all 3 had baseline HCV RNA \\u2265800,000 IU/mL, a non-CC IL-28B genotype, and pretreatment NS5A resistance-associated variants. None of the patients who relapsed had cirrhosis. The most common adverse events were asthenia, headache, and fatigue. No patients experienced a serious adverse event.\",\"Influenza A and B viruses are major causes for respiratory infections in children and adults. Viral and host factors determine clinical manifestations which range from self-resolving uncomplicated infections, severe viral or bacterial secondary pneumonia, to death. Emergence of transmissible resistant variants and time-dependent effectiveness are the major challenges for the currently approved antivirals, M2 ion channel blockers and neuraminidase (NA) inhibitors. Favipiravir that inhibits the RNA-dependent RNA polymerase of multiple RNA viruses is approved in Japan against influenza strains resistant to available antivirals. With expanded knowledge on viral nucleoprotein (NP) and polymerase structures, novel small molecule inhibitors targeting NP oligomer formation, PA endonuclease domain, and the PB2 cap-binding domain are being developed. Combination therapy with different antiviral compounds or with host immune response modulators may further benefit clinical outcomes.\",\"While addition of the first-approved protease inhibitors (PIs), telaprevir and boceprevir, to pegylated interferon (PEG-IFN) and ribavirin (RBV) combination therapy significantly increased sustained virologic response (SVR) rates, PI-based triple therapy for the treatment of chronic hepatitis C virus (HCV) infection was prone to the emergence of resistant viral variants. Meanwhile, multiple direct acting antiviral agents (DAAs) targeting either the HCV NS3/4A protease, NS5A or NS5B polymerase have been approved and these have varying potencies and distinct propensities to provoke resistance. The pre-clinical in vivo assessment of drug efficacy and resistant variant emergence underwent a great evolution over the last decade. This field had long been hampered by the lack of suitable small animal models that robustly support the entire HCV life cycle. In particular, chimeric mice with humanized livers (humanized mice) and chimpanzees have been instrumental for studying HCV inhibitors and the evolution of drug resistance. In this review, we present the different in vivo HCV infection models and discuss their applicability to assess HCV therapy response and emergence of resistant variants.\",\"Favipiravir, a viral RNA-dependent RNA polymerase inhibitor, has recently been approved in Japan for influenza pandemic preparedness. Here, we conducted a cell-based screening system to evaluate the susceptibility of influenza viruses to favipiravir. In this assay, the antiviral activity of favipiravir is determined by inhibition of virus-induced cytopathic effect, which can be measured by using a colorimetric cell proliferation assay. To demonstrate the robustness of the assay, we compared the favipiravir susceptibilities of neuraminidase (NA) inhibitor-resistant influenza A(H1N1)pdm09, A(H3N2), A(H7N9) and B viruses and their sensitive counterparts. No significant differences in the favipiravir susceptibilities were found between NA inhibitor-resistant and sensitive viruses. We, then, examined the antiviral susceptibility of 57 pairs of influenza viruses isolated from patients pre- and post-administration of favipiravir in phase 3 clinical trials. We found that there were no viruses with statistically significant reduced susceptibility to favipiravir or NA inhibitors, although two of 20 paired A(H1N1)pdm09, one of 17 paired A(H3N2) and one of 20 paired B viruses possessed amino acid substitutions in the RNA-dependent RNA polymerase subunits, PB1, PB2 and PA, after favipiravir administration. This is the first report on the antiviral susceptibility of influenza viruses isolated from patients after favipiravir treatment.\",\"The hepatitis C virus (HCV), of the family flaviviridae, is one of the major causes of chronic liver diseases. Until the year 2012, HCV infections were treated using PEG-interferon and ribavirin combinations, which have a low cure rate and severe side effects. Currently, many direct-acting antivirals (DAAs) are available, e.g. protease inhibitors, NS5A and polymerase inhibitors. These drugs have proven to be efficient in interferon-free treatment combinations and capable of enhancing the cure rate to above 90 %. Unlike PEG-interferon and ribavirin combinations, DAAs select for resistance in HCV. The R155K mutation in the HCV was found to resist all the currently available protease inhibitors. Here, we studied biophysical parameters like pocket (cavity) geometries and stabilizing residues of HCV 1a NS3/4A protease in wild type and mutants. We also studied HCV 1a NS3/4A protease's catalytic residues: their accessibility, energy, flexibility and binding to Phase II oral protease inhibitor vedroprevir (GS-9451), and compared these parameters between wild type and mutant(s). All these studies were performed using various bioinformatics tools (e.g. Swiss-PdbViewer and Schr\\u00f6dinger's Maestro) and web servers (e.g. DoGSiteScorer, SRide, ASA-View, WHAT IF, elN\\u00e9mo, CABS-flex, PatchDock and PLIP). From our study, we found that introduction of R155K, A156T or D168A mutation to wild-type NS3/4A protease increases the pocket's volume, surface (in the R155K mutant, surface decreases), lipo surface and depth and decreases the number of stabilizing residues. Additionally, differences in catalytic residues' solvent accessibility, energy, root-mean-square deviation (RMSD) and flexibility between wild type and mutants might explain changes in the protease activity and the resistance to protease inhibitors.\",\"To address the therapeutic efficacy of various treatment regimens in genotype 3 selecting randomized clinical trials and prospective National Cohort Studies.\",\"We evaluated the effects of baseline hepatitis C virus (HCV) NS5A, NS5B, and NS3 resistance-associated substitutions (RASs) on response to the combination of ledipasvir and sofosbuvir, with or without ribavirin, in patients with HCV genotype 1 infection.\",\"Grazoprevir (GZR) is a second-generation hepatitis C virus NS3/4A protease inhibitor. The aim of this study was to evaluate GZR plus ribavirin (RBV) in patients with HCV GT1 infection. Noncirrhotic, IL28B CC patients with HCV genotype 1 infection were randomized to GZR 100 mg once daily and RBV for 12 or 24 weeks. Patients in the 12-week arm with detectable HCV RNA at treatment week 4 (TW4) had treatment extended to 24 weeks (response-guided therapy, RGT). The primary endpoint was sustained virologic response (SVR12) at follow-up week 12 (HCV RNA <25 IU/mL) in the per-protocol (PP) population (excluding patients with important protocol deviations). Twenty-six patients were randomized and 22 were included in the PP population. SVR12 was 58.3% (7 of 12) and 90% (9 of 10) in the RGT and 24-week arms, respectively. Seven PP patients had virologic failure, including one patient in the 24-week arm who relapsed after follow-up week 12. All three breakthrough patients had wild-type (WT) virus at baseline and developed breakthrough at TW6 or TW12 with Y56H, A156T and D168A/N mutations. Of the five relapse patients, four had WT at baseline (at relapse three had WT and one had V55A and D168A), and one had S122A/T at baseline and S122T at relapse. There were no serious adverse events (AEs), discontinuations due to AEs or grade 3/4 elevations in total and/or direct bilirubin. Grazoprevir plus RBV was associated with a rapid and sustained suppression of HCV RNA. These results support further evaluation of grazoprevir-based regimens (NCT01716156; protocol P039).\",\"Pegylated interferon and ribavirin plus simeprevir therapy (simeprevir-based triple therapy) has been recently introduced, providing excellent results for nontransplant patients with hepatitis C virus (HCV) infection. However, there are limited data available on its effect on liver transplant recipients. In the present study, we evaluated the efficacy and tolerability of simeprevir-based triple therapy in liver transplant recipients. We treated 9 liver transplant recipients for genotype 1b HCV reinfection with simeprevir-based triple therapy. The efficacy and adverse effects were evaluated until 24 weeks after therapy. All recipients continued immunosuppressive therapy at the same dose as that before therapy induction. Seven of the 9 recipients (77.8%) achieved sustained virological response at 24 weeks. Two recipients (22.2%) experienced viral breakthrough (BT) at 12 and 16 weeks; NS3 HCV mutations conferring resistance to simeprevir were detected in both these patients after BT. Anemia was the most common adverse effect, requiring ribavirin dose reduction and blood transfusion. However, all recipients, except those with BT, completed the 24-week therapy. No recipient experienced cellular rejection during therapy. In conclusion, simeprevir-based triple therapy exhibited high efficacy and tolerability in liver transplant recipients with genotype 1b HCV reinfection.\",\"Standard of care for chronic hepatitis C (CHC) in India is peginterferon and ribavirin (RBV). The response to treatment in real life stetting is unclear. The objectives of this study were to evaluate the demographic profile and assess the virological response and predictors of response in CHC patients.\",\"We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed.\",\"Current anti-influenza therapy depends on administering drugs soon after infection, which is often impractical. We assessed whether combinations of oseltamivir (a neuraminidase inhibitor) and T-705 (a nonspecific inhibitor of viral polymerases) could extend the window for treating lethal infection with highly pathogenic A(H5N1) influenza virus in mice. Combination therapy protected 100% of mice, even when delayed until 96 h postinoculation. Compared to animals receiving monotherapy, mice receiving combination therapy had reduced viral loads and restricted viral spread in lung tissues, limited lung damage, and decreased inflammatory cytokine production. Next-generation sequencing showed that virus populations in T-705-treated mice had greater genetic variability, with more frequent transversion events, than did populations in control and oseltamivir-treated mice, but no substitutions associated with resistance to oseltamivir or T-705 were detected. Thus, combination therapy extended the treatment window for A(H5N1) influenza infection in mice and should be considered for evaluation in a clinical setting.\",\"High rates of sustained virologic response (SVR) has been achieved in Japanese patients with chronic hepatitis C virus (HCV) genotype (GT)1 and GT2 infection treated with ledipasvir/sofosbuvir (LDV/SOF) \\u00b1ribavirin (RBV) and SOF+RBV, respectively. We evaluated the effect of baseline HCV NS5A and NS5B resistance-associated variants (RAVs) on treatment outcome and characterized variants at virologic failure. Baseline deep sequencing for NS5A and NS5B genes was performed for all GT1 patients. Deep sequencing of NS5A (GT1 only) and NS5B (GT1 and GT2) was performed for patients who failed treatment or discontinued early with detectable HCV RNA (i.e., >25 IU/mL). In patients with HCV GT1 infection, 22.3% (GT1a: 2/11; GT1b: 74/330) had \\u22651 baseline NS5A RAV. The most frequent NS5A RAVs in GT1b were Y93H (17.9%, 59/330) and L31M (2.4%, 8/330). Despite the presence of NS5A RAVs at baseline, 100% and 97% of patients achieved SVR12, compared with 100% and 99% for those with no NS5A RAVs with LDV/SOF and LDV/SOF+RBV, respectively. All patients with NS5B RAVs at baseline achieved SVR12. Of the 153 patients with GT2 infection (GT2a 60.1%, GT2b 39.9%), 3.3% (5/153) experienced viral relapse. No S282T or other NS5B RAVs were detected at baseline or relapse; no change in susceptibility to SOF or RBV was observed at relapse. In conclusion, LDV/SOF and SOF+RBV demonstrate a high barrier to resistance in Japanese patients with HCV GT1 and GT2 infection. The presence of baseline NS5A RAVs did not impact treatment outcome in GT1 Japanese patients treated with LDV/SOF for 12 weeks.\",\"Background. The pre-existence of minority hepatitis C virus (HCV) variants and their impact on treatment outcome, as well as the persistence of emerging resistant variants posttreatment in patients failing treatment with simeprevir/peginterferon/ribavirin (SMV/PR), were assessed by deep sequencing (DS). Methods. Population sequencing (PS) and Illumina DS were performed on HCV genotype 1 isolates from patients treated with SMV/PR in Phase 2b (PILLAR [NCT00882908] and ASPIRE [NCT00980330]) and Phase 3 (QUEST-1 [NCT01289782], QUEST-2 [NCT01290679], and PROMISE [NCT01281839]) trials. Results. Minority polymorphisms (ie, detected pretreatment by DS only) reducing SMV activity in vitro were uncommon (3.6%, 19 of 534 patients). These SMV-resistant minority polymorphisms were detected in similar proportions of patients achieving (3.7%) and not achieving (3.3%) sustained virologic response with SMV/PR and generally did not emerge as major variants at time of failure. SMV-resistant variants emerging at time of failure were no longer detected at end of study in 69.3% and 52.0% of the patients by PS and DS, respectively. Conclusions. Minority polymorphisms did not impact outcome of SMV/PR treatment. The majority of emerging variants that became undetectable at end of study by PS were also undetectable by DS. These results suggest no added value of DS for clinical usage of SMV.\",\"Ribavirin monotherapy is the preferred treatment for chronic hepatitis E, although occasional treatment failure occurs. We present a patient with chronic hepatitis E experiencing ribavirin treatment failure with a completely resistant phenotype. We aimed to identify viral mutations associated with treatment failure and explore the underlying mechanisms.\",\"Chronic hepatitis C virus (HCV) infection has become a curable disease. Sustained virologic response rates above 90% have been achieved with recommended direct-acting antiviral (DAA) combinations in most registration trials. However, outcomes in real-world patients are lower. In patients experiencing DAA failure, resistance-associated variants (RAVs) are almost universally selected. At this time it is unclear when and how to re-treat hepatitis C in patients with prior DAA failure.\",\"The treatment of HCV infection has evolved at an extremely rapid pace over the past few years. The development of direct-acting antiviral agents, which potently inhibit different stages in the viral life cycle, has led to the replacement of interferon with well-tolerated oral therapies with cure rates of >90% in most patient populations. Understanding the mechanisms of action of the various agents as well as related issues, including the molecular basis for resistance, helps to guide drug development and clinical use. In this Review, we provide a mechanistic description of NS3/4A protease inhibitors, nucleotide and non-nucleotide inhibitors of the NS5B viral polymerase and inhibitors of the NS5A protein, followed by a summary of clinical data from studies of each drug class alone and in combination. Remaining challenges in drug development efforts are also discussed.\",\"We previously characterized a foot-and-mouth disease virus (FMDV) with three amino acid replacements in its polymerase (3D) that conferred resistance to the mutagenic nucleoside analogue ribavirin. Here we show that passage of this mutant in the presence of high ribavirin concentrations resulted in selection of viruses with the additional replacement I248T in 2C. This 2C substitution alone (even in the absence of replacements in 3D) increased FMDV fitness mainly in the presence of ribavirin, prevented an incorporation bias in favor of A and U associated with ribavirin mutagenesis, and conferred the ATPase activity of 2C decreased sensitivity to ribavirin-triphosphate. Since in previous studies we described that 2C with I248T was selected under different selective pressures, this replacement qualifies as a joker substitution in FMDV evolution. The results have identified a role of 2C in nucleotide incorporation, and have unveiled a new polymerase-independent mechanism of virus escape to lethal mutagenesis.\",\"Real-life effectiveness data of new hepatitis C direct-acting antivirals are now required. The present study aims to assess the rate of sustained viral response (SVR) and virological failure (VF) in patients infected with chronic HCV treated with sofosbuvir (SOF)-based regimens in routine medical practice.\",\"A series of 1,6-bis[(benzyloxy)methyl]uracil derivatives combining structural features of both diphenyl ether and pyridone types of NNRTIs were synthesized. Target compounds were found to inhibit HIV-1 reverse transcriptase at micro- and submicromolar levels of concentrations and exhibited anti-HIV-1 activity in MT-4 cell culture, demonstrating resistance profile similar to first generation NNRTIs. The synthesized compounds also showed profound activity against influenza virus (H1N1) in MDCK cell culture without detectable cytotoxicity. The lead compound of this assay appeared to exceed rimantadine, amantadine, ribavirin and oseltamivir carboxylate in activity. The mechanism of action of 1,6-bis[(benzyloxy)methyl]uracils against influenza virus is currently under investigation.\",\"Egypt has the highest prevalence of a difficult to treat chronic hepatitis C virus (HCV), genotype 4. Pretreatment factors could guide individualization of therapy which aids in treatment optimization and interleukin IL28B gene polymorphism has been shown to closely relate to HCV treatment response. Polymorphisms in genes encoding inhibitors of T-cell response, which have role in disease progression as Programmed Cell Death 1 (PD-1), and Cytotoxic T-Lymphocytes Antigen-4 (CTLA-4), could be candidate markers predicting treatment response.\",\"The burden of HCV cirrhosis is high and projected to increase significantly over the next decade. While interferon therapy is problematic in HCV cirrhosis, the era of direct-acting anti-viral (DAA) therapy provides effective treatment for patients with cirrhosis.\",\"Long lasting hepatocytes damage related to HCV infection stimulates liver fibrosis resulting in cirrhosis, hepatic failure and hepatocellular carcinoma. Until 2011 the only therapeutic option was 24-48 weeks of pegylated interferon alfa and ribavirin (RBV) with efficacy of 40-70%. New generation of direct-acting antivirals (DAA), available from 2014, can be combined and improve efficacy above 90% with 12 weeks of treatment.\",\"The hepatitis C virus (HCV) genotype 1b is known to exhibit treatment resistance with respect to interferon (IFN) therapy. Substitution of amino acids 70 and 91 in the core region of the 1b genotype is a significant predictor of liver carcinogenesis and poor response to pegylated-IFN-\\u03b1 and ribavirin therapy. However, the molecular mechanism has not yet been clearly elucidated because of limitations of the HCV genotype 1b infectious model. Recently, the TPF1-M170T HCV genotype 1b cell culture system was established, in which the clone successfully replicates and infects Huh-7-derived Huh7-ALS32.50 cells. Therefore, the purpose of this study was to compare IFN resistance in various HCV clones using this system.\",\"To clarify the role of virus resistance in the efficiency of antiviral therapy with protease inhibitors (PIs) chronic hepatitis C (CHC) patients, with moderate sensitivity to interferon-\\u03b1.\",\"To evaluate daclatasvir vs telaprevir, each combined with peginterferon alfa-2a/ribavirin (pegIFN/RBV), in treatment-naive hepatitis C virus (HCV) genotype (GT) 1-infected patients.\",\"The treatment of hepatitis C virus has changed dramatically with the rapid advent of numerous new antiviral agents, including direct-acting antivirals and agents with non-viral targets (cyclophilin inhibitors, interferon-lambda, vaccine therapy). Given the better safety profile and high antiviral potency of direct-acting antivirals, their combination in interferon-free oral regimens is becoming the standard of care for hepatitis C virus infection, tailored to individual patients according to the degree of disease progression (fibrosis), hepatitis C virus genotype and subtype, resistance profile, and prior therapeutic history. Results from clinical studies as well as preliminary real-life data regarding the combination of sofosbuvir (a nucleotide polymerase inhibitor) and daclatasvir, a first-in-class NS5A replication complex inhibitor, demonstrate that it is one of the most promising antiviral therapies, with once-daily oral dosing, a low pill burden, good tolerability, and limited drug-drug interactions, in addition to high antiviral potency, with >90% sustained virologic response rates. This combination has high pangenotypic antiviral potency regardless of the severity and patient characteristics. The combination of sofosbuvir and an NS5A inhibitor with ribavirin for 12 weeks appears to be a very good further treatment option in both cirrhotic and treatment-experienced patients whatever the stage of fibrosis.\",\"Without a vaccine, hepatitis C virus (HCV) remains a global medical and socio-economic burden, predisposing about 170 million carriers worldwide to end-stage liver diseases including cirrhosis and hepatocellular carcinoma. Although the recently developed direct-acting antivirals (DAAs) have revolutionized hepatitis C treatment, most of them are unsuitable for monotherapy due to risks of resistance, thus necessitating combination with interferon (IFN)-alpha, ribavirin, or additional DAAs. More importantly, the high cost associated with the DAAs restricts their accessibility to most parts of the world. Developing novel cost-effective anti-HCV therapeutics may help expand the scope of antivirals and treatment strategies against hepatitis C. Herein, we applied an activity-based and fraction-guided analysis of extracts from the medicinal plant Phyllanthus urinaria (P. urinaria), which yielded fraction 13 (F13) as possessing the most potent inhibitory activity against early viral entry of cell-culture HCV infection. Chemical analysis (silica gel chromatography followed by ESI LC-MS plus (1)H and (13)C NMR) of F13 identified loliolide (LOD), a monoterpenoid lactone, as a novel inhibitor of HCV entry. Specifically, LOD could efficiently inactivate HCV free virus particles, abrogate viral attachment, and impede viral entry/fusion, with minimal effect on viral replication/translation, particle production, and induction of type I IFN host antiviral immune response. ELISA-based binding analysis confirmed the monoterpenoid's ability in efficiently blocking HCV particle attachment to the host cell surface. Furthermore, LOD could inhibit infection by several genotypic strains of HCV. This is the first report characterizing P. urinaria and its bioactive compound LOD as potent HCV entry inhibitors, which merit further evaluation for development as candidate antiviral agents against hepatitis C.\",\"Daclatasvir plus asunaprevir (DCV + ASV) has demonstrated potent antiviral activity in patients with hepatitis C virus (HCV) genotype 1b (GT-1b) infection in the HALLMARK DUAL trial. This post hoc analysis was conducted to determine the efficacy and safety of this treatment in Asian patients.\",\"The treatment of hepatitis C virus (HCV) infection has progressed markedly over the last 2 decades, with a dramatic acceleration the last 3 years. The combination of two or three direct-acting antiviral drugs (DAAs) targeting viral proteins [NS3/4A protease inhibitors, NS5B nucleos(t)idic and non-nucleos(t)idic polymerase inhibitors, NS5A replication complex inhibitors], with or without ribavirin but without interferon (interferon-free regimen), for 8-24 weeks, achieved high sustained virological response (>90%), whatever fibrosis stage, genotype and subtype, baseline viral load, prior therapeutic history of the patient (na\\u00efve or experienced) and pre-existing resistance-associated variants with a fair tolerance and reduced pill burden. International guidelines recommend to ideally treat all infected patients even if a prioritization of the most severe patients (extensive fibrosis or cirrhosis, symptomatic cryoglobulinaemic vasculitis\\u2026) appears to be the best cost-effective and urgent policy. Patients with stage 4-5 chronic kidney disease (CKD) have to be considered as priority patients. Updating of the Kidney Disease: Improving Global Outcomes recommendations is due to start soon, but awaiting their availability, we present here an overview of recent developments in the field.\",\"Daclatasvir plus asunaprevir has demonstrated efficacy and safety in patients with chronic hepatitis C virus genotype 1b infection. This study focused on evaluating daclatasvir plus asunaprevir in interferon (\\u00b1ribavirin)-ineligible or -intolerant Asian patients with genotype 1b infection from mainland China, Korea, and Taiwan.\",\"The introduction of direct-acting antiviral agents (DAAs) has markedly improved the sustained virological response (SVR) rates in patients with chronic hepatitis C. Currently, four classes of DAAs targeting three HCV proteins (NS3, NS5A, and NS5B) have been approved for treatment in many countries. Since drugs show advantages and disadvantages, use of a combination of two or more DAAs with different targets or addition of ribavirin in a difficult-to-treat patient shows an SVR rate of ~90% after 12 weeks of treatment or expanded treatment for 24 weeks. Various types of DAA are awaiting approval which will improve the treatment of chronic hepatitis C virus genotype 1 infection. However, high costs, drug resistance and interactions between various drugs remain to be overcome. With further advances in the development of antiviral agents, it could be expected that in the near future, there will be DAAs that are affordable and cost effective, require shorter treatment duration, effective in a broad range of patients, and have less side effects and drug-drug interactions.\",\"In the phase III registration studies conducted in Japan, Japanese HCV gt1 patients administered vaniprevir 300 mg twice daily plus pegylated interferon/ribavirin for 12 or 24 weeks achieved SVR24 rates of 83.7-84.5% among treatment-na\\u00efve patients, and 92.0-96.2% and 61.9% among breakthrough/relapsers or null-responders to prior interferon based therapy. As evidenced by direct sequencing, patients who did not achieve SVR24 principally failed due to treatment-emerging mutations at D168 or in a few cases R155. In this work, additional sequence analysis was conducted to address whether there were baseline polymorphisms associated with failure, evaluate the persistence of resistant virus among treatment failures, and assess for evidence of second site co-evolution with R155 or D168 mutations. To accomplish this, clonal sequencing (up to 40 clones per sample) was conducted on baseline, failure, and follow-up samples from all 38 patients among the vaniprevir treatment arms who met virologic failure criteria (37 gt1b, 1 gt1a, herein referred to as virologic failures) and baseline samples from 41 vaniprevir-treated SVR24 patients (all gt1b) selected among the three studies. SVR24 and virologic failure patients showed similar distributions of baseline polymorphisms previously associated with failure to one or more protease inhibitors. Furthermore, there was no evidence for baseline polymorphisms or a genetic signature across the NS3 protease domain specific to virologic failure patients, and which distinguishes them from baseline SVR24 sequences beyond a chance distribution. 24 of 32 virologic failures for whom baseline, failure, and follow-up samples were available showed reduced prevalence of the resistant virus first observed at the time of failure during the protocol-defined follow-up period of 24 weeks. Finally, pairwise analysis using either alignment or phylogenetic based methodologies provided no evidence for second site evolution with either the R155 or D168 mutations attributed to failure. This work supports and extends earlier findings based upon direct sequencing that attributed virologic failure to vaniprevir in the Phase III studies solely to the emergence of R155 or D168 mutations, with no apparent influence by other residues within the NS3 protease domain on treatment outcome. CLINICALTRIALS.\",\"Pancreatic cancer is a devastating disease characterized by treatment resistance and high recurrence rate. Repopulation of surviving tumor cells undergoing radiotherapy is one of the most common reasons for recurrence. Our previous studies have discovered a novel mechanism for repopulation after irradiation that activation of caspase-3 in irradiated tumor cells activates PKC\\u03b4/p38 axis to transmit proliferation signals promoting repopulation of surviving tumor cells. Here we found Sox2 expression is up-regulated in irradiated pancreatic cancer cells, which played a major role in tumor cell repopulation after irradiation. Over-expression of Sox2 strongly enhanced the growth-stimulating effect of irradiated dying tumor cells on living tumor cells through a paracrine modality. Furthermore, we identified activated eIF4E, which is phosphorylated by MNK1, as a regulator of Sox2 expression after irradiation, and pharmacologic inhibition of eIF4E with CGP57380 and Ribavirin significantly weakened Sox2-mediated tumor cell repopulation. Finally, we showed the activation of caspase 3/PKC\\u03b4/p38/MNK1 signal pathway in irradiated pancreatic tumor cells. Together, we showed a novel pathway regulating Sox2 expression and Sox2 may be a promising target to reduce recurrence due to repopulation of surviving tumor cells after radiotherapy.\",\"Chronic hepatitis C virus (HCV) infection is an important source of morbidity and mortality among haemophiliacs. Limited data are available regarding treatment intervention using direct-acting antivirals (DAAs) and theoretical concerns regarding accumulation of drug-associated resistance variants (RAVs) remain. We conducted a pilot study of treatment with telaprevir/pegylated interferon-alfa/ribavirin to evaluate treatment response and the role of lead-in DAA therapy on mutational selection of resistance variants.\",\"Therapeutic options for patients with HCV-related liver disease have increased over the last two decades. In fact, the old standard of care based on the combination of pegylated interferon and ribavirin did not result in satisfactory eradication rates, particularly in patients with liver cirrhosis. With the advent of direct-acting antivirals (DAAs), higher rates of viral clearance became possible and, patients with contraindications to interferon obtained access to treatment. However, several concerns have been raised regarding first-generation DAAs, namely their high costs, and the emergence of resistant-associated variants with low susceptibility to these drugs.\",\"The African American/Black population in the United States (US) is disproportionately affected by hepatitis C virus (HCV) and has lower response rates to current treatments. This analysis evaluates the participation of African American/Blacks in North American and European HCV clinical trials. The data source for this analysis was the PubMed database. Randomized controlled clinical trials (RCT) on HCV treatment with interferon 2a or 2b between January 2000 and December 2011 were reviewed. Inclusion criteria included English language and participants 18 years or older with chronic HCV. Exclusion criteria included non-randomized trials, case reports, cohort studies, ethnic specific studies, or studies not using interferon-alfa or PEG-interferon. Of the 588 trials identified, 314 (53.4%) fit inclusion criteria. The main outcome was the rate of African American/ Black participation in North American HCV clinical trials. A meta-analysis comparing the expected and observed rates was performed. Of the RCT's that met search criteria, 123 (39.2%) reported race. Clinical trials in North America were more likely to report racial data than European trials. Racial reporting increased over time. There was a statistically significant difference among the expected and observed participation of African Americans in HCV clinical trials in North America based on the prevalence of this disease within the population. The burden of HCV among African Americans in North America is not reflected in those clinical trials designed to treat HCV. Research on minority participation in clinical trials and how to increase minority participation in clinical trials is needed.\",\"The selection of resistance-associated variants (RAVs) against single agents administered to patients chronically infected with hepatitis C virus (HCV) necessitates that direct-acting antiviral agents (DAAs) targeting multiple viral proteins be developed to overcome failure resulting from emergence of resistance. The combination of grazoprevir (formerly MK-5172), an NS3/4A protease inhibitor, and elbasvir (formerly MK-8742), an NS5A inhibitor, was therefore studied in genotype 1a (GT1a) replicon cells. Both compounds were independently highly potent in GT1a wild-type replicon cells, with 90% effective concentration (EC90) values of 0.9 nM and 0.006 nM for grazoprevir and elbasvir, respectively. No cross-resistance was observed when clinically relevant NS5A and NS3 RAVs were profiled against grazoprevir and elbasvir, respectively. Kinetic analyses of HCV RNA reduction over 14 days showed that grazoprevir and elbasvir inhibited prototypic NS5A Y93H and NS3 R155K RAVs, respectively, with kinetics comparable to those for the wild-type GT1a replicon. In combination, grazoprevir and elbasvir interacted additively in GT1a replicon cells. Colony formation assays with a 10-fold multiple of the EC90 values of the grazoprevir-elbasvir inhibitor combination suppressed emergence of resistant colonies, compared to a 100-fold multiple for the independent agents. The selected resistant colonies with the combination harbored RAVs that required two or more nucleotide changes in the codons. Mutations in the cognate gene caused greater potency losses for elbasvir than for grazoprevir. Replicons bearing RAVs identified from resistant colonies showed reduced fitness for several cell lines and may contribute to the activity of the combination. These studies demonstrate that the combination of grazoprevir and elbasvir exerts a potent effect on HCV RNA replication and presents a high genetic barrier to resistance. The combination of grazoprevir and elbasvir is currently approved for chronic HCV infection.\",\"Insulin resistance is considered to be an important factor in the progression of fibrosis and the enhancement of the risk of hepatocellular carcinoma (HCC) for chronic hepatitis C patients. The aim of this study was to assess the effect of insulin resistance on the development of HCC by non-cirrhotic chronic hepatitis C patients treated with pegylated interferon alpha-2b (PEG-IFN\\u03b12b) and ribavirin.\",\"Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A protein. The first generation of DAAs includes boceprevir and telaprevir, which are protease inhibitors and were approved for clinical use in 2011. The cure rate for genotype 1 patients increased from 45% to 70% when boceprevir or telaprevir was added to standard PEG-IFN/ribavirin. More effective and less toxic second generation DAAs supplanted these drugs by 2013. The second generation of DAAs includes sofosbuvir (Sovaldi), simeprevir (Olysio), and fixed combination medicines Harvoni and Viekira Pak. These drugs increase cure rates to over 90% without the need for interferon and effectively treat all HCV genotypes. With these drugs the \\\"cure HCV\\\" goal has become a reality. Concerns remain about drug resistance mutations and the high cost of these drugs. The investigation of new HCV drugs is progressing rapidly; fixed dose combination medicines in phase III clinical trials include Viekirax, asunaprevir+daclatasvir+beclabuvir, grazoprevir+elbasvir and others.\",\"In a previous study, ribavirin-resistant porcine reproductive and respiratory syndrome virus (PRRSV) mutants (RVRp13 and RVRp22) were selected, and their resistance against random mutation was shown in cultured cells. In the present study, these ribavirin-resistant mutants were evaluated in terms of their genetic and phenotypic stability during three pig-to-pig passages in comparison with modified live virus (MLV) (Ingelvac PRRS MLV). Pigs challenged with RVRp22 had significantly lower (P< 0.05) viral loads in sera and tissues than pigs challenged with MLV or RVRp13 at the first passage, and the attenuated replication of RVRp22 was maintained until the third passage. Viral loads in sera and tissues dramatically increased in pigs challenged with MLV or RVRp13 during the second passage. Consistently, all five sequences associated with the attenuation of virulent PRRSV in RVRp13 and MLV quickly reverted to wild-type sequences during the passages, but two attenuation sequences were maintained in RVRp22 even after the third passage. In addition, RVRp22 showed a significantly lower (P< 0.001) mutation frequency in nsp2, which is one of the most variable regions in the PRRSV genome, than MLV. Nine unique mutations were found in open reading frames (ORFs) 1a, 2, and 6 in the RVRp22 genome based on full-length sequence comparisons with RVRp13, VR2332 (the parental virus of RVRp13 and RVRp22), and MLV. Based on these results, it was concluded that RVRp22 showed attenuated replication in pigs; further, because of the high genetic stability of RVRp22, its attenuated phenotype was stable even after three sequential passages in pigs.\",\"Effective and safe antiviral treatment regimens are needed for patients with chronic hepatitis C (CHC) and cirrhosis.\",\"The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p < 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p < 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p < 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.\",\"Patients 1 and 2 were treatment-naive women who had genotype 1b chronic hepatitis C. Both had IL-28B genotype TT, and amino acid substitutions of core 70 and 91 were both wild type. Search for the presence of resistance-associated variants (RAV) in non-structural (NS)3 and NS5A regions confirmed wild-type D168 and L31, along with Y93H, in both patients. These patients participated in a Japanese phase III clinical study of asunaprevir and daclatasvir at the age of 52 and 67 years, respectively, and were treated with the combination regimen for 24 weeks. However, both experienced post-treatment relapse, and then treated with triple combination therapy with simeprevir, pegylated interferon (IFN) and ribavirin at the age of 53 and 68 years, respectively, and achieved sustained virological response. A search for RAV prior to simeprevir treatment identified multiple resistance including D168E, Y93H and L31V in both patients. It has been demonstrated that, in many cases, a treatment failure with a combination of asunaprevir and daclatasvir results in acquisition of RAV in NS3 and NS5A regions and that drug-resistant mutants, particularly those in the NS5A region, survive for a long time. In these cases, direct-acting antivirals targeted towards the NS5A region may have a limited efficacy. The present case report is based on an idea that a regimen containing IFN with simeprevir could be a therapeutic option particularly for those who are likely to be highly sensitive and tolerable to IFN.\",\"Despite the enormous disease burden associated with dengue virus infections, a licensed antiviral drug is lacking. Here, we show that the paracetamol (acetaminophen) metabolite AM404 inhibits dengue virus replication. Moreover, we find that mutations in NS4B that were previously found to confer resistance to the antiviral compounds NITD-618 and SDM25N also render dengue virus insensitive to AM404. Our work provides further support for NS4B as a direct or indirect target for antiviral drug development.\",\"Failure to achieve sustained virological response (SVR) with hepatitis C virus (HCV) direct-acting antiviral-based regimens is commonly associated with emergence of resistance-associated variants (RAVs). To avoid cross-resistance, recent guidelines recommend that patients who have failed on nonstructural protein 5A (NS5A) inhibitors should be retreated with sofosbuvir (SOF; NS5B inhibitor) combined with simeprevir (SIM; protease inhibitor [PI]); however, supporting evidence is lacking. This \\\"real-world\\\" study comprised patients who had failed to achieve SVR on previous NS5A-based therapy with daclatasvir (DCV) plus pegylated interferon (Peg-IFN) and ribavirin (RBV), with (n = 3) or without (n = 13) asunaprevir (ASV; PI). All 16 patients were retreated for 12 weeks with SOF plus SIM, without RBV. Antiviral efficacy was evaluated using the primary endpoint of SVR12 (SVR 12 weeks post-treatment); on-treatment response was also assessed. Patients (N = 16; 13 male; mean age: 54 years [range, 43-73]) were chronically infected with HCV genotype (GT) 1 (1a, n = 11; 1b, n = 3) or 4 (n = 2); they had advanced fibrosis or compensated cirrhosis (FibroScan, 9.6-70 kPa; cirrhosis, n = 9); median baseline HCV-RNA level was 1.38 \\u00d7 10(6) IU/mL. No patient discontinued treatment because of adverse events or virological failure. All patients achieved HCV RNA below lower limit of quantification (<12 IU/mL) by end of treatment (EOT) and 10 of 16 had a rapid response (week 4). SVR12 was achieved by 14 of 16 patients; the remaining 2 relapsed by 4 weeks post-EOT (both were GT 1a infected with cirrhosis; 1 had previously failed DCV-ASV plus Peg-IFN and RBV). Presence of SIM RAVs/polymorphisms (R155K and Q80K) at study baseline did not predict retreatment failure.\",\"Approximately 130 - 150 million people have chronic hepatitis C virus (HCV) infection and upwards of 500,000 deaths annually are attributed to HCV related liver disease worldwide. Pegylated interferon and ribavirin have been the mainstay of treatment for greater than 25 years until recent advent of protease inhibitors which has led to all oral HCV treatment regimens that have changed the outlook of hepatitis C treatment.\",\"Hepatitis C virus (HCV) is the most common blood-borne infection in the United States. The high morbidity and mortality due to untreated infection have prompted updated screening recommendations that now include one-time HCV screening for all patients born between 1945 and 1965, in addition to risk factor-based screening. Current guidelines recommend treatment for all patients with chronic HCV. Treatment for HCV genotype 1 has evolved dramatically since the approval of the direct-acting antivirals. The approval of ledipasvir-sofosbuvir, ombitasvir-paritaprevir-ritonavir and dasabuvir, and simeprevir with sofosbuvir has dramatically altered the treatment landscape. High sustained virologic response (SVR) rates favor treatment, yet access to care poses a challenge for patients and providers. Current and emerging data with new therapies indicate high SVR rates in treatment-na\\u00efve and treatment-experienced patients, including patients with cirrhosis and in other special populations. Additional data suggest the addition of ribavirin can decrease treatment duration without compromising SVR rates. Resistance is an increasing area of interest in HCV, with baseline mutations identified and the potential for the development of resistance-associate variants in patients undergoing treatment. Due to the rapid evolution of HCV treatment, pharmacists should address challenges and play an integral role in agent selection, dosing, drug interaction screening, adverse effect monitoring, and the coordination of treatment. Clinical application of the latest information will reduce patient risk and improve outcomes.\",\"Chronic hepatitis C virus (HCV) infection affects 80-160 million people worldwide and is one of the leading causes of chronic liver disease. It is only a few years ago that standard treatment regimes were based on pegylated interferon alpha and ribavirin. However, treatment of HCV has undergone a revolutionary change in recent years. The admission of the nucleotide polymerase inhibitor Sofosbuvir enabled an interferon-free regimen with direct antiviral agents (DAA). Meanwhile seven DAAs are available and can be applied in several combinations for 8 to 24 wk depending on HCV genotype and patient characteristics such as cirrhosis and chronic renal failure. High rates of sustained virological response (SVR) rates can be achieved with these novel drugs. Even in difficult to treat populations such as patients with liver cirrhosis, HCV-human immunodeficiency virus co-infections, after liver transplantion, or with chronic kidney disease comparable high rates of SVR can be achieved. The anticipated 2(nd) generation DAAs are strikingly effective in patients so far classified as difficult to treat including decompensated liver cirrhosis or post-transplant patients. These 2(nd) generations DAAs will have higher resistance barriers, higher antiviral effects and a pan-genotypic spectrum. This review highlights the current state of the art of antiviral treatment in hepatitis C and gives an outlook for upcoming therapies.\",\"The hepatitis C virus (HCV) RNA-dependent RNA-polymerase NS5B is essentially required for viral replication and serves as a prominent drug target. Sofosbuvir is a prodrug of a nucleotide analog that interacts selectively with NS5B and has been approved for HCV treatment in combination with ribavirin. Although the emergence of resistance to sofosbuvir is rarely seen in the clinic, the S282T mutation was shown to decrease susceptibility to this drug. S282T was also shown to confer hypersusceptibility to ribavirin, which is of potential clinical benefit. Here we devised a biochemical approach to elucidate the underlying mechanisms. Recent crystallographic data revealed a hydrogen bond between S282 and the 2'-hydroxyl of the bound nucleotide, while the adjacent G283 forms a hydrogen bond with the 2'-hydroxyl of the residue of the template that base pairs with the nucleotide substrate. We show that DNA-like modifications of the template that disrupt hydrogen bonding with G283 cause enzyme pausing with natural nucleotides. However, the specifically introduced DNA residue of the template reestablishes binding and incorporation of sofosbuvir in the context of S282T. Moreover, the DNA-like modifications of the template prevent the incorporation of ribavirin in the context of the wild-type enzyme, whereas the S282T mutant enables the binding and incorporation of ribavirin under the same conditions. Together, these findings provide strong evidence to show that susceptibility to sofosbuvir and ribavirin depends crucially on a network of interdependent hydrogen bonds that involve the adjacent residues S282 and G283 and their interactions with the incoming nucleotide and complementary template residue, respectively.\",\"Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a challenging population in urgent need of optimally effective therapies. The combination of daclatasvir (DCV; pangenotypic nonstructural protein 5A inhibitor) and sofosbuvir (SOF; nucleotide nonstructural protein 5B inhibitor) for 12 weeks previously showed high efficacy (96%) in noncirrhotic genotype 3 infection. The phase III ALLY-3+ study (N = 50) evaluated DCV-SOF with ribavirin (RBV) in treatment-na\\u00efve (n = 13) or treatment-experienced (n = 37) genotype 3-infected patients with advanced fibrosis (n = 14) or compensated cirrhosis (n = 36). Patients were randomized 1:1 to receive open-label DCV-SOF (60 + 400 mg daily) with weight-based RBV for 12 or 16 weeks. The primary endpoint was sustained virological response at post-treatment week 12 (SVR12). SVR12 (intention-to-treat) was 90% overall (45 of 50): 88% (21 of 24) in the 12-week (91% observed) and 92% (24 of 26) in the 16-week group. All patients with advanced fibrosis achieved SVR12. SVR12 in patients with cirrhosis was 86% overall (31 of 36): 83% (15 of 18) in the 12-week (88% observed) and 89% (16 of 18) in the 16-week group; for treatment-experienced patients with cirrhosis, these values were 87% (26 of 30), 88% (14 of 16; 93% observed), and 86% (12 of 14), respectively. One patient (12-week group) did not enter post-treatment follow-up (death unrelated to treatment). There were 4 relapses (2 per group) and no virological breakthroughs. The most common adverse events (AEs) were insomnia, fatigue, and headache. There were no discontinuations for AEs and no treatment-related serious AEs.\",\"About 130-170 million people, is estimated to be infected with the hepatitis C virus (HCV). Chronic HCV infection is one of the leading causes of liver-related death and in many countries it is the primary reason for having a liver transplant. The main aim of antiviral treatment is to eradicate the virus. Until a few years ago the only treatment strategy was based on the combination of pegylated interferon and ribavirin (PEG/RBV). However, in genotypes 1 and 4 the rates of viral response did not surpass 50%, reaching up to 80% in the rest. In 2011 approval was given for the first direct acting antiviral agents (DAA), boceprevir and telaprevir, for treatment of genotype 1, in combination with traditional dual therapy. This strategy managed to increase the rates of sustained viral response (SVR) in both naive patients and in retreated patients, but with greater toxicity, interactions and cost, as well as being less safe in patients with advanced disease, in whom this treatment can trigger decompensation or even death. The recent, accelerated incorporation since 2013 of new more effective DAA, with pan-genomic properties and excellent tolerance, besides increasing the rates of SVR (even up to 100%), has also created a new scenario: shorter therapies, less toxicity and regimens free of PEG/RBV. This has enabled their almost generalised applicability in all patients. However, it should be noted that most of the scientific evidence available is based on expert opinion, case-control series, cohort studies and phase 2 and 3 trials, some with a reduced number of patients and select groups. Few data are currently available about the use of these drugs in daily clinical practice, particularly in relation to the appearance of side effects and interactions with other drugs, or their use in special populations or persons with the less common genotypes. This situation suggests the need for the generalised implementation of registries of patients receiving antiviral therapy. The main inconvenience of these new drugs is their high cost. This necessitates selection and prioritization of candidate patients to receive them, via strategies established by the various national organs, in accordance with the recommendations of scientific societies.\",\"Chronic hepatitis C virus (HCV) infection has been shown to be linked to a higher prevalence of type 2 diabetes compared with the general population or with patients with chronic hepatitis B infection and diabetes is the most common extra-hepatic manifestation of HCV. The HCV-diabetes association is due to insulin resistance (IR) that occurs early in the course of the disease even in patients without or with minimal fibrosis. The mechanisms for HCV-induced IR are only partly understood and include a direct inhibitory effect of HCV on insulin signaling pathway. IR in chronic HCV results in an increased progression rate of hepatic fibrosis, cirrhosis and hepatocellular carcinoma. Some but not all studies found that IR reduces the response rate to interferon/ribavirin therapy. Whether IR affects the response to the new direct-acting antiviral treatments is still unknown.\",\"Before the advent of direct acting antiviral agents (DAAs) ribavirin, associated to pegylated-interferon played a crucial role in the treatment of chronic hepatitis C, preventing relapses and breakthroughs. In the present era of new potent DAAs, a place is still devoted to the drug. Ribavirin associated with sofosbuvir alone is efficient in the treatment of most cases of G2 infected patients. All options currently available for the last difficult-to-treat cirrhotic G3 patients contain ribavirin. Reducing treatment duration to 12 wk in G1 or G4 cirrhotic compensated patients is feasible thanks to ribavirin. Retreating patients with acquired anti NS5A resistance-associated variants using ribavirin-based strategies could be useful. The addition of ribavirin with DAAs combinations however, leads to more frequent but mild adverse events especially in cirrhotic patients. Preliminary data with interferon-free second generation DAAs combinations without ribavirin suggest that future of the drug is jeopardized even in difficult-to-treat patients: The optimization of ribavirin dosage according to an early monitoring of blood levels has been suggested to be relevant in double therapy with peginterferon or sofosbuvir but not with very potent combinations of more than two DAAs.\",\"A target-free and cell-based approach was applied to evaluate the anti-influenza properties of six newly synthesized benzoic acid derivatives. SA-2, the ethyl 4-(2-hydroxymethyl-5-oxopyrrolidin-1-yl)-3-[3-(3-methylbenzoyl)-thioureido] benzoate (compound 2) was screened as a potential drug candidate. In a cytopathic effect assay, SA-2 dose dependently inhibited H1N1, H3N2 and the oseltamivir-resistant mutant H1N1-H275Y influenza viruses in both virus-infected MDCK and A549 cells, with 50% effective concentrations (EC50) in MDCK cells of 9.6, 19.2 and 19.8 \\u03bcM respectively, and 50% cytotoxic concentration (CC50) of 444.5 \\u03bcM, showing competitive antiviral activity with oseltamivir in vitro. Orally administered SA-2 effectively protected mice infected with lethal doses of H1N1 or oseltamivir-resistant strain H1N1-H275Y, conferring 70% or 50% survival at a dosage of 100 mg/kg/d, reducing body weight loss, alleviating the influenza-induced acute lung injury, and reducing lung virus titer. Mechanistic studies showed that SA-2 efficiently inhibited the activity of RNA polymerase and suppressed NP and M1 levels during viral biosynthesis by interfering with gene transcription without having an obvious influence on virus entry and release. Based on these favourable findings, SA-2, a novel anti-influenza agent, with its potent anti-influenza activity in vitro and in vivo, could be a promising antiviral for the treatment of infection of influenza A viruses, including oseltamivir-resistant mutants.\",\"Among many subtypes of influenza A viruses, influenza A(H1N1) and A(H3N2) subtypes are currently circulating among humans (WHO report 2014-15). Therapeutically, the emergence of viral resistance to currently available drugs (adamantanes and neuraminidase inhibitors) has heightened alarms for developing novel drugs that could address diverse targets in the viral replication cycle in order to improve treatment outcomes. To this regard, the design and synthesis of nucleoside analog inhibitors as potential anti-influenza A agents is a very active field of research nowadays. In this study, we designed and synthesized a series of hitherto unknown 6-methyl-7-substituted-7-deaza purine nucleoside analogs, and evaluated for their biological activities against influenza A virus strains, H1N1 and H3N2. From the viral inhibition assay, we identified some effective compounds, among which, compounds 5x (IC50 = 5.88 \\u03bcM and 6.95 \\u03bcM for H1N1 and H3N2, respectively) and 5z (IC50 = 3.95 \\u03bcM and 3.61 \\u03bcM for H1N1 and H3N2, respectively) demonstrated potent anti-influenza A activity. On the basis of selectivity index, we conceive that compound 5x may serve as a chemical probe of interest for further lead optimization studies with a general aim of developing novel and effective anti-influenza A virus agents.\",\"Direct-acting anti-virals (DAAs) licensed to treat chronic HCV infection have revolutionised treatment algorithms by drastically mitigating side effects while enhancing efficacy relative to interferon-based therapy.\",\"ABT-530 is a next-generation hepatitis C virus (HCV) NS5A inhibitor with potent pangenotypic antiviral activity in vitro. Paritaprevir is an NS3/4A protease inhibitor codosed with ritonavir that displays in vitro activity against HCV genotypes 1-4 and 6.\",\"The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumour growth, metastasis and therapy resistance. As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E. Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy. This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.\",\"Intravenous drug users (IDUs) represent a highly-infected reservoir for Hepatitis C virus (HCV) worldwide, harboring some of the most elevated prevalences and majority of the epidemic in developed nations. Studies aimed at sequencing regions of the viral genome uncovered amino acid mutations, some of which have been implicated in resistance to standard of care pegylated interferon/Ribavirin double therapy. Using the nested PCR method on the Core region of HCV strains in Moroccan IDUs living in the Tangier region this study sought to identify genotype-specific amino acid mutations, followed by Phylogenetic methods in order to compare them with international strains so as to identify sequences of highest homology. Genotyping was confirmed and recombination events excluded by line-probe assay. Italy was found most homologous for genotypes 1a and 3a, Iran for genotype 1a and Egypt for genotype 4a. Amino Acid Mutation analysis revealed the following novel genotype 3a-specific mutations: N16I, L36V, T49A, P71S, T75S, and T110N. The outcome of this work describes the HCV genetic heterogeneity in high-risk intravenous drug users, and it gives clues to the global migratory flow of genotypes as they cross geographical boundaries between various IDU populations and identifies \\\"signature\\\" amino acid mutations traceable to HCV genotype 3a. Identification of key amino acid positions in the HCV Core region with higher rates of mutations paves the way for eventual clinical trials seeking to establish a link between these recurrent mutations and response to standard of care Interferon and Ribavirin antiviral therapy. J. Med. Virol. 88:1376-1383, 2016. \\u00a9 2016 Wiley Periodicals, Inc.\",\"To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). While a number of candidate drugs have shown limited efficacy in vitro and/or in non-human primate studies, differences in experimental methodologies make it difficult to compare their therapeutic effectiveness. Using an in vitro model of Ebola Zaire replication with transcription-competent virus like particles (trVLPs), requiring only level 2 biosafety containment, we compared the activities of the type I interferons (IFNs) IFN-\\u03b1 and IFN-\\u00df, a panel of viral polymerase inhibitors (lamivudine (3TC), zidovudine (AZT) tenofovir (TFV), favipiravir (FPV), the active metabolite of brincidofovir, cidofovir (CDF)), and the estrogen receptor modulator, toremifene (TOR), in inhibiting viral replication in dose-response and time course studies. We also tested 28 two- and 56 three-drug combinations against Ebola replication. IFN-\\u03b1 and IFN-\\u00df inhibited viral replication 24 hours post-infection (IC50 0.038\\u03bcM and 0.016\\u03bcM, respectively). 3TC, AZT and TFV inhibited Ebola replication when used alone (50-62%) or in combination (87%). They exhibited lower IC50 (0.98-6.2\\u03bcM) compared with FPV (36.8\\u03bcM), when administered 24 hours post-infection. Unexpectedly, CDF had a narrow therapeutic window (6.25-25\\u03bcM). When dosed >50\\u03bcM, CDF treatment enhanced viral infection. IFN-\\u00df exhibited strong synergy with 3TC (97.3% inhibition) or in triple combination with 3TC and AZT (95.8% inhibition). This study demonstrates that IFNs and viral polymerase inhibitors may have utility in EVD. We identified several 2 and 3 drug combinations with strong anti-Ebola activity, confirmed in studies using fully infectious ZEBOV, providing a rationale for testing combination therapies in animal models of lethal Ebola challenge. These studies open up new possibilities for novel therapeutic options, in particular combination therapies, which could prevent and treat Ebola infection and potentially reduce drug resistance.\",\"Most patients with chronic hepatitis C virus (HCV) genotype 1 infection who have had a previous null response (<2-log10 reduction in HCV RNA by treatment week 12) to peginterferon/ribavirin (PegIFN/RBV) do not achieve a sustained virological response (SVR) when re-treated with a first-generation HCV protease inhibitor (PI) administered in combination with PegIFN/RBV. We studied the incremental benefits associated with adding mericitabine (nucleoside analog inhibitor of HCV polymerase) to PI plus PegIFN alfa-2a/RBV-based therapy in two double-blind randomized multicenter phase 2 trials (with boceprevir in DYNAMO 1, and with telaprevir in DYNAMO 2). The primary endpoint in both trials was SVR, defined as HCV RNA <25 IU/mL 12 weeks after the end of treatment (SVR12). Overall, the addition of mericitabine to PI plus PegIFN alfa-2a/RBV therapy resulted in SVR12 rates of 60-70% in DYNAMO 1 and of 71-96% in DYNAMO 2. SVR12 rates were similar in patients infected with HCV genotype 1a and 1b in both trials. The placebo control arms in both studies were stopped because of high rates of virological failure. Numerically lower relapse rates were associated with longer treatment with mericitabine (24 versus 12 weeks), telaprevir-containing regimens, and regimens that included 48 weeks of PegIFN alfa-2a/RBV therapy. No mericitabine resistance mutations were identified in any patient in either trial. The addition of mericitabine did not add to the safety burden associated with either telaprevir or boceprevir-based regimens. These studies demonstrate increased SVR rates and reduced relapse rates in difficult-to-treat patients when a nucleoside polymerase inhibitor with intermediate antiviral potency is added to regimens containing a first-generation PI.\",\"Daclatasvir is a nonstructural protein 5A inhibitor of hepatitis C virus (HCV) replication. Asunaprevir is an NS3/4A complex inhibitor of HCV replication. The combination of daclatasvir and asunaprevir has been approved in Japan for the treatment of genotype 1 chronic HCV infection. In vitro studies have documented potent activity of these drugs, individually and in combination, against genotype 1 HCV. Results from completed and ongoing clinical studies have confirmed this potent activity in patients, with better responses noted in genotype 1b patients compared to patients with genotype 1a HCV. Response rates are also better in treatment-naive patients compared to those who are treatment-experienced; in these cases, the addition of interferon and ribavirin appears to enhance the treatment response. The combination of daclatasvir and asunaprevir is, in general, well tolerated. Daclatasvir and asunaprevir are substrates for cytochrome P450 3A4 enzymatic pathway; thus, there is a substantial potential for drug interactions.\",\"Marginal zone lymphomas have been associated with several infectious agents covering both viral and bacterial pathogens and in some cases a clear aetiological role has been established. Pathogenetic mechanisms are currently not completely understood. However, the role of chronic stimulation of the host immune response with persistent lymphocyte activation represents the most convincing explanation for lymphoproliferation. Gastric MALT lymphoma is strictly associated with Helicobacter pylori infection and various eradicating protocols, developed due to increasing antibiotic resistance, represent the first line therapy for gastric MALT. The response rate to eradication is good with 80% of response at 1 year; this finding is also noteworthy because it recapitulates cancer cured only by the antibacterial approach and it satisfies the Koch postulates of causation, establishing a causative relationship between Hp and gastric MALT lymphoma. Patients with chronic HCV infection have 5 times higher risk to develop MZL, in particular, an association with splenic and nodal MZL has been shown in several studies. Moreover, there is evidence of lymphoma regression after antiviral therapy with interferon+ribavirin, thus raising hope that newly available drugs, extremely efficient against HCV replication, could improve outcome also in HCV-driven lymphomas. Another case-study are represented by those rare cases of MZL localized to orbital fat and eye conjunctivas that have been associated with Chlamydophila psittaci infection carried by birds. Efficacy of antibacterial therapy against C. psittaci are conflicting and generally poorer than gastric MALT. Finally, some case reports will cover the relationship between primary cutaneous B-cell Lymphomas and Borrelia Burgdorferi.\",\"Hepatitis C virus (HCV) infection is a major global health issue. Although the search for HCV treatments has resulted in great achievements, the current treatment methods have limitations, and new methods and drugs for hepatitis C treatment are still required. The aim of the present study was to investigate the effects of artesunate (ART) on HCV replication and compared these effects with those of ribavirin (RBV) and interferon-2b (IFN). The study was performed in HCV-infection cell models (JFH1-infected Huh7.5.1 and OR6 cell lines). Our results showed that the antimalarial drug ART inhibited HCV replicon replication in a dose- and time-dependent manner at a concentration that had no effect on the proliferation of exponentially growing host cells, and the inhibitory effect on HCV replication was stronger than RBV but weaker than IFN, as determined by qPCR, luciferase assays, and Western blot analysis. Furthermore, the combination of ART and IFN resulted in a greater inhibition of HCV replication. These findings demonstrated that ART had an inhibitive effect on HCV replication and may be a novel supplemental co-therapy with IFN and RBV for HCV and as an alternative strategy to combat resistance mechanisms that have emerged in the presence of DAA agents.\",\"Hepatitis disease caused by hepatitis C virus (HCV) is a severe threat to global public health, affecting approximately 3% of the world's population. Sofosbuvir (PSI-7977), a uridine nucleotide analog inhibitor targeting the HCV NS5B polymerase, was approved by FDA at the end of 2013 and represents a key step towards a new era in the management of HCV infection. Previous study identified NITD008, an adenosine nucleoside analog, as the specific inhibitor against dengue virus and showed good antiviral effect on other flaviviruses or enteroviruses. In this report, we systematically analyzed the anti-HCV profile of NITD008, which was discovered to effectively suppress the replication of different strains of HCV in human hepatoma cells with a low nanomolar activity. On genotype 2a virus, or 2a, 1a, and 1b replicon cells, EC50 values were 8.7 nM, 93.3 nM, 60.0 nM and 67.2 nM, and selective index values were >2298.9, >214.4, >333.3, >298.5 respectively. We demonstrated that resistance to NITD008 was conferred by mutation in NS5B (S282T) in the HCV infectious virus genotype 2a (JFH-1). Then, we compared the resistant profiles of NITD008 and PSI-7977, and found that the folds change of EC50 of NITD008 to full replicon cells containing mutation S282T was much bigger than PSI-7977(folds 76.50 vs. 4.52). Analysis of NITD008 cross-resistance against previously reported NS5B drug-selected mutations showed that the resistance pattern of NITD008 was not completely similar to PSI-7977, and meanwhile, S282T resistant mutation to NITD008 emerge more easily in cell culture than PSI-7977. Interestingly, NITD008 displayed significant synergistic effects with the NS5B polymerase inhibitor PSI-7977, however, only additive effects with alpha interferon (IFN\\u03b1-2b), ribavirin, and an NS3 protease inhibitor. These results verify that NITD008 is an effective analog inhibitor against hepatitis C virus and a good research tool as a supplement to other types of nucleoside analogs.\",\"Hepatitis E virus (HEV) can lead to chronic infection in solid-organ transplant patients. Ribavirin is efficient for treatment of chronically infected patients. Recently, the1634R mutation in the HEV polymerase has been associated with treatment failure. However, it is unclear if this mutation can be used as a prognostic marker of treatment outcome. We studied the prevalence of the 1634R mutation in the HEV polymerase of patients starting ribavirin therapy, the influence of the 1634R variants on the viral response, the frequency of the 1634R mutation in patients whose treatment failed, and its impact on ribavirin retreatment. We analyzed pretreatment samples from 63 solid-organ transplant patients with chronic hepatitis E using deep sequencing; 42 patients had a sustained virologic response (SVR), and 21 were non-SVR patients. We detected the 1634R variant by deep sequencing in 36.5% (23/63) of the patients (proportions, 1.3 to 100%). The 1634R variant was detected in 31.0% (13/42) of baseline plasma samples from patients with SVR and in 47.6% (10/21) in the other patients (P = 0.2). The presence of this mutation did not influence the initial decrease in viral RNA. Lastly, a second prolonged ribavirin treatment led to SVR in 70% of the patients who initially did not have SVR, despite the presence of the 1634R variant. We conclude that the presence of the 1634R variant at ribavirin initiation does not lead to absolute ribavirin resistance. Although its proportion increased in patients whose treatment failed, the presence of the 1634R variant did not compromise the response to a second ribavirin treatment.\",\"Approximately 1 million South Africans are infected with Hepatitis C virus (HCV). The standard of care (SOC) in South Africa is combination therapy (pegylated interferon and ribavirin). HCV genotypes and/or mutations in the core/non-structural regions have been associated with response to therapy and/or disease progression. This study examines mutations in the core (29-280 amino acids, including \\u223c 90 E1 amino acids) and NS5B (241-306 amino acids) regions on pre-treatment isolates from patients attending Johannesburg hospitals or asymptomatic South African blood donors. Diversity within known CD4+ and CD8+ T-cell epitopes was also explored. Samples grouped into subtypes 1a(N = 10) 1b(N = 12), 3a(N = 5), 4a(N = 3) and 5a(N = 61). Two mutations, associated with interferon resistance-R70Q and T110N-were present in 29 genotype 5a core sequences. No resistance mutation to NS5B nucleotide inhibitors, sofosbuvir was found. Six putative CD8+ and one CD4+ T-cell epitope sequence in the core region showed binding scores of <300 IC50nM to HLA alleles frequently observed in the South African population. No known CD8+ and CD4+ T-cell epitopes were mapped in the NS5B region. The analysis begs the question whether those infected with genotype 5a will benefit better on interferon-free combination therapies. This study provides new insight into one of the lesser studied HCV genotypes and compares the diversity seen in a large pre-treatment cohort with other subtypes.\",\"Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-\\u03b1 plus ribavirin combination therapy (PEG-IFN\\u03b1/RBV). But the exact mechanisms remain unclear. The aim of this study was to investigate the dynamic response of wild and mutant core codon 70 strains to PEG-IFN\\u03b1/RBV treatment.\",\"Direct-acting antiviral (DAA)-based therapy is the new standard treatment for chronic hepatitis C virus (HCV) infection. However, protease inhibitor (PI)-resistant viral variants have been often described. This study aimed to examine HCV-NS3 protease variants at baseline and at 4 weeks under triple therapy. To this end, we analyzed the presence of variants in HCV-NS3 protease region from peripheral blood samples of 16 patients infected with HCV-1 at baseline and at 4 weeks of combined therapy with telaprevir, pegylated interferon, and ribavirin, using next-generation sequencing. Several variants with synonymous and non-synonymous amino acid substitutions were detected at both time points. Variants detected at low frequency corresponded to 74% (HCV-1a) and 35% (HCV-1b) of non-synonymous substitutions. We found nine PI-resistance-associated variants (V36A, T54S, V55I, Q80K, Q80R, V107I, I132V, D168E, M175L) in HCV-NS3 of 10 patients. There was no correspondence of resistance-associated variant profile between baseline and at 4 weeks. Moreover, these resistance variants at baseline and short-term treatment are not good predictors of outcome under triple therapy. Our study also shows a large number of others minor and major non-synonymous variants in HCV-NS3 early in telaprevir-based therapy that can be important for further drug resistance association studies with newly developed PI agents.\",\"Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and young children. In addition, RSV causes significant morbidity and mortality in hospitalized elderly and immunocompromised patients. Currently, only palivizumab, a monoclonal antibody against the RSV fusion (F) protein, and inhaled ribavirin are approved for the prophylactic and therapeutic treatment of RSV, respectively. Therefore, there is a clinical need for safe and effective therapeutic agents for RSV infections. GS-5806, discovered via chemical optimization of a hit from a high-throughput antiviral-screening campaign, selectively inhibits a diverse set of 75 RSV subtype A and B clinical isolates (mean 50% effective concentration [EC50] = 0.43 nM). The compound maintained potency in primary human airway epithelial cells and exhibited low cytotoxicity in human cell lines and primary cell cultures (selectivity > 23,000-fold). Time-of-addition and temperature shift studies demonstrated that GS-5806 does not block RSV attachment to cells but interferes with virus entry. Follow-up experiments showed potent inhibition of RSV F-mediated cell-to-cell fusion. RSV A and B variants resistant to GS-5806, due to mutations in F protein (RSV A, L138F or F140L/N517I, and RSV B, F488L or F488S), were isolated and showed cross-resistance to other RSV fusion inhibitors, such as VP-14637, but remained fully sensitive to palivizumab and ribavirin. In summary, GS-5806 is a potent and selective RSV fusion inhibitor with antiviral activity against a diverse set of RSV clinical isolates. The compound is currently under clinical investigation for the treatment of RSV infection in pediatric, immunocompromised, and elderly patients.\",\"Insulin resistance (IR) modifies the anti-viral effects of interferon (IFN) therapy in patients with chronic hepatitis C (CHC). This prospective study evaluated whether lifestyle interventions improve the anti-viral response to treatment with pegylated (PEG)-IFN plus ribavirin (RBV) in patients with CHC.\",\"For many years, the standard of treatment for hepatitis C virus (HCV) infection was a combination of pegylated interferon alpha (Peg-IFN-\\u03b1) and ribavirin for 24-48 weeks. This treatment regimen results in a sustained virologic response (SVR) rate in about 50% of cases. The failure of IFN-\\u03b1-based therapy to eliminate HCV is a result of multiple factors including a suboptimal treatment regimen, severity of HCV-related diseases, host factors and viral factors. In recent years, advances in HCV cell culture have contributed to a better understanding of the viral life cycle, which has led to the development of a number of direct-acting antiviral agents (DAAs) that target specific key components of viral replication, such as HCV NS3/4A, HCV NS5A, and HCV NS5B proteins. To date, several new drugs have been approved for the treatment of HCV infection. Application of DAAs with IFN-based or IFN-free regimens has increased the SVR rate up to >90% and has allowed treatment duration to be shortened to 12-24 weeks. The impact of HCV proteins in response to IFN-based and IFN-free therapies has been described in many reports. This review summarizes and updates knowledge on molecular mechanisms of HCV proteins involved in anti-IFN activity as well as examining amino acid variations and mutations in several regions of HCV proteins associated with the response to IFN-based therapy and pattern of resistance associated amino acid variants (RAV) to antiviral agents.\",\"Over the last several years, many advances have been made in the treatment of chronic hepatitis C virus (HCV) infection with the development of direct-acting antivirals. Paritaprevir/ritonavir/ombitasvir with dasabuvir (PrOD) is a novel combination of a nonstructural (NS) 3/4A protein inhibitor boosted by ritonavir, an NS5A protein inhibitor, and an NS5B nonnucleoside polymerase inhibitor. This review aims to discuss the pharmacology, efficacy, safety, drug interactions, and viral drug resistance of PrOD in the treatment of HCV genotype 1 infections. Phase I, II, and III human and animal studies that describe the pharmacology, pharmacokinetics, efficacy, and safety of PrOD for HCV were identified and included. Studies that evaluated patients without cirrhosis (n=2,249) and with cirrhosis (n=422) demonstrated that PrOD for 12 or 24 weeks was effective at achieving sustained virologic response rates (>90%) in patients with genotype 1a or 1b HCV infection. Although indicated for the treatment of HCV genotype 1 infection, PrOD is also recommended for the treatment of HCV in patients coinfected with HIV. Additionally, promising data exist for the use of PrOD in liver-transplant recipients. The most common adverse drug events associated with PrOD included nausea, pruritus, insomnia, diarrhea, asthenia, dry skin, vomiting, and anemia. The high efficacy rates seen coupled with a favorable side effect profile seen with PrOD with or without ribavirin have led to its addition as a recommended treatment regimen for HCV genotype 1 infection.\",\"Chronic hepatitis C is a systemic disease inducing metabolic alterations leading to extrahepatic consequences. In particular, hepatitis C virus (HCV) infection seems to increase the risk of incident type 2 diabetes mellitus in predisposed individuals, independently of liver disease stage. The mechanisms through which hepatitis C induces T2DM involve direct viral effects, insulin resistance, pro-inflammatory cytokines and other immune-mediated processes. Many studies have reported the clinical consequences of type 2 diabetes mellitus on hepatitis C outcome, but very few studies have addressed the issue of microangiopathic complications among patients with hepatitis C only, who develop type 2 diabetes mellitus. Moreover, clinical trials in HCV-positive patients have reported improvement in glucose metabolism after antiviral treatment; recent studies have suggested that this metabolic amelioration might have a clinical impact on type 2 diabetes mellitus-related complications. These observations raise the question as to whether the HCV eradication may also have an impact on the future morbidity and mortality due to type 2 diabetes mellitus. The scope of this review is to summarise the current evidence linking successful antiviral treatment and the prevention of type 2 diabetes mellitus and its complications in hepatitis C-infected patients.\",\"Hepatitis C virus (HCV) infection is a major health concern worldwide. Interferon-\\u03b1 (IFN-\\u03b1) therapy has been the main antiviral treatment for more than 20 years. Because of its established antitumor effects, IFN-based treatments for chronic HCV infection still have a clinical impact, particularly for patients with high risk conditions of developing hepatocellular carcinoma, such as older age and advanced liver fibrosis. As a result of exhaustive research, several viral factors, including NS5A amino acid mutations such as the IFN sensitivity-determining region and the IFN/ribavirin resistance-determining region, and mutations of amino acids in the core protein region (core 70 and 91) were shown to be associated with the response to IFN-\\u03b1 treatment. In addition, among the host factors related to the response to IFN-\\u03b1 treatment, polymorphisms of the interleukin-28B gene were identified to be the most important factor. In this article, we review the factors associated with the efficacy of IFN-\\u03b1 treatment for chronic HCV infection. In addition, our recent findings regarding the possible involvement of anti-IFN-\\u03b1 neutralizing antibodies in a non-response to pegylated-IFN-\\u03b1 treatment are also described.\",\"Sofosbuvir (SOF) exhibits a high barrier to resistance, with no S282T NS5B substitution or phenotypic resistance detected in phase 3 registration studies.\",\"Approximately 3% of the world's population is chronically infected with hepatitis C virus (HCV). In some southeast Asian countries the prevalence of HCV (\\u223c6%-7%) far exceeds that seen in the United States (1.8%). The lesser known HCV genotype 6 (HCV-6) is also common in patients from southeast Asia and the surrounding regions. Most data on direct-acting antivirals (DAAs) to date have been derived from clinical trials conducted in Western countries, where HCV-6 is rare. The standard of care for patients with HCV-6 is still pegylated interferon and ribavirin. However, data are emerging for several DAA combinations.\",\"The combination of ombitasvir (an NS5A inhibitor), paritaprevir (an NS3/4A inhibitor) coadministered with ritonavir (r), and dasabuvir (an NS5B nonnucleoside polymerase inhibitor), referred to as the 3D regimen, and the combination of ombitasvir-paritaprevir-r, referred to as the 2D regimen, have demonstrated high efficacy with and without ribavirin in hepatitis C virus (HCV)-infected subjects. These regimens have potential for coadministration with sofosbuvir (nucleoside NS5B inhibitor) in the treatment of HCV. This phase 1, drug-drug interaction, open-label, multiple-dose study enrolled 32 healthy subjects to receive the 3D or 2D regimen in combination with sofosbuvir. Doses of study drugs were as follows: ombitasvir-paritaprevir-r, 25/150/100 mg daily (QD); dasabuvir, 250 mg twice daily (BID); and sofosbuvir, 400 mg QD. Blood samples were collected on study days 7, 14, and 21 for evaluating drug interaction at steady state. The effect of the 3D and 2D regimens on the pharmacokinetics of sofosbuvir and its circulating metabolite GS-331007 and vice versa was assessed by a repeated-measures analysis. Exposures of the 3D and 2D regimens were similar (\\u226420% change) during coadministration with sofosbuvir and during administration alone. Sofosbuvir exposures were 61% to 112% higher with the 3D regimen and 64% to 93% higher with the 2D regimen than with sofosbuvir alone. GS-331007 total exposures were 27% and 32% higher with the 3D and 2D regimens, respectively, than with sofosbuvir alone. Increases in sofosbuvir and GS-331007 exposures likely resulted from breast cancer resistance protein (BCRP) and/or P glycoprotein (P-gp) transporter inhibition by paritaprevir and ritonavir. No subjects discontinued the study due to study drug-related adverse events. No dose adjustment is recommended for 3D, 2D, or sofosbuvir in clinical trials exploring the safety and efficacy of the combination. (This study has been registered at ClinicalTrials.gov under registration no. NCT02356562 and NCT02292719.).\",\"Sofsobuvir is the first-in-class NS5B nucleotide inhibitor to be launched as a treatment for the hepatitis C virus (HCV). Its viral potency, pan genotypic activity and high barrier to resistance make it the ideal candidate to become a backbone for several IFN-free regimens. Ledipasvir is a NS5A inhibitor with multi genotypic activity but modest barrier to resistance. The once-daily fixed-dose combination of sofosbuvir plus ledipasvir is the first-in-market single-tablet regimen for the treatment of hepatitis C infection. Recent data demonstrated that this FDC alone, or in combination with ribavirin, is able to achieve HCV cure of at least 90% or more among genotype 1,4, 5 and 6 patients. This combination appears to be suboptimal in genotype 3 patients and other direct acting antiviral combinations with sofosbuvir will help to fulfill this gap in the near future. The safety profile of the fixed dose combination is good. Resistance is not an issue with sofosbuvir but may be a significant issue with regards to ledipasvir for those rare individuals who harbor baseline HCV NS5A resistance-associated variants that conferred a high resistance level. The rational for using FDCs and the available clinical data are reviewed.\",\"Current combination therapy of PEG-INF and ribavirin against the Hepatitis C Virus (HCV) genotype-1 infections is ineffective in maintaining sustained viral response in 50% of the infection cases. New compounds in the form of protease inhibitors can complement the combination therapy. Asunaprevir is new to the drug regiment as the NS3-4A protease inhibitor, but it is susceptible to two mutations, namely, R155K and D168A in the protein. Thus, in our study, we sought to evaluate Andrographolide, a labdane-diterpenoid from the Andrographis paniculata plant as an effective compound for inhibiting the NS3-4A protease as well as its concomitant drug-resistant mutants by using molecular docking and dynamic simulations. Our study shows that Andrographolide has best docking scores of -15.0862, -15.2322, and -13.9072 compared to those of Asunaprevir -3.7159, -2.6431, and -5.4149 with wild-type R155K and D168A mutants, respectively. Also, as shown in the MD simulations, the compound was good in binding the target proteins and maintains strong bonds causing very less to negligible perturbation in the protein backbone structures. Our results validate the susceptibility of Asunaprevir to protein variants as seen from our docking studies and trajectory period analysis. Therefore, from our study, we hope to add one more option in the drug regiment to tackle drug resistance in HCV infections.\",\"In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3.\",\"As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase.\",\"Hepatitis C virus (HCV) affects nearly 1.3% of US population and around 2% of people worldwide. It is associated with serious complication of Cirrhosis and Hepatocellular carcinoma leading to significant morbidity and mortality. Until now the only treatment option for this serious disease was interferon based therapy which had poor tolerance and at best SVR (Sustained virological response) in only 50% of cases. With the introduction of other direct - acting antiviral agents the treatment of HCV has been revolutionized with significantly high rates of cure. Among novel Direct acting antivirals are non-nucleoside inhibitor NS5B which is highly effective in treatment of HCV genotype 1 a and 1b including those with compensated cirrhosis achieving high cure rates with SVR more than 97 % in pooled analysis from six different phase 3 trials. This review will discuss the DAA - Dasabuvir, a non - nucleoside NS5B inhibitor, its mechanism of action, efficacy, safety & tolerance, and drug resistance. Dasabuvir is approved by FDA in combination with other DAA agents called as the 3D(Viekira Pak) in various interferon free regimens achieving high cure rates (SVR >95%) with low adverse effects. In Europe, it is approved by European medicines agency for use in combination with Ombitasvir, Paritaprevir, and ritonavir with or without ribavirin. The drug is used in treatment naive as well as previously treated patient with high success rates. It is also approved in patients with compensated cirrhosis, patients with HIV co-infection and liver transplant recipients which were in the past were excluded from treatment with interferon based therapy. Dasabuvir is extensively evaluated in large clinical trials and shown excellent SVR among HCV genotype1 patient population in combination with other oral DAAs, with good safety profile and tolerance. Its drawback is its genotype restriction, need for ribavirin (RBV) for 1a genotype, low resistance barrier and high cost. It is well tolerated with less than 1 % of patients permanently discontinuing treatment and 2% of patient experiencing a serious adverse reaction. It is contraindicated in patients with known hypersensitivity to ritonavir (e.g. Steven - Johnson syndrome) and strong inducers of CYP3A and CYP2CB.\",\"Sofosbuvir is the first pan-genotypic direct acting antiviral agent to be approved. This article provides an overview of the pharmacology of sofosbuvir and ribavirin and a comprehensive summary of the phase 2 and 3 studies supporting dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. With the production of generic formulations of sofosbuvir, we anticipate this regimen leading the first wave for widespread, IFN-free treatment and becoming first line for all genotypes (including genotype 1) for much of the world-in particular in developing and middle income countries. We discuss the continued challenges with this regimen including among patients with decompensated liver disease and post-liver transplant, and renal failure. We address concerns of emerging resistance. We also discuss the future prospects including the global uptake of sofosbuvir and ribavirin for the treatment of all genotypes.\",\"The combination of hepatitis B immune globulin with entecavir or tenofovir (at least for a certain period of time) seems to be the most reasonable prophylaxis against recurrent hepatitis B after liver transplantation. Entecavir represents an attractive option for treatment of na\\u00efve kidney transplant recipients, because of its high efficacy and the low rates of resistance. However antiviral treatment should be individualized in the view of kidney function and the previous resistance. To date, new captivating therapeutic strategies could make interferon-free regimens viable for treatment of hepatitis C virus positive liver transplant recipients. The recent combinations of sofosbuvir with simeprevir or daclatasvir or ledipasvir plus/minus ribavirin have boosted the on treatment and sustained virological response to rates approaching 100% within liver transplant recipients with recurrent chronic hepatitis C (CHC). Preliminary data showed that the second generation direct oral antivirals could result to high treatment rates of recurrent CHC in kidney transplant recipients as well. Ongoing studies will clarify the optimal treatment of recurrent CHC in kidney transplant recipients.\",\"Within the development and approval of several new direct-acting antivirals (DAA) against hepatitis C virus (HCV), a new era of hepatitis C therapy has begun. Even more treatment options are likely to become available during the next 1-2 years.\",\"Effective, pangenotypic treatments for hepatitis C virus (HCV) infection are needed.\",\"Direct-acting antiviral agents (DAAs) combined with pegylated-interferon (PegIFN) and ribavirin (RBV) are still a standard treatment in patients with genotype 1HCV infection. However, virologic response could be impaired by baseline or early selection of resistant HCV strains.\",\"Patients with chronic hepatitis C virus (HCV) infection and cirrhosis have a higher risk for liver-related complications and have historically been more difficult to cure than patients without cirrhosis. We evaluated the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir, without ribavirin, for 12weeks in patients with HCV genotype 1b infection and compensated cirrhosis.\",\"We evaluated the combination of daclatasvir (pan-genotypic NS5A inhibitor) and simeprevir (NS3/4A protease inhibitor), with or without ribavirin, in hepatitis C virus genotype 1-infected patients.\",\"Standard of care for chronic hepatitis C in Japan is currently a pegylated interferon (IFN)-\\u03b1 + ribavirin (PR)-based regimen, notably associated with efficacy and tolerability issues. The advent of novel direct-acting antivirals (DAA) has provided more efficacious and better tolerated treatments. This study investigated the cost-effectiveness of the daclatasvir + asunaprevir (DCV + ASV) DAA regimen in patients infected with hepatitis C virus (HCV) genotype 1b who had previously not responded to or were ineligible for IFN-containing regimens.\",\"There is an unmet need for interferon- and ribavirin-free treatment for chronic HCV infection in patients with comorbidities including cardiovascular disease (CVD). The aim of this study was to evaluate the rates of sustained virological response (SVR) and adverse events in a cohort of patients with nosocomially acquired HCV genotype-1b following 12 weeks of therapy with fixed-dose combination (FDC) ledipasvir/sofosbuvir (LDV/SOF).\",\"The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-\\u03b1-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development, and direct-acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens.\",\"Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries. All patients who undergo LT with detectable serum HCV RNA experience graft reinfection progressing to cirrhosis within five years in 20% to 30% of them. Obtaining a sustained virological response (SVR) greatly improves overall and graft survival. Until 2011, standard antiviral therapy using PEGylated interferon (PEG-IFN) and ribavirin (RBV) was the only effective therapy, with an SVR rate around 30% in this setting. For patients infected with genotype 1, first generation NS3/4A protease inhibitors (PIs), boceprevir (BOC) or telaprevir (TVR), associated with PEG-IFN and RBV for 48 weeks have increased the SVR rates to 60% in non-transplant patients. However, tolerability and drug-drug interactions with calcineurin inhibitors (CNI) are both limiting factors of their use in the liver transplant setting. Over recent years, the efficacy of antiviral C therapy has improved dramatically using new direct-acting antiviral (DAA) agents without PEG-IFN and/or RBV, leading to SVR rates over 90% in non-transplant patients. Results available for transplant patients showed a better efficacy and tolerability and less drug-drug interactions than with first wave PIs. However, some infrequent cases of viral resistance have been reported using PIs or NS5A inhibitors pre- or post-LT that can lead to difficulties in the management of these patients.\",\"Despite available treatment, Hepatitis C remains one of most serious burdens to public health. Current therapy based on pegylated interferon-alpha and ribavirin has significant side effects and its effectiveness varies for different genotypes of the virus. Four novel drugs - viral protease inhibitors (telaprevir, boceprevir, simeprevir) and polymerase inhibitor - sofosbuvir have been introduced in last years for use in combination with standard-of-care treatment. For the first time interferon free therapies were approved with the use of combination of sofosbuvir+ribavirin. New therapies improve virological response rates but also increase the cost, side effects and raise the issue of drug resistance. Numerous novel anti-HCV compounds have been evaluated in advanced clinical trials including inhibitors of viral proteins (protease, polymerase and NS5A) and inhibitors of host factors involved in HCV replication (cyclophilin A, microRNA - miR-122). New interferon-free therapies reducing severe side effects are expected to enter the market within few months. At the same time efforts are undertaken to determine the host and viral factors with predictive value for HCV treatment response, enabling personalized therapy approach. The main success in this field was the discovery of interleukin IL28B polymorphism, which correlates with positive standard-of-care treatment response. An effective vaccination may be an alternative for antiviral drugs, but no anti-HCV vaccine is available currently. It is well proved that successful vaccination should induce antibody and T-cell responses specific against a range of HCV genotypes. With this aim, new subunit and genetic candidate vaccines have been evaluated in I and II phase clinical trials. This review summarizes the recent developments in the field of new drug development and vaccine studies against hepatitis C virus.\",\"Influenza is a major cause of severe respiratory infections leading to excessive hospitalizations and deaths globally; annual epidemics, pandemics, and sporadic/endemic avian virus infections occur as a result of rapid, continuous evolution of influenza viruses. Emergence of antiviral resistance is of great clinical and public health concern. Currently available antiviral treatments include four neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, laninamivir), M2-inibitors (amantadine, rimantadine), and a polymerase inhibitor (favipiravir). In this review, we focus on resistance issues related to the use of neuraminidase inhibitors (NAIs). Data on primary resistance, as well as secondary resistance related to NAI exposure will be presented. Their clinical implications, detection, and novel therapeutic options undergoing clinical trials are discussed.\",\"The phase 2 C-SALVAGE study (Hepatitis C-Salvage Study for Patients who Failed DAA/PR Therapy) demonstrated a 96.2% sustained virologic response at 12 weeks (SVR12) rate using the NS3/4A protease inhibitor grazoprevir and the NS5A inhibitor elbasvir together with ribavirin in treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection.\",\"We investigated the susceptibility of 10 enterovirus D68 (EV-D68) isolates (belonging to clusters A, B, and C) to (entero)virus inhibitors with different mechanisms of action. The 3C-protease inhibitors proved to be more efficient than enviroxime and pleconaril, which in turn were more effective than vapendavir and pirodavir. Favipiravir proved to be a weak inhibitor. Resistance to pleconaril maps to V69A in the VP1 protein, and resistance to rupintrivir maps to V104I in the 3C protease. A structural explanation of why both substitutions may cause resistance is provided.\",\"The presence of resistance-associated variants (RAVs) of hepatitis C virus (HCV) attenuates the efficacy of direct acting antivirals (DAAs). The objective of this study was to characterize the susceptibility of RAVs to interferon-based therapy.\",\"Grazoprevir (MK-5172, Merck & Co., Inc.) is a selective inhibitor of the hepatitis C virus (HCV) NS3/4a protease. The aim of this study was to evaluate the safety and efficacy of grazoprevir at doses of 25-100 mg/day in combination with peginterferon and ribavirin (PEG-IFN/RBV). In this randomized, dose-ranging, multicentre trial, treatment-naive adults with chronic HCV genotype 1 infection received once-daily grazoprevir 25 mg, 50 mg or 100 mg plus PEG-IFN/RBV for 12 weeks. Patients with quantifiable HCV RNA (\\u226525 IU/mL) at week 4 received an additional 12 weeks of PEG-IFN/RBV. The primary endpoint was sustained virologic response (HCV RNA <25 IU/mL 12 weeks after completing therapy [SVR12]). Eighty-seven patients were randomly assigned and received \\u22651 dose of therapy. Median time to undetectable HCV RNA was 16 days in the 100-mg arm and 22 days in the 25- and 50-mg arms. All patients except one had HCV RNA undetectable or unquantifiable at week 4 and received 12 weeks of therapy. SVR12 was achieved by 13 of 24 (54.2%), 21 of 25 (84.0%) and 23 of 26 (88.5%) patients in the 25-, 50- and 100-mg arms, respectively (per-protocol analysis). Three patients discontinued as a result of nonserious adverse events (AEs) and three patients experienced serious AEs. Transaminase elevations occurred in two patients (one each in the 25- and 100-mg arms).\",\"The addition of the first direct-acting antiviral agents, the NS3 protease inhibitors boceprevir or telaprevir, to peg interferon and ribavirin was a major advance in the treatment of genotype 1 hepatitis C individuals with sustained virological response (SVR) rates of 63-75 %. Those who did not achieve SVR had high rates of resistance-associated variants against NS3 protease domain. Retreatment options for those who have failed first-generation protease inhibitors generally are guided by retreatment with direct-acting antiviral agents from other classes. Phase 2 and phase 3 data have demonstrated that retreatment with 12-24 weeks of a NS5B inhibitor (sofosbuvir) in combination with a NS5a inhibitor (daclatasvir or ledipasvir) with or without ribavirin can achieve SVR at high rates comparable to treatment-naive individuals.\",\"To evaluate virological response to telaprevir or boceprevir in combination with pegylated interferon and ribavirin and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus (HCV-HIV) coinfected patients in a real life setting.\",\"Chronic hepatitis C virus (HCV) infection is associated with several extrahepatic manifestations. Patients with HCV may develop mixed cryoglobulinemia and its sequelae, ranging from cutaneous and visceral vasculitis to glomerulonephritis and B-cell non-Hodgkin lymphoma. HCV-infected patients have increased rates of insulin resistance, diabetes, and atherosclerosis, which may lead to increased cardiovascular morbidity and mortality. Neurological manifestations of HCV infection include fatigue and cognitive impairment. The mechanisms causing the extrahepatic effects of HCV infection are likely multifactorial and may include endocrine effects, HCV replication in extrahepatic cells, or a heightened immune reaction with systemic effects. Successful eradication of HCV with interferon alfa and ribavirin was shown to improve some of these extrahepatic effects; sustained virological response is associated with resolution of complications of cryoglobulinemia, reduced levels of insulin resistance, reduced incidence of diabetes and stroke, and improved fatigue and cognitive functioning. The availability of new interferon-free, well-tolerated anti-HCV treatment regimens is broadening the spectrum of patients available for therapy, including those in whom interferon was contraindicated, and will likely result in greater improvements in the extrahepatic manifestations of HCV. If these regimens are shown to confer significant benefit in the metabolic, cardiovascular, or neuropsychiatric conditions associated with HCV infection, extrahepatic manifestations of HCV may become a major indication for treatment even in the absence of liver disease.\",\"To date, the majority of work on RNA virus replication fidelity has focused on the viral RNA polymerase, while the potential role of other viral replicase proteins in this process is poorly understood. Previous studies used resistance to broad-spectrum RNA mutagens, such as ribavirin, to identify polymerases with increased fidelity that avoid misincorporation of such base analogues. We identified a novel variant in the alphavirus viral helicase/protease, nonstructural protein 2 (nsP2) that operates in concert with the viral polymerase nsP4 to further alter replication complex fidelity, a functional linkage that was conserved among the alphavirus genus. Purified chikungunya virus nsP2 presented delayed helicase activity of the high-fidelity enzyme, and yet purified replication complexes manifested stronger RNA polymerization kinetics. Because mutagenic nucleoside analogs such as ribavirin also affect intracellular nucleotide pools, we addressed the link between nucleotide depletion and replication fidelity by using purine and pyrimidine biosynthesis inhibitors. High-fidelity viruses were more resistant to these conditions, and viral growth could be rescued by the addition of exogenous nucleosides, suggesting that mutagenesis by base analogues requires nucleotide pool depletion. This study describes a novel function for nsP2, highlighting the role of other components of the replication complex in regulating viral replication fidelity, and suggests that viruses can alter their replication complex fidelity to overcome intracellular nucleotide-depleting conditions.\",\"Patients with chronic hepatitis C virus (HCV) infection are at a greater risk of developing insulin resistance (IR). However, little is known about when insulin sensitivity may improve during or after treatment for hepatitis C. In this study, we examined the effect of combination therapy with pegylated interferon-\\u03b1 and ribavirin on IR in patients with chronic HCV infection. We also analyzed factors associated with changes in insulin sensitivity. IR was estimated by homeostasis model assessment (HOMA-IR). HOMA-IR was measured before therapy, during therapy (12 and 24 weeks), and at the end of therapy (EOT; 24 or 48 weeks). We analyzed 78 HCV patients receiving combination therapy. Twenty-two patients (28.2%) exhibited pretreatment IR (HOMA-IR >2.5). In all patients, HOMA-IR was not significantly different from baseline values at 12 weeks (P = 0.823), 24 weeks (P = 0.417), or at EOT (P = 0.158). In patients with pretreatment IR, a significant decrease in HOMA-IR was observed at 12 weeks (P = 0.023), 24 weeks (P = 0.008), and at EOT (P = 0.002). Multivariate analysis using a logistic regression model showed that baseline HOMA-IR is the only factor associated with the decline in HOMA-IR during and after therapy. The eradication of HCV infection was associated with improved insulin sensitivity among patients with pretreatment IR. This significant improvement in insulin sensitivity may occur as early as 12 weeks after the initiation of antiviral therapy.\",\"Myxoviruses such as influenza A virus (IAV) and respiratory syncytial virus (RSV) are major human pathogens, mandating the development of novel therapeutics. To establish a high-throughput screening protocol for the simultaneous identification of pathogen- and host-targeted hit candidates against either pathogen or both, we have attempted co-infection of cells with IAV and RSV. However, viral replication kinetics were incompatible, RSV signal window was low, and an IAV-driven minireplicon reporter assay used in initial screens narrowed the host cell range and restricted the assay to single-cycle infections. To overcome these limitations, we developed an RSV strain carrying firefly luciferase fused to an innovative universal small-molecule assisted shut-off domain, which boosted assay signal window, and a hyperactive fusion protein that synchronized IAV and RSV reporter expression kinetics and suppressed the identification of RSV entry inhibitors sensitive to a recently reported RSV pan-resistance mechanism. Combined with a replication-competent recombinant IAV strain harboring nanoluciferase, the assay performed well on a human respiratory cell line and supports multicycle infections. Miniaturized to 384-well format, the protocol was validated through screening of a set of the National Institutes of Health Clinical Collection (NCC) in quadruplicate. These test screens demonstrated favorable assay parameters and reproducibility. Application to a LOPAC library of bioactive compounds in a proof-of-concept campaign detected licensed antimyxovirus therapeutics, ribavirin and the neuraminidase inhibitor zanamivir, and identified two unexpected RSV-specific hit candidates, Fenretinide and the opioid receptor antagonist BNTX-7. Hits were evaluated in direct and orthogonal dose-response counterscreens using a standard recRSV reporter strain expressing Renilla luciferase.\",\"Treatment for hepatitis C virus (HCV) infection has progressed at remarkable speed. From poorly tolerated injectable therapy with very low cure rates, treatment has moved to highly effective well-tolerated all oral direct-acting antiviral therapies with cure rates above 90% for almost all patients populations. Direct-acting antivirals have developed out of an improved understanding of the viral lifecycle with recognition of targets that could be inhibited by small molecules. To date protease inhibitors, non-structural 5a inhibitors and nucleotide and non-nucleotide polymerase inhibitors have been developed. These agents have been used initially with peginterferon and ribavirin and subsequently in combination without the need for interferon. Rational combinations have overcome the major challenge of rapid emergence of drug resistance and second-generation agents in each class have improved safety and efficacy profiles with fewer drug-drug interactions and very few adverse effects. The progress of direct-acting antiviral development is outlined with a review of each class of agent as well as a discussion of challenges for the future.\",\"Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment registration studies, with rates of 1% to 7%, depending on the patients' baseline characteristics. In real life, failure is slightly higher, likely because of lower compliance. Treatment failures are usually related to relapse and less often to on-treatment viral breakthrough. Hepatitis C drug-resistant variants are detected in most patients who do not achieve viral eradication. The risk of developing these variants depends on host- and virus-related factors, the properties of the drugs used, and the treatment strategies applied. Patients who carry resistance-associated variants may not obtain benefits from treatment and are at risk of disease progression and transmission of the variants. Whether hepatitis C resistance-associated variants persist depends on their type: NS3-4A variants often disappear gradually after therapy is stopped, whereas NS5A variants tend to persist for more than 2 years. The best way to prevent emergence of resistant variants is to eliminate the virus at the first treatment using highly potent antivirals with genetic barriers to resistance. In patients failing first-generation protease inhibitors, combination therapies with sofosbuvir and NS5 inhibitors have proven effective. Some salvage regimens can be shortened to 12 weeks by addition of ribavirin. The optimal treatment for patients who fail an NS5A inhibitor and those with multidrug-resistant variants remains to be defined, and research efforts should continue to focus on treatment for these patients.\",\"Viral dynamic modelling has proven useful for designing clinical studies and predicting treatment outcomes for patients infected with the hepatitis C virus. Generally these models aim to capture and predict the on-treatment viral load dynamics from a small study of individual patients. Here, we explored extending these models (1) to clinical studies with numerous patients and (2) by incorporating additional data types, including sequence data and prior response to interferon. Data from Phase 3 clinical studies of the direct-acting antiviral telaprevir (T; total daily dose of 2250 mg) combined with pegylated-interferon alfa and ribavirin (PR) were used for the analysis. The following data in the treatment-na\\u00efve population were reserved to verify the model: (1) a T/PR regimen where T was dosed every 8 h for 8 weeks (T8(q8h)/PR) and (2) a T/PR regimen where T was dosed twice daily for 12 weeks (T12(b.i.d.)/PR). The resulting model accurately predicted (1) sustained virologic response rates for both of these dosing regimens and (2) viral breakthrough characteristics of the T8(q8h)/PR regimen. Since the observed viral variants depend on the T exposure, the second verification suggested that the model was correctly sensitive to the different T regimen even though the model was developed using data from another T regimen. Furthermore, the model predicted that b.i.d. T dosing was comparable to q8h T dosing in the PR-experienced population, a comparison that has not been made in a controlled clinical study. The methods developed in this work to estimate the variability occurring below the limit of detection for the viral load were critical for making accurate predictions.\",\"Hepatitis C virus (HCV) genotype 4 (GT4) is genetically diverse, with 17 confirmed subtypes, and comprises approximately 13% of infections worldwide. In this study, we identified GT4 subtypes by phylogenetic analysis, assessed differences in patient demographics across GT4 subtypes, examined baseline sequence variability among subtypes and the potential impact on treatment outcome, and analyzed the development of viral resistance in patients who received a regimen of ombitasvir (nonstructural protein 5A [NS5A] inhibitor) plus ritonavir-boosted paritaprevir (NS3/4A inhibitor) with or without ribavirin (RBV) for the treatment of HCV GT4 infection. Phylogenetic analysis of HCV NS3/4A, NS5A, and NS5B nucleotide sequences identified 7 subtypes (4a, 4b, 4c, 4d, 4f, 4g/4k, and 4o) among 132 patient samples. Subtype prevalence varied by country, and the distributions of patient birth cohort and race were significantly different across GT4 subtypes 4a, 4d, and non-4a/4d. Baseline amino acid variability was detected in NS5A across GT4 subtypes but had no impact on treatment outcome. Three patients experienced virologic failure and were infected with subtype 4d, and the predominant resistance-associated variants at the time of failure were D168V in NS3 and L28V in NS5A. Overall, high response rates were observed among patients infected with 7 HCV GT4 subtypes, with no impact of baseline variants on treatment outcome. GT4 subtype distribution in this study differed based on patient demographics and geography.\",\"Hepatitis C virus (HCV) infection is a common liver disease worldwide with a high rate of chronicity (75-80%) in infected individuals. The chronic form of HCV leads to steatosis, cirrhosis and hepatocellualr carcinoma. Steatosis is prevalent in HCV patients (55%) due to a combination of viral factors (effect of viral proteins on some of the intracellular pathways) and host factors (overweight, insulin resistance, diabetes mellitus, and alcohol consumption). The response rates to treatment of chronic HCV with pegylated interferon (PEG-IFN) and (in the case of genotype-1 HCV, the most common infecting genotype in the USA) ribavirin (RBV) is low, with a sustained viral response rate \\u2264 40%. Adding direct-acting antiviral agents-recently approved by the FDA-to the standard protocol has increased the response rate; however HCV-related end-stage liver disease is still the primary indication for liver transplantation in the USA. The focus of this article is on the interrelation between HCV, steatosis and metabolic syndrome.\",\"Influenza is a major cause of substantial morbidity and mortality in humans every year. Vaccination is the main strategy to prevent influenza infection, but antiviral agents also play an important role in the control of both seasonal and pandemic influenza. During the influenza A/H1N1 pandemic in 2009, early prompt antiviral therapy may have reduced the severity of the influenza outcomes including pneumonia, hospitalization and mortality in the Republic of Korea. Since the 2009 H1N1 pandemic, there have been increasing usages of antiviral agents for the treatment of patients with seasonal influenza. Although currently rare, antiviral resistance among influenza viruses may emerge and increase with increased use of neuraminidase inhibitors. New agents with different modes of action are under investigation, including favipiravir, DAS181, nitazoxanide and broad-spectrum neutralizing monoclonal antibodies. Data are limited with respect to high-dose and combination antiviral therapies. So, clinical trials are warranted to evaluate diverse antiviral combinations that may be synergistic and less likely to induce breakthrough resistance.\",\"In the era of direct-acting antiviral agents (DAAs), hepatitis C virus (HCV) genotyping tests at baseline are controversial. The HCV NS3-Q80K polymorphism is associated with resistance to the recently approved NS3 inhibitor simeprevir (SMV) when combined with PEG-interferon and ribavirin (PEG-IFN/RBV) and alternative therapy should be considered for patients with baseline Q80K. The aim of this study was to provide an estimate of Q80K prevalence at baseline in a study group of 205 DAA-na\\u00efve patients (21% of them with HIV coinfection) using NS3 full-population direct sequencing to detect resistance-associated amino acid variants (RAVs). NS3 RAVs were identified in 56 patients (27.3%). Q80K was the most frequently reported one (41%), in both HIV/HCV-coinfected and HCV-monoinfected patients, but it was only detectable in cases of HCV-subtype 1a infection. Therefore, in clinical practice, an NS3-Q80K genotyping test prior to simeprevir plus PEG-IFN/RBV treatment is highly recommended.\",\"Thrombocytopaenia and hypoalbuminaemia are surrogate markers for portal hypertension and hepatic synthetic dysfunction respectively. Patients infected with hepatitis C virus (HCV) with these surrogates have reduced likelihood of sustained virologic response and increased risk for hepatic decompensation or death when treated with peginterferon/ribavirin plus either telaprevir or boceprevir.\",\"This article examines the dynamics and factors underlying hepatitis C virus (HCV) resistance, along with their impact on daily clinical management of HCV-infected patients.\",\"Dual oral therapy with daclatasvir plus asunaprevir yielded an SVR rate of 85% among patients with genotype 1b HCV. Treatment failure mainly occurred in patients with pre-existing HCV with NS5A-Y93H mutation. The significance of the mutation was evaluated.\",\"Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance.\",\"To examined the efficacy and safety of treatment with boceprevir, PEGylated-interferon and ribavirin (PR) in hepatitis C virus genotype 1 (HCVGT1) PR treatment-failures in Asia.\",\"Analysis of data pooled from multiple phase 2 (SILEN-C1 to 3) and phase 3 studies (STARTVerso1 to 4) of the hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) protease inhibitor faldaprevir plus pegylated interferon alpha/ribavirin (PR) provides a comprehensive evaluation of baseline and treatment-emergent NS3/4A amino acid variants among HCV genotype-1 (GT-1)-infected patients. Pooled analyses of GT-1a and GT-1b NS3 population-based pretreatment sequences (n = 3,124) showed that faldaprevir resistance-associated variants (RAVs) at NS3 R155 and D168 were rare (<1%). No single, noncanonical NS3 protease or NS4A cofactor baseline polymorphism was associated with a reduced sustained virologic response (SVR) to faldaprevir plus PR, including Q80K. The GT-1b NS3 helicase polymorphism T344I was associated with reduced SVR to faldaprevir plus PR (P < 0.0001) but was not faldaprevir specific, as reduced SVR was also observed with placebo plus PR. Among patients who did not achieve SVR and had available NS3 population sequences (n = 507 GT-1a; n = 349 GT-1b), 94% of GT-1a and 83% of GT-1b encoded faldaprevir treatment-emergent RAVs. The predominant GT-1a RAV was R155K (88%), whereas GT-1b encoded D168 substitutions (78%) in which D168V was predominant (67%). The novel GT-1b NS3 S61L substitution emerged in 7% of virologic failures as a covariant with D168V, most often among the faldaprevir breakthroughs; S61L in combination with D168V had a minimal impact on faldaprevir susceptibility compared with that for D168V alone (1.5-fold difference in vitro). The median time to loss of D168 RAVs among GT-1b-infected patients who did not have a sustained virologic response at 12 weeks posttreatment (non-SVR12) after virologic failure was 5 months, which was shorter than the 14 months for R155 RAVs among GT-1a-infected non-SVR12 patients, suggesting that D168V is less fit than R155K in the absence of faldaprevir selective pressure.\",\"Hepatitis E virus (HEV) is yearly responsible for approximately 20 million infections worldwide. Although most infections occur in developing countries, HEV appears to be an emerging problem in several industrialized countries, where it is mostly associated with either traveling to an HEV endemic area or contact with pigs, which represent a major reservoir of HEV. The major risk groups for HEV infection and its ensuing complications are elderly men, pregnant women, young children, immunocompromised patients, patients with preexisting liver disease, and workers that come into close contact with HEV-infected animals. Whereas HEV mainly causes acute self-limiting infections, chronic infections may occur among immunocompromised patients (e.g., transplant recipients and human immunodeficiency virus [HIV]-infected patients). Accordingly, HEV-HIV coinfection leads to accelerated liver cirrhosis and increased mortality rates compared to HEV infection alone, which is, except during pregnancy, usually associated with only low mortality. In the Western world, the most common genotype (gt) causing HEV infection is gt 3. Ribavirin (RBV) and interferon have been used successfully for treatment of HEV, but this treatment is contraindicated in certain patient groups. Therefore, novel antiviral compounds are highly needed, especially given that viral isolates with RBV resistance have been recently identified. Moreover, eradication of HEV is hampered by long-term environmental persistence of the virus, which represents a continuous source of the virus. In 2011, the first prophylactic HEV vaccine, Hecolin, was approved in China, but it is not yet globally available. In this review, we will discuss the molecular virology of HEV, mode of transmission in industrialized countries, and potential implications for different specific patient populations.\",\"Interferon-free treatment options are rapidly evolving for patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection with cirrhosis and for nonresponders to prior pegylated interferon and ribavirin therapy. We performed a phase 2b, open-label trial of the combination of ombitasvir (a NS5A replication complex inhibitor), paritaprevir, and ritonavir (an NS3/4A protease inhibitor)-an interferon- and ribavirin-free regimen-in difficult-to-treat patients, including prior null responders and patients with cirrhosis.\",\"The objective of this systematic review was to summarize evidence regarding hepatitis C in hepatitis C virus/human immunodeficiency virus (HCV/HIV)-co-infected children focusing on mother-to-child transmission, clinical and laboratory features, outcome, and therapies.\",\"Persons with hepatitis C virus (HCV) genotype 1a (GT1a) infections harboring a baseline Q80K polymorphism in nonstructural protein 3 (NS3) have a reduced virologic response to simeprevir in combination with pegylated interferon-alfa and ribavirin. We aimed to develop, validate, and freely disseminate an NS3 clinical sequencing assay to detect the Q80K polymorphism and potentially other HCV NS3 drug resistance mutations. HCV RNA was extracted from frozen plasma using a NucliSENS easyMAG automated nucleic acid extractor, amplified by nested reverse transcription-PCR, and sequenced using Sanger and/or next-generation (MiSeq) methods. Sanger chromatograms were analyzed using in-house software (RECall), and nucleotide mixtures were called automatically. MiSeq reads were iteratively mapped to the H77 reference genome, and consensus NS3 sequences were generated with nucleotides present at >20% called as mixtures. The accuracy, precision, and sensitivity for detecting the Q80K polymorphism were assessed in 70 samples previously sequenced by an external laboratory. A comparison of the sequences generated by the Sanger and MiSeq methods with those determined by an external lab revealed >98.5% nucleotide sequence concordance and zero discordant calls of the Q80K polymorphism. The results were both highly repeatable and reproducible (>99.7% nucleotide concordance and 100% Q80K concordance). The limits of detection (>2 and \\u223c5 log10 IU/ml for the Sanger and MiSeq assays, respectively) are sufficiently low to allow genotyping in nearly all chronically infected treatment-naive persons. No systematic bias in the under- or overamplification of minority variants was observed. Coinfection with other viruses (e.g., HIV and hepatitis B virus [HBV]) did not affect the assay results. The two independent HCV NS3 sequencing assays with the automated analysis procedures described here are useful tools to screen for the Q80K polymorphism and other HCV protease inhibitor drug resistance mutations.\",\"Alisporivir is a cyclophilin inhibitor with pan-genotypic anti-hepatitis C virus (HCV) activity and a high barrier to viral resistance. The VITAL-1 study assessed alisporivir as interferon (IFN)-free therapy in treatment-na\\u00efve patients infected with HCV genotype 2 or 3. Three hundred forty patients without cirrhosis were randomized to: arm 1, alisporivir (ALV) 1,000 mg once-daily (QD); arm 2, ALV 600 mg QD and ribavirin (RBV); arm 3, ALV 800 mg QD and RBV; arm 4, ALV 600 mg QD and pegylated IFN (Peg-IFN); or arm 5, Peg-IFN and RBV. Patients receiving IFN-free ALV regimens who achieved rapid virological response (RVR) continued the same treatment throughout, whereas those with detectable HCV RNA at week 4 received ALV, RBV, and Peg-IFN from weeks 6 to 24. Overall, 300 patients received ALV-based regimens. In arm 1 to arm 4, the intent-to-treat rates of sustained virological response (SVR) 24 weeks after treatment (SVR24) were from 80% to 85%, compared with 58% (n = 23 of 40) with Peg-IFN/RBV. Per-protocol analysis showed higher SVR24 rates in patients who received ALV/RBV, IFN-free after RVR (92%; n = 56 of 61) than with ALV alone after RVR (72%; n = 13 of 18) or with Peg-IFN/RBV (70%; n = 23 of 33). Both RVRs and SVRs to ALV IFN-free regimens were numerically higher in genotype 3- than in genotype 2-infected patients. Viral breakthrough was infrequent (3%; n = 7 of 258). IFN-free ALV treatment showed markedly better safety/tolerability than IFN-containing regimens.\",\"The strong impact of interleukin 28B (IL28B) polymorphisms on sustained virological response (SVR) after peginterferon and ribavirin treatment in patients with chronic hepatitis C (CHC) is well-known. We investigated IL28B variability and hepatic expression of IP10, IFI27, ISG15, and MX1 in CHC patients, the relation of each with their clinical characteristics, and how they associated with responses to combined therapy. Genotyping and gene expression analysis were conducted in a selected cohort of treatment-na\\u00efve patients who underwent interferon and ribavirin treatment. Differential expression of IP10, IFI27, ISG15, and MX1 genes was assessed from pretreatment liver biopsies using quantitative PCR. Histopathological evaluation of liver specimens was performed on the basis of the Scheuer's modified scale. We showed that hepatic IFI27, ISG15, and MX1 expression was lower in the IL28B CC 12979860 and TT rs8099917 groups than in the CT-TT rs12979860 and TG-GG rs8099917 groups (P < 0.001). We found no differences in IP10 expression between the IL28B genotypes (P > 0.05); in contrast, IP10 expression was significantly affected by the progression of fibrosis (P = 0.007). We showed that the rs12979860 CC genotype was associated with successful treatment when compared to the rs12979860 CT-TT genotype (P = 0.004). Additionally, the expression levels of IP10, IFI27 and ISG15, but not MX1, were significantly higher in non-SVR patients than in SVR patients. The effect of variation in IL28B on the results of IFN-based treatment may be associated with changes in IFI27 and ISG15, but not with IP10. Silencing of IP10 is positive and independent from IL28B prediction of SVR, which is strongly associated with liver fibrosis in CHC patients.\",\"Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes severe and often persistent arthritis. In recent years, millions of people have been infected with this virus for which registered antivirals are still lacking. Using our recently established in vitro assay, we discovered that the approved anti-parasitic drug suramin inhibits CHIKV RNA synthesis (IC50 of \\u223c5\\u03bcM). The compound inhibited replication of various CHIKV isolates in cell culture with an EC50 of \\u223c80\\u03bcM (CC50>5mM) and was also active against Sindbis virus and Semliki Forest virus. In vitro studies hinted that suramin interferes with (re)initiation of RNA synthesis, whereas time-of-addition studies suggested it to also interfere with a post-attachment early step in infection, possibly entry. CHIKV (nsP4) mutants resistant against favipiravir or ribavirin, which target the viral RNA polymerase, did not exhibit cross-resistance to suramin, suggesting a different mode of action. The assessment of the activity of a variety of suramin-related compounds in cell culture and the in vitro assay for RNA synthesis provided more insight into the moieties required for antiviral activity. The antiviral effect of suramin-containing liposomes was also analyzed. Its approved status makes it worthwhile to explore the use of suramin to prevent and/or treat CHIKV infections.\",\"AVIATOR, a phase 2 clinical trial, evaluated ritonavir-boosted paritaprevir (a protease inhibitor), ombitasvir (an NS5A inhibitor), and dasabuvir (a nonnucleoside polymerase inhibitor) (the three-drug [3D] regimen) with or without ribavirin (RBV) for 8, 12, or 24 weeks in 406 HCV genotype 1 (GT1)-infected patients. The rate of sustained virologic response 24 weeks after treatment ranged from 88% to 100% across the arms of the 3D regimen with or without RBV; 20 GT1a-infected patients and 1 GT1b-infected patient experienced virologic failure (5.2%). Baseline resistance-conferring variants in NS3 were rare. M28V in GT1a and Y93H in GT1b were the most prevalent preexisting variants in NS5A, and C316N in GT1b and S556G in both GT1a and GT1b were the most prevalent variants in NS5B. Interestingly, all the GT1a sequences encoding M28V in NS5A were from the United States, while GT1b sequences encoding C316N and S556G in NS5B were predominant in the European Union. Variants preexisting at baseline had no significant impact on treatment outcome. The most prevalent treatment-emergent resistance-associated variants (RAVs) in GT1a were R155K and D168V in NS3, M28T and Q30R in NS5A, and S556G in NS5B. The single GT1b-infected patient experiencing virologic failure had no RAVs in any target. A paritaprevir-ritonavir dose of 150/100 mg was more efficacious in suppressing R155K in NS3 than a 100/100-mg dose. In patients who failed after receiving 12 or more weeks of treatment, RAVs were selected in all 3 targets, while most patients who relapsed after 8 weeks of treatment did so without any detectable RAVs. Results from this study guided the selection of the optimal treatment regimen, treatment duration, and paritaprevir dose for further development of the 3D regimen. (This study has been registered at ClinicalTrials.gov under registration number NCT01464827.).\",\"Since 2011, treatment of chronic hepatitis C virus (HCV) includes direct-acting antivirals (DAAs) in addition to pegylated interferon-\\u03b1 (peg-IFN) and ribavirin (RBV). IFN-based treatment induces strong cytotoxic T-lymphocyte activity directed to the protease- and polymerase-derived epitopes. This enhanced immunological pressure could favour the emergence of viral epitope variants able to evade immune surveillance and, when resistance-associated variants (RAVs) are implicated, could also be co-selected as a hitchhiking effect. This study analysed the dynamics of the frequency of protease and polymerase inhibitor RAVs that could affect future HCV treatment in human immunodeficiency virus (HIV) co-infected patients on stable antiretroviral therapy with previous IFN-based treatment failure. HCV genotype 1a RNA was extracted from plasma samples of 18 patients prior to and during (24h and 4, 12, 24 and 48 weeks) therapy with peg-IFN+RBV. Next-generation sequencing was performed on HCV-RNA populations using NS3 and NS5B PCR-amplified coding regions. Two measures of genetic diversity were used to compare virus populations: average pairwise nucleotide diversity (\\u03c0) and Tajima's D statistic. Several protease and polymerase RAVs were detected in all subjects at very low frequencies (<5%), and in most cases their presence was not constant during follow-up. Only samples from two patients for each region exhibited Q80R/K/L and A421V as highly predominant variants. No significant differences were observed among sampling times for either \\u03c0 or D values. In conclusion, previous therapy and failure of peg-IFN+RBV were not associated with an increase in DAA-targeting NS3 or NS5B RAVs that naturally exist in HIV co-infected subjects.\",\"An estimated 184 million people worldwide have hepatitis C virus (HCV) infection. Chronic infection can ultimately result in liver cirrhosis and hepatic failure. Eradication of the virus by antiviral treatment can hinder the development of the aforementioned complications. Historically, the combination therapy of PEGylated interferon/ribavirin was considered the standard-of-care therapy for HCV. Such therapy did not demonstrate satisfactory cure rates and had significant side effects that precluded its widespread use among HCV patients. In view of this situation, scientific advances have led to the development of new interferon-free regimens that are better tolerated, more effective and with shorter duration of therapy. One of the newest members of this family is the all-oral regimen (ombitasvir/paritaprevir/ritonavir co-packaged with dasabuvir) that has recently received FDA approval for the treatment of adult patients with genotype 1 HCV infection, including those with compensated cirrhosis. This new combination was found to be safe and well tolerated with high rates of sustained virologic response of up to 100%. An overview of the current knowledge about this regimen is reviewed herein.\",\"The treatment environment for chronic hepatitis C has undergone a revolution, particularly in genotype 1. Gone are interferon-based therapy and its associated tolerability challenges, inadequate response rates and numerous baseline factors that affect response to therapy. New and emerging treatment regimens employ all-oral combinations of direct-acting antiviral agents, and results of clinical trials suggest that these regimens routinely achieve cure rates >90%, even in patients who failed prior interferon-based triple therapy. In 2015, three all-oral FDA-approved regiments will be available for genotype 1 (sofosbuvir /ledipasvir, sofosbuvir/simeprevir, and paritaprevir/r/ombitasvir/dasabuvir). Furthermore, new treatment combinations appear to be more tolerable and require shorter duration of therapy. We provide an overview of the classes of direct-acting antiviral agents (DAAs), the clinical factors affecting their integration into combination therapies and recent findings from trials of such combination therapies in patients with genotype 1 HCV infection.\",\"A number of statins, the cholesterol-lowering drugs, inhibit the in vitro replication of hepatitis C virus (HCV). In HCV-infected patients, addition of statins to the earlier standard of care therapy (pegIFN-\\u03b1 and ribavirin) resulted in increased sustained virological response rates. The mechanism by which statins inhibit HCV replication has not yet been elucidated. In an attempt to gain insight in the underlying mechanism, hepatoma cells carrying an HCV replicon were passaged in the presence of increasing concentrations of fluvastatin. Fluvastatin-resistant replicon containing cells could be generated and proved \\u223c8-fold less susceptible to fluvastatin than wild-type cultures. The growth efficiency of the resistant replicon containing cells was comparable to that of wild-type replicon cells. The fluvastatin-resistant phenotype was not conferred by mutations in the viral genome but is caused by cellular changes. The resistant cell line had a markedly increased HMG-CoA reductase expression upon statin treatment. Furthermore, the expression of the efflux transporter P-gp was increased in fluvastatin-resistant replicon cells (determined by qRT-PCR and flow cytometry). This increased expression resulted also in an increased functional transport activity as measured by the P-gp mediated efflux of calcein AM. In conclusion, we demonstrate that statin resistance in HCV replicon containing hepatoma cells is conferred by changes in the cellular environment.\",\"The role of interleukin (IL) 28B in the treatment of chronic hepatitis C (CHC) has recently been examined in many studies, while a possible relationship between IL28B and the presence of mixed cryoglobulinemia (MC) remains to be clarified. In this study, we analyzed the influence of IL28B rs8099917/rs12979860 on the presence of MC and the role in treatment with PEG-IFN. We retrospectively examined 541 patients affected by CHC who were treated with pegylated interferon (PEG-IFN) and ribavirin from 2003 to 2012. We included all treatment-na\\u00efve patients without other viral co-infections or major contraindications to the PEG-IFN and ribavirin standard of care. One hundred seventy-five patients (32.3 %) had MC; 49 of these (33.3 %) had symptomatic MC. The IL28B rs8099917/rs12979860 TT/CC genotype was the most frequent in MC-positive patients with sustained virological response (SVR) (p < 0.001), while the TG/TC genotype was most frequent in non-SVR (p < 0.001). The TT/CC genotype was found to be the main positive predictive factor of MC in HCV patients (OR = 11.914; IQR = 7.092-18.776; p < 0.001); HCV genotype 2/3 was the strongest positive predictive factor of SVR (OR = 10.448; IQR = 8.352-21.561; p < 0.001); IL28B rs8099917/rs12979860 TT/CC was a better predictive factor than rs12979860 CC alone (OR = 9.829 vs. 2.663). Negative predictive factors were Metavir score F3-F4 (OR = 0.625; IQR = 0.416-0.779; p = 0.008), insulin-resistance (OR = 0.315; IQR = 0.224-0.585; p < 0.001) and presence of symptoms (OR = 0.716; IQR = 0.492-0.855; p < 0.001). IL28B rs8099917/rs12979860 is useful in the treatment of MC-positive HCV patients with PEG-IFN and ribavirin; the TT/CC genotype is associated with SVR, the TG/TC with non-SVR; TT/CC is also predictive of MC in HCV patients.\",\"A fixed-dose tablet comprising ombitasvir (an NS5A replication complex inhibitor), paritaprevir (an NS3/4A protease inhibitor) and ritonavir (a cytochrome P450 inhibitor) taken in combination with dasabuvir (an NS5B polymerase inhibitor) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in several countries, including the USA (copackaged as Viekira Pak(\\u2122)) and those of the EU (Viekirax(\\u00ae) and Exviera(\\u00ae)). In phase II and III trials, this interferon-free regimen, taken \\u00b1 ribavirin, provided high rates of sustained virological response 12 weeks post-treatment in adults with chronic HCV genotype 1a or 1b infection, including those with compensated cirrhosis, liver transplants or HIV-1 co-infection. The regimen was generally well tolerated, with nausea, insomnia, asthenia, pruritus, other skin reactions and fatigue being among the most common tolerability issues. Thus, ombitasvir/paritaprevir/ritonavir plus dasabuvir is an effective interferon-free, direct-acting antiviral regimen for use \\u00b1 ribavirin in a broad range of adults chronically infected with HCV genotype 1.\",\"Chronic hepatitis C virus (HCV) infection can cause liver cirrhosis and hepatocellular carcinoma (HCC). Several studies have demonstrated that the eradication of HCV reduces the occurrence of HCC. In Japan, as many people live to an advanced age, HCV-infected patients are also getting older, and the age at HCC diagnosis has also increased. Although older HCV-infected patients have a risk of developing HCC, the treatment response to peginterferon-alpha plus ribavirin therapy is relatively poor in these patients because of drop-out or discontinuation of this treatment due to adverse events. It is established that the mechanism of action between interferon-alpha and interferon-beta is slightly different. Short-term natural interferon-beta monotherapy is effective for patients with acute hepatitis C and patients infected with HCV genotype 2 and low viral loads. Natural interferon-beta plus ribavirin for 48 wk or for 24 wk are also effective for some patients with HCV genotype 1 or HCV genotype 2. Natural interferon-beta plus ribavirin has been used for certain \\\"difficult-to-treat\\\" HCV-infected patients. In the era of direct-acting anti-virals, natural interferon-beta plus ribavirin may be one of the therapeutic options for special groups of HCV-infected patients. In the near future, signal transduction pathways of interferon-beta will inform further directions.\",\"More than twenty years of study has provided a better understanding of hepatitis C virus (HCV) life cycle, including the general properties of viral RNA and proteins. This effort facilitates the development of sensitive diagnostic tools and effective antiviral treatments. At present, serologic screening test is recommended to perform on individuals in the high risk groups and nucleic acid tests are recommended to confirm the active HCV infections. Quantization and genotyping of HCV RNAs are important to determine the optimal duration of anti-viral therapy and predict the likelihood of response. In the early 2000s, pegylated interferon plus ribavirin became the standard anti-HCV treatment. However, this therapy is not ideal. To 2014, boceprevir, telaprevir, simeprevir, sofosbuvir and Harvoni are approved by Food and Drug Administration for the treat of HCV infections. It is likely that the new all-oral, interferon-free, pan-genotyping anti-HCV therapy will be available within the next few years. Majority of HCV infections will be cured by these anti-viral treatments. However, not all patients are expected to be cured due to viral resistance and the high cost of antiviral treatments. Thus, an efficient prophylactic vaccine will be the next challenge in the fight against HCV infection.\",\"Anno 2015, the race for developing the ideal therapy, or what is now called \\\"cure,\\\" for hepatitis C virus infection has continued unabatedly. The targets (NS3/4A protease, NS5A protein, and NS5B polymerase) have remained the same, and the number of compounds [direct-acting antivirals (DAAs)] interacting with these targets has continued to increase. Whereas pan-genotypic activity has remained a mandatory requirement, the problem of virus drug resistance has become less crucial. The need for combining DAAs acting at different sites has remained compelling, with the drugs used for combinations emanating from the same pharmaceutical company, that is, Gilead (sofosbuvir and ledipasvir) (Gilead Sciences, Foster City, CA, USA) (AbbVie, North Chicago, IL, USA), AbbVie (ABT/r, ombitasvir, and dasabuvir), and BMS (Bristol-Myers Squibb), (New York City, NY, USA) (asunaprevir and daclatasvir) among the leading contenders. At stake is the definitive cure of HCV infection [as reflected by a sustained viral response (SVR) after 12 weeks of treatment]. This SVR is expected to reduce cirrhosis and hepatocellular carcinoma, two complications inherently linked to HCV infection. Unlike hepatitis B virus and human immunodeficiency virus, HCV infection can be definitely and permanently cured by antiviral therapy because HCV has no long-term reservoir in the body. Peginterferon combined with ribavirin and even the first-wave protease inhibitors telaprevir and boceprevir now belong to the milestones that had an important, although historical, role in the final conquest of hepatitis C.\",\"This study describes the discovery of novel dengue virus inhibitors targeting both a crucial viral protein-protein interaction and an essential host cell factor as a strategy to reduce the emergence of drug resistance. Starting from known c-Src inhibitors, a virtual screening was performed to identify molecules able to interact with a recently discovered allosteric pocket on the dengue virus NS5 polymerase. The selection of cheap-to-produce scaffolds and the exploration of the biologically relevant chemical space around them suggested promising candidates for chemical synthesis. A series of purines emerged as the most interesting candidates able to inhibit virus replication at low micromolar concentrations with no significant toxicity to the host cell. Among the identified antivirals, compound 16i proved to be 10 times more potent than ribavirin, showed a better selectivity index and represents the first-in-class DENV-NS5 allosteric inhibitor able to target both the virus NS5-NS3 interaction and the host kinases c-Src/Fyn.\",\"The treatment of chronic hepatitis C has developed significantly during the last 25 years. In patients with genotype 1 infection 40-50% sustained virologic response could be achieved using pegylated interferon and ribavirin dual combination, which could be increased significantly with the introduction of direct acting antivirals. Three major groups of direct acting antivirals are known, which directly inhibit different phases of viral life cycle, by inhibiting the function of several non-structural proteins (NS3/4A protease, NS5A protein and NS5B polymerase). Due to the rapid replication rate of hepatitis C virus and the error-prone NS5B polymerase activity, mutant virions are generated, which might have reduced susceptibility to direct acting antiviral therapy. Since these resistance associated variants might exist before the antiviral therapy, they are still able to replicate during the direct acting antiviral treatment. Due to this selection pressure, the resistant virus will replace the wild type. This was especially detected during monotherapy, therefore, the first generation of direct acting antivirals have been combined with pegylated interferon and ribavirin, while recently interferon-free combinations are being developed including 2 or 3 direct acting antivirals. Using the first generation protease inhibitors boceprevir and telaprevir, it could have been seen, that the rate of resistance associated variants is higher and the therapeutic outcome is worse in patients with hepatitis C virus genotype 1a, than in 1b. Similar phenomenon was seen with the second generation of NS3/4A protease inhibitors as well as with NS5A or NS5B polymerase. This is due to the lower genetic barrier to resistance, ie. usually fewer mutations are enough for the emergence of resistance in genotype 1a. The selection of resistance associated variants is one of the most important challenges during the interferon-free therapy.\",\"Neuraminidase inhibitors (NAIs) are the only available licensed therapeutics against human H7N9 influenza virus infections. The emergence of NAI-resistant variants of H7N9viruses with an NA R292K mutation poses a therapeutic challenge. A comprehensive understanding of the susceptibility of these viruses to clinically available NAIs, non-NAIs and their combinations is crucial for effective treatment. In this study, by using limited serial passage and plaque purification, an R292K variant of the Anhui1 lineage was isolated from a patient with clinical evidence of resistance to oseltamivir. In vitro and cell-based assays confirmed a high level of resistance conferred by the R292K mutation to oseltamivir carboxylate and a moderate level of resistance to zanamivir and peramivir. Non-NAI antivirals, such as T-705, ribavirin and NT-300, efficiently inhibited both the variant and the wild-type in cell-based assays. A combination of NAIs and non-NAIs did not exhibit a marked synergistic effect against the R292K variant. However, the combination of two non-NAIs (T-705 and ribavirin) exhibited significant synergism against the mutant virus. In experimentally infected mice, the variant showed delayed onset of symptoms, a reduced viral load and attenuated lethality compared with the wild-type. Our study suggested non-NAIs should be tested clinically for H7N9 patients with a sustained high viral load. Possible drug combination regimens, such as T-705 plus ribavirin, should be further tested in animal models. The pathogenicity and transmissibility of the R292K H7N9 variant should be further assessed with genetically well-characterized pairs of viruses and, most-desirably, with competitive fitness experiments.\",\"Tegobuvir (GS-9190) is a non-nucleoside inhibitor of HCV RNA replication with proven antiviral activity in HCV-infected patients. The in vitro antiviral activity of Tegobuvir, when combined with one or two other direct acting antivirals (DAA) was assessed. When Tegobuvir was combined with either interferon \\u03b1-2b, ribavirin, the protease inhibitor (PI) VX-950, the nucleoside polymerase inhibitor (NI) 2'-C-methylcytidine or various non-nucleoside polymerase inhibitors, an overall additive antiviral activity was observed. Adding Tegobuvir (at concentrations of 6, 30 or 150nM) to replicon-containing cells in the presence of suboptimal concentrations of the PI or of the various polymerase inhibitors either markedly delayed or completely prevented resistance development against these latter compounds. Tegobuvir (15nM), when combined with the PI, was able to cure replicon-containing cells from their replicon after a single passage, whereas either compound alone (at 2-fold higher concentration) was not. The triple combination of Tegobuvir (10nM), the PI and the NI resulted in clearance of replicon RNA after only two passages. In contrast, the inhibitors when used alone at 3-fold higher concentrations were not able to cure the cells from the replicon, after as long as 6 passages. Combinations containing low concentrations of Tegobuvir are thus highly effective in curing cells from HCV replicon and in delaying or preventing the development of resistance against other DAA.\",\"Antiviral medication is used for the treatment of severe influenza infections, of which the neuraminidase inhibitors (NAIs) are the most effective drugs, approved so far. Here, we investigated the antiviral efficacy of the peptidomimetic furin inhibitor MI-701 in combination with oseltamivir carboxylate and ribavirin against the infection of highly pathogenic avian influenza viruses (HPAIV) that are activated by the host protease furin. Cell cultures infected with the strains A/Thailand/1(KAN-1)/2004 (H5N1) and A/FPV/Rostock/1934 (H7N1) were treated with each agent alone, or in double and triple combinations. MI-701 alone achieved a concentration-dependent reduction of virus propagation. Double treatment of MI-701 with oseltamivir carboxylate and triple combination with ribavirin showed synergistic inhibition and a pronounced delay of virus propagation. MI-701 resistant mutants were not observed. Emergence of NA mutation H275Y conferring high oseltamivir resistance was significantly delayed in the presence of MI-701. Our data indicate that combination with a potent furin inhibitor significantly enhances the therapeutic efficacy of conventional antivirals drugs against HPAIV infection.\",\"A series of 2-pyridinyl-3-substituted-4(3H)-quinazolinones were synthesized, and their anti-influenza A virus activities were determined using the cytopathic effect inhibition assay. Most of the compounds were potent with IC50 values ranging from 51.6 to 93.0 \\u03bcm, which are better than that of the currently marketed drug ribavirin. The molecular mechanisms of the new compounds were investigated using neuraminidase inhibition assay, cellular NF-\\u03baB signaling pathway inhibition assay, and computational docking. Compound 4e, which is a N3 imidazol-1-ylpropyl-substituted derivative of 2-pyridinyl-4(3H)-quinazolinone, had the most potent anti-influenza A virus activity in vitro, and inhibited both virus neuraminidase and cellular NF-\\u03baB signaling pathway. In conclusion, 2-pyridinyl-4(3H)-quinazolinone is a new scaffold for the design of potent anti-influenza A virus compounds, offering an alternative approach to tackle influenza drug resistance.\",\"Recurrent hepatitis C infection after liver transplantation (LT) is associated with lower rates of graft and patient survival.\",\"The availability of direct-acting antiviral (DAA) therapy has launched a new era in the management of chronic hepatitis C. Sofosbuvir, a uridine nucleotide analog that inhibits the hepatitis C RNA-dependent RNA polymerase, is the backbone of chronic hepatitis C therapy. Acting at the catalytic site of the polymerase, sofosbuvir is highly potent in suppressing viral replication and has a high genetic barrier to resistance. Sofosbuvir is effective across all hepatitis C genotypes, and is a mainstay of interferon-free combination therapy. In Phase II and III studies, genotype 1 patients who took sofosbuvir in combination with another DAA such as the NS3-4A protease inhibitor, simeprevir, or the NS5A replication complex inhibitors, ledipasvir or daclatasvir, achieved a sustained virologic response rate of over 90%. Harvoni(\\u00ae), a combination tablet of sofosbuvir and ledipasvir, dosed once daily is recommended for 24 weeks for treatment-experienced genotype 1 patients with cirrhosis, but 12 weeks of therapy is sufficient for all other populations. While genotype 2 (12 weeks or 16 weeks) and treatment-na\\u00efve genotype 3 patients (24 weeks) have excellent response rates with sofosbuvir and ribavirin, treatment-experienced cirrhotic genotype 3 patients may need the addition of another DAA such as daclatasvir. Sofosbuvir is efficacious in special populations such as HIV-hepatitis C virus-coinfected patients and liver transplant recipients and has already made a profound impact in these groups. Since it is renally eliminated, patients with advanced kidney disease or on dialysis must await dosing recommendations. Sofosbuvir-based regimens appear to be well tolerated with headache and fatigue being the most common side effects. The opportunity to cure patients with hepatitis C with sofosbuvir combination therapy is likely to change the future for our patients, particularly if the emphasis shifts to identifying those patients unaware that they are infected and providing affordable access to treatment.\",\"An influenza A(H1N1)pdm09 infection was diagnosed in a hematopoietic stem cell transplant recipient during conditioning regimen. He was treated with oral oseltamivir, later combined with intravenous zanamivir. The H275Y neuraminidase (NA) mutation was first detected, and an E119D NA mutation was identified during zanamivir therapy.\",\"Although cirrhosis has long been recognized as an important negative predictor of treatment response for hepatitis C virus (HCV) therapy, the mechanisms underlying this association remain relatively poorly understood. Treatment has progressed rapidly with the introduction of highly effective all-oral therapies, with promising outcomes even in patients with advanced cirrhosis. However, even with the new therapies, it is clear that patients with cirrhosis require special attention. Efficacy continues to be somewhat reduced compared to non-cirrhotic patients and safety is an important concern. In this review, we explore the reasons for treatment non-response in patients with cirrhosis. We focus on how cirrhosis impacts on four important areas including drug delivery, drug uptake and metabolism, immune responses and drug toxicity with examples from the clinical and basic literature. Fortunately, as treatment continues to progress, many of the challenges of treating patients with cirrhosis will become less and less problematic.\",\"The pretherapeutic presence of protease inhibitor (PI) resistance-associated variants (RAVs) has not been shown to be predictive of triple-therapy outcomes in treatment-naive patients. However, they may influence the outcome in patients with less effective pegylated interferon (pegIFN)-ribavirin (RBV) backbones. Using hepatitis C virus (HCV) population sequence analysis, we retrospectively investigated the prevalence of baseline nonstructural 3 (NS3) RAVs in a multicenter cohort of poor IFN-RBV responders (i.e., prior null responders or patients with a viral load decrease of <1 log IU/ml during the pegIFN-RBV lead-in phase). The impact of the presence of these RAVs on the outcome of triple therapy was studied. Among 282 patients, the prevalances (95% confidence intervals) of baseline RAVs ranged from 5.7% (3.3% to 9.0%) to 22.0% (17.3% to 27.3%), depending to the algorithm used. Among mutations conferring a >3-fold shift in 50% inhibitory concentration (IC50) for telaprevir or boceprevir, T54S was the most frequently detected mutation (3.9%), followed by A156T, R155K (0.7%), V36M, and V55A (0.35%). Mutations were more frequently found in patients infected with genotype 1a (7.5 to 23.6%) than 1b (3.3 to 19.8%) (P = 0.03). No other sociodemographic or viroclinical characteristic was significantly associated with a higher prevalence of RAVs. No obvious effect of baseline RAVs on viral load was observed. In this cohort of poor responders to IFN-RBV, no link was found with a sustained virological response to triple therapy, regardless of the algorithm used for the detection of mutations. Based on a cross-study comparison, baseline RAVs are not more frequent in poor IFN-RBV responders than in treatment-naive patients and, even in these difficult-to-treat patients, this study demonstrates no impact on treatment outcome, arguing against resistance analysis prior to treatment.\",\"The HCV NS3/4A serine protease inhibitors (PIs) boceprevir (BOC), telaprevir (TVR) and simeprevir (SMV) are approved for treatment of chronic hepatitis C infection in combination with pegylated interferon and ribavirin. The present study investigated the prevalence of HCV NS3 drug resistance mutations (DRMs) associated with HCV genotype-1-infected individuals at baseline and in viral breakthrough following BOC and TVR treatment.\",\"Although modified live virus (MLV) vaccines are commonly used for porcine reproductive and respiratory syndrome virus (PRRSV) control, there have been safety concerns due to the quick reversion of MLV to virulence during replication in pigs. Previous studies have demonstrated that mutant viruses emerged from lethal mutagenesis driven by antiviral mutagens and that those viruses had higher genetic stability compared to their parental strains because they acquired resistance to random mutation. Thus, this strategy was explored to stabilize the PRRSV genome in the current study.\",\"A series of novel isoflavonoids were synthesized based on structural modifications of daidzein, an active ingredient of traditional Chinese medicine (TCM) and evaluated for their anti-influenza activity, in vitro, against H1N1 Tamiflu-resistant (H1N1 TR) virus in the MDCK cell line. Among them, 4-oxo-4H-1-benzopyran-8-carbaldehydes 11a-11g were most promising, and they demonstrated better activities and selectivities comparable to those the reference ribarivin, a nucleoside antiviral agent. 3-(4-Bromophenyl)-7-hydroxy-4-oxo-4H-1-benzopyran-8-carboxaldehyde (11c) displayed the best inhibitory activity (EC50 , 29.0 \\u03bcM) and selectivity index (SI>10.3). Analysis of the structure(?)activity relationships (SAR) indicated that both the non-naturally-occurring Br-substituted B-ring and appropriate CHO and OH groups on the A-ring might be critical for the activity and selectivity against H1N1 TR influenza viruses.\",\"Daclatasvir (DCV) is an approved NS5A inhibitor with potent anti-HCV activity and broad genotype coverage. DCV resistance-associated variants (RAVs) have been described for patients infected with genotype (GT) 1, but increased GT4 prevalence in European countries as a result of immigration has boosted interest in this genotype.\",\"Hepatitis C virus (HCV) infection affects an estimated 185 million people worldwide, with chronic infection often leading to liver cirrhosis and hepatocellular carcinoma. Although HCV is curable, there is an unmet need for the development of effective and affordable treatment options. Through a cell-based high-throughput screen, we identified chlorcyclizine HCl (CCZ), an over-the-counter drug for allergy symptoms, as a potent inhibitor of HCV infection. CCZ inhibited HCV infection in human hepatoma cells and primary human hepatocytes. The mode of action of CCZ is mediated by inhibiting an early stage of HCV infection, probably targeting viral entry into host cells. The in vitro antiviral effect of CCZ was synergistic with other anti-HCV drugs, including ribavirin, interferon-\\u03b1, telaprevir, boceprevir, sofosbuvir, daclatasvir, and cyclosporin A, without significant cytotoxicity, suggesting its potential in combination therapy of hepatitis C. In the mouse pharmacokinetic model, CCZ showed preferential liver distribution. In chimeric mice engrafted with primary human hepatocytes, CCZ significantly inhibited infection of HCV genotypes 1b and 2a, without evidence of emergence of drug resistance, during 4 and 6 weeks of treatment, respectively. With its established clinical safety profile as an allergy medication, affordability, and a simple chemical structure for optimization, CCZ represents a promising candidate for drug repurposing and further development as an effective and accessible agent for treatment of HCV infection.\",\"To determine the association between rapid viral response and IL28B, IL28RA, IL10RB and MxA polymorphisms in the Chinese Han population.\",\"Retreatment of patients who have not achieved sustained virological response (SVR) after treatment with investigational direct-acting antiviral agents (DAAs) has not been extensively studied. We conducted an open-label trial to assess the efficacy and safety of sofosbuvir (SOF) plus pegylated interferon (Peg-IFN) and ribavirin (RBV) in patients with genotype 1 hepatitis C virus (HCV) who participated in previous studies of one or more Gilead investigational DAAs in combination with RBV with or without Peg-IFN. We enrolled 80 patients at 40 sites. All patients received SOF 400 mg once daily plus Peg-IFN-\\u03b1 180 \\u03bcg/week and weight-based ribavirin (1,000 or 1,200 mg/day) for 12 weeks. The efficacy endpoint was the proportion of patients with SVR 12 weeks after discontinuation of therapy (SVR12). Of the 80 patients enrolled, 36 (45%) had received two or more courses of earlier treatment for HCV and 74 (93%) had at least one resistance-associated variant (RAV) at baseline. SVR12 was achieved by 63 of the 80 patients (79%) treated. Rates of SVR12 were similar across patient subgroups. Presence of RAVs at baseline did not appear to be associated with treatment failure. Seventy-one of eighty patients (89%) experienced at least one adverse event (AE), but most events were mild to moderate in severity. The most common AEs were fatigue, headache, and nausea. No patients discontinued all treatment because of AEs.\",\"Objective. To investigate the relationship between insulin resistance and viral load decay in nondiabetic and noncirrhotic genotype 1 chronic HCV patients during peginterferon and ribavirin treatment and the possible influence of BMI and leptin as metabolic confounders. Methods. 75 consecutive noncirrhotic, nonobese, and nondiabetic patients with genotype 1 chronic hepatitis C treated with peginterferon alpha 2a plus ribavirin were evaluated. HOMA-IR, serum leptin, and BMI were measured in all patients at baseline and at weeks 12 and 48, whereas viral load was measured at the same time points and then 24 weeks after the end of treatment. Results. HOMA-IR was significantly associated with both BMI and leptin at baseline. During peginterferon plus ribavirin treatment, there was a significant reduction of HOMA-IR at weeks 12 and 48 from baseline (P = 0.033 and 0.048, resp.) in patients who achieved an early viral load decay (EVR), a trend not observed in patients who not achieved EVR. No variations during treatment were observed regarding BMI and leptin irrespective of EVR. Conclusion. The early reduction of HOMA-IR but not of BMI and leptin during antiviral treatment in noncirrhotic, chronic hepatitis C genotype 1 patients who achieved EVR suggests a viral genesis of insulin resistance in patients with nonmetabolic phenotype.\",\"Because of recent advances in deep sequencing technology, detailed analysis of hepatitis C virus (HCV) quasispecies and their dynamic changes in response to direct antiviral agents (DAAs) became possible, although the role of quasispecies is not fully understood. In this study, to clarify the evolution of viral quasispecies and the origin of drug-resistant mutations induced by interferon (IFN)-based protease inhibitor therapy, the nonstructural-3 (NS3) region of genotype 1b HCV in 34 chronic hepatitis patients treated with telaprevir (TVR)/pegylated interferon (PEG-IFN)/ribavirin (RBV) was subjected to a deep sequencing study coupled with phylogenetic analysis. Twenty-six patients (76.5%) achieved a sustained viral response (SVR), while 8 patients did not (non-SVR; 23.5%). When the complexity of the quasispecies was expressed as the mutation frequency or Shannon entropy value, a significant decrease in the IFNL3 (rs8099917) TT group and a marginal decrease in the SVR group were found soon (12 h) after the introduction of treatment, whereas there was no decrease in the non-SVR group and no significant decrease in mutation frequency in the IFNL3 TG/GG group. In the analysis of viral quasispecies composition in non-SVR patients, major populations greatly changed, accompanied by the appearance of resistance, and the compositions were unlikely to return to the pretreatment composition even after the end of therapy. Clinically TVR-resistant variants were observed in 5 non-SVR patients (5/8, 62.5%), all of which were suspected to have acquired resistance by mutations through phylogenetic analysis. In conclusion, results of the study have important implications for treatment response and outcome in interferon-based protease inhibitor therapy.\",\"Drug resistance remains a major impediment in the development of durable cancer therapies. Studies in acute myelogenous leukemia (AML) patients revealed a new form of multidrug resistance. Here, increased glioma-associated protein GLI1 leads to elevation of the UDP-glucuronosyl transferase (UGT) enzymes. UGTs add glucuronic acid to xenobiotics and metabolites. Traditionally, the loss of these enzymes is thought to contribute to cancer as a result of impaired clearance of environmental carcinogens. However, we demonstrate that overexpression of UGTs can contribute to oncogenesis by promoting drug resistance. Indeed, UGT levels in AML patients treated with ribavirin and/or cytarabine were elevated at relapse relative to diagnosis. This was reversed by GLI1 inhibition, suggesting a clinically relevant strategy to overcome drug resistance. Further, overexpression of UGTs can also lead to drug resistance in other cancers, such as certain Hsp90 inhibitors and vorinostat in colorectal and chronic lymphoblastic leukemia, respectively. Not all drugs are targets of glucuronidation, suggesting that UGT status could be relevant to treatment choice. Here, we describe several facets of UGT biology and how these could be exploited clinically. These studies demonstrate how drugs in cancer cells can be metabolized differentially than their normal counterparts. In summary, we describe a new form of drug resistance relevant to a variety of cancer contexts.\",\"Clinical phase II/III studies of the nucleotide analogue HCV NS5B inhibitor sofosbuvir (SOF) have demonstrated high efficacy in HCV-infected patients in combination therapy. To date, resistance to SOF (S282T in NS5B) has rarely been detected in patients. In this study, we investigated the evolution of S282T viral variants detected in one HCV genotype 2b-infected patient who relapsed following 12 weeks of SOF monotherapy. Deep sequencing of the NS5B gene was performed on longitudinal plasma samples at baseline, days 2 and 3 on SOF, and longitudinal samples post-SOF treatment through week 48. Intrapatient HCV evolution was analysed by maximum-likelihood phylogenetic analysis. Deep sequencing analysis revealed a low level pre-existence of S282T at 0.05% of viral sequences (4/7755 reads) at baseline and 0.03% (6/23 415 reads) at day 2 on SOF. Viral relapse was detected at week 4 post-treatment where 99.8% of the viral population harboured S282T. Follow-up analysis determined that S282T levels diminished post-treatment reaching undetectable levels 24-48 weeks post-SOF. Phylogenetic analysis together with the persistence of unique post-treatment mutations in all post-SOF samples suggested that growth of wild type resulted from reversion of the S282T mutant to a wild type and not outgrowth of the baseline wild-type population. Our data suggest that a very low level of pre-existing S282T at baseline in this patient was enriched and transiently detected following SOF monotherapy. Despite relapse with drug resistance to SOF, this patient was successfully retreated with SOF plus ribavirin for 12 weeks and is now cured from HCV infection.\",\"Great progress has been made in understanding the HCV genome and its molecular virology. This understanding has culminated in the development of direct-acting antiviral (DAA) agents targeting HCV viral proteins. Telaprevir (TVR) and boceprevir (BOC) were the first DAAs introduced for treatment of genotype 1 HCV in 2011; when used in combination with pegylated interferon (pegIFN) and ribavirin (RBV), these protease inhibitors improved efficacy in patients with chronic HCV infection compared to the traditional dual therapy. However, this combination was associated with adverse events that often led to early termination of therapy. In late 2013, the FDA approved a second wave of DAAs, sofosbuvir (SOF) and simeprevir (SMV). The use of SOF with SMV opened the door for IFN-free combination regimens. This combination was highly efficacious and well tolerated in patients with HCV genotype 1. Sofosbuvir and ledipasvir (LDV) fixed-dose oral combination (FDC) therapy, and paritaprevir/ritonavir, ombitasvir and dasabuvir \\u00b1 RBV were recently approved, elevating sustained virologic response (SVR) rates to over 95 %. We are anticipating the approval of additional IFN-free regimens with comparable efficacy and tolerability but with the addition of pangenotypic coverage, fewer drug-drug interactions, and a high barrier to resistance. This review will summarize current management for chronic HCV infection.\",\"Hepatitis C virus (HCV) is a leading cause of chronic hepatitis and infects approximately three to four million people per year, about 170 million infected people in total, making it one of the major global health problems. In a minority of cases HCV is cleared spontaneously, but in most of the infected individuals infection progresses to a chronic state associated with high risk to develop liver cirrhosis, hepatocellular cancer, or liver failure. The treatment of HCV infection has evolved over the years. Interferon (IFN)-\\u03b1 in combination with ribavirin has been used for decades as standard therapy. More recently, a new standard-of-care treatment has been approved based on a triple combination with either HCV protease inhibitor telaprevir or boceprevir. In addition, various options for all-oral, IFN-free regimens are currently being evaluated. Despite substantial improvement of sustained virological response rates, some intrinsic limitations of these new direct-acting antivirals, including serious side effects, the risk of resistance development and high cost, urge the development of alternative or additional therapeutic strategies. Gene therapy represents a feasible alternative treatment. Small RNA technology, including RNA interference (RNAi) techniques and antisense approaches, is one of the potentially promising ways to investigate viral and host cell factors that are involved in HCV infection and replication. With this, newly developed gene therapy regimens will be provided to treat HCV. In this chapter, a comprehensive overview guides you through the current developments and applications of RNAi and microRNA-based gene therapy strategies in HCV treatment.\",\"We analyzed the impact of pretreatment variants conferring boceprevir-resistance on sustained virologic response (SVR) rates achieved with boceprevir plus peginterferon-\\u03b1/ribavirin (P/R) for hepatitis C virus (HCV)-genotype-1 infection.\",\"Daclatasvir (Daklinza\\u00ae) is an inhibitor of hepatitis C virus (HCV) NS5A protein. It is a new, oral, direct-acting antiviral with potent pangenotypic activity. This article provides a narrative review of the efficacy and tolerability of daclatasvir in combination with other agents in the treatment of patients with chronic HCV infection and summarizes its pharmacological properties. Since daclatasvir has a different mechanism of action to other current direct-acting antivirals, it provides additive or synergistic antiviral activity when used in combination. It produces high sustained virological response rates when used in combination with peginterferon-\\u03b1 plus ribavirin in patients chronically infected with HCV genotypes 1-4, and provides even higher response rates when used in an interferon-free, all-oral combination with sofosbuvir, with or without ribavirin. Daclatasvir has a moderately high genetic barrier to resistance, is effective during short-term treatment over 12 weeks and has a tolerability profile similar to that of placebo. In conclusion, daclatasvir is a highly effective and well tolerated, oral, once-daily, direct-acting antiviral for use in combination therapy in adult patients chronically infected with HCV.\",\"There is an unmet need for interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in patients co-infected with human immunodeficiency virus (HIV).\",\"HIV-1/HCV co-infection is a significant health problem. Highly active antiretroviral treatment (HAART) against HIV-1 has proved to be fairly successful. On the other hand, direct acting antiviral drugs against HCV have improved cure rates but high cost and development of drug resistance are important concerns. Therefore PEGylated interferon (PEG-IFN) and ribavirin (RBV) still remain essential components of HCV treatment, and identification of host factors that predict IFN/RBV treatment response is necessary for effective clinical management of HCV infection. Impaired dendritic cell (DC) and T cell responses are associated with HCV persistence. It has been shown that IFN/RBV treatment enhances HCV-specific T cell functions and it is likely that functional restoration of DCs is the underlying cause. To test this hypothesis, we utilized an antibody cocktail (consisting of DC maturation, adhesion and other surface markers) to perform comprehensive phenotypic characterization of myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) in a cohort of HIV-1/HCV co-infected individuals undergoing IFN/RBV treatment. Our results show that pre-treatment frequencies of mDCs are lower in non-responders (NRs) compared to responders (SVRs) and healthy controls. Although, the treatment was able to restore the frequency of mDCs in NRs, it downregulated the frequency of CCR7[+], CD54[+] and CD62L[+] mDCs. Pre-treatment frequencies of pDCs were lower in NRs and decreased further upon treatment. Compared to SVRs, NRs exhibited higher ratio of PD-L1[+]/CD86[+] pDCs prior to treatment; and this ratio remained high even after treatment. These findings demonstrate that enumeration and phenotypic assessment of DCs before/during therapy can help predict the treatment outcome. We also show that before treatment, PBMCs from SVRs secrete higher amounts of IFN-\\u03b3 compared to controls and NRs. Upon genotyping IFNL3 polymorphisms rs12979860, rs4803217 and ss469415590, we found rs12979860 to be a better predictor of treatment outcome. Collectively, our study led to identification of important correlates of IFN/RBV treatment response in HIV-1/HCV co-infected individuals.\",\"Ribavirin (RBV) is a potential partner of interferon-based therapy and recently approved therapy using direct acting antivirals for patients with chronic hepatitis C. However, the precise mechanisms underlying RBV action against hepatitis C virus (HCV) replication are not yet understood. To clarify this point, we attempted to develop RBV-resistant cells from RBV-sensitive HCV RNA-replicating cells.\",\"Influenza is an important cause of annual epidemics of respiratory viral infection associated with significant morbidity and mortality. Three classes of drugs, the M2 ion channel, neuraminidase and RNA-dependent RNA polymerase inhibitors, are approved for the prevention and treatment of influenza. Due to widespread resistance to the class, the M2 ion channel inhibitors are not recommended currently for therapy. The only polymerase inhibitor, favipiravir, is approved only in Japan and its use is highly restricted. Despite significant data to support the early use of the neuraminidase inhibitors, their use in all patient populations is suboptimal. The data to support the early use of neuraminidase inhibitors will be reviewed, as will current data on the utilization rates in ambulatory and hospitalized populations.\",\"The development of boceprevir and telaprevir was a major step forward in the treatment of chronic hepatitis C. In addition, the treatment of these infections has been recently revolutionized by the approval of sofosbuvir and simeprevir. However, there are several challenges associated with the application of novel drugs, such as new and more frequent adverse events, new drug interactions, and excessively high treatment costs. An additional concern is viral resistance. These considerations highlight the fact that direct-acting antiviral agents are not a panacea and may not be the best option for all patients who are in need of therapy. This retrospective study revealed that the sustained virologic response was not significantly reduced following peginterferon and ribavirin retreatment compared with the new therapy. We suggest that patients who experience relapse shortly after completing treatment with peginterferon and ribavirin have a reasonable chance of achieving a sustained virologic response when retreated with these drugs alone.\",\"To use existing hepatitis C virus (HCV) antiviral therapies as access to new treatments is limited.\",\"To review the data with ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.\",\"Dual or triple combination regimens of novel hepatitis C direct-acting antivirals (DAA, daclatasvir, asunaprevir, or beclabuvir) provide high sustained virological response rates and reduced frequency of resistance compared to clinical monotherapy. To support pharmacokinetic (PK) assessments in clinical studies, a multiplexed liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantitation of daclatasvir, asunaprevir, beclabuvir (BMS-791325) and its active metabolite (BMS-794712) in human plasma was developed and validated. Human plasma samples were extracted with methyl-t-butyl ether followed by an LC-MS/MS analysis, which was conducted in a multiple reaction monitoring (MRM) mode. The lower limits of quantitation (LLOQ) were 1 ng/mL for daclatasvir, asunaprevir, and BMS-794712, and 2 ng/mL for beclabuvir. Intra-run precision (\\u22644.5% CV), inter-run precision (\\u22642.9% CV), and accuracy (\\u00b15.3% deviation) based on different concentration levels (low, geometric mean, mid and high) of the quality control samples (QCs) provided evidence of the methods accuracy and precision. Selectivity and matrix effect on LC-MS/MS detection, stability in plasma, and potential interference of coadministered drugs (ribavirin and interferon) were all evaluated and the results were acceptable. Method reproducibility was demonstrated by the reanalysis of a portion of study samples. The cross-validation results for QCs demonstrated the equivalency between this method and two single-analyte methods which were previously validated for quantitation of daclatasvir in human plasma. This approach of using a multiplexed LC-MS/MS method for the simultaneous quantitation of three DAAs is time- and cost-effective, and can maintain good data quality in sample analysis.\",\"Treatment of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) has revolutionized the care of infected patients. Among these novel compounds are non-nucleoside analogs, which bind viral RNA-dependent RNA polymerase resulting in a conformational change inhibiting RNA synthesis.\",\"Ribavirin is phosphorylated by adenosine kinase 1 (AK1) and cytosolic 5'-nucleotidase 2 and it is transported into cells by concentrative nucleoside transporters (CNT) 2/3, coded by SLC28A2/3 genes, and equilibrative nucleoside transporters (ENT) 1/2, coded by SLC29A1/2 genes. We evaluated the association of some polymorphisms of IL28B, SLC28A2/3, SLC29A1, ABCB1, NT5C2, AK1, HNF4\\u03b1 genes and ribavirin treatment outcome and pharmacokinetics after 4weeks of therapy, in a cohort of HCV-1/4 Italian patients. Allelic discrimination was performed by real-time PCR; plasma concentrations were determined at the end of dosing interval (Ctrough) using an HPLC-UV method. Non response was negatively predicted by cryoglobulinemia and IL28B_rs12980275 AA genotype and positively by Metavir score; Metavir score, insulin resistance and SLC28A2_rs1060896 CA/AA and HNF4\\u03b1_rs1884613 CC genotypes were negative predictive factors of SVR, whereas HCV viral load at baseline and IL28B_rs12980275 AA and rs8099917 TT genotypes positively predicted this outcome; RVR was negatively predicted by insulin resistance and positively by cryoglobulinemia and IL28B_rs12980275 AA genotype; Metavir score and insulin resistance were able to negatively predict EVR, whereas cryoglobulinemia and IL28B_rs12980275 AA genotype positively predicted it; at last, virological relapse was negatively predicted by IL28B_rs8099917 TT and AK1_rs1109374 TT genotypes, insulin resistance was a positive predictor factor. Concerning ribavirin pharmacokinetics, SLC28A2_rs11854488 TT was related to lower Ctrough levels; conversely patients with TC profile of SLC28A3_rs10868138 and SLC29A1_rs760370 GG genotype had higher ribavirin levels. These results might contribute to the clarification of mechanisms causing the individuality in the response to ribavirin containing therapy.\",\"Although interferon-free regimens are approved for patients co-infected with HIV and genotype-2 or genotype-3 hepatitis C virus (HCV), interferon-based regimens are still an option for those co-infected with HIV and HCV genotypes 1 or 4. These regimens are limited by clinically significant toxic effects and drug interactions with antiretroviral therapy. We aimed to assess the efficacy and safety of an interferon-free, all-oral regimen of sofosbuvir plus ribavirin in patients with HIV and HCV co-infection.\",\"In a prospective cohort of 18 patients treated with boceprevir, we examined the role of boceprevir plasma concentration at the onset of breakthrough during the treatment. Nine patients experienced breakthrough during therapy. The resistance patterns were as follows: S122S/R, I132V, T54A/I132V, V156S/I170A, V36M/T54S/R155K, V36M/R155K and T54/R155K. Boceprevir-S isomer (SCH 534128) median concentration in patients with breakthrough was 48.3 ng/mL (interquartile range 43-58 ng/mL); in others, it was significantly (p 0.019) higher: 151 ng/mL. Low boceprevir plasma concentration can lead to virologic resistance; therapeutic drug monitoring should be used to prevent the onset of viral breakthrough during triple-regimen therapy with boceprevir.\",\"To describe chronic hepatitis C virus (HCV) infection, including its epidemiology and pathophysiology; review current treatment options for HCV infection; recognize investigational agents being studied as part of interferon-free therapy; and summarize clinical trials for the new agents.\",\"The present study was designed to assess the evolution of simeprevir-resistant variants (amino acid substitutions of aa80, aa155, aa156, and aa168 positions in HCV NS3 region) over time in virological non-responders (patients with positive HCV-RNA during and at end of treatment). The study enrolled 136 patients infected with HCV genotype 1b who received 12-week simeprevir-PEG-IFN-ribavirin therapy, and data of 87 patients were available for analysis. Twelve patients (14%) were considered virological non-responders, including 9 (75%) who showed absolute no-response (HCV RNA: \\u22653.0 log IU/ml at 12 weeks after start of therapy). Multivariate analysis of these patients identified lack of response to prior treatment, use of low ribavirin dose, and old age as independent and significant determinants of virological non-response. Using ultra-deep sequencing, de novo variants of D168 were detected in all of 9 absolute non-responders. The majority of these variants emerged within 5 weeks of triple therapy. In comparison, de novo variants of Q80 were detected in only 3 of 9 absolute non-responders and emerged at 6-12 weeks. Variants of Q80 detected at baseline increased during the course of treatment in 5 of 9 absolute non-responders, while no such increase was noted in variants of R155 and/or A156 detected at baseline during the 12-week course. De novo variants of R155 and/or A156 were not detected in this study. The results demonstrated the emergence of simeprevir-resistant variants during the early stage of triple therapy.\",\"IFN-free regimens with direct antiviral agents (DAAs) against hepatitis C virus (HCV) are likely to greatly expand patients' access and response to hepatitis C therapy, while safety and tolerability of treatments seem substantially improved. Sofosbuvir (SOF), a NS5B nucleotide polymerase inhibitor with pan-genotypic activity and a high-barrier to resistance, has been approved by FDA and EMA in an all oral combination therapy for chronic hepatitis C with ribavirin (RBV) alone, or in combination with either pegylated interferon/RBV or other DAAs.\",\"The enteroviruses (EVs) of the Picornaviridae family are the most common viral pathogens known. Most EV infections are mild and self-limiting but manifestations can be severe in children and immunodeficient individuals. Antiviral development is actively pursued to benefit these high-risk patients and, given the alarming problem of antimicrobial drug resistance, antiviral drug resistance is a public-health concern. Picornavirus antivirals can be used off-label or as part of outbreak control measures. They may be used in the final stages of poliovirus eradication and to mitigate EV-A71 outbreaks. We review the potential emergence of drug-resistant strains and their impact on EV transmission and endemic circulation. We include non-picornavirus antivirals that inhibit EV replication, for example, ribavirin, a treatment for infection with HCV, and amantadine, a treatment for influenza A. They may have spurred resistance emergence in HCV or influenza A patients who are unknowingly coinfected with EV. The public-health challenge is always to find a balance between individual benefit and the long-term health of the larger population.\",\"The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients.\",\"To assess within the ANRS CO20-CUPIC cohort whether the viral load (VL) at week 2/week 6 for telaprevir/boceprevir-based triple therapy, respectively, was predictive of sustained virological response (SVR) in patients with hepatitis C virus (HCV) infection and to study the relevance of this measurement to early diagnose drug resistance.\",\"Objective: To evaluate the clinical role of sofosbuvir (Solvadi) in the treatment of hepatitis C virus (HCV). Data Sources: A MEDLINE, EMBASE, and Cochrane search indexed from January 2000 to July 2014 was performed using the search terms GS-7977 and sofosbuvir. Study Selection and Data Extraction: Studies including humans subjects, published in English, and assessing efficacy and safety of sofosbuvir in management of chronic HCV were evaluated. Data Synthesis: Sofosbuvir, a nucleotide analogue NS5B polymerase inhibitor, competes with nucleotides within the hepatocytes resulting in chain termination and inhibition of RNA replication. Trials evaluating the efficacy of sofosbuvir combination therapy have demonstrated significant advantage in sustained virologic response (SVR) over previous therapies. Genotype 1, 4, 5, and 6 patients treated with peginterferon-\\u03b1, ribavirin, and sofosbuvir for 12 weeks achieved SVR rates of 90%. Twelve-week peginterferon-free regimens have resulted in SVR rates of 90% in genotype 2 patients, whereas genotype 3 patients required 24 weeks of therapy to achieve similar results. Favorable SVR rates were also seen in previously difficult-to-treat patient populations including cirrhosis, HIV coinfection, and treatment-experienced. Sofosbuvir appears to be well tolerated and relatively safe, avoiding severe adverse drug reactions, laboratory abnormalities, and resistance issues associated with traditional HCV therapies. The biggest limitation of sofosbuvir is the high cost associated with therapy. Conclusions: Sofosbuvir is a safe and effective treatment option for patients infected with genotypes 1 to 6 HCV including previously difficult-to-treat populations. The shorter duration, oral route, minimal side effects, and decreased resistance potential makes it a welcome addition to the treatment of chronic HCV.\",\"Identifying HCV drug resistance mutations (DRMs) is increasingly important as new direct acting antiviral therapies (DAA) become available. Tagged pooled pyrosequencing (TPP) was originally developed as cost-effective approach for detecting low abundance HIV DRMs. Using 127 HCV-positive samples from a Canadian injection drug user cohort, we demonstrated the suitability and efficiency of TPP for evaluating DRMs in HCV NS5B gene. At a mutation identification threshold of 1%, no nucleoside inhibitor DRMs were detected among these DAA na\\u00efve subjects. Clinical NS5B resistance to non-nucleoside inhibitors and interferon/ribavirin was predicted to be low within this cohort. S282T mutation, the primary mutation selected by sofosbuvir in vitro, was not identified while S282G/C/R variants were detected in 9 subjects. Further characterization on these new S282 variants using in silico molecular modeling implied their potential association with resistance. Combining TPP with in silico analysis detects NS5B polymorphisms that may explain differences in treatment outcomes.\",\"Lethal mutagenesis is a broad-spectrum antiviral strategy that exploits the high mutation rate and low mutational tolerance of many RNA viruses. This approach uses mutagenic drugs to increase viral mutation rates and burden viral populations with mutations that reduce the number of infectious progeny. We investigated the effectiveness of lethal mutagenesis as a strategy against influenza virus using three nucleoside analogs, ribavirin, 5-azacytidine, and 5-fluorouracil. All three drugs were active against a panel of seasonal H3N2 and laboratory-adapted H1N1 strains. We found that each drug increased the frequency of mutations in influenza virus populations and decreased the virus' specific infectivity, indicating a mutagenic mode of action. We were able to drive viral populations to extinction by passaging influenza virus in the presence of each drug, indicating that complete lethal mutagenesis of influenza virus populations can be achieved when a sufficient mutational burden is applied. Population-wide resistance to these mutagenic agents did not arise after serial passage of influenza virus populations in sublethal concentrations of drug. Sequencing of these drug-passaged viral populations revealed genome-wide accumulation of mutations at low frequency. The replicative capacity of drug-passaged populations was reduced at higher multiplicities of infection, suggesting the presence of defective interfering particles and a possible barrier to the evolution of resistance. Together, our data suggest that lethal mutagenesis may be a particularly effective therapeutic approach with a high genetic barrier to resistance for influenza virus.\",\"The identification of mutations in the HVR1 region of hepatitis type C virus (HCV) is time-consuming and expensive, and there is a need for a rapid, inexpensive method of screening for these mutations to predict the ineffectiveness of pegylated interferon alpha combined with ribavirin (PEG-IFN\\u03b1/RBV) therapy. The project was designed to evaluate the usefulness of the high resolution melting (HRM) technique to screen for mutation in the cDNAs encoding the HVR1 and protein kinase R-binding domain (PKR-BD) regions in a group of 36 patients infected with HCV and resistant to 12 months of combined therapy with PEG-IFN\\u03b1/RBV. Viral RNA was isolated, reverse transcribed, and the fragments encoding the HVR1 and PKR-BD regions were polymerase chain reaction (PCR)-amplified, cloned, sequenced, and the melting profiles and the melting temperature (Tm) were determined by the HRM technique. After the treatment, the melting profiles of HVR1 cDNAs revealed a dominant peak corresponding to the Tm of about 85 \\u00b0C (HCVs85) in almost all patients. One or more minor peaks were also observed, indicating the existence of cDNA(s) of different Tm. The HMR analysis suggested four typical forms of response to treatment. These suppositions were supported by sequencing. The HRM analysis revealed no changes in the melting profiles of PKR-BD cDNAs in the same patient before and after the therapy, suggesting that, within 12 months of treatment, new mutations were not introduced in PKR-BD. These findings were substantiated by sequencing. The HRM technique can be applied for the rapid screening for mutations in the cDNAs encoding the HVR and PKR-BD regions of HCV. We suggest that the detection of HCVs85 peak before the IFN\\u03b1/RBV therapy might predict the ineffectiveness of treatment.\",\"Prior assessment of insulin resistance by HOMA-IR is emerging as an important milestone in the treatment of patients with chronic hepatitis C. This cost-effective tool is recommended to individualize treatment duration, or to exclude those with low insulin sensitivity from being treated until ameliorating their state of insulin resistance (IR). The present work aims to elucidate further the effect IR state on early viral kinetic response to Chronic hepatitis C virus (HCV) therapy and the impact of HCV treatment and viral eradication on insulin sensitivity. Insulin sensitivity was assessed using the HOMA-IR method. All enrolled patients were treated with a dual therapy (pegylated interferon-alpha plus ribavirin) for 48 weeks and evaluated using qRT-PCR for early virologic response as well as the impact of treatment on insulin sensitivity throughout the early period of therapy. Of a total 392 chronic HCV cases, early virologic response was achieved by 318 (81.1%). IR was detected in 241 (61.5%) chronic HCV patient of which 73.4% responded to treatment. Early virologic response among patients with > 2.18 HOMA-IR value were significantly lower than those with HOMA-IR values \\u22642.18 (P < 0.0001). IR was significantly associated with high baseline BMI. Steatosis and fibrosis correlated with IR but neither independently predicted early virologic response. Pretreatment IR < 2.18, low fasting blood glucose, low and intermediate HCV viral load, normal BMI, and non-smoking were independent factors associated with early virologic response. IR interferes with early virologic response to the antiviral care. Clinical application of pretreatment HOMA-IR assessment could help in predicting early treatment outcome and thus enable treatment regimens to be optimized and individually tailored.\",\"Chronic hepatitis C (CHC) constitutes a major health concern. Hepatitis C virus eradication by antiviral treatment can markedly reduce the risk of developing cirrhosis, hepatocellular carcinoma and liver-related death. A plethora of new direct antiviral agents have been developed and are being explored in clinical trials. One of the newest members of this family is the NS3/4A protease inhibitor ABT-450. The multi-targeted approach combining ritonavir-enhanced ABT-450 with ombitasvir and dasabuvir has been evaluated for the treatment of CHC Gt1 in treatment-na\\u00efve and treatment-experienced adults. In this article, we sought to discuss the current knowledge on ABT-450-containing regimens, with special emphasis on treatment-experienced CHC Gt1 patients. This new combination was found to be potent, safe and well tolerated. Future Phase III trials with larger sample size in patients with decompensated cirrhosis, non-Gt1, end-stage renal disease and liver transplant recipients are eagerly awaited.\",\"The presence of resistance-associated variants (RAV) may attenuate the efficacy of direct-acting antivirals (DAA) in combination therapy for hepatitis C. The aim of this study was to characterize the NS3 and NS5A regions of hepatitis C virus (HCV) in naturally occurring RAV.\",\"To construct a tricistronic hepatitis C virus (HCV) replicon with double internal ribosome entry sites (IRESes) of only 22 nucleotides for each, substituting the encephalomyocarditis virus (EMCV) IRESes, which are most often used as the translation initiation element to form HCV replicons.\",\"Chemoresistance remains a major impediment in cancer therapy. Although major progress has been made in understanding the mechanisms underlying resistance in cancer, there is still more to learn. Our studies provide evidence that Gli1 drives a novel form of drug resistance involving Phase II drug metabolism enzymes, specifically the UGT1A family.\",\"Triple therapy with telaprevir/boceprevir + pegylated-interferon+ribavirin can achieve excellent antiviral efficacy, but it can be burdened with resistance development at failure.\",\"Chronic Hepatitis C virus (HCV) infection is the leading cause of advanced liver disease worldwide. The virus successfully evades host immune detection and for many years has hampered efforts to find a safe, uncomplicated, and reliable oral antiviral therapy. Initially, interferon and ribavirin therapy was the treatment standard of care, but it offered limited performance across the wide spectrum of HCV disease and was fraught with excessive and often limiting side effects. Sofosbuvir (SOF) is a potent first-in-class nucleoside inhibitor that has recently been approved for treatment of HCV. The drug has low toxicity, a high resistance barrier, and minimal drug interactions with other HCV direct-acting antiviral agents such as protease inhibitors or anti-NS5A agents. SOF is safe and can be used across different viral genotypes, disease stages, and special patient groups, such as those coinfected with human immunodeficiency virus. When used in combination with ribavirin or another direct-acting antiviral agent, SOF has revolutionized the HCV treatment spectrum and set the stage for nearly universal HCV antiviral therapy. More so than any other anti-HCV drug developed to date, SOF offers the widest applicability for all infected patients, and new regimens will be tailored to maximize performance.\",\"Hepatitis C disease is a virus mediated infection causing major health problem worldwide. Conversions of immune surveillance play an important role in response to virus clearance. Immune modulating molecules such as HLA-G and IL-10 that convert immune response toward Th2 may play a role to inhibit response from combined therapy with IFN-\\u03b12\\u03b1 and ribavirin. The objective of this study was to investigate the expression of HLA-G and IL-10 in responder and non-responder HCV positive patients. In this study, characteristics of the virus and 48 responder and non-responder patients in response to the combined therapy with IFN-\\u03b12\\u03b1 and ribavirin were analyzed. The expression levels of HLA-G and IL-10 were conducted using real-time PCR. Also, soluble HLA-G in both groups of patients and healthy individuals were determined by enzyme-linked immunosorbent assay. According to the obtained data, HCV 1a was the predominant genotype in responder and non-responder patients. Expression levels of HLA-G and IL-10 in non-responder group was significantly more than responder and control groups (P<0.001). Additionally, expression levels of HLA-G and IL-10 were remarkably higher compared to healthy individuals at the beginning of treatment. Soluble HLA-G in non-responder patients was noticeably increased in comparison to responder patients after treatment (P<0.05). These findings suggest that elevation of HLA-G and IL-10 in HCV infected patients may play an important role in response to combined therapy with IFN-\\u03b12\\u03b1 and ribavirin.\",\"Cancer cells rapidly evolve a multitude of defense mechanisms to evade the effects of the oncologist's drug arsenal. Unfortunately, clinical strategies to overcome these lag far behind. This mismatch likely underlies our inability to implement new durable treatment strategies. Here, a new form of multidrug resistance, inducible drug glucuronidation, is discussed. This form was discovered while developing means to target a specific oncogene, the eukaryotic translation initiation factor 4E (eIF4E), with its inhibitor ribavirin. In two clinical studies, ribavirin treatment led to substantial clinical responses, but all responding patients eventually relapsed. In most cases, this was due to the overexpression of the sonic hedgehog transcription factor Gli1, which elevated the UDP glucuronsyltransferase UGT1A enzymes. UGT1As add glucuronic acid to many drugs. Indeed, these cells are resistant to not only ribavirin, but also Ara-C, and likely other drugs. Inhibition of Gli1 reduced UGT1As, eliminated drug glucuronides, and renewed sensitivity to ribavirin and Ara-C. These studies highlight that cancer cells and their resistant counterparts metabolize drugs differently from each other as well as from normal cells. Likely, these inducible modifications go beyond glucuronidation. Understanding the extent of inducible drug modifications and the pathways that drive expression of the corresponding enzymatic machinery will better position us to finally make resistance futile.\",\"Pegylated interferon (IFN) \\u03b1-2a or 2b in combination with ribavirin for children aged 3 years and older is the standard treatment for paediatric chronic hepatitis C. This treatment regimen was developed firstly in adults. In recent years, a number of direct-acting antiviral agents (DAAs) are under development for treatment of chronic hepatitis C virus (HCV) infection. These agents block viral replication inhibiting directly one of the several steps of HCV lifecycle. DAAs are classified into several categories based on their molecular target: HCV NS3/4A protease inhibitors, HCV NS5B polymerase inhibitors and HCV NS5A inhibitors. Other promising compounds are cyclophilin A inhibitors, mi-RNA122 and IFN-\\u03bb. Several new drugs associations will be developed in the near future starting from the actual standard of care. IFN-based and IFN-free regimens are being studied in adults. In this constantly evolving scenario new drug regimens targeted and suitable for children would be possible in the next future. Especially for children, it is crucial to identify the right combination of drugs with the highest potency, barrier to resistance and the best safety profile.\",\"Both hepatitis C virus (HCV) mono-infected and HIV/HCV co-infected patients are in need of safe, effective, all-oral HCV regimens. In a phase 2 study we aimed to assess the efficacy and safety of grazoprevir (MK-5172; HCV NS3/4A protease inhibitor) and two doses of elbasvir (MK-8742; HCV NS5A inhibitor) in patients with HCV mono-infection and HIV/HCV co-infection.\",\"Treatment of hepatitis C is changing dramatically. Various new direct-acting antivirals (DAA) against HCV have recently been approved or will become available during the next months.\",\"In the era of Directly Acting anti HCV Antivirals treatment of hepatitis C is successful in the majority of persons treated. However, treatment of persons with HIV or who inject drugs remains challenging because of special issues: drug-drug interactions with antiretroviral, psychiatric and drug substitution therapies, treatment adherence, impact of treatment on HIV disease course or on risk of bacterial infections. Sofosbuvir induced sustained virologic response in 91% of 23 HIV/HCV coinfected persons treated in combination with ribavirin and pegylated interferon, in 83% of 497 treated in combination with ribavirin and in all 50 patients infected with HCV GT1 treated in combination with ledipasvir and ribavirin. The rates of efficacy in HCV-HIV coinfected were almost the same as those observed in HCV monoinfected suggesting that the efficacy of sofosbuvir is not reduced by HIV coinfection. There are no data on the efficacy of sofosbuvir in injection drugs users. The pangenotypic activity, the high barrier to resistance, the modest potential for drug-drug interactions makes sofosbuvir a reference drug for the treatment of these two special populations.\",\"Sofosbuvir is the first-in-class NS5B nucleotide analogues to be launched for hepatitis C virus (HCV) treatment. Its viral potency, pangenotypic activity and high barrier to resistance make it the ideal candidate to become a backbone for several IFN-free regimens. Recent data demonstrated that sofosbuvir either with ribavirin alone or in combination with other direct-acting antivirals (DAAs) as daclatasvir, ledipasvir or simeprevir are able to cure HCV in at least 90% or over of patients. Treatment experienced genotype 3 population may remain the most difficult to treat population, but ongoing DAA combination studies will help to fill this gap. Safety profile of sofosbuvir or combination with other DAAs is good. Resistance to sofosbuvir did not appear as a significant issue. The rationale for using this class of drug and the available clinical data are reviewed.\",\"Although the development of anti-interferon (IFN)-\\u03b1 neutralizing antibodies (NAbs) is likely to be a common clinical problem for patients with various diseases treated with IFN, anti-IFN-\\u03b1 NAb has been exceptionally considered to have no clinical significance in the treatment of chronic hepatitis C with pegylated IFN-\\u03b1 (Peg-IFN-\\u03b1). However, we recently clarified that the presence of NAb was associated with a non-response to the Peg-IFN plus ribavirin (RBV) therapy. In this study, we used the HCV-replicon system with genotype 1b, and investigated the role of anti-IFN-\\u03b1 NAb in the response to telaprevir (TVR)-containing new antiviral therapy for hepatitis C virus (HCV). Anti-IFN-\\u03b1 NAb-positive sera specifically inhibited the anti-HCV effects of IFN-\\u03b1, without any effect on the activity of IFN-\\u03b2 in vitro. The NAb-positive sera also inhibited the IFN-\\u03b1-dependent induction of interferon-stimulated genes, MxA and OAS-1, in a dose-dependent manner. Although TVR monotherapy decreased the HCV-RNA in vitro, the HCV-RNA was increased again with the development of TVR-resistant mutations. When IFN-\\u03b1 was administrated with TVR, the replication of HCV was continuously suppressed for more than a month. However, in the presence of anti-IFN-\\u03b1 NAb-positive sera, even when IFN-\\u03b1 was combined with TVR, the levels of HCV-RNA exhibited a time-course similar to that with TVR monotherapy, and HCV with TVR-resistant mutations emerged. In conclusion, our findings suggest that the presence of IFN-\\u03b1 NAb decreases the antiviral effects of IFN-\\u03b1 and may be related to the development of TVR-resistant mutated viruses.\",\"Chronic hepatitis C virus (HCV) infection increases the risk of liver cirrhosis and hepatocellular carcinoma. In the last decade, the current standard HCV treatment, pegylated interferon and ribavirin, have limited efficacy and significant side effects. Novel direct acting antivirals show promise, but escape mutants are expected, along with potential side effects. Pycnogenol\\u00ae, a French maritime pine extract, has been reported to have antioxidant and antiviral effects. Here, we evaluated the effect of Pycnogenol\\u00ae on HCV replication. Wild-type and protease inhibitor (VX-950; telaprevir)-resistant HCV replicon cells were treated with Pycnogenol\\u00ae, Pycnogenol\\u00ae and interferon-alpha, and ribavirin and telaprevir. Pycnogenol\\u00ae effects on replication were also evaluated in HCV-infected chimeric mice. Pycnogenol\\u00ae treatment showed antiviral effects without cytotoxicity at doses up to 50 \\u03bcg/mL. Pycnogenol\\u00ae in combination with interferon-alpha or ribavirin showed synergistic effects. Moreover, Pycnogenol\\u00ae inhibited HCV replication in telaprevir-resistant replicon cells; telaprevir and Pycnogenol\\u00ae acted additively to reduce HCV RNA levels in wild-type HCV replicon cells without significantly increasing cytotoxicity. Pycnogenol\\u00ae antiviral activity was higher than its components procyanidin and taxifolin. Further, treatment of infected chimeric mice with Pycnogenol\\u00ae suppressed HCV replication and showed a synergistic effect with interferon-alpha. In addition, Pycnogenol\\u00ae treatment resulted in dose-dependent reduction of reactive oxygen species in HCV replicon cell lines. Pycnogenol\\u00ae is a natural product that may be used to improve the efficacy of the current standard antiviral agents and even to eliminate resistant HCV mutants.\",\"Simeprevir is an oral hepatitis C virus (HCV) NS3/4A protease inhibitor approved for treatment of chronic HCV infection. Baseline NS3 polymorphisms in all patients and emerging mutations in patients who failed to achieve sustained virologic response (SVR) with simeprevir plus peginterferon/ribavirin (PR) in Phase IIb/III studies are described.\",\"It has been suggested that HCV proteins, core, NS3/4A, NS4B, and NS5A, contribute to the resistance of HCV to IFN and ribavirin (RBV) treatments.\",\"The establishment of robust HCV cell culture systems and characterization of the viral life cycle provided the molecular basis for highly innovative, successful years in HCV drug development. With the identification of direct-acting antiviral agents (DAAs), such as NS3/4A protease inhibitors, NS5A replication complex inhibitors, nucleotide and non-nucleoside polymerase inhibitors, as well as host cell targeting agents, novel therapeutic strategies were established and competitively entered clinical testing. The first-in-class NS3/4A protease inhibitors telaprevir and boceprevir, approved in 2011, were recently outpaced by the pan-genotypic nucleotide polymerase inhibitor sofosbuvir that in combination with pegylated interferon and ribavirin, further shortens therapy durations and also offers the first interferon-free HCV treatment option. In the challenging race towards the goal of interferon-free HCV therapies, however, several oral DAA regimens without nucleotide polymerase inhibitors that combine a NS3/4A protease inhibitor, a NS5A inhibitor and/or a non-nucleoside polymerase inhibitor yielded competitive results. Second generation NS3/4A protease and NS5A inhibitors promise an improved genotypic coverage and a high resistance barrier. Results of novel DAA combination therapies without the backbone of a nucleotide polymerase inhibitor, as well as treatment strategies involving host targeting agents are reviewed herein.\",\"The first standard of care in treatment of chronic HCV genotype 1 infection involving directly acting antivirals was protease inhibitors telaprevir or boceprevir combined with pegylated-interferon and ribavirin (triple therapy). Phase III studies include highly selected patients. Thus, treatment response and development of viral resistance during triple therapy in a routine clinical setting needs to be determined. The aims of this study were to investigate treatment outcome and identify sequence variations after triple therapy in patients with chronic HCV genotype 1 infection in a routine clinical setting.\",\"Hepatitis C currently infects more than 170 million people around the world, leading to significant morbidity and mortality. The current standard of care for HCV infection, including one of the two protease inhibitors, telaprevir or boceprevir, for 12-32 weeks, along with pegylated interferon alfa-2a (PEG-IFN-\\u03b1) and ribavirin for up to 48 weeks, is unsatisfactory in many cases, either because of lack of efficacy or because of treatment-related adverse effects. There is an urgent need of new drugs with improved efficacy as well as a safety profile. Sofosbuvir, a recently approved nucleotide analog, is a highly potent inhibitor of the NS5B polymerase in the Hepatitis C virus (HCV), and has shown high efficacy in combination with several other drugs, with and without PEG-INF, against HCV. It offers many advantages due to its high potency, low side effects, oral administration, and high barrier to resistance. The efficacy and safety were demonstrated in many large and well-designed phase 2 and phase 3 clinical trials like NEUTRINO, PROTON, ELECTRON, ATOMIC, COSMOS, FUSION, FISSION, NUCLEAR, POSITRON, and the like. It is generally well-tolerated. Adverse events that occurred include: Headache, insomnia, fatigue, nausea, dizziness, pruritis, upper respiratory tract infections, rash, back pain, grade 1 anemia, and grade 4 lymphopenia; however, the exact safety profile can only be judged when this drug is actually used on a large scale.\",\"Orally administered anti-CD3 antibodies are biologically active in the gut through induction of regulatory T cells, exert an immune-modulatory effect, and alleviate insulin resistance and liver damage in patients with NASH.\",\"Miravirsen is a \\u03b2-D-oxy-locked nucleic acid-modified phosphorothioate antisense oligonucleotide targeting the liver-specific microRNA-122 (miR-122). Miravirsen demonstrated antiviral activity against hepatitis C virus (HCV) genotype 1b replicons with a mean 50% effective concentration (EC50) of 0.67 \\u03bcM. No cytotoxicity was observed up to the highest concentration tested (>320 \\u03bcM) in different cell culture models, yielding a therapeutic index of \\u2265 297. Combination studies of miravirsen with interferon \\u03b12b, ribavirin, and nonnucleoside (VX-222) and nucleoside (2'-methylcytidine) inhibitors of NS5B, NS5A (BMS-790052), or NS3 (telaprevir) indicated additive interactions. Miravirsen demonstrated broad antiviral activity when tested against HCV replicons resistant to NS3, NS5A, and NS5B inhibitors with less than 2-fold reductions in susceptibility. In serial passage studies, an A4C nucleotide change was observed in the HCV 5' untranslated region (UTR) from cells passaged in the presence of up to 20 \\u03bcM (40-fold the miravirsen EC50 concentration) at day 72 of passage but not at earlier time points (up to 39 days of passage). Likewise, a C3U nucleotide change was observed in the HCV 5'UTR from subjects with viral rebound after the completion of therapy in a miravirsen phase 2 clinical trial. An HCV variant constructed to contain the A4C change was fully susceptible to miravirsen. A C3U HCV variant demonstrated overall reductions in susceptibility to miravirsen but was fully susceptible to all other anti-HCV agents tested. In summary, miravirsen has demonstrated broad antiviral activity and a relatively high genetic barrier to resistance. The identification of nucleotide changes associated with miravirsen resistance should help further elucidate the biology of miR-122 interactions with HCV. (The clinical trial study has been registered at ClinicalTrials.gov under registration no. NCT01200420).\",\"Chronic infection with HCV is a public health problem with approximately 170 million people infected worldwide. Interferon alpha (IFN\\u03b1) sensitivity in liver and IL28B genotype has been identified as important determinants of HCV clearance in the setting of pegylated interferon/ribavirin treatment. Herein, we explored IFN\\u03b1 sensitivity in PBMC from 21 healthy donors and 21 HCV-infected patients treated with pegylated interferon/ribavirin and HCV nonstructural protein-3 inhibitors (i.e. telaprevir/boceprevir). We explored phospho-STAT1 level as read-out for IFN signalling pathway activation in PBMC, T cells and monocytes and correlated results with virological response. We found that PBMC from healthy donors are desensitized to IFN\\u03b1 after priming and challenged with IFN\\u03b1, with a subsequent decrease of phospho-STAT1 and interferon-stimulated genes. Furthermore, we show that CD3+ T cells, but not monocytes, become desensitized after 4 weeks of treatment, with a significant decrease of phospho-STAT1 after ex vivo IFN\\u03b1 stimulation. Finally, we identified baseline phospho-STAT1 level in CD3+ T cells as a potential biomarker of sustained virological response, regardless of the IL28B genotype. In the upcoming costly era of IFN-sparing regimen, baseline IFN\\u03b1 sensitivity could act as biomarker to define cost-effectiveness strategies of treatment by identifying patients who will or will not respond to IFN-based treatments.\",\"The Fat Mass and Obesity-Associated Protein (FTO) gene rs9939609 single nucleotide polymorphism (SNP) has been associated with obesity, metabolic syndrome, insulin resistance (IR), and type 2 diabetes mellitus in the general population. The aim of our study was to examine for the first time the association of the rs9939609 polymorphism with metabolic disturbances, liver disease and virologic response to hepatitis C virus (HCV) therapy with pegylated-interferon-alpha plus ribavirin (pegIFN\\u03b1/RBV) in human immunodeficiency virus (HIV)/HCV coinfected patients.\",\"In 247 subjects with hepatitis C virus genotype 1 infection treated with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports the use of the earlier time point as a primary efficacy endpoint for trials of this interferon-free regimen.\",\"Despite preventive strategies and increased awareness, a high incidence of respiratory viral infections still occur in patients with hematologic malignancies (HMs) and in recipients of hematopoietic cell transplant (HCT). Progression of these viral infections to lower respiratory tract may prove fatal, especially in HCT recipients. Increasing evidence on the successful use of ribavirin (alone or in combination with immunomodulators) for the treatment of respiratory syncytial virus infections in HM patients and HCT recipients is available from retrospective studies; however, prospective clinical trials are necessary to establish its efficacy with confidence. The impact on progression to pneumonitis and/or mortality of treating parainfluenza virus infections with available (ribavirin) or investigational (DAS181) antiviral agents still needs to be determined. Influenza infections have been successfully treated with neuraminidase inhibitors (oseltamivir or zanamivir); however, the efficacy of these agents for influenza pneumonia has not been established, and immunocompromised patients are highly susceptible to emergence of antiviral drug resistance, most probably due to prolonged viral shedding. Infection control measures and an appreciation of the complications following respiratory viral infections in immunocompromised patients remain crucial for reducing transmission. Future studies should focus on strategies to identify patients at high risk for increased morbidity and mortality from these infections and to determine the efficacy of novel or available antiviral drugs.\",\"Chronic hepatitis C infection is a global disease with 160 million people infected worldwide. Until recently, therapy was characterized by long duration, suboptimal success rates and significant adverse drug reactions. The development of direct-acting antivirals initiated a dramatic change in the treatment of hepatitis C.\",\"Ribavirin (RBV) continues to be an important component of interferon-free hepatitis C treatment regimens, as RBV alone does not inhibit hepatitis C virus (HCV) replication effectively; the reason for this ineffectiveness has not been established. In this study, we investigated the RBV resistance mechanism using a persistently HCV-infected cell culture system. The antiviral activity of RBV against HCV was progressively impaired in the persistently infected culture, whereas interferon lambda 1 (IFN-\\u03bb1), a type III IFN, showed a strong antiviral response and induced viral clearance. We found that HCV replication in persistently infected cultures induces an autophagy response that impairs RBV uptake by preventing the expression of equilibrative nucleoside transporter 1 (ENT1). The Huh-7.5 cell line treated with an autophagy inducer, Torin 1, downregulated membrane expression of ENT1 and terminated RBV uptake. In contrast, the autophagy inhibitors hydroxychloroquine (HCQ), 3-methyladenine (3-MA), and bafilomycin A1 (BafA1) prevented ENT1 degradation and enhanced RBV antiviral activity. The HCV-induced autophagy response, as well as treatment with Torin 1, degrades clathrin heavy chain expression in a hepatoma cell line. Reduced expression of the clathrin heavy chain by HCV prevents ENT1 recycling to the plasma membrane and forces ENT1 to the lysosome for degradation. This study provides a potential mechanism for the impairment of RBV antiviral activity in persistently HCV-infected cell cultures and suggests that inhibition of the HCV-induced autophagy response could be used as a strategy for improving RBV antiviral activity against HCV infection.\",\"Sofosbuvir (SOF) in combination with ribavirin (RBV) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis C virus (HCV) genotypes 2 and 3, respectively. However, in clinical trials treatment-experienced patients, particularly those with cirrhosis, had suboptimal sustained virological response (SVR) rates. We assessed the efficacy and safety of sofosbuvir plus peginterferon and ribavirin (SOF+Peg-IFN+RBV) administered for 12 weeks to treatment-experienced patients with HCV genotypes 2 and 3, with and without cirrhosis. We enrolled 47 patients in this open-label, nonrandomized, uncontrolled phase 2 study. The primary endpoint was the proportion of patients with SVR at 12 weeks after cessation of study treatment (SVR12). The overall rate of SVR12 was 89% (95% confidence interval [CI]: 77-97). Rates of SVR12 were higher in patients with genotype 2 than in those with genotype 3, 96% (95% CI: 78-100) and 83% (95% CI: 62-95), respectively. Rates of SVR12 were similar in patients with and without cirrhosis: for genotype 2, 93% of patients with cirrhosis and 100% of patients without cirrhosis achieved SVR12, and for genotype 3, the SVR12 rate was 83% in patients both with and without cirrhosis. One patient discontinued study treatment because of an adverse event and four patients experienced serious adverse events. The most common adverse events were influenza-like illness, fatigue, anemia, and neutropenia.\",\"The hepatitis C virus remains a global health issue, and the established standard of care has consisted of pegylated interferon alpha in conjunction with ribavirin. However, this regimen is associated with significant side-effects and poor sustained virological responses. The aim of this review is to assess the effects of the direct-acting antivirals upon hepatitis C genotypes 2-6 from publications from the past 18 months.\",\"Interferon alfa-based regimens used to treat recurrent hepatitis C virus (HCV) infection after liver transplantation are poorly tolerated, associated with generally modest efficacy, and can interact with immunosuppressive agents. We evaluated the efficacy and safety of an interferon-free regimen of the nucleotide polymerase inhibitor sofosbuvir combined with ribavirin for 24 weeks in treating post-transplantation HCV infection.\",\"Advances in understanding the hepatitis C virus (HCV) life cycle and the urgent need to find complementary direct-acting antiviral (DAA) therapies has led to substantial advancements in treating chronic hepatitis C. The introduction of telaprevir and boceprevir in 2011 increased the sustained virological response (SVR) rate from approximately 50% to > 70%, but this therapy further restricted patient eligibility and is only approved for treating HCV genotype 1 infection. Interferon has long remained the backbone of HCV therapy and helps prevent viral breakthrough. However, interferon has limited effectiveness and is associated with severe adverse effects and toxicity, especially among cirrhotic patients. Moving to interferon-free therapies should greatly improve SVR rates and offer new treatments for other HCV genotypes and for ineligible patients or patients failing to respond to prior therapies. However, without the relative safety of interferon to suppress viral escape, vigilance will be required to select appropriate therapies and monitor resistance. Several DAAs are currently undergoing clinical trials and will soon undergo the approval process. Goals of future HCV clinical research will be to identify combinations of DAAs with high genetic barriers, investigate optimal treatment doses and durations, and determine the role of ribavirin in DAA therapies.\",\"Virologic failure following treatment of hepatitis C virus (HCV) genotype 1 with direct-acting antiviral agents is often accompanied by the emergence of resistant variants. MK-5172 is an investigational once-daily protease inhibitor. We analyzed variants in treatment-naive noncirrhotic patients with virologic failure on MK-5172 (100-800 mg/day) plus pegylated interferon alfa/ribavirin (peg-IFN/RBV) during a phase 2 trial.\",\"Chronic Hepatitis C Virus (HCV)-infected patients with liver cirrhosis (LC) respond poorly to interferon-alpha (IFN-\\u03b1) and ribavirin (RBV) combination therapy, but the reason for this is unclear. We previously reported that HCV-infection induces endoplasmic reticulum (ER) stress and autophagy response that selectively down regulates the type I IFN-\\u03b1 receptor-1 (IFNAR1) and RBV transporters (CNT1 and ENT1), leading to IFN-\\u03b1/RBV resistance. The goal of this study is to verify whether an increase in ER stress and autophagy response is also associated with the reduced expression of IFNAR1 and RBV transporters in chronic HCV-infected patients.\",\"Chronic hepatitis C treatment for prior non-responders to peginterferon (PegIFN)/ribavirin remains suboptimal. The MATTERHORN study evaluated regimens containing ritonavir-boosted danoprevir (danoprevir/r) in prior PegIFN alfa/ribavirin non-responders.\",\"Hepatitis C virus (HCV) is a major cause of chronic liver disease, with about 170 million people infected worldwide. The standard regimen for treatment of HCV consists of a combination of pegylated interferon with ribavirin. Failure of interferon-\\u03b1 treatment in patients with chronic HCV infection remains a challenging obstacle. Both viral and host environmental factors have been implicated in reducing responsiveness to IFN-\\u03b1 therapy. Host genetic diversity is also believed to contribute to the different clinical outcomes in HCV infection. The objective of the study was to investigate the association of both IL-10 (-819 and -592) and MxA (-88 and -123) single-nucleotide polymorphisms (SNPs) of the promoter regions, with response to interferon (IFN) therapy in Egyptian patients infected with HCV genotype 4. Polymorphisms of both genes in 85 HCV patients and 100 controls were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. The frequency of SNP was compared between sustained responders (n = 52) and non-responders (n = 33), as determined by biochemical and virological response to IFN and ribavirin combined therapy. The frequency of the -819T/T and the -592A/A genotypes of IL-10 was significantly higher among responders compared to non-responders (51.92 vs 39.4 %, P = 0.03; 51.92 vs 42.42 %;P = 0.046 respectively). The G/G genotype at position -88 of the MxA gene was significantly lower in responders than in non-responders (25 vs 75.76 %, P = 0.046), whereas heterozygotes (G/T) were more likely responders (65.38 vs 18.18 %, P = 0). The -123C/A genotype was significantly associated with responders (48.08 vs 30.30 %, P = 0.014). Findings suggest that homozygosity for both -819T/T and -592A/A polymorphisms of IL-10 gene and that heterozygosity for both -88G/T and -123C/A polymorphisms of the MxA gene are important host factors that influence the response to IFN therapy in patients with chronic HCV infection.\",\"The combination of pegylated interferon (PEG-IFN) and ribavirin (RBV), the current therapy for hepatitis C virus (HCV) infection, has saved the lives of many HCV-infected patients. Direct-acting antivirals (DAAs) target several sites of HCV nonstructural proteins, resulting in the cessation of viral replication. The first NS3/4A protease inhibitors consisted of boceprevir and telaprevir, which have shown superior efficacy against genotype 1 HCV infection when combined with PEG-IFN/RBV compared with the standard therapy in both treatment-naive and -experienced patients. Simeprevir, faldaprevir, and asunaprevir are second-wave, first-generation NS3/4A inhibitors that have already been or will soon be approved. Second-generation protease inhibitors are in clinical trials. Daclatasvir is the first approved DAA belonging to the class of NS5A replication complex inhibitors. The potency of daclatasvir is very high, and this drug is an important and essential component of combination regimens for all genotypes. Sofosbuvir, the first approved NS5B polymerase inhibitor, is characterized by high potency and genetic barriers to resistance. Sofosbuvir combined with RBV achieved an interferon-free regimen in genotype 2 or 3 patients with a reduced treatment duration. It can also be used in combination with PEG-IFN/RBV in genotype 1 patients for 12 weeks. DAAs have provided new hope for curing HCV infections with a short treatment duration and acceptable adverse events.\",\"Hepatitis C virus (HCV) modulates intrahepatic cholesterol biosynthetic pathways to promote viral replication. Chronic HCV infection is associated with altered metabolism, including dyslipidemia and insulin resistance (IR), which contributes to disease progression and influences response to therapy. To further understand the impact of HCV infection on host metabolism, we examined changes in serum lipid profiles and intrahepatic expression of lipid-related genes during interferon (IFN)-free treatment of chronic HCV, genotype 1 infection with sofosbuvir and ribavirin (RBV), and explored associations with treatment outcome. Serum lipids (total cholesterol, low-density lipoprotein [LDL], high-density lipoprotein [HDL], and triglycerides [TGs]) and hemoglobin A1C (HbA1C) were measured during treatment, while gene expression of lipid-related genes was assessed using paired pre- and end-of-treatment (EOT) liver biopsies from 8 patients (n=7 sustained virologic response [SVR]; n=1 relapse) and unpaired EOT liver biopsies from 25 patients (n=17 SVR; n=8 relapse). Serum LDL concentration and particle size increased early in therapy, whereas TG concentration and very-low-density lipoprotein particle size decreased concomitantly, irrespective of treatment outcome. Whereas LDL increased in patients regardless of treatment outcome, average LDL concentration was lower at baseline and post-treatment in patients who relapsed. Analysis of paired liver biopsies revealed altered expression of genes associated with lipid transport, assembly, and signaling. In unpaired EOT liver biopsies, intrahepatic expression of fatty acid metabolism and lipid transport genes was lower in patients who experienced treatment relapse.\",\"Adult intestinal stem cells (ISCs) possess both a long-term proliferation ability and differentiation capability into enterocytes. As a novel in vitro system for the evaluation of drug absorption, we characterized a human small intestinal epithelial cell (HIEC) monolayer that differentiated from adult ISCs. Continuous proliferation/differentiation from ISCs consistently conferred the capability of maturation of enterocytes to HIECs over 25 passages. The morphologically matured HIEC monolayer consisted of polarized columnar epithelia with dense microvilli, tight junctions, and desmosomes 8 days after seeding onto culture inserts. Transepithelial electrical resistance across the monolayer was 9-fold lower in HIECs (98.9 \\u03a9 \\u00d7 cm(2)) than in Caco-2 cells (900 \\u03a9 \\u00d7 cm(2)), which indicated that the looseness of the tight junctions in the HIEC monolayer was similar to that in the human small intestine (approximately 40 \\u03a9 \\u00d7 cm(2)). No significant differences were observed in the overall gene expression patterns of the major drug-metabolizing enzymes and transporters between the HIEC and Caco-2 cell monolayers. Furthermore, the functions of P-glycoprotein and breast cancer resistance protein in the HIEC monolayer were confirmed by the vectorial transport of marker substrates and their disappearance in the presence of specific inhibitors. The apparent drug permeability values of paracellularly transported compounds (fluorescein isothiocyanate-dextran 4000, atenolol, and terbutaline) and nucleoside transporter substrates (didanosine, ribavirin, and doxifluridine) in the HIEC monolayer were markedly higher than those of Caco-2 cells, whereas transcellularly transported drugs (pindolol and midazolam) were equally well permeated. In conclusion, the HIEC monolayer can serve as a novel and superior alternative to the conventional Caco-2 cell monolayer for predicting oral absorption in humans.\",\"We analyzed blood samples collected from 15 patients with chronic hepatitis E who were recipients of solid-organ transplants. All patients cleared the hepatitis E virus (HEV) except for 2 (nonresponders); 1 patient died. A G1634R mutation in viral polymerase was detected in the HEV RNA of the nonresponders; this mutation did not provide the virus with resistance to ribavirin in vitro. However, the mutant form of a subgenomic replicon of genotype 3 HEV replicated more efficiently in vitro than HEV without this mutation, and the same was true for infectious virus, including in competition assays. Similar results were obtained for genotype 1 HEV. The G1634R mutation therefore appears to increase the replicative capacity of HEV in the human liver and hence reduce the efficacy of ribavirin.\",\"To provide an overview of a novel anti-hepatitis C agent, sofosbuvir.\",\"Chronic hepatitis C virus (HCV) infection has been a tremendous health burden worldwide with an annual mortality of 300,000 people due to decompensated cirrhosis or hepatocellular carcinoma. A combination of interferon (IFN), ribavirin (RBV), and/or direct-acting antivirals (DAAs) can eradicate HCV in a various proportion of infected patients. Unfortunately, IFN-based therapy is associated with significant adverse effects, contraindications, and limited tolerability, leading to lower adherence or even treatment discontinuation. With the rapid evolution of newer DAAs or host-targeting agents, emerging HCV therapy is moving towards an IFN- and RBV-free strategy. To this end, a recently developed NS3 protease inhibitor, asunaprevir (ASV), in combination with other DAAs as IFN/RBV-containing or -free regimen, has shown promising results with fewer adverse effects. In this review, preclinical profiles and clinical proof-of-concept studies of ASV, including viral resistance, host polymorphism, and role of ASV in future HCV therapy are reviewed and discussed.\",\"The launch of first-generation protease inhibitors (PIs) was a major step forward in hepatitis C virus (HCV) treatment. However, this major advance is, up to now, restricted to genotype-1 (GT-1) patients. However, the ongoing development of new direct-acting antiviral agents (DAAs) allows new hope for the future. The development of second-wave and second-generation PIs yields higher antiviral potency through plurigenotypic activity, more convenient daily administration, fewer side effects and, for the second-generation PIs, potential activity against resistance-associated variants. NS5B inhibitors (NS5B.I) include nucleoside/nucleotide inhibitors (NIs) and nonnucleotide inhibitors (NNIs). NIs have high efficacy across all genotypes. Sofosbuvir has highly potent antiviral activity across all genotypes in association with pegylated interferon (IFN) and ribavirin (PR), thus allowing shortened treatment duration. NS5A inhibitors (NS5A.I) have highly potent antiviral activity. It has recently been shown for the first time that NS5A.I in combination with PI can cure GT-1b null-responder patients in an IFN-free regimen. In addition, several studies demonstrate that IFN-free regimens with DAA combinations are able to cure a large number of either na\\u00efve or treatment-experienced GT-1 patients. Moreover, a quadruple regimen with PR is able to cure almost all GT-1 null-responders. The development of pan-genotypic DAAs (NIs or NS5A.I) allows new combinations with or without PR that increase the rate of sustained virological response (SVR) for all patients, even for those with cirrhosis and independently of the genotype. Therefore, the near future of HCV treatment looks promising. The purpose of this article is to provide an overview of the clinical results recently reported for HCV treatment in GT-1 patients.\",\"Treatment with GS-9669, a novel nonnucleoside inhibitor (site II) of hepatitis C virus (HCV) nonstructural 5B (NS5B) polymerase, resulted in significant antiviral activity in HCV genotype (GT) 1 patients dosed at 50 and 500 mg once daily (QD) and at 50, 100, and 500 mg twice daily (BID) for 3 days. This report characterizes the virologic resistance to GS-9669 in vitro and in GT1 HCV-infected patients from a phase I clinical study. An in vitro resistance selection study with GS-9669 revealed substitutions at several NS5B residues that conferred resistance. The M423 variants were selected at low drug concentrations (5\\u00d7 the 50% effective concentration [EC50]), and the L419, R422, and I482 variants were selected at higher drug concentrations (20\\u00d7 the EC50). During the phase I clinical study, substitutions at NS5B residues 419, 422, and 486 were the predominant changes associated with GS-9669 monotherapy. Substitutions at position 423 were observed only in GT1a patients in the low-dose groups (50 and 100 mg BID). Interestingly, four HCV patients had substitutions at position 423 at baseline. Consistent with the low resistance level at this position, three patients with M423I or M423V at baseline achieved >2-log10 reductions of HCV RNA when treated with 100 mg BID or with 500 mg QD or BID of GS-9669. The fourth patient, who had the M423V substitution at baseline, had a 4.4-log10 reduction of HCV RNA with 500 mg BID of GS-9669. Phenotypic analyses demonstrated that the viral isolates with multiple GS-9669 resistance-associated variants have reduced susceptibility to GS-9669 and lomibuvir (VX-222) but are not cross-resistant to other classes of HCV inhibitors. (This study has been registered at ClinicalTrials.gov under registration no. NCT01431898.).\",\"Appropriate antiviral treatment is essential for living donor liver transplantation (LDLT) to be effective for treating hepatitis C. However, it has never been reported that pre-LDLT genetic analyses of both host and virus, with prediction of the outcome of post-LDLT antiviral treatment, indicated LDLT for a borderline case.\",\"Sofosbuvir (Sovaldi, SOF) is a nucleotide analog prodrug that targets the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase and inhibits viral replication. High sustained virological response rates are achieved when SOF is used in combination with ribavirin with or without pegylated interferon in subjects with chronic HCV infection. Potential mechanisms of HCV resistance to SOF and other nucleos(t)ide analog NS5B polymerase inhibitors are not well understood. SOF was the first U.S. Food and Drug Administration (FDA)-approved antiviral drug for which genotypic resistance analyses were based almost entirely on next-generation sequencing (NGS), an emerging technology that lacks a standard data analysis pipeline. The FDA Division of Antiviral Products developed an NGS analysis pipeline and performed independent analyses of NGS data from five SOF clinical trials. Additionally, structural bioinformatics approaches were used to characterize potential resistance-associated substitutions. Using protocols we developed, independent analyses of the NGS data reproduced results that were comparable to those reported by Gilead Sciences, Inc. Low-frequency, treatment-emergent substitutions occurring at conserved NS5B amino acid positions in subjects who experienced virological failure were also noted and further evaluated. The NS5B substitutions, L159F (sometimes in combination with L320F or C316N) and V321A, emerged in 2.2%-4.4% of subjects who failed SOF treatment across clinical trials. Moreover, baseline polymorphisms at position 316 were potentially associated with reduced response rates in HCV genotype 1b subjects. Analyses of these variants modeled in NS5B crystal structures indicated that all four substitutions could feasibly affect SOF anti-HCV activity.\",\"Passage of hepatitis C virus (HCV) in human hepatoma cells resulted in populations that displayed partial resistance to alpha interferon (IFN-\\u03b1), telaprevir, daclatasvir, cyclosporine, and ribavirin, despite no prior exposure to these drugs. Mutant spectrum analyses and kinetics of virus production in the absence and presence of drugs indicate that resistance is not due to the presence of drug resistance mutations in the mutant spectrum of the initial or passaged populations but to increased replicative fitness acquired during passage. Fitness increases did not alter host factors that lead to shutoff of general host cell protein synthesis and preferential translation of HCV RNA. The results imply that viral replicative fitness is a mechanism of multidrug resistance in HCV. Importance: Viral drug resistance is usually attributed to the presence of amino acid substitutions in the protein targeted by the drug. In the present study with HCV, we show that high viral replicative fitness can confer a general drug resistance phenotype to the virus. The results exclude the possibility that genomes with drug resistance mutations are responsible for the observed phenotype. The fact that replicative fitness can be a determinant of multidrug resistance may explain why the virus is less sensitive to drug treatments in prolonged chronic HCV infections that favor increases in replicative fitness.\",\"The hepatitis C virus (HCV) genotype-specific impacts on the host metabolic alterations remained inconclusive.\",\"HCV NS3/4A serine protease inhibitors are the first class of direct acting antivirals (DAA) introduced in clinical practice. The first generation agents, selective against HCV genotype 1, are used in association with pegylated interferons and ribavirin allowing increased cure rates at the price of increased toxicity, significant drug interactions and high risk of selecting mutants conferring cross-resistance to the entire class. A large number of second-wave HCV protease inhibitors are currently in clinical development. Advancements include higher potency, activity against a wider number of genotypes, improved tolerability, easier dosing schedules, although their genetic barrier to resistance remains low, especially for subtype 1a, except for the most recent grazoprevir and ACH-2684. The most relevant progress regards the combination with other classes of DAA allowing construction of interferon-free regimens of short duration, good tolerability with exceptionally high cure rates.\",\"Vaniprevir (MK-7009) is a hepatitis C virus (HCV) non-structural 3/4a protease inhibitor which significantly increases virologic response rates in HCV genotype (GT) 1-infected patients when added to peginterferon and ribavirin (PR).\",\"Infection with the hepatitis C virus (HCV) is a major cause of chronic liver diseases and hepatocellular carcinoma worldwide, and thus represents a significant public health problem. The type I interferon (IFN), IFN\\u03b1, has been successful in treating HCV-infected patients, but current IFN-based treatment regimens for HCV have suboptimal efficacy, and relatively little is known about why IFN therapy eliminates the virus in some patients but not in others. Therefore, it is critical to understand the basic mechanisms that underlie the therapeutic resistance to IFN action in HCV-infected individuals, and there is an urgent need to identify those patients most likely to respond to IFN therapy for HCV. To characterize the response of HCV-infected patients to treatment with IFN\\u03b1, the expression of an IFN-response gene signature comprised of IFN-stimulated genes and genes that play an important role in the innate immune response was examined in liver biopsies from HCV-infected patients enrolled in a clinical trial. In the present study we found that the expression of a subset of IFN-response genes was dysregulated in liver biopsy samples from nonresponsive hepatitis C patients as compared with virologic responders. Based on these findings, a statistical model was developed to help predict the response of patients to IFN therapy, and compared to results obtained to the IL28 mutation model, which is highly predictive of the response to IFN-based therapy in HCV-infected patients. We found that a model incorporating gene expression data can improve predictions of IFN responsiveness compared to IL28 mutation status alone.\",\"For patients infected with hepatitis C virus (HCV), the combination of the direct-acting antiviral agent telaprevir, pegylated-interferon alfa (Peg-IFN), and ribavirin (RBV) significantly increases the chances of sustained virologic response (SVR) over treatment with Peg-IFN and RBV alone. If patients do not achieve SVR with telaprevir-based treatment, their viral population is often significantly enriched with telaprevir-resistant variants at the end of treatment. We sought to quantify the evolutionary dynamics of these post-treatment resistant variant populations. Previous estimates of these dynamics were limited by analyzing only population sequence data (20% sensitivity, qualitative resistance information) from 388 patients enrolled in Phase 3 clinical studies. Here we add clonal sequence analysis (5% sensitivity, quantitative) for a subset of these patients. We developed a computational model which integrates both the qualitative and quantitative sequence data, and which forms a framework for future analyses of drug resistance. The model was qualified by showing that deep-sequence data (1% sensitivity) from a subset of these patients are consistent with model predictions. When determining the median time for viral populations to revert to 20% resistance in these patients, the model predicts 8.3 (95% CI: 7.6, 8.4) months versus 10.7 (9.9, 12.8) months estimated using solely population sequence data for genotype 1a, and 1.0 (0.0, 1.4) months versus 0.9 (0.0, 2.7) months for genotype 1b. For each individual patient, the time to revert to 20% resistance predicted by the model was typically comparable to or faster than that estimated using solely population sequence data. Furthermore, the model predicts a median of 11.0 and 2.1 months after treatment failure for viral populations to revert to 99% wild-type in patients with HCV genotypes 1a or 1b, respectively. Our modeling approach provides a framework for projecting accurate, quantitative assessment of HCV resistance dynamics from a data set consisting of largely qualitative information.\",\"Hepatitis C virus (HCV) is an RNA virus that chronically infects 2-3% of the world's population. About 25% of these chronic carriers evolve towards liver cirrhosis, a disease that is significantly associated with reduced survival and quality of life. Antiviral therapy can eradicate the infection - a process that is associated with a reduced disease progression rate. Several oral direct agents have been developed and tested for the treatment of HCV infection. This review focuses on the mechanism of action, pharmacokinetics, efficacy, safety and resistance of GS-9669, a non-nucleoside inhibitor of viral polymerase, active against HCV genotype 1. In combination with other oral antivirals, GS-9669 results: in very high rates of viral eradication (90-100%) in patients with HCV genotype 1 infection, with a good tolerability and safety profile. In conclusion, GS-9669 is a good candidate to be used in interferon-free combinations for the treatment of chronic HCV infection.\",\"Hepatitis C virus (HCV) chronically infects about 150,000,000 people worldwide and is a relevant cause of liver cirrhosis, hepatocellular carcinoma and death. Antiviral treatment is rapidly moving from interferon (IFN)-based therapy to IFN-free approaches. This review focuses on the mechanism of action, pharmacokinetics, efficacy, tolerability, safety and resistance of ombitasvir, which is an inhibitor of the HCV nonstructural protein 5A. The pharmacokinetics of ombitasvir enables its once daily administration. In vivo, in combinations with other oral direct acting antivirals, ombitasvir achieves very high rates of sustained virological response (about 95%) in patients with HCV genotype 1 infection with a good tolerability. Resistance profiling revealed a low barrier to resistance when given as monotherapy. However, coadministration of ombitasvir and other antivirals enhances its barrier to resistance. In conclusion, ombitasvir is a good drug to be used in IFN-free combinations for the treatment of chronic hepatitis C.\",\"According to the World Health Organization, approximately 150 million people worldwide are chronic carriers of hepatitis C virus (HCV). HCV infection can evolve into cirrhosis of the liver and its complications, which are ultimately responsible for more than 350,000 deaths every year. Antiviral therapy, when successful, is able to decrease the rate of progression and increase survival. Two types of therapies are currently available, ie, interferon-based therapies and interferon-free ones. The latter have several advantages in terms of safety and tolerability, and could be used even in the most advanced stages of the disease. However, their use is restricted to some viral genotypes (genotype 2 and 3) and they are expensive. Several molecules are in an advanced phase of development. This review deals with the pharmacokinetics, pharmacodynamics, tolerability, and safety of asunaprevir, an inhibitor of HCV nonstructural 3 protease. Asunaprevir exerts optimal in vitro activity particularly against HCV genotypes 1 and 4, and its pharmacokinetic profile enables twice daily administration. The drawback of asunaprevir, and of all protease inhibitors, is its low barrier to resistance. Consequently, it is used in association with other drugs to prevent resistance. Specifically, when combined with daclatasvir, an NS5A inhibitor, asunaprevir results in a very high rate of viral eradication in both treatment-na\\u00efve and treatment-experienced patients, with a sustained virological response rate of 80%-90%. Tolerability is fair; in fact, asunaprevir is associated with a transient increase in aminotransferase levels, which is mild in most cases. In conclusion, asunaprevir is a good candidate component of interferon-free combinations and may revolutionize the treatment of chronic HCV infection in the near future.\",\"Daclatasvir is a novel NS5A inhibitor of hepatitis C virus (HCV). Daclatasvir combined with peginterferon \\u03b1-2a and ribavirin in Japanese patients infected with genotype 1b HCV achieved sustained virological response (SVR) in 100% of treatment-na\\u00efve patients, due to high rates of favorable IL28B allele and genotype 1b. SVR 24 was achieved by asunaprevir and daclatasvir in 87.4% of intolerant and 80.5% of nonresponder patients. Baseline NS5A-resistant variants were detected and they failed to achieve SVR. Most patients with genotype 1a experienced virological breakthrough by dual oral treatment, and should be treated QUAD or replaced by all oral regimens that are more potent and have fewer side effects. IFN-free regimens including daclatasvir and asunaprevir for genotype 1 null responders should be tailored to subtype, and preexisting NS5A-resistant variants should be evaluated carefully before choosing the drugs. This regimen alone is unlikely to move forward without additional agents.\",\"Telaprevir and boceprevir, the two first hepatitis C virus (HCV) NS3 protease inhibitors (PIs), considerably increase rates of sustained virologic response in association with pegylated interferon and ribavirin in chronic HCV genotype 1 infections. The 30 first patients treated by telaprevir or boceprevir including anti-HCV therapies since 2011 in Marseille University hospitals, France, were monitored. HCV loads and plasmatic concentrations of telaprevir and boceprevir were determined on sequential blood samples. HCV NS3 protease gene population sequencing was performed at baseline of treatment and in case of treatment failure. Fifteen patients (including 7 co-infected with HIV) received telaprevir and the other 15 patients (including 4 co-infected with HIV) received boceprevir. At baseline, HCV NS3 protease from six patients harbored amino acid substitutions associated with PI-resistance. Treatment failure occurred at week 12 for 7 patients. Amino acid substitutions associated with PI-resistance were observed in six of these cases. HCV NS3 R155K and T54A/S mutants, all of genotype 1a, were found from four patients. Median (interquartile range) plasma concentrations were 3,092 ng/ml (2,320-3,525) for telaprevir and 486 ng/ml (265-619) for boceprevir. For HIV-HCV co-infected patients, median concentrations were 3,162 ng/ml (2,270-4,232) for telaprevir and 374 ng/ml (229-519) for boceprevir. Plasma drug concentration monitoring revealed undetectable concentrations for two patients at week 4, and probable non-adherence to therapy for another patient. These findings indicate that routine HCV NS3 protease sequencing and plasma PI concentration monitoring might be helpful to characterize cases of therapy failure, at a cost dramatically low compared to that of anti-HCV therapy.\",\"Recently direct-acting antiviral agents, such as hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) protease inhibitors (PI), have been introduced, and triple therapy regimens that include PI with conventional pegylated interferon \\u03b1 and ribavirin have significantly improved the sustained virological response (SVR) rate, up to 80% for both treatment-na\\u00efve and treatment-experienced patients with HCV genotype 1. We here report for the first time a case of the successful treatment of HCV genotype 1 infection with a first generation PI drug (telaprevir) based triple therapy after treatment failure with a second generation PI drug (vaniprevir) based triple therapy. A 67-year-old treatment-na\\u00efve Japanese man with HCV genotype 1b infection took part in a phase III clinical trial of vaniprevir-based triple therapy. His serum HCV RNA had become undetectable at week 2 and SVR was highly expected, but HCV RNA reappeared at week 4 after vaniprevir treatment. Polymerase chain reaction direct sequence of the HCV NS3/4A gene at week 8 after vaniprevir treatment showed the emergence of a vaniprevir-resistance mutation (D168V), the probable reason for the treatment failure. Six months later, retreatment with telaprevir-based triple therapy was started. Although the dosages of telaprevir and ribavirin had to be reduced due to severe anemia, the patient achieved an SVR. This case shows the value of repeating PI-based triple therapy with a different drug, a process that would reduce the chance of drug resistant mutation.\",\"Hepatitis C infection represents a major health problem in Egypt; only 20% of patients undergo spontaneous clearance of the virus and around 25% of all patients progress to develop cirrhosis. More than 90% of Egyptian patients have hepatitis C virus (HCV) genotype-4. Combined pegylated interferon and oral ribavirin are the current standard therapies for HCV-4. The aim of the work is to evaluate the predictive power of the rs12979860 IL28B SNP and rs12980275 IL28B SNP for treatment response in Egyptian patients infected with HCV genotype 4. One hundred eleven HCV patients receiving combined treatment were studied for rs12979860 and rs12980275 polymorphisms by the restriction fragment length polymorphism technique. The rs12979860 CC and rs12979860 AA genotypes were significantly associated with sustained virological response (p=0.001). Our results suggest that studying IL28B polymorphisms contribute to proper prediction of response to standard therapies in Egyptian patients, optimizing cost effectiveness, and minimizing unneeded adverse effect of therapy.\",\"Antiviral drugs are being used for therapeutic purposes against influenza illness in humans. However, antiviral-resistant variants often nullify the effectiveness of antivirals. Combined medications, as seen in the treatment of cancers and other infectious diseases, have been suggested as an option for the control of antiviral-resistant influenza viruses. Here, we evaluated the therapeutic value of combination therapy against oseltamivir-resistant 2009 pandemic influenza H1N1 virus infection in DBA/2 mice. Mice were treated for five days with favipiravir and peramivir starting 4 hours after lethal challenge. Compared with either monotherapy, combination therapy saved more mice from viral lethality and resulted in increased antiviral efficacy in the lungs of infected mice. Furthermore, the synergism between the two antivirals, which was consistent with the survival outcomes of combination therapy, indicated that favipiravir could serve as a critical agent of combination therapy for the control of oseltamivir-resistant strains. Our results provide new insight into the feasibility of favipiravir in combination therapy against oseltamivir-resistant influenza virus infection.\",\"Hepatitis C virus (HCV) is a major cause of liver disease worldwide. HCV is able to evade host defense mechanisms, including both innate and acquired immune responses, to establish persistent infection, which results in a broad spectrum of pathogenicity, such as lipid and glucose metabolism disorders and hepatocellular carcinoma development. The HCV genome is characterized by a high degree of genetic diversity, which can be associated with viral sensitivity or resistance (reflected by different virological responses) to interferon (IFN)-based therapy. In this regard, it is of importance to note that polymorphisms in certain HCV genomic regions have shown a close correlation with treatment outcome. In particular, among the HCV proteins, the core and nonstructural proteins (NS) 5A have been extensively studied for their correlation with responses to IFN-based treatment. This review aims to cover updated information on the impact of major HCV genetic factors, including HCV genotype, mutations in amino acids 70 and 91 of the core protein and sequence heterogeneity in the IFN sensitivity-determining region and IFN/ribavirin resistance-determining region of NS5A, on virological responses to IFN-based therapy.\",\"Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC). Whether add-on oral hypoglycemic agents (OHAs) to PR improve SVR remains unclear; therefore, we conducted a prospective, randomized pilot trial on 23 consecutive patients with genotype 1 CHC and IR in Taiwan.\",\"Hepatitis C virus (HCV) is a successful pathogen on the grounds that it exploits its host's metabolism to build up viral particles; moreover it favours its own survival by inducing chronic disease and the development of specific anatomic changes in the infected organ. Steatosis, therefore, is associated with HCV infection by necessity rather than by chance alone. Approximately 6% of HCV patients have steatohepatitis. Interestingly, HCV steatosis occurs in the setting of multiple metabolic abnormalities (hyperuricemia, reversible hypocholesterolemia, insulin resistance, arterial hypertension and expansion of visceral adipose tissue) collectively referred to as \\\"hepatitis C-associated dysmetabolic syndrome\\\" (HCADS). General, nonalcoholic fatty liver disease (NAFLD)-like, mechanisms of steatogenesis (including increased availability of lipogenic substrates and de novo lipogenesis; decreased oxidation of fatty substrates and export of fatty substrates) are shared by all HCV genotypes. However, genotype 3 seemingly amplifies such steatogenic molecular mechanisms reported to occur in NAFLD via more profound changes in microsomal triglyceride transfer protein; peroxisome proliferator-activated receptor alpha; sterol regulatory element-binding proteins and phosphatase and tensin homologue. HCV steatosis has a remarkable clinical impact in as much as it is an acknowledged risk factor for accelerated fibrogenesis; for impaired treatment response to interferon and ribavirin; and development of hepatocellular carcinoma. Recent data, moreover, suggest that HCV-steatosis contributes to premature atherogenesis via both direct and indirect mechanisms. In conclusion, HCV steatosis fulfills all expected requirements necessary to perpetuate the HCV life cycle. A better understanding of the physiology of HCADS will likely result in a more successful handling of disease with improved antiviral success rates.\",\"Sofosbuvir (Sovaldi(\\u00ae)) is a nucleotide hepatitis C virus (HCV) NS5B polymerase inhibitor that has pangenotypic antiviral activity and a high genetic barrier to resistance. This article reviews the clinical efficacy and tolerability of sofosbuvir in patients with chronic hepatitis C and summarizes its pharmacological properties. Interferon-free treatment with sofosbuvir plus ribavirin achieved high sustained virological response (SVR) rates in treatment-na\\u00efve and treatment-experienced patients with HCV genotype 2 or 3 infection, and also had efficacy in patients with HCV genotype 1 infection. Sofosbuvir plus ribavirin was also effective in patients co-infected with HCV and HIV, and sofosbuvir plus ribavirin administered prior to liver transplantation prevented recurrent HCV infection in the majority of patients who had HCV RNA levels below the limit of quantification at the time of transplantation. Sofosbuvir plus peginterferon-\\u03b1-2a and ribavirin achieved high SVR rates in patients with HCV genotype 1 infection, and also appeared effective in patients with HCV genotype 4, 5 or 6 infection. Oral sofosbuvir was generally well tolerated in patients with chronic hepatitis C. The most commonly reported adverse events and laboratory abnormalities were consistent with those expected with ribavirin and peginterferon-\\u03b1. In conclusion, sofosbuvir represents an important advance in the treatment of chronic hepatitis C.\",\"Despite the introduction of protease inhibitors (PI) in the treatment of hepatitis C, the sensitivity of interferon continues to be essential to achieve a sustained virological response (SVR) and to eradicate the viral infection. Currently, pegylated interferon (PEG-IFN) and ribavirin (RBV) are required to avoid selection of PI-resistance mutations. The likelihood of obtaining an SVR with dual therapy in treatment-na\\u00efve patients with genotype 1 infection varies from 40% to 50%. That is, almost half of these patients would not require a PI, thus avoiding their adverse effects and considerably reducing the cost of the treatment. Identifying which patients could potentially respond to dual therapy is one of the main challenges in clinical practice. The genetic variability of the host is one of the main factors affecting the sensitivity of PEG-IFN and therefore in the response to current treatment. Other baseline factors related to the host, the virus and, especially, to intratreatment factors such as rapid virological response (RVR) are strongly associated with the probability of achieving an SVR. The evidence on the decision to prescribe dual or triple therapy according to the factors predictive of response is based on retrospective studies or post-hoc analyses of pivotal studies on PI. Study of the polymorphisms of the IFNL3 gene (IL28B), ITPA, IFN-stimulated genes (ISGs), TT/\\u0394G (ss469415590; IFNL4)) and RBV transporters could help in the decision to prescribe dual or triple therapy in treatment na\\u00efve patients.\",\"Resistance to direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) infection is driven by the selection of mutations at different positions in the NS3 protease, NS5B polymerase and NS5A proteins. With the exception of NS5B nucleos(t)ide inhibitors, most DAAs possess a low genetic barrier to resistance, with significant cross-resistance between compounds belonging to the same family. However, a specific mutation profile is associated with each agent or drug class and varies depending on the genotype/subtype (e.g., genotype 1b showed higher rates of sustained virological response (SVR) and a higher genetic barrier for resistance than genotype 1a). Moreover, some resistance mutations exist as natural polymorphisms in certain genotypes/subtypes at frequencies that require baseline drug resistance testing before recommending certain antivirals. For example, the polymorphism Q80K is frequently found among genotype 1a (19-48%) and is associated with resistance to simeprevir. Similarly, L31M and Y93H, key resistance mutations to NS5A inhibitors, are frequently found (6-12%) among NS5A genotype 1 sequences. In particular, the presence of these polymorphisms may be of relevance in poorly interferon-responsive patients (i.e., null responders and non-CC IL28B) under DAA-based therapies in combination with pegylated interferon-\\u03b1 plus ribavirin. The relevance of pre-existing resistance mutations for responses to interferon-free DAA therapies is unclear for most regimens and requires further study.\",\"Previous studies have shown that RNA viruses can be attenuated by either increased or decreased viral polymerase replication fidelity. Although foot-and-mouth disease virus (FMDV) high-fidelity RNA-dependent RNA polymerase (RdRp) variants with an attenuated phenotype have been isolated using mutagens, no FMDV mutant with a low-fidelity polymerase has been documented to date. Here, we describe the generation of several FMDV RdRp mutants using site-directed mutagenesis via a reverse genetic system. Mutation frequency assays confirmed that five rescued FMDV RdRp mutant populations had lower replication fidelity than the wild-type virus population, which allowed us to assess the effects of the change in replication fidelity on the virus phenotype. These low-fidelity FMDV RdRp mutants showed increased sensitivity to ribavirin or 5-fluorouracil (5-FU) treatment without a loss of growth capacity in cell cultures. In addition, decreased fitness and attenuated virulence were observed for the RdRp mutants with lower fidelity. Importantly, based on a quantitative analysis for fidelity and virulence, we concluded that lower replication fidelity is associated with a more attenuated virus phenotype. These results further contribute to our understanding of the replication fidelity of polymerases of RNA viruses and its relationship to virulence attenuation.\",\"Study C210 was a Phase IIa, exploratory trial to assess the activity of telaprevir on hepatitis C virus (HCV) early viral kinetics in treatment-na\\u00efve patients infected with genotype 4 (G4) HCV.\",\"Hepatitis C virus (HCV) is a single-stranded, positive-sense RNA virus. About 70% of patients exposed to HCV develop a chronic infection, which can lead to scarring of the liver and ultimately to cirrhosis, liver failure, and hepatocellular carcinoma. For the past decade, the standard therapy for HCV infection has been a combination of interferon-\\u03b1 and ribavirin. In recent years, direct-acting antiviral agents, boceprevir and telaprevir, have been added to the therapeutic regimen and considerably improve the cure rates for HCV infection. However, the treatment continues to cause substantial side effects and is associated with drug resistance due to frequent mutations in the HCV RNA genome resulting from the low fidelity of its RNA polymerase. MicroRNAs (miRNAs) are a class of small, non-coding RNAs approximately 22 nucleotides in length. They are derived from cellular or viral transcripts and bind to their target mRNAs in a sequence-specific manner, resulting in either mRNA cleavage or translational repression and subsequent modulation of the expression of the majority of the protein-coding genes. miRNAs have been implicated in regulating multiple aspects of HCV life cycles and certain miRNAs serve as essential mediators for the interferon-based antiviral therapy. Furthermore, recent studies have documented the potential values of miRNAs as novel therapeutic targets against hepatitis C infectivity.\",\"Drug resistance is a major hurdle in oncology. Responses of acute myeloid leukaemia (AML) patients to cytarabine (Ara-C)-based therapies are often short lived with a median overall survival of months. Therapies are under development to improve outcomes and include targeting the eukaryotic translation initiation factor (eIF4E) with its inhibitor ribavirin. In a Phase II clinical trial in poor prognosis AML, ribavirin monotherapy yielded promising responses including remissions; however, all patients relapsed. Here we identify a novel form of drug resistance to ribavirin and Ara-C. We observe that the sonic hedgehog transcription factor glioma-associated protein 1 (GLI1) and the UDP glucuronosyltransferase (UGT1A) family of enzymes are elevated in resistant cells. UGT1As add glucuronic acid to many drugs, modifying their activity in diverse tissues. GLI1 alone is sufficient to drive UGT1A-dependent glucuronidation of ribavirin and Ara-C, and thus drug resistance. Resistance is overcome by genetic or pharmacological inhibition of GLI1, revealing a potential strategy to overcome drug resistance in some patients.\",\"New nucleos(t)ide analogues (NAs) with high genetic barrier to hepatitis B virus (HBV) resistance (such as entecavir, tenofovir) have improved the prognosis of patients with HBV decompensated cirrhosis and have prevented HBV recurrence after liver transplantation (LT). NAs are considered the most proper approach for HBV infection in patients under renal replacement therapy but their doses should be adjusted according to the patient's creatinine clearance. In addition, physicians should be aware of the potential nephrotoxicity. However, patients with chronic hepatitis C and decompensated cirrhosis can receive only one therapeutic option before LT, as well as for Hepatitis C virus (HCV) recurrence after LT, which is the combination of subcutaneous Peg-IFN and ribavirin. Generally, therapy for HCV after renal transplantation should be avoided. Although the optimal antiviral therapy for HCV infection has not been established, attention has turned to a new, oral direct acting antiviral treatment which marks a promising strategy in prognosis and in amelioration of these diseases.\",\"The hepatitis C virus (HCV) nonstructural 5A (NS5A) protein is a clinically validated target for drugs designed to treat chronic HCV infection. This study evaluated the in vitro activity, selectivity, and resistance profile of a novel anti-HCV compound, samatasvir (IDX719), alone and in combination with other antiviral agents. Samatasvir was effective and selective against infectious HCV and replicons, with 50% effective concentrations (EC50s) falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons and with a 10-fold EC50 shift in the presence of 40% human serum in the genotype 1b replicon. The EC90/EC50 ratio was low (2.6). A 50% cytotoxic concentration (CC50) of >100 \\u03bcM provided a selectivity index of >5 \\u00d7 10(7). Resistance selection experiments (with genotype 1a replicons) and testing against replicons bearing site-directed mutations (with genotype 1a and 1b replicons) identified NS5A amino acids 28, 30, 31, 32, and 93 as potential resistance loci, suggesting that samatasvir affects NS5A function. Samatasvir demonstrated an overall additive effect when combined with interferon alfa (IFN-\\u03b1), ribavirin, representative HCV protease, and nonnucleoside polymerase inhibitors or the nucleotide prodrug IDX184. Samatasvir retained full activity in the presence of HIV and hepatitis B virus (HBV) antivirals and was not cross-resistant with HCV protease, nucleotide, and nonnucleoside polymerase inhibitor classes. Thus, samatasvir is a selective low-picomolar inhibitor of HCV replication in vitro and is a promising candidate for future combination therapies with other direct-acting antiviral drugs in HCV-infected patients.\",\"Approximately 30% of HIV-infected patients are co-infected with hepatitis C virus (HCV). After the release of highly active antiretroviral therapy, liver disease has become the leading cause of morbidity and mortality in HIV patients. Prior to 2011, HCV treatment with pegylated-interferon and ribavirin in HCV/HIV co-infected patients only allowed 14-38% of patients with HCV genotype 1 to achieve a sustained virologic response (SVR). Additionally, treatment was commonly discontinued as a result of adverse events. Recently, simeprevir and sofosbuvir have been approved by the US Food and Drug Administration (FDA) for HCV mono-infection. Sofosbuvir has been given FDA approval in co-infected patients offering unprecedented SVR rates and the potential for interferon-free therapy. HCV therapies that are in the pipeline offer improved treatment times, safety profiles, and rates of SVR. Despite these improvements, several new issues including adherence, drug-drug interactions with antiretroviral therapies, adverse events, resistance, and patient selection may complicate therapy. This article reviews the current status of direct-acting antivirals (DAA)-containing regimens for HIV/HCV co-infected patients in the USA. New results investigating telaprevir and boceprevir are also discussed as they are relevant for locations where new DAAs are not available. The impact future interferon-free therapies may have on co-infected patients is also discussed.\",\"Ribavirin has proven to be effective against several viruses in the clinical setting and a multitude of viruses in vitro. With up to five different proposed mechanisms of action, recent advances have begun to discern the hierarchy of antiviral effects at play depending on the virus and the host conditions under scrutiny. Studies reveal that for many viruses, antiviral mechanisms may differ depending on cell type in vitro and in vivo. Further analyses are thus required to accurately identify mechanisms to more optimally determine clinical treatments. In recent years, a growing number of ribavirin resistant and sensitive variants have been identified. These variants not only inform on the specific mechanisms by which ribavirin enfeebles the virus, but also can themselves be tools to identify new antiviral compounds.\",\"The phase 3 studies of telaprevir (T) in combination with peginterferon \\u03b1-2a and ribavirin (PR) in treatment-naive genotype 1 chronic hepatitis C virus-infected patients (ADVANCE/ILLUMINATE) were not designed a priori to assess the effect of race and ethnicity on treatment response. However, these factors are important given the lower sustained virologic response (SVR) rates observed in black and Hispanic/Latino patients treated with PR.\",\"In recent years, clinical research in the field of new treatments for chronic hepatitis C (HCV) has been devoted to developing regimens based on direct-acting antivirals (DAAs), with the goal of increasing treatment efficacy and improving tolerability and safety. This can be achieved by Peginterferon (PegIFN)-free anti-HCV regimens, as PegIFN is responsible for many side effects and limits treatment access due to contraindications in some patient categories. Sofosbuvir (SOF) is the first compound to enter the market with IFN-free combination regimens; it belongs to the nucleotide inhibitors of viral polymerase NS5B and acts as a chain terminator during the HCV replication process, exhibiting pan-genotypic antiviral activity with a high barrier to resistance. Clinical trials in HCV genotype 2/3 patients have demonstrated optimal efficacy in HCV-2, where the combination SOF/ribavirin (Rbv) for 12 weeks resulted in >90% sustained virological response (SVR) rates, while HCV-3 patients with advanced liver fibrosis and previous failure to PegIFN plus Rbv therapy still require individualized and optimized treatment strategies. Historically difficult-to-treat genotypes HCV-1, -4-6 can benefit from reduced duration of PegIFN plus SOF and Rbv, while IFN-free regimens in these patients will be based on SOF in combination with other DAA classes. Due to an optimal tolerability and safety profile with no significant drug-to-drug interactions, SOF is currently undergoing clinical trials in the setting of pre- and post-liver transplantation and HIV-coinfected patients, with the objective to address the until now unmet need for safe and efficient treatment in these populations. This article provides an overview of SOF features and the main clinical trials, discussing key results and potential future developments.\",\"Despite advances in chronic hepatitis C treatment, a proportion of patients respond poorly to treatment. This study aimed to explore hepatic mRNA and microRNA signatures involved in hepatitis C treatment resistance. Global hepatic mRNA and microRNA expression profiles were compared using microarray data between treatment responses. Quantitative real-time polymerase chain reaction validated the gene signatures from 130 patients who were infected with hepatitis C virus genotype 1b and treated with pegylated interferon-alpha and ribavirin combination therapy. The correlation between mRNA and microRNA was evaluated using in silico analysis and in vitro siRNA and microRNA inhibition/overexpression experiments. Multivariate regression analysis identified that the independent variables IL28B SNP rs8099917, hsa-miR-122-5p, hsa-miR-17-5p, and MAP3K8 were significantly associated with a poor virologic response. MAP3K8 and miR-17-5p expression were inversely correlated with treatment response. Furthermore, miR-17-5p repressed HCV production by targeting MAP3K8. Collectively, the data suggest that several molecules and the inverse correlation between mRNA and microRNA contributed to a host genetic refractory hepatitis C treatment response.\",\"Safety and tolerability of peginterferon-based hepatitis C virus (HCV) infection therapy remains suboptimal, even when direct-acting antiviral agents are added. This study assessed the efficacy, safety and tolerability of mericitabine combined with ritonavir-boosted danoprevir (danoprevir/r) \\u00b1 ribavirin for up to 24 weeks in treatment-na\\u00efve HCV genotype (G)1 infected patients.\",\"Understanding hepatitis C virus (HCV) replication has been limited by access to serial samples of liver, the primary site of viral replication. Our understanding of how HCV replicates and develops drug-resistant variants in the liver is limited. We studied 15 patients chronically infected with genotype 1 HCV treated with telaprevir (TVR)/pegylated-interferon alpha/ribavirin. Hepatic fine needle aspiration was performed before treatment and at hour 10, days 4 and 15, and week 8 after initiation of antiviral therapy. We measured viral kinetics, resistance patterns, TVR concentrations, and host transcription profiles. All patients completed all protocol-defined procedures that were generally well tolerated. First-phase HCV decline (baseline/treatment day 4) was significantly slower in liver than in plasma (slope plasma: -0.29; liver, -0.009; P < 0.001), whereas second-phase decline (posttreatment days 4-15) did not differ between the two body compartments (-0.11 and -0.15, respectively; P = 0.1). TVR-resistant variants were detected in plasma, but not in liver (where only wild-type virus was detected). Based upon nonstructural protein 3 sequence analysis, no compartmentalization of viral populations was observed between plasma and liver compartments. Gene expression profiling revealed strong tissue-specific expression signatures. Human intrahepatic TVR concentration, measured for the first time, was lower, compared to plasma, on a gram per milliliter basis. We found moderate heterogeneity between HCV RNA levels from different intrahepatic sites, indicating differences in hepatic microenvironments.\",\"HCV infection is a major world health problem, leading to both end-stage liver disease and primary liver cancer. Great efforts have been made in developing new therapies for HCV infection; however, combination therapy with pegylated IFN-\\u03b1 and ribavirin (pegIFN-RBV) remains the first choice of treatment for chronic HCV infection in most countries. The treatment response to pegIFN-RBV remains relatively low. Understanding the molecular mechanisms of persistent HCV infection and pegIFN-RBV resistance will suggest ways of improving the current standard of care and offers new antiviral therapies for both HCV and other viral infections. Recent data suggest that increased expression of hepatic IFN-stimulated genes (ISGs) before treatment is associated with treatment nonresponse in patients chronically infected with HCV. Although ISGs are generally antiviral in nature, in the case of HCV, the virus may exploit some of them to its benefit. This is not unique to HCV: Blockade of type I IFN signaling has been shown to control persistent LCMV infection. Thus, in certain viral infections, preactivation or overactivation of type I IFN signaling may contribute to viral persistence. In this review, we briefly summarize the findings from high-throughput gene expression profiling from patients chronically infected with HCV, then focus on a novel ubiquitin-like signaling pathway (ISG15/USP18) and its potential role in HCV persistence. Finally, the role of activation of endogenous type I IFN signaling in persistent HCV infection will be discussed in the context of recent studies indicating that blocking IFN signaling controls persistent LCMV infection.\",\"Using ultra-deep sequencing technology, the present study was designed to investigate the evolution of simeprevir-resistant variants (amino acid substitutions of aa80, aa155, aa156, and aa168 positions in HCV NS3 region) over time. In Toranomon Hospital, 18 Japanese patients infected with HCV genotype 1b, received triple therapy of simeprevir/PEG-IFN/ribavirin (DRAGON or CONCERT study). Sustained virological response rate was 67%, and that was significantly higher in patients with IL28B rs8099917 TT than in those with non-TT. Six patients, who did not achieve sustained virological response, were tested for resistant variants by ultra-deep sequencing, at the baseline, at the time of re-elevation of viral loads, and at 96 weeks after the completion of treatment. Twelve of 18 resistant variants, detected at re-elevation of viral load, were de novo resistant variants. Ten of 12 de novo resistant variants become undetectable over time, and that five of seven resistant variants, detected at baseline, persisted over time. In one patient, variants of Q80R at baseline (0.3%) increased at 96-week after the cessation of treatment (10.2%), and de novo resistant variants of D168E (0.3%) also increased at 96-week after the cessation of treatment (9.7%). In conclusion, the present study indicates that the emergence of simeprevir-resistant variants after the start of treatment could not be predicted at baseline, and the majority of de novo resistant variants become undetectable over time. Further large-scale prospective studies should be performed to investigate the clinical utility in detecting simeprevir-resistant variants.\",\"In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients with hepatitis C virus (HCV) genotype 2 infection, with lower response rates among patients with HCV genotype 3 infection.\",\"The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin has shown efficacy in inducing a sustained virologic response in a phase 2 study involving patients with hepatitis C virus (HCV) genotype 1 infection. We conducted two phase 3 trials to examine the efficacy and safety of this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis.\",\"Treatment of chronic hepatitis C (HCV) is currently undergoing a significant change. Traditional interferon-based therapy has been limited by both efficacy and tolerability, and many direct acting antiviral (DAA) drugs are emerging. Sofosbuvir (GS-7977) is a HCV NS5B nucleotide polymerase inhibitor that has now been evaluated extensively in phase II and III interferon-free clinical trials. The focus of this review is on the clinical potential of sofosbuvir in the treatment of HCV. Sofosbuvir has a pan-genotypic effect on HCV, although viral genotype-specific differences in sustained virological response (SVR) have emerged in phase III clinical trials. Sofosbuvir has been studied both as dual therapy with ribavirin and also as triple therapy with either NS5A inhibitors or a protease inhibitor. High rates of SVR have been reported with these interferon-free combinations, particularly with genotypes 1 and 2, and the safety profile has been very favourable in both cirrhotic and noncirrhotic patients, without issues of viral resistance. Interferon-free, once-daily treatment of HCV is now becoming a reality.\",\"Certain host single nucleotide polymorphisms (SNPs) affect the likelihood of a sustained virological response (SVR) to treatment in subjects infected with hepatitis C virus (HCV). SNPs in the promoters of interleukin (IL)-10 (-1082 A/G, rs1800896), myxovirus resistance protein 1 (-123 C/A, rs17000900 and -88 G/T, rs2071430) and tumour necrosis factor (TNF) (-308 G/A, rs1800629 and -238 G/A, rs361525) genes and the outcome of PEGylated \\u03b1-interferon plus ribavirin therapy were investigated. This analysis was performed in 114 Brazilian, HCV genotype 1-infected patients who had a SVR and in 85 non-responders and 64 relapsers. A significantly increased risk of having a null virological response was observed in patients carrying at least one A allele at positions -308 [odds ratios (OR) = 2.58, 95% confidence intervals (CI) = 1.44-4.63, p = 0.001] or -238 (OR = 7.33, 95% CI = 3.59-14.93, p < 0.001) in the TNF promoter. The risk of relapsing was also elevated (-308: OR = 2.87, 95% CI = 1.51-5.44, p = 0.001; -238: OR = 4.20, 95% CI = 1.93-9.10, p < 0.001). Multiple logistic regression of TNF diplotypes showed that patients with at least two copies of the A allele had an even higher risk of having a null virological response (OR = 16.43, 95% CI = 5.70-47.34, p < 0.001) or relapsing (OR = 6.71, 95% CI = 2.18-20.66, p = 0.001). No statistically significant association was found between the other SNPs under study and anti-HCV therapy response.\",\"A key to effective interferon- (IFN-) free therapy for hepatitis C virus (HCV) infection is a direct-acting antiviral (DAA) with a high barrier to resistance that can act as the backbone to any regimen. Ideally, this agent should also be active against all HCV genotypes, be well tolerated and have few drug interactions. Nucleoside/nucleotide analogues (NAs) that inhibit the function of the HCV RNA-dependent-RNA polymerase fit these requirements and thus hold promise as a cornerstone for new IFN-free regimens. To date, the issue with this class of agents has been toxicity. Numerous NAs in early clinical development have led to significant toxicity leading to their abandonment. However, sofosbuvir, a prodrug of a uridine NA, has moved through development with a clean-safety profile leading to its recent approval. When combined with ribavirin (RBV) alone, sofosbuvir is effective against genotype 2 and even genotype 3 if duration is extended. There are currently limited data with this combination in genotype 1; however, when sofosbuvir is combined with other DAAs of different classes, it is highly effective in almost all patients. To date, sofosbuvir has been studied with protease, NS5A, and nonnucleoside HCV polymerase inhibitors, including as part of a fixed-dose combination single tablet with the NS5A inhibitor ledipasvir, with very high rates of SVR with as little as 8 weeks of therapy. Combining two DAAs to sofosbuvir may shorten therapy even further. Because of the poor replicative fitness of the S282T sofosbuvir-resistant variant, resistance to sofosbuvir has not been a significant clinical issue in trials thus far. In addition to sofosbuvir, other NAs are in early-stage development. Provided unanticipated toxicity does not emerge, NAs are likely to play a major role as a backbone for future HCV therapy. The rationale for using this class of agents and the clinical data available to date are reviewed.\",\"The development of new models and tools has led to the discovery and clinical development of a large number of new anti-hepatitis C virus (HCV) drugs, including direct-acting antivirals and host-targeted agents. Surprisingly, curing HCV infection appears to be easy with these new drugs, provided that a potent drug combination with a high barrier to resistance is used. HCV infection cure rates can be optimized by combining drugs with synergistic antiviral effects, tailoring treatment duration to the patients' needs, and/or using ribavirin. Two HCV drugs have been approved in 2011--telaprevir and boceprevir, both first-wave, first-generation NS3-4A protease inhibitors, two others in 2013/2014--simeprevir, a second-wave, first-generation NS3-4A protease inhibitor, and sofosbuvir, a nucleotide analogue inhibitor of the viral polymerase. Numerous other drugs have reached phase II or III clinical development. From 2015 and onwards, interferon-containing regimens will disappear, replaced by interferon-free regimens yielding infection cure rates over 90%. These therapies will raise new issues, including the need for broad-scale screening and access to care.\",\"Presently, interferon- (IFN-) containing treatment regimens are the standard of care for patients with hepatitis C virus (HCV) infections. Although this therapy eliminates the virus in a substantial proportion of patients, it has numerous side effects and contraindications. Recent approval of telaprevir and boceprevir, targeting the protease residing in nonstructural protein 3 (NS3) of the HCV genome, increased therapy success when given in combination with pegylated IFN and ribavirin, but side effects are more frequent and the management of treatment is complex. This situation will change soon with the introduction of new highly potent direct-acting antivirals. They target, in addition to the NS3 protease, NS5A, which is required for RNA replication and virion assembly and the NS5B RNA-dependent RNA polymerase. Moreover, host-cell factors such as cyclophilin A or microRNA-122, essential for HCV replication, have been pursued as therapeutic targets. In this review, the authors briefly summarize the main features of viral and cellular factors involved in HCV replication that are utilized as therapy targets for chronic hepatitis C.\",\"Lipid profile and insulin resistance (IR) are associated with hepatitis C virus (HCV) and may predict the chronic hepatitis C (CHC) treatment response. The aim of this study was to determine the association between CHC treatment response and lipid profile and IR change during treatment.\",\"The existing standard of care for chronic hepatitis C virus (HCV) infection includes the use of pegylated interferon and ribavirin as primary components of treatment, with the addition of a direct-acting antiviral for genotype 1 infection. Sofosbuvir, an oral nucleotide inhibitor of the HCV nonstructural protein 5B RNA-dependent RNA polymerase enzyme, was recently approved for use in combination with ribavirin and/or pegylated interferon for chronic HCV infection, depending on the genotype. Sofosbuvir is orally administered, and peak plasma concentrations are not affected by food. The drug is renally eliminated and does not require adjustment in mild to moderate renal insufficiency or in any degree of hepatic impairment. Sofosbuvir is not metabolized by cytochrome P450 isoenzymes, nor does it induce or inhibit the metabolism of agents that are substrates of these enzymes. Sofosbuvir demonstrates a high barrier to resistance and was well tolerated by patients in clinical trials. Overall efficacy rates vary between 70% and 90%.\",\"BMS-791325 is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. BMS-791325 inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 at 50% inhibitory concentrations (IC50) below 28 nM. In cell culture, BMS-791325 inhibited replication of HCV subgenomic replicons representing genotypes 1a and 1b at 50% effective concentrations (EC50s) of 3 nM and 6 nM, respectively, with similar (3 to 18 nM) values for genotypes 3a, 4a, and 5a. Potency against genotype 6a showed more variability (9 to 125 nM), and activity was weaker against genotype 2 (EC50, 87 to 925 nM). Specificity was demonstrated by the absence of activity (EC50s of >4 \\u03bcM) against a panel of mammalian viruses, and cytotoxic concentrations (50%) were >3,000-fold above the HCV EC50. Resistance substitutions selected by BMS-791325 in genotype 1 replicons mostly mapped to a single site, NS5B amino acid 495 (P495A/S/L/T). Additive or synergistic activity was observed in combination studies using BMS-791325 with alfa interferon plus ribavirin, inhibitors of NS3 protease or NS5A, and other classes of NS5B inhibitor (palm site 2-binding or nucleoside analogs). Plasma and liver exposures in vivo in several animal species indicated that BMS-791325 has a hepatotropic disposition (liver-to-plasma ratios ranging from 1.6- to 60-fold across species). Twenty-four hours postdose, liver exposures across all species tested were \\u2265 10-fold above the inhibitor EC50s observed with HCV genotype 1 replicons. These findings support the evaluation of BMS-791325 in combination regimens for the treatment of HCV. Phase 3 studies are ongoing.\",\"MK-5172 is an inhibitor of the hepatitis C virus (HCV) nonstructural protein 3/4A protease; MK-5172 is taken once daily and has a higher potency and barrier to resistance than licensed protease inhibitors. We investigated the efficacy and tolerability of MK-5172 with peginterferon and ribavirin (PR) in treatment-naive patients with chronic HCV genotype 1 infection without cirrhosis.\",\"The current treatment of HCV-4 patients is dual therapy with PEG-IFN and ribavirin; however, new drugs against this genotype will be available within few months. Despite the evidenced good virological response in IFN-free regimens, the high cost of these new therapies will require patient selection. In our paper we propose the use of both rs8099917 and rs12979860 IL28-B polymorphisms, in order to identify potentially categories of SVR, null-responder and relapse and consequently to choose the dual therapy or novel approach.\",\"In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection.\",\"Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir (ABT-267), the nonnucleoside polymerase inhibitor dasabuvir (ABT-333), and ribavirin in an open-label phase 3 trial involving previously untreated and previously treated adults with HCV genotype 1 infection and compensated cirrhosis.\",\"Development of antiviral drugs that have broad-spectrum activity against a number of viral infections would be of significant benefit. Due to the evolution of resistance to currently licensed antiviral drugs, development of novel anti-influenza drugs is in progress, including Favipiravir (T-705), which is currently in human clinical trials. T-705 displays broad-spectrum in vitro activity against a number of viruses, including Rift Valley Fever virus (RVFV). RVF is an important neglected tropical disease that causes human, agricultural, and economic losses in endemic regions. RVF has the capacity to emerge in new locations and also presents a potential bioterrorism threat. In the current study, the in vivo efficacy of T-705 was evaluated in Wistar-Furth rats infected with the virulent ZH501 strain of RVFV by the aerosol route.\",\"High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir. This study examined 8 weeks of treatment with this regimen.\",\"Hepatitis C virus (HCV) infection represents a major health issue worldwide due to its burden of chronic liver disease and extrahepatic manifestations including cardiovascular diseases, which are associated with excess mortality. Analysis of published studies supports the view that HCV infection should be considered a risk factor for the development of carotid atherosclerosis, heart failure and stroke. In contrast, findings from studies addressing coronary artery disease and HCV have yielded conflicting results. Therefore, meta-analytic reviews and prospective studies are warranted. The pathogenic mechanisms connecting HCV infection, chronic liver disease, and atherogenesis are not completely understood. However, it has been hypothesized that HCV may promote atherogenesis and its complications through several direct and indirect biological mechanisms involving HCV colonization and replication within arterial walls, liver steatosis and fibrosis, enhanced and imbalanced secretion of inflammatory cytokines, oxidative stress, endotoxemia, mixed cryoglobulinemia, perturbed cellular and humoral immunity, hyperhomocysteinemia, hypo-adiponectinaemia, insulin resistance, type 2 diabetes and other components of the metabolic syndrome. Understanding these complex mechanisms is of fundamental importance for the development of novel therapeutic approaches to prevent and to treat vascular complications in patients with chronic HCV infection. Currently, it seems that HCV clearance by interferon and ribavirin treatment significantly reduces non-liver-related mortality; moreover, interferon-based treatment appears to decrease the risk of ischemic stroke.\",\"Approximately 170 million people worldwide are chronic carriers of the hepatitis C virus (HCV). Twenty-five percent of them develop liver cirrhosis and hepatocellular carcinoma during their life. Successful antiviral treatment dramatically reduces the risk of disease progression. HCV infection is treated with pegylated interferon and ribavirin; the addition of a protease inhibitor (boceprevir or telaprevir) can also be considered for patients with genotype 1.\",\"Some direct-acting antiviral agents for hepatitis C virus (HCV), such as telaprevir and boceprevir have been available since 2011. It was reported that HCV NS5A is associated with interferon signaling related to HCV replication and hepatocarcinogenesis. HCV NS5A inhibitors efficiently inhibited HCV replication in vitro. Human studies showed that dual, triple and quad regimens with HCV NS5A inhibitors, such as daclatasvir and ledipasvir, in combination with other direct-acting antiviral agents against other regions of HCV with or without peginterferon/ribavirin, could efficiently inhibit HCV replication according to HCV genotypes. These combinations might be a powerful tool for \\\"difficult-to-treat\\\" HCV-infected patients. \\\"First generation\\\" HCV NS5A inhibitors such as daclatasvir, ledipasvir and ABT-267, which are now in phase III clinical trials, could result in resistance mutations. \\\"Second generation\\\" NS5A inhibitors such as GS-5816, ACH-3102, and MK-8742, have displayed improvements in the genetic barrier while maintaining potency. HCV NS5A inhibitors are safe at low concentrations, which make them attractive for use despite low genetic barriers, although, in fact, HCV NS5A inhibitors should be used with HCV NS3/4A inhibitors, HCV NS5B inhibitors or peginterferon plus ribavirin. This review article describes HCV NS5A inhibitor resistance mutations and recommends that HCV NS5A inhibitors be used in combination regimens potent enough to prevent the emergence of resistant variants.\",\"Liver cirrhosis (LC) is a critical stage of chronic liver disease, including that caused by hepatitis C virus (HCV). In the absence of antiviral therapy, 67%-91% of patients with HCV-related LC patients die of liver-related causes, including hepatocellular carcinoma (HCC) and liver failure. Among the therapeutic strategies used to prevent liver-related complications in these patients is standard therapy with pegylated interferon and ribavirin, which induces a sustained virological response (SVR) in 25% of HCV genotype 1-infected patients and in 69% of patients infected with genotypes 2 and 3. SVR in patients with HCV-related LC has been associated with reduced rates of hepatic decompensation, HCC, and mortality. More recently developed direct-acting antiviral agents have shown excellent antiviral efficacy, with preliminary data demonstrating that an interferon-free regimen that includes these direct-acting antiviral agents achieved SVR in more than 50% of patients with HCV genotype 1 LC. Branched-chain amino acid supplementation, improvement of insulin resistance, and the use of \\u03b2-blockers for portal hypertension may also reduce liver-related complications. Here, we review advances in antiviral and adjunctive therapies for improved outcomes in patients with HCV-associated LC.\",\"Genetic factors can play an important role for treatment response and disease progression in chronic viral hepatitis.\",\"Telaprevir, a non-structural (NS)3/4A protease inhibitor, is a direct-acting antiviral drug that inhibits viral replication. Triple therapy with telaprevir, pegylated interferon, and ribavirin is a standard therapeutic regimen for patients with genotype 1b chronic hepatitis C virus (HCV) infection and a high viral load. Several factors, including mutations in the NS5A gene, are important predictors of the efficacy of interferon therapy. In this study, we examined the mutational diversity of NS5A and its impact on the efficacy of triple therapy. We enrolled patients with genotype 1b chronic HCV infection and a high viral load (31 males/17 females; mean age, 57.6 years), who were treated with triple therapy. This study was conducted at Kobe University Hospital and at three affiliated hospitals in Hyogo prefecture, Japan, between November 2011 and June 2013. A sustained viral response after 12 weeks (SVR12) was achieved in 37/48 patients (77%). Based on intent-to-treat analysis, SVR12 was significantly greater in patients with the major allele than in those with the minor allele for the IL28B single nucleotide polymorphism (SNP; 88 vs. 56%; P<0.05). The prevalence of the V2334I mutation in NS5A was significantly higher in patients who achieved SVR12, while that of G2356E was significantly higher in patients who did not achieve SVR12 (P<0.05). Mutations in the NS3 region that are thought to confer resistance to telaprevir were detected in 3/27 patients who achieved SVR12 (Val36, n=3) and in 5/10 patients who did not achieve SVR12 (Val36, n=4; Thr54, n=1). In conclusion, the IL28B SNP and mutations in the NS5A region were associated with the therapeutic response to triple therapy. Half of the patients who did not achieve SVR12 had mutations conferring resistance to telaprevir. However, pre-existing mutations in NS3 did not affect the efficacy of triple therapy.\",\"Therapy for hepatitis C is undergoing a revolution. Several new drugs against the hepatitis C virus (HCV) have reached the market and many others, including direct-acting antivirals and host-targeted agents, are in phase II or III clinical development. All-oral, interferon-free combinations of drugs are expected to cure more than 90% of infections. A vast amount of data from clinical trials are presented regularly at international conferences or released to the press before peer-review, creating confusion in the viral hepatitis field. The goal of this review is to clarify the current stage of HCV therapy and drug development. This review describes the different classes of drugs and their mechanisms and properties, as well as treatment strategies in development, including those that are interferon-based and interferon-free. HCV treatment options that will be available in 2014-2015 are presented for each genotype. A number of unanswered questions and challenges remain, such as how to treat special populations, the role of ribavirin in interferon-free regimens, the role of HCV resistance in treatment failures, and how to best re-treat patients who failed on treatment. Strategic choices, cost issues, HCV screening, and improving access to care in resource-constrained areas also are discussed.\",\"St John's wort (SJW; Hypericum perforatum) induces CYP3A4 that is involved in the metabolism of the hepatitis C virus (HCV) protease inhibitor boceprevir. Reduced boceprevir exposure and efficacy would contribute to therapeutic failure and increase the risk for resistance development. Boceprevir is co-administered with interferon/ribavirin, and depression has been described frequently in patients undergoing HCV treatment. Patients may purchase over-the-counter herbals to manage depression, and knowing the interaction between SJW and boceprevir is desirable.\",\"The treatment for patients infected with hepatitis C virus (HCV) genotype 1 has undergone major changes with the availability of direct-acting antivirals. Triple therapy, containing telaprevir or boceprevir, first-wave NS3 protease inhibitors, in combination with peginterferon and ribavirin, improved rates of sustained virologic response compared with peginterferon and ribavirin alone in patients with HCV genotype 1. However, the development of drug-resistant variants is a concern. In patients treated with telaprevir or boceprevir, different patterns of resistance are observed for the two major HCV genotype 1 subtypes, 1a and 1b. Genotype 1b is associated with a lower rate of resistant variant selection and better response to triple therapy compared with genotype 1a. Similar subtype-specific patterns have been observed for investigational direct-acting antivirals, including second-wave NS3 protease inhibitors, NS5A inhibitors and non-nucleoside NS5B inhibitors. This review explores resistance to approved and investigational direct-acting antivirals for the treatment of HCV, focusing on the differences between genotype 1a and genotype 1b. Finally, given the importance of HCV genotype 1 subtype on resistance and treatment outcomes, clinicians must also be aware of the tests currently available for genotype subtyping and their limitations.\",\"The use of triple-therapy, pegylated-interferon, ribavirin and either of the first generation hepatitis C virus (HCV) protease inhibitors telaprevir or boceprevir, is the new standard of care for treating genotype 1 chronic HCV. Clinical trials have shown response rates of around 70-80%, but there is limited data from the use of this combination outside this setting. Through an expanded access programme, we treated 59 patients, treatment na\\u00efve and experienced, with triple therapy. Baseline factors predicting treatment response or failure during triple therapy phase were identified in 58 patients. Thirty seven (63.8%) of 58 patients had undetectable HCV RNA 12weeks after the end of treatment. Genotype 1a (p=0.053), null-response to previous treatment (p=0.034), the rate of viral load decline after 12weeks of previous interferon-based treatment (p=0.033) were all associated with triple-therapy failure. The most common cause of on-treatment failure for telaprevir-based regimens was the development of resistance-associated variants (RAVs) at amino acids 36 and/or 155 of HCV protease (p=0.027) whereas in boceprevir-based regimens mutations at amino acid 54 were significant (p=0.015). SVR12 rates approaching 64% were achieved using triple therapy outside the clinical trial setting, in a patient cohort that included cirrhotics.\",\"Epidemiological studies have shown an increased occurrence of metabolic disorders such as insulin resistance (IR) and steatosis in patients with hepatitis C virus (HCV) infection. IR is believed to represent one of the central clinical features of the \\\"metabolic syndrome\\\" and the major pathogenetic factor for type 2 diabetes mellitus. In patients with chronic HCV hepatitis, IR may have several dangerous consequences such as accelerated progression of liver fibrosis, resistance to antiviral therapy and development of hepatocellular carcinoma. According to recent evidence, the global epidemic of metabolic disorders related to incorrect diets will lead physicians to deal with 1.2 billion patients with diabetes in the world in 2025. Given the high prevalence of HCV infection in several countries, metabolic manifestations will contribute to increasing morbidity and mortality in patients with HCV chronic infection in the near future. HCV treatment, shown able to decrease both the occurrence of HCV-related IR and diabetes, may reduce the risk of the associated morbidities.\",\"Hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular carcinoma worldwide. HCV establishes a chronic infection in the majority of cases. However, some individuals clear the virus, demonstrating a protective role for the host immune response. Although new all-oral drug combinations may soon replace traditional ribavirin-interferon therapy, the emerging drug cocktails will be expensive and associated with side-effects and resistance, making a global vaccine an urgent priority. T cells are widely accepted to play an essential role in clearing acute HCV infection, whereas the role antibodies play in resolution and disease pathogenesis is less well understood. Recent studies have provided an insight into viral neutralizing determinants and the protective role of antibodies during infection. This review provides a historical perspective of the role neutralizing antibodies play in HCV infection and discusses the therapeutic benefits of antibody-based therapies. This article forms part of a symposium in Antiviral Research on \\\"Hepatitis C: next steps toward global eradication.\\\"\",\"The resistance of Babesia parasites to current anti-babesiosis drugs is an issue of major concern. The inosine 5'-monophosphate dehydrogenase (IMPDH) of Babesia gibsoni has been identified and characterized as a molecular drug target in our previous studies. In the present study, inhibitory effects of IMPDH inhibitors (mycophenolate mofetil, mizoribine, ribavirin, 7-nitroindole, and mycophenolic acid) were evaluated in vitro or in vivo. In the inhibition assay of recombinant B. gibsoni IMPDH activity, mycophenolate mofetil was the most potent inhibitor (IC(50) = 2.58 \\u00b1 1.32 \\u03bcM) while ribavirin was the least potent. The inhibitory effects of mycophenolate mofetil, mizoribine, ribavirin, and 7-nitroindole on the in vitro growths of B. gibsoni and Babesia bovis were also assessed. The results revealed that mycophenolate mofetil was the most potent inhibitor of the multiplications of both B. gibsoni (IC(50) = 0.13 \\u00b1 0.05 \\u03bcM) and B. bovis (IC(50) = 0.97 \\u00b1 0.49 \\u03bcM). Ribavirin was also the least potent for both B. gibsoni and B. bovis in vitro. Mycophenolic acid, a metabolite of mycophenolate mofetil, caused an inhibition of Babesia microti in mice with noticeable improvement in hematological parameters of the infected mice (ED(50) = 44.15 \\u00b1 12.53 mg/kg). Although the report provides a non-exhaustive view of potential treatment strategy without addressing the potential adverse effect of immune suppression on infections, these results indicated that the IMPDH might be a molecular target of MPA for B. microti . Altogether, we provide a basis for development of antibabesia prodrugs by targeting IMPDH of the parasites in the treatment of babesiosis.\",\"Mutations in NS5B gene of Hepatitis C virus (HCV) have been reported in patients undergoing antiviral therapy. In the present study, we report emerging clade of HCV-3a in patients administered with IFN plus ribavirin therapy for 24 weeks and having low viral loads (<250 IU/mL). Mutations D/N244E, K304R, N/K307G, Q/T329V, and A338V were found associated with these emerging strains. This distinct HCV could be associated with the increased antiviral drug pressure.\",\": Insulin resistance is associated with nonresponse to hepatitis C virus (HCV) treatment. In this multicenter, single-arm pilot study, adult, HIV/HCV genotype 1-coinfected previous nonresponders to peginterferon/ribavirin (PegIFN/RBV) with homeostatic model assessment of insulin resistance >2.5 were treated with pioglitazone (PIO) for 24 weeks followed by PegIFN/RBV/PIO. Three of 19 subjects (15.8%) achieved undetectable HCV RNA at week 24 of PegIFN/RBV/PIO, which was not significantly different than the historical null rate of 10% (P = 0.29, lower limit of the exact 1-sided 90% confidence interval 5.9%). Over the 24 weeks of PIO monotherapy, alanine aminotransferase and aspartate aminotransferase declined significantly and correlated with improved metabolic parameters.\",\"In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported. The aim of this study was to investigate the association of IR and IL28B genotype in two cohorts of well-characterized HCV patients.\",\"This phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VDV), non-nucleoside NS5B inhibitor tegobuvir (TGV), and ribavirin (RBV) in treatment-na\\u00efve patients with chronic hepatitis C virus (HCV) genotype 1 without cirrhosis. Patients were randomized 1:2 to LDV 30 mg once daily (QD; Arm 1; n = 46) or LDV 90 mg QD (Arm 2; n = 94); patients in both arms also received VDV 200 mg QD, TGV 30 mg twice-daily, and RBV 1,000-1,200 mg/day. Patients in Arm 2 with vRVR, defined as HCV RNA below the lower limit of quantification (LLOQ) from treatment weeks 2 to 10, were randomized 1:1 to stop treatment at 12 weeks or continue for 24 weeks. Sustained virologic response 12 weeks after treatment (SVR12) was higher in patients receiving 90 mg of LDV for 24 weeks (63%), compared with LDV 90 mg for 12 weeks (54%) and LDV 30 mg for 24 weeks (48%). In patients with very rapid virologic response (vRVR) in Arm 2, SVR12 was achieved by 68% and 81% of patients treated for 12 and 24 weeks, respectively. Virologic breakthrough was more common in patients with HCV genotype 1a and was associated with resistance-associated variants for all three direct-acting antiviral agents (DAAs); however, in all but 1 patient who relapsed, resistance-associated variants directed against only one or two of the DAAs were detected. The most common adverse events were fatigue, headache, nausea, rash, and diarrhea.\",\"Using hepatitis C virus (HCV) and interferon (IFN) resistance as a proof of concept, we have devised a new method for calculating the effect of a drug on a viral population, as well as the resistance of the population's individual intrahost variants. By means of next-generation sequencing, HCV variants were obtained from sera collected at nine time points from 16 patients during the first 48 h after injection of IFN-\\u03b1. IFN-resistance coefficients were calculated for individual variants using changes in their relative frequencies, and for the entire intrahost viral population using changes in viral titer. Population-wide resistance and presence of IFN-resistant variants were highly associated with pegylated IFN-\\u03b12a/ribavirin treatment outcome at week 12 (P = 3.78 \\u00d7 10(-5) and 0.0114, respectively). This new method allows an accurate measurement of resistance based solely on changes in viral titer or the relative frequency of intrahost viral variants during a short observation time.\",\"The launch of first-generation protease inhibitors (PIs) is a major step forward in HCV treatment. However, the major advance is up to now restricted to genotype 1 (GT-1) patients. The development of second-wave and second-generation PIs yields higher antiviral potency through plurigenotypic activity, more convenient daily administration, fewer side effects and, for the second-generation PIs, potential activity against resistance-associated variants. NS5B inhibitors include nucleoside/nucleotide inhibitors (NIs) and non-nucleotide inhibitors (NNIs). NIs have high efficacy across all genotypes. Sofosbuvir has highly potent antiviral activity across all genotypes in association with pegylated interferon and ribavirin (PR), thus allowing shortened treatment duration. NS5A inhibitors (NS5A.I) have highly potent antiviral activity. It has recently been shown for the first time that NS5A.I in combination with protease inhibitors can cure GT-1b null responders in an interferon-free regimen. Besides, several studies demonstrate that interferon (IFN)-free regimens with direct-acting antiviral agent combinations are able to cure a large number of either na\\u00efve or treatment-experienced GT-1 patients. Moreover, quadruple regimen with PR is able to cure almost all GT-1 null responders. The development of pan-genotypic direct-acting antiviral agents (NIs or NS5A.I) allows new combinations with or without PR that increase the rate of sustained virological response for all patients, even for those with cirrhosis and independently of the genotype. Therefore, the near future of HCV treatment looks promising. The purpose of this article is to provide an overview of the clinical results recently reported for HCV treatment.\",\"Direct-acting antivirals (DAAs) are either part of the current standard of care or are in advanced clinical development for the treatment of patients chronically infected with hepatitis C virus (HCV) genotype 1, but concern exists with respect to the patients who fail these regimens with emergent drug-resistant variants. In the present study, ultradeep sequencing was performed to analyze resistance to daclatasvir (DCV), which is a highly selective nonstructural protein 5A (NS5A) inhibitor. Eight patients with HCV genotype 1b, who were either treatment naive or prior nonresponders to pegylated interferon plus ribavirin (Rebetol; Schering-Plough) (PEG-IFN/RBV) therapy, were treated with DCV combined with PEG-IFN alpha-2b (Pegintron; Schering-Plough, Kenilworth, NJ) and RBV. To identify the cause of viral breakthrough, the preexistence and emergence of DCV-resistant variants at NS5A amino acids were analyzed by ultradeep sequencing. Sustained virological response (SVR) was achieved in 6 of 8 patients (75%), with viral breakthrough occurring in the other 2 patients (25%). DCV-resistant variant Y93H preexisted as a minor population at higher frequencies (0.1% to 0.5%) in patients who achieved SVR. In patients with viral breakthrough, DCV-resistant variant mixtures emerged at NS5A-31 over time that persisted posttreatment with Y93H. Although enrichment of DCV-resistant variants was detected, the preexistence of a minor population of the variant did not appear to be associated with virologic response in patients treated with DCV/PEG-IFN/RBV. Ultradeep sequencing results shed light on the complexity of DCV-resistant quasispecies emerging over time, suggesting that multiple resistance pathways are possible within a patient who does not rapidly respond to a DCV-containing regimen. (This study has been registered at ClinicalTrials.gov under registration no. NCT01016912.).\",\"With the introduction of direct-acting antiviral (DAA) therapy against hepatitis C virus (HCV) infection, the field is rapidly evolving towards interferon-free regimens with high sustained virologic response (SVR) rates. The ultimate goal of therapy in chronic HCV infection should include an easily dosed all-oral regimen that is highly effective, inexpensive, pan-genotypic, safe and tolerable, with minimal to no resistance. Various investigational DAA regimens are currently under evaluation with and without ribavirin (Rbv). With the projected arrival of improved therapies over the next 5years, the future role of Rbv comes into question. Despite being plagued by the lack of understanding of its mechanism of action and significant side effects such as anemia, Rbv has been a part of the standard-of-care therapies in chronic HCV infection for more than 10years. As we look towards the future HCV therapy, Rbv may still have utility in the care of patients infected with HCV because of its low cost and potentially added value in combination with other DAAs. This article forms part of a symposium in Antiviral Research on \\\"Hepatitis C: next steps toward global eradication.\\\"\",\"Since 2011, outbreaks caused by influenza A(H3N2) variant [A(H3N2)v] viruses have become a public health concern in the United States. The A(H3N2)v viruses share the A(H1N1)pdm09 M gene containing the marker of M2 blocker resistance, S31N, but do not contain any known molecular markers associated with resistance to neuraminidase (NA) inhibitors (NAIs). Using a fluorescent NA inhibition (NI) assay, the susceptibilities of recovered A(H3N2)v viruses (n=168) to FDA-approved (oseltamivir and zanamivir) and other (peramivir, laninamivir, and A-315675) NAIs were assessed. All A(H3N2)v viruses tested, with the exception of a single virus strain, A/Ohio/88/2012, isolated from an untreated patient, were susceptible to the NAIs tested. The A/Ohio/88/2012 virus contained two rare substitutions, S245N and S247P, in the NA and demonstrated reduced inhibition by oseltamivir (31-fold) and zanamivir (66-fold) in the NI assay. Using recombinant NA (recNA) proteins, S247P was shown to be responsible for the observed altered NAI susceptibility, in addition to an approximately 60% reduction in NA enzymatic activity. The S247P substitution has not been previously reported as a molecular marker of reduced susceptibility to the NAIs. Using cell culture assays, the investigational antiviral drugs nitazoxanide, favipiravir, and fludase were shown to inhibit the replication of A(H3N2)v viruses, including the virus with the S247P substitution in the NA. This report demonstrates the importance of continuous monitoring of susceptibility of zoonotic influenza viruses to available and investigational antiviral drugs.\",\"Daclatasvir (DCV; BMS-790052) is a picomolar inhibitor of HCV non-structural protein 5A (NS5A) and has demonstrated efficacy in patients chronically infected with HCV.\",\"Patients with chronic hepatitis C virus (HCV) infection and prior null response (<2 log HCV RNA decline after \\u2a7e 12 weeks of PegIFN/RBV) have limited options. We evaluated daclatasvir plus once- or twice-daily asunaprevir in non-cirrhotic genotype 1 null responders.\",\"The standard of care for HCV genotype 1 is a protease inhibitor (telaprevir or boceprevir) combined with pegylated interferon (PEG-IFN) and ribavirin (RBV). A lead-in phase of PEG-IFN/RBV therapy before addition of the protease inhibitor has been used, with the aim of improving response rates by reducing the development of protease inhibitor resistance. However, whether such a strategy can bring benefit to patients is unclear.\",\"Previous studies have shown that single nucleotide polymorphisms (SNP) in IL28B and IL10R are associated with sustained virological response (SVR) in chronic hepatitis C patients treated with pegilated interferon plus ribavirin (P/R). The present study extends our earlier investigations on a large East-Central European cohort. The allele frequencies of IL28B and IL10R in genotype 1 HCV infection were compared with that of healthy controls for the purpose of examining the relationship between the polymorphisms and the SVR to P/R treatment.\",\"The treatment of chronic hepatitis C is changing rapidly.\",\"Baseline homeostasis model assessment-estimated insulin resistance (HOMA-IR), a marker for insulin resistance, has been associated with poor virologic response to peginterferon alpha/ribavirin (PR) in chronic hepatitis C. We evaluated the association between baseline HOMA-IR and pretreatment factors on sustained virologic response (SVR) to telaprevir (TVR) in genotype 1 patients with hepatitis C and prior peginterferon/ribavirin (PR) treatment failure. Patients were randomized to 12 weeks of TVR (750 mg q8h) plus peginterferon (180 \\u03bcg/week) and ribavirin (1,000-1,200 mg/day) (with or without a 4-week lead-in) followed by PR, or PR alone (PR48), for 48 weeks. Univariate and multiple logistic regression analyses explored the prognostic significance of baseline HOMA-IR alone and adjusted for other pretreatment factors and SVR. The TVR arms were pooled for the purposes of this analysis. In all, 662 patients were randomized; 578 had baseline HOMA-IR and other prognostic data and were included in this analysis. Median baseline HOMA-IR was 2.6 (interquartile range [IQR] 1.7-4.3); 207 (36%), 206 (36%), and 165 (29%) patients had baseline HOMA-IR <2, 2 to <4, and \\u2265 4, respectively. Male gender, higher body mass index, triglycerides, gamma-glutamyl transpeptidase, maximum alanine aminotransferase/aspartate aminotransferase, and fibrosis stage were associated with higher baseline HOMA-IR. Baseline HOMA-IR was associated with SVR in univariate analysis, but not after adjustment for other baseline prognostic factors (TVR: OR = 0.95, 95% confidence interval [CI]: 0.71,1.29; PR48: 0.60; 95% CI: 0.25,1.43).\",\"Hepatitis C virus (HCV) infection is the leading cause of chronic liver-related diseases, including cirrhosis, liver failure, and hepatocellular carcinoma. Currently, no effective vaccine is available for HCV infection. Polyethylene glycol interferon-\\u03b1 (PegIFN-\\u03b1) in combination with ribavirin (RBV) is the standard of care (SOC) for chronic hepatitis C. However, the efficacy of PegIFN-\\u03b1 and RBV combination therapy is less than 50% for genotype 1 HCV, which is the dominant virus in humans. In addition, IFN and RBV have several severe side effects. Therefore, strategies to improve sustained virological response (SVR) rates have been an important focus for clinical physicians. The serine protease inhibitors telaprevir and boceprevir were approved by the United States Food and Drug Administration in 2011. The addition of HCV protease inhibitors to the SOC has significantly improved the efficacy of treatments for HCV infection. Several direct-acting antiviral drugs currently in late-stage clinical trials, both with and without peg-IFN and RBV, have several advantages over the previous SOC, including higher specificity and efficacy, fewer side effects, and the ability to be administered orally, and might be optimal regimens in the future. Factors affecting the efficacy of anti-HCV treatments based on IFN-\\u03b1 include the HCV genotype, baseline viral load, virological response during treatment, host IL28B gene polymorphisms and hepatic steatosis. However, determining the effect of the above factors on DAA therapy is necessary. In this review, we summarize the development of anti-HCV agents and assess the main factors affecting the efficacy of antiviral treatments.\",\"Direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection are one of the major advances in its medical treatment. The HCV protease inhibitors boceprevir and telaprevir were the first approved DAAs in the United States, Europe, and Japan. When combined with peginterferon plus ribavirin, these agents increase sustained virologic response rates to 70%-80% in treatment-na\\u00efve patients and previous-treatment relapsers with chronic HCV genotype 1 infection. Without peginterferon plus ribavirin, DAA mono-therapies increased DAA-resistance mutations. Several new DAAs for HCV are now in clinical development and are likely to be approved in the near future. However, it has been reported that the use of these drugs also led to the emergence of DAA-resistance mutations in certain cases. Furthermore, these mutations exhibit cross-resistance to multiple drugs. The prevalence of DAA-resistance mutations in HCV-infected patients who were not treated with DAAs is unknown, and it is as yet uncertain whether such variants are sensitive to DAAs. We performed a population sequence analysis to assess the frequency of such variants in the sera of HCV genotype 1-infected patients not treated with HCV protease inhibitors. Here, we reviewed the literature on resistance variants of HCV protease inhibitors in treatment na\\u00efve patients with chronic HCV genotype 1, as well as our experience.\",\"For HCV infection, there have been major advancements during last several years with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high potency, favourable tolerability profile, higher barrier to resistance, shortened treatment duration, all oral regimen, pan-genotypic, fewer drug interactions and reduced pill burden. By 2014, several DAAs are anticipated to complete successful phase III trials and will be commercially available. Initially, a wave of IFN-based regimen (sofosbuvir, faldaprevir and simeprevir) will be available for treatment of HCV genotype 1. In the near future, combination of antiviral agents with additive potency that lack cross-resistance with good safety profile will likely be the new recommended regimens, making HCV, the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN or ribavirin. The aim of this review was to summarize the results obtained from recent DAA combination studies without IFN.\",\"With the approval of second-wave direct-acting antivirals simeprevir, sofosbuvir and faldaprevir in 2014-2015, for genotype 1 hepatitis C, patients and doctors will have more treatment options. During a first period, these treatments will still be used with peginterferon and ribavirin. The second wave of IFN-based triple therapy will have benefits and risk. These treatments have the following advantages: higher efficacy with more patient candidates for a shorten treatment duration (12-24 weeks, instead of 48 weeks). These new treatments appear to have a better safety profile than first generation, with no additional increase in anaemia over peginterferon/ribavirin. Then, these treatments are to take for patients with a decrease in pill burden (these three direct-acting antivirals are given orally one pill a day). Simeprevir and sofosbuvir may be approved in the US and Europe, in 2014, at the time this manuscript will be released. Approval of faldaprevir will follow. These direct-acting antivirals with many others will hopefully be combined in future interferon-free regimens. The goal of this review to summarize the results and safety of simeprevir, faldaprevir and sofosbuvir, to advise physicians and to inform patients on the benefits and risks of these second-wave IFN-based regimens for HCV genotype infection.\",\"Boceprevir with peginterferon/ribavirin (BOC/PR) leads to significantly higher sustained virological response (SVR) rates in patients with chronic hepatitis C and partial response or relapse after prior treatment with peginterferon/ribavirin. We studied the efficacy of BOC/PR in patients with prior treatment failure, including those with a null response (<2-log10 decline in HCV RNA), to peginterferon/ribavirin.\",\"Triple therapy combining the protease inhibitor telaprevir with interferon-\\u03b1 and ribavirin is a promising new option for long-term treatment of hepatitis C. The interaction potential of telaprevir has not yet been fully elucidated. The in vitro potency of telaprevir to inhibit P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP, ABCG2) was assessed and its substrate characteristics for P-gp, BCRP and the multidrug resistance-associated proteins (MRPs, ABCCs) 1-3 were evaluated. The inducing properties of telaprevir on important drug-metabolising enzymes and transporters were also assessed and its ability to activate the pregnane X receptor (PXR) was investigated. Using growth inhibition assays, it was confirmed that telaprevir is a substrate of P-gp and it was demonstrated for the first time that it is not transported by BCRP and MRPs. Telaprevir only moderately inhibited P-gp in the calcein assay and did not inhibit BCRP in the pheophorbide A assay. In LS180 cells, telaprevir strongly induced mRNA expression of ABCG2 (4.3-fold at 30 \\u03bcmol/L) and weakly induced ABCB11, CYP2C19 and UGT1A3. In contrast, telaprevir had no significant influence on mRNA expression of CYP3A4, UGT1A9, ABCB1, ABCC2 and SLCO1B1. In a reporter gene assay, telaprevir did not activate PXR. Thus, it appears unlikely that telaprevir induces CYP3A4 and P-gp in vivo in such a way as to provoke clinically relevant drug interactions. From the numerous perpetrator characteristics, telaprevir's inhibitor properties, especially of CYP3A4 and P-gp, appear to be the most relevant mechanism for drug interactions. The clinical relevance of the strong inducing effects on ABCG2 requires proper assessment.\",\"Type I interferons (IFN-\\u03b1/\\u03b2), with or without ribavirin, have been the only agents that can eradicate the hepatitis C virus (HCV). An IFN-free regimen combining oral direct-acting antiviral agents (DAA) will be approved soon for genotype 1 patients. Here, we discuss the role of IFN-\\u03b1/\\u03b2 in the forthcoming \\\"era of DAA\\\" with consideration of limitations and concerns about IFN-free therapies. First, the therapeutic efficacy of first-generation DAA varies among the different subtypes. While the rate of sustained virological response (SVR) is 60-90% among patients with genotype 1b, the rate often falls short of 50% in patients with genotype 1a. IFN and ribavirin can still be indicated for patients with genotype 1a as a platform for combination with DAA. Second, there is concern about the emergence of drug-resistance resulting from inappropriate use of DAA. The clinical significance of pre-existing resistant variants has not been elucidated. Drug resistance may affect the efficacy of next-generation treatments. An IFN and ribavirin backbone in combination with DAA is an effective measure to prevent the emergence of drug resistance and/or to suppress pre-existing resistant viruses. Third, it remains unknown whether the incidence of hepatocellular carcinoma (HCC) will be reduced in patients who achieve SVR with IFN-free regimens. In contrast, there are many reports in Japan demonstrating the preventive effects of IFN on the development of HCC. When patients do not achieve SVR with first-generation DAA, low-dose IFN maintenance therapy is a treatment option until the next-generation therapy with pan-genotypic potency and high genetic barrier become available.\",\"Hepatitis C virus (HCV) induces insulin resistance, which improves upon viral clearance. Telaprevir is a protease inhibitor effective against HCV genotype 1. We reported a case, whose history suggests that telaprevir may induce some antidiabetic effect independently of its suppression of HCV. A 56-year-old woman with obesity, type 2 diabetes treated with sitagliptin and metformin, and HCV-related cirrhosis was given triple therapy with pegylated interferon-alpha, ribavirin and telaprevir. After 2 weeks of treatment, HCV RNA was no longer detectable but the patient described a pronounced drop in the capillary glucose levels and episodes of hypoglycaemia that compelled her to stop all antidiabetic treatment. One month after stopping telaprevir, she had to resume her antidiabetic treatment, despite a persisting virological response. Despite reaching a sustained virological response, her diabetes progressed. Although the suppression of HCV replication may have played a role in reducing glucose intolerance, the fact that this patient resumed her prior antidiabetic treatment upon completing the telaprevir treatment, while still aviremic, suggests that telaprevir may have an additional antidiabetic effect. Further evidence about the possible role and mechanisms of telaprevir as antidiabetic agent is warranted.\",\"Evaluation of metabolic factors and elevated \\u03b3-glutamyltransferase (GGT) levels as independent predictors of treatment failure in a thoroughly documented cohort of HIV-/HCV-coinfected patients (HIV/HCV). Sixty-four HIV/HCV patients treated with pegylated interferon-\\u03b1-2a plus ribavirin (PEGIFN + RBV) at the Medical University of Vienna within a prospective trial were included in this study. In addition, 124 patients with HIV/HCV from the AIFA-HIV and AHIVCOS cohorts were included as a validation cohort. Advanced liver fibrosis, GGT elevation, insulin resistance (IR) and low CD4+ nadir were defined as METAVIR F3/F4, GGT levels >1.5\\u00d7 sex-specific upper limit of normal, homoeostasis model assessment of insulin resistance >2 and CD4+ nadir <350 cells/\\u03bcL, respectively. HCV-genotype 1/4 (OR26.3; P = 0.006), advanced liver fibrosis (OR20.2; P = 0.009), interleukin 28B rs12979860 non-C/C SNP (OR8.27; P = 0.02) and GGT elevation (OR7.97; P = 0.012) were independent predictors of treatment failure, while both IR (OR3.51; P = 0.106) and low CD4 + nadir (OR2.64; P = 0.263) were not independently associated with treatment failure. A statistically significant correlation between GGT elevation and prior alcohol abuse (r = 0.259; P = 0.039), liver steatosis (r = 0.301; P = 0.034) and low-density lipoprotein-cholesterol (r = -0.256; P = 0.041) was observed. The importance of GGT elevation as an independent predictor of treatment failure was confirmed in a validation cohort (OR2.76; P = 0.026). While GGT elevation emerged as an independent predictor of treatment failure in both the derivation and the validation cohort, no independent associations between metabolic factors and treatment failure were observed. Thus, our findings suggest that GGT elevation is an independent predictor of treatment failure in HIV/HCV that can easily be incorporated into predictive algorithms.\",\"Pretreatment up-regulation of hepatic interferon (IFN)-stimulated genes (ISGs) has a stronger association with the treatment-resistant interleukin (IL)28B minor genotype (MI; TG/GG at rs8099917) than with the treatment-sensitive IL28B major genotype (MA; TT at rs8099917). We compared the expression of ISGs in the liver and blood of 146 patients with chronic hepatitis C who received pegylated IFN and ribavirin combination therapy. Gene expression profiles in the liver and blood of 85 patients were analyzed using an Affymetrix GeneChip (Affymetrix, Santa Clara, CA). ISG expression was correlated between the liver and blood of the MA patients, whereas no correlation was observed in the MI patients. This loss of correlation was the result of the impaired infiltration of immune cells into the liver lobules of MI patients, as demonstrated by regional gene expression analysis in liver lobules and portal areas using laser capture microdissection and immunohistochemical staining. Despite having lower levels of immune cells, hepatic ISGs were up-regulated in the liver of MI patients and they were found to be regulated by multiple factors, namely, IL28A/B, IFN-\\u03bb4, and wingless-related MMTV integration site 5A (WNT5A). Interestingly, WNT5A induced the expression of ISGs, but also increased hepatitis C virus replication by inducing the expression of the stress granule protein, GTPase-activating protein (SH3 domain)-binding protein 1 (G3BP1), in the Huh-7 cell line. In the liver, the expression of WNT5A and its receptor, frizzled family receptor 5, was significantly correlated with G3BP1.\",\"Few anti-influenza drugs are licensed in the United States for the prevention and therapy of influenza A and B virus infections. This shortage, coupled with continuously emerging drug resistance, as detected through a global surveillance network, seriously limits our anti-influenza armamentarium. Combination therapy appears to offer several advantages over traditional monotherapy in not only delaying development of resistance but also potentially enhancing single antiviral activity. In the present study, we evaluated the antiviral drug susceptibilities of fourteen pandemic influenza A (H1N1) virus isolates in MDCK cells. In addition, we evaluated favipiravir (T-705), an investigational drug with a broad antiviral spectrum and a unique mode of action, alone and in dual combination with the neuraminidase inhibitors (NAIs) oseltamivir, peramivir, or zanamivir, against oseltamivir-sensitive pandemic influenza A/California/07/2009 (H1N1) and oseltamivir-resistant A/Hong Kong/2369/2009 (H1N1) virus. Mean inhibitory values showed that the tested virus isolates remained sensitive to commonly used antiviral drugs, with the exception of the Hong Kong virus isolate. Drug dose-response curves confirmed complete drug resistance to oseltamivir, partial sensitivity to peramivir, and retained susceptibility to zanamivir and favipiravir against the A/Hong Kong/2369/2009 virus. Three-dimensional analysis of drug interactions using the MacSynergy(TM) II program indicated an overall synergistic interaction when favipiravir was combined with the NAIs against the oseltamivir-sensitive influenza virus, and an additive effect against the oseltamivir-resistant virus. Although the clinical relevance of these drug combinations remains to be evaluated, results obtained from this study support the use of combination therapy with favipiravir and NAIs for treatment of human influenza virus infections.\",\"Interferon-based standard of care treatments (SOC) for chronic hepatitis C are unable to provide high cure rates in certain subgroups of the infected population and can cause debilitating side effects. Clinical trials evaluating all-oral, interferon-free treatments have demonstrated high rates of sustained virologic response with no resistance or major adverse events in most populations. As these drug regimens move towards FDA approval, it will be important to assess their cost-effectiveness in addition to their clinical efficacy. A decision-analytic Markov model with a lifetime, societal perspective was used to evaluate the cost-effectiveness of a generalized all-oral drug regimen compared to SOC by modelling the progression of a 50-year-old, HCV-positive cohort through disease natural history and treatment. In base case analysis, all-oral treatment dominated SOC across a range of willingness-to-pay (WTP) thresholds with an incremental cost-effectiveness ratio (ICER) of US$44,514/quality-adjusted life year (QALY). In sensitivity analyses, the model was sensitive to all-oral drug costs as well as rates of SVR and treatment uptake among noncirrhotic subjects, but robust to variations in all other parameters. All-oral treatment was most cost-effective among genotype 1 subjects but remained cost-effective for genotypes 2 and 3 at WTP thresholds \\u2265$80,000/QALY. Quality-adjusted life years gained per dollar spent were maximized in younger treatment cohorts. Using this model, the degree of cost-effectiveness depended on the WTP threshold and the final cost set for approved drug combinations.\",\"Thrombocytopenia in patients with chronic hepatitis C may represent an obstacle for the initiation of antiviral treatment. The aim of this study was to evaluate factors predictive of successful pegylated interferon (PEG-IFN) \\u03b12b and ribavirin (RBV) treatment for patients with thrombocytopenia with no history of splenectomy or partial splenic embolization. One hundred and fifty-one chronic hepatitis C patients (genotype 1: n = 110, genotype 2: n = 41) with TCP (<100 \\u00d7 10(9) /L) at baseline were enrolled. Pretreatment variables included interleukin 28B (IL28B) genotype (rs8099917) and homoeostasis model assessment of insulin resistance score (HOMA-IR). The kinetics of haemoglobin and platelets according to the inosine triphosphatase (ITPA) genotype (rs1127354) were investigated. Sustained virological response (SVR) was significantly more frequent in hepatitis C virus (HCV) genotype 2 (65.9%) than in genotype 1 (34.5%) patients (P < 0.0001). Multiple logistic regression analysis of HCV genotype 1 extracted IL28B TT genotype [odds ratio (OR) 5.97, P = 0.006] and HOMA-IR <2.5 (OR 7.14, P = 0.0016) as significant independent pretreatment predictors of SVR. The analyses of HCV genotype 2 showed that HOMA-IR was significantly related to SVR, but IL28B genotype was not. Patients with ITPA CC genotype showed a significant haemoglobin reduction and lower degree of platelets decrease than those with ITPA CA/AA genotypes. The most common reason for premature discontinuation of treatment was the development of hepatocellular carcinoma (n = 8, 5.3%). In conclusion, HOMA-IR is a useful predictor of SVR for patients with thrombocytopenia infected with HCV genotype 1 or 2 treated with PEG-IFN\\u03b12b and RBV. The inclusion of IL28B, ITPA genotypes and HOMA-IR adds valuable therapeutic information.\",\"Danoprevir (DNV) is a hepatitis C virus (HCV) protease inhibitor that achieves high sustained virologic response (SVR) rates in combination with peginterferon alfa-2a-ribavirin in treatment-naive HCV genotype 1 (G1)-infected patients. This study explored the efficacy and safety of ritonavir-boosted DNV (DNVr) plus peginterferon alfa-2a-ribavirin in G1-infected prior peginterferon-ribavirin null responders. Null responders (<2-log10 reduction in HCV RNA level at week 12) were given an open-label combination of 100 mg of ritonavir and 100 mg of DNV (100/100 mg DNVr) every 12 h (q12h) plus peginterferon alfa-2a-ribavirin for 12 weeks. All patients achieving an early virologic response (EVR; \\u22652-log10 decrease in HCV RNA by week 12) continued treatment with peginterferon alfa-2a-ribavirin; those without an EVR discontinued all study drugs. Twenty-four prior null responders were enrolled; 16 patients (67%) were infected with HCV G1b, and 8 (33%) were infected with G1a. Ninety-six percent of patients had an IL28B non-CC genotype. A sustained virologic response at 24 weeks posttreatment (SVR24) was achieved in 67% of patients, with a higher rate in G1b-infected (88%) than G1a-infected (25%) patients. Resistance-related breakthrough occurred in 4/8 G1a and 1/16 G1b patients through the DNV resistance-associated variant (RAV) NS3 R155K. NS3 R155K was also detected in 2/2 G1a patients who relapsed. Treatment was well tolerated. Two patients withdrew prematurely from study medications due to adverse events. Two serious adverse events were reported; both occurred after completion of DNVr therapy and were considered unrelated to treatment. No grade 3 or 4 alanine aminotransferase (ALT) elevations were observed. DNVr plus peginterferon alfa-2a-ribavirin demonstrated high SVR24 rates in HCV G1b-infected prior null responders and was well tolerated. (This study has been registered at ClinicalTrials.gov under registration no. NCT01185860.).\",\"The current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct-acting antivirals (DAAs) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG-IFN) and ribavirin (RBV) regimen. In 2014, sofosbuvir, simeprevir and faldaprevir may be available, each in combination with PEG-IFN/RBV triple therapy. All the HCV enzymes are essential for HCV replication, and are potential drug discovery targets. Therefore, DAAs with different viral targets, including NS3 protease inhibitors, nucleoside/nucleotide analogue and nonnucleoside inhibitors of the RNA-dependent RNA polymerase, and NS5A replication complex inhibitors are under development.\",\"Currently, hepatitis C virus (HCV) infection is considered a serious health-care problem all over the world. A good number of direct-acting antivirals (DAAs) against HCV infection are in clinical progress including NS3-4A protease inhibitors, RNA-dependent RNA polymerase inhibitors, and NS5A inhibitors as well as host targeted inhibitors. Two NS3-4A protease inhibitors (telaprevir and boceprevir) have been recently approved for the treatment of hepatitis C in combination with standard of care (pegylated interferon plus ribavirin). The new therapy has significantly improved sustained virologic response (SVR); however, the adverse effects associated with this therapy are still the main concern. In addition to the emergence of viral resistance, other targets must be continually developed. One such underdeveloped target is the helicase portion of the HCV NS3 protein. This review article summarizes our current understanding of HCV treatment, particularly with those of NS3 inhibitors.\",\"We assessed the outcome of double-filtration plasmapheresis (DFPP) combined with pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients infected with hepatitis C virus (HCV)-1b whose HCV had not disappeared during PEG-IFN/RBV combination therapy, or who had relapsed after the end of the therapy. Additionally, we investigated factors predictive of sustained virological response (SVR), including host and viral genetic factors, to DFPP plus IFN/RBV therapy.\",\"We investigated the impact of host genetics represented by the single nucleotide polymorphism (SNP) of the IL28B gene and viral genetic variations within the nonstructural protein 5A (NS5A) [including the interferon (IFN)/ribavirin (RBV) resistance-determining region (IRRDR) and the IFN sensitivity-determining region (ISDR)] on the outcome of pegylated IFN and RBV (PEG-IFN/RBV) treatment.\",\"This study explores viral factors of the interferon (IFN) and ribavirin (RBV) resistance-determining region (IRRDR), the IFN sensitivity-determining region (ISDR) and the core protein, and host factor interleukin 28B associated with response to pegylated IFN (PEG-IFN) and RBV combination therapy, and the correlation of viral and host factors with IFN-\\u03bb1.\",\"We assessed drug susceptibilities of 125 avian influenza A(H5N1) viruses isolated from poultry in Vietnam during 2009-2011. Of 25 clade 1.1 viruses, all possessed a marker of resistance to M2 blockers amantadine and rimantadine; 24 were inhibited by neuraminidase inhibitors. One clade 1.1 virus contained the R430W neuraminidase gene and reduced inhibition by oseltamivir, zanamivir, and laninamivir 12-, 73-, and 29-fold, respectively. Three of 30 clade 2.3.4 viruses contained a I223T mutation and showed 7-fold reduced inhibition by oseltamivir. One of 70 clade 2.3.2.1 viruses had the H275Y marker of oseltamivir resistance and exhibited highly reduced inhibition by oseltamivir and peramivir; antiviral agents DAS181 and favipiravir inhibited H275Y mutant virus replication in MDCK-SIAT1 cells. Replicative fitness of the H275Y mutant virus was comparable to that of wildtype virus. These findings highlight the role of drug susceptibility monitoring of H5N1 subtype viruses circulating among birds to inform antiviral stockpiling decisions for pandemic preparedness.\",\"Advances in our understanding of the HCV lifecycle and refinement of in vitro methods to select candidate compounds with anti-HCV activity have led to development of DAA agents and other novel antiviral therapies capable of increasing the curative SVR rates in patients with CHC. The use of the liner protease inhibitors telaprevir and boceprevir, in combination with Peg-IFN-a and ribavirin has become the new SOC for treatment of CHC genotype 1. Rapid development of new protease inhibitors, NI and NNI NS5B polymerase inhibitors, NS5A inhibitors, Peg-IFN-l, cyclophilin inhibitors, caspase inhibitors, and therapeutic vaccines promises to provide even safer and more effective therapy. Combination therapies with 2 or more oral agents may permit elimination of Peg-IFN-a in the near future. Introduction of DAA therapies will confront physicians and patients with regimens of increased complexity, a greater need for compliance, and the necessity of monitoring for virological resistance. Patients with CHC should continue to consider participation in clinical trials of new therapies to accelerate progress.\",\"Hepatitis C virus (HCV) infections remain an increasingly prevalent and emergent health problem worldwide, causing a wide spectrum of liver diseases. Combination therapy with pegylated interferon (PEG-IFN) of peginterferon alfa-2a and oral ribavirin is currently recognized as the standard treatment of chronic HCV infection. Several complex immunological mechanisms are involved during the course of HCV treatment using interferons. The role of endogenous interferon gamma (IFN\\u03b3) in Egyptian patients infected with chronic HCV and treated with PEG-IFN/ribavirin is uncertain. The goal of this study was to evaluate the association of IFN\\u03b3 and chronic HCV infection among patients treated with combination therapy of PEG-IFN/ribavirin.\",\"The high rate of sustained viral response (SVR) to boceprevir or telaprevir-based triple therapy in hepatitis C (HCV)-related, non-cirrhotic na\\u00efve patients or relapsers to previous antiviral treatment leads clinicians to believe that the impact of metabolic host factors on SVR is minimal when triple therapy is used, unlike what is observed with the peginterferon and ribavirin schedules. This concept is strongly expressed by some opinion leaders on the basis of the data derived from sub-analyses of registrative trials as well as from a post-hoc analysis of the phase II C208 clinical trial. The perception of unrestrainable therapeutic success with the use of newer, more powerful antivirals is now reinforced by the brilliant results obtained with sofosbuvir, an HCV NS5B polymerase inhibitor, as well as by the data from the phase II and III studies on the various combinations of second-generation NS3/4A inhibitors and NS5A and/or NS5B inhibitors. However, a great deal of concern has emerged from the real world scenario in which patients are often older and have more comorbidities than patients in the \\\"world of trials\\\". Furthermore, many of them have advanced fibrosis and previous failure with peginterferon and ribavirin treatment. Some data from the recent literature suggest that the host metabolic factors may play a minor but non-negligible role in these difficult-to-treat patients, an issue that will hopefully be investigated in further studies. This editorial aims to provide a detailed analysis of the role that host metabolic factors played in the past and what role they may play in the era of direct antiviral agents.\",\"A stable and persistent Hepatitis C virus (HCV) replication cell culture model was developed to examine clearance of viral replication during long-term treatment using interferon-\\u03b1 (IFN-\\u03b1), IFN-\\u03bb, and ribavirin (RBV). Persistently HCV-infected cell culture exhibited an impaired antiviral response to IFN-\\u03b1+RBV combination treatment, whereas IFN-\\u03bb treatment produced a strong and sustained antiviral response that cleared HCV replication. HCV replication in persistently infected cells induced chronic endoplasmic reticulum (ER) stress and an autophagy response that selectively down-regulated the functional IFN-\\u03b1 receptor-1 chain of type I, but not type II (IFN-\\u03b3) or type III (IFN-\\u03bb) IFN receptors. Down-regulation of IFN-\\u03b1 receptor-1 resulted in defective JAK-STAT signaling, impaired STAT phosphorylation, and impaired nuclear translocation of STAT. Furthermore, HCV replication impaired RBV uptake, because of reduced expression of the nucleoside transporters ENT1 and CNT1. Silencing ER stress and the autophagy response using chemical inhibitors or siRNA additively inhibited HCV replication and induced viral clearance by the IFN-\\u03b1+RBV combination treatment. These results indicate that HCV induces ER stress and that the autophagy response selectively impairs type I (but not type III) IFN signaling, which explains why IFN-\\u03bb (but not IFN-\\u03b1) produced a sustained antiviral response against HCV. The results also indicate that inhibition of ER stress and of the autophagy response overcomes IFN-\\u03b1+RBV resistance mechanisms associated with HCV infection.\",\"Suppressor of cytokine signaling 3, myxovirus resistance protein and osteopontin gene polymorphisms may influence the therapeutic response in patients with chronic hepatitis C, and an association with IL28 might increase the power to predict sustained virologic response. Our aims were to evaluate the association between myxovirus resistance protein, osteopontin and suppressor of cytokine signaling 3 gene polymorphisms in combination with IL28B and to assess the therapy response in hepatitis C patients treated with pegylated-interferon plus ribavirin.\",\"Chronic hepatitis C virus (HCV) infection is responsible for the development of liver cirrhosis and hepatocellular carcinoma. It has been a tremendous burden on global health care systems. With the advent of a number of new direct-acting and host-targeting antiviral agents, current interferon-\\u03b1- and ribavirin-based HCV therapy has started to move towards an interferon-sparing or even interferon-free strategy. In this regard, a recently identified NS5A inhibitor, daclatasvir, showed a great promise in clinical trials as another new class of direct-acting anti-HCV therapeutics, with a distinct mechanism of action. In this review, a variety of preclinical as well as clinical proof-of-concept studies of daclatasvir, including the studies of its discovery, mechanism of action, viral resistance, and host polymorphism profiles are reviewed. In addition, a role of daclatasvir in the future therapy for HCV patients is discussed briefly.\",\"Until very recently, treatment for chronic hepatitis C virus (HCV) infection has been based on the combination of two non-viral specific drugs: pegylated interferon-\\u03b1 and ribavirin, which is effective in, overall, about 40%-50% of cases. To improve the response to treatment, novel drugs have been designed to specifically block viral proteins. Multiple compounds are under development, and the approval for clinical use of the first of such direct-acting antivirals in 2011 (Telaprevir and Boceprevir), represents a milestone in HCV treatment. HCV therapeutics is entering a new expanding era, and a highly-effective cure is envisioned for the first time since the discovery of the virus in 1989. However, any antiviral treatment may be limited by the capacity of the virus to overcome the selective pressure of new drugs, generating antiviral resistance. Here, we try to provide a basic overview of new treatments, HCV resistance to new antivirals and some considerations derived from a Public Health perspective, using HCV resistance to protease and polymerase inhibitors as examples.\",\"Antiviral treatment is the only option to prevent or defer the occurrence of hepatocellular carcinoma (HCC) in patients chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV). The approved medication for the treatment of chronic HBV infection is interferon-\\u03b1 (IFN\\u03b1) and nucleos(t)ide analogues (NAs), including lamivudine, adefovir dipivoxil, telbivudine, entecavir and tenofovir disoproxil fumarate. IFN\\u03b1 is the most suitable for young patients with less advanced liver diseases and those infected with HBV genotype A. IFN\\u03b1 treatment significantly decreases the overall incidence of HBV-related HCC in sustained responders. However, side effects may limit its long-term clinical application. Orally administered NAs are typically implemented for patients with more advanced liver diseases. NA treatment significantly reduces disease progression of cirrhosis and therefore HCC incidence, especially in HBV e antigen-positive patients. NA-resistance due to the mutations in HBV polymerase is a major limiting factor. Of the NA resistance-associated mutants, A181T mutant significantly increases the risk of HCC development during the subsequent course of NA therapy. It is important to initiate treatment with NAs that have a high genetic barrier to resistance, to counsel patients on medication adherence and to monitor virological breakthroughs. The recommended treatment for patients with chronic HCV infection is peg-IFN plus ribavirin that can decrease the occurrence of HCC in those who achieve a sustained virological response and have not yet progressed to cirrhosis. IFN-based treatment is reserved for patients with decompensated cirrhosis who are under evaluation of liver transplantation to reduce post-transplant recurrence of HCV. More effective therapeutic options such as direct acting antiviral agents will hopefully increase the response rate in difficult-to-treat patients with HCV genotype 1. However, the risk of HCC remains in cirrhotic patients (both chronic HBV and HCV infection) if treatment is initiated after cirrhosis is established. Future research should focus on investigating new agents, especially for those patients with hepatic decompensation or post-transplantation.\",\"Enhanced endogenous interferon (IFN) stimulated gene (ISG) signature has been associated with nonresponsiveness to hepatitis C treatment using pegylated-IFN\\u03b1 (pegIFN\\u03b1) and ribavirin (RBV) in human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. Using a proteomic approach, we identified high levels of IFN\\u03b1 receptor 2a (IFN\\u03b1R2a) in the serum of null responders to pegIFN\\u03b1/RBV. IFN\\u03b1R2a inhibited antiviral activity of all formulations of IFN\\u03b1 in JFH/Huh7.5 cells. Furthermore, serum from null responders, but not from those who achieved sustained virologic response, suppressed IFN-signaling and ISG expression in IFN\\u03b1-stimulated PBMCs of healthy donors in an IFN\\u03b1R2a specific fashion. An IFN\\u03b1R2a transgenic mice model (C57BL/6) was generated that had significantly higher levels of IFN\\u03b1R2a in the serum than the controls (P=0.001). Total ISG expression in the lymph nodes was significantly higher compared to wild-type mice (P value=0.0016). In addition, IFITM1 and SP110 had significantly increased expression in the liver, IFITM1 and ISG15 in the lymph node, and ISG15 and PLSCR1 in the spleen (P value<0.05). The underlying mechanism of resistance to hepatitis C treatment may involve transsignaling of the JAK/STAT pathway by the sIFN\\u03b1R2a-IFN\\u03b1/\\u03b2 complex and result in the enhanced ISG signature observed in null responders. In this regard, the transgenic mice model simulated nonresponders to IFN\\u03b1 therapy and provides valuable insights into the role of sIFN\\u03b1R2a-IFN\\u03b1 interactions in vivo.\",\"Narlaprevir, a hepatitis C virus (HCV) NS3/4A serine protease inhibitor, has demonstrated robust antiviral activity in a placebo-controlled phase 1 study. To study evolutionary dynamics of resistant variants, the NS3 protease sequence was clonally analysed in thirty-two HCV genotype 1-infected patients following treatment with narlaprevir. Narlaprevir monotherapy was administered for one week (period 1) followed by narlaprevir/pegylated interferon-alpha-2b combination therapy with or without ritonavir (period 2) during two weeks, interrupted by a washout period of one month. Thereafter, all patients initiated pegylated interferon-alpha-2b/ribavirin combination therapy. Longitudinal clonal analysis was performed in those patients with NS3 mutations. After narlaprevir re-exposure, resistance-associated mutations at position V36, T54, R155 and A156 were detected in five patients in >95% of the clones. Narlaprevir retreatment resulted in a 2.58 and 5.06 log10 IU/mL viral load decline in patients with and without mutations, respectively (P=<0.01). After treatment, resistant variants were replaced with wild-type virus within 2-24 weeks in three patients. However, the R155K mutation was still observed 3.1 years after narlaprevir dosing in two patients in 5% and 45% of the viral population. Resistant variants could be detected early during treatment with narlaprevir. A slower viral load decline was observed in those patients with resistance-associated mutations detectable by direct population sequencing. These mutations disappeared within six months following treatment with the exception of R155K mutation, which persisted in two patients.\",\"Resistance to mericitabine (prodrug of HCV NS5B polymerase inhibitor PSI-6130) is rare and conferred by the NS5B S282T mutation.\",\"Specific human polymorphisms, most commonly found in Central Africa, can predict the success of drug treatment against the hepatitis C virus (HCV), a significant and globally-distributed human pathogen. However, this association is only found for a subset of HCV genotypes. Despite receiving considerable attention in the medical and virological literature, no evolutionary explanation for this curious pattern has been put forward. Here we suggest that the 'drug treatment resistance' phenotype exhibited today by some HCV genotypes evolved hundreds to thousands of years ago in response to human genetic variation local to Central Africa: an adaptation that has since accrued a new function in the era of anti-viral drug treatment. This could represent one of the oldest known examples of viral exaptation at the population level.\",\"In HCV genotype 1-infected patients with HIV co-infection, tritherapy [HCV protease inhibitors (PIs) plus peg-interferon and ribavirin] has been shown to have an increased rate of sustained virological response. However, complex drug-to-drug interactions and tolerability issues remain a concern.\",\"Hepatitis C virus (HCV) infection is causally associated with insulin resistance and diabetes mellitus. This population-based cohort study aimed to investigate whether antiviral therapy for HCV infection was associated with improved clinical outcomes related to diabetes. From the Taiwan National Health Insurance Research Database, 2,267,270 Taiwanese residents diagnosed with diabetes mellitus were screened for eligibility. HCV infection was defined by a specific diagnosis code and measurement of serum antibody. After excluding patients with serious comorbidity, we enrolled a total of 1,411 eligible patients who received pegylated interferon plus ribavirin (treated cohort), and matched them 1:1 with 1,411 untreated controls by propensity scores (untreated cohort). We also matched the treated cohort 1:4 with 5,644 diabetic patients without HCV infection (uninfected cohort). Participants were followed up for the occurrence of endstage renal disease (ESRD), ischemic stroke, and acute coronary syndrome (ACS) after receiving antiviral treatment or the corresponding calendar date. From 2003 to 2011, the 8-year cumulative incidences of ESRD in the treated, untreated, and uninfected cohorts were 1.1% (95% confidence interval [CI], 0.3-2.0%), 9.3% (95% CI, 5.9-12.7%), and 3.3% (95% CI, 2.3-4.3%), respectively (P < 0.001); those of stroke were 3.1% (95% CI, 1.1-5.0%), 5.3% (95% CI, 3.0-7.5%), and 6.1% (95% CI, 4.8-7.4%), respectively (P = 0.01); and those for ACS were 4.1% (95% CI, 2.1-6.1%), 6.6% (95% CI, 3.7-9.5%), and 7.4% (95% CI, 5.9-9.0%), respectively (P = 0.05). As compared with the untreated cohort, antiviral treatment was associated with multivariate-adjusted hazard ratios of 0.16 (95% CI, 0.07-0.33%) for ESRD, 0.53 (95% CI, 0.30-0.93) for ischemic stroke, and 0.64 (95% CI, 0.39-1.06) for ACS.\",\"The combination of vaniprevir (a NS3/4A protease inhibitor) with peginterferon and ribavirin was shown to increase rates of sustained virologic response (SVR) significantly, compared with peginterferon and ribavirin alone, in treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection without cirrhosis. We performed a blinded, randomized, controlled trial of the effects of vaniprevir with peginterferon and ribavirin in patients with cirrhosis who did not respond to prior therapy with peginterferon and ribavirin.\",\"About 2.35% of the world population can be infected with hepatitis C virus (HCV) responsible for chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Currently available interferon-based medication is successful in up to 75% of the patients infected with HCV genotypes 1, 2 or 3 and lower efficacy in other genotypes. Unfortunately sustained virologic response (SVR) rate in genotype 1 infected non-responders to previous therapy with advanced hepatic fibrosis even after retreatment with the first generation direct acting antivirals (DAA) is about 40% only.\",\"Telaprevir is a linear, peptidomimetic small molecule that inhibits hepatitis C virus (HCV) replication by specifically inhibiting the NS3\\u00b74A protease. In phase 3 clinical studies, telaprevir in combination with peginterferon and ribavirin (PR) significantly improved sustained virologic response (SVR) rates in genotype 1 chronic HCV-infected patients compared with PR alone. In patients who do not achieve SVR after treatment with telaprevir-based regimens, variants with mutations in the NS3\\u00b74A protease region have been observed. Such variants can contribute to drug resistance and limit the efficacy of treatment. To gain a better understanding of the viral resistance profile, we conducted phenotypic characterization of the variants using HCV replicons carrying site-directed mutations. The most frequently observed (significantly enriched) telaprevir-resistant variants, V36A/M, T54A/S, R155K/T, and A156S, conferred lower-level resistance (3- to 25-fold), whereas A156T and V36M+R155K conferred higher-level resistance (>25-fold) to telaprevir. Rarely observed (not significantly enriched) variants included V36I/L and I132V, which did not confer resistance to telaprevir; V36C/G, R155G/I/M/S, V36A+T54A, V36L+R155K, T54S+R155K, and R155T+D168N, which conferred lower-level resistance to telaprevir; and A156F/N/V, V36A+R155K/T, V36M+R155T, V36A/M+A156T, T54A+A156S, T54S+A156S/T, and V36M+T54S+R155K, which conferred higher-level resistance to telaprevir. All telaprevir-resistant variants remained fully sensitive to alpha interferon, ribavirin, and HCV NS5B nucleoside and nonnucleoside polymerase inhibitors. In general, the replication capacity of telaprevir-resistant variants was lower than that of the wild-type replicon.\",\"Despite the incontestable benefits of telaprevir and boceprevir-based triple therapy in patients infected with genotype 1, the practitioner faces a number of new challenges. In daily clinical practice, a checklist approach may facilitate the management of triple therapy. Before initiation, several specific issues should be reviewed with the patient in order to optimize adherence and treatment outcome: potential drug to drug interaction, treatment duration and stopping rules, possible treatment outcomes, side effects, dose and administration with food advice, management of side effects. Because treatment failure is associated with the emergence of resistance-associated variants with reduced sensitivity to protease inhibitors, adherence is of major importance. In this setting, the role of educational nurse should be emphasized for the management of triple therapy in daily clinical practice.\",\"Hepatitis C virus (HCV) is a major cause of liver disease and a potential cause of substantial morbidity and mortality worldwide. The overall prevalence of HCV infection is 2%, representing 120 million people worldwide. Current standard treatment using pegylated interferon and ribavirin is effective in only 50% of the patients infected with HCV genotype 1, and is associated with significant side effects. Therefore, it is still of importance to develop new drugs for treatment of HCV. Antiviral substances obtained from natural products, including medicinal plants, are potentially good targets to study. In this study, we evaluated Indonesian medicinal plants for their anti-HCV activities.\",\"Hepatitis C virus (HCV) subgenotypes 1a and 1b have different impacts on the treatment response to peginterferon plus ribavirin with direct-acting antivirals (DAAs) against patients infected with HCV genotype 1, as the emergence rates of resistance mutations are different between these two subgenotypes. In Japan, almost all of HCV genotype 1 belongs to subgenotype 1b.\",\"Telaprevir is an extremely potent antiviral drug. However, as with other direct-acting antiviral agents against the hepatitis C virus (HCV), this potency can be compromised by the rapid emergence of resistance mutations. This phenomenon is favored by the high rate of HCV replication, the lack of corrective activity to HCV polymerase errors, a low genetic barrier to resistance, and poor treatment adherence. Like other HCV protease inhibitors, telaprevir has a low genetic barrier to resistance. Phase II/III clinical trials (ADVANCE, ILLUMINATE and REALIZE) have characterized resistance to telaprevir in combination with pegylated interferon and ribavirin both genotypically and phenotypically. Mutations are selected mainly in positions 36, 54, 55, 155 and 156. The resistance profile depends on the genetic subtype of HCV, with selection of mutations in positions 36 and 155 for subtype 1a and in positions 36, 54, 55 and 156 for subtype 1b. The V36M+R155K and A156F/T/V variants confer a high degree of resistance (>25-fold increase), while the impact on resistance of other mutations such as V36A/G/M, T54A/S, R155G/K/M/T and A156S is lower (3-25- fold increase). The presence of polymorphisms or mutations associated with telaprevir resistance is very low (< 1%), especially for mutations with a higher impact on resistance. There is a high degree of cross resistance among protease inhibitors. However, the rapid reversion of telaprevir resistance mutations after the end of treatment could allow the use of \\\"recycling\\\" strategies with protease inhibitors.\",\"The introduction of telaprevir in the therapeutic armamentarium for hepatitis C virus infection is a major advance, even in patients unresponsive to prior treatment with interferon and ribavirin. In this group of patients, sustained viral response is achieved in more than 80% of those with recurrence and who received triple therapy. In partial responders, more than half achieve cure with the triple combination of pegylated interferon, ribavirin and telaprevir. Unfortunately, the results are less good in null responders, especially given that many are of a certain age and have advanced fibrosis. Patients in this group should be carefully selected to identify those most likely to derive a benefit from triple therapy.\",\"Chronic hepatitis due to the hepatitis C virus (HCV) infection affects nearly 180 million people worldwide. This infection is curable. Until 1 year ago, the only treatment for genotype 1 HCV was the combination of pegylated interferon and ribavirin, which was only moderately effective (40-50%). The introduction of new antiviral agents, such as telaprevir, represents a change of paradigm and has revolutionized the treatment of this infection. This drug has increased the likelihood of viral response (to 80%) and has allowed treatment length to be shortened in more than 50% of patients. New stopping rules have been developed to avoid the development of resistances. Finally, special attention should be paid to potentially serious adverse effects, particularly anemia and cutaneous alterations.\",\"Controversial results have been found in literature for the association between insulin resistance and sustained virologic response to standard chronic hepatitis C treatment. This study aims to provide a systematic literature review with meta-analysis, in order to evaluate if insulin resistance interferes with sustained virologic response in patients infected by the HCV genotype 1 versus HCV genotypes 2 and 3, undergoing treatment with interferon and ribavirin or pegylated interferon and ribavarin.\",\"Despite improved virologic response with the addition of direct acting agents to peginterferon and ribavirin treatment in chronic hepatitis C virus (HCV) genotype 1 infection, a subset of patients experience viral breakthrough while on therapy. Defining viral breakthrough and patient characteristics is important for ongoing and future HCV treatment.\",\"While ribavirin mono-therapy regimens have minimal effect on patients with chronic hepatitis C virus (HCV) infections, they can be efficacious when combined with interferon. Clinical studies show that interferon-free combination therapies containing ribavirin are also efficacious, suggesting that an interferon-free therapy could be adopted in the near future. However, generation of drug resistant mutants and cross resistance to other drugs could impair the efficacy of the treatment. Therefore, understanding the mechanism of HCV resistance to ribavirin and cross resistance to other antiviral drugs could be of major importance.\",\"Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical and social problem. The expanding knowledge of HCV lifecycle has led to the development of novel antiviral agents that: a) specifically target a viral function (direct-acting antivirals), or b) specifically inhibit viral replication. The present review describes the novel anti-HCV drugs that have been better studied at the time of this writing and the current two types of treatment, namely interferon-based and interferon-free regimens. In addition, predictive factors, virological responses, side-effects, and resistance mechanisms of the novel agents are summarized.\",\"Hepatitis C virus (HCV) infection is the most important problem across the world. It causes acute and chronic liver infection. Different approaches are in use to inhibit HCV infection, including small organic compounds, siRNA, shRNA and peptide inhibitors. This review article summarizes the current and future therapies for HCV infection. PubMed and Google Scholar were searched for articles published in English to give an insight into the current inhibitors against this life-threatening virus. HCV NS3/4A protease inhibitors and nucleoside/nucleotide inhibitors of NS5B polymerase are presently in the most progressive stage of clinical development, but they are linked with the development of resistance and viral breakthrough. Boceprevir and telaprevir are the two most important protease inhibitors that have been approved recently for the treatment of HCV infection. These two drugs are now the part of standard-of-care treatment (SOC). There are also many other drugs in phase III of clinical development. When exploring the various host-cell-targeting compounds, the most hopeful results have been demonstrated by cyclophilin inhibitors. The current SOC treatment of HCV infection is Peg-interferon, ribavirin and protease inhibitors (boceprevir or telaprevir). The future treatment of this life-threatening disease must involve combinations of therapies hitting multiple targets of HCV and host factors. It is strongly expected that the near future, treatment of HCV infection will be a combination of direct-acting agents (DAA) without the involvement of interferon to eliminate its side effects.\",\"Reversibility of advanced fibrosis after HCV-clearance is an important goal of therapy.\",\"No therapeutics or vaccines currently exist for human coronaviruses (HCoVs). The Severe Acute Respiratory Syndrome-associated coronavirus (SARS-CoV) epidemic in 2002-2003, and the recent emergence of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in April 2012, emphasize the high probability of future zoonotic HCoV emergence causing severe and lethal human disease. Additionally, the resistance of SARS-CoV to ribavirin (RBV) demonstrates the need to define new targets for inhibition of CoV replication. CoVs express a 3'-to-5' exoribonuclease in nonstructural protein 14 (nsp14-ExoN) that is required for high-fidelity replication and is conserved across the CoV family. All genetic and biochemical data support the hypothesis that nsp14-ExoN has an RNA proofreading function. Thus, we hypothesized that ExoN is responsible for CoV resistance to RNA mutagens. We demonstrate that while wild-type (ExoN+) CoVs were resistant to RBV and 5-fluorouracil (5-FU), CoVs lacking ExoN activity (ExoN-) were up to 300-fold more sensitive. While the primary antiviral activity of RBV against CoVs was not mutagenesis, ExoN- CoVs treated with 5-FU demonstrated both enhanced sensitivity during multi-cycle replication, as well as decreased specific infectivity, consistent with 5-FU functioning as a mutagen. Comparison of full-genome next-generation sequencing of 5-FU treated SARS-CoV populations revealed a 16-fold increase in the number of mutations within the ExoN- population as compared to ExoN+. Ninety percent of these mutations represented A:G and U:C transitions, consistent with 5-FU incorporation during RNA synthesis. Together our results constitute direct evidence that CoV ExoN activity provides a critical proofreading function during virus replication. Furthermore, these studies identify ExoN as the first viral protein distinct from the RdRp that determines the sensitivity of RNA viruses to mutagens. Finally, our results show the importance of ExoN as a target for inhibition, and suggest that small-molecule inhibitors of ExoN activity could be potential pan-CoV therapeutics in combination with RBV or RNA mutagens.\",\"A novel reassortant avian-origin influenza A (H7N9) virus was isolated from respiratory specimens obtained from three patients and was identified as H7N9 in China. Antiviral agents are required to treat patients with avian influenza H7N9 virus infection.\",\"GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1 (GT1) HCV infection. Key preclinical properties of GS-9451, including in vitro antiviral activity, selectivity, cross-resistance, and combination activity, as well as pharmacokinetic properties, were determined. In multiple GT1a and GT1b replicon cell lines, GS-9451 had mean 50% effective concentrations (EC50s) of 13 and 5.4 nM, respectively, with minimal cytotoxicity; similar potency was observed in chimeric replicons encoding the NS3 protease gene of GT1 clinical isolates. GS-9451 was less active in GT2a replicon cells (EC50 = 316 nM). Additive to synergistic in vitro antiviral activity was observed when GS-9451 was combined with other agents, including alpha interferon, ribavirin, and the polymerase inhibitors GS-6620 and tegobuvir (GS-9190), as well as the NS5A inhibitor ledipasvir (GS-5885). GS-9451 retained wild-type activity against multiple classes of NS5B and NS5A inhibitor resistance mutations. GS-9451 was stable in hepatic microsomes and hepatocytes from human and three other tested species. Systemic clearance was low in dogs and monkeys but high in rats. GS-9451 showed good oral bioavailability in all three species tested. In rats, GS-9451 levels were \\u223c40-fold higher in liver than plasma after intravenous dosing, and elimination of GS-9451 was primarily through biliary excretion. Together, these results are consistent with the antiviral activity observed in a recent phase 1b study. The results of in vitro cross-resistance and combination antiviral assays support the ongoing development of GS-9451 in combination with other agents for the treatment of chronic HCV infection.\",\"Chronic Hepatitis C virus (HCV) infection is a major pandemic. The current standard of care includes peginterferon and ribavirin plus one of two protease inhibitors, boceprevir and telaprevir, for Genotype 1 patients and peginterferon and ribavirin for all other genotypes. The treatment landscape is rapidly evolving as a number of direct-acting antivirals (DAA) are being developed in clinical trials.\",\"Presently the development of new therapies for hepatitis C virus (HCV) is rapidly moving forward. Almost every week new data appear on how direct acting antivirals (DAAs) succeed or fail in clinical trials. Despite the potency of many of the DAA combinations, the effect exerted by ribavirin (RBV) is still needed for an effective therapy in many new DAA combinations. Due to the strong antiviral effect of DAAs, it is likely that a major complementary therapeutic effect exerted by RBV is immune modulation resulting in an increased barrier to development of resistance. For HCV genotype 1a infections elimination of pegylated interferon, is not possible in many DAA combinations without jeopardizing the results. The host immune response is thus likely to play a key role even during DAA-based therapies. Hence, T cells may recognize and eliminate viral variants with resistance to the DAAs. We herein show several examples where this may be the case, supporting the rationale of including the host response also in the new therapeutic regimens. This review will describe the potential benefits of combining various DAAs with means to activate the specific immune response against HCV.\",\"The HCV RNA-dependent RNA polymerase is an essential enzyme in HCV viral replication and has been a prominent target in the search for therapies to treat individuals infected with HCV. The development of both nucleoside and nucleotide HCV inhibitors has been pursued because of their potential for showing pangenotypic activity and because of their high barrier to resistance. Even though nucleoside inhibitors were shown to be effective in a clinical setting, their potency limited their effectiveness. The exploitation of prodrug strategies to deliver nucleoside 5'-monophosphates has resulted in the development of a number of very potent inhibitors of HCV replication. In addition, several of these nucleotide prodrugs have demonstrated liver-targeting characteristics when administered orally. Human clinical studies have shown that a number of nucleotide prodrugs are potent inhibitors of viral replication leading to significant reductions in viral load when given orally. Combinations of these nucleotide prodrugs with either pegylated interferon-\\u03b1 and ribavirin or another direct acting antiviral alone has lead to cure rates as high as 100% after only 12 weeks of therapy. The combination of a nucleotide prodrug and another direct-acting antiviral agent holds the promise of delivering an interferon-free therapy for HCV patients thus eliminating the undesirable side effects associated with taking interferon.\",\"Faldaprevir (BI 201335) is a selective NS3/4A protease inhibitor under development for the treatment of chronic hepatitis C virus (HCV) infection. NS3/4A genotyping and NS3 protease phenotyping analyses were performed to monitor the emergence of resistance in patients with HCV genotype 1 infection receiving faldaprevir alone or combined with pegylated interferon alfa 2a and ribavirin (PegIFN-RBV) during a phase 1b study. Among all baseline variants, a maximum 7-fold reduction in in vitro sensitivity to faldaprevir was observed for a rare NS3 (V/I)170T polymorphism. During faldaprevir monotherapy in treatment-naive patients, virologic breakthrough was common (77%, 20/26) and was associated with the emergence of resistance mutations predominantly carrying NS3 substitutions R155K in GT1a and D168V in GT1b. D168V conferred a greater reduction in faldaprevir sensitivity (1,800-fold) than R155K (330-fold); however, D168V was generally less fit than R155K in the absence of selective drug pressure. Treatment-experienced patients treated with faldaprevir-PegIFN-RBV triple therapy showed higher viral load reductions, lower rates of breakthrough (8%, 5/62), and less frequent emergence of resistance-associated variants compared with faldaprevir monotherapy. (This study has been registered at ClinicalTrials.gov under registration no. NCT00793793.).\",\"GS-5885 is a novel hepatitis C virus (HCV) NS5A inhibitor. In a 3-day monotherapy study in treatment-naive genotype 1a (GT1a) and GT1b HCV-infected subjects, median viral load reductions ranged from 2.3 to 3.3 log10 HCV RNA IU/ml across dosing cohorts (1, 3, 10, 30, or 90 mg once daily). Here, we report viral sequencing and phenotypic analysis of clinical isolates from this study. Detection of baseline NS5A amino acid substitutions at positions 28, 30, 31, or 93 in GT1a was associated with a reduced treatment response. In the GT1b cohort, Y93H was detected in 100% of subjects at day 4 or 14. In the Gt1a cohort, population sequencing detected NS5A resistance-associated mutations at day 4 or 14 for 3/10 subjects at the 1-mg dose and for all subjects dosed at \\u22653 mg. A subset of mutants that confer a low level of reduced susceptibility to GS-5885 was not detected by population sequencing at the 30- and 90-mg doses. Subject-derived M28T, Q30R, L31M, and Y93C mutations all conferred >30-fold reductions in GS-5885 and daclatasvir susceptibilities in vitro. Site-directed NS5A mutants also showed reduced susceptibility to GS-5885. However, all NS5A mutants tested remained fully susceptible to other classes of direct-acting antivirals (DAAs), interferon alpha, and ribavirin. Importantly, the nonoverlapping resistance profile and high potency of GS-5885 support its further development with other direct-acting antivirals for the treatment of chronic HCV. (This study has been registered at ClinicalTrials.gov under registration number NCT01193478.).\",\"The addition of protease inhibitors, boceprevir or telaprevir, to peginterferon+ribavirin (PegIFN/RBV) increases the frequency as well as the severity, and hence, clinical relevance of anemia, which has now become one of the major complications associated with triple therapy. Most significant factors associated with anemia in patients receiving triple therapy include older age, lower body mass index (BMI), advanced fibrosis, and lower baseline hemoglobin. The variability in inosine triphosphate pyrophosphatase (ITPA) gene, which encodes a protein that hydrolyses inosine triphosphate (ITP), has been identified as an essential genetic factor for anemia both in dual and triple therapy. The correct management of anemia is based on anticipation, characterization and therapeutic management. Basically, anemia can be characterized in 3 types: ferropenic (mostly in fertile women), thalassemic type hemolytic anemia, and anemia from chronic processes. Functional deficit of iron should also be excluded in patients with normal ferritin and lower saturation of transferrin. Ribavirin dose reduction and epoetin, sequentially, are indicated in the management of anemia. Epoetin non-response can be caused by lack of time, type of anemia, functional iron deficit or erythropoietin resistance. In the transplantation setting, adding a protease inhibitor to PegIFN/RBV results in a significant increase in the incidence and severity of anemia and, as a consequence, a greater need for epoetin, transfusions, and ribavirin dose reductions. Packed red cell transfusions are utilized when hemoglobin decreases to less than 7.5g/dl and/or there are clinical symptoms and/or there is no response to other therapeutic measures.\",\"More than two decades of intense research has provided a detailed understanding of hepatitis C virus (HCV), which chronically infects 2% of the world's population. This effort has paved the way for the development of antiviral compounds to spare patients from life-threatening liver disease. An exciting new era in HCV therapy dawned with the recent approval of two viral protease inhibitors, used in combination with pegylated interferon-\\u03b1 and ribavirin; however, this is just the beginning. Multiple classes of antivirals with distinct targets promise highly efficient combinations, and interferon-free regimens with short treatment duration and fewer side effects are the future of HCV therapy. Ongoing and future trials will determine the best antiviral combinations and whether the current seemingly rich pipeline is sufficient for successful treatment of all patients in the face of major challenges, such as HCV diversity, viral resistance, the influence of host genetics, advanced liver disease and other co-morbidities.\",\"Hepatitis C virus (HCV) is one of the foremost causes of chronic liver disease affecting over 300 million globally. HCV contains a positive-stranded RNA of ~9600 nt and is surrounded by the 5' and 3'untranslated regions (UTR). The only successful treatment regimen includes interferon (IFN) and ribavirin. Like many other viruses, HCV has also evolved various mechanisms to circumvent the IFN response by blocking (1) downstream signaling actions via STAT1, STAT2, IRF9 and JAK-STAT pathways and (2) repertoire of IFN Stimulatory Genes (ISGs). Several studies have identified complex host demographic and genetic factors as well as viral genetic heterogeneity associated with outcomes of IFN therapy. The genetic predispositions of over 2000 ISGS may render the patients to become resistant, thus identification of such parameters within a subset of population are necessary for management corollary. The ability of various HCV genotypes to diminish IFN antiviral responses plays critical role in the establishment of chronic infection at the acute stage of infection, thus highlighting importance of the resistance in HCV treated groups. The recently defined role of viral protein such as C, E2, NS3/NS4 and NS5A proteins in inducing the IFN resistance are discussed in this article. How the viral and host genetic composition and epistatic connectivity among polymorphic genomic sites synchronizes the evolutionary IFN resistance trend remains under investigation. However, these signals may have the potential to be employed for accurate prediction of therapeutic outcomes. In this review article, we accentuate the significance of host and viral components in IFN resistance with the aim to determine the successful outcome in patients.\",\"Combination of several direct-acting antiviral agents will be necessary to overcome viral resistance in interferon-free treatment regimens for chronic HCV infection. HCV p7 inhibitors may be part of such combination regimens. Understanding why amantadine, despite showing inhibition of HCV p7 in vitro, appears ineffective in clinical trials, may help in the design of novel HCV p7 inhibitors. So far it is unknown whether viral escape mutations within HCV p7 explain the ineffectiveness of amantadine in vivo.\",\"Respiratory syncytial virus (RSV) is a highly contagious pathogen that infects mainly ciliated cells of respiratory epithelium and type 1 pneumocytes in the alveoli frequently causing serious respiratory disease in infants, elderly, and immunocompromised patients. At present, prevention/treatment of RSV infection is limited to the use of specific anti-RSV antibody or an aerosol formulation of ribavirin, a drug of suboptimal efficacy and low safety profile. There is an urgent need for development of novel anti-RSV drugs and virucides. Here we describe the cell culture-based methods used in our laboratory in identification of novel inhibitors of RSV including the P13 fusion inhibitor, and the PG545 virucide. Protocols for antiviral screening, evaluation of anti-RSV potency, and elucidation of mode of antiviral activity of test compounds are described.\",\"The current standard of care (SOC) for hepatitis C virus (HCV) genotype 1-infected patients consists of telaprevir or boceprevir in addition to pegylated interferon and ribavirin treatment. Other selective inhibitors of HCV replication are being developed. Drug pressure may, depending on the class of inhibitors, (rapidly) select for drug-resistant variants. Here we describe four different approaches to select in vitro for drug-resistant HCV subgenomic replicons.\",\"Asunaprevir is a selective NS3 protease inhibitor with in vitro activity against HCV genotypes 1 and 4.\",\"RNA viruses, such as hepatitis C virus (HCV), have markedly error-prone replication, resulting in high rates of mutagenesis. In addition, the standard treatment includes ribavirin, a base analog that is likely to cause mutations in different regions of the HCV genome, resulting in deleterious effects on HCV itself. The N-terminal region of the core protein is reported to block interferon (IFN) signaling by interaction with the STAT1\\u2011SH2 domain, resulting in HCV resistance to IFN therapy. In this study, mutations in the HCV core protein from IFN/ribavirin\\u2011treated patients were analyzed, with particular focus on the N\\u2011terminal domain of the HCV core which is reported to interact with STAT1. HCV PCR positive patients enrolled in this study were either undergoing pegylated IFN/ribavirin bitherapy and had completed 12 weeks of initial treatment or were treatment\\u2011na\\u00efve patients. The HCV core protein was cloned and sequenced from these patients and mutations observed in the STAT1\\u2011interacting domain of the core protein from treated patients were characterized using in silico interaction to depict the role of these mutations in disease outcomes. Our results suggest that the amino acids at positions 2, 3, 8, 16 and 23 of the HCV core protein are critical for core-STAT1 interaction and ribavirin-induced mutations at these positions interfere with the interaction, resulting in a better response of the treated patients. In conclusion, this study anticipates that HCV core residues 2, 3, 8, 16 and 23 directly interact with STAT1. We propose that IFN/ribavirin bitherapy\\u2011induced mutations in the STAT1\\u2011interacting domain of the HCV core protein may be responsible for the improved therapeutic response and viral clearance, thus amino acids 1-23 of the N-terminus of the core protein are an ideal antiviral target. However, this treatment may give rise to resistant variants that are able to escape the current therapy. We propose similar studies in responsive and non-responsive genotypes in order to gain a broader picture of this proposed mechanism of viral clearance.\",\"Many challenges exist for the study of HCV in the laboratory. Therapy using interferon (IFN) is expensive, not well tolerated and ineffective for many patients. HCV research has been hampered by the lack of a robust tissue culture system, but recent advances have made virus growth in culture possible. Cell culture systems using genetically engineered viruses have been reviewed extensively, but here we review recent advances made in the use of natural isolates and the molecular challenges that have been used to overcome the limitations in their growth. Six major genotypes have been identified for HCV that are further divided into numerous subtypes. Combination therapy utilizing IFN-\\u03b1 and ribavirin is the standard of care, but is successful in only one-half of patients. The reasons for IFN resistance may be viral- or host-related and may be due to multiple factors. Recently, telaprevir and boceprevir, together with IFN-\\u03b1 and ribavirin, have been added to the standard of care in patients infected with IFN-resistant genotypes. A major obstacle in the development of effective vaccines and improved therapeutics has been the lack of a reproducible and efficient tissue culture system for propagation of HCV. Many cell culture systems have used genetically-engineered viruses to gain growth in culture through the use of replicons, but recent advances using natural isolates may improve the outlook for progress in HCV research.\",\"Host cell lipid rafts form a scaffold required for replication of hepatitis C virus (HCV). Serine palmitoyltransferases (SPTs) produce sphingolipids, which are essential components of the lipid rafts that associate with HCV nonstructural proteins. Prevention of the de novo synthesis of sphingolipids by an SPT inhibitor disrupts the HCV replication complex and thereby inhibits HCV replication. We investigated the ability of the SPT inhibitor NA808 to prevent HCV replication in cells and mice.\",\"Colorectal cancer cells exhibit limited cytotoxicity towards Tiazofurin, a pro-drug metabolized by cytosolic nicotinamide mononucleotide adenylyltransferase2 (NMNAT2) to thiazole-4-carboxamide adenine dinucleotide, a potent inhibitor of inosine 5'-monophosphate dehydrogenase required for cellular guanylate synthesis. We tested the hypothesis that colorectal cancer cells that exhibit low levels of NMNAT2 and are refractory to Tiazofurin can be rendered sensitive to Tiazofurin by overexpressing NMNAT2. Transfection of hNMNAT2 resulted in a six- and threefold cytoplasmic overexpression in Caco2 and HT29 cell lines correlating with Tiazofurin-induced enhanced cell-kill. Folate receptors expressed on the cell surface of 30-50% colorectal carcinomas were exploited for cellular targeting with Tiazofurin encapsulated in folate-tethered nanoparticles. Our results indicated that in wild-type colorectal cancer cells, free Tiazofurin-induced EC50 cell-kill was 1500-2000 \\u03bcM, which was reduced to 66-156 \\u03bcM in hNMNAT2-overexpressed cells treated with Tiazofurin encapsulated in non-targeted nanoparticles. This efficacy was improved threefold by encapsulating Tiazofurin in folate-tethered nanoparticles to obtain an EC(50) cell-kill of 22-59 \\u03bcM, an equivalent of 100-300 mg m(-2) (one-tenth of the approved dose of Tiazofurin in humans), which will result in minimal toxicity leading to cancer cell-kill. This proof-of-principle study suggests that resistance of colorectal cancer cell-kill to Tiazofurin can be overcome by sequentially overexpressing hNMNAT2 and then facilitating the uptake of Tiazofurin by folate-tethered nanoparticles, which enter cells via folate receptors.\",\"Vaniprevir with P/R improved SVR rates over P/R alone in treatment-experienced patients with chronic HCV-genotype 1 infection, but treatment failure presents therapeutic challenges. We identified RAVs from non-cirrhotic patients failing to achieve SVR on vaniprevir-containing regimens from a dose/duration-ranging trial of triple-combination therapy.\",\"Vaniprevir is a competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease that has potent anti-HCV activity in preclinical models. This placebo-controlled dose-ranging study assessed the safety, tolerability, and antiviral efficacy of vaniprevir monotherapy in patients with genotype 1 chronic HCV infection. Treatment-naive and treatment-experienced non-cirrhotic adult patients with baseline HCV RNA >10(6)IU/ml were randomized to receive placebo or vaniprevir at doses of 125 mg qd, 600 mg qd, 25mg bid, 75 mg bid, 250 mg bid, 500 mg bid, and 700 mg bid for 8 days. Forty patients (82.5% male, 75% genotype 1a) received at least one dose of placebo or vaniprevir. After 1 week of vaniprevir, the decrease in HCV RNA from baseline ranged from 1.8 to 4.6 log10IU/ml across all treatment groups, and there was a greater than dose-proportional increase in vaniprevir exposure at doses above 75 mg bid. The most commonly reported drug-related adverse events (AEs) were diarrhea (n=5) and nausea (n=5). No pattern of laboratory or ECG abnormalities was observed, all AEs resolved during the study, and there were no discontinuations due to AEs. No serious AEs were reported. Resistance-associated amino acid variants were identified at positions R155 and D168 in patients infected with genotype 1a virus. Vaniprevir monotherapy demonstrated potent antiviral activity in patients with chronic genotype 1 HCV infection, and was generally well tolerated with no serious AEs or discontinuations due to AEs. Further development of vaniprevir, including studies in combination with other anti-HCV agents, is ongoing.\",\"The introduction of direct-acting anti-virals has increased sustained virological response (SVR) rates in chronic hepatitis C genotype 1 infection. At present, data on long-term durability of viral eradication after successful triple therapy are lacking.\",\"Suppressor of cytokine signaling-1 (SOCS-1) is a negative regulator of the Janus kinase/signal transducer and activation of transcription pathway. The purpose of this study was to investigate the relationship between methylation of SOCS-1 and sustained virologic response (SVR) in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN)-alpha and ribavirin (RBV).\",\"Telaprevir (TVR) is a protease inhibitor (PI) used in chronic hepatitis C treatment with pegylated interferon plus ribavirin. We analysed the prevalence and kinetic development of TVR resistance upon treatment.\",\"We investigated the association between hepatic steatosis and hepatic expression of genes involved in innate immunity, both of which are reportedly associated with resistance to peginterferon (PEG-IFN) and ribavirin combination therapy for hepatitis C virus (HCV) infection.\",\"There is evidence that natural killer (NK) cells help control persistent viral infections including hepatitis C virus (HCV). The phenotype and function of blood and intrahepatic NK cells, in steady state and after interferon (IFN) \\u03b1 treatment has not been fully elucidated.\",\"Hepatitis C virus (HCV) infection is a global health concern with chronic liver damage threatening 3% of the world's population. To date, the standard of care is a combination of pegylated interferon-alpha with ribavirin, and recently two direct acting antivirals have entered the clinics. However, because of side effects, drug resistance and viral genotype-specific differences in efficacy current and potentially also future therapies have their limitations. Here, we describe the development of a phenotypic high-throughput assay to identify new cross-genotype inhibitors with novel mechanism of action, by combining a genotype (gt) 1 replicon with the infectious HCV gt2 cell culture system. To develop this phenotypic multiplex assay, HCV reporter cells expressing RFP-NLS-IPS and gt1b replicon cells expressing NS5A-GFP were co-plated and treated with compounds followed by inoculation with gt2a HCV. At 72h post treatment, RFP translocation as a marker for HCV infection and GFP fluorescence intensity as a marker for gt1 RNA replication were measured. Additionally, the total cell number, which serves as an indicator of cytotoxicity, was determined. This phenotypic strategy supports multi-parameter data acquisition from a single well to access cross-genotypic activity, provides an indication of the stage of the viral life cycle targeted, and also assesses compound cytotoxicity. Taken together, this multiplex phenotypic platform facilitates the identification of novel compounds for drug development and chemical probes for continuing efforts to understand the HCV life cycle.\",\"HCV (hepatitis C virus) infection affects an estimated 180 million people in the world's population. Adverse effects occur frequently with current standard treatment of interferon and ribavirin, while resistance of new direct anti-viral agents, NS3 protease inhibitors, is a major concern because of their single anti-HCV mechanism against the viral factor. New anti-viral agents are needed to resolve the problems. Amiodarone, an anti-arrhythmic drug, has recently been shown to inhibit HCV infection in vitro. The detailed mechanism has yet to be clarified. The aim of the present study was to elucidate the molecular mechanism of the inhibitory effect of amiodarone on HCV life cycle. The effect of amiodarone on HCV life cycle was investigated in Huh-7.5.1 cells with HCVcc (cell culture-derived HCV), HCVpp (HCV pseudoviral particles), sub-genomic replicons, IRES (internal ribosomal entry site)-mediated translation assay, and intracellular and extracellular infectivity assays. The administration of amiodarone appeared to inhibit HCV entry independent of genotypes, which was attributed to the down-regulation of CD81 receptor expression. The inhibitory effect of amiodarone also manifested in the HCV assembly step, via the suppression of MTP (microsomal triacylglycerol transfer protein) activity. Amiodarone revealed no effects on HCV replication and translation. With the host factor-targeting characteristics, amiodarone may be an attractive agent for the treatment of HCV infection.\",\"Genetic polymorphisms observed in various disease states associated with sensitivity or resistance to specific treatments have been a robust area of investigation for decades, with the potential to allow clinicians to make evidence-based decisions on the appropriate course of treatment. This study aimed to evaluate whether genetic polymorphisms of the signal transducer and activator of transcription 6 gene (STAT6) could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFN\\u03b1-RBV). We analyzed the associations between SVR to PEG-IFN\\u03b1-RBV therapy and 4 single nucleotide polymorphisms (SNPs) in STAT6. This study included Taiwanese Chinese patients infected with either HCV-1 (n = 265) or HCV-2 (n = 195) in the presence or absence of an SVR. Among the STAT6 SNPs examined, the dosage effect of the A allele and allele frequency in rs1059513 were inversely correlated with SVR in patients infected with HCV-1 (P = 0.0179 and P = 0.0235, respectively). This effect was not observed in patients infected with HCV-2. The GG, GGG, and GGGC STAT6 haplotypes comprising 2, 3, and 4 SNPs (rs1059513, rs703817, rs324015, and rs3024974) were found to be associated with SVR, and their presence may increase the probability of a successful treatment outcome in patients infected with HCV-1 (P = 0.0273, 0.0352, and 0.0368, respectively). Moreover, a multivariate logistic regression model for predicting an SVR revealed that the presence of the GGGC haplotype carriers mutually affected the outcome of PEG-IFN\\u03b1-RBV treatment. The presence of STAT6 SNPs and the association with SVR demonstrated that STAT6 polymorphisms might influence the therapeutic outcomes of patients infected with HCV-1 under standard-of-care (SOC) treatment.\",\"Study C209 evaluated the activity of telaprevir in treatment-na\\u00efve patients with genotypes 2 or 3 (G2, G3) hepatitis C virus (HCV) infection. Telaprevir monotherapy showed potent activity against HCV G2, but limited activity against G3. This analysis was performed to characterize HCV viral variants emerging during telaprevir-based treatment of G2/G3 HCV-infected patients. Patients were randomized to receive 2 weeks of treatment with telaprevir (telaprevir monotherapy), telaprevir plus peginterferon alfa-2a and ribavirin (triple therapy), or placebo plus peginterferon alfa-2a and ribavirin (control), followed by 22-24 weeks of peginterferon/ribavirin alone. Viral breakthrough was defined as an increase >1 log10 in HCV RNA from nadir, or HCV RNA >100 IU/mL in patients previously reaching <25 IU/mL. Twenty-three patients (47%) had G2 and 26 (53%) had G3 HCV. Viral breakthrough occurred during the initial 2-week treatment phase in six G2 patients (66.7%; subtypes 2, 2a and 2b) and three G3 patients (37.5%; all subtype 3a), all in the telaprevir monotherapy arm. Four breakthrough patients (three G2, one G3) subsequently achieved sustained virologic response (SVR). In all patients with breakthrough and available sequence data, mutations associated with reduced susceptibility to telaprevir in genotype 1 (G1) HCV were observed. No novel G2/G3-specific mutations were associated with telaprevir resistance. The telaprevir resistance profile appeared consistent across HCV genotypes 1, 2 and 3. Although viral breakthrough with resistance occurred in patients receiving telaprevir monotherapy, half of these patients achieved an SVR upon addition of peginterferon/ribavirin highlighting the importance of combination therapy.\",\"Achievement of early viral suppression is important in patients with chronic HCV infection treated with telaprevir (TLV) or boceprevir (BOC) to avoid selection of drug resistance and attain cure. No head-to-head studies comparing TLV and BOC have been performed so far.\",\"Cell culture-produced hepatitis C virus (HCV) has been subjected to up to 100 serial passages in human hepatoma cells in the absence or presence of different doses of alpha interferon (IFN-\\u03b1). Virus survival, genetic changes, fitness levels, and phenotypic traits have been examined. While high initial IFN-\\u03b1 doses (increasing from 1 to 4 IU/ml) did not allow HCV survival beyond passage 40, a gradual exposure (from 0.25 to 10 IU/ml) allowed the virus to survive for at least 100 passages. The virus passaged in the presence of IFN-\\u03b1 acquired IFN-\\u03b1 resistance as evidenced by enhanced progeny production and viral protein expression in an IFN-\\u03b1 environment. A partial IFN-\\u03b1 resistance was also noted in populations passaged in the absence of IFN-\\u03b1. All lineages acquired adaptative mutations, and multiple, nonsynonymous mutations scattered throughout the genome were present in IFN-\\u03b1-selected populations. Comparison of consensus sequences indicates a dominance of synonymous versus nonsynonymous substitutions. IFN-\\u03b1-resistant populations displayed decreased sensitivity to a combination of IFN-\\u03b1 and ribavirin. A phenotypic trait common to all assayed viral populations is the ability to increase shutoff host cell protein synthesis, accentuated in infections with IFN-\\u03b1-selected populations carried out in the presence of IFN-\\u03b1. The trait was associated with enhanced phosphorylation of protein kinase R (PKR) and eIF2\\u03b1, although other contributing factors are likely. The results suggest that multiple, independent mutational pathways can confer IFN-\\u03b1 resistance to HCV and might explain why no unified picture has been obtained regarding IFN-\\u03b1 resistance in vivo.\",\"Several HCV polymerase inhibitors are in advanced stages of clinical development. They are nucleos(t)ide and non-nucleoside analogs. Nucleos(t)ides inhibit viral replication acting as chain terminators whereas non-nucleosides block allosterically the HCV polymerase. Sofosbuvir is an uridine analog and currently the most promising HCV polymerase inhibitor, being active across all HCV genotypes. It has good tolerability and a robust barrier to resistance. In contrast, non-nucleoside analogs have low to moderate antiviral potency, a low barrier to resistance and inhibit only HCV genotype 1.\",\"The clinical correlation between hepatitis C virus (HCV) NS5A gene mutations and response to antiviral treatment in HCV-3a-infected patients is not as well known as that in HCV-1a-infected and HCV-1b-infected patients.\",\"Considering the similarities between the transcriptional programming involved in cancer progression and somatic cell reprogramming, we tried to identify drugs that would be effective against malignant cancers. We used the early transposon Oct4 and Sox2 enhancer (EOS) system to select human prostate cancer (PCA) cells expressing high levels of OCT4. Patients with metastatic castration-resistant PCA that does not respond to treatment with docetaxel have few therapeutic options. The OCT4-expressing PCA cells selected using the EOS system showed increased tumorigenicity and high resistance to docetaxel, both in vitro and in vivo. By using their gene expression data, expression signature-based prediction for compound candidates identified an antiviral drug, ribavirin, as a conversion modulator from drug resistance to sensitivity. Treatment of PCA cells with ribavirin decreased their resistance against treatment with docetaxel. This indicated that ribavirin reversed the gene expression, including that of humoral factors, in the OCT4-expressing PCA cells selected using the EOS system. Thereby, ribavirin increased the efficacy of docetaxel for cancer cells. We propose a novel cell reprogramming approach, named drug efficacy reprogramming, as a new model for identifying candidate antitumor drugs.\",\"The hepatitis C virus (HCV) infects an estimated 150 million people worldwide and is the major cause of viral hepatitis, cirrhosis, and liver cancer. The available antiviral therapies, which include PEGylated interferon, ribavirin, and one of the HCV NS3/4A protease inhibitors telaprevir or boceprevir, are ineffective for some patients and cause severe side effects. More potent NS3/4A protease inhibitors are in clinical development, but the long-term effectiveness of these drugs is challenged by the development of drug resistance. Here, we investigated the role of macrocycles in the susceptibility of NS3/4A protease inhibitors to drug resistance in asunaprevir, danoprevir, vaniprevir, and MK-5172, with similar core structures but varied P2 moieties and macrocyclizations. Linear and macrocyclic analogues of these drugs were designed, synthesized, and tested against wild-type and drug-resistant variants R155K, V36M/R155K, A156T, and D168A in enzymatic and antiviral assays. Macrocyclic inhibitors were generally more potent, but the location of the macrocycle was critical for retaining activity against drug-resistant variants: the P1-P3 macrocyclic inhibitors were less susceptible to drug resistance than the linear and P2-P4 macrocyclic analogues. In addition, the heterocyclic moiety at P2 largely determined the inhibitor resistance profile, susceptibility to drug resistance, and the extent of modulation by the helicase domain. Our findings suggest that to design robust inhibitors that retain potency to drug-resistant NS3/4A protease variants, inhibitors should combine P1-P3 macrocycles with flexible P2 moieties that optimally contact with the invariable catalytic triad of this enzyme.\",\"Using ultra-deep sequencing technology, the present was designed to investigate whether the emergence of telaprevir-resistant variants (amino acid substitutions of aa36, aa54, aa155, aa156, and aa170 positions in HCV NS3 region) after commencement of triple therapy of telaprevir/peginterferon (PEG-IFN)/ribavirin could be predicted at baseline in previous non-responders to dual therapy. Fourteen patients infected with HCV genotype 1 who did not respond to previous PEG-IFN/ribavirin, received a 24-week regimen of triple therapy, and were evaluated for appearance of telaprevir-resistant variants (amino acid substitutions of more than 0.2% among the total coverage) by ultra-deep sequencing. The sustained virological response rate was 28.6% (4 of 14 patients), which was significantly higher in patients with Arg70 (substitution at core aa70) and partial response (type of previous response to PEG-IFN/ribavirin) than in other patients. Telaprevir-resistant variants at baseline were detected in 7.1% (1 of 14 patients) by direct sequencing and in 21.4% (3 of 14 patients) by ultra-deep sequencing. The appearance of telaprevir-resistant variants was examined by ultra-deep sequencing in 10 who did not show sustained virological responders. De novo variants emerged at re-elevation of viral load, regardless of variant frequencies at baseline (one patient with very high frequency variants [T54S: 99.9%], two patients with very low frequency variants [V36A: 0.2%; and V170A: 0.4%], and seven patients of undetectable variants). It is concluded that it is difficult to predict at baseline the emergence of telaprevir-resistant variants after commencement of triple therapy in prior non-responders of HCV genotype 1, even with the use of ultra-deep sequencing.\",\"Foot-and-mouth disease (FMD) is a highly contagious disease of livestock caused by a highly variable RNA virus (FMDV) that has seven serotypes and more than sixty subtypes. Both prophylactic and post-infection means of controlling the disease outbreak, including universally applicable vaccines and emergency response measures such as therapeutic treatments, are on high demand. In this study, we analyzed the long-term exposure outcome to a previously identified inhibitor of 3D polymerase (FMDV 3Dpol) for controlling FMDV infection and for the selection of resistance mutants. The results showed that no escape mutant viruses were isolated from FMDV A24 Cruzeiro infections in cell culture treated with gradually increasing concentrations of the antiviral compound 5D9 (4-chloro-N'-thieno, [2,3-d]pyrimidin-4-ylbenzenesulfonohydrazide) over ten passages. Biochemical and plaque assays revealed that when 5D9 was used at concentrations within a non-toxic range in cells, it drove the virus to undetectable levels at passage eight to ten. This is in contrast with observations made on parallel control (untreated) passages exhibiting fully viable and stable virus progenies. Collectively, the results demonstrated that under the experimental conditions, treatment with 5D9 does not confer a resistant phenotype and the virus is unable to evade the antiviral effect of the inhibitor. Further efforts using quantitative structure-property relationship (QSPR) based modifications of the 5D9 compound may result in the successful development of an effective in vivo antiviral drug targeting FMDV.\",\"Even though new drugs have been approved for treatment of hepatitis C virus (HCV) infection, the risk of drug-drug interactions and concern about overlapping toxicities has hindered the development of studies in HIV/HCV-coinfected individuals. Traditional treatment with pegylated interferon plus ribavirin (peg-IFN + RBV) is very expensive and has a low rate of sustained virological response in coinfected patients, especially if they are infected with HCV genotype 1. Nitazoxanide (NTZ) is a drug that is being evaluated for the treatment of chronic HCV infection, both in HCV-monoinfected and HIV/HCV-coinfected patients. Understanding the NTZ resistance mechanism could allow the development of resistance to be minimized and would expand the treatment options, mainly in special populations such as HIV/HCV-coinfected patients. Similarly to IFN, NTZ increases the activity of the cellular protein kinase activated by double-stranded RNA (PKR), a key kinase in the innate antiviral response. In order to elucidate whether sequence heterogeneity in the PKR-binding domain of HCV NS5A genotype 1 could influence the antiviral activity of either NTZ monotherapy or peg-IFN + RBV, baseline and end-of-therapy plasma samples from two groups of eleven non-responder HIV/HCV-coinfected patients that had received NTZ or peg-IFN + RBV were studied. Most of the HCV NS5A sequences examined at the end of therapy did not change from the baseline, even after 30 days course of antiviral therapy. An extensive comparison of HCV NS5A genotype 1 and 4 sequences from the database with reported IFN therapy outcome was performed in order to infer their phylogenetic relationships. The HCV genotype 1 NS5A nucleotide sequences from therapy-non-responder patients were intermingled amongst those from the database, irrespective of their IFN-therapy outcome. When comparing NS5A-PKRBD amino acid sequences, significant differences were observed in genotype 4, but not in genotype 1 (p < 0.0001 and p > 0.05, respectively). In conclusion, despite IFN and NTZ sharing the protein kinase activated by double-stranded RNA as their cellular target, the HCV genotype 1 strategy to counteract the IFN action mediated by NS5A ISDR/PKRBD does not explain drug resistance in HIV/HCV-coinfected patients. Other viral factors that are possibly involved are discussed as well.\",\"This article provides an unbiased review of the pharmacokinetic, pharmacodynamic, and drug-drug interaction data of telaprevir, an NS3/4A protease inhibitor. Telaprevir is well absorbed with fatty food, moderately protein bound (59-76 %) with a large volume of distribution (~252 L), primarily metabolized by cytochrome P450 (CYP) 3A4 and P-glycoprotein, and is largely excreted into feces. Pharmacokinetic and pharmacodynamic parameters are well described in healthy subjects and individuals infected with hepatitis C virus (HCV), although only limited data are available in specific patient subpopulations. Telaprevir is recommended to be given at 750 mg by mouth every 8 h for 12 weeks, in combination with peginterferon and ribavirin (the standard care). The addition of telaprevir to the standard care regimen results in increased sustained virological response in treatment-na\\u00efve patients (30 %) and treatment-experienced patients (up to 50 %), and works synergistically to lower viral resistance. Telaprevir is a substrate and/or inhibitor of CYP3A4 and P-glycoprotein, and drug-drug interaction studies in humans have focused on these pathways. Based on our analysis, a few reported drug-drug interactions may be classified as clinically significant, but more experiments under dosing conditions that resemble those given in the clinic are needed to understand the relevance of some of the reported interactions. Future studies should focus on the pharmacokinetics/pharmacodynamics of telaprevir in special populations or patients with concomitant conditions that will likely co-exist with HCV infection, with an emphasis on establishing pharmacokinetic-pharmacodynamic relationships. In vitro characterization of other phase 1-3 metabolic pathways could assist in elucidating the mechanisms of the drug-drug interactions observed in humans.\",\"Ribavirin (RBV) is often used in conjunction with interferon-based therapy for patients with chronic hepatitis C. There is a drastic difference in the anti-hepatitis C virus (HCV) activity of RBV between the HuH-7-derived assay system, OR6, possessing the RBV-resistant phenotype (50% effective concentration [EC50 ]: >100 \\u00b5M) and the recently discovered Li23-derived assay system, ORL8, possessing the RBV-sensitive phenotype (EC50 : 8 \\u00b5M; clinically achievable concentration). This is because the anti-HCV activity of RBV was mediated by the inhibition of inosine monophosphate dehydrogenase in RBV-sensitive ORL8 cells harboring HCV RNA. By means of comparative analyses using RBV-resistant OR6 cells and RBV-sensitive ORL8 cells, we tried to identify host factor(s) determining the anti-HCV activity of RBV. We found that the expression of adenosine kinase (ADK) in ORL8 cells was significantly higher than that in RBV-resistant OR6 cells harboring HCV RNA. Ectopic ADK expression in OR6 cells converted them from an RBV-resistant to an RBV-sensitive phenotype, and inhibition of ADK abolished the activity of RBV. We showed that the differential ADK expression between ORL8 and OR6 cells was not the result of genetic polymorphisms in the ADK gene promoter region and was not mediated by a microRNA control mechanism. We found that the 5' untranslated region (UTR) of ADK messenger RNA in ORL8 cells was longer than that in OR6 cells, and that only a long 5' UTR possessed internal ribosome entry site (IRES) activity. Finally, we demonstrated that the long 5' UTR functioned as an IRES in primary human hepatocytes.\",\"Lipid pathway impairment, decrease in the antioxidant pool and downregulation in amino-acid metabolism are just some of the metabolic variations attributed to chronic HCV infection. All of them have been studied separately, mainly in animal models. Thanks to proteomic analysis we managed to describe (for the fist time to the best of our knowledge), in vivo and in humans, the metabolic alterations caused by HCV, and the recovery of the same alterations during HCV treatment. We performed proteomic analysis on liver specimens of a 28-year-old woman affected by hepatitis C genotype 1a, alcoholism and diabetes mellitus type 1, before and after antiviral treatment with pegylated interferon alpha 2b and ribavirin. The subject, thanks to a patient-tailored therapy, reached Sustained Virological Response. Throughout the treatment period the patient was monitored with subsequent biochemical, clinical and psychological examinations. The data obtained by the patient's close monitoring suggest a direct interaction between insulin resistance and an active HCV genotype 1 infection, with a leading role played by the infection, and not by insulin resistance, as demonstrated by the sharp fall of the insulin units needed per day during treatment. The proteomic analysis showed that after therapy, a downregulation of enzymes involved in amino acid metabolism, glycolysis/gluconeogenesis and alcohol catabolism takes place, the latter probably due to cessation of alcohol abuse. On the contrary, the metabolic pathways linked to metabolism of the reactive oxygen species were upregulated after therapy. Finally, a significant alteration in the pathway regulated by peroxisome proliferator-activated receptor alpha (PPARA), a major regulator of lipid metabolism in the liver, was reported. These \\\"real time\\\" data confirm in vivo, in humans, that during HCV infection, the pathways related to fatty acids, glucose metabolism and free radical scavenging are inhibited. The same enzyme deficit is completely recovered after HCV eradication.\",\"Insulin resistance (IR) is a key factor in the development of hepatic steatosis and fibrosis in chronic hepatitis C virus infection. Little is known about the impact of viral clearance on IR.\",\"In a sentinel cohort, hepatitis C virus (HCV) patients (primarily genotype [GT] 1a) were treated with daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor). Preexistence, emergence, and persistence of resistance variants in patients who failed this treatment are described. HCV-infected null responders received daclatasvir (60 mg once daily) and asunaprevir (600 mg twice daily) alone (Group A, 11 patients) or with peginterferon alfa-2a and ribavirin (Group B, 10 patients) for 24 weeks. Resistance testing was performed on baseline samples and samples with HCV RNA \\u22651,000 IU/mL at Week 1 through posttreatment Week 48. Resistance substitution susceptibility to inhibition by asunaprevir and daclatasvir was assessed using HCV replicon assays. In Group A, six GT1a patients experiencing viral breakthrough and one GT1a patient who relapsed had detectable NS5A (Q30E/R, L31V/M, Y93C/N) and NS3 (R155K, D168A/E/V/Y) resistance-associated variants at failure. Two of six viral breakthrough patients achieved SVR48 after treatment intensification with peginterferon alfa-2a and ribavirin. For 2/4 viral breakthrough patients not responding to treatment intensification, NS3 resistance variants changed (D168Y to D168T; R155K to V36M-R155K). At posttreatment Week 48, daclatasvir-resistant variants persisted while asunaprevir-resistant variants were generally replaced by wild-type sequences. The NS3 sequence remained unchanged in the one patient with NS3-R155K at baseline, relapse, and posttreatment Week 48. In Group B, no viral breakthrough was observed.\",\"Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug interactions, and side-effects restrict their use. We assessed the safety and efficacy of sofosbuvir, a uridine nucleotide analogue, in treatment-naive patients with genotype 1-3 HCV infection.\",\"Since the discovery of the hepatitis C virus (HCV), a plethora of experimental models have evolved, allowing the virus's life cycle and the pathogenesis of associated liver diseases to be investigated. These models range from inoculation of cultured cells with serum from patients with hepatitis C to the use of surrogate models for the study of specific stages of the HCV life cycle: retroviral pseudoparticles for the study of HCV entry, replicons for the study of HCV replication, and the HCV cell culture model, which reproduces the entire life cycle (replication and production of infectious particles). The use of these tools has been and remains crucial to identify potential therapeutic targets in the different stages of the virus's life cycle and to screen new antiviral drugs. A clear example is the recent approval of two viral protease inhibitors (boceprevir and telaprevir) in combination with pegylated interferon and ribavirin for the treatment of chronic hepatitis C. This review analyzes the advances made in the molecular biology of HCV and highlights possible candidates as therapeutic targets for the treatment of HCV infection.\",\"The development of novel direct antiviral agents (DAAs) against hepatitis C virus (HCV) has represented a breakthrough in the treatment of chronic hepatitis C. Telaprevir and boceprevir are the first two protease inhibitor (PI) DAAs to be approved for combination therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV). In genotype 1 monoinfected patients, triple PI therapy has increased sustained viral response (SVR) rates by approximately 30% compared with conventional combination therapy. The introduction of these drugs into clinical practice will modify the timing of monitoring parameters in diagnostic laboratories, especially with regard to stopping rules and to faster delivery of results. In the near future, new DAAs, directed against different targets of the HCV cycle (polymerase inhibitors, viral replication complex inhibitors and cyclophilin inhibitors), which are currently in various stages of clinical development, will be available. Some of these DAAs have already reached advanced phases of development, both in combination with PEG-IFN and RBV and in interferon-free therapy, with very high rates of SVR.\",\"Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites for nonnucleos(t)ide inhibitors. Two NS3/4A protease inhibitors have been approved recently, and more than 40 new NS3/4A, NS5A, or NS5B inhibitors are in development. These agents can achieve very high cure rates when combined with pegylated interferon-\\u03b2 and ribavirin and show promising clinical results when administered in all-oral combinations. In addition to the more canonical drug targets, new alternative viral targets for small-molecule drug development are emerging, such as p7 or NS4B and viral entry. Future research will need to define well-tolerated and cost-effective DAA combinations that provide the highest rates of viral eradication in all patients (including those with advanced liver disease), the broadest spectrum of action on viral genotypes showing minimal or no clinical resistance, and the shortest treatment duration.\",\"Hepatitis C virus (HCV) infection has major health impact worldwide and is a significant cause of chronic liver disease. In Egypt, HCV is highly endemic (up to 15% of the population); 91% of the patients are infected with genotype 4. Searching for new predictors of response to therapy is mandatory to decrease the cost and the adverse effects of current therapy.\",\"Two classes of hepatitis C antiviral agents currently exist, i.e., direct-acting antivirals and host-targeting antivirals. Direct-acting antivirals target viral proteins including NS3/NS4A protease, NS5B polymerase and NS5A protein, while host-targeting antivirals target various host proteins critical for replication of the hepatitis C virus (HCV). Alisporivir is the most advanced host-targeting antiviral in clinical development. Alisporivir blocks HCV replication by neutralizing the peptidyl-prolyl isomerase activity of the abundant host cytosolic protein, cyclophilin A. Due to its unique mechanism of antiviral action, alisporivir is pangenotypic, provides a high barrier for development of viral resistance, and does not permit cross-resistance to direct-acting antivirals. Alisporivir has an excellent pharmacokinetic and safety profile. Phase I and II clinical studies have demonstrated that alisporivir causes a dramatic reduction in viral loads in HCV-infected patients. Alisporivir was shown to be highly potent in treatment-na\\u00efve and treatment-experienced patients with genotype 1 as well as in those with genotypes 2 or 3. Low viral breakthrough rates were observed and the most frequent clinical and laboratory adverse events associated with alisporivir in combination with pegylated interferon-alpha and ribavirin were similar to those associated with pegylated interferon-alpha and ribavirin used alone. A laboratory abnormality observed in some patients receiving alisporivir is hyperbilirubinemia, which is related to transporter inhibition and not to liver toxicity. The most recent clinical results suggest that alisporivir plus other direct-acting antivirals should provide a successful treatment option for difficult-to-treat populations, such as nonresponders to prior interferon-alpha therapy and patients with cirrhosis. In conclusion, alisporivir represents an attractive candidate component of future interferon-free regimens.\",\"The goal of treatment of chronic hepatitis C is to achieve a sustained virological response, which is defined as exhibiting undetectable hepatitis C virus (HCV) RNA levels in serum following therapy for at least six months. However, the current treatment is only effective in 50% of patients infected with HCV genotype 1, the most prevalent genotype in Brazil. Inhibitors of the serine protease non-structural protein 3 (NS3) have therefore been developed to improve the responses of HCV-infected patients. However, the emergence of drug-resistant variants has been the major obstacle to therapeutic success. The goal of this study was to evaluate the presence of resistance mutations and genetic polymorphisms in the NS3 genomic region of HCV from 37 patients infected with HCV genotype 1 had not been treated with protease inhibitors. Plasma viral RNA was used to amplify and sequence the HCV NS3 gene. The results indicate that the catalytic triad is conserved. A large number of substitutions were observed in codons 153, 40 and 91; the resistant variants T54A, T54S, V55A, R155K and A156T were also detected. This study shows that resistance mutations and genetic polymorphisms are present in the NS3 region of HCV in patients who have not been treated with protease inhibitors, data that are important in determining the efficiency of this new class of drugs in Brazil.\",\"IDX184 is a liver-targeted nucleotide prodrug that selectively inhibits HCV NS5B polymerase.\",\"Autoantibodies were studied in a well-characterized cohort of children with chronic hepatitis C during treatment with pegylated interferon and ribavirin to assess the relation with treatment and development of autoimmune disease.\",\"A patient classified as HCV-1a-positive by both LiPA Siemens 2.0 and Abbott RealTime HCV Genotype II was instead found to be infected with HCV-1g, as determined by phylogenetic analysis of NS3 sequences. HCV-1g NS3 sequences available to date naturally harbour the resistance substitution T54S, plus P131S and L135F changes, located in the highly conserved NS3 positions within the boceprevir-binding site, as determined by structural modelling. HCV-1g NS3 sequences show some similarities to HCV-4 and are poorly responsive to interferon/ribavirin and to boceprevir/telaprevir; this patient was also a null-responder to boceprevir treatment. Baseline genotypic resistance testing may provide crucial information for the management of first-generation protease-inhibitor-based regimens, including both HCV genotype/subtype and natural resistance.\",\"About sixty thousand new cases of Hepatitis C virus (HCV) infection are recorded in Brazil each year. These cases are currently treated with pegylated interferon (PEG-IFN) and ribavirin (RBV) with an overall success rate of 50%. New compounds for anti-HCV therapy targeted to the HCV NS3 protease are being developed and some already form the components of licensed therapies. Mapping NS3 protease resistance mutations to protease inhibitors or anti-viral drug candidates is important to direct anti-HCV drug treatment.\",\"Resistance to direct-acting antivirals represents a new challenge in the treatment of chronic hepatitis C.\",\"The addition of hepatitis C virus (HCV) protease inhibitors (PIs) to interferon and ribavirin therapy has significantly improved the efficacy of treatment for HCV infection. However, for patients who do not respond to therapy, the selection of HCV variants with resistance to PIs is likely. Resistant variants, such as R155K and A156T/V, result in extensive cross-resistance to other HCV PIs. Despite the rapid and frequent appearance of PI-resistant HCV variants, the long-term clinical implications are unknown. In particular, progress in the development of other HCV antivirals, such as NS5A inhibitors, next-generation NS3 protease inhibitors, and NS5B nucleoside and nonnucleoside inhibitors, has provided a broad selection of potent antivirals such that interferon-free therapy is a reality. Promising results from early stages of interferon-free trials will be reviewed.\",\"Daclatasvir (DCV; BMS-790052) is a hepatitis C virus (HCV) NS5A replication complex inhibitor (RCI) with picomolar to low nanomolar potency and broad genotypic coverage in vitro. Viral RNA declines have been observed in the clinic for both alpha interferon-ribavirin (IFN-\\u03b1-RBV) and IFN-RBV-free regimens that include DCV. Follow-up specimens (up to 6 months) from selected subjects treated with DCV in 14-day monotherapy studies were analyzed for genotype and phenotype. Variants were detected by clonal sequencing in specimens from baseline and were readily detected by population sequencing following viral RNA breakthrough and posttreatment. The major amino acid substitutions generating resistance in vivo were at residues M28, Q30, L31, and Y93 for genotype 1a (GT-1a) and L31 and Y93 for GT-1b, similar to the resistance substitutions observed with the in vitro replicon system. The primary difference in the resistance patterns observed in vitro and in vivo was the increased complexity of linked variant combinations observed in clinical specimens. Changes in the percentage of individual variants were observed during follow-up; however, the overall percentage of variants in the total population persisted up to 6 months. Our results suggest that during the 14-day monotherapy, most wild-type virus was eradicated by DCV. After the end of DCV treatment, viral fitness, rather than DCV resistance, probably determines which viral variants emerge as dominant in populations.\",\"Soluble CD36 (sCD36) plasma levels, a known marker of cardiometabolic disorders, are associated with surrogate markers of steatosis, while experimental and human studies show a link between CD36 expression in the liver and steatosis. In a cohort of patients with genotype 1 chronic hepatitis C (G1 CHC), we tested the association of sCD36 plasma levels with host and viral factors and sustained virological response (SVR). One hundred and seventy-five consecutive biopsy-proven patients were studied. sCD36 plasma levels were assessed by an in-house ELISA. All biopsies were scored by one pathologist for staging and grading (Scheuer) and graded for steatosis, which was considered moderate-severe if \\u226520%. Patients underwent standard of care therapy with pegylated interferon and ribavirin. The severity of steatosis progressively increased according to sCD36 quartiles (P = 0.02); total and low-density lipoprotein (LDL) cholesterol levels were significantly higher in patients in the lower quartile compared to all the others. Gamma-glutamyl transferase (P = 0.02), homoeostasis model assessment (HOMA) score (P = 0.002) and sCD36 (P = 0.04) were independently associated with the severity of steatosis as continuous variable. Multivariate logistic regression analysis showed that HOMA (OR 1.243, 95% CI 1.04-1.484, P = 0.01) and sCD36 (OR 1.445, 95%CI 1.135-1.839, P = 0.003) were independently linked to steatosis \\u226520%. No association was found between sCD36 and SVR. CD36 is linked to steatosis and insulin resistance in patients with G1 CHC, but does not predict response to treatment. The potential of sCD36 as a surrogate marker of steatosis should be further investigated.\",\"Mericitabine is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, with activity across all HCV genotypes. Treatment-na\\u00efve patients infected with HCV genotype 1 or 4 were randomized to 24 weeks of double-blind treatment with either mericitabine 1,000 mg (N = 81) or placebo (N = 85) twice-daily (BID) in combination with pegylated interferon alpha-2a (Peg-IFN\\u03b1-2a)/ribavirin (RBV). Patients randomized to mericitabine with HCV RNA <15 IU/mL from week 4 to 22 (extended rapid virologic response; eRVR) stopped all treatment at week 24; all other patients continued Peg-IFN\\u03b1-2a/RBV to complete 48 weeks of treatment. The primary efficacy endpoint was sustained virologic response (SVR; HCV RNA <15 IU/mL after 24 weeks of treatment-free follow-up). SVR was achieved in 56.8% (95% confidence interval [CI]: 45.9-67.0) of mericitabine-treated patients and 36.5% (95% CI: 27.0-47.1) of placebo-treated patients (\\u0394 = 20.3%; 95% CI 5.5-35.2). SVR rates were higher in mericitabine- than placebo-treated patients when subdivided by IL28B genotype (CC, 77.8% versus 56.0%; non-CC, 44.1% versus 16.2%) and hepatic fibrosis (noncirrhotic, 63.3% versus 41.9%; cirrhotic, 38.1% versus 21.7%). Overall relapse rates were 27.7% and 32.0% in mericitabine- and placebo-treated patients, respectively. No evidence of NS5B S282T-variant virus or phenotypic resistance to mericitabine was observed in the one patient who experienced partial response. No S282T variants were detected in any baseline samples. The safety profile of mericitabine was similar to that of, and fewer patients in the mericitabine than in the placebo group discontinued treatment for safety reasons.\",\"Rapid allograft infection complicates liver transplantation (LT) in patients with hepatitis C virus (HCV). Pegylated interferon-\\u03b1 and ribavirin therapy after LT has significant toxicity and limited efficacy. The effect of a human monoclonal antibody targeting the HCV E2 glycoprotein (MBL-HCV1) on viral clearance was examined in a randomized, double-blind, placebo-controlled pilot study in patients infected with HCV genotype 1a undergoing LT. Subjects received 11 infusions of 50 mg/kg MBL-HCV1 (n=6) or placebo (n=5) intravenously with three infusions on day of transplant, a single infusion on days 1 through 7 and one infusion on day 14 after LT. MBL-HCV1 was well-tolerated and reduced viral load for a period ranging from 7 to 28 days. Median change in viral load (log10 IU/mL) from baseline was significantly greater (p=0.02) for the antibody-treated group (range -3.07 to -3.34) compared to placebo group (range -0.331 to -1.01) on days 3 through 6 posttransplant. MBL-HCV1 treatment significantly delayed median time to viral rebound compared to placebo treatment (18.7 days vs. 2.4 days, p<0.001). As with other HCV monotherapies, antibody-treated subjects had resistance-associated variants at the time of viral rebound. A combination study of MBL-HCV1 with a direct-acting antiviral is underway.\",\"Mericitabine is a nucleoside analog polymerase inhibitor of hepatitis C virus (HCV). Treatment-na\\u00efve HCV genotype 1 or 4 patients were randomized to double-blind treatment with oral mericitabine at a dosage of 500 mg twice-daily (BID) for 12 weeks (A), 1,000 mg BID for 8 (B) or 12 weeks (C and D), or placebo BID for 12 weeks (E). All patients received pegylated interferon alpha-2a (Peg-IFN\\u03b1-2a; 40 kD)/ribavirin (RBV) at standard doses for 24 or 48 weeks during and after mericitabine/placebo therapy. Patients in arms A-C who maintained a virologic response (VR) (HCV RNA <15 IU/mL) from weeks 4 to 22 stopped all treatment at week 24; all other patients (arms A-E) continued Peg-IFN\\u03b1-2a/RBV to complete 48 weeks. The primary outcome was sustained VR (SVR) (HCV RNA <15 IU/mL after 24 weeks of untreated follow-up; SVR-24). VR rates were higher in arms A-D than in arm E at weeks 4 and 12 overall, in patients with and without cirrhosis and in patients with CC and non-CC IL28B genotypes. However, the overall SVR-24 rate in arms D (50.6%) and E (placebo, 51.2%) was similar and those in the response-guided therapy arms A, B, and C were lower (48.8%, 42.0%, and 32.9%, respectively). No viral breakthrough or mericitabine-resistance mutations (S282T) were observed during mericitabine therapy.\",\"Hepatitis C virus (HCV) infection is one of the most important causes of cirrhosis and hepatocellular carcinoma and has a tremendous impact on public health worldwide. HCV is both hepatotropic and lymphotropic. Replication of HCV in diseased extrahepatic organs and tissues may either trigger latent autoimmunity or induce autoimmune disorders. In addition to established liver injury, type 2 diabetes mellitus (T2DM) is an important feature of extrahepatic metabolic disorders which is attributed to HCV infection. It also has some impact on the disease activity, disease course, clinical outcomes, and treatment efficacy of antiviral therapy. Previous experimental and clinical findings have highly suggested that HCV per se is diabetogenic. The cause-effect interaction between a common endocrine disorder and an infectious disease is an important issue to elucidate. Although the precise mechanisms whereby HCV infection leads to insulin resistance (IR) and glucose abnormalities are not entirely clear, it differs from the usual pathogenesis of T2DM in those with non-HCV liver diseases. This review initially highlights epidemiological and pathophysiological studies addressing the mutual link between chronic HCV infection (CHC) and T2DM. The characteristics of glucose abnormalities in this special population are depicted from the current evidence. The mutual roles of IR and CHC with respect to the prediction of treatment efficacy, how treatment response affects IR, and the role of pancreatic beta cell function in the entire suite are discussed. With the rapid progression of antiviral therapy for CHC in the past decade, we have also listed some points of future perspective in this issue.\",\"A major challenge for antiviral treatment of hepatitis C virus (HCV) infection is viral resistance, potentially resulting from the high variability of HCV envelope glycoproteins and subsequent selection of strains with enhanced infectivity and/or immune escape.\",\"Until recently, the standard-of-care therapy of patients with HCV infection involves treatment with interferon (IFN) and ribavirin (RBV). Host demographic and genetic factors as well as HCV genetic heterogeneity have been shown to be associated with outcomes of therapy. Although resistance to IFN/RBV remains an important clinical and public health problem, there are no reliable genetic markers for the prediction of the therapy outcomes. Recently, it was shown that adaptation to IFN, a major constituent of the host innate immunity, is reflected in the HCV genetic composition and epistatic connectivity among polymorphic genomic sites, thus providing novel genetic markers of IFN resistance. Consideration of coordinated evolution among HCV genomic sites allows for identification of these genetic markers from short regions of the HCV genome and for accurate prediction of therapeutic outcomes. HCV genomic co-evolution offers a general framework for the detection of predisposition to IFN resistance, and possibly to resistance to direct-acting antivirals.\",\"The current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct-acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG-IFN) plus ribavirin (RBV) regimen. Major progress has been made in the past few years: numerous ongoing trials with different compounds, increasing sustained virological response (SVR) rates with oral regimens and shortened treatment duration. Combinations of antivirals with additive potency that lack cross-resistance and with a good safety profile may provide new regimens in the future to make HCV the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN.\",\"Telaprevir and boceprevir are the first direct-acting antiviral agents approved for use in HCV treatment and represent a significant advance in HCV therapy. However, these first-generation drugs also have significant limitations related to thrice-daily dosing, clinically challenging side-effect profiles, low barriers to resistance and a lack of pan-genotype activity. A second wave of protease inhibitors are in phase II and III trials and promise to provide a drug regimen with a better dosing schedule and improved tolerance. These second-wave protease inhibitors will probably be approved in combination with PEG-IFN and Ribavirin (RBV), as well as future all-oral regimens. The true second-generation protease inhibitors are in earlier stages of development and efficacy data are anxiously awaited as they may provide pan-genotypic antiviral activity and a high genetic barrier to resistance.\",\"HCV is a worldwide disease with an estimated prevalence by WHO of 3%. Hepatitis C virus 4 is prevalent in Africa and the Middle East, especially Egypt. The treatment of HCV4 is affected by many factors, related to the virus itself (genotype, pretreatment viral load and prevalent quasispecies), to the host (genetic factors, age, ethnicity and liver histology), to the presence of comorbidities (obesity, insulin resistance and co-infections) and to the therapeutic drugs (type, dose and duration). Optimizing treatment is the goal of daily practice to obtain the best results for the patient.\",\"Hepatitis C virus (HCV) is a major cause of hepatocellular carcinoma, cirrhosis and end stage liver disease. More than 200million people are living with HCV worldwide with high morbidity and mortality. There is no vaccine available for this virus; the approved treatment option for the majority of HCV genotypes is the combination of pegylated (Peg) interferon and ribavirin. The therapy has a different response rate on different HCV genotypes and has a number of side effects. Recently, as well as Peg interferon and ribavirin, two protease inhibitors have been introduced to treat patients with HCV genotype 1 infection. The protease inhibitors have rapid onset of resistance and are not approved for use for infections with other HCV genotypes. The HCV NS5B gene encodes RNA dependent RNA polymerase (RdRp), which is the key player in viral replication and is a promising target for the development of antiviral drugs. HCV NS5B has been studied in various biochemical assays, cell based assays and animal model systems. So far, a number of nucleoside and non-nucleoside inhibitors have been screened for effects on viral replication. This review presents a deep insight into the structure and function of HCV polymerase and the effect of various nucleoside and non-nucleoside inhibitors on viral replication.\",\"Hepatocellular carcinoma (HCC) is one of the common sequelae of hepatitis C virus (HCV) infection. It remains controversial, however, whether HCV itself plays a direct role in the development of HCC. Although HCV core, NS3, and NS5A proteins were reported to display tumorigenic activities in cell culture and experimental animal systems, their clinical impact on HCC development in humans is still unclear. In this study we investigated sequence polymorphisms in the core protein, NS3, and NS5A of HCV genotype 1b (HCV-1b) in 49 patients who later developed HCC during a follow-up of an average of 6.5 years and in 100 patients who did not develop HCC after a 15-year follow-up. Sequence analysis revealed that Gln at position 70 of the core protein (core-Gln(70)), Tyr at position 1082 plus Gln at 1112 of NS3 (NS3-Tyr(1082) /Gln(1112)), and six or more mutations in the interferon/ribavirin resistance-determining region of NS5A (NS5A-IRRDR\\u22656) were significantly associated with development of HCC. Multivariate analysis identified core-Gln(70) , NS3-Tyr(1082) /Gln(1112) , and \\u03b1-fetoprotein (AFP) levels (>20 ng/L) as independent factors associated with HCC. Kaplan-Meier analysis revealed a higher cumulative incidence of HCC for patients infected with HCV isolates with core-Gln(70) , NS3-Tyr(1082) /Gln(1112) or both than for those with non-(Gln(70) plus NS3-Tyr(1082) /Gln(1112)). In most cases, neither the residues at position 70 of the core protein nor positions 1082 and 1112 of the NS3 protein changed during the observation period.\",\"Hepatitis C virus (HCV) infects more than 2 % of the world population with highest prevalence in parts of Africa and Asia. Past standard of care using interferon \\u03b1 and ribavirin had adverse effects and showed modest efficacy for some HCV genotypes spurring the development of direct acting antivirals (DAAs). Such DAAs target viral proteins and are thus better tolerated but they suffer from emergence of vial resistance. Furthermore, DAAs are often HCV genotype specific. Novel drug candidates targeting host factors required for HCV propagation, so called host-targeting antivirals (HTAs), promise to overcome both caveats. The genetic barrier to resistance is usually considered to be high for HTAs and all HCV genotypes presumably use the same host factors. Recent data, however, challenge these assumptions, at least for some HTAs. Here, we highlight the most important host-targeting strategies against hepatitis C and critically discuss their opportunities and risks.\",\"Antiviral resistance among influenza A viruses is associated with high morbidity and mortality in immunocompromised hosts. However, treatment strategies for drug-resistant influenza A are not established. A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL) and ribavirin (RBV) demonstrated good efficacy in an animal model.\",\"Increased \\u03b3-glutamyl transferase (GGT) activity is associated with liver injury and with mortality in the general population. Less is known about its association with chronic hepatitis C (HCV) outcomes. We examined GGT as a predictor of both virological response to treatment and long-term clinical outcomes in the Hepatitis C Anti-viral Treatment Against Cirrhosis Trial (HALT-C). HALT-C enrolled patients with advanced liver disease (Ishak fibrosis score \\u22653) in two phases: a lead-in to establish lack of sustained viral response with full dose pegylated interferon (IFN) and ribavirin followed by a 3.5-year randomized trial with low-dose IFN. Low-dose IFN did not prevent liver disease progression, and patients were then followed for up to an additional 5 years off therapy. Analyses were performed for 1,319 patients who had GGT measured prior to initiation of treatment. Increases in risk with each increase in quintile of GGT (10-57, 58-89, 90-139, 140-230, 231-2,000 IU/L) were determined by logistic regression for treatment response or Cox regression for clinical outcomes. Baseline GGT was associated with male sex, nonwhite ethnicity, diabetes and insulin resistance, interleukin (IL)28B rs12979860 CT and TT genotypes, and numerous markers of liver disease injury and severity. In the lead-in phase, increasing GGT was strongly associated with diminished week 20 response, end of treatment response, and sustained virological response in both univariate and multivariate analyses controlling for factors known to be associated with treatment response (P < 0.0001). GGT was also associated with all clinical outcomes in univariate and multivariate analysis (P < 0.05) except for hepatocellular carcinoma (P = 0.46 in multivariate analysis).\",\"Cytokines play a key role in the regulation of immune responses. In hepatitis C virus infection, the production of abnormal cytokine levels appears to contribute in the progression of the disease, viral persistence, and affects response to therapy. Cytokine genes polymorphisms located within the coding/regulatory regions have been shown to affect the overall expression and secretion of cytokines. The aim of the study was to evaluate the association of of IL28B rs12979860, TGF-\\u03b21-509, TNF-\\u03b1 308, and IL-10-1082 polymorphisms with the susceptibility to hepatitis C virus genotype 4 infection and response to pegylated interferon-\\u03b1 and ribavirin therapy.\",\"Recent data suggest that vitamin A modulates the expression of type I interferon receptor enhancing the antireplication effect of interferon-\\u03b1 on hepatitis C virus (HCV). This study aimed to investigate the prevalence of vitamin A deficiency among patients with chronic HCV infection and to assess whether vitamin A deficiency could be associated with unresponsiveness to interferon-based antiviral therapy. The analysis included 199 consecutive treatment-na\\u00efve chronic HCV patients in whom pretreatment serum vitamin A and 25-OH vitamin D were measured; 119 healthy blood donors were used as controls. Median (interquartile range) serum vitamin A in HCV-positive patients was significantly lower than in controls: 256 ng/mL (128-440) versus 742 (624-942, P<0.0001). Overall sustained viral response was achieved in 122/199 patients, 46/109 infected by difficult to treat HCV genotypes. In these latter, 39/104 (37.5%) were nonresponders. At multivariate analysis, nonresponse to antiviral therapy was predicted by carriage of interleukin (IL)-28B T/* genotypes, baseline serum levels of \\u03b3GT>60 IU/mL, of HCV RNA>600,000 IU/mL, of vitamin A\\u2264100 ng/mL, and a cumulative dose of ribavirin\\u226480%. Seventeen patients (9.0%) had both serum levels of vitamin A\\u2264100 ng/mL and of vitamin D\\u226420 ng/mL; the presence of a combined vitamin A and D deficiency was found to be a strong independent predictor of nonresponse to antiviral therapy.\",\"Hepatitis C virus (HCV) is a major cause of liver disease world-wide. Current interferon and ribavirin (IFN/RBV) therapy is effective in 50%-60% of patients. HCV exists in infected patients as a large viral population of intra-host variants (quasispecies), which may be differentially resistant to interferon treatment. We present a method for measuring differential interferon resistance of HCV quasispecies based on mathematical modeling and analysis of HCV population dynamics during the first hours of interferon therapy. The mathematical models showed that individual intra-host HCV variants have a wide range of resistance to IFN treatment in each patient. Analysis of differential IFN resistance among intra-host HCV variants allows for accurate prediction of response to IFN therapy. The models strongly suggest that resistance to interferon may vary broadly among closely related variants in infected hosts and therapy outcome may be defined by a single or a few variants irrespective of their frequency in the intra-host HCV population before treatment.\",\"Machine-learning methods in the form of Bayesian networks (BN), linear projection (LP) and self-organizing tree (SOT) models were used to explore association among polymorphic sites within the HVR1 and NS5a regions of the HCV genome, host demographic factors (ethnicity, gender and age) and response to the combined interferon (IFN) and ribavirin (RBV) therapy. The BN models predicted therapy outcomes, gender and ethnicity with accuracy of 90%, 90% and 88.9%, respectively. The LP and SOT models strongly confirmed associations of the HVR1 and NS5A structures with response to therapy and demographic host factors identified by BN. The data indicate host specificity of HCV evolution and suggest the application of these models to predict outcomes of IFN/RBV therapy.\",\"Recurrent HCV disease is the most common cause of graft loss and patient mortality in HCV-infected liver transplant (LT) recipients. Risk factors for more severe recurrence that are potentially modifiable are older donor age, prolonged cold ischaemia time, prior treated acute rejection, CMV hepatitis, IL28B donor genotype, and post-LT insulin resistance. The most effective means of preventing HCV recurrence is eradicating HCV prior to LT. Select wait-list candidates with compensated or mildly decompensated disease can be considered for antiviral treatment with peginterferon, ribavirin (and protease inhibitor if genotype 1). For the majority of LT patients, HCV treatment must be delayed until post-transplant. Treatment is generally undertaken if histologic severity reaches grade 3 or 4 necroinflammation or stage \\u22652 fibrosis, or if cholestatic hepatitis. Achievement of sustained viral response (SVR) post-LT is associated with stabilization of fibrosis and improved graft survival. SVR is attained in ~30% of patients treated with peginterferon and ribavirin. Poor tolerability of therapy is a limitation. Combination therapy with telaprevir or boceprevir added to peginterferon and ribavirin is anticipated to increase efficacy but with higher rates of adverse effects and challenges in managing drug-drug interactions between the protease inhibitors and calcineurin inhibitors/sirolimus.\",\"The recent development of small molecule compounds that directly inhibit the viral life cycle represents a major milestone for the treatment of chronic hepatitis C virus (HCV) infection. These new drugs that are collectively termed direct-acting antivirals (DAA) include a range of inhibitors of the non-structural (NS) 3/4A protease, NS5B polymerase and NS5A protein. Two NS3/4A protease inhibitors (boceprevir and telaprevir) in combination with pegylated interferon and ribavirin have now been approved for the treatment of chronic HCV genotype 1 infection and cure rates could be increased by 20-30%. However, the majority of DAAs is still in early clinical development. The rapid replication rate of HCV, along with the error-prone polymerase activity leads to a high genetic diversity among HCV virions that includes mutants with reduced susceptibility to DAA-therapy. These resistance-associated variants often occur at very low frequencies. However, during DAA-based treatment, rapid selection of resistance mutations may occur, eventually leading to viral break-through. A number of variants with different levels of resistance have been described in vitro and in vivo for virtually all DAAs. We review the parameters that determine DAA resistance as well as the clinical implications of resistance testing. In addition, the most recent literature and conference data on resistance profiles of DAAs in clinical development and future strategies to avoid the emergence of viral resistance are also discussed.\",\"Understanding of the natural history and treatment responsiveness of chronic hepatitis C virus (HCV) infection has evolved rapidly in recent years. Advances in HCV molecular virology and host genetics can now better predict spontaneous clearance and treatment outcomes. HCV genotype is the most important viral factor predicting interferon-\\u03b1 treatment responsiveness; HCV-1 subtype is emerging as a key determinant of the efficacy of direct acting antiviral therapy. Genome-wide association studies have recently identified several clinically important host determinants of the outcomes of peginterferon-\\u03b1 and ribavirin treatment outcome: IL28B polymorphism is associated with spontaneous clearance and treatment responsiveness; ITPA polymorphism protects against ribavirin-induced anaemia and dose reductions; genetic determinants of liver fibrosis progression rate have been proposed. In this review, we evaluate the role of viral and host genetics in the natural history and treatment outcomes of chronic HCV infection, and consider how this knowledge might help individualize clinical management in the era of DAA therapy.\",\"Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past months, important steps have been made towards a more effective antiviral therapy. However, we are still far from both highly efficient and well-tolerable ideal therapy. The development of new drugs against HCV is a very dynamic field. This review summarizes the up-to-date knowledge of the most significant anti-HCV compounds in development.\",\"The current epidemic of HCV infection affects almost 180 million people, of whom one quarter already has cirrhosis. The number with hepatocellular carcinoma and liver failure are projected to treble over the next three decades. The only means of reducing this health burden is through increased eradication with antiviral therapy. However, current antiviral therapies are limited by poor efficacy and tolerability, especially in patients with HCV genotype 1. Pegylated interferon (PEG-IFN) plus ribavirin (RBV) has significant side effects, must be administered for up to 48 weeks and cures about less than half of patients. Many patients diagnosed with chronic hepatitis C are unsuitable for or refuse to undertake such therapy. Although the recent approval of triple therapy with telaprevir or boceprevir with PEG-IFN/RBV has increased cure and reduced duration of therapy, this is still unsuitable for patients either intolerant of or with contraindications to IFN or RBV. In addition, triple therapy will have limited benefit in previous null responders to PEG-IFN/RBV, and in those with advanced fibrosis. Finally, few protease inhibitors have antiviral efficacy in patients infected with non-1 genotype HCV. Thus, there is an urgent need for the development of an IFN-free, all-oral treatment regimen consisting of direct-acting antiviral drugs with different mechanisms of stopping the virus and a higher barrier to resistance, which can improve cure rates across all HCV genotypes. The likely successful regimen will contain at least two direct-acting antivirals with different targets of action, of which at least one will have a high barrier to resistance. The likely duration of IFN-free direct-acting antiviral therapy will be between 6 and 12 weeks depending on early-on-treatment virological responses.\",\"HCV infection is a major cause of chronic liver disease and affects nearly 170 million people worldwide. Whereas the previous standard of care with pegylated interferon and ribavirin had a modest effectiveness, the recent approval of two highly potent protease inhibitors and the ongoing development of dozens of direct-acting antiviral agents (DAAs) constitute a major milestone for HCV therapy. Mathematical modelling of viral kinetics under treatment has played an instrumental role in improving our understanding of virus pathogenesis and in guiding drug development. Here, we review the current state of HCV kinetic modelling, and challenges to the standard biphasic viral decline model that arise when fitting viral kinetic models to data obtained with DAAs.\",\"We assessed the safety and efficacy of boceprevir (BOC) plus peginterferon-ribavirin (PR) in patients with HCV-G1 infection and advanced fibrosis/cirrhosis (Metavir F3/F4).\",\"GS-9669 is a highly optimized thumb site II nonnucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase, with a binding affinity of 1.35 nM for the genotype (GT) 1b protein. It is a selective inhibitor of HCV RNA replication, with a mean 50% effective concentration (EC(50)) of \\u2264 11 nM in genotype 1 and 5 replicon assays, but lacks useful activity against genotypes 2 to 4. The M423T mutation is readily generated clinically upon monotherapy with the thumb site II inhibitors filibuvir and lomibuvir, and it is notable that GS-9669 exhibited only a 3-fold loss in potency against this variant in the genotype 1b replicon. Rather than M423T, resistance predominantly tracks to residues R422K and L419M and residue I482L in GT 1b and 1a replicons, respectively. GS-9669 exhibited at least additive activity in combination with agents encompassing four other direct modes of action (NS3 protease, NS5A, NS5B via an alternative allosteric binding site, and NS5B nucleotide) as well as with alpha interferon or ribavirin in replicon assays. It exhibited high metabolic stability in in vitro human liver microsomal assays, which, in combination with its pharmacokinetic profiles in rat, dog, and two monkey species, is predictive of good human pharmacokinetics. GS-9669 is well suited for combination with other orally active, direct-acting antiviral agents in the treatment of genotype 1 chronic HCV infection. (This study has been registered at ClinicalTrials.gov under registration number NCT01431898.).\",\"NS5A protein plays a key role in hepatitis C virus (HCV) replication. Daclatasvir (DCV, BMS-790052) is a first-in-class inhibitor of the HCV NS5A replication complex with potent antiviral activity but a low barrier to resistance. DCV as triple therapy in combination with pegylated interferon and ribavirin resulted in a high rate of early virologic response in treatment-na\\u00efve patients with genotype 1 infection; as quadruple therapy in combination with asunaprevir (BMS-650032, NS3 protease inhibitor), pegylated interferon, and ribavirin, it resulted in a high rate of sustained virologic response in genotype 1 prior null responders.\",\"Nucleoside/nucleotide analogue polymerase inhibitors (NPIs) are analogues of natural substrates that bind the active site of NS5B and terminate viral RNA chain generation and generally provide a high genetic barrier to resistance and are effective in all genotypes. NPIs such as sofosbuvir (GS-7977) show high antiviral activities that, together with their high genetic barrier to resistance, suggest that they are optimal backbone candidates for all-oral combination therapies. Several trials are ongoing to further define the potential of all-oral regimens with sofosbuvir (GS-7977). Recent interim analyses indicate that many patients treated with only 2 direct-acting antiviral agents experience viral breakthrough, which can be significantly reduced by the addition of ribavirin without pegylated interferon \\u03b1.\",\"Monotherapy is an ineffective way to treat hepatitis C and it leads to rapid development of resistance. An increasing number of drugs are currently being developed for the treatment of hepatitis C. This allows combination strategies that can overcome the development of resistance and improve sustained virologic response rates. This article focuses on the 2 main strategies in development: quadruple combination therapies, including pegylated-interferon and triple/quadruple pegylated-interferon free combination therapies. If the first combinations are leading to extremely high sustained virologic responses, the second ones offer hope that the era of pegylated-interferon will end soon.\",\"Antiviral treatment of chronic hepatitis C is not invariably successful, costly and associated with serious side-effects, and therefore should be indicated only when the chances of benefitting patients exceed the potential risks. The suppressor of cytokine signalling (SOCS) family members have been suggested to affect the rate of virological response to therapy, but the published evidence is conflicting.\",\"Over the last decade, the standard of care for the treatment of chronic hepatitis C has been the combination of pegylated-interferon-alfa (PEG-IFN) and ribavirin (RBV) which results in sustained virological response (SVR) rates of 75%-85% in patients with genotypes 2 or 3 but only of 40%-50% in patients with genotype 1. Currently, there are rapid and continuous developments of numerous new agents against hepatitis C virus (HCV), which are the focus of this review. Boceprevir and telaprevir, two first-generation NS3/4A HCV protease inhibitors, have been recently licensed in several countries around the world to be used in combination with PEG-IFN and RBV for the treatment of genotype 1 patients. Boceprevir or telaprevir based triple regimens, compared with the PEG-IFN/RBV combination, improve the SVR rates by 25%-31% in treatment-na\\u00efve genotype 1 patients, by 40%-64% in prior relapsers, by 33%-45% in prior partial responders and by 24%-28% in prior null responders. At the same time, the application of response-guided treatment algorithms according to the on-treatment virological response results in shortening of the total therapy duration to only 24 wk in 45%-55% of treatment-na\\u00efve patients. There are, however, several challenges with the use of the new triple combinations in genotype 1 patients, such as the need for immediate results of HCV RNA testing using sensitive quantitative assays, new and more frequent adverse events (anemia and dysgeusia for boceprevir; pruritus, rash and anemia for telaprevir), new drug interactions and increasing difficulties in compliance. Moreover, the SVR rates are still poor in very difficult to treat subgroups of genotype 1 patients, such as null responders with cirrhosis, while there is no benefit for patients who cannot tolerate PEG-IFN/RBV or who are infected with non-1 HCV genotype. Many newer anti-HCV agents of different classes and numerous combinations are currently under evaluation with encouraging results. Preliminary data suggest that the treatment of chronic HCV patients with well tolerated combinations of oral agents without PEG-IFN is feasible and may lead to a universal HCV cure over the next 5-10 years.\",\"Hepatitis C Virus (HCV) is a major cause of chronic liver disease worldwide. In addition to viral and environmental behavioral factors, host genetic diversity is believed to contribute to the spectrum of the disease. The sequencing of the human genome, together with the development of high-throughput technologies that measure the function of the genome, have afforded unique opportunities to develop profiles that can distinguish and classify discrete subsets of a disease and predict a response to therapy. In 2011, 2 directly acting antivirals (DAAs) have been approved for chronic HCV genotype 1 infection, Telaprevir and Boceprevir, and open a new area for HCV therapy. These 2 NS3/4 protease inhibitors are given in combination with pegylated interferon and ribavirin. Several DAAs are in development. Since a significant number of patients will fail to respond to treatment, or will have significant side effects, it is of major interest to predict a response to treatment as early as possible. Several studies are ongoing to identify biomarkers that could predict treatment outcome in patients with hepatitis C before treatment. Many of the genes upregulated in the liver between nonresponders and responders codes molecules secreted in the serum and can constitute a logical functional approach for the development of serum markers predictors of response to treatment. In the next future, further studies have several challenges to fight. First, large prospective cohorts with well phenotyped patients and appropriate tissue controls are needed. For response to treatment, the appropriate definition of sustained response and the same treatment regimen have to be addressed. Furthermore, improved technology and analytical procedures and the use of large numbers of patients for validation are needed.\",\"The response rate to treatment of chronic hepatitis C virus-genotype 1 and 4 infections was recently found to be strongly influenced by many polymorphisms. The aim of our study was to carry out an integrated analysis of the effects of polymorphisms and ribavirin (RBV) plasma exposure on outcome.\",\"Present interferon-based therapy for chronic hepatitis C is limited by both efficacy and tolerability. Telaprevir and boceprevir are the first two direct-acting antiviral drugs (DAAs) that inhibit hepatitis C virus replication to be licensed for use in conjunction with pegylated interferon and ribavirin. Numerous other DAAs are in clinical development, and phases 2 and 3 trials are evaluating interferon-free combination DAA therapy. Interferon-free sustained virologic responses have now been achieved with combinations of asunaprevir and daclatasvir; sofosbuvir and ribavirin; sofosbuvir and daclatasvir; faldaprevir and BI207127; ABT-450, ritonovir and ABT-333; ABT-450, ritonovir and ABT-072; miracitabine, danoprevir and ritonavir; and alisporivir and ribavirin. Some drugs are genotype-specific in their activity, whereas others are pan-genotypic, and differential responses for the genotype 1 subtypes 1a and 1b have emerged with many DAA combinations. Viral breakthrough and resistance are important considerations for future trial design. The prospect of interferon-free combination DAA therapy for hepatitis C virus is now finally becoming a reality.\",\"Insulin is critical for controlling energy functions including glucose and lipid metabolism. Insulin resistance seems to interact with hepatitis C promoting fibrosis progression and impairing sustained virological response to peginterferon and ribavirin. The main aim was to elucidate the direct effect of hepatitis C virus (HCV) infection on insulin signaling both in vitro analyzing gene expression and protein abundance. Huh7.5 cells and JFH-1 viral particles were used for in vitro studies. Experiments were conducted by triplicate in control cells and infected cells. Genes and proteins involved in insulin signaling pathway were modified by HCV infection. Moreover, metformin treatment increased gene expression of PI3K, IRS1, MAP3K, AKT and PTEN more than >1.5 fold. PTP1B, encoding a tyrosin phosphatase, was found highly induced (>3 fold) in infected cells treated with metformin. However, PTP1B protein expression was reduced in metformin treated cells after JFH1 infection. Other proteins related to insulin pathway like Akt, PTEN and phosphorylated MTOR were also found down-regulated. Viral replication was inhibited in vitro by metformin. A strong effect of HCV infection on insulin pathway-related gene and protein expression was found in vitro. These results could lead to the identification of new therapeutic targets in HCV infection and its co-morbidities.\",\"Insulin resistance has been strongly associated with the attainment of sustained viral response (SVR) in hepatitis C patients.\",\"To evaluate the association of insulin resistance (IR), viral load, and adipokine levels with liver histology in patients with chronic hepatitis C (CHC).\",\"Precore (PC) (G1896A) and basal core promoter (BCP) (A1762T/G1764A) mutations of the hepatitis B virus (HBV) genome often emerge in chronic hepatitis B (CHB) patients. Their roles in hepatitis B e antigen (HBeAg) seroconversion induced by interferon (IFN) therapy remain controversial, partly because quantitative analysis for these mutants is lacking. This study aimed to develop a new assay to accurately quantify the PC and BCP mutant percentages and correlate their dynamic changes with IFN-induced HBeAg seroconversion in HBeAg-positive CHB patients. The PC and BCP mutant percentages were analyzed by polymerase chain reaction (PCR)-pyrosequencing. Our results showed that this quantitative assay for PC and BCP mutants achieved high accuracy (R(2) > 0.99) within a range between 10% and 90% mutants. We examined dynamic changes of the PC and BCP mutant percentages following IFN treatment in 203 HBeAg-positive CHB patients. By multiple logistic regression analysis, we found that the chance of HBeAg seroconversion increased by 2.2% (odds ratio [OR] = 1.022, 95% confidence interval [CI]: 1.009-1.034, P = 0.001) and 2.3% (OR = 1.023, 95% CI: 1.010-1.037, P = 0.001) per 1% increase of the pretreatment PC and BCP mutant percentages, respectively, after adjustment for other predictors. However, only the pretreatment PC mutation percentage was significantly associated with HBeAg seroconversion with HBV DNA < 2,000 IU/mL (OR = 1.030, 95% CI: 1.014-1.047, P < 0.001). Furthermore, the mutant percentage of PC, but not BCP, in patients achieving HBeAg seroclearance with HBV DNA < 20,000 IU/mL increased significantly during IFN treatment (P = 0.039). Interestingly, patients with HBeAg seroconversion who had a high PC mutant percentage at the end of IFN treatment tended to exhibit high viremia after seroconversion.\",\"Combination therapy with pegylated interferon and ribavirin is the standard of care (SOC) for the treatment of chronic hepatitis C (CHC). Treating CHC with SOC may show a sustained virological response (SVR) in approximately 50-70 % of genotype 1 CHC patients and an SVR in 70-90 % of genotype 2 CHC patients. The genotype, baseline viral load, and viral kinetics (i.e., rapid virologic response and early virologic response) can be used as predictors of response-guided therapy. Nonetheless, host factors, e.g. age, ethnicity, insulin resistance, and genetic variations, may also play important roles in the SVR in CHC patients treated with SOC. Recent genome-wide association studies have demonstrated that single-nucleotide polymorphisms near the interleukin 28B gene (IL28B) were associated with SVR to treatment with SOC in CHC patients. The IL28B polymorphisms may contribute to the viral kinetics during treatment. Asian people have favorable IL28B polymorphisms. This factor may at least partly explain the high eradication rate of hepatitis C by SOC in Asia. Combination therapy with direct-acting antivirals (DAAs) and SOC can increase the SVR rates both in treatment-na\\u00efve and treatment-experienced patients. Although the IL28B polymorphisms also affect the SVR of triple therapy with SOC and first-generation protease inhibitors, pilot studies have demonstrated that potent DAAs might overcome the influence of IL28B polymorphisms. Thus, the treatment of hepatitis C virus infection could be simplified in the near future.\",\"The results from clinical trials testing new direct-acting antivirals (DAAs) for chronic hepatitis C were the major focus of interest at the 2012 annual meeting of the European Association for the Study of the Liver. Besides triple combinations, in which any one of the new DAAs is given along with peginterferon-\\u03b1/ribavirin, clinical trials exploring interferon-free oral regimens combining several DAAs attracted major attention. The good tolerance, broad hepatitis C virus (HCV) genotype activity, and high resistance barrier of sofosbuvir make this nucleotide analogue one of the most promising DAAs. Among HCV protease inhibitors, the safety, potency, and convenient dosing of simeprevir, asunaprevir, faldaprevir, and ABT-450/r were particularly highlighted. Among NS5A inhibitors, the good performance of daclatasvir encourages further clinical development. Finally, intriguing results were released about the role of interleukin 28B (IL-28B) polymorphisms using interferon-free regimens, indirectly supporting the role of innate immunity for clearing HCV definitively.\",\"The addition of boceprevir to therapy with peginterferon alfa-2b and ribavirin results in significantly higher rates of sustained virologic response (SVR) in previously treated patients with chronic hepatitis C virus (HCV) genotype-1 infection, compared with peginterferon alfa-2b and ribavirin alone. We assessed SVR with boceprevir plus peginterferon alfa-2a-ribavirin (PEG2a/R) in patients with identical study entry criteria.\",\"We here report on the activity of 2'-C-methylcytidine (2CMC) [a nucleoside polymerase inhibitor of the hepatitis C virus (HCV)] on the in vitro replication of (murine) norovirus (MNV). 2CMC inhibits (i) virus-induced CPE formation, (ii) viral RNA synthesis and (iii) infectious progeny formation with EC(50) values of \\u223c2\\u03bcM. 2CMC acts at a time-point that coincides with the onset of viral RNA synthesis. Even following 30 passages of selective pressure no MNV-resistant virus was selected, which is in line with the high barrier to resistance of the nucleoside analogue for HCV. When combined with the broad-spectrum RNA virus inhibitor ribavirin, a marked antagonistic activity was observed indicating that these molecules should not be combined for the treatment of norovirus infections. Our results suggest that 2'-C-methyl nucleoside analogues should be further explored for the treatment and prophylaxis of norovirus infections.\",\"The standard therapeutic approach currently recommended for patients infected with genotype 1 hepatitis C virus (HCV) is the triple therapy combining pegylated interferon (PEG-IFN), ribavirin (RBV)and NS3/NS4 protease inhibitors, boceprevir or telaprevir [1]. Protease inhibitors (PIs) are direct acting antiviral drugs (DAA) which, when added to PEG-IFN and RBV, are able to achieve a significant gain in terms of sustained virological response (SVR), both in na\\u00efve and treatment-experienced patients [2\\u20135]. The use of these new molecules, despite its in contestable benefits, reveals on the other hand new challenges: the emergence of variants with reduced sensitivity to PIs, the development of new or higher rate of side effects, drug to drug interactions, and significant increase in the overall cost of antiviral therapy. Among the two DAAs commonly used in combination with PEG-IFN and RBV (PEG-IFN/RBV) for the treatment of genotype 1 HCV patients, boceprevir has been licensed with a lead-in phase, while telaprevir has been licensed without. EMA approved regimens of both drugs are reported in Figs. 1 and 2. The lead-in phase represents an initial period of 4 weeks of dual therapy with PEG-IFN/RBV, in standard doses, followed by triple therapy. The concept of lead-in phase was initiated by the Schering\\u2013Plough company in order to improve efficacy of boceprevir-based triple therapy. Indeed, by lowering HCV RNA level, a short course of PEG-IFN/RBV may theoretically reduce the risk of viral breakthrough or resistance. However, there is still much controversy regarding the utility of the lead-in phase, some authors advocating its role in improving, and/or predicting triple therapy effectiveness, while others view it as a useless complication of the therapeutic regimen, its chief disadvantage being the inconvenience to the patient.\",\"Several host (age, sex, race, fibrosis stage, interleukin 28B polymorphism) and viral factors (hepatitis C virus [HCV] genotype, viral load) allow estimating the response to interferon-based therapies (which includes first-generation protease inhibitors) before treatment. However, treatment should not be denied to any patient based on unfavorable factors alone. Metabolic conditions associated with poor response (diabetes, insulin resistance, obesity) and alcohol abuse can be influenced before starting treatment. \\\"On-treatment\\\" predictors of response allow treatment to be tailored to the individual need of the patient. Patients with undetectable HCV RNA after 4 weeks (rapid virologic response [RVR]) have the highest chance for cure (>85%) both by dual and triple therapy. For triple therapy, the decision to shorten treatment requires that the virus remains undetectable for an additional 8 (telaprevir) to 20 (boceprevir) weeks (extended RVR). Based on viral kinetics, an even earlier prediction after 2 weeks of treatment with direct acting antivirals appears feasible.\",\"Influenza epidemics and pandemics are constant threats to human health. The application of antiviral drugs provides an immediate and direct control of influenza virus infection. At present, the major strategy for managing patients with influenza is through targeting conserved viral proteins critical for viral replication. Two classes of conventional antiviral drugs, the M2 ion channel blockers and the neuraminidase inhibitors, are frequently used. In recent years, increasing levels of resistance to both drug classes has become a major public health concern, highlighting the urgent need for the development of alternative treatments. Novel classes of antiviral compounds or biomolecules targeting viral replication mechanism are under development, using approaches including high-throughput small-molecule screening platforms and structure-based designs. In response to influenza virus infection, host cellular mechanisms are triggered to defend against the invaders. At the same time, viruses as obligate intracellular pathogens have evolved to exploit cellular responses in support of their efficient replication, including antagonizing the host type I interferon response as well as activation of specific cellular pathways at different stages of the replication cycle. Numerous studies have highlighted the possibility of targeting virus-host interactions and host cellular mechanisms to develop new treatment regimens. This review aims to give an overview of current and novel concepts targeting the virus and the host for managing influenza.\",\"Hepatitis C virus (HCV) is a modern-day pandemic; 2-3% of the world's population are thought to be infected with the virus and are subsequently at risk of developing end-stage liver diseases. The traditional standard of care (SOC) for HCV-infected patients has been limited to a regimen of pegylated-interferon alpha (pegIFN) and ribavirin; displaying low cure rates in a majority of patients and severe side effects. However, in 2011 the first direct-acting antivirals (DAA) were licensed to treat HCV-infected patients in combination with SOC, which served to elevate treatment response rates. The HCV drug development pipeline is currently populated with many additional and improved DAAs; primarily molecules that target the virus-encoded protease or polymerase enzymes. These molecules are being evaluated both in combination with the traditional SOC and together with other DAAs as all-oral pegIFN-free regimens with the ultimate goal of developing multiple DAA-containing HCV therapies that do not rely on an pegIFN backbone. A recent addition to the arsenal of HCV inhibitors in development is represented by an entirely new DAA class; molecules that target the HCV-encoded non-enzymatic NS5A protein. NS5A is essential for HCV propagation and, although its actual functions are largely unknown, it is likely a key regulator of viral genome replication and virion assembly. The protein is exquisitely sensitive to small molecule-mediated inhibition; NS5A-targeting molecules are probably the most potent antiviral molecules ever discovered and exhibit a number of other attractive drug-like properties, including activity against many HCV genotypes/subtypes and once-daily dosing potential. Although their mechanism of action is unclear, NS5A-targeting molecules are already proving their utility in clinical evaluation; particularly as components of pegIFN-sparring DAA combination regimens. This review will aim to amalgamate our current understanding and knowledge of NS5A-targeting molecules; their discovery, properties, applications, and insight into their future impact as components of all-oral pegIFN-free DAA combination therapies to combat HCV infection.\",\"Foot-and-mouth disease (FMD) is an economically significant animal disease because of the speed of its transmission. The current FMD vaccine provides no protection until 7days after the vaccination, which reduces its effectiveness in the case of an outbreak. Therefore, to find an alternative method of applying antiviral agents for rapid and enhanced inhibition of the FMD virus (FMDV), we compared the antiviral effects of promising antiviral agents and attempted to apply them in combination. First, we measured and compared the 50% effective concentration (EC(50)) to the mean inhibition effects of FMDV, and the 50% cytotoxic concentration (CC(50)) to the mean cytotoxicity of antiviral agents such as ribavirin, guanidine-hydrochloride (guanidine-HCl), 6-azauridine, and recombinant adenovirus expressing three small interference RNAs (Ad-siRNA) or porcine interferon-\\u03b1 (Ad-porcine IFN-\\u03b1) in swine kidney cells (IBRS-2). The selectivity indices of ribavirin (35.2) and 6-azauridine (34.6) were higher than that of guanidine-HCl (26.9). The selectivity indices of Ad-siRNA or Ad-porcine IFN-\\u03b1 were 7\\u00d710(3) or 7\\u00d710(4) based on the adenoviral titer. Next, we tested the combined effects of the FMDV inhibition agents. Enhanced inhibition effects were observed in the IBRS-2 cells and in suckling mice from the combination of Ad-porcine IFN-\\u03b1 and Ad-siRNA or ribavirin. The combined application of these recombinant adenoviruses and ribavirin may enhance their inhibitory effect on FMDV and overcome FMDV resistance against antiviral agents.\",\"Recent reports show that R70Q and L/C91M amino acid substitutions in the core from different hepatitis C virus (HCV) genotypes have been associated with variable responses to interferon (IFN) and ribavirin (RBV) therapy, as well to an increase of hepatocellular carcinoma (HCC) risk, liver steatosis and insulin resistance (IR). Mutations in NS5B have also been associated to IFN, RBV, nucleoside and non-nucleoside inhibitors drug resistance. The prevalence of these mutations was studied in HCV RNA samples from chronically HCV-infected drug-na\\u00efve patients.\",\"Hepatitis C virus genotype 4 (HCV-4) is the cause of approximately 20% of the 180 million cases of chronic hepatitis C in the world. HCV-4 infection is common in the Middle East and Africa, with an extraordinarily high prevalence in Egypt. Viral genetic polymorphisms, especially within core and NS5A regions, have been implicated in influencing the response to pegylated-interferon and ribavirin (PEG-IFN/RBV) combination therapy in HCV-1 infection. However, this has not been confirmed in HCV-4 infection. Here, we investigated the impact of heterogeneity of NS5A and core proteins of HCV-4, mostly subtype HCV-4a, on the clinical outcomes of 43 Egyptian patients treated with PEG-IFN/RBV. Sliding window analysis over the carboxy terminus of NS5A protein identified the IFN/RBV resistance-determining region (IRRDR) as the most prominent region associated with sustained virological response (SVR). Indeed, 21 (84%) of 25 patients with SVR, but only 5 (28%) of 18 patients with non-SVR, were infected with HCV having IRRDR with 4 or more mutations (IRRDR \\u2265 4) (P = 0.0004). Multivariate analysis identified IRRDR \\u2265 4 as an independent SVR predictor. The positive predictive value of IRRDR \\u2265 4 for SVR was 81% (21/26; P = 0.002), while its negative predictive value for non-SVR was 76% (13/17; P = 0.02). On the other hand, there was no significant correlation between core protein polymorphisms, either at residue 70 or at residue 91, and treatment outcome. In conclusion, the present results demonstrate for the first time that IRRDR \\u2265 4, a viral genetic heterogeneity, would be a useful predictive marker for SVR in HCV-4 infection when treated with PEG-IFN/RBV.\",\"Cyclophilins (CyPs) are cellular proteins that are essential to hepatitis C virus (HCV) replication. Since cyclosporine A was discovered to inhibit HCV infection, the CyP pathway contributing to HCV replication is a potential attractive stratagem for controlling HCV infection. Among them, CyPA is accepted to interact with HCV nonstructural protein (NS) 5A, although interaction of CyPB and NS5B, an RNA-dependent RNA polymerase (RdRp), was proposed first.\",\"Telaprevir is a hepatitis C NS3/4A protease inhibitor approved by the US Food and Drug Administration as part of combination therapy for the management of chronic hepatitis C virus (HCV) genotype 1 infection.\",\"Patients coinfected with HIV and HCV are at risk for developing portal hypertension (PHT), hyperdynamic circulation and pulmonary arterial hypertension (PAH). Data on the influence of antiviral therapy with pegylated interferon-\\u03b1 (PEG-IFN-\\u03b1) and ribavirin (RBV) are limited.\",\"Substitution of amino acid 70 and/or 91 in the core region of hepatitis C virus (HCV) genotype 1b (HCV-1b) is an important predictor of hepatocellular carcinoma (HCC), but its impact on HCC in nonresponders to interferon (IFN) and ribavirin (RIB) combination therapy is not clear.\",\"Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-\\u03b1 and ribavirin) has an effectiveness rate of only 40%-50%. Novel virus-specific drugs have recently been designed, and multiple compounds are under development. The approval for the clinical use of direct-acting antivirals in 2011 (boceprevir [BOC] and telaprevir, viral NS3 protease inhibitors) has increased recovery rates by up to 70%. Therefore, a highly effective treatment has been envisioned for the first time. This paper focuses on BOC and the implementation of new BOC-based treatment regimes.\",\"For patients chronically infected with hepatitis C virus (HCV), mutations in the non-structural 5A (NS5A) gene are important predictive factors for the response to interferon (IFN) therapy. In the present study, factor analysis of the therapeutic response of patients following pegylated IFN and ribavirin combination therapy was assessed in a multicenter study. Chronic HCV-infected patients with genotype 1b and high viral load (n=96, mean age 56.5 years; 59 males, 68 females) treated with pegylated IFN-\\u03b1-2b and ribavirin combination therapy were enrolled. This study was conducted at Kobe University Hospital and 25 affiliated hospitals in Hyogo prefecture. Sixty-five patients (68%) completed treatment with both pegylated IFN and ribavirin at >80% of the weight-based scheduled dosages. Patients who reduced or terminated therapy were frequently aged women (mean age 60.8 years; 11 males, 17 females). Overall, a sustained viral response (SVR) was achieved in 42 (44%) patients out of 96. Based on per-protocol-based (PPB) analysis, the SVR rate in patients with \\u22656 amino acid (aa) mutations in the IFN resistance-determining region (IRRDR) (75%) or \\u22651 aa mutation in the IFN sensitivity-determining region (ISDR) (61%) was significantly higher than that in patients with <5 aa mutations in IRRDR (30%) or no mutation in ISDR (29%). Multivariate analysis revealed that rapid viral response (RVR) (odds ratio, 18.1) and mutations of \\u22656 in IRRDR (odds ratio, 15.5) were significantly associated with SVR. In conclusion, mutations in the NS5A region, particularly in patients with \\u22656 aa mutations in IRRDR were strongly associated with a therapeutic response to pegylated IFN and ribavirin combination therapy.\",\"The recent marketing authorizations and hence availability of the new protease inhibitors, telaprevir and boceprevir, have profoundly changed the management of chronic hepatitis C patients. Guidelines for the use of these new drugs as part of a triple therapy, in combination with the standard therapy of peginterferon plus ribavirin, are proposed. The guidelines have been drawn up and evaluated by a meeting of the French Association for the Study of the Liver, posted online for comments, and extensively reviewed by international experts. The current published data on the various treatment strategies are reviewed. The guidelines address the majority of patient profiles including treatment-na\\u00efve patients and patients with failure of previous treatment. They recommend which patients should be treated with triple therapy and consider the results of triple therapy including the factors that are predictive of response. They consider the circumstances in which the length of triple therapy can be shortened and the advantages of a peginterferon plus ribavirin lead-in phase. Virological monitoring, stopping criteria, the evaluation of resistance to protease inhibitors, practical treatment management, treatment adherence and the management of side effects are discussed and simple guidelines proposed.\",\"In the TMC435-C101 study, 6 patients infected with hepatitis C virus genotype 1 were treated with the protease inhibitor TMC435 (200 mg once daily) as monotherapy for 5 days. Approximately 1.5 years later, 5 of these patients were re-treated with TMC435 (200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFN\\u03b1-2a and RBV) for 4 weeks, followed by PegIFN\\u03b1-2a and RBV until week 48 (in the Optimal Protease inhibitor Enhancement of Response to therApy [OPERA-1] study). TMC435-resistant variants, which emerged in all 5 patients during the TMC435-C101 study, were no longer detected at the beginning of the OPERA-1 study based on virus population sequencing. During the OPERA-1 study, 3 patients had a sustained virologic response; deep sequencing indicated low-level persistence of resistant variants in the remaining 2 patients, which might have affected their response to re-treatment.\",\"GS-9451, a novel hepatitis C virus (HCV) nonstructural 3/4a (NS3/4a) protease inhibitor, is highly active in patients infected with HCV genotype 1 (GT 1). The aim of this study is to characterize the clinical resistance profile of GS-9451 in GT 1 HCV-infected patients in a phase 1, 3-day monotherapy study. The full-length NS3/4A gene was population sequenced at baseline, on the final treatment day, and at follow-up time points. NS3 protease domains from patient isolates with emerging mutations were cloned into an NS3 shuttle vector, and their susceptibilities to GS-9451 and other HCV inhibitors were determined using a transient replication assay. No resistance mutations at NS3 position 155, 156, or 168 were detected in any of the baseline samples or in viruses from patients treated with 60 mg of GS-9451 once daily. Among patients who received 200 mg and 400 mg of GS-9451, viruses with mutations at position D168 (D168E/G/V) and R155 (R155K), which confer high-level resistance to GS-9451, were detected in those with GT 1b and GT 1a virus, respectively. Viruses with D168 mutations were no longer detected in any GT 1b patient at day 14 and subsequent time points. In GT 1a patients, R155K mutants were replaced by the wild type in 57% of patients at week 24. These NS3 clinical mutants were sensitive to NS5B and NS5A inhibitors, as well as alpha interferon (IFN-\\u03b1) and ribavirin. The lack of cross-resistance between GS-9451 and other classes of HCV inhibitors supports the utility of combination therapy.\",\"Telaprevir and boceprevir have received US Food and Drug Administration approval for use as triple therapy with pegylated interferon and ribavirin in genotype 1 chronic hepatitis C virus (HCV) infection. Clinical trials of these agents included few African Americans, despite the overwhelming need for improved therapies in this racial group. Although African Americans are predicted to have improved response rates with this new treatment paradigm, clinical trials illustrate lower rates of sustained virologic response for this racial group versus whites. African Americans with genotype 1 HCV infection appear to require longer durations of therapy than do whites to achieve a sustained virologic response. Further investigation is required to adequately counsel African Americans with genotype 1 chronic HCV infection on the efficacy of telaprevir and boceprevir in their racial group. Increased participation of this racial group in HCV clinical trials is needed to improve therapies in this difficult-to-treat population.\",\"Herpes simplex virus type 1 (HSV-1) is known to cause diseases of various severities. There is increasing interest to find drug combinations to treat HSV-1 by reducing drug resistance and cytotoxicity. Drug combinations offer potentially higher efficacy and lower individual drug dosage. In this paper, we report a new application of fractional factorial designs to investigate a biological system with HSV-1 and six antiviral drugs, namely, interferon alpha, interferon beta, interferon gamma, ribavirin, acyclovir, and tumor necrosis factor alpha. We show how the sequential use of two-level and three-level fractional factorial designs can screen for important drugs and drug interactions, as well as determine potential optimal drug dosages through the use of contour plots. Our initial experiment using a two-level fractional factorial design suggests that there is model inadequacy and that drug dosages should be reduced. A follow-up experiment using a blocked three-level fractional factorial design indicates that tumor necrosis factor alpha has little effect and that HSV-1 infection can be suppressed effectively by using the right combination of the other five antiviral drugs. These observations have practical implications in the understanding of antiviral drug mechanism that can result in better design of antiviral drug therapy.\",\"Hepatitis C (HCV), a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma, is the most common indication for liver transplantation in the United States. Although annual incidence of infection has declined since the 1980s, aging of the currently infected population is expected to result in an increase in HCV burden. HCV is prone to develop resistance to antiviral drugs, and despite considerable efforts to understand the virus for effective treatments, our knowledge remains incomplete. This paper reviews HCV resistance mechanisms, the traditional treatment with and the new standard of care for hepatitis C treatment. Although these new treatments remain PEG-IFN-\\u03b1- and ribavirin-based, they add one of the newly FDA approved direct antiviral agents, telaprevir or boceprevir. This new \\\"triple therapy\\\" has resulted in greater viral cure rates, although treatment failure remains a possibility. The future may belong to nucleoside/nucleotide analogues, non-nucleoside RNA-dependent RNA polymerase inhibitors, or cyclophilin inhibitors, and the treatment of HCV may ultimately parallel that of HIV. However, research should focus not only on effective treatments, but also on the development of a HCV vaccine, as this may prove to be the most cost-effective method of eradicating this disease.\",\"Telaprevir, a hepatitis C virus NS3/4A protease inhibitor has significantly improved sustained viral response rates when given in combination with pegylated interferon alfa-2a and ribavirin, compared with current standard of care in hepatitis C virus genotype 1 infected patients. In patients with a failed sustained response, the emergence of drug-resistant variants during treatment has been reported. It is unclear to what extent these variants persist in untreated patients. The aim of this study was to assess using ultra-deep pyrosequencing, whether after 4 years follow-up, the frequency of resistant variants is increased compared to pre-treatment frequencies following 14 days of telaprevir treatment.\",\"The management of non-responders (NR) represents the most challenging of all aspects in the care of patients with chronic hepatitis C (CHC). The purpose of the study was to evaluate the efficacy of amantadine.\",\"Influenza A/Mississippi/03/2001 (H1N1) and A/Hong Kong/2369/2009 (H1N1) viruses containing the neuraminidase gene mutation H275Y (conferring resistance to oseltamivir) were adapted to mice and evaluated for suitability as models for lethal infection and antiviral treatment. The viral neuraminidases were resistant to peramivir and oseltamivir carboxylate but sensitive to zanamivir. Similar pattern of antiviral activity were seen in MDCK cell assays. Lethal infections were achieved in mice with the two viruses. Oral oseltamivir at 100 and 300mg/kg/day bid for 5day starting at -2h gave 30% and 60% protection from death, respectively, due to the A/Mississippi/03/2001 infection. Intraperitoneal treatments with zanamivir at 30 and 100mg/kg/day starting at -2h gave 60% and 90% protection, respectively. Neither compound at <300mg/kg/day protected mice when treatments began at +24h. Amantadine was effective at 10, 30, and 100mg/kg/day, rimantadine was protective at 10 and 30mg/kg/day (highest dose tested), and ribavirin was active at 30 and 75mg/kg/day, with survival ranging from 60-100% for oral treatments initiated at -2h. For treatments begun at +24h, amantadine was protective at 30 and 100mg/kg/day, rimantadine showed efficacy at 10 and 30mg/kg/day, and ribavirin was active at 75mg/kg/day, with 60-100% survival per group. In the A/Hong Kong/2369/2009 infection, oral oseltamivir at 100 and 300mg/kg/day starting at -2h gave 50% and 70% protection from death, respectively. These infection models will be useful to study newly discovered anti-influenza virus agents and to evaluate compounds in combination.\",\"In the Phase 3 REALIZE study, 662 genotype 1 hepatitis C virus (HCV)-infected patients with prior peginterferon/ribavirin treatment failure (including relapsers, partial, and null responders) were randomized to 12 weeks of telaprevir given immediately (T12/PR48) or following 4 weeks of peginterferon/ribavirin (lead-in T12/PR48), or 12 weeks of placebo (PR48), combined with a total of 48 weeks of peginterferon alfa-2a/ribavirin. Sustained virologic response (SVR) rates were 64% (T12/PR48), 66% (lead-in T12/PR48), and 17% (PR48). This analysis aimed to characterize treatment outcomes and viral variants emerging in telaprevir-treated patients not achieving SVR. HCV NS3\\u00b74A population sequencing was performed at baseline, during treatment, and follow-up. Telaprevir-resistant variants were classified into lower-level (3- to 25-fold 50% inhibitory concentration [IC(50) ] increase: V36A/M, T54A/S, R155I/K/M/T, and A156S) and higher-level (>25-fold IC(50) increase: V36M+R155K and A156T/V) resistance. Resistant variants were uncommon at baseline. Overall, 18% (52%, 19%, and 1% of prior null and partial responders and relapsers, respectively) of telaprevir-treated patients had on-treatment virologic failure, with no significant difference with or without a lead-in. Virologic failure during the telaprevir-treatment phase was predominantly associated with higher-level resistance; virologic failure during the peginterferon/ribavirin-treatment phase was associated with higher- or lower-level, or wildtype variants, depending on genotype. Relapse occurred in 9% of patients completing assigned treatment and was generally associated with lower-level resistant variants or wildtype. Resistant variants were no longer detectable by study end (median follow-up of 11 months) in 58% of non-SVR patients.\",\"HCV subtype 1a has emerged as a predictor of poor response to triple hepatitis C therapy including boceprevir or telaprevir, which largely has been attributed to a lower resistance barrier in HCV-1a compared to -1b.\",\"The rate of non-response to pegylated interferon plus ribavirin (peg-IFN+RBV) in HCV/HIV coinfected patients is higher than in HCV-monoinfected patients. In this sense, the contribution of HCV genetic variability is unknown. The 5' untranslated (5'UTR), the nonstructural 5A (NS5A) and the second envelope (E2) HCV genomic regions have been implicated to peg-IFN therapy response. The proteins appear to block interferon (IFN)-induced RNA-dependent protein kinase (PKR) and the 5'UTR may influence the viral lymphotropism.\",\"Approximately 50% of patients with chronic hepatitis C (CHC) have a sustained virologic response to treatment with pegylated interferon (pegIFN)-\\u03b1 and ribavirin. Nonresponse to treatment is associated with constitutively increased expression of IFN-stimulated genes (ISGs) in the liver. Treatment of patients with acute hepatitis C (AHC) is more effective, with sustained virologic response rates greater than 90%. We investigated mechanisms of the different responses of patients with CHC and AHC to pegIFN-\\u03b1 therapy.\",\"Some regions associated with sensitivity to interferon-\\u03b1 and ribavirin have been identified in the hepatitis C virus (HCV) genome, including amino acid 70 in the core region (core a.a. 70), a.a. 2209-2248 (interferon sensitivity-determining region, ISDR) and a.a. 2334-2379 (interferon and ribavirin resistance-determining region, IRRDR).\",\"For the past decade, the standard treatment for chronic hepatitis C infection has been pegylated-interferon plus ribavirin. With US Food and Drug Administration approval of boceprevir and telaprevir--two protease inhibitors--the standard-of-care treatment for genotype-1 infection, the main genotype worldwide, is now peginterferon plus ribavirin and a protease inhibitor. Rates of sustained virological response or cure with triple combination treatment have improved substantially, both in patients who have had previous treatment and in those who have not. Improvements have been most substantial in populations regarded as difficult to treat, such as individuals with cirrhosis. However, despite improved response rates, protease inhibitors have incremental toxic effects, high costs, increased pill burden, and many drug interactions. Moreover, because new antiviral drugs directly inhibit hepatitis C virus, viral resistance has become an important issue, essentially precluding use of protease inhibitor monotherapy, and potentially restricting future treatment options for patients who consequently do not achieve sustained virological response. Protease inhibitors are the first of many antiviral medications that will probably be combined in future interferon-free regimens.\",\"We report a population pharmacokinetic (PK) and pharmacodynamic (PD) model of orally administered ribavirin in patients with chronic hepatitis C virus (HCV) infection enrolled in a multicenter clinical trial, including the estimation of covariate effects on ribavirin PK parameters and sustained viral response (SVR). Ribavirin concentrations obtained from 144 patients, consisting of n = 71 African American (AA) and n = 73 Caucasian Americans (CA), during 24 weeks of therapy were best described by a two-compartment model with first-order absorption and elimination parameterized in terms of apparent oral clearance (CL/F), apparent central volume (Vc/F), apparent peripheral volume (Vp/F), and apparent intercompartmental clearance (Q/F). The typical population parameters were CL/F (19.0 L/h), Vc/F (1,130 L), Vp/F (4,020 L), and Q/F (38.6). The Vp/F was approximately 50% greater in AA compared to CA. Significant covariates in the SVR model included IL-28B genotype, homeostasis model assessment of insulin resistance, and ribavirin exposure during the first week (AUC(0-7)). The population PK and logistic regression models both described the observed ribavirin concentration data and SVR data well. These findings suggest that optimization of ribavirin plasma concentrations during the first week of ribavirin dosing is most critical in AA patients in order to increase the rate of SVR, especially those with the IL-28B TT genotype.\",\"Insulin resistance, fibrosis and steatosis are established predictors of response to peg-interferon/ribavirin therapy in chronic hepatitis C (CHC). Several host genetic polymorphisms (IL28B, PNPLA3) modify treatment-outcome, the degree of steatosis or fibrosis. The aim of our study was to evaluate the role of these polymorphisms on insulin resistance (IR) in treatment-na\\u00efve patients with chronic hepatitis C.\",\"Hepatitis C virus (HCV) infection is associated with insulin resistance (IR), which is a condition known to influence the progression of liver fibrosis and the response to pegylated interferon (PEG-IFN)/ribavirin (RBV) therapy. We aimed to assess whether a sustained virological response (SVR) after antiviral therapy prevents the development of IR in the long term. Members of the Milan Safety Tolerability study cohort, who received PEG-IFN\\u03b12a/RBV or PEG-IFN\\u03b12b/RBV, underwent a homeostasis model assessment (HOMA) at the baseline and 24 months after treatment completion. For all patients (n = 431), a liver biopsy sample was scored for grading, staging (Ishak), and steatosis. At the baseline, IR (HOMA value > 2) was detected in 48 patients (12%), and it was associated with body weight (P = 0.03), an HCV load < 0.6 \\u00d7 10(6) IU/L (P = 0.006), fibrosis staging \\u2265 4 (P = 0.01), and moderate to severe steatosis (P = 0.03). IR did not influence the rates of end-of-treatment response (75% versus 69%, P = 0.4), SVR (63% versus 60%, P = 0.8), or relapse (19% versus 24%, P = 0.5). After treatment, IR developed in 49 of the 384 nondiabetic patients (14%). Although the mean baseline and posttreatment HOMA values were similar in SVR patients (1.11 \\u00b1 0.8 versus 1.18 \\u00b1 1.1, P = 0.25), patients experiencing treatment failure showed a significant increase in the mean HOMA value at the follow-up visit (1.20 \\u00b1 0.85 versus 1.49 \\u00b1 1.3, P = 0.007), and there was an increased rate of de novo IR in non-SVR patients versus SVR patients (17% versus 7%, P = 0.007). According to a logistic regression analysis, treatment failure (odds ratio = 2.81, 95% confidence interval = 1.39-5.67, P = 0.004) and a 10% body mass index increase (odds ratio = 6.42, 95% confidence interval = 1.69-24.3, P = 0.006) were significantly associated with the development of de novo IR.\",\"In comparison with peginterferon/ribavirin alone, boceprevir with peginterferon/ribavirin significantly improves sustained virological response (SVR) rates in patients with chronic hepatitis C virus (HCV) genotype 1 infections, but treatment failure remains a significant problem. Using phase 3 trial databases, we sought to develop stopping rules for patients destined to fail boceprevir-based combination therapy in order to minimize drug toxicity, resistance, and costs in the face of ultimate futility. Exploratory post hoc analyses using data from the Serine Protease Inhibitor Therapy 2 (SPRINT-2) study (treatment-naive patients) and the Retreatment With HCV Serine Protease Inhibitor Boceprevir and Pegintron/Rebetol 2 (RESPOND-2) study (treatment-experienced patients) were undertaken to determine whether protocol-specified stopping rules (detectable HCV RNA at week 24 for SPRINT-2 and at week 12 for RESPOND-2) could be refined and harmonized. In SPRINT-2, a week 12 rule with an HCV RNA cutoff of \\u2265 100 IU/mL would have discontinued therapy in 65 of 195 failures (sensitivity = 33%) without sacrificing a single SVR among 475 successes (specificity = 100%). Viral variants emerged after week 12 in 36 of the 49 evaluable patients (73%) who would have discontinued at week 12 using a \\u2265 100 IU/mL stopping rule. In RESPOND-2, five of six patients with week 12 HCV RNA levels between the lower limit of detection (9.3 IU/mL) and the lower limit of quantification (25 IU/mL) who continued therapy despite the protocol-stipulated futility rule achieved SVR; one additional patient with a week 12 HCV RNA level of 148 IU/mL also continued therapy, had undetectable HCV RNA at week 16, and attained SVR.\",\"Chronic hepatitis C (CHC) virus infection affects more than 170 million people globally. The aim of treatment of CHC is to effect sustained elimination of the virus (a sustained virological response, SVR). Prior to the development of direct-acting antiviral (DAA) agents, the standard of care (SOC) for CHC comprised combined treatment with pegylated interferon (PegIFN) and ribavirin (RBV).\",\"HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C virus infection, with boceprevir and telaprevir having recently received regulatory approval as add-on therapy to pegylated interferon/ribavirin for patients harboring genotype 1 infections. Overcoming antiviral resistance, broad genotype coverage, and a convenient dosing regimen are important attributes for future agents to be used in combinations without interferon. In this communication, we report the preclinical profile of MK-5172, a novel P2-P4 quinoxaline macrocyclic NS3/4a protease inhibitor currently in clinical development. The compound demonstrates subnanomolar activity against a broad enzyme panel encompassing major hepatitis C virus (HCV) genotypes as well as variants resistant to earlier protease inhibitors. In replicon selections, MK-5172 exerted high selective pressure, which yielded few resistant colonies. In both rat and dog, MK-5172 demonstrates good plasma and liver exposures, with 24-h liver levels suggestive of once-daily dosing. When administered to HCV-infected chimpanzees harboring chronic gt1a or gt1b infections, MK-5172 suppressed viral load between 4 to 5 logs at a dose of 1 mg/kg of body weight twice daily (b.i.d.) for 7 days. Based on its preclinical profile, MK-5172 is anticipated to be broadly active against multiple HCV genotypes and clinically important resistance variants and highly suited for incorporation into newer all-oral regimens.\",\"Recent studies have suggested that insulin resistance exerts a strong influence on chronic hepatitis C virus (HCV) infection. We analyzed pretreatment factors useful for predicting sustained virological response (SVR), especially interleukin (IL) 28B polymorphism and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR).\",\"In hepatitis C infection, the production of inappropriate cytokines levels may contribute to viral persistence and may affect the response to antiviral therapy. We investigate the effect of IL4 C-590T and C-33T polymorphisms on the response to combination therapy with interferon and ribavirin in chronic HCV patients. These single nucleotide polymorphisms were determined by PCR-RFLP in 235 responder and 210 non-responder to combination therapy. The IL4-590 T/T and -33 T/T genotypes were associated with resistance to the therapy (p<0.001, p=0.001 respectively). Haplotypes T(-590) T(-33) and T(-590) C(-33) were associated with a higher risk in non-responder patients than the responders (p<0.001 for each) while frequency of haplotype C(-590) C(-33) (with all wild alleles) was significantly higher in responders as compared to non-responders (p<0.001). These results suggest that inheritance of the IL4 polymorphisms may be associated with resistance to combined antiviral therapy in Egyptian HCV patients.\",\"Patients who do not achieve sustained virological response to telaprevir/peginterferon (PEG-IFN)/ribavirin need to be identified. Predictive factors of virological response to the triple therapy in non-responders to previous PEG-IFN/ribavirin therapy are not clear. The aims of this study were to determine the predictive factors of virological response to a 24-week regimen of triple therapy in 15 non-responders to previous PEG-IFN/ribavirin therapy among 61 Japanese adults infected with HCV genotype 1. Overall, sustained virological response and end-of-treatment response were achieved by 27% and 60%, respectively. Telaprevir-resistant variants (by direct sequencing) appeared during or after treatment in 82% of patients who did not show sustained virological response, but disappeared at the end of study, except for one patient with resistant variant at baseline. Substitution at aa 70 (Arg70) and type of previous response to PEG-IFN/ribavirin (partial response) were identified as significant determinants of sustained virological response. In addition, alpha-fetoprotein level (<10 \\u00b5g/L) and type of previous response (partial response) were identified as significant determinants of end-of-treatment response. Prediction of response to therapy based on the combination of these factors had high sensitivity, specificity, positive, and negative predictive values. In conclusion, this study identified amino acid substitution of the core region, alpha-fetoprotein level, and type of previous response as predictors of virological response to telaprevir/PEG-IFN/ribavirin in patients infected with HCV genotype 1b who had not responded to previous PEG-IFN/ribavirin therapy.\",\"To comprehensively characterize the contribution of virological factors as well as interleukin-28B (IL28B) single-nucleotide polymorphisms (SNPs) in determining treatment responses in pegylated-interferon plus ribavirin (Peg-IFN/RBV) therapy for chronic hepatitis C virus (HCV)-1b infection, we undertook a retrospective cohort analysis for the pretreatment dominant complete HCV open reading frame (ORF) amino-acid (aa) sequence study in 103 consecutive HCV-1b Japanese patients. The dominant HCV sequences classified by the response were subjected to systematic sliding-window comparison analysis to characterize response-specific viral sequences, along with IL28B SNP analyses (rs8099917). In each comparison of the patients between with and without rapid viral response (RVR), nonearly viral response (nEVR), sustained virological response (SVR), or relapse, the following regions were extracted as most significantly associated with the different responses respectively: nonstructural protein 5A (NS5A) aa.2224-2248 (P = 1.2E-07); core aa.70 (P = 4E-04); NS5A aa.2340-2382 (P = 7.0E-08); and NS5A aa.2360-2377 (P = 1.1E-05). Those NS5A regions nearly coincided with the interferon (IFN) sensitivity-determining region (NS5A aa.2209-2248) and the IFN/RBV resistance-determining region (NS5A aa.2339-2379). In a multivariate analysis, the IL28B SNP (odds ratio [OR] = 16.8; P = 0.009) and NS5A aa.2340-2382 (OR = 13.8; P = 0.0003) were extracted as the two most-significant independent variables contributing to the final outcome.\",\"Chronic hepatitis C infection is a leading cause of morbidity and mortality worldwide, with hepatitis C related cirrhosis being the most common indication for transplant and a major cause for the increase in hepatocellular carcinoma worldwide. Treatment for hepatitis C has consisted of nonspecific immunomodulatory therapies that stimulate the immune system and inhibit hepatitis C replication. Pegylated (peg-)interferon and ribavirin have been the standard of care with an overall sustained response rate of 40-50% in patients with genotype 1 infection, and 80% in genotype 2 or 3. Recently, direct-acting antiviral agents, including boceprevir, have demonstrated improved sustained response rates in patients with genotype 1 infection when given in combination with interferon and ribavirin. Boceprevir is a structurally novel hepatitis C virus (HCV) nonstructural 3 (NS3) protease inhibitor that has demonstrated robust antiviral activity in HCV replicons. Clinically, in phase II and III trials, boceprevir 800 mg three times daily with peginterferon and ribavirin has led to improved sustained response rates in genotype 1 infection treatment-naive patients, relapsers, partial responders, and null responders. Phase II data have demonstrated that ribavirin is essential for optimal boceprevir response. Moreover, phase II data have suggested that a 4-week peginterferon or ribavirin lead-in strategy may reduce relapse rates and provide crucial on-treatment data for treatment response with boceprevir addition. Side effects of boceprevir when added to peginterferon and ribavirin are similar to peginterferon and ribavirin, though higher rates of anemia have been noted, with an incremental increase in erythropoietin use. The addition of boceprevir represents a major advance in patients with genotype 1 infection who are treatment na\\u00efve.\",\"Molecular biology techniques are routinely used to diagnose and monitor treatment of patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These tools can detect and quantify viral genomes and analyze their sequence to determine their genotype or subtype and to identify nucleotide or amino acid substitutions associated with resistance to antiviral drugs. They include real-time target amplification methods, which have been standardized and are widely used in clinical practice to diagnose and monitor HBV and HCV infections, and next-generation sequencing techniques, which are still restricted to research laboratories. In addition, new enzyme immunoassays can quantify hepatitis B surface and hepatitis C core antigens, and point-of-care tests and alternatives to biologic tests that require whole-blood samples obtained by venipuncture have been developed. We review these new virologic methods and their clinical and research applications to HBV and HCV infections.\",\"Until recently, the standard of care (SOC) for patients with chronic hepatitis C virus (HCV) infection has consisted of a combination of pegylated interferon-\\u03b1 [corrected] plus ribavirin, administered for 24- to 48-weeks depending on the HCV genotype. The sustained virologic response rate for this SOC has been only about 50% in patients infected with genotype 1 HCV, the most prevalent genotype in Europe and North America. HCV therapy has been revolutionised recently by the approval of two direct-acting antiviral agents (DAA) against the NS3/4A serine protease for use in genotype 1 HCV, the ketoamide inhibitors boceprevir and telaprevir. The novel SOC marks the beginning of an extraordinary new era in HCV therapy. We review this new SOC with an emphasis on practical issues related to protease inhibitors, e.g. prescribing guidelines, futility rules and management of adverse events. We also give a perspective on what to expect in the coming years. Newer DAA with simplified dosing regimens and/or minimal toxicity which, when used in combination, will lead to viral eradication in most if not all CHC patients who undergo treatment. The novel agents in clinical development are paving the way for future interferon-sparing regimens.\",\"Hepatitis C virus (HCV) causes chronic infection in almost 2% of the world's population. If untreated, chronic carriers can develop severe liver disease including fibrosis, cirrhosis and hepatocellular carcinoma. Until recently, hepatitis C was treated with a combination of pegylated interferon and ribavirin, a treatment which was only partially effective and was plagued with side effects. In 2011 two inhibitors of the virally encoded NS3/4 protease have become part of standard therapy, which have improved treatment rates but can exacerbate the problematic side effects. While the addition of these first directly acting antivirals (DAAs) marks a milestone in anti-HCV therapy, new and improved combinations of drugs are desperately needed. New generations of drugs will have to address genetic variability of HCV and issues of viral resistance. Furthermore, combination therapies have to be tailored to effectively cure patient populations that have traditionally been hardest to treat, including patients with cirrhosis, those receiving liver transplants and individuals who are co-infected with HIV or hepatitis B virus. Since the discovery of HCV a plethora of experimental tools have been developed which enabled detailed analysis of various aspects of the viral life cycle and the interaction of HCV with its human host. Such studies have revealed a growing list of targets for therapeutic intervention, some of which will be discussed in this review.\",\"In patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination with peginterferon and ribavirin (PR) significantly increased sustained virologic response (SVR) rates compared with PR alone. However, genotypic changes could be observed in TVR-treated patients who did not achieve an SVR.\",\"The aim of this study is to review clinical trial data on the newly approved protease inhibitors boceprevir and telaprevir to develop consensus recommendations on the optimal use of these agents for the treatment of patients with chronic hepatitis C virus (HCV) infection. An expert panel of seven leading authorities in viral hepatitis was convened to establish and disseminate a practical guide on best practices for incorporating boceprevir and telaprevir into therapy for HCV infection in both treatment-naive and treatment-experienced patients. The topics covered include selecting candidates for boceprevir- or telaprevir-based treatments, predictors of response and early viral kinetics, response-guided therapy approaches, on-treatment management strategies to optimize the likelihood of response and minimize the risk of drug resistance, management of adverse effects during therapy and key considerations for special populations. The expert panel incorporated the best available clinical evidence into recommendations on how boceprevir and telaprevir should be used in the clinical setting. They indicated how treatment regimens may differ according to the baseline factors, such as presence of cirrhosis and when therapy may need to be modified or stopped altogether because of adverse events or poor virologic response. This practical guide will serve as a valuable resource for clinicians embarking on the new treatment paradigm of boceprevir or telaprevir in combination with peginterferon/ribavirin for chronic genotype 1 HCV infection.\",\"Genotype 1 (G1) chronic hepatitis C (CHC) patients achieving a rapid virological response (RVR) on pegylated interferon (PEG-IFN) plus ribavirin have a high chance of sustained virological response (SVR), influenced by IL28B status, viral load, fibrosis and insulin resistance. We assessed whether 25-hydroxyvitamin D (25[OH]D) serum levels are linked to RVR and can be used together with IL28B to construct a pretreatment model to predict RVR.\",\"HCV genotypes 2- or 3-infected patients with a rapid virological response (RVR) to therapy with pegylated interferon and ribavirins who have a low viral load, noncirrhotic and nonobese may be considered for a shorter course of treatment. However, no studies have assessed host-viral factors associated with relapse in genotype 2 and 3 separately. Accordingly, we assessed whether 12 weeks of pegylated interferon and ribavirin was an optimized regimen for treatment of HCV genotype 2 and 3 with positive predictors of response. Power and sample size were a priori calculated and 96 consecutive chronic hepatitis C patients (53, genotype 2 and 43, genotype 3) without cirrhosis who were not obese and who achieved a RVR to therapy with peg-IFN-\\u03b1-2a and ribavirin were enrolled. Fibrosis, steatosis, homeostatic model assessment-insulin resistance and HCV RNA were predefined variables to be evaluated in relapse. An intention-to-treat analysis was performed. SVR rates were 98% and 84% for genotype 2 and 3, respectively. Analysis of genotype 3 patients who had relapse showed a negative correlation with steatosis (P < 0.0001) and HCV RNA (P < 0.015). Multivariate analysis showed that steatosis was the independent predictor of relapse (OR, 0.988; 95% CI, 0.981-0.993; P < 0.001). Genotype 3 patients with steatosis had a relapse rate of 36.4% and 15.8% in those with high and low viral load, respectively, whereas there was no relapse in those without steatosis. In conclusion, a 12-week course of therapy is sufficient for patients without cirrhosis, not obese and infected with HCV genotype 2 achieve a RVR. This is not the case for genotype 3. Steatosis is the independent predictor of relapse. New therapeutic strategies are necessary for this subgroup of HCV genotype 3.\",\"Insulin resistance is a risk factor for non-response to interferon/ribavirin therapy in patients with chronic hepatitis C. The aim of this study was to determine the role played by protein-tyrosine phosphatases (PTPs) in the absence of interferon-\\u03b1 (IFN\\u03b1) response associated with insulin resistance. We induced insulin resistance by silencing IRS-2 or by treating HepG2 cells with tumor necrosis factor-\\u03b1 (TNF\\u03b1) and analyzed insulin response by evaluating Akt phosphorylation and IFN\\u03b1 response by measuring Stat-1 tyrosine phosphorylation and 2',5'-oligoadenylate synthase and myxovirus resistance gene expression. The response to IFN\\u03b1 was also measured in insulin-resistant obese mice (high fat diet and ob/ob mice) untreated and treated with metformin. Silencing IRS-2 mRNA induces insulin resistance and inhibits IFN\\u03b1 response. Likewise, TNF\\u03b1 suppresses insulin and IFN\\u03b1 response. Treatment of cells with pervanadate and knocking down PTP-1B restores insulin and IFN\\u03b1 response. Both silencing IRS-2 and TNF\\u03b1 treatment increase PTP and PTP-1B activity. Metformin inhibits PTP and improves IFN\\u03b1 response in insulin-resistant cells. Insulin-resistant ob/ob mice have increased PTP-1B gene expression and activity in the liver and do not respond to IFN\\u03b1 administration. Treatment with metformin improves this response. In HepG2 cells, insulin resistance provokes IFN\\u03b1 resistance, which is associated with an increased PTP-1B activity in the liver. Inhibition of PTP-1B activity with pervanadate and metformin or knocking down PTP-1B reestablishes IFN\\u03b1 response. Likewise, metformin decreases PTP-1B activity and improves response to IFN\\u03b1 in insulin-resistant obese mice. The use of PTP-1B inhibitors may improve the response to IFN\\u03b1/ribavirin therapy.\",\"Development of more effective hepatitis C (HCV) antivirals has been rapid. The addition of orally administered medications that target the virus (direct acting antivirals [DAA]) to pegylated interferon and ribavirin have dramatically increased sustained virologic response rates in genotype 1-infected patients. However, the side effect profile remains challenging and the dosing schedule complicated. The DAAs currently in development possess the promise of once- or twice-daily dosing schedules, improved tolerance profiles, higher resistance barriers, and pan-genotypic antiviral activity. Emerging interferon-sparing, combination DAA data demonstrates that an interferon is not essential to achieve sustained virological response. This will expand the proportion of HCV-infected patients who can be considered for therapy and will allow for better-tolerated regimens. Expertise in HCV antiviral resistance, drug metabolism, and drug-drug interactions and optimization of drug adherence are now key requirements in the DAA era.\",\"The purpose of this report is to illustrate the US Food and Drug Administration's rationale for approving response-guided therapy (RGT) for telaprevir (TVR) in combination with pegylated interferon-\\u03b1 and ribavirin (P/R) for the treatment of adults with genotype 1 chronic hepatitis C who were prior relapsers. RGT was prospectively evaluated in two registration trials of treatment-na\\u00efve subjects. In these studies, RGT allowed subjects who achieved undetectable hepatitis C virus RNA from weeks 4 and 12, known as extended rapid virologic response (eRVR), to stop all treatments at 24 weeks. A patient without eRVR received an additional 36 weeks of P/R after 12 weeks of a TVR triple regimen (total of 48 weeks). However, RGT in prior P/R relapsers was not prospectively evaluated. Empirical cross-trial data indicated high sustained virologic response rates (>90%) in prior relapsers achieving eRVR, irrespective of P/R duration (24 or 48 weeks). Further analyses demonstrated that interferon responsiveness does not change in P/R-experienced subjects with a second round of P/R. The comparability in interferon responsiveness across treatment courses allowed us to bridge data between treatment-na\\u00efve and P/R-experienced subjects to support the approval of RGT in prior relapse subjects.\",\"Because the current interferon (IFN)-based treatment for hepatitis C virus (HCV) infection has a therapeutic limitation and side effects, a more efficient therapeutic strategy is desired. Recent studies show that supplementation of vitamin D significantly improves sustained viral response via IFN-based therapy. However, mechanisms and an active molecular form of vitamin D for its anti-HCV effects have not been fully clarified. To address these questions, we infected HuH-7 cells with cell culture-generated HCV in the presence or absence of vitamin D(3) or its metabolites. To our surprise, 25-hydroxyvitamin D(3) [25(OH)D(3) ], but not vitamin D(3) or 1,25-dihydroxyvitamin D(3) , reduced the extra- and intracellular levels of HCV core antigen in a concentration-dependent manner. Single-cycle virus production assay with a CD81-negative cell line reveals that the inhibitory effect of 25(OH)D(3) is at the level of infectious virus assembly but not entry or replication. Long-term 25(OH)D(3) treatment generates a HCV mutant with acquired resistance to 25(OH)D(3) , and this mutation resulting in a N1279Y substitution in the nonstructural region 3 helicase domain is responsible for the resistance.\",\"Insulin resistance (IR) affects sustained virological response (SVR) in chronic hepatitis C (CHC). The aim of this study was to investigate the effect of adding metformin to peginterferon alfa-2a and ribavirin on the efficacy in patients with genotype 1 CHC and IR.\",\"Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. The aim of the present phase II study was to examine virologic response rates with vaniprevir in combination with pegylated interferon alpha-2a (Peg-IFN-\\u03b1-2a) plus ribavirin (RBV). In this double-blind, placebo-controlled, dose-ranging study, treatment-na\\u00efve patients with HCV genotype 1 infection (n = 94) were randomized to receive open-label Peg-IFN-\\u03b1-2a (180 \\u03bcg/week) and RBV (1,000-1,200 mg/day) in combination with blinded placebo or vaniprevir (300 mg twice-daily [BID], 600 mg BID, 600 mg once-daily [QD], or 800 mg QD) for 28 days, then open-label Peg-IFN-\\u03b1-2a and RBV for an additional 44 weeks. The primary efficacy endpoint was rapid viral response (RVR), defined as undetectable plasma HCV RNA at week 4. Across all doses, vaniprevir was associated with a rapid two-phase decline in viral load, with HCV RNA levels approximately 3 log(10) IU/mL lower in vaniprevir-treated patients, compared to placebo recipients. Rates of RVR were significantly higher in each of the vaniprevir dose groups, compared to the control regimen (68.8%-83.3% versus 5.6%; P < 0.001 for all comparisons). There were numerically higher, but not statistically significant, early and sustained virologic response rates with vaniprevir, as compared to placebo. Resistance profile was predictable, with variants at R155 and D168 detected in a small number of patients. No relationship between interleukin-28B genotype and treatment outcomes was demonstrated in this study. The incidence of adverse events was generally comparable between vaniprevir and placebo recipients; however, vomiting appeared to be more common at higher vaniprevir doses.\",\"This study explores pretreatment predictive factors for ultimate virological responses to pegylated interferon-\\u03b1 (1.5 \\u03bcg/kg/week) and ribavirin (600-1000 mg/day) (PEG-IFN/RBV) combination therapy for patients infected with hepatitis C virus (HCV)-1b and a high viral load.\",\"Several directly acting and host targeting antivirals that inhibit hepatitis C virus replication have entered clinical trials. Among the most advanced of these are RG7128, an inhibitor of the NS5B polymerase; BMS-790052, an inhibitor of NS5A; and alisporivir, an inhibitor of human cyclophilins. These agents have potent antiviral activity in chronic HCV patients, act additively or synergistically with inhibitors of the HCV NS3/4A protease, and improve the rate of virologic response produced by traditional pegylated interferon plus ribavirin therapy. No cross resistance has been observed; moreover, nucleoside NS5B and cyclophilin inhibitors appear to suppress resistance to non-nucleoside NS5B and NS3/4A inhibitors. Several recent reports of virologic responses produced by combinations of agents that inhibit HCV replication in the absence of interferon provide optimism that eradication of HCV will be possible without interferon in the future.\",\"BI 207127 is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor in vitro.\",\"Insulin resistance (IR) is induced by chronic hepatitis C virus (HCV) genotypes 1 and 4 infections. It is not known whether drugs that affect IR such as Pioglitazone and Prednisone also affect serum HCV RNA titers independently of PEG-Interferon-\\u03b12/ribavirin treatment. The primary aim was to assess whether Pioglitazone by improving IR and/or inflammation decreases HCV viral load independently of standard of care HCV treatment. A secondary aim was to assess whether Prednisone, a drug that induces insulin resistance and stimulates HCV viral entry and replication in replicon culture systems, increases HCV viral load in this population.\",\"Hepatitis C virus (HCV) infects and associates with B cells, leading to abnormal B-cell activation and development of lymphoproliferative and autoimmune disorders. This immune perturbation may in turn be associated with the resistance of HCV against the host immune system. The objective of this study was to analyse the effects of HCV infection of B cells on the efficacy of interferon (IFN)-based therapy. The study enrolled 102 patients with chronic hepatitis C who were treated with pegylated IFN plus ribavirin. HCV RNA titres in B cells were compared in patients with rapid viral responder (RVR) vs non-RVR, sustained viral responder (SVR) vs non-SVR and null viral responder (NVR) vs VR. The levels of HCV RNA in B cells were significantly higher in non-RVR, non-SVR and NVR groups. Association between the therapy outcome and the positive B-cell HCV RNA was also investigated in relation to other known viral and host factors. Multivariable analyses showed that the positive B-cell HCV RNA and the minor single-nucleotide polymorphism near the IL28B gene (rs8099917) were independent factors associated with NVR in patients infected with HCV genotype 1. When these two factors were combined, the sensitivity, specificity, positive and negative predictive values for NVR were 92.3%, 98.2%, 92.3% and 98.2%, respectively. Genotype 1 and the presence of one or no mutations in the IFN-sensitivity determining region were associated with higher levels of B-cell HCV RNA. B-cell-tropic HCV appears to have an IFN-resistant phenotype. B-cell HCV RNA positivity is a predictive factor for resistance to IFN-based therapy.\",\"Mericitabine (RG7128), an orally administered prodrug of PSI-6130, is the most clinically advanced nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV. This review describes what has been learnt so far about the resistance profile of mericitabine. A serine to threonine substitution at position 282 (S282T) of the RdRp that reduces its replication capacity to approximately 15% of wild-type is the only variant that has been consistently generated in serial in vitro passage experiments. To date, no evidence of genotypic resistance to mericitabine has been detected by population or clonal sequence analysis in any baseline or on-treatment samples collected from >600 patients enrolled in Phase I/II trials of mericitabine administered as monotherapy, in combination with pegylated interferon/ribavirin, or in combination with the protease inhibitor, danoprevir, for 14 days in the proof-of-concept study of interferon-free therapy.\",\"Insulin resistance, as measured by surrogate markers, is associated with lower response to hepatitis C virus (HCV) therapy and may improve with HCV eradication. We prospectively evaluated the impact of directly measured insulin resistance and abnormal glucose metabolism on achieving sustained virologic response (SVR) with HCV therapy and assessed whether SVR results in improved insulin sensitivity and fasting glucose.\",\"Hepatitis C virus (HCV) infection affects over 170 million people worldwide and is the most common blood-borne infection in the United States. Standard treatment with peginterferon alfa-ribavirin results in low sustained virologic response (SVR) rates in many patients, especially those who are African-American, are coinfected with human immunodeficiency virus (HIV), or have liver cirrhosis. Because of suboptimal SVR rates, new direct-acting antiviral agents that target HCV viral replication steps are in development. Boceprevir is one of the novel NS3/4A protease inhibitors that was recently approved by the U.S. Food and Drug Administration. We evaluated the literature regarding boceprevir by performing a MEDLINE search (January 1996-July 2011) to identify relevant clinical trials. Abstracts and poster and oral presentations from hepatology and HIV conferences were also reviewed. Potent anti-HCV activity was seen in clinical trials with boceprevir when it was studied in HCV genotype 1-infected patients who were na\\u00efve to or had experience with HCV therapy. Data with boceprevir in HIV-HCV-coinfected patients are currently lacking; however, initial data on drug-drug interactions between boceprevir and antiretrovirals have become available. Resistance to boceprevir has been evaluated in trials as well, although more data are needed in this area. The most common adverse events with boceprevir included anemia and dysgeusia. Based on available data, boceprevir is one of the promising novel direct-acting antiviral agents that will likely reshape the treatment of patients with HCV infection.\",\"Insulin resistance is a predictor of poor response to peginterferon/ribavirin in patients infected with the chronic hepatitis C virus (HCV). There are no data on direct-acting antivirals. This exploratory analysis assessed the effect of metabolic factors and insulin resistance, measured by homoeostatic model assessment (HOMA), on virological response to telaprevir in Study C208.\",\"More than 1% of the Hungarian population is infected with hepatitis B, C, or D viruses. Since 2006 the diagnostics and therapy of these infections are carried out in treatment centers according to national guidelines - since 2010 according to financial protocols. The consensus-based guidelines for 2012 are published in this paper. The guidelines stress the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection is pegylated interferon for 48 weeks or continuous entecavir therapy. The later must be continued for at least 6 months after hepatitis B surface antigen (HBsAg) seroconversion. Tenofovir disoproxil fumarat is not yet reimbursed by the National Health Insurance Fund. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection. Treatment naive chronic hepatitis C patients should initially receive pegylated interferon and ribavirin dual combination therapy. In genotype 1 infection if response is insufficient at 4 or 12 weeks one of the two new direct acting antivirals (boceprevir or telaprevir) should be added. The length of treatment is usually 48 weeks; in cases of extended early viral response shorter courses are recommended. Previous treatment failure patients with genotype 1 infection should receive a protease inhibitor backed triple combination therapy, mostly for 48 weeks. However, relapsers without cirrhosis and with extended rapid viral response, shorter telaprevir based combination therapy is sufficient. Drug-drug interactions as well as emergence of viral resistance are of particular importance. For genotype 2 or 3 HCV infections 24 weeks, for genotype 4 infections 24, 48 or 72 weeks of pegylated interferon plus ribavirin therapy is recommended in general. The guidelines published here become protocols when published as official publications of the Hungarian Health Authority.\",\"Both viral and host factors influence response to peginterferon-\\u03b1 plus ribavirin (pegIFN\\u03b1/RBV) in patients with chronic hepatitis C. The impact of these variables is more pronounced in HIV/Hepatitis C virus (HCV)-coinfected individuals, in whom treatment response rates are lower.\",\"The manner in which ribavirin (RBV) enhances the antiviral effects of interferon (IFN) against hepatitis C virus (HCV) remains unknown. We investigated whether RBV modifies IFN-stimulated genes (ISGs) in vivo and in vitro.\",\"Patients with chronic hepatitis C and insulin resistance are less likely to respond to anti-hepatitis C virus (HCV) therapy and are at risk for more rapid fibrosis progression. Coadministration of pioglitazone with peginterferon/ribavirin improves insulin sensitivity and increases virologic response rates in insulin-resistant HCV genotype 4 patients, but it is unclear whether this finding applies to genotype 1 patients. For this reason we randomized treatment-naive HCV genotype 1 patients with insulin resistance to receive either standard care (peginterferon alpha-2a plus ribavirin for 48 weeks, n = 73) or pioglitazone 30-45 mg/day plus standard care (n = 77) in an open-label multicenter trial. Patients randomized to pioglitazone received the drug during a 16-week run-in phase, the 48-week standard-care phase, and the 24-week untreated follow-up phase. Pioglitazone treatment improved hemoglobin A1c (HbA1c), plasma glucose, insulin levels, and homeostasis model assessment of insulin resistance score and increased serum adiponectin levels during the 16-week run-in phase and maintained these improvements during the standard-care phase. However, we observed no statistically significant difference between the two groups in the primary efficacy endpoint, the decrease from baseline to Week 12 of peginterferon alpha-2a/ribavirin treatment in mean log(10) HCV RNA titer (-3.5 \\u00b1 1.71 and -3.7 \\u00b1 1.62 IU/mL in the pioglitazone and standard-care groups, respectively, \\u0394 = 0.21 IU/mL, P = 0.4394).\",\"Pegylated-interferon plus ribavirin (PEG-IFN/RBV) therapy is a current standard treatment for chronic hepatitis C. We previously reported that the viral sequence heterogeneity of part of NS5A, referred to as the IFN/RBV resistance-determining region (IRRDR), and a mutation at position 70 of the core protein of hepatitis C virus genotype 1b (HCV-1b) are significantly correlated with the outcome of PEG-IFN/RBV treatment. Here, we aimed to investigate the impact of viral genetic variations within the NS5A and core regions of other genotypes, HCV-2a and HCV-2b, on PEG-IFN/RBV treatment outcome. Pretreatment sequences of NS5A and core regions were analyzed in 112 patients infected with HCV-2a or HCV-2b, who were treated with PEG-IFN/RBV for 24 weeks and followed up for another 24 weeks. The results demonstrated that HCV-2a isolates with 4 or more mutations in IRRDR (IRRDR[2a]\\u22654) was significantly associated with rapid virological response at week 4 (RVR) and sustained virological response (SVR). Also, another region of NS5A that corresponds to part of the IFN sensitivity-determining region (ISDR) plus its carboxy-flanking region, which we referred to as ISDR/+C[2a], was significantly associated with SVR in patients infected with HCV-2a. Multivariate analysis revealed that IRRDR[2a]\\u22654 was the only independent predictive factor for SVR. As for HCV-2b infection, an N-terminal half of IRRDR having two or more mutations (IRRDR[2b]/N\\u22652) was significantly associated with RVR, but not with SVR. No significant correlation was observed between core protein polymorphism and PEG-IFN/RBV treatment outcome in HCV-2a or HCV-2b infection.\",\"Hepatitis C virus (HCV) subverts host cholesterol metabolism for key processes in its lifecycle. How this interference results in the frequently observed, genotype-dependent clinical sequelae of hypocholesterolemia, hepatic steatosis, and insulin resistance (IR) remains incompletely understood. Hypocholesterolemia typically resolves after sustained viral response (SVR), implicating viral interference in host lipid metabolism. Using a targeted cholesterol metabolomic platform we evaluated paired HCV genotype 2 (G2) and G3 patient sera for changes in in vivo HCV sterol pathway metabolites. We compared HCV genotypic differences in baseline metabolites and following antiviral treatment to assess whether sterol perturbation resolved after HCV eradication. We linked these metabolites to IR and urine oxidative stress markers. In paired sera from HCV G2 (n = 13) and G3 (n = 20) patients, baseline sterol levels were lower in G3 than G2 for distal metabolites (7-dehyrocholesterol (7DHC) 0.017 versus 0.023 mg/dL; P(adj) = 0.0524, cholesterol 140.9 versus 178.7 mg/dL; P(adj) = 0.0242) but not the proximal metabolite lanosterol. In HCV G3, SVR resulted in increased levels of distal metabolites (cholesterol [\\u039455.2 mg/dL; P(adj) = 0.0015], 7DHC [\\u03940.0075 mg/dL; P(adj) = 0.0026], lathosterol [\\u03940.0430 mg/dL P(adj) = 0.0405]). In contrast, lanosterol was unchanged after SVR (P = 0.9515).\",\"There are two classes of anti-hepatitis C virus (HCV) agents currently in development: direct-acting antivirals (DAA) and host-targeting antivirals (HTA). Cyclophilin inhibitor alisporivir (ALV) , previously known as Debio-025 is the most advanced HTA in development.\",\"Multiple clinical trials have demonstrated that herpes simplex virus 2 (HSV-2) suppressive therapy using acyclovir (ACV) or valacyclovir in HIV-1/HSV-2-infected persons increased the patient's survival and decreased the HIV-1 load. It has been shown that the incorporation of ACV-monophosphate into the nascent DNA chain instead of dGMP results in the termination of viral DNA elongation and directly inhibits laboratory strains of HIV-1. We evaluated here the anti-HIV activity of ACV against primary HIV-1 isolates of different clades and coreceptor specificity and against viral isolates resistant to currently used drugs, including zidovudine, lamivudine, nevirapine, a combination of nucleoside reverse transcriptase inhibitors (NRTIs), a fusion inhibitor, and two protease inhibitors. We found that, at clinically relevant concentrations, ACV inhibits the replication of these isolates in human tissues infected ex vivo. Moreover, addition of ribavirin, an antiviral capable of depleting the pool of intracellular dGTP, potentiated the ACV-mediated HIV-1 suppression. These data warrant further clinical investigations of the benefits of using inexpensive and safe ACV alone or in combination with other drugs against HIV-1, especially to complement or delay highly active antiretroviral therapy (HAART) initiation in low-resource settings.\",\"Only about 50% of patients chronically infected with hepatitis C virus genotype 1 achieve a successful response to standard treatment with pegylated interferon-alfa and ribavirin. Moreover, the recently approved protease inhibitors will have to be administered together with these drugs. Consequently, predicting response to standard treatment, ideally before starting it, remains an important challenge. Although several baseline predictors of treatment failure have been described, including clinical and virological factors, none of them is able to provide reliable predictions at the individual level. In addition, the development of multivariate models combining several predictive factors has not yet yielded predictions with the requisite reliability for use in clinical practice. Therefore, further research is needed to improve predictive models and to describe new factors that would enable us to predict treatment outcome with greater reliability and reproducibility. The development of candidate selection algorithms that help clinicians to identify which patients could benefit from the new therapies on the basis of their chances of responding to standard therapy is of major interest for both patient well-being and healthcare expense. This review attempts to provide a view of the current options for predicting the response to pegylated interferon-alfa plus ribavirin therapy in patients chronically infected with hepatitis C virus genotype 1.\",\"Data concerning the influence of insulin resistance (IR) and ethnicity on early phases of viral kinetics after initiation of peginterferon plus ribavirin in treatment-naive, chronic hepatitis C (CHC) patients are limited.\",\"The limited efficacy of existing antiviral therapies for influenza--coupled with widespread baseline antiviral resistance--highlights the urgent need for more effective therapy. We describe a triple combination antiviral drug (TCAD) regimen composed of amantadine, oseltamivir, and ribavirin that is highly efficacious at reducing mortality and weight loss in mouse models of influenza infection. TCAD therapy was superior to dual and single drug regimens in mice infected with drug-susceptible, low pathogenic A/H5N1 (A/Duck/MN/1525/81) and amantadine-resistant 2009 A/H1N1 influenza (A/California/04/09). Treatment with TCAD afforded >90% survival in mice infected with both viruses, whereas treatment with dual and single drug regimens resulted in 0% to 60% survival. Importantly, amantadine had no activity as monotherapy against the amantadine-resistant virus, but demonstrated dose-dependent protection in combination with oseltamivir and ribavirin, indicative that amantadine's activity had been restored in the context of TCAD therapy. Furthermore, TCAD therapy provided survival benefit when treatment was delayed until 72 hours post-infection, whereas oseltamivir monotherapy was not protective after 24 hours post-infection. These findings demonstrate in vivo efficacy of TCAD therapy and confirm previous reports of the synergy and broad spectrum activity of TCAD therapy against susceptible and resistant influenza strains in vitro.\",\"Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032), a novel HCV NS3 protease inhibitor in clinical development, was evaluated for safety, antiviral activity, and resistance in four double-blind, placebo-controlled, sequential-panel, single- and multiple-ascending-dose (SAD and MAD) studies in healthy subjects or subjects with chronic HCV genotype 1 infection. In SAD studies, subjects (healthy or with chronic HCV infection) were randomized to receive asunaprevir in dose groups of 10 to 1,200 mg or a placebo. In MAD studies, healthy subjects were randomized to receive asunaprevir in dose groups of 10 to 600 mg twice daily or a placebo for 14 days; subjects with HCV infection received asunaprevir in dose groups of 200 to 600 mg twice daily, or a placebo, for 3 days. Across all four studies, headache and diarrhea were the most frequent adverse events in asunaprevir recipients. Asunaprevir at doses of 200 to 600 mg resulted in rapid HCV RNA decreases from the baseline; maximal mean changes in HCV RNA over time were 2.7 and 3.5 log(10) IU/ml in the SAD and MAD studies, respectively. No enrichment of signature asunaprevir-resistant viral variants was detected. In conclusion, the novel NS3 protease inhibitor asunaprevir, when administered at single or multiple doses of 200 to 600 mg twice daily, is generally well tolerated, achieving rapid and substantial decreases in HCV RNA levels in subjects chronically infected with genotype 1 HCV.\",\"ITX 5061 is a scavenger receptor B1 antagonist that has entered phase 1 clinical trials in hepatitis C virus (HCV)-infected humans. We evaluated ITX 5061 in combination with interferon-\\u03b1, ribavirin, and HCV protease and polymerase inhibitors in a genotype 2a infectious virus system. ITX 5061 is a potent inhibitor of HCV replication and is additive to synergistic with interferon-\\u03b1, ribavirin, BILN2061, VX950, VX1, and 2'-C-methyladenosine. Resistance selection experiments were performed using a Jc1-FEO virus co-culture system and intermittent ITX 5061 exposure under neomycin selection. We identified a mutant virus with a substitution of aspartic acid for asparagine at the highly conserved position 415 in E2 (N415D). Introduction of this mutation into wild-type virus conferred high-level resistance to ITX 5061. There was no cross-resistance between ITX 5061 and HCV protease inhibitors or interferon-\\u03b1. These results suggest that ITX 5061 is a promising compound for study in combination with other HCV inhibitors.\",\"The role of insulin resistance in predicting virological response to therapy of chronic hepatitis C is debated. We assessed the association between basal (defined as homeostasis model assessment of insulin resistance (HOMA-IR)>2) and post-load insulin resistance (as oral glucose insulin sensitivity index<9.8 mg/kg/min) with the rapid and sustained virological responses in chronic hepatitis C.\",\"The launch of first-generation protease inhibitors (PIs) was a major step forward in hepatitis C virus (HCV) treatment. However, this major advance has, up to now, only been applicable to genotype-1 patients. Second-wave and second-generation PIs appear to achieve higher antiviral potency, with pan-genotype activities, fewer side-effects and potential activity against PI-resistant mutation by second-generation PIs, through more convenient daily administration. Other direct-acting antivirals (DAAs) include NS5B inhibitors such as nucleoside/nucleotide inhibitors (NIs) and non-nucleoside inhibitors (NNIs). NIs have similar efficacy across all genotypes and present with the highest barrier to resistance of all DAAs to date. PSI-7977, a pyrimidine nucleotide analogue, also has highly potent antiviral activity across all HCV genotypes. In combination with ribavirin in an interferon-free regimen, it can achieve a 100% sustained viral response (SVR) rate in genotype 2/3 treatment-na\\u00efve patients. In association with pegylated interferon and ribavirin (PR), it achieves an SVR of 91% in genotype-1 na\\u00efve patients. NNIs in association with PR appear to be less potent, but they may nonetheless play a key role in many of the combination trials including either PIs or NIs. NS5A inhibitors also exhibit highly potent antiviral activity. Evaluation of their activity in combination with PIs demonstrated for the first time that an interferon-free regimen can cure genotype-1b null-responder patients. Furthermore, quadruple therapy with PR can achieve a 100% SVR in genotype-1 null-responder patients. Other players in the field, such as cyclophilin inhibitors and therapeutic vaccines, may have a role in combination with DAAs. The near future of HCV treatment looks promising. However, whether or not DAA combinations will lead to an interferon-free regimen for all patients remains an open question.\",\"Around 50% of hepatitis C virus (HCV)-positive patients infected with genotype 1 are nonresponders to the combination of pegylated interferon (pegIFN) and ribavirin, including relapsers, and partial and null responders and, as such, are exposed to the risk of progression to cirrhosis and its complications, resulting in HCV-related morbidity and mortality. Repeat treatment using the same combination in such patients results in <5% viral eradication and there are no therapeutic prospects for patients who fail, as maintenance therapy has not proved efficacious. The triple association of direct-acting antivirals specific of HCV, and especially the first-generation protease inhibitors boceprevir and telaprevir, increases this percentage to around 65%, with variations according to the previous response to therapy of patients (85% of relapsers, 50% of partial responders and 30% of null responders). These encouraging results extend the therapeutic indications and costs of therapy during virological follow-up, and influence the rules of discontinuation. Information on the management of these new molecules also allows a larger number of patients to be cured and reduces the occurrence of viral resistance. Thus, the aim of the present review is to summarize the efficacy of the triple association of pegIFN, ribavirin and telaprevir or boceprevir in treatment-experienced patients who failed to respond to dual pegIFN and ribavirin therapy.\",\"The treatment of chronic hepatitis C virus (HCV) infection has substantially evolved over the past decade, following the Consensus Conference organized by the European Association for the Study of the Liver in 1999. Since then, the standard of care (SoC) for patients with chronic hepatitis C has been the combination of pegylated interferon (pegIFN) alpha-2a or -2b and ribavirin. In patients infected with HCV genotype 1, by far the most frequent HCV genotype worldwide, such treatment leads to a cure of infection in only 40-50% of cases. After a decade in which pegIFN alpha and ribavirin therapy was the only available option, triple therapy with HCV protease inhibitors (PIs; boceprevir and telaprevir) in combination with pegIFN alpha and ribavirin has become the new SoC for genotype-1-infected patients. With PI therapy, higher cure rates can be achieved, but specific issues are also raised, such as the emergence of resistance to PIs. For this reason, the present report examines the antiviral activity of PIs and what is currently known about resistance to them, while focusing on telaprevir and boceprevir, two HCV PIs recently licensed for the treatment of treatment-na\\u00efve and treatment-experienced genotype-1 patients with chronic hepatitis C. The clinical relevance of resistance testing is also discussed.\",\"Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen.\",\"About half of the patients with chronic hepatitis C are still not cured by treatment with the current standard of care, peginterferon \\u03b1/ribavirin. Direct antiviral drugs may overcome the limitations of standard antiviral therapy. The most promising new agents are inhibitors of the NS3/4A protease, the NS5B polymerase and the NS5A protein. Several compounds against these targets have entered clinical evaluation. Early clinical trials have emphasized the high potential for selecting resistant Hepatitis C virus variants. Furthermore, development of several new direct antivirals was stopped because of concerns over tolerability and safety. Then, in 2010, two phase III trials with the NS3/4A protease inhibitors boceprevir (SPRINT-2) and telaprevir (ADVANCE) showed that the combination of these compounds with standard care increases sustained virologic response rates in treatment-na\\u00efve genotype 1 patients from 38-44% to 66-75%. Future goals of therapy with direct antiviral agents are to improve tolerability, shorten the duration of therapy and overcome the issue of resistance. Several studies have been initiated that combine different novel therapies, with and without interferon \\u03b1/ribavirin.\",\"The combination of pegylated interferon-\\u03b1 plus ribavirin (pegIFN\\u03b1-RBV) has been the only therapeutic option for patients with chronic hepatitis C virus (HCV) infection during the last decade. Unfortunately, it provides cure to less than a half of individuals infected with HCV genotype 1, which is by far the most prevalent worldwide. The recent introduction of new direct-acting antivirals (DAA) has revolutionized the hepatitis C field. The addition of any of the two recently approved HCV protease inhibitors, boceprevir or telaprevir, to pegIFN\\u03b1-RBV results in the cure for two-thirds of HCV genotype 1, interferon-naive patients.\",\"Mutations located in the 109-amino acid fragment of NS5B are typically associated with resistance to interferon (IFN) and ribavirin (RIB) and to new antiviral drugs. The prevalence of these mutations was examined in 69 drug-na\\u00efve individuals with hepatitis C virus (HCV) infections in Rio de Janeiro, Brazil. Mutations related to non-response to IFN/RIB were observed in all subtypes studied (1a, 1b, 2b, 3a and 4). The most common mutation was Q309R, present in all subtypes, except subtype 2b with frequency above 20%. D244N was detected only in subtype 3a and A333E was detected only in subtype 2b. We did not detect the S282T, S326G or T329I mutations in any of the samples analysed. Of note, the C316N mutation, previously related to a new non-nucleoside compound (HCV796 and AG-021541), was observed in only eight of 33 (24%) samples from subtype 1b. Site 316 was under positive selection in this HCV variant. Our data highlight the presence of previously described resistance mutations in HCV genotypes from drug-na\\u00efve patients.\",\"Antiviral effect of interferon is mediated by the expression of interferon-stimulated genes (ISGs). However, because of the difficulty in obtaining paired liver biopsies before and after interferon treatment, the key ISGs expressed in human hepatocytes and responsible for interferon-based antiviral activities in chronic hepatitis C remain illusive. Prior to a standard course of peginterferon plus ribavirin therapy, 104 patients underwent a liver biopsy. A small piece of the liver biopsy sample from each patient was submitted for ex vivo tissue culture in the presence or absence of interferon. Hepatic expression of 8 ISGs was detected by RT-PCR. The ISG expression patterns and clinicopathological variables were correlated with subsequent treatment outcomes. Multivariate logistic regression analysis showed that hepatic MxA expression (P = 0.008) and leucocyte count (P = 0.040) independently predicted the end of therapeutic virological response, while hepatic OAS1 expression (P = 0.003), genotype 1 (P = 0.002), HCV-RNA level (P = 0.007), AST/ALT ratio (P = 0.004) and leucocyte count (P = 0.034) independently predicted the sustained virological response. Immunohistochemistry analysis showed that interferon-induced OAS1 expression localized to the hepatocytes. In conclusion, hepatic MxA and OAS1 expression predicted, respectively, the end of therapeutic and sustained virological responses in interferon-based treatment of chronic hepatitis C.\",\"Obesity and insulin resistance have been reported as negative predictors for sustained virological response (SVR) in hepatitis C virus (HCV) genotype 1 infected patients treated with pegylated interferon-\\u03b1 plus ribavirin. They are also known to affect serum levels of several cytokines including adipocytokines. But the association between these cytokines and treatment outcome has not been fully elucidated. We examined pretreatment serum levels of 14 cytokines among 190 patients who were treated with pegylated interferon-\\u03b1-2b plus ribavirin for chronic HCV-1b infection with high viral load (\\u2265 5 log IU/mL) and analyzed their contribution to treatment response. Plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor, and 11 clinical factors showed significant association with SVR in univariate logistic regression analysis. Four significant factors in multivariate analysis; serum PAI-1 (odds ratio [OR] = 15.42), body mass index (OR = 4.56), rs8099917 (OR = 4.95) and fibrosis stage (OR = 5.18) were identified as independent predictors. We constructed a simple and minimally invasive prediction score for SVR based on the presence of these factors except for fibrosis stage. The accuracy of this score was 73%, and was confirmed using an independent validation cohort consisting of 31 patients (68%). The strongest correlation was between PAI-1 level and platelet count (r = 0.38, P = 1.8 \\u00d7 10(-7)), and PAI-1 level was inversely correlated with fibrosis stage. Serum PAI-1 is a novel predictor for the response to combination therapy against chronic HCV-1b infection and may be associated with liver fibrosis.\",\"Telaprevir in combination with peginterferon and ribavirin is a promising advancement in chronic hepatitis C treatment. However, the safety, tolerability, pharmacokinetics and antiviral profiles of telaprevir alone beyond 2 weeks have not been studied.\",\"Despite years of clinical use and extensive research efforts, the mechanism of action of ribavirin (RBV) is not well understood. Although it has only a mild, transient antiviral effect on HCV replication when administered as monotherapy, when combined with interferon, RBV improves sustained virological response (SVR) rates by approximately 25-30%. Proposed mechanisms of action for RBV against HCV include (1) a direct effect against the HCV RNA dependent RNA polymerase; (2) induction of misincorporation of nucleotides leading to lethal mutagenesis; (3) depletion of intracellular pools via inhibition of inosine monophosphate dehydrogenase; (4) alteration in the cytokine balance between a Th2 profile (anti-inflammatory) to a Th1 profile (pro-inflammatory); and (5) potentiating the effect of interferon via up-regulation of genes involved in interferon signalling. Given the lack of a clear understanding of RBV mechanism of action, it has been challenging to confidently position this drug with new direct antiviral agents (DAA). However, early clinical studies provide strong evidence for a benefit of RBV in combination with DAAs for both IFN containing and sparing regimens. The addition of RBV reduces viral breakthroughs and/or relapses, at least when drugs with low to moderate genetic barriers to resistance are paired together. This is particularly true in patients harbouring HCV subtype 1a. Ongoing studies are now addressing the utility of RBV in nucleoside containing DAA regimens, which offer both potent antiviral activity as well as a high genetic barrier to resistance. It is remarkable that the age-old question of the role of RBV in the future of HCV therapy remains as real today as it was two decades ago.\",\"Chronic hepatitis C is one of the leading causes of chronic liver disease with approximately 170 million people infected worldwide. Sustained virological response (SVR) is equivalent to viral eradication and associated with a reduction in the risk of cirrhosis. Nowadays the treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG-IFN) plus ribavirin (RBV) regimen. The future management of patients with these new molecules will require good clinical practice, knowledge of indications, management of side effects and monitoring for antiviral resistance. Certain major medical needs are still unmet and require studies in special populations (HIV-HCV coinfected patients, transplanted patients, etc.\\u2026) and also in HCV non-1 genotype patients and in non-responders. Second generation DAA are in development. Combinations of antivirals with additive potency that lack cross resistance and with a good safety profile may provide new regimens in the future to make HCV the first chronic viral infection eradicated worldwide with a finite duration of combination DAA therapy without IFN. The aim of this review is to summarize mechanisms of action and results obtained with DAAs.\",\"This is an excellent time for patients with hepatitis C virus infection who have failed past treatment with standard of care (SOC) peginterferon (PEG-IFN) and ribavirin (RBV). New treatments have been shown to increase sustained virological response (SVR) rates. Previous relapsers and those with some responsiveness to interferon will clearly benefit from protease inhibitor-based therapy. Patients with little interferon response may not be suited for these regimens, but can be treated by careful selection on a case-by-case basis. Resistance needs to be carefully monitored as these newer and more potent drugs are added to IFN and RBV backbone drugs. Adverse events will be more frequent and will require special attention.\",\"Treatment for chronic hepatitis C virus (HCV) infection has evolved considerably in the last few years. Combination therapy with pegylated interferon (PEG-IFN)-\\u03b1 plus ribavirin (RBV) has been the standard of care (SoC) treatment in the past few years. Several viral and host factors have been associated with treatment failure, including age, male gender, ethnicity, genotype, IL28B genotype, steatosis, obesity and insulin resistance. Several studies have also shown that in patients who fail treatment, several interferon-stimulated genes are upregulated before treatment. Recently, the NS3/4A protease inhibitors telaprevir and boceprevir have been approved and are considered the new SoC therapy in combination with PEG-IFN-\\u03b1/RBV in HCV genotype 1 treatment-na\\u00efve patients, as well as in previously treated patients, with significant improvements in SVR rates. The REALIZE phase III trial with telaprevir in previously treated patients showed SVR rates of 83-88% in prior relapsers, 54-58% in prior partial responders and, 29-33% in prior non-responders.\",\"Telaprevir is a potent HCV NS3/4A protease inhibitor. A completed development program has demonstrated the superior efficacy of a regimen of telaprevir combined with pegylated interferon alfa and ribavirin (PR) over PR alone in patients with HCV genotype 1. In the ADVANCE trial in treatment-na\\u00efve patients, 12 weeks of telaprevir, peginterferon alfa-2a and ribavirin followed by either 12 or 36 weeks of PR alone (depending upon extended rapid virologic response, or eRVR, i.e. HCV RNA undetectability at weeks 4 and 12), was associated with sustained virological response (SVR) in 75% of patients compared with 46% receiving PR for 48 weeks. The ILLUMINATE trial established the foundation for response-guided therapy in patients with eRVR. The REALIZE trial in treatment-experienced patients showed a gradient of SVR from prior relapsers (86%) to partial responders (57%) to null responders (31%), with rates of virologic failure and emergent resistance highest in the latter group. Incremental adverse effects of telaprevir include rash, anemia, pruritus, diarrhea, and nausea. Treatment na\\u00efve patients and relapsers are eligible for response-guided therapy. Stopping rules of telaprevir-based treatment include HCV RNA > 1000 IU/ml at weeks 4 and 12.\",\"Until recently, chronic hepatitis C caused by persistent infection with the hepatitis C virus (HCV) has been treated with a combination of pegylated interferon-alpha (PEG-IFN\\u03b1) and ribavirin (RBV). This situation has changed with the development of two drugs targeting the NS3/4A protease, approved for combination therapy with PEG-IFN\\u03b1/RBV for patients infected with genotype 1 viruses. Moreover, two additional viral proteins, the RNA-dependent RNA polymerase (residing in NS5B) and the NS5A protein have emerged as promising drug targets and a large number of antivirals targeting these proteins are at different stages of clinical development. Although this progress is very promising, it is not clear whether these new compounds will suffice to eradicate the virus in an infected individual, ideally by using a PEG-IFN\\u03b1/RBV-free regimen, or whether additional compounds targeting other factors that promote HCV replication are required. In this respect, host cell factors have emerged as a promising alternative. They reduce the risk of development of antiviral resistance and they increase the chance for broad-spectrum activity, ideally covering all HCV genotypes. Work in the last few years has identified several host cell factors used by HCV for productive replication. These include, amongst others, cyclophilins, especially cyclophilinA (cypA), microRNA-122 (miR-122) or phosphatidylinositol-4-kinase III alpha. For instance, cypA inhibitors have shown to be effective in combination therapy with PEG-IFN/RBV in increasing the sustained viral response (SVR) rate significantly compared to PEG-IFN/RBV. This review briefly summarizes recent advances in the development of novel antivirals against HCV.\",\"Widespread resistance among circulating influenza A strains to at least one of the anti-influenza drugs is a major public health concern. A triple combination antiviral drug (TCAD) regimen comprised of amantadine, oseltamivir, and ribavirin has been shown to have synergistic and broad spectrum activity against influenza A strains, including drug resistant strains. Here, we used mathematical modeling along with three different experimental approaches to understand the effects of single agents, double combinations, and the TCAD regimen on resistance in influenza in vitro, including: 1) serial passage at constant drug concentrations, 2) serial passage at escalating drug concentrations, and 3) evaluation of the contribution of each component of the TCAD regimen to the suppression of resistance. Consistent with the modeling which demonstrated that three drugs were required to suppress the emergence of resistance in influenza A, treatment with the TCAD regimen resulted in the sustained suppression of drug resistant viruses, whereas treatment with amantadine alone or the amantadine-oseltamivir double combination led to the rapid selection of resistant variants which comprised \\u223c100% of the population. Furthermore, the TCAD regimen imposed a high genetic barrier to resistance, requiring multiple mutations in order to escape the effects of all the drugs in the regimen. Finally, we demonstrate that each drug in the TCAD regimen made a significant contribution to the suppression of virus breakthrough and resistance at clinically achievable concentrations. Taken together, these data demonstrate that the TCAD regimen was superior to double combinations and single agents at suppressing resistance, and that three drugs at a minimum were required to impede the selection of drug resistant variants in influenza A virus. The use of mathematical modeling with multiple experimental designs and molecular readouts to evaluate and optimize combination drug regimens for the suppression of resistance may be broadly applicable to other infectious diseases.\",\"To explore mutations around the interferon sensitivity-determining region (ISDR) which are associated with the resistance of hepatitis C virus 1b (HCV-1b) to interferon-\\u03b1 treatment.\",\"The current standard of care for hepatitis C infection is peginterferon/ribavirin (PegIFN/RBV). We are entering the era where direct-acting antiviral agents (DAAs) will be added to PegIFN/RBV, leading to higher sustained response rates in genotype 1 infected individuals. Currently DAAs are directed toward specific proteins involved in hepatitis C replication with NS3/NS4A protease inhibitors furthest in development. Telaprevir and boceprevir are both NS3/NS4a inhibitors that significantly improve sustained response when added to PegIFN and RBV. The hepatitis C virus (HCV) polymerase inhibitors are another promising DAA class. These molecules are divided into nucleoside/nucleotide polymerase inhibitors and nonnucleotide/nucleoside polymerase inhibitors. Nucleoside/nucleotide polymerase inhibitors have a high barrier to resistance and appear to be effective across a broad range of genotypes. Nonnucleoside polymerase inhibitors have a lower barrier of resistance and appear to be genotype specific. Preliminary data with these compounds are also promising. A third class, NS5A inhibitors, has also shown potent HCV RNA suppression in preliminary studies as monotherapy and with PegIFN and RBV. Combinations of these agents are also entering clinical trials and indeed a preliminary report has demonstrated that the combination of an NS3/4A protease inhibitor and NS5B polymerase inhibitor can effectively suppress virus in genotype 1 individuals. Future studies will concentrate on combinations of direct-acting antiviral agents without and with PegIFN and RBV. Clinicians will need to be familiar with managing side effects as well as resistance as we enter this new era.\",\"Double-filtration plasmapheresis (DFPP) together with interferon (IFN) administration produces a substantial reduction in the viral load during the early stages of treatment.\",\"Insulin resistance (IR) has been reported to be an independent predictor of treatment outcome in chronic hepatitis C patients.\",\"Combination therapy of pegylated interferon-\\u03b1 with ribavirin (PEG-IFN/RBV) is a standard of care for chronic hepatitis C (CHC). The majority of CHC patients are infected with HCV genotype I. The recent discovery revealed by a genome-wide association study technology provides the important role of interleukin-28B (IL28B) and inosine triphosphatase (ITPA) in HCV infection. In addition, response to PEG-IFN/RBV therapy is correlated with insulin resistance, hepatic steatosis, and hepatic fibrosis in CHC patients. Double-filtration plasmapheresis together with IFN therapy has proved to be effective in the reduction of viral load during the early stage of treatment. In CHC patients, not only IL28B status, but also the treatment period of PEG-IFN/RBV is important. Even when new polymerase/protease inhibitors are introduced in the treatment of CHC, tailor-made treatment for CHC using IL28B, inosine triphosphatase testing or double-filtration plasmapheresis treatment prolonged treatment strategy is highly recommended. The relative etiologic role of prior hepatitis B virus infection in the development of non-B non-C hepatocellular carcinoma is also known in hepatitis B-endemic areas.\",\"The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, drug interactions, viral drug resistance, dosage and administration, and place in therapy of telaprevir are reviewed.\",\"Hepatitis C virus (HCV) infection is a major and rising global health problem, affecting about 170 million people worldwide. The current standard of care treatment with interferon alpha and ribavirin in patients with the genotype 1 infection, the most frequent genotype in the USA and Western Europe, leads to a successful outcome in only about 50% of individuals. Accurate prediction of hepatitis C treatment response is of great benefit to patients and clinicians. The informational spectrum method, a virtual spectroscopy method for structure/function analysis of nucleotide and protein sequences, is applied here for the identification of the conserved information of the HCV proteins that correlate with the combination therapy outcome. Among the HCV proteins that we have analyzed the informational property of the p7 of HCV genotype 1b was best related to the therapy outcome. On the basis of these results, a simple bioinformatics criterion that could be useful in assessment of the response of HCV-infected patients to the combination therapy has been proposed.\",\"With the approval in 2011 of the protease inhibitors Victrelis and Incivek, direct-acting antivirals have begun to revolutionize HCV treatment. Although the addition of Incivek or Victrelis to PEGylated IFN\\u03b1 and ribavarin (pIFN\\u03b1/RBV) may improve cure rates and shorten the treatment duration of the \\\"old\\\" standard of care (SOC), this triple therapy will not be suitable for patients intolerant to pIFN\\u03b1 or RBV. The efficacy of this triple therapy will also certainly be attenuated in pIFN\\u03b1/RBV non-responders. As Incivek is inactive against genotype 3 (GT3) combined with the fact that all protease inhibitors and most of the non-nucleoside polymerase inhibitors in development are active primarily against GT1, pIFN\\u03b1/RBV will remain the SOC for non-GT1 until new classes of inhibitors enter into clinical practice. GT1 patients who do not respond to this new triple therapy will have developed resistance to protease inhibitors that will limit future treatment options. There is thus an important need for the identification of new potent HCV agents. A novel class of HCV inhibitors that have great potential for the treatment for HCV has recently emerged: the host-targeting antivirals cyclophilin inhibitors.\",\"Direct-acting antiviral agents in combination with pegylated interferon (PEG-IFN) and ribavirin (RBV) significantly improve sustained virologic response rate and reduce duration of therapy among both treatment-na\\u00efve and treatment-experienced patients with genotype 1 chronic hepatitis C. One of the most important considerations with both boceprevir and telaprevir is the potential development of resistant variants with therapy. Patients with poor intrinsic responsiveness to interferon, and those with incomplete virological suppression on protease inhibitor therapy, appear to be at higher risk for resistance. In this article we will define antiviral resistance and review the data on both in vitro and in vivo resistance to protease inhibitors, concentrating on data on boceprevir and telaprevir. We will also explore the significance of resistant variants present at the baseline, as well as the fate of the resistant variants and the ways to minimize the development of resistance to protease inhibitors.\",\"Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) offers a major advance in the management of HCV infection. These DAAs, boceprevir and telaprevir, when given with pegylated interferon alfa (Peg-IFN) and ribavirin (RBV), result in a much higher sustained virologic response rate compared with Peg-IFN and RBV. The DAA-containing regimens are approved for HCV genotype 1 infection in HCV treatment-naive and HCV treatment-experienced patients. In this review, we present an overview of pharmacology, efficacy, adverse events, and emergence of resistance-associated variants with the use of these agents. As with all drugs, especially newly approved drugs, clinicians must consult the package insert for detailed prescribing information, list of all reported adverse events, contraindications, and drug interactions.\",\"Boceprevir and telaprevir are the first HCV protease inhibitors to be approved for the treatment of chronic hepatitis C genotype 1 infection. These drugs must be used in combination with pegylated interferon plus ribavirin (P/R) to maximize efficacy and prevent the emergence of resistance-associated variants (RAVs). In randomized, placebo-controlled international studies in treatment-naive and previously treated HCV patients, treatment with either boceprevir- or telaprevir-based triple therapy regimens significantly increased sustained virological response rates compared with placebo plus P/R. Protease inhibitors have the potential, not only to significantly increase cure rates among patients with genotype 1 infection, but also to reduce the duration of treatment for patients who have an extended rapid virological response. Boceprevir is associated with an increased incidence of anaemia and dysgeusia and telaprevir is associated with an increased incidence of rash and anaemia. The emergence of RAVs was associated with an increased risk of virological failure in clinical studies. Although these new drugs bring significant promise, it remains unclear if all genotype 1 patients will need triple therapy. Here, we review some of the complexities uncovered and controversies highlighted by the introduction of HCV protease inhibitors.\",\"Although several direct-acting antivirals (DAAs) are now available, the therapy regimen for chronic hepatitis C will continue to include pegylated interferon and ribavirin for the foreseeable future. Despite their improved rate of sustained virological response (SVR), DAAs pose increased risks of side effects and selection for antiviral resistance. Not all patients require DAA to achieve SVR, whereas others are unlikely to respond even to triple therapy. Therefore, a personalized approach to candidate selection is necessary.\",\"Advances in hepatitis C pharmacogenomics identified modulations of a sustained virologic response (SVR) by frequent IL28B gene variants and of ribavirin-induced hemolysis by frequent ITPA gene variants. These associations have been widely reproduced in various ethnicities, clinical settings and hepatitis C viral genotypes. The IL28B minor alleles rs8099917G, rs12979860T and rs12980275G have been associated with non-SVR whereas the ITPA minor alleles rs1127354A and rs7270101C were associated with less hemolytic side effects, an effect also attributed to a nucleoside transporter gene SLC28A3 rs10868138G/rs56350726T haplotype. The significance levels of these associations, especially in genome-wide studies, were very high. We nevertheless tested how good clinical outcomes of peginterferon \\u03b1/ribavirin therapy, such as SVR or hemolytic side effects, were predicted by these variants. An analysis in an example dataset of 115 patients revealed that the prediction of non-SVR or hemolysis by single variants was often only slightly better than guessing. Using combinations of IL28B variants provided a higher accuracy (64.5%) of predicting non-SVR than with single IL28B variants (accuracy 60-63%). Similarly, a decline in blood hemoglobin by \\u22653 g/dl could be better predicted at an accuracy of 70% (10% better than guessing) with a combination of an ITPA variant with a nucleoside transporter gene (SLC28A3) haplotype. Thus, genotyping information about single IL28B or ITPA variants is reproducibly and statistically significantly associated with hepatitis C therapy outcomes; however, the clinical predictive utility of single variants can be increased by combinations of genotypes.\",\"Telaprevir is an NS3/4A protease inhibitor that has recently received US FDA approval for the treatment of chronic HCV infection. Telaprevir is given in combination with peg-IFN-\\u03b1 and ribavirin and is indicated for both treatment-naive and treatment-experienced patients with genotype 1 infection. Along with the other first generation NS3/4A protease inhibitor boceprevir, these combination regimens have immediately become the standard of care for genotype 1 patients. The adverse event profile for the combination regimen remains dominated by peg-IFN-\\u03b1 and ribavirin, but there is additional anemia and rash with telaprevir. Owing to telaprevir's metabolism by the CYP3/4A pathway, drug-drug interactions could lead to toxicity from other medications or decreased efficacy of telaprevir. Viral resistance can develop during treatment with telaprevir, and patients will need to be educated on their role in adherence to minimize the risk of resistance and improve their chances of cure of HCV infection.\",\"The nucleoside analogue Ribavirin significantly increases patient response to IFN-\\u03b1 treatment of HCV, by directly inhibiting viral replication. Recent studies indicate that Ribavirin also regulates immunity and we propose that Ribavirin enhances specific interferon sensitive gene (ISG) expression by amplifying the IFN-\\u03b1-JAK/STAT pathway. We found that IFN-\\u03b1-induced STAT1 and STAT3 phosphorylation was increased in hepatocytes co-treated with Ribavirin and IFN-\\u03b1, compared to IFN-\\u03b1 alone. Ribavirin specifically enhanced IFN-\\u03b1 induced mRNA and protein of the anti-viral mediator MxA, which co-localised with HCV core protein. These novel findings indicate for the first time that Ribavirin, in addition to its viral incorporation, also enhances IFN-\\u03b1-JAK/STAT signalling, leading to a novel MxA-mediated immuno-modulatory mechanism that may enhance IFN-\\u03b1 anti-viral activity against HCV.\",\"Hepatitis C virus (HCV) exhibits a high level of genetic variability, and variants with reduced susceptibility to antivirals can occur even before treatment begins. In addition, alcohol decreases efficacy of antiviral therapy and increases sequence heterogeneity of HCV RNA but how ethanol affects HCV sequence is unknown. Ethanol metabolism and HCV infection increase the level of reactive species that can alter cell metabolism, modify signaling, and potentially act as mutagen to the viral RNA. Therefore, we investigated whether ethanol and reactive species affected the basal sequence variability of HCV RNA in hepatocytes. Human hepatoma cells supporting a continuous replication of genotype 1b HCV RNA (Con1, AJ242652) were exposed to ethanol, acetaldehyde, hydrogen peroxide, or L-buthionine-S,R-sulfoximine (BSO) that decreases intracellular glutathione as seen in patients. Then, NS5A region was sequenced and compared with genotype 1b HCV sequences in the database. Ethanol and BSO elevated nucleotide and amino acid substitution rates of HCV RNA by 4-18 folds within 48 hrs which were accompanied by oxidative RNA damage. Iron chelator and glutathione ester decreased both RNA damage and mutation rates. Furthermore, infectious HCV and HCV core gene were sufficient to induce oxidative RNA damage even in the absence of ethanol or BSO. Interestingly, the dn/ds ratio and percentage of sites undergoing positive selection increased with ethanol and BSO, resulting in an increased detection of NS5A variants with reduced susceptibility to interferon alpha, cyclosporine, and ribavirin and others implicated in immune tolerance and modulation of viral replication. Therefore, alcohol is likely to synergize with virus-induced oxidative/nitrosative stress to modulate the basal mutation rate of HCV. Positive selection induced by alcohol and reactive species may contribute to antiviral resistance.\",\"Interleukin (IL)-6, a pleiotropic cytokine, is increased in various types of chronic liver disease, including chronic hepatitis C (CHC). It was reported recently that IL-6 is associated with insulin resistance, iron metabolism and interferon resistance, which may affect the outcome of antiviral treatment. In this study, we investigated the association of serum IL-6 levels with outcomes of pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy.\",\"Protease inhibitor (PI)-resistant hepatitis C virus (HCV) variants may be present in substantial numbers in PI-untreated patients according to recent reports. However, influence of these viruses in the clinical course of chronic hepatitis C has not been well characterized.\",\"The IL28B genotype is the most important pretreatment predictor of treatment outcome in patients with chronic hepatitis C. The impact of the rs12979860 genotype on relapse was retrospectively evaluated in genotype 1/4 patients who received response-guided therapy with peginterferon alpha-2a 180 \\u03bcg/week plus ribavirin 1,000/1,200 mg/day in a large, randomized, multicenter study. Patients with a rapid virologic response (RVR: hepatitis C virus [HCV] RNA <50 IU/mL) at week 4 were treated for 24 weeks; those with a slow virologic response (no RVR but undetectable HCV RNA or \\u2265 2-log(10) decrease at week 12) were randomized to 48 (group A) or 72 weeks of treatment (group B). Relapse rates were compared by rs12979860 genotype (C/C versus combined T/C or T/T [T/*]) in patients with confirmed end-of-treatment response and known end-of-follow-up status (sustained virologic response [SVR] or relapse). The rs12979860 genotype was determined for 340/551 study participants. In patients with RVR and C/C or T/* genotype, relapse rates were similar (10.7% versus 15.2%). In patients randomized to groups A and B, relapse rates were similar in patients with C/C genotype randomized to group A (26.9%) and group B (20.0%). In contrast, relapse rates in T/* patients differed markedly between groups A and B, overall (42.9% and 18.8%; P < 0.025, respectively) and in those with low (<400,000 IU/mL: 37.5% versus 18.8%) and high (\\u2265 400,000 IU/mL: 45.0% versus 18.8%) baseline viral loads.\",\"The approval of the first direct-acting antiviral (DAA) drugs for treatment of HCV in 2011 has lead to improved sustained viral response rates of up to 79% in treatment-na\\u00efve or relapse genotype 1 patients.\",\"More than 20 years after the identification of the hepatitis C virus (HCV) as a novel human pathogen, the only approved treatment remains a combination of pegylated interferon-\\u03b1 and ribavirin. This rather non-specific therapy is associated with severe side effects and by far not everyone benefits from treatment. Recently, progress has been made in the development of specifically targeted antiviral therapy for HCV (STAT-C). A major target for such direct acting antivirals (DAAs) is the HCV RNA-dependent RNA polymerase or non-structural protein 5B (NS5B), which is essential for viral replication. This review will examine the current state of development of inhibitors targeting the polymerase and issues such as the emergence of antiviral resistance during treatment, as well as strategies to address this problem.\",\"Natural killer (NK) cells constitute a first line of defense against viral infections; their function is governed by the integration of signals from multiple activating and inhibitory surface receptors. We hypothesized that because NKs become rapidly activated by cytokines, response to anti-hepatitis C virus (HCV) therapy would be predicted by the phenotype and function of NKs. We used a cohort of 101 patients (55 African, 46 Caucasian-American) who received pegylated-interferon (IFN) and ribavirin for 48 weeks. Multiparameter FACS analysis was used to examine relative expression of 14 different inhibitory/activating receptors. Interleukin (IL)-28B genotyping (rs12979860) was also performed. Pretreatment levels of inhibitory receptors CD158a, CD158b, and CD158e were higher in patients who demonstrated poor viral decline within the first 28 days of therapy. Higher expression levels of inhibitory receptors NKG2A, CD158b, and CD158e were demonstrable in patients who failed to achieve sustained virologic response (SVR). Patients carrying the IL-28B T allele had higher NKG2A expression on effector NKs. We created a mathematical regression model incorporating race, viral level, and two inhibitory receptors. The area-under-the curve was 0.88, which is highly predictive of SVR. Moreover, the model performed complementarily with IL-28B across the CC, CT, and TT genotypes. Purified NKG2A(neg) NKs treated with pegylated-IFN-\\u03b1 for 4 hours demonstrated higher levels of IFN-\\u03b3-inducible protein-10 (IP-10) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) compared with their NKG2A(pos) counterparts.\",\"Hepatic complications currently represent one of the leading reasons for medical consultations, hospitalisation, and death in the HIV-infected population. This is due to a large extent to viral hepatitis, given its disproportionate frequency in this population. Chronic hepatitis B affects 5-10% of the HIV-infected population. Vaccination has reduced the incidence of liver disease related to hepatitis-B virus (HBV), and the availability of tenofovir has dramatically improved the prognosis of HIV/HBV carriers. Delta hepatitis affects around 15% of HIV-infected individuals in Europe harbouring positive HBsAg. It has the worst prognosis, given its accelerated course to cirrhosis and the absence of successful therapy. Lastly, chronic hepatitis C is the major cause of liver disease in the HIV population. Although classically linked to persons infected parenterally (i.e., intravenous drug users), outbreaks of acute hepatitis C among homosexual men have been reported over the last decade. Treatment with pegylated interferon plus ribavirin provides a cure in less than 40% of patients. However, the introduction of new direct acting antivirals against hepatitis- C virus (HCV) (telaprevir, boceprevir) has revolutionised the field, as HAART did in 1996 in the HIV field, improving the prognosis of co-infected patients. However, interactions between these drugs and antiretroviral agents and the risk of selective resistance pose huge threats in this population.\",\"The hepatitis C virus (HCV) invariably shows wide heterogeneity in infected patients, referred to as a quasispecies population. Massive amounts of genetic information due to the abundance of HCV variants could be an obstacle to evaluate the viral genetic heterogeneity in detail.\",\"Most viral diseases, with the exception of those caused by human immunodeficiency virus, are self-limited illnesses that do not require specific antiviral therapy. The currently available antiviral drugs target 3 main groups of viruses: herpes, hepatitis, and influenza viruses. With the exception of the antisense molecule fomivirsen, all antiherpes drugs inhibit viral replication by serving as competitive substrates for viral DNA polymerase. Drugs for the treatment of influenza inhibit the ion channel M(2) protein or the enzyme neuraminidase. Combination therapy with Interferon-\\u03b1 and ribavirin remains the backbone treatment for chronic hepatitis C; the addition of serine protease inhibitors improves the treatment outcome of patients infected with hepatitis C virus genotype 1. Chronic hepatitis B can be treated with interferon or a combination of nucleos(t)ide analogues. Notably, almost all the nucleos(t) ide analogues for the treatment of chronic hepatitis B possess anti-human immunodeficiency virus properties, and they inhibit replication of hepatitis B virus by serving as competitive substrates for its DNA polymerase. Some antiviral drugs possess multiple potential clinical applications, such as ribavirin for the treatment of chronic hepatitis C and respiratory syncytial virus and cidofovir for the treatment of cytomegalovirus and other DNA viruses. Drug resistance is an emerging threat to the clinical utility of antiviral drugs. The major mechanisms for drug resistance are mutations in the viral DNA polymerase gene or in genes that encode for the viral kinases required for the activation of certain drugs such as acyclovir and ganciclovir. Widespread antiviral resistance has limited the clinical utility of M(2) inhibitors for the prevention and treatment of influenza infections. This article provides an overview of clinically available antiviral drugs for the primary care physician, with a special focus on pharmacology, clinical uses, and adverse effects.\",\"Polymorphisms in the region of the interleukin (IL)28B gene have been associated with pegylated-interferon (PEG-IFN) and ribavirin treatment response mainly in genotype 1 HCV infections. However, there are few data on HCV genotype 4 (HCV-4) infection. We evaluated, in a unique well-characterized cohort of HCV-4 patients, the association of IL28B polymorphism with response to treatment or liver disease severity.\",\"Hepatic steatosis is one of the factors limiting the virological response to interferon-based antiviral therapy for chronic hepatitis C (CH-C) patients infected with genotype 1, while contradictory results have been reported for genotype 2. We aimed to clarify the effect of hepatic steatosis on therapeutic outcome and cumulative positivity of serum HCV RNA in CH-C patients infected with genotype 2 treated by peginterferon (PEG-IFN)\\u03b12b and ribavirin (RBV) combination therapy.\",\"Hepatitis C virus (HCV) infection affects millions of people worldwide; however, standard therapy with peginterferon and ribavirin has resulted in suboptimal responses. Thus, new anti-HCV drugs with novel mechanisms of action are being studied. In particular, new drugs are being developed that target the NS3/4A protease complex. We evaluated the literature on telaprevir, a new, oral, covalent, reversible NS3/4A HCV protease inhibitor. A MEDLINE search (January 1996-July 2011) was performed to identify relevant clinical trials, and abstracts from hepatology and human immunodeficiency virus (HIV) conferences were reviewed. In large clinical trials, the addition of telaprevir to peginterferon and ribavirin resulted in high sustained virologic response rates in both treatment-na\\u00efve and treatment-experienced patients infected with HCV genotype 1. Clinical data with telaprevir in the HIV-HCV coinfected population are emerging, as well as data on potential drug-drug interactions with this agent. Preliminary data describe the resistance profile of telaprevir; however, more information is needed in this evolving area. Telaprevir's most common adverse events included rash, pruritis, and anemia. Based on available data, this new anti-HCV drug will likely be widely used and may revolutionize the treatment of HCV-infected individuals.\",\"Insulin resistance, HIV, antiviral drugs and hepatitis C virus (HCV) infection contribute to a complex interaction involving the metabolic syndrome. The objective of this review was to explore the meaning of insulin resistance in HIV-HCV-coinfected patients and how it may impact on sustained virological response (SVR) and disease progression.\",\"Telaprevir and boceprevir are highly selective hepatitis C virus (HCV) NS3/4A proteaseinhibitors in phase 3 development. Viral breakthrough during mono- and triple-therapies with PEG-interferon and ribavirin and relapse is associated with resistance.\",\"Lethal mutagenesis or virus transition into error catastrophe is an antiviral strategy that aims at extinguishing a virus by increasing the viral mutation rates during replication. The molecular basis of lethal mutagenesis is largely unknown. Previous studies showed that a critical substitution in the foot-and-mouth disease virus (FMDV) polymerase was sufficient to allow the virus to escape extinction through modulation of the transition types induced by the purine nucleoside analogue ribavirin. This substitution was not detected in mutant spectra of FMDV populations that had not replicated in the presence of ribavirin, using standard molecular cloning and nucleotide sequencing. Here we selectively amplify and analyze low-melting-temperature cDNA duplexes copied from FMDV genome populations passaged in the absence or presence of ribovirin Hypermutated genomes with high frequencies of A and U were present in both ribavirin -treated and untreated populations, but the major effect of ribavirin mutagenesis was to accelerate the occurrence of AU-rich mutant clouds during the early replication rounds of the virus. The standard FMDV quasispecies passaged in the absence of ribavirin included the salient transition-modulating, ribavirin resistance mutation, whose frequency increased in populations treated with ribavirin. Thus, even nonmutagenized FMDV quasispecies include a deep, mutationally biased portion of sequence space, in support of the view that the virus replicates close to the error threshold for maintenance of genetic information.\",\"Chronic infection with hepatitis C virus (HCV) can induce insulin resistance (IR) in a genotype-dependent manner and contributes to steatosis, progression of fibrosis and resistance to interferon plus ribavirin therapy. Our understanding of HCV-induced IR has improved considerably over the years, but certain aspects concerning its evaluation still remain elusive to clinical researchers. One of the most important issues is elucidating the ideal method for assessment of IR in the setting of hepatitis C. The hyperinsulinaemic euglycaemic clamp is the gold standard method for determining insulin sensitivity, but is impractical as it is labour intensive and time-consuming. To date, all human studies except for four where IR was evaluated in the HCV setting, an estimation of IR has been used rather than direct measurements of insulin-mediated glucose uptake. The most commonly used estimation in the HCV population is the homeostasis model assessment of insulin resistance (HOMA-IR) which is calculated from a single measurement of fasting insulin and glucose. In this article, we review the use and reporting of HOMA in the literature and provide guidance on its appropriate as well as inappropriate use in the hepatitis setting.\",\"Minority drug-resistant hepatitis C virus (HCV) variants may go undetected yet be clinically important. NS3/4A protease resistance substitutions V36A and A156S/T/V were selected in patients treated with protease inhibitors. The aim of this study was to investigate whether these substitutions pre-existed in HCV infected patients. An allele-specific PCR protocol that detected the NS3/4A protease resistance substitutions V36A and A156S/T/V was used to determine the prevalence of naturally occurring variants in 45 patients. All patient samples were infected with HCV of genotype 1b and were na\\u00efve for pegIFN\\u03b1/ribavirin treatment. Thirty samples (67%) had at least one HCV PI-resistant variant. A156T (23, 51%) was detected more frequently than A156V (13, 29%) or A156S (1, 2%). V36A was detected in 12 samples (27%). These results demonstrate the high prevalence of minority drug-resistant NS3/4 protease resistance substitutions. Our results also demonstrate that allele-specific PCR can be used to detect minor HCV NS3 protease resistant variants in pretreatment samples and to study in detail the evolution of mutant viruses during targeted antiviral therapy.\",\"The continuous emergence of drug-resistant viruses is a major obstacle for the successful treatment of viral infections, thus representing a persistent spur to the search for new therapeutic strategies. Among them, multidrug treatments are currently at the forefront of pharmaceutical, clinical, and computational investigation. Still, there are many unknowns in the way that different drugs interact among themselves and with the pathogen that they aim to control. Inspired by experimental studies with picornavirus, here, we discuss the performance of sequential vs. combination therapies involving two dissimilar drugs: the mutagen ribavirin and an inhibitor of viral replication, guanidine. Because a systematic analysis of viral response to drug doses demands a precious amount of time and resources, we present and analyze an in silico model describing the dynamics of the viral population under the action of the two drugs. The model predicts the response of the viral population to any dose combination, the optimal therapy to be used in each case, and the way to minimize the probability of appearance of resistant mutants. In agreement with the theoretical predictions, in vitro experiments with foot-and-mouth disease virus confirm that the suitability of simultaneous or sequential administration depends on the drug doses. In addition, intrinsic replicative characteristics of the virus (e.g., replication through RNA only or a DNA intermediate) play a key role to determine the appropriateness of a sequential or combination therapy. Knowledge of several model parameters can be derived by means of few, simple experiments, such that the model and its predictions can be extended to other viral systems.\",\"Natural killer (NK) cells exhibit a polarized phenotype with increased cytotoxicity and decreased interferon gamma (IFN-\\u03b3) production in chronic hepatitis C virus (HCV) infection. Here, we asked whether this is caused by type I interferon (IFN)-induced expression and phosphorylation levels of signal transducer and activator of transcription (STAT) molecules in NK cells and whether it affects the response and refractoriness of NK cells to IFN-\\u03b1-based therapy of HCV. STAT1 levels in NK cells were significantly higher in patients with chronic HCV infection than in uninfected controls. STAT1 levels and induction of phosphorylated STAT1 (pSTAT1) increased further during IFN-\\u03b1-based therapy with preferential STAT1 over STAT4 phosphorylation. Induction of pSTAT1 correlated with increased NK cytotoxicity (tumor necrosis factor-apoptosis-inducing ligand [TRAIL] expression and degranulation) and decreased IFN-\\u03b3 production. NK cells from patients with a greater than 2 log(10) first-phase HCV RNA decline to IFN-\\u03b1-based therapy (>99% IFN effectiveness) displayed strong pSTAT1 induction in vivo and were refractory to further stimulation in vitro. In contrast, NK cells from patients with a less than 2 log(10) first-phase HCV RNA decline exhibited lower pSTAT1 induction in vivo (P = 0.024), but retained greater IFN-\\u03b1 responsiveness in vitro (P = 0.024). NK cells of all patients became refractory to in vivo and in vitro stimulation by IFN-\\u03b1 during the second-phase virological response.\",\"Innate immunity plays an important role in host antiviral response to hepatitis C viral (HCV) infection. Recently, single nucleotide polymorphisms (SNPs) of IL28B and host response to peginterferon \\u03b1 (PEG-IFN\\u03b1) and ribavirin (RBV) were shown to be strongly associated. We aimed to determine the gene expression involving innate immunity in IL28B genotypes and elucidate its relation to response to antiviral treatment. We genotyped IL28B SNPs (rs8099917 and rs12979860) in 88 chronic hepatitis C patients treated with PEG-IFN\\u03b1-2b/RBV and quantified expressions of viral sensors (RIG-I, MDA5, and LGP2), adaptor molecule (IPS-1), related ubiquitin E3-ligase (RNF125), modulators (ISG15 and USP18), and IL28 (IFN\\u03bb). Both IL28B SNPs were 100% identical; 54 patients possessed rs8099917 TT/rs12979860 CC (IL28B major patients) and 34 possessed rs8099917 TG/rs12979860 CT (IL28B minor patients). Hepatic expressions of viral sensors and modulators in IL28B minor patients were significantly up-regulated compared with that in IL28B major patients (\\u2248 3.3-fold, P < 0.001). However, expression of IPS-1 was significantly lower in IL28B minor patients (1.2-fold, P = 0.028). Expressions of viral sensors and modulators were significantly higher in nonvirological responders (NVR) than that in others despite stratification by IL28B genotype (\\u2248 2.6-fold, P < 0.001). Multivariate and ROC analyses indicated that higher RIG-I and ISG15 expressions and RIG-I/IPS-1 expression ratio were independent factors for NVR. IPS-1 down-regulation in IL28B minor patients was confirmed by western blotting, and the extent of IPS-1 protein cleavage was associated with the variable treatment response.\",\"Chronic hepatitis C (HCV) infection is considered a metabolic disease. It is associated with a specific metabolic syndrome, HCV-associated dysmetabolic syndrome (HCADS), consisting of steatosis, hypocholesterolemia and insulin resistance/diabetes. These metabolic derangements contribute to a decrease in sustained virological response (SVR) to pegylated-interferon-\\u03b1-ribavirin as standard of care (SOC), and are associated with progression of liver fibrosis.\",\"Individuals infected with hepatitis C virus (HCV) are at risk for cirrhosis and/or hepatocellular carcinoma. Treatment of HCV infection has undergone several revisions over the past 15 years and continues to evolve. The current major advance is with the protease inhibitors in addition to pegylated interferon and ribavirin. The emergence of resistance needs to be monitored carefully as newer and more potent drugs are added to the interferon and ribavirin backbone drugs. In addition, adverse events will be more frequent and some novel ones will require special attention.\",\"Given its essential role in the process of hepatitis C virus (HCV) replication, the viral NS3/4A serine protease is arguably the most thoroughly characterized HCV enzyme and the most intensively pursued anti-HCV target for drug development thus far. Recent data have demonstrated promise for the NS3 protease inhibitor boceprevir, which, when added to the standard of care peginterferon and ribavirin, improves sustained virological response while shortening duration of therapy in genotype-1-infected individuals. This review discusses the mechanism of action of boceprevir, its effects on HCV, and its viral resistance.\",\"The approval of the first direct-acting antivirals (DAAs) against the hepatitis C virus (HCV) has been eagerly expected for treating chronic hepatitis C in HIV individuals given that progression to cirrhosis and end-stage liver disease occurs faster in the co-infected population. The appropriate and judicious use of DAAs may provide cure to a large number of HIV-HCV patients. On the contrary, the widespread use of DAAs will occasionally be off-label or under unsatisfactory medical conditions, which may result in undesirable toxicities, drug interactions or selection of drug resistance in HCV. As a result of using first-generation DAAs in HIV-HCV-co-infected patients, a growing proportion of the remaining hepatitis C individuals will be those harboring non-HCV 1 genotypes or drug-resistant HCV variants. Over time, the largest reservoir of HCV genotype 1 patients will accumulate in resource-poor nations where access to hepatitis C therapy has been elusive and HIV treatment remains the primary health issue for the co-infected population.\",\"Given the side effects associated with intravenous injections of interferon, an interferon-free regimen for the treatment of HCV infections is highly desirable. Recently published clinical studies show that interferon-free combination therapies containing ribavirin are efficacious, suggesting that an interferon-free therapy could be adopted in the near future. Therefore, understanding HCV resistance to ribavirin could be of major importance. In an approach to understand the effect of ribavirin on HCV replication and HCV resistance, we have selected a ribavirin resistant mutant of HCV in vitro.\",\"To review the pharmacology, pharmacokinetics, safety, and efficacy of boceprevir, a novel oral hepatitis C virus (HCV) nonstructural 3 (NS3) protease inhibitor for the treatment of chronic HCV infection, specifically, genotype 1.\",\"The treatment of hepatitis C virus infection (HCV) by a combination of pegylated interferon and ribavirin, according to early viral kinetics, leads to a sustained virological response (SVR) in more than 50% of patients with chronic infection. This SVR is a complete recovery of the infection but more than 50% of genotype 1-infected patients do not achieve SVR. A better understanding of the viral cycle, and the characterization of viral enzymes which are potential targets, resulted in the development of new molecules, direct acting antivirals (DAA) targeted against HCV, either specific of genotype 1 (protease inhibitors NS3/NS4A and polymerase inhibitors NS5B) or with a wider spectrum (NS5A or entry inhibitors), and non-specific antivirals (new interferons, cyclophilin inhibitors). We describe the results of phase II and III trials which clearly demonstrated a 20 to 30% increase in the SVR rate of genotype 1-infected patients, either na\\u00efve or treatment experienced. These new drugs should be approved by the end of 2011, after a temporary approval for compassionate use in cirrhotic patients with previous relapse or partial response to the combination therapy. In the future, the main limitations of triple therapy will be safety (cutaneous rash or anemia which may be controlled), cost, compliance, viral resistance, and drug interactions that must be avoided by educating patients and physicians.\",\"Treatment of chronic hepatitis C virus (HCV) infection has substantially evolved over the past decade after the Consensus Conference organized by the European Association for the Study of the Liver in 1999. Since then, the standard of care (SOC) for patients with chronic hepatitis C has been the combination of pegylated interferon (pegIFN) alpha-2a or -2b and ribavirin. In patients infected with HCV genotype 1, by far the most frequent HCV genotype worldwide, such treatment leads to a cure of infection in only 40% to 50% of cases. Several factors have been identified to play a role in the outcome of therapy, including the treatment schedule, disease characteristics, viral, and host factors. Human genetic factors have been identified by a recent landmark discovery. However, these factors only partly explain the ability of IFN and ribavirin therapy to cure HCV infection. Several studies have demonstrated that, in non-responders, interferon-stimulated genes were up-regulated prior to therapy through unclear mechanisms. These findings, together with clinical, biochemical and histological data, may help better identify responders before starting therapy. This becomes particularly important as the standard treatment is physically and economically demanding. The future treatment of patients infected with HCV genotype 1 will be based on the combination of pegIFN and ribavirin with a protease inhibitor, telaprevir or boceprevir. Promising results of this triple combination in phase III clinical trials have been recently reported at the Liver Meeting 2010. With this therapy, higher cure rates will be achieved, but specific issues will be raised, such as the emergence of resistance to the protease inhibitors. The goal of this review is to discuss mechanisms involved in the non-response to current and future standard treatments.\",\"Mutations in the core and NS5A region of hepatitis C virus (HCV) genotype 1b have been associated with response to interferon (IFN) therapy. Genome-wide association studies have revealed that the single-nucleotide polymorphism (SNP) of interleukin 28B (IL28B) contributes to IFN response. The aim of this study was to investigate whether the SNP of IL28B (rs8099917) and amino acid substitutions in the core and NS5A region affect the response to IFN therapy.\",\"Pretreatment insulin resistance (IR) is associated with treatment response to peginterferon plus ribavirin (PegIFN/RBV) combination therapy in chronic hepatitis C (CHC) infection. However, the impact of PegIFN/RBV therapy on both IR and \\u03b2-cell function in CHC patients has rarely been investigated.\",\"An association has been reported between genetic polymorphism near IL28B gene and the prevalence of mutation of hepatitis C virus (HCV) core region residue 70, both of which have been associated with a lack of virologic response to antiviral combination therapy with peginterferon (PEG-IFN) and ribavirin. This study investigated whether PEG-IFN/ribavirin combination therapy induces amino acid (AA) mutation at residue 70 of HCV and whether genetic polymorphism near IL28B gene affects it. AA substitutions at residue 70 of the HCV core region were measured and compared before and after combination therapy in 65 non-responders and 88 relapsers to the combination therapy. In three patients in whom both wild-type AA (arginine) and mutant-type AA (glutamine or histidine) were detected at residue 70 before treatment, only mutant-type AA was identified after treatment. In two patients who had wild-type AA solely before treatment, both wild-type and mutant-type AAs were identified at residue 70 after treatment. In five patients, in whom the AA had changed at residue 70 between before and after treatment, four patients carried the TT genotype at a polymorphic locus (rs8099917) near the IL28B gene and one carried the TG/GG genotype. No difference was found in the prevalence of this change of AA at residue 70 between the TT and the TG/GG genotype. Antiviral combination therapy with PEG-IFN and ribavirin does not appear to induce mutation of HCV core region residue 70 regardless of genetic polymorphism near the IL28B gene in Japanese patients infected with HCV genotype 1b.\",\"Recent studies suggested that SVR rates might be lower in HCV patients with insulin resistance (IR) than in patients without IR, but the extent of the impact of IR on treatment response has not been established. We aimed to confirm the role of IR assessed by the homoeostasis model assessment (HOMA-IR) on SVR and to determine its magnitude.\",\"The triglycerides \\u00d7 glucose (TyG) index is a recently proposed surrogate marker of insulin resistance (IR), calculated from fasting plasma triglyceride and glucose concentrations. We tested the host and viral factors associated with Tyg and homeostasis model assessment (HOMA) scores, comparing their associations with histological features and with sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C(G1CHC). Three hundred and forty consecutive patients with G1CHC were considered. All had a liver biopsy scored by one pathologist for staging and grading (Scheuer), and graded for steatosis, which was considered moderate-severe if \\u226530%. Anthropometric and metabolic measurements, including IR measured by both HOMA and TyG, were registered. By linear regression analysis, TyG was independently associated with waist circumference (WC), total cholesterol, presence of arterial hypertension, Log10 HCV-RNA and steatosis. Similarly, WC and steatosis were significantly associated with HOMA. Older age (OR, 1.036; 95%CI, 1.004-1.070, P = 0.02), higher WC (1.031; 1.004-1.060; P = 0.02) and higher TyG (11.496; 3.163-41.784; P < 0.001) were linked to moderate-to-severe steatosis (\\u226530%) by multiple logistic regression analysis. When TyG was replaced by HOMA-IR in the model, the latter remained significantly associated with steatosis \\u226530% (1.237; 1.058-1.448; P = 0.008). Receiver operating characteristic curves showed a similar performance of TyG (AUC 0.682) and HOMA-IR (AUC 0.699) in predicting moderate-severe steatosis. No independent associations were found between both TyG and HOMA and fibrosis or SVR. In patients with G1CHC , TyG, an easy-to-calculate and low-cost surrogate marker of IR, is linked to liver steatosis and shows an independent association with viral load.\",\"The approval of directly acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection will represent a major breakthrough for the 180 million persons infected worldwide. Paradoxically, hepatitis C is the only human chronic viral disease that can be cured, as all other pathogenic viruses infecting humans either display self-limited courses or establish non-eradicable persistent infections. Until now, treatment of chronic hepatitis C consisted of the combination of peginterferon-\\u03b1 plus ribavirin, which provided limited rates of cure and was associated with frequent side effects. Several DAA have been identified that inhibit the NS3 protease, the NS5B polymerase or the NS5A replication complex, and have entered the final steps of clinical development. These molecules, coupled with significant progress made in the recognition of more potent and safe interferon forms (e.g. interferon-\\u03bb) and host protein targets (e.g. alisporivir), are opening a new era in hepatitis C therapeutics. The expectations are so great that, to some extent, it is reminiscent of what happened in 1996 in the HIV field when the introduction of the first protease inhibitors as part of triple combinations revolutionized antiretroviral therapy. To maximize treatment success and reduce the likelihood of drug resistance selection, a proper individualization of hepatitis C therapy will be required, choosing the most convenient drugs and strategies according to distinct viral and host profiles. The complexity of HCV therapeutics has reached a point that presumably will lead to the birth of a new specialist, the HCV doctor.\",\"A higher baseline homeostasis model assessment of insulin resistance (HOMA-IR) score has sometimes predicted a poorer sustained virological response (SVR) rate to peginterferon/ribavirin therapy in treatment-na\\u00efve chronic hepatitis C patients.\",\"HCV infection is a very common cause of chronic viral hepatitis. It is a worldwide health problem with approximately 170 million persons infected and areas of high endemicity in which the percentage of the population infected reaches 30%. It is a progressive disease that can lead to complications such as severe liver fibrosis and cirrhosis, ascites, esophageal varices, gastrointestinal bleeding and, in 30-50% of patients with cirrhosis, hepatocellular carcinoma. Extrahepatic pathologies such as mixed cryoglobulinemia, non-Hodgkin lymphoma and membrano-proliferative glomerulonephritis have been associated with HCV infection. Effective treatment exists, and is based on IFN-\\u03b1. Sustained disappearance of the virus (sustained virological response) radically changes the natural history of chronic hepatitis C, with reduced or no disease progression and complications. Interferon-based treatment has improved over the years owing to the association with ribavirin and subsequently with 'pegylation' of interferon molecules. The present standard of care results in a response rate of up to 80% in some subpopulations. Nevertheless, some patients do not respond to this therapy. Several factors predicting nonresponse to interferon therapy have been investigated since it became available. These factors include the characteristics of the virus and of the subject infected, and the therapy used. The aim of this article is to provide an overview of these factors, and insights into the newly recognized causes of nonresponse to help clinicians select the most appropriate therapy for HCV viral hepatitis.\",\"It has been reported that genetic polymorphisms near the IL28B gene or amino acid substitutions in hepatitis C virus (HCV) core protein are associated with the clinical outcome of peginterferon (PEG-IFN) and ribavirin combination therapy. The impact of these factors on the pure sensitivity/resistance to interferon was evaluated. Changes in the HCV RNA levels 24, 48, 72, and 120 hr after administering a single dose of standard interferon (IFN) were measured in 156 HCV-infected patients. The changes were compared based on the genetic polymorphisms near the IL28B gene or amino acid substitutions in the HCV core region. Among patients with HCV genotype 1b, there were differences in the reduction and subsequent increase in HCV RNA levels after administering IFN based on rs8099917 genetic polymorphisms. Amino acid substitutions at residue 70 were associated with differences in the changes in HCV RNA levels only in patients with TG/GG genotype. Multivariate analyses showed that genetic polymorphisms near the IL28B gene was the sole independent factor that was associated with the reduction in HCV RNA levels after administering IFN and the final response to the combination therapy. Among patients infected with HCV genotype 2a or 2b, there were no differences in the changes in HCV RNA levels based on the genetic polymorphisms near the IL28B gene. In HCV genotype 1b, genetic variations near the IL28B gene affected the sensitivity/resistance to IFN strongly. Genetic polymorphisms near the IL28B gene did not affect the sensitivity/resistance to IFN in HCV genotype 2.\",\"Chronic hepatitis C virus (HCV) infection is the major etiology and the reason of chronic liver disease, liver cirrhosis, hepatic decompensation, hepatocellular cancer and liver transplantation. Less than half of patients with HCV-related chronic hepatitis achieve sustained viral clearance with current pegylated interferon and ribavirin (P+R) combination therapy. Due to the insufficient treatment success, an extended search for new, direct acting anti-HCV agents (DAAs) is ongoing, already leading to submissions of applications for marketing authorization of the protease-inhibitors boceprevir and telaprevir. Both are effective only in triple combinations with P+R. Studies demonstrate a 50% success rate advantage for triple therapies above current standards. In addition, treatment duration can be shortened, and half of the patients who failed previous therapy with P+R can be cured with triple therapies. A major concern with new DAAs is rapid development of DAA-resistant viral mutants, a reason as well as a consequence of insufficient triple therapy. Clinical studies with boceprevir and telaprevir are reviewed in this paper.\",\"To review the use of telaprevir for the treatment of chronic hepatitis C.\",\"Anemia is commonly observed as a side effect in a treatment with protease inhibitors combined with peginterferon alpha and ribavirin for hepatitis C virus infection. This study assessed the safety, tolerability, viral kinetics, and selection of variants in telaprevir monotherapy for 24 weeks, and outcomes of the off-study treatment with peginterferon alpha-2b and ribavirin among Japanese female patients at a median age of 54 years who were difficult to treat with the standard therapy (peginterferon alpha-2b and ribavirin) alone in Japan.\",\"Hepatitis C virus (HCV), a major cause of liver disease throughout the world, is difficult to treat with interferon (IFN) (and various formulations and combinations thereof) being the only approved molecule available. It has been investigated recently that proinflammatory chemokine interleukin-8 (IL-8) induced by HCV partially inhibits the antiviral IFN-\\u03b1 therapy. Therefore, the current study was aimed to prospectively utilize the baseline IL-8 levels in the HCV infected serum and predicts its role in sustained virological response (SVR) to IFN-\\u03b1+ribavirin therapy, in chronic HCV patients in Pakistan. One hundred and ten hepatitis C patients without any other infections underwent IFN-\\u03b1+ribavirin combination treatment. Baseline IL-8 levels were determined before starting of the therapy for all these patients. Fifteen normal volunteers negative for HCV were kept as control. The baseline IL-8 levels were found significantly higher in all HCV positive patients as compared to normal healthy volunteers (1083.54 \\u00b1 85.72 pg/ml versus 6.99 \\u00b1 1.05 pg/ml [mean \\u00b1 SEM], p<0.01) and were also significantly higher in non-responders than responders (p<0.05). Comparatively higher mean baseline IL-8 levels were observed in non-responders (2442.02 \\u00b1 159.92 pg/ml), than late (1009.31 \\u00b1 45.31) and rapid (540.91 \\u00b1 27.06 pg/ml) responders. Significant relation was observed between baseline IL-8 level and response to IFN therapy (p<0.01). Results of this study suggest that increased levels of IL-8 in HCV infection might be involved in pathogenesis, persistence and resistance to IFN-\\u03b1+ribavirin combination therapy.\",\"Many individuals infected with hepatitis C virus (HCV) develop a chronic infection, and of those who are treated with pegylated interferon and ribavirin (RBV), many do not respond. While the nucleoside analog RBV improves treatment outcome, and will likely be an important component of therapy with next-generation viral inhibitors, RBV's mechanism is controversial. Most of RBV's proposed mechanisms require RBV import into cells. Therefore, we explored whether host-based RBV resistance develops through reduced cellular uptake, akin to chemotherapy resistance in some cancers. We examined the effect of host-based RBV resistance on HCV replication in cultured hepatoma Huh7.5 liver cells and whether RBV resistance develops in HCV patients. When Huh7.5 cells were exposed to RBV, resistance developed through reduced RBV uptake via the ENT1 nucleoside transporter and antiviral efficacy was reduced. The uptake defect in RBV-resistant cells was specific to RBV, since transport of another ENT1 substrate, cytidine, was unaffected. Importantly, RBV uptake significantly declined in HCV patient peripheral blood mononuclear cells (PBMCs) following 4 weeks of therapy. Furthermore, maintenance of RBV uptake correlated with rapid treatment response. Our results uncovered a novel form of antiviral drug resistance and suggest that host-based RBV resistance develops in HCV patients undergoing therapy and that maintenance of RBV uptake may contribute to rapid viral clearance.\",\"Insulin resistance (IR) is common in chronic hepatitis C (CHC) and associates with reduced virological response to pegylated-interferon (PEG-IFN)/ribavirin therapy, but the underlying mechanisms are still unclear. We have previously shown that, in CHC patients, insulin plasma levels are inversely related to antiviral effect induced by PEG-IFN. Therefore, we investigated the in vitro effect of insulin on interferon alpha (IFN-\\u03b1) intracellular signaling as well as that of IFN-\\u03b1 on insulin signaling. HepG2 cells, preincubated with or without insulin, were stimulated with IFN-\\u03b12b and messenger RNA (mRNA) and protein expression of IFN-stimulated genes (ISGs) were measured at different timepoints. The role of intracellular suppressors of cytokine signaling 3 (SOCS3) was evaluated with the small interfering RNA (siRNA) strategy. To assess the effect of IFN-\\u03b1 on insulin signaling, HepG2 were preincubated with or without IFN before addition of insulin and cells were then analyzed for IRS-1 and for Akt/PKB Ser473 phosphorylation. Insulin (100 and 1000 nM) significantly reduced in a dose-dependent fashion IFN-induced gene expression of PKR (P=0.017 and P=0.0017, respectively), MxA (P=0.0103 and P=0.00186), and 2'-5' oligoadenylatesynthetase 1 (OAS-1) (P=0.002 and P=0.006). Insulin also reduced IFN-\\u03b1-induced PKR protein expression. Although insulin was confirmed to increase SOCS3 expression, siRNA SOCS3 did not restore ISG expression after insulin treatment. IFN-\\u03b1 was found to reduce, in a dose-dependent fashion, IRS-1 gene expression as well as Akt/PKB Ser473 phosphorylation induced by insulin.\",\"Several studies recently revealed that single nucleotide polymorphisms (SNPs) in the interleukin28B (IL28B) region are associated with the response to pegylated interferon-alfa (PEG-IFN-alfa) and ribavirin (RBV) treatment among hepatitis C virus (HCV)-infected individuals of European, African and Asian ancestry. The purpose of the study was to establish methods for determining the SNP rs8099917 associated with IL28B, which might be useful for further research of the treatment of HCV.\",\"Substitution of amino acids 70 and 91 in the hepatitis C virus (HCV) core region is a significant predictor of poor responses to peginterferon-plus-ribavirin therapy, while their molecular mechanisms remain unclear. Here we investigated these differences in the response to alpha interferon (IFN) by using HCV cell culture with R70Q, R70H, and L91M substitutions. IFN treatment of cells transfected or infected with the wild type or the mutant HCV clones showed that the R70Q, R70H, and L91M core mutants were significantly more resistant than the wild type. Among HCV-transfected cells, intracellular HCV RNA levels were significantly higher for the core mutants than for the wild type, while HCV RNA in culture supernatant was significantly lower for these mutants than for the wild type. IFN-induced phosphorylation of STAT1 and STAT2 and expression of the interferon-inducible genes were significantly lower for the core mutants than for the wild type, suggesting cellular unresponsiveness to IFN. The expression level of an interferon signal attenuator, SOCS3, was significantly higher for the R70Q, R70H, and L91M mutants than for the wild type. Interleukin 6 (IL-6), which upregulates SOCS3, was significantly higher for the R70Q, R70H, and L91M mutants than for the wild type, suggesting interferon resistance, possibly through IL-6-induced, SOCS3-mediated suppression of interferon signaling. Expression levels of endoplasmic reticulum (ER) stress proteins were significantly higher in cells transfected with a core mutant than in those transfected with the wild type. In conclusion, HCV R70 and L91 core mutants were resistant to interferon in vitro, and the resistance may be induced by IL-6-induced upregulation of SOCS3. Those mechanisms may explain clinical interferon resistance of HCV core mutants.\",\"Protease inhibitors (PIs) have proven to be effective adjuncts to interferon/ribavirin treatment of hepatitis C virus (HCV) infections. Little clinical or in vitro data exists, however, on their effectiveness for nontype 1 genotypes that predominate in Europe, the Middle East, Africa, and most of Asia. NS3 protease and NS4A genes from genotypes 1-6 were inserted into the JFH clone to generate replication-competent intergenotype chimeras. Susceptibility to PIs was determined by replication and infectivity assays. To study resistance development, chimeras were cultured in subinhibitory concentrations of PIs and mutations phenotypically characterized. Marked differences in susceptibility of different genotypes to danoprevir (ITMN-191) and telaprevir (VX-950) were observed. Genotypes 1, 4, and 6 showed median inhibitory concentration (IC(50)) values of 2-3 nM, >100-fold lower than genotypes 2/3/5 (250-750 nM). Telaprevir susceptibilities varied over a 4-fold range, with genotypes 1 and 2 being most susceptible and genotypes 4 and 5 most resistant. Culture of genotypes 1-6 in PIs induced numerous mutations in the NS3 protease domain, highly variable between genotypes. Introduction of danoprevir and BILN 2061-induced mutations into the original clones by site-directed mutagenesis (n = 29) all conferred resistant phenotypes, with particularly large increases (1-2 log greater IC(50) values) in the initially susceptible genotypes 1/4/6. Most introduced mutations and showed little or no effect on replicative fitness.\",\"Hepatitis C virus (HCV) nonstructural protein 3-4A (NS3-4A) is a complex composed of NS3 and its cofactor NS4A. It harbours serine protease as well as NTPase/RNA helicase activities and is essential for viral polyprotein processing, RNA replication and virion formation. Specific inhibitors of the NS3-4A protease significantly improve sustained virological response rates in patients with chronic hepatitis C when combined with pegylated interferon-\\u03b1 and ribavirin. The NS3-4A protease can also target selected cellular proteins, thereby blocking innate immune pathways and modulating growth factor signalling. Hence, NS3-4A is not only an essential component of the viral replication complex and prime target for antiviral intervention but also a key player in the persistence and pathogenesis of HCV. This review provides a concise update on the biochemical and structural aspects of NS3-4A, its role in the pathogenesis of chronic hepatitis C and the clinical development of NS3-4A protease inhibitors.\",\"PSI-352938 is a novel cyclic phosphate prodrug of \\u03b2-D-2'-deoxy-2'-\\u03b1-fluoro-2'-\\u03b2-C-methylguanosine 5'-monophosphate that has potent activity against hepatitis C virus (HCV) in vitro. The studies described here characterize the in vitro anti-HCV activity of PSI-352938, alone and in combination with other inhibitors of HCV, and the cross-resistance profile of PSI-352938. The effective concentration required to achieve 50% inhibition for PSI-352938, determined using genotype 1a-, 1b-, and 2a-derived replicons stably expressed in the Lunet cell line, were 0.20, 0.13, and 0.14 \\u03bcM, respectively. The active 5'-triphosphate metabolite, PSI-352666, inhibited recombinant NS5B polymerase from genotypes 1 to 4 with comparable 50% inhibitory concentrations. In contrast, PSI-352938 did not inhibit the replication of hepatitis B virus or human immunodeficiency virus in vitro. PSI-352666 did not significantly affect the activity of human DNA and RNA polymerases. PSI-352938 and its cyclic phosphate metabolites did not affect the cyclic GMP-mediated activation of protein kinase G. Clearance studies using replicon cells demonstrated that PSI-352938 cleared cells of HCV replicon RNA and prevented replicon rebound. An additive to synergistic effect was observed when PSI-352938 was combined with other classes of HCV inhibitors, including alpha interferon, ribavirin, NS3/4A inhibitors, an NS5A inhibitor, and nucleoside/nucleotide and nonnucleoside inhibitors. Cross-resistance studies showed that PSI-352938 remained fully active against replicons containing the S282T or the S96T/N142T amino acid alteration. Replicons that contain mutations conferring resistance to various classes of nonnucleoside inhibitors also remained sensitive to inhibition by PSI-352938. PSI-352938 is currently being evaluated in a phase I clinical study in genotype 1-infected individuals.\",\"Hepatitis C virus (HCV) is a major cause of chronic liver disease, cirrhosis and hepatocellular carcinoma and the identification of the predictors of response to antiviral therapy is an important clinical issue.\",\"The aim of this study was to evaluate the influence of clinical and epidemiological characteristics of 183 HIV/HCV coinfected patients and HCV clearance after antiviral treatment on serum sFas and sFasL levels. Thirty out of 183 patients underwent HCV antiviral therapy with IFN-\\u03b1 + RBV for a duration of 48 weeks. HCV genotype 1 and homeostasis model assessment for insulin resistance (HOMA-IR) had a significant positive relationship, and CD4+/\\u03bcL had a significant negative relationship with sFas (R-square = 0.582; p < 0.001) and sFasL (R-square = 0.216; p < 0.001) in multivariate linear regression analysis. HCV genotype 1 was the only significant variable associated with the sFas/sFasL ratio (R-square = 0.201; p < 0.001). sFas and sFasL levels had positive significant correlations with serum sICAM-1, sVCAM-1, and HOMA levels (p < 0.05). Among patients on IFN-\\u03b1 + RBV therapy, 15 patients showed a sustained virologic response (SVR), while 15 patients were non-responders (NR). Patients with SVR had significant decreases in sFas (p = 0.008) and sFas/sFasL ratio (p = 0.002), while non-responders had a significant increase in sFasL values (p = 0.013). In conclusion, HCV genotype 1, high HOMA, and low CD4+/\\u03bcL were associated with high serum levels of sFas and sFasL, which indicate higher levels of inflammation and, possibly, increased cardiovascular risk. Moreover, response to HCV antiviral therapy is known to reduce inflammation.\",\"In patients with chronic hepatitis C who failed to respond to standard therapy, high-dose pegylated interferon (IFN)-\\u03b1 and/or ribavirin could induce a stronger antiviral response and prevent treatment failure and HCV resistance when combined with direct-acting antivirals. The influence of genetic determinants in this context remains unknown.\",\"In the present work, we described the activity of the thiosemicarbazone derived from 5,6-dimethoxy-1-indanone (TSC), which we previously characterized as a new compound that inhibits bovine viral diarrhea virus (BVDV) infection. We showed that TSC acts at a point of time that coincides with the onset of viral RNA synthesis and that it inhibits the activity of BVDV replication complexes (RCs). Moreover, we have selected five BVDV mutants that turned out to be highly resistant to TSC but still susceptible to ribavirin (RBV). Four of these resistant mutants carried an N264D mutation in the viral RNA-dependent RNA polymerase (RdRp). The remaining mutant showed an A392E mutation within the same protein. Some of these mutants replicated slower than the wild-type (wt) virus in the absence of TSC, whereas others showed a partial reversion to the wt phenotype over several passages in the absence of the compound. The docking of TSC in the crystal structure of the BVDV RdRp revealed a close contact between the indane ring of the compound and several residues within the fingers domain of the enzyme, some hydrophobic contacts, and hydrogen bonds with the thiosemicarbazone group. Finally, in the mutated RdRp from resistant BVDV, these interactions with TSC could not be achieved. Interestingly, TSC inhibited BVDV replication in cell culture synergistically with RBV. In conclusion, TSC emerges as a new nonnucleoside inhibitor of BVDV RdRp that is synergistic with RBV, a feature that turns it into a potential compound to be evaluated against hepatitis C virus (HCV).\",\"The role of insulin resistance (IR) and hepatic steatosis in fibrogenesis in chronic hepatitis C infection (CHC) has yielded conflicting data and few studies have been performed in Asian-region populations. We retrospectively investigated the relationship between host metabolic variables, including IR and hepatic steatosis, to hepatic fibrosis in Asian-region CHC genotype 2/3 patients.\",\"Current treatment of chronic hepatitis C virus (HCV) infection is based on the combination of pegylated interferon-\\u03b1 and ribavirin. The recent development of direct-acting antiviral (DAA) molecules that are active on HCV, together with in vitro and in vivo studies showing that these drugs may lead to the selection of resistant viruses if administered alone, has raised concerns that resistance may undermine therapy based on DAAs. A new standard-of-care treatment will soon be available for both treatment-naive and treatment-experienced patients infected with HCV genotype 1, based on a triple combination of pegylated interferon-\\u03b1, ribavirin, and a protease inhibitor (either telaprevir or boceprevir). With this therapy, most failures to eradicate infection in treatment-adherent patients are due to an inadequate response to pegylated interferon-\\u03b1 and ribavirin, in the context of a low genetic barrier to resistance of first-generation protease inhibitors. This article reviews patterns of resistance to HCV DAA drugs in development, the mechanisms underlying treatment failure when these drugs are combined with pegylated interferon-\\u03b1 and ribavirin, the consequences of treatment failure, and possible means of optimizing future therapies that use DAAs.\",\"Both host and viral factors have been implicated in influencing the response to pegylated-interferon/ribavirin (PEG-IFN/RBV) therapy for hepatitis C virus (HCV) infection. Among the viral factors, sequence heterogeneity within NS5A and core regions has been proposed. This study aimed to clarify the relationship between virological responses to PEG-IFN/RBV therapy and sequence heterogeneity within NS5A, including the IFN/RBV resistance-determining region (IRRDR), the interferon sensitivity-determining region (ISDR) and the core region. Pretreatment sequences of NS5A and the core regions were analyzed in 57 HCV-1b-infected patients who were to be treated with PEG-IFN/RBV. Of 40 patients infected with HCV having an IRRDR with four or more mutations (IRRDR \\u2265 4), 28 (70%) patients achieved a sustained virological response (SVR). On the other hand, only 4 (24%) of 17 patients infected with HCV having an IRRDR with three or fewer mutations (IRRDR \\u2264 3) achieved a SVR (P = 0.001). Similarly, 22 (71%) of 31 patients infected with HCV and having an ISDR with one or more mutations (ISDR \\u2265 1) achieved a SVR while 10 (38%) of 26 patients infected with HCV and having an ISDR without any mutations (ISDR = 0) achieved a SVR (P = 0.014). As for the core region, there was significant correlation between a single mutation at position 70 (Gln(70)) and non-SVR (P = 0.02). Notably, Gln(70) was more prominently associated with the null response (P = 0.0007). In conclusion, sequence heterogeneity within the IRRDR and ISDR, and a single point mutation at position 70 of the core region of HCV-1b are likely to be correlated with virological responses to PEG-IFN/RBV therapy.\",\"INX-08189 is an aryl-phosphoramidate of 6-O-methyl-2'-C-methyl guanosine. INX-08189 was highly potent in replicon assays, with a 50% effective concentration of 10\\u00b16 nM against hepatitis C genotype 1b at 72 h. The inhibitory effect on viral replication was rapid, with a 50% effective concentration (EC50) of 35\\u00b18 nM at 24 h. An intracellular 2'-C-methyl guanosine triphosphate (2'-C-MeGTP) concentration of 2.43\\u00b10.42 pmol/10(6) cells was sufficient to achieve 90% inhibition of viral replication. In vitro resistance studies confirmed that the S282T mutation in the NS5b gene conferred an approximately 10-fold reduction in sensitivity to INX-08189. However, the complete inhibition of S282T mutant replicons still could be achieved with an EC90 of 344\\u00b1170 nM. Drug combination studies of INX-08189 and ribavirin indicated significant synergy in antiviral potency both in wild-type and S282T-expressing replicons. Genotype 1b replicons could be cleared after 14 days of culture when exposed to as little as 20 nM INX-08189. No evidence of mitochondrial toxicity was observed after 14 days of INX-08189 exposure in both HepG2 and CEM human cell lines. In vivo studies of rats and cynomolgus monkeys demonstrated that 2'-C-MeGTP concentrations in liver equivalent to the EC90 could be attained after a single oral dose of INX-08189. Rat liver 2'-C-MeGTP concentrations were proportional to dose, sustained for greater than 24 h, and correlated with plasma concentrations of the nucleoside metabolite 2'-C-methyl guanosine. The characteristics displayed by INX-08189 support its continued development as a clinical candidate for the treatment of chronic HCV infection.\",\"Danoprevir (RG7227; ITMN-191) is a potent inhibitor of the HCV NS3/4A serine protease. The aims of this double-blind, placebo-controlled, multiple-ascending dose phase Ib study were to evaluate safety, tolerability, antiviral activity, resistance, and pharmacokinetics of once- and twice-daily danoprevir in the presence of low-dose ritonavir (danoprevir/r) and in combination with peginterferon alfa-2a (40KD)/ribavirin in treatment-naive HCV genotype 1 patients.\",\"Chronic hepatitis C virus (HCV) infection is a major cause of liver disease worldwide. HCV infection is currently treated with IFN\\u03b1 plus ribavirin for 24 to 48 weeks. This demanding therapy fails in up to 50% of patients, so the use of pharmacogenetic biomarkers to predict the outcome of treatment would reduce futile treatment of non-responders and help identify patients in whom therapy would be justified. Both IFN\\u03b1 and ribavirin primarily act by modulating the immune system of the patient, and HCV uses multiple mechanisms to counteract the antiviral effects stimulated by therapy. Therefore, response to therapy is influenced by variations in human genes governing the immune system and by differences in HCV genes that blunt antiviral immune responses. This article summarizes recent advances in understanding how host and viral genetic variation affect outcome of therapy. The most notable human associations are polymorphisms within the IL28B gene, but variations in human leukocyte antigen and cytokine genes have also been associated with treatment outcome. The most prominent viral genetic association with outcome of therapy is that HCV genotype 1 is much less sensitive to treatment than genotypes 2 and 3, but genetic differences below the genotype level also influence outcome of therapy, presumably by modulating the ability of viral genes to blunt antiviral immune responses. Pharmacogenetic prediction of the outcome of IFN-based therapy for HCV will require integrating the efficacies of the immunosuppressive mechanisms of a viral isolate, and then interpreting the viral resistance potential in context of the genetic profile of the patient at loci associated with outcome of therapy. Direct-acting inhibitors of HCV that will be used in combination with IFN\\u03b1 are nearing approval, so genetic prediction for anti-HCV therapy will soon need to incorporate viral genetic markers of viral resistance to the new drugs.\",\"Genotypes 2 and 3 (G2/G3) of hepatitis C virus have been lumped together as 'easy to treat'. As a result, guidelines recommend 24 weeks of peginterferon/ribavirin for both. However, a closer look at trials shows that these genotypes are not the same, with G2 infection proving more responsive to peginterferon. The data supporting this conclusion are presented along with possible explanations for the differences observed. Ultimately, decisions must be made about therapy. Rapid virological response (RVR) may be the best parameter predicting successful antiviral therapy. For patients with G2 infection who achieve an RVR, shortened courses of therapy are effective. In contrast, for G3 patients without an RVR, there may be benefit to extending therapy to 48 weeks; however, this requires confirmation in prospective studies. Using RVR to guide therapy may level the playing field between these 'easy to treat' genotypes.\",\"Hepatitis C is a major health problem affecting more than 200 million individuals in world including Pakistan. Current treatment regimen consisting of interferon alpha and ribavirin does not always succeed to eliminate virus completely from the patient's body.\",\"Chronic hepatitis C patients with coexisting heart disease are often denied antiviral treatment due to safety concerns. However, this is not evidence-based.\",\"Hepatitis C virus (HCV genome) polymorphisms are thought to influence the outcome of pegylated-interferon/ribavirin (PEG-IFN/RBV) therapy. This study aimed to examine non-structural protein 5A (NS5A) polymorphisms, e.g. IFN/RBV resistance-determining region (IRRDR) and IFN sensitivity-determining region (ISDR), and core protein polymorphism as predictive therapeutic markers.\",\"Hepatitis C virus (HCV), a RNA virus belonging to the family Flaviviridae, has been considered to be a significant risk factor in HCV induced liver diseases and development of hepatocellular carcinoma (HCC). Current combination treatment of pegylated interferon-\\u03b1 (PEG-IFN-\\u03b1) and ribavirin has shown limited efficiency, poor tolerability and significant expense mainly depending upon the HCV genotype. HCV has been divided into six genotypes and 52 subtypes present all over the world. The genetic diversity is more than 30% in different genotypes and 20% in subtypes. It has been suggested that different genotypes do vary in their infectivity and pathogenicity due to the variations in amino acid sequence, thereby influencing the rate of disease progression, severity to cirrhosis and the risk of HCC. HCV Core protein has multifunctional activities in regulation of cells growth and host genes expression essential for infectivity including apoptosis, HCV associated steatosis, immune cell functions, cell transformation, signal transduction and transcriptional regulation. Recent studies have shown variable responses for IFN-ribavirin combination therapy, steatosis, insulin resistance and HCC due to amino acid substitutions in HCV Core region of different genotypes. In the present review, we emphasize on the pathogenicity cause by HCV Core and effect of amino acid sequence variation in disease progression and HCV life cycle.\",\"Polymorphisms of the IL28B gene are highly associated with sustained virological response (SVR) in patients with chronic hepatitis C treated with peginterferon and ribavirin. Quantitation of interferon-\\u03b3-inducible protein-10 (IP-10) may also differentiate antiviral response. We evaluated IP-10 levels in pretreatment serum from 115 nonresponders and 157 sustained responders in the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C cohort, including African American (AA) and Caucasian American (CA) patients. Mean IP-10 was lower in sustained responders compared with nonresponders (437 \\u00b1 31 vs 704 \\u00b1 44 pg/mL, P < 0.001), both in AA and CA patients. The positive predictive value of low IP-10 levels (<600 pg/mL) for SVR was 69%, whereas the negative predictive value of high IP-10 levels (>600 pg/mL) was 67%. We assessed the combination of pretreatment IP-10 levels with IL28B genotype as predictors of treatment response. The IL28B polymorphism rs12979860 was tested in 210 participants. The CC, CT, and TT genotypes were found in 30%, 49%, and 21% of patients, respectively, with corresponding SVR rates of 87%, 50%, and 39% (P < 0.0001). Serum IP-10 levels within the IL28B genotype groups provided additional information regarding the likelihood of SVR (P < 0.0001). CT carriers with low IP-10 had 64% SVR versus 24% with high IP-10. Similarly, a higher SVR rate was identified for TT and CC carriers with low versus high IP-10 (TT, 48% versus 20%; CC, 89% versus 79%). IL28B genotype and baseline IP-10 levels were additive but independent when predicting SVR in both AA and CA patients.\",\"Genotype-specific sensitivity of the hepatitis C virus (HCV) to interferon-ribavirin (IFN-RBV) combination therapy and reduced HCV response to IFN-RBV as infection progresses from acute to chronic infection suggest that HCV genetic factors and intrahost HCV evolution play important roles in therapy outcomes. HCV polyprotein sequences (n = 40) from 10 patients with unsustainable response (UR) (breakthrough and relapse) and 10 patients with no response (NR) following therapy were identified through the Virahep-C study. Bayesian networks (BNs) were constructed to relate interrelationships among HCV polymorphic sites to UR/NR outcomes. All models showed an extensive interdependence of HCV sites and strong connections (P \\u2264 0.003) to therapy response. Although all HCV proteins contributed to the networks, the topological properties of sites differed among proteins. E2 and NS5A together contributed \\u223c40% of all sites and \\u223c62% of all links to the polyprotein BN. The NS5A BN and E2 BN predicted UR/NR outcomes with 85% and 97.5% accuracy, respectively, in 10-fold cross-validation experiments. The NS5A model constructed using physicochemical properties of only five sites was shown to predict the UR/NR outcomes with 83.3% accuracy for 6 UR and 12 NR cases of the HALT-C study. Thus, HCV adaptation to IFN-RBV is a complex trait encoded in the interrelationships among many sites along the entire HCV polyprotein. E2 and NS5A generate broad epistatic connectivity across the HCV polyprotein and essentially shape intrahost HCV evolution toward the IFN-RBV resistance. Both proteins can be used to accurately predict the outcomes of IFN-RBV therapy.\",\"Chronic hepatitis C is one of the leading causes of chronic liver disease, with approximately 170 million people infected worldwide. The severity of disease varies from asymptomatic chronic infection to cirrhosis and hepatocellular carcinoma (HCC). Sustained virological response (SVR) is long lasting, associated with a reduced risk of cirrhosis and HCC. In the near future, standard of care (SOC) treatment of hepatitis C virus (HCV) will include the addition of direct-acting antivirals (DAAs) with a protease inhibitor to the pegylated interferon (PEG-IFN) plus ribavirin (RBV). In HCV genotype 1 patients, promising results have been reported when the protease inhibitor telaprevir or boceprevir is added to the SOC, increasing SVR rates from less than 50% (PEG-IFN plus RBV) to 70% (in patients treated with a triple combination of PEG-IFN, RBV plus a protease inhibitor). The future management of patients with these new molecules will require good clinical practice, knowledge of indications, prediction of side effects and monitoring for antiviral resistance. Certain major medical needs are still unmet, requiring studies in special populations (human immunodeficiency virus-HCV-coinfected patients, transplanted patients, etc.) in genotype non-1 patients and in absolute non-responders. Combinations of antivirals with additive potency that lack cross resistance and with a good safety profile may provide new regimens in the future to make HCV the first chronic viral infection eradicated worldwide with a finite duration of combination DAA therapy without IFN. There is ongoing development of new molecules such as HCV enzyme inhibitors. The aim of this review is to summarize the results obtained with DAAs: protease and polymerase inhibitors.\",\"An estimated million people have chronic hepatitis C virus (HCV) infection. With current treatment success rates, by 2030, more than 40% will be cirrhotic and the number of cases with end-stage liver disease is projected to treble. Current standard-of-care is the combination of pegylated interferon plus ribavirin for 24-48 weeks. Unfortunately this is associated with poor efficacy (45% in HCV GT1; 75% in GT2 and 65% in GT 3) and tolerability. Many patients are either unsuitable for or decline current treatment infection because of the significant side-effects associated with this treatment, including those with decompensated cirrhosis or sever psychiatric illness. It is hoped that the development of direct acting antiviral agents (DAAs) will address this huge unmet medical need. The addition of a protease inhibitor to pegylated interferon plus ribavirin is associated with increase in efficacy and shortened duration of therapy in patients with HCV GT1 and is likely to become the new standard-of-care. However, triple therapy will not be suitable for patients with non-1 HCV infection, or contraindications to interferon. It is hoped that the combination of multiple DAAs which target different steps of HCV replication should provide interferon-free treatment regimen. Current and planned studies will determine which combination (protease, nonnucleoside polymerase, nucleoside polymerase, NS5A, cyclophyllin B inhibitors), how many DAAs and duration of therapy will be required to optimise cure. It will also be important to minimise the emergence of multi-resistance, which would jeopardise future retreatment options.\",\"The ability to achieve a sustained virological response (SVR) to peginterferon (PEG-IFN) and ribavirin (RBV) depends on numerous host and virological factors, as well as adherence to a prescribed treatment regimen. Patients who have failed to achieve a SVR to PEG-IFN and RBV have limited options for retreatment. Emerging data from phase II and phase III clinical trials of direct-acting antiviral agents suggest that new therapeutic regimens will be available for many patients. Treatment with protease inhibitors such as PEG-IFN, RBV, ribavirin. and boceprevir, combined with PEG-IFN and RBV, has been shown to produce high rates of virological response in both prior relapsers and, to a lesser extent, prior non-responders. The benefits of these novel treatment regimens for each individual patient must be weighed against the side effects, costs and potential of developing viral resistance. Regulatory approval of telaprevir and boceprevir is expected to begin in mid-late 2011.\",\"With the introduction of direct-acting oral antiviral agents we are on the verge of a new era that will transform the treatment landscape. This review discusses recent developments in drug discovery for hepatitis C protease inhibitors. First generation protease inhibitors will offer higher sustained viral response rates in na\\u00efve populations when combined with standard pegylated interferon and ribavirin. However, these dramatic gains will be partially offset by new challenges in viral resistance and increased adverse events.\",\"Hepatitis C is a common cause of chronic viral infection of the liver. It is associated with insulin resistance and the development of type 2 diabetes mellitus. It is also associated with the development of hepatic steatosis. The presence of hepatic steatosis is associated with an increased risk of having hepatic fibrosis. This is also associated with the severity of insulin resistance. These findings are specifically germane for those with genotype1 infection. Genotype 3 infection independently causes steatosis and successful treatment of the virus is followed by resolution of steatosis. In genotype 1 infection, the presence of hepatic steatosis is also a risk factor for failure to respond to pegylated interferon and ribavirin therapy. Unfortunately efforts to treat insulin resistance prior to antiviral therapy have not been very successful. Newer efforts focused on the role of specific micro RNAs in mediating the metabolic effects of hepatitis C virus infection may provide to ameliorate the metabolic risks of HCV infection.\",\"Approximately 180 million individuals are chronically infected with hepatitis C, which is strongly associated with the development of cirrhosis, end-stage liver disease and hepatocellular carcinoma. Several virological tools (anti-HCV antibody assays, measurement of HCV-RNA, HCV-genotyping) are useful in management of hepatitis C infected patients. The primary goal of antiviral therapy in chronic hepatitis C is a sustained virological response (SVR). The HCV genotype should be determined in every patient considered for antiviral therapy because the currently recommended treatment duration and ribavirin doses differ among HCV genotypes. Exact subtyping might gain increased importance for future therapies with direct-acting antiviral agents (DAA) because of differences of antiviral activities and barriers to resistance among HCV subtypes. Monitoring HCV RNA by a highly sensitive assay (LOD \\u2264 15 IU/ml) is the basis for management of response guided therapy of chronic hepatitis C with pegylated IFN plus ribavirin. Rules for early discontinuation of antiviral therapy in non-responders and determination of optimal treatment durations in virologic responders have been developed for application of individualized treatment strategies.\",\"Hepatic steatosis is commonly seen in patients with chronic hepatitis C virus (HCV) infection, and the prevalence is much higher prevalence than in the general population or in patients with chronic hepatitis B. Hepatic steatosis in patients with chronic hepatitis C can be due to alcohol consumption and host metabolic factors such as high body mass index (BMI), obesity, hyperlipidemia, metabolic syndrome and diabetes mellitus in which insulin resistance plays an important role. However, in genotype 3 HCV infection, hepatic steatosis can result from direct viral cytopathic effect. Demographic and clinical characteristics associated with hepatic steatosis in patients with chronic hepatitis C including older age, higher BMI, more genotype 3 infection, and higher mean serum levels of triglyceride, alanine aminotransferase and \\u03b3-glutamyl transpeptidase. The clinical relevance of hepatic steatosis in patients with chronic hepatitis C includes a close correlation with hepatic fibrosis, and a poor response to combination peginterferon and ribavirin treatment. In addition, hepatic steatosis has been reported to associate with increased frequency of hepatocellular carcinoma in patients with chronic HCV infection. Whether life style modification such as weight reduction or adding an insulin resistance reducing agent such as metformin or thiazolidinediones combined with current standard peginterferon plus ribavirin treatment will benefit to the chronic hepatitis C patients with hepatic steatosis deserves further evaluation.\",\"As an RNA virus, hepatitis C virus (HCV) shows a characteristically high level of nucleotide diversity. Accumulation of nucleotide substitutions in the virus has resulted in diversification into quasispecies, subtypes and distinct genotypes. Pathobiological studies linking nucleotide and amino acid sequences with clinical findings have identified relationships between certain genotypes and characteristic biological properties. Genotype 3 HCV infection was found to be associated with a high level of liver steatosis. Genotypes 1 and 4 were found to be more resistant to interferon (IFN) based therapies than genotypes 2 and 3. Studies of genotype 1 sequences obtained from patients treated with IFN have identified a relationship between favorable response to interferon therapy and amino acid substitutions in the NS5A region (interferon response determining region; ISDR). Further studies have identified a relationship between the effect of IFN therapy and other regions of the NS5A protein. More recently, a relationship has been found between poor response to peg-IFN plus ribavirin combination therapy and substitutions at amino acid 70 and 91 in the core protein. Furthermore, a correlation between human genetic variation in the IL28B (IFN-lamda 3) locus and core amino acid substitutions has been characterized. In this review we briefly summarize the discovery, classification and nomenclature of HCV genotypes and subtypes. We also discuss amino acid substitutions within specific regions that have been reported to be associated with outcome of IFN and peg-IFN plus ribavirin combination therapy.\",\"Response to interferon therapy and disease progression in hepatitis C virus (HCV) infected patients differs among individuals, suggesting a possibility of a contribution of host genetic factors. 2'-5'-oligoadenylate synthetase 1 (OAS1), an important component of the innate immune system with a proven antiviral function, may therefore have a relationship with the response to interferon therapy and clinical course of HCV disease. Our aim was to determine the frequency of single nucleotide polymorphism (SNP) at exon 7 splice acceptor site (SAS) of the OAS1 gene in relation to the interferon response and status of HCV infection.\",\"Danoprevir is a potent and selective inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. The present study assessed the safety, pharmacokinetics, and antiviral activity of danoprevir in a randomized, placebo-controlled, 14-day multiple ascending dose study in patients with chronic HCV genotype 1 infection.\",\"BI201335 is a highly specific and potent HCV protease inhibitor. This multiple rising dose trial evaluated antiviral activity and safety in chronic HCV genotype-1 patients.\",\"The current treatment regimen for chronic hepatitis C virus (HCV) infection is peg-interferon plus ribavirin combination therapy. The majority of developing therapeutic strategies also contain peg-interferon with or without ribavirin. However, interferon is expensive and sometimes intolerable for some patients because of severe side effects.\",\"Polymorphisms of the IL28B gene (rs12979860 and rs8099917) are associated with high sustained virological response (SVR) rates in HCV genotype 1 patients. This study analyzes the impact of these IL28B polymorphisms on early treatment response (weeks 2 and 4) and SVR in HCV genotype 3 patients.\",\"Common genetic variation within the IL28 locus has been found to influence the effect of peg-interferon and ribavirin combination therapy against chronic hepatitis C virus (HCV) infection. Expression of IL28 in peripheral blood cells has been reported to be higher in patients with IL28 SNP genotypes associated with favorable response.\",\"Pegylated interferon and ribavirin (PEG-IFN/RBV) therapy for chronic hepatitis C virus (HCV) genotype 1 infection is effective in 50% of patients. Recent studies revealed an association between the IL28B genotype and treatment response. We aimed to develop a model for the pre-treatment prediction of response using host and viral factors.\",\"Common IL28B locus polymorphisms (SNPs rs8099917 and rs12979860) have been reported to affect peg-interferon plus ribavirin combination therapy (PEG-RBV) for hepatitis C virus (HCV) genotype 1b, but few reports have examined their effect on other two common genotypes, 2a and 2b.\",\"Improved understanding of the hepatitis C virus (HCV) life cycle has led to the discovery of numerous potential targets for antiviral therapy. HCV polyprotein processing and replication have been identified as the most promising viral targets. However, viral entry and fusion, RNA translation, virus assembly and release and several host cell factors may provide alternative attractive targets for future anti-HCV therapies. Inhibitors of the HCV NS3/4A protease are currently the most advanced in clinical development. Monotherapy with protease inhibitors has shown high antiviral activity, but is associated with frequent selection of resistant HCV variants, often resulting in viral breakthrough. However, there is encouraging evidence from phase 2/3 trials indicating that the addition of a protease inhibitor (e.g. telaprevir and boceprevir) to pegylated interferon-\\u03b1/ribavirin substantially improves sustained virological response rates in both treatment-na\\u00efve and treatment-experienced patients with HCV genotype 1. Nucleos(t)ide inhibitors of the HCV NS5B polymerase have shown variable antiviral activity against different HCV genotypes, but seem to have a higher genetic barrier to resistance than protease inhibitors. In addition, several allosteric binding sites have been identified for non-nucleoside inhibitors of the NS5B polymerase. However, the development of a substance with high antiviral activity and a high genetic barrier to resistance seems to be difficult. Among the different host cell-targeting compounds in early clinical development, cyclophilin inhibitors have shown the most promising results. Although advances have also been made in improving interferons, combinations of antiviral agents with different mechanisms of action may lead to the eventual possibility of interferon-free regimens.\",\"Chronic hepatitis C is associated with an increased prevalence of insulin resistance, which might result from liver disease, metabolic factors, or the hepatitis C virus (HCV) itself. The effect of antiviral treatment on insulin sensitivity is not well-known. We evaluated changes in insulin resistance and weight in patients with hepatitis C during and after peginterferon and ribavirin therapy.\",\"Several host and viral factors have been reported to influence the effectiveness of pegylated interferon plus ribavirin combination therapy for chronic hepatitis C. In Japan, where the age of treated patients is comparatively high, recent studies have reported poor response to treatment in older female patients, but little is known about the relationship between advanced age in women and previously reported factors.\",\"A lack of antiviral response in patients with chronic hepatitis C treated with pegylated (PEG)-interferon (IFN)-\\u03b1-2a + ribavirin (RIBA) may be explained by neutralizing antibodies to IFN-\\u03b1-2a. The aim of this study was to assess neutralizing antibodies to IFN-\\u03b1-2a and IFN levels in non-responder patients who were re-treated by PEG IFN-\\u03b1-2a and RIBA for 12 weeks. Non-responders to a first-line treatment of PEG IFN-\\u03b1-2a + RIBA were included for treatment with PEG IFN-\\u03b1-2a (180 \\u00b5g/week) + RIBA (1,000 mg/day if <75 kg, 1,200 mg otherwise) for 48 weeks. HCV RNA was measured at week 12. IFN levels and neutralizing antibodies to IFN-\\u03b1-2a were measured retrospectively on stored sera at baseline and weeks 4 and 12, using a quantitative sandwich ELISA for neutralizing antibodies to IFN-\\u03b1-2a. Twenty-three patients were non-responders and 19 patients were responders at week 12 of the initial phase of the second-line treatment. Non-responders and responders did not differ statistically: baseline age (median age 47 vs. 50 years), HCV RNA (median 6.8 vs. 6.4 log(10) copies/ml), gender (70% vs. 73% males), genotype (genotype 1: 91% vs. 80%). The median IFN-\\u03b1-2a levels (pg/ml) at weeks 0, 4, and 12 (interquartile range) did not differ between the 19 responders to initial phase of second-line treatment and the 23 non-responders: <3.3 (<3.3-371.4), 1457.3 (106.8-3284.8), and 1,652 (90.8-5,000); 84.5 (3.3-277.4), 1407.4 (120.2-2443.4), and 1620.1 (120.2-2287.1), respectively. Among non-selected consecutive non-responder patients, re-treatment with PEG IFN-\\u03b1-2a + RIBA is associated with virological response regardless of the presence of antibody-mediated resistance to conventional IFN treatment.\",\"Few studies evaluated the efficacy of HCV re-treatment and the predictors of response in HIV/HCV co-infected patients. The role of insulin resistance as a predictor of response in this population is unknown. The aim of this study is to evaluate the safety and efficacy of pegylated interferon-\\u03b1-2a and ribavirin in re-treatment of HIV/HCV co-infected patients, predictors of sustained virological response, including insulin resistance, and the relationship between insulin resistance and liver histology.\",\"Classical antiviral therapies target viral proteins and are consequently subject to resistance. To counteract this limitation, alternative strategies have been developed that target cellular factors. We hypothesized that such an approach could also be useful to identify broad-spectrum antivirals. The influenza A virus was used as a model for its viral diversity and because of the need to develop therapies against unpredictable viruses as recently underlined by the H1N1 pandemic. We proposed to identify a gene-expression signature associated with infection by different influenza A virus subtypes which would allow the identification of potential antiviral drugs with a broad anti-influenza spectrum of activity. We analyzed the cellular gene expression response to infection with five different human and avian influenza A virus strains and identified 300 genes as differentially expressed between infected and non-infected samples. The most 20 dysregulated genes were used to screen the connectivity map, a database of drug-associated gene expression profiles. Candidate antivirals were then identified by their inverse correlation to the query signature. We hypothesized that such molecules would induce an unfavorable cellular environment for influenza virus replication. Eight potential antivirals including ribavirin were identified and their effects were tested in vitro on five influenza A strains. Six of the molecules inhibited influenza viral growth. The new pandemic H1N1 virus, which was not used to define the gene expression signature of infection, was inhibited by five out of the eight identified molecules, demonstrating that this strategy could contribute to identifying new broad anti-influenza agents acting on cellular gene expression. The identified infection signature genes, the expression of which are modified upon infection, could encode cellular proteins involved in the viral life cycle. This is the first study showing that gene expression-based screening can be used to identify antivirals. Such an approach could accelerate drug discovery and be extended to other pathogens.\",\"Treatment-induced control and spontaneous clearance of hepatitis C virus (HCV) infection are affected by various host factors. Polymorphisms in the region of the gene IL28B are associated with HCV clearance, implicating the gene product, interferon (IFN)-\\u03bb3, in the immune response to HCV. Although it is not clear how the IL28B haplotype affects HCV clearance, IFN-\\u03bb3 up-regulates interferon-stimulated genes, similar to IFN-\\u03b1 and IFN-\\u03b2 but via a different receptor. There is also evidence that IFN-\\u03bb3 affects the adaptive immune response. The IL28B genotype can be considered, along with other factors, in predicting patient responses to therapy with pegylated IFN-\\u03b1 and ribavirin. We review the genetic studies that uncovered the association between IL28B and HCV clearance, the biology of IFN-\\u03bb3, the clinical implications of the genetic association, and areas of future research.\",\"RG7128 (prodrug of PSI-6130) shows potent antiviral efficacy in patients infected with hepatitis C virus (HCV) genotypes 1, 2, or 3, with mean viral load decreases of 2.7 and 5 log(10) IU/mL, respectively, associated with 1500-mg doses twice daily after monotherapy for 2 weeks and with 1000-mg and 1500-mg doses twice daily after treatment in combination with the standard of care (SOC) for 4 weeks.\",\"Recent development of proteomic array technology, including protein profiling coupling ProteinChip array with surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF/MS), provides a potentially powerful tool for discovery of new biomarkers by comparison of its profiles according to patient phenotypes. We used this approach to identify the host factors associated with treatment response in patients with chronic hepatitis C (CHC) receiving a 48-wk course of pegylated interferon (PEG-IFN) alpha 2b plus ribavirin (RBV). Protein profiles of pretreatment serum samples from 32 patients with genotype 1b and high viral load were conducted by SELDI-TOF/MS by using the three different ProteinChip arrays (CM10, Q10, IMAC30). Proteins showed significantly different peak intensities between sustained virological responders (SVRs), and non-SVRs were identified by chromatography, SDS-PAGE, TOF/MS and tandem mass spectrometry (MS/MS) assay. Eleven peak intensities were significantly different between SVRs and non-SVRs. The three SVR-increased peaks could be identified as two apolipoprotein (Apo) fragments and albumin and, among the eight non-SVR-increased proteins, four peaks identified as two iron-related and two fibrogenesis-related protein fragments, respectively. Multivariate analysis showed that the serum ferritin and three peak intensity values (Apo A1, hemopexin and transferrin) were independent variables associated with SVRs, and the area under the receiver operating characteristic (ROC) curves for SVR prediction by using the Apo A1/hemopexin and hemopexin/transferrin were 0.964 and 0.936. In conclusion, pretreatment serum protein profiling by SELDI-TOF/MS is variable for identification of response-related host factors, which are useful for treatment efficacy prediction in CHC receiving PEG-IFN plus RBV. Our data also may help us understand the mechanism for treatment resistance and development of more effective antiviral therapy targeted toward the modulation of lipogenesis or iron homeostasis in CHC patients.\",\"Resistance of viruses to mutagenic agents is an important problem for the development of lethal mutagenesis as an antiviral strategy. Previous studies with RNA viruses have documented that resistance to the mutagenic nucleoside analogue ribavirin (1-\\u03b2-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide) is mediated by amino acid substitutions in the viral polymerase that either increase the general template copying fidelity of the enzyme or decrease the incorporation of ribavirin into RNA. Here we describe experiments that show that replication of the important picornavirus pathogen foot-and-mouth disease virus (FMDV) in the presence of increasing concentrations of ribavirin results in the sequential incorporation of three amino acid substitutions (M296I, P44S and P169S) in the viral polymerase (3D). The main biological effect of these substitutions is to attenuate the consequences of the mutagenic activity of ribavirin -by avoiding the biased repertoire of transition mutations produced by this purine analogue-and to maintain the replicative fitness of the virus which is able to escape extinction by ribavirin. This is achieved through alteration of the pairing behavior of ribavirin-triphosphate (RTP), as evidenced by in vitro polymerization assays with purified mutant 3Ds. Comparison of the three-dimensional structure of wild type and mutant polymerases suggests that the amino acid substitutions alter the position of the template RNA in the entry channel of the enzyme, thereby affecting nucleotide recognition. The results provide evidence of a new mechanism of resistance to a mutagenic nucleoside analogue which allows the virus to maintain a balance among mutation types introduced into progeny genomes during replication under strong mutagenic pressure.\",\"Insulin resistance (IR) is a major predictor of treatment failure in patients with hepatitis C virus (HCV) infection treated with peginterferon/ribavirin. The aim of this study was to evaluate the short-term effect of an HCV protease inhibitor monotherapy on IR in parallel with an antiviral effect.\",\"Less than half of patients infected with hepatitis C virus (HCV) achieve sustained viral clearance after pegylated interferon (peginterferon) and ribavirin therapy. S-adenosyl methionine (SAMe) improves interferon signaling in cell culture. We assessed the effect of SAMe on the kinetics of the early antiviral response and interferon signaling in nonresponders to previous antiviral therapy and investigated the mechanisms involved.\",\"To investigate the independent association between the homeostasis model assessment of the insulin resistance (HOMA-IR) score and rapid virological response (RVR) and sustained virological response (SVR) in chronic hepatitis C (CHC).\",\"Small molecule inhibitors of hepatitis C virus (HCV) are being developed to complement or replace treatments with pegylated interferons and ribavirin, which have poor response rates and significant side effects. Resistance to these inhibitors emerges rapidly in the clinic, suggesting that successful therapy will involve combination therapy with multiple inhibitors of different targets. The entry process of HCV into hepatocytes represents another series of potential targets for therapeutic intervention, involving viral structural proteins that have not been extensively explored due to experimental limitations. To discover HCV entry inhibitors, we utilized HCV pseudoparticles (HCVpp) incorporating E1-E2 envelope proteins from a genotype 1b clinical isolate. Screening of a small molecule library identified a potent HCV-specific triazine inhibitor, EI-1. A series of HCVpp with E1-E2 sequences from various HCV isolates was used to show activity against all genotype 1a and 1b HCVpp tested, with median EC50 values of 0.134 and 0.027 \\u00b5M, respectively. Time-of-addition experiments demonstrated a block in HCVpp entry, downstream of initial attachment to the cell surface, and prior to or concomitant with bafilomycin inhibition of endosomal acidification. EI-1 was equally active against cell-culture adapted HCV (HCVcc), blocking both cell-free entry and cell-to-cell transmission of virus. HCVcc with high-level resistance to EI-1 was selected by sequential passage in the presence of inhibitor, and resistance was shown to be conferred by changes to residue 719 in the carboxy-terminal transmembrane anchor region of E2, implicating this envelope protein in EI-1 susceptibility. Combinations of EI-1 with interferon, or inhibitors of NS3 or NS5A, resulted in additive to synergistic activity. These results suggest that inhibitors of HCV entry could be added to replication inhibitors and interferons already in development.\",\"Despite recent success after the introduction of combination therapy with interferon (IFN)-\\u03b1 and ribavirin, approximately 60% of patients with hepatitis C virus (HCV) genotype 4 fail to respond. Resistance to antiviral therapy remains a serious problem in the management of chronic hepatitis C. In most patients, HCV RNA could be detected in peripheral blood mononuclear cell (PBMC).\",\"The mechanisms of treatment resistance to interferon (IFN) and ribavirin (Rib) combination therapy for hepatitis C virus (HCV) infection are not known. This study aims to gain insight into these mechanisms by exploring hepatic gene expression before and during treatment.\",\"By mathematically describing early hepatitis C virus (HCV) RNA decay after initiation of interferon (IFN)-based antiviral therapy, crucial parameters of the in vivo viral kinetics have been estimated, such as the rate of production and clearance of free virus, and the rate of loss of infected cells. Furthermore, by suggesting mechanisms of action for IFN and ribavirin mathematical modelling has provided a means for evaluating and optimizing treatment strategies. Here, we review recent modelling developments for understanding complex viral kinetics patterns, such as triphasic HCV RNA declines and viral rebounds observed in patients treated with pegylated interferon and ribavirin. Moreover, we discuss new modelling approaches developed to interpret the viral kinetics observed in clinical trials with direct-acting antiviral agents, which induce a rapid decline of wild-type virus but also engender a higher risk for emergence of drug-resistant variants. Lastly, as in vitro systems have allowed a better characterization of the virus lifecycle, we discuss new modelling approaches that combine the intracellular and the extracellular viral dynamics.\",\"Patients with hepatitis C virus (HCV)-related liver disease frequently undergo orthotopic liver transplantation, but recurrent hepatitis C is still a major cause of morbidity. Patients are treated with peg-interferon and ribavirin (PEG-IFN/RBV), which has substantial side effects and is costly. We investigated genetic factors of host, liver donor, and virus that might predict sensitivity of patients with recurrent hepatitis C to PEG-IFN/RBV.\",\"Chronic hepatitis C virus (HCV) infection is a global health problem, but the current therapy is effective in <50% of patients infected with genotype 1. With advances in cell culture systems over the past decade, the development of directly acting antivirals (DAAs) for HCV has become possible. There are currently >50 active clinical trials in this therapeutic area and NS3/4A protease inhibitors are now entering Phase III study. To date, we have learned that DAAs are potent inhibitors of HCV replication, resulting in rapid declines in serum HCV RNA levels, and have the potential to allow shortening of therapy. However, these agents drive selective pressure for mutant viruses that can develop rapidly and have reduced susceptibility to the drug. Therefore, for now, the current standard of care including pegylated interferon \\u03b1 (pegIFN) and ribavirin remains a crucial part of new drug development. Furthermore, the adverse event profile for the early DAAs has added to the concerns of tolerability that are so common for the current standard of care. Ongoing issues include the optimal duration of therapy, how and when to combine DAAs, and the long-term role of pegIFN and ribavirin. Here, we summarize the current information regarding the effectiveness of protease inhibitors in treating chronic HCV and discuss the key challenges now facing the field.\",\"Patients with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection for whom prior treatment of HCV with interferon-ribavirin has failed may require subsequent treatment with new HCV protease inhibitors (PIs). We evaluated the diversity of HCV nonstructural protein 3 (NS3) in 26 HCV- and HIV-coinfected patients receiving stable antiretroviral therapy (ART) who were treated with interferon-ribavirin. Plasma HCV RNA clonal analysis was performed. There was greater baseline NS3 diversity in patients with nonresponse or relapse than in those with sustained virologic response. Interferon-ribavirin treatment did not result in significant changes in HCV protease gene diversity or significant HCV PI resistance mutations. The effect of prior interferon-ribavirin treatment on HCV NS3 will likely not impact HCV PI efficacy in HIV-coinfected patients receiving ART.\",\"Infection with Hepatitis C Virus (HCV) continues to be a major global health problem. To overcome the limitations of current therapies using interferon-\\u03b1 in combination with ribavirin, there is a need to develop drugs that specifically block viral proteins. Highly efficient protease and polymerase inhibitors are currently undergoing clinical testing and will become available in the next few years. However, with resistance mutations emerging quickly, additional enzymatic activities or functions of HCV have to be targeted by novel compounds. One candidate molecule is the nonstructural protein 2 (NS2), which contains a proteolytic activity that is essential for viral RNA replication. In addition, NS2 is crucial for the assembly of progeny virions and modulates various cellular processes that interfere with viral replication. This review describes the functions of NS2 in the life cycle of HCV and highlights potential antiviral strategies involving NS2.\",\"The emergence of pandemic H1N1 influenza viruses in April 2009 and the continuous evolution of highly pathogenic H5N1 influenza viruses underscore the urgency of novel approaches to chemotherapy for human influenza infection. Anti-influenza drugs are currently limited to the neuraminidase inhibitors (oseltamivir and zanamivir) and to M2 ion channel blockers (amantadine and rimantadine), although resistance to the latter class develops rapidly. Potential targets for the development of new anti-influenza agents include the viral polymerase (and endonuclease), the hemagglutinin, and the non-structural protein NS1. The limitations of monotherapy and the emergence of drug-resistant variants make combination chemotherapy the logical therapeutic option. Here we review the experimental data on combination chemotherapy with currently available agents and the development of new agents and therapy targets.\",\"Hepatitis C virus (HCV) infection is a global medical problem. The role of Nitric oxide (NO) in chronic viral hepatitis is still unknown. It may play a prominent role as an antiviral agent that reduces its replication or as a mediator that causes accumulation of oxidative DNA damage and oncogenesis. The present study was carried out to study effect of combined peginterferon and ribavirin therapy for hepatitis C on NO in both responders and in non responder patients. The study included seventy three patients with positive serological markers for HCV. They were classified according to presence or absence of HCV viremia and the response to therapy. In addition sixteen control subjects were included. NO levels were determined as the stable end product nitrate and nitrite. Serum nitrite and nitrate concentrations in the patients with viral hepatitis were significantly higher than normal subjects and patients with serological evidence of hepatitis C infection in absence of viral load. The levels of nitrite >or= 31 microM, nitrate >or= 15 microM and NO(2)/NO(3) ratio < 1.5 microM were associated with increased risk of resistance to therapy. The multivariate logistic regression analysis showed that NO(2)/NO(3) ratio at levels < 1.5 microM was associated with HCV eradication independently. This study provides new insight into the pathogenesis of hepatitis C and highlights the effect of combined peginterferon and ribavirin on nitrite and nitrate as markers of endogenous NO system. There is a limitation level of NO that if it is increased above it may lead to non response to antiviral therapy. Therefore, it may be an important factor for chronic hepatitis C, which suggests an additional therapeutic pathway of anti-oxidants in combination with the standard regimen for further study.\",\"As combination therapy with peginterferon (PEG-IFN) and ribavirin has a high morbidity, identifying individuals with hepatitis C virus (HCV) who will not respond to the treatment would be beneficial. The early responses of serum HCV RNA levels to standard interferon (IFN) and PEG-IFN were examined to determine if it was possible to identify resistance to combination therapy. One hundred thirty-one patients infected with HCV genotype 1b were enrolled. Patients were given 6 MU of standard IFN alpha-2b at least 2 weeks before initiating combination therapy. Serum HCV RNA levels were measured before, 24 hr after the administration of standard IFN, and 24 hr after the administration of PEG-IFN (at the start of the combination therapy). The association between reductions in HCV RNA levels at 24 hr after the administration of standard IFN and PEG-IFN and the outcome of combination therapy were analyzed. Reductions in HCV RNA levels were poorer in patients who did not respond than in those with a sustained virologic responses or relapses (P < 0.0001), both 24 hr after the administration of standard IFN and 24 hr after the administration of PEG-IFN. Reductions in HCV RNA levels 24 hr after the administration of standard IFN were an independent factor associated with non-response by multivariate analysis. An early reduction in viral load to a single administration of standard IFN is a useful predictor of non-response in patients with HCV genotype 1, allowing for pretreatment identification of patients who will not benefit from combination therapy.\",\"Treatment for chronic hepatitis C virus (HCV) infection has evolved considerably in the last years. The standard of care (SOC) for HCV infection consists in the combination of pegylated interferon (PEG-IFN) plus ribavirin. However, it only induces a sustained virological response (SVR) in half of genotype 1-infected patients. Several viral and host factors have been associated with non-response: steatosis, obesity, insulin resistance, age, male sex, ethnicity and genotypes. Many studies have demonstrated that in non-responders, some interferon-stimulated genes were upregulated before treatment. Those findings associated to clinical, biochemical and histological data may help detect responders before starting any treatment. This is a very important issue because the standard treatment is physically and economically demanding. The future of HCV treatment would probably consist in the addition of specifically targeted antiviral therapy for HCV such as protease and/or polymerase inhibitors to the SOC. In genotype 1 patients, very promising results have been reported when the protease inhibitor telaprevir or boceprevir is added to the SOC. It increases the SVR rates from approximately 50% (PEG-IFN plus ribavirin) to 70% (for patients treated with a combination of PEG-IFN plus ribavirin plus telaprevir). Different elements are associated with non-response: (i) viral factors, (ii) host factors and (iii) molecular mechanisms induced by HCV proteins to inhibit the IFN signalling pathway. The goal of this review is to present the mechanisms of non-response, to overcome it and to identify factors that can help to predict the response to anti-HCV therapy.\",\"This study explored gene expression differences in predicting response to pegylated interferon (IFN-PEG) and ribavirin (RBV) in hepatitis C infection. Current treatment for hepatitis C virus (HCV) with IFN-PEG alpha-2a/b and RBV is an expensive regimen with frequent significant side-effects where less than 60% of patients ultimately achieve a sustained virological response. Responders and nonresponders may not be identified for up to 6 months post-treatment. This dichotomy may be because of differences in the molecular genetic response.\",\"The current treatment of chronic hepatitis C based on the combination of pegylated interferon and ribavirin is effective in only 50% of patients. Specific targeted antiviral therapies represent a promising approach to eradicate the infection.\",\"Liver disease related to infection with hepatitis C virus (HCV) and/or hepatitis B virus (HBV) is a frequent cause of morbidity and mortality in those infected with the human immunodeficiency virus (HIV) in this era of highly active antiretroviral therapy (HAART). Although progress has been made in the treatment of HBV and HCV in the setting of HIV-coinfection, there is a lack of data in certain areas and several aspects of the management are unclear at this time.\",\"Studies on the association between sequence variability of the interferon sensitivity-determining region (ISDR) of hepatitis C virus and the outcome of treatment have reached conflicting results. In this study, 25 patients infected with HCV 6a who had received interferon-alpha/ribavirin combination treatment were analyzed for the sequence variations. 14 of them had the full genome sequences obtained from a previous study, whereas the other 11 samples were sequenced for the extended ISDR (eISDR). This eISDR fragment covers 192 bp (64 amino acids) upstream and 201 bp (67 amino acids) downstream from the ISDR previously defined for HCV 1b. The comparison between interferon-alpha resistance and response groups for the amino acid mutations located in the full genome (6 and 8 patients respectively) as well as the mutations located in the eISDR (10 and 15 patients respectively) showed that the mutations I2160V, I2256V, V2292I (P<0.05) within eISDR were significantly associated with resistance to treatment. However, the extent of amino acid variations within previously defined ISDR was not associated with resistance to treatment as previously reported. Four amino acid variations I248V (P=0.03-0.06) within E1, R445K (P=0.02-0.05) and S747T (P=0.03) within E2, I861V (P=0.01) within NS2 which located outside the eISDR may also associate with treatment outcome as identified by a prescreening of variations within 14 HCV 6a full genomes.\",\"The treatment response to interferon could differ with mutations in the interferon-sensitivity-determining region (ISDR) in patients infected with hepatitis C virus (HCV) genotype-1b (HCV-Ib). We examined the pattern of ISDR mutations and analyzed whether the number of amino acid substitutions influences the treatment response to peginterferon plus ribavirin in chronic hepatitis or cirrhotic patients infected with HCV-Ib.\",\"The combination of pegylated-interferon (PEG-IFN)/ribavirin is currently the standard of care antiviral treatment for chronic hepatitis C (CHC), but optimal results require an individual approach. Key issues are to deliver doses that confer optimal antiviral efficacy against hepatitis C virus (HCV) for a time sufficient to minimise relapse. Viral monitoring during therapy guides the subsequent treatment course, particularly HCV RNA results at 4 weeks (rapid viral response [RVR]) and 12 weeks (complete early viral response [cEVR]). There is strong evidence that for most patients with genotypes 2 or 3 HCV infection, RVR allows truncation of treatment to 16 weeks, provided ribavirin dose is weight-based. However, those patients with cirrhosis, insulin resistance/diabetes or older than 50 years need 6-12 months treatment. For \\\"difficult-to-treat\\\" CHC (genotypes 1 and 4), RVR is infrequent (approximately 15% in European studies), but allows treatment to be truncated from 48 to 24 weeks. Without RVR, there is some evidence that longer treatment (72 weeks) improves sustained viral response (SVR). However, \\\"induction dosing\\\" first 12 weeks of PEG-IFN clearly does not improve SVR. To prevent dose reductions and complete therapy, it is critical to detect and treat depression and other disabling side-effects, including judicious use of growth factors for severe anemia or neutropenia and possibly, thrombocytopenia. Another potentially important aspect may be attempts to counter central obesity and insulin resistance, which confer suboptimal antiviral response with any HCV genotype. Treatment partnerships with specialist nurses, psychological therapists and other healthcare workers are also essential for optimal individual management of patients with CHC.\",\"We prospectively compared the sensitivity to interferon (IFN) and the efficacy of antiviral combination therapy with peginterferon (PEG-IFN) and ribavirin for chronic hepatitis C virus (HCV) genotype 1b infection according to the amino acid sequences of the HCV core, E1, and NS5A regions reported to be associated with the outcome of antiviral therapy.\",\"Ribavirin (RBV) is a synthetic nucleoside analog with broad spectrum antiviral activity. Although RBV is approved for the treatment of hepatitis C virus, respiratory syncytial virus, and Lassa fever virus infections, its mechanism of action and therapeutic efficacy remains highly controversial. Recent reports show that the development of cell-based resistance after continuous RBV treatment via decreased RBV uptake can greatly limit its efficacy. Here, we examined whether certain cell types are naturally resistant to RBV even without prior drug exposure. Seven different cell lines from various host species were compared for RBV antiviral activity against two nonsegmented negative-strand RNA viruses, vesicular stomatitis virus (VSV, a rhabdovirus) and Sendai virus (SeV, a paramyxovirus). Our results show striking differences between cell types in their response to RBV, ranging from virtually no antiviral effect to very effective inhibition of viral replication. Despite differences in viral replication kinetics for VSV and SeV in the seven cell lines, the observed pattern of RBV resistance was very similar for both viruses, suggesting that cellular rather than viral determinants play a major role in this resistance. While none of the tested cell lines was defective in RBV uptake, dramatic variations were observed in the long-term accumulation of RBV in different cell types, and it correlated with the antiviral efficacy of RBV. While addition of guanosine neutralized RBV only in cells already highly resistant to RBV, actinomycin D almost completely reversed the RBV effect (but not uptake) in all cell lines. Together, our data suggest that RBV may inhibit the same virus via different mechanisms in different cell types depending on the intracellular RBV metabolism. Our results strongly point out the importance of using multiple cell lines of different origin when antiviral efficacy and potency are examined for new as well as established drugs in vitro.\",\"Controversy exists about whether insulin resistance (IR) affects response to treatment of hepatitis C. We evaluated the effect of IR on sustained virologic response (SVR) in HIV/hepatitis C virus (HCV)-coinfected patients treated with interferon plus ribavirin.\",\"1,2,3-Thiadiazoles, an important synthetic active substructure, are nowadays becoming one of the important branches in novel pesticide development. To develop pesticide candidates with diverse biological activities and probe their structure-activity relationship, three series of 5-methyl-1,2,3-thiadiazoles were rationally designed and synthesized using a simple and convenient one-step synthetic procedure via Ugi reaction. Biological activities of the target compounds including fungicidal activity, antivirus activity in vitro and in vivo, and systemic acquired resistance were systematically evaluated. The results indicated that compound III(10) showed broad-spectrum of activities against most fungi tested, and compounds I(10) and II(17) showed excellent potential antivirus activities as compared to positive control agent ribavirin. The preliminary structure-activity relationship was also discussed. The results of these studies indicated that the 5-position-substituted 1,2,3-thiadiazoles exhibited good antivirus activity and were worthy of further study in pesticide development.\",\"Conflicting results have been reported in studies evaluating the relationship between serum markers of iron overload, liver iron deposits, and HFE mutations (C282Y and H63D) in chronic hepatitis C patients, and also their impact on the response to therapy in these patients.\",\"HCV is a leading cause of liver disease in the US, where ~3.4 million people are chronically infected. The standard of care (SOC) of pegylated IFN and ribavirin combination therapy has limited efficacy with ~50% sustained viral response, and is associated with a considerable adverse event profile in many patients. New drugs that directly target the virus are in development, and promise more effective therapies for chronic HCV infection.\",\"In a genome-wide association study of patients being treated for chronic hepatitis C, 2 functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to protect against ribavirin (RBV)-induced hemolytic anemia during early stages of treatment. We aimed to replicate this finding in an independent cohort from the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C and to investigate the effects of these variants beyond week 4.\",\"Many patients with chronic hepatitis C do not respond to antiviral treatment. In adult patients the re-treatment of these patients has been extensively investigated. Because the response to re-treatment in children is not well defined we evaluated the efficacy and safety of interferon (IFN)-alpha plus ribavirin in patients who have failed to respond to previous treatment.\",\"We recently identified a compound, clemizole hydrochloride, that inhibits NS4B's RNA binding and hepatitis C virus (HCV) replication. Although significant, clemizole's antiviral effect is moderate (50% effective concentration of 8 microM against an HCV genotype 2a clone). We hypothesized that the combination of clemizole with other anti-HCV agents can increase the antiviral effect over that achieved with each drug alone and could also decrease the emergence of viral resistance.\",\"Insulin resistance has been found to be an independent factor predicting sustained response to peginterferon plus ribavirin in patients with chronic hepatitis C. Insulin resistance seems to be involved in decreased sensitivity to interferon and could block interferon intracellular signaling. Insulin resistance promotes steatosis and fibrosis progression, induces pro-inflammatory cytokine secretion and increases adipose tissue, decreasing interferon availability. Moreover, suppressor of cytokines 3 and protein tyrosine-phosphatase seems to be able to block interferon and insulin signaling, building a feed-forward loop. Insulin resistance can be treated with exercise, diet or through the use of drugs that improve insulin sensitivity, like biguanides or glitazones. A recent controlled, randomized, double-blind clinical trial (TRIC-1) examined the effect of adding metformin to standard therapy in the treatment of hepatitis C. This study demonstrated that women infected with hepatitis C virus genotype 1 and HOMA >2 treated with metformin showed a greater drop in viral load during the first 12 weeks and a doubled sustained viral response in comparison with females receiving placebo. Pioglitazone has been used in previous nonresponders and na\\u00efve patients with disappointing results in two pilot trials. The mechanisms by which the virus promotes insulin resistance seems to be genotype-dependent and could explain, at least in part, the discrepancies between insulin sensitizers. Insulin resistance is a new target in the challenging management of chronic hepatitis C.\",\"Killer cell immunoglobulin-like receptors (KIR) are involved in the activation/inhibition of NK cells through an interaction with HLA class I molecules on target cells. Our study aimed to evaluate the association between KIR gene polymorphisms and the response of patients with CHC to antiviral therapy.\",\"Chronic hepatitis C virus (HCV) infection is associated with a higher risk of the development of insulin resistance. If HCV is a causal factor for insulin resistance, then clearance of HCV might decrease insulin resistance. The aim of this study was to elucidate the effects of clearance of HCV on insulin resistance.\",\"Human rhinoviruses (HRVs), members of the Picornaviridae family, are composed of over 100 different virus serotypes. Until now there is no recorded clinically effective antiviral chemotherapeutic agent for treatment of diseases caused by HRVs. Our previous study of raoulic acid tested against serotype human rhinoviruses showed anti-HRV2 (species A) and -3 (species B) activities. In this study, raoulic acid was found to possess broad-spectrum antiviral activity against six HRVs with a 50% inhibition concentration of less than 9.5 microg/mL through inhibition of the cellular absorption of the HRV particles. Furthermore, the effect of raoulic acid on resistance of HRV5 exhibited to pleconaril was more pronounced than the effect on HRV1b, -6, -14, -15, and -40. However, ribavirin did possess weak antiviral activity against HRVs. Collectively, the results demonstrate that raoulic acid is a novel therapeutic candidate for two different groups of human rhinovirus.\",\"The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people. Current therapy relies upon a combination of pegylated interferon-alpha and ribavirin, a poorly tolerated regimen typically associated with less than 50% sustained virological response rate in those infected with genotype 1 virus. The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B. Here we describe the profile of BMS-790052, a small molecule inhibitor of the HCV NS5A protein that exhibits picomolar half-maximum effective concentrations (EC(50)) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture. In a phase I clinical trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was associated with a 3.3 log(10) reduction in mean viral load measured 24 h post-dose that was sustained for an additional 120 h in two patients infected with genotype 1b virus. Genotypic analysis of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants observed had substitutions at amino-acid positions identified using the in vitro replicon system. These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.\",\"Passage of poliovirus (PV) or foot-and-mouth disease virus (FMDV) in the presence of ribavirin selected for viruses with decreased sensitivity to R, which included different mutations in their polymerase (3D): G64S located in the finger subdomain in the case of PV and M296I located within loop beta9-alpha11 at the active site in the case of FMDV. To investigate why disparate substitutions were selected in two closely related 3Ds, we constructed FMDVs with a 3D that included either G62S (the equivalent replacement in FMDV of PV G64S), M296I, or both substitutions. G62S, but not M296I, inflicts upon FMDV a strong selective disadvantage which is partially compensated for by the substitution M296I. The corresponding mutant polymerases, 3D(G62S), 3D(M296I), and 3D(G62S-M296I), were analyzed functionally and structurally. G62S in 3D impairs RNA-binding, polymerization, and R monophosphate incorporation activities. The X-ray structures of the 3D(G62S)-RNA, 3D(M296I)-RNA, and 3D(G62S-M296I)-RNA complexes show that although the two positions are separated by 13.1 A, the loops where the replacements reside are tightly connected through an extensive network of interactions that reach the polymerase active site. In particular, G62S seems to restrict the flexibility of loop beta9-alpha11 and, as a consequence, the flexibility of the active site and its ability to bind the RNA template. Thus, a localized change in the finger subdomain of 3D may affect the catalytic domain. The results provide a structural interpretation of why different amino acid substitutions were selected to confer R resistance in closely related viruses and reveal a complex network of intra-3D interactions that can affect the recognition of both the RNA template and incoming nucleotide.\",\"Dendritic cell (DC) dysfunction has been suggested to play a role in the weak antiviral T-cell responsiveness observed during the course of chronic hepatitis C virus (HCV) infection. This study was undertaken to evaluate whether changes in DC functions might be related to a different therapeutic outcome in HCV-infected patients.\",\"Assessing hepatitis C virus (HCV)-RNA levels is integral to response-guided therapy. Rules for early discontinuation and determination of treatment duration were mainly established with HCV-RNA assays with a detection limit of 50IU/ml (COBAS Amplicor HCV [CA]). The currently used real-time PCR-based COBAS Ampliprep/COBAS-TaqMan HCV (CAP-CTM) test has a detection limit of approximately 10IU/ml. It is unknown whether shortening of treatment duration to 16/24 weeks in patients with rapid virological response at week 4 (RVR) and viral loads between 10 and 50IU/ml is possible.\",\"More than 50% of hepatitis C virus (HCV)-infected patients do not respond to the classical pegylated interferon (PEG-IFN)/ribavirin combination therapy. However, failing to respond to one course of treatment is not synonymous of therapy failure and retreatment is often beneficial. Alternative retreatment strategies include repeating the classical standard of care with an optimized drug regimen and adherence, including ribavirin serum concentration adjustment, correcting, if at all possible, comorbidities, and the addition of new specific anti-HCV molecules to the backbone of pegylated interferon/ribavirin. Options of retreatment should include consensus and natural interferons. For patients with advanced disease exposed to a high risk of lethal complications, customized maintenance therapy could be an effective option since it may slow down complications in some patients. Since low-dose interferon monotherapy is not sufficient, such a maintenance therapy remains to be verified via clinical trials. New possibilities of noninvasive assessment of fibrosis and the use of genetic tests to predict fibrosis progression and responsiveness to interferon are major emerging opportunities that run parallel to the revolution of the pharmacologic armentarium.\",\"Favipiravir (T-705) has previously been shown to have a potent antiviral effect against influenza virus and some other RNA viruses in both cell culture and in animal models. Currently, favipiravir is undergoing clinical evaluation for the treatment of influenza A and B virus infections. In this study, favipiravir was evaluated in vitro for its ability to inhibit the replication of a representative panel of seasonal influenza viruses, the 2009 A(H1N1) strains, and animal viruses with pandemic (pdm) potential (swine triple reassortants, H2N2, H4N2, avian H7N2, and avian H5N1), including viruses which are resistant to the currently licensed anti-influenza drugs. All viruses were tested in a plaque reduction assay with MDCK cells, and a subset was also tested in both yield reduction and focus inhibition (FI) assays. For the majority of viruses tested, favipiravir significantly inhibited plaque formation at 3.2 muM (0.5 microg/ml) (50% effective concentrations [EC(50)s] of 0.19 to 22.48 muM and 0.03 to 3.53 microg/ml), and for all viruses, with the exception of a single dually resistant 2009 A(H1N1) virus, complete inhibition of plaque formation was seen at 3.2 muM (0.5 microg/ml). Due to the 2009 pandemic and increased drug resistance in circulating seasonal influenza viruses, there is an urgent need for new drugs which target influenza. This study demonstrates that favipiravir inhibits in vitro replication of a wide range of influenza viruses, including those resistant to currently available drugs.\",\"The results of post-transplant antiviral therapy for recurrent hepatitis C virus (HCV) are poor, and significant pre-transplant predictors for sustained viral response (SVR) have not yet been identified.\",\"Recent advances in the development of agents that act specifically to inhibit hepatitis C virus (HCV) are set to fundamentally change the way that patients will be treated. New directly acting anti-HCV agents such as protease and polymerase inhibitors will initially be added to standard of care with pegylated interferon-alpha and ribavirin. However, future therapy is likely to constitute combinations of agents which act at distinct stages of viral replication and have differing resistance profiles. While directly acting anti-HCV agents will undoubtedly improve treatment outcomes, the introduction of combination therapy may not be without complications in some patient groups. HIV-positive patients who are receiving antiretrovirals (ARVs) are relatively highly represented among those with HCV infection, and are at high risk of drug-drug interactions (DDIs). As combination anti-HCV treatment gradually evolves to resemble anti-HIV therapy, it is essential to consider the increased potential for DDIs in patients receiving combination anti-HCV therapy, and particularly in HCV/HIV-co-infected individuals. Therapeutic drug monitoring is likely to play a role in the clinical management of such interactions.\",\"Small-molecule hepatitis C virus (HCV) NS3 protease inhibitors such as boceprevir (SCH 503034) have been shown to have antiviral activity when they are used as monotherapy and in combination with pegylated alpha interferon and ribavirin in clinical trials. Improvements in inhibitor potency and pharmacokinetic properties offer opportunities to increase drug exposure and to further increase the sustained virological response. Exploration of the structure-activity relationships of ketoamide inhibitors related to boceprevir has led to the discovery of SCH 900518, a novel ketoamide protease inhibitor which forms a reversible covalent bond with the active-site serine. It has an overall inhibition constant (K*(i)) of 7 nM and a dissociation half-life of 1 to 2 h. SCH 900518 inhibited replicon RNA at a 90% effective concentration (EC(90)) of 40 nM. In biochemical assays, SCH 900518 was active against proteases of genotypes 1 to 3. A 2-week treatment with 5x EC(90) of the inhibitor reduced the replicon RNA level by 3 log units. Selection of replicon cells with SCH 900518 resulted in the outgrowth of several resistant mutants (with the T54A/S and A156S/T/V mutations). Cross-resistance studies demonstrated that the majority of mutations for resistance to boceprevir and telaprevir caused similar fold losses of activity against all three inhibitors; however, SCH 900518 retained more activity against these mutants due to its higher intrinsic potency. Combination treatment with alpha interferon enhanced the inhibition of replicon RNA and suppressed the emergence of resistant replicon colonies, supporting the use of SCH 900518-pegylated alpha interferon combination therapy in the clinic. In summary, the results of the preclinical characterization of the antiviral activity of SCH 900518 support its evaluation in clinical studies.\",\"In patients with chronic hepatitis C (CHC) of genotype 4, the predictors of rapid virologic response (RVR) have not been determined adequately. We aimed to assess which pretreatment variables might predict an RVR and a sustained virologic response (SVR).\",\"The present review discusses recent developments in drug discovery for hepatitis C. We are on the verge of a new era with the introduction of direct acting oral agents that will transform the treatment landscape. Both healthcare providers and patients need to stay abreast of these changes that will influence decisions to treat. This article will discuss the most promising up-to-date hepatitis C virus antiviral therapies in clinical investigation as well as the associated clinical trial results.\",\"The objective of this analysis was to identify predictors of relapse in genotype 1 patients after 48 weeks of treatment with peginterferon plus ribavirin.\",\"Insulin resistance is a predictive factor of response to treatment with peginterferon and ribavirin in patients with hepatitis C. Insulin resistance impairs sensitivity to interferon and can block its intracellular signalling. Insulin resistance also induces the development of steatosis, progression of fibrosis and proinflammatory cytokine release and reduces the bioavailability of interferon. Suppressor of cytokine signalling 3 and protein tyrosine phosphatases are involved in blocking the intracellular signalling of interferon and insulin. Insulin resistance can be treated through diet, physical exercise and the use of insulin-sensitizing agents such as biguanides or glitazones. The TRIC-1 study demonstrated that adding metformin to routine treatment improves the possibilities of cure in women and in patients whose insulin sensitivity returns to normal during treatment.\",\"The association of hepatitis C virus genotype 4 (HCV-4) with hepatic steatosis has not been clarified. We aimed to determine the parameters associated with steatosis among HCV-4 patients and to assess the effect of steatosis on treatment with peginterferon and ribavirin.\",\"Pegylated interferon (PEG-IFN) alfa-2b plus ribavirin (RBV) is the standard of care for adults with chronic hepatitis C but was not approved for the treatment of children at the time of this study. The aim of this study was to evaluate the efficacy and safety of PEG-IFN alfa-2b plus RBV in children.\",\"The rapid emergence and subsequent spread of the novel 2009 Influenza A/H1N1 virus (2009 H1N1) has prompted the World Health Organization to declare the first pandemic of the 21st century, highlighting the threat of influenza to public health and healthcare systems. Widespread resistance to both classes of influenza antivirals (adamantanes and neuraminidase inhibitors) occurs in both pandemic and seasonal viruses, rendering these drugs to be of marginal utility in the treatment modality. Worldwide, virtually all 2009 H1N1 and seasonal H3N2 strains are resistant to the adamantanes (rimantadine and amantadine), and the majority of seasonal H1N1 strains are resistant to oseltamivir, the most widely prescribed neuraminidase inhibitor (NAI). To address the need for more effective therapy, we evaluated the in vitro activity of a triple combination antiviral drug (TCAD) regimen composed of drugs with different mechanisms of action against drug-resistant seasonal and 2009 H1N1 influenza viruses. Amantadine, ribavirin, and oseltamivir, alone and in combination, were tested against amantadine- and oseltamivir-resistant influenza A viruses using an in vitro infection model in MDCK cells. Our data show that the triple combination was highly synergistic against drug-resistant viruses, and the synergy of the triple combination was significantly greater than the synergy of any double combination tested (P<0.05), including the combination of two NAIs. Surprisingly, amantadine and oseltamivir contributed to the antiviral activity of the TCAD regimen against amantadine- and oseltamivir-resistant viruses, respectively, at concentrations where they had no activity as single agents, and at concentrations that were clinically achievable. Our data demonstrate that the TCAD regimen composed of amantadine, ribavirin, and oseltamivir is highly synergistic against resistant viruses, including 2009 H1N1. The TCAD regimen overcomes baseline drug resistance to both classes of approved influenza antivirals, and thus may represent a highly active antiviral therapy for seasonal and pandemic influenza.\",\"The current standard of care for hepatitis C virus (HCV) infection, pegylated alpha interferon in combination with ribavirin, has a limited response rate and adverse side effects. Drugs targeting viral proteins are in clinical development, but they suffer from the development of high viral resistance. The inhibition of cellular proteins that are essential for viral amplification is thought to have a higher barrier to the emergence of resistance. Three cyclophilin inhibitors, the cyclosporine analogs DEBIO-025, SCY635, and NIM811, have shown promising results for the treatment of HCV infection in early clinical trials. In this study, we investigated the frequency and mechanism of resistance to cyclosporine (CsA), NIM811, and a structurally unrelated cyclophilin inhibitor, SFA-1, in replicon-containing Huh7 cells. Cross-resistance between all clones was observed. NIM811-resistant clones were selected only after obtaining initial resistance to either CsA or SFA-1. The time required to select resistance against cyclophilin inhibitors was significantly longer than that required for resistance selection against viral protein inhibitors, and the achievable resistance level was substantially lower. Resistance to cyclophilin inhibitors was mediated by amino acid substitutions in NS3, NS5A, and NS5B, with NS5A mutations conferring the majority of resistance. Mutation D320E in NS5A mediated most of the resistance conferred by NS5A. Taken together, the results indicate that there is a very low frequency and level of resistance to cyclophilin-binding drugs mediated by amino acid substitutions in three viral proteins. The interaction of cyclophilin with NS5A seems to be the most critical, since the NS5A mutations have the largest impact on resistance.\",\"Hepatitis C virus (HCV) infection is associated with an increased prevalence of diabetes and insulin resistance (IR); whether this is a causal relationship has not been established.\",\"To compare 14 and 24 weeks treatment to patients with HCV genotype 2 or 3 infection and rapid virological response (RVR).\",\"Hepatic steatosis is commonly seen in patients with chronic hepatitis C infection, and the two together have a greater association than by chance alone. Hepatitis C virus is closely associated with lipid metabolism throughout its lifecycle. Hepatic steatosis is more common in genotype 3 infection, due to direct viral effects including through microsomal triglyceride transfer protein, peroxisome proliferator activating receptor, and sterol regulatory element binding protein. In non-genotype 3 infection, hepatic steatosis is considered largely to be due to alterations in host metabolism, particularly through insulin resistance. The clinical relevance of this association has yet to be fully explored. Hepatic steatosis is associated with increased hepatic fibrosis and a reduced level of sustained virological response to pegylated interferon and ribavirin. Small studies trialing adjuvant anti-diabetic therapies or HMG-CoA reductase inhibitors with pegylated-interferon and ribavirin have shown an improved sustained virological response and reduced viral titer. Furthermore, simple lifestyle alterations showed positive effects on parameters of disease activity. These insights raise the possibility of novel treatment options.\",\"The neuraminidase inhibitors oseltamivir and zanamivi are used to treat H5N1 influenza. However, oseltamivir-resistant H5N1 viruses have been isolated from oseltamivir-treated patients. Moreover, reassortment between H5N1 viruses and oseltamvir-resistant human H1N1 viruses currently circulating could create oseltamivir-resistant H5N1 viruses, rendering the oseltamivir stockpile obsolete. Therefore, there is a need for unique and effective antivirals to combat H5N1 influenza viruses. The investigational drug T-705 (favipiravir; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has antiviral activity against seasonal influenza viruses and a mouse-adapted H5N1 influenza virus derived from a benign duck virus. However, its efficacy against highly pathogenic H5N1 viruses, which are substantially more virulent, remains unclear. Here, we demonstrate that T-705 effectively protects mice from lethal infection with oseltamivir-sensitive or -resistant highly pathogenic H5N1 viruses. Furthermore, our biochemical analysis suggests that T-705 ribofuranosyl triphosphate, an active form of T-705, acts like purines or purine nucleosides in human cells and does not inhibit human DNA synthesis. We conclude that T-705 shows promise as a therapeutic agent for the treatment of highly pathogenic H5N1 influenza patients.\",\"We investigated whether sustained virological response (SVR) and non-SVR by chronic hepatitis C patients to pegylated interferon plus ribavirin (PEG-IFN/RBV) combination therapy are distinguishable by viral factors such as the IFN/RBV resistance-determining region (IRRDR) and by on-treatment factors through new indices such as the rebound index (RI). The first RI (RI-1st; the viral load at week 1 divided by the viral load at 24 h) and the second RI (RI-2nd; the viral load at week 2 divided by the viral load at 24 h) were calculated. The subject patients were divided into 3 groups based on RI-1st and RI-2nd: an RI-A group (RI-1st < or = 1.0), an RI-B group (RI-1st >1.0 and RI-2nd <0.7) and an RI-C group (RI-1st >1.0 and RI-2nd > or = 0.7). The SVR rate was 71.4% (10/14) in the RI-A group, 46.2% (6/13) in the RI-B group and 20.0% (3/15) in the RI-C group (p = 0.005 between the RI-A group and the RI-C group). In IRRDR > or = 6 and IRRDR < or = 5 the SVR rate was 81.3% (13/16) and 23.1% (6/26) (p = 0.0002), respectively. By combining RI and IRRDR as a predicting factor, the SVR rate was 87.5% (7/8) in the RI-A group (> or = 6 mutations in the IRRDR) and 7.7% (1/13) in the RI-C group (< or = 5 IRRDR mutations) (p = 0.0003).\",\"Ribavirin (RBV), a nucleoside analogue, is used in the treatment of hepatitis C virus (HCV) infection in combination with interferons. However, potential mechanisms of RBV resistance during HCV replication remain poorly understood. Serial passage of cells harboring HCV genotype 2a replicon in the presence of RBV resulted in the reduced susceptibility of the replicon to RBV. Transfection of fresh cells with RNA from RBV-resistant replicon cells demonstrated that the RBV resistance observed is largely replicon-derived. Four major amino acid substitutions: T1134S in NS3, P1969S in NS4B, V2405A in NS5A, and Y2471H in NS5B region, were identified. Site-directed mutagenesis of these mutations into the replicon indicated that Y2471H plays a role in the reduced susceptibility to RBV and leads to decrease in replication fitness. The results, in addition to analysis of sequence database, suggest that HCV variants with reduced susceptibility to RBV identified are preferential to genotype 2a.\",\"Persistent hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma and the major indication for liver transplantation in adults. Current standard of care treatment (SOC) with pegylated-interferon-\\u03b1 2 and ribavirin (RBV) has a limited efficacy and is associated with significant side effects frequently associated with poor compliance or treatment discontinuation, requiring specialized and frequent monitoring. To overcome the limited efficacy of SOC, more than 50 direct-acting antiviral agents (DAA) designed to target viral-encoded proteins essential in the HCV life cycle are currently under development. The rapid selection of resistant mutants associated with the quasispecies nature of HCV with high mutation and replication rates is one of the main challenges for the new HCV therapies. Predictive host and viral factors together with combination of DAAs with or without IFN and/or RBV need to be accurately evaluated to design the most effective individualized treatment strategy within the shortest time interval and with minimum side effects.\",\"Abstract Hepatitis C virus (HCV) genotypes 4, 5 and 6 represent >20% of all HCV cases worldwide. HCV-4 is mainly seen in Egypt, where it represents 90% of all HCV cases. Antischistosomal therapy was the main cause of contamination there, followed by procedures performed by informal providers and traditional healers such as dental care, wound treatment, circumcision, deliveries, excision and scarification. It is also highly prevalent in sub-Saharan Africa and in the Middle East. In Europe, its prevalence has recently increased particularly among intravenous drug users and in immigrants. HCV-5 is mainly found in South Africa, where it represents 40% of all HCV genotypes, but four pockets of HCV-5 were found in France, Spain, Syria and Belgium and sporadic cases were found elsewhere. The mode of transmission is mainly iatrogenic and transfusion. HCV-6 is found in Hong Kong, Vietnam, Thailand and Myanmar and also in American and Australian from Asian origin. The response to treatment in HCV-4 is intermediate between HCV-1 and HCV-2 and HCV-3. A sustained viral response is achieved in 43-70% with pegylated interferon and ribavirin. It is higher in Egyptians than Europeans and Africans and is negatively related to insulin resistance and to the severity of fibrosis. It increases to >80% with 24 weeks of therapy only if a rapid virological response is achieved. In HCV-5, a sustained virological response is achieved in >60% with 48 weeks of therapy. HCV-6 is also considered an easy-to-treat genotype, leading to a response in 60-85% of cases.\",\"Chronic hepatitis C virus (HCV) infection is one of the major causes of cirrhosis, hepatocellular carcinoma, and liver failure that leads to transplantation. The current standard treatment, a combination of pegylated interferon alfa and ribavirin, eradicates the virus in only about 50% of patients. Directly acting antiviral (DAA) agents, which inhibit HCV replication, are in phase 1, 2, and 3 trials; these include reagents that target the nonstructural (NS)3 protease, the NS5A protein, the RNA-dependent RNA-polymerase NS5B, as well as compounds that directly inhibit HCV replication through interaction with host cell proteins. Because of the high genetic heterogeneity of HCV and its rapid replication, monotherapy with DAA agents poses a high risk for selection of resistant variants. We review the parameters that determine resistance, genotypic and phenotypic resistance profiles of DAA agents, and strategies to avoid the selection of resistant variants.\",\"The prevalence of hepatitis C virus (HCV) infection varies across the world, with the highest number of infections reported in Egypt. Expression of the MxA gene has been found to be a reliable and sensitive marker for the induction of endogenous type I interferons (IFNs) during viral infections. This study examined the correlation of gene expression of MxA with the response to treatment with pegylated-IFN-alfa2b and ribavirin. Fifty patients with type 4 HCV and 20 healthy volunteers as controls were enrolled in a prospective study designed with strict inclusion criteria to nullify the effect of confounding variables and further minimize selection bias. Quantification of HCV-RNA and MxA gene by real-time PCR was performed for every patient, and quantification of MxA gene was performed for controls. There was a statistically significant difference between patients and control group as regards the quantity of MxA gene expression (P < 0.05) (Mann-Whitney test) (P = 0.004). There was a statistically significant difference between responders and nonresponders (P < 0.05): responders showed a higher percentage of cases with initial MxA <2(6) (P < 0.05). We conclude that MxA protein expression is a sensitive biological marker for ongoing virus replication and presence of type 1 IFN. These results highlight the importance of the detection of MxA expression at the start of therapy as a factor for assessing the likelihood of HCV genotype 4 patients to achieving a sustained virological response to treatment with IFN-\\u03b12 in combination with ribavirin.\",\"One year of interferon therapy inhibits HBV replication in one third of the patients whereas long-term administration of oral nucleos(t)ide analogues is efficient in most of them, as long as early treatment adaptation in patients with partial virological response and resistance is provided. Following the demonstration of a more potent antiviral effect in terms of sustained virological response (SVR) rates, Pegylated-IFN coupled with Ribavirin has become the standard treatment for chronic hepatitis C, with nearly 65% of all treated patients achieving a SVR. Long-term suppression of HBV and eradication of HCV would halt the progression of chronic hepatitis to cirrhosis, hepatocellular carcinoma and liver decompensation.\",\"The clinical course of pandemic H1N1 2009 influenza can be severe, particularly in the very young and patients with comorbidities. Pandemic H1N1 2009 is sensitive to the antiviral agents oseltamivir and zanamivir but is resistant to the M2 inhibitors. Although few clinical data are yet available, treatment of pandemic H1N1 2009 influenza in hospital settings with oseltamivir or zanamivir appears to be beneficial. In hospitalized patients with severe influenza treated with oseltamivir, mortality and length of stay are significantly reduced, and viral load is reduced more quickly than in untreated patients. In patients at high risk treated with oseltamivir or zanamivir, reductions in the risk of complications and mortality after treatment have been demonstrated with oseltamivir and zanamivir, although there are fewer data on the latter. There is no evidence yet that other antiviral agents are effective in severe or pandemic H1N1 2009 influenza. Current World Health Organization guidance strongly recommends the use of oseltamivir for severe or progressive infection with pandemic H1N1 2009, with zanamivir as an alternative if the infecting virus is oseltamivir-resistant. Very little resistance to oseltamivir has been found to date.\",\"Insulin resistance (IR) affects sustained virological response (SVR). The use of insulin-sensitizing agents has been proposed to improve therapy outcome. The safety and efficacy of pioglitazone on insulin sensitivity and SVR in treatment-na\\u00efve patients with chronic hepatitis C (CHC) genotype 4 with IR receiving standard antiviral therapy were evaluated in a randomized-controlled study.\",\"This randomized multicenter trial evaluated individualization of treatment duration with peginterferon alfa-2a 180 microg/wk plus ribavirin 1000/1200 mg/day in patients with chronic hepatitis C genotype 1/4 based on the rapidity of virologic response (VR).\",\"Promising results have been observed with an investigational drug class for hepatitis C (HCV), the specifically targeted antiviral therapies for hepatitis C (STAT-Cs), when combined with peginterferon plus ribavirin (Peg-IFN/RBV). This class has the potential to increase sustained virological response (SVR) rates and reduce therapy duration in genotype 1 chronic HCV patients compared with Peg-IFN/RBV alone. However, because of the remarkable sequence variation in HCV (resulting from the high viral replication rate and intrinsically error-prone nature of HCV polymerase), variants with reduced susceptibility to STAT-Cs can occur naturally before treatment, usually at low levels, and can be selected in patients not responding to potent STAT-C treatment. This review first describes how resistance to a STAT-C can develop and then provides an overview of mutations that confer varying levels of resistance to STAT-Cs, which have been identified and characterized using both genotypic and phenotypic tools. We will discuss why an understanding of the selection of variants with reduced susceptibility to a treatment regimen may be important in optimizing the use of this new class of HCV therapy. Strategies for optimizing treatment regimens to increase response rates, and thereby minimize resistance, will be discussed. Finally, although resistance can be a consequence of not achieving an SVR on an initial regimen, there may be alternative treatment options for patients to achieve an SVR in the future. Future potential therapeutic strategies to address patients who do develop resistance to STAT-Cs are discussed, including combination therapy with multiple STAT-Cs with non-overlapping resistance profiles.\",\"Chronic hepatitis C virus (CHC) infection is treated with interferon/ribavirin, but only a subset of patients respond. Treatment nonresponders have marked pretreatment up-regulation of a subset of interferon stimulated genes (ISGs) in their livers, including ISG15. We here study how the nonresponder gene expression phenotype is influenced by clinical factors and uncover the cellular basis of the phenotype through ISG15 protein expression.\",\"In this study we sought to characterize the relationship between several pharmacokinetic and pharmacodynamic parameters and virologic responses among HIV/hepatitis C virus genotype-1 co-infected patients receiving pegylated interferon-alpha-2b (peg-IFN2b) and ribavirin. We also tried to establish the underlying mechanisms that lead to poor sustained virologic responder rates observed with African-Americans against Caucasians and compared their results with those observed in a cohort of hepatitis C virus mono-infected patients.\",\"Chronic hepatitis B virus (HBV) infection is overall recognised in 10% of HIV+ persons worldwide, with large differences according to geographical region. Chronic hepatitis C virus (HCV) infection affects 25% of HIV+ individuals, with greater rates (approximately 75%) in intravenous drug users and persons infected through contaminated blood or blood products. HIV-hepatitis co-infected individuals show an accelerated course of liver disease, with faster progression to cirrhosis. The number of anti-HBV drugs has increased in the last few years, and some agents (e.g. lamivudine, emtricitabine, tenofovir) also exert significant activity against HIV. Emergence of drug resistance challenges the long-term benefit of anti-HBV monotherapy, mainly with lamivudine. The results using new more potent anti-HBV drugs (e.g. tenofovir) are very promising, with prospects for stopping or even revert HBV-related liver damage in most cases. With respect to chronic hepatitis C, the combination of pegylated interferon plus ribavirin given for 1 year permits to achieve sustained HCV clearance in no more than 40% of HIV-HCV co-infected patients. Thus, new direct anti-HCV drugs are eagerly awaited for this population. Although being a minority, HIV+ patients with delta hepatitis and those with multiple hepatitis show the worst prognosis. Appropriate diagnosis and monitoring of chronic viral hepatitis, including the use of non-invasive tools for assessing liver fibrosis and measurement of viral load, may allow to confront adequately chronic viral hepatitis in HIV+ patients, preventing the development of end-stage liver disease, for which the only option available is liver transplantation. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010.\",\"Insulin resistance (IR) reduces response to pegylated-interferon (PEG-IFN)/ribavirin in chronic hepatitis C (CHC), but the mechanisms are still undefined. We examined the relationship between baseline insulin levels, the main component affecting homeostasis model of assessment - insulin resistance (HOMA-IR) for assessment of IR in non-diabetic patients, and the 'acute' virological response to PEG-IFN measured 24 h after the first injection and taken as correlate of intracellular interferon signalling. In 62 patients treated with PEG-IFN/Ribavirin, serum insulin and HOMA-IR were assessed at baseline, while hepatitis C virus (HCV)-RNA was measured at baseline and 24 h, 1, 2, 4 and 12 weeks after treatment initiation. Sustained virological response was examined 24 weeks after therapy discontinuation. Mean baseline insulin was 11.52 +/- 8.51 U/L and mean HOMA-IR was 2.65 +/- 2.01 both being significantly higher with advanced liver fibrosis. Hepatitis C virus-RNA decay observed 24 h after the first injection of PEG-IFN was significantly lower (0.7 +/- 0.8 log) in patients with HOMA > or =3 compared with those with HOMA <3 (1.7 +/- 0.8, P = 0.001). A highly significant (r = -0.42) inverse correlation was observed between baseline insulin levels and the 24-h HCV-RNA decay. The difference in early viral kinetics between patients with HOMA > or =3 or <3 resulted in a significant difference in the percentage of patients achieving rapid (week 4) and sustained virological response. Multivariate analysis, inclusive of patient age, HCV genotype and fibrosis stage, identified baseline insulin levels as the main independent variable affecting the 24-h response to PEG-IFN. Hyperinsulinaemia reduces the cellular response to Pegylated-interferon in CHC with IR. Strategies to reduce insulin levels before initiation of treatment should be pursued to improve efficacy of anti-viral treatment.\",\"Chronic hepatitis C virus (HCV) infection is a global health problem, with over 170 million people infected worldwide. The current therapy, pegylated interferon (PEG-IFN) plus ribavirin (RBV), provides only approximately a 40% sustained virological response (undetectable HCV RNA for greater than 24 weeks after cessation of therapy), in genotype 1-infected individuals. In addition to the limited sustained virological response, PEG-IFN/RBV treatment is associated with serious adverse effects. Nucleosides have long been the cornerstone of antiviral therapy because of their proven efficacy and high barrier to resistance. Through the use of surrogate viruses or the HCV subgenomic replicon, several classes of nucleoside analogs or their monophosphate prodrugs have been identified that inhibit HCV RNA replication. Nucleoside analogs that possess the 2\\u00b4-C-methyl modification vary in their ability to be phosphorylated and to act as alternative substrate inhibitors of the HCV RNA polymerase. Herein, we discuss various classes of nucleoside inhibitors, with a focus on available structure-activity relationships, their mode of action and resistance profile.\",\"Killer immunoglobulin-like receptors (KIRs) expressed on natural killer and natural killer T cells are involved in activation of these cells and can influence antiviral immunity in the liver. This study investigated the association between KIR genetic diversity and sustained virologic response (SVR) to Peginterferon and Ribavirin (Peg/RBV) therapy in liver transplant (LT) recipients with hepatitis C virus (HCV) recurrence. We tested KIR genotypes in 44 HCV-infected LT recipients treated with Peg/RBV for 48 weeks. Patients were categorized as having KIR genotypes A/A or B/x and analyzed for association with SVR. Fifteen of 44 (34%) patients had SVR. Only 2 of 18 (11%) who lacked KIR2DS2/KIR2DL2 achieved SVR compared to 13 of 26 (50%) who carried these two genes (odds ratio: 8.0, 95% confidence interval: 1.5-42.0, P = 0.008). The association between lack of KIR2DS2/KIR2DL2 and SVR remained significant after exclusion of 10 patients with non-genotype 1 HCV. No correlation was found with other activating or inhibitory KIR genes. Absence of KIR2DS2 and/or KIR2DL2 is associated with failure of Peg/RBV therapy in patients with recurrent HCV after LT. These findings support the role of natural killer and natural killer T cells in HCV clearance after LT and might be generalizable to treatment of HCV infection outside the setting of LT.\",\"In the non-structural protein 5A (NS5A) of hepatitis C virus (HCV), mutations within the interferon sensitivity-determining region (ISDR), the PKR-binding domain (PKR-BD), the variable region 3 (V3), and the interferon/ribavirin resistance-determining region (IRRDR) have been correlated with the IFN-based therapy response. In Tunisia, where a high prevalence of HCV-1b has been found, no data regarding the implication of NS5A in treatment response were available. The current study examined the relationship between the pre-treatment mutation number within ISDR, PKR-BD, V3, IRRDR, as well as in the entire ISDR-V3 region of NS5A (aa 2209-2379) and the response to the 48-week course of combined IFN plus ribavirin therapy in 15 HCV-1b-infected Tunisian patients. Referring to HCV-J sequence, a significant high genetic variability was observed within PKR-BD in the sustained virological responder patients compared to non-responders (P = 0.040). More importantly, when considering the entire region from ISDR to V3, referred to as NS5A(ISDR-V3), a clear difference in the mutation number was observed between sustained virological responders (19.6 +/- 3.16) and non-responders (15.0 +/- 1.41) (P = 0.002). Additionally, a more detailed analysis of NS5A(ISDR-V3) region revealed an elevated degree of mutation rate within the region located between amino acids 2282 and 2308 (P = 0.0006). Interestingly, an analysis of specific amino acid variations defined proline and serine at position 2300 as signature patterns for sensitive and resistant strains, respectively. The genetic variability within the NS5A region of HCV-1b strains was associated with the response to the combined IFN plus ribavirin therapy in our Tunisian cohort.\",\"Patients with chronic hepatitis C virus (HCV) infection are frequently treated with a combination of pegylated interferon (peginterferon) and ribavirin. This study compared the efficacy and safety of peginterferon alfa-2a and peginterferon alfa-2b, each in combination with ribavirin.\",\"Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial in 19 Spanish hospitals, including 123 consecutive patients with genotype 1 chronic hepatitis C and insulin resistance. Patients were randomized to receive either metformin (arm A; n = 59) or placebo (arm B; n = 64) in addition to peginterferon alfa-2a (180 microg/week) and ribavirin (1000-1200 mg/day). The primary end point was SVR, and secondary endpoints were viral clearance at weeks 12, 24, and 48, and changes in the homeostasis model assessment (HOMA) index over the first 24 weeks. There were no differences between arms at baseline. In the intent-to-treat analysis, SVR was observed in 53% versus 42% in arm A and arm B, respectively (P = NS). In the subgroup analyses, SVR was higher in females (n = 54) receiving metformin: arm A, 58% (15/26) versus 29% (8/28) arm B (P = 0.03). In the per protocol analysis (PPA; n = 101), SVR was 67% in arm A and 49% in arm B (P = 0.06). Viral decline during the first 12 weeks was greater in females receiving metformin: -4.88 (1.18) versus -4.0 (1.44) (P = 0.021), whereas no differences were seen in males. The triple therapy was well tolerated, but diarrhea was more often seen in arm A (34% versus 11%; P < 0.05).\",\"Viral hepatitis poses important problems for children. In preschoolers, hepatitis A virus (HAV) infection frequently causes acute liver failure. Vaccinating toddlers against HAV in countries with high endemicity is expected to decrease mortality. HAV vaccine demonstrates efficacy (comparable to immunoglobulin) as post-exposure prophylaxis. A recently developed vaccine against hepatitis E virus (HEV) may benefit fetal health, because pregnant women are most prone to acute liver failure as a result of HEV. Hepatitis B vaccine continues to demonstrate value and versatility for preventing serious liver disease. With chronic infection, undetectable levels of serum HBV DNA complement e-seroconversion as the preferred outcome measure; suppressed viral load correlates with long-term complications better than HBeAg status. Among Taiwanese children, low pretreatment HBV DNA (<2 x 10(8) copies/ml) strongly predicted response to interferon-alpha. Future paediatric studies must incorporate HBV DNA levels. The rationale for routine treatment of immunotolerant hepatitis B during childhood remains uncertain. Any treatment of chronic hepatitis B in childhood requires consideration of the risks and benefits. Childhood hepatitis C virus (HCV) infection results mainly from mother-to-infant transmission. Babies of HCV-infected women should be tested for serum HCV RNA at 1 month of age. If negative, confirmatory anti-HCV antibody testing may be performed between 12 and 15 months of age. Children with chronic hepatitis C may develop progressive fibrosis/cirrhosis, particularly in the setting of obesity and insulin resistance. Treatment of children chronically infected with genotype 2 or 3 is highly successful: combination therapy of pegylated interferon-alpha and ribavirin is well tolerated and superior to pegylated interferon-alpha alone.\",\"The aim of this study was to assess the effect of insulin resistance (IR) on the response to hepatitis C virus (HCV) therapy in HIV-HCV-coinfected patients.\",\"Combination therapy for chronic hepatitis C is associated with depression, which may lead to worse treatment outcomes. The objectives of this study were to determine the association between patient characteristics and depression before and during treatment and to evaluate the relationship between depression and treatment outcomes.\",\"Boceprevir is a hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor that is currently being evaluated in combination with peginterferon alfa-2b and ribavirin in phase 3 studies. The clinical resistance profile of boceprevir is not characterized in detail so far. The NS3 protease domain of viral RNA was cloned from HCV genotype 1-infected patients (n = 22). A mean number of 47 clones were sequenced before, at the end, and after treatment with 400 mg boceprevir twice or three times daily for 14 days for genotypic, phenotypic, and viral fitness analysis. At the end of treatment, a wild-type an NS3 protease sequence was observed with a mean frequency of 85.9%. In the remaining isolates, five previously observed resistance mutations (V36M/A, T54A/S, R155K/T, A156S, V170A) and one mutation (V55A) with unknown resistance to boceprevir were detected either alone or in combination. Phenotypic analysis in the HCV replicon assay showed low (V36G, T54S, R155L; 3.8- to 5.5-fold 50% inhibitory concentration [IC(50)]), medium (V55A, R155K, V170A, T54A, A156S; 6.8- to 17.7-fold IC(50)) and high level (A156T; >120-fold IC(50)) resistance to boceprevir. The overall frequency of resistant mutations and the level of resistance increased with greater declines in mean maximum HCV RNA levels. Two weeks after the end of treatment, the frequency of resistant variants declined and the number of wild-type isolates increased to 95.5%. With the exception of V36 and V170 variants all resistant mutations declined by more than 50%. Mathematical modeling revealed impaired replicative fitness for all single mutations, whereas for combined mutations a relative increase of replication efficiency was suggested.\",\"High serum total cholesterol and low-density lipoprotein (LDL) levels have been demonstrated to increase the probability of a sustained viral response (SVR) in chronic hepatitis C. Conversely, insulin resistance reduces SVR rates. We investigated the influence of baseline glucose and lipid values on the outcome of hepatitis C virus (HCV) treatment in HIV-1 infected subjects.\",\"Individualized treatment with a combination of peg-interferon and ribavirin for patients with hepatitis C virus (HCV) infection has been validated in randomized controlled clinical trials, but its usefulness in the real world is unknown. The aim of the present study was to assess the feasibility of individualized treatment for HCV patients compared with standard therapy in a real-life clinical setting.\",\"Ribavirin (RBV) combined with either pegylated interferon (PegIFN) alpha2a or PegIFNalpha2b is the standard of care for chronic hepatitis C virus (HCV) infection. Due to the lack of head-to-head studies, the 2 PegIFNs have not been directly compared. The endpoints of our study were safety and antiviral efficacy of the 2 regimens.\",\"Dramatic progress is being made toward the development of less-toxic and simpler alternatives to the current standard-of-care therapy for chronic hepatitis C, which involves a combination of pegylated interferon (peg-IFN) and ribavirin (RBV). Several accessible viral targets have been identified and licensure of the most advanced clinical compounds can be anticipated within the next several years. However, the highly replicative nature of HCV infection, coupled with error-prone viral RNA synthesis and considerable genome diversity, pose extraordinary challenges to drug development. Peg-IFN is likely to remain a mainstay of therapy for the foreseeable future, or until such time that multiple direct-acting antiviral (STAT-C) inhibitors are available and shown to provide a sufficiently high barrier to resistance when used in combination.\",\"Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated interferon-alpha (PEG-IFN-alpha) and ribavirin (RBV). To identify genetic variants associated with HCV treatment response, we conducted a genome-wide association study of sustained virological response (SVR) to PEG-IFN-alpha/RBV combination therapy in 293 Australian individuals with genotype 1 chronic hepatitis C, with validation in an independent replication cohort consisting of 555 individuals. We report an association to SVR within the gene region encoding interleukin 28B (IL28B, also called IFNlambda3; rs8099917 combined P = 9.25 x 10(-9), OR = 1.98, 95% CI = 1.57-2.52). IL28B contributes to viral resistance and is known to be upregulated by interferons and by RNA virus infection. These data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-alpha.\",\"It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.\",\"Hepatitis C virus (HCV) is a major cause of chronic liver disease infecting more than 170 million people worldwide. HCV produces a wide gamut of manifestations varying from mild self-limiting disease to cirrhosis and hepatocellular carcinoma. A variety of viral, environmental and host genetic factors contribute to the clinical spectrum of patients infected with HCV and influence response to interferon (IFN) therapy. Predicting the probable outcome of treatment in patients with HCV infection has always been a challenging task. Treatment of HCV by pegylated interferon (peg-IFN) plus ribavirin eradicates the virus in approximately 60% of patients - HCV genotype 1 (42-51% response rates) and genotypes 2 and 3 (76-84% response rates); however, a significant number of patients do not respond to therapy or relapse following discontinuation of treatment or have significant side effects that preclude further treatment. Accurately predicting the patients who will respond to therapy is becoming increasingly important, both from the point of patient care and also with respect to the healthcare cost as clinicians need to continue treatment in patients who will respond and stop treatment in patients who are unlikely to respond. Viral RNA measurements and genotyping are used to optimize treatment as a low viral load and nongenotype 1 is more likely to be associated with sustained virological response (SVR). Rapid virological response (RVR) defined by undetectable HCV RNA at 4 weeks of treatment is increasingly being recognized as a powerful tool for predicting treatment response. A variety of host factors including single nuclear polymorphisms (SNPs) of IFN response genes, insulin resistance, obesity, ethnicity, human leukocyte antigens and difference in T-cell immune response has been found to modulate the response to antiviral treatment. The presence of severe fibrosis/cirrhosis on pretreatment liver biopsy predicts a poor response to treatment. Recent studies on gene expression profiling and characterization of the liver and serum proteome provide options to accurately predict the outcome of patients infected with HCV in the future. Future studies on the factors that predict treatment response and tailoring treatment based on this is required if we are to conquer this disease.\",\"The rapid decline in hepatitis C virus RNA is crucial for determining the outcome of therapy in patients with genotype 1 chronic hepatitis C. However, the variables influencing the early phase of viral decay are still largely unexplored. We aimed to assess which pre-treatment variable may predict rapid virologic response (RVR) and sustained virologic response (SVR).\",\"Hepatitis C virus (HCV) quasispecies diversity is more likely to affect early viral decline during treatment of hepatitis C than is having human immunodeficiency virus (HIV) infection. We evaluated the influence of HCV therapy on changes in the nonstructural 5A (NS5A) protein.\",\"Hepatitis C virus (HCV) genotype 4 (HCV-4) is increasing in prevalence in Western countries. However, little is known about the severity of the disease and response to treatment. The aim of this study was to assess the predictors (logistic regression) of severe fibrosis (METAVIR score F3-F4), and sustained virological response (SVR) to peginterferon and ribavirin in 226 consecutive HCV-4 patients (Egyptians 40%, Europeans 35% and Africans 24%).\",\"Patients chronically infected with hepatitis C virus (HCV) require significantly different durations of therapy and achieve substantially different sustained virologic response rates to interferon-based therapies, depending on the HCV genotype with which they are infected. There currently exists no systematic framework that explains these genotype-specific response rates. Since humans are the only known natural hosts for HCV-a virus that is at least hundreds of years old-one possibility is that over the time frame of this relationship, HCV accumulated adaptive mutations that confer increasing resistance to the human immune system. Given that interferon therapy functions by triggering an immune response, we hypothesized that clinical response rates are a reflection of viral evolutionary adaptations to the immune system.\",\"Investigating the evolution of the hepatitis C viral (HCV) genome in the small number of patients that experience viral breakthrough might shed light on the problem of resistance to interferon therapy. Within the HCV genome, sequence diversity of the viral nonstructural 5A protein-coding region (NS5A) has been linked to interferon responsiveness. We analysed the temporal sequence changes within NS5A in genotype 1a patients: 6 breakthrough (BT), 12 sustained virologic responders (SVR) and 12 non-responders (NR), all of whom had received full dose peg-interferon and ribavirin therapy. The entire NS5A region was amplified by reverse transcription (RT)-PCR followed by direct sequencing of serum samples from baseline and three on-treatment time points for each group. Comparing baseline sequences with week 12 and later time points, BT patients resembled SVR patients in having a higher number of amino acid substitutions at week 12 than NR patients; however, the number of amino acid substitutions in this group decreased at and after BT. Substitutions were focused in the V3 and flanking regions in BT patients but not in SVR patients. The high number of substitutions in NS5A in both BT and SVR groups suggests that selective pressure is associated with viral response to therapy. Our results provide evidence that amino acid substitutions within the NS5A coding region may reflect a host response that drives selective pressure for viral adaptation.\",\"To report on the long-term followup of a cohort of patients with hepatitis C virus (HCV)-related vasculitis treated with rituximab with or without PEGylated interferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin.\",\"Chronic hepatitis C virus (HCV) infection affects approximately 4 million persons and is the major indication for liver transplantation in the United States. The current standard for treatment of HCV is pegylated interferon in combination with ribavirin. Despite significant advances in treatment, only approximately 50% of patients of treated patients clear HCV infection. Polymerase inhibitors, given their potent antiviral effects, represent a major contribution to the future of HCV treatment. Whether these new drugs will have a role in the treatment of the difficult patient (non-responders, those co-infected with HIV, decompensated liver disease and liver transplant recipients) remains to be determined.\",\"Standard therapy with pegylated interferon and ribavirin for chronic hepatitis C is effective in 40% to 50% of individuals with genotype 1 hepatitis C virus (HCV) infection and is associated with significant treatment-related toxicities. Newly developed small molecules that target key enzymes essential for HCV replication are in development. Telaprevir, a peptidomimetic inhibitor of the HCV NS3/4A protease, has shown great promise in early trials and is currently in advanced stages of clinical development. In treatment-na\\u00efve patients and those with previous treatment failure, the addition of telaprevir to standard interferon and ribavirin therapy is well tolerated and enhances rates of sustained virologic response while shortening the treatment duration. In this report, the current experience using telaprevir to treat chronic HCV infection as monotherapy and in combination with other agents is reviewed.\",\"Hepatitis C virus (HCV) is a major cause of chronic liver disease leading to death from liver failure or hepatocellular carcinoma. Hepatitis C is the most common indication for liver transplantation worldwide and is a major cause of the increased incidence of hepatocellular cancer in the United States. The current paradigm for HCV treatment relies on pegylated interferon and ribavirin as agents that enhance endogenous mechanisms for viral clearance and are dependent on host factors. In patients with genotype 1 HCV infection, sustained viral response (SVR) rates remain suboptimal, with less than half of genotype 1-infected individuals going on to achieve SVR. This has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. This review focuses on boceprevir, a protease inhibitor, and discusses its mechanism of action, effects on HCV, and viral resistance.\",\"The current standard of care for treatment of hepatitis C is pegylated interferon and ribavirin. Despite the large number of new oral agents under development, interferon will likely remain the backbone of future therapy. Interferon has unique antiviral and immunomodulatory properties, which have been critical in limiting resistance to protease inhibitors and improving efficacy. Hence, optimizing pharmacokinetics and promoting adherence to interferon dosing regimens will become even more critical as new regimens enter the clinical arena. This review highlights novel interferons under development that may offer therapeutic advantages over the formulations currently available.\",\"Suppressor of cytokine signaling 3 (SOCS3) can suppress Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling by blocking an IFN-induced protein. In this study, the relationship between SOCS3 and phosphorylation of STAT1 in the liver and outcome of interferon therapy were examined.\",\"The recurring emergence of influenza virus strains that are resistant to available antiviral medications has become a global health concern, especially in light of the potential for a new influenza virus pandemic. Currently, virtually all circulating strains of influenza A virus in the United States are resistant to either of the two major classes of anti-influenza drugs (adamantanes and neuraminidase inhibitors). Thus, new therapeutic approaches that can be rapidly deployed and that will address the issue of recurring resistance should be developed. We have tested double and triple combinations of the approved anti-influenza drugs oseltamivir and amantadine together with ribavirin against three influenza virus strains using cytopathic effect inhibition assays in MDCK cells. We selected A/New Caledonia/20/99 (H1N1) and A/Sydney/05/97 (H3N2) as representatives of the wild-type versions of the predominant circulating seasonal influenza virus strains and A/Duck/MN/1525/81 (H5N1) as a representative of avian influenza virus strains. Dose-response curves were generated for all drug combinations, and the degree of drug interaction was quantified using a model that calculates the synergy (or antagonism) between the drugs in double and triple combinations. This report demonstrates that a triple combination of antivirals was highly synergistic against influenza A virus. Importantly, the synergy of the triple combination was 2- to 13-fold greater than the synergy of any double combination depending on the influenza virus subtype. These data support the investigation of a novel combination of oseltamivir, amantadine, and ribavirin as an effective treatment for both seasonal and pandemic influenza virus, allowing the efficient use of the existing drug supplies.\",\"In this study we evaluated the pharmacologic costs of hepatitis C treatment, considering recommendations on both the duration of therapy and sustained virological response. With this aim, we analyzed relevant scientific articles published in the previous 10 years, considering the most common genotypes present in Spain. In this analysis, we estimated overall costs to be 1,636,524.58-1,761,365.73 euro and 1,794.586.39-1,917,013.73 euro with the use of pegylated interferon (PegIFN)-alpha-2a and PegIFN-alpha-2b, respectively. Sustained virological response was 59.18% and 64.58% respectively, with no significant difference between the two formulations. Finally, we assess the economic costs of the use of high-dose PegIFN-alpha-2a and ribavirin in patients with genotype 1 and treatment resistance (baseline HCV-RNA values > 800.000UI/ml, without early viral response at 12 weeks and weight > 85kg).\",\"Analysis of hepatitis C virus (HCV) RNA kinetics during antiviral therapy may allow estimation of the probability of response.\",\"Despite improvements to treatments for HCV infection, almost half of patients cannot be cured with standard combination therapy (pegylated interferon alpha and ribavirin). The HCV life cycle offers a number of potential targets for molecular therapy, and several specifically targeted antiviral therapies for HCV (STAT-Cs) are in preclinical and clinical stages of development. Evidence to date suggests that monotherapy with any antiviral drug is unlikely to eradicate HCV infection. Combination therapy with interferon and ribavirin is necessary for the augmentation of antiviral drug activity and/or prevention of drug resistance. Results from clinical trials carried out in the past few years on STAT-C agents in combination with standard therapy with peginterferon and ribavirin provide great promise of higher rates of sustained virological response and, potentially, shorter duration of therapy than standard therapy alone achieves. Although pegylated interferon and ribavirin are likely to remain a cornerstone of therapeutic regimens in the short term, combinations of antiviral drugs of different classes, possibly along with novel agents that target host factors and modulate viral replication or augment antiviral defenses, offer the eventual possibility of interferon-free regimens.\",\"Treatment of chronic hepatitis C is currently based on a combination of pegylated interferon-o! and ribavirin. Neither drug exerts direct selective pressure on viral functions, meaning that interferon-a/ribavirin treatment failure is not due to selection of interferon-a- or ribavirin-resistant viral variants. Several novel antiviral approaches are currently in preclinical or clinical development, and most target viral enzymes and functions, such as hepatitis C virus protease and polymerase. These new drugs all potentially select resistant viral variants both in vitro and in vivo, and resistance is therefore likely to become an important issue in clinical practice.\",\"Hepatitis C virus (HCV) infection represents a global health problem due to its evolution to hepatic cirrhosis and hepatocellular carcinoma. The viral pathogenesis and infectious processes are not yet fully understood. The development of natural viral resistance towards the host immune system represents a mayor challenge for the design of alternative therapeutic interventions and development of viral vaccines. The molecular mechanisms of hepatic fibrosis are well described. New alternatives for the treatment of patients with HCV infection and hepatic cirrhosis are under intensive research. New drugs such as viral protease inhibitors and assembly inhibitors, as well as immune modulators have been studied in clinical trials. Additional alternatives include antifibrotic drugs, which reverse the hepatic cellular damage caused by HCV infection. This review makes reference to viral infective mechanisms, molecular pathways of liver fibrosis and overviews conventional and new treatments for HCV infection and liver fibrosis.\",\"After the discovery of the hepatitis B virus in 1968 and of the hepatitis A virus in 1973, many years were needed to identify the hepatitis C virus (HCV) in 1989. The discovery of HCV was a revolution for hepatology because of the magnitude of the global burden related to HCV infection, a major cause of cirrhosis and hepatocellular carcinoma. Therapy of hepatitis C has rapidly evolved with currently nearly 60% of sustained virological response with the combination of pegylated interferon plus ribavirin. In patients with sustained virological response, viral eradication, corresponding to the cure of infection, and regression of histological liver lesions have been demonstrated. Recently, the availability of in vitro culture systems allowed to characterize viral enzymes, potential therapeutic targets. A novel therapeutic era is open with the protease and polymerase inhibitors, used as a first step in association with pegylated interferon and ribavirin, both to increase efficacy and decrease the risk of resistance. Thanks to these new molecules with a potent antiviral activity, one can reasonably predict a rapid improvement of treatments becoming more efficient and also better tolerated with the progressive replacement of interferon and ribavirin by combinations of these virus specific enzyme inhibitors.\",\"The recommended therapy for chronic hepatitis C, pegylated interferon and ribavirin for 24 or 48 weeks, has many known adverse side effects. The aim of this study was to evaluate the impact of antiviral therapy on male sexual health.\",\"Chronic hepatitis C (CHC) genotype 1b patients with high viral load are resistant to peginterferon (PEG-IFN) and ribavirin (RBV) combination therapy, especially older and female patients.\",\"A 49-year-old white man presented to his primary-care clinic with fatigue and poor concentration. He had an enlarged liver with a minimally tender edge and was subsequently referred to our liver clinic.\",\"Approximately 3% of the worldwide population (i.e., more than 170 million people) are chronically infected with the hepatitis C virus (HCV). An estimated 20% of these patients will develop liver cirrhosis within a mean of 20 years, and 2-5% of cirrhotic patients will die of end-stage liver disease or hepatocellular carcinoma. The currently approved antiviral therapy with pegylated interferon (pegIFN) and ribavirin induces a sustained virological response (SVR) in 40-50% of patients infected with genotype 1, the most prevalent HCV type. In this review, we focus on the development and clinical application of serine protease inhibitors as anti-HCV agents. Although highly active in inducing a significant decline of serum HCV RNA, the rapid development of resistance must be counteracted in combination with other antiviral agents, currently pegIFN-alpha and ribavirin. Two serine protease inhibitors have reached clinical Phase III trials, increasing SVR rates and shortening treatment duration when combined with pegIFN and ribavirin. Trials of interferon-free targeted combination therapies are currently underway.\",\"Hepatitis C virus (HCV) is a major health problem worldwide, infecting an estimated 170 million people. In this study, we have employed a large data set of sequences (14,654 sequences from between 25 and 100 clone sequences per analyzed region and per patient) from 67 patients infected with HCV genotype 1 (23 subtype 1a and 44 subtype 1b). For all patients, a sample prior to combined therapy with alpha interferon plus ribavirin was available, whereas for some patients additional samples after 6 or 12 months of treatment were also available. Twenty-seven patients responded to treatment (12 subtype 1a and 15 subtype 1b) and forty patients did not respond to treatment (11 subtype 1a vs. 29 subtype 1b). Two regions of the HCV genome were analyzed, one compressing the hypervariable regions (HVR1, HVR2 and HVR3) of the envelope 2 glycoprotein and another one including the interferon sensitive determining region (ISDR) and the V3 domain of the NS5A protein. Previously (Cuevas, J.M., Torres-Puente, M., Jim\\u00e9nez-Hern\\u00e1ndez, N., Bracho, M.A., Garc\\u00eda-Robles, I., Wrobel, B., Carnicer, F., del Olmo, J., Ortega, E., Moya, A., Gonz\\u00e1lez-Candelas, F., 2008b. Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin. Plos One 3 (8), e3058), several amino acid positions in both regions analyzed were detected to be under positive selection. Here, we have compared the amino acid composition of each positively selected position between responder and non-responder patients for both subtypes. If we exclude some non-conclusive cases, no clear differences were detected in any case. In conclusion, identifying specific positions as completely discriminatory of treatment response seems to be a difficult task. Our results, in concordance with previous studies, suggest that HCV evasion strategies are more likely based on a global increased variability, which would yield combinations of mutations with an increased resistance, than on the fixation of specific amino acids conferring resistance to antiviral treatment or immune response. In this sense, the particular systemic response from each patient could play an essential role in determining the outcome of the antiviral treatment.\",\"Cyclic and periodic IFN treatment (CPIT) consisting of induction treatment with nIFN-beta followed by maintenance treatment with IFN-alpha could prevent viral breakthrough and achieve rapid virological response (RVR) and early virological response (EVR) in chronic hepatitis C (CHC). The efficacy and immune response of RBV+PEG-IFN-alpha2b using induction approach with CPIT (novel combination treatment: NCT) in 7 CHC patients with genotype 1b and high viral load were evaluated. A biometric multiplex serum cytokine assay was utilized to characterize the immunomodulatory effect. RVR and EVR were 7/7 and 7/7, respectively. Viral titers dropped below detectable levels in five patients with sustained virological response (SVR) before the end of CPIT (early virological responder: EAVR), and two patients without SVR after the end of CPIT (late virological responder: LAVR). At baseline, in EAVR compared with the controls, IL-6 and IL-15, CXCL-8 and CXCL-10 levels were significantly higher (P < 0.05); IL-10 and IL-13 levels were significantly lower (P < 0.05); and the IL-12 level was lower. In LAVR, GM-CSF, CXCL-8 and CXCL-10, and CCL-4 levels were significantly higher (P < 0.05); and IL-10 and IL-12 were lower than the controls. In EAVR but not LAVR, the IL-12 increased and the CCXL-8 decreased significantly (P < 0.05). In conclusion, NCT-induced viral clearance leading to improvement in the innate immune response resulting in SVR in CHC with genotype 1b and high viral load.\",\"Lethal mutagenesis, or virus extinction promoted by mutagen-induced elevation of mutation rates of viruses, may meet with the problem of selection of mutagen-resistant variants, as extensively documented for standard, non-mutagenic antiviral inhibitors. Previously, we characterized a mutant of foot-and-mouth disease virus that included in its RNA-dependent RNA polymerase replacement M296I that decreased the sensitivity of the virus to the mutagenic nucleoside analogue ribavirin.\",\"The amount of inosine monophosphate dehydrogenase (IMPDH), a pivotal enzyme for the biosynthesis of the guanosine tri-phosphate (GTP), is frequently increased in tumor cells. The anti-viral agent ribavirin and the immunosuppressant mycophenolic acid (MPA) are potent inhibitors of IMPDH. We recently showed that IMPDH inhibition led to a necrotic signal requiring the activation of Cdc42.\",\"Half of the population of genotype 1 HCV is resistant to current pegylated-interferon-alpha (PEG-IFN-alpha) and ribavirin therapy. The resistance to IFN therapy is an urgent problem, especially in patients with genotype 1 HCV infection. However, sensitivities among HCV strains to anti-HCV reagents including IFNs have not been thoroughly addressed. Here, we established three different subgenomic replicons (1B-4, 1B-5, and KAH5 strains) in addition to our previously established replicon (O strain). We comparatively examined the sensitivities of four replicons to IFN-alpha, IFN-gamma, IFN-lambda, cyclosporine A, and fluvastatin. Among the replicons, the 1B-4 and KAH5 replicons were the most sensitive and resistant, respectively to IFN-lambda (EC(50): 1.50 ng/ml vs. 8.50 ng/ml) and fluvastatin (EC(50): 2.82 microM vs. 7.87 microM), although these replicons possessed similar features in terms of genetic distance from the O strain, HCV RNA expression levels, and sensitivity to IFN-alpha (EC(50): 1.44 IU/ml vs. 1.37 IU/ml) and cyclosporine A (EC(50): 0.71 microg/ml vs. 0.96 microg/ml). These replicons are thus useful tools for examining the mechanism of anti-HCV activity, especially in IFN-lambda and statins.\",\"With an increasing worldwide burden of liver failure and liver cancer from chronic hepatitis C virus (HCV) infection, discovery and development efforts for new antiviral medicines for HCV are expanding rapidly. Two HCV protease inhibitors (PIs), telaprevir (VX950) and boceprevir (SCH503034), are now furthest along in clinical development, with Phase II data suggesting a potential treatment advance with triple combination regimens comprising a protease inhibitor, pegylated interferon and ribavirin. However, the current data suggest that such regimens will fail to produce sustained virologic responses in > or = 30 - 40% of patients, and tolerance of interferon/ribavirin treatment regimens is often problematic; hence, there is a need for continued development of new anti-HCV agents to further optimize treatment efficacy and safety. The HCV polymerase (HCV Pol) is an attractive target for antiviral therapy because the gene sequences encoding HCV Pol are relatively conserved across the six main HCV genotypes and the emergence of viral resistance is expected to be relatively slow for pharmaceutical agents, such as nucleoside analogues, that are targeted to the active (catalytic) site of HCV Pol.\",\"Treatment of hepatitis C virus (HCV) infection with pegylated interferon/ribavirin achieves sustained virological response in up to 56% of HCV mono-infected patients and 40% of HCV/human immunodeficiency virus (HIV)-co-infected patients. The relationship of patient adherence to outcome warrants study.\",\"The present review is a concise review of recent developments in the field of viral hepatitis, based on publications between December 2007 and November 2008.\",\"Previous studies provided a direct experimental evidence for the contribution of HCV core protein in the development of insulin resistance (IR), but the clinical impact of HCV core region on IR is still not clear. The present study evaluated the impact of Amino acid (aa) substitutions of HCV-1b core region on IR in 123 Japanese patients infected with HCV-1b without cirrhosis and diabetes mellitus, and investigated the treatment efficacy of 48-week pegylated interferon (PEG-IFN) plus ribavirin (RBV) according to HOMA-IR values. Patients with IR (HOMA-IR > or = 2.5) and severe IR (HOMA-IR > or = 3.5) were present in 51.2% and 27.6%, respectively. Multivariate analysis identified body mass index (> or = 25 kg/m(2)) and hepatocyte steatosis (> or = 5%) as significant determinants of IR. Furthermore, multivariate analysis identified hepatocyte steatosis (> or = 5%), aa substitutions of the core region (Gln70 (His70) and/or Met91), and age (> or = 55 years) as significant determinants of severe IR. Especially, significantly lower proportions of patients with Gln70 (His70) and/or Met91 were noted among those without severe IR (59.6%) than those with severe IR (82.4%). The rates of sustained virological response in patients with IR (50.0%) were not significantly different from those without IR (52.9%). Furthermore, the rates of non-virological response in patients with IR (28.9%) were not significantly also different from those without IR (20.6%). In conclusion, the present study indicated that substitutions of HCV-1b core region were the important predictor of severe IR in patients without cirrhosis and diabetes mellitus, but HOMA-IR values might be not useful as predictors of 48-week PEG-IFN plus RBV therapy.\",\"Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and can lead to hepatocellular carcinoma and end-stage liver disease. The current FDA-approved treatment for HCV (pegylated interferon-alpha (IFNalpha) with ribavirin) is effective in only about 50% of patients. Epidemiological evidence suggests that obesity, alcohol, smoking, and environmental pollutants may contribute to resistance to IFNalpha therapy in HCV. Acrolein, a ubiquitous environmental pollutant and major component of cigarette smoke, is also generated endogenously by cellular metabolism and lipid peroxidation. This study examines the effects of acrolein on (i) IFNalpha-mediated signaling and antiviral gene expression in cultured and primary human hepatocytes and (ii) HCV replication in an HCV-replicon system. Our data demonstrate that nontoxic concentrations of acrolein significantly inhibited IFNalpha-induced tyrosine phosphorylation of both cytoplasmic and nuclear STAT1 and STAT2, without altering the total levels. Also, acrolein down-regulated IFNalpha-stimulated gene transcription, resulting in reduced expression of antiviral genes. Importantly, acrolein abolished the IFNalpha-mediated down-regulation of HCV viral expression in the HCV-replicon system. This study defines mechanisms involved in resistance to IFNalpha and identifies the pathogenic role of acrolein, and potentially other environmental pollutants, in suppressing IFNalpha antiviral activity and establishes their adverse impact on HCV therapy.\",\"Albinterferon-alpha-2b (albIFN) is a long-acting fusion polypeptide composed of albumin and IFN-alpha-2b. In a phase 2 study of albIFN 1500 mug q2wk or q4wk in patients with genotype 2/3 chronic hepatitis C, albIFN demonstrated sustained virological response (SVR) rates of 62-77% (intent-to-treat population).\",\"Early changes in hepatitis C virus (HCV) RNA levels were assessed in a large cohort of African American and white patients with chronic hepatitis C due to HCV genotype 1 who underwent therapy with peginterferon alfa-2a and ribavirin in the Study of Viral Resistance to Antiviral Therapy of Hepatitis C (Virahep-C). Analyses were restricted to 341 patients who completed the first 28 days of therapy without dose modification. HCV RNA levels decreased in virtually all patients, but the amount of the change varied markedly. The overall 28-day decrease in HCV RNA levels was at least as predictive of a sustained virological response as the first- or second-phase viral kinetics responses. Factors associated with a smaller decrease in the HCV RNA level between baseline and day 28 included African American race, higher initial HCV RNA level, more severe hepatic fibrosis, and higher body weight. African American patients with similar 28-day decreases in viral levels as white patients were still less likely to achieve a sustained virological response. These results suggest that racial differences in the response to antiviral therapy are due to greater unresponsiveness to intracellular actions of interferon in African American individuals and that standard doses of peginterferon and ribavirin may be suboptimal for patients with higher body weights. Trial registration. ClinicalTrials.gov identifier: NCT00038974 .\",\"An amantadine-resistant influenza A/Duck/MN/1525/81 (H5N1) virus was developed from the low-pathogenic North American wild-type (amantadine-sensitive) virus for studying treatment of infections in cell culture and in mice. Double combinations of amantadine, oseltamivir (or the cell culture-active form, oseltamivir carboxylate), and ribavirin were used. Amantadine-oseltamivir carboxylate and amantadine-ribavirin combinations showed synergistic interactions over a range of doses against wild-type virus in Madin-Darby canine kidney (MDCK) cell culture, but oseltamivir carboxylate-ribavirin combinations did not. Primarily additive interactions were seen with oseltamivir carboxylate-ribavirin combinations against amantadine-resistant virus. The presence of amantadine in drug combinations against the resistant virus did not improve activity. The wild-type and amantadine-resistant viruses were lethal to mice by intranasal instillation. The resistant virus infection could not be treated with amantadine up to 100 mg/kg body weight/day, whereas the wild-type virus infection was treatable with oral doses of 10 (weakly effective) to 100 mg/kg/day administered twice a day for 5 days starting 4 h prior to virus exposure. Drug combination studies showed that treatment of the amantadine-resistant virus infection with amantadine-oseltamivir or amantadine-ribavirin combinations was not significantly better than using oseltamivir or ribavirin alone. In contrast, the oseltamivir-ribavirin (25- and 75-mg/kg/day combination) treatments produced significant reductions in mortality. The wild-type virus infection was markedly reduced in severity by all three combinations (amantadine, 10 mg/kg/day combined with the other compounds at 20 or 40 mg/kg/day) compared to monotherapy with the three compounds. Results indicate a lack of benefit of amantadine in combinations against amantadine-resistant virus, but positive benefits in combinations against amantadine-sensitive virus.\",\"Signal transducers and activators of transcription (STATs) play a critical role in antiviral defense. To better understand pegylated interferon (IFN)-alpha and ribavirin combination therapy resistance, we examined the STAT expression in the liver.\",\"Treatment for hepatitis C virus infection currently consists of pegylated interferon and ribavirin (RBV), a nucleoside analog. Although RBV clearly plays a role in aiding the treatment response, its antiviral mechanism is unclear. Regardless of the specific mechanism of RBV, we hypothesize that differences in levels of cellular uptake of RBV may affect antiviral efficacy and treatment success and that cells may become RBV resistant through reduced uptake. We monitored RBV uptake in various cell lines and determined the effect of uptake capacity on viral replication. RBV-resistant cells demonstrated reduced RBV uptake and increased growth of a model RNA virus, poliovirus, in the presence of RBV. Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. However, CNT3 is not expressed in Huh-7 liver cells, and inhibition of concentrative transport did not affect RBV uptake. Blocking equilibrative transport using the inhibitor nitrobenzylmercaptopurine riboside recapitulated the RBV-resistant phenotype in RBV-sensitive cell lines, with a reduction in RBV uptake and increased poliovirus growth. Taken together, these results indicate that RBV uptake is restricted primarily to ENT1 in the cell lines examined. Interestingly, some RBV-resistant cell lines may compensate for reduced ENT1-mediated nucleoside uptake by increasing the activity of an alternative nucleoside transporter, ENT2. It is possible that RBV uptake affects the antiviral treatment response, either through natural differences in patients or through acquired resistance.\",\"Debio 025 is a cyclophilin (Cyp) inhibitor without calcineurin-binding properties. The drug inhibits viral replication of genotype 1b and 2a replicons in nanomolar concentrations and shows an additive to synergistic antiviral effect with interferon, ribavirin, and specifically targeted antiviral therapy for hepatitis C (STAT-C) drugs. There is no cross-resistance with protease and polymerase inhibitors. In humans, Debio 025 has shown activity against genotypes 1, 2, 3, and 4, and displays an additive antiviral effect with pegylated interferon (peg-IFN)alpha2a in genotype 1 and 4 patients. The most prominent side effect is reversible hyperbilirubinaemia caused by inhibition of biliary transporters. Debio 025 is a potent anti-HCV drug, with a novel mechanism of action and an efficacy profile that makes it an attractive candidate for combination with current and future HCV treatments.\",\"Hepatitis C virus (HCV) presents several regions involved potentially in evading antiviral treatment and host immune system. Two regions, known as PKR-BD and V3 domains, have been proposed to be involved in resistance to interferon. Additionally, hypervariable regions in the envelope E2 glycoprotein are also good candidates to participate in evasion from the immune system. In this study, we have used a cohort of 22 non-responder patients to combined therapy (interferon alpha-2a plus ribavirin) for which samples obtained just before initiation of therapy and after 6 or/and 12 months of treatment were available. A range of 25-100 clones per patient, genome region and time sample were obtained. The predominant amino acid sequences for each time sample and patient were determined. Next, the sequences of the PKR-BD and V3 domains and the hypervariable regions from different time samples were compared for each patient. The highest levels of variability were detected at the three hypervariable regions of the E2 protein and, to a lower extent, at the V3 domain of the NS5A protein. However, no clear patterns of adaptation to the host immune system or to antiviral treatment were detected. In summary, although high levels of variability are correlated to viral adaptive response, antiviral treatment does not seem to promote convergent adaptive changes. Consequently, other regions must be involved in evasion strategies likely based on a combination of multiple mechanisms, in which pools of changes along the HCV genome could confer viruses the ability to overcome strong selective pressures.\",\"Insulin resistance (IR) might be associated with hepatitis C virus (HCV) infection. This study aimed to elucidate impact of IR and beta-cell function on the response to peginterferon-alpha (PEG-IFN)/ribavirin combination therapy in chronic hepatitis C (CHC) patients.\",\"To evaluate the possible influence of baseline insulin resistance in sustained virological response.\",\"The natural history of chronic hepatitis C has been defined in several retrospective and prospective studies conducted in the last 20 years. These studies have clearly demonstrated that the outcome of chronic hepatitis C virus infection is profoundly influenced by a variety of cofactors and comorbidities. Many of the cofactors that affect the course of liver disease in hepatitis C also have a significant influence on the result of antiviral therapy. Unfortunately, comorbidities that have been shown to negatively influence the course and outcome of liver disease often reduce the chance of achieving a sustained virological response with pegylated interferon (PEG-IFN) and ribavirin treatment. The most important and frequent comorbidity influencing the course of chronic hepatitis C and the response to antiviral therapy is represented by the metabolic syndrome, and by the associated state of insulin resistance. Other comorbidities that have a negative influence on the progression of hepatitis C and on the response to antiviral therapy include excess alcohol intake, human immunodeficiency virus and hepatitis B virus co-infection and a number of conditions that reduce the benefit of therapy by affecting negatively compliance and/or adherence to adequate PEG-IFN or ribavirin doses.\",\"Hepatitis C virus (HCV) infection remains a serious health problem worldwide. The current standard treatment of HCV infection is pegylated interferon-alpha plus ribavirin, but this is clearly not sufficiently effective and tolerable.\",\"Specifically Targeted Antiviral Therapy against hepatitis C virus (STAT-C) stands for a new era in the treatment of patients with chronic hepatitis C. Results from recent trials with protease and polymerase inhibitors indicate that therapy with a single HCV specific compound will not be sufficient to eradicate hepatitis C virus infection and that combination therapy will be necessary to improve sustained virologic response rates. The search for the optimal combination of STAT-C compounds with peginterferon alfa with or without ribavirin is currently under investigation in several clinical trials. Overall the current studies indicate that peginterferon alfa and ribavirin remain the backbone of antiviral therapy of chronic hepatitis C even in the era of STAT-C. Nevertheless, it can be anticipated that combination of STAT-C compounds with non-overlapping resistance profiles could improve response to antiviral therapy. Promising combinations are protease inhibitors plus nucleoside analogue and non-nucleoside analogue polymerase inhibitors.\",\"Insulin resistance is a candidate predictive factor for virological response to peginterferon plus ribavirin (PEG/RBV) therapy in chronic hepatitis C patients. We examined whether indices of insulin resistance could serve as a predictor of sustained virological response (SVR). Fifty-one patients with genotype 1b and high viral load who received PEG/RBV therapy for 48 weeks were included. Homeostasis model assessment of insulin resistance (HOMA-IR) and whole-body insulin sensitivity index (WBISI) calculated from the 75-g oral glucose tolerance test and serum levels of soluble tumor necrosis factor receptor 2 (sTFNR2) were evaluated before therapy. Patients who achieved SVR had significantly lower HOMA-IR and sTNFR2 levels and a higher WBISI compared with non-SVR patients. The positive predictive value for SVR was 0.653 for a HOMA-IR of <2 and 0.846 for a WBISI of 6 or higher. WBISI may serve as a highly specific predictor for SVR in PEG/RBV therapy.\",\"The need for effective treatment for chronic hepatitis C infection has driven the development of novel antiviral agents that target specific steps in the viral replication cycle.\",\"Hepatitis C virus (HCV) infection is a major and growing global health problem, affecting about 170 million people worldwide, and is a leading cause of liver cirrhosis and hepatocellular carcinoma. Currently, treatment is restricted to interferon alfa and ribavirin, which leads to a successful outcome in only about 50% of individuals. New effective treatments with tolerable side-effect profiles are needed urgently, but development has been hindered by an inability to culture HCV and a scarcity of animal models. Herein, we review progress in HCV biology, including cell culture and new animal models, and the contribution of this work to our understanding of the virus' life-cycle and pathogenesis and development of specifically targeted antiviral treatment. We also discuss changes in our understanding of HCV epidemiology, clinical manifestations, and diagnostics.\",\"Insulin resistance may promote hepatic fibrosis in chronic hepatitis C (HCV) and has emerged as a cofactor in failure to achieve sustained viral response (SVR).\",\"Influenza pneumonia causes high mortality every year, and pandemic episodes kill millions of people. Influenza-related mortality has been variously ascribed to an ineffective host response that fails to limit viral replication, an excessive host inflammatory response that results in lung injury and impairment of gas exchange, or to bacterial superinfection. We sought to determine whether lung inflammation promoted or impaired host survival in influenza pneumonia.\",\"Chronic hepatitis C virus (HCV) infection remains a global health threat with approximately 175 million carriers worldwide. Currently, treatment consists of pegylated interferon alpha plus ribavirin for 12-72 weeks, depending on HCV genotype, baseline viral load, and initial virological response to therapy. Serious adverse effects and limited sustained virological responses with this therapy warrant the need for novel HCV therapies. Specifically targeted antiviral therapies designed to inhibit the HCV serine protease and the RNA-dependent RNA polymerase have recently entered clinical development. Herein, the main characteristics of these new antiviral agents and the most important challenges arising with their use--namely, toxicities and rapid selection of resistance--are discussed.\",\"Hepatitis C virus (HCV) is a common RNA virus that causes hepatitis and liver cancer. Infection is treated with IFN-alpha and ribavirin, but this expensive and physically demanding therapy fails in half of patients. The genomic sequences of independent HCV isolates differ by approximately 10%, but the effects of this variation on the response to therapy are unknown. To address this question, we analyzed amino acid covariance within the full viral coding region of pretherapy HCV sequences from 94 participants in the Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C) clinical study. Covarying positions were common and linked together into networks that differed by response to therapy. There were 3-fold more hydrophobic amino acid pairs in HCV from nonresponding patients, and these hydrophobic interactions were predicted to contribute to failure of therapy by stabilizing viral protein complexes. Using our analysis to detect patterns within the networks, we could predict the outcome of therapy with greater than 95% coverage and 100% accuracy, raising the possibility of a prognostic test to reduce therapeutic failures. Furthermore, the hub positions in the networks are attractive antiviral targets because of their genetic linkage with many other positions that we predict would suppress evolution of resistant variants. Finally, covariance network analysis could be applicable to any virus with sufficient genetic variation, including most human RNA viruses.\",\"Debio 025 is a potent inhibitor of hepatitis C virus (HCV) replication (J. Paeshuyse et al., Hepatology 43:761-770, 2006). In phase I clinical studies, monotherapy (a Debio 025 dose of 1,200 mg twice a day) resulted in a mean maximal decrease in the viral load of 3.6 log(10) units (R. Flisiak et al., Hepatology 47:817-826, 2008), whereas a reduction of 4.6 log(10) units was obtained in phase II studies when Debio 025 was combined with interferon (R. Flisiak et al., J. Hepatol., 48:S62, 2008). We here report on the particular characteristics of the in vitro anti-HCV activities of Debio 025. The combination of Debio 025 with either ribavirin or specifically targeted antiviral therapy for HCV (STAT-C) inhibitors (NS3 protease or NS5B [nucleoside and nonnucleoside] polymerase inhibitors) resulted in additive antiviral activity in short-term antiviral assays. Debio 025 has the unique ability to clear hepatoma cells from their HCV replicon when it is used alone or in combination with interferon and STAT-C inhibitors. Debio 025, when it was used at concentrations that have been observed in human plasma (0.1 or 0.5 muM), was able to delay or prevent the development of resistance to HCV protease inhibitors as well as to nucleoside and nonnucleoside polymerase inhibitors. Debio 025 forms an attractive drug candidate for the treatment of HCV infections in combination with standard interferon-based treatment and treatments that directly target the HCV polymerase and/or protease.\",\"Hypokalaemic thyrotoxic periodic paralysis is an enigmatic and uncommon condition which occurs exclusively in males of Asian descent. The underlying causes of thyrotoxicosis may be any of the well-recognized etiologies including a toxic multinodular goiter, Graves' disease or iodine excess. Beside thyrotoxicosis, a number of other hormonal factors have been hypothesized to contribute to hypokalaemic thyrotoxic periodic paralysis, particularly postprandial hyperinsulinaemia and testosterone. We hereby present a case of a 48-year-old hepatitis C positive gender-assigned man in whom all of these factors are proposed to interact, lending further support to these hypotheses. The patient presented with interferon-induced thyroiditis causing acute generalized weakness whilst undergoing combination interferon-alpha-2beta and ribavirin therapy. As part of his hepatitis C infection, marked insulin resistance with hyperinsulinaemia was also present, exacerbating the paresis. Initial treatment with beta-blocker failed to normalize his serum potassium concentration, requiring the novel use of spironolactone, despite euthyroidism. This continued to be required until his testosterone supplement dissipated.\",\"Hepatitis C virus (HCV) has evolved remarkable mechanisms that favor viral persistence by interfering with host innate and adaptive immune responses. These same mechanisms are likely to contribute to resistance to exogenously administered interferon used for HCV treatment. We review the host innate and adaptive immune responses in the context of HCV infection as well as the strategies by which these responses are subverted by the virus. In addition, the contribution of host factors, such as race and insulin resistance, to interferon non-responsiveness is discussed. Our progress in understanding the molecular underpinnings of interferon treatment failure in HCV infection has resulted in several promising and novel treatment strategies for HCV treatment non-responders.\",\"Antiviral agents for the treatment of influenza are urgently needed to circumvent the limitations of current drugs in several critical areas: high frequencies of resistance to M2 inhibitors among currently circulating strains and variable frequencies of resistance to oseltamivir among A(H1N1) strains, limited efficacy of treatment and treatment-emergent antiviral resistance in cases of avian influenza A(H5N1) illness in humans, and lack of parenteral agents for seriously ill patients. Two neuraminidase inhibitors (NAIs), zanamivir and peramivir, have undergone or are undergoing clinical trials for use by intravenous or intramuscular administration, and one long-acting NAI, designated CS-8958, is under study for use by inhalation. Advances in understanding the mechanisms involved in influenza virus replication have revealed a number of potential targets that might be exploited in the development of new agents. Among these agents are T-705, a polymerase inhibitor, and DAS181, an attachment inhibitor. Combination therapy with currently available agents is supported by data from animal models but has received limited clinical study to date.\",\"The majority of patients with chronic hepatitis C fail to respond to antiviral therapy. The genetic basis of this resistance is unknown. The quasispecies nature of HCV may have an important implication concerning viral persistence and response to therapy. The HCV nonstructural 5A (NS5A) protein has been controversially implicated in the inherent resistance of HCV to interferon (IFN) antiviral therapy. To evaluate whether the NS5A quasispecies pre-treatment composition of HCV 1a/1b is related to responsiveness to combined pegylated interferon (PEG-IFN) and Ribavirin therapy, detailed analyses of the complete NS5A were performed. Fifteen full-length NS5A clones were sequenced from 11 pre-treatment samples of patients infected with genotype 1 HCV (3 virological sustained responders, 4 non-responders, and 4 end-of-treatment responders). Our study could not show a significant correlation between the mean number of mutations in HCV NS5A before treatment and treatment outcome, and the phylogenetic construction of complete NS5A sequences obtained from all patients failed to show any clustering associated with a specific response pattern. No single amino acid position was associated with different responses to therapy in any of the NS5A regions analyzed, and mutations were clustered downstream the ISDR, primarily in the V3 region. We observed that the CRS and NLS regions of the NS5A protein were conflicting for some variables analyzed, although no significant differences were found. If these two regions can have antagonistic functions, it seems viable that they present different mutation profiles when compared with treatment response. The patient sample that presented the lowest genetic distance values also presented the smallest number of variants, and the most heterogeneous pattern was seen in the end-of-treatment patients. These results suggest that a detailed molecular analysis of the NS5A region on a larger sample size may be necessary for understanding its role in the therapy outcome of HCV 1a/1b infection.\",\"Hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are a major threat worldwide. Combination therapy of interferon-alpha and ribavirin is currently the treatment of choice for HCV-infected patients. However, this regimen is only effective in approximately 50% of patients and provokes severe side-effects. Numerous natural alternatives for treating HCV have been suggested. Deoxynojirimycin and its derivatives are iminosugars which exert anti-HCV activity by inhibiting alpha-glucosidases. A non-immunosuppressive derivate of cyclosporine A, NIM811, exerts anti-HCV activity by binding to cyclophilin. Other natural products with promising anti-HCV activity are 2-arylbenzofuran derivatives, Mellein, and pseudoguaianolides. For HBV treatment, several drugs are available, specifically targeting the virus polymerase (lamivudine, entecavir, telbivudine, and adefovir dipivoxil). The efficacy of these drugs is hampered by the development of resistance due to point mutations in the HBV polymerase. Due to drug resistance and adverse side-effects, the search for novel drugs is mandatory. Wogonin, ellagic acid, artemisinin and artesunate, chrysophanol 8-O-beta-D-glucoside, saikosaponin C, and protostane triterpenes are active against HBV. Natural products need to be investigated in more detail to explore their potential as novel adjuncts to established HBV or HCV therapy.\",\"The importance of metabolic disorders in the pathophysiology of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections is becoming increasingly apparent. Metabolic anomalies, with their potential for multiple-organ involvement, are to be expected, given the chronic nature of these diseases, and the intracellular dysregulation associated with them. Not only have the endocrine and cytokine metabolic anomalies seen in HIV and HCV infections been linked with the metabolic syndrome, but they also appear to have some pathways in common. Studying the differences and similarities between these metabolic anomalies may add to our understanding of HIV and HCV infection, and provide guidance on how to treat these chronic diseases. This review highlights the principal underlying factors for metabolic disorders in these chronic viral diseases-namely insulin resistance and liver damage. Both the chronic viral state itself and the host immune response give rise to glucose and lipid metabolic disorders that, in turn, are risk factors for hepatic damage. The various interactions between HIV and/or HCV with insulin resistance, type 2 diabetes, steatosis and fibrogenesis should be considered when determining the treatment and long-term follow-up of patients. Recent data indicate that HCV clearance improves insulin resistance and hepatic function in HCV-infected patients treated with interferon with or without ribavirin.\",\"Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in <1% of the viral quasispecies may still allow >1000-fold viral load reductions upon treatment, consistent with their reported reduced replicative fitness in vitro. Recently, however, an R155K protease mutation was reported as the dominant quasispecies in a treatment-na\\u00efve individual, raising concerns about possible full drug resistance. To investigate the prevalence of dominant resistance mutations against specifically targeted antiviral therapy for HCV (STAT-C) in the population, we analyzed HCV genome sequences from 507 treatment-na\\u00efve patients infected with HCV genotype 1 from the United States, Germany, and Switzerland. Phylogenetic sequence analysis and viral load data were used to identify the possible spread of replication-competent, drug-resistant viral strains in the population and to infer the consequences of these mutations upon viral replication in vivo. Mutations described to confer resistance to the protease inhibitors Telaprevir, BILN2061, ITMN-191, SCH6 and Boceprevir; the NS5B polymerase inhibitor AG-021541; and to the NS4A antagonist ACH-806 were observed mostly as sporadic, unrelated cases, at frequencies between 0.3% and 2.8% in the population, including two patients with possible multidrug resistance. Collectively, however, 8.6% of the patients infected with genotype 1a and 1.4% of those infected with genotype 1b carried at least one dominant resistance mutation. Viral loads were high in the majority of these patients, suggesting that drug-resistant viral strains might achieve replication levels comparable to nonresistant viruses in vivo.\",\"Interferon-alpha induces 2'-5'-oligoadenylate synthetase which activates RNase L. Viral RNA is cleaved by RNase L at UU/UA dinucleotides. The clinical relevance of RNase L cleavage for response to an interferon-alpha-based therapy in chronic hepatitis C is unknown.\",\"Overweight/obesity is an independent negative predictive factor of steatosis in chronic hepatitis C virus infection. The nonresponse to combined peginterferon and ribavirin treatment in infection caused by genotype 1 is associated with the waist circumference, body mass index (BMI), diabetes, steatosis, and degree of fibrosis. The obesity is an independent negative predictive factor of inefficacy of antiviral treatment.\",\"The dynamics of the viral decline immediately after the start of therapy for chronic hepatitis C virus (HCV) infection may have prognostic potential for ultimate sustained virologic response. Considerable interindividual variability in the decline has been reported, including differences by race. The human major histocompatability complex (MHC) genes encode the human leukocyte antigens, which are important in the immune response to viral infections. We examined whether carriage of specific human MHC alleles are associated with the rate of the early viral decline. Longitudinal viral level data (baseline and days 1, 2, 7, 14, and 28 of treatment), medium resolution MHC genotyping, and random coefficients models were used to examine associations between MHC class I and class II allele carriage and the dynamics of the viral decline in 180 African-Americans (AAs) and 194 Caucasian Americans (CAs) with genotype-1 HCV infection over the first 28 days of treatment with peginterferon alpha2a plus ribavirin. Baseline viral levels were similar by race, irrespective of allele carriage. However, the rate of change in the viral decline was associated with both allele and race. Among the four subgroups defined by race and specific allele, the fastest rates of decline were observed (in terms of estimated mean viral declines log(10) IU/ml during the first four weeks) in CA noncarriers for A*03 (2.75; P = 0.018), in CA carriers for Cw*03 (2.99; P = 0.046), and in CA noncarriers for DQA1*04 (2.66; P = 0.018) or DQB1*0402 (2.65; P = 0.018). MHC alleles are associated with the viral decline during the first 28 days of peginterferon therapy.\",\"Chronic hepatitis C virus (HCV) infection is a pressing medical problem worldwide. Current therapy with pegylated interferon plus ribavirin (Peg-IFN/RBV) is associated with a poor risk benefit profile, a long treatment duration (48 weeks) and inadequate success rate (approximately 40-50%) of SVR (sustained viral response) in patients infected with genotype 1 HCV. This review is focused on recent clinical trial results with specifically targeted antiviral therapy for HCV (STAT-C) protease and polymerase inhibitors. In the past decade, anti-HCV drug discovery has focused first on targeting host factors required for viral replication and second on multiple HCV antiviral agents. Owing to the large number of HCV inhibitors currently in pre-clinical and clinical development today, we have focused on the most advanced compounds in the HCV polymerase and HCV protease inhibitor classes. Within each class, compounds will be used to illustrate some of the properties associated with inhibitors that bind to the active site of HCV polymerase, the active site of HCV protease (macrocyclic and linear ketoamide inhibitors) and allosteric polymerase inhibitors.\",\"The emergence of influenza strains that are resistant to commonly used antivirals has highlighted the need to develop new compounds that target viral gene products or host mechanisms that are essential for effective virus replication. Existing assays to identify potential antiviral compounds often use high throughput screening assays that target specific viral replication steps. To broaden the search for antivirals, cell-based replication assays can be performed, but these are often labor intensive and have limited throughput.\",\"Oral Silibinin (SIL) is widely used for treatment of hepatitis C, but its efficacy is unclear. Substantially higher doses can be administered intravenously (IV).\",\"Treatment predictors are important tools for the management of therapy in patients with chronic hepatitis B and C virus (HBV, HCV) infection. In chronic hepatitis B, several pretreatment parameters have been identified for prediction of virologic response to interferon alfa-based antiviral therapies or treatment with polymerase inhibitors. In interferon alfa and pegylated interferon alfa-treated patients, low baseline HBV DNA concentrations, HBV genotype A (B), and high baseline ALT levels are significantly associated with treatment response. In patients treated with nucleos(t)ide analogues, low baseline HBV DNA but not viral genotype is positively associated with virologic response. During treatment the best predictor of response is HBV DNA kinetics. Early viral suppression is associated with favourable virologic response and reduced risk for subsequent resistance mutations. For the current standard treatment with pegylated interferon alfa and ribavirin in patients with chronic hepatitis C, infection with HCV genotypes 2 and 3, baseline viral load below 400,000-800,000 IU/ml, Asian and Caucasian ethnicity, younger age, low GGT levels, absence of advanced fibrosis/cirrhosis, and absence of steatosis in the liver have been identified as independent pretreatment predictors of a sustained virologic response. After initiation of treatment, initial viral decline with undetectable HCV-RNA at week 4 of therapy (RVR) is the best predictor of sustained virologic response independent of HCV genotype.\",\"Nitazoxanide and its primary metabolite, tizoxanide, inhibit hepatitis C virus (HCV) replication in HCV replicon systems. To study the potential for resistance, we subjected Huh7 cells harboring HCV replicons to serial passage in 250 muM G418 and increasing concentrations of nitazoxanide or tizoxanide. Passage of the replicon-containing cell lines in either compound resulted in increases in the 50% effective concentrations (EC(50)s) (7- to 13-fold), EC(90)s (14- to 36-fold), and 50% cytotoxic concentrations (2- to 4-fold) of both compounds. Serial passage in either compound did not alter the susceptibility of HCV replicons to ribavirin or 2'-C-methylcytidine. Interestingly, serial passage in nitazoxanide or tizoxanide resulted in increased sensitivity to alpha interferon 2b: EC(50)s and EC(90)s were reduced three- and eightfold, respectively. Replicons isolated from these cell lines had no greater ability to confer tizoxanide resistance, or increased susceptibility to alpha interferon, than replicons isolated from the parental cell line that had not previously been exposed to nitazoxanide or tizoxanide. These findings are indicative of a cell-mediated activity differing from that of other anti-HCV drugs but complementary with interferon and are consistent with the enhanced response rates observed clinically when nitazoxanide is combined with pegylated interferon therapy. Finally, unlike data for other compounds in advanced clinical development for HCV, these data are consistent with resistance in HCV replicon-containing cell lines conferred by changes in the host and not by mutations in the virus.\",\"Patients with chronic hepatitis C are at risk of developing type 2 diabetes mellitus (DM) and impaired fasting glucose (IFG), and this risk may increase among hepatitis C virus (HCV) patients not responding to an antiviral therapy.\",\"Cross-sectional studies suggest insulin resistance is strongly associated with hepatic steatosis and fibrosis in patients with chronic hepatitis C (CHC), which might affect the efficacy of antiviral therapy. Aim To investigate retrospectively the impact of insulin resistance on treatment response in Chinese genotype 1 CHC patients receiving a 24-week course therapy with peginterferon alpha-2b/ribavirin.\",\"After a treatment by peginterferon alpha and ribavirin, the percentages of non response and relapse are approximatively 33 and 18 % respectively. These treatment failures may be due either to viral resistance or to an insufficient treatment. The prevention of treatment failure is based on a good knowledge of the predictive factors of failure before and during the treatment. Among the patients who did not respond to interferon alpha and ribavirin, a new treatment with peginterferon alpha-2b and ribavirin makes it possible to obtain 45 % of sustained virological response (SVR) among the relapsers and 17 % of SVR among the non responders. Among the patients who did not respond to peginterferon alpha and ribavirin, a new treatment with peginterferon alpha-2b and ribavirin makes it possible to obtain 36 % of SVR among the relapsers and only 4 % of SVR among the non responders. New therapeutic strategies are necessary for the non responders. Until now no new therapeutic strategy allowed a significant benefit in term of SVR. Protease inhibitors are currently tested in non responders but there are some concerns about the risk of selection of multi-resistant strains.\",\"The prevalence and clinical implications of naturally occurring variants that are resistant to hepatitis C virus (HCV) protease inhibitors in treatment-naive patients has not been reported. We report here the prevalence of such variants and their effect on clinical response.\",\"Insulin resistance is extremely common and frequently is associated with comorbid conditions such as cardiovascular disease, hypertension, obesity, infertility, and neurodegeneration. In addition, insulin resistance is the driving force for type 2 diabetes mellitus. Interestingly, co-existence of insulin resistance and chronic hepatitis C occurs more often than predicted by chance, with recent estimates indicating that 30% to 70% of patients with chronic hepatitis C display some evidence of insulin resistance. Recent research revealed several molecules, including tumor necrosis factor alpha, suppressor of cytokine signaling 1 and 3 proteins, insulin-receptor substrates 1 and 2, and other adipocytokines, potentially are involved in the development of insulin resistance in patients with chronic hepatitis C. Unfortunately, baseline insulin resistance has a negative impact on treatment outcomes in patients with chronic hepatitis C. However, successfully managing insulin resistance or diabetes mellitus in these patients may improve patients' likelihoods of successful outcomes with antiviral therapy. Likewise, eradication of hepatitis C virus in patients with insulin resistance or diabetes mellitus appears to improve glucose metabolism. Although adjunctive therapies such as insulin sensitizers and weight loss often are recommended, their ability to improve antiviral treatment response in patients with chronic hepatitis C is unproven. Studies are under way to determine whether improving insulin sensitivity results in better outcomes in patients receiving pegylated interferon alfa plus ribavirin therapy for chronic hepatitis C.\",\"R1626, a prodrug of the hepatitis C virus (HCV) RNA polymerase inhibitor R1479, showed time-dependent and dose-dependent reduction of HCV RNA levels in a previous study. The present study evaluated the efficacy and safety of R1626 administered for 4 weeks in combination with peginterferon alfa-2a +/- ribavirin in HCV genotype 1-infected treatment-naive patients. Patients were randomized to: DUAL 1500 (1500 mg R1626 twice daily [bid] + peginterferon alfa-2a; n = 21); DUAL 3000 (3000 mg R1626 bid + peginterferon alfa-2a; n = 32); TRIPLE 1500 (1500 mg R1626 bid + peginterferon alfa-2a + ribavirin; n = 31); or standard of care (SOC) (peginterferon alfa-2a + ribavirin; n = 20). At 4 weeks HCV RNA was undetectable (<15 IU/mL) in 29%, 69%, and 74% of patients in the DUAL 1500, DUAL 3000, and TRIPLE 1500 arms, respectively, compared with 5% of patients receiving SOC, with respective mean reductions in HCV RNA from baseline to week 4 of 3.6, 4.5, 5.2, and 2.4 log(10) IU/mL. Synergy was observed between R1626 and peginterferon alfa-2a and between R1626 and ribavirin. There was no evidence of development of viral resistance. Adverse events (AEs) were mainly mild or moderate; seven patients had nine serious AEs (including one patient with one serious AE in SOC). The incidence of Grade 4 neutropenia was 48%, 78%, 39%, and 10% in DUAL 1500, DUAL 3000, TRIPLE 1500, and SOC, respectively, and was the main reason for dose reductions.\",\"HCV-796 selectively inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. In hepatoma cells containing a genotype 1b HCV replicon, HCV-796 reduced HCV RNA levels by 3 to 4 log(10) HCV copies/mug total RNA (the concentration of the compound that inhibited 50% of the HCV RNA level was 9 nM). Cells bearing replicon variants with reduced susceptibility to HCV-796 were generated in the presence of HCV-796, followed by G418 selection. Sequence analysis of the NS5B gene derived from the replicon variants revealed several amino acid changes within 5 A of the drug-binding pocket. Specifically, mutations were observed at Leu314, Cys316, Ile363, Ser365, and Met414 of NS5B, which directly interact with HCV-796. The impacts of the amino acid substitutions on viral fitness and drug susceptibility were examined in recombinant replicons and NS5B enzymes with the single-amino-acid mutations. The replicon variants were 10- to 1,000-fold less efficient in forming colonies in cells than the wild-type replicon; the S365L variant failed to establish a stable cell line. Other variants (L314F, I363V, and M414V) had four- to ninefold-lower steady-state HCV RNA levels. Reduced binding affinity with HCV-796 was demonstrated in an enzyme harboring the C316Y mutation. The effects of these resistance mutations were structurally rationalized using X-ray crystallography data. While different levels of resistance to HCV-796 were observed in the replicon and enzyme variants, these variants retained their susceptibilities to pegylated interferon, ribavirin, and other HCV-specific inhibitors. The combined virological, biochemical, biophysical, and structural approaches revealed the mechanism of resistance in the variants selected by the potent polymerase inhibitor HCV-796.\",\"Insulin resistance reduces the response to interferon alfa-based therapy of chronic hepatitis C patients. It has been speculated that improvement of insulin sensitivity might increase the chances of responding to treatment of such individuals.\",\"The nucleoside analog R1479 is a potent and highly selective inhibitor of nonstructural protein 5B-directed hepatitis C virus (HCV) replication in vitro. R1626, a tri-isobutyl ester prodrug of R1479, was developed to increase bioavailability and improve antiviral activity. A multicenter, observer-blinded, randomized, placebo-controlled, multiple ascending dose, phase 1b study was designed to evaluate the safety, pharmacokinetics, and antiviral activity and to potentially identify the maximum tolerated dose of R1626 in patients with chronic hepatitis C. Forty-seven treatment-na\\u00efve patients infected with HCV genotype 1 were treated with R1626 orally at doses of 500 mg, 1500 mg, 3000 mg, or 4500 mg or placebo twice daily for 14 days with 14 days of follow-up. Safety, tolerability, pharmacokinetics, and antiviral activity were assessed. Doses up to and including 3000 mg twice daily were well tolerated after 14 days of treatment. There was an increase in frequency of adverse events at the highest dose (4500 mg). Reversible mild to moderate hematological changes were observed with increasing doses. R1626 was efficiently converted to R1479, with dose-proportional pharmacokinetics observed over the entire dose range. The pharmacokinetics of R1479 were linear over the dose range evaluated. Dose-dependent and time-dependent reductions in HCV RNA were observed. Mean decreases (median; range) in viral load after 14 days of treatment with doses of 500, 1500, 3000, and 4500 mg were 0.32 (0.22; 0.01-0.71), 1.2 (0.8; 0.49-2.46), 2.6 (2.7; 1.27-3.93) and 3.7 (4.1; 2.15-4.39) log(10), respectively. No resistance to R1479 was observed after 14 days of treatment with R1626.\",\"A substantial proportion of hepatitis C virus (HCV)-1b-infected patients still do not respond to interferon-based therapy. This study aims to explore a predictive marker for the ultimate virological response of HCV-1b-infected patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy. Nonstructural protein 5A (NS5A) sequences of HCV in the pretreated sera of 45 patients infected with HCV-1b were analyzed. The mean number of mutations in the variable region 3 (V3) plus its upstream flanking region of NS5A (amino acid 2334-2379), referred to as IFN/RBV resistance-determining region (IRRDR), was significantly higher for HCV isolates obtained from patients who later achieved sustained virological response (SVR) by PEG-IFN/RBV than for those in patients undergoing non-SVR. The receiver operating characteristic curve analysis estimated six mutations in IRRDR as the optimal threshold for SVR prediction. Indeed, 16 (76%) of 21 SVR, but only 2 (8%) of 24 non-SVR, had HCV with six or more mutations in IRRDR (IRRDR > or = 6) (P < 0.0001). All of 18 patients infected with HCV of IRRDR of 6 or greater examined showed a significant (> or =1 log) reduction or disappearance of serum HCV core antigen titers within 24 hours after initial dose of PEG-IFN/RBV, whereas 10 (37%) of 27 patients with HCV of IRRDR of 5 or less did (P < 0.0001). The positive predictive value of IRRDR of 6 or greater for SVR was 89% (16/18; P = 0.0007), with its negative predictive value for non-SVR being 81% (22/27; P = 0.0008).\",\"Hepatitis C infection (HCV) remains a global problem and the current anti-HCV therapies available in the clinic have sustained virologic response rates (SVR) of only about 50%, especially in HCV genotype 1-infected subjects. The SVR is even lower in HIV-HCV co-infected patients, estimated at only about 30-40%. However, exciting new research is under way to find new anti-HCV therapies. Presently, efforts to develop new anti-HCV agents for HCV-infected persons who fail pegylated interferon and ribavirin-based therapies have focused on inhibitors of key HCV enzymes such as the HCV NS3 protease and the NS5B polymerase. There are two protease inhibitors, telaprevir (VX-950, Vertex) and boceprevir (SCH 503034, Schering-Plough); and three polymerase inhibitors, valopicitabine (NM283, Idenix), R1626 (Roche), and HCV-796 (Viropharma) that have advanced to late-stage clinical trials. Of these aforementioned agents, telaprevir is the most advanced in clinical development. Early trial results on efficacy, safety, and HCV drug-resistance profiles of these novel agents will be discussed in this review paper.\",\"Clinical significance of molecules involving innate immunity in treatment response remains unclear. The aim is to elucidate the mechanisms underlying resistance to antiviral therapy and predictive usefulness of gene quantification in chronic hepatitis C (CH-C).\",\"A phase 2, randomized, multicenter, open-label study evaluated the safety and efficacy of albinterferon alfa-2b in interferon-alpha treatment-na\\u00efve patients with genotype 2/3, chronic hepatitis C virus infection.\",\"Hepatitis C virus (HCV) infects approximately 3% of the world population. The chronicity of hepatitis C seems to depend on the level of genetic variability. We have recently (Torres-Puente et al., J Viral Hepat, 2008; 15: 188) reported genetic variability estimates from a large-scale sequence analysis of 67 patients infected with HCV subtypes 1a (23 patients) and 1b (44 patients) and related them to response, or lack of, to alpha-interferon plus ribavirin treatment.. Two HCV genome regions were analysed in samples prior to antiviral therapy, one compressing the three hypervariable regions of the E2 glycoprotein and another one including the interferon sensitive determining region and the V3 domain of the NS5A protein. Haplotype and nucleotide diversity measures showed a clear tendency to higher genetic variability levels in nonresponder than in responder patients. Here, we have refined the analysis of genetic variability (haplotype and nucleotide diversity, number of haplotypes and mutations) by considering their distribution in each of the biologically meaningful subregions mentioned above, as well as in their surrounding and intervening regions. Variability levels are very heterogeneous among the different subregions, being higher for nonresponder patients. Interestingly, significant differences were detected in the biologically relevant regions, but also in the surrounding regions, suggesting that the level of variability of the whole HCV genome, rather than exclusively that from the hypervariable regions, is the main indicator of the treatment response. Finally, the number of haplotypes and mutations seem to be better discriminators than haplotype and nucleotide diversity, especially in the NS5A region.\",\"To investigate the association between insulin resistance and rapid virologic response.\",\"This is a concise review of recent developments in the field of viral hepatitis, based on publications between December 2006 and November 2007.\",\"Ribavirin has a minor and transient effect on hepatitis C virus (HCV) replication and has been suggested to select a novel mutation, F415Y, in the RNA-dependent RNA polymerase of subtype 1a viruses. Twenty-nine patients with chronic hepatitis C (subtyped by INNO LiPA as 1a, 17; 1b, 11; 1a/1b, 1) who were nonresponders to interferon-based therapies were identified retrospectively and screened at Baseline, week 24 of treatment, and 24 weeks post-treatment. Selection of resistance mutations, including at amino acid position 415 of the polymerase, was investigated. Using clonal sequencing and pyrosequencing of the NS5B gene, we screened for the F415Y resistance mutation among patients who received combination therapy with ribavirin and interferon \\u03b1. Of the 15 subtype 1a patients treated with interferon plus ribavirin, only one had the F415Y change at week 24, and an F/Y mixture was still present 24 weeks after therapy. Four additional patients in this group had the F415Y change 24 weeks post-therapy. The NS5B genes were sequenced in order to identify amino acid changes associated with ribavirin therapy, but no evidence was found that ribavirin selects for particular amino acids in the RNA-dependent RNA polymerase. Ribavirin, a weak inhibitor of HCV replication, does not select for resistance mutations in the sequence of the HCV RNA polymerase.\",\"Chronic hepatitis C virus (HCV) infection remains a global health threat with approximately 200 million carriers worldwide. Current treatment consists of the use of peginterferon (pegIFN)/ribavirin (RBV) for 24 or 48 weeks depending on HCV genotype. Serious side effects and the fact that less than half of patients infected with HCV genotypes 1 and 4 (which are the most common) accomplish sustained virological response with this medication warrant the need for novel anti-HCV therapies.\",\"We previously reported the relationship between viral polymerase polymorphisms and the initial decline in viral load induced by interferon-alpha and ribavirin therapy in genotype 1b-related chronic hepatitis C patients. The presence of E124K and I85V of NS5B was closely associated with viral clearance at 8 weeks of treatment. The aim of this study was to investigate the mechanisms by which this polymorphism of NS5B protein affects early viral clearance. We used a replicon system derived from strain O, genotype 1b virus. Three mutants (V85I), (K124E), and (V85I/K124E) were introduced to the replicon. OR6c, a derivative of HuH7 cells, was transfected with the replicon including a luciferase reporter gene. Luciferase activities were measured 72 hr post-transfection. All three mutants showed higher luciferase activity than that of the wild type, and the V85I mutant showed the highest activity. This result was also confirmed by neomycin gene-containing replicons with same mutations. All replicons were down-regulated by ribavirin, but the level of reduction in the V85I mutant was the lowest. Our results suggested that this mutation at least partly contributes to resistance to early viral clearance during interferon and ribavirin combination therapy.\",\"The efficacy of treatment against hepatitis C virus has improved, but it is still far from ideal. Thus, new antihepatitis C virus therapies are required.\",\"While newer neuraminidase inhibitors have been used recently to treat influenza A and B virus infections, emergence of drug resistance poses potential problems. Previous ribavirin aerosol treatments of influenza were effective and drug resistance was not observed. To make ribavirin aerosol treatment a quicker process and limited to once or twice daily treatments, a MegaRibavirin formulation (100 mg of ribavirin/mL) was developed that when used with the Aerotech II nebulizer was effective in preventing death in a lethal influenza A virus mouse model. Aerosol generated using the Aerotech II nebulizer flowing at 10 L of air/min produced aerosol droplets that contained 2.3 mg of ribavirin/L with a mass median aerodynamic diameter of 1.8 microm. Using this system for treatment, a single daily 30-min exposure on days 1-4 produced a survival rate of greater than 90%. Delaying the start of aerosol treatment for 48 or 72 h and treating once daily for 30 min for two days (days 2-3 and 3-4, respectively) still significantly increased the number of survivors and mean time to death. For the treatment of influenza in general and for pandemic avian influenza, the MegaRibavirin-Aerotech II method of aerosol treatment allows for short treatment periods, minimizes environmental issues and costs less.\",\"Interferon-alpha and ribavirin combined therapy has been a mainstream treatment for hepatitis C infection. The efficacy of this combined treatment is around 30% to 60%, and the factors affecting the responsiveness are still poorly defined. Our study is intended to investigate the genetic differences between responder and non-responder patients. The genome-wide linkage disequilibrium screening for loci associated with genetic difference between two patient groups was conducted by using 382 autosomal short tandem repeat (STR) markers involving 92 patients. We have identified 19 STR markers displaying different allele frequencies between the two patient groups. In addition, based on their genomic location and biological function, we selected the CD81 and IL15 genes to perform single nucleotide polymorphism genotyping. In conclusion, this study may provide a new approach for identifying the associated polymorphisms and the susceptible loci for interferon-alpha and ribavirin combined therapy in patients with chronic hepatitis C.\",\"Peginterferon with ribavirin therapy for chronic hepatitis C leads to sustained loss of serum hepatitis C virus (HCV) RNA in half of treated patients. Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression.\",\"A novel small-molecule inhibitor, referred to here as R706, was discovered in a high-throughput screen of chemical libraries against Huh-7-derived replicon cells carrying autonomously replicating subgenomic RNA of hepatitis C virus (HCV). R706 was highly potent in blocking HCV RNA replication as measured by real-time reverse transcription-PCR and Western blotting of R706-treated replicon cells. Structure-activity iterations of the R706 series yielded a lead compound, R803, that was more potent and highly specific for HCV replication, with no significant inhibitory activity against a panel of HCV-related positive-stranded RNA viruses. Furthermore, HCV genotype 1 replicons displayed markedly higher sensitivity to R803 treatment than a genotype 2a-derived replicon. In addition, R803 was tested by a panel of biochemical and cell-based assays for on-target and off-target activities, and the data suggested that the compound had a therapeutic window close to 100-fold, while its exact mechanism of action remained elusive. We found that R803 was more effective than alpha interferon (IFN-alpha) at blocking HCV RNA replication in the replicon model. In combination studies, R803 showed a weak synergistic effect with IFN-alpha/ribavirin but only additive effects with a protease inhibitor and an allosteric inhibitor of RNA-dependent RNA polymerase (20). We conclude that R803 and related heterocyclic compounds constitute a new class of HCV-specific inhibitors that could potentially be developed as a treatment for HCV infection.\",\"Viral breakthroughs (VB), defined as having detectable HCV VL while on anti-HCV therapy after achieving maximal suppression, have not yet been characterized with the use of PEG-IFN in HIV/HCV-coinfected patients. We evaluated possible mechanisms for VB among HIV/HCV-coinfected patients receiving PEG-IFN/RBV. Thirty HIV/HCV coinfected patients were treated with PEG-IFN (1.5 mug/kg sc qwk) and RBV (1-1.2 g daily) for 48 weeks. Liver chemistry, HCV VL, genotyping, DNA microarray, and sequencing of HCV E-2 envelope were performed before and during treatment. VB had lower baseline HCV VL but higher ALT and AST than relapsers (ETR) (p < 0.05) and lower CD4+ T lymphocytes (%) than patients with sustained virological responses (SVR), but similar first and second phase HCV viral kinetics (vs. ETR and SVR; p > 0.05). HCV genotypes and envelope sequences were similar for patients with VB pretreatment and at break-through. VB had higher levels of interferon-induced gene (IFIG) expression pretreatment than patients with ETR (p < 0.01). HIV/HCV-coinfected patients have a high rate of VB on PEG-IFN/RBV therapy characterized by higher levels of IFIG expression, immunodeficiency, and hepatic inflammation. Novel strategies are required for the treatment of persons with VB.\",\"RNA viruses exhibit extraordinarily high mutation rates during genome replication. Nonnatural ribonucleosides that can increase the mutation rate of RNA viruses by acting as ambiguous substrates during replication have been explored as antiviral agents acting through lethal mutagenesis. We have synthesized novel N-6-substituted purine analogues with ambiguous incorporation characteristics due to tautomerization of the nucleobase. The most potent of these analogues reduced the titer of poliovirus (PV) and coxsackievirus (CVB3) over 1,000-fold during a single passage in HeLa cell culture, with an increase in transition mutation frequency up to 65-fold. Kinetic analysis of incorporation by the PV polymerase indicated that these analogues were templated ambiguously with increased efficiency compared to the known mutagenic nucleoside ribavirin. Notably, these nucleosides were not efficient substrates for cellular ribonucleotide reductase in vitro, suggesting that conversion to the deoxyriboucleoside may be hindered, potentially limiting genetic damage to the host cell. Furthermore, a high-fidelity PV variant (G64S) displayed resistance to the antiviral effect and mutagenic potential of these analogues. These purine nucleoside analogues represent promising lead compounds in the development of clinically useful antiviral therapies based on the strategy of lethal mutagenesis.\",\"No new therapy has been approved for the treatment of chronic hepatitis C in the last 5 years in the USA since the approval of pegylated interferon (IFN)-alpha(2a) and ribavirin. Multiple new drugs are currently in development and are expected to be approved for use in the USA and/or the EU by 2011-2013. Although the mechanism of action of pegylated IFN and ribavirin are not completely known, it is likely that they will continue to be used in combination regimens for a number of years. Direct antivirals are likely to be the first new drugs to be used in combination with pegylated IFN and ribavirin. Viral resistance will prove to be a significant barrier and require that consolidation therapy with at least 24 weeks of pegylated IFN and ribavirin be used to successfully prevent the selection or emergence of resistant variants. Numerous other compounds, such as ribavirin analogs, long-acting IFNs, hepatoprotectants and immunomodulators, are in development and may replace the drugs that are used currently. The combination of direct antivirals, such as protease and polymerase inhibitors, may rapidly follow in development, as has occurred in HIV drug therapy.\",\"Liver transplantation is indicated in end-stage chronic viral liver disease, but unless adequate prophylaxis is administered, the patient will in most cases develop recurrent hepatitis B (HBV) and C (HCV) virus infection. Today, patients receiving prophylaxis using nucleoside analogue drugs with or without specific immune globulin drugs in connection with orthotopic liver transplantation for HBV related cirrhosis, present low risk of relapse and high 5-10 year survival rates. Lamivudine was the first drug used in the prophylactic treatment, but this drug has increasingly been combined with or replaced by adefovir due to the low genetic barrier, which causes viral resistance. Most patients develop viral recurrence after orthotopic liver transplantation for HCV related cirrhosis, and in an elevated number of cases, cirrhosis and hepatic insufficiency set in after a few years. Prophylaxis before transplantation and pre-emptive treatment using interferon and ribavirin present numerous side effects resulting in reduction of doses and suspension of therapy, with consequently low sustained virological remission rates and risk of rejection.The treatment is better tolerated by patients with histologically confirmed chronic disease, but also in these patients virological remission rates are low. This pathology requires new therapeutic protocols and/or new drugs in order to obtain better compliance and better responses.\",\"The quasispecies nature of hepatitis C virus (HCV) may have important implications concerning resistance to antiviral agents. To determine whether HCV NS5A quasispecies composition and dynamics are related to responsiveness to combined interferon (IFN) and ribavirin therapy, extensive sequence analyses of cloned RT-PCR amplification products of HCV-1b NS5A quasispecies of sequential isolates from 15 treated (nine sustained responders and six non-responders) and three untreated patients were performed. Accumulation of mutations in NS5A during therapy was relatively frequent in the V3 domain, but unusual elsewhere. Amino acid changes were the result of the imposition of minor variants that were already present before treatment and always occurred within the first week of therapy. Before treatment, the complexity and diversity of quasispecies were lower in isolates from responders than in those from non-responders, particularly in the V3 domain, where differences in nucleotide entropy (0.35 vs 0.64, P=0.003), genetic distance (0.0145 vs 0.0302, P=0.05) and non-synonymous substitutions (0.0102 vs 0.0203, P=0.036) were statistically significant. These differences became more apparent during treatment, because complexity and diversity remained stable or tended to increase in non-responders, whereas they tended to decrease in responders. These observations suggest that the composition and dynamics of HCV NS5A quasispecies, particularly in the V3 domain, may play a role in the response to combined IFN/ribavirin therapy.\",\"Hepatitis C virus (HCV) persists in the majority of infected individuals and is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Chronic hepatitis C is currently treated with interferon (IFN)-alpha or with a combination of IFN-alpha and ribavirin. The availability of an HCV replicon system (Lohmann et al., SCIENCE: 285, 110-113, 1999) allowed the investigation of the effects of IFN on genuine HCV replication in cultured cells. It is shown here that IFN-alpha inhibits subgenomic HCV RNA replication in HuH-7 human hepatoma cells. Immunofluorescence, Western blot and Northern blot analysis revealed that levels of both HCV protein and replicon RNA were reduced after treatment with IFN-alpha in a dose-dependent manner. In further experiments, it was investigated whether MxA plays a role in the inhibition of HCV. The human MxA protein is an IFN-induced GTPase that has antiviral activity against various RNA viruses. However, HCV RNA replication was not affected in transfected HuH-7 cells that transiently overexpressed MxA. Moreover, a dominant-negative mutant of MxA did not interfere with the antiviral activity of IFN-alpha against HCV RNA replication. Taken together, these results demonstrate that IFN-alpha inhibits HCV replicons via an MxA-independent pathway.\"],\"doi\":[\"10.2147/IDR.S353605\",\"16230\",\"527\",\"10.1038/s41467-022-29104-y\",\"S0166-3542(22)00042-0\",\"10.2174/1871526522666220303142837\",\"dkac048\",\"10.1128/mbio.03705-21\",\"172\",\"10.1002/ccr3.5355\",\"S0753-3322(22)00088-9\",\"10.1111/liv.15175\",\"S0924-8579(22)00030-9\",\"10.1021/acs.accounts.1c00697\",\"10.1126/sciadv.abj5908\",\"S0166-3542(22)00015-8\",\"10.7883/yoken.JJID.2021.751\",\"10.1111/liv.15150\",\"10.1007/s11427-021-2031-7\",\"2535\",\"S1471-4892(21)00166-1\",\"2021.11.08.21266069\",\"10.1038/s41598-021-02972-y\",\"10.1080/19390211.2021.2006387\",\"10.1186/s12951-021-01148-0\",\"10.1080/19390211.2021.2006388\",\"S0001-37652021000800707\",\"S0166-3542(21)00199-6\",\"10.1002/ps.6728\",\"10.35772/ghm.2021.01083\",\"89815\",\"S1874-6047(21)00003-2\",\"10.1007/s00210-021-02169-0\",\"10.52547/rbmb.10.2.233\",\"S1473-3099(21)00485-0\",\"10.3389/fimmu.2021.721328\",\"10.1038/s41598-021-97160-3\",\"1181\",\"10.1021/acs.jafc.1c04098\",\"10.1002/jmv.27285\",\"10.1002/1873-3468.14182\",\"10.12688/wellcomeopenres.16594.2\",\"10.1128/JVI.00643-21\",\"10.1208/s12249-021-02089-5\",\"10.2174/1573406417666210806154129\",\"10.2147/IJN.S315705\",\"1189\",\"S1341-321X(21)00171-9\",\"10.47162/RJME.61.4.20\",\"10.1039/d1ay00606a\",\"10.1111/liv.14991\",\"10.1038/s41467-021-23974-4\",\"1094\",\"10.1371/journal.ppat.1008937\",\"S1198-743X(21)00259-7\",\"S0168-8278(21)00339-1\",\"10.1080/07391102.2021.1921032\",\"10.1111/ijcp.14304\",\"616\",\"10.1186/s12879-021-06080-0\",\"10.3389/fmolb.2021.645216\",\"S0166-3542(21)00068-1\",\"10.2147/IDR.S301032\",\"10.1371/journal.pone.0249770\",\"10.1021/acsptsci.1c00022\",\"e00493-21\",\"413\",\"10.1002/jmv.26971\",\"e02718-20\",\"2021.03.13.435256\",\"10.5582/bst.2021.01092\",\"S1567-5769(21)00158-2\",\"S0168-8278(21)00169-0\",\"10.1002/jmv.26935\",\"10.1186/s13063-021-05139-2\",\"10.1093/cid/ciaa1510\",\"10.1021/acs.jcim.0c01277\",\"S0048-9697(21)00807-X\",\"10.34172/aim.2021.22\",\"10.3389/fmicb.2020.621463\",\"10.47665/tb.37.4.1083\",\"10.5334/gh.906\",\"S0166-3542(21)00023-1\",\"10.1038/s41397-021-00209-9\",\"10.5005/jp-journals-10018-1326\",\"2021.01.24.427991\",\"10.1111/liv.14797\",\"10.1016/j.isci.2020.101992\",\"S0166-3542(21)00006-1\",\"10.1080/14787210.2021.1866545\",\"E1968\",\"10.1038/s41467-020-19761-2\",\"10.2147/IDR.S267809\",\"S0168-8278(20)33770-3\",\"10.1080/17476348.2021.1854092\",\"10.1186/s13063-020-04891-1\",\"10.1097/MEG.0000000000002003\",\"S1368-7646(20)30063-7\",\"10.2174/156802662023201001094634\",\"S1368-7646(20)30050-9\",\"eabc7112\",\"10.1124/dmd.120.000138\",\"10.1186/s13063-020-04619-1\",\"E1139\",\"10.1007/s12250-020-00302-6\",\"10.1073/pnas.2012294117\",\"S0004-28032020000300267\",\"10.1038/s41598-020-73641-9\",\"E376\",\"S0021-9258(17)50437-8\",\"10.1021/acs.jafc.0c04868\",\"10.3851/IMP3369\",\"e01417-20\",\"10.1615/CritRevEukaryotGeneExpr.2020033704\",\"S0300-9084(20)30203-0\",\"10.1136/bmj.m3379\",\"E725\",\"10.1007/s00705-020-04797-y\",\"S0375-0906(20)30088-4\",\"10.1016/j.jhepr.2020.100138\",\"10.1093/jac/dkaa332\",\"10.1097/MEG.0000000000001903\",\"10.2147/DDDT.S254754\",\"S0166-3542(20)30297-7\",\"10.1371/journal.pone.0237162\",\"10.1186/s12879-020-05212-2\",\"10.1007/s12328-020-01182-9\",\"10.1021/acs.jafc.0c03994\",\"10.1111/hepr.13546\",\"S0166-3542(20)30263-1\",\"e00835-20\",\"10.1021/acs.jpcb.0c04198\",\"10.5152/tjg.2020.19273\",\"E1770\",\"10.1038/s41586-020-2423-5\",\"10.1002/jgh3.12294\",\"10.26434/chemrxiv.12084822.v2\",\"10.1111/tmi.13450\",\"10.1080/03007995.2020.1775075\",\"10.1080/14787210.2020.1771180\",\"10.1055/a-1131-8058\",\"10.2174/1381612826666200509233215\",\"10.1111/liv.14502\",\"10.1097/MEG.0000000000001759\",\"S0166-3542(20)30207-2\",\"eabb5883\",\"10.1080/13543776.2020.1751817\",\"10.1186/s12879-020-4921-3\",\"S0006-291X(20)30513-1\",\"S0042-6822(20)30035-0\",\"a038687\",\"S1931-5244(20)30018-9\",\"10.1007/s10096-020-03840-9\",\"10.3855/jidc.11190\",\"10.1093/infdis/jiaa028\",\"a036855\",\"E341\",\"S1931-5244(19)30256-7\",\"S0166-3542(19)30576-5\",\"10.1093/cid/ciz1167\",\"10.3934/publichealth.2019.4.502\",\"10.1111/jvh.13254\",\"10.1055/s-0039-3402001\",\"S0166-3542(19)30206-2\",\"S0042-6822(19)30279-X\",\"10.1021/acs.jafc.9b05357\",\"eaax5866\",\"10.26402/jpp.2019.4.09\",\"10.1186/s12879-019-4514-1\",\"10.14218/JCTH.2019.00033\",\"S0924-8579(19)30251-1\",\"10.3892/etm.2019.7995\",\"10.1002/jmv.25602\",\"e01348-19\",\"10.2147/IDR.S214735\",\"S2210-7401(19)30181-0\",\"10.1016/j.jceh.2018.07.004\",\"S0166-3542(19)30022-1\",\"10.1371/journal.pone.0221231\",\"S0168-8278(19)30461-1\",\"10.1080/00365521.2019.1652846\",\"S0016-5085(19)41199-2\",\"10.1134/S002689841904013X\",\"10.1007/s12328-019-01029-y\",\"10.1017/S0950268819000827\",\"10.1111/liv.14201\",\"e00263-19\",\"S0168-8278(19)30394-0\",\"10.21873/anticanres.13535\",\"10.1111/hepr.13401\",\"S0166-3542(19)30195-0\",\"S0166-3542(19)30099-3\",\"E560\",\"10.3889/oamjms.2019.459\",\"10.1186/s12876-019-1003-3\",\"10.1111/liv.14168\",\"10.1371/journal.pone.0217751\",\"10.3748/wjg.v25.i18.2229\",\"10.12998/wjcc.v7.i9.1043\",\"S0016-5085(19)40865-2\",\"10.3350/cmh.2019.0022\",\"10.1055/s-0039-1687823\",\"S1665-2681(19)30045-6\",\"S0006-291X(19)30681-3\",\"e00576-19\",\"10.1038/s41598-019-42114-z\",\"S0006-291X(19)30509-1\",\"E252\",\"10.1097/INF.0000000000002137\",\"10.1111/ctr.13514\",\"10.1021/acschembio.8b01118\",\"S0006-2952(19)30030-9\",\"S0223-5234(19)30035-2\",\"10.1007/s00535-018-01541-x\",\"10.2174/1566524019666190104110439\",\"10.5604/01.3001.0012.7196\",\"10.20524/aog.2018.0322\",\"10.4254/wjh.v10.i11.856\",\"S0929-6646(18)30756-3\",\"10.1111/hepr.13292\",\"10.1038/s41388-018-0567-7\",\"10.2147/IDR.S169512\",\"10.1186/s12879-018-3465-2\",\"S1879-6257(18)30020-8\",\"10.1111/jvh.13037\",\"E80\",\"E610\",\"S1879-6257(18)30019-1\",\"10.1615/CritRevEukaryotGeneExpr.2018025121\",\"10.3851/IMP3266\",\"10.3389/fimmu.2018.01946\",\"10.1093/cid/ciy760\",\"10.1111/hepr.13246\",\"10.2147/IDR.S156581\",\"10.2174/1871526518666180816101124\",\"10.1093/cid/ciy547\",\"S0042-6822(18)30232-0\",\"S0167-5273(17)37528-9\",\"10.1002/hep.30123\",\"10.1002/jcph.1262\",\"e01249-18\",\"S0004-28032018000200179\",\"10.3851/IMP3253\",\"10.1007/s12072-018-9878-6\",\"10.2174/0929867325666180719121142\",\"10.1097/MEG.0000000000001215\",\"10.1093/infdis/jiy401\",\"S0006-291X(18)31469-4\",\"S0016-5085(18)34684-5\",\"10.1099/jgv.0.001095\",\"10.4103/jgid.jgid_48_17\",\"E325\",\"10.1111/cbdd.13341\",\"10.1007/s40506-017-0124-x\",\"10.3760/cma.j.issn.1007-3418.2018.03.012\",\"10.2174/1573406414666180524074648\",\"10.1080/00365521.2018.1473486\",\"10.1186/s13256-018-1691-2\",\"10.2147/HMER.S130103\",\"10.1021/acs.jafc.8b01297\",\"S0378-1119(18)30458-X\",\"10.1002/hep.29921\",\"10.1007/s00108-018-0429-y\",\"10.1111/apt.14647\",\"10.1097/MEG.0000000000001134\",\"10.1021/acs.jmedchem.8b00082\",\"10.3748/wjg.v24.i12.1361\",\"10.1080/14656566.2018.1454428\",\"10.1002/jmv.25073\",\"10.1038/s41598-018-22620-2\",\"10.1080/03009734.2018.1441928\",\"10.1111/apt.14592\",\"S0166-3542(18)30017-2\",\"e00221-18\",\"10.1093/jac/dky053\",\"10.1111/hepr.13074\",\"10.3851/IMP3228\",\"S1590-8658(18)30179-8\",\"10.1080/17512433.2018.1447923\",\"10.1080/23744235.2018.1445281\",\"10.1080/15284336.2018.1439714\",\"10.1002/hep.29852\",\"10.1097/TXD.0000000000000758\",\"10.1111/liv.13727\",\"10.1038/s41598-018-21303-2\",\"10.3851/IMP3226\",\"10.1186/s40249-018-0386-7\",\"10.1111/liv.13638\",\"10.1002/jmv.25048\",\"10.1021/acsinfecdis.7b00236\",\"10.1002/hep4.1060\",\"10.3892/br.2017.1012\",\"10.4254/wjh.v10.i1.88\",\"10.1097/MD.0000000000009271\",\"10.1186/s12985-018-0936-4\",\"10.1007/s00280-018-3520-0\",\"10.1111/jgh.14096\",\"10.1111/apt.14507\",\"10.5604/01.3001.0010.7532\",\"10.5604/01.3001.0010.7536\",\"10.3748/wjg.v23.i46.8120\",\"10.1615/CritRevEukaryotGeneExpr.2017020437\",\"S0016-5085(17)36303-5\",\"10.1017/S0950268817002928\",\"10.1007/s11427-017-9221-4\",\"S0166-3542(17)30651-4\",\"10.1007/s40506-017-0136-6\",\"10.1093/ve/vex035\",\"10.1002/hep.29693\",\"10.1080/17474124.2018.1411802\",\"10.3205/id000034\",\"10.1038/s41598-017-16336-y\",\"e01965-17\",\"10.12669/pjms.335.12973\",\"10.1097/MEG.0000000000001027\",\"e01503-17\",\"10.1002/jbt.22007\",\"10.1007/s12094-017-1786-z\",\"10.1093/cid/cix916\",\"10.1371/journal.pone.0186255\",\"S1499-3872(17)60044-4\",\"S1098-3015(17)30249-8\",\"10.1093/jac/dkx302\",\"S1476-9271(17)30364-X\",\"10.2146/ajhp160558\",\"10.2147/IDR.S145362\",\"10.1002/jmv.24947\",\"10.1186/s40794-016-0038-5\",\"10.3748/wjg.v23.i31.5645\",\"10.1111/ctr.13109\",\"10.1097/MEG.0000000000000965\",\"10.5009/gnl17209\",\"10.1111/hepr.12977\",\"10.4103/ijmr.IJMR_1410_14\",\"10.1093/gbe/evx138\",\"10.1002/jmv.24923\",\"10.1111/jvh.12782\",\"10.1111/jvh.12783\",\"10.1007/s00535-017-1380-8\",\"e00323-17\",\"S1198-743X(17)30429-9\",\"e01095-17\",\"10.1097/MEG.0000000000000929\",\"10.3748/wjg.v23.i25.4538\",\"10.1080/21505594.2017.1358349\",\"S1684-1182(17)30100-7\",\"10.1002/jmv.24897\",\"10.1002/hep.29358\",\"10.2146/ajhp60632\",\"10.1007/s00705-017-3444-8\",\"S0168-8278(17)32069-X\",\"10.3851/IMP3177\",\"10.1515/prilozi-2017-0003\",\"10.1186/s12985-017-0760-2\",\"10.1080/1040841X.2017.1329277\",\"10.1093/cid/cix289\",\"e00081-17\",\"10.1002/hep.29256\",\"10.1111/hepr.12914\",\"10.1007/s40265-017-0753-x\",\"10.14740/gr810w\",\"10.1177/1060028017704857\",\"S0223-5234(17)30344-6\",\"10.1111/jvh.12719\",\"10.1080/17474124.2017.1326817\",\"E962\",\"E906\",\"S1879-6257(16)30133-X\",\"S0025-7753(17)30228-2\",\"S2468-1253(17)30071-7\",\"S1198-743X(17)30210-0\",\"S0168-8278(17)30211-8\",\"10.1007/s11262-017-1447-x\",\"S1043-4666(17)30073-X\",\"e00487-17\",\"10.1002/phar.1933\",\"10.1111/jgh.13796\",\"10.1093/cid/cix214\",\"10.18683/germs.2017.1107\",\"S0960-894X(17)30254-8\",\"10.1080/17474124.2017.1309284\",\"10.1007/s00535-017-1328-z\",\"10.2147/CEOR.S117650\",\"10.3851/IMP3149\",\"10.1097/MEG.0000000000000866\",\"10.1007/s12328-017-0722-7\",\"10.1556/650.2017.30688\",\"S0016-5085(17)30150-6\",\"10.14309/crj.2017.21\",\"reina08feb2017\",\"10.5812/ircmj.28566\",\"10.3238/arztebl.2017.0011\",\"10.1007/s00535-017-1310-9\",\"10.1002/hep.29081\",\"10.3851/IMP3132\",\"10.1111/liv.13327\",\"10.1007/s40261-017-0492-5\",\"10.17179/excli2016-582\",\"10.3851/IMP3130\",\"10.3350/cmh.2016.0107\",\"10.1080/14787210.2017.1279970\",\"10.1002/jmv.24763\",\"10.1007/s40506-016-0085-5\",\"S0929-6646(16)30436-3\",\"10.3851/IMP3120\",\"10.1111/hepr.12853\",\"10.1038/srep39454\",\"S0168-8278(16)30699-7\",\"10.1111/apt.13882\",\"10.1111/jvh.12635\",\"10.1007/s15010-016-0962-3\",\"10.7326/M16-1205\",\"10.1371/journal.pone.0165658\",\"10.1002/jcph.830\",\"10.1111/evo.13041\",\"10.1111/jgh.13328\",\"10.1111/hepr.12817\",\"S0016-5085(16)35241-6\",\"10.1002/med.21401\",\"10.3851/IMP3065\",\"E283\",\"10.1111/1744-9987.12407\",\"10.1038/srep34652\",\"10.1111/jvh.12614\",\"S1198-743X(16)30424-4\",\"10.1111/jvh.12609\",\"10.3748/wjg.v22.i35.8050\",\"10.1002/hep.28846\",\"S0168-8278(16)30396-8\",\"10.12688/f1000research.8740.2\",\"10.3748/wjg.v22.i29.6573\",\"10.1556/650.2016.30538\",\"10.1371/journal.pone.0160668\",\"10.1111/hiv.12429\",\"S1386-6532(16)30145-7\",\"10.1016/j.virusres.2016.07.008\",\"10.1515/prilozi-2015-0060\",\"10.3748/wjg.v22.i25.5623\",\"10.3390/ijms17071070\",\"10.1159/000445330\",\"10.1016/j.dld.2016.06.004\",\"10.1016/j.ijid.2016.06.020\",\"10.3350/cmh.2016.0020\",\"10.20524/aog.2016.0041\",\"10.1007/s11908-016-0527-8\",\"10.1002/hep.28706\",\"10.1016/j.coviro.2016.05.004\",\"10.3390/v8060176\",\"10.1016/j.antiviral.2016.06.007\",\"10.1007/s12539-016-0177-4\",\"10.3748/wjg.v22.i22.5285\",\"10.1053/j.gastro.2016.06.002\",\"10.1111/jvh.12552\",\"10.1089/jir.2015.0147\",\"10.4103/0971-5916.182624\",\"10.1093/cid/ciw349\",\"10.1038/srep26742\",\"10.1111/jvh.12549\",\"10.1093/ofid/ofw052\",\"10.1016/j.jhep.2016.05.002\",\"10.1080/14656566.2016.1182156\",\"10.1038/nrgastro.2016.60\",\"10.1016/j.virol.2016.04.023\",\"10.3851/IMP3053\",\"10.1016/j.bmc.2016.04.010\",\"10.1371/journal.pone.0153895\",\"10.1111/apt.13633\",\"10.1080/14656566.2016.1176143\",\"10.14218/JCTH.2015.00047\",\"10.17116/terarkh201688362-67\",\"10.3748/wjg.v22.i12.3418\",\"10.2147/HMER.S62014\",\"10.1016/j.antiviral.2016.03.012\",\"10.1111/liv.13128\",\"10.1093/ndt/gfw023\",\"10.1111/jgh.13379\",\"10.4166/kjg.2016.67.3.127\",\"10.1016/j.antiviral.2016.03.004\",\"S0304-3835(16)30130-6\",\"10.1111/hae.12918\",\"10.1517/13543784.2016.1161023\",\"10.1016/j.jnma.2015.12.004\",\"10.1128/AAC.00051-16\",\"10.1186/s13027-016-0056-y\",\"10.1016/j.apsb.2015.09.008\",\"10.1128/JVI.02836-15\",\"10.1007/s12072-015-9699-9\",\"10.1007/s00705-016-2777-z\",\"10.1111/hepr.12667\",\"10.1128/AAC.02462-15\",\"10.1002/hep.28491\",\"10.1517/17425255.2016.1148685\",\"10.1002/phar.1700\",\"10.4254/wjh.v8.i3.139\",\"10.1128/AAC.02436-15\",\"10.1002/hep.28473\",\"10.3748/wjg.v22.i4.1421\",\"10.4254/wjh.v8.i2.131\",\"10.4254/wjh.v8.i2.123\",\"10.1016/j.antiviral.2016.01.011\",\"S0166-3542(16)30007-9\",\"10.1111/apt.13514\",\"10.1111/liv.13067\",\"10.1017/erm.2015.20\",\"10.1002/jmv.24470\",\"10.1371/journal.pntd.0004364\",\"10.1371/journal.pone.0145409\",\"10.1358/dot.2015.51.11.2414528\",\"10.4084/MJHID.2016.006\",\"10.1007/s11262-015-1285-7\",\"10.1016/j.antiviral.2015.12.010\",\"10.1128/AAC.02496-15\",\"10.1016/j.antiviral.2015.11.011\",\"10.1186/s12985-015-0451-9\",\"10.1016/j.bbacli.2015.01.004\",\"10.1128/AAC.01497-15\",\"10.2169/internalmedicine.54.5574\",\"10.1186/s12985-015-0450-x\",\"10.2147/DDDT.S80226\",\"10.1016/j.dld.2015.10.016\",\"10.4254/wjh.v7.i26.2681\",\"10.1093/infdis/jiv564\",\"10.1016/j.gtc.2015.07.010\",\"10.1128/AAC.01913-15\",\"10.1586/17474124.2015.1111757\",\"10.1155/2015/972067\",\"10.1056/NEJMoa1512612\",\"10.1056/NEJMoa1512614\",\"10.1586/14787210.2016.1120668\",\"10.1586/17474124.2016.1119042\",\"10.4292/wjgpt.v6.i4.105\",\"10.1159/000433594\",\"10.7326/M15-1000\",\"10.1016/j.jcv.2015.08.015\",\"S0168-8278(15)00676-5\",\"S0168-8278(15)00672-8\",\"10.1111/hepr.12570\",\"10.3851/IMP2997\",\"10.3390/v7102868\",\"10.3390/v7092864\",\"10.5604/17322693.1165197\",\"10.3390/v7092850\",\"10.1093/cid/civ722\",\"10.1128/AAC.01375-15\",\"10.1371/journal.pone.0138060\",\"10.1111/jvh.12464\",\"10.1007/s11894-015-0462-0\",\"10.4254/wjh.v7.i18.2177\",\"10.1053/j.gastro.2015.08.035\",\"10.1128/JVI.01553-15\",\"10.1089/jir.2014.0200\",\"10.1021/acs.biochem.5b00623\",\"10.2174/1389450116666150825111314\",\"10.1016/j.jhep.2015.08.010\",\"10.1007/s10928-015-9435-z\",\"10.1128/AAC.01229-15\",\"10.1093/gastro/gov040\",\"10.1586/14787210.2015.1076334\",\"10.1007/s00705-015-2563-3\",\"10.1111/liv.12931\",\"10.1097/COH.0000000000000177\",\"10.1007/s00535-015-1106-8\",\"10.1111/apt.13342\",\"10.3748/wjg.v21.i28.8660\",\"10.1128/AAC.00932-15\",\"10.1002/hep.27990\",\"10.1053/j.gastro.2015.07.001\",\"10.1097/MPG.0000000000000895\",\"10.1128/JCM.00650-15\",\"10.1002/hep.27960\",\"10.1371/journal.pone.0130899\",\"10.1016/j.antiviral.2015.06.013\",\"10.1128/AAC.00998-15\",\"10.1016/j.ijantimicag.2015.04.011\",\"10.1358/dot.2015.51.5.2332992\",\"10.1111/jvh.12422\",\"10.1016/j.bcp.2015.06.003\",\"10.1007/s00705-015-2482-3\",\"10.1007/s40265-015-0412-z\",\"10.4254/wjh.v7.i8.1125\",\"10.4254/wjh.v7.i10.1377\",\"10.1002/rmv.1842\",\"10.1021/acs.jmedchem.5b00108\",\"10.1556/650.2015.30180\",\"10.1038/emi.2014.80\",\"10.1016/j.antiviral.2015.05.011\",\"10.1016/j.antiviral.2015.05.006\",\"10.1111/cbdd.12589\",\"10.1159/000382075\",\"10.2147/DDDT.S65255\",\"10.1093/infdis/jiv288\",\"10.1111/liv.12861\",\"10.1128/JCM.03633-14\",\"10.3851/IMP2964\",\"10.1186/s12917-015-0330-z\",\"10.1002/cbdv.201400337\",\"10.1016/j.jcv.2015.02.001\",\"10.1126/scitranslmed.3010286\",\"10.3748/wjg.v21.i13.4006\",\"10.1002/hep.27836\",\"10.1155/2015/975695\",\"10.1128/JVI.03127-14\",\"10.1158/1078-0432.CCR-14-1370\",\"10.1111/jvh.12405\",\"10.1007/s11904-014-0243-7\",\"10.1007/978-1-4939-2432-5_1\",\"10.1093/ofid/ofu078\",\"10.1007/s40265-015-0362-5\",\"10.1001/jama.2015.1373\",\"1000271\",\"10.1371/journal.pone.0118313\",\"10.1586/14787210.2015.1018183\",\"10.3748/wjg.v21.i6.1994\",\"10.3748/wjg.v21.i6.1972\",\"10.1177/1060028015570729\",\"10.1016/j.jpba.2015.01.027\",\"10.1517/14656566.2015.1012493\",\"10.1016/j.biopha.2014.10.030\",\"10.1016/S0140-6736(14)62483-1\",\"10.1016/j.cmi.2014.07.009\",\"10.1331/JAPhA.2015.15508\",\"10.1002/jmv.24113\",\"10.1517/14740338.2015.1009035\",\"10.3851/IMP2939\",\"10.1016/j.dld.2014.12.004\",\"10.1016/j.clinre.2014.12.007\",\"10.1177/8755122514548897\",\"S0042-6822(14)00586-8\",\"10.1128/JVI.03483-14\",\"10.1007/s13353-014-0267-0\",\"10.1002/jmv.24092\",\"10.1586/14787210.2015.1001746\",\"10.1111/hepr.12474\",\"10.3748/wjg.v20.i48.18284\",\"10.4161/23723548.2014.961827\",\"10.1016/j.dld.2014.11.010\",\"10.2147/PGPM.S52629\",\"10.1016/j.humimm.2014.12.012\",\"10.1158/0008-5472.CAN-14-2607\",\"10.3748/wjg.v20.i43.15965\",\"10.1016/S0140-6736(14)61793-1\",\"10.1007/s00108-014-3554-2\",\"10.1016/j.dld.2014.09.027\",\"10.1016/j.dld.2014.09.024\",\"10.1016/j.bbrc.2014.10.111\",\"10.1016/j.antiviral.2014.10.017\",\"10.1016/j.jhep.2014.11.032\",\"10.1016/j.virusres.2014.11.003\",\"10.1016/j.jhep.2014.08.014\",\"10.1371/journal.pone.0113034\",\"10.4103/0976-500X.142464\",\"10.1111/jvh.12369\",\"10.1128/AAC.04220-14\",\"10.1111/jvh.12355\",\"10.1186/s12916-014-0198-y\",\"10.1093/cid/ciu865\",\"10.1093/cid/ciu623\",\"10.1517/14656566.2014.972364\",\"10.1128/JVI.02492-14\",\"10.1002/hep.27567\",\"10.1097/QCO.0000000000000114\",\"10.1053/j.gastro.2014.10.001\",\"10.1016/j.jfma.2014.09.001\",\"10.1093/cid/ciu696\",\"10.1371/journal.pone.0108616\",\"10.1016/j.jhep.2014.09.013\",\"10.1007/s12013-014-0241-9\",\"10.5009/gnl14083\",\"10.1002/hep.27424\",\"10.1124/dmd.114.059493\",\"10.1053/j.gastro.2014.08.040\",\"10.1111/jphp.12294\",\"10.1586/17474124.2014.953930\",\"10.1177/2049936113502647\",\"10.1128/AAC.02815-14\",\"10.1016/j.transproceed.2013.09.059\",\"10.1002/hep.27375\",\"10.1128/JVI.01860-14\",\"10.1371/journal.pone.0104783\",\"10.1016/j.coph.2014.07.016\",\"10.1007/s00535-014-0979-2\",\"10.1371/journal.pone.0104202\",\"10.1371/journal.pcbi.1003772\",\"10.1586/14787210.2014.945432\",\"10.1586/14787210.2014.940898\",\"10.2147/TCRM.S66731\",\"10.1586/14787210.2014.942282\",\"10.1002/jmv.24016\",\"10.1016/j.jiac.2014.06.002\",\"10.1089/dna.2014.2489\",\"10.1371/journal.pone.0101325\",\"10.3748/wjg.v20.i24.7555\",\"10.1016/j.jfma.2014.05.007\",\"10.3748/wjg.v20.i23.7089\",\"10.1007/s40265-014-0247-z\",\"10.1016/j.gastrohep.2014.04.004\",\"10.1016/j.antiviral.2014.05.015\",\"10.1007/s00705-014-2126-z\",\"10.1186/1743-422X-11-93\",\"10.1016/j.clinre.2014.04.008\",\"10.1038/nature13283\",\"10.4254/wjh.v6.i5.315\",\"10.1128/AAC.02777-13\",\"10.1007/s40265-014-0232-6\",\"10.1016/j.coviro.2014.04.011\",\"10.1097/MCG.0000000000000150\",\"10.2147/HMER.S44375\",\"10.1371/journal.pone.0097078\",\"10.1111/liv.12588\",\"10.1002/hep.27202\",\"10.1002/rmv.1795\",\"10.1002/jmv.23966\",\"10.1056/NEJMoa1316145\",\"10.1056/NEJMoa1402338\",\"10.1177/1756283X13515825\",\"S0074-02762014005030372\",\"10.1055/s-0034-1371009\",\"10.1055/s-0034-1371007\",\"10.1055/s-0034-1371006\",\"10.3350/cmh.2014.20.1.38\",\"10.1093/cid/ciu265\",\"10.1128/AAC.02495-13\",\"10.1053/j.gastro.2014.04.006\",\"10.1016/j.antiviral.2014.03.016\",\"10.1056/NEJMoa1402454\",\"10.1056/NEJMoa1402869\",\"10.1371/journal.pntd.0002790\",\"10.1056/NEJMoa1402355\",\"10.3748/wjg.v20.i13.3410\",\"10.1517/13543784.2014.902049\",\"10.3748/wjg.v20.i11.2902\",\"10.3748/wjg.v20.i11.2876\",\"10.1111/apt.12717\",\"10.3892/ijmm.2014.1706\",\"10.1053/j.gastro.2014.03.003\",\"10.1093/jac/dku060\",\"10.1111/jvh.12230\",\"10.1016/j.antiviral.2014.02.019\",\"10.1007/s12072-013-9460-1\",\"10.1016/j.antiviral.2014.02.013\",\"10.1645/13-278.1\",\"10.1007/s11262-014-1047-y\",\"10.1097/QAI.0000000000000073\",\"10.3851/IMP2743\",\"10.1002/hep.27053\",\"10.1038/clpt.2014.20\",\"10.2147/CPAA.S30338\",\"10.1128/AAC.02068-13\",\"10.1016/j.antiviral.2014.01.005\",\"10.1128/AAC.02556-13\",\"10.3851/IMP2729\",\"10.1016/j.jhep.2013.10.019\",\"10.3851/IMP2725\",\"10.1186/1756-0500-7-12\",\"10.1111/apt.12601\",\"10.1002/hep.26437\",\"10.3748/wjg.v19.i47.8963\",\"10.3748/wjg.v19.i47.8940\",\"10.1111/liv.12423\",\"10.1111/liv.12424\",\"10.1016/j.jhep.2013.12.013\",\"10.1016/j.ijantimicag.2013.10.003\",\"10.1111/hepr.12289\",\"10.1111/liv.12440\",\"10.1111/jvh.12118\",\"10.1002/hep.26788\",\"10.1007/s00705-013-1922-1\",\"10.1111/jvh.12111\",\"10.1111/jvh.12109\",\"10.1128/AAC.01515-13\",\"10.1517/14656566.2014.857656\",\"10.1155/2013/467869\",\"10.1159/000355241\",\"10.1159/000355381\",\"10.1159/000355239\",\"10.3201/eid1912.130705\",\"10.1016/j.mcna.2013.10.011\",\"10.3855/jidc.2937\",\"10.3748/wjg.v19.i41.6947\",\"10.1016/j.ajpath.2013.10.005\",\"10.6061/clinics/2013(10)06\",\"10.2147/DDDT.S40310\",\"10.5501/wjv.v2.i1.6\",\"10.5501/wjv.v1.i6.174\",\"10.1089/jir.2013.0032\",\"10.1111/jvh.12104\",\"10.1093/infdis/jit562\",\"10.1016/j.meegid.2013.09.029\",\"10.1111/liv.12363\",\"10.1002/hep.26892\",\"10.1016/j.cgh.2013.09.067\",\"10.1517/14728214.2013.847089\",\"10.1128/AAC.01578-13\",\"10.1016/j.dld.2013.07.011\",\"10.1186/1743-422X-10-259\",\"10.1371/journal.pone.0073615\",\"10.1016/S0213-005X(13)70121-6\",\"10.1016/S0213-005X(13)70119-8\",\"10.1016/S0213-005X(13)70118-6\",\"10.1016/j.bjid.2013.02.009\",\"10.1097/MCG.0b013e3182a8824c\",\"10.1371/journal.pone.0074027\",\"10.1016/j.jinf.2013.08.019\",\"10.1007/s00705-013-1803-7\",\"10.5812/hepatmon.7176\",\"10.1371/journal.ppat.1003565\",\"10.3851/IMP2672\",\"10.1128/AAC.00487-13\",\"10.1517/13543784.2013.826189\",\"10.1016/j.drup.2013.06.001\",\"10.1016/B978-0-12-405880-4.00002-0\",\"10.1128/AAC.00822-13\",\"10.1128/AAC.02193-12\",\"10.1016/j.jhep.2013.07.014\",\"10.1038/nm.3248\",\"10.1016/j.meegid.2013.06.025\",\"10.3851/IMP2663\",\"10.1007/978-1-62703-484-5_27\",\"10.1007/978-1-62703-484-5_8\",\"10.3851/IMP2660\",\"10.3892/mmr.2013.1541\",\"10.3851/IMP2593\",\"10.1053/j.gastro.2013.06.012\",\"10.1038/cgt.2013.33\",\"10.1016/j.virol.2013.05.013\",\"10.1016/j.antiviral.2013.05.015\",\"10.1111/apt.12350\",\"10.1007/s10875-013-9903-4\",\"10.3851/IMP2632\",\"10.1016/j.cyto.2013.04.012\",\"10.1136/gutjnl-2013-304472\",\"10.1016/j.antiviral.2013.04.020\",\"10.1042/CS20120594\",\"10.1186/1471-2172-14-21\",\"10.1111/jvh.12046\",\"10.3851/IMP2614\",\"10.1128/JVI.02824-12\",\"10.1517/14656566.2013.795543\",\"10.1097/MEG.0b013e328360aeb4\",\"10.1111/cas.12183\",\"10.1021/cb400100g\",\"10.1002/jmv.23579\",\"10.1016/j.antiviral.2013.03.022\",\"10.1007/s00705-013-1687-6\",\"10.1007/s40262-013-0053-x\",\"10.1002/hep.26421\",\"10.1016/j.jcv.2013.03.002\",\"10.1111/imj.12136\",\"10.1002/hep.26388\",\"10.1016/S1473-3099(13)70033-1\",\"10.1016/j.gastrohep.2012.11.005\",\"10.1016/S0213-005X(13)70113-7\",\"10.1002/hep.26371\",\"10.1097/MEG.0b013e32835f2726\",\"10.2147/DDDT.S30946\",\"S0074-02762013000100002\",\"10.3851/IMP2552\",\"10.1097/MPG.0b013e3182774cae\",\"10.3851/IMP2529\",\"10.1186/1743-422X-10-57\",\"10.3851/IMP2549\",\"10.1093/infdis/jis761\",\"10.1128/AAC.02494-12\",\"10.1111/j.1365-2893.2012.01641.x\",\"10.1002/hep.26275\",\"10.1111/ajt.12083\",\"10.1002/hep.26274\",\"10.1016/j.kjms.2012.11.001\",\"10.1093/infdis/jit032\",\"10.3851/IMP2478\",\"10.1111/liv.12076\",\"10.1111/liv.12061\",\"10.1111/liv.12059\",\"10.1016/j.meegid.2012.12.004\",\"10.1002/hep.26205\",\"10.1007/s11901-013-0187-1\",\"10.3851/IMP2475\",\"10.1002/hep.26203\",\"10.1016/j.cyto.2012.11.003\",\"10.1002/hep.26186\",\"10.3233/ISB-2012-0460\",\"10.3233/ISB-2012-0456\",\"10.1016/j.bpg.2012.09.010\",\"10.1016/j.bpg.2012.09.011\",\"10.1016/j.bpg.2012.09.004\",\"10.3851/IMP2425\",\"10.3851/IMP2431\",\"10.3851/IMP2428\",\"10.1016/j.jhep.2012.11.020\",\"10.1128/AAC.02052-12\",\"10.1016/j.cld.2012.09.006\",\"10.1016/j.cld.2012.09.007\",\"10.1016/j.cld.2012.09.001\",\"10.1111/liv.12031\",\"10.3748/wjg.v18.i42.6060\",\"10.1089/jir.2012.0059\",\"10.1097/FTD.0b013e318272e55a\",\"10.1111/jgh.12028\",\"10.1371/journal.pone.0047904\",\"10.1111/apt.12113\",\"10.1097/MEG.0b013e3283585863\",\"10.1002/hep.26121\",\"10.1007/s00535-012-0669-x\",\"10.1093/cid/cis915\",\"10.1016/j.cgh.2012.10.006\",\"10.1016/j.bbrc.2012.10.003\",\"10.1016/j.jhep.2012.09.023\",\"10.1093/cid/cis843\",\"10.1016/j.antiviral.2012.09.013\",\"10.1016/j.virusres.2012.09.007\",\"10.1016/j.antiviral.2012.09.009\",\"10.1186/1743-422X-9-214\",\"10.1128/JCM.02109-12\",\"10.1016/j.bbagen.2012.08.017\",\"10.1016/j.clinthera.2012.07.011\",\"10.3851/IMP2349\",\"10.1159/000339993\",\"10.2147/BTT.S24413\",\"10.3892/ijmm.2012.1093\",\"10.1111/j.1478-3231.2012.02856.x\",\"S0016-5085(12)01160-2\",\"10.1128/AAC.00780-12\",\"10.1097/SMJ.0b013e31825f033e\",\"10.1002/sim.5526\",\"10.1155/2012/267483\",\"10.1371/journal.pone.0041191\",\"10.5754/hge10341\",\"10.1016/j.antiviral.2012.07.002\",\"10.1002/hep.25962\",\"10.1016/j.jcv.2012.05.012\",\"10.1016/j.antiviral.2012.05.015\",\"S0016-5085(12)00810-4\",\"10.1111/j.1872-034X.2012.01046.x\",\"10.1016/S1473-3099(12)70060-9\",\"10.1208/s12248-012-9368-z\",\"10.1016/j.jhep.2012.04.036\",\"10.1002/hep.25867\",\"10.1002/hep.25865\",\"10.1517/13543784.2012.690392\",\"10.1128/AAC.00324-12\",\"10.1016/j.jhep.2012.04.027\",\"10.1016/j.cellimm.2012.04.009\",\"10.1002/jmv.23262\",\"10.1002/hep.25826\",\"10.1177/1756283X11436317\",\"10.1053/j.gastro.2012.02.027\",\"10.1136/gutjnl-2012-302144\",\"10.1136/gutjnl-2012-302048\",\"10.1371/journal.pone.0034372\",\"10.1111/j.1365-2893.2012.01590.x\",\"10.3851/IMP2100\",\"10.1111/j.1365-2893.2011.01555.x\",\"10.1074/jbc.M112.342709\",\"10.1093/cid/cis375\",\"10.1002/hep.25764\",\"10.1002/hep.25763\",\"10.1016/j.ijid.2012.02.004\",\"10.1002/hep.25743\",\"10.1007/s00535-012-0578-z\",\"10.1016/j.coviro.2011.10.019\",\"10.1016/j.jhep.2012.02.015\",\"10.1371/journal.pone.0031516\",\"10.1111/j.1365-2893.2011.01541.x\",\"10.3851/IMP2088\",\"10.2337/dc11-1837\",\"10.1002/PHAR.1046\",\"10.1136/gutjnl-2011-300749\",\"10.1556/OH.2012.29338\",\"10.1097/QAI.0b013e31824f5506\",\"10.1093/infdis/jis025\",\"10.1002/hep.25661\",\"10.1371/journal.pone.0030513\",\"10.1002/hep.25631\",\"10.1517/13543784.2012.658641\",\"10.1128/AAC.05986-11\",\"10.1016/S0213-005X(11)70044-1\",\"10.1097/MCG.0b013e31822a2dc6\",\"10.1371/journal.pone.0031006\",\"10.1128/AAC.05854-11\",\"10.1093/infdis/jir802\",\"10.1016/j.dld.2011.12.006\",\"10.1016/S2210-7401(11)70013-4\",\"10.1016/S2210-7401(11)70009-2\",\"10.1016/S2210-7401(11)70007-9\",\"10.1056/NEJMoa1104430\",\"10.1111/j.1365-2893.2011.01526.x\",\"10.1517/14656566.2012.653341\",\"S0074-02762011000800011\",\"10.1111/j.1365-2893.2011.01538.x\",\"10.1111/j.1365-2893.2011.01516.x\",\"10.1111/j.1365-2893.2011.01514.x\",\"10.1111/j.1478-3231.2011.02711.x\",\"10.1111/j.1478-3231.2011.02699.x\",\"10.1111/j.1478-3231.2011.02700.x\",\"10.1111/j.1478-3231.2011.02720.x\",\"10.1111/j.1478-3231.2011.02708.x\",\"10.1111/j.1478-3231.2011.02701.x\",\"10.1371/journal.pone.0029778\",\"10.3748/wjg.v17.i48.5317\",\"10.5009/gnl.2011.5.4.406\",\"10.1159/000333209\",\"10.1159/000333208\",\"10.1159/000333207\",\"10.2146/ajhp110123\",\"10.1007/s10930-011-9381-6\",\"10.1007/s12026-011-8263-5\",\"10.1007/s11894-011-0237-1\",\"10.1093/cid/cir774\",\"10.3851/IMP1934\",\"10.1093/infdis/jir726\",\"10.2217/pgs.11.99\",\"10.1586/eri.11.133\",\"10.1371/journal.pone.0027866\",\"10.1371/journal.pone.0027436\",\"10.3851/IMP1864\",\"10.1007/s12072-011-9306-7\",\"10.1002/hep.24546\",\"10.1517/14712598.2011.627851\",\"10.3390/v2102169\",\"10.1002/hep.24556\",\"10.1016/j.eimc.2011.07.003\",\"10.1371/journal.pone.0024907\",\"10.4065/mcp.2011.0309\",\"10.1016/j.jhep.2011.09.008\",\"10.1111/j.1872-034X.2011.00886.x\",\"10.1592/phco.31.10.951\",\"10.1097/COH.0b013e32834bd21d\",\"10.1016/j.jcv.2011.08.015\",\"10.1128/JVI.00716-11\",\"10.1111/j.1365-2893.2011.01474.x\",\"10.1111/j.1365-2893.2011.01490.x\",\"10.1073/pnas.1110489108\",\"10.1002/hep.24628\",\"10.1002/hep.24623\",\"10.1517/14656566.2011.597742\",\"10.1016/j.cld.2011.05.001\",\"10.1016/j.cld.2011.05.005\",\"10.1097/QAD.0b013e32834bbb90\",\"10.1186/1743-422X-8-402\",\"10.1345/aph.1P744\",\"10.1016/j.medmal.2011.04.003\",\"10.1016/S2210-7401(11)70005-5\",\"10.1111/j.1478-3231.2011.02571.x\",\"10.1111/j.1478-3231.2011.02545.x\",\"10.1002/jmv.22145\",\"10.1016/j.jhep.2011.03.010\",\"10.1111/j.1365-2893.2011.01439.x\",\"10.1093/jac/dkr215\",\"10.1111/j.1365-2036.2011.04716.x\",\"10.1586/eri.11.10\",\"10.1002/jmv.22092\",\"10.1556/OH.2011.29112\",\"10.1345/aph.1P430\",\"10.1007/s00535-011-0411-0\",\"10.1016/j.meegid.2011.04.021\",\"10.1128/JVI.00629-11\",\"10.1002/hep.24394\",\"10.3109/00365521.2011.574731\",\"10.1128/JVI.02583-10\",\"10.1002/hep.24172\",\"10.1111/j.1365-2893.2011.01451.x\",\"10.1128/AAC.00032-11\",\"10.1111/j.1365-2036.2011.04635.x\",\"10.1007/s10096-011-1215-0\",\"10.1053/j.gastro.2011.03.039\",\"10.1128/JVI.00859-10\",\"10.1111/j.1440-1746.2011.06722.x\",\"10.1002/hep.24262\",\"10.1111/j.1348-0421.2011.00331.x\",\"10.1128/AAC.01335-10\",\"10.1016/j.jhep.2011.01.046\",\"10.1186/gm222\",\"10.1016/j.jhep.2011.02.004\",\"10.1186/1743-422X-8-71\",\"10.1016/j.dld.2010.12.011\",\"10.1159/000322219\",\"10.1016/j.meegid.2011.01.017\",\"10.1002/hep.24056\",\"10.1128/JVI.02197-10\",\"10.1111/j.1478-3231.2010.02411.x\",\"10.1111/j.1478-3231.2010.02383.x\",\"10.1111/j.1478-3231.2010.02410.x\",\"10.1111/j.1478-3231.2010.02391.x\",\"10.1111/j.1478-3231.2010.02397.x\",\"10.1111/j.1478-3231.2010.02398.x\",\"10.1111/j.1440-1746.2010.06542.x\",\"10.1111/j.1440-1746.2010.06550.x\",\"10.1111/j.1440-1746.2010.06605.x\",\"10.1016/j.jhep.2010.11.001\",\"10.1016/j.jhep.2010.08.040\",\"10.1016/j.jhep.2010.08.033\",\"10.1016/j.jhep.2010.08.024\",\"10.1016/j.jhep.2010.09.019\",\"10.1016/j.jhep.2010.07.037\",\"10.1016/j.jhep.2010.07.032\",\"10.1111/j.1469-0691.2010.03430.x\",\"10.1053/j.gastro.2010.11.002\",\"10.1111/j.1872-034X.2010.00726.x\",\"10.1002/jmv.21909\",\"10.1016/j.jhep.2010.06.025\",\"10.1371/journal.pone.0013169\",\"10.1053/j.gastro.2010.10.004\",\"10.1086/656774\",\"10.2119/molmed.2010.00124\",\"10.1371/journal.ppat.1001072\",\"10.1136/gut.2010.219089\",\"10.1053/j.gastro.2010.09.010\",\"10.1111/j.1478-3231.2010.02343.x\",\"10.1371/journal.ppat.1001086\",\"10.1097/MAJ.0b013e3181ec435e\",\"10.1016/j.jhep.2010.04.036\",\"10.1111/j.1365-2893.2010.01348.x\",\"10.1053/j.gastro.2010.07.058\",\"10.1093/jac/dkq284\",\"10.1086/655784\",\"10.3390/v2081635\",\"10.3390/v2081510\",\"10.3109/08820131003720710\",\"10.1002/jmv.21858\",\"10.1111/j.1478-3231.2010.02283.x\",\"10.1097/MEG.0b013e32833caf7b\",\"10.1517/13543784.2010.500285\",\"10.1517/14656566.2010.500615\",\"10.1016/j.virusres.2010.07.004\",\"10.3350/kjhep.2010.16.2.158\",\"10.1111/j.1440-1746.2010.06392.x\",\"10.1111/j.1440-1746.2010.06240.x\",\"10.1371/journal.pone.0011265\",\"10.1097/QAI.0b013e3181e5b1f0\",\"10.1021/jf1006193\",\"10.1097/MEG.0b013e32833bec1e\",\"10.1517/14740338.2010.495942\",\"10.1053/j.gastro.2010.06.016\",\"10.1097/MPG.0b013e3181d9c7f6\",\"10.1086/653080\",\"10.1159/000282104\",\"10.1111/j.1478-3231.2010.02212.x\",\"10.5009/gnl.2009.3.2.108\",\"10.1089/jmf.2009.1149\",\"10.1038/nature08960\",\"10.1128/JVI.02420-09\",\"10.1007/s10875-010-9387-4\",\"10.1016/j.jhep.2010.01.030\",\"10.1586/eri.10.17\",\"10.1128/AAC.01739-09\",\"10.1016/j.jhep.2009.10.034\",\"10.1093/jac/dkq086\",\"10.1128/AAC.00135-10\",\"10.1038/ajg.2010.110\",\"10.1097/MOG.0b013e3283383c8f\",\"10.1097/MEG.0b013e32832d237d\",\"10.1016/j.gastrohep.2009.12.008\",\"10.1097/MCG.0b013e3181d2ef1a\",\"10.1016/j.jhep.2010.01.016\",\"10.1371/journal.pone.0009332\",\"10.1128/AAC.01236-09\",\"10.1016/j.cgh.2010.01.022\",\"10.1097/MEG.0b013e328335b29e\",\"10.1093/qjmed/hcp192\",\"10.1073/pnas.0909603107\",\"10.1159/000252784\",\"10.1016/j.antiviral.2009.12.008\",\"10.2147/IDR.S7136\",\"10.1111/j.1478-3231.2009.02188.x\",\"10.1053/j.gastro.2009.11.055\",\"10.1111/j.1365-2893.2009.01241.x\",\"10.3390/v1030484\",\"10.1097/CCM.0b013e3181c85229\",\"10.1111/j.1478-3231.2009.02171.x\",\"10.1053/j.gastro.2009.10.058\",\"10.1093/jac/dkp388\",\"10.1053/j.gastro.2009.10.046\",\"10.1097/QAD.0b013e32832ff1c0\",\"10.1016/j.antiviral.2009.10.021\",\"10.1111/j.1365-2893.2009.01204.x\",\"10.4155/fmc.09.88\",\"10.1002/lt.21878\",\"10.1002/jmv.21641\",\"10.1053/j.gastro.2009.10.005\",\"10.1002/hep.23206\",\"10.1111/j.1478-3231.2009.02145.x\",\"10.3851/IMP1298\",\"10.1038/ajg.2009.528\",\"10.1002/hep.23192\",\"10.1111/j.1468-1293.2009.00729.x\",\"10.1111/j.1440-1746.2009.05946.x\",\"10.1053/j.gastro.2009.08.071\",\"10.1016/j.coph.2009.08.008\",\"10.1038/ng.447\",\"10.1016/j.dld.2009.08.001\",\"10.1177/1756283X09339079\",\"10.1016/j.jhep.2009.07.008\",\"10.1086/605475\",\"10.1136/gut.2009.185074\",\"10.1371/journal.pone.0006579\",\"10.1111/j.1365-2893.2009.01169.x\",\"10.1002/art.24703\",\"10.1016/j.cld.2009.05.001\",\"10.1016/j.cld.2009.05.009\",\"10.1016/j.cld.2009.05.008\",\"10.1016/j.cld.2009.05.004\",\"10.1111/j.1872-034X.2009.00529.x\",\"10.1128/AAC.00476-09\",\"10.1016/j.gastrohep.2009.01.181\",\"10.1086/600887\",\"10.1038/nrgastro.2009.92\",\"10.1177/1756283X09336045\",\"/S0034-98872009000200015\",\"10.1016/j.gcb.2009.05.002\",\"10.1053/j.gastro.2009.05.060\",\"10.1007/s00535-009-0087-x\",\"10.1038/nrgastro.2009.65\",\"10.1586/eri.09.30\",\"10.1016/j.meegid.2009.05.007\",\"10.1089/jir.2008.0110\",\"10.1371/journal.pone.0005554\",\"10.1371/journal.pone.0005493\",\"10.1016/j.antiviral.2009.01.007\",\"10.1517/13543780902854194\",\"10.1111/j.1365-2036.2009.04004.x\",\"10.1097/MOG.0b013e328324f478\",\"10.1002/jmv.21473\",\"10.1016/j.freeradbiomed.2009.03.021\",\"10.1111/j.1478-3231.2009.02005.x\",\"10.1086/597384\",\"10.1128/AAC.01012-08\",\"10.1159/000205264\",\"10.1128/JVI.02280-08\",\"10.1517/13543780802651583\",\"10.1002/jmv.21460\",\"10.1016/j.jhep.2008.12.017\",\"10.1016/j.jhep.2008.10.032\",\"10.1111/j.1478-3231.2008.01945.x\",\"10.1517/14656560802694481\",\"10.1016/j.bpg.2008.12.002\",\"10.1007/s10620-008-0691-2\",\"10.1111/j.1365-2036.2009.03927.x\",\"10.1016/S1473-3099(09)70020-9\",\"10.1007/s10620-008-0683-2\",\"10.1371/journal.pone.0004176\",\"10.1086/595848\",\"10.1172/JCI37085\",\"10.1128/AAC.00939-08\",\"10.1097/MAJ.0b013e3181643e3d\",\"10.1016/j.jhep.2008.11.010\",\"10.1086/591851\",\"10.1016/j.meegid.2008.11.001\",\"10.1038/aps.2008.5\",\"10.1016/j.diabet.2008.08.003\",\"10.1002/hep.22549\",\"10.1016/j.jhep.2008.08.024\",\"10.1556/OH.2008.28493\",\"10.1128/AAC.00947-08\",\"10.1016/j.coph.2008.09.007\",\"10.1186/1743-422X-5-109\",\"10.1053/j.gastro.2008.07.072\",\"10.1016/j.jhep.2008.07.013\",\"10.1128/AAC.00078-08\",\"10.1111/j.1572-0241.2008.02002.x\",\"10.1111/j.1365-2036.2008.03823.x\",\"10.1016/S0399-8320(08)73273-1\",\"10.1086/591141\",\"10.1016/j.cgh.2008.03.024\",\"10.1002/hep.22357\",\"10.1128/AAC.00238-08\",\"10.1016/j.jhep.2008.03.033\",\"10.1002/hep.22321\",\"10.1002/hep.22339\",\"10.1089/apc.2007.0199\",\"10.1053/j.gastro.2008.02.019\",\"10.1016/j.cgh.2008.02.056\",\"10.1111/j.1365-2893.2008.00991.x\",\"10.1097/QAD.0b013e3282fbd1c4\",\"10.1097/MOG.0b013e3282f70285\",\"10.1111/j.1365-2893.2008.00980.x\",\"10.1517/14728214.13.1.1\",\"10.1002/jmv.21125\",\"10.1111/j.1365-2036.2008.03644.x\",\"10.1016/j.antiviral.2008.01.005\",\"10.1111/j.1744-313X.2008.00754.x\",\"10.1016/j.cgh.2007.11.020\",\"10.1128/AAC.00525-07\",\"10.1089/aid.2007.0091\",\"10.1128/AAC.01056-07\",\"10.1586/17474124.1.1.145\",\"10.1016/j.jus.2007.02.001\",\"10.1099/vir.0.80526-0\",\"10.1099/0022-1317-82-4-723\"],\"index\":[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,444,445,446,447,448,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,677,678,679,680,681,682,683,684,685,686,687,688,689,690,691,692,693,694,695,696,697,698,699,700,701,703,704,705,706,707,708,709,710,711,712,713,714,715,716,717,718,719,720,721,722,723,724,725,726,727,728,729,730,731,732,733,734,735,736,737,738,739,740,741,742,744,745,746,747,748,749,750,751,752,753,754,755,756,757,759,760,761,762,763,764,765,766,767,768,769,770,772,773,774,775,776,777,778,779,780,781,782,783,784,785,786,787,788,789,790,791,792,793,794,795,796,797,798,799,800,801,802,803,804,805,806,807,808,809,810,811,812,813,814,815,816,817,818,819,820,821,823,824,825,826,827,828,829,830,831,832,833,834,835,836,837,838,839,840,841,842,843,844,845,846,847,848,849,850,851,852,853,854,855,856,857,858,859,860,861,862,863,864,865,866,867,868,869,870,871,872,873,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,891,892,893,894,895,896,897,898,899,900,901,902,903,904,906,907,908,909,910,911,912,913,914,915,916,917,918,919,920,921,922,923,924,925,926,927,928,929,930,931,932,933,934,935,936,937,938,939,940,941,942,943,944,945,946,947,948,949,950,951,952,953,954,955,956,957,958,959,960,961,962,963,964,965,966,967,968,969,970,971,972,973,974,975,976,977,978,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998,999,1000,1001,1002,1003,1004,1005,1006,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018,1019,1020,1021,1022,1023,1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,1037,1038,1039,1040,1041,1042,1043,1044,1045,1046,1047,1048,1049,1050,1051,1052,1053,1054,1055,1056,1057,1058,1059,1060,1061,1062,1063,1064,1065,1066,1067,1068,1069,1070,1071,1072,1073,1074,1075,1076,1077,1078,1079,1080,1081,1082,1083,1084,1085,1086,1087,1088,1089,1090,1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119,1120,1121,1122,1123,1124,1125,1126,1127,1128,1129,1130,1131,1132,1133,1134,1135,1136,1137,1138,1139,1140,1141,1142,1143,1144,1145,1146,1147,1148,1149,1150,1151,1152,1153,1154,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175,1176,1177,1178,1179,1180,1181,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192,1193,1194,1195,1196,1197,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1208,1209,1210,1211,1212,1213,1214,1215,1216,1217,1218,1219,1220,1221,1222,1223,1224,1225,1226,1227,1228,1229,1230,1231,1232,1233,1234,1235,1236,1237,1238,1239,1240,1241,1242,1243,1244,1245,1246,1247,1248,1249,1250,1251,1252,1253,1254,1255,1256,1257,1258,1259,1260,1261,1262,1263,1264,1265,1266,1267,1268,1269,1270,1271,1272,1273,1274,1275,1276,1277,1278,1279,1280,1281,1282,1283,1284,1285,1286,1287,1288,1289,1290,1291,1292,1293,1294,1295,1296,1297,1298,1299,1300],\"key\":[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false],\"processed_abstract\":[\"treatment hcv infection peginterferon ribavirin result low sustained virologic response rate number undesirable adverse effect direct-acting antiviral daa offer high efficacy low risk short treatment time existence resistance-associated mutation particularly ns5b polymerase attenuate efficacy daa objective study identify amino acid change ns5b gene link daa resistance treatment-naive vietnamese chronic hepatitis c patient\",\"polish recommendation regard management patient covid-19 publish polish society epidemiologists infectiologists pteilchz march 31 2020 annex date november 12 2021 ongoing state pandemic emergence new variant virus availability new drug necessitate updating change introduce current version recommendation management covid-19 comprise possibility use remedesivir outpatient setting previously reserve inpatient treatment antiviral drugs-molnupiravir nirmatrelvir ritonavir revise possibility use monoclonal antibody resistance currently dominant omicron variant anakinra antagonist interleukin 1 receptor add treatment option advanced stage disease recommend daily dose glucocorticosteroid use severe form covid-19 increase information vaccination pre-exposure prophylaxis specific population update\",\"disease yellow fever prevent live attenuate vaccine strain 17d french neurotropic vaccine fnv derive serial passage wild-type wt strain asibi french viscerotropic virus fvv respectively 17d fnv display decrease genetic diversity resistance antiviral ribavirin compare wt parental strain think contribute attenuate phenotype subsequent study find passage wt strain fvv hela cell result attenuate virus current study genome sequence fvv follow passage hela cell fvv hela p5 determine generation sequencing ngs aim investigate molecular basis viral attenuation find wt fvv fvv hela p5 virus differ amino acid substitution e-d155a e-k331r e-i412v ns2a-t105a ns4b-v98i surprisingly genetic diversity ribavirin resistance fvv hela p5 virus statistically different wt parent fvv finding suggest fvv hela p5 attenuate dependent high-fidelity replication complex characterize reduce genetic diversity increase ribavirin stability fnv 17d vaccine\",\"sars-cov-2 remdesivir resistance mutation generate vitro report patient receive treatment antiviral agent present case immunocompromised patient acquire b-cell deficiency develop indolent protracted course sars-cov-2 infection remdesivir therapy alleviate symptom produce transient virologic response course complicate recrudescence high-grade viral shedding genome sequencing identify mutation e802d nsp12 rna-dependent rna polymerase present pre-treatment specimen vitro experiment demonstrate mutation confer ~6-fold increase remdesivir ic50 result fitness cost absence remdesivir sustained clinical virologic response achieve treatment casirivimab-imdevimab fitness cost observe vitro limit risk pose e802d case illustrate importance monitoring remdesivir resistance potential benefit combinatorial therapy immunocompromised patient sars-cov-2 infection\",\"hepatitis e virus hev important cause viral hepatitis worldwide currently fda-approved anti-hev drug commonly use drug ribavirin rbv achieve viral clearance patient induce drug resistance recent study sofosbuvir sof inhibit hev replication vitro add-on effect combine rbv clinical effect sof hev infection remain controversial dosage sof warrant exploration study rabbit model acute hev infection use evaluate effect sof different dose hev 3 4 compare antiviral effect sof-plus-rbv therapy rbv monotherapy virological parameter fecal serological intrahepatic level test real-time pcr elisa liver function test histopathological assay perform 200 mg/d 300 mg/d sof treatment inhibit hev replication relieve liver inflammation decline level fecal hev rna antigenemia 300 mg/d sof eliminate hev replication short viral rebound observe 200 mg/d sof treatment sof-plus-rbv therapy strong anti-hev effect rbv monotherapy study suggest high dose sof anti-hev effect rabbit model de novo sof-plus-rbv therapy eliminate acute hev infection efficiently rbv monotherapy serve alternative treatment strategy warrant far preclinical clinical study\",\"hepatitis c viral hcv infection major clinical burden globally pegylated ifn-\\u03b1-2a peg-ifn-\\u03b1-2a ribavirin rib therapy induce array cellular antiviral response include dsrna kinase pkr chemokine cytokine tackle hcv infection hcv patient develop resistance peg-ifn/rib therapy render theray ineffective\",\"antiviral efficacy remdesivir covid-19 hospitalize patient remain controversial\",\"combination direct-acting antiviral need minimize drug resistance mutation stably suppress replication rna virus currently limited therapeutic option severe acute respiratory syndrome coronavirus 2 sars-cov-2 testing number drug regimen lead conflicting result cobicistat fda-approved drug booster block activity drug-metabolizing protein cytochrome p450 3as cyp3as p-glycoprotein p-gp inhibit sars-cov-2 replication independent cell-to-cell membrane fusion assay antiviral effect cobicistat exert inhibition spike protein-mediated membrane fusion line incubation low-micromolar concentration cobicistat decrease viral replication different cell line include cell lung gut origin cobicistat use combination remdesivir synergistic effect inhibition viral replication observe cell line primary human colon organoid consistent effect cobicistat known target cyp3a4 p-gp silencing boost vitro antiviral activity remdesivir cobicistat-like manner administer vivo syrian hamster high dose cobicistat decrease viral load mitigate clinical progression datum highlight cobicistat therapeutic candidate treat sars-cov-2 infection potential building block combination therapy covid-19 importance lack effective antiviral treatment sars-cov-2 significant limitation fight covid-19 pandemic single-drug regimen far yield limited result indicate combination antiviral require previously rna virus work introduce drug booster cobicistat approve fda typically use potentiate effect anti-hiv protease inhibitor candidate inhibitor sars-cov-2 replication direct activity antiviral cobicistat enhance effect remdesivir drug propose treatment sars-cov-2 overall dual action cobicistat direct antiviral drug booster provide new approach design combination therapy rescue activity compound partially effective monotherapy\",\"covid-19 pandemic continue threaten healthcare system worldwide limited access vaccine suboptimal treatment option continuous emergence new transmissible sars-cov-2 variant reverse-genetics study viral gene mutation prove highly valuable advance basic virus research lead development therapeutic develop functional highly versatile full-length sars-cov-2 infectious system clone sequence covid-19 associate virus isolate dk-ahh1 bacterial artificial chromosome bac virus recover rna-transfection vitro transcript vero e6 cell growth kinetic remdesivir susceptibility similar dk-ahh1 virus isolate insertion reporter gene green fluorescent protein nanoluciferase orf7 genomic region lead high level reporter activity facilitate high throughput treatment experiment find putative coronavirus remdesivir resistance-associated substitution f480l v570l-and naturally find polymorphism a97v p323l n491s nsp12-did decrease sars-cov-2 susceptibility remdesivir nanoluciferase reporter clone deletion spike s envelope e membrane m protein exhibit high level transient replication inhibit remdesivir function efficient non-infectious subgenomic replicon system develop sars-cov-2 reverse-genetics system include recombinant modify infectious virus non-infectious subgenomic replicon autonomous genomic rna replication permit high-throughput cell culture studies-providing fundamental understanding basic biology coronavirus prove utility system rapidly introduce mutation nsp12 study effect efficacy remdesivir use worldwide treatment covid-19 system provide platform effectively test antiviral activity drug phenotype sars-cov-2 mutant\",\"report case spontaneous pneumothorax pneumomediastinitis patient covid-19 iran treat different drug hydroxychloroquine sofosbuvir atazanavir remdesivir antiviral agent despite difference type drug pneumothorax occur patient\",\"coronavirus disease 2019 covid-19 represent unmet clinical need high mortality rate rapid mutation rate virus increase chance reinfection lack effectiveness repurposed drug economic damage covid-19 pandemic create urgent need effective molecule clinically prove efficacy safety profile favipiravir fvp remdesivir rdv promise therapeutic option use severe acute respiratory syndrome coronavirus 2 sars-cov-2 infection prodrug molecule antiviral role base similar mechanism action difference pharmacological pharmacokinetic pharmacotoxicological mechanism identify present study aim provide comprehensive comparative assessment fvp rdv sars-cov-2 infection centralize medical datum provide significant literature authorize clinical trial focus importance understanding interaction drug molecule infectious agent order improve global management covid-19 patient reduce risk antiviral resistance\",\"accord pivotal clinical trial cure rate sofosbuvir-based antiviral therapy exceed 96 treatment failure usually assume virological resistance-associated substitution clinical risk factor role patient-specific genetic factor explore determine patient-specific genetic factor help predict patient likely fail sofosbuvir treatment real-world treatment situation\",\"key element prevention management coronavirus disease 2019 development effective therapeutic drug combination strategy offer advantage monotherapie potential achieve great efficacy increase therapeutic index drug reduce emergence drug resistance assess vitro synergistic interaction remdesivir ivermectin approve food drug administration demonstrate enhance antiviral activity severe acute respiratory syndrome coronavirus-2 whilst vitro synergistic activity report support clinical application combination treatment strategy insufficient exposure ivermectin vivo datum warrant investigation effort define mechanism underpin observe synergistic action lead development novel treatment strategy\",\"modified nucleoside therapeutic promise antiviral therapy issue include emergence drug resistance toxicity coinfection pose new challenge nucleoside-based antiviral drug discovery particularly era coronavirus disease 2019 covid-19 pandemic chemical manipulation impact antiviral potency safety drug resistance nucleoside generally modify nucleoside difficult recognize intracellular important enzyme substrate exhibit low toxicity 4'-modified nucleoside represent important subclass modify nucleoside antiviral therapy prevent occurrence drug resistance 4'-modified nucleoside 3'-oh chemically unreactive proviral dna biosynthesis absence 3'-oh explain occurrence drug resistance censavudine introduction 4'-substituent improve enzymatic acidic stability nucleoside lipophilic improve cell permeability bioavailability steric hindrance 4'-substituent 3'-oh change furanose conformation 3'-endo type oxygen lone pair furanose ring form oxocarbonium ion glycolysis currently seven 4'-modified nucleoside drug candidate azvudine know fnc islatravir censavudine balapiravir lumicitabine al-335 4-azidothymidine progress clinical stage treat viral infection note fnc officially approve nmpa july 2021 use adult patient high hiv-1 virus load nos. h20210035 h20210036 provide alternative therapeutic patient hiv-1 long-term cellular retention fnc suggest potential long-lasting pre-exposure prophylaxis prep agent prevent hiv-1 infection mechanistically fnc inhibit hiv-1 reverse transcription replication restore a3 g expression peripheral blood cd4[+ t cell hiv-1 patient receive fnc 4'-azido group azvudine stabilize 3'-c-endo north conformation steric effect formation intramolecular hydrogen bond 3'-oh group decrease nucleophilicity 3'-oh north conformation enhance phosphorylation efficiency fnc cellular kinase encouragingly fnc islatravir balapiravir promise treatment coronaviruse fnc advance phase 3 clinical trial different country treat patient covid-19 clinical trial number nct04668235 nct04425772 fnc cure covid-19 disease patient therapeutic efficacy remdesivir account provide overview 4'-modified nucleoside analog clinical stage antiviral therapy highlight drug discovery strategy structure-activity relationship study preclinical/clinical study perspective nucleoside-based antiviral drug discovery\",\"hepatotropic virus naturally narrow host tissue tropism challenge development robust experimental model advent organoid technology provide unique opportunity field forward demonstrate three-dimensional culture organoid fetal adult human liver cholangiocyte hepatocyte phenotype support hepatitis e virus hev replication inoculation infectious hev particle demonstrate human liver \\u2013 derive organoid support life cycle hev infection direct organoid polarize monolayer transwell system observe predominantly apical secretion hev particle genome-wide transcriptomic trnaome analysis reveal robust host response trigger viral replication drug screening organoid identify brequinar homoharringtonine potent hev inhibitor effective ribavirin resistance variant harbor g1634r mutation successful recapitulation hev infection liver-derived organoid shall facilitate study virus-host interaction development antiviral therapy\",\"massive usage antiviral compound pandemic create ideal ground emergence resistant strain remdesivir broad-spectrum inhibitor viral rna-dependent rna polymerase rdrp extensively prescribe emergency use authorization 18 month covid19 pandemic randomize control trial poor efficacy hospitalize patient rdrp mutation confer resistance remdesivir know vitro study huge sars-cov-2 sequencing effort ongoing covid19 pandemic represent unprecedented opportunity assess emergence fitness antiviral resistance vivo gisaid database extrapolate frequency remdesivir escape mutation analysis reveal low level remdesivir resistance worldwide despite massive usage\",\"circulation avian influenza virus poultry public health concern virus cause severe disease human potential transmissible human monitor susceptibility virus antiviral important influenza pandemic preparedness information antiviral susceptibility limited determine susceptibility avian influenza a(h5n1 a(h5n2 a(h5n8 a(h7n7 a(h7n9 a(h9n1 a(h9n2 virus isolate japan antiviral approve use m2 inhibitor amantadine neuraminidase inhibitor oseltamivir peramivir zanamivir laninamivir rna polymerase inhibitor baloxavir favipiravir genotypic method detect amino acid substitution associate antiviral resistance phenotypic method assess viral susceptibility drug reveal avian influenza virus susceptible neuraminidase inhibitor rna polymerase inhibitor result suggest neuraminidase inhibitor rna polymerase inhibitor currently approve japan treatment option influenza virus infection human\",\"discovery 1989 road cure hepatitis c virus hcv slow patient expect achieve sustained virological response svr direct-acting antiviral daa combination therapy glecaprevir/pibrentasvir velpatasvir/sofosbuvir 98 patient successfully eradicate virus previous treatment fail resistance-associated substitution ras present adverse event rare mild patient compensate cirrhosis co-morbiditie eligible treatment small number patient fail eradicate virus retreatment cause failure mainly emergence ns5a p32 deletion mutant initial daa therapy 1b patient reason unknown patient alternative therapy rely ns5a inhibitor sofosbuvir plus ribavirin attempt patient scaled-up treatment effort present challenge problem carrier unaware infection long-term damage liver irreversible patient diagnose time develop liver cancer liver failure eliminate virus long-term cost treatment advanced liver disease undiagnosed patient relative immediate cost daa therapy consider vaccine available eventual elimination virus require identify treat undiagnosed case screening high-risk population injection drug user man sex man female sex worker\",\"coronavirus disease 2019 covid-19 pandemic cause severe acute respiratory syndrome coronavirus 2 sars-cov-2 global crisis clinical candidate high efficacy ready availability develop resistance urgent need despite screening repurpose clinically approve drug provide variety hit effective sars-cov-2 infection cell culture confirm antiviral candidate vivo study 94 compound high antiviral activity sars-cov-2 vero e6 cell identify 2,580 fda-approved small-molecule drug 24 compound low cytotoxicity select 17 compound effectively suppress sars-cov-2 infection hela cell transduce human ace2 compound disturb multiple process sars-cov-2 life cycle prophylactic efficacy determine vivo use syrian hamster challenge sars-cov-2 infection seven compound reduce weight loss promote weight regain hamster infect original strain d614 g variant cisatracurium compound reduce hamster pulmonary viral load il-6 tnf-\\u03b1 mrna assay 4 d postinfection particular sertraline salinomycin gilteritinib similar protective effect remdesivir vivo induce antiviral drug resistance 10 serial passage sars-cov-2 vitro suggest promising application covid-19 treatment\",\"frequent mump outbreak vaccinate population occurrence neurological complication e.g. aseptic meningitis encephalitis patient mump indicate need development efficient vaccine specific antiviral therapy rna virus genetically highly heterogeneous population exist edge error threshold additional increase mutational burden lead extinction virus population deliberate modulation natural mutation rate exploit antiviral strategy possibility rational vaccine design aim study examine ability ribavirin broad-spectrum antiviral agent introduce mutation mumps virus muv genome investigate resistance develop long-term vitro exposure ribavirin increase muv population heterogeneity presence ribavirin observe passage cell culture bias c-to-u g-to-a transition previously define ribavirin-related high ribavirin concentration muv lose infectivity serial passaging recover low ribavirin concentration serial passaging lead significant increase population diversity strong bias ribavirin-related transition independently viral strain cell culture condition virus retain initial growth capacity development resistance whole-virus population level\",\"clinical trial start covid-19 pandemic discover effective therapeutic lead identify candidate major clinical trial past month sars-cov-2 variant emerge significant mutation major mutation s-glycoprotein genome lead antibody escape small molecule-based therapeutic resistance mutation s-glycoprotein trigger antibody escape/resistance mutation rdrp cause remdesivir resistance article illustrate emerge mutation result antibody escape therapeutic resistance direction article illustrate presently develop neutralize antibody preclinical clinical stage antibody escape associate mutation finally owe rdrp mutation antiviral small molecule resistance illustrate\",\"sars-cov-2 remdesivir resistance mutation generate vitro report patient receive treatment antiviral agent present case immunocompromised patient acquire b-cell deficiency develop indolent protracted course sars-cov-2 infection remdesivir therapy alleviate symptom produce transient virologic response course complicate recrudescence high-grade viral shedding genome sequencing identify mutation e802d nsp12 rna-dependent rna polymerase present pre-treatment specimen vitro experiment demonstrate mutation confer \\u223c6-fold increase remdesivir ic50 result fitness cost absence remdesivir sustained clinical virologic response achieve treatment casirivimab-imdevimab fitness cost observe vitro limit risk pose e802d case illustrate importance monitoring remdesivir resistance potential benefit combinatorial therapy immunocompromised patient sars-cov-2 infection\",\"human coronavirus nl63 hcov-nl63 mainly affect young child immunocompromised patient cause morbidity mortality subset patient specific treatment available study aim explore anti-sars-cov-2 agent include favipiravir remdesivir treat hcov-nl63 infection successfully model 3d structure hcov-nl63 rna-dependent rna polymerase rdrp base experimentally solve sars-cov-2 rdrp structure molecular docking indicate favipiravir similar binding affinity sars-cov-2 hcov-nl63 rdrp libdock score 75 74 respectively libdock score remdesivir sars-cov-2 hcov-nl63 135 151 suggest remdesivir high affinity hcov-nl63 compare sars-cov-2 rdrp cell culture model infect hcov-nl63 favipiravir remdesivir significantly inhibit viral replication production infectious virus overall remdesivir compare favipiravir potent inhibit hcov-nl63 cell culture importantly evidence resistance development long-term exposure remdesivir furthermore combine favipiravir remdesivir clinically use antiviral cytokine interferon-alpha result synergistic effect finding provide proof-of-concept anti-sars-cov-2 drug particular remdesivir potential repurpose treat hcov-nl63 infection\",\"emergence fast-spreading sars-cov-2 mutant spark new phase covid-19 pandemic dire necessity antiviral target highly conserve genomic domain sars-cov-2 prone mutation nsp12 know rna-dependent rna-polymerase rdrp core component sars-cov-2 replication-transcription complex potential well-conserved druggable antiviral target fda-approved rdrp nucleotide analog inhibitor nai remdesivir repurpose treat covid-19 infection nai target rdrp protein translation competitively block nucleotide insertion rna chain result inhibition viral replication replication proofreading function nsp14-exon provide resistance sars-cov-2 nai conversely non-nucleoside analog inhibitor nnai bind allosteric site viral polymerase surface change redox state exert antiviral activity alter interaction enzyme substrate active core catalytic site rdrp nnai require metabolic activation unlike nai compete intracellular pool nucleotide triphosphate ntp anti-rdrp activity nnai phytonutrient origin potential antiviral candidate compare synthetic counterpart in-silico study report antiviral spectrum natural phytonutrient-nnai suramin silibinin flavonolignan theaflavin tea polyphenol baicalein 5,6,7-trihydroxyflavone corilagin gallotannin hesperidin citrus bioflavonoid lycorine pyrrolidine alkaloid superior redox characteristic free binding energy hydrogen-bond etc antiviral drug i.e. remdesivir favipiravir phytonutrient-nnai exert anti-inflammatory antioxidant immunomodulatory cardioprotective function multifunctional therapeutic benefit clinical management covid-19\",\"consider threat covid-19 pandemic cause sars-cov-2 urgent need develop effective treatment present neutralize antibody small-molecule drug remdesivir promising compound treat infection attract considerable attention potential problem need concern include viral resistance antibody-mediated neutralization cause selective pressure single antibody treatment unexpected antibody-dependent enhancement ade effect toxic effect small-molecule drug\",\"genomic reshuffling mutagenicity high transmission rate sars-cov-2 pathogen highlight urgent need effective antiviral intervention covid-19 control target highly conserve viral gene and/or gene-encode viral protein main proteinase m[pro rna-dependent rna polymerase rdrp helicase plausible antiviral approach prevent replication propagation sars-cov-2 infection coronaviruse covs prone extensive mutagenesis genetic alteration highly conserve m[pro enzyme detrimental viral pathogen inhibitor target m[pro enzyme reduce risk mutation-mediated drug resistance provide effective antiviral protection exist antiviral drug dietary bioactive currently repurpose treat covid-19 dietary bioactive ayurvedic medicinal herb 18 \\u03b2-glycyrrhetinic acid \\u03b4g 8.86 kcal/mol solanocapsine \\u03b4g 8.59 kcal/mol vasicoline \\u03b4g 7.34 kcal/mol high-affinity binding m[pro enzyme native n3 inhibitor \\u03b4g 5.41 kcal/mol flavonoid strongly inhibit sars-cov-2 m[pro comparable high potency antiviral drug remdesivir tannin hydrolysate avidly bind receptor-binding domain catalytic dyad his41 cys145 sars-cov-2 m[pro h-bonding force quercetin bind m[pro alter thermostability viral protein redox-based mechanism inhibit viral enzymatic activity interaction quercetin-derivative m[pro influence 7-oh group acetoxylation sugar moiety ligand molecule base pharmacokinetic admet profile phytonutrient serve promising redox nutraceutical covid-19 management\",\"influenza virus main flu agent affect billion people worldwide conventional treatment present limitation related drug-resistance severe effect result natural product-derived molecule increasingly investigate prospect drug candidate aim study investigate possible anti-flu activity evaluate toxicity pharmacokinetic parameter silico approach schinopsis brasiliensis engl phytochemical compound phytocompound antiviral drug amantadine umifenovir favipiravir nitazoxanide oseltamivir zanamivir select analysis influenza protein neuraminidase polymerase basic protein 2 hemagglutinin m2 ion channel protein molecular docking predict antiviral activity predict toxicity pharmacokinetic investigation conduct obtain result demonstrate syringaresinol cycloartenone display promise silico antiviral activity bind energy 5.0 \\u2265 9.0 kcal/mol safety low toxicity commercial anti-flu drug overall study corroborate hypothesis s. brasiliensis bark extract biological activity influenza virus additionally syringaresinol cycloartenone multiple target influenza virus promising phytocompound isolate consider therapeutic arsenal flu\",\"severe acute respiratory syndrome coronavirus-2 sars-cov-2 causative agent coronavirus disease 2019 covid-19 pandemic despite intensive global effort discover develop novel antiviral therapy remdesivir approve treatment covid-19 effective antiviral therapeutic urgently need combat halt pandemic viral rna-dependent rna polymerase rdrp sars-cov-2 demonstrate high potential reliable target development antiviral previously develop cell-based assay assess efficiency compound target sars-cov-2 rdrp tolerance viral exoribonuclease-mediated proof-reading previous study discover 2-((1h-indol-3-yl)thio)-n-phenyl-acetamide specifically target rdrp respiratory virus rsv influenza virus hypothesize 2-((1h-indol-3-yl)thio)-n-phenyl-acetamide ability inhibit sars-cov-2 replication target rdrp activity research test compound library contain 103 2-((1h-indol-3-yl)thio)-n-phenyl-acetamide sars-cov-2 rdrp use cell-based assay compound candidate strongly inhibit sars-cov-2 rdrp activity exhibit low cytotoxicity resistance viral exoribonuclease compound 6 72 2a promising candidate low ec50 value 1.41 \\u03bcm high selectivity index cc50/ec50 70.92 furthermore datum suggest 4 46b 6 72 2a inhibit replication hcov-oc43 hcov-nl63 virus dose-dependent manner compound 4 46b 6 72 2a exhibit ec50 value 1.13 \\u03bcm 0.94 \\u03bcm respectively hcov-oc43 viral replication high concentration compound need effectively block hcov-nl63 replication finding successfully identify 4 46b 6 72 2a promise inhibitor sars-cov-2 rdrp\",\"plant elicitor class plant protection agent stimulate plant immunity phytopathogen potential resistance problem search novel plant elicitor candidate series novel n-(2-phenyl-3-pyridyl thiadiazole/isothiazole carboxamide analog design synthesize\",\"hepatitis c virus hcv discover 1989 patient infect hcv initially treat interferon ifn monotherapy 2000s pegylated ifn combined ribavirin mainstay therapy infected patient sustained virologic response svr rate 50 patient hcv 1 far improve therapeutic effect direct-acting antiviral daa develop combination therapy daa ifn available 2011 addition ifn-free daa therapy available 2014 svr achieve 95 patient chronic hepatitis compensate cirrhosis 30 year discovery hcv aim eliminate hcv patient remain issue address patient achieve svr daa therapy advance liver fibrosis necessary verify extent daa therapy improve prognosis term liver function hepatocellular carcinoma occurrence mortality resistance-associated substitution cause failure daa therapy search effective therapy high-level resistant virus p32 deletion particularly important daa therapy approve use patient decompensated cirrhosis japan 2019 unmet need far important verify efficacy safety real-world setting world health organization aim eliminate hcv 2030 japan tackle remain issue achieve goal\",\"study aim assess correlation genotyping interleukin-10 il-10 polymorphism rs 1800871 incidence hepatocellular carcinoma hcc patient hepatitis c virus hcv treat direct act antiviral daa\",\"therapeutic targeting nonstructural protein 5b ns5b rna-dependent rna polymerase rdrp hepatitis c virus hcv nucleotide analog lead deep understanding enzyme structure function substrate specificity unlike previously study dna polymerase include reverse transcriptase human immunodeficiency virus development biochemical assay hcv rdrp prove challenge low solubility full-length protein inefficient acceptance exogenous primer/template despite poor apparent specific activity hcv rdrp find support rapid processive transcription elongation initiate vitro consistent high level viral replication liver patient understanding substrate specificity hcv rdrp lead discovery active triphosphate sofosbuvir nonobligate chain-terminator viral rna transcript ternary crystal structure hcv rdrp primer/template incoming nucleotide interaction nucleotide analog 2'-hydroxyl binding pocket unfit mutation serine 282 threonine result resistance interact uracil base modify 2'-position analog host polymerase mediate off-target toxicity nucleotide analog active metabolite sofosbuvir find efficiently incorporate host polymerase include mitochondrial rna polymerase polrmt knowledge study inhibitor hcv rdrp serve advance antiviral drug discovery emerge rna virus include discovery remdesivir inhibitor severe acute respiratory syndrome coronavirus 2 sars-cov2 virus cause covid-19\",\"massive vaccination campaign global covid-19 pandemic cause sars-cov-2 virus begin worldwide january 2021 study continue investigate effective safe drug therapy manage stage viral infection critical therapeutic management patient ongoing covid-19 infection reduce viral load replication regulate generalize hyperinflammatory state cause cytokine storm occur severe phase probably right drug therapy represent use different drug act different modality different target avoid viral drug resistance article describe interesting scientific pharmacological hypothesis arise evidence literature believe association baricitinib/remdesivir/rhace2 administer right time dose represent important pharmacological synergism therapeutically effective treatment covid-19 infection single administration drug avoid phenomenon drug resistance cause virus\",\"hepatitis c virus hcv major cause chronic liver disease hold significant role develop liver cirrhosis hepatocellular carcinoma combination therapy pegaferon ribavirin lead viral clearance 50 patient host antiviral response protein kinase r pkr interact eukaryotic translation initiation factor 2 alpha eif2\\u03b1 lead inhibition viral protein synthesis viral ns5a protein appear interfere antiviral action evade host immune response mutation ns5a gene observe render hcv susceptible treatment aim study determine mutation present ifn sensitivity determine region isdr ns5a-pkrbinde domain region chronic hcv infected patient therapy\",\"antiviral efficacy remdesivir sars-cov-2 controversial aim evaluate clinical efficacy remdesivir plus standard care compare standard care patient admit hospital covid-19 indication oxygen ventilator support\",\"unprecedented 2013 2016 west africa ebola outbreak accelerate medical countermeasure mcms ebola virus disease evd investigational product ip use outbreak conclusive efficacy result randomized controlled trial rct zmapp promise inconclusive recently second-largest ebola outbreak north kivu ituri province democratic republic congo drc ip include small molecule remdesivir monoclonal antibody mab cocktail zmapp regn-eb3 single mab mab114 evaluate rct pamoja tulinde maisha palm study product regn-eb3 mab114 demonstrate efficacy compare control arm zmapp remarkably effect record trial fda approve medication scientifically sound study mark watershed moment field evd therapy product produce relatively inexpensively stockpile administration mab evd patient appear safe effective critical knowledge gap remain impact early administration ebola-specific mab develop robust immune response future ebola virus exposure unknown viral mutation escape lead resistance present potential limitation single mab therapy improvement need explore understand contribution fc-mediated antibody function antibody-dependent cellular cytotoxicity adcc approve mab critical potential merit combination therapy post-exposure prophylaxis pep need demonstrate furthermore palm trial account 30 mortality despite administration specific treatment putative role ebov soluble glycoprotein sgp decoy immune system virus persistence relapse investigate treatment failure development pan-filovirus pan-species mab remain essential protection interaction fda-approved mab vaccine remain unclear need investigate review summarize efficacy safety result palm study review current research question development mab pre-exposure emergency post-exposure use\",\"transporter human liver play major role clearance endo- xenobiotic apical canalicular transporter extrude compound bile basolateral hepatocyte transporter promote uptake expel compound from/into venous blood stream present work examine vitro interaction key repurposed drug advocate treat covid-19 lopinavir ritonavir ivermectin remdesivir favipiravir key drug transporter hepatocyte transporter include abcb11/bsep abcc2/mrp2 slc47a1/mate1 canalicular membrane abcc3/mrp3 abcc4/mrp4 slc22a1/oct1 slco1b1/oatp1b1 slco1b3/oatp1b3 slc10a1/ntcp reside basolateral membrane lopinavir ritonavir low micromolar concentration inhibit bsep mate1 exporter oatp1b1/1b3 uptake transporter ritonavir similar inhibitory pattern inhibit oct1 remdesivir strongly inhibit mrp4 oatp1b1/1b3 mate1 oct1 favipiravir significant effect transporter general drug metabolism drug-induced liver toxicity strongly dependent functioning transporter interaction report important clinical relevance drug treatment viral disease exist co-morbiditie\",\"antiviral remdesivir approve regulatory body european medicines agency ema food drug administration fda treatment covid-19 efficacy debate toxicity concern limit therapeutic range drug computational model aid balance efficacy toxicity great help parametrize model difficult prodrug remdesivir metabolize active form rdv-tp cell entry complicate dose-activity relationship employ computational model allow drug efficacy prediction base binding affinity rdv-tp target polymerase sars-cov-2 identify optimal infusion rate maximize remdesivir efficacy assess drug efficacy suppress wild-type resistant strain describe drug regimen select resistance result differ prediction use prodrug dose-response curve pseudo-ec50s expect reach 90 inhibition ec90 insufficient suppress sars-cov-2 lung standard dosing mildly inhibit viral polymerase likely reduce morbidity expect selection resistant mutant realistic parameter range increase efficacy safeguard resistance recommend clinical trial dose regimen substantially increase level rdv-tp and/or pair remdesivir companion antiviral\",\"increase severity plant disease emergence pathogen resistance urgent need development new efficient environment-friendly pesticide marine natural product mnp resource rich diverse structural simplification base mnp important strategy find novel pesticide candidate work marine natural product 6\\u2033-debromohamacanthin 1a efficiently prepare select parent structure series hamacanthin derivative design synthesize study antiviral antifungal activity compound display high antiviral activity ribavirin antiviral activity compound 1a 13e-13h similar high ningnanmycin efficient anti-plant-virus agent compound 13h select antiviral mechanism research transmission electron microscopy molecular docking fluorescence titration result compound 13h bind tmv cp interfere assembly process tmv cp rna addition hamacanthin derivative exhibit broad-spectrum inhibitory effect common agricultural pathogen compound 1a 12b 12f excellent fungicidal activity consider new fungicidal candidate research result provide basis application hamacanthin alkaloid crop protection\",\"detailed information intrahost viral evolution sars-cov-2 treatment limited sequential viral load deep sequencing sars-cov-2 upper respiratory tract hospitalize child treat remdesivir reveal remdesivir treatment suppress viral load patient second infect identical strain evidence drug resistance find reduce level subgenomic rna treatment second patient suggest additional effect remdesivir viral replication haplotype reconstruction uncover persistent sars-cov-2 variant patient likely arise within-host evolution superinfection exclude case dataset small observe sample-to-sample heterogeneity variant frequency patient suggest presence discrete viral population lung incomplete population sampling diagnostic swab compartmentalization compromise penetration remdesivir lung limit drug vivo efficacy observe lung infection\",\"favipiravir broad-spectrum inhibitor viral rna-dependent rna polymerase rdrp currently use manage covid-19 accumulation mutation severe acute respiratory syndrome coronavirus 2 sars-cov-2 rdrp facilitate antigenic drift generate favipiravir resistance focusse chain-termination mechanism utilize favipiravir use high-throughput interface-based protein design generate 100 000 design favipiravir-binding site rdrp identify mutational hotspot identify single-point mutant design sequence identity 97%-98 wild-type rdrp suggest sars-cov-2 develop favipiravir resistance mutation 134 mutation document cov-glue database 63 specific mutation predict resistant calculation attain \\u02dc 47 correlation sequencing datum finding improve understanding potential signature adaptation sars-cov-2 favipiravir\",\"background world health organization identify need understanding patient hepatitis c virus hcv cure ultrashort course hcv therapy method total 202 individual chronic hcv randomise fixed-duration shorten therapy 8 week vs variable-duration ultrashort strategy vus1/2 participant cure follow first-line treatment retreat 12 week sofosbuvir/ledipasvir/ribavirin primary outcome sustain virological response 12 week svr12 first-line treatment retreatment participant factorially randomise receive ribavirin first-line treatment result evaluable participant achieve svr12 overall 197/197 100 95 ci 98 100 demonstrate non-inferiority fixed-duration variable-duration strategy difference 0 95 ci -3.8 3.7 4 pre-specified non-inferiority margin first-line svr12 91 86%-97 92/101 fixed-duration vs 48 39%-57 47/98 variable-duration significantly high vus2 72 56%-87 23/32 vus1 36 25%-48 24/66 overall first-line svr12 72 65%-78 70/101 ribavirin 68 61%-76 69/98 ribavirin p=0.48 treatment failure emergence viral resistance low ribavirin 12 2%-30 3/26 38 21%-58 11/29 p=0.01 conclusion unsuccessful first-line short-course therapy compromise retreatment sofosbuvir/ledipasvir/ribavirin 100 svr12 svr12 rate significantly increase ultrashort treatment vary 4 7 week 4 6 week ribavirin significantly reduce resistance emergence fail first-line therapy isrctn registration 37915093 11/04/2016\",\"member genus ebolavirus cause lethal disease human zaire ebolavirus ebov pathogenic 90 morality bundibugyo ebolavirus bdbv pathogenic \\u223c37 mortality historically lack research bdbv mean study bdbv outside high-containment laboratory describe minigenome replication system study bdbv transcription compare efficacy small-molecule inhibitor ebov bdbv use system examine ability polymerase complex protein ebov bdbv interact form functional unit impact genomic untranslated end know contain important signal transcription 3'-untranslated region replication 5'-untranslated region level compatibility observe protein polymerase complex ebolavirus result difference genome transcription efficiency pronounced effect nucleoprotein 3'-untranslated region datum suggest intrinsic specificity polymerase complex untranslated signaling region offer insight regard observe pathogenic difference far add difference polymerase complex posttransfection/infection treatment compound remdesivir gs-5734 great inhibitory effect bdbv ebov delay growth kinetic bdbv great susceptibility polymerase inhibitor indicate disruption polymerase complex viable target therapeutic importance ebolavirus disease viral infection fatal 25 90 case depend viral specie supportive care available specie cause outbreak democratic republic congo zaire ebolavirus ebov bundibugyo ebolavirus bdbv pathogenesis clinical outcome differ specie limited information regard viral mechanism difference previous study suggest bdbv replicate slow ebov unknown difference polymerase complex role transcription replication study detail construction minigenome replication system use biosafety level 2 laboratory system important study polymerase complex bdbv compare filovirus use tool screen inhibitor viral growth\",\"present global vaccination sars-cov2 virus 2019 covid-19 95 effective generally viral infection arduous cure mutating nature viral genome consequent quick development resistance pose significant fatality hazard novel corona viral strain increasingly lethal early variant evolve fast imagine despite emergence present innovative treatment option vaccine available drug need time repurpose approve pharmaceutical drug well-known safety profile ascertain provide fast antiviral approach new strain covid-19 recently combination remdesivir competitively inhibitory effect nucleotide uptake virus merimepodib inhibitor enzyme inosine monophosphate dehydrogenase role synthesis nucleotide guanine basis use phase 2 clinical trial new investigation suggest use remdesivir statistically significant difference uncertain clinical importance moderate covid-19 patient intellectual selection approve drug base safety profile describe target essential enzyme require virus-receptor contact fusion and/or different stage life cycle virus help screen drug newer strain covid-19.graphical abstract\",\"current sars-cov-2 pandemic identification effective antiviral drug crucial unfortunately specific treatment vaccine available date\",\"antiviral drug avds primary resource global battle virus include recent fight corona virus disease 2019 covid-19 avd require multiple medication use frequently lead drug resistance poor oral bioavailability low efficacy low solubility/low permeability characterize vivo metabolism pharmacokinetic characteristic avds help solve problem associate avds enhance efficacy review avds systematically investigate structure-based metabolic reaction related enzyme cellular pharmacology effect metabolism avd pharmacodynamic pharmacokinetic far assess delivery system achieve metabolism pharmacology avds review suggest suitable nanosystem help achieve pharmacological activity pharmacokinetic behavior avds alter drug metabolism utilization advanced nanotechnology appropriate administration route notably avds ribavirin remdesivir favipiravir chloroquine lopinavir ritonavir confirm bind severe acute respiratory syndrome-like coronavirus sars-cov-2 receptor represent anti-covid-19 treatment elucidate metabolic pharmacokinetic characteristic avds help pharmacologist identify new formulation high bioavailability efficacy help physician treat virus-related disease include covid-19\",\"chronic viral infection cd8 t cell rapidly lose antiviral immune-stimulatory function sustained program term exhaustion addition loss function cd8 t cell high affinity viral antigen physically delete consequently treatment design restore function exhausted cell control chronic viral replication limit onset decrease breadth antiviral t cell response remain unclear certain population cd8 t cell delete preserve exhausted state report cd8 t cell deletion chronic viral infection prevent therapeutically lower viral replication early infection initial resistance deletion enable long-term maintenance antiviral cytolytic activity delete high-affinity cd8 t cell combination decrease virus titer cd4 t cell help prolonged interaction costimulatory molecule b7 1/b7 2 require prevent cd8 t cell deletion therapeutic strategy decrease early virus replication enhance virus-specific cd8 t cell diversity function chronic infection\",\"clinical study report efficacy favipiravir reduce viral load shorten duration symptom viability sars-cov-2 context favipiravir therapy potential resistance development unclear\",\"complex interplay host viral factor pathogenesis chronic hepatitis c chc consider challenging issue infection hepatitis c virus hcv confine liver induce disturbance organ system primary aim study evaluate biological response rate sustained virological response svr patient diagnose chc treat interferon-alpha ifn-\\u03b1 pegylated (peg)-ifn-\\u03b12a -\\u03b12b plus ribavirin second aim study identification predictive factor favorable response antiviral therapy patient diagnose chc enrol study 210 patient diagnose chc accomplish inclusion exclusion criterion treat peg-ifn plus ribavirin patient recovery progress evaluate determine age gender biochemical test alanine aminotransferase alt aspartate aminotransferase ast serological assay detect anti-hcv antibody molecular assay detect quantify and/or characterize hepatitis c viral load ribonucleic acid hcv-rna liver histopathological hp examination accord response treatment classify responder n=145 non-responder n=65 liver biopsy histopathologically evaluate necroinflammatory grade fibrosis stage accord modify ishak metavir scoring system chronic hepatitis demographic laboratory hp result introduce statistical analysis parameter include area curve auc analysis order estimate degree influence early virological response evr svr study demonstrate factor connect treatment failure chc link old age high hepatitis c viral load impair glucose tolerance beginning treatment high fasting glucose insulin high homeostatic model assessment insulin resistance homa-ir index liver histology feature high fibrosis score liver steatosis iron infiltration high necroinflammatory activity analyze result study homa-ir index serum insulin level baseline hcv-rna baseline mean blood glucose hp score like ishak fibrosis score steatosis score liver iron score predictive value obtain evr patient diagnose chc\",\"abuse ribavirin antiviral drug poultry breeding cause quality degradation drug resistance great importance establish simple effective method detect ribavirin food work aptamer especially bind ribavirin high affinity obtain capture-selex method 15 round enrichment ssdna library pool enriched analyze high-throughput sequencing seven enriched sequence select candidate aptamer affinity specificity characterization candidate aptamer apt-1 prove optimal aptamer dissociation constant kd value apt-1 obtain method colorimetric fluorescence 34.34 \\u00b1 6.038 nmol l[-1 61.19 \\u00b1 21.48 nmol l[-1 respectively study binding mechanism select aptamer molecular docking conduct result indicate hydrogen bond form bind site located g37 t38 a40 t53 a54 furthermore confirm practicability select aptamer fluorescence assay design liner range 1.0 50 ng ml[-1 low detection limit 0.67 ng ml[-1 aptamer apply detection ribavirin chicken sample recovery range 87.26 105.57 great application potential food safety\",\"shorten treatment duration chronic hepatitis c increase feasibility reduce cost cure aim study compare 4 week glecaprevir/pibrentasvir gle/pib treatment ribavirin patient chronic hepatitis c favourable baseline characteristic monitor development resistance-associated substitution ra re-treatment outcome treatment fail\",\"interactive network transcription factor tf critical role epigenetic gene regulation cancer progression require clarify underlie mechanism transcriptional activation concerted effort tf essential role disease phase-specific tf collaboration change advanced prostate cancer pc investigation transcriptome castration-resistant pc crpc reveal oct4 key tf disease pathology oct4 confer epigenetic change promote complex formation foxa1 androgen receptor ar central signal progression crpc oct4 facilitate distinctive complex formation nuclear respiratory factor 1 nrf1 gain chemo-resistance absence ar mechanistically reveal oct4 increase large droplet formation ar/foxa1 nrf1 vitro disruption tf collaboration use nucleoside analogue ribavirin inhibit treatment-resistant pc tumor growth finding highlight formation tf collaboration potent therapeutic target advanced cancer\",\"variety antiviral treatment covid-19 investigate involve repurposed drug currently sars-cov-2 rna-dependent rna polymerase rdrp encode nsp12-nsp7-nsp8 target numerous inhibitor e.g. remdesivir provisionally approve treatment to-date clinical impact intervention remain inconclusive potential emergence antiviral resistance pose threat efficacy successful therapy wide scale propose framework monitor emergence antiviral resistance proof concept address interaction rdrp remdesivir sars-cov-2 rdrp purifying selection potential escape mutation rare circulate lineage mutation present destabilise rdrp 56,000 viral genome 105 country pandemic wave find negative selective pressure affect nsp12 tajima d -2.62 potential antiviral escape mutation 0.3 sequence genome potential escape mutation include know key residue nsp12:val473 nsp12:arg555 potential escape mutation involve globally silico structural model find unlikely associate loss stability rdrp potential escape mutation find local cohort remdesivir treat patient collectively finding indicate rdrp suitable drug target remdesivir exert high selective pressure anticipate framework start point large effort global monitoring drug resistance covid-19 pandemic\",\"favipiravir nucleoside analogue treat influenza event new pandemic previously describe favipiravir resistant influenza virus generate vitro passage presence drug mutation k229r pb1 confer resistance cost polymerase activity p653l pa compensate cost polymerase activity clinical relevance mutation unclear mutation find natural isolate unknown virus harbour mutation replicate transmit vivo infect ferret mix wild type p(h1n1 2009 correspond favipiravir-resistant virus test replication transmission absence drug favipiravir-resistant virus successfully infect ferret transmit contact transmission respiratory droplet route sequencing reveal mutation confer resistance k229r decrease frequency time ferret modelling reveal fitness advantage pa p653l mutant reassortment wild-type virus gain wild-type pb1 segment vivo result loss pb1 resistance mutation k229r demonstrate fitness advantage pa p653l background start virus a/england/195/2009 maladapte pa wave isolate 2009 pandemic fitness advantage p653l recent ph1n1 influenza virus whilst favipiravir-resistant virus transmit vivo likelihood resistance mutation retain absence drug pressure vary depend genetic background start viral strain\",\"evaluate clinical virological safety outcome lopinavir/ritonavir lopinavir/ritonavir-interferon (ifn)-\\u03b2-1a hydroxychloroquine remdesivir comparison standard care control coronavirus 2019 disease covid-19 inpatient require oxygen and/or ventilatory support\",\"retreatment glecaprevir/pibrentasvir g/p result rate sustained virologic response 12 week treatment completion svr12 90 hcv 1 gt1 patient previously fail regimen sofosbuvir plus ns5a inhibitor ns5ai study investigate prevalence impact baseline ns3 ns5a resistance-associated substitution ras efficacy g/p prior gt1 sofosbuvir+ns5ai failure persistence treatment-emergent ras\",\"covid-19 pandemic severely destruct human life worldwide suitable treatment sars-cov-2 virus unprecedented resistance number therapeutic spread rapidly high mortality warrant need discover new effective drug combat situation current study undertake explore antiviral potential marine algal compound inhibit viral entry multiplication use computational analysis prove drug discovery target sars-cov-2 spike glycoprotein 3-chymotrypsin-like protease responsible virus attachment viral genome replication host cell study above-mentioned drug target dock marine algal compound sulfated polysaccharide polysaccharide derivative polyphenol use molecular docking tool autodocktool obtain result indicate \\u03ba-carrageenan laminarin eckol trifucol \\u03b2-d-galactose top-ranking compound docking score sars-cov-2 target current experimental covid-19 antiviral drug like dexamethasone remdesivir favipiravir miv-150 far molecular dynamic simulation admet density functional theory calculation evaluate substantiate finding good knowledge report silico analysis aforesaid algal metabolite sars-cov-2 target study conclude metabolite curative covid-19 hour need validation vitro vivo testing communicate ramaswamy h. sarma\",\"current recommendation treat hepatitis c virus hcv hiv patient include combination sofosbuvir sof daclatasvir dcv dcv use different dose compensate interaction antiretroviral therapy art pill day require significantly add pill burden patient study use single-tablet approach treat hcv-hiv coinfection\",\"replication rna virus characterize exploration sequence space facilitate adaptation change environment generally accept exploration place mainly response positive selection diversification boost modification virus population size particularly bottleneck event recent result hepatitis c virus hcv expansion sequence space viral clone continue despite prolonged replication stable cell culture environment diagnosis expansion base quantification diversity index occurrence intra-population mutational wave variation mutant frequency great individual residue variation mutant spectrum anticipate sequence alignment data bank present report review previous result additionally mutational wave amplicon ns5a-ns5b-coding region equally prominent hcv passage absence presence mutagenic nucleotide analogue favipiravir ribavirin addition extend previous analysis amplicon ns3- ns5a-coding region provide evidence incongruence amino acid conservation score mutant spectrum infected patient los alamos national laboratory hcv datum bank hypothesize observation common origin permanent state hcv population disequilibrium extensive viral replication absence external selective constraint change population size persistent disequilibrium-reveale change composition mutant spectrum-may facilitate find alternative mutational pathway hcv antiviral resistance possible significance model genetically variable virus discuss\",\"direct-acting agent daa target inhibit essential viral replication protein revolutionize treatment hepatitis c virus hcv infection reach high level sustained virologic response detection basal resistance-associated substitution ras daa na\\u00efve patient important predict treatment outcome patient exhibit failure daa-based therapy aim work evaluate presence ras minority variant intra-host viral population assess relationship response therapy multiple time relapser patient infect chronically hcv\",\"number confirm covid-19 case rapidly increase direct treatment disease repurposed drug remdesivir chloroquine hydroxychloroquine lopinavir ritonavir test sars-cov-2 remdesivir drug choice ebola virus disease authorize emergency use drug act sars-cov-2 inhibit rna-dependent-rna-polymerase rdrp sars-cov-2 rdrp virus prone mutation confer drug resistance recent study pachetti 2020 identify p323l mutation rdrp protein sars-cov-2 study aim determine potency lead compound similar remdesivir use alternative variant sars-cov-2 develop resistance rdrp mutation initial screening yield 704 compound 90 similar control drug remdesivir evaluation drugability antiviral inhibition percentage analysis shortlist 32 seven compound respectively seven compound far analyze molecular interaction reveal seven compound interact rdrp high affinity remdesivir native condition compound fail interact mutant protein high affinity remdesivir dynamic cross-correlation matrix dccm vector field collective motion analysis perform identify precise movement dock complex residue furthermore compound schembl20144212 high affinity native mutant protein provide alternative sars-cov-2 variant confer resistance remdesivir validation vitro vivo study need confirm efficacy lead compound inhibition sars-cov-2\",\"antiviral therapeutic effective avenue control end devastating covid-19 pandemic viral rna-dependent rna polymerase rdrp sars-cov-2 recognize valuable target antiviral cell-free sars-cov-2 rdrp biochemical assay require conversion nucleotide prodrug active triphosphate form regularly occur cell complicated multiple-step chemical process vitro hinder utility cell-free assay rapid discovery rdrp inhibitor addition sars-cov-2 exoribonuclease provide proof-reading capacity viral rdrp create relatively high resistance threshold viral rdrp nucleotide analog inhibitor examine evaluate development class antiviral report cell-based assay evaluate efficacy nucleotide analog compound sars-cov-2 rdrp assess tolerance viral exoribonuclease-mediated proof-reading test seven commonly use nucleotide analog viral polymerase inhibitor remdesivir molnupiravir ribavirin favipiravir penciclovir entecavir tenofovir find molnupiravir remdesivir strong inhibition sars-cov-2 rdrp ec50 value 0.22 \\u03bcm 0.67 \\u03bcm respectively result suggest exoribonuclease nsp14 increase resistance sars-cov-2 rdrp nucleotide analog inhibitor determine remdesivir present high resistance viral exoribonuclease activity cell develop cell-based sars-cov-2 rdrp assay deploy discover sars-cov-2 rdrp inhibitor urgently need treat covid-19 patient\",\"limited literature prevalence baseline resistance associate substitution bl-ras hcv-hiv co-infecte patient association treatment outcome available especially india present study aim study naturally occur ras non-cirrhotic hcv-hiv co-infecte patient impact response anti-hcv therapy\",\"ns5b polymerase inhibitor represent cornerstone present treatment hepatitis c virus infection hcv naturally occur substitution mutation ns5b inhibitor record current study intend demonstrate possible natural direct act antiviral (daa)-mutation hcv ns5b region hcv patient minia governorate egypt\",\"sars-cov-2 replication transcription complex rtc comprise nonstructural protein nsp 2 16 play crucial role viral replication reduce efficacy broad-spectrum nucleoside analog drug remdesivir evade innate immune response study target specific viral component rtc main protease rna-dependent rna polymerase contrast strategy target multiple conserve domain rtc prevent sars-cov-2 genome replication create high barrier viral resistance and/or evasion antiviral drug clinically safe zn-ejector drug disulfiram ebselen target conserve zn[2 site sars-cov-2 nsp13 nsp14 inhibit nsp13 atpase nsp14 exoribonuclease activity sars-cov-2 nsp14 domain target disulfiram/ebselen involve rna fidelity control strategy allow coupling zn-ejector drug broad-spectrum nucleoside analog excise nsp14 proofreading domain proof-of-concept disulfiram/ebselen combine remdesivir synergistically inhibit sars-cov-2 replication vero e6 cell present mechanism action advantage multitargeting strategy apply type coronavirus conserve zn[2 site\",\"rna virus demonstrate vast range variant quasispecie error-prone replication viral rna-dependent rna polymerase live attenuate vaccine effective prevent rna virus infection risk reversal virulence administration test hypothesis high-fidelity viral polymerase reduce diversity influenza virus quasispecie result inhibition reversal attenuate phenotype screen high-fidelity viral polymerase use serial virus passage selection guanosine analog ribavirin consequently identify leu66-to-val single amino acid mutation polymerase basic protein 1 pb1 high-fidelity phenotype pb1-l66v confirm use next-generation sequencing analysis biochemical assay purify influenza viral polymerase expect pb1-l66v two-times-lower mutation rate decrease misincorporation rate compare wild type wt generate attenuate pb1-l66v virus temperature-sensitive ts phenotype base flumist live attenuate influenza vaccine laiv restrict virus propagation ts mutation examine genetic stability attenuate pb1-l66v virus use serial virus passage pb1-l66v mutation prevent reversion ts phenotype wt phenotype suggest high-fidelity viral polymerase contribute generate laiv high genetic stability revert pathogenic virus importance laiv currently use prescribe actively immunize individual aged 2 49 year approve infant elderly individual actually need prolong virus propagation cause apparent infection individual weak immune system recently reversion ts phenotype laiv strain currently use pathogenic virus demonstrate culture cell generation mutation associate enhance virulence laiv consider study isolate novel influenza virus strain leu66-to-val single amino acid mutation pb1 display significantly high fidelity wt generate novel laiv candidate strain harbor mutation strain high genetic stability ts phenotype reversion high-fidelity strain useful development safe laiv\",\"treatment coronavirus disease 2019 covid-19 challenge efficacy drug evaluate variability drug response observe pharmacogenetic explain variation improve patient outcome complex disease disease-related issue carefully review pharmacogenetic study covid-19 treatment aim describe pharmacogenetic variant report drug use covid-19 treatment remdesivir oseltamivir lopinavir ritonavir azithromycin chloroquine hydroxychloroquine ivermectin dexamethasone addition factor relevant design pharmacogenetic study mention variant cyp3a4 cyp3a5 cyp2c8 cy2d6 abcb1 abcc2 slco1b1 variant include pharmacogenetic study covid-19 treatment nongenetic factor drug-drug interaction inflammation consider search personalized therapy covid-19\",\"direct-acting antiviral daa drug associate high 95 sustain virological response 12 week svr12 chronic hepatitis c chc patient paucity datum regard characteristic re-treatment outcome daa treatment failure patient retrospective analysis prospectively collect database assess outcome re-treatment patient previous daa failure patient characteristic viral characteristic include resistance-associated substitution ra subgroup patient svr12 clinical outcome study 40 patient daa failure 36 retreat mean age 45.7 year 63.9 n 23 male 63.9 n 23 genotype-3 infection 63.9 n 23 cirrhotic re-treatment regimen include combination pan-genotypic daa mainly sofosbuvir velpatasvir ribavirin patient decline retreatment treatment exclude patient complete re-treatment svr12 100 irrespective svr12 3 75 15 20 lose follow-up consider treatment failure patient die liver-related cause include 83.3 hepatocellular carcinoma ras analysis 17 randomly select patient reveal dominant substitution ns5a ns5b region affect svr12 novel mutation observe conclusion re-treatment chc patient prior daa failure use pan-genotypic daa associate high svr12 rate irrespective presence ras\",\"molecular surveillance whole-genome sequencing use monitor susceptibility circulate influenza virus polymerase complex inhibitor total 12 resistance substitution find 285 genome analyze associate high level resistance natural resistance influenza antiviral currently uncommon\",\"backtrack reverse motion transcriptase enzyme nucleic acid template universal regulatory feature transcription cellular organism role virus establish present evidence backtrack extend viral realm backtrack sars-cov-2 rna-dependent rna polymerase rdrp aid viral transcription replication structure sars-cov-2 rdrp bind essential nsp13 helicase rna suggest helicase facilitate backtrack use cryo-electron microscopy rna-protein crosslinking unbiased molecular dynamic simulation characterize sars-cov-2 rdrp backtracking result establish single-stranded 3'-segment product-rna generate backtrack extrude rdrp ntp-entry tunnel mismatched nucleotide product-rna 3'-end fray enter ntp-entry tunnel initiate backtrack nsp13 stimulate rdrp backtracking backtrack aid proofreading crucial process sars-cov-2 resistance antiviral\",\"despite strict control measure implement worldwide covid-19 pandemic continue rage drug include lopinavir/ritonavir hydroxychloroquine dexamethasone remdesivir evaluate treatment covid-19 past year drug fail display efficacy treat covid-19 scientist encourage herd immunity control pandemic immunity generate natural infection sars-cov-2 precarious indicate real-world evidence form epidemiological datum manaus brazil vaccine use different platform promising approach help return normality vaccine authorize emergency use concern regard accessibility vaccination rate importantly efficacy prevent infection emerge virus variant continued virus surveillance rapid redesign new vaccine counter new variant crucial fight covid-19 rapid production extensive vaccination essential prevent emergence new variant antiviral include monoclonal antibody oral medicine need develop light uncertainty regard vaccination battle human sars-cov-2 speed fight virus especially emerge variant key win\",\"examine safety efficacy treatment protocol contain favipiravir treatment sars-cov-2\",\"viral resistance major reason virological failure patient treat direct-acting antiviral daa chronic hcv infection importance viral resistance mainly depend daa regimen hcv first-line therapy glecaprevir/pibrentasvir g/p velpatasvir/sofosbuvir vel/sof general baseline resistance analysis require high antiviral activity high barrier resistance available resistance testing help optimise therapy certain subgroup patient hcv 3 rare hcv geno/subtype voxilaprevir/velpatasvir/sofosbuvir vox/vel/sof choice second-line treatment patient follow previous daa failure rate viral eradication 90 irrespective presence resistance-associated substitution ras resource-limited setting first-generation daa available second-line therapy ras select initial antiviral therapy consider testing available rescue treatment include switch regimen new daa class optimise treatment response patient hcv 3 overrepresente group experience daa treatment failure limited datum available third-line therapy promise result achieve g/p plus sof vox/vel/sof ribavirin 12 24 week regimen administer irrespective patient ras profile\",\"use direct-acting antiviral agent daa patient chronic hcv gt 1 infection result sustained virologic response svr rate 95%-97 3%-5 patient experience virologic failure observe 41 patient infect hcv 1b fail previous treatment daa include 37 subject 90.2 liver cirrhosis total 30 73.2 subject previously receive ns5a inhibitor generation ledipasvir daclatasvir ombitasvir 11 subject 26.8 receive ns5a inhibitor second generation velpatasvir patient receive retreatment combination ombitasvir/paritaprevir/ritonavir dasabuvir 3d sofosbuvir sof ribavirin rbv compare svr12 rate depend fibrosis stage presence single double ns5a mutation l31m/v/i and/or y93h generation previously use ns5a inhibitor observe svr12 rate follow 97.6 40/41 patient overall 100 patient cirrhosis n 4 versus 97.3 cirrhosis n 37 100 single l31m/v/i y93h mutation n 22 versus 94.4 double mutation n 18 100 patient fail previous treatment first-generation n 30 versus 90.9 fail previous treatment second-generation ns5a inhibitor n 11 retreatment 3d sof rbv highly effective safe patient chronic hcv gt1b infection include liver cirrhosis fail previous treatment daa contain ns5a inhibitor fibrosis stage single simultaneous presence ns5a ras l31m/v/i y93h baseline generation previously use ns5a inhibitor impact svr12 rate\",\"objective trial assess early antiviral therapy outpatient covid-19 favipiravir plus lopinavir/ritonavir lopinavir/ritonavir favipiravir associate decrease viral load sars-cov-2 compare placebo\",\"despite current highly effective therapy direct-acting antiviral agent daa patient chronic hepatitis c virus hcv infection achieve sustained virological response svr require retreatment sofosbuvir/velpatasvir/voxilaprevir svv recommend first-line retreatment option patient aim study evaluate efficacy svv salvage therapy course daa\",\"sars-cov-2 positive-sense rna virus require rna-dependent rna polymerase rdrp replication viral genome nucleoside analog remdesivir \\u03b2-d-n[4]-hydroxycytidine antiviral candidate function chain terminator induce viral mutation impair rdrp function recently disclose cryo-em structure apo rna-bound inhibitor-bound sars-cov-2 rdrp provide insight inhibitor-bound structure capture enzyme reaction product remdesivir covalently bind rna primer strand gain structural understanding binding nucleoside analog precatalytic state molecular model develop predict noncovalent interaction complex sars-cov-2 rdrp rna catalytic metal cation mm-gbsa evaluation interaction consistent resistance-conferring mutation exist structure-activity relationship sar datum approach yield insight antiviral mechanism guide development experimental drug covid-19 treatment\",\"antiviral drug use treat ever-growing number coronavirus disease 2019 covid-19 patient consequently unprecedented drug residue discharge ambient water raise concern potential ecotoxicological effect aquatic life development antiviral drug-resistance wildlife estimate occurrence fate ecotoxicological risk 11 therapeutic agent suggest drug covid-19 treatment 13 metabolite wastewater environmental water base drug consumption physical-chemical property ecotoxicological pharmacological datum drug aid quantitative structure-activity relationship qsar modelling result suggest removal efficiency conventional wastewater treatment plant remain low 20 half substance consequently high drug residue e.g. 7402 ng/l ribavirin 4231 ng/l favipiravir 730 ng/l lopinavir 319 ng/l remdesivir combined unchanged form metabolite drug administer 100 patient 100,000 population day present secondary effluent persist environmental water ecotoxicological risk receive river water high risk quotient 1 use favipiravir lopinavir umifenovir ritonavir medium risk quotient 0.1 use chloroquine hydroxychloroquine remdesivir ribavirin risk remain low risk quotient 0.1 dexamethasone oseltamivir potential wild animal acquire antiviral drug resistance estimate low prediction suggest pressing need proper usage waste management antiviral drug improve removal efficiency drug residue wastewater\",\"severe coronavirus disease 2019 covid-19 lead cytokine storm syndrome cause acute respiratory failure syndrome death aim investigate therapeutic effect infliximab intravenous gammaglobulin ivig combination therapy patient severe covid-19 disease admit intensive care unit icu\",\"rift valley fever virus rvfv mosquito-borne bunyavirus cause rift valley fever rvf zoonotic disease wild domestic ruminant cause economic loss threat human health control vaccination rvf vaccine available livestock rvf vaccine veterinary use non-endemic country human population rvf risk area recent work favipiravir promise drug antiviral activity number rna virus lead extinction rvfv infected cell culture certain drug concentration allow recovery virus variant increase resistance favipiravir work characterize novel resistant variant genomic phenotypic level vitro vivo interestingly resistant virus display reduce growth rate c6/36 insect cell mammalian cell line highly attenuate immunogenic vivo amino acid substitution identify viral rna-dependent rna-polymerase rdrp gene virus encode type i-interferon ifn-i antagonist ns gene catalytic core motif nuclear localization associate position respectively datum help characterize novel potential virulence marker offer additional strategy safety improvement rvf live attenuate vaccine candidate\",\"hcv 4 dominate hcv epidemic egypt drug resistance effect reflect bad clinical outcome study demonstrate baseline serum interferon-\\u03b3-inducible-protein 10 ip-10 level interleukin 28b polymorphism associate resistance standard care pegylated interferon alpha ribavirin peg-ifn\\u03b1/rbv therapy development post-treatment relapse purpose assess predictive value combine ip-10 level il28b peg-ifn\\u03b1/rbv therapy response egyptian chronic hcv infection patient 4 ninety egyptian patient chronically infect hcv genotype-4 treat pegylated interferon alpha ribavirin peg-ifn\\u03b1/rbv therapy enrol serum ip-10 level determine enzyme link immunosorbent assay pre- post- treatment il-28b rs12979860 rs8099917 polymorphism perform pcr-rflp patient overall 38 patient 42.2 achieve sustained virologic response svr 52 57.8 patient non-viral response nvr pretreatment serum ip-10 mean level significantly low patient achieve svr nvr p<0.05 cc il28b polymorphism rs12979860 favorable 65.8 achieve svr tt il-28b polymorphism rs8099917 favorable 81.5 achieve svr baseline ip-10 significantly correlate cc rs12979860 tt rs8099917 combined use serum baseline ip-10 level il-28b polymorphism improve prediction svr peg-ifn\\u03b1/rbv therapy egyptian chronic hcv infection patient 4\",\"egyptian national committee viral hepatitis program lead national hepatitis c virus hcv management program globally limited datum available effect new directly act antiviral agent cardiovascular system\",\"remdesivir rdv exhibit potent antiviral activity sars-cov-2 currently drug approve treatment covid-19 little currently know potential pre-existing resistance rdv possibility sars-cov-2 genetic diversification impact rdv efficacy virus continue spread globally study 90,000 sars-cov-2 sequence globally circulate clinical isolate include sequence recently emerge united kingdom south africa variant 300 mink isolate analyze genetic diversity rna replication complex nsp7 nsp8 nsp10 nsp12 nsp13 nsp14 focus rna-dependent rna polymerase nsp12 molecular target rdv overall low genetic variation observe 12 amino acid substitution present entire rna replication complex \\u22650.5 analyze sequence high overall frequency 82.2 observe nsp12 p323l consistently increase time low sequence variation rna replication complex observe mink isolate importantly coronavirus nsp12 mutation previously select vitro presence rdv identify 2 isolate 0.002 analyze sequence addition sequence variant observe \\u22650.5 clinical isolate include p323l located near established polymerase active site site critical rdv mechanism inhibition summary low diversity high genetic stability rna replication complex observe time recently emerge sars-cov-2 variant suggest minimal global risk pre-existing sars-cov-2 resistance rdv\",\"outbreak coronavirus disease 2019 covid-19 evolve emergent global pandemic drug establish efficacy use treat covid-19 patient offlabel/compassionate use clinical trial drug repurposing attractive approach reduce time cost need prediction success start therapy optimum use repurposed drug factor consider drug-gene dug-drug interaction drug toxicity patient co-morbidity limited datum pharmacogenomic agent constitute obstacle successful covid-19 therapy article review available human genome interaction promising repurposed drug covid-19 management drug include chloroquine cq hydroxychloroquine hcq azithromycin lopinavir/ritonavir lpv/r atazanavir atv favipiravir fvp nevirapine nvp efavirenz efv oseltamivir remdesivir anakinra tocilizumab tcz eculizumab heme oxygenase 1 ho-1 regulator renin-angiotensin-aldosterone system raas inhibitor ivermectin nitazoxanide drug-gene variant pair alter therapeutic outcome covid-19 patient present major drug variant pair associate variation clinical efficacy include cq/hcq cyp2c8 cyp2d6 ace2 ho-1 azithromycin abcb1 lpv/r slco1b1 abcb1 abcc2 cyp3a nvp abcc10 oseltamivir ces1 abcb1 remdesivir cyp2c8 cyp2d6 cyp3a4 oatp1b1 anakinra il-1a tcz il6r fcgr3a major drug variant pair associate variation adverse effect include cq/hcq g6pd hemolysis abca4 retinopathy atv mdr1 ugt1a1 28 hyperbilirubinemia apoa5 dyslipidemia nvp hla-drb1 01 hla-b*3505 cyp2b6 skin rash mdr1 hepatotoxicity efv cyp2b6 depression suicidal tendency\",\"hepatitis c virus hcv account hepatitis liver cirrhosis hepatocellular carcinoma liver transplantation virus single-stranded rna virus belong flaviviridae family accord 71 million people chronic hcv infection globe 2020 plague humankind credit discovery hcv michael houghton harvey alter charles rice award 2020 nobel prize medicine contribution hope mankind cure hcv time history use pegylated interferon ribavirin jointly high svr find comparatively patient chronic liver disease excessive pain tolerate patient interferon (ifn)-based therapy rapidly replace ifn-free daa regimen onset resistance daa drug crispr-cas system use modify viral genome impair ability develop resistance cite article laugi h. discovery hepatitis c virus 2020 nobel prize medicine euroasian j hepato-gastroenterol 2020;10(2 ): 105 108\",\"coronavirus disease 2019 covid-19 cause severe acute respiratory syndrome coronavirus 2 sars-cov-2 result million death worldwide massive societal economic burden recently new variant sars-cov-2 know b.1.1.7 detect united kingdom spread country heighten public health concern raise question result effectiveness vaccine therapeutic intervention previously identify host-directed therapy antiviral efficacy sars-cov-2 infection prone development therapy resistance host-directed drug represent promise therapeutic option combat emerge viral variant host gene possess low propensity mutate compare viral gene study full-length b.1.1.7 variant virus find host-directed drug plitidepsin aplidin inhibit translation elongation factor eef1a ralimetinib inhibit p38 map kinase cascade remdesivir possess similar antiviral activity early-lineage sars-cov-2 b.1.1.7 variant evaluate human gastrointestinal lung epithelial cell line find plitidepsin order magnitude potent remdesivir virus result highlight importance continued development host-directed therapeutic combat current future coronavirus variant outbreak\",\"study aim investigate role resistance-associated substitution ras direct-acting-antiviral daa hcv 3 gt3\",\"use remdesivir treat covid-19 likely continue clinical trial complete lengthen pandemic evolving nature virus predict potential residue prone mutation crucial management remdesivir resistance use rational ligand-based interface design complement mutational mapping generate total 100,000 mutation provide insight functional outcome mutation remdesivir-binding site nsp12 subunit rdrp design 46 residue remdesivir-binding site nsp12 design retain 97%-98 sequence identity suggest mutation nsp12 require sars-cov-2 attain remdesivir resistance mutant display decrease binding affinity remdesivir suggest drug resistance hotspot residue high probability undergo selective mutation confer remdesivir resistance identify potential residue prone mutation improve understanding sars-cov-2 drug resistance covid-19 pathogenesis\",\"abma analogue dabma molecule adamantane family know perturbate endosomal pathway inhibit cell infection rna dna virus activity rabies virus rabv infection demonstrate vitro wu 2017 2019 describe detail mechanism action comparison arbidol umifenovir ribavirin broad spectrum antiviral emerge virus lassa ebola influenza hantaan virus abma dabma deliver 2 h pre-infection inhibit rabv infection vitro ec50 7.8 \\u03bcm 14 \\u03bcm respectively act post-entry cause rabv accumulation endosomal compartment dabma specifically diminish expression gtpase rab7a control fusion early endosome late endosome lysosome suggest abma dabma act different stage late endosomal pathway support different profile synergy/antagonism fusion inhibitor arbidol difference far confirm rabv mutant induce successive passage increase selective pressure particular involvement viral g protein dabma inhibition abma inhibition induce mutation disperse m g l viral protein result suggest new therapeutic perspective rabie\",\"time specific therapeutic vaccine treatment severe acute respiratory syndrome coronavirus 2 sars-cov-2 available drug treatment viral infection useful treat covid-19\",\"prolonged treatment immunosuppressed individual anti-influenza monotherapie lead emergence drug-resistant variant evaluate oseltamivir polymerase inhibitor combination influenza a/h3n2 infection mouse model mouse cyclophosphamide infect 3 \\u00d7 10[3 pfu mouse-adapted a/switzerland/9715293/2013 h3n2 virus forty-eight hour post-infection animal start oseltamivir favipiravir baloxavir marboxil bxm single combined therapy 10 day weight loss survival rate lung viral titer lvt determine neuraminidase na polymerase gene lung viral sample sequence untreated animal die oseltamivir favipiravir monotherapie delay mortality mean day death mdd 21.4 24 compare 11.4 day untreated synergistic improvement survival 80 lvt reduction observe oseltamivir/favipiravir group compare oseltamivir group bxm double/triple combination provide complete protection significantly reduce lvt oseltamivir bxm monotherapie induce e119v na i38 t pa substitution respectively resistance mutation detect combination find multiple dose regiman bxm provide superior benefit compare oseltamivir favipiravir monotherapie suggest potential drug combination reduce incidence resistance\",\"response coronavirus disease 2019 covid-19 pandemic hamper lack effective severe acute respiratory syndrome coronavirus 2 sars-cov-2 antiviral therapy report use remdesivir patient covid-19 prototypic genetic antibody deficiency x-linked agammaglobulinaemia xla despite evidence complement activation robust t cell response patient develop persistent sars-cov-2 pneumonitis progress multi-organ involvement unusual clinical course consistent contribution antibody viral clearance progression severe disease absence confounder experimental medicine approach examine vivo utility remdesivir independent course treatment observe temporally correlate clinical virological response lead clinical resolution viral clearance evidence acquire drug resistance provide evidence antiviral efficacy remdesivir vivo potential benefit select patient\",\"identification characterization develop antiviral drug resistance mutation key success antiviral therapy hepatitis c virus hcv remain worldwide highly prevalent pathogenic disease study focus hcv 1 2 3 investigation drug resistance hcv 4 predominant north africa especially significant egypt\",\"limited datum patient chronic hcv infection combination voxilaprevir vox velpatasvir vel sofosbuvir sof retreatment fail aim assess treatment failure rescue treatment option patient\",\"introduction severe acute respiratory syndrome coronavirus-2 sars-cov-2 know novel member coronavirus family cause sudden outbreak coronavirus disease-2019 covid-19 china quickly develop global pandemic effective approach find therapy epidemiological control new virus search literature pubmed scopus web knowledge google scholar mesh article abstract describe sars-cov-2 covid-19 pneumonia clinical trial drug treatment medicine area cover present study aim comprehensively overview current literature effective anti-sars-cov-2 drug expert opinion beginning pandemic disease study conduct find effective drug prevent covid-19 specific drug treatment disease drug antiviral potential effect covid-19 use treatment infectious disease drug promising therapeutic potential initial clinical study include remdesivir inhibitor rna-dependent rna polymerase favipiravir inhibitor virus replication currently remdesivir receive fda authorize use experimental drug emergency use covid-19 patient\",\"getafix trial test hypothesis favipiravir effective treatment covid-19 infection patient early stage disease compare current standard care study provide important opportunity investigate safety tolerability favipiravir pharmacokinetic pharmacodynamic profile drug mechanism resistance context covid-19 infection effect favipiravir hospitalisation duration post covid-19 health psycho-social wellbeing patient recruit study\",\"patient inherit blood disorder ibld high risk hepatitis c virus hcv infection aim work assess efficacy safety hcv direct-acting antiviral (daa)-base treatment patient ibld chronic hcv infection\",\"covid-19 pandemic cause severe acute respiratory syndrome coronavirus 2 sars-cov-2 represent unprecedented challenge global public health time review covid-19 diagnose 40 million case associate 1.1 million death worldwide current management strategy covid-19 largely supportive 2000 interventional clinical trial register u.s. national library medicine clinicaltrials.gov result clarify benefit risk candidate therapy gradually available describe recent advance understand sars-cov-2 pathobiology potential therapeutic target involve viral entry host cell viral spread body subsequent covid-19 progression highlight major line therapeutic strategy covid-19 treatment 1 repurpose exist drug use covid-19 patient antiviral medication e.g. remdesivir immunomodulator e.g. dexamethasone previously approve disease condition 2 novel biological product design target specific molecule involve sars-cov-2 viral entry include neutralize antibody spike protein sars-cov-2 regn-cov2 antibody cocktail recombinant human soluble ace2 protein counteract sars-cov-2 bind transmembrane ace2 receptor target cell finally discuss potential drug resistance mechanism provide thought regard clinical trial design address diversity covid-19 clinical manifestation note preventive vaccine cell gene therapy scope current review\",\"multidrug resistance microbe pose major health crisis demand discovery novel antimicrobial agent recent pandemic sars-cov-2 raise public health emergency country world unlike virus bacterium play significant role environmental issue bioremediation furthermore biosurfactant produce bacterial specie edge traditionally produce chemical surfactant biodegradability low toxicity interfacial activity application agriculture industry special issue focus global perspective drug discovery antimicrobial antiviral antifungal agent infectious disease issue emphasize ongoing development role microbe environmental remediation wish article publish issue enhance current understanding microbiology reader serve seed idea drug development ongoing covid-19 pandemic\",\"coronaviridae peculiar viral family large rna genome characteristic appearance endowed remarkable tendency transfer animal human beginning 21st century highly transmissible pathogenic coronaviruse cross specie barrier cause deadly pneumonia inflict severe outbreak cause human health emergency inconceivable magnitude past decade human coronaviruse emerge cause respiratory illness severe acute respiratory syndrome coronavirus sars-cov-1 middle eastern respiratory syndrome coronavirus mers-cov cause 10,000 cumulative case mortality rate 10 sars-cov-1 34.4 mers-cov. recently severe acute respiratory syndrome coronavirus virus 2 sars-cov-2 emerge china identify etiological agent recent covid-19 pandemic outbreak rapidly spread world cause nearly 22 million case \\u223c 770,000 death worldwide estimate mortality rate \\u223c3.6 pose challenge adequate effective prevention treatment currently exception nucleotide analogue prodrug remdesivir despite effort known specific prove pharmacological treatment capable efficiently rapidly induce viral containment clearance sars-cov-2 infection broad-spectrum drug human pathogenic coronaviruse confound factor paucity molecular information regard tendency coronaviruse acquire drug resistance gap fill order optimize efficacy antiviral drug light present review provide systematic update current knowledge marked global effort development antiviral strategy aim cope infection sustain sars-cov-2 human pathogenic coronaviruse display drug resistance profile attention focus antiviral drug mainly target viral protease rna polymerase spike glycoprotein test vitro and/or clinical trial promise compound prove active coronaviruse silico drug repurposing approach respect novel insight compound identify structure-based virtual screening drugbank database endow multi-targeting profile report specifically identify 14 promise compound characterize good silico binding affinity study target viral host protein ceftolozane nadh good multi-targeting profile potentially reduce emergence resistant virus strain focus potentially novel pharmacological target development compound anti-pan coronavirus activity analysis large set viral genomic sequence current review provide comprehensive specific map conserve region human coronavirus protein essential virus replication limited tendency mutate represent key druggable target novel compound virus family respect identification highly effective innovative pharmacological strategy paramount importance treatment and/or prophylaxis current pandemic potentially future unavoidable outbreak human pathogenic coronaviruse\",\"affect covid-19 pandemic lifesaving antiviral therapy identify number clinical trial perform limited develop mathematical model project multiple therapeutic approach model recapitulate off-treatment viral dynamic predict three-phase immune response simulated treatment remdesivir selinexor neutralize antibody cellular immunotherapy demonstrate rapid viral elimination possible vivo potency sufficiently high therapy dose soon peak viral load symptom develop decrease shed duration immune response intensity little effect viral area curve auc drive high early viral load potent therapy dose viral peak presymptomatic infection lower auc drug resistance emerge moderately potent agent dose viral peak result support early treatment covid-19 shed duration auc predictive clinical severity\",\"intestinal permeability critical factor orally administer drug facilitate uptake transporter limit efflux transporter metabolic enzyme intestine present study aim characterize ussing chamber system incorporate human intestinal tissue vitro model investigate impact intestinal uptake/efflux transporter intestinal absorption substrate drug human confirm function major intestinal uptake/efflux drug transporter freshly isolate human jejunum section demonstrate significant decrease mucosal uptake cefadroxil peptide transporter 1 methotrexate proton-coupled folate transporter mucosal-to-serosal permeability ribavirin concentrative nucleoside transporters/equilibrative nucleoside transporter serosal-to-mucosal permeability p-glycoprotein breast cancer resistance protein substrate presence typical inhibitor mucosal-to-serosal apparent permeability coefficient papp 19 drug include substrate drug transporter cytochrome p450 3a range 0.60 \\u00d7 10[-6 29 \\u00d7 10[-6 cm/s good correlation report fraction oral dose enter gut wall pass portal circulation escape intestinal metabolism fafg value human furthermore papp value cefadroxil methotrexate ribavirin presence corresponding transporter inhibitor underestimate fafg drug clearly intestinal uptake transporter facilitate intestinal absorption human conclusion function major intestinal uptake/efflux drug transporter maintain freshly isolate human jejunum section ussing chamber system incorporate human intestinal tissue useful evaluate impact intestinal uptake/efflux transporter intestinal absorption type drug human significance statement previous study predict intestinal absorption drug human use ussing chamber system incorporate human intestinal tissue little systematic information drug transport mediate multiple transporter system confirm function major intestinal uptake/efflux transporter freshly isolate human jejunum section demonstrate mucosal-to-serosal apparent permeability coefficient type drug good correlation report human fafg value\",\"assess efficacy repurposed drug prevent hospitalisation death patient aged 65 recent symptomatic sars-cov-2 infection covid-19 criterion hospitalisation\",\"antiviral class neuraminidase inhibitor nai polymerase inhibitor baloxavir marboxil favipiravir use prevent treat influenza infection seasonal epidemic pandemic prolonged treatment lead emergence drug resistance therapeutic combination constitute alternative prevent resistance reduce antiviral dose evaluate vitro combination baloxavir acid bxa approve drug influenza a(h1n1)pdm09 a(h3n2 determination effective concentration inhibit virus cytopathic effect 50 ec50 drug combination index ci base cell viability compusyn software use determine synergism additivity antagonism drug combination bxa nai favipiravir synergistic effect cell viability influenza effect confirm use physiological predictive ex vivo reconstruct human airway epithelium model hand combination bxa ribavirin mixed result overall bxa stand good candidate combination exist drug notably oseltamivir favipiravir improve vitro antiviral activity result consider animal clinical evaluation\",\"honeysuckle use treatment influenza virus infection thousand year china main active component functional mechanism remain elucidate honeysuckle extract include acid extract flavonoid extract total extract acids-flavonoid mixture prepare clarify main active antiviral component cytopathic effect reduction assay extract inhibit replication influenza virus h1n1 h3n2 oseltamivir-resistant mutant strain h1n1-h275y acids-flavonoids mixture strong inhibitory effect vitro ec50 value 3.8 4.1 20 \\u03bcg/ml h1n1 h3n2 h1n1-h275y respectively competitive antiviral activity oseltamivir ribavirin honeysuckle acid extract significant antiviral activity vivo oral administration acid extract dosage 600 mg/kg/d effectively alleviate viral pneumonia maintained body weight improve survival rate 30 mouse infect lethal dose h1n1 result time-of-drug addition experiment neuraminidase na inhibition assay honeysuckle extract broad-spectrum inhibitory effect influenza virus na flavonoid extract strong inhibitory effect na influenza virus h7n9 ic50 24.7 \\u03bcg/ml. result suggest extract exert antiviral activity suppress release influenza virus briefly finding demonstrate acid flavonoid extract honeysuckle major antiviral active component acid extract potential develop antiviral agent influenza virus especially oseltamivir-resistant virus\",\"remdesivir broad-spectrum antiviral nucleotide prodrug clinically evaluate ebola virus patient recently receive emergency use authorization eua treatment covid-19 approval federal select agent program centers disease control prevention institutional biosecurity board characterize resistance profile remdesivir serially passage ebola virus remdesivir selection generate lineage low-level reduce susceptibility remdesivir 35 passage find single amino acid substitution f548s ebola virus polymerase confer low-level reduce susceptibility remdesivir f548 residue highly conserve filovirus subject specific surveillance novel filovirus newly emerge variant ongoing outbreak ebola virus patient undergo remdesivir therapy homology modeling suggest ebola virus polymerase f548 residue lie f-motif polymerase active site region previously identify susceptible resistance mutation coronaviruse datum suggest molecular surveillance region polymerase remdesivir-treated covid-19 patient warrant\",\"chronic hepatitis c important cause morbidity brazilian population closely associate metabolic disturbance include insulin resistance ir evaluate homeostatic model assessment homa-ir ir entail lower sustained virologic response svr certain therapeutic regimen fast progression advanced hepatic fibrosis arrival direct act agent daa hepatitis c treatment increase need observe impact patient ir profile use therapy\",\"sars-cov-2 responsible covid-19 result large pandemic year examine molecular structure activity hepatitis c viral inhibitor compare hepatitis c virus coronavirus replication previously postulate fda-approved hepatitis c drug epclusa sofosbuvir/velpatasvir inhibit sars-cov-2 subsequently demonstrate sofosbuvir triphosphate incorporate relatively low fidelity sars-cov sars-cov-2 rna-dependent rna polymerase rdrps serve immediate polymerase reaction terminator host-like high fidelity dna polymerase investigator demonstrate ability sofosbuvir inhibit sars-cov-2 replication lung brain cell additionally covid-19 clinical trial epclusa sofosbuvir plus daclatasvir initiate country sars-cov-2 exonuclease-based proofreader maintain viral genome integrity effective antiviral target sars-cov-2 rdrp display certain level resistance proofreading activity report sofosbuvir terminate rna resist removal exonuclease substantially high extent rna terminate remdesivir drug use covid-19 therapeutic result offer molecular basis support current use sofosbuvir combination drug covid-19 clinical trial\",\"global threat sars-cov-2 effort focus treatment disease control coronaviruse react treatment survive virus alter characteristic unanswered question medical importance end bovine coronavirus bcov genus sars-cov-2 use test model finding follow treatment antiviral remdesivir select bcov variant altered genome structure develop resistance pathogenicity increase comparison wild type wt bcov. selection pressure innate immunity genome structure alter resistance develop pathogenicity increase select bcov variant furthermore select bcov variant efficiency adapt alternative host cell wt bcov. addition previously unidentified feature spike protein common target mutation different antiviral treatment pose problem vaccine development spike protein common target antibody vaccine design finding derive fundamental research contribute disease control treatment coronaviruse include sars-cov-2\",\"remdesivir rdv direct-acting antiviral agent use treat patient severe coronavirus disease 2019 covid-19 rdv target viral rna-dependent rna polymerase rdrp severe acute respiratory syndrome coronavirus 2 sars-cov-2 previously incorporation active triphosphate form rdv rdv-tp position cause delay chain termination position 3 demonstrate s861 g mutation rdrp eliminate chain termination confirm existence steric clash ser-861 incorporate rdv-tp wt rdrp increase concentration ntp pool cause gradual decrease termination result read-through increase full-length product formation rdv residue embed copy rna strand later use template efficiency incorporation complementary utp opposite template rdv compromise provide second opportunity inhibit replication structural model suggest rdv serve template incoming utp properly positioned significant clash ala-558 adjacent val-557 direct contact template base v557l mutation implicate low-level resistance rdv far v557l mutation rdrp lower nucleotide concentration require bypass template-dependent inhibition collective datum provide strong evidence template-dependent inhibition sars-cov-2 rdrp rdv biologically relevant\",\"plant disease seriously endanger agricultural production emergence drug resistance bring great challenge prevention control plant disease urgent need emergence new drug candidate work achieve efficient synthesis pulmonarin b 64 59 overall yield respectively pulmonarins b find good antiviral activity tobacco mosaic virus tmv time series pulmonarin derivative design synthesize evaluate antiviral fungicidal activity systematically compound display high anti-tmv activity commercial ribavirin compound 6a 6c 6n inactivation effect ningnanmycin emerge new antiviral candidate select 6c antiviral mechanism research reveal inhibit virus assembly interact tmv coat protein cp molecular docking result far confirm compound interact cp hydrogen bonding compound display broad spectrum fungicidal activity especially compound 6u prominent antifungal activity emerge new fungicidal candidate research current work provide reference understand application pulmonarin alkaloid plant protection\",\"evaluate impact baseline resistance-associated substitution ras direct-acting antiviral daa treatment response pegylated interferon combination ribavirin pr fail patient real-life setting\",\"ribavirin use 25 year treat patient chronic hepatitis c virus hcv infection antiviral mechanism action remain unclear study virus evolution subset sample randomized 24-week trial ribavirin monotherapy versus placebo chronic hcv patient viral resistance mechanism observe ribavirin-associated mutation cell culture perform next-generation sequencing full-length code sequence hcv recover patient week 0 12 20 32 40 analyze novel single nucleotide polymorphism snp diversity mutation-linkage week 20 increase genetic diversity observe 5 ribavirin-treated compare 4 placebo-treated hcv patient new synonymous snp particularly g-to-a c-to-u ribavirin-associated transition emergence 14 nonsynonymous snp hcv nonstructural 5b ns5b occur treat patient placebo control substitution located close ns5b polymerase nucleotide entry site linkage analysis putative resistance mutation find majority genome ribavirin-treated patient identify ns5b mutation 3a patient far introduce 3a cell-culture-adapted dbn strain study huh7.5 cell specific ns5b substitution include dbn-d148n+i363v dbn-a150v+i363v dbn-t227s+s183p confer resistance ribavirin long-term cell culture treatment possibly reduce hcv polymerase error rate conclusion prolonged exposure hcv ribavirin chronic hepatitis c patient induce ns5b resistance mutation lead increase polymerase fidelity mechanism ribavirin resistance\",\"induction highly pathogenic hepatitis c virus hcv cause chronic hepatitis round world virus easily prone develop resistance antiviral drug viral polymerase possess proofreading overlap reading frame ability explanation virus build resistance antiviral drug treatment assay available detect hcv-resistant variant base phenotypic genotypic assay generation sequencing assay little value baseline influential therapeutic decision hcv patient hcv monitoring essential clinical practice special patient thalassemia renal transplant renal failure patient undergo hemodialysis high risk acquire infection management hcv infection patient group complicate multiple effect include flu-like symptom neutropenia fever neuropsychiatric disorder limit use ribavirin coexist iron overload hcv patient suffer depression treatment discontinue defect neurochemical pathway cause interferon enhance level depression patient addition obesity find marker failure hcv treatment resistance tolerant hcv treatment option available near future\",\"obese patient present metabolic dysfunction-associated fatty liver disease mafld risk severe presentation coronavirus disease 2019 covid-19 patient likely hospitalize receive antiviral agent drug require treat acute respiratory distress syndrome systemic inflammation combat bacterial fungal superinfection reverse multi-organ failure pharmaceutical antiretroviral lopinavir/ritonavir remdesivir antibiotic antifungal agent induce drug-induced liver injury dili mechanism understand present article hypothesize obese covid-19 patient mafld high risk dili non-infected healthy individual mafld patient patient present concomitant factor individually favour dili polypharmacy systemic inflammation risk cytokine storm fatty liver nonalcoholic steatohepatitis nash insulin resistance disease link obesity obese covid-19 patient drug cause severe and/or frequent dili trigger transition fatty liver nash worsen pre-existing steatosis necroinflammation fibrosis present main mechanism drug hepatotoxic mafld include impaired activity xenobiotic-metabolizing enzyme mitochondrial dysfunction altered lipid homeostasis oxidative stress comprehensive investigation need confirm hypothesis believe current epidemic obesity related metabolic disease extensively contribute increase number case dili covid-19 patient participate presentation severity death\",\"ninth version eighth update living guideline replace early version available data supplement new recommendation publish update guideline\",\"influenza a(h1n1)pdm09 virus carry dual neuraminidase na substitution isolate immunocompromised patient administration na inhibitor mutant virus possess h275y/i223r h275y/i223 k h275y/g147r substitution na enhance cross-resistance oseltamivir peramivir reduce susceptibility zanamivir compare single h275y mutant virus baloxavir treatment option multidrug-resistant virus dual h275y mutant virus susceptibility drug g147r substitution appear stabilize na structure fitness h275y/g147r mutant virus similar somewhat wild-type virus multidrug-resistant virus able transmit human surveillance virus continue improve clinical management protect public health\",\"oxidative stress os insulin resistance ir induce hepatitis c virus hcv infection involve development chronic hepatitis c chc complication progression hepatocellular carcinoma aim study investigate effect pegylated interferon alpha ifn\\u03b1 ribavirin pegifn\\u03b1+rvb sofosbuvir ns5a inhibitor sof+inns5a ir component os hcv 20 chc patient group treatment pegifn\\u03b1+rvb n 10 sof+inns5a n 10 treatment effect os-induced damage lipid hne-hdl protein advanced glycation end product age dna 8-ohdg concentration proinflammatory cytokine il-2 tnf\\u03b1 ifn\\u03b3 alt ast gsh platelet determine superoxide dismutase sod catalase activity ir determine homa1-ir index evaluate hcv gt find gt1b 45 gt1a 30 gt2b 20 gt2a 5 viral rna undetectable week 12 sof+inns5a 100 case pegifn\\u03b1+rvb 70 case viral rna undetectable regardless treatment gt significant increase platelet concentration sod activity observe alt insulin ir decrease p 0.05 sof+inns5a treat group increase oxidative damage lipid p 0.017 protein p 0.05 parameter demonstrate difference datum confirm os persist treatment sof+inns5a pegifn\\u03b1+rvb ir consider response biomarker treatment direct-acting antiviral\",\"aim study evaluate association insulin resistance response ifn-alpha ribavirin pediatric patient chronic hepatitis c.\",\"aim clarify feature resistance-associated substitution ras failure multiple interferon (ifn)-free regimen hcv 1b infection\",\"new therapeutic option urgently need tackle novel coronavirus disease 2019 covid-19 repurpose exist pharmaceutical provide immediate treatment opportunity assess efficacy sofosbuvir daclatasvir ribavirin treat patient covid-19\",\"evaluate effect generic sofosbuvir daclatasvir sof/dcv treatment glycemic state insulin resistance lipid profile achieve sustained virological response svr diabetic chronic hepatitis c virus chc patient\",\"june 8 2018 ns3/4a protease inhibitor danoprevir approve china treat infection hcv gt 1b common hcv worldwide base phase 2 3 clinical trial 12-week regimen ritonavir-boosted danoprevir danoprevir/r plus peginterferon alpha-2a ribavirin offer 97.1 200/206 sustained virologic response post-treatment week 12 svr12 treatment-na\\u00efve non-cirrhotic patient infect hcv 1b adverse event anemia fatigue fever headache associate inclusion peginterferon alpha-2a ribavirin danoprevir-based regiman drug resistance danoprevir trace amino acid substitution q80k/r r155 k d168a/e/h/n/t/v near drug-binding pocket hcv ns3 protease despite approval clinical use danoprevir currently limit combination peginterferon alpha-2a ribavirin drive development interferon-free ribavirin-free regimen improve tolerability adherence foreseeable future pan-genotypic direct-acting antiviral clinical efficacy adverse event available treat hcv infection worldwide\",\"alphavirus arthropod-borne virus public health concern date efficient vaccine antiviral available safe human use viral replication nonstructural protein 1 nsp1 catalyze capping genomic subgenomic rna capping reaction unique alphavirus genus three-step process follow particular order transfer methyl group s-adenosyl methionine sam gtp form [m7]gtp ii guanylylation enzyme form [m7]gmp-nsp1adduct iii transfer [m7]gmp 5'-diphosphate rna yield capped rna specificity reaction designate nsp1 promising target antiviral drug development current study perform mutational analysis nsp1 position associate sindbis virus sinv ribavirin resistance venezuelan equine encephalitis virus veev context reverse genetic correlate enzyme assay use purify recombinant veev nsp1 protein result demonstrate target position strongly associate regulation capping reaction increase affinity gtp nsp1 datum veev s21a substitution naturally occur virus chikv hallmark ribavirin susceptibility finding uncover specific mechanistic contribution residue nsp1-mediated methyl-transfer guanylylation reaction\",\"viral diversity important feature hepatitis c virus hcv infection important predictor disease progression treatment response hiv/hcv co-infection associate enhance hcv replication increase fibrosis development liver disease hiv increase quasispecie diversity hcv structural gene limited datum available regard impact hiv non-structural gene hcv particularly absence direct-acting therapy genetic diversity presence drug resistance mutation rna-dependent rna polymerase ns5b gene examine 3 group woman hcv 1a infection include hcv mono-infection antiretroviral (art)-na\\u00efve woman hiv/hcv co-infection cd4 cell count 350 cells/mm3 art-na\\u00efve woman hiv/hcv co-infection cd4 cell count \\u2265350 cells/mm3 treat hcv infection evidence significant diversity entire ns5b gene woman nucleotide amino acid distinct distribution study group obvious clustering ns5b sequence observe base hiv co-infection cd4 cell count polymorphism amino acid position associate resistance dasabuvir sofosbuvir limited q309r variant associate ribavirin resistance present 12 individual hcv mono-infection 8 hiv/hcv co-infecte individual cd4 350 cells/mm3 12 hiv/hcv co-infecte individual cd4 \\u2265350 cells/mm3 previously report fitness alter mutation rare cd8 t cell response human leukocyte antigen hla b57-restricted epitope ns5b2629 2637 ns5b2936 2944 critical hcv control completely conserve 44 51.8 70 82.4 study participant datum demonstrate extensive variation ns5b gene genotypic variation profound impact hcv replication pathogenesis deserve careful evaluation\",\"hepatitis e virus hev resistant immunosuppression reduction ribavirin treatment kidney transplant recipient mutant strain severe effect ribavirin conduct dose reduction sofosbuvir efficacy controversial peg-interferon 2 alpha peg-ifn currently contraindicate high risk acute humoral cellular rejection present study assess time effect peg-ifn kidney transplant recipient infect hev\",\"hepatitis c virus hcv ns5a-p32 deletion p32del confer potent resistance ns5a inhibitor chronic hepatitis c patient ns5a-p32del variant emerge prior direct-acting antiviral daa therapy ns5a inhibitor poor response daa retreatment report patient hcv ns5a-p32del infection treat sofosbuvir velpatasvir plus ribavirin sof/vel rbv real-world setting patient develop hcv ns5a-p32del l31f p32del l31v p32del variant follow failure daclatasvir plus asunaprevir dcv/asv therapy patient fail respond subsequent dcv/asv beclabuvir therapy remain patient fail respond subsequent glecaprevir pibrentasvir therapy patient complete 24-week sof/vel rbv therapy serum hcv rna negative end therapy patient patient ns5a-p32del ns5a-l31f p32del achieve sustained virological response 12 week completion treatment svr12 hcv relapse remain ns5a-l13v p32del patient direct sequence analysis detect additional variant ns5a ns5b region time relapse conclusion patient prior ns5a-p32del-associated daa treatment failure receive 24 week sof/vel rbv therapy patient achieve svr12\",\"plant disease cause plant virus pathogen seriously affect production storage food crop emergence drug resistance difficult control natural product source new drug discovery natural product streptindole find good antiviral activity tobacco mosaic virus tmv fungicidal activity 14 kind phytopathogenic fungi series derivative streptindole design synthesize evaluate antiviral fungicidal activity compound 4 5 11 12c 12d 13d 13i-13l high anti-tmv activity ribavirin inhibitory rate 38 37 40 500 \\u03bcg/ml inactivation curative protection activity vivo respectively compound 12d inhibitory rate 57 55 53 500 \\u03bcg/ml inactivation curative protection activity vivo respectively excellent antiviral activity far evaluate mode action mechanism research reveal 12d break three-dimensional structure tmv coat protein cp hydrogen bond inhibit assembly virus particle molecular docking result compound 12d exhibit strong interaction tmv cp derivative streptindole display broad-spectrum fungicidal activity current study provide valuable insight antiviral fungicidal activity streptindole derivative\",\"combination ledipasvir sofosbuvir ldv/sof approve treatment hepatitis c virus hcv country article present integrate analysis prospective phase ii/iii trial asia-pacific region evaluate efficacy safety 12 week ldv/sof hcv 2 patient cirrhosis compensate cirrhosis\",\"decade multiple mump outbreak occur u.s. despite high dose mmr coverage case detect dose mmr vaccine recipient wane immunity evolution wild-type virus strain setting intense exposure contribute resurgence mump typically mumps virus infection resolve clinical sequela complication occur unvaccinated severely immunocompromise individual favipiravir t-705 vitro anti-viral activity broad range positive negative strand rna virus demonstrate t-705 inhibit growth wildtype vaccine strain mumps virus vitro low micro-molar concentration ec50 8 10\\u03bcm observe development resistance subsequent passage low concentration drug viral rna protein synthesis selectively reduce compare host mrna protein synthesis antiviral treatment option mumps virus infection valuable especially area high disease burden case severe complication result present suggest study warrant\",\"picornavirus asexual sexual rna replication mechanism asexual rna replication mechanism involve parental template sexual rna replication mechanism involve parental template sexual rna replication mechanism counteract ribavirin-induced error catastrophe select ribavirin-resistant identify polymerase residue facilitate sexual rna replication mechanism use serial passage ribavirin begin variety ribavirin-sensitive ribavirin-resistant parental virus ribavirin-sensitive virus contain l420a polymerase mutation ribavirin-resistant virus contain g64s polymerase mutation g64 codon mutation g64[fix use inhibit emergence g64s-mediated ribavirin resistance revertant l420 pseudorevertant l420v l420i select independent lineage l420a g64[fix l420a g64s l420a parental virus ribavirin resistance g64s mutation select independent lineage novel ribavirin resistance mutation select polymerase lineage m299i m323i m392v t353i structural orientation m392 immediately adjacent l420 polymerase primer grip region lead engineer additional polymerase mutation m392a m392l m392v k375r r376 k l420a revertant pseudorevertant l420v l420i restore efficient viral rna recombination confirm ribavirin-induced error catastrophe coincide defect sexual rna replication mechanism virus contain m392 mutation m392a m392l m392v primer grip mutation k375r r376 k exhibit divergent rna recombination ribavirin sensitivity biochemical phenotype consistent change fidelity rna synthesis conclude extend primer grip polymerase include l420 m392 k375 r376 contribute fidelity rna synthesis efficient sexual rna replication mechanism importance picornavirus asexual sexual rna replication mechanism sexual rna replication shape picornavirus specie group contribute emergence vaccine-derived counteract error catastrophe virus distinguish homologous nonhomologous partner sexual rna replication implicate extend primer grip viral polymerase sexual rna replication mechanism sense rna sequence complementarity near active site extend primer grip polymerase potential distinguish homologous nonhomologous rna template sexual rna replication\",\"start late 2019 coronavirus disease 2019 covid-19 emerge once-in-a-century pandemic deadly consequence urgently new treatment cure support apparatus recently positive result clinical trial remdesivir approve food drug administration treat covid-19 emergency use authorization use molecular dynamic simulation free energy perturbation method study inhibition mechanism remdesivir target sars-cov-2 virus rna-dependent rna polymerase rdrp construct homology model polymerase base previously available structure sars-cov nsp12 rdrp sequence identity 95.8 build putative preinsertion binding structure align remdesivir rdrp complex atp bind rdrp rna template putative binding structure far optimize molecular dynamic simulation result stable preinsertion state remdesivir appear form hydrogen bond rna template align newly solve cryo-em structure sars-cov-2 rdrp relative bind free energy remdesivir atp calculate -2.80 \\u00b1 0.84 kcal/mol remdesivir bind strong sars-cov-2 rdrp natural substrate atp \\u223c100-fold improvement kd remdesivir atp indicate effective replacement atp blocking rdrp preinsertion site key residue d618 s549 r555 find contributor binding affinity remdesivir finding suggest remdesivir potentially act sars-cov-2 rna-chain terminator effectively stop rna replication key residue identify future lead optimization and/or drug resistance study\",\"previous study investigate impact direct-acting antiviral daa treatment lipid metabolism insulin resistance chronic hepatitis c patient compare baseline value end treatment post-treatment value result inconsistent evaluate patient treatment treatment\",\"covid-19 illness cause infection novel coronavirus sars-cov-2 rapidly spread global pandemic urgent need effective treatment present comprehensive examination host- virus-targeted function flavonolignan silibinin potential drug candidate covid-19/sars-cov-2 direct inhibitor stat3-a master checkpoint regulator inflammatory cytokine signaling immune response-silibinin expect phenotypically integrate mechanism action il-6-targeted monoclonal antibody pan-jak1/2 inhibitor limit cytokine storm t-cell lymphopenia clinical setting severe covid-19 computationally predict remdesivir-like inhibitor rna-dependent rna polymerase (rdrp)-the central component replication/transcription machinery sars-cov-2-silibinin expect reduce viral load impede delay interferon response dual ability silibinin target host cytokine storm virus replication machinery provide strong rationale clinical testing silibinin covid-19 global public health emergency randomized open-label phase ii multicentric clinical trial sil-covid19 evaluate therapeutic efficacy silibinin prevention acute respiratory distress syndrome moderate-to-severe covid-19-positive onco-hematological patient catalan institute oncology catalonia spain\",\"effective therapy treat coronavirus disease 2019 covid-19 urgently need investigational approve repurposed drug suggest potential treatment preclinical datum animal model guide search effective treatment rule lack efficacy vivo remdesivir gs-5734 nucleotide analogue prodrug broad antiviral activity[1,2 currently investigate covid-19 clinical trial recently receive emergency use authorization food drug administration[3,4 animal model remdesivir effective infection middle east respiratory syndrome coronavirus mers-cov severe acute respiratory syndrome coronavirus (sars-cov)[2,5,6 vitro remdesivir inhibit replication sars-cov-2[7,8 investigate efficacy remdesivir rhesus macaque model sars-cov-2 infection[9 unlike vehicle-treated animal macaque treat remdesivir sign respiratory disease reduce pulmonary infiltrate radiograph reduce virus titre bronchoalveolar lavage hour dose virus shed upper respiratory tract reduce remdesivir treatment necropsy remdesivir-treated animal low lung viral load reduce lung damage treatment remdesivir initiate early infection clinical benefit rhesus macaque infect sars-cov-2 rhesus macaque model represent severe disease observe patient covid-19 datum support early initiation remdesivir treatment patient covid-19 prevent progression pneumonia\",\"information exist regard direct-acting antiviral daa salvage therapy hepatitis c (hcv)-infected patient type cancer prospectively evaluate safety efficacy svr12 salvage therapy patient\",\"coronavirus disease 19 covid-19 severe acute respiratory syndrome cause sars-cov-2 2019-ncov drug approve treat disease small molecule effective viral infection clinical evaluation therapeutic abatement sars-cov-2 infection ongoing clinical trial include kaletra combination protease inhibitor approve hiv treatment remdesivir investigational drug target rna-dependent rna polymerase rdrp sars-cov-2 hydroxychloroquine approve anti-malarial immuno-modulatory drug sars-cov-2 replication depend virally encode protein rdrp papain-like proteinase helicase screen 54 fda-approved antiviral drug ~3300 investigational drug bind protein use target unbiased docking simulation computational modeling elbasvir drug approve treat hepatitis c predict bind stably preferentially protein therapeutic dosage elbasvir low toxicity liver enzyme transiently elevate 1 subject well-characterized drug-drug interaction predict treatment elbasvir combination drug grazoprevir efficiently block sars-cov-2 replication concerted action elbasvir target essential viral replication render viral mutation drug resistance extremely unlikely\",\"highly effective direct-acting antiviral daa hepatitis c treatment largely inaccessible sub-saharan africa datum treatment feasibility outcome clinical setting limit assess feasibility achieve high \\u226590 cure rate daa gastroenterology clinic cameroon\",\"background united states number new case hepatitis c virus infection rise recent year drive largely transmission young white adult 20s 30 report integrated analysis participant hepatitis c virus infection aged \\u226435 year 12 phase ii/iii clinical trial elbasvir/grazoprevir method treatment-naive -experienced adult hepatitis c virus 1 4 infection receive elbasvir 50 mg/day)/grazoprevir 100 mg/day 12 week ribavirin analysis stratify accord participant age \\u226435 year vs 35 year primary endpoint sustained virologic response hepatitis c virus rna low limit quantitation 12 week completion therapy).result sustained virologic response achieve 98.9 271/274 participant aged \\u226435 year 96.9 2093/2160 aged 35 year participant aged \\u226435 year 1b infection relapsed participant 1a infection baseline non-structural protein 5 resistance-associated substitution achieve sustained virologic response similarly 85 participant aged \\u226435 year 1a infection baseline non-structural protein 5 resistance-associated substitution achieve sustained virologic response safety favorable incidence drug-related adverse event similar young old participant 30.1 vs 30.6 participant 0.4 aged \\u226435 year 15 participant 0.7 aged 35 year discontinue treatment owe adverse event conclusion elbasvir/grazoprevir 12 week safe highly effective participant aged \\u226435 year hepatitis c virus 1 4 infection\",\"background despite outstanding result direct-acting antiviral therapy daa hepatitis c infection hcv non-responder define aim assess outcome daa linkage interferon lambda 3 ifnl3 hcv patient method case-control-study conduct 495 chronic-hcv genotype-4a previously treat egyptians daa responder 195 120 relapser interferon/ribavirin ifn/rbv 140 responder 60 relapser 98 healthy control ifnl3 distribution clinical laboratory datum assess result ct predominant egyptians 51 sensitive daa mainly ct 60 tt resistant ifn/rbv 40 29.2 sensitivity ct predominant sofosbuvir/daclatasvir responder 67.6 0.66 non-ct prevail relapser 56.7 tt respond sof/ledi regimen 66.7 ifn/rbv relapser ct commoner 50 cc predominate responder 54.3 c allele common responder ifn/rbv 71.4 t allele resistant treatment 65 relapser addition rbv sof/dcv report high resistance ct 42.2%-50 tt 17.8%-27.8 conclusion study recommend ifnl3 genotyping prerequisite stratify treatment hcv-4a egyptians\",\"relapse therapy direct-acting antiviral agent daa chronic hepatitis c virus hcv infection rare high efficacy interferon-free therapy regimen presence resistance-associated substitution ra protein target therapy lead low rate sustained virological response svr patient receive daa-therapy little evidence exist treat patient\",\"study perform develop antiviral therapy hepatitis c virus hcv infection usual treatment hcv infection combination pegylated interferon ribavirin offer restricted efficiency major effect recent development molecular biology hcv life cycle lead design drug target viral protein host factor require viral replication drug direct-acting antiviral daa specifically design inhibition viral life cycle promise tolerability short duration treatment high barrier resistance drug interaction use daa treatment hcv infection result high virological cure rate patient use combined daa regimen present drug interaction especially patient treatment co-morbiditie hand drug resistance virus infection determine success long-term therapy high genetic diversity hcv virion error-prone polymerase activity lead reduce susceptibility daa-therapy preclinical clinical analysis hcv resistance novel drug need review describe pharmaceutical approach hcv treatment structural functional property daa principle hcv drug-drug interaction finally hcv resistance daa\",\"1b common hcv worldwide account large proportion infection europe russia latin america asia reduce treatment duration improve adherence reduce drug exposure cost accordingly evaluate efficacy 8 week fixed-dose combination grazoprevir-elbasvir treatment-na\\u00efve patient non-severe fibrosis\",\"treatment 1a gt1a infection elbasvir/grazoprevir german guideline recommend differentiate approach depend baseline viral load bvl low bvl \\u2264800 000 iu/ml treatment 12 week elbasvir/grazoprevir consider high bvl 800 000 iu/ml regimen recommend nonstructural protein 5a ns5a resistance-associated substitution ras absence present ns5a ras ras-testing available 16 week elbasvir/grazoprevir ribavirin prefer investigate adherence recommendation effectiveness elbasvir/grazoprevir large german hepatitis c-registry gt1a cohort\",\"rapid global emergence sars-cov-2 cause significant health concern highlight immediate need antiviral viral rna-dependent rna polymerase rdrp play essential role viral rna synthesis remain target choice prophylactic curative treatment viral disease high sequence structural conservation date promising broad-spectrum class viral rdrp inhibitor nucleoside analogue na 25 approve treatment medically important viral disease coronaviruse stand particularly challenging case na drug design presence exonuclease exon domain capable excise incorporate na provide resistance available antiviral use available structure sars-cov rdrp exon protein lassa virus n exonuclease derive model catalytically competent sars-cov-2 enzyme map promise na candidate gs-441524 active metabolite remdesivir nucleoside active site protein identify residue important nucleotide recognition discrimination excision interestingly gs-441524 address enzyme active site manner consistent significant incorporation delay chain termination alter excision ribose 1'-cn group account increase antiviral effect compare available analogue additionally propose structural function implication previously identify rdrp resistance mutation relation resistance remdesivir study highlight importance consider balance incorporation excision property na rdrp exon.\",\"coronaviruse cov traffic frequently specie result novel disease outbreak recently exemplify newly emerge sars-cov-2 causative agent covid-19 ribonucleoside analog \\u03b2-d-n[4]-hydroxycytidine nhc eidd-1931 broad-spectrum antiviral activity sars-cov-2 mers-cov sars-cov related zoonotic group 2b 2c bat-covs increase potency cov bear resistance mutation nucleoside analog inhibitor remdesivir mouse infect sars-cov mers-cov prophylactic therapeutic administration eidd-2801 orally bioavailable nhc prodrug \\u03b2-d-n[4]-hydroxycytidine-5'-isopropyl ester improve pulmonary function reduce virus titer body weight loss decrease mers-cov yield vitro vivo associate increase transition mutation frequency viral host cell rna support mechanism lethal mutagenesis cov. potency nhc/eidd-2801 multiple covs oral bioavailability highlight potential utility effective antiviral sars-cov-2 future zoonotic covs\",\"introduction virus chikv reemerging human arthropod bear virus cause global epidemic outbreak health concern unavailability antiviral therapy/vaccine extensive research conduct target different protein chikv curtail spread virus area cover review provide overview grant patent include current status antiviral strategy target chikv.expert opinion current scenario potential molecule different approach utilize suppress chikv infection mv-chikv vrc-chkvlp059 00-vp vaccine candidate successfully complete phase clinical trial ribavirin inhibitor significant inhibition chikv replication promising candidate drug resistance toxicity modulate use inhibitors/drug combination nanoparticle formulation improve efficacy bioavailability drug\",\"hepatitis c virus hcv infection leading cause chronic liver disease hepatocellular carcinoma treatment generation protease inhibitor pi peg-interferon pegifn ribavirin rbv achieve sustained virologic response svr rate 65 75 associate multiple effect aim study evaluate safety efficacy ombitasvir/paritaprevir/ritonavir dasabuvir 3d \\u00b1 rbv hcv 1 patient fail previous treatment generation pi\",\"high-fat diet hfd predispose factor metabolic syndrome-related systemic inflammation non-alcoholic fatty liver disease nafld effective therapeutic treatment nafld remdesivir rdv gs-5734 broad-spectrum antiviral nucleotide prodrug anti-inflammatory effect effective attenuate hfd-induced metabolic disorder insulin resistance result reveal liver weight hepatic dysfunction lipid accumulation markedly increase compare control group rdv group exhibit significant reduction accompany improve signaling pathway regulate fatty acid metabolism agreement reduce lipid deposition rdv supplementation suppress systematic hepatic inflammation evidence reduction inflammatory cytokine blockage nuclear factor \\u03bab nf-\\u03bab signaling addition stimulator interferon gene sting down-streaming factor interferon regulatory factor 3 irf3 greatly increase liver hfd-fed mouse considerably restrain rdv treatment vitro analysis suggest rdv function inhibitor sting contribute suppression dyslipidemia inflammation induce palmitate pa pa-triggered lipid deposition inflammatory response far accelerate hepatocyte sting over-expression notably rdv-attenuated lipid disorder inflammation significantly abrogate over-expression sting pa-stimulated hepatocyte finding indicate rdv exhibit protective effect nafld development mainly repress sting signaling consider potential therapeutic strategy\",\"emergence resistant mutant wildly use neuraminidase inhibitor nai development novel drug necessary favipiravir t-705 rna-dependent rna polymerase rdrp inhibitor develop recent year examine efficacy t-705 influenza b virus infection vivo c57bl/6 mouse infect wild-type oseltamivir-resistant influenza b/memphis/20/96 virus treat t-705 start 2 h post inoculation hpi t-705 orally administer mouse bid dosage 50 150 300 mg/kg/day 5 day oseltamivir use control t-705 protect mouse lethal infection dose-dependent manner t-705 administration significantly reduce viral load suppress pulmonary pathology addition phenotypic assay demonstrate t-705-resistant virus emerge t-705 treatment conclusion t-705 effective protect mouse lethal infection wild-type oseltamivir-resistant influenza b virus\",\"influenza virus rna-dependent rna polymerase highly conserve influenza b c d virus comprise subunit polymerase basic protein 1 pb1 polymerase basic protein 2 pb2 polymerase acidic protein pa influenza b virus polymerase 3 protein p3 influenza c d virus polymerase essential influenza virus replication consider target antiviral agent recently polymerase inhibitor target subunit develop review discuss mechanism action antiviral activity emergence resistance inhibitor approve treatment influenza late-phase clinical trial pb1 inhibitor favipiravir pb2 inhibitor pimodivir pa inhibitor baloxavir marboxil\",\"influenza virus major threat human health globally addition far improve vaccine prophylaxis disease management antiviral therapeutic constitute important component current intervention strategy prevent advance complicated disease reduce case-fatality rate standard-of-care treatment neuraminidase inhibitor prevent viral dissemination 2018 mechanistically new influenza drug class treatment uncomplicated seasonal influenza 2 decade approve human use target pa endonuclease subunit viral polymerase complex class suppress viral replication genetic barrier viral resistance drug class low pre-existing resistance observe circulate strain resistant virus pathogenic transmit efficiently address resistance problem emerge important objective development next-generation influenza virus therapeutic review discuss status influenza therapeutic include endonuclease inhibitor baloxavir marboxil year clinical use evaluate subset direct-acting antiviral candidate different stage preclinical clinical development\",\"influenza affect approximately 1 billion individual year result 290,000 650,000 death young child immunocompromised individual particularly high risk severe illness attributable influenza group individual reduce susceptibility neuraminidase inhibitor frequently high level resistance emerge previous adamantane therapy influenza despite long use treat influenza lack selection pressure high level adamantane resistance continue persist currently circulate influenza strain resistance neuraminidase inhibitor remain low level date majority resistance influenza h1n1 pdm09 infected immunocompromised individual receive oseltamivir frequently influenza h3n2 b. rarely resistance immunocompetent evidence suggest resistant strain particularly h1n1 pdm09 able maintain replicative fitness transmissibility clear evidence infect resistant strain associate worse clinical outcome neuraminidase inhibitor resistance problematic future small number alternative novel agent anti-influenza armoury different mechanism action neuraminidase inhibitor potentially effective neuraminidase inhibitor resistant strain limited datum use novel agent baloxavir marboxil favipiravir resistance variant emerge presence drug\",\"interleukin 28b il28b associate change lipid metabolism patient infect hepatitis c virus hcv association steatosis serum level adiponectin chronic hepatitis c chc patient document study aim evaluation serum level il28b adiponectin association il28b snp different clinicopathological parameter hcv-infected patient\",\"presatovir oral respiratory virus rsv fusion inhibitor target rsv f protein double-blind placebo-controlled study healthy adult experimentally infect rsv memphis-37b presatovir significantly reduce viral load clinical disease severity dose-dependent manner\",\"hepatitis c virus hcv infection major cause chronic liver disease \\u223c71 million chronically infected individual worldwide treatment patient hcv-related liver disease advance considerably thank development new direct-acting antiviral drug administer highly potent safe well-tolerated combination high barrier resistance international organization european association study liver american association study liver diseases jointly infectious diseases society america world health organization publish detailed treatment guideline therapy widely available elimination hepatitis c public health threat 2030 envisage country region screening diagnosis linkage care necessary achieve ambitious goal\",\"hepatitis e virus hev infection emerge disease industrialized country usually characterize self-limited course increase risk hev persistence immunocompromised risk population comprise patient follow solid organ transplantation hematological malignancy recently chronic hev infection follow rituximab-containing treatment regimen describe report patient chronic hepatitis e prior rituximab therapy indication determine immunological characteristic patient analyze development ribavirin rbv treatment failure-associated mutation hev genome patient chronically hev-infected 110 month administration rituximab rtx immunological characterization reveal patient exhibit significant hypogammaglobulinemia cd4 t cell lymphopenia patient permanently clear hev follow weight-based ribavirin treatment patient fail reach sustained virological response depth mutational analysis confirm presence specific mutation associate rbv treatment failure patient case indicate rituximab-containing treatment regimen imply relevant risk persistent hev infection year rituximab application provide evidence prior observation suggest chronically hev infected patient follow rtx-containing treatment regimen difficult treat\",\"seasonal influenza virus cause major morbidity mortality worldwide threaten particular old adult immunocompromised class influenza therapeutic dominate current disease management compromise pre-existing rapidly emerge viral resistance recently report novel ribonucleoside analog clinical candidate eidd-2801 combine potent antiviral efficacy ferret human airway epithelium culture high barrier viral escape study establish fundamental eidd-2801 efficacy paradigm pandemic seasonal influenza virus iav strain ferret use inform exposure target treatment regimen base reduction shed virus titer alleviation clinical sign lower virus burden upper low respiratory tract tissue low efficacious oral dose concentration eidd-2801 twice daily 2.3 7 mg/kg body weight seasonal pandemic iav respectively late opportunity initiation efficacious treatment 36 hour infection ferret administer 12-hour interval 7 mg/kg dose eidd-2801 sufficient maximal therapeutic benefit pandemic iav significantly shorten time resolution clinical sign ferret infect pandemic iav treat follow minimally efficacious eidd-2801 regimen demonstrate significantly shed virus inflammatory cellular infiltrate nasal lavage mount robust humoral antiviral response recovery indistinguishable vehicle-treated animal result provide experimental basis human disease-relevant influenza animal model clinical testing eidd-2801\",\"sofosbuvir licensed nucleotide analog target hepatitis c virus hcv rna-dependent rna polymerase rdrp recently evaluate broad anti-flavivirus lead candidate revealing activity zika dengue virus vitro animal model study vitro antiviral activity sofosbuvir west nile virus wnv determine plaque assay pa immunodetection assay ia human cell line enzymatic rdrp assay pa sofosbuvir half-maximal inhibitory concentration ic50 1.2 \\u00b1 0.3 \\u03bcm huh-7 5.3 \\u00b1 0.9 \\u03bcm u87 7.8 \\u00b1 2.5 \\u03bcm ln-18 63.4 \\u00b1 14.1 \\u03bcm a549 cell ia anti-wnv activity confirm hepatic huh-7 1.7 \\u00b1 0.5 \\u03bcm neuronal u87 7.3 \\u00b1 2.0 \\u03bcm cell type sofosbuvir confirm inhibit purify wnv rdrp ic50 11.1 \\u00b1 4.6 \\u03bcm vitro resistance selection experiment perform propagate wnv huh-7 cell line two-fold increase concentration sofosbuvir 80 \\u03bcm significantly long time viral breakthrough observe compare low concentration 18 vs. 7 9 day post infection p 0.029 detection s604 t mutation correspond well-known s282 t substitution motif b hcv ns5b confer resistance sofosbuvir molecular docking experiment confirm s604 t mutation catalytic site rdrp affect binding mode sofosbuvir knowledge report antiviral activity sofosbuvir wnv selection mutant vitro\",\"presatovir significantly reduce nasal viral load sign symptom respiratory virus rsv infection human challenge study evaluate presatovir hematopoietic-cell transplant hct recipient rsv low respiratory tract infection lrti\",\"current ebolavirus disease evd outbreak province north kivu ituri tenth outbreak affect democratic republic congo drc outbreak occur war context second deadly ebolavirus outbreak record follow 2014 outbreak west africa drc government response consist apply package intervention include detection rapid isolation case contact trace population mapping identification high-risk area inform coordinate effort coordinate effort screen ring vaccinate conduct laboratory diagnosis use genexpert cepheid polymerase chain reaction effort include ensure safe dignified burial promote risk communication community engagement social mobilization follow adoption monitor emergency use unregistered products protocol randomized controlled trial investigational treatment mab114 zmapp regn-eb3 remdesivir carry consent patient laboratory-confirmed evd regn-eb3 mab114 promise treatment evd addition investigational vaccine rvsv-zebov-gp use follow second prophylactic vaccine ad26.zebov/mva-bn-filo reinforce prevention provision clinical supportive care remain cornerstone evd outbreak management drc response face daunting challenge include general insecurity violence community resistance appal poverty entrench distrust authority ebolavirus remain public health threat fully curative treatment unlikely game-changer setting transmission zoonotic nature limit effectiveness therapeutic intervention timing presentation\",\"use direct-acting antiviral agent daa patient chronic hcv 1 infection result sustained virologic response svr rate 95%-97 3%-5 patient experience virologic failure observe 17 patient infect hcv 1b fail previous treatment daa include 13 subject 76.5 liver cirrhosis subject 70.6 previously receive ns5a inhibitor generation ledipasvir daclatasvir subject 29.4 second generation velpatasvir patient retreat combination ombitasvir/paritaprevir/ritonavir dasabuvir 3d sofosbuvir sof ribavirin rbv compare svr12 rate depend fibrosis stage presence single double ns5a mutation l31m/v/i and/or y93h generation previously use ns5a inhibitor observe svr12 rate follow 94.1 16/17 patient overall 100 patient cirrhosis n 4 vs 92.3 cirrhosis n 13 100 single l31m/v/i y93h mutation n 7 vs 88.9 double mutation n 9 100 patient previously fail generation n 12 vs 80.0 fail second-generation ns5a inhibitor n 5 retreatment 3d 0sof rbv highly effective safe patient chronic hcv gt1b infection fail previous use ns5a inhibitor fibrosis stage baseline presence ns5a ras mutation generation previously use ns5a inhibitor impact probability achieve svr12 statistical significance demonstrate small retrospective cohort study large population need confirm predictive value baseline factor\",\"ns5a-p32 deletion p32del resistance-associated amino acid change recently gain popularity direct-acting antiviral treatment chronic hepatitis c. detect naive patient appear 5 10 hepatitis c 1b patient fail respond daclatasvir/asunaprevir sofosbuvir/ledipasvir treatment contrast signature resistance-associated substitution substitution ns5a-l31 ns5a-y93 position complete resistance ns5a inhibitor replicon cell culture study humanize liver mouse suggest p32del retain good replication fitness require class antiviral ns5a inhibitor suppress effectively patient p32del virus respond glecaprevir/pibrentasvir respond sofosbuvir/velpatasvir/voxilaprevir presumably sofosbuvir glecaprevir/pibrentasvir partially sofosbuvir/velpatasvir ribavirin attention p32del patient experience failure ns5a inhibitor especially 1b infection\",\"percentage hepatitis c virus (hcv)-infected patient fail direct act antiviral (daa)-base treatment regimen drug resistance-associated substitution ra aim study characterize resistance profile large cohort patient fail daa-based treatment investigate relationship hcv failure aid optimize management patient new standardized hcv-ras testing protocol base deep sequencing design apply 220 previously sample patient fail daa treatment collect 39 spanish hospital majority receive daa-based interferon ifn \\u03b1-free regimen 79 fail sofosbuvir-containing therapy genomic region encode nonstructural protein ns 3 ns5a ns5b daa target region analyze use subtype-specific primer viral distribution follow g 1 62.7 g3a 21.4 g4d 12.3 g2 1.8 mixed infection 1.8 overall 88.6 patient carry 1 ras 19 carry ras frequency 20 mutant spectrum difference ras selection treatment ribavirin regardless treatment receive hcv specific type ras note ras detect target protein 18.6 patient fail treatment 30.4 patient ras protein target inhibitor receive hcv patient fail daa therapy high diversity ras ribavirin use influence type number ras failure subtype-specific pattern ras emergence underscore importance accurate hcv subtyping frequency extra-target ras suggest need ras screen daa target region\",\"ribavirin remain relevant successful treatment chronic hepatitis c virus hcv infection low-income setting therapy difficult-to-treat hcv patient study effect ribavirin cell-culture adapt hcv 1 2 3 represent ~80 global infection tncc(1a sensitive ribavirin j6/jfh1(2a resistant ec50s range 21 \\u03bcm 95%ci 20 22 \\u03bcm 189 \\u03bcm 95%ci 173 207 \\u03bcm substitution position 415 ns5b result little change ribavirin sensitivity 0.7 0.9 fold confer moderate drug resistance extend treatment 1 1.8-fold ns5a ns5b sequence alter ribavirin sensitivity 2 4-fold contribution simply additive finally detect limited accumulation mutation associate ribavirin treatment finding antiviral effect ribavirin hcv strain-dependent influence specific sequence multiple hcv nonstructural protein\",\"series compound potential activity induce plant resistance synthesize indole thiol compound methodically evaluate antiviral activity result indicate synthesize compound high antipotato virus y pvy anticucumber mosaic virus antitobacco mosaic virus activity notably compound d21 exhibit good activity pvy compound vivo 50 effective concentration ec50 protection activity 122 \\u03bcg/ml distinctively corresponding value ribavirin 653 \\u03bcg/ml ningnanmycin 464 \\u03bcg/ml xiangcaoliusuobingmi 279 \\u03bcg/ml interestingly find protection activity d21 associate improvement chlorophyll content defense-related enzyme activity d21 trigger malate dehydrogenase mdh signaling pathway far confirm mdh activity evaluation d21 protect plant viral activity potential novel activator plant resistance induction\",\"influenza virus constitute major health threat economic burden globally frequently exacerbate preexist rapidly emerge resistance antiviral therapeutic address unmet need improve influenza therapy create eidd-2801 isopropylester prodrug ribonucleoside analog n [4]-hydroxycytidine nhc eidd-1931 broad anti-influenza virus activity culture cell mouse pharmacokinetic profiling demonstrate eidd-2801 orally bioavailable ferret nonhuman primate therapeutic oral dosing influenza virus-infected ferret reduce group pandemic 1 group 2 seasonal influenza shed virus load multiple order magnitude alleviated fever airway epithelium histopathology inflammation postexposure prophylactic dosing sterilize deep sequencing highlight lethal viral mutagenesis underlie mechanism activity reveal prohibitive barrier development viral resistance inhibitory concentration low nanomolar influenza b virus disease-relevant well-differentiated human air-liquid interface airway epithelia correlating antiviral efficacy cytotoxicity threshold pharmacokinetic profile human airway epithelium model reveal therapeutic window 1713 establish dosing parameter require efficacious human therapy datum recommend eidd-2801 clinical candidate high potential monotherapy seasonal pandemic influenza virus infection result inform eidd-2801 clinical trial design drug exposure target\",\"established correlation pnpla3 rs738409 c g single nucleotide polymorphism snp hepatic steatosis fibrosis hepatitis c virus hcv infected patient datum convergent regard exact impact snp pattern disease progression different clinical setting study aim far bridge knowledge gap topic investigate role g allele promote steatosis fibrosis disease progression relation metabolic anthropometric host factor consecutive patient previously diagnose chronic hepatitis c chc undergo liver biopsy histology assess use metavir scoring system transient elastography use follow-up ninety-eight patient pnpla3 rs738409 follow fibrosis progression pnpla3 rs738409[g allele significantly correlate severe steatosis p 0.04 severe fibrosis time enrollment p 0.0005 fibrosis progression 10.31 95 ci 1.06 99.59 p 0.04 mean follow-up time 62.85 95%ci 52.21 76.15 month severe steatosis time enrollment 11.02 95 ci 1.48 82.09 p 0.01 association fibrosis progression homa-ir index positively correlate severe fibrosis p 0.03 fibrosis progression univariate analysis p 0.02 pnpla3 rs738409[g allele reliable predictor steatosis fibrosis chc presence g allele severe steatosis insulin resistance significant predictor fibrosis progression\",\"hepatitis c virus hcv infection major cause chronic liver disease globally direct act antiviral daa prove effective cure hcv current standard care soc botswana remain pegylated interferon-\\u03b1 ifn-\\u03b1 ribavirin mutation report confer resistance interferon-based treatment need determine hcv botswana datum guide new treatment guideline understanding hcv epidemiology botswana\",\"background aim ravidasvir rdv new generation pangenotypic hepatitis c virus hcv ns5a inhibitor high barrier baseline resistance-associated specie phase 2/3 study conduct mainland china confirm efficacy safety rdv ritonavir-boosted danoprevir ribavirin 12 week treatment-na\\u00efve noncirrhotic patient 1 infection large population method multicenter randomize double-blinded placebo-controlled phase 2/3 trial nct03362814 enrol 424 treatment-na\\u00efve noncirrhotic adult hcv 1 patient patient randomize 3:1 ratio receive combination rdv 200 mg daily plus ritonavir-boosted danoprevir 100mg/100 mg twice daily oral ribavirin 1000/1200mg/day body weight 75/\\u226575 kg n 318 placebo n 106 12 week primary end-point rate sustained virologic response 12 week end treatment safety evaluate compare treatment placebo group result overall rate sustained virological response 12 week treatment 99 306/309 95 ci 97%-100 protocol set analysis patient harbor baseline ns5a resistance-associated specie treatment group 76/76 protocol set achieve sustained virological response 12 week treatment treatment-related adverse event report laboratory abnormality mild moderate severity grade 1 grade 2 liver function test conclusion treatment-na\\u00efve noncirrhotic hcv chinese patient infect hcv 1 all-oral regimen rdv ritonavir-boosted danoprevir ribavirin 12 week highly efficacious safe tolerated\",\"incidence fungal infection increase continuously recent year drug resistance especially resistance fluconazole flc emerge overcome challenge research antifungal activity non-antifungal agent gain attention study determine anti-candida activity ribavirin rbv antiviral drug commonly use clinic find rbv display potent antifungal activity use combination flc vitro vivo vitro mic80 value rbv 2 4 \\u00b5g/ml flc-susceptible candida albican 8 \\u00b5g/ml flc-resistant c. albican rbv dose 1 \\u00b5g/ml combine flc significant synergistic effect exhibit flc-resistant c. albican mic flc decrease 512 \\u00b5g/ml 0.25 1 \\u00b5g/ml. synergism exhibit c. albicans biofilm vivo rbv plus flc significantly improve survival infected galleria mellonella larva compare flc-treated group 4-day period attenuate damage flc-resistant c. albicans g. mellonella larva tissue furthermore mechanistic study indicate antifungal effect rbv use combination flc associate inhibition biofilm formation reduce extracellular phospholipase activity inhibition hyphal growth related promotion flc uptake inhibition flc efflux result provide promising direction overcome drug resistance expand clinical application exist drug\",\"sustained virological response svr hepatitis c virus hcv patient treat pegylated interferon \\u03b1-2a ribavirin associate reduce insulin resistance ir measure reduction homeostasis model assessment homa score 24 week therapy reduce fast serum insulin serum glucose level present meta-analysis aim evaluate effect hcv treatment response ir hcv patient achieve svr non-svr receive interferon (ifn)-based therapy pubmed cochrane embase database search use combination follow search term hcv hepatitis c interferon antiviral treatment response insulin resistance incidence ir homa-ir homa-\\u03b2 fast glucose fast insulin level summarize term basal value value end treatment study total 8 study include final analysis significant difference reduction ir svr non-svr group odd ratio 0.995 95 ci=0.613 1.616 p=0.984 svr group significantly high mean reduction homa-ir difference means=-0.485 95%ci=-0.713 -0.256 p<0.001 homa-\\u03b2 difference means=-15.448 95%ci=-23.326 -7.570 p<0.001 compare non-svr group conclusion hcv patient achieve svr ifn-based therapy exhibit improvement homa-ir homa-\\u03b2 present result suggest clinical management ir serum glucose level important way impact therapeutic response hcv patient\",\"ribavirin rbv induce nucleotide nt substitution hepatitis c virus hcv genome nonstructural ns region emergence drug resistance-associated variant associate direct-acting antiviral treatment failure effect rbv genome substitution patient unknown 1b hcv subgenomic replicon cell treat rbv 120 hour patient chronic 1b hcv-infected patient fail respond prior daclatasvir plus asunaprevir dcv/asv therapy treat 12 week sofosbuvir ledipasvir plus rbv 4 week rbv monotherapy rbv-induced genome mutation hcv ns region nt3493 9301 replicon cell patient 4 week rbv monotherapy analyze deep sequencing rbv-associated g-to-a c-to-u transition increase dose-dependent manner hcv replicon cell rbv treatment patient prior dcv/asv treatment failure median serum hcv rna level 6.25 \\u00b1 0.31 log iu/ml start rbv therapy decrease significantly 5.95 \\u00b1 0.4 log iu/ml p .03 4 week rbv monotherapy predominant hcv genome substitution rate similar nontreatment rbv-treatment period 0.042 0.031 base pair respectively p .248 frequency g-to-a c-to-u transition significantly increase rbv monotherapy transition enriched particularly hcv ns3 region patient rbv treatment induce g-to-a c-to-u transition hcv genome chronic patient hepatitis c prior dcv/asv treatment failure\",\"coronaviruse covs emerge animal reservoir cause severe lethal disease human currently fda-approved antiviral treat infection class antiviral compound nucleoside analogue mimic naturally occur nucleoside inhibit viral replication compound successful therapeutic viral infection mutagenic nucleoside analogue ribavirin 5-fluorouracil ineffective inhibit covs attribute proofreading activity viral 3'-5 exoribonuclease exon \\u03b2-d-n [4]-hydroxycytidine nhc eidd-1931 emory institute drug development recently report inhibit multiple virus demonstrate nhc inhibit murine hepatitis virus mhv 50 effective concentration ec50 0.17 \\u03bcm middle east respiratory syndrome cov mers-cov ec50 0.56 \\u03bcm minimal cytotoxicity nhc inhibit mhv lack exon proofreading activity similarly wild-type wt mhv suggest ability evade overcome exon activity nhc inhibit mhv add early infection decrease viral specific infectivity increase number proportion g c u transition mutation present single infection low-level nhc resistance difficult achieve associate multiple transition mutation genome mhv mers-cov. result point virus-mutagenic mechanism nhc inhibition covs indicate high genetic barrier nhc resistance datum support development nhc treatment covs suggest novel mechanism nhc interaction cov replication complex shed light critical aspect replication importance emergence coronaviruse covs human population animal reservoir demonstrate epidemic capability pandemic potential ability cause severe disease antiviral approve treat infection demonstrate potent antiviral activity broad-spectrum ribonucleoside analogue \\u03b2-d-n [4]-hydroxycytidine nhc divergent covs viral proofreading activity markedly impact sensitivity nhc inhibition suggest novel interaction nucleoside analogue inhibitor cov replicase far passage presence nhc generate low-level resistance likely accumulation multiple potentially deleterious transition mutation datum support mutagenic mechanism inhibition nhc far support development nhc treatment cov infection\",\"study resistance-associated substitution use next-generation sequencing egyptian hepatitis c virus-infected patient fail direct-acting antiviral treatment\",\"world health organization estimate 1 world population 71 million infect hepatitis c virus hcv 2015 direct-acting antiviral daa simeprevir smv sofosbuvir sof daclatasvir dcv include brazilian protocol treatment chronic hepatitis c. despite fact use drug associate high treatment response rate low incidence effect study association presence viral resistance mutation failure pharmacological treatment\",\"new direct-acting antiviral agent daa approve treatment patient infect hepatitis c virus hcv tolerated increase sustained virological response svr rate summarize current evidence efficacy safety comparative randomized control trial rct daa\",\"antiviral drug resistance develop new virus emerge pressing need develop strategy rapidly develop antiviral therapeutic use phospho-specific flow cytometry assess perturbation different cellular signaling pathway treatment drug combination highly effective block herpes simplex virus type 1 hsv-1 infection discover antiviral drug combination act distinct signaling pathway stat1 s6 phosphorylation block hsv-1 infection focus upregulation s6 phosphorylation hsv-1 infection subsequent find ribavirin antagonize upregulation s6 phosphorylation s6 kinase inhibitor sl0101 block hsv-1 replication vitro vivo animal model hsv-1 infection overall use unbiased analysis cellular signaling pathway treatment antiviral drug combination discover novel antiviral drug target hsv-1 infection outcome approach present highlight importance analyze antiviral drug modulate cellular pathogen-induced signaling method discover new drug therapy target\",\"treatment guideline differ recommendation determine baseline resistance associate substitution ra start first-line treatment direct-acting antiviral daa analyze efficacy daa treatment baseline ras information conduct prospective study involve 23 center collaborate gehep-004 daa resistance cohort baseline ns5a ns3 ras study sanger sequencing issue comprehensive resistance report treat physician decide therapy duration ribavirin use sustained virological response svr12 datum available 275 patient baseline ns5a ras prevalence 4.3 26.8 accord ns3 ras prevalence gt1a 6.3 overall svr12 97.8 hcv-gt1a patient 75.0 800,000 iu/ml start grazoprevir/elbasvir treat 12 week 3 ns5a y93h detect 9 patient 42.8 hcv-gt3 patient start sofosbuvir/velpatasvir include ribavirin 14.7 carry y93h efficacy baseline resistance-guided treatment cohort high prevalent hcv spain duration grazoprevir/elbasvir treatment adhere aasld/idsa recommendation cirrhotic patient infect gt-3 high use ribavirin\",\"sofosbuvir/velpatasivr/voxilaprevir sof/vel/vox approve retreatment patient hcv previous failure direct-acting antiviral daa real-life datum limit aim study assess effectiveness safety sof/vel/vox real-life setting\",\"background ns5a resistance-associated substitution ras y93h find frequently 5 10 baseline direct-acting antiviral agent daa treatment-na\\u00efve gt 3a patient study population-sequencing method cut-off 20 ras impair hcv daa treatment response possess high fold vitro resistance daclatasvir dcv velpatasvir vel gt 3 investigate effect baseline y93h patient gt 3a infection treatment outcome resistance-based daa-treatment 2014 2017 patients/method treatment intervention group n 130 tailor baseline resistance-finding population-sequencing method detection baseline y93h 20 prompt prolonged treatment duration ns5a-inhibitor sofosbuvir sof and/or addition ribavirin rbv patient baseline y93h intervention group patient control group n 78 receive recommend standard daa-treatment result higher sustained virologic response rate svr intervention group compare control group 95.4 124/130 88.5 69/78 respectively p .06 patient baseline y93h intervention group achieve svr personalised treatment base result resistance testing addition rbv prolonged treatment duration 24w control group 2/4 patient y93h baseline treat ledipasvir/sof/rbv dcv/sof rbv fail treatment conclusion result real-life study accordance finding randomised control trial 2015 easl-guideline 2016 baseline y93h impact dcv vel treatment outcome\",\"treatment option limited patient hepatitis c hcv infection treatment failure sofosbuvir plus ns5a inhibitor datum efficacy glecaprevir/pibrentasvir g/p patient perform randomized trial safety efficacy 12 16 week g/p ribavirin patient hcv 1 infection treatment failure sofosbuvir ns5a inhibitor\",\"human respiratory virus rsv common viral pathogen affect low respiratory tract reason bronchiolitis and/or pneumonia currently available effective way treat rsv infection attempt develop preventive vaccine unsuccessful therapeutic agent use rsv treatment virazole ribavirin induce adverse effect medication base neutralize monoclonal antibody igiv respigam palivizumab synagis medi-524 numab clinical trial use limit high cost promising approach antiviral therapy use natural peptide defensin cathelicidin synthetic analog majority currently describe antiviral peptide develop human immunodeficiency virus herpes simplex virus influenza virus time body experimental datum evidence anti-rsv activity peptide accumulate main advantage peptide drug wide spectrum antiviral activity low toxicity obstacle implement peptide-based drug clinical practice low resistance action serum protease consider peptide promise local application rsv affect epithelium respiratory tract protease activity low systemic circulation possible develop locally active peptide drug example inhalation form stability increase synthesis dendrimer peptide development recombinant peptide precursor protein anti-rsv peptide divide group 1 attachment and/or fusion blocker 2 peptide display direct virucidal activity disrupt viral envelope peptide suppress early stage viral life cycle consider prophylactic agent peptide immunoregulatory property describe open possibility therapeutic use review summarize information antiviral property peptide mechanism action describe prospect future development antiviral peptide\",\"direct-acting antiviral agent (daa)-based therapy 1st choice antiviral agent chronic hepatitis c world treatment period daa-based therapy greatly shorten improvement efficiency glecaprevir (gle)/pibrentasvir pib therapy enable therapeutic period reduce 12 8 week case 1 2 chronic hepatitis c liver cirrhosis currently established rescue therapy patient experience treatment failure gle/pib therapy patient rescue regimen include sofosbuvir (sof)/velpatasvir vel plus ribavirin rbv therapy gle/pib sof rbv therapy experience case daa-na\\u00efve non-cirrhotic patient 2a virologic relapse post-treatment week 13 follow 8-week gle/pib therapy confirm resistance-associated substitution gle pib try rescue patient use prolonged 12-week gle/pib therapy fortunately sustained virologic response achieve adverse event single-case report assume rare regimen effective treatment failure 8-week gle/pib therapy\",\"human innate immune play essential role spontaneous clearance acute infection therapy hcv investigate snp retinoic acid-inducible gene i-like receptor family associate hcv spontaneous clearance response treatment evaluate clinical value ddx58 rs3824456 rs10813831 rs10738889 hcv spontaneous clearance treatment response chinese han population 1001 hcv persistent infector 599 participant hcv natural clearance 354 patient pegylated interferon-\\u03b1 ribavirin peg ifn-\\u03b1/rbv treatment people carry rs10813831-g allele liable achieve spontaneous clearance carriage t allele dominant model adjust 1.35 95 ci 1.08 1.71 p 0.008 rs10738889 rate persistent infection significantly low patient tc compare tt dominant model adjust 1.36 95 ci 1.06 1.74 p 0.015 multivariate stepwise analysis indicate rs10738889 age alanine aminotransferase alt aspartate aminotransferase ast independent predictor hcv spontaneous clearance significant difference selection snp non-svr group svr group result suggest ddx58 rs10813831 rs10738889 associate spontaneous clearance hcv identify predictive marker chinese han population hcv\",\"despite highly effective direct-acting antiviral daa therapy chronic hepatitis c virus hcv infection patient experience virological relapse salvage regimen include multiple agent suppress emergence resistance-associated substitution ra minimise treatment failure combination sofosbuvir sof elbasvir/grazoprevir elb/gzr \\u00b1ribavirin rbv effective retreatment strategy hcv (gt)1 4 infection hypothesise sof elb/gzr \\u00b1rbv effective salvage regiman daa-experienced gt3 patient\",\"use antifungal agent clinical setting limit appearance drug resistance adverse effect urgent need develop new drug strengthen treatment invasive fungal disease aim study describe potential repurposing ribavirin adjunct therapy candida spp primary screening prestwick chemical library candida albicans atcc 90028 fluconazole-resistant candida albicans strain perform subsequently evaluate response 100 candida sp. strain ribavirin antiviral agent use broth microdilution method recommend clsi check involvement efflux pump activity development ribavirin resistance study time-kill curve perform checkerboard assay ribavirin-antifungal combination study twenty-one nonstandard antifungal compound identify include ribavirin ribavirin antifungal activity vitro 63 candida strain include strain c. albican c. parapsilosis c. tropicali mic range 0.37 3.02 \\u03bcg/ml mic c. krusei c. glabrata c. lusitaniae c. albicans strain remain high \\u226524.16 \\u03bcg/ml relation observe efflux pump activity ribavirin resistance ribavirin exhibit fungistatic activity multidrug-resistant mdr c. albican fungicidal activity c. parapsilosis strain addition ribavirin act synergistically azole candida strain ribavirin mic 24.4 \\u03bcg/ml study highlight potential clinical application ribavirin association antifungal agent adjunct anti-candida drug\",\"hepatitis c virus (hcv)-infected patient fail ns5a inhibitor develop resistance-associated substitution ras report use resistance-guided retreatment patient fail prior ns5a inhibitor-containing regimen gehep-004 cohort large direct-acting antiviral (daa)-resistance cohort study conduct spain aim provide indication use resistance information setting sofosbuvir/velpatasvir/voxilaprevir available\",\"examine treatment efficacy datum long-term outcome real-world japanese patient infect hepatitis c virus hcv 2 treat 12-week sofosbuvir/ribavirin combination therapy\",\"development direct-acting antiviral daa antihepatitis c virus hcv treatment highly safe effective emergence resistant-associated variant rav failure daa therapy affect retreatment outcome particular 1 hcv p32 deletion report highly resistant approve non-structural protein (ns)5a inhibitor analysis ravs 2 hcv limit accordingly study evaluate role 2 hcv variant antiviral drug efficacy\",\"current influenza antiviral limitation regard effectiveness potential emergence resistance encouragingly new compound inhibit polymerase influenza virus recently enhance pre-clinical clinical effectiveness compare neuraminidase inhibitor mainstay influenza antiviral therapy decade review focus compound inhibit polymerase function baloxavir marboxil favipiravir pimodivir al-794 discuss clinical virological effectiveness propensity select resistance potential future combination therapy commonly use neuraminidase inhibitor oseltamivir\",\"genetically diverse orthocoronavirinae cov family prone cross specie transmission disease emergence human livestock virus similar known epidemic strain circulate wild domestic animal far increase probability emergence future currently approve therapeutic human cov present clear unmet medical need remdesivir rdv gs-5734 monophosphoramidate prodrug adenosine analog potent activity array rna virus family include filoviridae paramyxoviridae pneumoviridae orthocoronavirinae targeting viral rna dependent rna polymerase rdrp develop multiple assay far define breadth rdv antiviral activity cov family potent antiviral activity rdv endemic human covs oc43 hcov-oc43 229e hcov-229e submicromolar ec50 value know covs member deltacoronavirus genus divergent rdrp compare sars- mers-cov avian porcine member harbor native residue rdrp confer resistance beta-cov rdv highly efficacious porcine deltacoronavirus pdcov datum far extend know breadth antiviral activity rdv include contemporary human highly divergent zoonotic cov potentially enhance ability fight future emerge cov.\",\"chronic viral disease constitute major global health problem million people affect associate elevated number death increase number disorder cause human flavivirus related capacity establish persistent infection usutu virus usuv emerge zoonotic flavivirus link sporadic neurologic disease human establish persistent infection cell culture independent lineage vero cell survive usuv lytic infection culture 82 day 41 cell transfer apparent cytopathology crisis associate find elevated titer supernatant cell modest fluctuation passage overall tendency increase decrease infectivity addition full-length genome viral rna isolate cell passage 40 reveal presence defective genome contain different deletion 5 end truncate transcript predict encode short polyprotein product lack membrane envelope structural protein non-structural protein 1 treatment different broad-range antiviral nucleoside reveal usuv sensitive compound context persistent infection agreement previous observation lytic infection exposure infected cell prolonged treatment 10 day favipiravir and/or ribavirin result complete clearance infectivity cellular supernatant decrease ~5 log10 virus titer rna level modest change intracellular viral rna level record 2 log10 decrease drug withdrawal treatment day 10 result relapse virus titer result encourage use persistently-infected culture surrogate system identification improve antiviral flaviviral chronic disease\",\"chronic hepatitis c virus infection represent frequent cause liver cirrhosis hepatocellular carcinoma statin inhibit hcv replication vitro enhance antiviral effect know antiviral drug reduce resistance\",\"hepatitis c virus hcv infection commonly associate disturbance glucose metabolism conflict report clearance hcv follow change serum blood glucose insulin resistance aim present study evaluate impact hcv antiviral treatment serum glucose level glucose metabolism parameter\",\"investigate hcv-rna variability prevalence resistance-associated substitution ras plasma hepatic tumoral non-tumoral tissue sample patient undergo liver-transplant/hepatic-resection lt/hr hepatocellular carcinoma and/or cirrhosis\",\"hepatitis c virus hcv infection associate insulin resistance lead type 2 diabete complication hcv infect mainly hepatocyte impair insulin sensitivity level uninfected extrahepatic tissue muscle adipose tissue aim study assess interferon-free antiviral therapy improve hcv-associated hepatic vs. peripheral insulin sensitivity\",\"hepatitis c virus hcv ns5a inhibitor abt-267 ombitasvir obv hcv ns4/4a protease inhibitor abt-450 paritaprevir ptv cyp3a inhibitor ritonavir r non-nucleoside ns5b polymerase inhibitor abt-333 dasabuvir dsv obv/ptv/r dsv ribavirin rbv direct-acting antiviral regiman approve united states major country treatment hcv 1 gt1 infected patient patient hcv consider hard-to-cure generally exclude registration trial rigorous study inclusion criterion presence comorbiditie previous treatment failure\",\"effectiveness sofosbuvir/ribavirin sof/rbv combination therapy 1[st]-choice therapeutic option patient hepatitis c virus hcv 2 hcv-g2 japan accord recent version japan society hepatology guideline patient experience failure ombitasvir/paritaprevir/ritonavir plus ribavirin obv/ptv/r+rbv combination therapy option patient hcv-g2 unknown\",\"sofosbuvir frequently use pan-genotype inhibitor hepatitis c virus hcv polymerase drug eliminate chronic hcv infection resistance-associated substitution polymerase rare hcv 3 respond slightly sofosbuvir-based therapy collect datum england national health service early access program search virus factor associate sofosbuvir treatment failure\",\"despite high efficacy direct act antiviral daa patient successfully clear hepatitis c virus infection fact approximately 1 3 fail reach sustained virological response 12 week end treatment daa failure characterize advanced liver disease specific genotypes/subtype resistance associate substitution daa class treat current european association study liver guideline recommend therapeutic option patient 12 week course sofosbuvir sof velpatasvir vel voxilaprevir vox effective 90 99 patient grant a1 level recommendation second option reserve patient predictor failure consist 12 week regiman glecaprevir gle pibrentasvir pib effective 90 97 finally support publish datum especially difficult treat patient theoretically benefit prolonged combination sof+gle/pib sof/vel/vox\\u00b1ribavirin review present late evidence clinical trial real-life therapeutic strategy\",\"treatment chronic hepatitis c virus hcv infection considerably evolve development safe well-tolerated combination direct-acting antiviral daa drug yield high rate infection cure patient fail achieve sustained virological response receive recent daa combination wave treatment failure occur concomitantly use different drug combination outcome retreatment strongly depend daa(s receive retreatment regimen(s available article discuss virological failure rate successive wave hcv combination regimen reason failure role hcv resistance current retreatment option triple combination sofosbuvir velpatasvir voxilaprevir 12 week first-line retreatment strategy patient previously expose daa difficult-to-retreat patient benefit combination sofosbuvir plus glecaprevir/pibrentasvir and/or addition ribavirin and/or long retreatment duration\",\"cirrhotic patient hepatitis c virus 3 infection unsatisfactory outcome 12 week treatment direct antiviral agent national italian drug agency allow 24 week therapy difficult-to-treat patient include 3 cirrhotic aim study evaluate efficacy safety 24-week course sofosbuvir plus daclatasvir\\u00b1ribavirin population\",\"overexpression eukaryotic translation initiation factor 4e eif4e associate enhance growth poor prognosis nasopharyngeal carcinoma npc function eif4e npc response chemotherapy reveal work demonstrate eif4e inhibition use ribavirin sirna target npc cell enhance efficacy 5-fluorouracil 5-fu mechanism study indicate 5-fu treatment increase phosphorylation eif4e npc cell dependent erk activation eif4e inhibition significantly sensitize npc cell response 5-fu note ribavirin clinically available anti-viral drug ribavirin exhibit preferential toxicity npc normal nasopharyngeal epithelial cell largely unaffected ribavirin act npc cell inhibit eif4e/akt signaling suppression eif4e ribavirin consequence inhibition eif4e upstream signaling mnk mtor independent npc xenograft mouse model ribavirin well-tolerated dose significantly inhibit npc growth single drug combination 5-fu completely arrest tumor growth duration treatment cause toxicity mouse finding provide understanding role eif4e npc response 5-fu preclinical rationale explore ribavirin sensitize strategy treat npc particularly develop 5-fu resistance\",\"senecavirus sva reemerging virus recent evidence emphasize importance sva recombination vivo virus evolution study report development infectious cdna clone sva/hlj/cha/2016 strain use strain develop reporter virus expressing enhance green fluorescent protein egfp use screen recombination-deficient sva egfp retention assay sequencing virus retain egfp follow passage allow identify nonsynonymous mutation s460l i212v-s460l combination rna-dependent rna polymerase rdrp region genome develop senecavirus-specific cell culture-based recombination assay use elucidate role rdrp sva recombination result demonstrate polymerase variant s460l i212/s460l reduce recombination capacity result indicate rdrp play central role sva replicative recombination notably result recombination-deficient variant high replication fidelity wild type wt display decrease ribavirin sensitivity compare wt addition mutant exhibit significantly increase fitness vitro compare wt result demonstrate recombination mutation rate intimately link result important implication understand crucial role rdrp virus recombination fitness especially molecular mechanism sva evolution pathogenicity importance recent evidence emphasize importance sva recombination virus evolution vivo describe assay study senecavirus recombination result rna-dependent rna polymerase play crucial role recombination recombination impact fitness sva cell culture far sva polymerase fidelity closely related recombination efficiency result provide key insight role recombination positive-strand rna virus\",\"resistance-associated substitution ras hepatitis c virus hcv ns5a region impair efficacy ns5a inhibitor study evaluate characteristic novel ras observe treatment-failure patient a92 k deletion p32 p32del susceptibility virus ras anti-hcv reagent use jfh-1 based recombinant hcv ns5a 1b con1 strain jfh1/5acon1 introduce a92 k p32del solely combination q24 k l28 m r30q l31f ns5a jfh1/5acon1 virus harbor r30q/a92 k high extracellular core antigen infectivity titer virus ras low replication level infectivity titer virus a92 k p32del markedly resistant ledipasvir velpatasvir elbasvir interestingly virus r30q/a92 k susceptible grazoprevir virus ras virus similar susceptibility ribavirin sofosbuvir conclusion combination ras r30q/a92 k enhance virus production ras impair virus replication a92 k p32del confer severe resistance second generation ns5a inhibitor virus susceptible grazoprevir ribavirin sofosbuvir combination regimen reagent eradicate virus harbor a92 k p32del\",\"resistance adjuvant chemotherapy remain therapeutic challenge nasopharyngeal carcinoma npc work demonstrate target eukaryotic translation initiation factor 4e eif4e potential sensitizing strategy overcome chemoresistance npc observe aberrant activation eif4e translational upregulation eif4e-regulated oncogene npc cell pro-longed exposure cisplatin functional analysis demonstrate eif4e depletion effectively inhibit proliferation induce apoptosis cisplatin-resistant npc cell consistently eif4e knockdown significantly enhance cisplatin efficacy cisplatin-sensitive cell identify eif4e therapeutically actionable target ribavirin anti-viral drug phenocopie effect eif4e knockdown npc far demonstrate ribavirin act chemoresistant npc cell suppress eif4e activity oncogenic protein translation use independent npc xenograft mouse model ribavirin effective inhibit chemoresistant npc growth significantly augment inhibitory effect cisplatin efficacy vivo cause significant toxicity mouse work activation eif4e-mediated growth survival mechanism response chemotherapy suggest inhibition eif4e activity represent attractive sensitizing strategy npc treatment finding suggest ribavirin useful addition treatment armamentarium npc\",\"chronic hepatitis c hcv infection perturb lipid glucose metabolism influenceof direct act antiviral daa treatment ribavirin measure evaluate furthermore effect hcv cure parameter assess participant allocatedto 12-week treatment group non-cirrhotic 1aparitaprevir/ritonavir/ombitasvir/dasabuvir prod plus ribavirin non-cirrhotic 1b-prod;compensate cirrhotic 1a 1b-prod plus ribavirin fast insulin glucose lipid andapolipoprotein measure assess baseline treatment week 4 12 12 24 weekspost-dosing twenty-three 24 participant achieve svr pp= 23/24 96 svr overall totalcholesterol low-density lipoprotein cholesterol ldl-c triglyceride level increase intreatment post-dosing ldl-c level decrease treatment ribavirinrecipient fast glucose insulin homa-ir unchanged treatment 12 weekspost-treatment 12 week post-treatment control attenuation parameter cap score ameasure steatosis increase baseline mean 30.3 \\u00b1 63.5 p 0.05 regimen safe andhighly effective influence glucose metabolism ribavirin exposure mitigate someon-treatment lipid change far mechanistic study need understand ribavirinimpact lipid pathway therapeutic implication metabolic pathophysiologyof increase cap score hcv treatment require explanation\",\"preexistence appearance resistance-associated substitution limit efficacy direct-acting antiviral treatment hepatitis c. case report adolescent chronic hepatitis c virus 4 infection cirrhosis fail treatment ombitasvir/paritaprevir/ritonavir ribavirin resistance analysis baseline resistance-associated substitution m28v y93c emergent d168h\",\"updated guideline infectious diseases community practice american society transplantation review diagnosis prevention management viral hepatitis pre- post-transplant period current guideline reflect declining need hepatitis b immunoglobulin follow liver transplant replace nucleos(t)ide analogue effectively suppress viral replication long term minimal risk drug resistance describe limitation pegylated interferon alpha treatment chronic hepatitis d. guideline feature paradigm shift treatment arena chronic hepatitis c consist highly effective direct-acting antiviral daa medication effect cure universally safety profile easy tolerance permit use patient decompensated cirrhosis and/or end-stage renal disease high potency daa fuel rapidly expand utilization hepatitis c-exposed graft non-hepatitis c-infected liver heart kidney recipient structured protocol follow viral eradication daa therapy peri- post-transplant period chronic hepatitis e recognize solid-organ transplant recipient therapeutic approach streamline start reduction immunosuppression indicate afterward ribavirin monotherapy\",\"cancer therapy plague resistance previously discover novel form cancer drug resistance glioma-associated protein 1 gli1 elevate ugt1a glucuronidation enzyme glucuronidate cytarabine ribavirin lead resistance leukemia patient demonstrate gli1 impart resistance \\u223c40 compound include fda-approved drug disparate chemotype e.g. methotrexate venetoclax gli1 indirectly elevate ugt1as chaperone calreticulin require resistance far demonstrate resistant cell sensitive atp inhibitor suggest achilles heel exploit future identify gli1-inducible glucuronidation broad-spectrum multidrug resistance pathway\",\"ribavirin broad-spectrum nucleoside-derived antiviral drug use combination pharmacotherapy treatment hepatitis c virus infection current evidence indicate ribavirin-associated teratogenicity significant human information developmental toxicity mechanism involve ribavirin placental kinetic require assure safe use pregnancy investigate potential role equilibrative nucleoside transporter ent slc29a na[+]-dependent influx-mediating concentrative nucleoside transporter cnt slc28a atp-binding cassette abc efflux pump ribavirin placental pharmacokinetic datum indicate ent1 participate uptake ribavirin bewo cell fresh human placental villous fragment microvillous plasma membrane mvm vesicle activity cnts probably cnt2 observe bewo cell situ dual perfusion experiment rat term placenta open circuit setup ent inhibition significantly decrease total ribavirin maternal-to-foetal foetal-to-maternal clearance contrast contribution abc transporter p-glycoprotein abcb1 breast cancer resistance protein abcg2 multidrug resistance-associated protein abcc2 detect assay mdckii cell overexpresse closed circuit dual perfusion experiment rat term placenta summary datum ribavirin placental pharmacokinetic largely control ent1 activity independent abcb1 abcg2 abcc2 efflux pump\",\"hepatitis c virus hcv affect approx 3 world population account 300 000 death year 80 individual hcv develop chronic symptom untreated cause cirrhosis 27 hepatocellular carcinoma 25 hepatitis c virus (+)ssrna envelop virus family flaviviridae seven major hcv b identify 1990 interferon alpha-2 use treatment hcv decade hcv therapy base pegylated interferon alpha-2 combination ribavirin 2011 interferon alpha dna rna polymerase inhibitor ns3/4a rna protease inhibitor ns5 rna serine protease inhibitor ns5b rna polymerase inhibitor approve clinical use monotherapy avoid medication rapidly develop viral resistance total 113 paper include comprise original publication review paper review molecular target chemical structure drug use hcv treatment indication contraindication anti-hcv drug discuss application regimen\",\"emergence deletion mutant hepatitis c virus hcv ns5a-p32 p32del recently report subset chronic hepatitis c patient experience virologic failure direct-acting antiviral drug daa treatment mutation confer extremely high resistance ns5a inhibitor effective treatment establish case mutation\",\"chronic hepatitis c chc virus infection associate hepatic disease challenging disease burden remain significant world overall treatment rate chronically infected patient dismally poor treatment completion dual-therapy- pegylated interferon peg-ifn ribavirin rbv suboptimal real-world clinical setting approval second next-generation direct-acting antiviral daa represent major breakthrough hepatitis c virus hcv therapeutic treat chc infected individual therapeutic regimen fixed dose combination fdc rbv prove clinical efficacy different hcv harder-to-treat special population continue development novel pan-genotypic anti-hcv regimen high sustained virologic response svr undetectable viral load week 12 end therapy rate high barrier drug resistance low frequency adverse event drug-drug interaction compare old rbv base triple daa therapy oral interferon-free daa highly successful strategic treatment approach hepatitis c impulse health policy maker establish treatment priortie policy reduce rate hepatitis c-related morbidity mortality review article comprehensively overview interferon-free anti-hcv regimen totally shift treatment paradigm hepatitis c additional benefit galvanize effort achieve global goal hcv elimination near future\",\"approximately 650,000 people brazil chronic hepatitis c virus hcv infection evaluate safety efficacy ombitasvir (obv)/paritaprevir (ptv)/ritonavir r plus dasabuvir dsv with/without ribavirin rbv openlabel multicenter phase 3b trial treatment-naive interferon ifn treatment-experienced brazilian patient advanced hepatic fibrosis metavir f3/4 hcv gt 1 infection\",\"intergenotypic recombinant hepatitis c virus hcv strain emerge rarely coinfection individual hcv recombinant hcv strain identify date crf01 2k/1b worldwide concern study reevaluate genotyping hcv 2 strain group patient unusually low rate sustained virological response pegylated interferon/ribavirin treatment addition genetic determinant host interferon resistance evaluate\",\"describe factor associate treatment failure frequency resistance-associated substitution ra\",\"treatment daclatasvir plus asunaprevir dcv asv 24 week provide sustained virologic response svr rate 90 hepatitis c virus 1b hcv-1b infected patient non-structural 5a ns5a resistance-associated substitution ras l31 y93 site study investigate add ribavirin dcv asv combination shorten original treatment regiman 12 week compromise treatment efficacy hcv-1b patient ns5a ras\",\"aim study evaluate efficacy safety community-based ombitasvir/paritaprevir/ritonavir plus ribavirin therapy non-cirrhotic patient hepatitis c virus hcv 2a infection real-world setting\",\"poor outcome infant acute lymphoblastic leukemia necessitate new treatment discover eif4e protein elevated case infant test eif4e target repurposed antiviral agent ribavirin anticancer property eif4e inhibition potential treatment find ribavirin treatment actively divide infant cell bone marrow stromal cell bmsc clinically achievable concentration cause robust proliferation inhibition proportion eif4e expression far find ribavirin treatment kmt2a-rearranged kmt2a-r infant cell kmt2a-aff1 cell line rs4:11 inhibit eif4e lead decrease oncogenic eif4e-regulate cell growth survival protein ribavirin-sensitive kmt2a-r infant cell rs4:11 cell eif4e-regulate protein reduce level expression follow ribavirin treatment include myc mcl1 nbn bcl2 birc5 ribavirin-treated rs4:11 cell exhibit impaired eif4e-dependent nuclear cytoplasmic export and/or translation corresponding mrna reduce phosphorylation p-akt1 p-eif4ebp1 p-rps6 p-eif4e signaling protein lead s-phase cell cycle arrest rs4:11 cell correspond decrease proliferation ribavirin cause nuclear eif4e re-localize cytoplasm kmt2a-aff1 infant rs4:11 cell provide evidence eif4e inhibition ribavirin slow increase peripheral blast kmt2a-r infant xenograft-bearing mouse ribavirin cooperate chemotherapy particularly l-asparaginase reduce live kmt2a-aff1 infant cell bmsc co-culture work establish eif4e broadly elevated infant clinically relevant ribavirin exposure preclinical activity effectively inhibit eif4e kmt2a-r case suggest promise eif4e target use ribavirin means treatment\",\"direct-acting antiviral agent daa permit use interferon (ifn)-free regimen treat hepatitis c hcv patient chronic kidney disease ckd hemo-dialysis hd renal transplant rtx recipient excellent response rate safety occurrence basal therapy-induced resistance-associated substitution ras daa result treatment failure aim study estimate prevalence ras ns3a ns5a ns5b inhibitor particularly q80 k polymorphism ckd patient hd rtx recipient infect hcv\",\"accord easl aasld guideline recommend treatment patient fail achieve sustained virologic response svr prior interferon-based triple therapy protease inhibitor pi combination sofosbuvir ns5a inhibitor polish national recommendation allow use paritaprevir/ritonavir/ombitasvir+dasasbuvir\\u00b1ribavirin prodr group patient aim study evaluate efficacy safety prodr vs. ledipasvir/sofosbuvir\\u00b1rbv lsr pi-experienced patient real-life setting\",\"introduction new multi-genotypic direct act antiviral daa clinical practice revolutionize hcv treatment permit achievement 95 rate sustained virological response patient virological failure occur particularly treatment sub optimal and/or short duration failure associate development resistance wide genetic variability term different natural presence and/or easy development resistance treatment intrinsic characteristic hcv affect treatment outcome chance achieve virological cure review explore detail aspect hcv innate treatment-induced resistance new interferon-free daa regimen\",\"european treatment guideline hepatitis c virus hcv infection recommend people gt 1a infection baseline viral load \\u2264800 000 iu/ml receive elbasvir/grazoprevir ebr/gzr 12 week baseline viral load 800 000 iu/ml receive ebr/gzr plus ribavirin 16 week analysis conduct clarify baseline viral load serve accurate sensitive specific stratification factor define ebr/gzr regimen post hoc integrate analysis participant gt1a infection receive ebr 50 mg/gzr 100 mg 12 week stratify accord baseline viral load sustained virologic response 12 week post-treatment achieve 95.2 911/957 participant high participant baseline viral load \\u2264800 000 iu/ml vs 800 000 iu/ml 98.5 vs 93.9 800 000 iu/ml threshold positive predictive value 98.5 negative predictive value 6.1 specificity 91.3 sensitivity 28.4 overall accuracy 31.5 baseline viral load cutpoint 800 000 iu/ml high positive predictive value specificity poor negative predictive value sensitivity accuracy predict treatment outcome population baseline ns5a resistance-associated substitution ras detect 25 1/4 virologic failure baseline viral load \\u2264800 000 iu/ml 59.5 25/42 baseline viral load 800 000 iu/ml. overall datum suggest compare use baseline viral load cutpoint baseline testing ns5a ras enable individual receive 12-week ebr/gzr regiman compromise opportunity svr\",\"pakistan burden hepatitis c virus hcv infection second high world development chronic hepatitis interferon-based combination therapy ribavirin available treatment year severe side-effect high failure rate different hcv interferon-free all-oral direct-acting antiviral agent daa approve fda revolutionize hcv therapeutic landscape efficiency target different different category patient include treatment na\\u00efve treatment failure relapse patient patient compensate decompensated cirrhosis availability use daa limit develop world sofosbuvir sof uridine nucleotide analogue inhibitor hcv encode ns5b polymerase widely available in-use daa pakistan daclatasvir recently add list accord document result hope disease effectively cure pakistan concern remain aim article review effectiveness daa current status treatment hcv 3 infection pakistan factor associate svr limitation effective treatment regime future implication\",\"immunosuppressed individual shed influenza virus prolonged period time lead frequent emergence antiviral resistance evaluate benefit oseltamivir favipiravir combination therapy compare single antiviral agent monitor emergence drug-resistant variant pharmacologically immunosuppressed mouse model infect a(h1n1 pandemic influenza virus c57bl/6 mouse immunosuppresse cyclophosphamide infect lethal dose pandemic influenza a(h1n1 virus forty-eight hour post-infection mouse treat oseltamivir 20 mg/kg favipiravir 20 50 mg/kg agent bid 5 10 day body weight loss survival rate lung viral titer cytokine level emergence resistant virus evaluate treatment immunosuppressed mouse high 50 mg/kg low 20 mg/kg dose favipiravir combination oseltamivir 20 mg/kg significantly delay mortality reduce lung viral titer compare treatment single drug regiman oseltamivir prevent emergence oseltamivir-resistant h275y neuraminidase variant combination therapy oseltamivir favipiravir consider evaluation clinical trial\",\"hepatitis e virus hev cause chronic infection immunosuppressed patient adverse clinical outcome intervention strategy limit ribavirin rbv main therapeutic option off-label drug recent report rbv monotherapy failure coherence presence certain single nucleotide variant snv in-frame insertion hypervariable region open reading frame 1 hev genome importantly alteration present viral population minor variant rbv administration individualized infection medicine early detection emerge viral variant patient improve treatment outcome prognosis\",\"rapid development direct-acting antiviral agent daa hepatitis c virus hcv therapy dramatically alter treatment landscape disease daa regimen associate advantage include high sustained virological response svr minimum effect low pill load specific inhibition viral replication lower dependence host cell regimen substantially replace conventional interferon therapy high cure rate 90 hcv population review provide insight clinical study ns3/4a protease inhibitor ns5b viral polymerase inhibitor nucleotide non-nucleotide ns5a inhibitor combination\",\"despite high efficacy direct-acting antiviral daa report clinical trial treatment failure real-life practice occur 5 10 case associate emergence resistance-associated substitution ras little know efficacy retreatment patient especially decompensated cirrhosis retreatment study perform far present case report successful sofosbuvir-based treatment patient advanced class b cirrhosis prior pegylated interferon/ribavirin all-oral daa failure multiclass drug resistance hcv resistance testing failure perform guide choice salvage therapy\",\"influenza virus iv continual threat global health high mutation rate iv genome virus incredibly successful genetic drift allow annual epidemic result thousand death million hospitalization emergence new strain genetic shift e.g. swine-origin influenza cause devastating global outbreak infection neuraminidase inhibitor nai currently use treat iv infection act directly viral protein halt iv spread effectivity limit late infection drug resistance develop new therapy target highly conserve feature iv antibody stem region hemagglutinin iv rna polymerase inhibitor favipiravir currently clinical trial compare nai treatment high tolerance resistance long therapeutic window prove effective clinical experimental evidence demonstrate viral spread host inflammatory response damage lung epithelium dictate outcome iv infection therapeutic regimen iv infection regulate host inflammatory response protect epithelial cell unnecessary cell death anti-inflammatory drug etanercept statin cyclooxygenase enzyme 2 inhibitor temper iv induce inflammation demonstrate possibility repurpose drug single adjunct therapy iv infection iv bind sialic acid receptor host cell surface initiate infection productive iv replication primarily restricted airway epithelial cell accordingly target therapy epithelium directly inhibit iv spread minimize target consequence activation immune cell neuraminidase mimic fludase cleave sialic acid receptor epithelium inhibit iv entry cell type iii interferon activate antiviral gene program epithelial cell minimal perturbation iv specific immune response review discuss above-mentioned candidate anti-iv therapeutic preclinical clinical trial stage\",\"use oral ribavirin rbv respiratory virus rsv infection study drastic increase cost aerosolized rbv aim compare outcome hematopoietic cell transplant hct recipient treat oral aerosolized rbv rsv infection\",\"study aim describe real-world efficacy safety sofosbuvir sof ribavirin rbv chronic hepatitis c 2\",\"detailed analysis hepatitis c virus hcv resistance-associated substitution ras require understand people fail direct-acting antiviral therapy study conduct assess ras analysis 2 trial evaluate second-generation ns3/4a protease inhibitor grazoprevir gzr combination peginterferon/ribavirin\",\"chronic hepatitis c remain major public health concern prevalence 1 worldwide late discovery newer drug chronic hcv treatment touch new dimension treatment progress interferon pegylated interferon peg ifn base therapy ribavirin treatment orally active direct acting antivirals daa peg ifn ribavirin eventually combination daa ifn introduction newer daa transfigure treatment chronic hcv chronic hcv patient advanced liver disease psychiatric condition anemia autoimmune disease eligible peg ifn based therapy ray hope daa nucleoside inhibitor promising agent present review focus sofosbuvir effective nucleoside inhibitor term potency resistance profile activity hcv adverse effect fda approve sofobuvir clinical use 2013 chemically 2'-deoxy-2'-\\u03b1-fluoro-\\u03b2-cmethyluridine- 5'-triphosphate phosphoramidate prodrug activate enzyme present human liver highly potent inhibitor hcv ns5b polymerase efficacy sofosbuvir establish phase 2 phase 3 clinical trial like proton electron fusion positron etc sofosbuvir good safety profile mild moderate adverse effect evidence reveal sofosbuvir substantial impact treatment hcv\",\"study perform investigate efficacy safety grazoprevir-elbasvir guide baseline resistance-associated substitution ras swiss hcvree trial\",\"viral fitness quantify degree virus adaptation environment viral fitness influence mutant spectrum complexity viral quasispecie subject lethal mutagenesis investigate document high fitness hepatitis c virus population display high resistance mutagenic nucleoside analogue favipiravir ribavirin parental low fitness hcv population exhibit mutation transition bias indicative active mutagenesis resistance analogue associate limited expansion mutant spectrum complexity evidence diversity index use characterize mutant spectrum result consistent replicative site-drug competition mechanism previously propose hcv fitness-associated resistance non-mutagenic inhibitor alternative non-mutually exclusive mechanism consider result introduce viral fitness relevant parameter evaluate response virus lethal mutagenesis implication antiviral design\",\"chronic hepatitis c virus infection hcv associate extrahepatic manifestation increase prevalence cardiovascular disease new direct act antiviral daa revolutionize hcv treatment high rate sustained virological response svr recently demonstrate svr reduce morbidity overall mortality solely explain hepatic effect suggest treatment daa affect cardiovascular disease aim pilot study identify possible underlying mechanism hcv-associated cardiovascular mortality report\",\"currently interferon-free treatment available hepatitis c virus (hcv)-infected patient young 12 year evaluate safety effectiveness all-oral regimen ledipasvir-sofosbuvir \\u00b1 ribavirin hcv-infected child aged 6 12 year open-label study patient aged 6 12 year receive ledipasvir 45 mg-sofosbuvir 200 mg fixed-dose combination tablet 22.5/100 mg daily ribavirin 12 24 week depend hcv cirrhosis status primary efficacy endpoint sustained virologic response 12 week therapy svr12 patient undergo intensive pharmacokinetic sampling confirm appropriateness ledipasvir sofosbuvir dosage ninety-two patient enrol 88 1 2 3 2 4 median age 9 year range 6 11 perinatally infect 97 treatment-naive 78 confirm cirrhosis degree fibrosis unknown 55 patient overall svr12 rate 99 91/92 95 confidence interval 94%-100 single patient reach svr relapse 4 week complete 12 week treatment common adverse event headache pyrexia patient adverse event consider related study treatment tooth abscess abdominal pain gastroenteritis area concentration-time curve maximum concentration value sofosbuvir primary metabolite gs-331007 ledipasvir predefined pharmacokinetic equivalence boundary 50%-200 compare value adult phase 2/3 ledipasvir sofosbuvir study conclusion ledipasvir-sofosbuvir tolerated highly effective child 6 12 year old chronic hcv\",\"treatment hepatitis c virus hcv infection revolutionize development all-oral combination regimen direct-acting antiviral agent current analysis characterize relationship exposure daclatasvir dcv tablet asunaprevir asv capsule sustained virologic response svr japanese patient hcv gt 1b nonresponder pegylated interferon ifn \\u03b1/ribavirin ifn\\u03b2/ribavirin ifn-based therapy-ineligible naive/intolerant patient receive dcv asv provide insight patient covariate closely associate efficacy relationship probability achieve svr 12 week treatment svr12 average steady-state plasma concentration estimate population pharmacokinetic model dcv asv describe use logistic regression model datum phase 2 phase 3 study japanese patient infect hcv gt 1b n=265 functional form characterization describe relationship dcv asv average steady-state plasma concentration svr12 covariate identification demographic laboratory prognostic treatment covariate investigate model development presence signature nonstructural protein 5a y93h mutation baseline significant parameter svr12 final exposure-response model model evaluation plot demonstrate final model able predict observe svr rate exposure-response analysis support clinical utility combination regiman 60-mg once-daily dcv 100-mg twice-daily asv japanese patient infect hcv gt 1b\",\"2,200 patient infect hepatitis c virus hcv gt 1 6 cirrhosis treatment naive experience interferon ribavirin and/or sofosbuvir treat glecaprevir/pibrentasvir 8 12 16 week registrational phase 2 3 clinical study high rate sustained virologic response 12 week postdosing svr12 achieve 1 virologic failure vf rate prevalence baseline polymorphism bp ns3 amino acid position 155 168 low <3 patient infect gt1 gt2 gt3 gt4 gt6 41.9 gt5-infected patient ns3-d168e bp detect position 156 ns3 prevalence ns5a-bps high drive common polymorphism amino acid position 30 31 gt2 58 gt4 28 gt6 prevalence ns5a t/y93 polymorphism 5.5 gt1 4.9 gt3 12.5 gt6 consistent activity glecaprevir pibrentasvir amino acid polymorphism vitro bp ns3 and/or ns5a impact treatment outcome patient infect gt1 gt6 exception treatment-experienced gt3-infected patient treat 12 week 16-week regimen glecaprevir/pibrentasvir require achieve svr12 rate \\u226595 22 patient experience vf treatment-emergent substitution detect ns3 50 patient ns5a 82 patient frequently combination substitution confer resistance glecaprevir and/or pibrentasvir glecaprevir/pibrentasvir regiman recommend duration use allow pan-genotypic treatment option need baseline resistance testing\",\"insulin resistance diabetes mellitus common extrahepatic manifestation chronic hepatitis c hcv insulin resistance assess homa-ir associate low rate sustained virological response especially hcv 1 positive patient treat peginterferon/ribavirin effect insulin resistance sustained virologic response hcv 3 positive patient treat peginterferon/ribavirin remain unclear\",\"hcv-infected people fail achieve sustained virological response receive direct-acting antiviral regiman virological failure accompany presence resistance-associated substitution ras target protein(s aim long-term observational study evaluate persistence ns3/4a ns5a ras participant gt 1 infection relapse follow treatment grazoprevir-containing treatment regiman\",\"japan grow population patient chronic hepatitis c virus hcv infection fail direct-acting antiviral (daa)-based regimen phase 3 study evaluate sofosbuvir-velpatasvir plus ribavirin japanese patient 1 2 hcv infection previously receive daa\",\"genetic polymorphism interferon \\u03bb ifn-\\u03bb chromosomal region mainly rs12979860 ifn-\\u03bb4 gene ifnl4 know associate spontaneous hepatitis c virus hcv resolution sustained viral response therapy pegylated interferon- \\u03b1 ribavirin strong linkage disequilibrium ifnl4 rs12979860 ifnl4 rs368234815 casually associate hcv spontaneous therapeutical eradication partially explain favorable hcv outcome attribute major homozygosity rs12979860 effect ifn-based antiviral treatment associate pretreatment expression ifn-\\u03bb1 receptor expression hepatic ifn-stimulated gene production ifn- \\u03bb4 preactivation jak-stat signaling nowadays direct-acting antiviral daa potent tool treatment hepatitis c ifn-\\u03bbs investigation potential antiviral option hcv infection daa resistance recurrent viremia adverse effect patient altered immunocompetence especially prone infection uremic subject polymorphism ifn-\\u03bb chromosomal region associate spontaneous hcv clearance similarly like non-uremic population circulate ifn-\\u03bb3 positive correlation plasma titer antibody surface antigen hepatitis b virus anti-hbs crucial protection hepatitis b virus efficient anti-hbs production presence high ifn-\\u03bb3 level occur ifn-\\u03bb3-induced regulation indoleamine 2,3-dioxygenase ido expression ifn-stimulated response element ido gene promoter worth investigation ido gene circulate ido genetic polymorphism ifn-\\u03bb region circulate ifn-\\u03bb3 act concordance immunological response hepatotropic virus\",\"insulin resistance ir common complication chronic hepatitis c virus hcv patient impact ir outcome therapy direct antiviral study\",\"hepatitis c virus hcv exhibit great genetic diversity classify 7 gt varied geographic prevalence recent development pangenotypic direct-acting antiviral regimen determination hcv gt necessary inform optimal treatment\",\"cancer patient initially respond chemotherapy eventually develop resistance relapse work demonstrate eif4e-targeting therapy potential sensitizing strategy overcome chemoresistance progression cancer ribavirin anti-viral drug pharmacological eif4e inhibitor effectively inhibit proliferation decrease viability paclitaxel-resistant cervical cancer 5-fu-resistant colon cancer cell toxic human fibroblast cell importantly oral administration ribavirin significantly inhibit paclitaxel-resistant colon 5-fu-resistant cervical cancer growth xenograft mouse cancer model cause significant toxicity mouse consistently combination ribavirin paclitaxel 5-fu sensitize colon cervical cancer cell chemotherapeutic agent treatment vitro vivo far confirm mechanism action ribavirin chemoresistant cancer cell suppress eif4e function addition specific eif4e knockdown independent sirna mimic effect ribavirin chemoresistant colon cervical cancer cell cell cycle analysis indicate ribavirin enhance anti-proliferative effect 5-fu additionally arrest cell g2/m phase increase cyclin b1 p-histone h3(ser10 mad2 level work demonstrate eif4e inhibition use inhibitor sirna single agent combination sensitize chemoresistant cancer cell paclitaxel 5-fu treatment improve efficacy chemodrug finding demonstrate therapeutic value inhibit eif4e particularly chemoresistant cancer finding suggest ribavirin promising sensitize drug cancer treatment\",\"phase 3 trial real-world setting small proportion patient 3 hepatitis c virus hcv infection cirrhosis sustained virologic response 12 week treatment svr12 combination sofosbuvir velpatasvir patient cirrhosis unclear add ribavirin treatment regiman increase svr patient 3 hcv infection cirrhosis\",\"ribavirin rbv use 20 year treat patient chronic hepatitis c virus hcv infection pluripotent drug believe induce mutagenesis hcv rna cell-cultured hcv hcvcc phenomenon investigate 2a recombinant study mutation develop hcvcc 1a 3a treat rbv ribavirin triphosphate rbv-tp compare non-treated control analysis perform amplify full-length open reading frame orf recovered virus follow next-generation sequencing clonal analysis compare non-treated control spread tncc(1a dbn3acc(3a hcvcc delay rbv rbv-tp concentration 40 \\u00b5m high delay hcvcc spread associate increase new single-nucleotide polymorphism snp significantly high number new snp observe tncc(1a virus treat rbv rbv-tp compare match non-treated control rbv rbv-tp treatment lead significantly increase proportion new g-to-a c-to-u snp compare non-treated tncc(1a clonal analysis confirm significantly increase mutation rate rbv-treated tncc(1a synonymous pairwise distance increase virus complete orf rbv rbv-tp treatment compare control consensus-shift single sample rbv- rbv-tp-treated tncc(1a virus occur protein e1 p7 ns3 ns4b non-synonymous consensus change observe dbn3acc(3a study support biased g-to-a c-to-u mutagenic effect rbv rbv-tp entire orf hcv 1a 3a\",\"hepatitis c virus hcv infection viral il28b clinical biochemical factor influence response rate pegylated interferon plus ribavirin peg-ifn-a/r therapy progression chronic hepatitis c chc\",\"influenza virus iav cause seasonal epidemic occasional devastate pandemic major public health concern effectiveness seasonal vaccine highly variable currently available drug limit efficacy emergence drug resistance urgent need develop novel antiviral study characterize recombinant iav-carrying gaussia luciferase gluc gene determine potential tool evaluate therapeutic demonstrate recombinant iav replication-competent tissue culture pathogenic mouse slightly attenuate compare parental virus luciferase expression correlate virus propagation vitro vivo provide simple measure viral replication tissue culture mouse lung demonstrate utility virus ribavirin oseltamivir phosphate use treat iav-infected cell mouse observe dose-dependent inhibition viral replication luciferase assay decrease luciferase expression infected lung predict protective efficacy antiviral intervention early day 2 post virus challenge summary study provide new quantitative approach evaluate antiviral iav\",\"trichomonas vaginalis infect approximately 300 million people worldwide annually infected individual high susceptibility condition cervical prostate cancer parasite develop increase resistance current drug therapy estimate 5 clinical case result resistant strain create need new therapeutic strategy novel mechanism action nucleoside salvage pathway enzyme represent novel drug target pathway essential parasite survival guanosine/adenosine/cytidine nucleoside hydrolase gacnh particularly important expression upregulate glucose-limiting condition mimic occur infection establishment gacnh screen nih clinical collection explore druggability seven compound identify ic50 value 20 \\u03bcm. extensive overlap find inhibitor gacnh adenosine/guanosine nucleoside hydrolase agnh overlap find inhibitor uridine nucleoside hydrolase guanosine analog ribavirin compound find specific gacnh compound inhibit agnh gacnh purine salvage pathway enzyme prove critical role gacnh appear play early stage infection\",\"landscape therapeutic option hcv infection dramatically change approval all-oral direct-acting antiviral daa regimen daa target important step hcv viral life cycle result high response rate adverse event afford interferon ribavirin prior standard care achievement sustained virologic response svr rate excess 90 use daa regimen translate hcv eradication thousand treat anticipate decrease incidence major complication associate chronic hcv infection additionally favorable effect profile daa hcv therapy feasible difficult-to-treat population include previous exposure interferon ribavirin cirrhosis decompensated liver disease hiv hcv co-infection severe renal dysfunction/end stage renal disease tremendous progress patient infect hcv infection treat\",\"chronic hepatitis c chc prevalence rate 0.43 china approximately 10 million chronically infected people urgent need treatment beginning 2013 pan-genotypic sofosbuvir sof potent antiviral activity minimal drug resistance drug-drug interaction good safety create new era hcv treatment combination ribavirin single tablet regiman ledipasvir velpatasvir widely use 1.6 million patient worldwide furthermore sof-based therapy prove effective safe terminal illness decompensated cirrhosis liver kidney transplantation hiv hbv co-infection bleed disorder intravenous drug user adolescent elderly sof-based regimen fill unmet medical need patient hcv\",\"search new antiviral anticancer agent essential emergence drug resistance recent year continuation effort identify new small molecule antiviral anticancer agent identify chalcone potent antiviral anticancer agent\",\"hepatitis c virus hcv unique virus interact cholesterol iron insulin metabolism limited datum effect direct-acting antiviral agent daa metabolic profile aim evaluate behavior metabolic risk factor chronically hcv-infected patient sustained virologic response svr compare outcome new daa versus old treatment regiman peg-interferon \\u00b1 ribavirin\",\"familial mediterranean fever autosomal recessive disorder characterize periodic febrile attack aseptic serositis and/or arthritis main treatment colchicine prevent attack majority patient group colchicine-resistant case chronic hepatitis c viral infection cause chronic inflammation liver tissue hepatitis ultimately progress fibrosis liver cirrhosis high chance hepatocellular carcinoma find datum literature concern impact hepatitis c course attack familial mediterranean fever\",\"chronic hepatitis c virus hcv infection impact approximately 71 million people approximately 400,000 death attribute hcv-related liver disease annually worldwide mainstay treatment 25 year pegylated interferon advent protease inhibitor lead all-oral hcv treatment regimen change outlook hepatitis c treatment grazoprevir/elbasvir provide high rate efficacy tolerability all-oral daily treatment option hcv infection efficacy grazoprevir/elbasvir prove patient cirrhosis patient previously fail treatment peginterferon ribavirin rbv patient end-stage renal disease patient hiv co-infection datum high barrier resistance despite presence resistance-associated substitution grazoprevir/elbasvir represent promising regimen treatment hcv infection review provide summary pharmacology efficacy safety grazoprevir/elbasvir treatment hcv infection\",\"series dithioacetal derivative bear strobilurin moiety design synthesize basis previous work antiviral activity compound potato virus y pvy cucumber mosaic virus cmv tobacco mosaic virus tmv systematically evaluate bioassay result indicate c14 elicit excellent curative protective activity pvy cmv tmv 50 effective concentration ec50 125.3 108.9 181.7 \\u03bcg/ml respectively 148.4 113.2 214.6 \\u03bcg/ml respectively significantly superior lead compound 6f 297.6 259.6 582.4 \\u03bcg/ml 281.5 244.3 546.3 \\u03bcg/ml respectively ningnanmycin 440.5 549.1 373.8 \\u03bcg/ml 425.3 513.3 242.7 \\u03bcg/ml respectively chitosan oligosaccharide 553.4 582.8 513.8 \\u03bcg/ml 547.3 570.6 507.9 \\u03bcg/ml respectively ribavirin 677.4 690.3 686.5 \\u03bcg/ml 652.7 665.4 653.4 \\u03bcg/ml respectively defensive enzyme activity rt-qpcr analysis demonstrate antiviral activity associate change sod cat pod activity tobacco prove related protein abscisic acid signaling pathway work provide basis design structural modification development dithioacetal derivative new antiviral agent\",\"genetic variant interferon lambda ifnl locus associate human phenotype disease health chronic hepatitis c virus hcv infection ifnl variant identify associate response interferon-\\u03b1-ribavirin therapy available datum clearly suggest causal variant dinucleotide polymorphism rs368234815 cause open reading frame-shift ifnl4 gene result expression functional ifn-\\u03bb4 new type iii ifn human diseases/phenotype ifnl variant recently associate causal mechanism remain unclear vitro evidence ifnl variant rs28416813 rs4803217 regulate expression type iii ifn ifn-\\u03bb3 expression functional ifn-\\u03bb4 quantitative difference ifn-\\u03bb3 expression potential causal mechanism observe phenotype potential causal mechanism involve feature mutual exclusivity overlap function difficult differentiate vivo absence implicate evidence addition strong linkage disequilibrium ld observe population ifnl locus difficult tease actual functional/causal variant responsible phenotype non-synonymous single nucleotide polymorphism rs117648444 alter activity ifn-\\u03bb4 ld structure ifnl region lead confound effect rs117648444 ifnl variant provide additional tool case-control study probe role ifn-\\u03bb4\",\"hepatitis c virus hcv infection induce interferon (ifn)-stimulated gene isg downstream innate immune response study investigate baseline on-treatment difference response predict response versus virological breakthrough therapy direct-acting antiviral daa thirteen hcv 1b-infected patient previously fail course pegylated ifn/ribavirin retreat asunaprevir/daclatasvir 24 week pretreatment biopsy patient randomize undergo second biopsy week 2 4 therapy microarray nanostring analysis perform paired liver biopsy analyze use linear mixed model biomarker peripheral ifn response peripheral blood natural killer cell assess phosphorylate signal transducer activator transcription 1 pstat1 tumor necrosis factor-related apoptosis-inducing ligand trail expression degranulation 13 69 patient achieve sustained virological response 12 week therapy svr12 4 experience virological breakthrough week 4 12 patient achieve svr12 display high isg expression level baseline liver biopsy high frequency pstat1 trail-expressing degranulate natural killer cell baseline blood sample experience virological breakthrough compare gene expression level baseline on-therapy biopsy 408 gene \\u00b11.2-fold p 0.01 differentially express gene down-regulate treatment predominantly isg down-regulation isg rapid correlate hcv rna suppression conclusion enhance ifn signature observe baseline liver blood patient achieve svr12 compare experience virological breakthrough finding suggest innate immunity contribute clearance hcv daa therapy prevent emergence resistance-associated substitution lead viral breakthrough daa therapy\",\"patient chronic hepatitis c 20 30 develop cirrhosis complication 30 year antiviral treatment hepatitis c interferon-free result improvement sustained virological response rate safety tolerability short duration treatment\",\"datum limit regard effectiveness safety generic velpatasvir plus sofosbuvir vel/sof hepatitis c virus hcv patient human immunodeficiency virus hiv coinfection\",\"past year grow body clinical evidence highlight risk vitamin d deficiency patient chronic hepatitis c vitamin d level associate course hepatitis c virus hcv infection adverse effect treatment response peginterferon/ribavirin recently study find vitamin d status related drug resistance increase risk infection patient liver cirrhosis vitamin d-related gene polymorphism find explain interaction vitamin d deficiency hcv infection offer new perspective understand current problem development insulin resistance racial difference sustained virological response study conduct determine vitamin d supplementation adjuvant yield result compare traditional hcv treatment provide brief review past present knowledge vitamin d hcv infection\",\"curative interferon ribavirin sparing treatment hepatitis c virus (hcv)-infected patient require combination mechanistically orthogonal direct acting antiviral share component treatment usually hcv ns5a inhibitor generation fda approve treatment include component ns5a inhibitor exhibit equivalent efficacy hcv virus 1 6 particular generation ns5a inhibitor tend select viral drug resistance ombitasvir generation hcv ns5a inhibitor include key component viekira pak treatment patient hcv 1 infection launch generation hcv treatment functional cure 1 6 hcv infection achieve shorten treatment duration wide spectrum paper modify anchor linker end-cap architecture ns5a inhibitor design template discover generation ns5a inhibitor pibrentasvir abt-530 exhibit potent inhibition replication wild-type 1 6 hcv replicon improve activity replicon variant demonstrate resistance generation ns5a inhibitor\",\"assess daclatasvir plus asunaprevir dual treatment-na\\u00efve patient mainland china russia south korea hepatitis c virus hcv 1b infection\",\"hepatitis c virus hcv affect estimate 80 million individual worldwide strain public health 25 30 patient europe infect hiv coinfecte hcv prior 2013 treatment modality contain ns3/4a protease inhibitor combination pegylated interferon ribavirin improve sustained virological response svr rate rate severe effect high nowadays oral direct-acting antiviral daa combination therapy offer excellent treatment efficacy safety tolerability\",\"report real-life 3d therapy failure patient treat ombitasvir (omv)/paritaprevir/ritonavir dasabuvir ribavirin 3d-r therapy failure week 12 end treatment detect resistance-associated substitution ras plus polymorphism ns3 ns5a ns5b target region population sequencing 15 cut-off baseline relapse follow-up ns5a ras generally persist long resistance target gene impact treatment outcome evaluate omv drug-resistance mechanism study acquire ras plus polymorphism ns5a phosphoprotein computational study omv high affinity baseline 93h/108 k mutant structure follow-up respect 93h/r108 mutant structure relapse phosphoprotein molecular dynamics simulation md structural information protein stability presence omv observe accord datum molecular modeling approach prove powerful method evaluate impact ras plus specific amino acid aa change phosphoprotein\",\"ribavirin rbv broad-spectrum antiviral active wide range rna virus despite use decade treatment chronic hepatitis c virus hcv infection precise mechanism action rbv unknown virus inhibit propagation increase rate g-to-a c-to-u transition utilize j6/jfh1 hcv cell-culture system investigate rbv inhibit hcv mechanism infected huh7.5 cell treat increase concentration rbv phosphorylated form fragment hcv ns5b-polymerase gene amplify clone sequence estimate genetic distance confirm antiviral effect rbv-drug form hcv rely induction specific transition g-to-a c-to-u mutation lead generation non-infectious virion reflect decrease spread hcv cell culture despite relatively limited effect virus genome titer treatment experiment conduct novel huh7.5 cell line stably overexpresse adenosine kinase key enzyme rbv activation yield comparable result study indicate rbv action hcv hepatoma cell-culture exert increase mutagenesis mediate rbv triphosphate lead production non-infectious virus\",\"clinical experience protease-inhibitor pi triple regiman appear disappointing regard effect effect high work load cost real-world study evaluate baseline emerge resistance-associated substitution ras significance treatment outcome\",\"week pangenotypic direct-acting antiviral daa combination sofosbuvir/velpatasvir sof/vel highly efficient patient hepatitis c virus hcv 3 gt3 infection astral-3 approval study presence resistance-associated substitution ras hcv nonstructural protein 5a ns5a associate low treatment response\",\"favipiravir know t-705 antiviral drug approve 2014 japan treat pandemic influenza virus infection drug convert intracellularly active phosphoribosylated form recognize substrate viral rna-dependent rna polymerase interestingly anti-influenza virus activity molecule able inhibit replication flavi- alpha- filo- bunya- arena- noro- rna virus include neglect (re)emerging virus antiviral therapy currently available discuss potential favipiravir broad-spectrum countermeasure infection cause neglect rna virus favipiravir use off-label treat patient infect ebola virus lassa virus particular set-up clinical trial outbreak clear conclusion efficacy favipiravir virus demonstrate barrier resistance development favipiravir high favipiravir tolerate healthy volunteer influenza virus-infected patient caution need teratogenic risk molecule antiviral activity different rna virus high barrier resistance potential favipiravir broad-spectrum antiviral promising safety potency issue overcome drug similar molecule use treat large patient group\",\"emerge coronaviruse covs cause severe disease human approve therapeutic available cov nsp14 exoribonuclease exon complicated development antiviral nucleoside proofreading activity recently report nucleoside analogue gs-5734 remdesivir potently inhibit human zoonotic covs vitro severe acute respiratory syndrome coronavirus sars-cov mouse model study gs-5734 report resistance associate gs-5734 understand action gs-5734 wild-type wt proofread covs gs-5734 inhibit murine hepatitis virus mhv similar 50 effective concentration value ec50 sars-cov middle east respiratory syndrome coronavirus mers-cov passage wt mhv presence gs-5734 parent nucleoside select mutation nsp12 polymerase residue conserve covs confer 5.6-fold resistance gs-5734 determine ec50 resistant virus unable compete wt direct coinfection passage absence gs-5734 introduction mhv resistance mutation sars-cov result vitro resistance phenotype attenuate sars-cov pathogenesis mouse model finally demonstrate mhv mutant lack exon proofreading significantly sensitive gs-5734 combine result indicate gs-5734 interfere nsp12 polymerase setting intact exon proofreading activity resistance overcome increase nontoxic concentration gs-5734 far support development gs-5734 broad-spectrum therapeutic protect contemporary emerge covs importance coronaviruse covs cause severe human infection approve antiviral treat infection development nucleoside-based therapeutic cov infection hamper presence proofreading exoribonuclease expand known efficacy nucleotide prodrug remdesivir gs-5734 include group \\u03b2-2a cov. far gs-5734 potently inhibit covs intact proofreading follow selection gs-5734 parent nucleoside 2 amino acid substitution nsp12 polymerase residue identical covs provide low-level resistance gs-5734 resistance mutation decrease viral fitness mhv vitro attenuate pathogenesis sars-cov animal model infection study define target gs-5734 activity demonstrate resistance difficult select partial impair fitness virulence mhv sars-cov support development gs-5734 potential effective pan-cov antiviral\",\"sofosbuvir potent nucleotide hcv ns5b polymerase inhibitor p-glycoprotein encode abcb1 gene breast cancer resistance protein encode abcg2 gene substrate concern previous anti-hcv therapy pharmacogenetic significant impact particularly consider association interleukin28b polymorphism dual-therapy ribavirin pegylated ifn outcome\",\"therapeutic benefit add ribavirin rbv 12 week ledipasvir/sofosbuvir ldv/sof patient experience failure previous nonstructural protein ns 5a inhibitor-containing regimen unclear\",\"datum available clinical presentation virological pattern case failure interferon (ifn)-free regimen patient genotype-3h paper identify virological clinical characteristic patient genotype-3h treat suboptimal indicate ifn-free regimen misclassification hcv\",\"ombitasvir/paritaprevir-ritonavir obt/ptv-r plus ribavirin rbv 12 week hepatitis c virus hcv 4 patient advanced fibrosis investigate clinical trial\",\"treatment hepatitis c virus hcv direct act antiviral daa able achieve cure infection totality patient independently characteristic individual virus use short treatment schedule need ribavirin high cost daa main limit factor universal treatment hcv strong evidence treatment infection early stage disease rewarding approach area cover review evaluate aspect underlie benefit treat chronic hcv infection early stage disease outline consideration account plan treatment patient hcv minimal liver disease assess positive reflex viral eradication hcv-associated extra-hepatic condition risk lymphoma insulin-resistance glycaemic control renal function lastly cover improvement patient quality life pharmaco-economic aspect associate early treatment expert commentary treatment patient hcv minimal liver disease associate beneficial pleiotropic effect viral eradication simplistic consideration improvement liver disease-related outcome\",\"follow approval new therapeutic combination european union 2017 swedish recommendation treatment hepatitis c virus hcv infection 2016 deem need update\",\"background epidemic acute hcv infection hiv-infected man sex man msm ongoing transmission drug-resistant variant drv hcv treatment failure pose major threat effectiveness future therapy determine baseline prevalence pre-existing drv hcv ns3 protease gene effect addition telaprevir tvr standard pegylated interferon ribavirin peg-ifn/rbv acute hcv infection individual enrol multicentre randomized control trial 2013 2014 method hcv ns3 viral protease analyze use sanger next-generation sequencing ngs drv baseline n 31 viral breakthrough follow tvr-based treatment n 3 peg-ifn/rbv n 2 result sequence analysis indicate individual infect hcv 1a complete 100 concordance sanger ngs high level mutant viral population simeprevir-associated q80 k variant present high frequency german sample 7/11 64 infrequently uk sample 1/20 5 tvr-based treatment failure v36m/l r155k/t emerge r155 g detectable low level individual baseline failure rate week 24 26.7 baseline drv vs. 6.3 baseline drv p 0.17 comparison sequence pre- post-therapy 5 fail therapy reveal emergence previously describe variant v193 g e176 k p189s tvr v181s instance conclusion presence baseline drv ns3 protease gene hcv 1a appear predict treatment failure patient cohort detect q80 k present high level 98 effect outcome remain high failure\",\"direct-acting antiviral regimen reduce activity people hepatitis c virus hcv gt 3 infection cirrhosis c-isle study assess efficacy safety elbasvir/grazoprevir ebr/gzr plus sofosbuvir sof ribavirin rbv compensate cirrhotic participant gt3 infection phase 2 randomize open-label study treatment-naive participant receive ebr/gzr sof rbv 8 week ebr/gzr sof 12 week peginterferon/rbv treatment-experienced participant receive ebr/gzr sof \\u00b1 rbv 12 week ebr/gzr sof 16 week primary endpoint hcv rna 15 iu/ml 12 week end treatment sustained virologic response 12 week svr12 treatment-naive participant svr12 91 21/23 treat rbv 8 week 96 23/24 treat 12 week treatment-experienced participant svr12 94 17/18 100 17/17 12-week arm rbv respectively 94 17/18 16-week arm participant fail achieve svr 2 relapsed 8-week arm 1 discontinue vomiting/cellulitis 16-week arm 2 discontinue consent withdrawn/lost follow-up svr12 affect presence resistance-associated substitution ras consistent change insulin resistance 5 participant report adverse event pneumonia chest pain opiate overdose cellulitis decrease creatinine high efficacy demonstrate participant hcv gt3 infection cirrhosis treatment 12 week require efficacy maintain regardless baseline ras\",\"elevated liver enzyme frequently observe renal transplant recipient warrant exploration immunosuppressed patient hepatitis e virus hev infection cause chronic hepatitis cirrhosis extrahepatic manifestation renal injury\",\"aim integrate analysis assess efficacy once-daily combination elbasvir 50 mg grazoprevir 100 mg ribavirin hcv 4 (gt4)-infected participant enrol phase 2/3 clinical programme elbasvir/grazoprevir\",\"baseline resistance-associated substitution ras variable impact clinical trial prevalence impact real-world patient remain unclear perform baseline resistance testing use commercial assay 10 cutoff 486 patient treat ldv/sof smv/sof ribavirin multi-center observational hcv-target cohort linkage ras evaluate select sample use novel quantitative single variant sequencing assay result prevalence ns3 ns5a ns5b ras 45 13 8 respectively 10 patient harbor ras 2 drug class baseline ldv ras gt1a te cirrhosis ldv/sof subgroup associate 2 4 low svr12 rate smv ras associate low svr12 rate gt1a treatment-experienced cirrhotic smv/sof subgroup pooled analysis patient baseline ras reveal svr12 100 19/19 patient treat long 98 day 87 81/93 patient treat short 98 day result demonstrate ras prevalence impact real world practice general agreement registration trial suggest long treatment duration overcome negative impact baseline ras svr12 rate clinical practice\",\"novel available interferon (ifn)-free regimen significantly improve sustained virological response svr patient chronic hepatitis c chc important effect short duration treatment subset patient treatment failure tf presence resistance-associated substitution ras lead virological breakthrough bt relapse analyse case serie role ras tf cirrhotic patient (gt)4 treat previous ifn-free regiman retreat combination sofosbuvir (sof)/velpatasvir vel 12 24 week ribavirin rbv\",\"approximately 10 million people pakistan infect hepatitis c virus hcv patient develop chronic hepatitis rare case spontaneous clearance little know multidrug resistant viral variant pakistan\",\"direct-acting antiviral daa transform traditional treatment option hepatitis c virus hcv infection daa combination highly effective reduce burden chronic hcv infection clinical trial recommend european association study liver easl treatment guideline review examine result second-generation daa combination real-life clinical practice patient 1 3 co-infecte hiv real-world datum 4 6 rare second generation daa sofosbuvir plus daclatasvir sofosbuvir/ledipasvir ombitasvir/paritaprevir/ritonavir plus dasabuvir sofosbuvir plus velpatasvir glecaprevir plus pibrentasvir grazoprevir plus elbasvir high svr rate good safety profile high resistance barrier convenient real-world datum 3 generally support easl guideline high overall sustained virological response rate report recommend regimen real-world datum available sofosbuvir plus daclatasvir sofosbuvir/ledipasvir ombitasvir/paritaprevir/ritonavir plus dasabuvir furthermore exist level evidence difficult define optimal regimen base real-world datum ie treatment duration include ribavirin option patient cirrhosis real-life challenge manage hiv-coinfected patient discuss additional burden avoid drug-drug interaction daa antiretroviral\",\"presence resistance-associated substitution ras ns5a region compromise efficacy direct acting antiviral agent daa hcv resistance ns5a region mainly focus patient hepatitis c virus hcv 1a g1a 3 g3 factor poor treatment response ie cirrhosis prior treatment-exposure hcv-rna 800 000 iu/ml evaluate cohort hcv g1a g3 infected patient prevalence ras domain ns5a use population-based sequencing impact ras optimization current therapeutic strategy ras consider clinically relevant m28a/g/t q30d/e/h/g/k/l/r l31m/v/f h58d y93c/h/n/s g1a y93h g3 total 232 patient na\\u00efve ns5a inhibitor include 166 g1a 66 g3 overall prevalence ns5a ras g1a g3 patient low 5.5 null respectively high proportion patient harbor factor poor response 78.9 g1a 75.8 g3 overall rate patient harbor ns5a ras combination factor low vast majority patient g1a 94 g3 100 treat standard treatment 12 week ribavirin conclusion test ns5a ras specific hcv-infected population ie g1a g3 cirrhosis prior treatment experience hcv-rna 800 000 iu/ml useful optimize current ns5a-based therapy avoid ribavirin-related toxicity shortening treatment duration majority patient\",\"arenavirus cause hemorrhagic fever hf disease human represent important public health problem endemic region addition evidence indicate worldwide-distributed prototypic arenavirus lymphocytic choriomeningitis virus neglect human pathogen clinical significance licensed arenavirus vaccine current antiarenavirus therapy limited off-label use ribavirin partially effective unmet need novel therapeutic combat human pathogenic arenavirus task facilitate identification compound antiarenaviral activity serve probe identify arenavirus-host interaction suitable targeting lead compound develop future antiarenaviral drug screening combinatorial library kr\\u00f6nhke pyridine identify compound kp-146 5-(5-(2,3-dihydrobenzo b][1,4 dioxin-6-yl)-4'-methoxy-[1,1'-biphenyl]-3-yl)thiophene-2-carboxamide strong anti-lymphocytic choriomeningitis virus lcmv activity culture cell kp-146 inhibit lcmv cell entry interfere activity lcmv ribonucleoprotein vrnp responsible direct virus rna replication gene transcription budding process mediate lcmv matrix z protein lcmv variant increase resistance kp-146 emerge serial passage presence kp-146 finding support consideration kr\\u00f6hnke pyridine scaffold valuable source identify compound serve tool dissect arenavirus-host interaction lead candidate structure develop antiarenaviral drug\",\"s282 t ns5b primary amino acid substitution associate resistance sofosbuvir sof rarely detect patient treat sof-based regiman emergence fitness s282 t substitution virologic failure patient administer sof-based regimen sof ledipasvir (ldv)/sof phase 2 3 program evaluate plasma sample collect baseline virologic failure amplify deep sequence 1 cutoff date 12,000 patient treat sof ldv/sof phase 2 3 study deep sequencing available baseline 8598 patient 62.4 gt 1 10.7 gt2 20.9 gt3 6.0 gt4 6 virologic failure 901 patient 8598 patient s282 t substitution detect baseline virologic failure 10 901 1 patient s282 t detect sof-based regiman associate treatment-emergent s282 t sof monotherapy patient retreatment ldv/sof prior ldv/sof failure patient ldv/sof 8 week 1 gt1 patient ldv/sof 12 week 1 patient gt3 gt4 gt5 ldv/sof ribavirin 12 week 1 gt6 patient 10 patient emergent s282 t receive sof-based retreatment regiman achieve sustained virologic response 12 week treatment fail retreatment conclusion emergence s282 t substitution rare patient fail sof-based regimen successful retreatment prior sof failure patient possible presence s282 t substitution sof combination direct-acting antiviral agent hepatology communications 2017;1:538 549\",\"incidence rate insulin resistance ir patient chronic hepatitis c chc high recently branched-chain amino acid bcaa attenuate ir chc patient effect patient quality life remain unclear aim current prospective study determine effect bcaa supplement ir health-related quality life hr-qol patient chc study 20 non-diabetic patient chc non-responder peginterferon-\\u03b1 ribavirin recruit patient bcaa supplement day 30 g minimum 10-h overnight fast 3 month serum level glucose insulin albumin triglyceride cholesterol measure 0 3 month additionally ir measure use homeostasis model assessment-ir hr-qol assess use 36-item short form health survey viral load measure reverse transcription polymerase chain reaction use taqman probe wilcoxon signed-rank test use determine statistical significance result indicate 70 subject positive ir decrease 50 end study furthermore 85 subject demonstrate level improvement overall bcaa treatment significantly decrease ir p=0.006 augment serum albumin concentration p=0.008 compare basal value additionally end treatment viral load triglyceride level decrease result significant p=0.084 p=0.080 respectively bcaa treatment improve hr-qol regard role limitation physical health problem p=0.017 role limitation emotional problem p=0.026 social function p=0.008 conclusion bcaa supplementation reduce ir improve hr-qol patient chc finding support application ir therapy possible therapeutic strategy hepatitis c infection\",\"evaluate efficacy direct-acting antiviral daa kanto rosai hospital\",\"advanced age major limitation interferon-based treatment chronic hepatitis c virus hcv infection poor response tolerability direct-acting antiviral daa drug regimen safe highly effective allow administration treatment elderly study aim assess efficacy safety paritaprevir/ritonavir ombitasvir dasabuvir prod ribavirin treatment patient aged \\u226570 year hcv 1b compensate cirrhosis total 1008 patient hcv 1b compensate cirrhosis prospectively treat prod ribavirin 12 week december 2015 july 2016 sustained virologic response 12 week end treatment svr12 adverse effect ae comorbiditie discontinuation death rate record efficacy safety therapy assess patient aged \\u226570 year compare datum patient 70 year 117 patient aged \\u226570 year preponderantly female 58.9 mean age 73.3 \\u00b1 2.8 year range 70 82 37 31.6 treatment-experienced comorbiditie report 60.6 patient \\u226570 year 39.8 70 year p .001 svr12 rate base intention-to-treat per-protocol analysis 97.4 100 respectively patient \\u226570 year compare 97.8 99.6 respectively patient 70 year p ns p ns severe ae report 4 3.4 patient \\u226570 year compare 23 2.6 70 year p ns death record patient aged 79 year 0.9 6 death 0.8 70 year p ns).treatment prod ribavirin patient 70 year age old hcv 1b compensate cirrhosis prove effective safe tolerated young patient\",\"simeprevir approve pegylated interferon ribavirin pr chronic hepatitis c virus hcv gt 1 gt4 infection usa european union\",\"hcv infection lead hepatocellular carcinoma hcc vitamin d deficiency related cancer investigate snp gene involve vitamin d pathway predict hcv-related hcc presence patient treat new anti-hcv drug\",\"need all-oral hepatitis c virus hcv treatment high response rate improve tolerability low pill burden compare interferon-inclusive regiman lead development new direct-acting antiviral agent ravidasvir rdv second-generation pan-genotypic ns5a inhibitor high barrier resistance aim phase 2 study everest study assess efficacy safety interferon-free 12-week rdv plus ritonavir-boosted danoprevir dnvr ribavirin rbv regimen treatment-na\\u00efve asian hcv 1 gt1 patient cirrhosis\",\"direct-acting antiviral daa regimen high efficacy tolerability patient hcv 1/1b gt1/1b clinical trial robust real-world evidence interferon (ifn)-free daa treatment hcv gt1-infected patient asia lack\",\"grazoprevir ns3/4a protease inhibitor pi elbasvir ns5a inhibitor perform meta-analysis directly compare grazoprevir plus elbasvir ribavirin regiman vs. grazoprevir elbasvir ribavirin treatment hepatitis c virus 1 infection precisely evaluate efficacy regiman cirrhotic il28 cc patient coinfecte human immunodeficiency virus\",\"host lipid metabolism influence viral replication lifecycle hepatitis c virus aim evaluate change glucose lipid metabolism patient chronic hepatitis c therapy direct act antiviral daa\",\"recent development direct-acting antiviral agent daa hepatitis c virus hcv infection lead higher sustained virological response svr rate short treatment duration adverse event compare regimen include interferon relatively small proportion patient achieve svr treatment include daa peginterferon and/or ribavirin retreatment combination daa conduct patient difficult achieve svr retreat patient resistance-associated substitution ras treatment-emergent substitution japan hcv 1b gt1b found 70 hcv-infected individual minireview summarize retreatment regimen svr rate hcv gt1b important avoid drug target region target initial drug next-generation combination daa sofosbuvir/velpatasvir/voxilaprevir 12 wk glecaprevir/pibrentasvir 12 wk propose potential solution hcv gt1b-infected patient treatment failure mainly basis target distinctive region clinician follow new information resource daa select proper combination daa retreatment hcv gt1b-infected patient treatment failure\",\"hepatitis c virus hcv predominant cause liver failure worldwide associate development diabetes mellitus dm insulin resistance ir vivo vitro dm ir aggravate rate fibrosis cirrhosis hepatocellular carcinoma hcc study reveal patient hcv great risk develop type 2 diabete t2d compare control patient hepatitis b. way patient t2d highly prone severe hcv clinical outcome increase progression fibrosis cirrhosis ultimately lead hcc hcv interfere insulin-signaling pathway modulate cellular gene expression up-regulation inflammatory cytokine tumor necrosis factor-\\u03b1 hypophosphorylation insulin receptor substrate-1 -2 phosphorylation protein kinase b akt up-regulation gluconeogenic gene accumulation lipid targeting lipid storage organelle owe pathological association hcv dm possibility hcv eradication result reduce morbidity mortality rate t2d rule hcv diabetes-associated ir target hcv therapy study reveal ir minimize interfere response rate interferon/ribavirin treatment\",\"4 hepatitis e virus hev infect human 1 4 vary geographical distribution transmission pathogenesis little know property hev host contribute variation primary isolate grow poorly cell culture study rely variant adapt cancer cell line likely alter virus biology investigate infection replication primary isolate hev hepatocyte-like cell hlc derive human embryonic induce pluripotent stem cell\",\"high rate chronic hepatitis c chc key issue global public health concern interferon (ifn)-\\u03bb relevant gene antiviral treatment pathway influence hepatitis c virus hcv spontaneous clearance affect ifn-mediated viral clearance aim study identify association interleukin 28b il28b myxovirus resistance mxa gene polymorphism hcv spontaneous clearance therapeutic response chinese chc patient il28b mxa gene detect 231 chc carrier 428 subject hcv spontaneous clearance 662 chc patient pegylated ifn-\\u03b1 ribavirin pegifn-\\u03b1/rbv treatment patient mxa rs2071430 tt likely develop hcv infection chronicity additive model odd ratio 1.22 95 confidence interval ci 1.01 1.48 p 0.042 il28b rs1298075 variant additive model 0.58 95 ci 0.34 0.98 p 0.040 mxa rs17000900 variant additive model 0.54 95 ci 0.30 0.99 p 0.048 likely achieve sustained virological response life table indicate patient il28b rs1298075 ag slow achieve viral load 106 copies/ml p 0.05 study illustrate carriage il28b rs12980275 aa positive effect treatment response pegifn-\\u03b1/rbv chinese chc patient\",\"identification novel reassortant avian influenza h7n9 virus china 2013 jun 30 2017 virus cause epidemic wave lead total 1,552 human infection fatality rate 40 spring 2017 highly pathogenic avian influenza hpai h7n9 virus emerge cause 25 human infection hpai h7n9 virus biological difference lpai multiple basic amino acid residue ha lead independence trypsin replication pathogenicity hpai h7n9 virus experimental animal human unclear a(h7n9 vaccine development pandemic preparedness ongoing include reassortment h7n9/pr8 reverse genetic base vaccine virus like particle vlp vaccine intranasal live attenuate influenza vaccine laiv non-adjuvant vero cell culture-derived inactivate whole-virus vaccine mdck culture-derived vaccine h7 dna vaccine recombinant replicative h7n9 virus h7n9 53tm vaccine neuramidinase resistant site a(h7n9 virus isolate patient report alternative drug study das181 fludase ribavirin troglitazone minocycline persistent surveillance enhance global control essential fight human infection a(h7n9 virus\",\"target host function essential viral replication consider broad spectrum resistance-refractory antiviral approach host function far validate broad-spectrum antiviral target vivo er \\u03b1-glucosidase ii demonstrate essential morphogenesis envelop virus include member family virus cause hemorrhagic fever vivo antiviral efficacy iminosugar-based er \\u03b1-glucosidase inhibitor report animal infect dengue japanese encephalitis ebola marburg influenza virus establish huh7.5-derived cell line er \\u03b1-glucosidase ii knockout use crispr/cas9 demonstrate replication dengue yellow fever zika virus reduce 1 2 log knockout cell line result clearly indicate partial suppression viral replication possibly achieve complete inhibition er-\\u03b1-glucosidase ii inhibitor explore improve antiviral efficacy lead iminosugar ihvr-19029 combination broad-spectrum antiviral agent favipiravir t-705 combination ihvr-19029 t-705 synergistically inhibit replication yellow fever ebola virus culture cell mouse model ebola virus infection combination sub-optimal dose ihvr-19029 t-705 significantly increase survival rate infected animal prove concept combinational therapeutic strategy treatment viral hemorrhagic fever broad spectrum host- viral- target antiviral agent\",\"despite excellent efficacy direct act antiviral daa hepatitis c virus hcv treatment failure occur recently retreatment decision daa failure influence number available agent concern hcv drug resistance lack datum regard retreatment recommend treatment approach previously depend limited clinical trial expert opinion article review current state evidence hcv retreatment daa failure base recent clinical trial datum patient fail hcv treatment daa agent excellent retreatment option patient benefit resistance testing daa therapy failure select optimal treatment duration newly approve salvage therapy significantly impact common mutation approve food drug administration hcv retreatment regard presence resistance associate substitution prior retreatment effort limit long course therapy addition ribavirin novel combination approve therapy base expert guidance current daa option hcv retreatment daa era streamlined evidence-based\",\"ultraviolet light uvc range commonly use disinfectant control virus clinical setting water treatment currently unknown human viral pathogen develop resistance stressor investigate adaptation enteric pathogen human echovirus 11 disinfection uvc characterize underlie phenotypic genotypic change repeat exposure uvc lead reduction uvc inactivation rate approximately 15 cent compare wild-type control population time-series next-generation sequencing datum reveal adaptation uvc accompany decrease virus mutation rate inactivation efficiency uvc additionally compromise shift first-order biphasic inactivation kinetic form viral persistence present uvc resistant control population importantly population biphasic inactivation kinetic exhibit resistance ribavirin antiviral drug uvc interfere viral replication overall ability echovirus 11 adapt uvc limited relevant consequence disinfection clinical setting water treatment plant\",\"highly effective interferon-free direct-acting antiviral (daa)-based regimen available treatment chronic hepatitis c virus hcv infection despite impressive efficacy overall small proportion patient registrational trial experience treatment failure case associate detection hcv resistance-associated substitution ras baseline article describe method key finding independent regulatory analysis investigate impact baseline nonstructural ns 3 q80 k ns5a ras efficacy current united states food drug administration (fda)-approve regimen patient hcv gt 1 gt3 infection analysis focus clinical trial include patient previously na\\u00efve daa class(es investigational regiman characterize impact baseline ras enrich viral population natural transmit polymorphism i.e. drug-selected ras use consistent approach optimize comparability result different daa regimen patient population include use 15 sensitivity cutoff next-generation sequencing result standardized list ns5a ras analysis confirm detection ns3 q80 k ns5a baseline ras associate reduce treatment efficacy multiple daa regimen impact minimize use intensified treatment regiman long treatment duration and/or addition ribavirin discuss drug resistance-related consideration contribute pretreatment resistance testing treatment recommendation drug labeling fda-approved daa regimen\",\"glecaprevir abt-493 pangenotypic ns3/4a protease inhibitor pibrentasvir abt-530 pangenotypic ns5a inhibitor second generation direct act antiviral daa treatment chronic hepatitis c hcv fix dose ribavirin (rbv)-free regimen activity gt 1 6 vitro antiviral synergistic activity high barrier resistance potent activity common polymorphism daily oral dosing minimal absorption primary biliary excretion negligible renal excretion safe patient renal impairment regimen review pangenotypic regiman suitable renal impairment prior daa failure area cover key phase 2 3 trial investigate efficacy safety glecaprevir/pibrentasvir review methodology primary end point baseline demographic datum response rate adverse event literature search methodology involve review key abstract present american association study liver disease european association study liver expert commentary advantage limitation glecaprevir/pibrentasvir review comparison competitor drug market\",\"hepatitis c virus hcv affect estimate 80 million individual worldwide strain public health 25 30 patient europe infect hiv coinfecte hcv despite treatment modality contain ns3/4a protease inhibitor combination pegylated interferon ribavirin prior 2013 improve svr rate severe effect high nowadays oral direct-acting antiviral daa combination therapy offer excellent treatment efficacy safety tolerability review focus current literature clinical evidence impact regard ns3/4a protease inhibitor addition pitfall treatment hiv- hbv-coinfected patient discuss era daa treatment third-generation pan-genotypic ns3/4a protease inhibitor mainly grazoprevir glecaprevir voxilaprevir high antiviral activity genetic resistance barrier cure rate 95 combine ns5a inhibitor irrespectively baseline resistance associate variant ras present new key component daa combination therapy impressive option eradicate hcv difficult-to-treat population e.g. compensate cirrhosis end-stage renal disease patient fail previous daa treatment\",\"hepatitis c virus hcv lead cause liver disease transplantation worldwide current available therapy hcv infection base interferon-\\u03b1 ribavirin new direct-acting antiviral daa ns3 protease ns5b polymerase inhibitor high cost drug design severe effect hcv resistance present exist treatment demonstrate need develop efficient anti-hcv agent study aim evaluate antiviral effect sorbifolin 1 pedalitin 2 flavonoid pterogyne nitens hcv replication cycle compound investigate anti-hcv activity use 2a jfh-1 subgenomic replicon infectious virus system flavonoid 1 2 inhibit virus entry 45.0 78.7 respectively non-cytotoxic concentration mechanism flavonoid 2 block virus entry demonstrate direct action virus particle interference host cell alternatively flavonoid 1 activity restricted virucidal effect additionally inhibitory effect hcv replication release observe treat cell flavonoid datum description 1 2 possess vitro anti-hcv activity\",\"venezuelan equine encephalitis virus veev representative member new world alphavirus transmit mosquito vector cause highly debilitating disease human equid vertebrate host despite continuous public health threat compound anti-veev activity cell culture mouse model identify date rapid development virus resistance record study investigate possibility use modify nucleoside analog \\u03b2-d-n [4]-hydroxycytidine nhc anti-veev agent define mechanism anti-veev activity result demonstrate nhc potent antiviral agent affect release genome rna-containing vee virion infectivity antiviral activity determine nhc-induced accumulation mutation virus-specific rna antiviral effect prominent nhc apply early infectious process amplification negative- positive-strand rna infected cell importantly low-level resistance veev nhc develop require acquisition cooperative function mutation nsp4 adaptive mutation closely located segment nsp4 datum suggest nhc potent ribavirin anti-veev agent likely use treat alphavirus infection importance venezuelan equine encephalitis virus veev cause widespread epidemic human domestic animal veev infection result severe meningoencephalitis long-term sequela approve therapeutic exist treatment veev infection study demonstrate \\u03b2-d-n [4]-hydroxycytidine nhc potent anti-veev compound 50 effective concentration 1 \\u03bcm. mechanism nhc antiviral activity base induction high mutation rate viral genome accordingly nhc treatment affect rate particle release particle infectivity importantly contrast anti-alphavirus drug development resistance veev nhc develop inefficiently low level resistance require acquisition multiple mutation gene veev-specific rna-dependent rna polymerase nsp4\",\"mutation hcv nonstructural protein 5a ns5a play vital role virus resistance aim study develop correlation ns5a mutation 3a virological response interferon alpha ifn-\\u03b1 plus ribavirin therapy\",\"era direct-acting antiviral hepatitis c virus hcv gt 3 remain difficult-to-treat hcv-gt currently datum efficacy ledipasvir/sofosbuvir plus ribavirin sof/ldv+rbv gt3-infected patient limit investigate efficacy regiman real-life cohort austria\",\"coronavirus cov rna genome large single-stranded positive-sense rna virus covs encode proofreading 3'-to-5 exoribonuclease nonstructural protein 14 nsp14-exon responsible cov high-fidelity replication alanine substitution exon catalytic residue exon(- severe acute respiratory syndrome-associated coronavirus sars-cov murine hepatitis virus mhv disrupt exon activity yield viable mutant virus defective replication 20-fold-decreased fidelity increase susceptibility nucleoside analogue test stability exon(- phenotype passage mhv-exon(- 250 time culture cell p250 parallel wild-type mhv wt-mhv compare mhv-exon(- p3 mhv-exon(- p250 demonstrate enhance replication increase competitive fitness reversion exon(- active site furthermore mhv-exon(- p250 susceptible mhv-exon(- p3 multiple nucleoside analogue suggest mhv-exon(- selection increase replication fidelity subsequently identify novel amino acid change rna-dependent rna polymerase nsp14 mhv-exon(- p250 partially account reduce susceptibility nucleoside analogue result suggest increase replication fidelity select exon(- covs significant barrier exon(- reversion result support hypothesis high-fidelity replication link cov fitness indicate multiple replicase protein compensate exon function replication importance uniquely rna virus covs encode proofreading exoribonuclease exon nsp14 mediate high-fidelity rna genome replication proofreading-deficient cov disrupted exon activity exon(- nonviable significant defect replication rna synthesis fidelity fitness virulence study exon(- murine hepatitis virus adapt long-term passage increase replication fitness revert exon-inactivating mutation passage-adapted exon(- mutant demonstrate increase resistance nucleoside analogue explain partially secondary mutation nsp12 nsp14 datum suggest enhance resistance nucleoside analogue mediate interplay multiple replicase protein support proposed link cov fidelity fitness\",\"activation eukaryotic translation initiation factor 4e eif4e cellular survival mechanism response chemotherapy cancer work demonstrate target eif4e ribavirin sensitize hepatocellular carcinoma hcc cell response doxorubicin ribavirin inhibit growth survival hcc cell great extent normal liver cell combination doxorubicin achieve great efficacy single drug vitro vivo ribavirin suppress phosphorylation molecule involve akt/mtor/eif4e pathway overexpression phosphomimetic form s209d nonphosphorylatable form s209a eif4e significantly reverse inhibitory effect ribavirin interestingly doxorubicin significantly increase p-eif4e(s209 level dose- time-dependent manner suggest doxorubicin induce eif4e activation hcc cell addition eif4e activation induce doxorubicin hcc cell inhibit ribavirin work demonstrate great efficacy ribavirin doxorubicin combination underlying mechanism\",\"overexpression eukaryotic translation initiation factor 4e eif4e detect patient renal cell carcinoma rcc associate poor prognosis possible role eif4e rcc reveal\",\"failure achieve sustained virological response svr hepatitis c virus hcv direct-acting antiviral (daa)-based regimen commonly associate emergence resistance-associated substitution ras retreatment patient fail prior daa remain challenging aim prospective randomize study evaluate efficacy primary endpoint svr 12 week end treatment svr12 safety sofosbuvir grazoprevir/elbasvir ribavirin 16 24 week patient fail achieve svr previous ns5a- ns3-based therapy evidence ras failure\",\"30 year ago 30 japanese hemophiliac infected hiv-1 hepatitis c virus hcv receive contaminate blood product study report high efficacy safety direct act antiviral daa hiv-1 co-infecte patient datum limit hemophiliacs\",\"availability novel direct-acting antiviral daa represent new era curative hepatitis c virus hcv treatment 95 patient infect hcv 1 achieve sustained virological response svr majority patient globally unable access treatment cost infrastructure constraint remain untreated uncured\",\"evaluate cost-utility treatment elbasvir/grazoprevir ebr/gzr regimen compare ledipasvir/sofosbuvir ldv/sof ombitasvir/paritaprevir/ritonavir dasabuvir \\u00b1 ribavirin 3d \\u00b1 rbv sofosbuvir/velpatasvir sof/vel patient chronic hepatitis c gt 1 infection\",\"pretreatment evaluation hcv-infected patient complex interplay multiple clinical viral parameter lead tailored approach bring real-life sustained virological response svr rate close 98%-99\",\"grow resistance malarial parasite particularly plasmodium falciparum need search discovery novel drug target inosine monophosphate dehydrogenase impdh important target antimalarial drug discovery process p. falciparum treatment malaria absence x-ray crystal structure enzyme homology modeling prove reasonable alternate study substrate binding mechanism enzyme study 3-d homology model p. falciparum impdh construct human impdh pdb code 1nf7 template furthermore in-silico combinatorial library ribavirin rvp derivative 1347 molecule design virtually screen ligand selectively great binding affinity plasmodium falciparum impdh relative human impdh ii total ribavirin derivative identify great binding affinity -126 -108kcal/mol -9.4 -8.6kcal/mol plasmodium falciparum impdh inhibitor use selective potent plasmodium falciparum impdh type study provide information synthetic medicinal chemist enhance potential compound rvp derivative chemotherapeutic agent fight increase burden malarial infection\",\"chemistry pharmacology pharmacodynamic pharmacokinetic efficacy safety dosage administration role elbasvir-grazoprevir treatment hepatitis c virus hcv infection review\",\"direct-acting antiviral daa resistance-associated substitution ras jeopardize effectiveness daa patient hepatitis c virus hcv selection pressure pegylated-interferon peg-ifn plus ribavirin p/r treatment enhance hcv genome variation p/r treatment alter rate change ras unclear\",\"daclatasvir asunaprevir asv beclabuvir bcv direct-acting antiviral daa patient hepatitis c virus 1 infection systematic review meta-analysis investigate efficacy safety three-drug combination hcv 1 infection electronic search engine search relevant publication study screen eligibility datum extract outcome pool event rate risk ratio rr protocol register prospero crd42017054391 include study study include meta-analysis n 1261 three-drug combination high response rate na\\u00efve patient sustained virologic response week-12 posttreatment svr12 rate 95.7 95%ci 93.8 97.1 difference detect add ribavirin rbv pooled rr 0.98 95%ci 0.90 1.08 p 0.70 compare interferon-experienced patient rr 1.02 95%ci 0.98 1.07 p 0.31 regardless 1 il28b treatment failure minimal difference regard previous comparison increase dose duration significant increase efficacy conclusion analysis high response rate hcv 1-infected patient treat daclatasvir asv bcv irrespective rbv use prior interferon-based therapy restriction non-cirrhotic patient il28b baseline resistance-associated variant\",\"hepatitis c virus hcv infect 130 170 million people worldwide recently direct-acting antiviral eradicate hcv infection 90 95 non-cirrhotic patient depend treatment experience regimen use similar rate achieve compensate cirrhotic long treatment duration and/or ribavirin require hcv use host lipid metabolism lifecycle cause hepatic steatosis insulin resistance hepatic steatosis define excessive triglyceride deposition hepatocyte affect approximately half hcv-infected individual genetic factor co-morbiditie drive steatosis turn instigate fibrosis progression cirrhosis hepatocellular carcinoma polymorphism gene modulate lipid deposition hepatocyte patatin-like phospholipase domain-containing protein 3 pnpla3 transmembrane superfamily member 2 tm6sf2 predispose people steatosis metabolic syndrome obesity insulin resistance increase worldwide far contribute hepatic steatosis alcohol long recognize cause lipid deposition liver hiv antiretroviral drug hbv far drive hepatic steatosis factor limit response interferon-based regimen treat hcv response direct-acting antiviral appear impaired effect hcv eradication hepatic steatosis progression fibrosis cirrhosis hepatocellular carcinoma warrant study era direct-acting antiviral\",\"hepatitis c virus hcv infection induce steatosis accompany multiple metabolic alteration include hyperuricemia reversible hypocholesterolemia insulin resistance total cholesterol low-density lipoprotein-cholesterol triglyceride level increase peginterferon ribavirin combination therapy sustained virologic response svr achieve patient hcv steatosis significantly common patient hcv 3 interferon-free regimen effective treat hcv 3 infection hcv infection increase fatty acid synthase level result accumulation fatty acid hepatocyte note low-density lipoprotein receptor scavenger receptor class b type niemann-pick c1-like 1 protein candidate receptor involve hcv require uptake cholesterol external environment hepatocyte hcv-infected patient human immunodeficiency virus infection change serum lipid profile observe interferon-free treatment achievement svr evident hcv affect cholesterol metabolism interferon-free regimen high svr rate achieve interferon-free treatment hcv special attention pay unexpected adverse event base host metabolic change include hyperlipidemia\",\"safety efficacy ifn-free regiman use asunaprevir asv daclatasvir dcv recurrent hepatitis c virus hcv infection liver transplantation lt evaluate japan multicenter study lt recipient n 74 recurrent hcv 1b infection treat asv-dcv 24 week perform medical history positive pegylated interferon ribavirin peg-ifn/rbv 40 54.1 patient simeprevir smv peg-ifn/rbv 12 16.2 patient resistance-associated variant rav positive d168 n 1 ns3 l31 n 4 y93 n 4 l31/y93 n 1 ns5a region hcv genome sixty-one 82.4 patient complete 24-week treatment protocol sustained viral response svr achieve 49 80.3 patient achieve 16.7 patient history receive smv n 12 univariate analysis history smv p .01 presence mutation ns5a p .02 significant factor no-svr exclude patient history smv-based treatment ravs ns3/ns5a svr rate 96.4 exclude patient history smv ravs ns3/ns5a viral clearance asv-dcv favorable high svr rate\",\"real-life datum available retreatment patient fail direct-acting antiviral (daa)-regimen report outcome retreatment approve daa regimen real-life cohort patient previously fail all-oral daa combination analyze association resistance substitution ras perform time virological failure\",\"chronic hepatitis c chc major comorbidity patient hemophilia\",\"40-year-old male patient virologic relapse daclatasvir plus asunaprevir therapy serogroup 1 hepatitis c virus hcv infection visit hospital retreatment virologic examination reveal 2b hcv strain carry ns3-s122n d168a na5a-r30q l31 m q54h y93h mutation relapse patient receive sofosbuvir plus ribavirin therapy virologic relapse occur sequencing hcv genome clarify intergenotypic recombination 2b 1b estimate crossover point nucleotide 3114 3115 correspond n-terminal end ns3 region ddbj/embl/genbank database accession no. lc273304 ns5b-s282 t mutation detect hcv strain resistance-association substitution ns3 ns5a region similar baseline direct sequencing core ns4a region correspond target site genotyping serogrouping respectively useful determine combination direct-acting antiviral discrepancy observe serogroup hcv strain\",\"multiple factor contribute virological response chronic hepatitis c chc interferon-gamma-inducible protein-10 ip-10 level reflect status interferon-stimulated gene turn associate virological response antiviral therapy aim study evaluate role serum ip-10 level sustained virological response svr association parameter insulin resistance ir liver histology\",\"influenza virus inflict heavy death toll annually resistance exist antiviral drug generate interest development agent novel mechanism action favipiravir antiviral drug act increase genome-wide mutation rate influenza virus iav potential synergistic benefit combine oseltamivir favipiravir demonstrate animal model influenza population-level effect combine drug unknown order elucidate underlying evolutionary process play perform genome-wide sequencing iav experimental population subject serial passaging vitro combined protocol oseltamivir favipiravir describe interplay mutation selection genetic drift ultimately culminate population extinction particular selective sweep oseltamivir resistance mutation reduce genome-wide variation deleterious mutation hitchhike fixation increase mutational load generate favipiravir effect reduce viral fitness accelerate extinction compare iav population treat favipiravir risk spread establish newly emerge mutation include possible drug resistance mutation transmission occur viral population eradicate\",\"treatment hcv gt 2-infected japanese patient paritaprevir ns3/4a inhibitor boost ritonavir ombitasvir ns5a inhibitor ribavirin 12 week phase 2 study m12 536 ribavirin 16 week phase 3 study gift ii result svr rate 72.2 91.5 overall 11 125 patient gt2a 37 79 patient gt2b infection experience virologic failure prevalence baseline polymorphism ns3 ns5a impact treatment outcome development viral resistance gt2-infected patient experience virologic failure evaluate hcv ns3 ns5a population clonal sequence analysis baseline polymorphism ns3 confer resistance paritaprevir rare gt2a- gt2b-infected patient baseline polymorphism ns5a confer resistance ombitasvir detect 11.2 14.1 gt2a- gt2b-infected patient respectively significant impact baseline polymorphism treatment outcome japanese patient common treatment-emergent substitution time virologic failure occur amino acid position 168 ns3 28 ns5a gt2a- gt2b-infected patient high rate virologic failure patient gt2b infection resistance analysis present report support conclusion testing baseline resistance-associated polymorphism warrant hcv gt2-infected patient treat regimen ombitasvir/paritaprevir/ritonavir ribavirin 16 week\",\"efficacy safety investigational combination ombitasvir/paritaprevir/ritonavir obv/ptv/r plus sofosbuvir sof \\u00b1 ribavirin rbv patient hcv 2 3 infection cirrhosis evaluate patient hcv 3 infection cirrhosis randomize receive obv/ptv/r sof \\u00b1 rbv 12 week obv/ptv/r sof rbv administer 3-infected patient cirrhosis 12 week 2-infected patient cirrhosis 6 8 week efficacy assess sustained virologic response hcv rna 25 iu/ml 12 week post-treatment svr12 safety assess treat patient patient 3 infection cirrhosis treat 12 week obv/ptv/r sof \\u00b1 rbv overall svr12 rate 98 50/51 virologic failure patient 2 infection treat obv/ptv/r sof rbv svr12 rate 90 9/10 44 4/9 follow 8- 6-week treatment duration respectively failure achieve svr12 patient relapse baseline treatment-emergent resistance-associated substitution investigational combination obv/ptv/r sof \\u00b1 rbv tolerated achieve high svr rate virologic failure patient 3 infection combine direct-acting antiviral complementary mechanism action different viral target effective treatment strategy allow short duration therapy\",\"study aim evaluate effect baseline hepatitis c virus hcv nonstructural protein 5a ns5a resistance-associated substitution ras sustained virologic response ledipasvir (ldv)-containe regimen absence sofosbuvir sof patient hcv gt 1 infection 6 phase 2 clinical study analyse datum 1103 patient receive ldv vedroprevir ns3 protease inhibitor tegobuvir ns5b inhibitor \\u00b1 ribavirin ldv ribavirin pegylated interferon population sequencing hcv ns5a perform baseline virologic failure patient plasma sample 1045 patient available baseline sequence 747 67.7 gt1a 298 26.9 gt1b infection overall prevalence ns5a ras baseline 9.4 7.6 57/747 13.8 41/298 patient gt1a gt1b infection respectively majority gt1a-infected patient ns5a ras baseline single ns5a ras 78.9 ns5a position k24r m28 t q30h/l l31 m y93h/n/c/s. spectrum ns5a ras detect gt1b patient diverse compare gt1a patient patient harbour single ns5a ras l31 m y93h/c. patient treat ldv-containing regimen absence sof presence baseline ns5a ras associate low svr rate patient virologic failure pre-existing and/or emergent ns5a ras 287/287 100 40/42 95.2 patient gt1a gt1b infection respectively novel ns5a substitution identify emergent ns5a ras k26e s38f gt1a l31i gt1b conclusion presence ns5a ras baseline reduce svr rate patient treat ldv combination vedroprevir tegobuvir \\u00b1 ribavirin ribavirin pegylated interferon virologic failure associate detection ns5a ras patient result suggest resistance barrier differ depend hcv drug combination important individual daa\",\"japan daclatasvir dcv asunaprevir asv therapy ifn-free treatment approve thousand patient successfully treat svr rate 90 converse 10 patient fail achieve viral eradication retreat use different approach study evaluate treatment efficacy ledipasvir/sofosbuvir ribavirin patient fail respond dcv asv therapy\",\"lethal mutagenesis broad-spectrum antiviral strategy employ mutagenic nucleoside analog exploit high mutation rate low mutational tolerance rna virus study mutagen-resistant virus identify determinant replicative fidelity importance mutation rate viral population dynamic previously demonstrate effective lethal mutagenesis influenza virus use nucleoside analog virus high genetic barrier mutagen resistance investigate mutagen-resistant phenotype mutation enriched drug-treated population find pb1 t123a high replicative fitness wild type pr8 maintain level genome production 5-fluorouracil 2,4-dihydroxy-5-fluoropyrimidine treatment surprisingly mutagen-resistant variant increase baseline rate c-to-u g-to-a mutation second drug-selected mutation pa t97i interact epistatically pb1 t123a mediate high-level mutagen resistance predominantly limit inhibitory effect nucleoside polymerase activity consistent importance epistatic interaction influenza virus polymerase datum suggest nucleoside analog resistance replication fidelity strain dependent previously identify ribavirin 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-1,2,4-triazole-3-carboxamide resistance mutation pb1 v43i pb1 d27n confer drug resistance pr8 background pr8-pb1 v43i polymerase exhibit normal baseline mutation rate result highlight genetic complexity influenza virus polymerase demonstrate increase replicative capacity mechanism rna virus counter negative effect elevated mutation rate importance rna virus exist genetically diverse population stand genetic diversity potential adapt rapidly evolve resistance antiviral therapeutic evade immune response viral mutant altered mutation rate mutational tolerance provide insight genetic diversity arise affect behavior rna virus end identify variant polymerase complex influenza virus able tolerate drug-mediated increase viral mutation rate find drug resistance highly dependent interaction mutation polymerase complex contrast virus influenza virus counter effect high mutation rate primarily maintain high level genome replication finding suggest importance maintain large population size virus high mutation rate multiple protein affect mutation rate genome synthesis\",\"genetic variability ns5a associate different level resistance currently ns5a inhibitor aim study detect ns5a inhibitor resistance associate substitution ras hepatitis c virus hcv 1 gt1 patient naive direct-acting hcv antiviral\",\"norovirus major cause acute gastroenteritis worldwide emerge important issue chronic infection transplantation patient approve antiviral available evaluate effect different immunosuppressant ribavirin norovirus explore mechanism action use human norovirus hunv replicon-harboring model surrogate murine norovirus mnv infectious model role corresponding drug target investigate gain- loss-of-function approach find calcineurin inhibitor cyclosporine csa tacrolimus fk506 moderately inhibit hunv replication gene silencing cellular target cyclophilin fkbp12 calcineurin significantly inhibit hunv replication low concentration therapeutically speak mycophenolic acid mpa uncompetitive imp dehydrogenase impdh inhibitor potently rapidly inhibit norovirus replication ultimately clear hunv replicon inducible resistance follow long-term drug exposure knockdown mpa cellular target impdh1 impdh2 suppress hunv replication consistent nucleotide-synthesizing function impdh exogenous guanosine counteract antinorovirus effect mpa furthermore competitive impdh inhibitor ribavirin efficiently inhibit norovirus result additive effect combine immunosuppressant result study demonstrate calcineurin phosphatase activity impdh guanine synthase activity crucial sustain norovirus infection therapeutically target result suggest mpa shall preferentially consider immunosuppressive medication transplantation patient risk norovirus infection ribavirin represent potential antiviral immunocompromised immunocompetent patient norovirus gastroenteritis\",\"million chronic hepatitis c chc virus-infected patient treat combination therapy interferon ribavirin achieve virological response svr worldwide aim study evaluate risk factor de-novo diabetes mellitus chc patient treat combination therapy interferon ribavirin achieve svr\",\"determine number mutation ns5a region hepatitis c virus hcv relationship response antiviral therapy patient chronic hepatitis c 1 non-responder treatment\",\"hepatitis e virus hev infection major cause acute hepatitis provoke chronic infection immunocompromised patient pathogenesis treatment outcome involve complex interplay virus host nature adaptive response hev host immune system remain obscure good study use large-scale proteomic bioinformatic profile characteristic mutation human hev isolate associate ribavirin treatment failure chronic hepatitis hepatic failure altered immunoreactivity prevalence specific mutation examine large number protein sequence orf1 orf2 region 3 major human-derived hev 1 3 4 analyze potential b cd4 cd8 t cell epitope find mutation overlap predict epitope frequently present 3 hev overlap mutation mediate reduce antigenicity finally delineation diversification evolution underlie epitope observe variant apparently evolve early 1 compare 3 4 result indicate hev substantial evolutionary pressure develop mutation enable evasion host immune response resistance antiviral treatment indicate existence ongoing evolutionary arm race human immunity antiviral medication hev\",\"t-705 favipiravir potent inhibitor rna-dependent rna polymerase influenza virus favipiravir-resistant virus isolate rna polymerase characterize isolation resistant virus examine\",\"chronic hcv infection emerge complex multifaceted disease manifestation extend liver hcv play direct role glucose metabolism lead insulin resistance type 2 diabete evaluate change glycemic state follow sofosbuvir-based treatment regimen diabetic hcv patient chronic hepatitis c patient undergo sofosbuvir-based treatment regimen retrospectively screen sixty-five diabetic hcv patient enrol analysis baseline demographic laboratory datum record pretreatment transient elastography perform 24-week post eot svr24 fast plasma glucose hemoglobin a1c re-evaluate compare baseline enrol diabetic patient responder statistically significant decline fasting plasma glucose hemoglobin a1c value svr24 degree hepatic fibrosis level fast plasma glucose hemoglobin a1c decrease svr24 comparison baseline level fifty-one patient improvement hemoglobin a1c value svr24 improvement likely occur patient low body mass index reduction fasting plasma glucose 20 mg/dl 1.1 mmol/l hemoglobin a1c \\u22650.5 associate age gender hepatic fibrosis stage sofosbuvir-based regimen highly efficient antiviral therapy diabetic chronic hcv patient result improvement fasting plasma glucose hemoglobin a1c\",\"people hepatitis c virus hcv infection fail treatment all-oral regimen represent challenging treatment population present study evaluate safety efficacy grazoprevir ruzasvir uprifosbuvir ribavirin participant fail ns5a inhibitor-containing regiman c-surge pn-3682 021 c-crest c pn-3682 011 -012 open-label multicenter study participant previously relapse follow ns5a inhibitor-containing all-oral regiman retreat grazoprevir 100 mg ruzasvir 60 mg uprifosbuvir 450 mg 24 week ribavirin 16 week primary efficacy endpoint sustained virologic response hcv rna limit quantitation 15 iu/ml 12 week treatment completion svr12 c-surge svr12 achieve 49/49 100 43/44 98 (gt)1 participant 24-week ribavirin arm 16-week plus ribavirin arm lose follow-up n 1 respectively c-crest c svr12 achieve 23/24 96 participant treat 16 week ribavirin gt1 2/2 100 gt2 13/14 93 gt3 8/8 100 participant gt2 infection discontinue study medication single dose grazoprevir ruzasvir uprifosbuvir plus ribavirin adverse event vomiting tachycardia presence baseline resistance-associated substitution impact svr12 participant complete treatment study experience virologic failure\",\"pharmacology pharmacokinetic interaction potential efficacy safety new direct-acting antiviral daa medication treatment chronic hepatitis c review\",\"hepatitis e virus hev infection emerge global health issue approve medication available nucleoside analogue 2'-c-methylcytidine 2cmc viral polymerase inhibitor inhibit infection variety virus include hepatitis c virus hcv report 2cmc significantly inhibit replication hev subgenomic replication model system use full-length infectious virus importantly long-term treatment 2cmc result loss antiviral potency indicate high barrier drug resistance development combination 2cmc ribavirin off-label treatment hev exert antagonistic effect result indicate 2cmc serve potential antiviral drug hev infection\",\"little know epidemiology frequency recombinant hcv 2/1 strain represent challenge direct antiviral therapy daa study aim identify epidemiology phylogeny hcv 2/1 strain encourage screening select daa-regimen achieve optimal sustained virologic response\",\"daclatasvir dcv non-structural [ns]5a inhibitor plus asunaprevir asv ns3 inhibitor plus beclabuvir bcv non-nucleoside ns5b inhibitor approved regiman hepatitis c virus hcv (gt)-1 treatment japan comprehensive analysis pre-treatment treatment-emergent hcv resistance regimen \\u00b1 ribavirin rbv perform\",\"success antiviral treatment patient chronic hepatitis c depend factor related virus host aim study analysis antiviral therapy combination pegylated interferon ribavirin consider factor identify predictor sustained virological response\",\"study tmc647055hpc2001 3-direct-acting-antiviral daa regiman combine ns3/4a protease inhibitor simeprevir smv non-nucleoside ns5b inhibitor tmc647055/ritonavir rtv ns5a inhibitor jnj-56914845 result high sustained virologic response 12 week actual end treatment svr12 chronic hepatitis c virus hcv 1-infected patient svr12 rate generally low 2-daa regimen smv tmc647055/rtv ribavirin objective study identify characterise pre-existing emerge resistance-associated variant rav patient enrol study tmc647055hpc2001\",\"2010 landscape hepatitis c therapeutic change rapidly today stand cusp pharmacological revolution highly effective interferon (ifn)-free direct act antiviral daa market treatment paradigm attain 90 95 sustain virologic response svr undetectable viral load week 12 24 end therapy rate treat individual compare 50 70 treatment completion dual-therapy-pegylated interferon peg-ifn ribavirin rbv major goal hepatologist clinician physician health care worker likely eradicate hepatitis c infection parallel treatment demand one-size-fits-all pill prescribe limitation hepatitis c viral load previous treatment history advanced hepatic manifestation fibrosis cirrhosis antiviral drug resistance new treatment strategy high cure rate clinical trial treatment paradigm pose dilemma real-world clinical practice therapy cost treatment access low middle-income country treatment-emergent adverse event lack effective viral screening disease progression simulation model potential challenge prospect review article deeply overview challenge encounter surmount burden hepatitis c world\",\"patient chronically infect 3 hepatitis c virus hcv fast disease progression responsive current direct-acting antiviral regimen patient infect conduct open-label trial evaluate safety tolerability efficacy ledipasvir sofosbuvir plus ribavirin patient 3 hcv infection\",\"foot-and-mouth disease virus fmdv rna-dependent rna polymerase rdrp 3d[pol catalyze viral rna synthesis characteristic low fidelity absence proofreading activity allow fmdv rapidly mutate adapt dynamic environment study use structure fmdv 3d[pol combination previously report result similar picornaviral polymerase design point mutation alter replication fidelity particular target trp237 conserve polymerase motif low reversion potential inherent single ugg codon use biochemical genetic tool replacement tryptophan 237 phenylalanine impart high fidelity replacement isoleucine leucine result lower-fidelity phenotype virus contain w237 substitution vitro growth kinetic plaque morphology similar wild-type wt a24 cruzeiro strain bhk cell high- low-fidelity variant retain fitness coinfection wild-type virus higher-fidelity w237f w237f[hf mutant virus resistant mutagenic nucleoside analog ribavirin 5-fluorouracil wt virus lower-fidelity w237i w237i[lf w237l[lf mutant virus exhibit low ribavirin resistance interestingly variant virus heterogeneous slightly delay growth kinetic primary porcine kidney cell significantly attenuate mouse infection experiment datum demonstrate single virus increase decrease rdrp fidelity attenuate virus growth animal desirable feature development safe genetically stable vaccine candidate importance foot-and-mouth disease fmd devastating disease affect livestock worldwide use structural biochemical analysis identify fmdv 3d[pol mutation affect polymerase fidelity recombinant fmdvs contain substitution 3d[pol tryptophan residue 237 genetically stable display plaque phenotype growth kinetic similar wild-type virus cell culture far demonstrate virus harbor w237f[hf substitution w237i[lf w237l[lf mutation highly attenuate animal study obtain 3d[pol fidelity variant protein engineering base polymerase structure function exploit development attenuate fmdv vaccine candidate safe stable strain obtain selective pressure mutagenic nucleotide adaptation approach\",\"optimal retreatment strategy patient chronically infect hepatitis c virus experience virologic failure treatment direct-acting antiviral-based therapy remain unclear multicenter open-label phase 2 study evaluate efficacy safety fixed-dose combination sofosbuvir-velpatasvir 400 mg/100 mg plus weight-adjusted ribavirin administer 24 week patient achieve sustained virologic response prior treatment direct-acting antiviral regimen include nucleotide analogue nonstructural protein 5b inhibitor sofosbuvir plus nonstructural protein 5a inhibitor velpatasvir nonstructural protein 3/4a protease inhibitor voxilaprevir primary efficacy endpoint proportion patient achieve sustained virologic response 12 week cessation treatment total 63 69 91 95 confidence interval 82%-97 patient achieve sustained virologic response 12 week include 36 37 97 95 confidence interval 86%-100 patient hepatitis c virus 1 infection 13 14 93 95 confidence interval 66%-100 patient 2 infection 14 18 78 95 confidence interval 52%-94 patient 3 infection adverse event mild moderate severity frequently report adverse event fatigue nausea headache insomnia rash patient 1 1a infection discontinue study drug adverse event irritability\",\"assess efficacy safety telaprevir tvr use combination natural human interferon-\\u03b2 ifn-\\u03b2 ribavirin rbv 1 patient depression compare ifn-\\u03b2/rbv therapy japan examine efficacy tvr/ifn-\\u03b2/rbv therapy treatment failure 2 patient depression\",\"multiple direct-acting antiviral (daa)-based regimen currently approve provide interferon-free treatment option hepatitis c virus hcv g 1 6 choice daa regimen duration therapy use ribavirin depend multiple viral host factor include hcv detection resistance-associated amino acid aa substitution ras prior treatment experience presence cirrhosis regard viral factor guide treatment choice important infect number daa genotype-designe potency genetic barrier impact choice treatment important debate possible virologic factor negatively influence response daa presence baseline ras baseline resistance testing currently routinely consider recommend initiate hcv treatment overall high response rate sustained virological response 90 obtain exception patient infect hcv g1a initiate treatment simeprevir elbasvir/grazoprevir cirrhosis prior daclatasvir/sofosbuvir treatment natural polymorphism demonstrate site resistance basis observation first-line strategy optimize overcome treatment failure hcv resistance\",\"pegylated interferon pegifn use treatment chronic hepatitis c virus hcv patient especially resource limited country treatment pegifn stimulate expression number host gene encode enzyme antiviral activity include myxovirus resistance gene-a mxa gene mxa gene find single nucleotide polymorphism snp position -88 promoter region affect expression mxa gene protein suggest affect treatment outcome aim work assess relation snp mxa gene impact treatment chronic hcv patient pegifn ribavirin\",\"review role utility baseline resistance testing currently available pipeline 1 hepatitis c virus hcv treatment\",\"identify series 1-aryl-4,6-diamino-1,2-dihydrotriazines structurally related antimalarial drug cycloguanil new inhibitor influenza b virus respiratory virus rsv targeting host dihydrofolate reductase dhfr enzyme analogue prove active influenza b virus low micromolar range good compound 11 13 14 16 reach sub-micromolar potency zanamivir ec50 0.060 \\u03bcm markedly exceed 327 time antiviral efficacy ribavirin activity observe influenza strain include virus s31n mutant form m2 proton channel prevalent resistance mutation amantadine importantly compound display nanomolar activity rsv superior selectivity index ratio cytotoxic antiviral concentration 10,000 active compound 11 14 16 ec50 \\u223c0.008 \\u03bcm far surpass potency safety profile licensed drug ribavirin ec50 5.8 \\u03bcm si 43\",\"elbasvir ebr hcv ns5a inhibitor grazoprevir gzr hcv ns3/4a protease inhibitor approve fixed-dose combination treat patient chronically infect hcv 1 4 development programme support vitro potency efficacy ebr+gzr assess hcv gt3-infected patient study aim determine efficacy tolerability 12 18 week ebr+gzr ribavirin rbv treatment-na\\u00efve noncirrhotic hcv gt3-infected patient randomized patient receive open-label ebr 50 mg daily gzr 100 mg daily rbv primary efficacy objective evaluate sustained virologic response rate 12 week end study therapy svr12 svr12 rate 95 confidence interval 45.0 23.1 68.5 57.1 34.0 78.2 treatment ebr+gzr+rbv 12 week 18 week respectively on-treatment virologic failure observe 41 17 41 patient virologic failure resistance-associated substitution ras five-fold shift potency occur ns3 region 35 patient ns5a region 16 94 patient common ras virologic failure y93h ns5a identify 13 17 76 patient efficacy ebr+gzr+rbv suboptimal hcv gt3-infected patient high rate on-treatment virologic failure treatment-emergent ras demonstrate inadequate barrier development gt3 resistance rapid viral clearance demonstrate antiviral activity ebr+gzr+rbv gt3-infected patients.clinicaltrials.gov nct01717326\",\"direct act antiviral revolutionize treatment chronic hepatitis c. specifically combination therapy sofosbuvir velpatasvir offer pangenotypic regiman high sustained viral response svr area cover review clinical trial lead fda approval sofosbuvir velpatasvir combination therapy adverse event registration trial drug-drug interaction sofosbuvir velpatasvir fix dose regimen interferon- ribavirin-free administer 12 week once-a-day pill cover hepatitis c achieve svr 95 non-cirrhotic patient patient compensate cirrhosis addition ribavirin recommend patient decompensated cirrhosis ctp b c baseline resistance-associated substitution appear impair ability achieve svr initial course treatment expert commentary availability highly efficacious tolerated oral regiman formulate single pill potentially simplify hepatitis c treatment utility pangenotypic regimen additionally limit resource utilization\",\"evaluate transition dominant resistance-associated substitution ras hepatitis c virus long-term follow-up failure daa direct act antivirals)-based therapy ras non-structure (ns)3/4a ns5a ns5b deletion ns5a 20 patient fail simeprevir/pegylated-interferon/ribavirin smv/peg-ifn/rbv 25 patient fail daclatasvir/asunaprevir dcv/asv treatment examine direct sequencing respect smv/peg-ifn/rbv treatment ras detect d168 ns3/4a detect ns5a ns5b treatment failure 16 20 patient median follow-up period 64 week ras d168 dominant 9 16 patient 25 dcv/asv failure ras d168 l31 y93 find 57.1 72.2 76.9 respectively ns5a deletion detect 3 10 patient treat previously smv/peg-ifn/rbv number ras breakthrough patient exceed relapser mean 3.9 vs. 2.7 p 0.05 ras d168 ns3/4a dominant 6 15 patient 80 week y93h emerge time relapse decrease gradually 99 130 week post-treatment emerged ras associate clinical course treatment detect long follow-up\",\"aim study characterize treatment response adverse event ledipasvir plus sofosbuvir therapy japanese patient infect hepatitis c virus hcv 1 gt1 retrospective study analyze 240 japanese hcv gt1 patient treat 12 week 90 mg ledipasvir plus 400 mg sofosbuvir daily sustained virological response 12 week post-treatment svr12 achieve 236 240 98.3 patient treatment-na\\u00efve patient svr12 achieve 136 138 98.6 patient treatment-experienced patient svr12 achieve 100 102 98.0 patient patient previously treat peginterferon plus ribavirin hcv ns3/4a inhibitor 100 svr rate 25/25 achieve relapser hcv ns5a resistance-associated variant ravs hcv ns5b-s282 observe relapse experience patient cardiac event treatment conclusion combination ledipasvir plus sofosbuvir 12 week potential therapy hcv gt1 patient caution need hcv ns5a ravs select hcv ns5a inhibitor cardiac adverse event\",\"directly-acting antiviral daa finally allow patient potentially cure chronic hepatitis c hcv infection all-oral interferon (ifn)-free regimen base combination molecule target different site hcv replication process class daa exist protease inhibitor anti-ns3/4a rna-dependent polymerase inhibitor anti-ns5b anti-ns5a inhibitor characterize different antiviral potency barrier resistance usually combine different treatment schedule treatment regimen largely dependent hcv stage liver disease duration range 12 week 24 week overall treatment efficacy climb nearly 95 patient group include historically difficult-to-treat category hcv 1 advanced liver disease elimination ifn allow safe efficacious treatment patient contraindicate antiviral therapy decompensated cirrhosis solid organ transplant recipient availability potent safe antiviral drug combine improvement worldwide access treatment finally lead hcv elimination decade\",\"inclusion direct-acting antiviral clinical practice patient chronic hcv chc milestone medicine\",\"clinical study high rate sustained virological response hepatitis c virus hcv rna 15 iu/ml post-treatment week 12 svr12 patient 1b infection cirrhosis receive coformulate ombitasvir paritaprevir ritonavir plus dasabuvir ribavirin 12 week study aim assess 8-week treatment ombitasvir paritaprevir ritonavir plus dasabuvir ribavirin patient infect hcv 1b cirrhosis\",\"first-generation protease-inhibitor pi suboptimal efficacy gt-1 patient advanced liver disease patient experience treatment failure require urgent retreatment objective analyse real-life efficacy interferon (ifn)-free retreatment pi-failure role genotypic-resistance-testing grt guide retreatment choice\",\"hepatitis c virus hcv therapy highly efficacious pangenotypic high barrier resistance short treatment duration desirable efficacy safety 8- 12-week treatment glecaprevir abt-493 ns3/4a protease inhibitor pibrentasvir abt-530 ns5a inhibitor evaluate non-cirrhotic patient chronic hcv 1 6 infection\",\"influenza highly contagious viral infection associate excessive hospitalization death world continuous antigenic shift drift responsible devastating effect influenza cause ineffectiveness antiviral drug vaccine study investigate effectiveness ribavirin oseltamivir amantadine drug vitro influenza isolate collect june 2012-august 2013 different slum dhaka city effectiveness drug determine measure inhibition virus-induced cytopathic effect mdck cell mtt assay 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide datum influenza isolate 6 h1n1 pdm09 3 h3n2 completely susceptible ribavirin 50 effective concentration ec50 3.0 \\u00b5g/ml oseltamivir ec50 0.35 \\u00b5g/ml influenza infection challenge amantadine drug isolate 88 demonstrate susceptibility amantadine drug ec50 0.30 \\u00b5g/ml h1n1 pdm09 isolate exhibit high ec50 value 10 \\u00b5g/ml cell tolerance level drug 5 \\u00b5g/ml genetic analysis transmembrane matrix protein 2 m2 target amantadine drug vital viral replication substitution amino acid position 31(s31 n amantadine-resistant isolate indicate possible reason amantadine drug resistance\",\"interleukin-10 il-10 play important role immunity hepatitis c virus hcv insofar il-10 variant associate altered level il-10 previous study examine association il-10 polymorphism susceptibility progression chronic hcv response anti-viral treatment inconsistent investigate association common il-10 variant intron promotor region hcv associate feature\",\"favipiravir t-705 broad-spectrum antiviral agent approve japan treatment influenza virus infection t-705 inhibit replication rna virus include virus chikv demonstrate early k291r mutation f1 motif rna-dependent rna polymerase rdrp chikv responsible low-level resistance t-705 interestingly lysine highly conserve rdrp positive-sense single-stranded rna ssrna virus obtain insight unique broad-spectrum antiviral activity t-705 explore role lysine use ssrna virus coxsackievirus b3 cvb3 introduction corresponding k-to-r substitution cvb3 rdrp k159r result nonviable virus replication competence k159r variant restore spontaneous acquisition a239 g substitution rdrp mutagenesis analysis position k159 identify k159 m variant viable variant acquire a239 g substitution k159 substitution markedly decrease processivity purify viral rdrp restore introduction a239 g mutation k159r a239 g k159 m a239 g variant prove surprisingly susceptible wild-type virus t-705 exhibit low fidelity polymerase assay furthermore k159r a239 g variant find highly attenuate mouse demonstrate conserve lysine f1 motif rdrp ssrna virus involve broad-spectrum antiviral activity t-705 key amino acid proper functioning enzyme importance study report key role highly conserve lysine residue viral polymerase broad-spectrum antiviral activity favipiravir t-705 positive-sense single-stranded rna virus substitution conserve lysine major negative impact functionality rdrp furthermore lysine involve fidelity rdrp rdrp fidelity influence sensitivity virus antiviral efficacy t-705 consequently result provide insight mechanism antiviral activity t-705 lay basis design novel chemical scaffold endow potent broad-spectrum antiviral activity t-705\",\"efficacy hepatitis c virus hcv treatment increase 5 year nearly 100 patient group patient gt 3 hcv infection specifically cirrhotic treatment-experienced patient low sustained virologic response svr rate patient gt gt 3 present clinical challenge gt review focus evolution efficacy direct-acting antiviral daa treatment option hcv gt 3 infection historical standard care pegylated interferon ribavirin objective review svr rate available late-pipeline daa hcv gt 3 infection discuss challenge successful gt 3 treatment perform literature search pubmed/medline database inception march 27 2017 narrow field clinical trial publish english trial evaluate alternative treatment non-daa historical treatment daa currently indicate hcv exclude trial involve patient human immunodeficiency virus/hcv coinfection exclude additional trial identify review clinicaltrials.gov database far identify reference review literature citation review annual meeting abstract american association study liver diseases european association study liver pipeline real-world gt 3 datum phase iii trial datum available support gt 3 treatment recommendation find guideline svr rate low treatment-experienced cirrhotic patient gt 3 hcv population treatment failure associate resistance current treatment regimen clinical study include patient level advanced liver disease patient decompensated cirrhosis represent recent advance pharmacologic treatment daa greatly increase svr rate patient hcv gt svr rate treatment-experienced cirrhotic patient gt 3 low gt limited datum observe svr rate patient population optimal therapy patient decompensated cirrhotic gt 3 hcv infection establish newer agent recommendation regard baseline resistance likely evolve treatment strategy near future\",\"multinational taiwan south korea russia phase 3 study evaluate all-oral ribavirin-free fixed-dose combination dcv-trio daclatasvir ns5a inhibitor 30 mg asunaprevir ns3 inhibitor 200 mg beclabuvir ns5b inhibitor 75 mg patient chronic hepatitis c virus genotype-1 infection compensate cirrhosis\",\"assess broadly use off-label combination sofosbuvir daclatasvir simeprevir ribavirin direct-acting antiviral-experienced patient recommend current guideline despite scarce datum 24 week treatment sustain virological response 12 week end treatment achieve 6 patient 60 cirrhotic patient relapsed 2 discontinue treatment adverse event\",\"need test resistance associated substitution ra intensively debate past year absence pangenotypic combination reasonable available ras testing ns5a gene baseline 1a 3 help avoid overtreatment term ribavirin usage and/or prolonged treatment duration patient fail treatment ras testing useful guide selection new regimen especially need urgent retreatment fail combination include ns5a inhibitor new drug pipeline combination pangenotypic potent high genetic barrier resistance new scenario ras testing play important role\",\"nucleoside analogue known drug commonly use antiviral anticancer chemotherapy feature five-membered ring nucleobase utmost interest anti-cancer agent aicar anti-viral drug ribavirin despite low activity vitro different cell line aicar clinical development pathology thank original mode action aicar induce autophagy cell death able follow mechanism circumvent resistance apoptotic drug include kinase inhibitor currently market improve activity aicar report efficient synthesis new series sulfonamide-4-substituted-1,2,3-triazolyl nucleoside use cu-catalyzed 1,3-dipolar cycloaddition molecule fully characterize evaluate aggressive tumor cell line rcc4 mda-mb-231 nucleoside analogue 5i belong ribose series find 19 66-fold active aicar western blot analysis rcc4 cell 5i display interesting mode action induce apoptosis autophagy cell death class molecule highly promise hit-to-lead optimization\",\"hepatitis c leading cause cirrhosis hepatocellular carcinoma responsible 700,000 death worldwide annually 2014 management hcv infection base interferon alfa contain regimen efficacy 40 70 high adverse event rate interferon-free therapeutic option improve sustained viral response svr rate 90 safety profile placebo-like level area cover article describe all-oral regiman consist direct act antiviral daa ombitasvir obv paritaprevir ptv dasabuvir dsv clinical practice boost ritonavir r ribavirin rbv combination register treatment patient infect hcv 1 4 focus regimen characteristic pharmacokinetic risk resistance efficacy safety clinical trial real world study expert commentary combination obv/ptv/r\\u00b1dsv\\u00b1rbv provide svr rate 95 good safety profile patient compensate liver cirrhosis failure previous therapy currently particular value area predominance 1b infection complexity risk drug drug interaction probably replace come year pangenotypic combination generation daa\",\"optimal retreatment regiman patient hepatitis c virus hcv infection fail interferon-free direct-acting antiviral daa therapy undetermined study aim evaluate efficacy safety 12-week retreatment ledipasvir ldv sofosbuvir sof add-on ribavirin rbv patient previously fail respond hcv-ns5a inhibitor daclatasvir dcv hcv-ns3 inhibitor asunaprevir asv therapy\",\"patient genotype-1 hepatitis c virus infection fail respond standard therapy relapse follow treatment consider interferon-free regiman incorporate nonstructural protein 5a ns5a inhibitor sustained virologic response svr regimen typically 90 reduce patient ns5a resistance european association study liver guideline recommend simeprevir sofosbuvir \\u00b1 ribavirin smv+sof\\u00b1r re-treate patient fail ns5a inhibitor-containing regiman alternative strategy test ns5a resistance prior treatment therapy optimize base result study investigate cost-effectiveness strategy\",\"sofosbuvir nucleoside analogue inhibitor hcv ns5b polymerase approve treatment hcv-infected patient combination ribavirin antiviral activity hcv resistance sofosbuvir genotype-1 -2 hcv confer s282 t substitution ns5b\",\"background ns3 protease inhibitor pi direct antiviral agent use treatment hepatitis c virus combination second-wave pi direct antiviral agent enable use interferon-free regimen chronic kidney disease patient dialysis renal transplant rtx recipient population use interferon ribavirin limited occurrence pi resistance-associated variant ravs baseline induce therapy result failure treatment strategy method aim study estimate prevalence pi rav q80 k polymorphism chronic kidney disease patient hemodialysis rtx recipient direct sequencing ns3 protease perform 67 patient 32 hemodialysis 35 rtx).result rav pi detect 18 patient v55a 9 v36l 1.5 t54s 1.5 s122n 1.5 i170l 1.5 m175l 1.5 1.5 patient carry q80 k polymorphism frequency mutation time high patient infect gt1a 25 gt1b 9.7 p=0.1 mutation detect 20 treatment-naive patient 15.6 peginterferon/ribavirin-experienced patient p=0.64 furthermore mutation confer high resistance pi detect conclusion q80 k polymorphism rare population study occurrence ravs common predominance gt1a variant observe associate low level resistance pi facilitate use drug special group patient\",\"previously report result interferon (ifn)-free daclatasvir asunaprevir treatment recurrent hepatitis c virus hcv 1 infection liver transplantation lt report patient achieve viral response effect blood concentration immunosuppressive agent follow sofosbuvir plus ledipasvir treatment patient 68-year-old female hcv-related liver cirrhosis fail respond pegylated-ifn ribavirin peg-ifn/rbv live donor lt treat 50 mg/day cyclosporine second 63-year-old male hcv-related liver cirrhosis hepatocellular carcinoma fail respond peg-ifn/rbv live donor lt treat 50 mg/day cyclosporine 63-year-old female hcv-related liver cirrhosis treat tacrolimus high alanine aminotransferase level persist lt liver biopsy examination reveal active hepatitis chronic rejection sofosbuvir plus ledipasvir therapy start combination treatment stop 4 week development interstitial pneumonia serum hcv rna negative time treatment discontinue remain negative 12 week cessation therapy case sofosbuvir plus ledipasvir treatment remarkable viral response little effect blood level immunosuppressive agent recurrent hcv 1 infection lt\",\"treatment hepatitis c base national consensus guideline update six-monthly accord local availability affordability approve therapy transparent allocation system hungary updated guideline incorporate special new aspect include recommendation screening diagnostic use allocation novel direct act antiviral agent indication therapy patient contraindication base demonstration viral replication consequent inflammation and/or fibrosis liver non-invasive method elastographie biochemical method prefer liver fibrosis staging budget allocate patient limited expensive novel direct act antiviral combination line treatment reimburse freely available effective toxic pegylated interferon plus ribavirin dual therapy deem prone high chance adverse event and/or low chance cure priority urgent need base pre-defined scoring system reflect mainly stage liver disease consider additional factor i.e. hepatic decompensation complication activity progression liver disease risk transmission special issue approve treatment restricted cost-effective combination base cost sustained virological response value different patient category consensus treat physician national health insurance fund patient organization interferon-free treatment short therapy duration prefer orv hetil 2017 158(suppl 1 3 22\",\"person hepatitis c virus hcv infection risk progressive liver disease cirrhosis decompensation analyze effect direct-acting antiviral agent elbasvir grazoprevir patient hcv infection compensate cirrhosis combine datum 6 clinical trial\",\"relapse hepatitis c virus hcv 1 infection combination therapy sofosbuvir ledipasvir unusual report treatment-na\\u00efve non-cirrhotic patient relapse 1b hcv infection accompany de novo cryoglobulinemic vasculitis glomerulonephritis require hemodialysis acute renal failure sequence analysis reveal resistance-associated variant hcv ns5a gene ns3/4a patient vasculitis successfully treat immunosuppression plasmapheresis follow retreatment hcv combination sofosbuvir simeprevir ribavirin patient achieve sustained virological response recover renal function remain remission cryoglobulinemia\",\"favipiravir t-705 new antiviral drug strong inhibitory activity rna-dependent rna polymerase rna virus genome influenza virus fully sensitive new antiviral include genetic strain neuraminidase inhibitor oseltamivir resistance mechanism action lie block viral replication induction lethal mutagenesis determine loss infective activity influenza virus activity particularly intense respiratory tract decrease viral load non-infectious level clinical trial human complete favourable result good therapy combination favipiravir oseltamivir antiviral synergistic avoid emergence resistance\",\"current medical treatment hepatitis c virus hcv infection pegylated interferon plus ribavirin 50 1 hcv patient 80 hcv 3 patient treat completely recently rs12979860 c/t polymorphism located 3 kb upstream il28b gene code ifn\\u03bb3 powerful association response treatment hcv patient\",\"patient chronic hepatitis c 20 30 develop hepatic cirrhosis complication 30 year antiviral treatment hepatitis c previously interferon-based recently inter feron-free result improvement sustained virological response rate safety tolerability short duration treatment\",\"optimal therapy recurrent hepatitis c virus hcv infection liver transplantation establish study aim clarify efficacy safety interferon-free therapy sofosbuvir ledipasvir ribavirin 12 week japanese patient hcv 1b infection live donor liver transplantation\",\"direct-acting antiviral daa therapy chronic hepatitis c virus hcv infection demonstrate high rate sustained virologic response virologic failure occur potentially lead emergence viral resistance decrease effectiveness subsequent treatment treatment option patient fail previous daa-containing regimen particularly nonstructural protein 5a inhibitor limited remain area unmet medical need phase 2 open-label study magellan-1 evaluate efficacy safety glecaprevir gle pibrentasvir pib \\u00b1 ribavirin rbv hcv 1-infected patient prior virologic failure hcv daa-containing therapy total 50 patient cirrhosis randomize arm 200 mg gle 80 mg pib arm 300 mg gle 120 mg pib 800 mg once-daily rbv arm b 300 mg gle 120 mg pib rbv arm c intent-to-treat analysis sustained virologic response posttreatment week 12 achieve 100 6/6 95 confidence interval 61 100 95 21/22 95 confidence interval 78 99 86 19/22 95 confidence interval 67 95 patient arm b c respectively virologic failure occur patient arm 1 patient arm b c patient lose follow-up arm c majority adverse event mild severity adverse event related study drug relevant laboratory abnormality alanine aminotransferase total bilirubin hemoglobin observe\",\"gs-9256 inhibitor hcv ns3 protease macrocyclic structure novel phosphinic acid pharmacophore\",\"despite excellent efficacy direct-acting antiviral daa report clinical trial virological failure occur associate development resistance-associated substitution ras study aim characterize presence clinically relevant ras class real-life daa failure\",\"elbasvir/grazoprevir demonstrate high sustained virologic response rate 12 week end treatment svr12 clinical trial subject infect chronic hepatitis c virus hcv 1 include advanced chronic kidney disease ckd gt4 despite favorable result overall food drug administration fda encounter challenging regulatory issue limitation clinical trial datum certain subpopulation gt1a-infected subject baseline ns5a resistance-associated polymorphism emerge strong baseline characteristic associate diminish svr12 rate follow 12 week elbasvir/grazoprevir treatment decision recommend 16 week elbasvir/grazoprevir ribavirin population extrapolate recommendation patient advanced ckd base benefit-versus-risk analysis use available datum conversely fda insufficient datum define specific elbasvir/grazoprevir treatment regiman gt1a-infected subject baseline ns5a resistance-associated polymorphism fail prior treatment pegylated interferon ribavirin pr boceprevir simeprevir telaprevir gt4 pr-experienced patient leveraging datum related population additional pooled analysis employ support labeling elbasvir/grazoprevir article describe fda rationale labeling determination situation limited datum decision challenge\",\"viral hepatitis inflammatory liver disease cause hepatitis c virus hcv hepatitis c slowly sprout fibrosis progress cirrhosis prolonged period time compensate cirrhosis advance decompensated cirrhosis culminate hepatic failure death conventional treatment hcv involve administration interferon association interferon adverse drug reaction lead development novel anti-hcv drug monotherapy combination drug advance drug delivery system dds improve pharmacokinetic profile stability drug ameliorate tissue damage extravasation increase targeting affect site liposome lipid based vehicle employ polyethylene glycol peg stabilize formulation peg drug complex sofosbuvir novel anti-hcv drug administer monotherapy combination daclatasvir ledipasivir protease inhibitor ribavirin interferon treatment hcv 1 2 3 drug combination highly effective eradicate interferon resistance recurrent hcv infection liver transplant concurrent hiv infection prevent interferon related adverse effect investigation improve drug targeting identification new drug target highly warrant rapid emergence drug resistance hcv\",\"direct-acting antiviral daa combination potent effective drug currently recommend treatment chronic hcv infection difficult treat important predictor treatment failure report case daa treatment failure hcv-infected patient carry recombinant 2k/1b strain isolate russian patient 2002 observe time italy\",\"current standard care patient chronic hepatitis c virus hcv infection combination direct-acting antiviral agent daa hcv patient treat drug achieve viral elimination 1 15 fail attain objective treatment failure usually related relapse on-treatment viral breakthrough hcv drug resistant associate substitution detect patient eliminate virus risk develop variant depend host- virus-related factor property drug use treatment strategy apply patient carry resistant associate substitution ras obtain benefit treatment risk disease progression hcv ras persist depend type ns3 4a variant disappear gradually daa therapy stop ns5a variant tend persist 2 year good way prevent emergence resistant variant eliminate virus treatment use highly potent daa genetic barrier resistance fail ns5a inhibitor deferral treatment recommend pende availability additional datum cirrhosis reason urgent re-treatment re-treatment need commonly use strategy sofosbuvir backbone therapy plus drug class previously use 24 week contraindicate weight-based ribavirin add available nucleotide-based eg sofosbuvir triple quadruple daa regimen consider optimal treatment patient fail ns5a inhibitor multidrug-resistant variant remain define research effort continue focus treatment patient\",\"respiratory virus influenza parainfluenza respiratory virus coronavirus human metapneumovirus rhinovirus represent common cause respiratory viral infection immunocompromised patient infection severe immunocompromised patient general population early diagnosis treatment viral infection continue paramount importance immunocompromised patient viral replication invasive infection evident prognosis grave area cover purpose review provide overview main antiviral agent use treatment respiratory viral infection immunocompromised patient review new agent pipeline expert commentary past decade important diagnostic advance specifically use rapid molecular testing help close gap clinical scenario pathogen identification enhance early diagnosis viral infection understanding role prolonged shedding viral load advancement novel antiviral therapeutic high resistance threshold effective immunization preventable infection immunocompromised patient need\",\"single nucleotide polymorphism snp near interferon lambda 4 ifnl4 gene located upstream ifnl3 associate response anti-hcv therapy interferon (ifn)-based ifn-free regimen ifnl4 encode ifn\\u03bb4 newly discover type iii ifn expression control rs368234815-tt/\\u03b4g strong linkage disequilibrium ld tag snp near ifnl4 rs12979860 rs8099917 intrahepatic expression level ifn-stimulated gene isg affect responsiveness ifn\\u03b1 associate ifnl4 ifnl4 expression role intrinsic antiviral innate immunity remain unclear study evaluate effect ifnl4 intrahepatic isg expression investigate relationship treatment outcome liver sample obtain 49 chronic hepatitis c patient treat pegylated (peg)-ifn/ribavirin therapy ifnl4 mrna detect 11 22 patient ifnl4-unfavorable snp patient favorable ifnl4 expression associate non-response peg-ifn/ribavirin therapy intrahepatic expression antiviral isg isg15 mx1 significantly high ifnl4-unfavorable patient detectable ifnl4 mrna patient undetectable ifnl4 mrna expression suppressive isg rnf125 socs1 socs3 rnf11 low patient detectable ifnl4 mrna summary intrahepatic expression ifnl4 associate increase antiviral isg expression decrease suppressive isg expression baseline result poor responsiveness ifn\\u03b1-based therapy hcv infection\",\"influenza management surveillance program japan possess unique feature national influenza surveillance affiliate national epidemiological surveillance infectious diseases nesid feature sentinel outpatient surveillance virological surveillance report hospitalization mortality influenza-associated encephalopathy note information number student absence class/grade/school closure influenza report government publically available private online influenza surveillance portal volunteer doctor provide real-time information source japanese clinician general public influenza treatment class drug approve cover national medical insurance japan m2 inhibitor neuraminidase inhibitor nai polymerase inhibitor nai oseltamivir zanamivir laninamivir peramivir japan prescribe seven million patient annually nai prescribe influenza outpatient limit severe case majority 80 95 patient start treatment 48 h onset laninamivir peramivir use solely japan approval drug fda observational study drug equal effectiveness oseltamivir zanamivir japanese approach influenza surveillance management facilitate bring new influenza antiviral market drive innovative research field new class antiviral include polymerase inhibitor cap-dependent endonuclease inhibitor provide novel tool treatment influenza japan rest world\",\"daclatasvir nonstructural protein 5a inhibitor potent activity hepatitis c virus 1 6 vitro asunaprevir nonstructural protein 3 protease inhibitor activity 1 4 5 6 despite 90 sustain virologic response svr rate svr rate patient baseline ns5a-l31/y93h polymorphism decrease 40 alternative regiman consideration cost-effectiveness important addition ribavirin improve svr rate group patient remain unknown case series report\",\"treatment hepatitis c virus hcv 3 gt3 medical priority all-oral treatment hcv gt3 daclatasvir dcv sofosbuvir sof ribavirin rbv recommend treatment guideline impact hcv minority population amino acid position ns5a ns5b associate drug resistance response dcv+sof\\u00b1rbv assess sof-naive sof-experienced hcv patient\",\"development direct-acting oral agent dramatically change treatment strategy hepatitis c virus hcv infection aim reveal efficacy safety daclatasvir dcv asunaprevir asv recurrent hcv 1 infection liver transplantation lt\",\"target bacterial virulence mechanism compromise bacterial growth promising strategy prevent drug resistance lysr-type transcriptional regulator lttr possess structural conservation bacterial specie regulate virulence numerous pathogen attractive target antimicrobial agent target aphb vibrio cholerae lttr regulate expression gene encode cholera toxin toxin-co-regulated pilus inhibitor designing aphb ligand unknown follow molecular fragment-based approach ligand design use fda-approved drug subsequent screen identify molecule exhibit high-affinity binding aphb ligand-binding pocket identify compound ribavirin anti-viral drug antagonize aphb function ribavirin perturb vibrio cholerae pathogenesis animal model inhibitory effect drug limited bacteria express wild type aphb constitutively active mutant aphbn100e represent ligand-bound state suggest ribavirin bind active site aphb exert inhibitory role exist aphb-independent mechanism action similarly ribavirin suppress function salmonella typhi lttr hrg indicate broad spectrum efficacy ribavirin affect bacterial viability culture study cite example drug repurposing anti-infective therapy\",\"ledipasvir/sofosbuvir combination treatment phase iii clinical trial result sustained viral suppression 94 99 patient study characterize drug resistance treatment failure help inform retreatment option\",\"presence baseline ns5a resistance-associated variant ravs impact treatment response hcv 1a (gt1a)-infected patient treat elbasvir/grazoprevir ebr/gzr 12 week patient treat ebr/gzr ribavirin rbv 16 week\",\"5 year availability direct-acting antiviral daa agent revolutionize treatment hepatitis c virus hcv compare interferon/ribavirin-the previous standard care-daa combination regimen offer improve sustained virological response svr rate short treatment duration 8 24 week convenient once-daily single-tablet formulation favourable tolerability profile hcv treatment complex choice therapy consider complex range factor include baseline viral load fibrosis stage hcv subgenotype presence resistance-associated substitution baseline globally hcv 1 predominate extensive datum treatment option available 2 6 prevalent predominate different geographical region reflect diverse factor include human migration pattern unsafe use injection drug blood product factor influence socio-economic factor poor region great unmet need effective hcv therapy late pan-genotypic daa combination regimen provide potential eradicate hcv globe regardless minimize need virological testing service unavailable poor region economic inevitably remain barrier access extensive cooperation require clinical organisation pharmaceutical manufacturer agree appropriate pricing policy especially poor economic region review consider key datum treatment guideline daa therapy include pan-genotypic combination regimen context regional difference hcv socio-economic factor\",\"treatment patient chronic hepatitis c fail triple therapy generation protease inhibitor define combined use sofosbuvir sof daclatasvir dcv promise high genetic barrier good tolerance effectiveness\",\"use interferon ribavirin treat chronic hepatitis c virus hcv infection kidney transplant recipient limited risk allograft rejection poor tolerability\",\"efficacy direct-acting antiviral agent daa attenuate presence resistance-associated variant rav aim study investigate natural prevalence ravs chinese hcv 1b patient analyze efficacy pegylated interferon (pegifn)/ribavirin rbv therapy patient ravs baseline\",\"review paper summarize epidemiology hepatitis c virus hcv chronic hcv infection include hcv virology treatment regimen specifically focus evolution past current future hcv treatment option reason treatment failure impact resistance-associated variant treatment success\",\"rapid evolution drug resistance remain critical public health concern treatment influenza virus iav prove particularly challenging ability virus develop resistance current antiviral vaccine evaluate novel antiviral drug therapy favipiravir mechanism action iav involve interaction viral rna-dependent rna polymerase result effective increase viral mutation rate use experimental evolution framework combine novel population genetic method development inference time-sampled datum evaluate effectiveness favipiravir iav evaluate genome polymorphism datum 15 time point multiple drug concentration control present evidence ability iav population effectively adapt low concentration favipiravir contrast high concentration observe population extinction indicative mutational meltdown discuss observe dynamic respect evolutionary force play emphasize utility evolutionary theory inform drug development\",\"vaniprevir macrocyclic hepatitis c virus hcv non-structural (ns)3/4a protease inhibitor objective phase 3 multicenter open-label trial evaluate safety efficacy vaniprevir peginterferon alfa-2b ribavirin pr japanese patient hcv (gt)1 infection previously fail treatment interferon-based regimen\",\"simeprevir (smv)-base triple therapy effective retreatment option follow failure telaprevir (tvr)-base triple therapy unclear persistence resistance-associated variant rav induce tvr-based therapy reduce treatment effect smv-based therapy\",\"elbasvir ns5a inhibitor grazoprevir ns3/4a protease inhibitor direct-acting antiviral agent recently approve united states treatment chronic hepatitis c virus hcv 1 4 infection fixed-dose combination trial elbasvir grazoprevir ribavirin demonstrate high rate sustained virologic response 12 week treatment end svr12 12 week treatment elbasvir grazoprevir fail small proportion patient hcv 1 infection summarize finding independent food drug administration analysis drug resistance datum trial elbasvir grazoprevir ribavirin\",\"influenza virus cause seasonal epidemic pandemic outbreak associate significant morbidity mortality huge cost resistance exist anti-influenza drug rise innovative inhibitor different mode action urgently need influenza polymerase complex widely recognize key drug target critical role virus replication high degree conservation influenza human zoonotic origin b virus review major progress recent year unravel structure function protein complex enable structure-aided drug design core region pa endonuclease pb1 polymerase cap-binding pb2 subunit alternatively inhibitor target protein-protein interaction site cellular factor involve viral rna synthesis viral rna nucleoprotein component viral ribonucleoprotein late advance diverse pharmacological target yield agent advanced i.e. favipiravir vx-787 early clinical testing experimental inhibitor stage development cover\",\"phase iiib study evaluate efficacy safety oral nucleotide analogue inhibitor sofosbuvir plus ribavirin special attention viral resistance russian patient hcv genotype-1 -3\",\"hepatitis e virus hev important agent viral hepatitis worldwide cause severe course infection pregnant woman immunosuppressed patient date hev infection treat ribavirin rbv major drawback therapy rbv approve administration pregnant woman virus acquire mutation render intra-host population sensitive resistant rbv propose mode action rbv direct mutagenic effect viral genome induce mismatch subsequent nucleotide substitution transition event drive error-prone viral replication error threshold cause viral population extinction contrast expand heterogeneous viral population facilitate selection mutant virus enhance replication fitness emergence mutant virus lead therapeutic failure consequently onset rbv treatment chronically hev-infected individual result divergent outcome viral extinction versus selection fitness-enhanced virus follow overview rna virus treat rbv clinic summary different antiviral mode action drug focus mutagenic effect rbv hev intrahost population hev able overcome lethal mutagenesis\",\"prevalence anti-hepatitis c virus (hcv)antibodies high hemodialysis patient general population study report poor vital prognosis hcv-infected dialysis patient infection hcv cause cirrhosis hepatocellular carcinoma risk factor cardiovascular disease sustained virologic response svr achievable interferon ribavirin dialysis patient svr rate low use ribavirin challenging risk hemolytic anemia recently interferon-ribavirin free direct act antiviral daa treatment strong efficacy adverse event chronic hcv infection patient use dialysis report daa patient conduct study examine effect safety daclatasvir asunaprevir chronic hepatitis c virus 1b-infected hemodialysis patient treat 10 patient seven male female treatment detect resistance-associated variant ns5a region l31 m site variant patient patient resistance-associated variant patient quick disappearance hcv rna serum achieve svr12 therapy patient display abnormal liver function treatment patient experience diarrhea patient complain nausea soon treatment relieve symptomatic therapy report good result treatment chronic hepatitis c virus 1b -infected patient hemodialysis oral daa daclatasvir asunaprevir\",\"direct-acting antiviral daa hepatitis c virus hcv potent anti-hcv effect provoke resistance-associated variant rav study assess characteristic rav explore efficacious anti-hcv reagent use recombinant hcv ns5a 1b strain replace ns5a jfh1 con1 jfh1/5acon1 introduce know ns5a inhibitor resistance mutation l31 m l31v l31i y93h individually combination susceptibility anti-hcv reagent investigate ravs y93h exhibit high extracellular core antigen level infectivity titer variant single mutation mild moderate resistance ns5a inhibitor variant double mutation l31 y93 severe resistance variant mutation exhibit similar level susceptibility interferon (ifn)-\\u03b1 ifn-\\u03bb1 ifn-\\u03bb3 ribavirin variant y93h mutation sensitive protease inhibitor compare jfh1/5acon1 conclusion vitro analysis indicate y93h mutation enhance infectious virus production suggest advantage propagation ravs mutation rav susceptible protease inhibitor therapeutic regimen include reagent promising mean eradicate rav\",\"simeprevir hepatitis c virus ns3/4a protease inhibitor hepatitis c virus baseline ns3/4a polymorphism emerge mutation characterize treatment-na\\u0457ve treatment-experienced 4-infected patient treat simeprevir+peginterferon/ribavirin restore study population sequencing ns3/4a region perform vitro simeprevir activity site-directed mutant chimeric replicon patient-derived ns3 protease sequence assess transient replicon assay simeprevir remain active 83/91 91 baseline isolate test chimeric replicon assay baseline isolate reduce simeprevir activity carry i132l d168e substitution reduce simeprevir median activity 4.6- 39-fold respectively isolate patient achieve sustained virologic response baseline ns3 q80 k polymorphism observe 4-infected patient 107 simeprevir-treated patient 37 achieve sustained virologic response reason 32 patient fail treatment sequencing information 28 88 emerge mutation ns3 position 80 122 155 156 and/or 168 time failure similar 1 emerge mutation mainly d168v d168e combine mutation position 80 general isolate obtain time failure display high-level vitro resistance simeprevir fold change \\u226550 chimeric replicon assay median simeprevir fold change value 440 consistent observe mutation conclusion emerge mutation 4 patient fail simeprevir+peginterferon/ribavirin treatment similar 1 confer high-level resistance simeprevir\",\"hiv-positive man sex man epidemic hepatitis c virus hcv ongoing transmission resistant variant hcv failure treatment directly act antiviral daa major threat effectivity therapy determine hcv-resistant variant daa prevalent patient acute hcv infection diagnose 2013 2014 netherlands\",\"sofosbuvir/ledipasvir sof/ldv all-oral ribavirin-free treatment approve chronic hepatitis c virus hcv 6 offer safe highly efficacious treatment option large study evaluate real-world outcome regimen lack aim evaluate real-world treatment outcome hcv 6 retrospective cohort study evaluate 65 adult age \\u226518 chronic hcv 6 treat sof/ldv ribavirin community gastroenterology clinic united states november 2014 2016 rate undetectable virus week 4 treatment end treatment eot svr12 stratify presence cirrhosis prior treatment treatment na\\u00efve vs treatment experience 65 patient chronic hcv 6 treat sof/ldv 52.3 male mean age 66.3 year sd 9.7 41.5 cirrhosis 15.4 treatment experience 97.3 undetectable virus week 4 treatment 96.9 undetectable virus eot 95.3 achieve svr12 svr12 100 female vs 91.2 male p=.096 92.3 patient cirrhosis vs 97.4 cirrhosis p=.347 resistance testing treatment failure attempt unsuccessful lack conform primer define possible resistance mutation large u.s. community-based real-world cohort asian chronic hcv 6 patient treat all-oral sof/ldv ribavirin svr12 similar svr12 report clinical trial confirm safety effectiveness regimen validate current hcv 6 treatment guideline recommendation\",\"gather datum antiviral efficacy safety second generation direct act antiviral daa treatment respect sustained virological response svr 12 wk conclusion treatment determine predictor svr12 setting\",\"hepatitis c virus hcv unique rna virus ability establish chronic infection majority expose adult hcv persist liver despite interferon (ifn)-stimulated gene isg induction robust induction actually predict treatment failure viral persistence unclear form hcv rna associate isg induction ifn resistance natural infection thoroughly delineate hcv rna population develop condition fully separate strand long double-stranded rna dsrna allow release rna quantify reverse transcription/polymerase chain reaction assay method reveal dsrna pathogen-associated molecular pattern pamp comprise 52 standard deviation 28 hcv rna liver patient chronic infection hcv dsrna proportionally high patient unfavorable il28b tt rs12979860 high ratio hcv double-stranded single-stranded rna ssrna correlate positively isg induction huh-7.5 cell ifn treatment increase total hcv dsrna process require de novo viral rna synthesis shift ratio viral dsrna/ssrna favor dsrna shift block ribavirin rbv antiviral drug reduce relapse hcv patient northern blotting establish hcv dsrna contain genome-length minus strand\",\"late all-oral interferon- ribavirin-free regimen base direct act antiviral hepatitis c virus hcv sustained virological response rate 90 achieve equivalent cure possible subgroup patient include difficult-to-treat population far prophylactic hcv vaccine available control hcv infection time rely use effective safe antiviral treatment accessibility affordability different approach apply different world eradication hcv represent major long-term goal hepatitis c chronic viral infection eradicate prophylactic vaccine remain briefly summarize advance molecular virology hepatitis c highlight lesson biological relevance learn study hcv translational clinical implication list select unsolved challenge emphasize hcv unique model advance direction yield knowledge broad biological significance novel technology insight related important human pathogen\",\"hepatitis c virus hcv consider major public health problem 200 million people infect worldwide treatment hcv chronic infection pegylated interferon alpha plus ribavirin inhibitor unspecific consequently treatment effective 50 patient infect prompt development direct-acting antiviral daa target virus protein daa demonstrate potent effect vitro vivo virus mutation associate development resistance describe\",\"use direct-acting antiviral daa treat chronic hepatitis c result significant increase rate sustained viral response 90%-95 compare standard treatment peginterferon/ribavirin despite rate therapeutic failure daily clinical practice range 10%-15 case presence resistant viral variant result mutation produce substitution amino acid viral target protein reduce viral sensitivity daa limit efficacy drug high genetic diversity hepatitis c virus result existence resistance-associated variant ravs start treatment daa generally low level pre-existe ravs appear impact sustained viral response appear daa therapy determinant virological failure future treatment presence ravs virological failure treatment daa generally associate factor related poor response degree fibrosis response previous therapy viral load viral nonetheless viral breakthrough relapse occur absence detectable rav use highly effective daa true clinical impact presence ravs therapeutic failure remain determine\",\"2011 2013 155 hungarian hepatitis c 1 infected patient advanced liver fibrosis respond prior peginterferon ribavirin dual therapy start boceprevir base triple therapy early access program\",\"resistance profile anti-hepatitis c virus hcv agent use combination important guide optimal treatment regimen evaluate baseline treatment-emergent ns3/4a ns5b amino-acid variant hcv (gt)-1a -1b-infected patient treat faldaprevir hcv protease inhibitor deleobuvir hcv polymerase non-nucleoside inhibitor ribavirin multiple clinical study\",\"clinical trial all-oral direct-acting antiviral daa chronic hepatitis c virus hcv infection report high response rate hcv/hiv coinfection similar obtain hcv monoinfection evaluate safety efficacy regimen clinical practice setting\",\"report previously undescribed case treatment-emergent non-structural protein 5a ns5a resistance mutation q30h y93c lead failure 24-week course sofosbuvir/ledipasvir+ribavirin therapy treatment hepatitis c virus hcv 1a interferon-experienced human immunodeficiency virus type 1 hiv-1 co-infecte patient cirrhosis\",\"hepatitis c virus hcv major cause global morbidity mortality estimate 130 150 million infected individual worldwide hcv leading cause chronic liver disease include cirrhosis hepatocellular carcinoma current treatment option develop country involve pegylated interferon-\\u03b1 ribavirin dual therapy combination direct-acting antiviral agent daa emergence resistance-associated variant rav treatment reveal great variability virus lead great difficulty develop effective antiviral strategy baseline rav detect daa treatment-na\\u00efve hcv-infected patient great importance clinical management outcome prediction frequency naturally occur hcv ns3 protease inhibitor mutation address country report prevalence south america study investigate presence ravs hcv ns3 serine protease region analyse cohort uruguayan patient chronic hepatitis c treat daa compare result find south american country result study reveal naturally occur mutation confer resistance ns3 inhibitor exist substantial proportion uruguayan treatment-na\\u00efve patient infect hcv 1 enrol study identification baseline ravs great importance patient management outcome prediction develop country\",\"hepatitis c virus hcv major etiologic agent non-a non-b hepatitis discover 26 year ago discovery interferon-\\u03b1 ifn use treatment infection decade series incremental improvement ifn therapy extend duration therapy use ifn combination oral ribavirin use pegylated ifn ribavirin recently add oral compound inhibit hcv replication directly act antiviral daa regimen daa target multiple step hcv life cycle use combination treat hcv infection need ifn ifn-free oral daa regimen highly efficacious minimal toxicity short duration approve daa cure 90 person chronic hcv infection reduce risk death cirrhosis hepatocellular carcinoma drug expensive currently exorbitant cost significantly restrict access therapy hcv infected patient\",\"hepatitis b c virus hbv hcv cause chronic infection lead fatal liver disease prototype therapy hbv hcv base ifn-\\u03b1 ribavirin advent direct-acting antiviral daa hbv hcv remarkably improve standard treatment infection hcv eliminate follow combination daa therapy hbv persist treatment require life-long therapy daa treatment daa associate high cost development resistance effect ample publish evidence hbv hcv eliminate infected host cell non-cytolytic immune mechanism need identify mechanism successful elimination replicate virus develop novel immunotherapeutic regimen synergy chemo- immuno-therapeutic strategy necessary eradicate hbv hcv host\",\"interleukin-23 il-23 downstream factor il-17 key cytokine involve immune inflammatory response chronic liver disease study aim investigate role molecular mechanism il-23/th17 axis chronic hepatitis c virus hcv infection efficacy il-23/th17 modulation response anti-hcv therapy sixty-six hcv-infected patient 20 healthy control enrol patient receive pegifna-2a ribavirin therapy 48 week plasma level il-23 number il-17a- ifn-\\u03b3- il-21-producing peripheral blood mononuclear cell pbmc baseline 12 24 48 week follow treatment determine mrna level th17 immune-associated molecule pbmc evaluate real-time quantitative reverse transcription polymerase chain reaction qrt-pcr follow treatment il-23 agonist antagonist datum compare healthy control hcv-infected patient increase plasma level il-23 increase frequency il-17a- ifn-\\u03b3-producing pbmc hcv patient exhibit reduce number il-21-producing pbmc baseline frequency il-21-producing pbmc markedly high hcv patient achieve rapid virological response rvr rvr additionally mrna expression il-21 ifn-\\u03b3 myxovirus resistance protein mxa suppressor cytokine signaling 3 socs3 significantly upregulate pbmc foxp3 expression suppress il-23 agonist il-23/th17 axis play important role development chronic hcv infection antiviral response il-23 enhance antiviral activity interferon-based therapy modulate expression th17 cells-associated molecule hcv-infected patient\",\"treatment chronic hepatitis c infection urgent patient severe liver fibrosis cirrhosis high risk decompensation hepatocellular carcinoma consecutively death development approval direct-acting antiviral drug daa past year revolutionize antiviral therapy especially patient liver cirrhosis\",\"chronic hepatitis c virus hcv infection major public health problem global level cause enormous burden hepatic extra-hepatic morbidity mortality treatment chronic hcv chc revolutionize year introduction highly effective tolerate direct act antiviral agent daa able achieve 90 rate sustained virological response svr group patient include previously exclude interferon-based regimen reason interferon-free regimen treatment choice patient successful anti-hcv treatment stop liver disease progression solve hcv-related extra hepatic manifestation eventually reduce liver-related overall mortality rapidly accumulate datum evolution treatment landscape different guideline national international liver scientific societies publish today recommendation apply worldwide high treatment cost identify priority group patient advanced liver disease type patient pose clinical management problem guideline provide useful answer aim treatment optimization fill gap current guideline address remain unmet need practice group italian expert experience treatment hcv infection meet stresa february 2016 summary consideration arise two-day meeting final statement report position paper\",\"effective treatment direct-acting antiviral drug hepatitis c virus hcv medical need cirrhotic hiv-hcv co-infecte patient\",\"treatment strategy hepatitis c virus hcv change rapidly introduction direct-acting antiviral daclatasvir dcv asunaprevir asv evaluate efficacy safety dcv asv hcv real-life practice\",\"daclatasvir daklinza \\u2122 new oral direct-acting antiviral inhibitor hepatitis c virus ns5a protein recently approve united states europe japan chronic hepatitis c. potent pangenotypic activity moderately high genetic barrier resistance improve sustained virological response svr rate command phase 2 trial daclatasvir demonstrate high svr rate hcv 1 4 chronically infected patient treat peginterferon-a pegifn\\u03b1 plus ribavirin rbv furthermore produce high response rate all-oral combination sofosbuvir interferon-free regiman ribavirin patient advanced liver disease hcv/hiv coinfection liver transplantation ally study real-world study narrative review provide information pharmacological property role efficacy safety daclatasvir-containing regimen chronic hepatitis c patient daclatasvir administer once-daily combination sofosbuvir effective 12-week treatment adult patient chronic hepatitis c generally safe tolerated\",\"therapy hepatitis c hcv evolving rapidly advent novel direct-acting antiviral agent daa review evidence currently imminently available regimen aide clinician understand current therapeutic option\",\"4 hepatitis c virus hcv consider difficult treat era pegylated interferon-alpha peg-ifn-\\u03b1 ribavirin regimen evaluate efficacy safety therapy nonstructural ns 5a inhibitor ledipasvir combine ns5b polymerase inhibitor sofosbuvir patient hcv 4 phase 2 open-label study 44 patient 22 treatment na\\u00efve 22 treatment experience receive fixed-dose combination tablet 90 mg ledipasvir 400 mg sofosbuvir orally once-daily 12 week primary endpoint percentage patient hcv rna 15 iu/ml 12 week stop therapy svr12 study participant hcv 4 represent 4a n 25 4d n 10 n 9 patient 23 compensate cirrhosis 22 treatment-experienced patient 21 95 non-cc il-28b 44 patient complete 12 week dosing svr12 rate 93 41 44 95 confidence interval 81 99 svr12 rate similar treatment-na\\u00efve 95 21 22 treatment-experienced 91 20 22 patient 3 patient achieve svr12 virological relapse 4 week end treatment 3 baseline hcv rna \\u2265800,000 iu/ml non-cc il-28b pretreatment ns5a resistance-associated variant patient relapse cirrhosis common adverse event asthenia headache fatigue patient experience adverse event\",\"influenza b virus major cause respiratory infection child adult viral host factor determine clinical manifestation range self-resolving uncomplicated infection severe viral bacterial secondary pneumonia death emergence transmissible resistant variant time-dependent effectiveness major challenge currently approve antiviral m2 ion channel blocker neuraminidase na inhibitor favipiravir inhibit rna-dependent rna polymerase multiple rna virus approve japan influenza strain resistant available antiviral expand knowledge viral nucleoprotein np polymerase structure novel small molecule inhibitor target np oligomer formation pa endonuclease domain pb2 cap-binding domain develop combination therapy different antiviral compound host immune response modulator far benefit clinical outcome\",\"addition first-approved protease inhibitor pi telaprevir boceprevir pegylated interferon peg-ifn ribavirin rbv combination therapy significantly increase sustained virologic response svr rate pi-based triple therapy treatment chronic hepatitis c virus hcv infection prone emergence resistant viral variant multiple direct act antiviral agent daa target hcv ns3/4a protease ns5a ns5b polymerase approve vary potency distinct propensity provoke resistance pre-clinical vivo assessment drug efficacy resistant variant emergence undergo great evolution decade field long hamper lack suitable small animal model robustly support entire hcv life cycle particular chimeric mouse humanize liver humanize mouse chimpanzee instrumental study hcv inhibitor evolution drug resistance review present different vivo hcv infection model discuss applicability assess hcv therapy response emergence resistant variant\",\"favipiravir viral rna-dependent rna polymerase inhibitor recently approve japan influenza pandemic preparedness conduct cell-based screening system evaluate susceptibility influenza virus favipiravir assay antiviral activity favipiravir determine inhibition virus-induced cytopathic effect measure use colorimetric cell proliferation assay demonstrate robustness assay compare favipiravir susceptibility neuraminidase na inhibitor-resistant influenza a(h1n1)pdm09 a(h3n2 a(h7n9 b virus sensitive counterpart significant difference favipiravir susceptibility find na inhibitor-resistant sensitive virus examine antiviral susceptibility 57 pair influenza virus isolate patient pre- post-administration favipiravir phase 3 clinical trial find virus statistically significant reduce susceptibility favipiravir na inhibitor 20 pair a(h1n1)pdm09 17 pair a(h3n2 20 paired b virus possess amino acid substitution rna-dependent rna polymerase subunit pb1 pb2 pa favipiravir administration report antiviral susceptibility influenza virus isolate patient favipiravir treatment\",\"hepatitis c virus hcv family flaviviridae major cause chronic liver disease year 2012 hcv infection treat use peg-interferon ribavirin combination low cure rate severe effect currently direct-acting antiviral daa available e.g. protease inhibitor ns5a polymerase inhibitor drug prove efficient interferon-free treatment combination capable enhance cure rate 90 unlike peg-interferon ribavirin combination daa select resistance hcv r155 k mutation hcv find resist currently available protease inhibitor study biophysical parameter like pocket cavity geometry stabilize residue hcv 1a ns3/4a protease wild type mutant study hcv 1a ns3/4a protease catalytic residue accessibility energy flexibility binding phase ii oral protease inhibitor vedroprevir gs-9451 compare parameter wild type mutant(s study perform use bioinformatic tool e.g. swiss-pdbviewer schr\\u00f6dinger maestro web server e.g. dogsitescorer sride asa-view eln\\u00e9mo cabs-flex patchdock plip study find introduction r155 k a156 t d168a mutation wild-type ns3/4a protease increase pocket volume surface r155 k mutant surface decrease lipo surface depth decrease number stabilize residue additionally difference catalytic residue solvent accessibility energy root-mean-square deviation rmsd flexibility wild type mutant explain change protease activity resistance protease inhibitor\",\"address therapeutic efficacy treatment regimen 3 select randomized clinical trial prospective national cohort study\",\"evaluate effect baseline hepatitis c virus hcv ns5a ns5b ns3 resistance-associated substitution ras response combination ledipasvir sofosbuvir ribavirin patient hcv 1 infection\",\"grazoprevir gzr second-generation hepatitis c virus ns3/4a protease inhibitor aim study evaluate gzr plus ribavirin rbv patient hcv gt1 infection noncirrhotic il28b cc patient hcv 1 infection randomize gzr 100 mg daily rbv 12 24 week patient 12-week arm detectable hcv rna treatment week 4 tw4 treatment extend 24 week response-guided therapy rgt primary endpoint sustained virologic response svr12 follow-up week 12 hcv rna 25 iu/ml per-protocol pp population exclude patient important protocol deviation twenty-six patient randomize 22 include pp population svr12 58.3 7 12 90 9 10 rgt 24-week arm respectively seven pp patient virologic failure include patient 24-week arm relapse follow-up week 12 breakthrough patient wild-type wt virus baseline develop breakthrough tw6 tw12 y56h a156 t d168a/n mutation relapse patient wt baseline relapse wt v55a d168a s122a/t baseline s122 t relapse adverse event ae discontinuation aes grade 3/4 elevation total and/or direct bilirubin grazoprevir plus rbv associate rapid sustained suppression hcv rna result support evaluation grazoprevir-based regimen nct01716156 protocol p039\",\"pegylated interferon ribavirin plus simeprevir therapy simeprevir-based triple therapy recently introduce provide excellent result nontransplant patient hepatitis c virus hcv infection limited datum available effect liver transplant recipient present study evaluate efficacy tolerability simeprevir-based triple therapy liver transplant recipient treat 9 liver transplant recipient 1b hcv reinfection simeprevir-based triple therapy efficacy adverse effect evaluate 24 week therapy recipient continue immunosuppressive therapy dose therapy induction seven 9 recipient 77.8 achieve sustained virological response 24 week recipient 22.2 experience viral breakthrough bt 12 16 week ns3 hcv mutation confer resistance simeprevir detect patient bt anemia common adverse effect require ribavirin dose reduction blood transfusion recipient bt complete 24-week therapy recipient experience cellular rejection therapy conclusion simeprevir-based triple therapy exhibit high efficacy tolerability liver transplant recipient 1b hcv reinfection\",\"standard care chronic hepatitis c chc india peginterferon ribavirin rbv response treatment real life stetting unclear objective study evaluate demographic profile assess virological response predictor response chc patient\",\"assess efficacy safety ledipasvir/sofosbuvir plus ribavirin 24 week 9 human immunodeficiency virus/hepatitis c virus-coinfected patient relapse receive 12 week treatment ledipasvir/sofosbuvir 9 89 achieve sustained virologic response 12 week end treatment patient relapse posttreatment week 4 result suggest effective salvage therapy patient direct-acting antiviral treatment fail\",\"current anti-influenza therapy depend administer drug soon infection impractical assess combination oseltamivir neuraminidase inhibitor t-705 nonspecific inhibitor viral polymerase extend window treat lethal infection highly pathogenic a(h5n1 influenza virus mouse combination therapy protect 100 mouse delay 96 h postinoculation compare animal receive monotherapy mouse receive combination therapy reduce viral load restricted viral spread lung tissue limited lung damage decrease inflammatory cytokine production next-generation sequencing virus population t-705-treated mouse great genetic variability frequent transversion event population control oseltamivir-treated mouse substitution associate resistance oseltamivir t-705 detect combination therapy extend treatment window a(h5n1 influenza infection mouse consider evaluation clinical setting\",\"high rate sustained virologic response svr achieve japanese patient chronic hepatitis c virus hcv (gt)1 gt2 infection treat ledipasvir/sofosbuvir ldv/sof \\u00b1ribavirin rbv sof+rbv respectively evaluate effect baseline hcv ns5a ns5b resistance-associated variant rav treatment outcome characterize variant virologic failure baseline deep sequencing ns5a ns5b gene perform gt1 patient deep sequencing ns5a gt1 ns5b gt1 gt2 perform patient fail treatment discontinue early detectable hcv rna i.e. 25 iu/ml patient hcv gt1 infection 22.3 gt1a 2/11 gt1b 74/330 \\u22651 baseline ns5a rav frequent ns5a ravs gt1b y93h 17.9 59/330 l31 m 2.4 8/330 despite presence ns5a ravs baseline 100 97 patient achieve svr12 compare 100 99 ns5a ravs ldv/sof ldv/sof+rbv respectively patient ns5b ravs baseline achieve svr12 153 patient gt2 infection gt2a 60.1 gt2b 39.9 3.3 5/153 experience viral relapse s282 t ns5b ravs detect baseline relapse change susceptibility sof rbv observe relapse conclusion ldv/sof sof+rbv demonstrate high barrier resistance japanese patient hcv gt1 gt2 infection presence baseline ns5a ravs impact treatment outcome gt1 japanese patient treat ldv/sof 12 week\",\"background pre-existence minority hepatitis c virus hcv variant impact treatment outcome persistence emerge resistant variant posttreatment patient fail treatment simeprevir/peginterferon/ribavirin smv/pr assess deep sequencing ds method population sequencing ps illumina ds perform hcv 1 isolate patient treat smv/pr phase 2b pillar nct00882908 aspire nct00980330 phase 3 quest-1 nct01289782 quest-2 nct01290679 promise nct01281839 trial result minority polymorphism ie detect pretreatment ds reduce smv activity vitro uncommon 3.6 19 534 patient smv-resistant minority polymorphism detect similar proportion patient achieve 3.7 achieve 3.3 sustain virologic response smv/pr generally emerge major variant time failure smv-resistant variant emerge time failure long detect end study 69.3 52.0 patient ps ds respectively conclusion minority polymorphism impact outcome smv/pr treatment majority emerge variant undetectable end study ps undetectable ds result suggest add value ds clinical usage smv\",\"ribavirin monotherapy preferred treatment chronic hepatitis e occasional treatment failure occur present patient chronic hepatitis e experience ribavirin treatment failure completely resistant phenotype aim identify viral mutation associate treatment failure explore underlying mechanism\",\"chronic hepatitis c virus hcv infection curable disease sustained virologic response rate 90 achieve recommend direct-acting antiviral daa combination registration trial outcome real-world patient low patient experience daa failure resistance-associated variant ravs universally select time unclear re-treat hepatitis c patient prior daa failure\",\"treatment hcv infection evolve extremely rapid pace past year development direct-acting antiviral agent potently inhibit different stage viral life cycle lead replacement interferon well-tolerated oral therapy cure rate 90 patient population understand mechanism action agent related issue include molecular basis resistance help guide drug development clinical use review provide mechanistic description ns3/4a protease inhibitor nucleotide non-nucleotide inhibitor ns5b viral polymerase inhibitor ns5a protein follow summary clinical datum study drug class combination remaining challenge drug development effort discuss\",\"previously characterize foot-and-mouth disease virus fmdv amino acid replacement polymerase 3d confer resistance mutagenic nucleoside analogue ribavirin passage mutant presence high ribavirin concentration result selection virus additional replacement i248 t 2c 2c substitution absence replacement 3d increase fmdv fitness mainly presence ribavirin prevent incorporation bias favor u associate ribavirin mutagenesis confer atpase activity 2c decrease sensitivity ribavirin-triphosphate previous study describe 2c i248 t select different selective pressure replacement qualify joker substitution fmdv evolution result identify role 2c nucleotide incorporation unveil new polymerase-independent mechanism virus escape lethal mutagenesis\",\"real-life effectiveness datum new hepatitis c direct-acting antiviral require present study aim assess rate sustained viral response svr virological failure vf patient infect chronic hcv treat sofosbuvir (sof)-based regimen routine medical practice\",\"series 1,6-bis[(benzyloxy)methyl]uracil derivative combine structural feature diphenyl ether pyridone type nnrti synthesize target compound find inhibit hiv-1 reverse transcriptase micro- submicromolar level concentration exhibit anti-hiv-1 activity mt-4 cell culture demonstrate resistance profile similar generation nnrti synthesize compound profound activity influenza virus h1n1 mdck cell culture detectable cytotoxicity lead compound assay appear exceed rimantadine amantadine ribavirin oseltamivir carboxylate activity mechanism action 1,6-bis[(benzyloxy)methyl]uracil influenza virus currently investigation\",\"egypt high prevalence difficult treat chronic hepatitis c virus hcv 4 pretreatment factor guide individualization therapy aid treatment optimization interleukin il28b gene polymorphism closely relate hcv treatment response polymorphism gene encode inhibitor t-cell response role disease progression programmed cell death 1 pd-1 cytotoxic t-lymphocyte antigen-4 ctla-4 candidate marker predict treatment response\",\"burden hcv cirrhosis high project increase significantly decade interferon therapy problematic hcv cirrhosis era direct-acting anti-viral daa therapy provide effective treatment patient cirrhosis\",\"long hepatocyte damage related hcv infection stimulate liver fibrosis result cirrhosis hepatic failure hepatocellular carcinoma 2011 therapeutic option 24 48 week pegylated interferon alfa ribavirin rbv efficacy 40 70 new generation direct-acting antiviral daa available 2014 combine improve efficacy 90 12 week treatment\",\"hepatitis c virus hcv 1b know exhibit treatment resistance respect interferon ifn therapy substitution amino acid 70 91 core region 1b significant predictor liver carcinogenesis poor response pegylated-ifn-\\u03b1 ribavirin therapy molecular mechanism clearly elucidate limitation hcv 1b infectious model recently tpf1-m170 t hcv 1b cell culture system establish clone successfully replicate infect huh-7-derived huh7-als32.50 cell purpose study compare ifn resistance hcv clone use system\",\"clarify role virus resistance efficiency antiviral therapy protease inhibitor pi chronic hepatitis c chc patient moderate sensitivity interferon-\\u03b1\",\"evaluate daclatasvir vs telaprevir combine peginterferon alfa-2a/ribavirin pegifn/rbv treatment-naive hepatitis c virus hcv gt 1-infected patient\",\"treatment hepatitis c virus change dramatically rapid advent numerous new antiviral agent include direct-acting antiviral agent non-viral target cyclophilin inhibitor interferon-lambda vaccine therapy safety profile high antiviral potency direct-acting antiviral combination interferon-free oral regimen standard care hepatitis c virus infection tailor individual patient accord degree disease progression fibrosis hepatitis c virus resistance profile prior therapeutic history result clinical study preliminary real-life datum regard combination sofosbuvir nucleotide polymerase inhibitor daclatasvir first-in-class ns5a replication complex inhibitor demonstrate promising antiviral therapy once-daily oral dosing low pill burden good tolerability limited drug-drug interaction addition high antiviral potency 90 sustain virologic response rate combination high pangenotypic antiviral potency regardless severity patient characteristic combination sofosbuvir ns5a inhibitor ribavirin 12 week appear good treatment option cirrhotic treatment-experienced patient stage fibrosis\",\"vaccine hepatitis c virus hcv remain global medical socio-economic burden predispose 170 million carrier worldwide end-stage liver disease include cirrhosis hepatocellular carcinoma recently develop direct-acting antiviral daa revolutionize hepatitis c treatment unsuitable monotherapy risk resistance necessitate combination interferon (ifn)-alpha ribavirin additional daa importantly high cost associate daa restrict accessibility world develop novel cost-effective anti-hcv therapeutic help expand scope antiviral treatment strategy hepatitis c. apply activity-based fraction-guided analysis extract medicinal plant phyllanthus urinaria p. urinaria yield fraction 13 f13 possess potent inhibitory activity early viral entry cell-culture hcv infection chemical analysis silica gel chromatography follow esi lc-ms plus (1)h (13)c nmr f13 identify loliolide lod monoterpenoid lactone novel inhibitor hcv entry specifically lod efficiently inactivate hcv free virus particle abrogate viral attachment impede viral entry/fusion minimal effect viral replication/translation particle production induction type ifn host antiviral immune response elisa-based binding analysis confirm monoterpenoid ability efficiently block hcv particle attachment host cell surface furthermore lod inhibit infection genotypic strain hcv report characterize p. urinaria bioactive compound lod potent hcv entry inhibitor merit evaluation development candidate antiviral agent hepatitis c.\",\"daclatasvir plus asunaprevir dcv asv demonstrate potent antiviral activity patient hepatitis c virus hcv 1b gt-1b infection hallmark dual trial post hoc analysis conduct determine efficacy safety treatment asian patient\",\"treatment hepatitis c virus hcv infection progress markedly 2 decade dramatic acceleration 3 year combination direct-acting antiviral drug daa target viral protein ns3/4a protease inhibitor ns5b nucleos(t)idic non-nucleos(t)idic polymerase inhibitor ns5a replication complex inhibitor ribavirin interferon interferon-free regimen 8 24 week achieve high sustained virological response 90 fibrosis stage baseline viral load prior therapeutic history patient na\\u00efve experience pre-existing resistance-associated variant fair tolerance reduce pill burden international guideline recommend ideally treat infected patient prioritization severe patient extensive fibrosis cirrhosis symptomatic cryoglobulinaemic vasculitis \\u2026 appear cost-effective urgent policy patient stage 4 5 chronic kidney disease ckd consider priority patient update kidney disease improve global outcomes recommendation start soon await availability present overview recent development field\",\"daclatasvir plus asunaprevir demonstrate efficacy safety patient chronic hepatitis c virus 1b infection study focus evaluate daclatasvir plus asunaprevir interferon (\\u00b1ribavirin)-ineligible -intolerant asian patient 1b infection mainland china korea taiwan\",\"introduction direct-acting antiviral agent daa markedly improve sustained virological response svr rate patient chronic hepatitis c. currently class daa target hcv protein ns3 ns5a ns5b approve treatment country drug advantage disadvantage use combination daa different target addition ribavirin difficult-to-treat patient svr rate ~90 12 week treatment expand treatment 24 week type daa await approval improve treatment chronic hepatitis c virus 1 infection high cost drug resistance interaction drug remain overcome advance development antiviral agent expect near future daa affordable cost effective require short treatment duration effective broad range patient effect drug-drug interaction\",\"phase iii registration study conduct japan japanese hcv gt1 patient administer vaniprevir 300 mg twice daily plus pegylated interferon/ribavirin 12 24 week achieve svr24 rate 83.7 84.5 treatment-na\\u00efve patient 92.0 96.2 61.9 breakthrough/relapser null-responder prior interferon based therapy evidence direct sequencing patient achieve svr24 principally fail treatment-emerging mutation d168 case r155 work additional sequence analysis conduct address baseline polymorphism associate failure evaluate persistence resistant virus treatment failure assess evidence second site co-evolution r155 d168 mutation accomplish clonal sequencing 40 clone sample conduct baseline failure follow-up sample 38 patient vaniprevir treatment arm meet virologic failure criterion 37 gt1b 1 gt1a refer virologic failure baseline sample 41 vaniprevir-treated svr24 patient gt1b select study svr24 virologic failure patient similar distribution baseline polymorphism previously associate failure protease inhibitor furthermore evidence baseline polymorphism genetic signature ns3 protease domain specific virologic failure patient distinguish baseline svr24 sequence chance distribution 24 32 virologic failure baseline failure follow-up sample available reduce prevalence resistant virus observe time failure protocol-defined follow-up period 24 week finally pairwise analysis use alignment phylogenetic base methodology provide evidence second site evolution r155 d168 mutation attribute failure work support extend early finding base direct sequencing attribute virologic failure vaniprevir phase iii study solely emergence r155 d168 mutation apparent influence residue ns3 protease domain treatment outcome clinicaltrials\",\"pancreatic cancer devastating disease characterize treatment resistance high recurrence rate repopulation survive tumor cell undergo radiotherapy common reason recurrence previous study discover novel mechanism repopulation irradiation activation caspase-3 irradiated tumor cell activate pkc\\u03b4/p38 axis transmit proliferation signal promote repopulation survive tumor cell find sox2 expression up-regulate irradiated pancreatic cancer cell play major role tumor cell repopulation irradiation over-expression sox2 strongly enhance growth-stimulating effect irradiated die tumor cell live tumor cell paracrine modality furthermore identify activate eif4e phosphorylate mnk1 regulator sox2 expression irradiation pharmacologic inhibition eif4e cgp57380 ribavirin significantly weaken sox2-mediated tumor cell repopulation finally activation caspase 3/pkc\\u03b4/p38/mnk1 signal pathway irradiated pancreatic tumor cell novel pathway regulate sox2 expression sox2 promising target reduce recurrence repopulation survive tumor cell radiotherapy\",\"chronic hepatitis c virus hcv infection important source morbidity mortality haemophiliacs limited datum available regard treatment intervention use direct-acting antiviral daa theoretical concern regard accumulation drug-associated resistance variant rav remain conduct pilot study treatment telaprevir/pegylated interferon-alfa/ribavirin evaluate treatment response role lead-in daa therapy mutational selection resistance variant\",\"therapeutic option patient hcv-related liver disease increase decade fact old standard care base combination pegylated interferon ribavirin result satisfactory eradication rate particularly patient liver cirrhosis advent direct-acting antiviral daa high rate viral clearance possible patient contraindication interferon obtain access treatment concern raise regard first-generation daa high cost emergence resistant-associated variant low susceptibility drug\",\"african american/black population united states disproportionately affect hepatitis c virus hcv low response rate current treatment analysis evaluate participation african american/blacks north american european hcv clinical trial datum source analysis pubmed database randomized control clinical trial rct hcv treatment interferon 2a 2b january 2000 december 2011 review inclusion criterion include english language participant 18 year old chronic hcv exclusion criterion include non-randomized trial case report cohort study ethnic specific study study use interferon-alfa peg-interferon 588 trial identify 314 53.4 fit inclusion criterion main outcome rate african american/ black participation north american hcv clinical trial meta-analysis compare expect observe rate perform rct meet search criterion 123 39.2 report race clinical trial north america likely report racial datum european trial racial reporting increase time statistically significant difference expect observe participation african americans hcv clinical trial north america base prevalence disease population burden hcv african americans north america reflect clinical trial design treat hcv research minority participation clinical trial increase minority participation clinical trial need\",\"selection resistance-associated variant rav single agent administer patient chronically infect hepatitis c virus hcv necessitate direct-acting antiviral agent daa target multiple viral protein develop overcome failure result emergence resistance combination grazoprevir mk-5172 ns3/4a protease inhibitor elbasvir mk-8742 ns5a inhibitor study 1a gt1a replicon cell compound independently highly potent gt1a wild-type replicon cell 90 effective concentration ec90 value 0.9 nm 0.006 nm grazoprevir elbasvir respectively cross-resistance observe clinically relevant ns5a ns3 ravs profile grazoprevir elbasvir respectively kinetic analysis hcv rna reduction 14 day grazoprevir elbasvir inhibit prototypic ns5a y93h ns3 r155 k ravs respectively kinetic comparable wild-type gt1a replicon combination grazoprevir elbasvir interact additively gt1a replicon cell colony formation assay 10-fold multiple ec90 value grazoprevir-elbasvir inhibitor combination suppress emergence resistant colony compare 100-fold multiple independent agent select resistant colony combination harbor ravs require nucleotide change codon mutation cognate gene cause great potency loss elbasvir grazoprevir replicon bear ravs identify resistant colony reduce fitness cell line contribute activity combination study demonstrate combination grazoprevir elbasvir exert potent effect hcv rna replication present high genetic barrier resistance combination grazoprevir elbasvir currently approve chronic hcv infection\",\"insulin resistance consider important factor progression fibrosis enhancement risk hepatocellular carcinoma hcc chronic hepatitis c patient aim study assess effect insulin resistance development hcc non-cirrhotic chronic hepatitis c patient treat pegylated interferon alpha-2b peg-ifn\\u03b12b ribavirin\",\"unlike human immunodeficiency virus hiv hepatitis b virus hbv hepatitis c virus hcv infection curable disease current direct antiviral agent daa target focus hcv ns3/4a protein protease ns5b protein polymerase ns5a protein generation daa include boceprevir telaprevir protease inhibitor approve clinical use 2011 cure rate 1 patient increase 45 70 boceprevir telaprevir add standard peg-ifn/ribavirin effective toxic second generation daa supplant drug 2013 second generation daa include sofosbuvir sovaldi simeprevir olysio fix combination medicine harvoni viekira pak drug increase cure rate 90 need interferon effectively treat hcv drug cure hcv goal reality concern remain drug resistance mutation high cost drug investigation new hcv drug progress rapidly fix dose combination medicine phase iii clinical trial include viekirax asunaprevir+daclatasvir+beclabuvir grazoprevir+elbasvir\",\"previous study ribavirin-resistant porcine reproductive respiratory syndrome virus prrsv mutant rvrp13 rvrp22 select resistance random mutation culture cell present study ribavirin-resistant mutant evaluate term genetic phenotypic stability pig-to-pig passage comparison modify live virus mlv ingelvac prrs mlv pig challenge rvrp22 significantly low p 0.05 viral load sera tissue pig challenge mlv rvrp13 passage attenuate replication rvrp22 maintain passage viral load serum tissue dramatically increase pig challenge mlv rvrp13 second passage consistently sequence associate attenuation virulent prrsv rvrp13 mlv quickly revert wild-type sequence passage attenuation sequence maintain rvrp22 passage addition rvrp22 significantly low p 0.001 mutation frequency nsp2 variable region prrsv genome mlv unique mutation find open reading frame orf 1a 2 6 rvrp22 genome base full-length sequence comparison rvrp13 vr2332 parental virus rvrp13 rvrp22 mlv base result conclude rvrp22 attenuate replication pig far high genetic stability rvrp22 attenuate phenotype stable sequential passage pig\",\"effective safe antiviral treatment regimen need patient chronic hepatitis c chc cirrhosis\",\"goal study identify host viral factor affect response pegylated interferon/ribavirin peg-ifn/rbv treatment patient chronic hepatitis c 1b baseline characteristic patient sequence p7 region analyze pre-treatment serum sample 53 individual chronic hepatitis c 1b related outcome therapy find significant correlation age response therapy p 0.001 furthermore pre-treatment viral load closely associate stage liver fibrosis p 0.001 presence 4 mutation age 40 significantly associate non-response nr p 0.001 finding useful estimate likelihood achieve sustained virologic response svr patient chronically infect hepatitis c virus 1b\",\"patient 1 2 treatment-naive woman 1b chronic hepatitis c. il-28b tt amino acid substitution core 70 91 wild type search presence resistance-associated variant rav non-structural (ns)3 ns5a region confirm wild-type d168 l31 y93h patient patient participate japanese phase iii clinical study asunaprevir daclatasvir age 52 67 year respectively treat combination regiman 24 week experience post-treatment relapse treat triple combination therapy simeprevir pegylated interferon ifn ribavirin age 53 68 year respectively achieve sustained virological response search rav prior simeprevir treatment identify multiple resistance include d168e y93h l31v patient demonstrate case treatment failure combination asunaprevir daclatasvir result acquisition rav ns3 ns5a region drug-resistant mutant particularly ns5a region survive long time case direct-acting antiviral target ns5a region limited efficacy present case report base idea regimen contain ifn simeprevir therapeutic option particularly likely highly sensitive tolerable ifn\",\"despite enormous disease burden associate dengue virus infection licensed antiviral drug lack paracetamol acetaminophen metabolite am404 inhibit dengue virus replication find mutation ns4b previously find confer resistance antiviral compound nitd-618 sdm25n render dengue virus insensitive am404 work provide support ns4b direct indirect target antiviral drug development\",\"failure achieve sustained virological response svr hepatitis c virus hcv direct-acting antiviral-based regimen commonly associate emergence resistance-associated variant rav avoid cross-resistance recent guideline recommend patient fail nonstructural protein 5a ns5a inhibitor retreat sofosbuvir sof ns5b inhibitor combine simeprevir sim protease inhibitor pi support evidence lack real-world study comprise patient fail achieve svr previous ns5a-based therapy daclatasvir dcv plus pegylated interferon peg-ifn ribavirin rbv n 3 n 13 asunaprevir asv pi 16 patient retreat 12 week sof plus sim rbv antiviral efficacy evaluate use primary endpoint svr12 svr 12 week post-treatment on-treatment response assess patient n 16 13 male mean age 54 year range 43 73 chronically infect hcv gt 1 1a n 11 1b n 3 4 n 2 advance fibrosis compensate cirrhosis fibroscan 9.6 70 kpa cirrhosis n 9 median baseline hcv-rna level 1.38 \\u00d7 10(6 iu/ml. patient discontinue treatment adverse event virological failure patient achieve hcv rna low limit quantification 12 iu/ml end treatment eot 10 16 rapid response week 4 svr12 achieve 14 16 patient remain 2 relapsed 4 week post-eot gt 1a infect cirrhosis 1 previously fail dcv-asv plus peg-ifn rbv presence sim ravs/polymorphism r155 k q80 k study baseline predict retreatment failure\",\"approximately 130 150 million people chronic hepatitis c virus hcv infection upward 500,000 death annually attribute hcv related liver disease worldwide pegylated interferon ribavirin mainstay treatment great 25 year recent advent protease inhibitor lead oral hcv treatment regimen change outlook hepatitis c treatment\",\"hepatitis c virus hcv common blood-borne infection united states high morbidity mortality untreated infection prompt update screening recommendation include one-time hcv screening patient bear 1945 1965 addition risk factor-based screening current guideline recommend treatment patient chronic hcv treatment hcv 1 evolve dramatically approval direct-acting antiviral approval ledipasvir-sofosbuvir ombitasvir-paritaprevir-ritonavir dasabuvir simeprevir sofosbuvir dramatically alter treatment landscape high sustained virologic response svr rate favor treatment access care pose challenge patient provider current emerge datum new therapy indicate high svr rate treatment-na\\u00efve treatment-experienced patient include patient cirrhosis special population additional datum suggest addition ribavirin decrease treatment duration compromise svr rate resistance increase area interest hcv baseline mutation identify potential development resistance-associate variant patient undergo treatment rapid evolution hcv treatment pharmacist address challenge play integral role agent selection dosing drug interaction screening adverse effect monitoring coordination treatment clinical application late information reduce patient risk improve outcome\",\"chronic hepatitis c virus hcv infection affect 80 160 million people worldwide lead cause chronic liver disease year ago standard treatment regime base pegylated interferon alpha ribavirin treatment hcv undergo revolutionary change recent year admission nucleotide polymerase inhibitor sofosbuvir enable interferon-free regimen direct antiviral agent daa seven daa available apply combination 8 24 wk depend hcv patient characteristic cirrhosis chronic renal failure high rate sustained virological response svr rate achieve novel drug difficult treat population patient liver cirrhosis hcv-human immunodeficiency virus co-infection liver transplantion chronic kidney disease comparable high rate svr achieve anticipate 2(nd generation daa strikingly effective patient far classified difficult treat include decompensated liver cirrhosis post-transplant patient 2(nd generation daa high resistance barrier high antiviral effect pan-genotypic spectrum review highlight current state art antiviral treatment hepatitis c outlook upcoming therapy\",\"hepatitis c virus hcv rna-dependent rna-polymerase ns5b essentially require viral replication serve prominent drug target sofosbuvir prodrug nucleotide analog interact selectively ns5b approve hcv treatment combination ribavirin emergence resistance sofosbuvir rarely clinic s282 t mutation decrease susceptibility drug s282 t confer hypersusceptibility ribavirin potential clinical benefit devise biochemical approach elucidate underlying mechanism recent crystallographic datum reveal hydrogen bond s282 2'-hydroxyl bind nucleotide adjacent g283 form hydrogen bond 2'-hydroxyl residue template base pair nucleotide substrate dna-like modification template disrupt hydrogen bonding g283 cause enzyme pausing natural nucleotide specifically introduce dna residue template reestablish binding incorporation sofosbuvir context s282 t dna-like modification template prevent incorporation ribavirin context wild-type enzyme s282 t mutant enable binding incorporation ribavirin condition finding provide strong evidence susceptibility sofosbuvir ribavirin depend crucially network interdependent hydrogen bond involve adjacent residue s282 g283 interaction incoming nucleotide complementary template residue respectively\",\"patient hepatitis c virus hcv 3 infection especially advanced liver disease challenging population urgent need optimally effective therapy combination daclatasvir dcv pangenotypic nonstructural protein 5a inhibitor sofosbuvir sof nucleotide nonstructural protein 5b inhibitor 12 week previously high efficacy 96 noncirrhotic 3 infection phase iii ally-3 study n 50 evaluate dcv-sof ribavirin rbv treatment-na\\u00efve n 13 treatment-experienced n 37 3-infected patient advanced fibrosis n 14 compensate cirrhosis n 36 patient randomize 1:1 receive open-label dcv-sof 60 400 mg daily weight-based rbv 12 16 week primary endpoint sustain virological response post-treatment week 12 svr12 svr12 intention-to-treat 90 overall 45 50 ): 88 21 24 12-week 91 observe 92 24 26 16-week group patient advanced fibrosis achieve svr12 svr12 patient cirrhosis 86 overall 31 36 ): 83 15 18 12-week 88 observe 89 16 18 16-week group treatment-experienced patient cirrhosis value 87 26 30 88 14 16 93 observe 86 12 14 respectively patient 12-week group enter post-treatment follow-up death unrelated treatment 4 relapse 2 group virological breakthrough common adverse event ae insomnia fatigue headache discontinuation ae treatment-related ae\",\"130 170 million people estimate infect hepatitis c virus hcv chronic hcv infection lead cause liver-related death country primary reason liver transplant main aim antiviral treatment eradicate virus year ago treatment strategy base combination pegylated interferon ribavirin peg/rbv 1 4 rate viral response surpass 50 reach 80 rest 2011 approval direct act antiviral agent daa boceprevir telaprevir treatment 1 combination traditional dual therapy strategy manage increase rate sustained viral response svr naive patient retreat patient great toxicity interaction cost safe patient advanced disease treatment trigger decompensation death recent accelerate incorporation 2013 new effective daa pan-genomic property excellent tolerance increase rate svr 100 create new scenario short therapy toxicity regimen free peg/rbv enable generalised applicability patient note scientific evidence available base expert opinion case-control serie cohort study phase 2 3 trial reduce number patient select group datum currently available use drug daily clinical practice particularly relation appearance effect interaction drug use special population person common situation suggest need generalised implementation registry patient receive antiviral therapy main inconvenience new drug high cost necessitate selection prioritization candidate patient receive strategy establish national organ accordance recommendation scientific society\",\"chronic hepatitis c virus hcv infection link high prevalence type 2 diabete compare general population patient chronic hepatitis b infection diabete common extra-hepatic manifestation hcv hcv-diabetes association insulin resistance ir occur early course disease patient minimal fibrosis mechanism hcv-induced ir partly understand include direct inhibitory effect hcv insulin signaling pathway ir chronic hcv result increase progression rate hepatic fibrosis cirrhosis hepatocellular carcinoma study find ir reduce response rate interferon/ribavirin therapy ir affect response new direct-acting antiviral treatment unknown\",\"advent direct act antiviral agent daa ribavirin associate pegylated-interferon play crucial role treatment chronic hepatitis c prevent relapse breakthrough present era new potent daa place devoted drug ribavirin associate sofosbuvir efficient treatment case g2 infected patient option currently available difficult-to-treat cirrhotic g3 patient contain ribavirin reduce treatment duration 12 wk g1 g4 cirrhotic compensate patient feasible thank ribavirin retreating patient acquire anti ns5a resistance-associated variant use ribavirin-based strategy useful addition ribavirin daa combination lead frequent mild adverse event especially cirrhotic patient preliminary datum interferon-free second generation daa combination ribavirin suggest future drug jeopardize difficult-to-treat patient optimization ribavirin dosage accord early monitoring blood level suggest relevant double therapy peginterferon sofosbuvir potent combination daa\",\"target-free cell-based approach apply evaluate anti-influenza property newly synthesize benzoic acid derivative sa-2 ethyl 4-(2-hydroxymethyl-5-oxopyrrolidin-1-yl)-3-[3-(3-methylbenzoyl)-thioureido benzoate compound 2 screen potential drug candidate cytopathic effect assay sa-2 dose dependently inhibit h1n1 h3n2 oseltamivir-resistant mutant h1n1-h275y influenza virus virus-infected mdck a549 cell 50 effective concentration ec50 mdck cell 9.6 19.2 19.8 \\u03bcm respectively 50 cytotoxic concentration cc50 444.5 \\u03bcm competitive antiviral activity oseltamivir vitro orally administer sa-2 effectively protect mouse infect lethal dose h1n1 oseltamivir-resistant strain h1n1-h275y confer 70 50 survival dosage 100 mg/kg/d reduce body weight loss alleviate influenza-induced acute lung injury reduce lung virus titer mechanistic study sa-2 efficiently inhibit activity rna polymerase suppress np m1 level viral biosynthesis interfere gene transcription obvious influence virus entry release base favourable finding sa-2 novel anti-influenza agent potent anti-influenza activity vitro vivo promising antiviral treatment infection influenza virus include oseltamivir-resistant mutant\",\"influenza virus influenza a(h1n1 a(h3n2 currently circulate human report 2014 15 therapeutically emergence viral resistance currently available drug adamantane neuraminidase inhibitor heighten alarm develop novel drug address diverse target viral replication cycle order improve treatment outcome regard design synthesis nucleoside analog inhibitor potential anti-influenza agent active field research nowadays study design synthesize series hitherto unknown 6-methyl-7-substituted-7-deaza purine nucleoside analog evaluate biological activity influenza virus strain h1n1 h3n2 viral inhibition assay identify effective compound compound 5x ic50 5.88 \\u03bcm 6.95 \\u03bcm h1n1 h3n2 respectively 5z ic50 3.95 \\u03bcm 3.61 \\u03bcm h1n1 h3n2 respectively demonstrate potent anti-influenza activity basis selectivity index conceive compound 5x serve chemical probe interest far lead optimization study general aim develop novel effective anti-influenza virus agent\",\"direct-acting anti-viral daa treat chronic hcv infection revolutionise treatment algorithms drastically mitigate effect enhance efficacy relative interferon-based therapy\",\"abt-530 next-generation hepatitis c virus hcv ns5a inhibitor potent pangenotypic antiviral activity vitro paritaprevir ns3/4a protease inhibitor codose ritonavir display vitro activity hcv 1 4 6\",\"translation initiation factor eif4e mediate rate-limiting process drive selective translation oncongenic protein cyclin d1 survivin vegf contribute tumour growth metastasis therapy resistance essential regulatory hub cancer signalling network oncogenic signalling pathway appear converge eif4e target eif4e-mediated cap-dependent translation consider promising anticancer strategy paper review strategy use target eif4e highlight agent target eif4e activity distinct level\",\"intravenous drug user idu represent highly-infected reservoir hepatitis c virus hcv worldwide harbor elevated prevalence majority epidemic develop nation study aim sequence region viral genome uncovered amino acid mutation implicate resistance standard care pegylated interferon/ribavirin double therapy use nested pcr method core region hcv strain moroccan idu live tangier region study seek identify genotype-specific amino acid mutation follow phylogenetic method order compare international strain identify sequence high homology genotyping confirm recombination event exclude line-probe assay italy find homologous 1a 3a iran 1a egypt 4a amino acid mutation analysis reveal follow novel 3a-specific mutation n16i l36v t49a p71s t75s t110n outcome work describe hcv genetic heterogeneity high-risk intravenous drug user clue global migratory flow cross geographical boundary idu population identify signature amino acid mutation traceable hcv 3a identification key amino acid position hcv core region high rate mutation pave way eventual clinical trial seek establish link recurrent mutation response standard care interferon ribavirin antiviral therapy j. med virol 88:1376 1383 2016 \\u00a9 2016 wiley periodicals inc.\",\"date approve antiviral drug treatment ebola virus disease evd number candidate drug limited efficacy vitro and/or non-human primate study difference experimental methodology difficult compare therapeutic effectiveness use vitro model ebola zaire replication transcription-competent virus like particle trvlp require level 2 biosafety containment compare activity type interferon ifn ifn-\\u03b1 ifn-\\u00df panel viral polymerase inhibitor lamivudine 3tc zidovudine azt tenofovir tfv favipiravir fpv active metabolite brincidofovir cidofovir cdf estrogen receptor modulator toremifene tor inhibit viral replication dose-response time course study test 28 two- 56 three-drug combination ebola replication ifn-\\u03b1 ifn-\\u00df inhibit viral replication 24 hour post-infection ic50 0.038\\u03bcm 0.016\\u03bcm respectively 3tc azt tfv inhibit ebola replication use 50 62 combination 87 exhibit low ic50 0.98 6.2\\u03bcm compare fpv 36.8\\u03bcm administer 24 hour post-infection unexpectedly cdf narrow therapeutic window 6.25 25\\u03bcm dose 50\\u03bcm cdf treatment enhance viral infection ifn-\\u00df exhibit strong synergy 3tc 97.3 inhibition triple combination 3tc azt 95.8 inhibition study demonstrate ifn viral polymerase inhibitor utility evd identify 2 3 drug combination strong anti-ebola activity confirm study use fully infectious zebov provide rationale testing combination therapy animal model lethal ebola challenge study open new possibility novel therapeutic option particular combination therapy prevent treat ebola infection potentially reduce drug resistance\",\"patient chronic hepatitis c virus hcv 1 infection previous null response 2-log10 reduction hcv rna treatment week 12 peginterferon/ribavirin pegifn/rbv achieve sustained virological response svr re-treate first-generation hcv protease inhibitor pi administer combination pegifn/rbv study incremental benefit associate add mericitabine nucleoside analog inhibitor hcv polymerase pi plus pegifn alfa-2a/rbv-based therapy double-blind randomize multicenter phase 2 trial boceprevir dynamo 1 telaprevir dynamo 2 primary endpoint trial svr define hcv rna 25 iu/ml 12 week end treatment svr12 overall addition mericitabine pi plus pegifn alfa-2a/rbv therapy result svr12 rate 60 70 dynamo 1 71 96 dynamo 2 svr12 rate similar patient infect hcv 1a 1b trial placebo control arm study stop high rate virological failure numerically low relapse rate associate long treatment mericitabine 24 versus 12 week telaprevir-containing regimen regimen include 48 week pegifn alfa-2a/rbv therapy mericitabine resistance mutation identify patient trial addition mericitabine add safety burden associate telaprevir boceprevir-based regimen study demonstrate increase svr rate reduce relapse rate difficult-to-treat patient nucleoside polymerase inhibitor intermediate antiviral potency add regimen contain first-generation pi\",\"daclatasvir nonstructural protein 5a inhibitor hepatitis c virus hcv replication asunaprevir ns3/4a complex inhibitor hcv replication combination daclatasvir asunaprevir approve japan treatment 1 chronic hcv infection vitro study document potent activity drug individually combination 1 hcv result complete ongoing clinical study confirm potent activity patient response note 1b patient compare patient 1a hcv response rate treatment-naive patient compare treatment-experienced case addition interferon ribavirin appear enhance treatment response combination daclatasvir asunaprevir general tolerated daclatasvir asunaprevir substrate cytochrome p450 3a4 enzymatic pathway substantial potential drug interaction\",\"marginal zone lymphoma associate infectious agent cover viral bacterial pathogen case clear aetiological role establish pathogenetic mechanism currently completely understand role chronic stimulation host immune response persistent lymphocyte activation represent convincing explanation lymphoproliferation gastric malt lymphoma strictly associate helicobacter pylori infection eradicating protocol develop increase antibiotic resistance represent line therapy gastric malt response rate eradication good 80 response 1 year finding noteworthy recapitulate cancer cure antibacterial approach satisfy koch postulate causation establish causative relationship hp gastric malt lymphoma patient chronic hcv infection 5 time high risk develop mzl particular association splenic nodal mzl study evidence lymphoma regression antiviral therapy interferon+ribavirin raise hope newly available drug extremely efficient hcv replication improve outcome hcv-driven lymphoma case-study represent rare case mzl localize orbital fat eye conjunctivas associate chlamydophila psittaci infection carry bird efficacy antibacterial therapy c. psittaci conflict generally poor gastric malt finally case report cover relationship primary cutaneous b-cell lymphomas borrelia burgdorferi\",\"hepatitis c virus hcv infection major global health issue search hcv treatment result great achievement current treatment method limitation new method drug hepatitis c treatment require aim present study investigate effect artesunate art hcv replication compare effect ribavirin rbv interferon-2b ifn study perform hcv-infection cell model jfh1-infected huh7.5.1 or6 cell line result antimalarial drug art inhibit hcv replicon replication dose- time-dependent manner concentration effect proliferation exponentially grow host cell inhibitory effect hcv replication strong rbv weak ifn determine qpcr luciferase assay western blot analysis furthermore combination art ifn result great inhibition hcv replication finding demonstrate art inhibitive effect hcv replication novel supplemental co-therapy ifn rbv hcv alternative strategy combat resistance mechanism emerge presence daa agent\",\"hepatitis disease cause hepatitis c virus hcv severe threat global public health affect approximately 3 world population sofosbuvir psi-7977 uridine nucleotide analog inhibitor target hcv ns5b polymerase approve fda end 2013 represent key step new era management hcv infection previous study identify nitd008 adenosine nucleoside analog specific inhibitor dengue virus good antiviral effect flavivirus enterovirus report systematically analyze anti-hcv profile nitd008 discover effectively suppress replication different strain hcv human hepatoma cell low nanomolar activity 2a virus 2a 1a 1b replicon cell ec50 value 8.7 nm 93.3 nm 60.0 nm 67.2 nm selective index value 2298.9 214.4 333.3 298.5 respectively demonstrate resistance nitd008 confer mutation ns5b s282 t hcv infectious virus 2a jfh-1 compare resistant profile nitd008 psi-7977 find fold change ec50 nitd008 replicon cell contain mutation s282 t big psi-7977(fold 76.50 vs. 4.52 analysis nitd008 cross-resistance previously report ns5b drug-selected mutation resistance pattern nitd008 completely similar psi-7977 s282 t resistant mutation nitd008 emerge easily cell culture psi-7977 interestingly nitd008 display significant synergistic effect ns5b polymerase inhibitor psi-7977 additive effect alpha interferon ifn\\u03b1-2b ribavirin ns3 protease inhibitor result verify nitd008 effective analog inhibitor hepatitis c virus good research tool supplement type nucleoside analog\",\"hepatitis e virus hev lead chronic infection solid-organ transplant patient ribavirin efficient treatment chronically infected patient recently the1634r mutation hev polymerase associate treatment failure unclear mutation use prognostic marker treatment outcome study prevalence 1634r mutation hev polymerase patient start ribavirin therapy influence 1634r variant viral response frequency 1634r mutation patient treatment fail impact ribavirin retreatment analyze pretreatment sample 63 solid-organ transplant patient chronic hepatitis e use deep sequencing 42 patient sustained virologic response svr 21 non-svr patient detect 1634r variant deep sequencing 36.5 23/63 patient proportion 1.3 100 1634r variant detect 31.0 13/42 baseline plasma sample patient svr 47.6 10/21 patient p 0.2 presence mutation influence initial decrease viral rna lastly second prolonged ribavirin treatment lead svr 70 patient initially svr despite presence 1634r variant conclude presence 1634r variant ribavirin initiation lead absolute ribavirin resistance proportion increase patient treatment fail presence 1634r variant compromise response second ribavirin treatment\",\"approximately 1 million south africans infect hepatitis c virus hcv standard care soc south africa combination therapy pegylated interferon ribavirin hcv and/or mutation core/non-structural region associate response therapy and/or disease progression study examine mutation core 29 280 amino acid include \\u223c 90 e1 amino acid ns5b 241 306 amino acid region pre-treatment isolate patient attend johannesburg hospital asymptomatic south african blood donor diversity known cd4 cd8 t-cell epitope explore sample group 1a(n 10 1b(n 12 3a(n 5 4a(n 3 5a(n 61 mutation associate interferon resistance-r70q t110n-were present 29 5a core sequence resistance mutation ns5b nucleotide inhibitor sofosbuvir find putative cd8 cd4 t-cell epitope sequence core region binding score 300 ic50nm hla allele frequently observe south african population known cd8 cd4 t-cell epitope map ns5b region analysis beg question infect 5a benefit interferon-free combination therapy study provide new insight lesser study hcv compare diversity large pre-treatment cohort\",\"amino acid aa 70 substitution r70q/h core protein hepatitis c virus hcv 1b key factor determine resistance pegylated interferon-\\u03b1 plus ribavirin combination therapy peg-ifn\\u03b1/rbv exact mechanism remain unclear aim study investigate dynamic response wild mutant core codon 70 strain peg-ifn\\u03b1/rbv treatment\",\"direct-acting antiviral (daa)-base therapy new standard treatment chronic hepatitis c virus hcv infection protease inhibitor (pi)-resistant viral variant describe study aim examine hcv-ns3 protease variant baseline 4 week triple therapy end analyze presence variant hcv-ns3 protease region peripheral blood sample 16 patient infect hcv-1 baseline 4 week combined therapy telaprevir pegylated interferon ribavirin use next-generation sequencing variant synonymous non-synonymous amino acid substitution detect time point variant detect low frequency correspond 74 hcv-1a 35 hcv-1b non-synonymous substitution find pi-resistance-associated variant v36a t54s v55i q80 k q80r v107i i132v d168e m175l hcv-ns3 10 patient correspondence resistance-associated variant profile baseline 4 week resistance variant baseline short-term treatment good predictor outcome triple therapy study large number minor major non-synonymous variant hcv-ns3 early telaprevir-based therapy important drug resistance association study newly develop pi agent\",\"respiratory virus rsv leading cause low respiratory tract infection infant young child addition rsv cause significant morbidity mortality hospitalize elderly immunocompromised patient currently palivizumab monoclonal antibody rsv fusion f protein inhale ribavirin approve prophylactic therapeutic treatment rsv respectively clinical need safe effective therapeutic agent rsv infection gs-5806 discover chemical optimization hit high-throughput antiviral-screening campaign selectively inhibit diverse set 75 rsv b clinical isolate mean 50 effective concentration ec50 0.43 nm compound maintain potency primary human airway epithelial cell exhibit low cytotoxicity human cell line primary cell culture selectivity 23,000-fold time-of-addition temperature shift study demonstrate gs-5806 block rsv attachment cell interfere virus entry follow-up experiment potent inhibition rsv f-mediated cell-to-cell fusion rsv b variant resistant gs-5806 mutation f protein rsv l138f f140l/n517i rsv b f488l f488s isolate cross-resistance rsv fusion inhibitor vp-14637 remain fully sensitive palivizumab ribavirin summary gs-5806 potent selective rsv fusion inhibitor antiviral activity diverse set rsv clinical isolate compound currently clinical investigation treatment rsv infection pediatric immunocompromise elderly patient\",\"insulin resistance ir modify anti-viral effect interferon ifn therapy patient chronic hepatitis c chc prospective study evaluate lifestyle intervention improve anti-viral response treatment pegylated (peg)-ifn plus ribavirin rbv patient chc\",\"year standard treatment hepatitis c virus hcv infection combination pegylated interferon alpha peg-ifn-\\u03b1 ribavirin 24 48 week treatment regimen result sustained virologic response svr rate 50 case failure ifn-\\u03b1-based therapy eliminate hcv result multiple factor include suboptimal treatment regiman severity hcv-related disease host factor viral factor recent year advance hcv cell culture contribute understanding viral life cycle lead development number direct-acting antiviral agent daa target specific key component viral replication hcv ns3/4a hcv ns5a hcv ns5b protein date new drug approve treatment hcv infection application daa ifn-based ifn-free regimen increase svr rate 90 allow treatment duration shorten 12 24 week impact hcv protein response ifn-based ifn-free therapy describe report review summarize update knowledge molecular mechanism hcv protein involve anti-ifn activity examine amino acid variation mutation region hcv protein associate response ifn-based therapy pattern resistance associate amino acid variant rav antiviral agent\",\"year advance treatment chronic hepatitis c virus hcv infection development direct-acting antiviral paritaprevir/ritonavir/ombitasvir dasabuvir prod novel combination nonstructural ns 3/4a protein inhibitor boost ritonavir ns5a protein inhibitor ns5b nonnucleoside polymerase inhibitor review aim discuss pharmacology efficacy safety drug interaction viral drug resistance prod treatment hcv 1 infection phase ii iii human animal study describe pharmacology pharmacokinetic efficacy safety prod hcv identify include study evaluate patient cirrhosis n=2,249 cirrhosis n=422 demonstrate prod 12 24 week effective achieve sustained virologic response rate 90 patient 1a 1b hcv infection indicate treatment hcv 1 infection prod recommend treatment hcv patient coinfecte hiv additionally promise datum exist use prod liver-transplant recipient common adverse drug event associate prod include nausea pruritus insomnia diarrhea asthenia dry skin vomiting anemia high efficacy rate couple favorable effect profile prod ribavirin lead addition recommend treatment regiman hcv 1 infection\",\"chronic hepatitis c systemic disease induce metabolic alteration lead extrahepatic consequence particular hepatitis c virus hcv infection increase risk incident type 2 diabete mellitus predisposed individual independently liver disease stage mechanism hepatitis c induce t2dm involve direct viral effect insulin resistance pro-inflammatory cytokine immune-mediated process study report clinical consequence type 2 diabete mellitus hepatitis c outcome study address issue microangiopathic complication patient hepatitis c develop type 2 diabetes mellitus clinical trial hcv-positive patient report improvement glucose metabolism antiviral treatment recent study suggest metabolic amelioration clinical impact type 2 diabete mellitus-related complication observation raise question hcv eradication impact future morbidity mortality type 2 diabete mellitus scope review summarise current evidence link successful antiviral treatment prevention type 2 diabetes mellitus complication hepatitis c-infected patient\",\"hepatitis c virus hcv infection major health concern worldwide interferon-\\u03b1 ifn-\\u03b1 therapy main antiviral treatment 20 year established antitumor effect ifn-based treatment chronic hcv infection clinical impact particularly patient high risk condition develop hepatocellular carcinoma old age advanced liver fibrosis result exhaustive research viral factor include ns5a amino acid mutation ifn sensitivity-determining region ifn/ribavirin resistance-determining region mutation amino acid core protein region core 70 91 associate response ifn-\\u03b1 treatment addition host factor related response ifn-\\u03b1 treatment polymorphism interleukin-28b gene identify important factor article review factor associate efficacy ifn-\\u03b1 treatment chronic hcv infection addition recent finding regard possible involvement anti-ifn-\\u03b1 neutralizing antibody non-response pegylated-ifn-\\u03b1 treatment describe\",\"sofosbuvir sof exhibit high barrier resistance s282 t ns5b substitution phenotypic resistance detect phase 3 registration study\",\"approximately 3 world population chronically infect hepatitis c virus hcv southeast asian country prevalence hcv \\u223c6%-7 far exceed united states 1.8 lesser known hcv 6 hcv-6 common patient southeast asia surround region datum direct-acting antiviral daa date derive clinical trial conduct western country hcv-6 rare standard care patient hcv-6 pegylated interferon ribavirin datum emerge daa combination\",\"combination ombitasvir ns5a inhibitor paritaprevir ns3/4a inhibitor coadministere ritonavir r dasabuvir ns5b nonnucleoside polymerase inhibitor refer 3d regiman combination ombitasvir-paritaprevir-r refer 2d regiman demonstrate high efficacy ribavirin hepatitis c virus (hcv)-infected subject regimen potential coadministration sofosbuvir nucleoside ns5b inhibitor treatment hcv phase 1 drug-drug interaction open-label multiple-dose study enrol 32 healthy subject receive 3d 2d regiman combination sofosbuvir dose study drug follow ombitasvir-paritaprevir-r 25/150/100 mg daily qd dasabuvir 250 mg twice daily bid sofosbuvir 400 mg qd blood sample collect study day 7 14 21 evaluate drug interaction steady state effect 3d 2d regimen pharmacokinetic sofosbuvir circulate metabolite gs-331007 vice versa assess repeated-measures analysis exposure 3d 2d regimen similar \\u226420 change coadministration sofosbuvir administration sofosbuvir exposure 61 112 high 3d regiman 64 93 high 2d regiman sofosbuvir gs-331007 total exposure 27 32 high 3d 2d regimen respectively sofosbuvir increase sofosbuvir gs-331007 exposure likely result breast cancer resistance protein bcrp and/or p glycoprotein p-gp transporter inhibition paritaprevir ritonavir subject discontinue study study drug-related adverse event dose adjustment recommend 3d 2d sofosbuvir clinical trial explore safety efficacy combination study register clinicaltrials.gov registration no. nct02356562 nct02292719\",\"sofsobuvir first-in-class ns5b nucleotide inhibitor launch treatment hepatitis c virus hcv viral potency pan genotypic activity high barrier resistance ideal candidate backbone ifn-free regimen ledipasvir ns5a inhibitor multi genotypic activity modest barrier resistance once-daily fixed-dose combination sofosbuvir plus ledipasvir first-in-market single-tablet regiman treatment hepatitis c infection recent datum demonstrate fdc combination ribavirin able achieve hcv cure 90 1,4 5 6 patient combination appear suboptimal 3 patient direct act antiviral combination sofosbuvir help fulfill gap near future safety profile fix dose combination good resistance issue sofosbuvir significant issue regard ledipasvir rare individual harbor baseline hcv ns5a resistance-associated variant confer high resistance level rational use fdc available clinical datum review\",\"current combination therapy peg-inf ribavirin hepatitis c virus hcv genotype-1 infection ineffective maintain sustained viral response 50 infection case new compound form protease inhibitor complement combination therapy asunaprevir new drug regiment ns3 4a protease inhibitor susceptible mutation r155 k d168a protein study seek evaluate andrographolide labdane-diterpenoid andrographis paniculata plant effective compound inhibit ns3 4a protease concomitant drug-resistant mutant use molecular docking dynamic simulation study andrographolide good docking score -15.0862 -15.2322 -13.9072 compare asunaprevir -3.7159 -2.6431 -5.4149 wild-type r155 k d168a mutant respectively md simulation compound good bind target protein maintain strong bond cause negligible perturbation protein backbone structure result validate susceptibility asunaprevir protein variant docking study trajectory period analysis study hope add option drug regiment tackle drug resistance hcv infection\",\"phase 2 trial treatment combination nucleotide polymerase inhibitor sofosbuvir ns5a inhibitor velpatasvir result high rate sustained virologic response patient chronically infect hepatitis c virus hcv 2 3\",\"population infect hepatitis c virus hcv age number patient decompensated cirrhosis expect increase\",\"hepatitis c virus hcv affect nearly 1.3 population 2 people worldwide associate complication cirrhosis hepatocellular carcinoma lead significant morbidity mortality treatment option disease interferon base therapy poor tolerance good svr sustained virological response 50 case introduction direct act antiviral agent treatment hcv revolutionize significantly high rate cure novel direct acting antiviral non-nucleoside inhibitor ns5b highly effective treatment hcv 1 1b include compensate cirrhosis achieve high cure rate svr 97 pooled analysis different phase 3 trial review discuss daa dasabuvir non nucleoside ns5b inhibitor mechanism action efficacy safety tolerance drug resistance dasabuvir approve fda combination daa agent 3d(viekira pak interferon free regimen achieve high cure rate svr 95 low adverse effect europe approve european medicine agency use combination ombitasvir paritaprevir ritonavir ribavirin drug use treatment naive previously treat patient high success rate approve patient compensate cirrhosis patient hiv co-infection liver transplant recipient past exclude treatment interferon based therapy dasabuvir extensively evaluate large clinical trial excellent svr hcv genotype1 patient population combination oral daa good safety profile tolerance drawback restriction need ribavirin rbv 1a low resistance barrier high cost tolerate 1 patient permanently discontinue treatment 2 patient experience adverse reaction contraindicate patient known hypersensitivity ritonavir e.g. steven johnson syndrome strong inducer cyp3a cyp2cb\",\"sofosbuvir pan-genotypic direct act antiviral agent approve article provide overview pharmacology sofosbuvir ribavirin comprehensive summary phase 2 3 study support dual sofosbuvir ribavirin therapy chronic hepatitis c infection production generic formulation sofosbuvir anticipate regiman lead wave widespread ifn-free treatment line include 1 world-in particular develop middle income country discuss continued challenge regimen include patient decompensated liver disease post-liver transplant renal failure address concern emerge resistance discuss future prospect include global uptake sofosbuvir ribavirin treatment\",\"combination hepatitis b immune globulin entecavir tenofovir certain period time reasonable prophylaxis recurrent hepatitis b liver transplantation entecavir represent attractive option treatment na\\u00efve kidney transplant recipient high efficacy low rate resistance antiviral treatment individualize view kidney function previous resistance date new captivate therapeutic strategy interferon-free regimen viable treatment hepatitis c virus positive liver transplant recipient recent combination sofosbuvir simeprevir daclatasvir ledipasvir plus/minus ribavirin boost treatment sustained virological response rate approach 100 liver transplant recipient recurrent chronic hepatitis c chc preliminary datum second generation direct oral antiviral result high treatment rate recurrent chc kidney transplant recipient ongoing study clarify optimal treatment recurrent chc kidney transplant recipient\",\"development approval new direct-acting antiviral daa hepatitis c virus hcv new era hepatitis c therapy begin treatment option likely available 1 2 year\",\"effective pangenotypic treatment hepatitis c virus hcv infection need\",\"direct-acting antiviral agent daa combine pegylated-interferon pegifn ribavirin rbv standard treatment patient 1hcv infection virologic response impair baseline early selection resistant hcv strain\",\"patient chronic hepatitis c virus hcv infection cirrhosis high risk liver-related complication historically difficult cure patient cirrhosis evaluate safety efficacy ombitasvir/paritaprevir/ritonavir dasabuvir ribavirin 12week patient hcv 1b infection compensate cirrhosis\",\"evaluate combination daclatasvir pan-genotypic ns5a inhibitor simeprevir ns3/4a protease inhibitor ribavirin hepatitis c virus 1-infected patient\",\"standard care chronic hepatitis c japan currently pegylated interferon (ifn)-\\u03b1 ribavirin (pr)-based regiman notably associate efficacy tolerability issue advent novel direct-acting antiviral daa provide efficacious tolerate treatment study investigate cost-effectiveness daclatasvir asunaprevir dcv asv daa regimen patient infect hepatitis c virus hcv 1b previously respond ineligible ifn-containing regimen\",\"unmet need interferon- ribavirin-free treatment chronic hcv infection patient comorbiditie include cardiovascular disease cvd aim study evaluate rate sustained virological response svr adverse event cohort patient nosocomially acquire hcv genotype-1b follow 12 week therapy fixed-dose combination fdc ledipasvir/sofosbuvir ldv/sof\",\"hepatitis c virus hcv pandemic human pathogen pose substantial health economic burden develop develop country control spread hcv behavioural prevention strategy meet limited success vaccine development remain slow development antiviral therapeutic agent challenging primarily lack efficient cell culture animal model hcv large genetic diversity hcv strain hand use interferon-\\u03b1-base treatment combination guanosine analogue ribavirin achieve limited success widespread use therapy hamper prevalent effect decade hcv rna-dependent rna polymerase rdrp target antiviral development direct-acting antiviral daa identify bind rdrp inhibitor-binding site mainstay highly effective tolerated antiviral treatment hcv infection review different class rdrp inhibitor mode action hcv furthermore mechanism antiviral resistance class describe include naturally occur resistance-associated variant rav different viral strain finally review impact rav treatment outcome newly develop regimen\",\"hepatitis c virus hcv infection lead cause end-stage liver disease main indication liver transplantation lt country patient undergo lt detectable serum hcv rna experience graft reinfection progress cirrhosis year 20 30 obtain sustained virological response svr greatly improve overall graft survival 2011 standard antiviral therapy use pegylated interferon peg-ifn ribavirin rbv effective therapy svr rate 30 setting patient infect 1 generation ns3/4a protease inhibitor pi boceprevir boc telaprevir tvr associate peg-ifn rbv 48 week increase svr rate 60 non-transplant patient tolerability drug-drug interaction calcineurin inhibitor cni limit factor use liver transplant setting recent year efficacy antiviral c therapy improve dramatically use new direct-acting antiviral daa agent peg-ifn and/or rbv lead svr rate 90 non-transplant patient result available transplant patient efficacy tolerability drug-drug interaction wave pi infrequent case viral resistance report use pi ns5a inhibitor pre- post-lt lead difficulty management patient\",\"despite available treatment hepatitis c remain burden public health current therapy base pegylated interferon-alpha ribavirin significant effect effectiveness vary different virus novel drug viral protease inhibitor telaprevir boceprevir simeprevir polymerase inhibitor sofosbuvir introduce year use combination standard-of-care treatment time interferon free therapy approve use combination sofosbuvir+ribavirin new therapy improve virological response rate increase cost effect raise issue drug resistance numerous novel anti-hcv compound evaluate advanced clinical trial include inhibitor viral protein protease polymerase ns5a inhibitor host factor involve hcv replication cyclophilin microrna mir-122 new interferon-free therapy reduce severe effect expect enter market month time effort undertake determine host viral factor predictive value hcv treatment response enable personalized therapy approach main success field discovery interleukin il28b polymorphism correlate positive standard-of-care treatment response effective vaccination alternative antiviral drug anti-hcv vaccine available currently prove successful vaccination induce antibody t-cell response specific range hcv aim new subunit genetic candidate vaccine evaluate ii phase clinical trial review summarize recent development field new drug development vaccine study hepatitis c virus\",\"influenza major cause severe respiratory infection lead excessive hospitalization death globally annual epidemic pandemic sporadic/endemic avian virus infection occur result rapid continuous evolution influenza virus emergence antiviral resistance great clinical public health concern currently available antiviral treatment include neuraminidase inhibitor oseltamivir zanamivir peramivir laninamivir m2-inibitor amantadine rimantadine polymerase inhibitor favipiravir review focus resistance issue relate use neuraminidase inhibitor nai datum primary resistance secondary resistance related nai exposure present clinical implication detection novel therapeutic option undergo clinical trial discuss\",\"phase 2 c-salvage study hepatitis c-salvage study patient fail daa/pr therapy demonstrate 96.2 sustain virologic response 12 week svr12 rate use ns3/4a protease inhibitor grazoprevir ns5a inhibitor elbasvir ribavirin treatment-experienced patient chronic hepatitis c virus hcv 1 infection\",\"investigate susceptibility 10 enterovirus d68 ev-d68 isolate belong cluster b c (entero)virus inhibitor different mechanism action 3c-protease inhibitor prove efficient enviroxime pleconaril turn effective vapendavir pirodavir favipiravir prove weak inhibitor resistance pleconaril map v69a vp1 protein resistance rupintrivir map v104i 3c protease structural explanation substitution cause resistance provide\",\"presence resistance-associated variant rav hepatitis c virus hcv attenuate efficacy direct act antiviral daa objective study characterize susceptibility ravs interferon-based therapy\",\"grazoprevir mk-5172 merck co. inc. selective inhibitor hepatitis c virus hcv ns3/4a protease aim study evaluate safety efficacy grazoprevir dose 25 100 mg/day combination peginterferon ribavirin peg-ifn/rbv randomized dose-ranging multicentre trial treatment-naive adult chronic hcv 1 infection receive once-daily grazoprevir 25 mg 50 mg 100 mg plus peg-ifn/rbv 12 week patient quantifiable hcv rna \\u226525 iu/ml week 4 receive additional 12 week peg-ifn/rbv primary endpoint sustained virologic response hcv rna 25 iu/ml 12 week complete therapy svr12 eighty-seven patient randomly assign receive \\u22651 dose therapy median time undetectable hcv rna 16 day 100-mg arm 22 day 25- 50-mg arm patient hcv rna undetectable unquantifiable week 4 receive 12 week therapy svr12 achieve 13 24 54.2 21 25 84.0 23 26 88.5 patient 25- 50- 100-mg arm respectively per-protocol analysis patient discontinue result nonserious adverse event ae patient experience ae transaminase elevation occur patient 25- 100-mg arm\",\"addition direct-acting antiviral agent ns3 protease inhibitor boceprevir telaprevir peg interferon ribavirin major advance treatment 1 hepatitis c individual sustained virological response svr rate 63 75 achieve svr high rate resistance-associated variant ns3 protease domain retreatment option fail first-generation protease inhibitor generally guide retreatment direct-acting antiviral agent class phase 2 phase 3 datum demonstrate retreatment 12 24 week ns5b inhibitor sofosbuvir combination ns5a inhibitor daclatasvir ledipasvir ribavirin achieve svr high rate comparable treatment-naive individual\",\"evaluate virological response telaprevir boceprevir combination pegylated interferon ribavirin resistance mutation ns3/4a inhibitor hepatitis c virus-human immunodeficiency virus hcv-hiv coinfecte patient real life set\",\"chronic hepatitis c virus hcv infection associate extrahepatic manifestation patient hcv develop mixed cryoglobulinemia sequelae range cutaneous visceral vasculitis glomerulonephritis b-cell non-hodgkin lymphoma hcv-infected patient increase rate insulin resistance diabete atherosclerosis lead increase cardiovascular morbidity mortality neurological manifestation hcv infection include fatigue cognitive impairment mechanism cause extrahepatic effect hcv infection likely multifactorial include endocrine effect hcv replication extrahepatic cell heightened immune reaction systemic effect successful eradication hcv interferon alfa ribavirin improve extrahepatic effect sustain virological response associate resolution complication cryoglobulinemia reduce level insulin resistance reduce incidence diabete stroke improve fatigue cognitive functioning availability new interferon-free well-tolerated anti-hcv treatment regimen broaden spectrum patient available therapy include interferon contraindicate likely result great improvement extrahepatic manifestation hcv regimen confer significant benefit metabolic cardiovascular neuropsychiatric condition associate hcv infection extrahepatic manifestation hcv major indication treatment absence liver disease\",\"date majority work rna virus replication fidelity focus viral rna polymerase potential role viral replicase protein process poorly understand previous study use resistance broad-spectrum rna mutagen ribavirin identify polymerase increase fidelity avoid misincorporation base analogue identify novel variant alphavirus viral helicase/protease nonstructural protein 2 nsp2 operate concert viral polymerase nsp4 far alter replication complex fidelity functional linkage conserve alphavirus genus purify virus nsp2 present delay helicase activity high-fidelity enzyme purify replication complex manifest strong rna polymerization kinetic mutagenic nucleoside analog ribavirin affect intracellular nucleotide pool address link nucleotide depletion replication fidelity use purine pyrimidine biosynthesis inhibitor high-fidelity virus resistant condition viral growth rescue addition exogenous nucleoside suggest mutagenesis base analogue require nucleotide pool depletion study describe novel function nsp2 highlight role component replication complex regulate viral replication fidelity suggest virus alter replication complex fidelity overcome intracellular nucleotide-depleting condition\",\"patient chronic hepatitis c virus hcv infection great risk develop insulin resistance ir little know insulin sensitivity improve treatment hepatitis c. study examine effect combination therapy pegylated interferon-\\u03b1 ribavirin ir patient chronic hcv infection analyze factor associate change insulin sensitivity ir estimate homeostasis model assessment homa-ir homa-ir measure therapy therapy 12 24 week end therapy eot 24 48 week analyze 78 hcv patient receive combination therapy twenty-two patient 28.2 exhibit pretreatment ir homa-ir 2.5 patient homa-ir significantly different baseline value 12 week p 0.823 24 week p 0.417 eot p 0.158 patient pretreatment ir significant decrease homa-ir observe 12 week p 0.023 24 week p 0.008 eot p 0.002 multivariate analysis use logistic regression model baseline homa-ir factor associate decline homa-ir therapy eradication hcv infection associate improve insulin sensitivity patient pretreatment ir significant improvement insulin sensitivity occur early 12 week initiation antiviral therapy\",\"myxovirus influenza virus iav respiratory virus rsv major human pathogen mandate development novel therapeutic establish high-throughput screening protocol simultaneous identification pathogen- host-targeted hit candidate pathogen attempt co-infection cell iav rsv viral replication kinetic incompatible rsv signal window low iav-driven minireplicon reporter assay use initial screen narrow host cell range restrict assay single-cycle infection overcome limitation develop rsv strain carry firefly luciferase fuse innovative universal small-molecule assist shut-off domain boost assay signal window hyperactive fusion protein synchronize iav rsv reporter expression kinetic suppress identification rsv entry inhibitor sensitive recently report rsv pan-resistance mechanism combined replication-competent recombinant iav strain harboring nanoluciferase assay perform human respiratory cell line support multicycle infection miniaturize 384-well format protocol validate screening set national institutes health clinical collection ncc quadruplicate test screen demonstrate favorable assay parameter reproducibility application lopac library bioactive compound proof-of-concept campaign detect licensed antimyxovirus therapeutic ribavirin neuraminidase inhibitor zanamivir identify unexpected rsv-specific hit candidate fenretinide opioid receptor antagonist bntx-7 hit evaluate direct orthogonal dose-response counterscreen use standard recrsv reporter strain express renilla luciferase\",\"treatment hepatitis c virus hcv infection progress remarkable speed poorly tolerate injectable therapy low cure rate treatment highly effective well-tolerated oral direct-acting antiviral therapy cure rate 90 patient population direct-acte antiviral develop improve understanding viral lifecycle recognition target inhibit small molecule date protease inhibitor non-structural 5a inhibitor nucleotide non-nucleotide polymerase inhibitor develop agent use initially peginterferon ribavirin subsequently combination need interferon rational combination overcome major challenge rapid emergence drug resistance second-generation agent class improve safety efficacy profile drug-drug interaction adverse effect progress direct-acting antiviral development outline review class agent discussion challenge future\",\"failure respond approve combination multiple direct-acting antiviral agent relatively low hepatitis c virus treatment registration study rate 1 7 depend patient baseline characteristic real life failure slightly high likely low compliance treatment failure usually related relapse on-treatment viral breakthrough hepatitis c drug-resistant variant detect patient achieve viral eradication risk develop variant depend host- virus-related factor property drug use treatment strategy apply patient carry resistance-associated variant obtain benefit treatment risk disease progression transmission variant hepatitis c resistance-associated variant persist depend type ns3 4a variant disappear gradually therapy stop ns5a variant tend persist 2 year good way prevent emergence resistant variant eliminate virus treatment use highly potent antiviral genetic barrier resistance patient fail first-generation protease inhibitor combination therapy sofosbuvir ns5 inhibitor prove effective salvage regimen shorten 12 week addition ribavirin optimal treatment patient fail ns5a inhibitor multidrug-resistant variant remain define research effort continue focus treatment patient\",\"viral dynamic modelling prove useful design clinical study predict treatment outcome patient infect hepatitis c virus generally model aim capture predict on-treatment viral load dynamic small study individual patient explore extend model 1 clinical study numerous patient 2 incorporate additional datum type include sequence datum prior response interferon datum phase 3 clinical study direct-acting antiviral telaprevir t total daily dose 2250 mg combine pegylated-interferon alfa ribavirin pr use analysis follow datum treatment-na\\u00efve population reserve verify model 1 t/pr regimen t dose 8 h 8 week t8(q8h)/pr 2 t/pr regimen t dose twice daily 12 week t12(b.i.d.)/pr result model accurately predict 1 sustain virologic response rate dose regimen 2 viral breakthrough characteristic t8(q8h)/pr regiman observe viral variant depend t exposure second verification suggest model correctly sensitive different t regimen model develop use datum t regimen furthermore model predict b.i.d t dosing comparable q8h t dosing pr-experienced population comparison control clinical study method develop work estimate variability occur limit detection viral load critical accurate prediction\",\"hepatitis c virus hcv 4 gt4 genetically diverse 17 confirm comprise approximately 13 infection worldwide study identify gt4 phylogenetic analysis assess difference patient demographic gt4 examine baseline sequence variability potential impact treatment outcome analyze development viral resistance patient receive regimen ombitasvir nonstructural protein 5a ns5a inhibitor plus ritonavir-boosted paritaprevir ns3/4a inhibitor ribavirin rbv treatment hcv gt4 infection phylogenetic analysis hcv ns3/4a ns5a ns5b nucleotide sequence identify 7 4a 4b 4c 4d 4f 4g/4k 4o 132 patient sample prevalence vary country distribution patient birth cohort race significantly different gt4 4a 4d non-4a/4d baseline amino acid variability detect ns5a gt4 impact treatment outcome patient experience virologic failure infect 4d predominant resistance-associated variant time failure d168v ns3 l28v ns5a overall high response rate observe patient infect 7 hcv gt4 impact baseline variant treatment outcome gt4 distribution study differ base patient demographic geography\",\"hepatitis c virus hcv infection common liver disease worldwide high rate chronicity 75 80 infected individual chronic form hcv lead steatosis cirrhosis hepatocellualr carcinoma steatosis prevalent hcv patient 55 combination viral factor effect viral protein intracellular pathway host factor overweight insulin resistance diabetes mellitus alcohol consumption response rate treatment chronic hcv pegylated interferon peg-ifn case genotype-1 hcv common infect usa ribavirin rbv low sustained viral response rate \\u2264 40 add direct-acting antiviral agents-recently approve fda-to standard protocol increase response rate hcv-related end-stage liver disease primary indication liver transplantation usa focus article interrelation hcv steatosis metabolic syndrome\",\"influenza major cause substantial morbidity mortality human year vaccination main strategy prevent influenza infection antiviral agent play important role control seasonal pandemic influenza influenza a/h1n1 pandemic 2009 early prompt antiviral therapy reduce severity influenza outcome include pneumonia hospitalization mortality republic korea 2009 h1n1 pandemic increase usage antiviral agent treatment patient seasonal influenza currently rare antiviral resistance influenza virus emerge increase increase use neuraminidase inhibitor new agent different mode action investigation include favipiravir das181 nitazoxanide broad-spectrum neutralize monoclonal antibody datum limit respect high-dose combination antiviral therapy clinical trial warrant evaluate diverse antiviral combination synergistic likely induce breakthrough resistance\",\"era direct-acting antiviral agent daa hepatitis c virus hcv genotyping test baseline controversial hcv ns3-q80 k polymorphism associate resistance recently approve ns3 inhibitor simeprevir smv combine peg-interferon ribavirin peg-ifn/rbv alternative therapy consider patient baseline q80 k aim study provide estimate q80 k prevalence baseline study group 205 daa-na\\u00efve patient 21 hiv coinfection use ns3 full-population direct sequencing detect resistance-associated amino acid variant rav ns3 ravs identify 56 patient 27.3 q80 k frequently report 41 hiv/hcv-coinfected hcv-monoinfected patient detectable case hcv-subtype 1a infection clinical practice ns3-q80 k genotyping test prior simeprevir plus peg-ifn/rbv treatment highly recommend\",\"thrombocytopaenia hypoalbuminaemia surrogate marker portal hypertension hepatic synthetic dysfunction respectively patient infect hepatitis c virus hcv surrogate reduce likelihood sustained virologic response increase risk hepatic decompensation death treat peginterferon/ribavirin plus telaprevir boceprevir\",\"article examine dynamic factor underlie hepatitis c virus hcv resistance impact daily clinical management hcv-infected patient\",\"dual oral therapy daclatasvir plus asunaprevir yield svr rate 85 patient 1b hcv treatment failure mainly occur patient pre-existing hcv ns5a-y93h mutation significance mutation evaluate\",\"alisporivir alv oral host-targeting agent pangenotypic anti-hepatitis c virus hcv activity high barrier resistance\",\"examine efficacy safety treatment boceprevir pegylated-interferon ribavirin pr hepatitis c virus 1 hcvgt1 pr treatment-failure asia\",\"analysis datum pool multiple phase 2 silen-c1 3 phase 3 study startverso1 4 hepatitis c virus hcv nonstructural protein 3/4a ns3/4a protease inhibitor faldaprevir plus pegylated interferon alpha/ribavirin pr provide comprehensive evaluation baseline treatment-emergent ns3/4a amino acid variant hcv genotype-1 (gt-1)-infected patient pooled analysis gt-1a gt-1b ns3 population-based pretreatment sequence n 3,124 faldaprevir resistance-associated variant rav ns3 r155 d168 rare 1 single noncanonical ns3 protease ns4a cofactor baseline polymorphism associate reduce sustained virologic response svr faldaprevir plus pr include q80 k gt-1b ns3 helicase polymorphism t344i associate reduce svr faldaprevir plus pr p 0.0001 faldaprevir specific reduce svr observe placebo plus pr patient achieve svr available ns3 population sequence n 507 gt-1a n 349 gt-1b 94 gt-1a 83 gt-1b encode faldaprevir treatment-emergent rav predominant gt-1a rav r155 k 88 gt-1b encode d168 substitution 78 d168v predominant 67 novel gt-1b ns3 s61l substitution emerge 7 virologic failure covariant d168v faldaprevir breakthrough s61l combination d168v minimal impact faldaprevir susceptibility compare d168v 1.5-fold difference vitro median time loss d168 ravs gt-1b-infected patient sustained virologic response 12 week posttreatment non-svr12 virologic failure 5 month short 14 month r155 ravs gt-1a-infected non-svr12 patient suggest d168v fit r155 k absence faldaprevir selective pressure\",\"hepatitis e virus hev yearly responsible approximately 20 million infection worldwide infection occur develop country hev appear emerge problem industrialized country associate travel hev endemic area contact pig represent major reservoir hev major risk group hev infection ensue complication elderly man pregnant woman young child immunocompromised patient patient preexist liver disease worker come close contact hev-infected animal hev mainly cause acute self-limiting infection chronic infection occur immunocompromised patient e.g. transplant recipient human immunodeficiency virus [hiv]-infected patient accordingly hev-hiv coinfection lead accelerate liver cirrhosis increase mortality rate compare hev infection pregnancy usually associate low mortality western world common gt cause hev infection gt 3 ribavirin rbv interferon use successfully treatment hev treatment contraindicate certain patient group novel antiviral compound highly need especially viral isolate rbv resistance recently identify eradication hev hamper long-term environmental persistence virus represent continuous source virus 2011 prophylactic hev vaccine hecolin approve china globally available review discuss molecular virology hev mode transmission industrialized country potential implication different specific patient population\",\"interferon-free treatment option rapidly evolving patient chronic hepatitis c virus hcv 1b gt1b infection cirrhosis nonresponder prior pegylated interferon ribavirin therapy perform phase 2b open-label trial combination ombitasvir ns5a replication complex inhibitor paritaprevir ritonavir ns3/4a protease inhibitor)-an interferon- ribavirin-free regimen-in difficult-to-treat patient include prior null responder patient cirrhosis\",\"objective systematic review summarize evidence regard hepatitis c hepatitis c virus/human immunodeficiency virus (hcv/hiv)-co-infecte child focus mother-to-child transmission clinical laboratory feature outcome therapy\",\"person hepatitis c virus hcv 1a gt1a infection harbor baseline q80 k polymorphism nonstructural protein 3 ns3 reduce virologic response simeprevir combination pegylated interferon-alfa ribavirin aim develop validate freely disseminate ns3 clinical sequencing assay detect q80 k polymorphism potentially hcv ns3 drug resistance mutation hcv rna extract frozen plasma use nuclisens easymag automate nucleic acid extractor amplify nested reverse transcription-pcr sequence use sanger and/or next-generation miseq method sanger chromatogram analyze use in-house software recall nucleotide mixture automatically miseq read iteratively map h77 reference genome consensus ns3 sequence generate nucleotide present 20 mixture accuracy precision sensitivity detect q80 k polymorphism assess 70 sample previously sequence external laboratory comparison sequence generate sanger miseq method determine external lab reveal 98.5 nucleotide sequence concordance zero discordant q80 k polymorphism result highly repeatable reproducible 99.7 nucleotide concordance 100 q80 k concordance limit detection 2 \\u223c5 log10 iu/ml sanger miseq assay respectively sufficiently low allow genotyping chronically infected treatment-naive person systematic bias under- overamplification minority variant observe coinfection virus e.g. hiv hepatitis b virus hbv affect assay result independent hcv ns3 sequencing assay automate analysis procedure describe useful tool screen q80 k polymorphism hcv protease inhibitor drug resistance mutation\",\"alisporivir cyclophilin inhibitor pan-genotypic anti-hepatitis c virus hcv activity high barrier viral resistance vital-1 study assess alisporivir interferon (ifn)-free therapy treatment-na\\u00efve patient infect hcv 2 3 patient cirrhosis randomize arm 1 alisporivir alv 1,000 mg once-daily qd arm 2 alv 600 mg qd ribavirin rbv arm 3 alv 800 mg qd rbv arm 4 alv 600 mg qd pegylated ifn peg-ifn arm 5 peg-ifn rbv patient receive ifn-free alv regimen achieve rapid virological response rvr continue treatment detectable hcv rna week 4 receive alv rbv peg-ifn week 6 24 overall 300 patient receive alv-based regimen arm 1 arm 4 intent-to-treat rate sustained virological response svr 24 week treatment svr24 80 85 compare 58 n 23 40 peg-ifn/rbv per-protocol analysis high svr24 rate patient receive alv/rbv ifn-free rvr 92 n 56 61 alv rvr 72 n 13 18 peg-ifn/rbv 70 n 23 33 rvr svr alv ifn-free regimen numerically high 3- 2-infected patient viral breakthrough infrequent 3 n 7 258 ifn-free alv treatment markedly safety/tolerability ifn-containing regimen\",\"strong impact interleukin 28b il28b polymorphism sustained virological response svr peginterferon ribavirin treatment patient chronic hepatitis c chc well-known investigate il28b variability hepatic expression ip10 ifi27 isg15 mx1 chc patient relation clinical characteristic associate response combined therapy genotyping gene expression analysis conduct select cohort treatment-na\\u00efve patient undergo interferon ribavirin treatment differential expression ip10 ifi27 isg15 mx1 gene assess pretreatment liver biopsy use quantitative pcr histopathological evaluation liver specimen perform basis scheuer modified scale hepatic ifi27 isg15 mx1 expression low il28b cc 12979860 tt rs8099917 group ct-tt rs12979860 tg-gg rs8099917 group p 0.001 find difference ip10 expression il28b p 0.05 contrast ip10 expression significantly affect progression fibrosis p 0.007 rs12979860 cc associate successful treatment compare rs12979860 ct-tt p 0.004 additionally expression level ip10 ifi27 isg15 mx1 significantly high non-svr patient svr patient effect variation il28b result ifn-based treatment associate change ifi27 isg15 ip10 silencing ip10 positive independent il28b prediction svr strongly associate liver fibrosis chc patient\",\"virus chikv mosquito-borne alphavirus cause severe persistent arthritis recent year million people infect virus register antiviral lack use recently establish vitro assay discover approve anti-parasitic drug suramin inhibit chikv rna synthesis ic50 \\u223c5\\u03bcm compound inhibit replication chikv isolate cell culture ec50 \\u223c80\\u03bcm cc50>5mm active sindbis virus semliki forest virus vitro study hint suramin interfere (re)initiation rna synthesis time-of-addition study suggest interfere post-attachment early step infection possibly entry chikv nsp4 mutant resistant favipiravir ribavirin target viral rna polymerase exhibit cross-resistance suramin suggest different mode action assessment activity variety suramin-related compound cell culture vitro assay rna synthesis provide insight moiety require antiviral activity antiviral effect suramin-containing liposome analyze approve status worthwhile explore use suramin prevent and/or treat chikv infection\",\"aviator phase 2 clinical trial evaluate ritonavir-boosted paritaprevir protease inhibitor ombitasvir ns5a inhibitor dasabuvir nonnucleoside polymerase inhibitor three-drug 3d regiman ribavirin rbv 8 12 24 week 406 hcv 1 (gt1)-infected patient rate sustained virologic response 24 week treatment range 88 100 arm 3d regimen rbv 20 gt1a-infected patient 1 gt1b-infected patient experience virologic failure 5.2 baseline resistance-conferring variant ns3 rare m28v gt1a y93h gt1b prevalent preexisting variant ns5a c316n gt1b s556 g gt1a gt1b prevalent variant ns5b interestingly gt1a sequence encode m28v ns5a united states gt1b sequence encode c316n s556 g ns5b predominant european union variant preexist baseline significant impact treatment outcome prevalent treatment-emergent resistance-associated variant rav gt1a r155 k d168v ns3 m28 t q30r ns5a s556 g ns5b single gt1b-infected patient experience virologic failure ravs target paritaprevir-ritonavir dose 150/100 mg efficacious suppress r155 k ns3 100/100-mg dose patient fail receive 12 week treatment ravs select 3 target patient relapse 8 week treatment detectable ravs result study guide selection optimal treatment regimen treatment duration paritaprevir dose development 3d regiman study register clinicaltrials.gov registration number nct01464827\",\"2011 treatment chronic hepatitis c virus hcv include direct-acting antiviral daa addition pegylated interferon-\\u03b1 peg-ifn ribavirin rbv ifn-based treatment induce strong cytotoxic t-lymphocyte activity direct protease- polymerase-derived epitope enhance immunological pressure favour emergence viral epitope variant able evade immune surveillance resistance-associated variant ravs implicate co-selecte hitchhike effect study analyse dynamic frequency protease polymerase inhibitor ravs affect future hcv treatment human immunodeficiency virus hiv co-infecte patient stable antiretroviral therapy previous ifn-based treatment failure hcv 1a rna extract plasma sample 18 patient prior 24h 4 12 24 48 week therapy peg-ifn+rbv next-generation sequencing perform hcv-rna population use ns3 ns5b pcr-amplified code region measure genetic diversity use compare virus population average pairwise nucleotide diversity \\u03c0 tajima d statistic protease polymerase ravs detect subject low frequency 5 case presence constant follow-up sample patient region exhibit q80r/k/l a421v highly predominant variant significant difference observe sample time \\u03c0 d value conclusion previous therapy failure peg-ifn+rbv associate increase daa-targeting ns3 ns5b ravs naturally exist hiv co-infected subject\",\"estimate 184 million people worldwide hepatitis c virus hcv infection chronic infection ultimately result liver cirrhosis hepatic failure eradication virus antiviral treatment hinder development aforementioned complication historically combination therapy pegylated interferon/ribavirin consider standard-of-care therapy hcv therapy demonstrate satisfactory cure rate significant effect preclude widespread use hcv patient view situation scientific advance lead development new interferon-free regimen tolerate effective short duration therapy new member family all-oral regimen ombitasvir/paritaprevir/ritonavir co-package dasabuvir recently receive fda approval treatment adult patient 1 hcv infection include compensate cirrhosis new combination find safe tolerate high rate sustained virologic response 100 overview current knowledge regimen review\",\"treatment environment chronic hepatitis c undergo revolution particularly 1 interferon-based therapy associate tolerability challenge inadequate response rate numerous baseline factor affect response therapy new emerge treatment regimen employ all-oral combination direct-acting antiviral agent result clinical trial suggest regimen routinely achieve cure rate 90 patient fail prior interferon-based triple therapy 2015 all-oral fda-approved regiment available 1 sofosbuvir /ledipasvir sofosbuvir/simeprevir paritaprevir/r/ombitasvir/dasabuvir furthermore new treatment combination appear tolerable require short duration therapy provide overview class direct-acting antiviral agent daa clinical factor affect integration combination therapy recent finding trial combination therapy patient 1 hcv infection\",\"number statin cholesterol-lowering drug inhibit vitro replication hepatitis c virus hcv hcv-infected patient addition statin early standard care therapy pegifn-\\u03b1 ribavirin result increase sustained virological response rate mechanism statin inhibit hcv replication elucidate attempt gain insight underlie mechanism hepatoma cell carry hcv replicon passage presence increase concentration fluvastatin fluvastatin-resistant replicon containing cell generate prove \\u223c8-fold susceptible fluvastatin wild-type culture growth efficiency resistant replicon containing cell comparable wild-type replicon cell fluvastatin-resistant phenotype confer mutation viral genome cause cellular change resistant cell line markedly increase hmg-coa reductase expression statin treatment furthermore expression efflux transporter p-gp increase fluvastatin-resistant replicon cell determine qrt-pcr flow cytometry increase expression result increase functional transport activity measure p-gp mediated efflux calcein conclusion demonstrate statin resistance hcv replicon contain hepatoma cell confer change cellular environment\",\"role interleukin il 28b treatment chronic hepatitis c chc recently examine study possible relationship il28b presence mixed cryoglobulinemia mc remain clarify study analyze influence il28b rs8099917/rs12979860 presence mc role treatment peg-ifn retrospectively examine 541 patient affect chc treat pegylated interferon peg-ifn ribavirin 2003 2012 include treatment-na\\u00efve patient viral co-infection major contraindication peg-ifn ribavirin standard care seventy-five patient 32.3 mc 49 33.3 symptomatic mc il28b rs8099917/rs12979860 tt/cc frequent mc-positive patient sustained virological response svr p 0.001 tg/tc frequent non-svr p 0.001 tt/cc find main positive predictive factor mc hcv patient 11.914 iqr 7.092 18.776 p 0.001 hcv 2/3 strongest positive predictive factor svr 10.448 iqr 8.352 21.561 p 0.001 il28b rs8099917/rs12979860 tt/cc predictive factor rs12979860 cc 9.829 vs. 2.663 negative predictive factor metavir score f3-f4 0.625 iqr 0.416 0.779 p 0.008 insulin-resistance 0.315 iqr 0.224 0.585 p 0.001 presence symptom 0.716 iqr 0.492 0.855 p 0.001 il28b rs8099917/rs12979860 useful treatment mc-positive hcv patient peg-ifn ribavirin tt/cc associate svr tg/tc non-svr tt/cc predictive mc hcv patient\",\"fixed-dose tablet comprise ombitasvir ns5a replication complex inhibitor paritaprevir ns3/4a protease inhibitor ritonavir cytochrome p450 inhibitor combination dasabuvir ns5b polymerase inhibitor indicate treatment chronic hepatitis c virus hcv 1 infection country include usa copackage viekira pak \\u2122 eu viekirax \\u00ae exviera \\u00ae phase ii iii trial interferon-free regiman \\u00b1 ribavirin provide high rate sustained virological response 12 week post-treatment adult chronic hcv 1a 1b infection include compensate cirrhosis liver transplant hiv-1 co-infection regimen generally tolerated nausea insomnia asthenia pruritus skin reaction fatigue common tolerability issue ombitasvir/paritaprevir/ritonavir plus dasabuvir effective interferon-free direct-acting antiviral regiman use \\u00b1 ribavirin broad range adult chronically infect hcv 1\",\"chronic hepatitis c virus hcv infection cause liver cirrhosis hepatocellular carcinoma hcc study demonstrate eradication hcv reduce occurrence hcc japan people live advanced age hcv-infected patient old age hcc diagnosis increase old hcv-infected patient risk develop hcc treatment response peginterferon-alpha plus ribavirin therapy relatively poor patient drop-out discontinuation treatment adverse event establish mechanism action interferon-alpha interferon-beta slightly different short-term natural interferon-beta monotherapy effective patient acute hepatitis c patient infect hcv 2 low viral load natural interferon-beta plus ribavirin 48 wk 24 wk effective patient hcv 1 hcv 2 natural interferon-beta plus ribavirin use certain difficult-to-treat hcv-infected patient era direct-acting anti-viral natural interferon-beta plus ribavirin therapeutic option special group hcv-infected patient near future signal transduction pathway interferon-beta inform direction\",\"year study provide understanding hepatitis c virus hcv life cycle include general property viral rna protein effort facilitate development sensitive diagnostic tool effective antiviral treatment present serologic screening test recommend perform individual high risk group nucleic acid test recommend confirm active hcv infection quantization genotyping hcv rna important determine optimal duration anti-viral therapy predict likelihood response early 2000s pegylated interferon plus ribavirin standard anti-hcv treatment therapy ideal 2014 boceprevir telaprevir simeprevir sofosbuvir harvoni approve food drug administration treat hcv infection likely new all-oral interferon-free pan-genotyping anti-hcv therapy available year majority hcv infection cure anti-viral treatment patient expect cure viral resistance high cost antiviral treatment efficient prophylactic vaccine challenge fight hcv infection\",\"anno 2015 race develop ideal therapy cure hepatitis c virus infection continue unabatedly target ns3/4a protease ns5a protein ns5b polymerase remain number compound direct-acting antiviral daa interact target continue increase pan-genotypic activity remain mandatory requirement problem virus drug resistance crucial need combine daa act different site remain compelling drug use combination emanate pharmaceutical company gilead sofosbuvir ledipasvir gilead sciences foster city usa abbvie north chicago il usa abbvie abt/r ombitasvir dasabuvir bms bristol-myers squibb new york city ny usa asunaprevir daclatasvir lead contender stake definitive cure hcv infection reflect sustained viral response svr 12 week treatment svr expect reduce cirrhosis hepatocellular carcinoma complication inherently link hcv infection unlike hepatitis b virus human immunodeficiency virus hcv infection definitely permanently cure antiviral therapy hcv long-term reservoir body peginterferon combine ribavirin first-wave protease inhibitor telaprevir boceprevir belong milestone important historical role final conquest hepatitis c.\",\"study describe discovery novel dengue virus inhibitor target crucial viral protein-protein interaction essential host cell factor strategy reduce emergence drug resistance start known c-src inhibitor virtual screening perform identify molecule able interact recently discover allosteric pocket dengue virus ns5 polymerase selection cheap-to-produce scaffold exploration biologically relevant chemical space suggest promising candidate chemical synthesis series purine emerge interesting candidate able inhibit virus replication low micromolar concentration significant toxicity host cell identify antiviral compound 16i prove 10 time potent ribavirin selectivity index represent first-in-class denv-ns5 allosteric inhibitor able target virus ns5-ns3 interaction host kinase c-src/fyn\",\"treatment chronic hepatitis c develop significantly 25 year patient 1 infection 40 50 sustain virologic response achieve use pegylated interferon ribavirin dual combination increase significantly introduction direct act antiviral major group direct act antiviral know directly inhibit different phase viral life cycle inhibit function non-structural protein ns3/4a protease ns5a protein ns5b polymerase rapid replication rate hepatitis c virus error-prone ns5b polymerase activity mutant virion generate reduce susceptibility direct act antiviral therapy resistance associate variant exist antiviral therapy able replicate direct act antiviral treatment selection pressure resistant virus replace wild type especially detect monotherapy generation direct act antiviral combine pegylated interferon ribavirin recently interferon-free combination develop include 2 3 direct act antiviral use generation protease inhibitor boceprevir telaprevir rate resistance associate variant high therapeutic outcome bad patient hepatitis c virus 1a 1b similar phenomenon second generation ns3/4a protease inhibitor ns5a ns5b polymerase low genetic barrier resistance ie usually mutation emergence resistance 1a selection resistance associate variant important challenge interferon-free therapy\",\"neuraminidase inhibitor nai available licensed therapeutic human h7n9 influenza virus infection emergence nai-resistant variant h7n9viruse na r292 k mutation pose therapeutic challenge comprehensive understanding susceptibility virus clinically available nai non-nais combination crucial effective treatment study use limited serial passage plaque purification r292 k variant anhui1 lineage isolate patient clinical evidence resistance oseltamivir vitro cell-based assay confirm high level resistance confer r292 k mutation oseltamivir carboxylate moderate level resistance zanamivir peramivir non-nai antiviral t-705 ribavirin nt-300 efficiently inhibit variant wild-type cell-based assay combination nai non-nai exhibit marked synergistic effect r292 k variant combination non-nai t-705 ribavirin exhibit significant synergism mutant virus experimentally infected mouse variant delay onset symptom reduce viral load attenuate lethality compare wild-type study suggest non-nais test clinically h7n9 patient sustained high viral load possible drug combination regimen t-705 plus ribavirin far test animal model pathogenicity transmissibility r292 k h7n9 variant far assess genetically well-characterized pair virus most-desirably competitive fitness experiment\",\"tegobuvir gs-9190 non-nucleoside inhibitor hcv rna replication prove antiviral activity hcv-infected patient vitro antiviral activity tegobuvir combine direct act antiviral daa assess tegobuvir combine interferon \\u03b1-2b ribavirin protease inhibitor pi vx-950 nucleoside polymerase inhibitor ni 2'-c-methylcytidine non-nucleoside polymerase inhibitor overall additive antiviral activity observe add tegobuvir concentration 6 30 150nm replicon-containing cell presence suboptimal concentration pi polymerase inhibitor markedly delay completely prevent resistance development compound tegobuvir 15nm combine pi able cure replicon-containing cell replicon single passage compound 2-fold high concentration triple combination tegobuvir 10nm pi ni result clearance replicon rna passage contrast inhibitor use 3-fold high concentration able cure cell replicon long 6 passage combination contain low concentration tegobuvir highly effective cure cell hcv replicon delaying prevent development resistance daa\",\"antiviral medication use treatment severe influenza infection neuraminidase inhibitor nai effective drug approve far investigate antiviral efficacy peptidomimetic furin inhibitor mi-701 combination oseltamivir carboxylate ribavirin infection highly pathogenic avian influenza virus hpaiv activate host protease furin cell culture infect strain a/thailand/1(kan-1)/2004 h5n1 a/fpv/rostock/1934 h7n1 treat agent double triple combination mi-701 achieve concentration-dependent reduction virus propagation double treatment mi-701 oseltamivir carboxylate triple combination ribavirin synergistic inhibition pronounced delay virus propagation mi-701 resistant mutant observe emergence na mutation h275y confer high oseltamivir resistance significantly delay presence mi-701 datum indicate combination potent furin inhibitor significantly enhance therapeutic efficacy conventional antiviral drug hpaiv infection\",\"series 2-pyridinyl-3-substituted-4(3h)-quinazolinone synthesize anti-influenza virus activity determine use cytopathic effect inhibition assay compound potent ic50 value range 51.6 93.0 \\u03bcm currently market drug ribavirin molecular mechanism new compound investigate use neuraminidase inhibition assay cellular nf-\\u03bab signaling pathway inhibition assay computational docking compound 4e n3 imidazol-1-ylpropyl-substituted derivative 2-pyridinyl-4(3h)-quinazolinone potent anti-influenza virus activity vitro inhibit virus neuraminidase cellular nf-\\u03bab signaling pathway conclusion 2-pyridinyl-4(3h)-quinazolinone new scaffold design potent anti-influenza virus compound offer alternative approach tackle influenza drug resistance\",\"recurrent hepatitis c infection liver transplantation lt associate low rate graft patient survival\",\"availability direct-acting antiviral daa therapy launch new era management chronic hepatitis c. sofosbuvir uridine nucleotide analog inhibit hepatitis c rna-dependent rna polymerase backbone chronic hepatitis c therapy act catalytic site polymerase sofosbuvir highly potent suppress viral replication high genetic barrier resistance sofosbuvir effective hepatitis c mainstay interferon-free combination therapy phase ii iii study 1 patient sofosbuvir combination daa ns3 4a protease inhibitor simeprevir ns5a replication complex inhibitor ledipasvir daclatasvir achieve sustained virologic response rate 90 harvoni \\u00ae combination tablet sofosbuvir ledipasvir dose daily recommend 24 week treatment-experienced 1 patient cirrhosis 12 week therapy sufficient population 2 12 week 16 week treatment-na\\u00efve 3 patient 24 week excellent response rate sofosbuvir ribavirin treatment-experienced cirrhotic 3 patient need addition daa daclatasvir sofosbuvir efficacious special population hiv-hepatitis c virus-coinfected patient liver transplant recipient profound impact group renally eliminate patient advanced kidney disease dialysis await dosing recommendation sofosbuvir-based regimen appear tolerate headache fatigue common effect opportunity cure patient hepatitis c sofosbuvir combination therapy likely change future patient particularly emphasis shift identify patient unaware infected provide affordable access treatment\",\"influenza a(h1n1)pdm09 infection diagnose hematopoietic stem cell transplant recipient conditioning regiman treat oral oseltamivir later combine intravenous zanamivir h275y neuraminidase na mutation detect e119d na mutation identify zanamivir therapy\",\"cirrhosis long recognize important negative predictor treatment response hepatitis c virus hcv therapy mechanism underlie association remain relatively poorly understand treatment progress rapidly introduction highly effective all-oral therapy promise outcome patient advanced cirrhosis new therapy clear patient cirrhosis require special attention efficacy continue somewhat reduce compare non-cirrhotic patient safety important concern review explore reason treatment non-response patient cirrhosis focus cirrhosis impact important area include drug delivery drug uptake metabolism immune response drug toxicity example clinical basic literature fortunately treatment continue progress challenge treat patient cirrhosis problematic\",\"pretherapeutic presence protease inhibitor pi resistance-associated variant rav predictive triple-therapy outcome treatment-naive patient influence outcome patient effective pegylated interferon (pegifn)-ribavirin rbv backbone use hepatitis c virus hcv population sequence analysis retrospectively investigate prevalence baseline nonstructural 3 ns3 ravs multicenter cohort poor ifn-rbv responder i.e. prior null responder patient viral load decrease 1 log iu/ml pegifn-rbv lead-in phase impact presence rav outcome triple therapy study 282 patient prevalance 95 confidence interval baseline ravs range 5.7 3.3 9.0 22.0 17.3 27.3 depend algorithm use mutation confer 3-fold shift 50 inhibitory concentration ic50 telaprevir boceprevir t54s frequently detect mutation 3.9 follow a156 t r155 k 0.7 v36 m v55a 0.35 mutation frequently find patient infect 1a 7.5 23.6 1b 3.3 19.8 p 0.03 sociodemographic viroclinical characteristic significantly associate high prevalence ravs obvious effect baseline ravs viral load observe cohort poor responder ifn-rbv link find sustained virological response triple therapy regardless algorithm use detection mutation base cross-study comparison baseline ravs frequent poor ifn-rbv responder treatment-naive patient difficult-to-treat patient study demonstrate impact treatment outcome argue resistance analysis prior treatment\",\"hcv ns3/4a serine protease inhibitor pi boceprevir boc telaprevir tvr simeprevir smv approve treatment chronic hepatitis c infection combination pegylated interferon ribavirin present study investigate prevalence hcv ns3 drug resistance mutation drm associate hcv genotype-1-infected individual baseline viral breakthrough follow boc tvr treatment\",\"modify live virus mlv vaccine commonly use porcine reproductive respiratory syndrome virus prrsv control safety concern quick reversion mlv virulence replication pig previous study demonstrate mutant virus emerge lethal mutagenesis drive antiviral mutagen virus high genetic stability compare parental strain acquire resistance random mutation strategy explore stabilize prrsv genome current study\",\"series novel isoflavonoid synthesize base structural modification daidzein active ingredient traditional chinese medicine tcm evaluate anti-influenza activity vitro h1n1 tamiflu-resistant h1n1 tr virus mdck cell line 4-oxo-4h-1-benzopyran-8-carbaldehyde 11a-11 g promising demonstrate activity selectivity comparable reference ribarivin nucleoside antiviral agent 3-(4-bromophenyl)-7-hydroxy-4-oxo-4h-1-benzopyran-8-carboxaldehyde 11c display good inhibitory activity ec50 29.0 \\u03bcm selectivity index si>10.3 analysis structure(?)activity relationship sar indicate non-naturally-occurring br-substituted b-ring appropriate cho oh group a-ring critical activity selectivity h1n1 tr influenza virus\",\"daclatasvir dcv approve ns5a inhibitor potent anti-hcv activity broad coverage dcv resistance-associated variant rav describe patient infect gt 1 increase gt4 prevalence european country result immigration boost interest\",\"hepatitis c virus hcv infection affect estimate 185 million people worldwide chronic infection lead liver cirrhosis hepatocellular carcinoma hcv curable unmet need development effective affordable treatment option cell-based high-throughput screen identify chlorcyclizine hcl ccz over-the-counter drug allergy symptom potent inhibitor hcv infection ccz inhibit hcv infection human hepatoma cell primary human hepatocyte mode action ccz mediate inhibit early stage hcv infection probably target viral entry host cell vitro antiviral effect ccz synergistic anti-hcv drug include ribavirin interferon-\\u03b1 telaprevir boceprevir sofosbuvir daclatasvir cyclosporin significant cytotoxicity suggest potential combination therapy hepatitis c. mouse pharmacokinetic model ccz preferential liver distribution chimeric mouse engraft primary human hepatocyte ccz significantly inhibit infection hcv 1b 2a evidence emergence drug resistance 4 6 week treatment respectively established clinical safety profile allergy medication affordability simple chemical structure optimization ccz represent promising candidate drug repurposing development effective accessible agent treatment hcv infection\",\"determine association rapid viral response il28b il28ra il10rb mxa polymorphism chinese han population\",\"retreatment patient achieve sustained virological response svr treatment investigational direct-acting antiviral agent daa extensively study conduct open-label trial assess efficacy safety sofosbuvir sof plus pegylated interferon peg-ifn ribavirin rbv patient 1 hepatitis c virus hcv participate previous study gilead investigational daa combination rbv peg-ifn enrol 80 patient 40 site patient receive sof 400 mg daily plus peg-ifn-\\u03b1 180 \\u03bcg/week weight-based ribavirin 1,000 1,200 mg/day 12 week efficacy endpoint proportion patient svr 12 week discontinuation therapy svr12 80 patient enrol 36 45 receive course early treatment hcv 74 93 resistance-associated variant rav baseline svr12 achieve 63 80 patient 79 treat rate svr12 similar patient subgroup presence ravs baseline appear associate treatment failure seventy-one eighty patient 89 experience adverse event ae event mild moderate severity common ae fatigue headache nausea patient discontinue treatment ae\",\"objective investigate relationship insulin resistance viral load decay nondiabetic noncirrhotic 1 chronic hcv patient peginterferon ribavirin treatment possible influence bmi leptin metabolic confounder method 75 consecutive noncirrhotic nonobese nondiabetic patient 1 chronic hepatitis c treat peginterferon alpha 2a plus ribavirin evaluate homa-ir serum leptin bmi measure patient baseline week 12 48 viral load measure time point 24 week end treatment result homa-ir significantly associate bmi leptin baseline peginterferon plus ribavirin treatment significant reduction homa-ir week 12 48 baseline p 0.033 0.048 resp patient achieve early viral load decay evr trend observe patient achieve evr variation treatment observe regard bmi leptin irrespective evr conclusion early reduction homa-ir bmi leptin antiviral treatment noncirrhotic chronic hepatitis c 1 patient achieve evr suggest viral genesis insulin resistance patient nonmetabolic phenotype\",\"recent advance deep sequencing technology detailed analysis hepatitis c virus hcv quasispecie dynamic change response direct antiviral agent daa possible role quasispecie fully understand study clarify evolution viral quasispecie origin drug-resistant mutation induce interferon (ifn)-based protease inhibitor therapy nonstructural-3 ns3 region 1b hcv 34 chronic hepatitis patient treat telaprevir (tvr)/pegylate interferon (peg-ifn)/ribavirin rbv subject deep sequencing study couple phylogenetic analysis twenty-six patient 76.5 achieve sustained viral response svr 8 patient non-svr 23.5 complexity quasispecie express mutation frequency shannon entropy value significant decrease ifnl3 rs8099917 tt group marginal decrease svr group find soon 12 h introduction treatment decrease non-svr group significant decrease mutation frequency ifnl3 tg/gg group analysis viral quasispecie composition non-svr patient major population greatly change accompany appearance resistance composition unlikely return pretreatment composition end therapy clinically tvr-resistant variant observe 5 non-svr patient 5/8 62.5 suspect acquire resistance mutation phylogenetic analysis conclusion result study important implication treatment response outcome interferon-based protease inhibitor therapy\",\"drug resistance remain major impediment development durable cancer therapy study acute myelogenous leukemia aml patient reveal new form multidrug resistance increase glioma-associated protein gli1 lead elevation udp-glucuronosyl transferase ugt enzyme ugt add glucuronic acid xenobiotic metabolite traditionally loss enzyme think contribute cancer result impaired clearance environmental carcinogen demonstrate overexpression ugt contribute oncogenesis promote drug resistance ugt level aml patient treat ribavirin and/or cytarabine elevated relapse relative diagnosis reverse gli1 inhibition suggest clinically relevant strategy overcome drug resistance far overexpression ugt lead drug resistance cancer certain hsp90 inhibitor vorinostat colorectal chronic lymphoblastic leukemia respectively drug target glucuronidation suggest ugt status relevant treatment choice describe facet ugt biology exploit clinically study demonstrate drug cancer cell metabolize differentially normal counterpart summary describe new form drug resistance relevant variety cancer context\",\"clinical phase ii/iii study nucleotide analogue hcv ns5b inhibitor sofosbuvir sof demonstrate high efficacy hcv-infected patient combination therapy date resistance sof s282 t ns5b rarely detect patient study investigate evolution s282 t viral variant detect hcv 2b-infected patient relapse follow 12 week sof monotherapy deep sequencing ns5b gene perform longitudinal plasma sample baseline day 2 3 sof longitudinal sample post-sof treatment week 48 intrapatient hcv evolution analyse maximum-likelihood phylogenetic analysis deep sequencing analysis reveal low level pre-existence s282 t 0.05 viral sequence 4/7755 read baseline 0.03 6/23 415 read day 2 sof viral relapse detect week 4 post-treatment 99.8 viral population harbour s282 t follow-up analysis determine s282 t level diminish post-treatment reach undetectable level 24 48 week post-sof phylogenetic analysis persistence unique post-treatment mutation post-sof sample suggest growth wild type result reversion s282 t mutant wild type outgrowth baseline wild-type population datum suggest low level pre-existing s282 t baseline patient enriched transiently detect follow sof monotherapy despite relapse drug resistance sof patient successfully retreat sof plus ribavirin 12 week cure hcv infection\",\"great progress understand hcv genome molecular virology understanding culminate development direct-acting antiviral daa agent target hcv viral protein telaprevir tvr boceprevir boc daa introduce treatment 1 hcv 2011 use combination pegylated interferon pegifn ribavirin rbv protease inhibitor improve efficacy patient chronic hcv infection compare traditional dual therapy combination associate adverse event lead early termination therapy late 2013 fda approve second wave daa sofosbuvir sof simeprevir smv use sof smv open door ifn-free combination regimen combination highly efficacious tolerate patient hcv 1 sofosbuvir ledipasvir ldv fixed-dose oral combination fdc therapy paritaprevir/ritonavir ombitasvir dasabuvir \\u00b1 rbv recently approve elevate sustained virologic response svr rate 95 anticipate approval additional ifn-free regimen comparable efficacy tolerability addition pangenotypic coverage drug-drug interaction high barrier resistance review summarize current management chronic hcv infection\",\"hepatitis c virus hcv leading cause chronic hepatitis infect approximately million people year 170 million infected people total major global health problem minority case hcv clear spontaneously infected individual infection progress chronic state associate high risk develop liver cirrhosis hepatocellular cancer liver failure treatment hcv infection evolve year interferon (ifn)-\\u03b1 combination ribavirin use decade standard therapy recently new standard-of-care treatment approve base triple combination hcv protease inhibitor telaprevir boceprevir addition option all-oral ifn-free regimen currently evaluate despite substantial improvement sustained virological response rate intrinsic limitation new direct-acting antiviral include effect risk resistance development high cost urge development alternative additional therapeutic strategy gene therapy represent feasible alternative treatment small rna technology include rna interference rnai technique antisense approach potentially promising way investigate viral host cell factor involve hcv infection replication newly develop gene therapy regimen provide treat hcv chapter comprehensive overview guide current development application rnai microrna-based gene therapy strategy hcv treatment\",\"analyze impact pretreatment variant confer boceprevir-resistance sustained virologic response svr rate achieve boceprevir plus peginterferon-\\u03b1/ribavirin p/r hepatitis c virus (hcv)-genotype-1 infection\",\"daclatasvir daklinza \\u00ae inhibitor hepatitis c virus hcv ns5a protein new oral direct-acting antiviral potent pangenotypic activity article provide narrative review efficacy tolerability daclatasvir combination agent treatment patient chronic hcv infection summarize pharmacological property daclatasvir different mechanism action current direct-acting antiviral provide additive synergistic antiviral activity use combination produce high sustained virological response rate use combination peginterferon-\\u03b1 plus ribavirin patient chronically infect hcv 1 4 provide high response rate use interferon-free all-oral combination sofosbuvir ribavirin daclatasvir moderately high genetic barrier resistance effective short-term treatment 12 week tolerability profile similar placebo conclusion daclatasvir highly effective tolerated oral once-daily direct-acting antiviral use combination therapy adult patient chronically infect hcv\",\"unmet need interferon- ribavirin-free treatment chronic hepatitis c virus hcv infection patient co-infecte human immunodeficiency virus hiv\",\"hiv-1/hcv co-infection significant health problem highly active antiretroviral treatment haart hiv-1 prove fairly successful hand direct act antiviral drug hcv improve cure rate high cost development drug resistance important concern pegylated interferon peg-ifn ribavirin rbv remain essential component hcv treatment identification host factor predict ifn/rbv treatment response necessary effective clinical management hcv infection impaired dendritic cell dc t cell response associate hcv persistence ifn/rbv treatment enhance hcv-specific t cell function likely functional restoration dc underlying cause test hypothesis utilize antibody cocktail consist dc maturation adhesion surface marker perform comprehensive phenotypic characterization myeloid dc mdc plasmacytoid dc pdcs cohort hiv-1/hcv co-infecte individual undergo ifn/rbv treatment result pre-treatment frequency mdcs low non-responder nr compare responder svr healthy control treatment able restore frequency mdcs nr downregulate frequency ccr7[+ cd54[+ cd62l[+ mdc pre-treatment frequency pdcs low nr decrease far treatment compare svr nr exhibit high ratio pd-l1[+]/cd86[+ pdcs prior treatment ratio remain high treatment finding demonstrate enumeration phenotypic assessment dc before/during therapy help predict treatment outcome treatment pbmc svr secrete high ifn-\\u03b3 compare control nr ifnl3 polymorphism rs12979860 rs4803217 ss469415590 find rs12979860 predictor treatment outcome collectively study lead identification important correlate ifn/rbv treatment response hiv-1/hcv co-infected individual\",\"ribavirin rbv potential partner interferon-based therapy recently approve therapy use direct act antiviral patient chronic hepatitis c. precise mechanism underlie rbv action hepatitis c virus hcv replication understand clarify point attempt develop rbv-resistant cell rbv-sensitive hcv rna-replicating cell\",\"influenza important cause annual epidemic respiratory viral infection associate significant morbidity mortality class drug m2 ion channel neuraminidase rna-dependent rna polymerase inhibitor approve prevention treatment influenza widespread resistance class m2 ion channel inhibitor recommend currently therapy polymerase inhibitor favipiravir approve japan use highly restricted despite significant datum support early use neuraminidase inhibitor use patient population suboptimal datum support early use neuraminidase inhibitor review current datum utilization rate ambulatory hospitalize population\",\"development boceprevir telaprevir major step forward treatment chronic hepatitis c. addition treatment infection recently revolutionize approval sofosbuvir simeprevir challenge associate application novel drug new frequent adverse event new drug interaction excessively high treatment cost additional concern viral resistance consideration highlight fact direct-acting antiviral agent panacea good option patient need therapy retrospective study reveal sustained virologic response significantly reduce follow peginterferon ribavirin retreatment compare new therapy suggest patient experience relapse shortly complete treatment peginterferon ribavirin reasonable chance achieve sustained virologic response retreat drug\",\"use exist hepatitis c virus hcv antiviral therapy access new treatment limited\",\"review datum ombitasvir/paritaprevir/ritonavir dasabuvir treatment chronic hepatitis c virus hcv 1 infection\",\"dual triple combination regimen novel hepatitis c direct-acting antiviral daa daclatasvir asunaprevir beclabuvir provide high sustained virological response rate reduce frequency resistance compare clinical monotherapy support pharmacokinetic pk assessment clinical study multiplexed liquid chromatography-tandem mass spectrometry lc-ms/ms method simultaneous quantitation daclatasvir asunaprevir beclabuvir bms-791325 active metabolite bms-794712 human plasma develop validate human plasma sample extract methyl-t-butyl ether follow lc-ms/ms analysis conduct multiple reaction monitoring mrm mode low limit quantitation lloq 1 ng/ml daclatasvir asunaprevir bms-794712 2 ng/ml beclabuvir intra-run precision \\u22644.5 cv inter-run precision \\u22642.9 cv accuracy \\u00b15.3 deviation base different concentration level low geometric mean mid high quality control sample qc provide evidence method accuracy precision selectivity matrix effect lc-ms/ms detection stability plasma potential interference coadministere drug ribavirin interferon evaluate result acceptable method reproducibility demonstrate reanalysis portion study sample cross-validation result qc demonstrate equivalency method single-analyte method previously validate quantitation daclatasvir human plasma approach use multiplexed lc-ms/ms method simultaneous quantitation daa time- cost-effective maintain good datum quality sample analysis\",\"treatment hepatitis c virus hcv infection direct-acting antiviral daa revolutionize care infected patient novel compound non-nucleoside analog bind viral rna-dependent rna polymerase result conformational change inhibit rna synthesis\",\"ribavirin phosphorylate adenosine kinase 1 ak1 cytosolic 5'-nucleotidase 2 transport cell concentrative nucleoside transporter cnt 2/3 code slc28a2/3 gene equilibrative nucleoside transporter ent 1/2 code slc29a1/2 gene evaluate association polymorphism il28b slc28a2/3 slc29a1 abcb1 nt5c2 ak1 hnf4\\u03b1 gene ribavirin treatment outcome pharmacokinetic 4weeks therapy cohort hcv-1/4 italian patient allelic discrimination perform real-time pcr plasma concentration determine end dosing interval ctrough use hplc-uv method non response negatively predict cryoglobulinemia il28b_rs12980275 aa positively metavir score metavir score insulin resistance slc28a2_rs1060896 ca/aa hnf4\\u03b1_rs1884613 cc negative predictive factor svr hcv viral load baseline il28b_rs12980275 aa rs8099917 tt positively predict outcome rvr negatively predict insulin resistance positively cryoglobulinemia il28b_rs12980275 aa metavir score insulin resistance able negatively predict evr cryoglobulinemia il28b_rs12980275 aa positively predict virological relapse negatively predict il28b_rs8099917 tt ak1_rs1109374 tt insulin resistance positive predictor factor concern ribavirin pharmacokinetic slc28a2_rs11854488 tt related low ctrough level conversely patient tc profile slc28a3_rs10868138 slc29a1_rs760370 gg high ribavirin level result contribute clarification mechanism cause individuality response ribavirin containing therapy\",\"interferon-free regimen approve patient co-infecte hiv genotype-2 genotype-3 hepatitis c virus hcv interferon-based regimen option co-infecte hiv hcv 1 4 regimen limit clinically significant toxic effect drug interaction antiretroviral therapy aim assess efficacy safety interferon-free all-oral regiman sofosbuvir plus ribavirin patient hiv hcv co-infection\",\"prospective cohort 18 patient treat boceprevir examine role boceprevir plasma concentration onset breakthrough treatment patient experience breakthrough therapy resistance pattern follow s122s/r i132v t54a/i132v v156s/i170a v36m/t54s/r155 k v36m/r155 k t54/r155 k boceprevir-s isomer sch 534128 median concentration patient breakthrough 48.3 ng/ml interquartile range 43 58 ng/ml significantly p 0.019 high 151 ng/ml. low boceprevir plasma concentration lead virologic resistance therapeutic drug monitoring use prevent onset viral breakthrough triple-regimen therapy boceprevir\",\"describe chronic hepatitis c virus hcv infection include epidemiology pathophysiology review current treatment option hcv infection recognize investigational agent study interferon-free therapy summarize clinical trial new agent\",\"present study design assess evolution simeprevir-resistant variant amino acid substitution aa80 aa155 aa156 aa168 position hcv ns3 region time virological non-responder patient positive hcv-rna end treatment study enrol 136 patient infect hcv 1b receive 12-week simeprevir-peg-ifn-ribavirin therapy datum 87 patient available analysis patient 14 consider virological non-responder include 9 75 absolute no-response hcv rna \\u22653.0 log iu/ml 12 week start therapy multivariate analysis patient identify lack response prior treatment use low ribavirin dose old age independent significant determinant virological non-response use ultra-deep sequencing de novo variant d168 detect 9 absolute non-responder majority variant emerge 5 week triple therapy comparison de novo variant q80 detect 3 9 absolute non-responder emerge 6 12 week variant q80 detect baseline increase course treatment 5 9 absolute non-responder increase note variant r155 and/or a156 detect baseline 12-week course de novo variant r155 and/or a156 detect study result demonstrate emergence simeprevir-resistant variant early stage triple therapy\",\"ifn-free regimen direct antiviral agent daa hepatitis c virus hcv likely greatly expand patient access response hepatitis c therapy safety tolerability treatment substantially improve sofosbuvir sof ns5b nucleotide polymerase inhibitor pan-genotypic activity high-barrier resistance approve fda ema oral combination therapy chronic hepatitis c ribavirin rbv combination pegylated interferon/rbv daa\",\"enterovirus ev picornaviridae family common viral pathogen know ev infection mild self-limiting manifestation severe child immunodeficient individual antiviral development actively pursue benefit high-risk patient alarming problem antimicrobial drug resistance antiviral drug resistance public-health concern picornavirus antiviral use off-label outbreak control measure use final stage eradication mitigate ev-a71 outbreak review potential emergence drug-resistant strain impact ev transmission endemic circulation include non-picornavirus antiviral inhibit ev replication example ribavirin treatment infection hcv amantadine treatment influenza a. spur resistance emergence hcv influenza patient unknowingly coinfecte ev public-health challenge find balance individual benefit long-term health large population\",\"use generation protease inhibitor hamper virological failure partially interferon-sensitive patient\",\"assess anrs co20-cupic cohort viral load vl week 2/week 6 telaprevir/boceprevir-based triple therapy respectively predictive sustained virological response svr patient hepatitis c virus hcv infection study relevance measurement early diagnose drug resistance\",\"objective evaluate clinical role sofosbuvir solvadi treatment hepatitis c virus hcv data sources medline embase cochrane search index january 2000 july 2014 perform use search term gs-7977 sofosbuvir study selection data extraction study include human subject publish english assess efficacy safety sofosbuvir management chronic hcv evaluate datum synthesis sofosbuvir nucleotide analogue ns5b polymerase inhibitor compete nucleotide hepatocyte result chain termination inhibition rna replication trial evaluate efficacy sofosbuvir combination therapy demonstrate significant advantage sustained virologic response svr previous therapy 1 4 5 6 patient treat peginterferon-\\u03b1 ribavirin sofosbuvir 12 week achieve svr rate 90 twelve-week peginterferon-free regimen result svr rate 90 2 patient 3 patient require 24 week therapy achieve similar result favorable svr rate previously difficult-to-treat patient population include cirrhosis hiv coinfection treatment-experienced sofosbuvir appear tolerated relatively safe avoid severe adverse drug reaction laboratory abnormality resistance issue associate traditional hcv therapy big limitation sofosbuvir high cost associate therapy conclusion sofosbuvir safe effective treatment option patient infect 1 6 hcv include previously difficult-to-treat population short duration oral route minimal effect decrease resistance potential welcome addition treatment chronic hcv\",\"identify hcv drug resistance mutation drm increasingly important new direct act antiviral therapy daa available tag pooled pyrosequencing tpp originally develop cost-effective approach detect low abundance hiv drm use 127 hcv-positive sample canadian injection drug user cohort demonstrate suitability efficiency tpp evaluate drm hcv ns5b gene mutation identification threshold 1 nucleoside inhibitor drm detect daa na\\u00efve subject clinical ns5b resistance non-nucleoside inhibitor interferon/ribavirin predict low cohort s282 t mutation primary mutation select sofosbuvir vitro identify s282g/c/r variant detect 9 subject characterization new s282 variant use silico molecular modeling imply potential association resistance combine tpp silico analysis detect ns5b polymorphism explain difference treatment outcome\",\"lethal mutagenesis broad-spectrum antiviral strategy exploit high mutation rate low mutational tolerance rna virus approach use mutagenic drug increase viral mutation rate burden viral population mutation reduce number infectious progeny investigate effectiveness lethal mutagenesis strategy influenza virus use nucleoside analog ribavirin 5-azacytidine 5-fluorouracil drug active panel seasonal h3n2 laboratory-adapted h1n1 strain find drug increase frequency mutation influenza virus population decrease virus specific infectivity indicate mutagenic mode action able drive viral population extinction passage influenza virus presence drug indicate complete lethal mutagenesis influenza virus population achieve sufficient mutational burden apply population-wide resistance mutagenic agent arise serial passage influenza virus population sublethal concentration drug sequencing drug-passaged viral population reveal genome-wide accumulation mutation low frequency replicative capacity drug-passaged population reduce high multiplicity infection suggest presence defective interfere particle possible barrier evolution resistance datum suggest lethal mutagenesis particularly effective therapeutic approach high genetic barrier resistance influenza virus\",\"identification mutation hvr1 region hepatitis type c virus hcv time-consuming expensive need rapid inexpensive method screen mutation predict ineffectiveness pegylated interferon alpha combine ribavirin peg-ifn\\u03b1/rbv therapy project design evaluate usefulness high resolution melting hrm technique screen mutation cdna encode hvr1 protein kinase r-binding domain pkr-bd region group 36 patient infect hcv resistant 12 month combined therapy peg-ifn\\u03b1/rbv viral rna isolate reverse transcribe fragment encode hvr1 pkr-bd region polymerase chain reaction (pcr)-amplified clone sequence melting profile melting temperature tm determine hrm technique treatment melting profile hvr1 cdna reveal dominant peak correspond tm 85 \\u00b0 c hcvs85 patient minor peak observe indicate existence cdna(s different tm hmr analysis suggest typical form response treatment supposition support sequencing hrm analysis reveal change melting profile pkr-bd cdna patient therapy suggest 12 month treatment new mutation introduce pkr-bd finding substantiate sequencing hrm technique apply rapid screening mutation cdna encode hvr pkr-bd region hcv suggest detection hcvs85 peak ifn\\u03b1/rbv therapy predict ineffectiveness treatment\",\"prior assessment insulin resistance homa-ir emerge important milestone treatment patient chronic hepatitis c. cost-effective tool recommend individualize treatment duration exclude low insulin sensitivity treat ameliorate state insulin resistance ir present work aim elucidate far effect ir state early viral kinetic response chronic hepatitis c virus hcv therapy impact hcv treatment viral eradication insulin sensitivity insulin sensitivity assess use homa-ir method enrol patient treat dual therapy pegylated interferon-alpha plus ribavirin 48 week evaluate use qrt-pcr early virologic response impact treatment insulin sensitivity early period therapy total 392 chronic hcv case early virologic response achieve 318 81.1 ir detect 241 61.5 chronic hcv patient 73.4 respond treatment early virologic response patient 2.18 homa-ir value significantly low homa-ir value \\u22642.18 p 0.0001 ir significantly associate high baseline bmi steatosis fibrosis correlate ir independently predict early virologic response pretreatment ir 2.18 low fast blood glucose low intermediate hcv viral load normal bmi non-smoking independent factor associate early virologic response ir interfere early virologic response antiviral care clinical application pretreatment homa-ir assessment help predict early treatment outcome enable treatment regimen optimize individually tailor\",\"chronic hepatitis c chc constitute major health concern hepatitis c virus eradication antiviral treatment markedly reduce risk develop cirrhosis hepatocellular carcinoma liver-related death plethora new direct antiviral agent develop explore clinical trial new member family ns3/4a protease inhibitor abt-450 multi-targeted approach combine ritonavir-enhanced abt-450 ombitasvir dasabuvir evaluate treatment chc gt1 treatment-na\\u00efve treatment-experienced adult article seek discuss current knowledge abt-450-containing regimen special emphasis treatment-experienced chc gt1 patient new combination find potent safe tolerated future phase iii trial large sample size patient decompensated cirrhosis non-gt1 end-stage renal disease liver transplant recipient eagerly await\",\"presence resistance-associated variant rav attenuate efficacy direct-acting antiviral daa combination therapy hepatitis c. aim study characterize ns3 ns5a region hepatitis c virus hcv naturally occur rav\",\"construct tricistronic hepatitis c virus hcv replicon double internal ribosome entry site ireses 22 nucleotide substitute encephalomyocarditis virus emcv ireses use translation initiation element form hcv replicon\",\"chemoresistance remain major impediment cancer therapy major progress understand mechanism underlie resistance cancer learn study provide evidence gli1 drive novel form drug resistance involve phase ii drug metabolism enzyme specifically ugt1a family\",\"triple therapy telaprevir/boceprevir pegylated-interferon+ribavirin achieve excellent antiviral efficacy burden resistance development failure\",\"chronic hepatitis c virus hcv infection lead cause advanced liver disease worldwide virus successfully evade host immune detection year hamper effort find safe uncomplicated reliable oral antiviral therapy initially interferon ribavirin therapy treatment standard care offer limited performance wide spectrum hcv disease fraught excessive limit effect sofosbuvir sof potent first-in-class nucleoside inhibitor recently approve treatment hcv drug low toxicity high resistance barrier minimal drug interaction hcv direct-acting antiviral agent protease inhibitor anti-ns5a agent sof safe use different viral disease stage special patient group coinfecte human immunodeficiency virus use combination ribavirin direct-acting antiviral agent sof revolutionize hcv treatment spectrum set stage nearly universal hcv antiviral therapy anti-hcv drug develop date sof offer wide applicability infected patient new regimen tailor maximize performance\",\"hepatitis c disease virus mediated infection cause major health problem worldwide conversion immune surveillance play important role response virus clearance immune modulate molecule hla-g il-10 convert immune response th2 play role inhibit response combined therapy ifn-\\u03b12\\u03b1 ribavirin objective study investigate expression hla-g il-10 responder non-responder hcv positive patient study characteristic virus 48 responder non-responder patient response combined therapy ifn-\\u03b12\\u03b1 ribavirin analyze expression level hla-g il-10 conduct use real-time pcr soluble hla-g group patient healthy individual determine enzyme-linked immunosorbent assay accord obtain datum hcv 1a predominant responder non-responder patient expression level hla-g il-10 non-responder group significantly responder control group p<0.001 additionally expression level hla-g il-10 remarkably high compare healthy individual beginning treatment soluble hla-g non-responder patient noticeably increase comparison responder patient treatment p<0.05 finding suggest elevation hla-g il-10 hcv infected patient play important role response combined therapy ifn-\\u03b12\\u03b1 ribavirin\",\"cancer cell rapidly evolve multitude defense mechanism evade effect oncologist drug arsenal unfortunately clinical strategy overcome lag far mismatch likely underlie inability implement new durable treatment strategy new form multidrug resistance inducible drug glucuronidation discuss form discover develop mean target specific oncogene eukaryotic translation initiation factor 4e eif4e inhibitor ribavirin clinical study ribavirin treatment lead substantial clinical response respond patient eventually relapsed case overexpression sonic hedgehog transcription factor gli1 elevate udp glucuronsyltransferase ugt1a enzyme ugt1as add glucuronic acid drug cell resistant ribavirin ara-c likely drug inhibition gli1 reduce ugt1as eliminate drug glucuronide renew sensitivity ribavirin ara-c. study highlight cancer cell resistant counterpart metabolize drug differently normal cell likely inducible modification glucuronidation understand extent inducible drug modification pathway drive expression corresponding enzymatic machinery position finally resistance futile\",\"pegylated interferon ifn \\u03b1-2a 2b combination ribavirin child aged 3 year old standard treatment paediatric chronic hepatitis c. treatment regimen develop firstly adult recent year number direct-acting antiviral agent daa development treatment chronic hepatitis c virus hcv infection agent block viral replication inhibit directly step hcv lifecycle daa classify category base molecular target hcv ns3/4a protease inhibitor hcv ns5b polymerase inhibitor hcv ns5a inhibitor promise compound cyclophilin inhibitor mi-rna122 ifn-\\u03bb new drug association develop near future start actual standard care ifn-based ifn-free regimen study adult constantly evolving scenario new drug regimen target suitable child possible future especially child crucial identify right combination drug high potency barrier resistance good safety profile\",\"hepatitis c virus hcv mono-infected hiv/hcv co-infecte patient need safe effective all-oral hcv regimen phase 2 study aim assess efficacy safety grazoprevir mk-5172 hcv ns3/4a protease inhibitor dose elbasvir mk-8742 hcv ns5a inhibitor patient hcv mono-infection hiv/hcv co-infection\",\"treatment hepatitis c change dramatically new direct-acting antiviral daa hcv recently approve available month\",\"era directly act anti hcv antiviral treatment hepatitis c successful majority person treat treatment person hiv inject drug remain challenging special issue drug-drug interaction antiretroviral psychiatric drug substitution therapy treatment adherence impact treatment hiv disease course risk bacterial infection sofosbuvir induce sustained virologic response 91 23 hiv/hcv coinfecte person treat combination ribavirin pegylated interferon 83 497 treat combination ribavirin 50 patient infect hcv gt1 treat combination ledipasvir ribavirin rate efficacy hcv-hiv coinfecte observe hcv monoinfected suggest efficacy sofosbuvir reduce hiv coinfection datum efficacy sofosbuvir injection drug user pangenotypic activity high barrier resistance modest potential drug-drug interaction sofosbuvir reference drug treatment special population\",\"sofosbuvir first-in-class ns5b nucleotide analogue launch hepatitis c virus hcv treatment viral potency pangenotypic activity high barrier resistance ideal candidate backbone ifn-free regimen recent datum demonstrate sofosbuvir ribavirin combination direct-acting antiviral daa daclatasvir ledipasvir simeprevir able cure hcv 90 patient treatment experience 3 population remain difficult treat population ongoing daa combination study help fill gap safety profile sofosbuvir combination daa good resistance sofosbuvir appear significant issue rationale use class drug available clinical datum review\",\"development anti-interferon (ifn)-\\u03b1 neutralizing antibody nabs likely common clinical problem patient disease treat ifn anti-ifn-\\u03b1 nab exceptionally consider clinical significance treatment chronic hepatitis c pegylated ifn-\\u03b1 peg-ifn-\\u03b1 recently clarify presence nab associate non-response peg-ifn plus ribavirin rbv therapy study use hcv-replicon system 1b investigate role anti-ifn-\\u03b1 nab response telaprevir (tvr)-containe new antiviral therapy hepatitis c virus hcv anti-ifn-\\u03b1 nab-positive sera specifically inhibit anti-hcv effect ifn-\\u03b1 effect activity ifn-\\u03b2 vitro nab-positive sera inhibit ifn-\\u03b1-dependent induction interferon-stimulated gene mxa oas-1 dose-dependent manner tvr monotherapy decrease hcv-rna vitro hcv-rna increase development tvr-resistant mutation ifn-\\u03b1 administrate tvr replication hcv continuously suppress month presence anti-ifn-\\u03b1 nab-positive sera ifn-\\u03b1 combine tvr level hcv-rna exhibit time-course similar tvr monotherapy hcv tvr-resistant mutation emerge conclusion finding suggest presence ifn-\\u03b1 nab decrease antiviral effect ifn-\\u03b1 related development tvr-resistant mutate virus\",\"chronic hepatitis c virus hcv infection increase risk liver cirrhosis hepatocellular carcinoma decade current standard hcv treatment pegylated interferon ribavirin limit efficacy significant effect novel direct act antiviral promise escape mutant expect potential effect pycnogenol \\u00ae french maritime pine extract report antioxidant antiviral effect evaluate effect pycnogenol \\u00ae hcv replication wild-type protease inhibitor vx-950 telaprevir)-resistant hcv replicon cell treat pycnogenol \\u00ae pycnogenol \\u00ae interferon-alpha ribavirin telaprevir pycnogenol \\u00ae effect replication evaluate hcv-infected chimeric mouse pycnogenol \\u00ae treatment antiviral effect cytotoxicity dose 50 \\u03bcg/ml. pycnogenol \\u00ae combination interferon-alpha ribavirin synergistic effect pycnogenol \\u00ae inhibit hcv replication telaprevir-resistant replicon cell telaprevir pycnogenol \\u00ae act additively reduce hcv rna level wild-type hcv replicon cell significantly increase cytotoxicity pycnogenol \\u00ae antiviral activity high component procyanidin taxifolin far treatment infected chimeric mouse pycnogenol \\u00ae suppress hcv replication synergistic effect interferon-alpha addition pycnogenol \\u00ae treatment result dose-dependent reduction reactive oxygen specie hcv replicon cell line pycnogenol \\u00ae natural product use improve efficacy current standard antiviral agent eliminate resistant hcv mutant\",\"simeprevir oral hepatitis c virus hcv ns3/4a protease inhibitor approve treatment chronic hcv infection baseline ns3 polymorphism patient emerge mutation patient fail achieve sustained virologic response svr simeprevir plus peginterferon/ribavirin pr phase iib/iii study describe\",\"suggest hcv protein core ns3/4a ns4b ns5a contribute resistance hcv ifn ribavirin rbv treatment\",\"establishment robust hcv cell culture system characterization viral life cycle provide molecular basis highly innovative successful year hcv drug development identification direct-acting antiviral agent daa ns3/4a protease inhibitor ns5a replication complex inhibitor nucleotide non-nucleoside polymerase inhibitor host cell targeting agent novel therapeutic strategy establish competitively enter clinical testing first-in-class ns3/4a protease inhibitor telaprevir boceprevir approve 2011 recently outpace pan-genotypic nucleotide polymerase inhibitor sofosbuvir combination pegylated interferon ribavirin far shorten therapy duration offer interferon-free hcv treatment option challenging race goal interferon-free hcv therapy oral daa regimen nucleotide polymerase inhibitor combine ns3/4a protease inhibitor ns5a inhibitor and/or non-nucleoside polymerase inhibitor yield competitive result second generation ns3/4a protease ns5a inhibitor promise improve genotypic coverage high resistance barrier result novel daa combination therapy backbone nucleotide polymerase inhibitor treatment strategy involve host targeting agent review\",\"standard care treatment chronic hcv 1 infection involve directly act antiviral protease inhibitor telaprevir boceprevir combine pegylated-interferon ribavirin triple therapy phase iii study include highly select patient treatment response development viral resistance triple therapy routine clinical setting need determine aim study investigate treatment outcome identify sequence variation triple therapy patient chronic hcv 1 infection routine clinical setting\",\"hepatitis c currently infect 170 million people world lead significant morbidity mortality current standard care hcv infection include protease inhibitor telaprevir boceprevir 12 32 week pegylated interferon alfa-2a peg-ifn-\\u03b1 ribavirin 48 week unsatisfactory case lack efficacy treatment-related adverse effect urgent need new drug improve efficacy safety profile sofosbuvir recently approve nucleotide analog highly potent inhibitor ns5b polymerase hepatitis c virus hcv high efficacy combination drug peg-inf hcv offer advantage high potency low effect oral administration high barrier resistance efficacy safety demonstrate large well-designed phase 2 phase 3 clinical trial like neutrino proton electron atomic cosmos fusion fission nuclear positron like generally well-tolerated adverse event occur include headache insomnia fatigue nausea dizziness pruritis upper respiratory tract infection rash pain grade 1 anemia grade 4 lymphopenia exact safety profile judge drug actually use large scale\",\"orally administer anti-cd3 antibody biologically active gut induction regulatory t cell exert immune-modulatory effect alleviate insulin resistance liver damage patient nash\",\"miravirsen \\u03b2-d-oxy-locked nucleic acid-modified phosphorothioate antisense oligonucleotide target liver-specific microrna-122 mir-122 miravirsen demonstrate antiviral activity hepatitis c virus hcv 1b replicon mean 50 effective concentration ec50 0.67 \\u03bcm. cytotoxicity observe high concentration test 320 \\u03bcm different cell culture model yield therapeutic index \\u2265 297 combination study miravirsen interferon \\u03b12b ribavirin nonnucleoside vx-222 nucleoside 2'-methylcytidine inhibitor ns5b ns5a bms-790052 ns3 telaprevir indicate additive interaction miravirsen demonstrate broad antiviral activity test hcv replicon resistant ns3 ns5a ns5b inhibitor 2-fold reduction susceptibility serial passage study a4c nucleotide change observe hcv 5 untranslated region utr cell passage presence 20 \\u03bcm 40-fold miravirsen ec50 concentration day 72 passage early time point 39 day passage likewise c3u nucleotide change observe hcv 5'utr subject viral rebound completion therapy miravirsen phase 2 clinical trial hcv variant construct contain a4c change fully susceptible miravirsen c3u hcv variant demonstrate overall reduction susceptibility miravirsen fully susceptible anti-hcv agent test summary miravirsen demonstrate broad antiviral activity relatively high genetic barrier resistance identification nucleotide change associate miravirsen resistance help far elucidate biology mir-122 interaction hcv clinical trial study register clinicaltrials.gov registration no. nct01200420\",\"chronic infection hcv public health problem approximately 170 million people infect worldwide interferon alpha ifn\\u03b1 sensitivity liver il28b identify important determinant hcv clearance setting pegylated interferon/ribavirin treatment explore ifn\\u03b1 sensitivity pbmc 21 healthy donor 21 hcv-infected patient treat pegylated interferon/ribavirin hcv nonstructural protein-3 inhibitor i.e. telaprevir/boceprevir explore phospho-stat1 level read-out ifn signalling pathway activation pbmc t cell monocyte correlate result virological response find pbmc healthy donor desensitized ifn\\u03b1 priming challenge ifn\\u03b1 subsequent decrease phospho-stat1 interferon-stimulated gene furthermore cd3 t cell monocyte desensitized 4 week treatment significant decrease phospho-stat1 ex vivo ifn\\u03b1 stimulation finally identify baseline phospho-stat1 level cd3 t cell potential biomarker sustained virological response regardless il28b upcoming costly era ifn-sparing regiman baseline ifn\\u03b1 sensitivity act biomarker define cost-effectiveness strategy treatment identify patient respond ifn-based treatment\",\"fat mass obesity-associated protein fto gene rs9939609 single nucleotide polymorphism snp associate obesity metabolic syndrome insulin resistance ir type 2 diabete mellitus general population aim study examine time association rs9939609 polymorphism metabolic disturbance liver disease virologic response hepatitis c virus hcv therapy pegylated-interferon-alpha plus ribavirin pegifn\\u03b1/rbv human immunodeficiency virus (hiv)/hcv coinfecte patient\",\"247 subject hepatitis c virus 1 infection treat interferon-free regimen abt-450/ritonavir ombitasvir dasabuvir plus ribavirin concordance sustained virologic response 12 24 week support use early time point primary efficacy endpoint trial interferon-free regiman\",\"despite preventive strategy increase awareness high incidence respiratory viral infection occur patient hematologic malignancy hm recipient hematopoietic cell transplant hct progression viral infection low respiratory tract prove fatal especially hct recipient increase evidence successful use ribavirin combination immunomodulator treatment respiratory virus infection hm patient hct recipient available retrospective study prospective clinical trial necessary establish efficacy confidence impact progression pneumonitis and/or mortality treat parainfluenza virus infection available ribavirin investigational das181 antiviral agent need determine influenza infection successfully treat neuraminidase inhibitor oseltamivir zanamivir efficacy agent influenza pneumonia establish immunocompromised patient highly susceptible emergence antiviral drug resistance probably prolonged viral shedding infection control measure appreciation complication follow respiratory viral infection immunocompromised patient remain crucial reduce transmission future study focus strategy identify patient high risk increase morbidity mortality infection determine efficacy novel available antiviral drug\",\"chronic hepatitis c infection global disease 160 million people infect worldwide recently therapy characterize long duration suboptimal success rate significant adverse drug reaction development direct-acting antiviral initiate dramatic change treatment hepatitis c.\",\"ribavirin rbv continue important component interferon-free hepatitis c treatment regimen rbv inhibit hepatitis c virus hcv replication effectively reason ineffectiveness establish study investigate rbv resistance mechanism use persistently hcv-infected cell culture system antiviral activity rbv hcv progressively impair persistently infected culture interferon lambda 1 ifn-\\u03bb1 type iii ifn strong antiviral response induce viral clearance find hcv replication persistently infected culture induce autophagy response impair rbv uptake prevent expression equilibrative nucleoside transporter 1 ent1 huh-7.5 cell line treat autophagy inducer torin 1 downregulate membrane expression ent1 terminate rbv uptake contrast autophagy inhibitor hydroxychloroquine hcq 3-methyladenine 3-ma bafilomycin a1 bafa1 prevent ent1 degradation enhance rbv antiviral activity hcv-induced autophagy response treatment torin 1 degrade clathrin heavy chain expression hepatoma cell line reduce expression clathrin heavy chain hcv prevent ent1 recycling plasma membrane force ent1 lysosome degradation study provide potential mechanism impairment rbv antiviral activity persistently hcv-infected cell culture suggest inhibition hcv-induced autophagy response use strategy improve rbv antiviral activity hcv infection\",\"sofosbuvir sof combination ribavirin rbv 12 24 week current standard care patient infect hepatitis c virus hcv 2 3 respectively clinical trial treatment-experienced patient particularly cirrhosis suboptimal sustained virological response svr rate assess efficacy safety sofosbuvir plus peginterferon ribavirin sof+peg-ifn+rbv administer 12 week treatment-experienced patient hcv 2 3 cirrhosis enrol 47 patient open-label nonrandomize uncontrolled phase 2 study primary endpoint proportion patient svr 12 week cessation study treatment svr12 overall rate svr12 89 95 confidence interval ci 77 97 rate svr12 high patient 2 3 96 95 ci 78 100 83 95 ci 62 95 respectively rate svr12 similar patient cirrhosis 2 93 patient cirrhosis 100 patient cirrhosis achieve svr12 3 svr12 rate 83 patient cirrhosis patient discontinue study treatment adverse event patient experience adverse event common adverse event influenza-like illness fatigue anemia neutropenia\",\"hepatitis c virus remain global health issue established standard care consist pegylated interferon alpha conjunction ribavirin regimen associate significant side-effect poor sustained virological response aim review assess effect direct-acting antiviral hepatitis c 2 6 publication past 18 month\",\"interferon alfa-based regimen use treat recurrent hepatitis c virus hcv infection liver transplantation poorly tolerate associate generally modest efficacy interact immunosuppressive agent evaluate efficacy safety interferon-free regimen nucleotide polymerase inhibitor sofosbuvir combine ribavirin 24 week treat post-transplantation hcv infection\",\"advance understand hepatitis c virus hcv life cycle urgent need find complementary direct-acting antiviral daa therapy lead substantial advancement treat chronic hepatitis c. introduction telaprevir boceprevir 2011 increase sustained virological response svr rate approximately 50 70 therapy far restricted patient eligibility approve treat hcv 1 infection interferon long remain backbone hcv therapy help prevent viral breakthrough interferon limit effectiveness associate severe adverse effect toxicity especially cirrhotic patient interferon-free therapy greatly improve svr rate offer new treatment hcv ineligible patient patient fail respond prior therapy relative safety interferon suppress viral escape vigilance require select appropriate therapy monitor resistance daa currently undergo clinical trial soon undergo approval process goal future hcv clinical research identify combination daa high genetic barrier investigate optimal treatment dose duration determine role ribavirin daa therapy\",\"virologic failure follow treatment hepatitis c virus hcv 1 direct-acting antiviral agent accompany emergence resistant variant mk-5172 investigational once-daily protease inhibitor analyze variant treatment-naive noncirrhotic patient virologic failure mk-5172 100 800 mg/day plus pegylated interferon alfa/ribavirin peg-ifn/rbv phase 2 trial\",\"chronic hepatitis c virus (hcv)-infected patient liver cirrhosis lc respond poorly interferon-alpha ifn-\\u03b1 ribavirin rbv combination therapy reason unclear previously report hcv-infection induce endoplasmic reticulum er stress autophagy response selectively regulate type ifn-\\u03b1 receptor-1 ifnar1 rbv transporter cnt1 ent1 lead ifn-\\u03b1/rbv resistance goal study verify increase er stress autophagy response associate reduce expression ifnar1 rbv transporter chronic hcv-infected patient\",\"chronic hepatitis c treatment prior non-responder peginterferon (pegifn)/ribavirin remain suboptimal matterhorn study evaluate regimen contain ritonavir-boosted danoprevir danoprevir/r prior pegifn alfa/ribavirin non-responder\",\"hepatitis c virus hcv major cause chronic liver disease 170 million people infect worldwide standard regiman treatment hcv consist combination pegylated interferon ribavirin failure interferon-\\u03b1 treatment patient chronic hcv infection remain challenging obstacle viral host environmental factor implicate reduce responsiveness ifn-\\u03b1 therapy host genetic diversity believe contribute different clinical outcome hcv infection objective study investigate association il-10 -819 -592 mxa -88 -123 single-nucleotide polymorphism snp promoter region response interferon ifn therapy egyptian patient infect hcv 4 polymorphism gene 85 hcv patient 100 control determine polymerase chain reaction-restriction fragment length polymorphism pcr-rflp technique frequency snp compare sustained responder n 52 non-responder n 33 determine biochemical virological response ifn ribavirin combined therapy frequency -819t/t -592a/a il-10 significantly high responder compare non-responder 51.92 vs 39.4 p 0.03 51.92 vs 42.42 p 0.046 respectively g/g position -88 mxa gene significantly low responder non-responder 25 vs 75.76 p 0.046 heterozygote g/t likely responder 65.38 vs 18.18 p 0 -123c/a significantly associate responder 48.08 vs 30.30 p 0.014 finding suggest homozygosity -819t/t -592a/a polymorphism il-10 gene heterozygosity -88g/t -123c/a polymorphism mxa gene important host factor influence response ifn therapy patient chronic hcv infection\",\"combination pegylated interferon peg-ifn ribavirin rbv current therapy hepatitis c virus hcv infection save life hcv-infected patient direct-acting antiviral daa target site hcv nonstructural protein result cessation viral replication ns3/4a protease inhibitor consist boceprevir telaprevir superior efficacy 1 hcv infection combine peg-ifn/rbv compare standard therapy treatment-naive -experienced patient simeprevir faldaprevir asunaprevir second-wave first-generation ns3/4a inhibitor soon approve second-generation protease inhibitor clinical trial daclatasvir approve daa belong class ns5a replication complex inhibitor potency daclatasvir high drug important essential component combination regimen sofosbuvir approve ns5b polymerase inhibitor characterize high potency genetic barrier resistance sofosbuvir combine rbv achieve interferon-free regimen 2 3 patient reduce treatment duration use combination peg-ifn/rbv 1 patient 12 week daa provide new hope cure hcv infection short treatment duration acceptable adverse event\",\"hepatitis c virus hcv modulate intrahepatic cholesterol biosynthetic pathway promote viral replication chronic hcv infection associate altered metabolism include dyslipidemia insulin resistance ir contribute disease progression influence response therapy far understand impact hcv infection host metabolism examine change serum lipid profile intrahepatic expression lipid-related gene interferon (ifn)-free treatment chronic hcv 1 infection sofosbuvir ribavirin rbv explore association treatment outcome serum lipid total cholesterol low-density lipoprotein ldl high-density lipoprotein hdl triglyceride tg hemoglobin a1c hba1c measure treatment gene expression lipid-related gene assess use pair pre- end-of-treatment eot liver biopsy 8 patient n=7 sustain virologic response svr n=1 relapse unpaired eot liver biopsy 25 patient n=17 svr n=8 relapse serum ldl concentration particle size increase early therapy tg concentration very-low-density lipoprotein particle size decrease concomitantly irrespective treatment outcome ldl increase patient regardless treatment outcome average ldl concentration low baseline post-treatment patient relapse analysis paired liver biopsy reveal altered expression gene associate lipid transport assembly signaling unpaired eot liver biopsy intrahepatic expression fatty acid metabolism lipid transport gene low patient experience treatment relapse\",\"adult intestinal stem cell isc possess long-term proliferation ability differentiation capability enterocyte novel vitro system evaluation drug absorption characterize human small intestinal epithelial cell hiec monolayer differentiate adult isc continuous proliferation/differentiation isc consistently confer capability maturation enterocyte hiec 25 passage morphologically matured hiec monolayer consist polarize columnar epithelia dense microvilli tight junction desmosome 8 day seed culture insert transepithelial electrical resistance monolayer 9-fold low hiec 98.9 \\u03c9 \\u00d7 cm(2 caco-2 cell 900 \\u03c9 \\u00d7 cm(2 indicate looseness tight junction hiec monolayer similar human small intestine approximately 40 \\u03c9 \\u00d7 cm(2 significant difference observe overall gene expression pattern major drug-metabolizing enzyme transporter hiec caco-2 cell monolayer furthermore function p-glycoprotein breast cancer resistance protein hiec monolayer confirm vectorial transport marker substrate disappearance presence specific inhibitor apparent drug permeability value paracellularly transport compound fluorescein isothiocyanate-dextran 4000 atenolol terbutaline nucleoside transporter substrate didanosine ribavirin doxifluridine hiec monolayer markedly high caco-2 cell transcellularly transport drug pindolol midazolam equally permeate conclusion hiec monolayer serve novel superior alternative conventional caco-2 cell monolayer predict oral absorption human\",\"analyze blood sample collect 15 patient chronic hepatitis e recipient solid-organ transplant patient clear hepatitis e virus hev 2 nonresponder 1 patient die g1634r mutation viral polymerase detect hev rna nonresponder mutation provide virus resistance ribavirin vitro mutant form subgenomic replicon 3 hev replicate efficiently vitro hev mutation true infectious virus include competition assay similar result obtain 1 hev g1634r mutation appear increase replicative capacity hev human liver reduce efficacy ribavirin\",\"provide overview novel anti-hepatitis c agent sofosbuvir\",\"chronic hepatitis c virus hcv infection tremendous health burden worldwide annual mortality 300,000 people decompensated cirrhosis hepatocellular carcinoma combination interferon ifn ribavirin rbv and/or direct-acting antiviral daa eradicate hcv proportion infected patient unfortunately ifn-based therapy associate significant adverse effect contraindication limited tolerability lead low adherence treatment discontinuation rapid evolution newer daa host-targeting agent emerge hcv therapy ifn- rbv-free strategy end recently develop ns3 protease inhibitor asunaprevir asv combination daa ifn/rbv-containe -free regiman promise result adverse effect review preclinical profile clinical proof-of-concept study asv include viral resistance host polymorphism role asv future hcv therapy review discuss\",\"launch first-generation protease inhibitor pi major step forward hepatitis c virus hcv treatment major advance restricted genotype-1 gt-1 patient ongoing development new direct-acting antiviral agent daa allow new hope future development second-wave second-generation pi yield high antiviral potency plurigenotypic activity convenient daily administration effect second-generation pi potential activity resistance-associated variant ns5b inhibitor ns5b.i include nucleoside/nucleotide inhibitor ni nonnucleotide inhibitor nni ni high efficacy sofosbuvir highly potent antiviral activity association pegylated interferon ifn ribavirin pr allow shorten treatment duration ns5a inhibitor ns5a.i highly potent antiviral activity recently time ns5a.i combination pi cure gt-1b null-responder patient ifn-free regiman addition study demonstrate ifn-free regimen daa combination able cure large number na\\u00efve treatment-experienced gt-1 patient quadruple regiman pr able cure gt-1 null-responder development pan-genotypic daa nis ns5a.i allow new combination pr increase rate sustained virological response svr patient cirrhosis independently near future hcv treatment look promise purpose article provide overview clinical result recently report hcv treatment gt-1 patient\",\"treatment gs-9669 novel nonnucleoside inhibitor site ii hepatitis c virus hcv nonstructural 5b ns5b polymerase result significant antiviral activity hcv gt 1 patient dose 50 500 mg daily qd 50 100 500 mg twice daily bid 3 day report characterize virologic resistance gs-9669 vitro gt1 hcv-infected patient phase clinical study vitro resistance selection study gs-9669 reveal substitution ns5b residue confer resistance m423 variant select low drug concentration 5 \\u00d7 50 effective concentration ec50 l419 r422 i482 variant select high drug concentration 20 \\u00d7 ec50 phase clinical study substitution ns5b residue 419 422 486 predominant change associate gs-9669 monotherapy substitution position 423 observe gt1a patient low-dose group 50 100 mg bid interestingly hcv patient substitution position 423 baseline consistent low resistance level position patient m423i m423v baseline achieve 2-log10 reduction hcv rna treat 100 mg bid 500 mg qd bid gs-9669 fourth patient m423v substitution baseline 4.4-log10 reduction hcv rna 500 mg bid gs-9669 phenotypic analysis demonstrate viral isolate multiple gs-9669 resistance-associated variant reduce susceptibility gs-9669 lomibuvir vx-222 cross-resistant class hcv inhibitor study register clinicaltrials.gov registration no. nct01431898\",\"appropriate antiviral treatment essential live donor liver transplantation ldlt effective treat hepatitis c. report pre-ldlt genetic analysis host virus prediction outcome post-ldlt antiviral treatment indicate ldlt borderline case\",\"sofosbuvir sovaldi sof nucleotide analog prodrug target hepatitis c virus hcv nonstructural protein 5b ns5b polymerase inhibit viral replication high sustained virological response rate achieve sof use combination ribavirin pegylated interferon subject chronic hcv infection potential mechanism hcv resistance sof nucleos(t)ide analog ns5b polymerase inhibitor understand sof u.s. food drug administration (fda)-approved antiviral drug genotypic resistance analysis base entirely next-generation sequencing ngs emerge technology lack standard data analysis pipeline fda division antiviral products develop ngs analysis pipeline perform independent analysis ngs datum sof clinical trial additionally structural bioinformatic approach use characterize potential resistance-associated substitution use protocol develop independent analysis ngs datum reproduce result comparable report gilead sciences inc. low-frequency treatment-emergent substitution occur conserve ns5b amino acid position subject experience virological failure note far evaluate ns5b substitution l159f combination l320f c316n v321a emerge 2.2%-4.4 subject fail sof treatment clinical trial baseline polymorphism position 316 potentially associate reduce response rate hcv 1b subject analysis variant model ns5b crystal structure indicate substitution feasibly affect sof anti-hcv activity\",\"passage hepatitis c virus hcv human hepatoma cell result population display partial resistance alpha interferon ifn-\\u03b1 telaprevir daclatasvir cyclosporine ribavirin despite prior exposure drug mutant spectrum analysis kinetic virus production absence presence drug indicate resistance presence drug resistance mutation mutant spectrum initial passaged population increase replicative fitness acquire passage fitness increase alter host factor lead shutoff general host cell protein synthesis preferential translation hcv rna result imply viral replicative fitness mechanism multidrug resistance hcv importance viral drug resistance usually attribute presence amino acid substitution protein target drug present study hcv high viral replicative fitness confer general drug resistance phenotype virus result exclude possibility genome drug resistance mutation responsible observe phenotype fact replicative fitness determinant multidrug resistance explain virus sensitive drug treatment prolonged chronic hcv infection favor increase replicative fitness\",\"hepatitis c virus hcv genotype-specific impact host metabolic alteration remain inconclusive\",\"hcv ns3/4a serine protease inhibitor class direct act antiviral daa introduce clinical practice generation agent selective hcv 1 use association pegylated interferon ribavirin allow increase cure rate price increase toxicity significant drug interaction high risk select mutant confer cross-resistance entire class large number second-wave hcv protease inhibitor currently clinical development advancement include high potency activity wide number improve tolerability easy dosing schedule genetic barrier resistance remain low especially 1a recent grazoprevir ach-2684 relevant progress regard combination class daa allow construction interferon-free regimen short duration good tolerability exceptionally high cure rate\",\"vaniprevir mk-7009 hepatitis c virus hcv non-structural 3/4a protease inhibitor significantly increase virologic response rate hcv gt 1-infected patient add peginterferon ribavirin pr\",\"infection hepatitis c virus hcv major cause chronic liver disease hepatocellular carcinoma worldwide represent significant public health problem type interferon ifn ifn\\u03b1 successful treat hcv-infected patient current ifn-based treatment regimen hcv suboptimal efficacy relatively little know ifn therapy eliminate virus patient critical understand basic mechanism underlie therapeutic resistance ifn action hcv-infected individual urgent need identify patient likely respond ifn therapy hcv characterize response hcv-infected patient treatment ifn\\u03b1 expression ifn-response gene signature comprise ifn-stimulated gene gene play important role innate immune response examine liver biopsy hcv-infected patient enrol clinical trial present study find expression subset ifn-response gene dysregulate liver biopsy sample nonresponsive hepatitis c patient compare virologic responder base finding statistical model develop help predict response patient ifn therapy compare result obtain il28 mutation model highly predictive response ifn-based therapy hcv-infected patient find model incorporate gene expression datum improve prediction ifn responsiveness compare il28 mutation status\",\"patient infect hepatitis c virus hcv combination direct-acting antiviral agent telaprevir pegylated-interferon alfa peg-ifn ribavirin rbv significantly increase chance sustained virologic response svr treatment peg-ifn rbv patient achieve svr telaprevir-based treatment viral population significantly enrich telaprevir-resistant variant end treatment seek quantify evolutionary dynamic post-treatment resistant variant population previous estimate dynamic limit analyze population sequence datum 20 sensitivity qualitative resistance information 388 patient enrol phase 3 clinical study add clonal sequence analysis 5 sensitivity quantitative subset patient develop computational model integrate qualitative quantitative sequence datum form framework future analysis drug resistance model qualified deep-sequence datum 1 sensitivity subset patient consistent model prediction determine median time viral population revert 20 resistance patient model predict 8.3 95 ci 7.6 8.4 month versus 10.7 9.9 12.8 month estimate use solely population sequence datum 1a 1.0 0.0 1.4 month versus 0.9 0.0 2.7 month 1b individual patient time revert 20 resistance predict model typically comparable fast estimate use solely population sequence datum furthermore model predict median 11.0 2.1 month treatment failure viral population revert 99 wild-type patient hcv 1a 1b respectively model approach provide framework project accurate quantitative assessment hcv resistance dynamic datum set consist largely qualitative information\",\"hepatitis c virus hcv rna virus chronically infect 2 3 world population 25 chronic carrier evolve liver cirrhosis disease significantly associate reduce survival quality life antiviral therapy eradicate infection process associate reduce disease progression rate oral direct agent develop test treatment hcv infection review focus mechanism action pharmacokinetic efficacy safety resistance gs-9669 non-nucleoside inhibitor viral polymerase active hcv 1 combination oral antiviral gs-9669 result high rate viral eradication 90 100 patient hcv 1 infection good tolerability safety profile conclusion gs-9669 good candidate use interferon-free combination treatment chronic hcv infection\",\"hepatitis c virus hcv chronically infect 150,000,000 people worldwide relevant cause liver cirrhosis hepatocellular carcinoma death antiviral treatment rapidly interferon (ifn)-based therapy ifn-free approach review focus mechanism action pharmacokinetic efficacy tolerability safety resistance ombitasvir inhibitor hcv nonstructural protein 5a pharmacokinetic ombitasvir enable daily administration vivo combination oral direct acting antiviral ombitasvir achieve high rate sustained virological response 95 patient hcv 1 infection good tolerability resistance profiling reveal low barrier resistance monotherapy coadministration ombitasvir antiviral enhance barrier resistance conclusion ombitasvir good drug use ifn-free combination treatment chronic hepatitis c.\",\"accord world health organization approximately 150 million people worldwide chronic carrier hepatitis c virus hcv hcv infection evolve cirrhosis liver complication ultimately responsible 350,000 death year antiviral therapy successful able decrease rate progression increase survival type therapy currently available ie interferon-based therapy interferon-free advantage term safety tolerability use advanced stage disease use restricted viral 2 3 expensive molecule advanced phase development review deal pharmacokinetic pharmacodynamic tolerability safety asunaprevir inhibitor hcv nonstructural 3 protease asunaprevir exert optimal vitro activity particularly hcv 1 4 pharmacokinetic profile enable twice daily administration drawback asunaprevir protease inhibitor low barrier resistance consequently use association drug prevent resistance specifically combine daclatasvir ns5a inhibitor asunaprevir result high rate viral eradication treatment-na\\u00efve treatment-experienced patient sustained virological response rate 80%-90 tolerability fair fact asunaprevir associate transient increase aminotransferase level mild case conclusion asunaprevir good candidate component interferon-free combination revolutionize treatment chronic hcv infection near future\",\"daclatasvir novel ns5a inhibitor hepatitis c virus hcv daclatasvir combine peginterferon \\u03b1-2a ribavirin japanese patient infect 1b hcv achieve sustained virological response svr 100 treatment-na\\u00efve patient high rate favorable il28b allele 1b svr 24 achieve asunaprevir daclatasvir 87.4 intolerant 80.5 nonresponder patient baseline ns5a-resistant variant detect fail achieve svr patient 1a experience virological breakthrough dual oral treatment treat quad replace oral regimen potent effect ifn-free regimen include daclatasvir asunaprevir 1 null responder tailor preexist ns5a-resistant variant evaluate carefully choose drug regiman unlikely forward additional agent\",\"telaprevir boceprevir hepatitis c virus hcv ns3 protease inhibitor pi considerably increase rate sustained virologic response association pegylated interferon ribavirin chronic hcv 1 infection 30 patient treat telaprevir boceprevir include anti-hcv therapy 2011 marseille university hospital france monitor hcv load plasmatic concentration telaprevir boceprevir determine sequential blood sample hcv ns3 protease gene population sequencing perform baseline treatment case treatment failure patient include 7 co-infecte hiv receive telaprevir 15 patient include 4 co-infecte hiv receive boceprevir baseline hcv ns3 protease patient harbor amino acid substitution associate pi-resistance treatment failure occur week 12 7 patient amino acid substitution associate pi-resistance observe case hcv ns3 r155 k t54a/s mutant 1a find patient median interquartile range plasma concentration 3,092 ng/ml 2,320 3,525 telaprevir 486 ng/ml 265 619 boceprevir hiv-hcv co-infecte patient median concentration 3,162 ng/ml 2,270 4,232 telaprevir 374 ng/ml 229 519 boceprevir plasma drug concentration monitoring reveal undetectable concentration patient week 4 probable non-adherence therapy patient finding indicate routine hcv ns3 protease sequencing plasma pi concentration monitoring helpful characterize case therapy failure cost dramatically low compare anti-hcv therapy\",\"recently direct-acting antiviral agent hepatitis c virus hcv non-structural 3/4a ns3/4a protease inhibitor pi introduce triple therapy regimen include pi conventional pegylated interferon \\u03b1 ribavirin significantly improve sustained virological response svr rate 80 treatment-na\\u00efve treatment-experienced patient hcv 1 report time case successful treatment hcv 1 infection generation pi drug telaprevir base triple therapy treatment failure second generation pi drug vaniprevir base triple therapy 67-year-old treatment-na\\u00efve japanese man hcv 1b infection phase iii clinical trial vaniprevir-based triple therapy serum hcv rna undetectable week 2 svr highly expect hcv rna reappear week 4 vaniprevir treatment polymerase chain reaction direct sequence hcv ns3/4a gene week 8 vaniprevir treatment emergence vaniprevir-resistance mutation d168v probable reason treatment failure month later retreatment telaprevir-based triple therapy start dosage telaprevir ribavirin reduce severe anemia patient achieve svr case value repeat pi-based triple therapy different drug process reduce chance drug resistant mutation\",\"hepatitis c infection represent major health problem egypt 20 patient undergo spontaneous clearance virus 25 patient progress develop cirrhosis 90 egyptian patient hepatitis c virus hcv genotype-4 combined pegylated interferon oral ribavirin current standard therapy hcv-4 aim work evaluate predictive power rs12979860 il28b snp rs12980275 il28b snp treatment response egyptian patient infect hcv 4 hcv patient receive combined treatment study rs12979860 rs12980275 polymorphism restriction fragment length polymorphism technique rs12979860 cc rs12979860 aa significantly associate sustained virological response p=0.001 result suggest study il28b polymorphism contribute proper prediction response standard therapy egyptian patient optimize cost effectiveness minimize unneeded adverse effect therapy\",\"antiviral drug use therapeutic purpose influenza illness human antiviral-resistant variant nullify effectiveness antiviral combined medication treatment cancer infectious disease suggest option control antiviral-resistant influenza virus evaluate therapeutic value combination therapy oseltamivir-resistant 2009 pandemic influenza h1n1 virus infection dba/2 mouse mouse treat day favipiravir peramivir start 4 hour lethal challenge compare monotherapy combination therapy save mouse viral lethality result increase antiviral efficacy lung infected mouse furthermore synergism antiviral consistent survival outcome combination therapy indicate favipiravir serve critical agent combination therapy control oseltamivir-resistant strain result provide new insight feasibility favipiravir combination therapy oseltamivir-resistant influenza virus infection\",\"hepatitis c virus hcv major cause liver disease worldwide hcv able evade host defense mechanism include innate acquire immune response establish persistent infection result broad spectrum pathogenicity lipid glucose metabolism disorder hepatocellular carcinoma development hcv genome characterize high degree genetic diversity associate viral sensitivity resistance reflect different virological response interferon (ifn)-based therapy regard importance note polymorphism certain hcv genomic region close correlation treatment outcome particular hcv protein core nonstructural protein ns 5a extensively study correlation response ifn-based treatment review aim cover updated information impact major hcv genetic factor include hcv mutation amino acid 70 91 core protein sequence heterogeneity ifn sensitivity-determining region ifn/ribavirin resistance-determining region ns5a virological response ifn-based therapy\",\"insulin resistance ir affect sustained virological response svr peginterferon alfa plus ribavirin pr patient chronic hepatitis c chc add-on oral hypoglycemic agent oha pr improve svr remain unclear conduct prospective randomized pilot trial 23 consecutive patient 1 chc ir taiwan\",\"hepatitis c virus hcv successful pathogen ground exploit host metabolism build viral particle favour survival induce chronic disease development specific anatomic change infected organ steatosis associate hcv infection necessity chance approximately 6 hcv patient steatohepatitis interestingly hcv steatosis occur setting multiple metabolic abnormality hyperuricemia reversible hypocholesterolemia insulin resistance arterial hypertension expansion visceral adipose tissue collectively refer hepatitis c-associated dysmetabolic syndrome hcads general nonalcoholic fatty liver disease (nafld)-like mechanism steatogenesis include increase availability lipogenic substrate de novo lipogenesis decrease oxidation fatty substrate export fatty substrate share hcv 3 seemingly amplify steatogenic molecular mechanism report occur nafld profound change microsomal triglyceride transfer protein peroxisome proliferator-activated receptor alpha sterol regulatory element-binding protein phosphatase tensin homologue hcv steatosis remarkable clinical impact acknowledge risk factor accelerate fibrogenesis impaired treatment response interferon ribavirin development hepatocellular carcinoma recent datum suggest hcv-steatosis contribute premature atherogenesis direct indirect mechanism conclusion hcv steatosis fulfill expect requirement necessary perpetuate hcv life cycle understanding physiology hcads likely result successful handling disease improve antiviral success rate\",\"sofosbuvir sovaldi \\u00ae nucleotide hepatitis c virus hcv ns5b polymerase inhibitor pangenotypic antiviral activity high genetic barrier resistance article review clinical efficacy tolerability sofosbuvir patient chronic hepatitis c summarize pharmacological property interferon-free treatment sofosbuvir plus ribavirin achieve high sustained virological response svr rate treatment-na\\u00efve treatment-experienced patient hcv 2 3 infection efficacy patient hcv 1 infection sofosbuvir plus ribavirin effective patient co-infecte hcv hiv sofosbuvir plus ribavirin administer prior liver transplantation prevent recurrent hcv infection majority patient hcv rna level limit quantification time transplantation sofosbuvir plus peginterferon-\\u03b1-2a ribavirin achieve high svr rate patient hcv 1 infection appear effective patient hcv 4 5 6 infection oral sofosbuvir generally tolerate patient chronic hepatitis c. commonly report adverse event laboratory abnormality consistent expect ribavirin peginterferon-\\u03b1 conclusion sofosbuvir represent important advance treatment chronic hepatitis c.\",\"despite introduction protease inhibitor pi treatment hepatitis c sensitivity interferon continue essential achieve sustained virological response svr eradicate viral infection currently pegylated interferon peg-ifn ribavirin rbv require avoid selection pi-resistance mutation likelihood obtain svr dual therapy treatment-na\\u00efve patient 1 infection vary 40 50 half patient require pi avoid adverse effect considerably reduce cost treatment identify patient potentially respond dual therapy main challenge clinical practice genetic variability host main factor affect sensitivity peg-ifn response current treatment baseline factor related host virus especially intratreatment factor rapid virological response rvr strongly associate probability achieve svr evidence decision prescribe dual triple therapy accord factor predictive response base retrospective study post-hoc analysis pivotal study pi study polymorphism ifnl3 gene il28b itpa ifn-stimulated gene isg tt/\\u03b4g ss469415590 ifnl4 rbv transporter help decision prescribe dual triple therapy treatment na\\u00efve patient\",\"resistance direct-acting antiviral daa agent hepatitis c virus hcv infection drive selection mutation different position ns3 protease ns5b polymerase ns5a protein exception ns5b nucleos(t)ide inhibitor daa possess low genetic barrier resistance significant cross-resistance compound belong family specific mutation profile associate agent drug class vary depend genotype/subtype e.g. 1b high rate sustained virological response svr higher genetic barrier resistance 1a resistance mutation exist natural polymorphism certain genotypes/subtype frequency require baseline drug resistance testing recommend certain antiviral example polymorphism q80 k frequently find 1a 19 48 associate resistance simeprevir similarly l31 m y93h key resistance mutation ns5a inhibitor frequently find 6 12 ns5a 1 sequence particular presence polymorphism relevance poorly interferon-responsive patient i.e. null responder non-cc il28b daa-based therapy combination pegylated interferon-\\u03b1 plus ribavirin relevance pre-existing resistance mutation response interferon-free daa therapy unclear regimen require study\",\"previous study rna virus attenuate increase decrease viral polymerase replication fidelity foot-and-mouth disease virus fmdv high-fidelity rna-dependent rna polymerase rdrp variant attenuate phenotype isolate use mutagen fmdv mutant low-fidelity polymerase document date describe generation fmdv rdrp mutant use site-directed mutagenesis reverse genetic system mutation frequency assay confirm rescue fmdv rdrp mutant population low replication fidelity wild-type virus population allow assess effect change replication fidelity virus phenotype low-fidelity fmdv rdrp mutant increase sensitivity ribavirin 5-fluorouracil 5-fu treatment loss growth capacity cell culture addition decrease fitness attenuate virulence observe rdrp mutant low fidelity importantly base quantitative analysis fidelity virulence conclude low replication fidelity associate attenuate virus phenotype result far contribute understanding replication fidelity polymerase rna virus relationship virulence attenuation\",\"study c210 phase iia exploratory trial assess activity telaprevir hepatitis c virus hcv early viral kinetic treatment-na\\u00efve patient infect 4 g4 hcv\",\"hepatitis c virus hcv single-stranded positive-sense rna virus 70 patient expose hcv develop chronic infection lead scarring liver ultimately cirrhosis liver failure hepatocellular carcinoma past decade standard therapy hcv infection combination interferon-\\u03b1 ribavirin recent year direct-acting antiviral agent boceprevir telaprevir add therapeutic regiman considerably improve cure rate hcv infection treatment continue cause substantial effect associate drug resistance frequent mutation hcv rna genome result low fidelity rna polymerase micrornas mirna class small non-coding rna approximately 22 nucleotide length derive cellular viral transcript bind target mrna sequence-specific manner result mrna cleavage translational repression subsequent modulation expression majority protein-coding gene mirna implicate regulate multiple aspect hcv life cycle certain mirna serve essential mediator interferon-based antiviral therapy furthermore recent study document potential value mirna novel therapeutic target hepatitis c infectivity\",\"drug resistance major hurdle oncology response acute myeloid leukaemia aml patient cytarabine (ara-c)-based therapy short live median overall survival month therapy development improve outcome include target eukaryotic translation initiation factor eif4e inhibitor ribavirin phase ii clinical trial poor prognosis aml ribavirin monotherapy yield promising response include remission patient relapse identify novel form drug resistance ribavirin ara-c. observe sonic hedgehog transcription factor glioma-associated protein 1 gli1 udp glucuronosyltransferase ugt1a family enzyme elevated resistant cell ugt1as add glucuronic acid drug modify activity diverse tissue gli1 sufficient drive ugt1a-dependent glucuronidation ribavirin ara-c drug resistance resistance overcome genetic pharmacological inhibition gli1 reveal potential strategy overcome drug resistance patient\",\"new nucleos(t)ide analogue na high genetic barrier hepatitis b virus hbv resistance entecavir tenofovir improve prognosis patient hbv decompensated cirrhosis prevent hbv recurrence liver transplantation lt na consider proper approach hbv infection patient renal replacement therapy dose adjust accord patient creatinine clearance addition physician aware potential nephrotoxicity patient chronic hepatitis c decompensated cirrhosis receive therapeutic option lt hepatitis c virus hcv recurrence lt combination subcutaneous peg-ifn ribavirin generally therapy hcv renal transplantation avoid optimal antiviral therapy hcv infection establish attention turn new oral direct act antiviral treatment mark promising strategy prognosis amelioration disease\",\"hepatitis c virus hcv nonstructural 5a ns5a protein clinically validate target drug design treat chronic hcv infection study evaluate vitro activity selectivity resistance profile novel anti-hcv compound samatasvir idx719 combination antiviral agent samatasvir effective selective infectious hcv replicon 50 effective concentration ec50s fall tight range 2 24 pm 1 5 replicon 10-fold ec50 shift presence 40 human serum 1b replicon ec90/ec50 ratio low 2.6 50 cytotoxic concentration cc50 100 \\u03bcm provide selectivity index 5 \\u00d7 10(7 resistance selection experiment 1a replicon testing replicon bear site-directed mutation 1a 1b replicon identify ns5a amino acid 28 30 31 32 93 potential resistance locus suggest samatasvir affect ns5a function samatasvir demonstrate overall additive effect combine interferon alfa ifn-\\u03b1 ribavirin representative hcv protease nonnucleoside polymerase inhibitor nucleotide prodrug idx184 samatasvir retain activity presence hiv hepatitis b virus hbv antiviral cross-resistant hcv protease nucleotide nonnucleoside polymerase inhibitor class samatasvir selective low-picomolar inhibitor hcv replication vitro promising candidate future combination therapy direct-acting antiviral drug hcv-infected patient\",\"approximately 30 hiv-infected patient co-infecte hepatitis c virus hcv release highly active antiretroviral therapy liver disease lead cause morbidity mortality hiv patient prior 2011 hcv treatment pegylated-interferon ribavirin hcv/hiv co-infected patient allow 14 38 patient hcv 1 achieve sustained virologic response svr additionally treatment commonly discontinue result adverse event recently simeprevir sofosbuvir approve food drug administration fda hcv mono-infection sofosbuvir fda approval co-infecte patient offer unprecedented svr rate potential interferon-free therapy hcv therapy pipeline offer improve treatment time safety profile rate svr despite improvement new issue include adherence drug-drug interaction antiretroviral therapy adverse event resistance patient selection complicate therapy article review current status direct-acting antiviral (daa)-containe regimen hiv/hcv co-infecte patient usa new result investigate telaprevir boceprevir discuss relevant location new daa available impact future interferon-free therapy co-infecte patient discuss\",\"ribavirin prove effective virus clinical setting multitude virus vitro different propose mechanism action recent advance begin discern hierarchy antiviral effect play depend virus host condition scrutiny study reveal virus antiviral mechanism differ depend cell type vitro vivo analysis require accurately identify mechanism optimally determine clinical treatment recent year grow number ribavirin resistant sensitive variant identify variant inform specific mechanism ribavirin enfeeble virus tool identify new antiviral compound\",\"phase 3 study telaprevir t combination peginterferon \\u03b1-2a ribavirin pr treatment-naive 1 chronic hepatitis c virus-infected patient advance/illuminate design priori assess effect race ethnicity treatment response factor important lower sustained virologic response svr rate observe black hispanic/latino patient treat pr\",\"recent year clinical research field new treatment chronic hepatitis c hcv devote develop regimen base direct-acting antiviral daa goal increase treatment efficacy improve tolerability safety achieve peginterferon (pegifn)-free anti-hcv regimen pegifn responsible effect limit treatment access contraindication patient category sofosbuvir sof compound enter market ifn-free combination regimen belong nucleotide inhibitor viral polymerase ns5b act chain terminator hcv replication process exhibit pan-genotypic antiviral activity high barrier resistance clinical trial hcv 2/3 patient demonstrate optimal efficacy hcv-2 combination sof/ribavirin rbv 12 week result 90 sustain virological response svr rate hcv-3 patient advanced liver fibrosis previous failure pegifn plus rbv therapy require individualized optimize treatment strategy historically difficult-to-treat hcv-1 -4 6 benefit reduce duration pegifn plus sof rbv ifn-free regimen patient base sof combination daa class optimal tolerability safety profile significant drug-to-drug interaction sof currently undergo clinical trial setting pre- post-liver transplantation hiv-coinfected patient objective address unmet need safe efficient treatment population article provide overview sof feature main clinical trial discuss key result potential future development\",\"despite advance chronic hepatitis c treatment proportion patient respond poorly treatment study aim explore hepatic mrna microrna signature involve hepatitis c treatment resistance global hepatic mrna microrna expression profile compare use microarray datum treatment response quantitative real-time polymerase chain reaction validate gene signature 130 patient infect hepatitis c virus 1b treat pegylated interferon-alpha ribavirin combination therapy correlation mrna microrna evaluate use silico analysis vitro sirna microrna inhibition/overexpression experiment multivariate regression analysis identify independent variable il28b snp rs8099917 hsa-mir-122 5p hsa-mir-17 5p map3k8 significantly associate poor virologic response map3k8 mir-17 5p expression inversely correlate treatment response furthermore mir-17 5p repress hcv production target map3k8 collectively datum suggest molecule inverse correlation mrna microrna contribute host genetic refractory hepatitis c treatment response\",\"safety tolerability peginterferon-based hepatitis c virus hcv infection therapy remain suboptimal direct-acting antiviral agent add study assess efficacy safety tolerability mericitabine combine ritonavir-boosted danoprevir danoprevir/r \\u00b1 ribavirin 24 week treatment-na\\u00efve hcv (g)1 infected patient\",\"understand hepatitis c virus hcv replication limit access serial sample liver primary site viral replication understanding hcv replicate develop drug-resistant variant liver limited study 15 patient chronically infect 1 hcv treat telaprevir (tvr)/pegylated-interferon alpha/ribavirin hepatic fine needle aspiration perform treatment hour 10 day 4 15 week 8 initiation antiviral therapy measure viral kinetic resistance pattern tvr concentration host transcription profile patient complete protocol-defined procedure generally tolerated first-phase hcv decline baseline/treatment day 4 significantly slow liver plasma slope plasma -0.29 liver -0.009 p 0.001 second-phase decline posttreatment day 4 15 differ body compartment -0.11 -0.15 respectively p 0.1 tvr-resistant variant detect plasma liver wild-type virus detect base nonstructural protein 3 sequence analysis compartmentalization viral population observe plasma liver compartment gene expression profiling reveal strong tissue-specific expression signature human intrahepatic tvr concentration measure time low compare plasma gram milliliter basis find moderate heterogeneity hcv rna level different intrahepatic site indicate difference hepatic microenvironment\",\"hcv infection major world health problem lead end-stage liver disease primary liver cancer great effort develop new therapy hcv infection combination therapy pegylated ifn-\\u03b1 ribavirin pegifn-rbv remain choice treatment chronic hcv infection country treatment response pegifn-rbv remain relatively low understand molecular mechanism persistent hcv infection pegifn-rbv resistance suggest way improve current standard care offer new antiviral therapy hcv viral infection recent datum suggest increase expression hepatic ifn-stimulated gene isg treatment associate treatment nonresponse patient chronically infect hcv isg generally antiviral nature case hcv virus exploit benefit unique hcv blockade type ifn signaling control persistent lcmv infection certain viral infection preactivation overactivation type ifn signaling contribute viral persistence review briefly summarize finding high-throughput gene expression profile patient chronically infect hcv focus novel ubiquitin-like signaling pathway isg15/usp18 potential role hcv persistence finally role activation endogenous type ifn signaling persistent hcv infection discuss context recent study indicate block ifn signaling control persistent lcmv infection\",\"use ultra-deep sequencing technology present study design investigate evolution simeprevir-resistant variant amino acid substitution aa80 aa155 aa156 aa168 position hcv ns3 region time toranomon hospital 18 japanese patient infect hcv 1b receive triple therapy simeprevir/peg-ifn/ribavirin dragon concert study sustained virological response rate 67 significantly high patient il28b rs8099917 tt non-tt patient achieve sustained virological response test resistant variant ultra-deep sequencing baseline time re-elevation viral load 96 week completion treatment 18 resistant variant detect re-elevation viral load de novo resistant variant 12 de novo resistant variant undetectable time seven resistant variant detect baseline persist time patient variant q80r baseline 0.3 increase 96-week cessation treatment 10.2 de novo resistant variant d168e 0.3 increase 96-week cessation treatment 9.7 conclusion present study indicate emergence simeprevir-resistant variant start treatment predict baseline majority de novo resistant variant undetectable time far large-scale prospective study perform investigate clinical utility detect simeprevir-resistant variant\",\"clinical trial treatment combination nucleotide polymerase inhibitor sofosbuvir antiviral drug ribavirin associate high response rate patient hepatitis c virus hcv 2 infection low response rate patient hcv 3 infection\",\"interferon-free regimen abt-450 ritonavir abt-450/r ombitasvir dasabuvir ribavirin efficacy induce sustained virologic response phase 2 study involve patient hepatitis c virus hcv 1 infection conduct phase 3 trial examine efficacy safety regiman previously untreated patient hcv 1 infection cirrhosis\",\"treatment chronic hepatitis c hcv currently undergo significant change traditional interferon-based therapy limit efficacy tolerability direct act antiviral daa drug emerge sofosbuvir gs-7977 hcv ns5b nucleotide polymerase inhibitor evaluate extensively phase ii iii interferon-free clinical trial focus review clinical potential sofosbuvir treatment hcv sofosbuvir pan-genotypic effect hcv viral genotype-specific difference sustained virological response svr emerge phase iii clinical trial sofosbuvir study dual therapy ribavirin triple therapy ns5a inhibitor protease inhibitor high rate svr report interferon-free combination particularly 1 2 safety profile favourable cirrhotic noncirrhotic patient issue viral resistance interferon-free once-daily treatment hcv reality\",\"certain host single nucleotide polymorphism snp affect likelihood sustained virological response svr treatment subject infect hepatitis c virus hcv snp promoter interleukin (il)-10 -1082 a/g rs1800896 myxovirus resistance protein 1 -123 c/a rs17000900 -88 g/t rs2071430 tumour necrosis factor tnf -308 g/a rs1800629 -238 g/a rs361525 gene outcome pegylated \\u03b1-interferon plus ribavirin therapy investigate analysis perform 114 brazilian hcv 1-infected patient svr 85 non-responder 64 relapser significantly increase risk null virological response observe patient carry allele position -308 odd ratio 2.58 95 confidence interval ci 1.44 4.63 p 0.001 -238 7.33 95 ci 3.59 14.93 p 0.001 tnf promoter risk relapsing elevated -308 2.87 95 ci 1.51 5.44 p 0.001 -238 4.20 95 ci 1.93 9.10 p 0.001 multiple logistic regression tnf diplotype patient copy allele high risk null virological response 16.43 95 ci 5.70 47.34 p 0.001 relapsing 6.71 95 ci 2.18 20.66 p 0.001 statistically significant association find snp study anti-hcv therapy response\",\"key effective interferon- ifn- free therapy hepatitis c virus hcv infection direct-acting antiviral daa high barrier resistance act backbone regimen ideally agent active hcv tolerated drug interaction nucleoside/nucleotide analogue na inhibit function hcv rna-dependent-rna polymerase fit requirement hold promise cornerstone new ifn-free regimen date issue class agent toxicity numerous na early clinical development lead significant toxicity lead abandonment sofosbuvir prodrug uridine na development clean-safety profile lead recent approval combine ribavirin rbv sofosbuvir effective 2 3 duration extend currently limited datum combination 1 sofosbuvir combine daa different class highly effective patient date sofosbuvir study protease ns5a nonnucleoside hcv polymerase inhibitor include fixed-dose combination single tablet ns5a inhibitor ledipasvir high rate svr little 8 week therapy combine daa sofosbuvir shorten therapy far poor replicative fitness s282 t sofosbuvir-resistant variant resistance sofosbuvir significant clinical issue trial far addition sofosbuvir na early-stage development provide unanticipated toxicity emerge na likely play major role backbone future hcv therapy rationale use class agent clinical datum available date review\",\"development new model tool lead discovery clinical development large number new anti-hepatitis c virus hcv drug include direct-acting antiviral host-targeted agent surprisingly cure hcv infection appear easy new drug provide potent drug combination high barrier resistance use hcv infection cure rate optimize combine drug synergistic antiviral effect tailor treatment duration patient need and/or use ribavirin hcv drug approve 2011 -telaprevir boceprevir first-wave first-generation ns3 4a protease inhibitor 2013/2014 -simeprevir second-wave first-generation ns3 4a protease inhibitor sofosbuvir nucleotide analogue inhibitor viral polymerase numerous drug reach phase ii iii clinical development 2015 onward interferon-containing regimen disappear replace interferon-free regimen yield infection cure rate 90 therapy raise new issue include need broad-scale screening access care\",\"presently interferon- ifn- contain treatment regimen standard care patient hepatitis c virus hcv infection therapy eliminate virus substantial proportion patient numerous effect contraindication recent approval telaprevir boceprevir target protease reside nonstructural protein 3 ns3 hcv genome increase therapy success combination pegylated ifn ribavirin effect frequent management treatment complex situation change soon introduction new highly potent direct-acting antiviral target addition ns3 protease ns5a require rna replication virion assembly ns5b rna-dependent rna polymerase host-cell factor cyclophilin microrna-122 essential hcv replication pursue therapeutic target review briefly summarize main feature viral cellular factor involve hcv replication utilize therapy target chronic hepatitis c.\",\"lipid profile insulin resistance ir associate hepatitis c virus hcv predict chronic hepatitis c chc treatment response aim study determine association chc treatment response lipid profile ir change treatment\",\"exist standard care chronic hepatitis c virus hcv infection include use pegylated interferon ribavirin primary component treatment addition direct-acting antiviral 1 infection sofosbuvir oral nucleotide inhibitor hcv nonstructural protein 5b rna-dependent rna polymerase enzyme recently approve use combination ribavirin and/or pegylated interferon chronic hcv infection depend sofosbuvir orally administer peak plasma concentration affect food drug renally eliminate require adjustment mild moderate renal insufficiency degree hepatic impairment sofosbuvir metabolize cytochrome p450 isoenzyme induce inhibit metabolism agent substrate enzyme sofosbuvir demonstrate high barrier resistance tolerate patient clinical trial overall efficacy rate vary 70 90\",\"bms-791325 allosteric inhibitor bind thumb site 1 hepatitis c virus hcv ns5b rna-dependent rna polymerase bms-791325 inhibit recombinant ns5b protein hcv 1 3 4 5 50 inhibitory concentration ic50 28 nm. cell culture bms-791325 inhibit replication hcv subgenomic replicon represent 1a 1b 50 effective concentration ec50s 3 nm 6 nm respectively similar 3 18 nm value 3a 4a 5a potency 6a variability 9 125 nm activity weak 2 ec50 87 925 nm specificity demonstrate absence activity ec50s 4 \\u03bcm panel mammalian virus cytotoxic concentration 50 3,000-fold hcv ec50 resistance substitution select bms-791325 1 replicon map single site ns5b amino acid 495 p495a/s/l/t additive synergistic activity observe combination study use bms-791325 alfa interferon plus ribavirin inhibitor ns3 protease ns5a class ns5b inhibitor palm site 2-binding nucleoside analog plasma liver exposure vivo animal specie indicate bms-791325 hepatotropic disposition liver-to-plasma ratio range 1.6- 60-fold specie twenty-four hour postdose liver exposure specie test \\u2265 10-fold inhibitor ec50s observe hcv 1 replicon finding support evaluation bms-791325 combination regimen treatment hcv phase 3 study ongoing\",\"mk-5172 inhibitor hepatitis c virus hcv nonstructural protein 3/4a protease mk-5172 daily high potency barrier resistance licensed protease inhibitor investigate efficacy tolerability mk-5172 peginterferon ribavirin pr treatment-naive patient chronic hcv 1 infection cirrhosis\",\"current treatment hcv-4 patient dual therapy peg-ifn ribavirin new drug available month despite evidence good virological response ifn-free regimen high cost new therapy require patient selection paper propose use rs8099917 rs12979860 il28-b polymorphism order identify potentially category svr null-responder relapse consequently choose dual therapy novel approach\",\"phase 2 study treatment all-oral combination nucleotide polymerase inhibitor sofosbuvir ns5a inhibitor ledipasvir result high rate sustained virologic response previously untreated patient hepatitis c virus hcv 1 infection\",\"interferon-containing regimen treatment hepatitis c virus hcv infection associate increase toxic effect patient cirrhosis evaluate interferon-free combination protease inhibitor abt-450 ritonavir abt-450/r ns5a inhibitor ombitasvir abt-267 nonnucleoside polymerase inhibitor dasabuvir abt-333 ribavirin open-label phase 3 trial involve previously untreated previously treat adult hcv 1 infection compensate cirrhosis\",\"development antiviral drug broad-spectrum activity number viral infection significant benefit evolution resistance currently antiviral drug development novel anti-influenza drug progress include favipiravir t-705 currently human clinical trial t-705 display broad-spectrum vitro activity number virus include rift valley fever virus rvfv rvf important neglect tropical disease cause human agricultural economic loss endemic region rvf capacity emerge new location present potential bioterrorism threat current study vivo efficacy t-705 evaluate wistar-furth rat infect virulent zh501 strain rvfv aerosol route\",\"high rate sustained virologic response observe patient hepatitis c virus hcv infection receive 12 week treatment nucleotide polymerase inhibitor sofosbuvir combine ns5a inhibitor ledipasvir study examine 8 week treatment regiman\",\"hepatitis c virus hcv infection represent major health issue worldwide burden chronic liver disease extrahepatic manifestation include cardiovascular disease associate excess mortality analysis publish study support view hcv infection consider risk factor development carotid atherosclerosis heart failure stroke contrast finding study address coronary artery disease hcv yield conflicting result meta-analytic review prospective study warrant pathogenic mechanism connect hcv infection chronic liver disease atherogenesis completely understand hypothesize hcv promote atherogenesis complication direct indirect biological mechanism involve hcv colonization replication arterial wall liver steatosis fibrosis enhance imbalanced secretion inflammatory cytokine oxidative stress endotoxemia mixed cryoglobulinemia perturb cellular humoral immunity hyperhomocysteinemia hypo-adiponectinaemia insulin resistance type 2 diabete component metabolic syndrome understand complex mechanism fundamental importance development novel therapeutic approach prevent treat vascular complication patient chronic hcv infection currently hcv clearance interferon ribavirin treatment significantly reduce non-liver-related mortality interferon-based treatment appear decrease risk ischemic stroke\",\"approximately 170 million people worldwide chronic carrier hepatitis c virus hcv twenty-five percent develop liver cirrhosis hepatocellular carcinoma life successful antiviral treatment dramatically reduce risk disease progression hcv infection treat pegylated interferon ribavirin addition protease inhibitor boceprevir telaprevir consider patient 1\",\"direct-acting antiviral agent hepatitis c virus hcv telaprevir boceprevir available 2011 report hcv ns5a associate interferon signaling related hcv replication hepatocarcinogenesis hcv ns5a inhibitor efficiently inhibit hcv replication vitro human study dual triple quad regimen hcv ns5a inhibitor daclatasvir ledipasvir combination direct-acting antiviral agent region hcv peginterferon/ribavirin efficiently inhibit hcv replication accord hcv combination powerful tool difficult-to-treat hcv-infected patient generation hcv ns5a inhibitor daclatasvir ledipasvir abt-267 phase iii clinical trial result resistance mutation second generation ns5a inhibitor gs-5816 ach-3102 mk-8742 display improvement genetic barrier maintain potency hcv ns5a inhibitor safe low concentration attractive use despite low genetic barrier fact hcv ns5a inhibitor use hcv ns3/4a inhibitor hcv ns5b inhibitor peginterferon plus ribavirin review article describe hcv ns5a inhibitor resistance mutation recommend hcv ns5a inhibitor use combination regimen potent prevent emergence resistant variant\",\"liver cirrhosis lc critical stage chronic liver disease include cause hepatitis c virus hcv absence antiviral therapy 67%-91 patient hcv-related lc patient die liver-related cause include hepatocellular carcinoma hcc liver failure therapeutic strategy use prevent liver-related complication patient standard therapy pegylated interferon ribavirin induce sustained virological response svr 25 hcv 1-infected patient 69 patient infect 2 3 svr patient hcv-related lc associate reduce rate hepatic decompensation hcc mortality recently develop direct-acting antiviral agent excellent antiviral efficacy preliminary datum demonstrate interferon-free regiman include direct-acting antiviral agent achieve svr 50 patient hcv 1 lc branched-chain amino acid supplementation improvement insulin resistance use \\u03b2-blocker portal hypertension reduce liver-related complication review advance antiviral adjunctive therapy improve outcome patient hcv-associated lc\",\"genetic factor play important role treatment response disease progression chronic viral hepatitis\",\"telaprevir non-structural (ns)3/4a protease inhibitor direct-acting antiviral drug inhibit viral replication triple therapy telaprevir pegylated interferon ribavirin standard therapeutic regiman patient 1b chronic hepatitis c virus hcv infection high viral load factor include mutation ns5a gene important predictor efficacy interferon therapy study examine mutational diversity ns5a impact efficacy triple therapy enrol patient 1b chronic hcv infection high viral load 31 males/17 female mean age 57.6 year treat triple therapy study conduct kobe university hospital affiliated hospital hyogo prefecture japan november 2011 june 2013 sustained viral response 12 week svr12 achieve 37/48 patient 77 base intent-to-treat analysis svr12 significantly great patient major allele minor allele il28b single nucleotide polymorphism snp 88 vs. 56 p<0.05 prevalence v2334i mutation ns5a significantly high patient achieve svr12 g2356e significantly high patient achieve svr12 p<0.05 mutation ns3 region think confer resistance telaprevir detect 3/27 patient achieve svr12 val36 n=3 5/10 patient achieve svr12 val36 n=4 thr54 n=1 conclusion il28b snp mutation ns5a region associate therapeutic response triple therapy half patient achieve svr12 mutation confer resistance telaprevir pre-existing mutation ns3 affect efficacy triple therapy\",\"therapy hepatitis c undergo revolution new drug hepatitis c virus hcv reach market include direct-acting antiviral host-targeted agent phase ii iii clinical development all-oral interferon-free combination drug expect cure 90 infection vast datum clinical trial present regularly international conference release press peer-review create confusion viral hepatitis field goal review clarify current stage hcv therapy drug development review describe different class drug mechanism property treatment strategy development include interferon-based interferon-free hcv treatment option available 2014 2015 present number unanswered question challenge remain treat special population role ribavirin interferon-free regimen role hcv resistance treatment failure good re-treat patient fail treatment strategic choice cost issue hcv screening improve access care resource-constrained area discuss\",\"st john wort sjw hypericum perforatum induce cyp3a4 involve metabolism hepatitis c virus hcv protease inhibitor boceprevir reduce boceprevir exposure efficacy contribute therapeutic failure increase risk resistance development boceprevir co-administere interferon/ribavirin depression describe frequently patient undergo hcv treatment patient purchase over-the-counter herbal manage depression know interaction sjw boceprevir desirable\",\"treatment patient infect hepatitis c virus hcv 1 undergo major change availability direct-acting antiviral triple therapy contain telaprevir boceprevir first-wave ns3 protease inhibitor combination peginterferon ribavirin improve rate sustained virologic response compare peginterferon ribavirin patient hcv 1 development drug-resistant variant concern patient treat telaprevir boceprevir different pattern resistance observe major hcv 1 1a 1b 1b associate low rate resistant variant selection response triple therapy compare 1a similar subtype-specific pattern observe investigational direct-acting antiviral include second-wave ns3 protease inhibitor ns5a inhibitor non-nucleoside ns5b inhibitor review explore resistance approve investigational direct-acting antiviral treatment hcv focus difference 1a 1b finally importance hcv 1 resistance treatment outcome clinician aware test currently available subtyping limitation\",\"use triple-therapy pegylated-interferon ribavirin generation hepatitis c virus hcv protease inhibitor telaprevir boceprevir new standard care treat 1 chronic hcv clinical trial response rate 70 80 limited datum use combination outside setting expand access programme treat 59 patient treatment na\\u00efve experienced triple therapy baseline factor predict treatment response failure triple therapy phase identify 58 patient thirty seven 63.8 58 patient undetectable hcv rna 12week end treatment 1a p=0.053 null-response previous treatment p=0.034 rate viral load decline 12week previous interferon-based treatment p=0.033 associate triple-therapy failure common cause on-treatment failure telaprevir-based regimen development resistance-associated variant rav amino acid 36 and/or 155 hcv protease p=0.027 boceprevir-based regimen mutation amino acid 54 significant p=0.015 svr12 rate approach 64 achieve use triple therapy outside clinical trial setting patient cohort include cirrhotic\",\"epidemiological study increase occurrence metabolic disorder insulin resistance ir steatosis patient hepatitis c virus hcv infection ir believe represent central clinical feature metabolic syndrome major pathogenetic factor type 2 diabete mellitus patient chronic hcv hepatitis ir dangerous consequence accelerate progression liver fibrosis resistance antiviral therapy development hepatocellular carcinoma accord recent evidence global epidemic metabolic disorder related incorrect diet lead physician deal 1.2 billion patient diabete world 2025 high prevalence hcv infection country metabolic manifestation contribute increase morbidity mortality patient hcv chronic infection near future hcv treatment able decrease occurrence hcv-related ir diabete reduce risk associate morbidity\",\"hepatitis c virus hcv major cause liver disease hepatocellular carcinoma worldwide hcv establish chronic infection majority case individual clear virus demonstrate protective role host immune response new all-oral drug combination soon replace traditional ribavirin-interferon therapy emerge drug cocktail expensive associate side-effect resistance global vaccine urgent priority t cell widely accept play essential role clear acute hcv infection role antibody play resolution disease pathogenesis understand recent study provide insight viral neutralizing determinant protective role antibody infection review provide historical perspective role neutralize antibody play hcv infection discuss therapeutic benefit antibody-based therapy article form symposium antiviral research hepatitis c step global eradication\",\"resistance babesia parasite current anti-babesiosis drug issue major concern inosine 5'-monophosphate dehydrogenase impdh babesia gibsoni identify characterize molecular drug target previous study present study inhibitory effect impdh inhibitor mycophenolate mofetil mizoribine ribavirin 7-nitroindole mycophenolic acid evaluate vitro vivo inhibition assay recombinant b. gibsoni impdh activity mycophenolate mofetil potent inhibitor ic(50 2.58 \\u00b1 1.32 \\u03bcm ribavirin potent inhibitory effect mycophenolate mofetil mizoribine ribavirin 7-nitroindole vitro growth b. gibsoni babesia bovis assess result reveal mycophenolate mofetil potent inhibitor multiplication b. gibsoni ic(50 0.13 \\u00b1 0.05 \\u03bcm b. bovis ic(50 0.97 \\u00b1 0.49 \\u03bcm ribavirin potent b. gibsoni b. bovis vitro mycophenolic acid metabolite mycophenolate mofetil cause inhibition babesia microti mouse noticeable improvement hematological parameter infected mouse ed(50 44.15 \\u00b1 12.53 mg/kg report provide non-exhaustive view potential treatment strategy address potential adverse effect immune suppression infection result indicate impdh molecular target mpa b. microti altogether provide basis development antibabesia prodrug target impdh parasite treatment babesiosis\",\"mutation ns5b gene hepatitis c virus hcv report patient undergo antiviral therapy present study report emerge clade hcv-3a patient administer ifn plus ribavirin therapy 24 week low viral load 250 iu/ml mutation d/n244e k304r n/k307 g q/t329v a338v find associate emerge strain distinct hcv associate increase antiviral drug pressure\",\"insulin resistance associate nonresponse hepatitis c virus hcv treatment multicenter single-arm pilot study adult hiv/hcv 1-coinfected previous nonresponder peginterferon/ribavirin pegifn/rbv homeostatic model assessment insulin resistance 2.5 treat pioglitazone pio 24 week follow pegifn/rbv/pio 19 subject 15.8 achieve undetectable hcv rna week 24 pegifn/rbv/pio significantly different historical null rate 10 p 0.29 low limit exact 1-sided 90 confidence interval 5.9 24 week pio monotherapy alanine aminotransferase aspartate aminotransferase decline significantly correlate improve metabolic parameter\",\"patient chronic hcv infection association il28b insulin-resistance ir known predictor sustained virological response svr pegylated interferon peg-ifn ribavirin rbv therapy report aim study investigate association ir il28b cohort well-characterized hcv patient\",\"phase ii trial assess efficacy safety combination regimen nonstructural protein (ns)5a inhibitor ledipasvir ldv ns3 protease inhibitor vedroprevir vdv non-nucleoside ns5b inhibitor tegobuvir tgv ribavirin rbv treatment-na\\u00efve patient chronic hepatitis c virus hcv 1 cirrhosis patient randomize 1:2 ldv 30 mg daily qd arm 1 n 46 ldv 90 mg qd arm 2 n 94 patient arm receive vdv 200 mg qd tgv 30 mg twice-daily rbv 1,000 1,200 mg/day patient arm 2 vrvr define hcv rna low limit quantification lloq treatment week 2 10 randomize 1:1 stop treatment 12 week continue 24 week sustained virologic response 12 week treatment svr12 high patient receive 90 mg ldv 24 week 63 compare ldv 90 mg 12 week 54 ldv 30 mg 24 week 48 patient rapid virologic response vrvr arm 2 svr12 achieve 68 81 patient treat 12 24 week respectively virologic breakthrough common patient hcv 1a associate resistance-associated variant direct-acting antiviral agent daa 1 patient relapse resistance-associated variant direct daa detect common adverse event fatigue headache nausea rash diarrhea\",\"use hepatitis c virus hcv interferon ifn resistance proof concept devise new method calculate effect drug viral population resistance population individual intrahost variant mean next-generation sequencing hcv variant obtain sera collect time point 16 patient 48 h injection ifn-\\u03b1 ifn-resistance coefficient calculate individual variant use change relative frequency entire intrahost viral population use change viral titer population-wide resistance presence ifn-resistant variant highly associate pegylated ifn-\\u03b12a/ribavirin treatment outcome week 12 p 3.78 \\u00d7 10(-5 0.0114 respectively new method allow accurate measurement resistance base solely change viral titer relative frequency intrahost viral variant short observation time\",\"launch first-generation protease inhibitor pi major step forward hcv treatment major advance restricted 1 gt-1 patient development second-wave second-generation pi yield high antiviral potency plurigenotypic activity convenient daily administration effect second-generation pi potential activity resistance-associated variant ns5b inhibitor include nucleoside/nucleotide inhibitor ni non-nucleotide inhibitor nni ni high efficacy sofosbuvir highly potent antiviral activity association pegylated interferon ribavirin pr allow shorten treatment duration ns5a inhibitor ns5a.i highly potent antiviral activity recently time ns5a.i combination protease inhibitor cure gt-1b null responder interferon-free regiman study demonstrate interferon (ifn)-free regimen direct-acting antiviral agent combination able cure large number na\\u00efve treatment-experienced gt-1 patient quadruple regiman pr able cure gt-1 null responder development pan-genotypic direct-acting antiviral agent nis ns5a.i allow new combination pr increase rate sustained virological response patient cirrhosis independently near future hcv treatment look promise purpose article provide overview clinical result recently report hcv treatment\",\"direct-acting antiviral daa current standard care advanced clinical development treatment patient chronically infect hepatitis c virus hcv 1 concern exist respect patient fail regimen emergent drug-resistant variant present study ultradeep sequencing perform analyze resistance daclatasvir dcv highly selective nonstructural protein 5a ns5a inhibitor patient hcv 1b treatment naive prior nonresponder pegylated interferon plus ribavirin rebetol schering-plough peg-ifn/rbv therapy treat dcv combine peg-ifn alpha-2b pegintron schering-plough kenilworth nj rbv identify cause viral breakthrough preexistence emergence dcv-resistant variant ns5a amino acid analyze ultradeep sequencing sustained virological response svr achieve 6 8 patient 75 viral breakthrough occur 2 patient 25 dcv-resistant variant y93h preexist minor population high frequency 0.1 0.5 patient achieve svr patient viral breakthrough dcv-resistant variant mixture emerge ns5a-31 time persist posttreatment y93h enrichment dcv-resistant variant detect preexistence minor population variant appear associate virologic response patient treat dcv/peg-ifn/rbv ultradeep sequencing result shed light complexity dcv-resistant quasispecie emerge time suggest multiple resistance pathway possible patient rapidly respond dcv-containing regiman study register clinicaltrials.gov registration no. nct01016912\",\"introduction direct-acting antiviral daa therapy hepatitis c virus hcv infection field rapidly evolving interferon-free regimen high sustained virologic response svr rate ultimate goal therapy chronic hcv infection include easily dose all-oral regimen highly effective inexpensive pan-genotypic safe tolerable minimal resistance investigational daa regimen currently evaluation ribavirin rbv project arrival improve therapy 5year future role rbv come question despite plague lack understanding mechanism action significant effect anemia rbv standard-of-care therapy chronic hcv infection 10year look future hcv therapy rbv utility care patient infect hcv low cost potentially add value combination daa article form symposium antiviral research hepatitis c step global eradication\",\"2011 outbreak cause influenza a(h3n2 variant a(h3n2)v virus public health concern united states a(h3n2)v virus share a(h1n1)pdm09 m gene contain marker m2 blocker resistance s31n contain known molecular marker associate resistance neuraminidase na inhibitor nai use fluorescent na inhibition ni assay susceptibility recovered a(h3n2)v virus n=168 fda-approved oseltamivir zanamivir peramivir laninamivir a-315675 nai assess a(h3n2)v virus test exception single virus strain a/ohio/88/2012 isolate untreated patient susceptible nai test a/ohio/88/2012 virus contain rare substitution s245n s247p na demonstrate reduce inhibition oseltamivir 31-fold zanamivir 66-fold ni assay use recombinant na recna protein s247p responsible observe alter nai susceptibility addition approximately 60 reduction na enzymatic activity s247p substitution previously report molecular marker reduce susceptibility nai use cell culture assay investigational antiviral drug nitazoxanide favipiravir fludase inhibit replication a(h3n2)v virus include virus s247p substitution na report demonstrate importance continuous monitoring susceptibility zoonotic influenza virus available investigational antiviral drug\",\"daclatasvir dcv bms-790052 picomolar inhibitor hcv non-structural protein 5a ns5a demonstrate efficacy patient chronically infect hcv\",\"patient chronic hepatitis c virus hcv infection prior null response 2 log hcv rna decline \\u2a7e 12 week pegifn/rbv limited option evaluate daclatasvir plus once- twice-daily asunaprevir non-cirrhotic 1 null responder\",\"standard care hcv 1 protease inhibitor telaprevir boceprevir combine pegylated interferon peg-ifn ribavirin rbv lead-in phase peg-ifn/rbv therapy addition protease inhibitor use aim improve response rate reduce development protease inhibitor resistance strategy bring benefit patient unclear\",\"previous study single nucleotide polymorphism snp il28b il10r associate sustained virological response svr chronic hepatitis c patient treat pegilated interferon plus ribavirin p/r present study extend early investigation large east-central european cohort allele frequency il28b il10r 1 hcv infection compare healthy control purpose examine relationship polymorphism svr p/r treatment\",\"treatment chronic hepatitis c change rapidly\",\"baseline homeostasis model assessment-estimated insulin resistance homa-ir marker insulin resistance associate poor virologic response peginterferon alpha/ribavirin pr chronic hepatitis c. evaluate association baseline homa-ir pretreatment factor sustained virologic response svr telaprevir tvr 1 patient hepatitis c prior peginterferon/ribavirin pr treatment failure patient randomize 12 week tvr 750 mg q8h plus peginterferon 180 \\u03bcg/week ribavirin 1,000 1,200 mg/day 4-week lead-in follow pr pr pr48 48 week univariate multiple logistic regression analysis explore prognostic significance baseline homa-ir adjust pretreatment factor svr tvr arm pool purpose analysis 662 patient randomize 578 baseline homa-ir prognostic datum include analysis median baseline homa-ir 2.6 interquartile range iqr 1.7 4.3 207 36 206 36 165 29 patient baseline homa-ir 2 2 4 \\u2265 4 respectively male gender high body mass index triglyceride gamma-glutamyl transpeptidase maximum alanine aminotransferase/aspartate aminotransferase fibrosis stage associate high baseline homa-ir baseline homa-ir associate svr univariate analysis adjustment baseline prognostic factor tvr 0.95 95 confidence interval ci 0.71,1.29 pr48 0.60 95 ci 0.25,1.43\",\"hepatitis c virus hcv infection lead cause chronic liver-related disease include cirrhosis liver failure hepatocellular carcinoma currently effective vaccine available hcv infection polyethylene glycol interferon-\\u03b1 pegifn-\\u03b1 combination ribavirin rbv standard care soc chronic hepatitis c. efficacy pegifn-\\u03b1 rbv combination therapy 50 1 hcv dominant virus human addition ifn rbv severe effect strategy improve sustained virological response svr rate important focus clinical physician serine protease inhibitor telaprevir boceprevir approve united states food drug administration 2011 addition hcv protease inhibitor soc significantly improve efficacy treatment hcv infection direct-acting antiviral drug currently late-stage clinical trial peg-ifn rbv advantage previous soc include high specificity efficacy effect ability administer orally optimal regimen future factor affect efficacy anti-hcv treatment base ifn-\\u03b1 include hcv baseline viral load virological response treatment host il28b gene polymorphism hepatic steatosis determine effect factor daa therapy necessary review summarize development anti-hcv agent assess main factor affect efficacy antiviral treatment\",\"direct-acting antiviral agent daa hepatitis c virus hcv infection major advance medical treatment hcv protease inhibitor boceprevir telaprevir approve daa united states europe japan combine peginterferon plus ribavirin agent increase sustained virologic response rate 70%-80 treatment-na\\u00efve patient previous-treatment relapser chronic hcv 1 infection peginterferon plus ribavirin daa mono-therapie increase daa-resistance mutation new daa hcv clinical development likely approve near future report use drug lead emergence daa-resistance mutation certain case furthermore mutation exhibit cross-resistance multiple drug prevalence daa-resistance mutation hcv-infected patient treat daa unknown uncertain variant sensitive daa perform population sequence analysis assess frequency variant sera hcv 1-infected patient treat hcv protease inhibitor review literature resistance variant hcv protease inhibitor treatment na\\u00efve patient chronic hcv 1 experience\",\"hcv infection major advancement year large number ongoing trial direct-acting antiviral daa high potency favourable tolerability profile high barrier resistance shorten treatment duration oral regimen pan-genotypic drug interaction reduce pill burden 2014 daa anticipate complete successful phase iii trial commercially available initially wave ifn-based regimen sofosbuvir faldaprevir simeprevir available treatment hcv 1 near future combination antiviral agent additive potency lack cross-resistance good safety profile likely new recommend regimen hcv chronic viral infection eradicate worldwide finite duration combination daa therapy ifn ribavirin aim review summarize result obtain recent daa combination study ifn\",\"approval second-wave direct-acting antiviral simeprevir sofosbuvir faldaprevir 2014 2015 1 hepatitis c patient doctor treatment option period treatment use peginterferon ribavirin second wave ifn-based triple therapy benefit risk treatment follow advantage high efficacy patient candidate shorten treatment duration 12 24 week instead 48 week new treatment appear safety profile generation additional increase anaemia peginterferon/ribavirin treatment patient decrease pill burden direct-acting antiviral orally pill day simeprevir sofosbuvir approve europe 2014 time manuscript release approval faldaprevir follow direct-acting antiviral hopefully combine future interferon-free regimen goal review summarize result safety simeprevir faldaprevir sofosbuvir advise physician inform patient benefit risk second-wave ifn-based regimen hcv infection\",\"boceprevir peginterferon/ribavirin boc/pr lead significantly higher sustained virological response svr rate patient chronic hepatitis c partial response relapse prior treatment peginterferon/ribavirin study efficacy boc/pr patient prior treatment failure include null response 2-log10 decline hcv rna peginterferon/ribavirin\",\"triple therapy combine protease inhibitor telaprevir interferon-\\u03b1 ribavirin promising new option long-term treatment hepatitis c. interaction potential telaprevir fully elucidate vitro potency telaprevir inhibit p-glycoprotein p-gp abcb1 breast cancer resistance protein bcrp abcg2 assess substrate characteristic p-gp bcrp multidrug resistance-associated protein mrp abcc 1 3 evaluate inducing property telaprevir important drug-metabolising enzyme transporter assess ability activate pregnane x receptor pxr investigate use growth inhibition assay confirm telaprevir substrate p-gp demonstrate time transport bcrp mrp telaprevir moderately inhibit p-gp calcein assay inhibit bcrp pheophorbide assay ls180 cell telaprevir strongly induce mrna expression abcg2 4.3-fold 30 \\u03bcmol/l weakly induce abcb11 cyp2c19 ugt1a3 contrast telaprevir significant influence mrna expression cyp3a4 ugt1a9 abcb1 abcc2 slco1b1 reporter gene assay telaprevir activate pxr appear unlikely telaprevir induce cyp3a4 p-gp vivo way provoke clinically relevant drug interaction numerous perpetrator characteristic telaprevir inhibitor property especially cyp3a4 p-gp appear relevant mechanism drug interaction clinical relevance strong induce effect abcg2 require proper assessment\",\"type interferon ifn-\\u03b1/\\u03b2 ribavirin agent eradicate hepatitis c virus hcv ifn-free regiman combine oral direct-acting antiviral agent daa approve soon 1 patient discuss role ifn-\\u03b1/\\u03b2 forthcome era daa consideration limitation concern ifn-free therapy therapeutic efficacy first-generation daa vary different rate sustained virological response svr 60 90 patient 1b rate fall short 50 patient 1a ifn ribavirin indicate patient 1a platform combination daa second concern emergence drug-resistance result inappropriate use daa clinical significance pre-existing resistant variant elucidate drug resistance affect efficacy next-generation treatment ifn ribavirin backbone combination daa effective measure prevent emergence drug resistance and/or suppress pre-existing resistant virus remain unknown incidence hepatocellular carcinoma hcc reduce patient achieve svr ifn-free regimen contrast report japan demonstrate preventive effect ifn development hcc patient achieve svr first-generation daa low-dose ifn maintenance therapy treatment option next-generation therapy pan-genotypic potency high genetic barrier available\",\"hepatitis c virus hcv induce insulin resistance improve viral clearance telaprevir protease inhibitor effective hcv 1 report case history suggest telaprevir induce antidiabetic effect independently suppression hcv 56-year-old woman obesity type 2 diabete treat sitagliptin metformin hcv-related cirrhosis triple therapy pegylated interferon-alpha ribavirin telaprevir 2 week treatment hcv rna long detectable patient describe pronounced drop capillary glucose level episode hypoglycaemia compel stop antidiabetic treatment month stop telaprevir resume antidiabetic treatment despite persist virological response despite reach sustained virological response diabete progress suppression hcv replication play role reduce glucose intolerance fact patient resume prior antidiabetic treatment complete telaprevir treatment aviremic suggest telaprevir additional antidiabetic effect far evidence possible role mechanism telaprevir antidiabetic agent warrant\",\"evaluation metabolic factor elevated \\u03b3-glutamyltransferase ggt level independent predictor treatment failure thoroughly document cohort hiv-/hcv-coinfected patient hiv/hcv sixty-four hiv/hcv patient treat pegylated interferon-\\u03b1-2a plus ribavirin pegifn rbv medical university vienna prospective trial include study addition 124 patient hiv/hcv aifa-hiv ahivcos cohort include validation cohort advanced liver fibrosis ggt elevation insulin resistance ir low cd4 nadir define metavir f3/f4 ggt level 1.5 \\u00d7 sex-specific upper limit normal homoeostasis model assessment insulin resistance 2 cd4 nadir 350 cells/\\u03bcl respectively hcv-genotype 1/4 or26.3 p 0.006 advanced liver fibrosis or20.2 p 0.009 interleukin 28b rs12979860 non-c/c snp or8.27 p 0.02 ggt elevation or7.97 p 0.012 independent predictor treatment failure ir or3.51 p 0.106 low cd4 nadir or2.64 p 0.263 independently associate treatment failure statistically significant correlation ggt elevation prior alcohol abuse r 0.259 p 0.039 liver steatosis r 0.301 p 0.034 low-density lipoprotein-cholesterol r -0.256 p 0.041 observe importance ggt elevation independent predictor treatment failure confirm validation cohort or2.76 p 0.026 ggt elevation emerge independent predictor treatment failure derivation validation cohort independent association metabolic factor treatment failure observe finding suggest ggt elevation independent predictor treatment failure hiv/hcv easily incorporate predictive algorithms\",\"pretreatment up-regulation hepatic interferon (ifn)-stimulated gene isg strong association treatment-resistant interleukin (il)28b minor mi tg/gg rs8099917 treatment-sensitive il28b major ma tt rs8099917 compare expression isg liver blood 146 patient chronic hepatitis c receive pegylated ifn ribavirin combination therapy gene expression profile liver blood 85 patient analyze use affymetrix genechip affymetrix santa clara isg expression correlate liver blood ma patient correlation observe mi patient loss correlation result impaired infiltration immune cell liver lobule mi patient demonstrate regional gene expression analysis liver lobule portal area use laser capture microdissection immunohistochemical staining despite low level immune cell hepatic isg up-regulate liver mi patient find regulate multiple factor il28a/b ifn-\\u03bb4 wingless-related mmtv integration site 5a wnt5a interestingly wnt5a induce expression isg increase hepatitis c virus replication induce expression stress granule protein gtpase-activating protein sh3 domain)-binde protein 1 g3bp1 huh-7 cell line liver expression wnt5a receptor frizzled family receptor 5 significantly correlate g3bp1\",\"anti-influenza drug united states prevention therapy influenza b virus infection shortage couple continuously emerge drug resistance detect global surveillance network seriously limit anti-influenza armamentarium combination therapy appear offer advantage traditional monotherapy delaying development resistance potentially enhance single antiviral activity present study evaluate antiviral drug susceptibility fourteen pandemic influenza h1n1 virus isolate mdck cell addition evaluate favipiravir t-705 investigational drug broad antiviral spectrum unique mode action dual combination neuraminidase inhibitor nai oseltamivir peramivir zanamivir oseltamivir-sensitive pandemic influenza a/california/07/2009 h1n1 oseltamivir-resistant a/hong kong/2369/2009 h1n1 virus mean inhibitory value test virus isolate remain sensitive commonly use antiviral drug exception hong kong virus isolate drug dose-response curve confirm complete drug resistance oseltamivir partial sensitivity peramivir retain susceptibility zanamivir favipiravir a/hong kong/2369/2009 virus three-dimensional analysis drug interaction use macsynergy(tm ii program indicate overall synergistic interaction favipiravir combine nai oseltamivir-sensitive influenza virus additive effect oseltamivir-resistant virus clinical relevance drug combination remain evaluate result obtain study support use combination therapy favipiravir nai treatment human influenza virus infection\",\"interferon-based standard care treatment soc chronic hepatitis c unable provide high cure rate certain subgroup infected population cause debilitating effect clinical trial evaluate all-oral interferon-free treatment demonstrate high rate sustained virologic response resistance major adverse event population drug regimen fda approval important assess cost-effectiveness addition clinical efficacy decision-analytic markov model lifetime societal perspective use evaluate cost-effectiveness generalize all-oral drug regiman compare soc model progression 50-year-old hcv-positive cohort disease natural history treatment base case analysis all-oral treatment dominate soc range willingness-to-pay wtp threshold incremental cost-effectiveness ratio icer us$ 44,514/quality-adjusted life year qaly sensitivity analysis model sensitive all-oral drug cost rate svr treatment uptake noncirrhotic subject robust variation parameter all-oral treatment cost-effective 1 subject remain cost-effective 2 3 wtp threshold \\u2265$80,000/qaly quality-adjusted life year gain dollar spend maximize young treatment cohort use model degree cost-effectiveness depend wtp threshold final cost set approve drug combination\",\"thrombocytopenia patient chronic hepatitis c represent obstacle initiation antiviral treatment aim study evaluate factor predictive successful pegylated interferon peg-ifn \\u03b12b ribavirin rbv treatment patient thrombocytopenia history splenectomy partial splenic embolization fifty-one chronic hepatitis c patient 1 n 110 2 n 41 tcp 100 \\u00d7 10(9 /l baseline enrol pretreatment variable include interleukin 28b il28b rs8099917 homoeostasis model assessment insulin resistance score homa-ir kinetic haemoglobin platelet accord inosine triphosphatase itpa rs1127354 investigate sustained virological response svr significantly frequent hepatitis c virus hcv 2 65.9 1 34.5 patient p 0.0001 multiple logistic regression analysis hcv 1 extract il28b tt odd ratio 5.97 p 0.006 homa-ir 2.5 7.14 p 0.0016 significant independent pretreatment predictor svr analysis hcv 2 homa-ir significantly related svr il28b patient itpa cc significant haemoglobin reduction low degree platelet decrease itpa ca/aa common reason premature discontinuation treatment development hepatocellular carcinoma n 8 5.3 conclusion homa-ir useful predictor svr patient thrombocytopenia infect hcv 1 2 treat peg-ifn\\u03b12b rbv inclusion il28b itpa homa-ir add valuable therapeutic information\",\"danoprevir dnv hepatitis c virus hcv protease inhibitor achieve high sustained virologic response svr rate combination peginterferon alfa-2a-ribavirin treatment-naive hcv 1 (g1)-infecte patient study explore efficacy safety ritonavir-boosted dnv dnvr plus peginterferon alfa-2a-ribavirin g1-infected prior peginterferon-ribavirin null responder null responder 2-log10 reduction hcv rna level week 12 open-label combination 100 mg ritonavir 100 mg dnv 100/100 mg dnvr 12 h q12h plus peginterferon alfa-2a-ribavirin 12 week patient achieve early virologic response evr \\u22652-log10 decrease hcv rna week 12 continue treatment peginterferon alfa-2a-ribavirin evr discontinue study drug twenty-four prior null responder enrol 16 patient 67 infect hcv g1b 8 33 infect g1a ninety-six percent patient il28b non-cc sustained virologic response 24 week posttreatment svr24 achieve 67 patient high rate g1b-infected 88 g1a-infected 25 patient resistance-related breakthrough occur 4/8 g1a 1/16 g1b patient dnv resistance-associated variant rav ns3 r155 k ns3 r155 k detect 2/2 g1a patient relapse treatment tolerate patient withdraw prematurely study medication adverse event adverse event report occur completion dnvr therapy consider unrelated treatment grade 3 4 alanine aminotransferase alt elevation observe dnvr plus peginterferon alfa-2a-ribavirin demonstrate high svr24 rate hcv g1b-infected prior null responder tolerate study register clinicaltrials.gov registration no. nct01185860\",\"current treatment hepatitis c virus hcv 1 chronic infection addition direct-acting antiviral daa protease inhibitor telaprevir boceprevir pegylated interferon peg-ifn ribavirin rbv regimen 2014 sofosbuvir simeprevir faldaprevir available combination peg-ifn/rbv triple therapy hcv enzyme essential hcv replication potential drug discovery target daa different viral target include ns3 protease inhibitor nucleoside/nucleotide analogue nonnucleoside inhibitor rna-dependent rna polymerase ns5a replication complex inhibitor development\",\"currently hepatitis c virus hcv infection consider health-care problem world good number direct-acting antiviral daa hcv infection clinical progress include ns3 4a protease inhibitor rna-dependent rna polymerase inhibitor ns5a inhibitor host target inhibitor ns3 4a protease inhibitor telaprevir boceprevir recently approve treatment hepatitis c combination standard care pegylated interferon plus ribavirin new therapy significantly improve sustained virologic response svr adverse effect associate therapy main concern addition emergence viral resistance target continually develop underdeveloped target helicase portion hcv ns3 protein review article summarize current understanding hcv treatment particularly ns3 inhibitor\",\"assess outcome double-filtration plasmapheresis dfpp combine pegylated interferon peg-ifn ribavirin rbv therapy patient infect hepatitis c virus (hcv)-1b hcv disappear peg-ifn/rbv combination therapy relapse end therapy additionally investigate factor predictive sustained virological response svr include host viral genetic factor dfpp plus ifn/rbv therapy\",\"investigate impact host genetic represent single nucleotide polymorphism snp il28b gene viral genetic variation nonstructural protein 5a ns5a include interferon (ifn)/ribavirin rbv resistance-determining region irrdr ifn sensitivity-determining region isdr outcome pegylated ifn rbv peg-ifn/rbv treatment\",\"study explore viral factor interferon ifn ribavirin rbv resistance-determining region irrdr ifn sensitivity-determining region isdr core protein host factor interleukin 28b associate response pegylated ifn peg-ifn rbv combination therapy correlation viral host factor ifn-\\u03bb1\",\"assess drug susceptibility 125 avian influenza a(h5n1 virus isolate poultry vietnam 2009 2011 25 clade 1.1 virus possess marker resistance m2 blocker amantadine rimantadine 24 inhibit neuraminidase inhibitor clade 1.1 virus contain r430w neuraminidase gene reduce inhibition oseltamivir zanamivir laninamivir 12- 73- 29-fold respectively 30 clade 2.3.4 virus contain i223 t mutation 7-fold reduce inhibition oseltamivir 70 clade 2.3.2.1 virus h275y marker oseltamivir resistance exhibit highly reduce inhibition oseltamivir peramivir antiviral agent das181 favipiravir inhibit h275y mutant virus replication mdck-siat1 cell replicative fitness h275y mutant virus comparable wildtype virus finding highlight role drug susceptibility monitoring h5n1 virus circulate bird inform antiviral stockpiling decision pandemic preparedness\",\"advance understanding hcv lifecycle refinement vitro method select candidate compound anti-hcv activity lead development daa agent novel antiviral therapy capable increase curative svr rate patient chc use liner protease inhibitor telaprevir boceprevir combination peg-ifn-a ribavirin new soc treatment chc 1 rapid development new protease inhibitor ni nni ns5b polymerase inhibitor ns5a inhibitor peg-ifn-l cyclophilin inhibitor caspase inhibitor therapeutic vaccine promise provide safe effective therapy combination therapy 2 oral agent permit elimination peg-ifn-a near future introduction daa therapy confront physician patient regimen increase complexity great need compliance necessity monitor virological resistance patient chc continue consider participation clinical trial new therapy accelerate progress\",\"hepatitis c virus hcv infection remain increasingly prevalent emergent health problem worldwide cause wide spectrum liver disease combination therapy pegylated interferon peg-ifn peginterferon alfa-2a oral ribavirin currently recognize standard treatment chronic hcv infection complex immunological mechanism involve course hcv treatment use interferon role endogenous interferon gamma ifn\\u03b3 egyptian patient infect chronic hcv treat peg-ifn/ribavirin uncertain goal study evaluate association ifn\\u03b3 chronic hcv infection patient treat combination therapy peg-ifn/ribavirin\",\"high rate sustained viral response svr boceprevir telaprevir-based triple therapy hepatitis c (hcv)-related non-cirrhotic na\\u00efve patient relapser previous antiviral treatment lead clinician believe impact metabolic host factor svr minimal triple therapy use unlike observe peginterferon ribavirin schedule concept strongly express opinion leader basis datum derive sub-analyse registrative trial post-hoc analysis phase ii c208 clinical trial perception unrestrainable therapeutic success use newer powerful antiviral reinforce brilliant result obtain sofosbuvir hcv ns5b polymerase inhibitor datum phase ii iii study combination second-generation ns3/4a inhibitor ns5a and/or ns5b inhibitor great deal concern emerge real world scenario patient old comorbiditie patient world trial furthermore advance fibrosis previous failure peginterferon ribavirin treatment datum recent literature suggest host metabolic factor play minor non-negligible role difficult-to-treat patient issue hopefully investigate study editorial aim provide detailed analysis role host metabolic factor play past role play era direct antiviral agent\",\"stable persistent hepatitis c virus hcv replication cell culture model develop examine clearance viral replication long-term treatment use interferon-\\u03b1 ifn-\\u03b1 ifn-\\u03bb ribavirin rbv persistently hcv-infected cell culture exhibit impaired antiviral response ifn-\\u03b1+rbv combination treatment ifn-\\u03bb treatment produce strong sustained antiviral response clear hcv replication hcv replication persistently infected cell induce chronic endoplasmic reticulum er stress autophagy response selectively down-regulate functional ifn-\\u03b1 receptor-1 chain type type ii ifn-\\u03b3 type iii ifn-\\u03bb ifn receptor down-regulation ifn-\\u03b1 receptor-1 result defective jak-stat signaling impaired stat phosphorylation impaired nuclear translocation stat furthermore hcv replication impair rbv uptake reduce expression nucleoside transporter ent1 cnt1 silence er stress autophagy response use chemical inhibitor sirna additively inhibit hcv replication induce viral clearance ifn-\\u03b1+rbv combination treatment result indicate hcv induce er stress autophagy response selectively impair type type iii ifn signaling explain ifn-\\u03bb ifn-\\u03b1 produce sustained antiviral response hcv result indicate inhibition er stress autophagy response overcome ifn-\\u03b1+rbv resistance mechanism associate hcv infection\",\"suppressor cytokine signaling 3 myxovirus resistance protein osteopontin gene polymorphism influence therapeutic response patient chronic hepatitis c association il28 increase power predict sustained virologic response aim evaluate association myxovirus resistance protein osteopontin suppressor cytokine signaling 3 gene polymorphism combination il28b assess therapy response hepatitis c patient treat pegylated-interferon plus ribavirin\",\"chronic hepatitis c virus hcv infection responsible development liver cirrhosis hepatocellular carcinoma tremendous burden global health care system advent number new direct-acting host-targeting antiviral agent current interferon-\\u03b1- ribavirin-based hcv therapy start interferon-sparing interferon-free strategy regard recently identify ns5a inhibitor daclatasvir great promise clinical trial new class direct-acting anti-hcv therapeutic distinct mechanism action review variety preclinical clinical proof-of-concept study daclatasvir include study discovery mechanism action viral resistance host polymorphism profile review addition role daclatasvir future therapy hcv patient discuss briefly\",\"recently treatment chronic hepatitis c virus hcv infection base combination non-viral specific drug pegylated interferon-\\u03b1 ribavirin effective overall 40%-50 case improve response treatment novel drug design specifically block viral protein multiple compound development approval clinical use direct-acting antiviral 2011 telaprevir boceprevir represent milestone hcv treatment hcv therapeutic enter new expand era highly-effective cure envision time discovery virus 1989 antiviral treatment limit capacity virus overcome selective pressure new drug generate antiviral resistance try provide basic overview new treatment hcv resistance new antiviral consideration derive public health perspective use hcv resistance protease polymerase inhibitor example\",\"antiviral treatment option prevent defer occurrence hepatocellular carcinoma hcc patient chronically infect hepatitis b virus hbv hepatitis c virus hcv approve medication treatment chronic hbv infection interferon-\\u03b1 ifn\\u03b1 nucleos(t)ide analogue na include lamivudine adefovir dipivoxil telbivudine entecavir tenofovir disoproxil fumarate ifn\\u03b1 suitable young patient advanced liver disease infect hbv a. ifn\\u03b1 treatment significantly decrease overall incidence hbv-related hcc sustained responder effect limit long-term clinical application orally administer na typically implement patient advanced liver disease na treatment significantly reduce disease progression cirrhosis hcc incidence especially hbv e antigen-positive patient na-resistance mutation hbv polymerase major limit factor na resistance-associated mutant a181 t mutant significantly increase risk hcc development subsequent course na therapy important initiate treatment na high genetic barrier resistance counsel patient medication adherence monitor virological breakthrough recommend treatment patient chronic hcv infection peg-ifn plus ribavirin decrease occurrence hcc achieve sustained virological response progress cirrhosis ifn-based treatment reserve patient decompensated cirrhosis evaluation liver transplantation reduce post-transplant recurrence hcv effective therapeutic option direct act antiviral agent hopefully increase response rate difficult-to-treat patient hcv 1 risk hcc remain cirrhotic patient chronic hbv hcv infection treatment initiate cirrhosis establish future research focus investigate new agent especially patient hepatic decompensation post-transplantation\",\"enhance endogenous interferon ifn stimulate gene isg signature associate nonresponsiveness hepatitis c treatment use pegylated-ifn\\u03b1 pegifn\\u03b1 ribavirin rbv human immunodeficiency virus/hepatitis c virus hiv/hcv coinfecte patient use proteomic approach identify high level ifn\\u03b1 receptor 2a ifn\\u03b1r2a serum null responder pegifn\\u03b1/rbv ifn\\u03b1r2a inhibit antiviral activity formulation ifn\\u03b1 jfh/huh7.5 cell furthermore serum null responder achieve sustained virologic response suppress ifn-signaling isg expression ifn\\u03b1-stimulated pbmc healthy donor ifn\\u03b1r2a specific fashion ifn\\u03b1r2a transgenic mouse model c57bl/6 generate significantly high level ifn\\u03b1r2a serum control p=0.001 total isg expression lymph node significantly high compare wild-type mouse p value=0.0016 addition ifitm1 sp110 significantly increase expression liver ifitm1 isg15 lymph node isg15 plscr1 spleen p value<0.05 underlying mechanism resistance hepatitis c treatment involve transsignaling jak/stat pathway sifn\\u03b1r2a-ifn\\u03b1/\\u03b2 complex result enhance isg signature observe null responder regard transgenic mouse model simulated nonresponder ifn\\u03b1 therapy provide valuable insight role sifn\\u03b1r2a-ifn\\u03b1 interaction vivo\",\"narlaprevir hepatitis c virus hcv ns3/4a serine protease inhibitor demonstrate robust antiviral activity placebo-controlled phase 1 study study evolutionary dynamic resistant variant ns3 protease sequence clonally analyse thirty-two hcv 1-infected patient follow treatment narlaprevir narlaprevir monotherapy administer week period 1 follow narlaprevir/pegylated interferon-alpha-2b combination therapy ritonavir period 2 week interrupt washout period month patient initiate pegylated interferon-alpha-2b/ribavirin combination therapy longitudinal clonal analysis perform patient ns3 mutation narlaprevir re-exposure resistance-associated mutation position v36 t54 r155 a156 detect patient 95 clone narlaprevir retreatment result 2.58 5.06 log10 iu/ml viral load decline patient mutation respectively p=<0.01 treatment resistant variant replace wild-type virus 2 24 week patient r155 k mutation observe 3.1 year narlaprevir dosing patient 5 45 viral population resistant variant detect early treatment narlaprevir slow viral load decline observe patient resistance-associated mutation detectable direct population sequencing mutation disappear month follow treatment exception r155 k mutation persist patient\",\"resistance mericitabine prodrug hcv ns5b polymerase inhibitor psi-6130 rare confer ns5b s282 t mutation\",\"specific human polymorphism commonly find central africa predict success drug treatment hepatitis c virus hcv significant globally-distributed human pathogen association find subset hcv despite receive considerable attention medical virological literature evolutionary explanation curious pattern forward suggest drug treatment resistance phenotype exhibit today hcv evolve thousand year ago response human genetic variation local central africa adaptation accrue new function era anti-viral drug treatment represent old known example viral exaptation population level\",\"hcv 1-infected patient hiv co-infection tritherapy hcv protease inhibitor pi plus peg-interferon ribavirin increase rate sustained virological response complex drug-to-drug interaction tolerability issue remain concern\",\"hepatitis c virus hcv infection causally associate insulin resistance diabetes mellitus population-based cohort study aim investigate antiviral therapy hcv infection associate improve clinical outcome related diabete taiwan national health insurance research database 2,267,270 taiwanese resident diagnose diabetes mellitus screen eligibility hcv infection define specific diagnosis code measurement serum antibody exclude patient comorbidity enrol total 1,411 eligible patient receive pegylated interferon plus ribavirin treat cohort match 1:1 1,411 untreated control propensity score untreated cohort match treat cohort 1:4 5,644 diabetic patient hcv infection uninfected cohort participant follow occurrence endstage renal disease esrd ischemic stroke acute coronary syndrome acs receive antiviral treatment corresponding calendar date 2003 2011 8-year cumulative incidence esrd treat untreated uninfected cohort 1.1 95 confidence interval ci 0.3 2.0 9.3 95 ci 5.9 12.7 3.3 95 ci 2.3 4.3 respectively p 0.001 stroke 3.1 95 ci 1.1 5.0 5.3 95 ci 3.0 7.5 6.1 95 ci 4.8 7.4 respectively p 0.01 acs 4.1 95 ci 2.1 6.1 6.6 95 ci 3.7 9.5 7.4 95 ci 5.9 9.0 respectively p 0.05 compare untreated cohort antiviral treatment associate multivariate-adjusted hazard ratio 0.16 95 ci 0.07 0.33 esrd 0.53 95 ci 0.30 0.93 ischemic stroke 0.64 95 ci 0.39 1.06 acs\",\"combination vaniprevir ns3/4a protease inhibitor peginterferon ribavirin increase rate sustained virologic response svr significantly compare peginterferon ribavirin treatment-experienced patient chronic hepatitis c virus hcv 1 infection cirrhosis perform blind randomize control trial effect vaniprevir peginterferon ribavirin patient cirrhosis respond prior therapy peginterferon ribavirin\",\"2.35 world population infect hepatitis c virus hcv responsible chronic hepatitis liver cirrhosis hepatocellular carcinoma currently available interferon-based medication successful 75 patient infect hcv 1 2 3 low efficacy unfortunately sustained virologic response svr rate 1 infected non-responder previous therapy advanced hepatic fibrosis retreatment generation direct act antiviral daa 40\",\"telaprevir linear peptidomimetic small molecule inhibit hepatitis c virus hcv replication specifically inhibit ns3\\u00b74a protease phase 3 clinical study telaprevir combination peginterferon ribavirin pr significantly improve sustained virologic response svr rate 1 chronic hcv-infected patient compare pr patient achieve svr treatment telaprevir-based regimen variant mutation ns3\\u00b74a protease region observe variant contribute drug resistance limit efficacy treatment gain understanding viral resistance profile conduct phenotypic characterization variant use hcv replicon carry site-directed mutation frequently observe significantly enriched telaprevir-resistant variant v36a/m t54a/s r155k/t a156s confer lower-level resistance 3- 25-fold a156 t v36m+r155 k confer higher-level resistance 25-fold telaprevir rarely observe significantly enriched variant include v36i/l i132v confer resistance telaprevir v36c/g r155g/i/m/s v36a+t54a v36l+r155 k t54s+r155 k r155t+d168n confer lower-level resistance telaprevir a156f/n/v v36a+r155k/t v36m+r155 t v36a/m+a156 t t54a+a156 t54s+a156s/t v36m+t54s+r155 k confer higher-level resistance telaprevir telaprevir-resistant variant remain fully sensitive alpha interferon ribavirin hcv ns5b nucleoside nonnucleoside polymerase inhibitor general replication capacity telaprevir-resistant variant low wild-type replicon\",\"despite incontestable benefit telaprevir boceprevir-based triple therapy patient infect 1 practitioner face number new challenge daily clinical practice checklist approach facilitate management triple therapy initiation specific issue review patient order optimize adherence treatment outcome potential drug drug interaction treatment duration stop rule possible treatment outcome effect dose administration food advice management effect treatment failure associate emergence resistance-associated variant reduce sensitivity protease inhibitor adherence major importance setting role educational nurse emphasize management triple therapy daily clinical practice\",\"hepatitis c virus hcv major cause liver disease potential cause substantial morbidity mortality worldwide overall prevalence hcv infection 2 represent 120 million people worldwide current standard treatment use pegylated interferon ribavirin effective 50 patient infect hcv 1 associate significant effect importance develop new drug treatment hcv antiviral substance obtain natural product include medicinal plant potentially good target study study evaluate indonesian medicinal plant anti-hcv activity\",\"hepatitis c virus hcv subgenotype 1a 1b different impact treatment response peginterferon plus ribavirin direct-acting antiviral daa patient infect hcv 1 emergence rate resistance mutation different subgenotype japan hcv 1 belong subgenotype 1b\",\"telaprevir extremely potent antiviral drug direct-acting antiviral agent hepatitis c virus hcv potency compromise rapid emergence resistance mutation phenomenon favor high rate hcv replication lack corrective activity hcv polymerase error low genetic barrier resistance poor treatment adherence like hcv protease inhibitor telaprevir low genetic barrier resistance phase ii/iii clinical trial advance illuminate realize characterize resistance telaprevir combination pegylated interferon ribavirin genotypically phenotypically mutation select mainly position 36 54 55 155 156 resistance profile depend genetic hcv selection mutation position 36 155 1a position 36 54 55 156 1b v36m+r155 k a156f/t/v variant confer high degree resistance 25-fold increase impact resistance mutation v36a/g/m t54a/s r155g/k/m/t a156s low 3 25- fold increase presence polymorphism mutation associate telaprevir resistance low 1 especially mutation high impact resistance high degree cross resistance protease inhibitor rapid reversion telaprevir resistance mutation end treatment allow use recycle strategy protease inhibitor\",\"introduction telaprevir therapeutic armamentarium hepatitis c virus infection major advance patient unresponsive prior treatment interferon ribavirin group patient sustained viral response achieve 80 recurrence receive triple therapy partial responder half achieve cure triple combination pegylated interferon ribavirin telaprevir unfortunately result good null responder especially certain age advance fibrosis patient group carefully select identify likely derive benefit triple therapy\",\"chronic hepatitis hepatitis c virus hcv infection affect nearly 180 million people worldwide infection curable 1 year ago treatment 1 hcv combination pegylated interferon ribavirin moderately effective 40 50 introduction new antiviral agent telaprevir represent change paradigm revolutionize treatment infection drug increase likelihood viral response 80 allow treatment length shorten 50 patient new stopping rule develop avoid development resistance finally special attention pay potentially adverse effect particularly anemia cutaneous alteration\",\"controversial result find literature association insulin resistance sustained virologic response standard chronic hepatitis c treatment study aim provide systematic literature review meta-analysis order evaluate insulin resistance interfere sustained virologic response patient infect hcv 1 versus hcv 2 3 undergo treatment interferon ribavirin pegylated interferon ribavarin\",\"despite improve virologic response addition direct act agent peginterferon ribavirin treatment chronic hepatitis c virus hcv 1 infection subset patient experience viral breakthrough therapy define viral breakthrough patient characteristic important ongoing future hcv treatment\",\"ribavirin mono-therapy regimen minimal effect patient chronic hepatitis c virus hcv infection efficacious combine interferon clinical study interferon-free combination therapy contain ribavirin efficacious suggest interferon-free therapy adopt near future generation drug resistant mutant cross resistance drug impair efficacy treatment understand mechanism hcv resistance ribavirin cross resistance antiviral drug major importance\",\"chronic hepatitis c virus hcv infection represent lead worldwide medical social problem expand knowledge hcv lifecycle lead development novel antiviral agent specifically target viral function direct-acting antiviral b specifically inhibit viral replication present review describe novel anti-hcv drug study time writing current type treatment interferon-based interferon-free regimen addition predictive factor virological response side-effect resistance mechanism novel agent summarize\",\"hepatitis c virus hcv infection important problem world cause acute chronic liver infection different approach use inhibit hcv infection include small organic compound sirna shrna peptide inhibitor review article summarize current future therapy hcv infection pubmed google scholar search article publish english insight current inhibitor life-threatening virus hcv ns3/4a protease inhibitor nucleoside/nucleotide inhibitor ns5b polymerase presently progressive stage clinical development link development resistance viral breakthrough boceprevir telaprevir important protease inhibitor approve recently treatment hcv infection drug standard-of-care treatment soc drug phase iii clinical development explore host-cell-targeting compound hopeful result demonstrate cyclophilin inhibitor current soc treatment hcv infection peg-interferon ribavirin protease inhibitor boceprevir telaprevir future treatment life-threatening disease involve combination therapy hit multiple target hcv host factor strongly expect near future treatment hcv infection combination direct-acting agent daa involvement interferon eliminate effect\",\"reversibility advanced fibrosis hcv-clearance important goal therapy\",\"therapeutic vaccine currently exist human coronaviruse hcovs severe acute respiratory syndrome-associated coronavirus sars-cov epidemic 2002 2003 recent emergence middle east respiratory syndrome coronavirus mers-cov april 2012 emphasize high probability future zoonotic hcov emergence cause severe lethal human disease additionally resistance sars-cov ribavirin rbv demonstrate need define new target inhibition cov replication covs express 3'-to-5 exoribonuclease nonstructural protein 14 nsp14-exon require high-fidelity replication conserve cov family genetic biochemical datum support hypothesis nsp14-exon rna proofreading function hypothesize exon responsible cov resistance rna mutagen demonstrate wild-type exon+ covs resistant rbv 5-fluorouracil 5-fu covs lack exon activity exon- 300-fold sensitive primary antiviral activity rbv covs mutagenesis exon- covs treat 5-fu demonstrate enhance sensitivity multi-cycle replication decrease specific infectivity consistent 5-fu function mutagen comparison full-genome next-generation sequencing 5-fu treated sars-cov population reveal 16-fold increase number mutation exon- population compare exon+ ninety percent mutation represent g u c transition consistent 5-fu incorporation rna synthesis result constitute direct evidence cov exon activity provide critical proofreading function virus replication furthermore study identify exon viral protein distinct rdrp determine sensitivity rna virus mutagen finally result importance exon target inhibition suggest small-molecule inhibitor exon activity potential pan-cov therapeutic combination rbv rna mutagen\",\"novel reassortant avian-origin influenza h7n9 virus isolate respiratory specimen obtain patient identify h7n9 china antiviral agent require treat patient avian influenza h7n9 virus infection\",\"gs-9451 selective hepatitis c virus hcv ns3 protease inhibitor development treatment 1 gt1 hcv infection key preclinical property gs-9451 include vitro antiviral activity selectivity cross-resistance combination activity pharmacokinetic property determine multiple gt1a gt1b replicon cell line gs-9451 mean 50 effective concentration ec50s 13 5.4 nm respectively minimal cytotoxicity similar potency observe chimeric replicon encode ns3 protease gene gt1 clinical isolate gs-9451 active gt2a replicon cell ec50 316 nm additive synergistic vitro antiviral activity observe gs-9451 combine agent include alpha interferon ribavirin polymerase inhibitor gs-6620 tegobuvir gs-9190 ns5a inhibitor ledipasvir gs-5885 gs-9451 retain wild-type activity multiple class ns5b ns5a inhibitor resistance mutation gs-9451 stable hepatic microsome hepatocyte human test specie systemic clearance low dog monkey high rat gs-9451 good oral bioavailability specie test rat gs-9451 level \\u223c40-fold high liver plasma intravenous dosing elimination gs-9451 primarily biliary excretion result consistent antiviral activity observe recent phase 1b study result vitro cross-resistance combination antiviral assay support ongoing development gs-9451 combination agent treatment chronic hcv infection\",\"chronic hepatitis c virus hcv infection major pandemic current standard care include peginterferon ribavirin plus protease inhibitor boceprevir telaprevir 1 patient peginterferon ribavirin treatment landscape rapidly evolving number direct-acting antiviral daa develop clinical trial\",\"presently development new therapy hepatitis c virus hcv rapidly forward week new datum appear direct act antiviral daa succeed fail clinical trial despite potency daa combination effect exert ribavirin rbv need effective therapy new daa combination strong antiviral effect daa likely major complementary therapeutic effect exert rbv immune modulation result increase barrier development resistance hcv 1a infection elimination pegylated interferon possible daa combination jeopardize result host immune response likely play key role daa-based therapy t cell recognize eliminate viral variant resistance daa example case support rationale include host response new therapeutic regimen review describe potential benefit combine daa mean activate specific immune response hcv\",\"hcv rna-dependent rna polymerase essential enzyme hcv viral replication prominent target search therapy treat individual infect hcv development nucleoside nucleotide hcv inhibitor pursue potential pangenotypic activity high barrier resistance nucleoside inhibitor effective clinical setting potency limit effectiveness exploitation prodrug strategy deliver nucleoside 5'-monophosphate result development number potent inhibitor hcv replication addition nucleotide prodrug demonstrate liver-targeting characteristic administer orally human clinical study number nucleotide prodrug potent inhibitor viral replication lead significant reduction viral load orally combination nucleotide prodrug pegylated interferon-\\u03b1 ribavirin direct act antiviral lead cure rate high 100 12 week therapy combination nucleotide prodrug direct-acting antiviral agent hold promise deliver interferon-free therapy hcv patient eliminate undesirable effect associate interferon\",\"faldaprevir bi 201335 selective ns3/4a protease inhibitor development treatment chronic hepatitis c virus hcv infection ns3/4a genotyping ns3 protease phenotyping analysis perform monitor emergence resistance patient hcv 1 infection receive faldaprevir combine pegylated interferon alfa 2a ribavirin pegifn-rbv phase 1b study baseline variant maximum 7-fold reduction vitro sensitivity faldaprevir observe rare ns3 (v/i)170 t polymorphism faldaprevir monotherapy treatment-naive patient virologic breakthrough common 77 20/26 associate emergence resistance mutation predominantly carry ns3 substitution r155 k gt1a d168v gt1b d168v confer great reduction faldaprevir sensitivity 1,800-fold r155 k 330-fold d168v generally fit r155 k absence selective drug pressure treatment-experienced patient treat faldaprevir-pegifn-rbv triple therapy high viral load reduction low rate breakthrough 8 5/62 frequent emergence resistance-associated variant compare faldaprevir monotherapy study register clinicaltrials.gov registration no. nct00793793\",\"gs-5885 novel hepatitis c virus hcv ns5a inhibitor 3-day monotherapy study treatment-naive 1a gt1a gt1b hcv-infected subject median viral load reduction range 2.3 3.3 log10 hcv rna iu/ml dose cohort 1 3 10 30 90 mg daily report viral sequencing phenotypic analysis clinical isolate study detection baseline ns5a amino acid substitution position 28 30 31 93 gt1a associate reduce treatment response gt1b cohort y93h detect 100 subject day 4 14 gt1a cohort population sequencing detect ns5a resistance-associated mutation day 4 14 3/10 subject 1-mg dose subject dose \\u22653 mg subset mutant confer low level reduce susceptibility gs-5885 detect population sequencing 30- 90-mg dose subject-derived m28 t q30r l31 m y93c mutation confer 30-fold reduction gs-5885 daclatasvir susceptibility vitro site-directed ns5a mutant reduce susceptibility gs-5885 ns5a mutant test remain fully susceptible class direct-acting antiviral daa interferon alpha ribavirin importantly nonoverlapping resistance profile high potency gs-5885 support development direct-acting antiviral treatment chronic hcv study register clinicaltrials.gov registration number nct01193478\",\"addition protease inhibitor boceprevir telaprevir peginterferon+ribavirin pegifn/rbv increase frequency severity clinical relevance anemia major complication associate triple therapy significant factor associate anemia patient receive triple therapy include old age low body mass index bmi advanced fibrosis low baseline hemoglobin variability inosine triphosphate pyrophosphatase itpa gene encode protein hydrolyse inosine triphosphate itp identify essential genetic factor anemia dual triple therapy correct management anemia base anticipation characterization therapeutic management basically anemia characterize 3 type ferropenic fertile woman thalassemic type hemolytic anemia anemia chronic process functional deficit iron exclude patient normal ferritin low saturation transferrin ribavirin dose reduction epoetin sequentially indicate management anemia epoetin non-response cause lack time type anemia functional iron deficit erythropoietin resistance transplantation setting add protease inhibitor pegifn/rbv result significant increase incidence severity anemia consequence great need epoetin transfusion ribavirin dose reduction pack red cell transfusion utilize hemoglobin decrease 7.5g/dl and/or clinical symptom and/or response therapeutic measure\",\"decade intense research provide detailed understanding hepatitis c virus hcv chronically infect 2 world population effort pave way development antiviral compound spare patient life-threatening liver disease exciting new era hcv therapy dawn recent approval viral protease inhibitor use combination pegylated interferon-\\u03b1 ribavirin beginning multiple class antiviral distinct target promise highly efficient combination interferon-free regimen short treatment duration effect future hcv therapy ongoing future trial determine good antiviral combination current seemingly rich pipeline sufficient successful treatment patient face major challenge hcv diversity viral resistance influence host genetic advanced liver disease co-morbiditie\",\"hepatitis c virus hcv foremost cause chronic liver disease affect 300 million globally hcv contain positive-stranded rna ~9600 nt surround 5 3'untranslated region utr successful treatment regiman include interferon ifn ribavirin like virus hcv evolve mechanism circumvent ifn response block 1 downstream signaling action stat1 stat2 irf9 jak-stat pathway 2 repertoire ifn stimulatory gene isg study identify complex host demographic genetic factor viral genetic heterogeneity associate outcome ifn therapy genetic predisposition 2000 isg render patient resistant identification parameter subset population necessary management corollary ability hcv diminish ifn antiviral response play critical role establishment chronic infection acute stage infection highlight importance resistance hcv treated group recently define role viral protein c e2 ns3/ns4 ns5a protein induce ifn resistance discuss article viral host genetic composition epistatic connectivity polymorphic genomic site synchronize evolutionary ifn resistance trend remain investigation signal potential employ accurate prediction therapeutic outcome review article accentuate significance host viral component ifn resistance aim determine successful outcome patient\",\"combination direct-acting antiviral agent necessary overcome viral resistance interferon-free treatment regimen chronic hcv infection hcv p7 inhibitor combination regimen understand amantadine despite inhibition hcv p7 vitro appear ineffective clinical trial help design novel hcv p7 inhibitor far unknown viral escape mutation hcv p7 explain ineffectiveness amantadine vivo\",\"respiratory virus rsv highly contagious pathogen infect mainly ciliated cell respiratory epithelium type 1 pneumocyte alveolus frequently cause respiratory disease infant elderly immunocompromised patient present prevention/treatment rsv infection limited use specific anti-rsv antibody aerosol formulation ribavirin drug suboptimal efficacy low safety profile urgent need development novel anti-rsv drug virucide describe cell culture-based method use laboratory identification novel inhibitor rsv include p13 fusion inhibitor pg545 virucide protocol antiviral screening evaluation anti-rsv potency elucidation mode antiviral activity test compound describe\",\"current standard care soc hepatitis c virus hcv 1-infected patient consist telaprevir boceprevir addition pegylated interferon ribavirin treatment selective inhibitor hcv replication develop drug pressure depend class inhibitor rapidly select drug-resistant variant describe different approach select vitro drug-resistant hcv subgenomic replicon\",\"asunaprevir selective ns3 protease inhibitor vitro activity hcv 1 4\",\"rna virus hepatitis c virus hcv markedly error-prone replication result high rate mutagenesis addition standard treatment include ribavirin base analog likely cause mutation different region hcv genome result deleterious effect hcv n-terminal region core protein report block interferon ifn signaling interaction stat1\\u2011sh2 domain result hcv resistance ifn therapy study mutation hcv core protein ifn/ribavirin\\u2011treated patient analyze particular focus n\\u2011terminal domain hcv core report interact stat1 hcv pcr positive patient enrol study undergo pegylated ifn/ribavirin bitherapy complete 12 week initial treatment treatment\\u2011na\\u00efve patient hcv core protein clone sequence patient mutation observe stat1\\u2011interacting domain core protein treat patient characterize use silico interaction depict role mutation disease outcome result suggest amino acid position 2 3 8 16 23 hcv core protein critical core-stat1 interaction ribavirin-induced mutation position interfere interaction result response treat patient conclusion study anticipate hcv core residue 2 3 8 16 23 directly interact stat1 propose ifn/ribavirin bitherapy\\u2011induced mutation stat1\\u2011interacting domain hcv core protein responsible improve therapeutic response viral clearance amino acid 1 23 n-terminus core protein ideal antiviral target treatment rise resistant variant able escape current therapy propose similar study responsive non-responsive order gain broad picture propose mechanism viral clearance\",\"challenge exist study hcv laboratory therapy use interferon ifn expensive tolerated ineffective patient hcv research hamper lack robust tissue culture system recent advance virus growth culture possible cell culture system use genetically engineer virus review extensively review recent advance use natural isolate molecular challenge use overcome limitation growth major identify hcv far divide numerous combination therapy utilize ifn-\\u03b1 ribavirin standard care successful one-half patient reason ifn resistance viral- host-related multiple factor recently telaprevir boceprevir ifn-\\u03b1 ribavirin add standard care patient infect ifn-resistant major obstacle development effective vaccine improve therapeutic lack reproducible efficient tissue culture system propagation hcv cell culture system use genetically-engineered virus gain growth culture use replicon recent advance use natural isolate improve outlook progress hcv research\",\"host cell lipid raft form scaffold require replication hepatitis c virus hcv serine palmitoyltransferase spt produce sphingolipid essential component lipid raft associate hcv nonstructural protein prevention de novo synthesis sphingolipid spt inhibitor disrupt hcv replication complex inhibit hcv replication investigate ability spt inhibitor na808 prevent hcv replication cell mouse\",\"colorectal cancer cell exhibit limited cytotoxicity tiazofurin pro-drug metabolize cytosolic nicotinamide mononucleotide adenylyltransferase2 nmnat2 thiazole-4-carboxamide adenine dinucleotide potent inhibitor inosine 5'-monophosphate dehydrogenase require cellular guanylate synthesis test hypothesis colorectal cancer cell exhibit low level nmnat2 refractory tiazofurin render sensitive tiazofurin overexpresse nmnat2 transfection hnmnat2 result six- threefold cytoplasmic overexpression caco2 ht29 cell line correlate tiazofurin-induced enhance cell-kill folate receptor express cell surface 30 50 colorectal carcinoma exploit cellular targeting tiazofurin encapsulate folate-tethered nanoparticle result indicate wild-type colorectal cancer cell free tiazofurin-induced ec50 cell-kill 1500 2000 \\u03bcm reduce 66 156 \\u03bcm hnmnat2-overexpressed cell treat tiazofurin encapsulate non-targeted nanoparticle efficacy improve threefold encapsulate tiazofurin folate-tethered nanoparticle obtain ec(50 cell-kill 22 59 \\u03bcm equivalent 100 300 mg m(-2 one-tenth approve dose tiazofurin human result minimal toxicity lead cancer cell-kill proof-of-principle study suggest resistance colorectal cancer cell-kill tiazofurin overcome sequentially overexpresse hnmnat2 facilitate uptake tiazofurin folate-tethered nanoparticle enter cell folate receptor\",\"vaniprevir p/r improve svr rate p/r treatment-experienced patient chronic hcv-genotype 1 infection treatment failure present therapeutic challenge identify ravs non-cirrhotic patient fail achieve svr vaniprevir-containing regimen dose/duration-ranging trial triple-combination therapy\",\"vaniprevir competitive inhibitor hepatitis c virus hcv ns3/4a protease potent anti-hcv activity preclinical model placebo-controlled dose-ranging study assess safety tolerability antiviral efficacy vaniprevir monotherapy patient 1 chronic hcv infection treatment-naive treatment-experienced non-cirrhotic adult patient baseline hcv rna 10(6)iu/ml randomize receive placebo vaniprevir dose 125 mg qd 600 mg qd 25 mg bid 75 mg bid 250 mg bid 500 mg bid 700 mg bid 8 day patient 82.5 male 75 1a receive dose placebo vaniprevir 1 week vaniprevir decrease hcv rna baseline range 1.8 4.6 log10iu/ml treatment group great dose-proportional increase vaniprevir exposure dose 75 mg bid commonly report drug-related adverse event ae diarrhea n=5 nausea n=5 pattern laboratory ecg abnormality observe ae resolve study discontinuation aes ae report resistance-associated amino acid variant identify position r155 d168 patient infect 1a virus vaniprevir monotherapy demonstrate potent antiviral activity patient chronic 1 hcv infection generally tolerate ae discontinuation aes far development vaniprevir include study combination anti-hcv agent ongoing\",\"introduction direct-acting anti-viral increase sustained virological response svr rate chronic hepatitis c 1 infection present datum long-term durability viral eradication successful triple therapy lack\",\"suppressor cytokine signaling-1 socs-1 negative regulator janus kinase/signal transducer activation transcription pathway purpose study investigate relationship methylation socs-1 sustained virologic response svr chronic hepatitis c chc patient treat pegylated interferon (peg-ifn)-alpha ribavirin rbv\",\"telaprevir tvr protease inhibitor pi use chronic hepatitis c treatment pegylated interferon plus ribavirin analyse prevalence kinetic development tvr resistance treatment\",\"investigate association hepatic steatosis hepatic expression gene involve innate immunity reportedly associate resistance peginterferon peg-ifn ribavirin combination therapy hepatitis c virus hcv infection\",\"evidence natural killer nk cell help control persistent viral infection include hepatitis c virus hcv phenotype function blood intrahepatic nk cell steady state interferon ifn \\u03b1 treatment fully elucidate\",\"hepatitis c virus hcv infection global health concern chronic liver damage threaten 3 world population date standard care combination pegylated interferon-alpha ribavirin recently direct act antiviral enter clinic effect drug resistance viral genotype-specific difference efficacy current potentially future therapy limitation describe development phenotypic high-throughput assay identify new cross-genotype inhibitor novel mechanism action combine gt 1 replicon infectious hcv gt2 cell culture system develop phenotypic multiplex assay hcv reporter cell express rfp-nls-ips gt1b replicon cell express ns5a-gfp co-plate treat compound follow inoculation gt2a hcv 72h post treatment rfp translocation marker hcv infection gfp fluorescence intensity marker gt1 rna replication measure additionally total cell number serve indicator cytotoxicity determine phenotypic strategy support multi-parameter datum acquisition single access cross-genotypic activity provide indication stage viral life cycle target assess compound cytotoxicity multiplex phenotypic platform facilitate identification novel compound drug development chemical probe continue effort understand hcv life cycle\",\"hcv hepatitis c virus infection affect estimate 180 million people world population adverse effect occur frequently current standard treatment interferon ribavirin resistance new direct anti-viral agent ns3 protease inhibitor major concern single anti-hcv mechanism viral factor new anti-viral agent need resolve problem amiodarone anti-arrhythmic drug recently inhibit hcv infection vitro detailed mechanism clarify aim present study elucidate molecular mechanism inhibitory effect amiodarone hcv life cycle effect amiodarone hcv life cycle investigate huh-7.5.1 cell hcvcc cell culture-derived hcv hcvpp hcv pseudoviral particle sub-genomic replicon ires internal ribosomal entry site)-mediate translation assay intracellular extracellular infectivity assay administration amiodarone appear inhibit hcv entry independent attribute down-regulation cd81 receptor expression inhibitory effect amiodarone manifest hcv assembly step suppression mtp microsomal triacylglycerol transfer protein activity amiodarone reveal effect hcv replication translation host factor-targeting characteristic amiodarone attractive agent treatment hcv infection\",\"genetic polymorphism observe disease state associate sensitivity resistance specific treatment robust area investigation decade potential allow clinician evidence-based decision appropriate course treatment study aim evaluate genetic polymorphism signal transducer activator transcription 6 gene stat6 associate sustained virological response svr patient infect hepatitis c virus 1 2 hcv-1 hcv-2 treat peginterferon plus ribavirin peg-ifn\\u03b1-rbv analyze association svr peg-ifn\\u03b1-rbv therapy 4 single nucleotide polymorphism snp stat6 study include taiwanese chinese patient infect hcv-1 n 265 hcv-2 n 195 presence absence svr stat6 snp examine dosage effect allele allele frequency rs1059513 inversely correlate svr patient infect hcv-1 p 0.0179 p 0.0235 respectively effect observe patient infect hcv-2 gg ggg gggc stat6 haplotype comprise 2 3 4 snp rs1059513 rs703817 rs324015 rs3024974 find associate svr presence increase probability successful treatment outcome patient infect hcv-1 p 0.0273 0.0352 0.0368 respectively multivariate logistic regression model predict svr reveal presence gggc haplotype carrier mutually affect outcome peg-ifn\\u03b1-rbv treatment presence stat6 snp association svr demonstrate stat6 polymorphism influence therapeutic outcome patient infect hcv-1 standard-of-care soc treatment\",\"study c209 evaluate activity telaprevir treatment-na\\u00efve patient 2 3 g2 g3 hepatitis c virus hcv infection telaprevir monotherapy potent activity hcv g2 limited activity g3 analysis perform characterize hcv viral variant emerge telaprevir-based treatment g2/g3 hcv-infected patient patient randomize receive 2 week treatment telaprevir telaprevir monotherapy telaprevir plus peginterferon alfa-2a ribavirin triple therapy placebo plus peginterferon alfa-2a ribavirin control follow 22 24 week peginterferon/ribavirin viral breakthrough define increase 1 log10 hcv rna nadir hcv rna 100 iu/ml patient previously reach 25 iu/ml. twenty-three patient 47 g2 26 53 g3 hcv viral breakthrough occur initial 2-week treatment phase g2 patient 66.7 2 2a 2b g3 patient 37.5 3a telaprevir monotherapy arm breakthrough patient g2 g3 subsequently achieve sustained virologic response svr patient breakthrough available sequence datum mutation associate reduce susceptibility telaprevir 1 g1 hcv observe novel g2/g3-specific mutation associate telaprevir resistance telaprevir resistance profile appear consistent hcv 1 2 3 viral breakthrough resistance occur patient receive telaprevir monotherapy half patient achieve svr addition peginterferon/ribavirin highlight importance combination therapy\",\"achievement early viral suppression important patient chronic hcv infection treat telaprevir tlv boceprevir boc avoid selection drug resistance attain cure head-to-head study compare tlv boc perform far\",\"cell culture-produced hepatitis c virus hcv subject 100 serial passage human hepatoma cell absence presence different dose alpha interferon ifn-\\u03b1 virus survival genetic change fitness level phenotypic trait examine high initial ifn-\\u03b1 dose increase 1 4 iu/ml allow hcv survival passage 40 gradual exposure 0.25 10 iu/ml allow virus survive 100 passage virus passage presence ifn-\\u03b1 acquire ifn-\\u03b1 resistance evidence enhance progeny production viral protein expression ifn-\\u03b1 environment partial ifn-\\u03b1 resistance note population passage absence ifn-\\u03b1 lineage acquire adaptative mutation multiple nonsynonymous mutation scatter genome present ifn-\\u03b1-selected population comparison consensus sequence indicate dominance synonymous versus nonsynonymous substitution ifn-\\u03b1-resistant population display decrease sensitivity combination ifn-\\u03b1 ribavirin phenotypic trait common assay viral population ability increase shutoff host cell protein synthesis accentuate infection ifn-\\u03b1-selected population carry presence ifn-\\u03b1 trait associate enhance phosphorylation protein kinase r pkr eif2\\u03b1 contribute factor likely result suggest multiple independent mutational pathway confer ifn-\\u03b1 resistance hcv explain unified picture obtain regard ifn-\\u03b1 resistance vivo\",\"hcv polymerase inhibitor advanced stage clinical development nucleos(t)ide non-nucleoside analog nucleos(t)ide inhibit viral replication act chain terminator non-nucleosides block allosterically hcv polymerase sofosbuvir uridine analog currently promising hcv polymerase inhibitor active hcv good tolerability robust barrier resistance contrast non-nucleoside analog low moderate antiviral potency low barrier resistance inhibit hcv 1\",\"clinical correlation hepatitis c virus hcv ns5a gene mutation response antiviral treatment hcv-3a-infected patient know hcv-1a-infected hcv-1b-infected patient\",\"consider similarity transcriptional programming involve cancer progression somatic cell reprogramming try identify drug effective malignant cancer use early transposon oct4 sox2 enhancer eos system select human prostate cancer pca cell express high level oct4 patient metastatic castration-resistant pca respond treatment docetaxel therapeutic option oct4-expressing pca cell select use eos system increase tumorigenicity high resistance docetaxel vitro vivo use gene expression datum expression signature-based prediction compound candidate identify antiviral drug ribavirin conversion modulator drug resistance sensitivity treatment pca cell ribavirin decrease resistance treatment docetaxel indicate ribavirin reverse gene expression include humoral factor oct4-expressing pca cell select use eos system ribavirin increase efficacy docetaxel cancer cell propose novel cell reprogramming approach drug efficacy reprogramming new model identify candidate antitumor drug\",\"hepatitis c virus hcv infect estimate 150 million people worldwide major cause viral hepatitis cirrhosis liver cancer available antiviral therapy include pegylated interferon ribavirin hcv ns3/4a protease inhibitor telaprevir boceprevir ineffective patient cause severe effect potent ns3/4a protease inhibitor clinical development long-term effectiveness drug challenge development drug resistance investigate role macrocycle susceptibility ns3/4a protease inhibitor drug resistance asunaprevir danoprevir vaniprevir mk-5172 similar core structure vary p2 moiety macrocyclization linear macrocyclic analogue drug design synthesize test wild-type drug-resistant variant r155 k v36m/r155 k a156 t d168a enzymatic antiviral assay macrocyclic inhibitor generally potent location macrocycle critical retain activity drug-resistant variant p1-p3 macrocyclic inhibitor susceptible drug resistance linear p2-p4 macrocyclic analogue addition heterocyclic moiety p2 largely determine inhibitor resistance profile susceptibility drug resistance extent modulation helicase domain finding suggest design robust inhibitor retain potency drug-resistant ns3/4a protease variant inhibitor combine p1-p3 macrocycle flexible p2 moiety optimally contact invariable catalytic triad enzyme\",\"use ultra-deep sequencing technology present design investigate emergence telaprevir-resistant variant amino acid substitution aa36 aa54 aa155 aa156 aa170 position hcv ns3 region commencement triple therapy telaprevir/peginterferon (peg-ifn)/ribavirin predict baseline previous non-responder dual therapy fourteen patient infect hcv 1 respond previous peg-ifn/ribavirin receive 24-week regimen triple therapy evaluate appearance telaprevir-resistant variant amino acid substitution 0.2 total coverage ultra-deep sequencing sustained virological response rate 28.6 4 14 patient significantly high patient arg70 substitution core aa70 partial response type previous response peg-ifn/ribavirin patient telaprevir-resistant variant baseline detect 7.1 1 14 patient direct sequencing 21.4 3 14 patient ultra-deep sequencing appearance telaprevir-resistant variant examine ultra-deep sequencing 10 sustained virological responder de novo variant emerge re-elevation viral load regardless variant frequency baseline patient high frequency variant t54s 99.9 patient low frequency variant v36a 0.2 v170a 0.4 seven patient undetectable variant conclude difficult predict baseline emergence telaprevir-resistant variant commencement triple therapy prior non-responder hcv 1 use ultra-deep sequencing\",\"foot-and-mouth disease fmd highly contagious disease livestock cause highly variable rna virus fmdv seven serotype prophylactic post-infection mean control disease outbreak include universally applicable vaccine emergency response measure therapeutic treatment high demand study analyze long-term exposure outcome previously identify inhibitor 3d polymerase fmdv 3dpol control fmdv infection selection resistance mutant result escape mutant virus isolate fmdv a24 cruzeiro infection cell culture treat gradually increase concentration antiviral compound 5d9 4-chloro-n'-thieno [2,3-d]pyrimidin-4-ylbenzenesulfonohydrazide passage biochemical plaque assay reveal 5d9 use concentration non-toxic range cell drive virus undetectable level passage contrast observation parallel control untreated passage exhibit fully viable stable virus progeny collectively result demonstrate experimental condition treatment 5d9 confer resistant phenotype virus unable evade antiviral effect inhibitor far effort use quantitative structure-property relationship qspr base modification 5d9 compound result successful development effective vivo antiviral drug target fmdv\",\"new drug approve treatment hepatitis c virus hcv infection risk drug-drug interaction concern overlap toxicity hinder development study hiv/hcv-coinfected individual traditional treatment pegylated interferon plus ribavirin peg-ifn rbv expensive low rate sustained virological response coinfecte patient especially infect hcv 1 nitazoxanide ntz drug evaluate treatment chronic hcv infection hcv-monoinfected hiv/hcv-coinfected patient understand ntz resistance mechanism allow development resistance minimize expand treatment option mainly special population hiv/hcv-coinfected patient similarly ifn ntz increase activity cellular protein kinase activate double-stranded rna pkr key kinase innate antiviral response order elucidate sequence heterogeneity pkr-binding domain hcv ns5a 1 influence antiviral activity ntz monotherapy peg-ifn rbv baseline end-of-therapy plasma sample group non-responder hiv/hcv-coinfected patient receive ntz peg-ifn rbv study hcv ns5a sequence examine end therapy change baseline 30 day course antiviral therapy extensive comparison hcv ns5a 1 4 sequence database report ifn therapy outcome perform order infer phylogenetic relationship hcv 1 ns5a nucleotide sequence therapy-non-responder patient intermingle database irrespective ifn-therapy outcome compare ns5a-pkrbd amino acid sequence significant difference observe 4 1 p 0.0001 p 0.05 respectively conclusion despite ifn ntz share protein kinase activate double-stranded rna cellular target hcv 1 strategy counteract ifn action mediate ns5a isdr/pkrbd explain drug resistance hiv/hcv-coinfected patient viral factor possibly involve discuss\",\"article provide unbiased review pharmacokinetic pharmacodynamic drug-drug interaction datum telaprevir ns3/4a protease inhibitor telaprevir absorb fatty food moderately protein bind 59 76 large volume distribution ~252 l primarily metabolize cytochrome p450 cyp 3a4 p-glycoprotein largely excrete fece pharmacokinetic pharmacodynamic parameter describe healthy subject individual infect hepatitis c virus hcv limited datum available specific patient subpopulation telaprevir recommend 750 mg mouth 8 h 12 week combination peginterferon ribavirin standard care addition telaprevir standard care regimen result increase sustained virological response treatment-na\\u00efve patient 30 treatment-experienced patient 50 work synergistically lower viral resistance telaprevir substrate and/or inhibitor cyp3a4 p-glycoprotein drug-drug interaction study human focus pathway base analysis report drug-drug interaction classify clinically significant experiment dose condition resemble clinic need understand relevance report interaction future study focus pharmacokinetics/pharmacodynamic telaprevir special population patient concomitant condition likely co-exist hcv infection emphasis establish pharmacokinetic-pharmacodynamic relationship vitro characterization phase 1 3 metabolic pathway assist elucidate mechanism drug-drug interaction observe human\",\"ribavirin rbv use conjunction interferon-based therapy patient chronic hepatitis c. drastic difference anti-hepatitis c virus hcv activity rbv huh-7-derived assay system or6 possess rbv-resistant phenotype 50 effective concentration ec50 100 \\u00b5m recently discover li23-derived assay system orl8 possess rbv-sensitive phenotype ec50 8 \\u00b5m clinically achievable concentration anti-hcv activity rbv mediate inhibition inosine monophosphate dehydrogenase rbv-sensitive orl8 cell harbor hcv rna mean comparative analysis use rbv-resistant or6 cell rbv-sensitive orl8 cell try identify host factor(s determine anti-hcv activity rbv find expression adenosine kinase adk orl8 cell significantly high rbv-resistant or6 cell harbor hcv rna ectopic adk expression or6 cell convert rbv-resistant rbv-sensitive phenotype inhibition adk abolish activity rbv differential adk expression orl8 or6 cell result genetic polymorphism adk gene promoter region mediate microrna control mechanism find 5 untranslated region utr adk messenger rna orl8 cell long or6 cell long 5 utr possess internal ribosome entry site ires activity finally demonstrate long 5 utr function ires primary human hepatocyte\",\"lipid pathway impairment decrease antioxidant pool downregulation amino-acid metabolism metabolic variation attribute chronic hcv infection study separately mainly animal model thank proteomic analysis manage describe fist time good knowledge vivo human metabolic alteration cause hcv recovery alteration hcv treatment perform proteomic analysis liver specimen 28-year-old woman affect hepatitis c 1a alcoholism diabetes mellitus type 1 antiviral treatment pegylated interferon alpha 2b ribavirin subject thank patient-tailored therapy reach sustained virological response treatment period patient monitor subsequent biochemical clinical psychological examination datum obtain patient close monitoring suggest direct interaction insulin resistance active hcv 1 infection leading role play infection insulin resistance demonstrate sharp fall insulin unit need day treatment proteomic analysis therapy downregulation enzyme involve amino acid metabolism glycolysis/gluconeogenesis alcohol catabolism place probably cessation alcohol abuse contrary metabolic pathway link metabolism reactive oxygen specie upregulate therapy finally significant alteration pathway regulate peroxisome proliferator-activated receptor alpha ppara major regulator lipid metabolism liver report real time datum confirm vivo human hcv infection pathway related fatty acid glucose metabolism free radical scavenging inhibit enzyme deficit completely recover hcv eradication\",\"insulin resistance ir key factor development hepatic steatosis fibrosis chronic hepatitis c virus infection little know impact viral clearance ir\",\"sentinel cohort hepatitis c virus hcv patient primarily gt 1a treat daclatasvir ns5a inhibitor asunaprevir ns3 protease inhibitor preexistence emergence persistence resistance variant patient fail treatment describe hcv-infected null responder receive daclatasvir 60 mg daily asunaprevir 600 mg twice daily group 11 patient peginterferon alfa-2a ribavirin group b 10 patient 24 week resistance testing perform baseline sample sample hcv rna \\u22651,000 iu/ml week 1 posttreatment week 48 resistance substitution susceptibility inhibition asunaprevir daclatasvir assess use hcv replicon assay group gt1a patient experience viral breakthrough gt1a patient relapse detectable ns5a q30e/r l31v/m y93c/n ns3 r155 k d168a/e/v/y resistance-associated variant failure viral breakthrough patient achieve svr48 treatment intensification peginterferon alfa-2a ribavirin 2/4 viral breakthrough patient respond treatment intensification ns3 resistance variant change d168y d168 t r155 k v36m-r155 k posttreatment week 48 daclatasvir-resistant variant persist asunaprevir-resistant variant generally replace wild-type sequence ns3 sequence remain unchanged patient ns3-r155 k baseline relapse posttreatment week 48 group b viral breakthrough observe\",\"protease inhibitor improve treatment infection hepatitis c virus hcv dosing low barrier resistance drug interaction side-effect restrict use assess safety efficacy sofosbuvir uridine nucleotide analogue treatment-naive patient 1 3 hcv infection\",\"discovery hepatitis c virus hcv plethora experimental model evolve allow virus life cycle pathogenesis associate liver disease investigate model range inoculation culture cell serum patient hepatitis c use surrogate model study specific stage hcv life cycle retroviral pseudoparticle study hcv entry replicon study hcv replication hcv cell culture model reproduce entire life cycle replication production infectious particle use tool remain crucial identify potential therapeutic target different stage virus life cycle screen new antiviral drug clear example recent approval viral protease inhibitor boceprevir telaprevir combination pegylated interferon ribavirin treatment chronic hepatitis c. review analyze advance molecular biology hcv highlight possible candidate therapeutic target treatment hcv infection\",\"development novel direct antiviral agent daa hepatitis c virus hcv represent breakthrough treatment chronic hepatitis c. telaprevir boceprevir protease inhibitor pi daa approve combination therapy pegylated interferon peg-ifn ribavirin rbv 1 monoinfected patient triple pi therapy increase sustained viral response svr rate approximately 30 compare conventional combination therapy introduction drug clinical practice modify timing monitor parameter diagnostic laboratory especially regard stop rule fast delivery result near future new daa direct different target hcv cycle polymerase inhibitor viral replication complex inhibitor cyclophilin inhibitor currently stage clinical development available daa reach advanced phase development combination peg-ifn rbv interferon-free therapy high rate svr\",\"direct-acting antiviral daa develop therapy hepatitis c virus target ns3/4a protease ns5a protein ns5b polymerase enzyme offer different target site catalytic domain nucleos(t)ide analogue number allosteric site nonnucleos(t)ide inhibitor ns3/4a protease inhibitor approve recently 40 new ns3/4a ns5a ns5b inhibitor development agent achieve high cure rate combine pegylated interferon-\\u03b2 ribavirin promise clinical result administer all-oral combination addition canonical drug target new alternative viral target small-molecule drug development emerge p7 ns4b viral entry future research need define well-tolerated cost-effective daa combination provide high rate viral eradication patient include advanced liver disease broad spectrum action viral minimal clinical resistance short treatment duration\",\"hepatitis c virus hcv infection major health impact worldwide significant cause chronic liver disease egypt hcv highly endemic 15 population 91 patient infect 4 search new predictor response therapy mandatory decrease cost adverse effect current therapy\",\"class hepatitis c antiviral agent currently exist i.e. direct-acting antiviral host-targeting antiviral direct-acting antiviral target viral protein include ns3/ns4a protease ns5b polymerase ns5a protein host-targeting antiviral target host protein critical replication hepatitis c virus hcv alisporivir advanced host-targeting antiviral clinical development alisporivir block hcv replication neutralize peptidyl-prolyl isomerase activity abundant host cytosolic protein cyclophilin a. unique mechanism antiviral action alisporivir pangenotypic provide high barrier development viral resistance permit cross-resistance direct-acting antiviral alisporivir excellent pharmacokinetic safety profile phase ii clinical study demonstrate alisporivir cause dramatic reduction viral load hcv-infected patient alisporivir highly potent treatment-na\\u00efve treatment-experienced patient 1 2 3 low viral breakthrough rate observe frequent clinical laboratory adverse event associate alisporivir combination pegylated interferon-alpha ribavirin similar associate pegylated interferon-alpha ribavirin use laboratory abnormality observe patient receive alisporivir hyperbilirubinemia related transporter inhibition liver toxicity recent clinical result suggest alisporivir plus direct-acting antiviral provide successful treatment option difficult-to-treat population nonresponder prior interferon-alpha therapy patient cirrhosis conclusion alisporivir represent attractive candidate component future interferon-free regimen\",\"goal treatment chronic hepatitis c achieve sustained virological response define exhibit undetectable hepatitis c virus hcv rna level serum following therapy month current treatment effective 50 patient infect hcv 1 prevalent brazil inhibitor serine protease non-structural protein 3 ns3 develop improve response hcv-infected patient emergence drug-resistant variant major obstacle therapeutic success goal study evaluate presence resistance mutation genetic polymorphism ns3 genomic region hcv 37 patient infect hcv 1 treat protease inhibitor plasma viral rna use amplify sequence hcv ns3 gene result indicate catalytic triad conserve large number substitution observe codon 153 40 91 resistant variant t54a t54s v55a r155 k a156 t detect study resistance mutation genetic polymorphism present ns3 region hcv patient treat protease inhibitor datum important determine efficiency new class drug brazil\",\"idx184 liver-targeted nucleotide prodrug selectively inhibit hcv ns5b polymerase\",\"autoantibody study well-characterized cohort child chronic hepatitis c treatment pegylated interferon ribavirin assess relation treatment development autoimmune disease\",\"patient classify hcv-1a-positive lipa siemens 2.0 abbott realtime hcv ii instead find infect hcv-1 g determine phylogenetic analysis ns3 sequence hcv-1 g ns3 sequence available date naturally harbour resistance substitution t54s plus p131s l135f change located highly conserve ns3 position boceprevir-binding site determine structural modelling hcv-1 g ns3 sequence similarity hcv-4 poorly responsive interferon/ribavirin boceprevir/telaprevir patient null-responder boceprevir treatment baseline genotypic resistance testing provide crucial information management first-generation protease-inhibitor-based regimen include hcv genotype/subtype natural resistance\",\"thousand new case hepatitis c virus hcv infection record brazil year case currently treat pegylated interferon peg-ifn ribavirin rbv overall success rate 50 new compound anti-hcv therapy target hcv ns3 protease develop form component licensed therapy map ns3 protease resistance mutation protease inhibitor anti-viral drug candidate important direct anti-hcv drug treatment\",\"resistance direct-acting antiviral represent new challenge treatment chronic hepatitis c.\",\"addition hepatitis c virus hcv protease inhibitor pi interferon ribavirin therapy significantly improve efficacy treatment hcv infection patient respond therapy selection hcv variant resistance pi likely resistant variant r155 k a156t/v result extensive cross-resistance hcv pi despite rapid frequent appearance pi-resistant hcv variant long-term clinical implication unknown particular progress development hcv antiviral ns5a inhibitor next-generation ns3 protease inhibitor ns5b nucleoside nonnucleoside inhibitor provide broad selection potent antiviral interferon-free therapy reality promise result early stage interferon-free trial review\",\"daclatasvir dcv bms-790052 hepatitis c virus hcv ns5a replication complex inhibitor rci picomolar low nanomolar potency broad genotypic coverage vitro viral rna decline observe clinic alpha interferon-ribavirin ifn-\\u03b1-rbv ifn-rbv-free regimen include dcv follow-up specimen 6 month select subject treat dcv 14-day monotherapy study analyze phenotype variant detect clonal sequencing specimen baseline readily detect population sequencing follow viral rna breakthrough posttreatment major amino acid substitution generate resistance vivo residue m28 q30 l31 y93 1a gt-1a l31 y93 gt-1b similar resistance substitution observe vitro replicon system primary difference resistance pattern observe vitro vivo increase complexity link variant combination observe clinical specimen change percentage individual variant observe follow-up overall percentage variant total population persist 6 month result suggest 14-day monotherapy wild-type virus eradicate dcv end dcv treatment viral fitness dcv resistance probably determine viral variant emerge dominant population\",\"soluble cd36 scd36 plasma level known marker cardiometabolic disorder associate surrogate marker steatosis experimental human study link cd36 expression liver steatosis cohort patient 1 chronic hepatitis c g1 chc test association scd36 plasma level host viral factor sustained virological response svr seventy-five consecutive biopsy-proven patient study scd36 plasma level assess in-house elisa biopsy score pathologist staging grading scheuer grade steatosis consider moderate-severe \\u226520 patient undergo standard care therapy pegylated interferon ribavirin severity steatosis progressively increase accord scd36 quartile p 0.02 total low-density lipoprotein ldl cholesterol level significantly high patient low quartile compare gamma-glutamyl transferase p 0.02 homoeostasis model assessment homa score p 0.002 scd36 p 0.04 independently associate severity steatosis continuous variable multivariate logistic regression analysis homa 1.243 95 ci 1.04 1.484 p 0.01 scd36 1.445 95%ci 1.135 1.839 p 0.003 independently link steatosis \\u226520 association find scd36 svr cd36 link steatosis insulin resistance patient g1 chc predict response treatment potential scd36 surrogate marker steatosis far investigate\",\"mericitabine selective nucleoside analog inhibitor hepatitis c virus hcv ns5b rna-dependent rna polymerase activity hcv treatment-na\\u00efve patient infect hcv 1 4 randomize 24 week double-blind treatment mericitabine 1,000 mg n 81 placebo n 85 twice-daily bid combination pegylated interferon alpha-2a (peg-ifn\\u03b1-2a)/ribavirin rbv patient randomize mericitabine hcv rna 15 iu/ml week 4 22 extend rapid virologic response ervr stop treatment week 24 patient continue peg-ifn\\u03b1-2a/rbv complete 48 week treatment primary efficacy endpoint sustained virologic response svr hcv rna 15 iu/ml 24 week treatment-free follow-up svr achieve 56.8 95 confidence interval ci 45.9 67.0 mericitabine-treated patient 36.5 95 ci 27.0 47.1 placebo-treated patient \\u03b4 20.3 95 ci 5.5 35.2 svr rate high mericitabine- placebo-treated patient subdivide il28b cc 77.8 versus 56.0 non-cc 44.1 versus 16.2 hepatic fibrosis noncirrhotic 63.3 versus 41.9 cirrhotic 38.1 versus 21.7 overall relapse rate 27.7 32.0 mericitabine- placebo-treated patient respectively evidence ns5b s282t-variant virus phenotypic resistance mericitabine observe patient experience partial response s282 t variant detect baseline sample safety profile mericitabine similar patient mericitabine placebo group discontinue treatment safety reason\",\"rapid allograft infection complicate liver transplantation lt patient hepatitis c virus hcv pegylated interferon-\\u03b1 ribavirin therapy lt significant toxicity limited efficacy effect human monoclonal antibody target hcv e2 glycoprotein mbl-hcv1 viral clearance examine randomized double-blind placebo-controlled pilot study patient infect hcv 1a undergo lt subject receive 11 infusion 50 mg/kg mbl-hcv1 n=6 placebo n=5 intravenously infusion day transplant single infusion day 1 7 infusion day 14 lt mbl-hcv1 well-tolerated reduce viral load period range 7 28 day median change viral load log10 iu/ml baseline significantly great p=0.02 antibody-treated group range -3.07 -3.34 compare placebo group range -0.331 -1.01 day 3 6 posttransplant mbl-hcv1 treatment significantly delay median time viral rebound compare placebo treatment 18.7 day vs. 2.4 day p<0.001 hcv monotherapie antibody-treated subject resistance-associated variant time viral rebound combination study mbl-hcv1 direct-acting antiviral underway\",\"mericitabine nucleoside analog polymerase inhibitor hepatitis c virus hcv treatment-na\\u00efve hcv 1 4 patient randomize double-blind treatment oral mericitabine dosage 500 mg twice-daily bid 12 week 1,000 mg bid 8 b 12 week c d placebo bid 12 week e patient receive pegylated interferon alpha-2a peg-ifn\\u03b1-2a 40 kd)/ribavirin rbv standard dose 24 48 week mericitabine/placebo therapy patient arm a-c maintain virologic response vr hcv rna 15 iu/ml week 4 22 stop treatment week 24 patient arm a-e continue peg-ifn\\u03b1-2a/rbv complete 48 week primary outcome sustained vr svr hcv rna 15 iu/ml 24 week untreated follow-up svr-24 vr rate high arm a-d arm e week 4 12 overall patient cirrhosis patient cc non-cc il28b overall svr-24 rate arm d 50.6 e placebo 51.2 similar response-guided therapy arm b c low 48.8 42.0 32.9 respectively viral breakthrough mericitabine-resistance mutation s282 t observe mericitabine therapy\",\"hepatitis c virus hcv infection important cause cirrhosis hepatocellular carcinoma tremendous impact public health worldwide hcv hepatotropic lymphotropic replication hcv diseased extrahepatic organ tissue trigger latent autoimmunity induce autoimmune disorder addition establish liver injury type 2 diabetes mellitus t2dm important feature extrahepatic metabolic disorder attribute hcv infection impact disease activity disease course clinical outcome treatment efficacy antiviral therapy previous experimental clinical finding highly suggest hcv se diabetogenic cause-effect interaction common endocrine disorder infectious disease important issue elucidate precise mechanism hcv infection lead insulin resistance ir glucose abnormality entirely clear differ usual pathogenesis t2dm non-hcv liver disease review initially highlight epidemiological pathophysiological study address mutual link chronic hcv infection chc t2dm characteristic glucose abnormality special population depict current evidence mutual role ir chc respect prediction treatment efficacy treatment response affect ir role pancreatic beta cell function entire suite discuss rapid progression antiviral therapy chc past decade list point future perspective issue\",\"major challenge antiviral treatment hepatitis c virus hcv infection viral resistance potentially result high variability hcv envelope glycoprotein subsequent selection strain enhance infectivity and/or immune escape\",\"recently standard-of-care therapy patient hcv infection involve treatment interferon ifn ribavirin rbv host demographic genetic factor hcv genetic heterogeneity associate outcome therapy resistance ifn/rbv remain important clinical public health problem reliable genetic marker prediction therapy outcome recently adaptation ifn major constituent host innate immunity reflect hcv genetic composition epistatic connectivity polymorphic genomic site provide novel genetic marker ifn resistance consideration coordinate evolution hcv genomic site allow identification genetic marker short region hcv genome accurate prediction therapeutic outcome hcv genomic co-evolution offer general framework detection predisposition ifn resistance possibly resistance direct-acting antiviral\",\"current treatment hepatitis c virus hcv 1 chronic infection addition direct-acting antiviral daa protease inhibitor telaprevir boceprevir pegylated interferon peg-ifn plus ribavirin rbv regimen major progress past year numerous ongoing trial different compound increase sustained virological response svr rate oral regimen shorten treatment duration combination antiviral additive potency lack cross-resistance good safety profile provide new regimen future hcv chronic viral infection eradicate worldwide finite duration combination daa therapy ifn\",\"telaprevir boceprevir direct-acting antiviral agent approve use hcv treatment represent significant advance hcv therapy first-generation drug significant limitation related thrice-daily dosing clinically challenge side-effect profile low barrier resistance lack pan-genotype activity second wave protease inhibitor phase ii iii trial promise provide drug regiman dosing schedule improve tolerance second-wave protease inhibitor probably approve combination peg-ifn ribavirin rbv future all-oral regimen true second-generation protease inhibitor early stage development efficacy datum anxiously await provide pan-genotypic antiviral activity high genetic barrier resistance\",\"hcv worldwide disease estimate prevalence 3 hepatitis c virus 4 prevalent africa middle east especially egypt treatment hcv4 affect factor related virus pretreatment viral load prevalent quasispecie host genetic factor age ethnicity liver histology presence comorbiditie obesity insulin resistance co-infection therapeutic drug type dose duration optimize treatment goal daily practice obtain good result patient\",\"hepatitis c virus hcv major cause hepatocellular carcinoma cirrhosis end stage liver disease 200million people live hcv worldwide high morbidity mortality vaccine available virus approve treatment option majority hcv combination pegylated peg interferon ribavirin therapy different response rate different hcv number effect recently peg interferon ribavirin protease inhibitor introduce treat patient hcv 1 infection protease inhibitor rapid onset resistance approve use infection hcv hcv ns5b gene encode rna dependent rna polymerase rdrp key player viral replication promising target development antiviral drug hcv ns5b study biochemical assay cell based assay animal model system far number nucleoside non-nucleoside inhibitor screen effect viral replication review present deep insight structure function hcv polymerase effect nucleoside non-nucleoside inhibitor viral replication\",\"hepatocellular carcinoma hcc common sequelae hepatitis c virus hcv infection remain controversial hcv play direct role development hcc hcv core ns3 ns5a protein report display tumorigenic activity cell culture experimental animal system clinical impact hcc development human unclear study investigate sequence polymorphism core protein ns3 ns5a hcv 1b hcv-1b 49 patient later develop hcc follow-up average 6.5 year 100 patient develop hcc 15-year follow-up sequence analysis reveal gln position 70 core protein core-gln(70 tyr position 1082 plus gln 1112 ns3 ns3-tyr(1082 /gln(1112 mutation interferon/ribavirin resistance-determining region ns5a ns5a-irrdr\\u22656 significantly associate development hcc multivariate analysis identify core-gln(70 ns3-tyr(1082 /gln(1112 \\u03b1-fetoprotein afp level 20 ng/l independent factor associate hcc kaplan-meier analysis reveal higher cumulative incidence hcc patient infect hcv isolate core-gln(70 ns3-tyr(1082 /gln(1112 non-(gln(70 plus ns3-tyr(1082 /gln(1112 case residue position 70 core protein position 1082 1112 ns3 protein change observation period\",\"hepatitis c virus hcv infect 2 world population high prevalence africa asia past standard care use interferon \\u03b1 ribavirin adverse effect modest efficacy hcv spur development direct act antiviral daa daa target viral protein tolerate suffer emergence vial resistance furthermore daa hcv specific novel drug candidate target host factor require hcv propagation host-targeting antiviral hta promise overcome caveat genetic barrier resistance usually consider high hta hcv presumably use host factor recent datum challenge assumption hta highlight important host-targeting strategy hepatitis c critically discuss opportunity risk\",\"antiviral resistance influenza virus associate high morbidity mortality immunocompromised host treatment strategy drug-resistant influenza establish triple-combination antiviral drug tcad regimen consist amantadine amt oseltamivir osl ribavirin rbv demonstrate good efficacy animal model\",\"increase \\u03b3-glutamyl transferase ggt activity associate liver injury mortality general population know association chronic hepatitis c hcv outcome examine ggt predictor virological response treatment long-term clinical outcome hepatitis c anti-viral treatment cirrhosis trial halt-c halt-c enrol patient advanced liver disease ishak fibrosis score \\u22653 phase lead-in establish lack sustained viral response dose pegylated interferon ifn ribavirin follow 3.5-year randomized trial low-dose ifn low-dose ifn prevent liver disease progression patient follow additional 5 year therapy analysis perform 1,319 patient ggt measure prior initiation treatment increase risk increase quintile ggt 10 57 58 89 90 139 140 230 231 2,000 iu/l determine logistic regression treatment response cox regression clinical outcome baseline ggt associate male sex nonwhite ethnicity diabete insulin resistance interleukin (il)28b rs12979860 ct tt numerous marker liver disease injury severity lead-in phase increase ggt strongly associate diminished week 20 response end treatment response sustained virological response univariate multivariate analysis control factor know associate treatment response p 0.0001 ggt associate clinical outcome univariate multivariate analysis p 0.05 hepatocellular carcinoma p 0.46 multivariate analysis\",\"cytokine play key role regulation immune response hepatitis c virus infection production abnormal cytokine level appear contribute progression disease viral persistence affect response therapy cytokine gene polymorphism located coding/regulatory region affect overall expression secretion cytokine aim study evaluate association il28b rs12979860 tgf-\\u03b21 509 tnf-\\u03b1 308 il-10 1082 polymorphism susceptibility hepatitis c virus 4 infection response pegylated interferon-\\u03b1 ribavirin therapy\",\"recent datum suggest vitamin modulate expression type interferon receptor enhance antireplication effect interferon-\\u03b1 hepatitis c virus hcv study aim investigate prevalence vitamin deficiency patient chronic hcv infection assess vitamin deficiency associate unresponsiveness interferon-based antiviral therapy analysis include 199 consecutive treatment-na\\u00efve chronic hcv patient pretreatment serum vitamin 25-oh vitamin d measure 119 healthy blood donor use control median interquartile range serum vitamin hcv-positive patient significantly low control 256 ng/ml 128 440 versus 742 624 942 p<0.0001 overall sustained viral response achieve 122/199 patient 46/109 infect difficult treat hcv 39/104 37.5 nonresponder multivariate analysis nonresponse antiviral therapy predict carriage interleukin (il)-28b t/ baseline serum level \\u03b3gt>60 iu/ml hcv rna>600,000 iu/ml vitamin a\\u2264100 ng/ml cumulative dose ribavirin\\u226480 seventeen patient 9.0 serum level vitamin a\\u2264100 ng/ml vitamin d\\u226420 ng/ml presence combined vitamin d deficiency find strong independent predictor nonresponse antiviral therapy\",\"hepatitis c virus hcv major cause liver disease world-wide current interferon ribavirin ifn/rbv therapy effective 50%-60 patient hcv exist infected patient large viral population intra-host variant quasispecie differentially resistant interferon treatment present method measure differential interferon resistance hcv quasispecie base mathematical modeling analysis hcv population dynamic hour interferon therapy mathematical model individual intra-host hcv variant wide range resistance ifn treatment patient analysis differential ifn resistance intra-host hcv variant allow accurate prediction response ifn therapy model strongly suggest resistance interferon vary broadly closely related variant infected host therapy outcome define single variant irrespective frequency intra-host hcv population treatment\",\"machine-learning method form bayesian network bn linear projection lp self-organizing tree sot model use explore association polymorphic site hvr1 ns5a region hcv genome host demographic factor ethnicity gender age response combined interferon ifn ribavirin rbv therapy bn model predict therapy outcome gender ethnicity accuracy 90 90 88.9 respectively lp sot model strongly confirm association hvr1 ns5a structure response therapy demographic host factor identify bn datum indicate host specificity hcv evolution suggest application model predict outcome ifn/rbv therapy\",\"recurrent hcv disease common cause graft loss patient mortality hcv-infected liver transplant lt recipient risk factor severe recurrence potentially modifiable old donor age prolonged cold ischaemia time prior treat acute rejection cmv hepatitis il28b donor post-lt insulin resistance effective mean prevent hcv recurrence eradicate hcv prior lt select wait-list candidate compensate mildly decompensated disease consider antiviral treatment peginterferon ribavirin protease inhibitor 1 majority lt patient hcv treatment delay post-transplant treatment generally undertake histologic severity reach grade 3 4 necroinflammation stage \\u22652 fibrosis cholestatic hepatitis achievement sustained viral response svr post-lt associate stabilization fibrosis improve graft survival svr attain ~30 patient treat peginterferon ribavirin poor tolerability therapy limitation combination therapy telaprevir boceprevir add peginterferon ribavirin anticipate increase efficacy high rate adverse effect challenge manage drug-drug interaction protease inhibitor calcineurin inhibitors/sirolimus\",\"recent development small molecule compound directly inhibit viral life cycle represent major milestone treatment chronic hepatitis c virus hcv infection new drug collectively term direct-acting antiviral daa include range inhibitor non-structural ns 3/4a protease ns5b polymerase ns5a protein ns3/4a protease inhibitor boceprevir telaprevir combination pegylated interferon ribavirin approve treatment chronic hcv 1 infection cure rate increase 20 30 majority daa early clinical development rapid replication rate hcv error-prone polymerase activity lead high genetic diversity hcv virion include mutant reduce susceptibility daa-therapy resistance-associated variant occur low frequency daa-based treatment rapid selection resistance mutation occur eventually lead viral break-through number variant different level resistance describe vitro vivo daa review parameter determine daa resistance clinical implication resistance testing addition recent literature conference datum resistance profile daa clinical development future strategy avoid emergence viral resistance discuss\",\"understand natural history treatment responsiveness chronic hepatitis c virus hcv infection evolve rapidly recent year advance hcv molecular virology host genetic predict spontaneous clearance treatment outcome hcv important viral factor predict interferon-\\u03b1 treatment responsiveness hcv-1 emerge key determinant efficacy direct act antiviral therapy genome-wide association study recently identify clinically important host determinant outcome peginterferon-\\u03b1 ribavirin treatment outcome il28b polymorphism associate spontaneous clearance treatment responsiveness itpa polymorphism protect ribavirin-induced anaemia dose reduction genetic determinant liver fibrosis progression rate propose review evaluate role viral host genetic natural history treatment outcome chronic hcv infection consider knowledge help individualize clinical management era daa therapy\",\"chronic hepatitis c affect approximately 170 million people worldwide lead cause liver-related morbidity mortality 2011 therapeutic option combination therapy pegylated interferon ribavirin efficacy rate 50 plenty effect past month important step effective antiviral therapy far highly efficient well-tolerable ideal therapy development new drug hcv dynamic field review summarize up-to-date knowledge significant anti-hcv compound development\",\"current epidemic hcv infection affect 180 million people quarter cirrhosis number hepatocellular carcinoma liver failure project treble decade mean reduce health burden increase eradication antiviral therapy current antiviral therapy limit poor efficacy tolerability especially patient hcv 1 pegylated interferon peg-ifn plus ribavirin rbv significant effect administer 48 week cure half patient patient diagnose chronic hepatitis c unsuitable refuse undertake therapy recent approval triple therapy telaprevir boceprevir peg-ifn/rbv increase cure reduce duration therapy unsuitable patient intolerant contraindication ifn rbv addition triple therapy limited benefit previous null responder peg-ifn/rbv advanced fibrosis finally protease inhibitor antiviral efficacy patient infect non-1 hcv urgent need development ifn-free all-oral treatment regiman consist direct-acting antiviral drug different mechanism stop virus high barrier resistance improve cure rate hcv likely successful regimen contain direct-acting antiviral different target action high barrier resistance likely duration ifn-free direct-acting antiviral therapy 6 12 week depend early-on-treatment virological response\",\"hcv infection major cause chronic liver disease affect nearly 170 million people worldwide previous standard care pegylated interferon ribavirin modest effectiveness recent approval highly potent protease inhibitor ongoing development dozen direct-acting antiviral agent daa constitute major milestone hcv therapy mathematical modelling viral kinetic treatment play instrumental role improve understanding virus pathogenesis guide drug development review current state hcv kinetic modelling challenge standard biphasic viral decline model arise fitting viral kinetic model datum obtain daa\",\"assess safety efficacy boceprevir boc plus peginterferon-ribavirin pr patient hcv-g1 infection advanced fibrosis/cirrhosis metavir f3/f4\",\"gs-9669 highly optimize thumb site ii nonnucleoside inhibitor hepatitis c virus hcv rna polymerase binding affinity 1.35 nm gt 1b protein selective inhibitor hcv rna replication mean 50 effective concentration ec(50 \\u2264 11 nm 1 5 replicon assay lack useful activity 2 4 m423 t mutation readily generate clinically monotherapy thumb site ii inhibitor filibuvir lomibuvir notable gs-9669 exhibit 3-fold loss potency variant 1b replicon m423 t resistance predominantly track residue r422 k l419 m residue i482l gt 1b 1a replicon respectively gs-9669 exhibit additive activity combination agent encompass direct mode action ns3 protease ns5a ns5b alternative allosteric bind site ns5b nucleotide alpha interferon ribavirin replicon assay exhibit high metabolic stability vitro human liver microsomal assay combination pharmacokinetic profile rat dog monkey specie predictive good human pharmacokinetic gs-9669 suited combination orally active direct-acting antiviral agent treatment 1 chronic hcv infection study register clinicaltrials.gov registration number nct01431898\",\"ns5a protein play key role hepatitis c virus hcv replication daclatasvir dcv bms-790052 first-in-class inhibitor hcv ns5a replication complex potent antiviral activity low barrier resistance dcv triple therapy combination pegylated interferon ribavirin result high rate early virologic response treatment-na\\u00efve patient 1 infection quadruple therapy combination asunaprevir bms-650032 ns3 protease inhibitor pegylated interferon ribavirin result high rate sustained virologic response 1 prior null responder\",\"nucleoside/nucleotide analogue polymerase inhibitor npi analogue natural substrate bind active site ns5b terminate viral rna chain generation generally provide high genetic barrier resistance effective npi sofosbuvir gs-7977 high antiviral activity high genetic barrier resistance suggest optimal backbone candidate all-oral combination therapy trial ongoing far define potential all-oral regimen sofosbuvir gs-7977 recent interim analysis indicate patient treat 2 direct-acting antiviral agent experience viral breakthrough significantly reduce addition ribavirin pegylated interferon \\u03b1\",\"monotherapy ineffective way treat hepatitis c lead rapid development resistance increase number drug currently develop treatment hepatitis c. allow combination strategy overcome development resistance improve sustained virologic response rate article focus 2 main strategy development quadruple combination therapy include pegylated-interferon triple/quadruple pegylated-interferon free combination therapy combination lead extremely high sustained virologic response second offer hope era pegylated-interferon end soon\",\"antiviral treatment chronic hepatitis c invariably successful costly associate side-effect indicate chance benefit patient exceed potential risk suppressor cytokine signalling socs family member suggest affect rate virological response therapy publish evidence conflict\",\"decade standard care treatment chronic hepatitis c combination pegylated-interferon-alfa peg-ifn ribavirin rbv result sustained virological response svr rate 75%-85 patient 2 3 40%-50 patient 1 currently rapid continuous development numerous new agent hepatitis c virus hcv focus review boceprevir telaprevir first-generation ns3/4a hcv protease inhibitor recently country world use combination peg-ifn rbv treatment 1 patient boceprevir telaprevir base triple regimen compare peg-ifn/rbv combination improve svr rate 25%-31 treatment-na\\u00efve 1 patient 40%-64 prior relapser 33%-45 prior partial responder 24%-28 prior null responder time application response-guided treatment algorithms accord on-treatment virological response result shortening total therapy duration 24 wk 45%-55 treatment-na\\u00efve patient challenge use new triple combination 1 patient need immediate result hcv rna testing use sensitive quantitative assay new frequent adverse event anemia dysgeusia boceprevir pruritus rash anemia telaprevir new drug interaction increase difficulty compliance svr rate poor difficult treat subgroup 1 patient null responder cirrhosis benefit patient tolerate peg-ifn/rbv infect non-1 hcv new anti-hcv agent different class numerous combination currently evaluation encouraging result preliminary datum suggest treatment chronic hcv patient tolerated combination oral agent peg-ifn feasible lead universal hcv cure 5 10 year\",\"hepatitis c virus hcv major cause chronic liver disease worldwide addition viral environmental behavioral factor host genetic diversity believe contribute spectrum disease sequencing human genome development high-throughput technology measure function genome afford unique opportunity develop profile distinguish classify discrete subset disease predict response therapy 2011 2 directly act antiviral daa approve chronic hcv 1 infection telaprevir boceprevir open new area hcv therapy 2 ns3/4 protease inhibitor combination pegylated interferon ribavirin daa development significant number patient fail respond treatment significant effect major interest predict response treatment early possible study ongoing identify biomarker predict treatment outcome patient hepatitis c treatment gene upregulate liver nonresponder responder code molecule secrete serum constitute logical functional approach development serum marker predictor response treatment future study challenge fight large prospective cohort phenotyped patient appropriate tissue control need response treatment appropriate definition sustained response treatment regiman address furthermore improve technology analytical procedure use large number patient validation need\",\"response rate treatment chronic hepatitis c virus-genotype 1 4 infection recently find strongly influence polymorphism aim study carry integrated analysis effect polymorphism ribavirin rbv plasma exposure outcome\",\"present interferon-based therapy chronic hepatitis c limit efficacy tolerability telaprevir boceprevir direct-acting antiviral drug daa inhibit hepatitis c virus replication use conjunction pegylated interferon ribavirin numerous daa clinical development phase 2 3 trial evaluate interferon-free combination daa therapy interferon-free sustain virologic response achieve combination asunaprevir daclatasvir sofosbuvir ribavirin sofosbuvir daclatasvir faldaprevir bi207127 abt-450 ritonovir abt-333 abt-450 ritonovir abt-072 miracitabine danoprevir ritonavir alisporivir ribavirin drug genotype-specific activity pan-genotypic differential response 1 1a 1b emerge daa combination viral breakthrough resistance important consideration future trial design prospect interferon-free combination daa therapy hepatitis c virus finally reality\",\"insulin critical control energy function include glucose lipid metabolism insulin resistance interact hepatitis c promote fibrosis progression impair sustained virological response peginterferon ribavirin main aim elucidate direct effect hepatitis c virus hcv infection insulin signaling vitro analyze gene expression protein abundance huh7.5 cell jfh-1 viral particle use vitro study experiment conduct triplicate control cell infected cell gene protein involve insulin signaling pathway modify hcv infection metformin treatment increase gene expression pi3 k irs1 map3 k akt pten 1.5 fold ptp1b encode tyrosin phosphatase find highly induce 3 fold infected cell treat metformin ptp1b protein expression reduce metformin treated cell jfh1 infection protein related insulin pathway like akt pten phosphorylate mtor find down-regulate viral replication inhibit vitro metformin strong effect hcv infection insulin pathway-related gene protein expression find vitro result lead identification new therapeutic target hcv infection co-morbiditie\",\"insulin resistance strongly associate attainment sustained viral response svr hepatitis c patient\",\"evaluate association insulin resistance ir viral load adipokine level liver histology patient chronic hepatitis c chc\",\"precore pc g1896a basal core promoter bcp a1762t/g1764a mutation hepatitis b virus hbv genome emerge chronic hepatitis b chb patient role hepatitis b e antigen hbeag seroconversion induce interferon ifn therapy remain controversial partly quantitative analysis mutant lack study aim develop new assay accurately quantify pc bcp mutant percentage correlate dynamic change ifn-induced hbeag seroconversion hbeag-positive chb patient pc bcp mutant percentage analyze polymerase chain reaction (pcr)-pyrosequence result quantitative assay pc bcp mutant achieve high accuracy r(2 0.99 range 10 90 mutant examine dynamic change pc bcp mutant percentage follow ifn treatment 203 hbeag-positive chb patient multiple logistic regression analysis find chance hbeag seroconversion increase 2.2 odd ratio 1.022 95 confidence interval ci 1.009 1.034 p 0.001 2.3 1.023 95 ci 1.010 1.037 p 0.001 1 increase pretreatment pc bcp mutant percentage respectively adjustment predictor pretreatment pc mutation percentage significantly associate hbeag seroconversion hbv dna 2,000 iu/ml 1.030 95 ci 1.014 1.047 p 0.001 furthermore mutant percentage pc bcp patient achieve hbeag seroclearance hbv dna 20,000 iu/ml increase significantly ifn treatment p 0.039 interestingly patient hbeag seroconversion high pc mutant percentage end ifn treatment tend exhibit high viremia seroconversion\",\"combination therapy pegylated interferon ribavirin standard care soc treatment chronic hepatitis c chc treat chc soc sustained virological response svr approximately 50 70 1 chc patient svr 70 90 2 chc patient baseline viral load viral kinetic i.e. rapid virologic response early virologic response use predictor response-guided therapy nonetheless host factor e.g. age ethnicity insulin resistance genetic variation play important role svr chc patient treat soc recent genome-wide association study demonstrate single-nucleotide polymorphism near interleukin 28b gene il28b associate svr treatment soc chc patient il28b polymorphism contribute viral kinetic treatment asian people favorable il28b polymorphism factor partly explain high eradication rate hepatitis c soc asia combination therapy direct-acting antiviral daa soc increase svr rate treatment-na\\u00efve treatment-experienced patient il28b polymorphism affect svr triple therapy soc first-generation protease inhibitor pilot study demonstrate potent daa overcome influence il28b polymorphism treatment hepatitis c virus infection simplify near future\",\"result clinical trial test new direct-acting antiviral daa chronic hepatitis c major focus interest 2012 annual meeting european association study liver triple combination new daa peginterferon-\\u03b1/ribavirin clinical trial explore interferon-free oral regimen combine daa attract major attention good tolerance broad hepatitis c virus hcv activity high resistance barrier sofosbuvir nucleotide analogue promising daa hcv protease inhibitor safety potency convenient dosing simeprevir asunaprevir faldaprevir abt-450/r particularly highlight ns5a inhibitor good performance daclatasvir encourage far clinical development finally intriguing result release role interleukin 28b il-28b polymorphism use interferon-free regimen indirectly support role innate immunity clear hcv definitively\",\"addition boceprevir therapy peginterferon alfa-2b ribavirin result significantly high rate sustained virologic response svr previously treat patient chronic hepatitis c virus hcv genotype-1 infection compare peginterferon alfa-2b ribavirin assess svr boceprevir plus peginterferon alfa-2a-ribavirin peg2a/r patient identical study entry criterion\",\"report activity 2'-c-methylcytidine 2cmc nucleoside polymerase inhibitor hepatitis c virus hcv vitro replication murine norovirus mnv 2cmc inhibit virus-induced cpe formation ii viral rna synthesis iii infectious progeny formation ec(50 value \\u223c2\\u03bcm. 2cmc act time-point coincide onset viral rna synthesis follow 30 passage selective pressure mnv-resistant virus select line high barrier resistance nucleoside analogue hcv combine broad-spectrum rna virus inhibitor ribavirin marked antagonistic activity observe indicate molecule combine treatment norovirus infection result suggest 2'-c-methyl nucleoside analogue far explore treatment prophylaxis norovirus infection\",\"standard therapeutic approach currently recommend patient infect 1 hepatitis c virus hcv triple therapy combine pegylated interferon peg-ifn ribavirin (rbv)and ns3/ns4 protease inhibitor boceprevir telaprevir 1 protease inhibitor pi direct act antiviral drug daa add peg-ifn rbv able achieve significant gain term sustained virological response svr na\\u00efve treatment-experienced patient 2\\u20135 use new molecule despite contestable benefit reveal hand new challenge emergence variant reduce sensitivity pi development new high rate effect drug drug interaction significant increase overall cost antiviral therapy daa commonly use combination peg-ifn rbv peg-ifn/rbv treatment 1 hcv patient boceprevir lead-in phase telaprevir ema approved regimen drug report figs. 1 2 lead-in phase represent initial period 4 week dual therapy peg-ifn/rbv standard dose follow triple therapy concept lead-in phase initiate schering \\u2013 plough company order improve efficacy boceprevir-based triple therapy lower hcv rna level short course peg-ifn/rbv theoretically reduce risk viral breakthrough resistance controversy regard utility lead-in phase advocate role improve and/or predict triple therapy effectiveness view useless complication therapeutic regiman chief disadvantage inconvenience patient\",\"host age sex race fibrosis stage interleukin 28b polymorphism viral factor hepatitis c virus hcv viral load allow estimate response interferon-based therapy include first-generation protease inhibitor treatment treatment deny patient base unfavorable factor metabolic condition associate poor response diabete insulin resistance obesity alcohol abuse influence start treatment on-treatment predictor response allow treatment tailor individual need patient patient undetectable hcv rna 4 week rapid virologic response rvr high chance cure 85 dual triple therapy triple therapy decision shorten treatment require virus remain undetectable additional 8 telaprevir 20 boceprevir week extend rvr base viral kinetic early prediction 2 week treatment direct act antiviral appear feasible\",\"influenza epidemic pandemic constant threat human health application antiviral drug provide immediate direct control influenza virus infection present major strategy manage patient influenza target conserve viral protein critical viral replication class conventional antiviral drug m2 ion channel blocker neuraminidase inhibitor frequently use recent year increase level resistance drug class major public health concern highlight urgent need development alternative treatment novel class antiviral compound biomolecule target viral replication mechanism development use approach include high-throughput small-molecule screening platform structure-based design response influenza virus infection host cellular mechanism trigger defend invader time virus obligate intracellular pathogen evolve exploit cellular response support efficient replication include antagonize host type interferon response activation specific cellular pathway different stage replication cycle numerous study highlight possibility target virus-host interaction host cellular mechanism develop new treatment regimen review aim overview current novel concept target virus host manage influenza\",\"hepatitis c virus hcv modern-day pandemic 2 3 world population think infect virus subsequently risk develop end-stage liver disease traditional standard care soc hcv-infected patient limit regimen pegylated-interferon alpha pegifn ribavirin display low cure rate majority patient severe effect 2011 direct-acting antiviral daa treat hcv-infected patient combination soc serve elevate treatment response rate hcv drug development pipeline currently populate additional improve daa primarily molecule target virus-encoded protease polymerase enzyme molecule evaluate combination traditional soc daa all-oral pegifn-free regimen ultimate goal develop multiple daa-containing hcv therapy rely pegifn backbone recent addition arsenal hcv inhibitor development represent entirely new daa class molecule target hcv-encoded non-enzymatic ns5a protein ns5a essential hcv propagation actual function largely unknown likely key regulator viral genome replication virion assembly protein exquisitely sensitive small molecule-mediated inhibition ns5a-targete molecule probably potent antiviral molecule discover exhibit number attractive drug-like property include activity hcv genotypes/subtype once-daily dosing potential mechanism action unclear ns5a-targete molecule prove utility clinical evaluation particularly component pegifn-sparre daa combination regimen review aim amalgamate current understanding knowledge ns5a-targete molecule discovery property application insight future impact component all-oral pegifn-free daa combination therapy combat hcv infection\",\"foot-and-mouth disease fmd economically significant animal disease speed transmission current fmd vaccine provide protection 7day vaccination reduce effectiveness case outbreak find alternative method apply antiviral agent rapid enhance inhibition fmd virus fmdv compare antiviral effect promise antiviral agent attempt apply combination measure compare 50 effective concentration ec(50 mean inhibition effect fmdv 50 cytotoxic concentration cc(50 mean cytotoxicity antiviral agent ribavirin guanidine-hydrochloride guanidine-hcl 6-azauridine recombinant adenovirus express small interference rna ad-sirna porcine interferon-\\u03b1 ad-porcine ifn-\\u03b1 swine kidney cell ibrs-2 selectivity index ribavirin 35.2 6-azauridine 34.6 high guanidine-hcl 26.9 selectivity index ad-sirna ad-porcine ifn-\\u03b1 7 \\u00d7 10(3 7 \\u00d7 10(4 base adenoviral titer test combined effect fmdv inhibition agent enhance inhibition effect observe ibrs-2 cell suckle mouse combination ad-porcine ifn-\\u03b1 ad-sirna ribavirin combined application recombinant adenovirus ribavirin enhance inhibitory effect fmdv overcome fmdv resistance antiviral agent\",\"recent report r70q l/c91 m amino acid substitution core different hepatitis c virus hcv associate variable response interferon ifn ribavirin rbv therapy increase hepatocellular carcinoma hcc risk liver steatosis insulin resistance ir mutation ns5b associate ifn rbv nucleoside non-nucleoside inhibitor drug resistance prevalence mutation study hcv rna sample chronically hcv-infected drug-na\\u00efve patient\",\"hepatitis c virus 4 hcv-4 cause approximately 20 180 million case chronic hepatitis c world hcv-4 infection common middle east africa extraordinarily high prevalence egypt viral genetic polymorphism especially core ns5a region implicate influence response pegylated-interferon ribavirin peg-ifn/rbv combination therapy hcv-1 infection confirm hcv-4 infection investigate impact heterogeneity ns5a core protein hcv-4 hcv-4a clinical outcome 43 egyptian patient treat peg-ifn/rbv slide window analysis carboxy terminus ns5a protein identify ifn/rbv resistance-determining region irrdr prominent region associate sustained virological response svr 21 84 25 patient svr 5 28 18 patient non-svr infect hcv irrdr 4 mutation irrdr \\u2265 4 p 0.0004 multivariate analysis identify irrdr \\u2265 4 independent svr predictor positive predictive value irrdr \\u2265 4 svr 81 21/26 p 0.002 negative predictive value non-svr 76 13/17 p 0.02 hand significant correlation core protein polymorphism residue 70 residue 91 treatment outcome conclusion present result demonstrate time irrdr \\u2265 4 viral genetic heterogeneity useful predictive marker svr hcv-4 infection treat peg-ifn/rbv\",\"cyclophilin cyps cellular protein essential hepatitis c virus hcv replication cyclosporine discover inhibit hcv infection cyp pathway contribute hcv replication potential attractive stratagem control hcv infection cypa accept interact hcv nonstructural protein ns 5a interaction cypb ns5b rna-dependent rna polymerase rdrp propose\",\"telaprevir hepatitis c ns3/4a protease inhibitor approve food drug administration combination therapy management chronic hepatitis c virus hcv 1 infection\",\"patient coinfecte hiv hcv risk develop portal hypertension pht hyperdynamic circulation pulmonary arterial hypertension pah datum influence antiviral therapy pegylated interferon-\\u03b1 peg-ifn-\\u03b1 ribavirin rbv limited\",\"substitution amino acid 70 and/or 91 core region hepatitis c virus hcv 1b hcv-1b important predictor hepatocellular carcinoma hcc impact hcc nonresponder interferon ifn ribavirin rib combination therapy clear\",\"chronic hepatitis c virus infection important public health problem standard treatment combination pegylated interferon-\\u03b1 ribavirin effectiveness rate 40%-50 novel virus-specific drug recently design multiple compound development approval clinical use direct-acting antiviral 2011 boceprevir boc telaprevir viral ns3 protease inhibitor increase recovery rate 70 highly effective treatment envision time paper focus boc implementation new boc-based treatment regime\",\"patient chronically infect hepatitis c virus hcv mutation non-structural 5a ns5a gene important predictive factor response interferon ifn therapy present study factor analysis therapeutic response patient follow pegylated ifn ribavirin combination therapy assess multicenter study chronic hcv-infected patient 1b high viral load n=96 mean age 56.5 year 59 male 68 female treat pegylated ifn-\\u03b1-2b ribavirin combination therapy enrol study conduct kobe university hospital 25 affiliate hospital hyogo prefecture sixty-five patient 68 complete treatment pegylated ifn ribavirin 80 weight-based schedule dosage patient reduce terminate therapy frequently aged woman mean age 60.8 year 11 male 17 female overall sustained viral response svr achieve 42 44 patient 96 base per-protocol-based ppb analysis svr rate patient \\u22656 amino acid aa mutation ifn resistance-determining region irrdr 75 \\u22651 aa mutation ifn sensitivity-determining region isdr 61 significantly high patient 5 aa mutation irrdr 30 mutation isdr 29 multivariate analysis reveal rapid viral response rvr odd ratio 18.1 mutation \\u22656 irrdr odd ratio 15.5 significantly associate svr conclusion mutation ns5a region particularly patient \\u22656 aa mutation irrdr strongly associate therapeutic response pegylated ifn ribavirin combination therapy\",\"recent marketing authorization availability new protease inhibitor telaprevir boceprevir profoundly change management chronic hepatitis c patient guideline use new drug triple therapy combination standard therapy peginterferon plus ribavirin propose guideline draw evaluate meeting french association study liver post online comment extensively review international expert current publish datum treatment strategy review guideline address majority patient profile include treatment-na\\u00efve patient patient failure previous treatment recommend patient treat triple therapy consider result triple therapy include factor predictive response consider circumstance length triple therapy shorten advantage peginterferon plus ribavirin lead-in phase virological monitoring stop criterion evaluation resistance protease inhibitor practical treatment management treatment adherence management effect discuss simple guideline propose\",\"tmc435-c101 study 6 patient infect hepatitis c virus 1 treat protease inhibitor tmc435 200 mg daily monotherapy 5 day approximately 1.5 year later 5 patient re-treate tmc435 200 mg daily plus pegylated interferon alfa-2a ribavirin pegifn\\u03b1-2a rbv 4 week follow pegifn\\u03b1-2a rbv week 48 optimal protease inhibitor enhancement response therapy opera-1 study tmc435-resistant variant emerge 5 patient tmc435-c101 study long detect beginning opera-1 study base virus population sequencing opera-1 study 3 patient sustained virologic response deep sequencing indicate low-level persistence resistant variant remain 2 patient affect response re-treatment\",\"gs-9451 novel hepatitis c virus hcv nonstructural 3/4a ns3/4a protease inhibitor highly active patient infect hcv 1 gt 1 aim study characterize clinical resistance profile gs-9451 gt 1 hcv-infected patient phase 1 3-day monotherapy study full-length ns3/4a gene population sequence baseline final treatment day follow-up time point ns3 protease domain patient isolate emerge mutation clone ns3 shuttle vector susceptibility gs-9451 hcv inhibitor determine use transient replication assay resistance mutation ns3 position 155 156 168 detect baseline sample virus patient treat 60 mg gs-9451 daily patient receive 200 mg 400 mg gs-9451 virus mutation position d168 d168e/g/v r155 r155 k confer high-level resistance gs-9451 detect gt 1b gt 1a virus respectively virus d168 mutation long detect gt 1b patient day 14 subsequent time point gt 1a patient r155 k mutant replace wild type 57 patient week 24 ns3 clinical mutant sensitive ns5b ns5a inhibitor alpha interferon ifn-\\u03b1 ribavirin lack cross-resistance gs-9451 class hcv inhibitor support utility combination therapy\",\"telaprevir boceprevir receive food drug administration approval use triple therapy pegylated interferon ribavirin 1 chronic hepatitis c virus hcv infection clinical trial agent include african americans despite overwhelming need improve therapy racial group african americans predict improve response rate new treatment paradigm clinical trial illustrate low rate sustained virologic response racial group versus white african americans 1 hcv infection appear require long duration therapy white achieve sustained virologic response far investigation require adequately counsel african americans 1 chronic hcv infection efficacy telaprevir boceprevir racial group increase participation racial group hcv clinical trial need improve therapy difficult-to-treat population\",\"herpes simplex virus type 1 hsv-1 know cause disease severity increase interest find drug combination treat hsv-1 reduce drug resistance cytotoxicity drug combination offer potentially high efficacy low individual drug dosage paper report new application fractional factorial design investigate biological system hsv-1 antiviral drug interferon alpha interferon beta interferon gamma ribavirin acyclovir tumor necrosis factor alpha sequential use two-level three-level fractional factorial design screen important drug drug interaction determine potential optimal drug dosage use contour plot initial experiment use two-level fractional factorial design suggest model inadequacy drug dosage reduce follow-up experiment use block three-level fractional factorial design indicate tumor necrosis factor alpha little effect hsv-1 infection suppress effectively use right combination antiviral drug observation practical implication understanding antiviral drug mechanism result design antiviral drug therapy\",\"hepatitis c hcv lead cause chronic liver disease cirrhosis hepatocellular carcinoma common indication liver transplantation united states annual incidence infection decline 1980s aging currently infected population expect result increase hcv burden hcv prone develop resistance antiviral drug despite considerable effort understand virus effective treatment knowledge remain incomplete paper review hcv resistance mechanism traditional treatment new standard care hepatitis c treatment new treatment remain peg-ifn-\\u03b1- ribavirin-based add newly fda approve direct antiviral agent telaprevir boceprevir new triple therapy result great viral cure rate treatment failure remain possibility future belong nucleoside/nucleotide analogue non-nucleoside rna-dependent rna polymerase inhibitor cyclophilin inhibitor treatment hcv ultimately parallel hiv research focus effective treatment development hcv vaccine prove cost-effective method eradicate disease\",\"telaprevir hepatitis c virus ns3/4a protease inhibitor significantly improve sustained viral response rate combination pegylated interferon alfa-2a ribavirin compare current standard care hepatitis c virus 1 infected patient patient failed sustained response emergence drug-resistant variant treatment report unclear extent variant persist untreated patient aim study assess use ultra-deep pyrosequencing 4 year follow-up frequency resistant variant increase compare pre-treatment frequency follow 14 day telaprevir treatment\",\"management non-responder nr represent challenging aspect care patient chronic hepatitis c chc purpose study evaluate efficacy amantadine\",\"influenza a/mississippi/03/2001 h1n1 a/hong kong/2369/2009 h1n1 virus contain neuraminidase gene mutation h275y confer resistance oseltamivir adapt mouse evaluate suitability model lethal infection antiviral treatment viral neuraminidase resistant peramivir oseltamivir carboxylate sensitive zanamivir similar pattern antiviral activity mdck cell assay lethal infection achieve mouse virus oral oseltamivir 100 300mg/kg/day bid 5day start -2h 30 60 protection death respectively a/mississippi/03/2001 infection intraperitoneal treatment zanamivir 30 100mg/kg/day start -2h 60 90 protection respectively compound 300mg/kg/day protect mouse treatment begin 24h amantadine effective 10 30 100mg/kg/day rimantadine protective 10 30mg/kg/day high dose test ribavirin active 30 75mg/kg/day survival range 60 100 oral treatment initiate -2h treatment begin 24h amantadine protective 30 100mg/kg/day rimantadine efficacy 10 30mg/kg/day ribavirin active 75mg/kg/day 60 100 survival group a/hong kong/2369/2009 infection oral oseltamivir 100 300mg/kg/day start -2h 50 70 protection death respectively infection model useful study newly discover anti-influenza virus agent evaluate compound combination\",\"phase 3 realize study 662 1 hepatitis c virus (hcv)-infected patient prior peginterferon/ribavirin treatment failure include relapser partial null responder randomize 12 week telaprevir immediately t12/pr48 follow 4 week peginterferon/ribavirin lead-in t12/pr48 12 week placebo pr48 combine total 48 week peginterferon alfa-2a/ribavirin sustained virologic response svr rate 64 t12/pr48 66 lead-in t12/pr48 17 pr48 analysis aim characterize treatment outcome viral variant emerge telaprevir-treated patient achieve svr hcv ns3\\u00b74a population sequencing perform baseline treatment follow-up telaprevir-resistant variant classify lower-level 3- 25-fold 50 inhibitory concentration ic(50 increase v36a/m t54a/s r155i/k/m/t a156s higher-level 25-fold ic(50 increase v36m+r155 k a156t/v resistance resistant variant uncommon baseline overall 18 52 19 1 prior null partial responder relapser respectively telaprevir-treated patient on-treatment virologic failure significant difference lead-in virologic failure telaprevir-treatment phase predominantly associate higher-level resistance virologic failure peginterferon/ribavirin-treatment phase associate higher- lower-level wildtype variant depend relapse occur 9 patient complete assign treatment generally associate lower-level resistant variant wildtype resistant variant long detectable study end median follow-up 11 month 58 non-svr patient\",\"hcv 1a emerge predictor poor response triple hepatitis c therapy include boceprevir telaprevir largely attribute low resistance barrier hcv-1a compare -1b\",\"rate non-response pegylated interferon plus ribavirin peg-ifn+rbv hcv/hiv coinfected patient high hcv-monoinfected patient sense contribution hcv genetic variability unknown 5 untranslated 5'utr nonstructural 5a ns5a second envelope e2 hcv genomic region implicate peg-ifn therapy response protein appear block interferon (ifn)-induced rna-dependent protein kinase pkr 5'utr influence viral lymphotropism\",\"approximately 50 patient chronic hepatitis c chc sustained virologic response treatment pegylated interferon (pegifn)-\\u03b1 ribavirin nonresponse treatment associate constitutively increase expression ifn-stimulated gene isg liver treatment patient acute hepatitis c ahc effective sustained virologic response rate great 90 investigate mechanism different response patient chc ahc pegifn-\\u03b1 therapy\",\"region associate sensitivity interferon-\\u03b1 ribavirin identify hepatitis c virus hcv genome include amino acid 70 core region core a.a 70 a.a 2209 2248 interferon sensitivity-determining region isdr a.a 2334 2379 interferon ribavirin resistance-determining region irrdr\",\"past decade standard treatment chronic hepatitis c infection pegylated-interferon plus ribavirin food drug administration approval boceprevir telaprevir -- protease inhibitor -- standard-of-care treatment genotype-1 infection main worldwide peginterferon plus ribavirin protease inhibitor rate sustained virological response cure triple combination treatment improve substantially patient previous treatment improvement substantial population regard difficult treat individual cirrhosis despite improve response rate protease inhibitor incremental toxic effect high cost increase pill burden drug interaction new antiviral drug directly inhibit hepatitis c virus viral resistance important issue essentially preclude use protease inhibitor monotherapy potentially restrict future treatment option patient consequently achieve sustained virological response protease inhibitor antiviral medication probably combine future interferon-free regimen\",\"report population pharmacokinetic pk pharmacodynamic pd model orally administer ribavirin patient chronic hepatitis c virus hcv infection enrol multicenter clinical trial include estimation covariate effect ribavirin pk parameter sustained viral response svr ribavirin concentration obtain 144 patient consist n 71 african american aa n 73 caucasian americans 24 week therapy describe two-compartment model first-order absorption elimination parameterize term apparent oral clearance cl/f apparent central volume vc/f apparent peripheral volume vp/f apparent intercompartmental clearance q/f typical population parameter cl/f 19.0 l/h vc/f 1,130 l vp/f 4,020 l q/f 38.6 vp/f approximately 50 great aa compare significant covariate svr model include il-28b homeostasis model assessment insulin resistance ribavirin exposure week auc(0 7 population pk logistic regression model describe observe ribavirin concentration datum svr datum finding suggest optimization ribavirin plasma concentration week ribavirin dosing critical aa patient order increase rate svr especially il-28b tt\",\"insulin resistance fibrosis steatosis establish predictor response peg-interferon/ribavirin therapy chronic hepatitis c chc host genetic polymorphism il28b pnpla3 modify treatment-outcome degree steatosis fibrosis aim study evaluate role polymorphism insulin resistance ir treatment-na\\u00efve patient chronic hepatitis c.\",\"hepatitis c virus hcv infection associate insulin resistance ir condition know influence progression liver fibrosis response pegylated interferon (peg-ifn)/ribavirin rbv therapy aim assess sustained virological response svr antiviral therapy prevent development ir long term member milan safety tolerability study cohort receive peg-ifn\\u03b12a/rbv peg-ifn\\u03b12b/rbv undergo homeostasis model assessment homa baseline 24 month treatment completion patient n 431 liver biopsy sample score grading staging ishak steatosis baseline ir homa value 2 detect 48 patient 12 associate body weight p 0.03 hcv load 0.6 \\u00d7 10(6 iu/l p 0.006 fibrosis staging \\u2265 4 p 0.01 moderate severe steatosis p 0.03 ir influence rate end-of-treatment response 75 versus 69 p 0.4 svr 63 versus 60 p 0.8 relapse 19 versus 24 p 0.5 treatment ir develop 49 384 nondiabetic patient 14 mean baseline posttreatment homa value similar svr patient 1.11 \\u00b1 0.8 versus 1.18 \\u00b1 1.1 p 0.25 patient experience treatment failure significant increase mean homa value follow-up visit 1.20 \\u00b1 0.85 versus 1.49 \\u00b1 1.3 p 0.007 increase rate de novo ir non-svr patient versus svr patient 17 versus 7 p 0.007 accord logistic regression analysis treatment failure odd ratio 2.81 95 confidence interval 1.39 5.67 p 0.004 10 body mass index increase odd ratio 6.42 95 confidence interval 1.69 24.3 p 0.006 significantly associate development de novo ir\",\"comparison peginterferon/ribavirin boceprevir peginterferon/ribavirin significantly improve sustained virological response svr rate patient chronic hepatitis c virus hcv 1 infection treatment failure remain significant problem use phase 3 trial database seek develop stop rule patient destine fail boceprevir-based combination therapy order minimize drug toxicity resistance cost face ultimate futility exploratory post hoc analysis use datum serine protease inhibitor therapy 2 sprint-2 study treatment-naive patient retreatment hcv serine protease inhibitor boceprevir pegintron/rebetol 2 respond-2 study treatment-experienced patient undertake determine protocol-specified stopping rule detectable hcv rna week 24 sprint-2 week 12 respond-2 refine harmonized sprint-2 week 12 rule hcv rna cutoff \\u2265 100 iu/ml discontinue therapy 65 195 failure sensitivity 33 sacrifice single svr 475 success specificity 100 viral variant emerge week 12 36 49 evaluable patient 73 discontinue week 12 use \\u2265 100 iu/ml stopping rule respond-2 patient week 12 hcv rna level low limit detection 9.3 iu/ml low limit quantification 25 iu/ml continue therapy despite protocol-stipulated futility rule achieve svr additional patient week 12 hcv rna level 148 iu/ml continue therapy undetectable hcv rna week 16 attain svr\",\"chronic hepatitis c chc virus infection affect 170 million people globally aim treatment chc effect sustained elimination virus sustained virological response svr prior development direct-acting antiviral daa agent standard care soc chc comprise combined treatment pegylated interferon pegifn ribavirin rbv\",\"hcv ns3/4a protease inhibitor prove therapeutic agent chronic hepatitis c virus infection boceprevir telaprevir recently receive regulatory approval add-on therapy pegylated interferon/ribavirin patient harbor 1 infection overcome antiviral resistance broad coverage convenient dosing regiman important attribute future agent use combination interferon communication report preclinical profile mk-5172 novel p2-p4 quinoxaline macrocyclic ns3/4a protease inhibitor currently clinical development compound demonstrate subnanomolar activity broad enzyme panel encompass major hepatitis c virus hcv variant resistant early protease inhibitor replicon selection mk-5172 exert high selective pressure yield resistant colony rat dog mk-5172 demonstrate good plasma liver exposure 24-h liver level suggestive once-daily dosing administer hcv-infected chimpanzee harbor chronic gt1a gt1b infection mk-5172 suppress viral load 4 5 log dose 1 mg/kg body weight twice daily b.i.d 7 day base preclinical profile mk-5172 anticipate broadly active multiple hcv clinically important resistance variant highly suit incorporation newer all-oral regimen\",\"recent study suggest insulin resistance exert strong influence chronic hepatitis c virus hcv infection analyze pretreatment factor useful predict sustained virological response svr especially interleukin il 28b polymorphism homeostasis model assessment insulin resistance homa-ir\",\"hepatitis c infection production inappropriate cytokine level contribute viral persistence affect response antiviral therapy investigate effect il4 c-590 t c-33 t polymorphism response combination therapy interferon ribavirin chronic hcv patient single nucleotide polymorphism determine pcr-rflp 235 responder 210 non-responder combination therapy il4 590 t/t -33 t/t associate resistance therapy p<0.001 p=0.001 respectively haplotype t(-590 t(-33 t(-590 c(-33 associate high risk non-responder patient responder p<0.001 frequency haplotype c(-590 c(-33 wild allele significantly high responder compare non-responder p<0.001 result suggest inheritance il4 polymorphism associate resistance combined antiviral therapy egyptian hcv patient\",\"patient achieve sustained virological response telaprevir/peginterferon (peg-ifn)/ribavirin need identify predictive factor virological response triple therapy non-responder previous peg-ifn/ribavirin therapy clear aim study determine predictive factor virological response 24-week regimen triple therapy 15 non-responder previous peg-ifn/ribavirin therapy 61 japanese adult infect hcv 1 overall sustained virological response end-of-treatment response achieve 27 60 respectively telaprevir-resistant variant direct sequencing appear treatment 82 patient sustained virological response disappear end study patient resistant variant baseline substitution aa 70 arg70 type previous response peg-ifn/ribavirin partial response identify significant determinant sustained virological response addition alpha-fetoprotein level 10 \\u00b5g/l type previous response partial response identify significant determinant end-of-treatment response prediction response therapy base combination factor high sensitivity specificity positive negative predictive value conclusion study identify amino acid substitution core region alpha-fetoprotein level type previous response predictor virological response telaprevir/peg-ifn/ribavirin patient infect hcv 1b respond previous peg-ifn/ribavirin therapy\",\"comprehensively characterize contribution virological factor interleukin-28b il28b single-nucleotide polymorphism snp determine treatment response pegylated-interferon plus ribavirin peg-ifn/rbv therapy chronic hepatitis c virus (hcv)-1b infection undertake retrospective cohort analysis pretreatment dominant complete hcv open reading frame orf amino-acid aa sequence study 103 consecutive hcv-1b japanese patient dominant hcv sequence classify response subject systematic sliding-window comparison analysis characterize response-specific viral sequence il28b snp analysis rs8099917 comparison patient rapid viral response rvr nonearly viral response nevr sustained virological response svr relapse follow region extract significantly associate different response respectively nonstructural protein 5a ns5a aa.2224 2248 p 1.2e-07 core aa.70 p 4e-04 ns5a aa.2340 2382 p 7.0e-08 ns5a aa.2360 2377 p 1.1e-05 ns5a region nearly coincide interferon ifn sensitivity-determining region ns5a aa.2209 2248 ifn/rbv resistance-determining region ns5a aa.2339 2379 multivariate analysis il28b snp odd ratio 16.8 p 0.009 ns5a aa.2340 2382 13.8 p 0.0003 extract most-significant independent variable contribute final outcome\",\"chronic hepatitis c infection leading cause morbidity mortality worldwide hepatitis c related cirrhosis common indication transplant major cause increase hepatocellular carcinoma worldwide treatment hepatitis c consist nonspecific immunomodulatory therapy stimulate immune system inhibit hepatitis c replication pegylated (peg-)interferon ribavirin standard care overall sustained response rate 40 50 patient 1 infection 80 2 3 recently direct-acting antiviral agent include boceprevir demonstrate improve sustained response rate patient 1 infection combination interferon ribavirin boceprevir structurally novel hepatitis c virus hcv nonstructural 3 ns3 protease inhibitor demonstrate robust antiviral activity hcv replicon clinically phase ii iii trial boceprevir 800 mg time daily peginterferon ribavirin lead improve sustained response rate 1 infection treatment-naive patient relapser partial responder null responder phase ii datum demonstrate ribavirin essential optimal boceprevir response phase ii datum suggest 4-week peginterferon ribavirin lead-in strategy reduce relapse rate provide crucial on-treatment datum treatment response boceprevir addition effect boceprevir add peginterferon ribavirin similar peginterferon ribavirin high rate anemia note incremental increase erythropoietin use addition boceprevir represent major advance patient 1 infection treatment na\\u00efve\",\"molecular biology technique routinely use diagnose monitor treatment patient chronic hepatitis b virus hbv hepatitis c virus hcv infection tool detect quantify viral genome analyze sequence determine identify nucleotide amino acid substitution associate resistance antiviral drug include real-time target amplification method standardize widely use clinical practice diagnose monitor hbv hcv infection next-generation sequencing technique restricted research laboratory addition new enzyme immunoassay quantify hepatitis b surface hepatitis c core antigen point-of-care test alternative biologic test require whole-blood sample obtain venipuncture develop review new virologic method clinical research application hbv hcv infection\",\"recently standard care soc patient chronic hepatitis c virus hcv infection consist combination pegylated interferon-\\u03b1 correct plus ribavirin administer 24- 48-week depend hcv sustained virologic response rate soc 50 patient infect 1 hcv prevalent europe north america hcv therapy revolutionise recently approval direct-acting antiviral agent daa ns3/4a serine protease use 1 hcv ketoamide inhibitor boceprevir telaprevir novel soc mark beginning extraordinary new era hcv therapy review new soc emphasis practical issue related protease inhibitor e.g. prescribe guideline futility rule management adverse event perspective expect come year newer daa simplified dosing regimen and/or minimal toxicity use combination lead viral eradication chc patient undergo treatment novel agent clinical development pave way future interferon-sparing regimen\",\"hepatitis c virus hcv cause chronic infection 2 world population untreated chronic carrier develop severe liver disease include fibrosis cirrhosis hepatocellular carcinoma recently hepatitis c treat combination pegylated interferon ribavirin treatment partially effective plague effect 2011 inhibitor virally encode ns3/4 protease standard therapy improve treatment rate exacerbate problematic effect addition directly act antiviral daa mark milestone anti-hcv therapy new improve combination drug desperately need new generation drug address genetic variability hcv issue viral resistance furthermore combination therapy tailor effectively cure patient population traditionally hard treat include patient cirrhosis receive liver transplant individual co-infecte hiv hepatitis b virus discovery hcv plethora experimental tool develop enable detailed analysis aspect viral life cycle interaction hcv human host study reveal grow list target therapeutic intervention discuss review\",\"patient 1 chronic hepatitis c infection telaprevir tvr combination peginterferon ribavirin pr significantly increase sustained virologic response svr rate compare pr genotypic change observe tvr-treated patient achieve svr\",\"aim study review clinical trial datum newly approve protease inhibitor boceprevir telaprevir develop consensus recommendation optimal use agent treatment patient chronic hepatitis c virus hcv infection expert panel seven lead authority viral hepatitis convene establish disseminate practical guide good practice incorporate boceprevir telaprevir therapy hcv infection treatment-naive treatment-experienced patient topic cover include select candidate boceprevir- telaprevir-based treatment predictor response early viral kinetic response-guided therapy approach on-treatment management strategy optimize likelihood response minimize risk drug resistance management adverse effect therapy key consideration special population expert panel incorporate good available clinical evidence recommendation boceprevir telaprevir use clinical setting indicate treatment regimen differ accord baseline factor presence cirrhosis therapy need modify stop altogether adverse event poor virologic response practical guide serve valuable resource clinician embark new treatment paradigm boceprevir telaprevir combination peginterferon/ribavirin chronic 1 hcv infection\",\"1 g1 chronic hepatitis c chc patient achieve rapid virological response rvr pegylated interferon peg-ifn plus ribavirin high chance sustained virological response svr influence il28b status viral load fibrosis insulin resistance assess 25-hydroxyvitamin d 25[oh]d serum level link rvr use il28b construct pretreatment model predict rvr\",\"hcv 2- 3-infected patient rapid virological response rvr therapy pegylated interferon ribavirin low viral load noncirrhotic nonobese consider short course treatment study assess host-viral factor associate relapse 2 3 separately accordingly assess 12 week pegylated interferon ribavirin optimized regimen treatment hcv 2 3 positive predictor response power sample size priori calculate 96 consecutive chronic hepatitis c patient 53 2 43 3 cirrhosis obese achieve rvr therapy peg-ifn-\\u03b1-2a ribavirin enrol fibrosis steatosis homeostatic model assessment-insulin resistance hcv rna predefine variable evaluate relapse intention-to-treat analysis perform svr rate 98 84 2 3 respectively analysis 3 patient relapse negative correlation steatosis p 0.0001 hcv rna p 0.015 multivariate analysis steatosis independent predictor relapse 0.988 95 ci 0.981 0.993 p 0.001 3 patient steatosis relapse rate 36.4 15.8 high low viral load respectively relapse steatosis conclusion 12-week course therapy sufficient patient cirrhosis obese infect hcv 2 achieve rvr case 3 steatosis independent predictor relapse new therapeutic strategy necessary subgroup hcv 3\",\"insulin resistance risk factor non-response interferon/ribavirin therapy patient chronic hepatitis c. aim study determine role play protein-tyrosine phosphatase ptp absence interferon-\\u03b1 ifn\\u03b1 response associate insulin resistance induce insulin resistance silence irs-2 treat hepg2 cell tumor necrosis factor-\\u03b1 tnf\\u03b1 analyze insulin response evaluate akt phosphorylation ifn\\u03b1 response measure stat-1 tyrosine phosphorylation 2',5'-oligoadenylate synthase myxovirus resistance gene expression response ifn\\u03b1 measure insulin-resistant obese mouse high fat diet ob/ob mouse untreated treat metformin silence irs-2 mrna induce insulin resistance inhibit ifn\\u03b1 response likewise tnf\\u03b1 suppress insulin ifn\\u03b1 response treatment cell pervanadate knock ptp-1b restore insulin ifn\\u03b1 response silence irs-2 tnf\\u03b1 treatment increase ptp ptp-1b activity metformin inhibit ptp improve ifn\\u03b1 response insulin-resistant cell insulin-resistant ob/ob mouse increase ptp-1b gene expression activity liver respond ifn\\u03b1 administration treatment metformin improve response hepg2 cell insulin resistance provoke ifn\\u03b1 resistance associate increase ptp-1b activity liver inhibition ptp-1b activity pervanadate metformin knock ptp-1b reestablish ifn\\u03b1 response likewise metformin decrease ptp-1b activity improve response ifn\\u03b1 insulin-resistant obese mouse use ptp-1b inhibitor improve response ifn\\u03b1/ribavirin therapy\",\"development effective hepatitis c hcv antiviral rapid addition orally administer medication target virus direct act antiviral daa pegylated interferon ribavirin dramatically increase sustained virologic response rate 1-infected patient effect profile remain challenging dose schedule complicated daa currently development possess promise once- twice-daily dosing schedule improve tolerance profile high resistance barrier pan-genotypic antiviral activity emerge interferon-sparing combination daa datum demonstrate interferon essential achieve sustained virological response expand proportion hcv-infected patient consider therapy allow better-tolerated regimen expertise hcv antiviral resistance drug metabolism drug-drug interaction optimization drug adherence key requirement daa era\",\"purpose report illustrate food drug administration rationale approve response-guided therapy rgt telaprevir tvr combination pegylated interferon-\\u03b1 ribavirin p/r treatment adult 1 chronic hepatitis c prior relapser rgt prospectively evaluate registration trial treatment-na\\u00efve subject study rgt allow subject achieve undetectable hepatitis c virus rna week 4 12 know extend rapid virologic response ervr stop treatment 24 week patient ervr receive additional 36 week p/r 12 week tvr triple regiman total 48 week rgt prior p/r relapser prospectively evaluate empirical cross-trial datum indicate high sustained virologic response rate 90 prior relapser achieve ervr irrespective p/r duration 24 48 week far analysis demonstrate interferon responsiveness change p/r-experienced subject second round p/r. comparability interferon responsiveness treatment course allow bridge datum treatment-na\\u00efve p/r-experienced subject support approval rgt prior relapse subject\",\"current interferon (ifn)-based treatment hepatitis c virus hcv infection therapeutic limitation effect efficient therapeutic strategy desire recent study supplementation vitamin d significantly improve sustained viral response ifn-based therapy mechanism active molecular form vitamin d anti-hcv effect fully clarify address question infect huh-7 cell cell culture-generated hcv presence absence vitamin d(3 metabolite surprise 25-hydroxyvitamin d(3 25(oh)d(3 vitamin d(3 1,25-dihydroxyvitamin d(3 reduce extra- intracellular level hcv core antigen concentration-dependent manner single-cycle virus production assay cd81-negative cell line reveal inhibitory effect 25(oh)d(3 level infectious virus assembly entry replication long-term 25(oh)d(3 treatment generate hcv mutant acquire resistance 25(oh)d(3 mutation result n1279y substitution nonstructural region 3 helicase domain responsible resistance\",\"insulin resistance ir affect sustained virological response svr chronic hepatitis c chc aim study investigate effect add metformin peginterferon alfa-2a ribavirin efficacy patient 1 chc ir\",\"vaniprevir mk-7009 macrocyclic hepatitis c virus hcv nonstructural protein 3/4a protease inhibitor aim present phase ii study examine virologic response rate vaniprevir combination pegylated interferon alpha-2a peg-ifn-\\u03b1-2a plus ribavirin rbv double-blind placebo-controlled dose-ranging study treatment-na\\u00efve patient hcv 1 infection n 94 randomize receive open-label peg-ifn-\\u03b1-2a 180 \\u03bcg/week rbv 1,000 1,200 mg/day combination blinded placebo vaniprevir 300 mg twice-daily bid 600 mg bid 600 mg once-daily qd 800 mg qd 28 day open-label peg-ifn-\\u03b1-2a rbv additional 44 week primary efficacy endpoint rapid viral response rvr define undetectable plasma hcv rna week 4 dose vaniprevir associate rapid two-phase decline viral load hcv rna level approximately 3 log(10 iu/ml low vaniprevir-treated patient compare placebo recipient rate rvr significantly high vaniprevir dose group compare control regimen 68.8%-83.3 versus 5.6 p 0.001 comparison numerically high statistically significant early sustained virologic response rate vaniprevir compare placebo resistance profile predictable variant r155 d168 detect small number patient relationship interleukin-28b treatment outcome demonstrate study incidence adverse event generally comparable vaniprevir placebo recipient vomiting appear common high vaniprevir dose\",\"study explore pretreatment predictive factor ultimate virological response pegylated interferon-\\u03b1 1.5 \\u03bcg/kg/week ribavirin 600 1000 mg/day peg-ifn/rbv combination therapy patient infect hepatitis c virus (hcv)-1b high viral load\",\"directly act host target antiviral inhibit hepatitis c virus replication enter clinical trial advance rg7128 inhibitor ns5b polymerase bms-790052 inhibitor ns5a alisporivir inhibitor human cyclophilin agent potent antiviral activity chronic hcv patient act additively synergistically inhibitor hcv ns3/4a protease improve rate virologic response produce traditional pegylated interferon plus ribavirin therapy cross resistance observe nucleoside ns5b cyclophilin inhibitor appear suppress resistance non-nucleoside ns5b ns3/4a inhibitor recent report virologic response produce combination agent inhibit hcv replication absence interferon provide optimism eradication hcv possible interferon future\",\"bi 207127 potent non-nucleoside hepatitis c virus hcv ns5b polymerase inhibitor vitro\",\"insulin resistance ir induce chronic hepatitis c virus hcv 1 4 infection know drug affect ir pioglitazone prednisone affect serum hcv rna titer independently peg-interferon-\\u03b12/ribavirin treatment primary aim assess pioglitazone improve ir and/or inflammation decrease hcv viral load independently standard care hcv treatment secondary aim assess prednisone drug induce insulin resistance stimulate hcv viral entry replication replicon culture system increase hcv viral load population\",\"hepatitis c virus hcv infect associate b cell lead abnormal b-cell activation development lymphoproliferative autoimmune disorder immune perturbation turn associate resistance hcv host immune system objective study analyse effect hcv infection b cell efficacy interferon (ifn)-based therapy study enrol 102 patient chronic hepatitis c treat pegylated ifn plus ribavirin hcv rna titre b cell compare patient rapid viral responder rvr vs non-rvr sustained viral responder svr vs non-svr null viral responder nvr vs vr level hcv rna b cell significantly high non-rvr non-svr nvr group association therapy outcome positive b-cell hcv rna investigate relation known viral host factor multivariable analysis positive b-cell hcv rna minor single-nucleotide polymorphism near il28b gene rs8099917 independent factor associate nvr patient infect hcv 1 factor combine sensitivity specificity positive negative predictive value nvr 92.3 98.2 92.3 98.2 respectively 1 presence mutation ifn-sensitivity determining region associate high level b-cell hcv rna b-cell-tropic hcv appear ifn-resistant phenotype b-cell hcv rna positivity predictive factor resistance ifn-based therapy\",\"mericitabine rg7128 orally administer prodrug psi-6130 clinically advanced nucleoside analogue inhibitor rna-dependent rna polymerase rdrp hcv review describe learn far resistance profile mericitabine serine threonine substitution position 282 s282 t rdrp reduce replication capacity approximately 15 wild-type variant consistently generate serial vitro passage experiment date evidence genotypic resistance mericitabine detect population clonal sequence analysis baseline on-treatment sample collect 600 patient enrol phase i/ii trial mericitabine administer monotherapy combination pegylated interferon/ribavirin combination protease inhibitor danoprevir 14 day proof-of-concept study interferon-free therapy\",\"insulin resistance measure surrogate marker associate low response hepatitis c virus hcv therapy improve hcv eradication prospectively evaluate impact directly measure insulin resistance abnormal glucose metabolism achieve sustained virologic response svr hcv therapy assess svr result improve insulin sensitivity fast glucose\",\"hepatitis c virus hcv infection affect 170 million people worldwide common blood-borne infection united states standard treatment peginterferon alfa-ribavirin result low sustained virologic response svr rate patient especially african-american coinfecte human immunodeficiency virus hiv liver cirrhosis suboptimal svr rate new direct-acting antiviral agent target hcv viral replication step development boceprevir novel ns3/4a protease inhibitor recently approve u.s. food drug administration evaluate literature regard boceprevir perform medline search january 1996-july 2011 identify relevant clinical trial abstract poster oral presentation hepatology hiv conference review potent anti-hcv activity clinical trial boceprevir study hcv 1-infected patient na\\u00efve experience hcv therapy datum boceprevir hiv-hcv-coinfected patient currently lack initial datum drug-drug interaction boceprevir antiretroviral available resistance boceprevir evaluate trial datum need area common adverse event boceprevir include anemia dysgeusia base available datum boceprevir promising novel direct-acting antiviral agent likely reshape treatment patient hcv infection\",\"insulin resistance predictor poor response peginterferon/ribavirin patient infect chronic hepatitis c virus hcv datum direct-acting antiviral exploratory analysis assess effect metabolic factor insulin resistance measure homoeostatic model assessment homa virological response telaprevir study c208\",\"1 hungarian population infect hepatitis b c d virus 2006 diagnostic therapy infection carry treatment center accord national guideline 2010 accord financial protocol consensus-based guideline 2012 publish paper guideline stress importance quick detailed virologic evaluation applicability transient elastography acceptable alternative liver biopsy regard relevance appropriate consistent follow schedule viral response therapy choice therapy chronic hepatitis b infection pegylated interferon 48 week continuous entecavir therapy later continue 6 month hepatitis b surface antigen hbsag seroconversion tenofovir disoproxil fumarat reimburse national health insurance fund adefovir dipivoxil recommend mainly combination therapy lamivudine long choice patient currently lamivudine switch response inadequate appropriate treatment patient immunosuppressive medication highly recommend pegylated interferon based therapy recommend treatment concomitant hepatitis d infection treatment naive chronic hepatitis c patient initially receive pegylated interferon ribavirin dual combination therapy 1 infection response insufficient 4 12 week new direct act antiviral boceprevir telaprevir add length treatment usually 48 week case extend early viral response short course recommend previous treatment failure patient 1 infection receive protease inhibitor triple combination therapy 48 week relapser cirrhosis extend rapid viral response short telaprevir base combination therapy sufficient drug-drug interaction emergence viral resistance particular importance 2 3 hcv infection 24 week 4 infection 24 48 72 week pegylated interferon plus ribavirin therapy recommend general guideline publish protocol publish official publication hungarian health authority\",\"viral host factor influence response peginterferon-\\u03b1 plus ribavirin pegifn\\u03b1/rbv patient chronic hepatitis c. impact variable pronounced hiv/hepatitis c virus (hcv)-coinfected individual treatment response rate low\",\"manner ribavirin rbv enhance antiviral effect interferon ifn hepatitis c virus hcv remain unknown investigate rbv modify ifn-stimulated gene isg vivo vitro\",\"patient chronic hepatitis c insulin resistance likely respond anti-hepatitis c virus hcv therapy risk rapid fibrosis progression coadministration pioglitazone peginterferon/ribavirin improve insulin sensitivity increase virologic response rate insulin-resistant hcv 4 patient unclear finding apply 1 patient reason randomize treatment-naive hcv 1 patient insulin resistance receive standard care peginterferon alpha-2a plus ribavirin 48 week n 73 pioglitazone 30 45 mg/day plus standard care n 77 open-label multicenter trial patient randomize pioglitazone receive drug 16-week run-in phase 48-week standard-care phase 24-week untreated follow-up phase pioglitazone treatment improve hemoglobin a1c hba1c plasma glucose insulin level homeostasis model assessment insulin resistance score increase serum adiponectin level 16-week run-in phase maintain improvement standard-care phase observe statistically significant difference group primary efficacy endpoint decrease baseline week 12 peginterferon alpha-2a/ribavirin treatment mean log(10 hcv rna titer -3.5 \\u00b1 1.71 -3.7 \\u00b1 1.62 iu/ml pioglitazone standard-care group respectively \\u03b4 0.21 iu/ml p 0.4394\",\"pegylated-interferon plus ribavirin peg-ifn/rbv therapy current standard treatment chronic hepatitis c. previously report viral sequence heterogeneity ns5a refer ifn/rbv resistance-determining region irrdr mutation position 70 core protein hepatitis c virus 1b hcv-1b significantly correlate outcome peg-ifn/rbv treatment aim investigate impact viral genetic variation ns5a core region hcv-2a hcv-2b peg-ifn/rbv treatment outcome pretreatment sequence ns5a core region analyze 112 patient infect hcv-2a hcv-2b treat peg-ifn/rbv 24 week follow 24 week result demonstrate hcv-2a isolate 4 mutation irrdr irrdr[2a]\\u22654 significantly associate rapid virological response week 4 rvr sustained virological response svr region ns5a correspond ifn sensitivity-determining region isdr plus carboxy-flanking region refer isdr/+c[2a significantly associate svr patient infect hcv-2a multivariate analysis reveal irrdr[2a]\\u22654 independent predictive factor svr hcv-2b infection n-terminal half irrdr mutation irrdr[2b]/n\\u22652 significantly associate rvr svr significant correlation observe core protein polymorphism peg-ifn/rbv treatment outcome hcv-2a hcv-2b infection\",\"hepatitis c virus hcv subvert host cholesterol metabolism key process lifecycle interference result frequently observe genotype-dependent clinical sequela hypocholesterolemia hepatic steatosis insulin resistance ir remain incompletely understand hypocholesterolemia typically resolve sustained viral response svr implicate viral interference host lipid metabolism use target cholesterol metabolomic platform evaluate paired hcv 2 g2 g3 patient serum change vivo hcv sterol pathway metabolite compare hcv genotypic difference baseline metabolite follow antiviral treatment assess sterol perturbation resolve hcv eradication link metabolite ir urine oxidative stress marker paired serum hcv g2 n 13 g3 n 20 patient baseline sterol level low g3 g2 distal metabolite 7-dehyrocholesterol 7dhc 0.017 versus 0.023 mg/dl p(adj 0.0524 cholesterol 140.9 versus 178.7 mg/dl p(adj 0.0242 proximal metabolite lanosterol hcv g3 svr result increase level distal metabolite cholesterol \\u03b455.2 mg/dl p(adj 0.0015 7dhc \\u03b40.0075 mg/dl p(adj 0.0026 lathosterol \\u03b40.0430 mg/dl p(adj 0.0405 contrast lanosterol unchanged svr p 0.9515\",\"class anti-hepatitis c virus hcv agent currently development direct-acting antiviral daa host-targeting antiviral hta cyclophilin inhibitor alisporivir alv previously know debio-025 advanced hta development\",\"multiple clinical trial demonstrate herpes simplex virus 2 hsv-2 suppressive therapy use acyclovir acv valacyclovir hiv-1/hsv-2-infected person increase patient survival decrease hiv-1 load incorporation acv-monophosphate nascent dna chain instead dgmp result termination viral dna elongation directly inhibit laboratory strain hiv-1 evaluate anti-hiv activity acv primary hiv-1 isolate different clade coreceptor specificity viral isolate resistant currently use drug include zidovudine lamivudine nevirapine combination nucleoside reverse transcriptase inhibitor nrti fusion inhibitor protease inhibitor find clinically relevant concentration acv inhibit replication isolate human tissue infect ex vivo addition ribavirin antiviral capable deplete pool intracellular dgtp potentiate acv-mediated hiv-1 suppression datum warrant far clinical investigation benefit use inexpensive safe acv combination drug hiv-1 especially complement delay highly active antiretroviral therapy haart initiation low-resource setting\",\"50 patient chronically infect hepatitis c virus 1 achieve successful response standard treatment pegylated interferon-alfa ribavirin recently approve protease inhibitor administer drug consequently predict response standard treatment ideally start remain important challenge baseline predictor treatment failure describe include clinical virological factor able provide reliable prediction individual level addition development multivariate model combine predictive factor yield prediction requisite reliability use clinical practice research need improve predictive model describe new factor enable predict treatment outcome great reliability reproducibility development candidate selection algorithms help clinician identify patient benefit new therapy basis chance respond standard therapy major interest patient well-being healthcare expense review attempt provide view current option predict response pegylated interferon-alfa plus ribavirin therapy patient chronically infect hepatitis c virus 1\",\"datum concern influence insulin resistance ir ethnicity early phase viral kinetic initiation peginterferon plus ribavirin treatment-naive chronic hepatitis c chc patient limited\",\"limited efficacy exist antiviral therapy influenza -- couple widespread baseline antiviral resistance -- highlight urgent need effective therapy describe triple combination antiviral drug tcad regiman compose amantadine oseltamivir ribavirin highly efficacious reduce mortality weight loss mouse model influenza infection tcad therapy superior dual single drug regimen mouse infect drug-susceptible low pathogenic a/h5n1 a/duck/mn/1525/81 amantadine-resistant 2009 a/h1n1 influenza a/california/04/09 treatment tcad afford 90 survival mouse infect virus treatment dual single drug regimen result 0 60 survival importantly amantadine activity monotherapy amantadine-resistant virus demonstrate dose-dependent protection combination oseltamivir ribavirin indicative amantadine activity restore context tcad therapy furthermore tcad therapy provide survival benefit treatment delay 72 hour post-infection oseltamivir monotherapy protective 24 hour post-infection finding demonstrate vivo efficacy tcad therapy confirm previous report synergy broad spectrum activity tcad therapy susceptible resistant influenza strain vitro\",\"hepatitis c virus hcv protease inhibitor combine pegylated alfa interferon-ribavirin demonstrate improve efficacy compare pegylated alfa interferon-ribavirin treatment chronic hepatitis c. asunaprevir bms-650032 novel hcv ns3 protease inhibitor clinical development evaluate safety antiviral activity resistance double-blind placebo-controlled sequential-panel single- multiple-ascending-dose sad mad study healthy subject subject chronic hcv 1 infection sad study subject healthy chronic hcv infection randomize receive asunaprevir dose group 10 1,200 mg placebo mad study healthy subject randomize receive asunaprevir dose group 10 600 mg twice daily placebo 14 day subject hcv infection receive asunaprevir dose group 200 600 mg twice daily placebo 3 day study headache diarrhea frequent adverse event asunaprevir recipient asunaprevir dose 200 600 mg result rapid hcv rna decrease baseline maximal mean change hcv rna time 2.7 3.5 log(10 iu/ml sad mad study respectively enrichment signature asunaprevir-resistant viral variant detect conclusion novel ns3 protease inhibitor asunaprevir administer single multiple dose 200 600 mg twice daily generally tolerated achieve rapid substantial decrease hcv rna level subject chronically infect 1 hcv\",\"itx 5061 scavenger receptor b1 antagonist enter phase 1 clinical trial hepatitis c virus (hcv)-infected human evaluate itx 5061 combination interferon-\\u03b1 ribavirin hcv protease polymerase inhibitor 2a infectious virus system itx 5061 potent inhibitor hcv replication additive synergistic interferon-\\u03b1 ribavirin biln2061 vx950 vx1 2'-c-methyladenosine resistance selection experiment perform use jc1-feo virus co-culture system intermittent itx 5061 exposure neomycin selection identify mutant virus substitution aspartic acid asparagine highly conserve position 415 e2 n415d introduction mutation wild-type virus confer high-level resistance itx 5061 cross-resistance itx 5061 hcv protease inhibitor interferon-\\u03b1 result suggest itx 5061 promising compound study combination hcv inhibitor\",\"role insulin resistance predict virological response therapy chronic hepatitis c debate assess association basal define homeostasis model assessment insulin resistance (homa-ir)>2 post-load insulin resistance oral glucose insulin sensitivity index<9.8 mg/kg/min rapid sustained virological response chronic hepatitis c.\",\"launch first-generation protease inhibitor pi major step forward hepatitis c virus hcv treatment major advance applicable genotype-1 patient second-wave second-generation pi appear achieve high antiviral potency pan-genotype activity side-effect potential activity pi-resistant mutation second-generation pi convenient daily administration direct-acting antiviral daa include ns5b inhibitor nucleoside/nucleotide inhibitor ni non-nucleoside inhibitor nni ni similar efficacy present high barrier resistance daa date psi-7977 pyrimidine nucleotide analogue highly potent antiviral activity hcv combination ribavirin interferon-free regiman achieve 100 sustained viral response svr rate 2/3 treatment-na\\u00efve patient association pegylated interferon ribavirin pr achieve svr 91 genotype-1 na\\u00efve patient nni association pr appear potent nonetheless play key role combination trial include pi ni ns5a inhibitor exhibit highly potent antiviral activity evaluation activity combination pi demonstrate time interferon-free regiman cure genotype-1b null-responder patient furthermore quadruple therapy pr achieve 100 svr genotype-1 null-responder patient player field cyclophilin inhibitor therapeutic vaccine role combination daa near future hcv treatment look promise daa combination lead interferon-free regimen patient remain open question\",\"50 hepatitis c virus (hcv)-positive patient infect 1 nonresponder combination pegylated interferon pegifn ribavirin include relapser partial null responder expose risk progression cirrhosis complication result hcv-related morbidity mortality repeat treatment use combination patient result 5 viral eradication therapeutic prospect patient fail maintenance therapy prove efficacious triple association direct-acting antiviral specific hcv especially first-generation protease inhibitor boceprevir telaprevir increase percentage 65 variation accord previous response therapy patient 85 relapser 50 partial responder 30 null responder encouraging result extend therapeutic indication cost therapy virological follow-up influence rule discontinuation information management new molecule allow large number patient cure reduce occurrence viral resistance aim present review summarize efficacy triple association pegifn ribavirin telaprevir boceprevir treatment-experienced patient fail respond dual pegifn ribavirin therapy\",\"treatment chronic hepatitis c virus hcv infection substantially evolve past decade follow consensus conference organize european association study liver 1999 standard care soc patient chronic hepatitis c combination pegylated interferon pegifn alpha-2a -2b ribavirin patient infect hcv 1 far frequent hcv worldwide treatment lead cure infection 40 50 case decade pegifn alpha ribavirin therapy available option triple therapy hcv protease inhibitor pi boceprevir telaprevir combination pegifn alpha ribavirin new soc genotype-1-infected patient pi therapy high cure rate achieve specific issue raise emergence resistance pi reason present report examine antiviral activity pi currently know resistance focus telaprevir boceprevir hcv pi recently treatment treatment-na\\u00efve treatment-experienced genotype-1 patient chronic hepatitis c. clinical relevance resistance testing discuss\",\"patient chronic hepatitis c virus hcv infection response therapy peginterferon ribavirin benefit addition multiple direct-acting antiviral agent treatment regiman\",\"half patient chronic hepatitis c cure treatment current standard care peginterferon \\u03b1/ribavirin direct antiviral drug overcome limitation standard antiviral therapy promising new agent inhibitor ns3/4a protease ns5b polymerase ns5a protein compound target enter clinical evaluation early clinical trial emphasize high potential select resistant hepatitis c virus variant furthermore development new direct antiviral stop concern tolerability safety 2010 phase iii trial ns3/4a protease inhibitor boceprevir sprint-2 telaprevir advance combination compound standard care increase sustained virologic response rate treatment-na\\u00efve 1 patient 38 44 66 75 future goal therapy direct antiviral agent improve tolerability shorten duration therapy overcome issue resistance study initiate combine different novel therapy interferon \\u03b1/ribavirin\",\"combination pegylated interferon-\\u03b1 plus ribavirin pegifn\\u03b1-rbv therapeutic option patient chronic hepatitis c virus hcv infection decade unfortunately provide cure half individual infect hcv 1 far prevalent worldwide recent introduction new direct-acting antiviral daa revolutionize hepatitis c field addition recently approve hcv protease inhibitor boceprevir telaprevir pegifn\\u03b1-rbv result cure two-third hcv 1 interferon-naive patient\",\"mutation located 109-amino acid fragment ns5b typically associate resistance interferon ifn ribavirin rib new antiviral drug prevalence mutation examine 69 drug-na\\u00efve individual hepatitis c virus hcv infection rio de janeiro brazil mutation related non-response ifn/rib observe study 1a 1b 2b 3a 4 common mutation q309r present 2b frequency 20 d244n detect 3a a333e detect 2b detect s282 t s326 g t329i mutation sample analyse note c316n mutation previously related new non-nucleoside compound hcv796 ag-021541 observe 33 24 sample 1b site 316 positive selection hcv variant datum highlight presence previously describe resistance mutation hcv drug-na\\u00efve patient\",\"antiviral effect interferon mediate expression interferon-stimulated gene isg difficulty obtain paired liver biopsy interferon treatment key isg express human hepatocyte responsible interferon-based antiviral activity chronic hepatitis c remain illusive prior standard course peginterferon plus ribavirin therapy 104 patient undergo liver biopsy small piece liver biopsy sample patient submit ex vivo tissue culture presence absence interferon hepatic expression 8 isg detect rt-pcr isg expression pattern clinicopathological variable correlate subsequent treatment outcome multivariate logistic regression analysis hepatic mxa expression p 0.008 leucocyte count p 0.040 independently predict end therapeutic virological response hepatic oas1 expression p 0.003 1 p 0.002 hcv-rna level p 0.007 ast/alt ratio p 0.004 leucocyte count p 0.034 independently predict sustained virological response immunohistochemistry analysis interferon-induced oas1 expression localize hepatocyte conclusion hepatic mxa oas1 expression predict respectively end therapeutic sustained virological response interferon-based treatment chronic hepatitis c.\",\"obesity insulin resistance report negative predictor sustained virological response svr hepatitis c virus hcv 1 infected patient treat pegylated interferon-\\u03b1 plus ribavirin know affect serum level cytokine include adipocytokine association cytokine treatment outcome fully elucidate examine pretreatment serum level 14 cytokine 190 patient treat pegylated interferon-\\u03b1-2b plus ribavirin chronic hcv-1b infection high viral load \\u2265 5 log iu/ml analyze contribution treatment response plasminogen activator inhibitor-1 pai-1 vascular endothelial growth factor 11 clinical factor significant association svr univariate logistic regression analysis significant factor multivariate analysis serum pai-1 odd ratio 15.42 body mass index 4.56 rs8099917 4.95 fibrosis stage 5.18 identify independent predictor construct simple minimally invasive prediction score svr base presence factor fibrosis stage accuracy score 73 confirm use independent validation cohort consist 31 patient 68 strong correlation pai-1 level platelet count r 0.38 p 1.8 \\u00d7 10(-7 pai-1 level inversely correlate fibrosis stage serum pai-1 novel predictor response combination therapy chronic hcv-1b infection associate liver fibrosis\",\"telaprevir combination peginterferon ribavirin promising advancement chronic hepatitis c treatment safety tolerability pharmacokinetic antiviral profile telaprevir 2 week study\",\"despite year clinical use extensive research effort mechanism action ribavirin rbv understand mild transient antiviral effect hcv replication administer monotherapy combine interferon rbv improve sustained virological response svr rate approximately 25 30 propose mechanism action rbv hcv include 1 direct effect hcv rna dependent rna polymerase 2 induction misincorporation nucleotide lead lethal mutagenesis 3 depletion intracellular pool inhibition inosine monophosphate dehydrogenase 4 alteration cytokine balance th2 profile anti-inflammatory th1 profile pro-inflammatory 5 potentiate effect interferon up-regulation gene involve interferon signalling lack clear understanding rbv mechanism action challenging confidently position drug new direct antiviral agent daa early clinical study provide strong evidence benefit rbv combination daa ifn containing spare regimen addition rbv reduce viral breakthrough and/or relapse drug low moderate genetic barrier resistance pair particularly true patient harbour hcv 1a ongoing study address utility rbv nucleoside contain daa regimen offer potent antiviral activity high genetic barrier resistance remarkable age-old question role rbv future hcv therapy remain real today decade ago\",\"chronic hepatitis c lead cause chronic liver disease approximately 170 million people infect worldwide sustained virological response svr equivalent viral eradication associate reduction risk cirrhosis nowadays treatment hepatitis c virus hcv 1 chronic infection addition direct act antiviral daa protease inhibitor telaprevir boceprevir pegylated interferon peg-ifn plus ribavirin rbv regimen future management patient new molecule require good clinical practice knowledge indication management effect monitoring antiviral resistance certain major medical need unmet require study special population hiv-hcv coinfected patient transplant patient etc \\u2026 hcv non-1 patient non-responder second generation daa development combination antiviral additive potency lack cross resistance good safety profile provide new regimen future hcv chronic viral infection eradicate worldwide finite duration combination daa therapy ifn aim review summarize mechanism action result obtain daa\",\"excellent time patient hepatitis c virus infection fail past treatment standard care soc peginterferon peg-ifn ribavirin rbv new treatment increase sustained virological response svr rate previous relapser responsiveness interferon clearly benefit protease inhibitor-based therapy patient little interferon response suit regimen treat careful selection case-by-case basis resistance need carefully monitor new potent drug add ifn rbv backbone drug adverse event frequent require special attention\",\"treatment chronic hepatitis c virus hcv infection evolve considerably year combination therapy pegylated interferon (peg-ifn)-\\u03b1 plus ribavirin rbv standard care soc treatment past year viral host factor associate treatment failure include age male gender ethnicity il28b steatosis obesity insulin resistance study patient fail treatment interferon-stimulated gene upregulate treatment recently ns3/4a protease inhibitor telaprevir boceprevir approve consider new soc therapy combination peg-ifn-\\u03b1/rbv hcv 1 treatment-na\\u00efve patient previously treat patient significant improvement svr rate realize phase iii trial telaprevir previously treat patient svr rate 83 88 prior relapser 54 58 prior partial responder 29 33 prior non-responder\",\"telaprevir potent hcv ns3/4a protease inhibitor complete development program demonstrate superior efficacy regimen telaprevir combine pegylated interferon alfa ribavirin pr pr patient hcv 1 advance trial treatment-na\\u00efve patient 12 week telaprevir peginterferon alfa-2a ribavirin follow 12 36 week pr depend extend rapid virologic response ervr i.e. hcv rna undetectability week 4 12 associate sustained virological response svr 75 patient compare 46 receive pr 48 week illuminate trial establish foundation response-guided therapy patient ervr realize trial treatment-experienced patient gradient svr prior relapser 86 partial responder 57 null responder 31 rate virologic failure emergent resistance high group incremental adverse effect telaprevir include rash anemia pruritus diarrhea nausea treatment na\\u00efve patient relapser eligible response-guided therapy stop rule telaprevir-based treatment include hcv rna 1000 iu/ml week 4 12\",\"recently chronic hepatitis c cause persistent infection hepatitis c virus hcv treat combination pegylated interferon-alpha peg-ifn\\u03b1 ribavirin rbv situation change development drug target ns3/4a protease approve combination therapy peg-ifn\\u03b1/rbv patient infect 1 virus additional viral protein rna-dependent rna polymerase reside ns5b ns5a protein emerge promise drug target large number antiviral target protein different stage clinical development progress promising clear new compound suffice eradicate virus infected individual ideally use peg-ifn\\u03b1/rbv-free regiman additional compound target factor promote hcv replication require respect host cell factor emerge promising alternative reduce risk development antiviral resistance increase chance broad-spectrum activity ideally cover hcv work year identify host cell factor use hcv productive replication include cyclophilin especially cyclophilina cypa microrna-122 mir-122 phosphatidylinositol-4-kinase iii alpha instance cypa inhibitor effective combination therapy peg-ifn/rbv increase sustained viral response svr rate significantly compare peg-ifn/rbv review briefly summarize recent advance development novel antiviral hcv\",\"widespread resistance circulate influenza strain anti-influenza drug major public health concern triple combination antiviral drug tcad regimen comprise amantadine oseltamivir ribavirin synergistic broad spectrum activity influenza strain include drug resistant strain use mathematical modeling different experimental approach understand effect single agent double combination tcad regiman resistance influenza vitro include 1 serial passage constant drug concentration 2 serial passage escalate drug concentration 3 evaluation contribution component tcad regiman suppression resistance consistent modeling demonstrate drug require suppress emergence resistance influenza treatment tcad regiman result sustained suppression drug resistant virus treatment amantadine amantadine-oseltamivir double combination lead rapid selection resistant variant comprise \\u223c100 population furthermore tcad regiman impose high genetic barrier resistance require multiple mutation order escape effect drug regimen finally demonstrate drug tcad regiman significant contribution suppression virus breakthrough resistance clinically achievable concentration datum demonstrate tcad regimen superior double combination single agent suppress resistance drug minimum require impede selection drug resistant variant influenza virus use mathematical model multiple experimental design molecular readout evaluate optimize combination drug regimen suppression resistance broadly applicable infectious disease\",\"explore mutation interferon sensitivity-determining region isdr associate resistance hepatitis c virus 1b hcv-1b interferon-\\u03b1 treatment\",\"current standard care hepatitis c infection peginterferon/ribavirin pegifn/rbv enter era direct-acting antiviral agent daa add pegifn/rbv lead higher sustained response rate 1 infected individual currently daa direct specific protein involve hepatitis c replication ns3/ns4a protease inhibitor furthest development telaprevir boceprevir ns3/ns4a inhibitor significantly improve sustained response add pegifn rbv hepatitis c virus hcv polymerase inhibitor promise daa class molecule divide nucleoside/nucleotide polymerase inhibitor nonnucleotide/nucleoside polymerase inhibitor nucleoside/nucleotide polymerase inhibitor high barrier resistance appear effective broad range nonnucleoside polymerase inhibitor low barrier resistance appear specific preliminary datum compound promising class ns5a inhibitor potent hcv rna suppression preliminary study monotherapy pegifn rbv combination agent enter clinical trial preliminary report demonstrate combination ns3/4a protease inhibitor ns5b polymerase inhibitor effectively suppress virus 1 individual future study concentrate combination direct-acting antiviral agent pegifn rbv clinician need familiar manage effect resistance enter new era\",\"double-filtration plasmapheresis dfpp interferon ifn administration produce substantial reduction viral load early stage treatment\",\"insulin resistance ir report independent predictor treatment outcome chronic hepatitis c patient\",\"combination therapy pegylated interferon-\\u03b1 ribavirin peg-ifn/rbv standard care chronic hepatitis c chc majority chc patient infect hcv i. recent discovery reveal genome-wide association study technology provide important role interleukin-28b il28b inosine triphosphatase itpa hcv infection addition response peg-ifn/rbv therapy correlate insulin resistance hepatic steatosis hepatic fibrosis chc patient double-filtration plasmapheresis ifn therapy prove effective reduction viral load early stage treatment chc patient il28b status treatment period peg-ifn/rbv important new polymerase/protease inhibitor introduce treatment chc tailor-made treatment chc use il28b inosine triphosphatase testing double-filtration plasmapheresis treatment prolonged treatment strategy highly recommend relative etiologic role prior hepatitis b virus infection development non-b non-c hepatocellular carcinoma know hepatitis b-endemic area\",\"pharmacology pharmacokinetic pharmacodynamic clinical efficacy safety drug interaction viral drug resistance dosage administration place therapy telaprevir review\",\"hepatitis c virus hcv infection major rise global health problem affect 170 million people worldwide current standard care treatment interferon alpha ribavirin patient 1 infection frequent usa western europe lead successful outcome 50 individual accurate prediction hepatitis c treatment response great benefit patient clinician informational spectrum method virtual spectroscopy method structure/function analysis nucleotide protein sequence apply identification conserve information hcv protein correlate combination therapy outcome hcv protein analyze informational property p7 hcv 1b related therapy outcome basis result simple bioinformatic criterion useful assessment response hcv-infected patient combination therapy propose\",\"approval 2011 protease inhibitor victrelis incivek direct-acting antiviral begin revolutionize hcv treatment addition incivek victrelis pegylated ifn\\u03b1 ribavarin pifn\\u03b1/rbv improve cure rate shorten treatment duration old standard care soc triple therapy suitable patient intolerant pifn\\u03b1 rbv efficacy triple therapy certainly attenuate pifn\\u03b1/rbv non-responder incivek inactive 3 gt3 combine fact protease inhibitor non-nucleoside polymerase inhibitor development active primarily gt1 pifn\\u03b1/rbv remain soc non-gt1 new class inhibitor enter clinical practice gt1 patient respond new triple therapy develop resistance protease inhibitor limit future treatment option important need identification new potent hcv agent novel class hcv inhibitor great potential treatment hcv recently emerge host-targeting antiviral cyclophilin inhibitor\",\"direct-acting antiviral agent combination pegylated interferon peg-ifn ribavirin rbv significantly improve sustained virologic response rate reduce duration therapy treatment-na\\u00efve treatment-experienced patient 1 chronic hepatitis c. important consideration boceprevir telaprevir potential development resistant variant therapy patient poor intrinsic responsiveness interferon incomplete virological suppression protease inhibitor therapy appear high risk resistance article define antiviral resistance review datum vitro vivo resistance protease inhibitor concentrate datum boceprevir telaprevir explore significance resistant variant present baseline fate resistant variant way minimize development resistance protease inhibitor\",\"recent approval direct-acting antiviral agent daa hepatitis c virus hcv offer major advance management hcv infection daa boceprevir telaprevir pegylated interferon alfa peg-ifn ribavirin rbv result higher sustained virologic response rate compare peg-ifn rbv daa-containing regimen approve hcv 1 infection hcv treatment-naive hcv treatment-experienced patient review present overview pharmacology efficacy adverse event emergence resistance-associated variant use agent drug especially newly approve drug clinician consult package insert detailed prescribing information list report adverse event contraindication drug interaction\",\"boceprevir telaprevir hcv protease inhibitor approve treatment chronic hepatitis c 1 infection drug use combination pegylated interferon plus ribavirin p/r maximize efficacy prevent emergence resistance-associated variant rav randomized placebo-controlled international study treatment-naive previously treat hcv patient treatment boceprevir- telaprevir-based triple therapy regimen significantly increase sustained virological response rate compare placebo plus p/r. protease inhibitor potential significantly increase cure rate patient 1 infection reduce duration treatment patient extend rapid virological response boceprevir associate increase incidence anaemia dysgeusia telaprevir associate increase incidence rash anaemia emergence ravs associate increase risk virological failure clinical study new drug bring significant promise remain unclear 1 patient need triple therapy review complexity uncover controversy highlight introduction hcv protease inhibitor\",\"direct-acting antiviral daa available therapy regiman chronic hepatitis c continue include pegylated interferon ribavirin foreseeable future despite improve rate sustained virological response svr daa pose increase risk effect selection antiviral resistance patient require daa achieve svr unlikely respond triple therapy personalized approach candidate selection necessary\",\"advance hepatitis c pharmacogenomic identify modulation sustained virologic response svr frequent il28b gene variant ribavirin-induced hemolysis frequent itpa gene variant association widely reproduce ethnicity clinical setting hepatitis c viral il28b minor allele rs8099917 g rs12979860 t rs12980275 g associate non-svr itpa minor allele rs1127354a rs7270101c associate hemolytic effect effect attribute nucleoside transporter gene slc28a3 rs10868138g/rs56350726 t haplotype significance level association especially genome-wide study high test good clinical outcome peginterferon \\u03b1/ribavirin therapy svr hemolytic effect predict variant analysis example dataset 115 patient reveal prediction non-svr hemolysis single variant slightly guess use combination il28b variant provide high accuracy 64.5 predict non-svr single il28b variant accuracy 60 63 similarly decline blood hemoglobin \\u22653 g/dl predict accuracy 70 10 guess combination itpa variant nucleoside transporter gene slc28a3 haplotype information single il28b itpa variant reproducibly statistically significantly associate hepatitis c therapy outcome clinical predictive utility single variant increase combination\",\"telaprevir ns3/4a protease inhibitor recently receive fda approval treatment chronic hcv infection telaprevir combination peg-ifn-\\u03b1 ribavirin indicate treatment-naive treatment-experienced patient 1 infection generation ns3/4a protease inhibitor boceprevir combination regimen immediately standard care 1 patient adverse event profile combination regiman remain dominate peg-ifn-\\u03b1 ribavirin additional anemia rash telaprevir owe telaprevir metabolism cyp3/4a pathway drug-drug interaction lead toxicity medication decrease efficacy telaprevir viral resistance develop treatment telaprevir patient need educate role adherence minimize risk resistance improve chance cure hcv infection\",\"nucleoside analogue ribavirin significantly increase patient response ifn-\\u03b1 treatment hcv directly inhibit viral replication recent study indicate ribavirin regulate immunity propose ribavirin enhance specific interferon sensitive gene isg expression amplify ifn-\\u03b1-jak/stat pathway find ifn-\\u03b1-induce stat1 stat3 phosphorylation increase hepatocyte co-treate ribavirin ifn-\\u03b1 compare ifn-\\u03b1 ribavirin specifically enhance ifn-\\u03b1 induced mrna protein anti-viral mediator mxa co-localise hcv core protein novel finding indicate time ribavirin addition viral incorporation enhance ifn-\\u03b1-jak/stat signalling lead novel mxa-mediated immuno-modulatory mechanism enhance ifn-\\u03b1 anti-viral activity hcv\",\"hepatitis c virus hcv exhibit high level genetic variability variant reduce susceptibility antiviral occur treatment begin addition alcohol decrease efficacy antiviral therapy increase sequence heterogeneity hcv rna ethanol affect hcv sequence unknown ethanol metabolism hcv infection increase level reactive specie alter cell metabolism modify signaling potentially act mutagen viral rna investigate ethanol reactive specie affect basal sequence variability hcv rna hepatocyte human hepatoma cell support continuous replication 1b hcv rna con1 aj242652 expose ethanol acetaldehyde hydrogen peroxide l-buthionine-s r-sulfoximine bso decrease intracellular glutathione patient ns5a region sequence compare 1b hcv sequence database ethanol bso elevated nucleotide amino acid substitution rate hcv rna 4 18 fold 48 hr accompany oxidative rna damage iron chelator glutathione ester decrease rna damage mutation rate furthermore infectious hcv hcv core gene sufficient induce oxidative rna damage absence ethanol bso interestingly dn/ds ratio percentage site undergo positive selection increase ethanol bso result increase detection ns5a variant reduce susceptibility interferon alpha cyclosporine ribavirin implicate immune tolerance modulation viral replication alcohol likely synergize virus-induced oxidative/nitrosative stress modulate basal mutation rate hcv positive selection induce alcohol reactive specie contribute antiviral resistance\",\"interleukin (il)-6 pleiotropic cytokine increase type chronic liver disease include chronic hepatitis c chc report recently il-6 associate insulin resistance iron metabolism interferon resistance affect outcome antiviral treatment study investigate association serum il-6 level outcome pegylated interferon peg-ifn plus ribavirin rbv combination therapy\",\"protease inhibitor (pi)-resistant hepatitis c virus hcv variant present substantial number pi-untreated patient accord recent report influence virus clinical course chronic hepatitis c characterize\",\"il28b important pretreatment predictor treatment outcome patient chronic hepatitis c. impact rs12979860 relapse retrospectively evaluate 1/4 patient receive response-guided therapy peginterferon alpha-2a 180 \\u03bcg/week plus ribavirin 1,000/1,200 mg/day large randomized multicenter study patient rapid virologic response rvr hepatitis c virus hcv rna 50 iu/ml week 4 treat 24 week slow virologic response rvr undetectable hcv rna \\u2265 2-log(10 decrease week 12 randomize 48 group 72 week treatment group b relapse rate compare rs12979860 c/c versus combined t/c t/t t/ patient confirm end-of-treatment response know end-of-follow-up status sustained virologic response svr relapse rs12979860 determine 340/551 study participant patient rvr c/c t/ relapse rate similar 10.7 versus 15.2 patient randomize group b relapse rate similar patient c/c randomize group 26.9 group b 20.0 contrast relapse rate t/ patient differ markedly group b overall 42.9 18.8 p 0.025 respectively low 400,000 iu/ml 37.5 versus 18.8 high \\u2265 400,000 iu/ml 45.0 versus 18.8 baseline viral load\",\"approval direct-acting antiviral daa drug treatment hcv 2011 lead improve sustained viral response rate 79 treatment-na\\u00efve relapse 1 patient\",\"20 year identification hepatitis c virus hcv novel human pathogen approve treatment remain combination pegylated interferon-\\u03b1 ribavirin non-specific therapy associate severe effect far benefit treatment recently progress development specifically target antiviral therapy hcv stat-c major target direct act antiviral daa hcv rna-dependent rna polymerase non-structural protein 5b ns5b essential viral replication review examine current state development inhibitor target polymerase issue emergence antiviral resistance treatment strategy address problem\",\"natural killer nk cell constitute line defense viral infection function govern integration signal multiple activate inhibitory surface receptor hypothesize nks rapidly activate cytokine response anti-hepatitis c virus hcv therapy predict phenotype function nks use cohort 101 patient 55 african 46 caucasian-american receive pegylated-interferon ifn ribavirin 48 week multiparameter facs analysis use examine relative expression 14 different inhibitory/activating receptor interleukin (il)-28b genotyping rs12979860 perform pretreatment level inhibitory receptor cd158a cd158b cd158e high patient demonstrate poor viral decline 28 day therapy high expression level inhibitory receptor nkg2a cd158b cd158e demonstrable patient fail achieve sustained virologic response svr patient carry il-28b t allele high nkg2a expression effector nks create mathematical regression model incorporate race viral level inhibitory receptor area-under-the curve 0.88 highly predictive svr model perform complementarily il-28b cc ct tt purify nkg2a(neg nk treat pegylated-ifn-\\u03b1 4 hour demonstrate high level ifn-\\u03b3-inducible protein-10 ip-10 tumor necrosis factor-related apoptosis-inducing ligand trail compare nkg2a(pos counterpart\",\"hepatic complication currently represent lead reason medical consultation hospitalisation death hiv-infected population large extent viral hepatitis disproportionate frequency population chronic hepatitis b affect 5 10 hiv-infected population vaccination reduce incidence liver disease related hepatitis-b virus hbv availability tenofovir dramatically improve prognosis hiv/hbv carrier delta hepatitis affect 15 hiv-infected individual europe harbour positive hbsag bad prognosis accelerate course cirrhosis absence successful therapy lastly chronic hepatitis c major cause liver disease hiv population classically link person infect parenterally i.e. intravenous drug user outbreak acute hepatitis c homosexual man report decade treatment pegylated interferon plus ribavirin provide cure 40 patient introduction new direct act antiviral hepatitis- c virus hcv telaprevir boceprevir revolutionise field haart 1996 hiv field improve prognosis co-infecte patient interaction drug antiretroviral agent risk selective resistance pose huge threat population\",\"hepatitis c virus hcv invariably wide heterogeneity infected patient refer quasispecie population massive genetic information abundance hcv variant obstacle evaluate viral genetic heterogeneity detail\",\"viral disease exception cause human immunodeficiency virus self-limited illness require specific antiviral therapy currently available antiviral drug target 3 main group virus herpes hepatitis influenza virus exception antisense molecule fomivirsen antiherpe drug inhibit viral replication serve competitive substrate viral dna polymerase drug treatment influenza inhibit ion channel m(2 protein enzyme neuraminidase combination therapy interferon-\\u03b1 ribavirin remain backbone treatment chronic hepatitis c addition serine protease inhibitor improve treatment outcome patient infect hepatitis c virus 1 chronic hepatitis b treat interferon combination nucleos(t)ide analogue notably nucleos(t ide analogue treatment chronic hepatitis b possess anti-human immunodeficiency virus property inhibit replication hepatitis b virus serve competitive substrate dna polymerase antiviral drug possess multiple potential clinical application ribavirin treatment chronic hepatitis c respiratory virus cidofovir treatment cytomegalovirus dna virus drug resistance emerge threat clinical utility antiviral drug major mechanism drug resistance mutation viral dna polymerase gene gene encode viral kinase require activation certain drug acyclovir ganciclovir widespread antiviral resistance limit clinical utility m(2 inhibitor prevention treatment influenza infection article provide overview clinically available antiviral drug primary care physician special focus pharmacology clinical use adverse effect\",\"polymorphism region interleukin (il)28b gene associate pegylated-interferon peg-ifn ribavirin treatment response mainly 1 hcv infection datum hcv 4 hcv-4 infection evaluate unique well-characterized cohort hcv-4 patient association il28b polymorphism response treatment liver disease severity\",\"hepatic steatosis factor limit virological response interferon-based antiviral therapy chronic hepatitis c ch-c patient infect 1 contradictory result report 2 aim clarify effect hepatic steatosis therapeutic outcome cumulative positivity serum hcv rna ch-c patient infect 2 treat peginterferon (peg-ifn)\\u03b12b ribavirin rbv combination therapy\",\"hepatitis c virus hcv infection affect million people worldwide standard therapy peginterferon ribavirin result suboptimal response new anti-hcv drug novel mechanism action study particular new drug develop target ns3/4a protease complex evaluate literature telaprevir new oral covalent reversible ns3/4a hcv protease inhibitor medline search january 1996-july 2011 perform identify relevant clinical trial abstract hepatology human immunodeficiency virus hiv conference review large clinical trial addition telaprevir peginterferon ribavirin result high sustained virologic response rate treatment-na\\u00efve treatment-experienced patient infect hcv 1 clinical datum telaprevir hiv-hcv coinfected population emerge datum potential drug-drug interaction agent preliminary datum describe resistance profile telaprevir information need evolving area telaprevir common adverse event include rash pruritis anemia base available datum new anti-hcv drug likely widely use revolutionize treatment hcv-infected individual\",\"insulin resistance hiv antiviral drug hepatitis c virus hcv infection contribute complex interaction involve metabolic syndrome objective review explore meaning insulin resistance hiv-hcv-coinfected patient impact sustained virological response svr disease progression\",\"telaprevir boceprevir highly selective hepatitis c virus hcv ns3/4a proteaseinhibitor phase 3 development viral breakthrough mono- triple-therapie peg-interferon ribavirin relapse associate resistance\",\"lethal mutagenesis virus transition error catastrophe antiviral strategy aim extinguish virus increase viral mutation rate replication molecular basis lethal mutagenesis largely unknown previous study critical substitution foot-and-mouth disease virus fmdv polymerase sufficient allow virus escape extinction modulation transition type induce purine nucleoside analogue ribavirin substitution detect mutant spectrum fmdv population replicate presence ribavirin use standard molecular cloning nucleotide sequencing selectively amplify analyze low-melting-temperature cdna duplex copy fmdv genome population passage absence presence ribovirin hypermutated genome high frequency u present ribavirin -treated untreated population major effect ribavirin mutagenesis accelerate occurrence au-rich mutant cloud early replication round virus standard fmdv quasispecie passage absence ribavirin include salient transition-modulating ribavirin resistance mutation frequency increase population treat ribavirin nonmutagenize fmdv quasispecie include deep mutationally biased portion sequence space support view virus replicate close error threshold maintenance genetic information\",\"chronic infection hepatitis c virus hcv induce insulin resistance ir genotype-dependent manner contribute steatosis progression fibrosis resistance interferon plus ribavirin therapy understanding hcv-induced ir improve considerably year certain aspect concern evaluation remain elusive clinical researcher important issue elucidate ideal method assessment ir setting hepatitis c. hyperinsulinaemic euglycaemic clamp gold standard method determine insulin sensitivity impractical labour intensive time-consuming date human study ir evaluate hcv setting estimation ir use direct measurement insulin-mediated glucose uptake commonly use estimation hcv population homeostasis model assessment insulin resistance homa-ir calculate single measurement fast insulin glucose article review use reporting homa literature provide guidance appropriate inappropriate use hepatitis setting\",\"minority drug-resistant hepatitis c virus hcv variant undetected clinically important ns3/4a protease resistance substitution v36a a156s/t/v select patient treat protease inhibitor aim study investigate substitution pre-existed hcv infected patient allele-specific pcr protocol detect ns3/4a protease resistance substitution v36a a156s/t/v use determine prevalence naturally occur variant 45 patient patient sample infect hcv 1b na\\u00efve pegifn\\u03b1/ribavirin treatment thirty sample 67 hcv pi-resistant variant a156 t 23 51 detect frequently a156v 13 29 a156s 1 2 v36a detect 12 sample 27 result demonstrate high prevalence minority drug-resistant ns3/4 protease resistance substitution result demonstrate allele-specific pcr use detect minor hcv ns3 protease resistant variant pretreatment sample study detail evolution mutant virus target antiviral therapy\",\"continuous emergence drug-resistant virus major obstacle successful treatment viral infection represent persistent spur search new therapeutic strategy multidrug treatment currently forefront pharmaceutical clinical computational investigation unknown way different drug interact pathogen aim control inspire experimental study picornavirus discuss performance sequential vs. combination therapy involve dissimilar drug mutagen ribavirin inhibitor viral replication guanidine systematic analysis viral response drug dose demand precious time resource present analyze silico model describe dynamic viral population action drug model predict response viral population dose combination optimal therapy use case way minimize probability appearance resistant mutant agreement theoretical prediction vitro experiment foot-and-mouth disease virus confirm suitability simultaneous sequential administration depend drug dose addition intrinsic replicative characteristic virus e.g. replication rna dna intermediate play key role determine appropriateness sequential combination therapy knowledge model parameter derive mean simple experiment model prediction extend viral system\",\"natural killer nk cell exhibit polarize phenotype increase cytotoxicity decrease interferon gamma ifn-\\u03b3 production chronic hepatitis c virus hcv infection ask cause type interferon (ifn)-induced expression phosphorylation level signal transducer activator transcription stat molecule nk cell affect response refractoriness nk cell ifn-\\u03b1-based therapy hcv stat1 level nk cell significantly high patient chronic hcv infection uninfected control stat1 level induction phosphorylate stat1 pstat1 increase far ifn-\\u03b1-based therapy preferential stat1 stat4 phosphorylation induction pstat1 correlate increase nk cytotoxicity tumor necrosis factor-apoptosis-inducing ligand trail expression degranulation decrease ifn-\\u03b3 production nk cell patient great 2 log(10 first-phase hcv rna decline ifn-\\u03b1-based therapy 99 ifn effectiveness display strong pstat1 induction vivo refractory stimulation vitro contrast nk cell patient 2 log(10 first-phase hcv rna decline exhibit low pstat1 induction vivo p 0.024 retain great ifn-\\u03b1 responsiveness vitro p 0.024 nk cell patient refractory vivo vitro stimulation ifn-\\u03b1 second-phase virological response\",\"innate immunity play important role host antiviral response hepatitis c viral hcv infection recently single nucleotide polymorphism snp il28b host response peginterferon \\u03b1 peg-ifn\\u03b1 ribavirin rbv strongly associate aim determine gene expression involve innate immunity il28b elucidate relation response antiviral treatment il28b snp rs8099917 rs12979860 88 chronic hepatitis c patient treat peg-ifn\\u03b1-2b/rbv quantify expression viral sensor rig-i mda5 lgp2 adaptor molecule ips-1 related ubiquitin e3-ligase rnf125 modulator isg15 usp18 il28 ifn\\u03bb il28b snp 100 identical 54 patient possess rs8099917 tt/rs12979860 cc il28b major patient 34 possess rs8099917 tg/rs12979860 ct il28b minor patient hepatic expression viral sensor modulator il28b minor patient significantly up-regulate compare il28b major patient \\u2248 3.3-fold p 0.001 expression ips-1 significantly low il28b minor patient 1.2-fold p 0.028 expression viral sensor modulator significantly high nonvirological responder nvr despite stratification il28b \\u2248 2.6-fold p 0.001 multivariate roc analysis indicate high rig-i isg15 expression rig-i/ips-1 expression ratio independent factor nvr ips-1 down-regulation il28b minor patient confirm western blotting extent ips-1 protein cleavage associate variable treatment response\",\"chronic hepatitis c hcv infection consider metabolic disease associate specific metabolic syndrome hcv-associated dysmetabolic syndrome hcads consist steatosis hypocholesterolemia insulin resistance/diabete metabolic derangement contribute decrease sustained virological response svr pegylated-interferon-\\u03b1-ribavirin standard care soc associate progression liver fibrosis\",\"individual infect hepatitis c virus hcv risk cirrhosis and/or hepatocellular carcinoma treatment hcv infection undergo revision past 15 year continue evolve current major advance protease inhibitor addition pegylated interferon ribavirin emergence resistance need monitor carefully new potent drug add interferon ribavirin backbone drug addition adverse event frequent novel require special attention\",\"essential role process hepatitis c virus hcv replication viral ns3/4a serine protease arguably thoroughly characterize hcv enzyme intensively pursue anti-hcv target drug development far recent datum demonstrate promise ns3 protease inhibitor boceprevir add standard care peginterferon ribavirin improve sustained virological response shortening duration therapy genotype-1-infected individual review discuss mechanism action boceprevir effect hcv viral resistance\",\"approval direct-acting antiviral daa hepatitis c virus hcv eagerly expect treat chronic hepatitis c hiv individual progression cirrhosis end-stage liver disease occur fast co-infecte population appropriate judicious use daa provide cure large number hiv-hcv patient contrary widespread use daa occasionally off-label unsatisfactory medical condition result undesirable toxicity drug interaction selection drug resistance hcv result use first-generation daa hiv-hcv-co-infected patient grow proportion remain hepatitis c individual harbor non-hcv 1 drug-resistant hcv variant time large reservoir hcv 1 patient accumulate resource-poor nation access hepatitis c therapy elusive hiv treatment remain primary health issue co-infecte population\",\"effect associate intravenous injection interferon interferon-free regiman treatment hcv infection highly desirable recently publish clinical study interferon-free combination therapy contain ribavirin efficacious suggest interferon-free therapy adopt near future understand hcv resistance ribavirin major importance approach understand effect ribavirin hcv replication hcv resistance select ribavirin resistant mutant hcv vitro\",\"review pharmacology pharmacokinetic safety efficacy boceprevir novel oral hepatitis c virus hcv nonstructural 3 ns3 protease inhibitor treatment chronic hcv infection specifically 1\",\"treatment hepatitis c virus infection hcv combination pegylated interferon ribavirin accord early viral kinetic lead sustained virological response svr 50 patient chronic infection svr complete recovery infection 50 1-infected patient achieve svr understanding viral cycle characterization viral enzyme potential target result development new molecule direct act antiviral daa target hcv specific 1 protease inhibitor ns3/ns4a polymerase inhibitor ns5b wide spectrum ns5a entry inhibitor non-specific antiviral new interferon cyclophilin inhibitor describe result phase ii iii trial clearly demonstrate 20 30 increase svr rate 1-infected patient na\\u00efve treatment experience new drug approve end 2011 temporary approval compassionate use cirrhotic patient previous relapse partial response combination therapy future main limitation triple therapy safety cutaneous rash anemia control cost compliance viral resistance drug interaction avoid educate patient physician\",\"treatment chronic hepatitis c virus hcv infection substantially evolve past decade consensus conference organize european association study liver 1999 standard care soc patient chronic hepatitis c combination pegylated interferon pegifn alpha-2a -2b ribavirin patient infect hcv 1 far frequent hcv worldwide treatment lead cure infection 40 50 case factor identify play role outcome therapy include treatment schedule disease characteristic viral host factor human genetic factor identify recent landmark discovery factor partly explain ability ifn ribavirin therapy cure hcv infection study demonstrate non-responder interferon-stimulated gene up-regulate prior therapy unclear mechanism finding clinical biochemical histological datum help identify responder start therapy particularly important standard treatment physically economically demanding future treatment patient infect hcv 1 base combination pegifn ribavirin protease inhibitor telaprevir boceprevir promise result triple combination phase iii clinical trial recently report liver meeting 2010 therapy high cure rate achieve specific issue raise emergence resistance protease inhibitor goal review discuss mechanism involve non-response current future standard treatment\",\"mutation core ns5a region hepatitis c virus hcv 1b associate response interferon ifn therapy genome-wide association study reveal single-nucleotide polymorphism snp interleukin 28b il28b contribute ifn response aim study investigate snp il28b rs8099917 amino acid substitution core ns5a region affect response ifn therapy\",\"pretreatment insulin resistance ir associate treatment response peginterferon plus ribavirin pegifn/rbv combination therapy chronic hepatitis c chc infection impact pegifn/rbv therapy ir \\u03b2-cell function chc patient rarely investigate\",\"association report genetic polymorphism near il28b gene prevalence mutation hepatitis c virus hcv core region residue 70 associate lack virologic response antiviral combination therapy peginterferon peg-ifn ribavirin study investigate peg-ifn/ribavirin combination therapy induce amino acid aa mutation residue 70 hcv genetic polymorphism near il28b gene affect aa substitution residue 70 hcv core region measure compare combination therapy 65 non-responder 88 relapser combination therapy patient wild-type aa arginine mutant-type aa glutamine histidine detect residue 70 treatment mutant-type aa identify treatment patient wild-type aa solely treatment wild-type mutant-type aa identify residue 70 treatment patient aa change residue 70 treatment patient carry tt polymorphic locus rs8099917 near il28b gene carry tg/gg difference find prevalence change aa residue 70 tt tg/gg antiviral combination therapy peg-ifn ribavirin appear induce mutation hcv core region residue 70 regardless genetic polymorphism near il28b gene japanese patient infect hcv 1b\",\"recent study suggest svr rate low hcv patient insulin resistance ir patient ir extent impact ir treatment response establish aim confirm role ir assess homoeostasis model assessment homa-ir svr determine magnitude\",\"triglyceride \\u00d7 glucose tyg index recently propose surrogate marker insulin resistance ir calculate fast plasma triglyceride glucose concentration test host viral factor associate tyg homeostasis model assessment homa score compare association histological feature sustained virological response svr patient 1 chronic hepatitis c(g1chc consecutive patient g1chc consider liver biopsy score pathologist staging grading scheuer grade steatosis consider moderate-severe \\u226530 anthropometric metabolic measurement include ir measure homa tyg register linear regression analysis tyg independently associate waist circumference wc total cholesterol presence arterial hypertension log10 hcv-rna steatosis similarly wc steatosis significantly associate homa old age 1.036 95%ci 1.004 1.070 p 0.02 high wc 1.031 1.004 1.060 p 0.02 high tyg 11.496 3.163 41.784 p 0.001 link moderate-to-severe steatosis \\u226530 multiple logistic regression analysis tyg replace homa-ir model remain significantly associate steatosis \\u226530 1.237 1.058 1.448 p 0.008 receiver operate characteristic curve similar performance tyg auc 0.682 homa-ir auc 0.699 predict moderate-severe steatosis independent association find tyg homa fibrosis svr patient g1chc tyg easy-to-calculate low-cost surrogate marker ir link liver steatosis independent association viral load\",\"approval directly act antiviral daa treatment chronic hepatitis c virus hcv infection represent major breakthrough 180 million person infect worldwide paradoxically hepatitis c human chronic viral disease cure pathogenic virus infect human display self-limited course establish non-eradicable persistent infection treatment chronic hepatitis c consist combination peginterferon-\\u03b1 plus ribavirin provide limited rate cure associate frequent effect daa identify inhibit ns3 protease ns5b polymerase ns5a replication complex enter final step clinical development molecule couple significant progress recognition potent safe interferon form e.g. interferon-\\u03bb host protein target e.g. alisporivir open new era hepatitis c therapeutic expectation great extent reminiscent happen 1996 hiv field introduction protease inhibitor triple combination revolutionize antiretroviral therapy maximize treatment success reduce likelihood drug resistance selection proper individualization hepatitis c therapy require choose convenient drug strategy accord distinct viral host profile complexity hcv therapeutic reach point presumably lead birth new specialist hcv doctor\",\"high baseline homeostasis model assessment insulin resistance homa-ir score predict poorer sustained virological response svr rate peginterferon/ribavirin therapy treatment-na\\u00efve chronic hepatitis c patient\",\"hcv infection common cause chronic viral hepatitis worldwide health problem approximately 170 million person infected area high endemicity percentage population infected reach 30 progressive disease lead complication severe liver fibrosis cirrhosis ascite esophageal varix gastrointestinal bleeding 30 50 patient cirrhosis hepatocellular carcinoma extrahepatic pathology mixed cryoglobulinemia non-hodgkin lymphoma membrano-proliferative glomerulonephritis associate hcv infection effective treatment exist base ifn-\\u03b1 sustained disappearance virus sustained virological response radically change natural history chronic hepatitis c reduce disease progression complication interferon-based treatment improve year owe association ribavirin subsequently pegylation interferon molecule present standard care result response rate 80 subpopulation patient respond therapy factor predict nonresponse interferon therapy investigate available factor include characteristic virus subject infected therapy use aim article provide overview factor insight newly recognize cause nonresponse help clinician select appropriate therapy hcv viral hepatitis\",\"report genetic polymorphism near il28b gene amino acid substitution hepatitis c virus hcv core protein associate clinical outcome peginterferon peg-ifn ribavirin combination therapy impact factor pure sensitivity/resistance interferon evaluate change hcv rna level 24 48 72 120 hr administer single dose standard interferon ifn measure 156 hcv-infected patient change compare base genetic polymorphism near il28b gene amino acid substitution hcv core region patient hcv 1b difference reduction subsequent increase hcv rna level administer ifn base rs8099917 genetic polymorphism amino acid substitution residue 70 associate difference change hcv rna level patient tg/gg multivariate analysis genetic polymorphism near il28b gene sole independent factor associate reduction hcv rna level administer ifn final response combination therapy patient infect hcv 2a 2b difference change hcv rna level base genetic polymorphism near il28b gene hcv 1b genetic variation near il28b gene affect sensitivity/resistance ifn strongly genetic polymorphism near il28b gene affect sensitivity/resistance ifn hcv 2\",\"chronic hepatitis c virus hcv infection major etiology reason chronic liver disease liver cirrhosis hepatic decompensation hepatocellular cancer liver transplantation half patient hcv-related chronic hepatitis achieve sustained viral clearance current pegylated interferon ribavirin p+r combination therapy insufficient treatment success extended search new direct act anti-hcv agent daa ongoing lead submission application marketing authorization protease-inhibitor boceprevir telaprevir effective triple combination p+r. study demonstrate 50 success rate advantage triple therapy current standard addition treatment duration shorten half patient fail previous therapy p+r cure triple therapy major concern new daa rapid development daa-resistant viral mutant reason consequence insufficient triple therapy clinical study boceprevir telaprevir review paper\",\"review use telaprevir treatment chronic hepatitis c.\",\"anemia commonly observe effect treatment protease inhibitor combine peginterferon alpha ribavirin hepatitis c virus infection study assess safety tolerability viral kinetic selection variant telaprevir monotherapy 24 week outcome off-study treatment peginterferon alpha-2b ribavirin japanese female patient median age 54 year difficult treat standard therapy peginterferon alpha-2b ribavirin japan\",\"hepatitis c virus hcv major cause liver disease world difficult treat interferon ifn formulation combination thereof approve molecule available investigate recently proinflammatory chemokine interleukin-8 il-8 induce hcv partially inhibit antiviral ifn-\\u03b1 therapy current study aim prospectively utilize baseline il-8 level hcv infected serum predict role sustained virological response svr ifn-\\u03b1+ribavirin therapy chronic hcv patient pakistan hepatitis c patient infection undergo ifn-\\u03b1+ribavirin combination treatment baseline il-8 level determine start therapy patient normal volunteer negative hcv control baseline il-8 level find significantly high hcv positive patient compare normal healthy volunteer 1083.54 \\u00b1 85.72 pg/ml versus 6.99 \\u00b1 1.05 pg/ml mean \\u00b1 sem p<0.01 significantly high non-responder responder p<0.05 comparatively high mean baseline il-8 level observe non-responder 2442.02 \\u00b1 159.92 pg/ml late 1009.31 \\u00b1 45.31 rapid 540.91 \\u00b1 27.06 pg/ml responder significant relation observe baseline il-8 level response ifn therapy p<0.01 result study suggest increase level il-8 hcv infection involve pathogenesis persistence resistance ifn-\\u03b1+ribavirin combination therapy\",\"individual infect hepatitis c virus hcv develop chronic infection treat pegylated interferon ribavirin rbv respond nucleoside analog rbv improve treatment outcome likely important component therapy next-generation viral inhibitor rbv mechanism controversial rbv propose mechanism require rbv import cell explore host-based rbv resistance develop reduce cellular uptake akin chemotherapy resistance cancer examine effect host-based rbv resistance hcv replication culture hepatoma huh7.5 liver cell rbv resistance develop hcv patient huh7.5 cell expose rbv resistance develop reduce rbv uptake ent1 nucleoside transporter antiviral efficacy reduce uptake defect rbv-resistant cell specific rbv transport ent1 substrate cytidine unaffected importantly rbv uptake significantly decline hcv patient peripheral blood mononuclear cell pbmc follow 4 week therapy furthermore maintenance rbv uptake correlate rapid treatment response result uncover novel form antiviral drug resistance suggest host-based rbv resistance develop hcv patient undergo therapy maintenance rbv uptake contribute rapid viral clearance\",\"insulin resistance ir common chronic hepatitis c chc associate reduce virological response pegylated-interferon (peg-ifn)/ribavirin therapy underlie mechanism unclear previously chc patient insulin plasma level inversely related antiviral effect induce peg-ifn investigate vitro effect insulin interferon alpha ifn-\\u03b1 intracellular signaling ifn-\\u03b1 insulin signaling hepg2 cell preincubate insulin stimulate ifn-\\u03b12b messenger rna mrna protein expression ifn-stimulated gene isg measure different timepoint role intracellular suppressor cytokine signaling 3 socs3 evaluate small interfere rna sirna strategy assess effect ifn-\\u03b1 insulin signaling hepg2 preincubate ifn addition insulin cell analyze irs-1 akt/pkb ser473 phosphorylation insulin 100 1000 nm significantly reduce dose-dependent fashion ifn-induced gene expression pkr p=0.017 p=0.0017 respectively mxa p=0.0103 p=0.00186 2'-5 oligoadenylatesynthetase 1 oas-1 p=0.002 p=0.006 insulin reduce ifn-\\u03b1-induced pkr protein expression insulin confirm increase socs3 expression sirna socs3 restore isg expression insulin treatment ifn-\\u03b1 find reduce dose-dependent fashion irs-1 gene expression akt/pkb ser473 phosphorylation induce insulin\",\"study recently reveal single nucleotide polymorphism snp interleukin28b il28b region associate response pegylated interferon-alfa peg-ifn-alfa ribavirin rbv treatment hepatitis c virus (hcv)-infected individual european african asian ancestry purpose study establish method determine snp rs8099917 associate il28b useful research treatment hcv\",\"substitution amino acid 70 91 hepatitis c virus hcv core region significant predictor poor response peginterferon-plus-ribavirin therapy molecular mechanism remain unclear investigate difference response alpha interferon ifn use hcv cell culture r70q r70h l91 m substitution ifn treatment cell transfecte infect wild type mutant hcv clone r70q r70h l91 m core mutant significantly resistant wild type hcv-transfected cell intracellular hcv rna level significantly high core mutant wild type hcv rna culture supernatant significantly low mutant wild type ifn-induced phosphorylation stat1 stat2 expression interferon-inducible gene significantly low core mutant wild type suggest cellular unresponsiveness ifn expression level interferon signal attenuator socs3 significantly high r70q r70h l91 m mutant wild type interleukin 6 il-6 upregulate socs3 significantly high r70q r70h l91 m mutant wild type suggest interferon resistance possibly il-6-induced socs3-mediated suppression interferon signaling expression level endoplasmic reticulum er stress protein significantly high cell transfecte core mutant transfecte wild type conclusion hcv r70 l91 core mutant resistant interferon vitro resistance induce il-6-induced upregulation socs3 mechanism explain clinical interferon resistance hcv core mutant\",\"protease inhibitor pi prove effective adjunct interferon/ribavirin treatment hepatitis c virus hcv infection little clinical vitro datum exist effectiveness nontype 1 predominate europe middle east africa asia ns3 protease ns4a gene 1 6 insert jfh clone generate replication-competent intergenotype chimera susceptibility pi determine replication infectivity assay study resistance development chimera culture subinhibitory concentration pi mutation phenotypically characterize marked difference susceptibility different danoprevir itmn-191 telaprevir vx-950 observe 1 4 6 median inhibitory concentration ic(50 value 2 3 nm 100-fold low 2/3/5 250 750 nm telaprevir susceptibility vary 4-fold range 1 2 susceptible 4 5 resistant culture 1 6 pi induce numerous mutation ns3 protease domain highly variable introduction danoprevir biln 2061-induced mutation original clone site-directed mutagenesis n 29 confer resistant phenotype particularly large increase 1 2 log great ic(50 value initially susceptible 1/4/6 introduce mutation little effect replicative fitness\",\"hepatitis c virus hcv nonstructural protein 3 4a ns3 4a complex compose ns3 cofactor ns4a harbour serine protease ntpase/rna helicase activity essential viral polyprotein processing rna replication virion formation specific inhibitor ns3 4a protease significantly improve sustained virological response rate patient chronic hepatitis c combine pegylated interferon-\\u03b1 ribavirin ns3 4a protease target select cellular protein block innate immune pathway modulate growth factor signalling ns3 4a essential component viral replication complex prime target antiviral intervention key player persistence pathogenesis hcv review provide concise update biochemical structural aspect ns3 4a role pathogenesis chronic hepatitis c clinical development ns3 4a protease inhibitor\",\"psi-352938 novel cyclic phosphate prodrug \\u03b2-d-2'-deoxy-2'-\\u03b1-fluoro-2'-\\u03b2-c-methylguanosine 5'-monophosphate potent activity hepatitis c virus hcv vitro study describe characterize vitro anti-hcv activity psi-352938 combination inhibitor hcv cross-resistance profile psi-352938 effective concentration require achieve 50 inhibition psi-352938 determine use 1a- 1b- 2a-derived replicon stably express lunet cell line 0.20 0.13 0.14 \\u03bcm respectively active 5'-triphosphate metabolite psi-352666 inhibit recombinant ns5b polymerase 1 4 comparable 50 inhibitory concentration contrast psi-352938 inhibit replication hepatitis b virus human immunodeficiency virus vitro psi-352666 significantly affect activity human dna rna polymerase psi-352938 cyclic phosphate metabolite affect cyclic gmp-mediated activation protein kinase g. clearance study use replicon cell demonstrate psi-352938 clear cell hcv replicon rna prevent replicon rebound additive synergistic effect observe psi-352938 combine class hcv inhibitor include alpha interferon ribavirin ns3/4a inhibitor ns5a inhibitor nucleoside/nucleotide nonnucleoside inhibitor cross-resistance study psi-352938 remain fully active replicon contain s282 t s96t/n142 t amino acid alteration replicon contain mutation confer resistance class nonnucleoside inhibitor remain sensitive inhibition psi-352938 psi-352938 currently evaluate phase clinical study 1-infected individual\",\"hepatitis c virus hcv major cause chronic liver disease cirrhosis hepatocellular carcinoma identification predictor response antiviral therapy important clinical issue\",\"aim study evaluate influence clinical epidemiological characteristic 183 hiv/hcv coinfected patient hcv clearance antiviral treatment serum sfas sfasl level thirty 183 patient undergo hcv antiviral therapy ifn-\\u03b1 rbv duration 48 week hcv 1 homeostasis model assessment insulin resistance homa-ir significant positive relationship cd4+/\\u03bcl significant negative relationship sfas r-square 0.582 p 0.001 sfasl r-square 0.216 p 0.001 multivariate linear regression analysis hcv 1 significant variable associate sfas/sfasl ratio r-square 0.201 p 0.001 sfas sfasl level positive significant correlation serum sicam-1 svcam-1 homa level p 0.05 patient ifn-\\u03b1 rbv therapy 15 patient sustained virologic response svr 15 patient non-responder nr patient svr significant decrease sfas p 0.008 sfas/sfasl ratio p 0.002 non-responder significant increase sfasl value p 0.013 conclusion hcv 1 high homa low cd4+/\\u03bcl associate high serum level sfas sfasl indicate high level inflammation possibly increase cardiovascular risk response hcv antiviral therapy know reduce inflammation\",\"patient chronic hepatitis c fail respond standard therapy high-dose pegylated interferon (ifn)-\\u03b1 and/or ribavirin induce strong antiviral response prevent treatment failure hcv resistance combine direct-acting antiviral influence genetic determinant context remain unknown\",\"present work describe activity thiosemicarbazone derive 5,6-dimethoxy-1-indanone tsc previously characterize new compound inhibit bovine viral diarrhea virus bvdv infection tsc act point time coincide onset viral rna synthesis inhibit activity bvdv replication complex rcs select bvdv mutant turn highly resistant tsc susceptible ribavirin rbv resistant mutant carry n264d mutation viral rna-dependent rna polymerase rdrp remain mutant a392e mutation protein mutant replicate slow wild-type wt virus absence tsc partial reversion wt phenotype passage absence compound docking tsc crystal structure bvdv rdrp reveal close contact indane ring compound residue finger domain enzyme hydrophobic contact hydrogen bond thiosemicarbazone group finally mutate rdrp resistant bvdv interaction tsc achieve interestingly tsc inhibit bvdv replication cell culture synergistically rbv conclusion tsc emerge new nonnucleoside inhibitor bvdv rdrp synergistic rbv feature turn potential compound evaluate hepatitis c virus hcv\",\"role insulin resistance ir hepatic steatosis fibrogenesis chronic hepatitis c infection chc yield conflict datum study perform asian-region population retrospectively investigate relationship host metabolic variable include ir hepatic steatosis hepatic fibrosis asian-region chc 2/3 patient\",\"current treatment chronic hepatitis c virus hcv infection base combination pegylated interferon-\\u03b1 ribavirin recent development direct-acting antiviral daa molecule active hcv vitro vivo study drug lead selection resistant virus administer raise concern resistance undermine therapy base daa new standard-of-care treatment soon available treatment-naive treatment-experienced patient infect hcv 1 base triple combination pegylated interferon-\\u03b1 ribavirin protease inhibitor telaprevir boceprevir therapy failure eradicate infection treatment-adherent patient inadequate response pegylated interferon-\\u03b1 ribavirin context low genetic barrier resistance first-generation protease inhibitor article review pattern resistance hcv daa drug development mechanism underlie treatment failure drug combine pegylated interferon-\\u03b1 ribavirin consequence treatment failure possible mean optimize future therapy use daa\",\"host viral factor implicate influence response pegylated-interferon/ribavirin peg-ifn/rbv therapy hepatitis c virus hcv infection viral factor sequence heterogeneity ns5a core region propose study aim clarify relationship virological response peg-ifn/rbv therapy sequence heterogeneity ns5a include ifn/rbv resistance-determining region irrdr interferon sensitivity-determining region isdr core region pretreatment sequence ns5a core region analyze 57 hcv-1b-infected patient treat peg-ifn/rbv 40 patient infect hcv irrdr mutation irrdr \\u2265 4 28 70 patient achieve sustained virological response svr hand 4 24 17 patient infect hcv irrdr mutation irrdr \\u2264 3 achieve svr p 0.001 similarly 22 71 31 patient infect hcv isdr mutation isdr \\u2265 1 achieve svr 10 38 26 patient infect hcv isdr mutation isdr 0 achieve svr p 0.014 core region significant correlation single mutation position 70 gln(70 non-svr p 0.02 notably gln(70 prominently associate null response p 0.0007 conclusion sequence heterogeneity irrdr isdr single point mutation position 70 core region hcv-1b likely correlate virological response peg-ifn/rbv therapy\",\"inx-08189 aryl-phosphoramidate 6-o-methyl-2'-c-methyl guanosine inx-08189 highly potent replicon assay 50 effective concentration 10\\u00b16 nm hepatitis c 1b 72 h. inhibitory effect viral replication rapid 50 effective concentration ec50 35\\u00b18 nm 24 h. intracellular 2'-c-methyl guanosine triphosphate 2'-c-megtp concentration 2.43\\u00b10.42 pmol/10(6 cell sufficient achieve 90 inhibition viral replication vitro resistance study confirm s282 t mutation ns5b gene confer approximately 10-fold reduction sensitivity inx-08189 complete inhibition s282 t mutant replicon achieve ec90 344\\u00b1170 nm. drug combination study inx-08189 ribavirin indicate significant synergy antiviral potency wild-type s282t-expresse replicon 1b replicon clear 14 day culture expose little 20 nm inx-08189 evidence mitochondrial toxicity observe 14 day inx-08189 exposure hepg2 cem human cell line vivo study rat cynomolgus monkey demonstrate 2'-c-megtp concentration liver equivalent ec90 attain single oral dose inx-08189 rat liver 2'-c-megtp concentration proportional dose sustain great 24 h correlate plasma concentration nucleoside metabolite 2'-c-methyl guanosine characteristic display inx-08189 support continued development clinical candidate treatment chronic hcv infection\",\"danoprevir rg7227 itmn-191 potent inhibitor hcv ns3/4a serine protease aim double-blind placebo-controlled multiple-ascending dose phase ib study evaluate safety tolerability antiviral activity resistance pharmacokinetic once- twice-daily danoprevir presence low-dose ritonavir danoprevir/r combination peginterferon alfa-2a (40kd)/ribavirin treatment-naive hcv 1 patient\",\"chronic hepatitis c virus hcv infection major cause liver disease worldwide hcv infection currently treat ifn\\u03b1 plus ribavirin 24 48 week demand therapy fail 50 patient use pharmacogenetic biomarker predict outcome treatment reduce futile treatment non-responder help identify patient therapy justify ifn\\u03b1 ribavirin primarily act modulate immune system patient hcv use multiple mechanism counteract antiviral effect stimulate therapy response therapy influence variation human gene govern immune system difference hcv gene blunt antiviral immune response article summarize recent advance understand host viral genetic variation affect outcome therapy notable human association polymorphism il28b gene variation human leukocyte antigen cytokine gene associate treatment outcome prominent viral genetic association outcome therapy hcv 1 sensitive treatment 2 3 genetic difference level influence outcome therapy presumably modulate ability viral gene blunt antiviral immune response pharmacogenetic prediction outcome ifn-based therapy hcv require integrate efficacy immunosuppressive mechanism viral isolate interpret viral resistance potential context genetic profile patient locus associate outcome therapy direct-acting inhibitor hcv use combination ifn\\u03b1 near approval genetic prediction anti-hcv therapy soon need incorporate viral genetic marker viral resistance new drug\",\"2 3 g2/g3 hepatitis c virus lump easy treat result guideline recommend 24 week peginterferon/ribavirin close look trial g2 infection prove responsive peginterferon datum support conclusion present possible explanation difference observe ultimately decision therapy rapid virological response rvr good parameter predict successful antiviral therapy patient g2 infection achieve rvr shorten course therapy effective contrast g3 patient rvr benefit extend therapy 48 week require confirmation prospective study use rvr guide therapy level playing field easy treat\",\"hepatitis c major health problem affect 200 million individual world include pakistan current treatment regiman consist interferon alpha ribavirin succeed eliminate virus completely patient body\",\"chronic hepatitis c patient coexist heart disease deny antiviral treatment safety concern evidence-based\",\"hepatitis c virus hcv genome polymorphism think influence outcome pegylated-interferon/ribavirin peg-ifn/rbv therapy study aim examine non-structural protein 5a ns5a polymorphism e.g. ifn/rbv resistance-determining region irrdr ifn sensitivity-determining region isdr core protein polymorphism predictive therapeutic marker\",\"hepatitis c virus hcv rna virus belong family flaviviridae consider significant risk factor hcv induced liver disease development hepatocellular carcinoma hcc current combination treatment pegylated interferon-\\u03b1 peg-ifn-\\u03b1 ribavirin limited efficiency poor tolerability significant expense mainly depend hcv hcv divide 52 present world genetic diversity 30 different 20 suggest different vary infectivity pathogenicity variation amino acid sequence influence rate disease progression severity cirrhosis risk hcc hcv core protein multifunctional activity regulation cell growth host gene expression essential infectivity include apoptosis hcv associate steatosis immune cell function cell transformation signal transduction transcriptional regulation recent study variable response ifn-ribavirin combination therapy steatosis insulin resistance hcc amino acid substitution hcv core region different present review emphasize pathogenicity cause hcv core effect amino acid sequence variation disease progression hcv life cycle\",\"polymorphism il28b gene highly associate sustained virological response svr patient chronic hepatitis c treat peginterferon ribavirin quantitation interferon-\\u03b3-inducible protein-10 ip-10 differentiate antiviral response evaluate ip-10 level pretreatment serum 115 nonresponder 157 sustained responder study viral resistance antiviral therapy chronic hepatitis c cohort include african american aa caucasian american patient mean ip-10 low sustained responder compare nonresponder 437 \\u00b1 31 vs 704 \\u00b1 44 pg/ml p 0.001 aa patient positive predictive value low ip-10 level 600 pg/ml svr 69 negative predictive value high ip-10 level 600 pg/ml 67 assess combination pretreatment ip-10 level il28b predictor treatment response il28b polymorphism rs12979860 test 210 participant cc ct tt find 30 49 21 patient respectively correspond svr rate 87 50 39 p 0.0001 serum ip-10 level il28b group provide additional information regard likelihood svr p 0.0001 ct carrier low ip-10 64 svr versus 24 high ip-10 similarly high svr rate identify tt cc carrier low versus high ip-10 tt 48 versus 20 cc 89 versus 79 il28b baseline ip-10 level additive independent predict svr aa patient\",\"genotype-specific sensitivity hepatitis c virus hcv interferon-ribavirin ifn-rbv combination therapy reduce hcv response ifn-rbv infection progress acute chronic infection suggest hcv genetic factor intrahost hcv evolution play important role therapy outcome hcv polyprotein sequence n 40 10 patient unsustainable response ur breakthrough relapse 10 patient response nr follow therapy identify virahep-c study bayesian network bn construct relate interrelationship hcv polymorphic site ur/nr outcome model extensive interdependence hcv site strong connection p \\u2264 0.003 therapy response hcv protein contribute network topological property site differ protein e2 ns5a contribute \\u223c40 site \\u223c62 link polyprotein bn ns5a bn e2 bn predict ur/nr outcome 85 97.5 accuracy respectively 10-fold cross-validation experiment ns5a model construct use physicochemical property site predict ur/nr outcome 83.3 accuracy 6 ur 12 nr case halt-c study hcv adaptation ifn-rbv complex trait encode interrelationship site entire hcv polyprotein e2 ns5a generate broad epistatic connectivity hcv polyprotein essentially shape intrahost hcv evolution ifn-rbv resistance protein use accurately predict outcome ifn-rbv therapy\",\"chronic hepatitis c lead cause chronic liver disease approximately 170 million people infect worldwide severity disease vary asymptomatic chronic infection cirrhosis hepatocellular carcinoma hcc sustained virological response svr long associate reduce risk cirrhosis hcc near future standard care soc treatment hepatitis c virus hcv include addition direct-acting antiviral daa protease inhibitor pegylated interferon peg-ifn plus ribavirin rbv hcv 1 patient promise result report protease inhibitor telaprevir boceprevir add soc increase svr rate 50 peg-ifn plus rbv 70 patient treat triple combination peg-ifn rbv plus protease inhibitor future management patient new molecule require good clinical practice knowledge indication prediction effect monitoring antiviral resistance certain major medical need unmet require study special population human immunodeficiency virus-hcv-coinfected patient transplant patient etc non-1 patient absolute non-responder combination antiviral additive potency lack cross resistance good safety profile provide new regimen future hcv chronic viral infection eradicate worldwide finite duration combination daa therapy ifn ongoing development new molecule hcv enzyme inhibitor aim review summarize result obtain daa protease polymerase inhibitor\",\"estimate million people chronic hepatitis c virus hcv infection current treatment success rate 2030 40 cirrhotic number case end-stage liver disease project treble current standard-of-care combination pegylated interferon plus ribavirin 24 48 week unfortunately associate poor efficacy 45 hcv gt1 75 gt2 65 gt 3 tolerability patient unsuitable decline current treatment infection significant side-effect associate treatment include decompensated cirrhosis sever psychiatric illness hope development direct act antiviral agent daa address huge unmet medical need addition protease inhibitor pegylated interferon plus ribavirin associate increase efficacy shorten duration therapy patient hcv gt1 likely new standard-of-care triple therapy suitable patient non-1 hcv infection contraindication interferon hope combination multiple daa target different step hcv replication provide interferon-free treatment regiman current plan study determine combination protease nonnucleoside polymerase nucleoside polymerase ns5a cyclophyllin b inhibitor daa duration therapy require optimise cure important minimise emergence multi-resistance jeopardise future retreatment option\",\"ability achieve sustained virological response svr peginterferon peg-ifn ribavirin rbv depend numerous host virological factor adherence prescribe treatment regiman patient fail achieve svr peg-ifn rbv limited option retreatment emerge datum phase ii phase iii clinical trial direct-acting antiviral agent suggest new therapeutic regimen available patient treatment protease inhibitor peg-ifn rbv ribavirin boceprevir combine peg-ifn rbv produce high rate virological response prior relapser extent prior non-responder benefit novel treatment regimen individual patient weigh effect cost potential develop viral resistance regulatory approval telaprevir boceprevir expect begin mid-late 2011\",\"introduction direct-acting oral antiviral agent verge new era transform treatment landscape review discuss recent development drug discovery hepatitis c protease inhibitor generation protease inhibitor offer higher sustained viral response rate na\\u00efve population combine standard pegylated interferon ribavirin dramatic gain partially offset new challenge viral resistance increase adverse event\",\"hepatitis c common cause chronic viral infection liver associate insulin resistance development type 2 diabete mellitus associate development hepatic steatosis presence hepatic steatosis associate increase risk hepatic fibrosis associate severity insulin resistance finding specifically germane genotype1 infection 3 infection independently cause steatosis successful treatment virus follow resolution steatosis 1 infection presence hepatic steatosis risk factor failure respond pegylated interferon ribavirin therapy unfortunately effort treat insulin resistance prior antiviral therapy successful newer effort focus role specific micro rna mediate metabolic effect hepatitis c virus infection provide ameliorate metabolic risk hcv infection\",\"approximately 180 million individual chronically infect hepatitis c strongly associate development cirrhosis end-stage liver disease hepatocellular carcinoma virological tool anti-hcv antibody assay measurement hcv-rna hcv-genotyping useful management hepatitis c infected patient primary goal antiviral therapy chronic hepatitis c sustained virological response svr hcv determine patient consider antiviral therapy currently recommend treatment duration ribavirin dose differ hcv exact subtyping gain increase importance future therapy direct-acting antiviral agent daa difference antiviral activity barrier resistance hcv monitor hcv rna highly sensitive assay lod \\u2264 15 iu/ml basis management response guide therapy chronic hepatitis c pegylated ifn plus ribavirin rule early discontinuation antiviral therapy non-responder determination optimal treatment duration virologic responder develop application individualized treatment strategy\",\"hepatic steatosis commonly patient chronic hepatitis c virus hcv infection prevalence high prevalence general population patient chronic hepatitis b. hepatic steatosis patient chronic hepatitis c alcohol consumption host metabolic factor high body mass index bmi obesity hyperlipidemia metabolic syndrome diabetes mellitus insulin resistance play important role 3 hcv infection hepatic steatosis result direct viral cytopathic effect demographic clinical characteristic associate hepatic steatosis patient chronic hepatitis c include old age high bmi 3 infection higher mean serum level triglyceride alanine aminotransferase \\u03b3-glutamyl transpeptidase clinical relevance hepatic steatosis patient chronic hepatitis c include close correlation hepatic fibrosis poor response combination peginterferon ribavirin treatment addition hepatic steatosis report associate increase frequency hepatocellular carcinoma patient chronic hcv infection life style modification weight reduction add insulin resistance reduce agent metformin thiazolidinedione combine current standard peginterferon plus ribavirin treatment benefit chronic hepatitis c patient hepatic steatosis deserve evaluation\",\"rna virus hepatitis c virus hcv characteristically high level nucleotide diversity accumulation nucleotide substitution virus result diversification quasispecie distinct pathobiological study link nucleotide amino acid sequence clinical finding identify relationship certain characteristic biological property 3 hcv infection find associate high level liver steatosis 1 4 find resistant interferon ifn base therapy 2 3 study 1 sequence obtain patient treat ifn identify relationship favorable response interferon therapy amino acid substitution ns5a region interferon response determining region isdr study identify relationship effect ifn therapy region ns5a protein recently relationship find poor response peg-ifn plus ribavirin combination therapy substitution amino acid 70 91 core protein furthermore correlation human genetic variation il28b ifn-lamda 3 locus core amino acid substitution characterize review briefly summarize discovery classification nomenclature hcv discuss amino acid substitution specific region report associate outcome ifn peg-ifn plus ribavirin combination therapy\",\"response interferon therapy disease progression hepatitis c virus hcv infected patient differ individual suggest possibility contribution host genetic factor 2'-5'-oligoadenylate synthetase 1 oas1 important component innate immune system prove antiviral function relationship response interferon therapy clinical course hcv disease aim determine frequency single nucleotide polymorphism snp exon 7 splice acceptor site sas oas1 gene relation interferon response status hcv infection\",\"danoprevir potent selective inhibitor hepatitis c virus hcv ns3/4a serine protease present study assess safety pharmacokinetic antiviral activity danoprevir randomized placebo-controlled 14-day multiple ascend dose study patient chronic hcv 1 infection\",\"bi201335 highly specific potent hcv protease inhibitor multiple rise dose trial evaluate antiviral activity safety chronic hcv genotype-1 patient\",\"current treatment regiman chronic hepatitis c virus hcv infection peg-interferon plus ribavirin combination therapy majority develop therapeutic strategy contain peg-interferon ribavirin interferon expensive intolerable patient severe effect\",\"polymorphism il28b gene rs12979860 rs8099917 associate high sustained virological response svr rate hcv 1 patient study analyze impact il28b polymorphism early treatment response week 2 4 svr hcv 3 patient\",\"common genetic variation il28 locus find influence effect peg-interferon ribavirin combination therapy chronic hepatitis c virus hcv infection expression il28 peripheral blood cell report high patient il28 snp associate favorable response\",\"pegylated interferon ribavirin peg-ifn/rbv therapy chronic hepatitis c virus hcv 1 infection effective 50 patient recent study reveal association il28b treatment response aim develop model pre-treatment prediction response use host viral factor\",\"common il28b locus polymorphism snp rs8099917 rs12979860 report affect peg-interferon plus ribavirin combination therapy peg-rbv hepatitis c virus hcv 1b report examine effect common 2a 2b\",\"improve understanding hepatitis c virus hcv life cycle lead discovery numerous potential target antiviral therapy hcv polyprotein processing replication identify promising viral target viral entry fusion rna translation virus assembly release host cell factor provide alternative attractive target future anti-hcv therapy inhibitor hcv ns3/4a protease currently advanced clinical development monotherapy protease inhibitor high antiviral activity associate frequent selection resistant hcv variant result viral breakthrough encouraging evidence phase 2/3 trial indicate addition protease inhibitor e.g. telaprevir boceprevir pegylated interferon-\\u03b1/ribavirin substantially improve sustained virological response rate treatment-na\\u00efve treatment-experienced patient hcv 1 nucleos(t)ide inhibitor hcv ns5b polymerase variable antiviral activity different hcv higher genetic barrier resistance protease inhibitor addition allosteric bind site identify non-nucleoside inhibitor ns5b polymerase development substance high antiviral activity high genetic barrier resistance difficult different host cell-targeting compound early clinical development cyclophilin inhibitor promising result advance improve interferon combination antiviral agent different mechanism action lead eventual possibility interferon-free regimen\",\"chronic hepatitis c associate increase prevalence insulin resistance result liver disease metabolic factor hepatitis c virus hcv effect antiviral treatment insulin sensitivity well-known evaluate change insulin resistance weight patient hepatitis c peginterferon ribavirin therapy\",\"host viral factor report influence effectiveness pegylated interferon plus ribavirin combination therapy chronic hepatitis c. japan age treat patient comparatively high recent study report poor response treatment old female patient little know relationship advanced age woman previously report factor\",\"lack antiviral response patient chronic hepatitis c treat pegylated (peg)-interferon (ifn)-\\u03b1-2a ribavirin riba explain neutralize antibody ifn-\\u03b1-2a aim study assess neutralizing antibody ifn-\\u03b1-2a ifn level non-responder patient re-treate peg ifn-\\u03b1-2a riba 12 week non-responder first-line treatment peg ifn-\\u03b1-2a riba include treatment peg ifn-\\u03b1-2a 180 \\u00b5g/week riba 1,000 mg/day 75 kg 1,200 mg 48 week hcv rna measure week 12 ifn level neutralize antibody ifn-\\u03b1-2a measure retrospectively store serum baseline week 4 12 use quantitative sandwich elisa neutralize antibody ifn-\\u03b1-2a twenty-three patient non-responder 19 patient responder week 12 initial phase second-line treatment non-responder responder differ statistically baseline age median age 47 vs. 50 year hcv rna median 6.8 vs. 6.4 log(10 copies/ml gender 70 vs. 73 male 1 91 vs. 80 median ifn-\\u03b1-2a level pg/ml week 0 4 12 interquartile range differ 19 responder initial phase second-line treatment 23 non-responder 3.3 3.3 371.4 1457.3 106.8 3284.8 1,652 90.8 5,000 84.5 3.3 277.4 1407.4 120.2 2443.4 1620.1 120.2 2287.1 respectively non-selected consecutive non-responder patient re-treatment peg ifn-\\u03b1-2a riba associate virological response regardless presence antibody-mediated resistance conventional ifn treatment\",\"study evaluate efficacy hcv re-treatment predictor response hiv/hcv co-infecte patient role insulin resistance predictor response population unknown aim study evaluate safety efficacy pegylated interferon-\\u03b1-2a ribavirin re-treatment hiv/hcv co-infected patient predictor sustained virological response include insulin resistance relationship insulin resistance liver histology\",\"classical antiviral therapy target viral protein consequently subject resistance counteract limitation alternative strategy develop target cellular factor hypothesize approach useful identify broad-spectrum antiviral influenza virus use model viral diversity need develop therapy unpredictable virus recently underline h1n1 pandemic propose identify gene-expression signature associate infection different influenza virus allow identification potential antiviral drug broad anti-influenza spectrum activity analyze cellular gene expression response infection different human avian influenza virus strain identify 300 gene differentially express infected non-infected sample 20 dysregulate gene use screen connectivity map database drug-associated gene expression profile candidate antiviral identify inverse correlation query signature hypothesize molecule induce unfavorable cellular environment influenza virus replication potential antiviral include ribavirin identify effect test vitro influenza strain molecule inhibit influenza viral growth new pandemic h1n1 virus use define gene expression signature infection inhibit identify molecule demonstrate strategy contribute identify new broad anti-influenza agent act cellular gene expression identify infection signature gene expression modify infection encode cellular protein involve viral life cycle study gene expression-based screening use identify antiviral approach accelerate drug discovery extend pathogen\",\"treatment-induced control spontaneous clearance hepatitis c virus hcv infection affect host factor polymorphism region gene il28b associate hcv clearance implicate gene product interferon (ifn)-\\u03bb3 immune response hcv clear il28b haplotype affect hcv clearance ifn-\\u03bb3 up-regulate interferon-stimulated gene similar ifn-\\u03b1 ifn-\\u03b2 different receptor evidence ifn-\\u03bb3 affect adaptive immune response il28b consider factor predict patient response therapy pegylated ifn-\\u03b1 ribavirin review genetic study uncover association il28b hcv clearance biology ifn-\\u03bb3 clinical implication genetic association area future research\",\"rg7128 prodrug psi-6130 potent antiviral efficacy patient infect hepatitis c virus hcv 1 2 3 mean viral load decrease 2.7 5 log(10 iu/ml respectively associate 1500-mg dose twice daily monotherapy 2 week 1000-mg 1500-mg dose twice daily treatment combination standard care soc 4 week\",\"recent development proteomic array technology include protein profiling couple proteinchip array surface-enhanced laser desorption ionization time-of-flight mass spectrometry seldi-tof/ms provide potentially powerful tool discovery new biomarker comparison profile accord patient phenotype use approach identify host factor associate treatment response patient chronic hepatitis c chc receive 48-wk course pegylated interferon peg-ifn alpha 2b plus ribavirin rbv protein profile pretreatment serum sample 32 patient 1b high viral load conduct seldi-tof/ms use different proteinchip array cm10 q10 imac30 protein significantly different peak intensity sustained virological responder svr non-svrs identify chromatography sds-page tof/ms tandem mass spectrometry ms/ms assay peak intensity significantly different svr non-svrs svr-increased peak identify apolipoprotein apo fragment albumin non-svr-increased protein peak identify iron-related fibrogenesis-related protein fragment respectively multivariate analysis serum ferritin peak intensity value apo a1 hemopexin transferrin independent variable associate svr area receiver operating characteristic roc curve svr prediction use apo a1/hemopexin hemopexin/transferrin 0.964 0.936 conclusion pretreatment serum protein profiling seldi-tof/ms variable identification response-related host factor useful treatment efficacy prediction chc receive peg-ifn plus rbv datum help understand mechanism treatment resistance development effective antiviral therapy target modulation lipogenesis iron homeostasis chc patient\",\"resistance virus mutagenic agent important problem development lethal mutagenesis antiviral strategy previous study rna virus document resistance mutagenic nucleoside analogue ribavirin 1-\\u03b2-d-ribofuranosyl-1-h-1,2,4-triazole-3-carboxamide mediate amino acid substitution viral polymerase increase general template copying fidelity enzyme decrease incorporation ribavirin rna describe experiment replication important picornavirus pathogen foot-and-mouth disease virus fmdv presence increase concentration ribavirin result sequential incorporation amino acid substitution m296i p44s p169s viral polymerase 3d main biological effect substitution attenuate consequence mutagenic activity ribavirin -by avoid biased repertoire transition mutation produce purine analogue-and maintain replicative fitness virus able escape extinction ribavirin achieve alteration pairing behavior ribavirin-triphosphate rtp evidence vitro polymerization assay purify mutant 3ds comparison three-dimensional structure wild type mutant polymerase suggest amino acid substitution alter position template rna entry channel enzyme affect nucleotide recognition result provide evidence new mechanism resistance mutagenic nucleoside analogue allow virus maintain balance mutation type introduce progeny genome replication strong mutagenic pressure\",\"insulin resistance ir major predictor treatment failure patient hepatitis c virus hcv infection treat peginterferon/ribavirin aim study evaluate short-term effect hcv protease inhibitor monotherapy ir parallel antiviral effect\",\"half patient infect hepatitis c virus hcv achieve sustained viral clearance pegylated interferon peginterferon ribavirin therapy s-adenosyl methionine improve interferon signaling cell culture assess effect kinetic early antiviral response interferon signaling nonresponder previous antiviral therapy investigate mechanism involve\",\"investigate independent association homeostasis model assessment insulin resistance homa-ir score rapid virological response rvr sustained virological response svr chronic hepatitis c chc\",\"small molecule inhibitor hepatitis c virus hcv develop complement replace treatment pegylated interferon ribavirin poor response rate significant effect resistance inhibitor emerge rapidly clinic suggest successful therapy involve combination therapy multiple inhibitor different target entry process hcv hepatocyte represent series potential target therapeutic intervention involve viral structural protein extensively explore experimental limitation discover hcv entry inhibitor utilize hcv pseudoparticle hcvpp incorporate e1-e2 envelope protein 1b clinical isolate screening small molecule library identify potent hcv-specific triazine inhibitor ei-1 series hcvpp e1-e2 sequence hcv isolate use activity 1a 1b hcvpp test median ec50 value 0.134 0.027 \\u00b5m respectively time-of-addition experiment demonstrate block hcvpp entry downstream initial attachment cell surface prior concomitant bafilomycin inhibition endosomal acidification ei-1 equally active cell-culture adapt hcv hcvcc block cell-free entry cell-to-cell transmission virus hcvcc high-level resistance ei-1 select sequential passage presence inhibitor resistance confer change residue 719 carboxy-terminal transmembrane anchor region e2 implicate envelope protein ei-1 susceptibility combination ei-1 interferon inhibitor ns3 ns5a result additive synergistic activity result suggest inhibitor hcv entry add replication inhibitor interferon development\",\"despite recent success introduction combination therapy interferon (ifn)-\\u03b1 ribavirin approximately 60 patient hepatitis c virus hcv 4 fail respond resistance antiviral therapy remain problem management chronic hepatitis c. patient hcv rna detect peripheral blood mononuclear cell pbmc\",\"mechanism treatment resistance interferon ifn ribavirin rib combination therapy hepatitis c virus hcv infection know study aim gain insight mechanism explore hepatic gene expression treatment\",\"mathematically describe early hepatitis c virus hcv rna decay initiation interferon (ifn)-based antiviral therapy crucial parameter vivo viral kinetic estimate rate production clearance free virus rate loss infected cell furthermore suggest mechanism action ifn ribavirin mathematical modelling provide means evaluate optimize treatment strategy review recent model development understand complex viral kinetic pattern triphasic hcv rna decline viral rebound observe patient treat pegylated interferon ribavirin discuss new modelling approach develop interpret viral kinetic observe clinical trial direct-acting antiviral agent induce rapid decline wild-type virus engender high risk emergence drug-resistant variant lastly vitro system allow characterization virus lifecycle discuss new modelling approach combine intracellular extracellular viral dynamic\",\"patient hepatitis c virus (hcv)-related liver disease frequently undergo orthotopic liver transplantation recurrent hepatitis c major cause morbidity patient treat peg-interferon ribavirin peg-ifn/rbv substantial effect costly investigate genetic factor host liver donor virus predict sensitivity patient recurrent hepatitis c peg-ifn/rbv\",\"chronic hepatitis c virus hcv infection global health problem current therapy effective 50 patient infect 1 advance cell culture system past decade development directly act antiviral daa hcv possible currently 50 active clinical trial therapeutic area ns3/4a protease inhibitor enter phase iii study date learn daa potent inhibitor hcv replication result rapid decline serum hcv rna level potential allow shortening therapy agent drive selective pressure mutant virus develop rapidly reduce susceptibility drug current standard care include pegylated interferon \\u03b1 pegifn ribavirin remain crucial new drug development furthermore adverse event profile early daa add concern tolerability common current standard care ongoing issue include optimal duration therapy combine daa long-term role pegifn ribavirin summarize current information regard effectiveness protease inhibitor treat chronic hcv discuss key challenge face field\",\"patient hepatitis c virus hcv human immunodeficiency virus hiv coinfection prior treatment hcv interferon-ribavirin fail require subsequent treatment new hcv protease inhibitor pi evaluate diversity hcv nonstructural protein 3 ns3 26 hcv- hiv-coinfected patient receive stable antiretroviral therapy art treat interferon-ribavirin plasma hcv rna clonal analysis perform great baseline ns3 diversity patient nonresponse relapse sustained virologic response interferon-ribavirin treatment result significant change hcv protease gene diversity significant hcv pi resistance mutation effect prior interferon-ribavirin treatment hcv ns3 likely impact hcv pi efficacy hiv-coinfected patient receive art\",\"infection hepatitis c virus hcv continue major global health problem overcome limitation current therapy use interferon-\\u03b1 combination ribavirin need develop drug specifically block viral protein highly efficient protease polymerase inhibitor currently undergo clinical testing available year resistance mutation emerge quickly additional enzymatic activity function hcv target novel compound candidate molecule nonstructural protein 2 ns2 contain proteolytic activity essential viral rna replication addition ns2 crucial assembly progeny virion modulate cellular process interfere viral replication review describe function ns2 life cycle hcv highlight potential antiviral strategy involve ns2\",\"emergence pandemic h1n1 influenza virus april 2009 continuous evolution highly pathogenic h5n1 influenza virus underscore urgency novel approach chemotherapy human influenza infection anti-influenza drug currently limit neuraminidase inhibitor oseltamivir zanamivir m2 ion channel blocker amantadine rimantadine resistance class develop rapidly potential target development new anti-influenza agent include viral polymerase endonuclease hemagglutinin non-structural protein ns1 limitation monotherapy emergence drug-resistant variant combination chemotherapy logical therapeutic option review experimental datum combination chemotherapy currently available agent development new agent therapy target\",\"hepatitis c virus hcv infection global medical problem role nitric oxide chronic viral hepatitis unknown play prominent role antiviral agent reduce replication mediator cause accumulation oxidative dna damage oncogenesis present study carry study effect combined peginterferon ribavirin therapy hepatitis c responder non responder patient study include seventy patient positive serological marker hcv classify accord presence absence hcv viremia response therapy addition sixteen control subject include level determine stable end product nitrate nitrite serum nitrite nitrate concentration patient viral hepatitis significantly high normal subject patient serological evidence hepatitis c infection absence viral load level nitrite or= 31 microm nitrate or= 15 microm no(2)/no(3 ratio 1.5 microm associate increase risk resistance therapy multivariate logistic regression analysis no(2)/no(3 ratio level 1.5 microm associate hcv eradication independently study provide new insight pathogenesis hepatitis c highlight effect combined peginterferon ribavirin nitrite nitrate marker endogenous system limitation level increase lead non response antiviral therapy important factor chronic hepatitis c suggest additional therapeutic pathway anti-oxidant combination standard regiman study\",\"combination therapy peginterferon peg-ifn ribavirin high morbidity identify individual hepatitis c virus hcv respond treatment beneficial early response serum hcv rna level standard interferon ifn peg-ifn examine determine possible identify resistance combination therapy thirty-one patient infect hcv 1b enrol patient 6 mu standard ifn alpha-2b 2 week initiate combination therapy serum hcv rna level measure 24 hr administration standard ifn 24 hr administration peg-ifn start combination therapy association reduction hcv rna level 24 hr administration standard ifn peg-ifn outcome combination therapy analyze reduction hcv rna level poor patient respond sustained virologic response relapse p 0.0001 24 hr administration standard ifn 24 hr administration peg-ifn reduction hcv rna level 24 hr administration standard ifn independent factor associate non-response multivariate analysis early reduction viral load single administration standard ifn useful predictor non-response patient hcv 1 allow pretreatment identification patient benefit combination therapy\",\"treatment chronic hepatitis c virus hcv infection evolve considerably year standard care soc hcv infection consist combination pegylated interferon peg-ifn plus ribavirin induce sustained virological response svr half 1-infected patient viral host factor associate non-response steatosis obesity insulin resistance age male sex ethnicity study demonstrate non-responder interferon-stimulated gene upregulate treatment finding associate clinical biochemical histological datum help detect responder start treatment important issue standard treatment physically economically demanding future hcv treatment probably consist addition specifically target antiviral therapy hcv protease and/or polymerase inhibitor soc 1 patient promising result report protease inhibitor telaprevir boceprevir add soc increase svr rate approximately 50 peg-ifn plus ribavirin 70 patient treat combination peg-ifn plus ribavirin plus telaprevir different element associate non-response viral factor ii host factor iii molecular mechanism induce hcv protein inhibit ifn signalling pathway goal review present mechanism non-response overcome identify factor help predict response anti-hcv therapy\",\"study explore gene expression difference predict response pegylated interferon ifn-peg ribavirin rbv hepatitis c infection current treatment hepatitis c virus hcv ifn-peg alpha-2a/b rbv expensive regimen frequent significant side-effect 60 patient ultimately achieve sustained virological response responder nonresponder identify 6 month post-treatment dichotomy difference molecular genetic response\",\"current treatment chronic hepatitis c base combination pegylated interferon ribavirin effective 50 patient specific target antiviral therapy represent promising approach eradicate infection\",\"liver disease related infection hepatitis c virus hcv and/or hepatitis b virus hbv frequent cause morbidity mortality infect human immunodeficiency virus hiv era highly active antiretroviral therapy haart progress treatment hbv hcv setting hiv-coinfection lack datum certain area aspect management unclear time\",\"study association sequence variability interferon sensitivity-determining region isdr hepatitis c virus outcome treatment reach conflicting result study 25 patient infect hcv 6a receive interferon-alpha/ribavirin combination treatment analyze sequence variation 14 genome sequence obtain previous study 11 sample sequence extend isdr eisdr eisdr fragment cover 192 bp 64 amino acid upstream 201 bp 67 amino acid downstream isdr previously define hcv 1b comparison interferon-alpha resistance response group amino acid mutation located genome 6 8 patient respectively mutation located eisdr 10 15 patient respectively mutation i2160v i2256v v2292i p<0.05 eisdr significantly associate resistance treatment extent amino acid variation previously define isdr associate resistance treatment previously report amino acid variation i248v p=0.03 0.06 e1 r445 k p=0.02 0.05 s747 t p=0.03 e2 i861v p=0.01 ns2 located outside eisdr associate treatment outcome identify prescreening variation 14 hcv 6a genome\",\"treatment response interferon differ mutation interferon-sensitivity-determining region isdr patient infect hepatitis c virus hcv genotype-1b hcv-ib examine pattern isdr mutation analyze number amino acid substitution influence treatment response peginterferon plus ribavirin chronic hepatitis cirrhotic patient infect hcv-ib\",\"combination pegylated-interferon (peg-ifn)/ribavirin currently standard care antiviral treatment chronic hepatitis c chc optimal result require individual approach key issue deliver dose confer optimal antiviral efficacy hepatitis c virus hcv time sufficient minimise relapse viral monitoring therapy guide subsequent treatment course particularly hcv rna result 4 week rapid viral response rvr 12 week complete early viral response cevr strong evidence patient 2 3 hcv infection rvr allow truncation treatment 16 week provide ribavirin dose weight-based patient cirrhosis insulin resistance/diabete old 50 year need 6 12 month treatment difficult-to-treat chc 1 4 rvr infrequent approximately 15 european study allow treatment truncate 48 24 week rvr evidence long treatment 72 week improve sustained viral response svr induction dose 12 week peg-ifn clearly improve svr prevent dose reduction complete therapy critical detect treat depression disable side-effect include judicious use growth factor severe anemia neutropenia possibly thrombocytopenia potentially important aspect attempt counter central obesity insulin resistance confer suboptimal antiviral response hcv treatment partnership specialist nurse psychological therapist healthcare worker essential optimal individual management patient chc\",\"prospectively compare sensitivity interferon ifn efficacy antiviral combination therapy peginterferon peg-ifn ribavirin chronic hepatitis c virus hcv 1b infection accord amino acid sequence hcv core e1 ns5a region report associate outcome antiviral therapy\",\"ribavirin rbv synthetic nucleoside analog broad spectrum antiviral activity rbv approve treatment hepatitis c virus respiratory virus lassa fever virus infection mechanism action therapeutic efficacy remain highly controversial recent report development cell-based resistance continuous rbv treatment decrease rbv uptake greatly limit efficacy examine certain cell type naturally resistant rbv prior drug exposure seven different cell line host specie compare rbv antiviral activity nonsegmented negative-strand rna virus vesicular stomatitis virus vsv rhabdovirus sendai virus sev paramyxovirus result striking difference cell type response rbv range virtually antiviral effect effective inhibition viral replication despite difference viral replication kinetic vsv sev seven cell line observe pattern rbv resistance similar virus suggest cellular viral determinant play major role resistance test cell line defective rbv uptake dramatic variation observe long-term accumulation rbv different cell type correlate antiviral efficacy rbv addition guanosine neutralize rbv cell highly resistant rbv actinomycin d completely reverse rbv effect uptake cell line datum suggest rbv inhibit virus different mechanism different cell type depend intracellular rbv metabolism result strongly point importance use multiple cell line different origin antiviral efficacy potency examine new establish drug vitro\",\"controversy exist insulin resistance ir affect response treatment hepatitis c. evaluate effect ir sustained virologic response svr hiv/hepatitis c virus (hcv)-coinfected patient treat interferon plus ribavirin\",\"1,2,3-thiadiazole important synthetic active substructure nowadays important branch novel pesticide development develop pesticide candidate diverse biological activity probe structure-activity relationship serie 5-methyl-1,2,3-thiadiazole rationally design synthesize use simple convenient one-step synthetic procedure ugi reaction biological activity target compound include fungicidal activity antivirus activity vitro vivo systemic acquire resistance systematically evaluate result indicate compound iii(10 broad-spectrum activity fungi test compound i(10 ii(17 excellent potential antivirus activity compare positive control agent ribavirin preliminary structure-activity relationship discuss result study indicate 5-position-substituted 1,2,3-thiadiazole exhibit good antivirus activity worthy study pesticide development\",\"conflict result report study evaluate relationship serum marker iron overload liver iron deposit hfe mutation c282y h63d chronic hepatitis c patient impact response therapy patient\",\"hcv leading cause liver disease ~3.4 million people chronically infected standard care soc pegylated ifn ribavirin combination therapy limited efficacy ~50 sustain viral response associate considerable adverse event profile patient new drug directly target virus development promise effective therapy chronic hcv infection\",\"genome-wide association study patient treat chronic hepatitis c 2 functional variant itpa cause inosine triphosphatase itpase deficiency protect ribavirin (rbv)-induced hemolytic anemia early stage treatment aim replicate finding independent cohort study viral resistance antiviral therapy chronic hepatitis c investigate effect variant week 4\",\"patient chronic hepatitis c respond antiviral treatment adult patient re-treatment patient extensively investigate response re-treatment child define evaluate efficacy safety interferon (ifn)-alpha plus ribavirin patient fail respond previous treatment\",\"recently identify compound clemizole hydrochloride inhibit ns4b rna binding hepatitis c virus hcv replication significant clemizole antiviral effect moderate 50 effective concentration 8 microm hcv 2a clone hypothesize combination clemizole anti-hcv agent increase antiviral effect achieve drug decrease emergence viral resistance\",\"insulin resistance find independent factor predict sustained response peginterferon plus ribavirin patient chronic hepatitis c. insulin resistance involve decrease sensitivity interferon block interferon intracellular signaling insulin resistance promote steatosis fibrosis progression induce pro-inflammatory cytokine secretion increase adipose tissue decrease interferon availability suppressor cytokine 3 protein tyrosine-phosphatase able block interferon insulin signaling build feed-forward loop insulin resistance treat exercise diet use drug improve insulin sensitivity like biguanide glitazone recent control randomize double-blind clinical trial tric-1 examine effect add metformin standard therapy treatment hepatitis c. study demonstrate woman infect hepatitis c virus 1 homa 2 treat metformin great drop viral load 12 week doubled sustained viral response comparison female receive placebo pioglitazone use previous nonresponder na\\u00efve patient disappointing result pilot trial mechanism virus promote insulin resistance genotype-dependent explain discrepancy insulin sensitizer insulin resistance new target challenging management chronic hepatitis c.\",\"killer cell immunoglobulin-like receptor kir involve activation/inhibition nk cell interaction hla class molecule target cell study aim evaluate association kir gene polymorphism response patient chc antiviral therapy\",\"chronic hepatitis c virus hcv infection associate high risk development insulin resistance hcv causal factor insulin resistance clearance hcv decrease insulin resistance aim study elucidate effect clearance hcv insulin resistance\",\"human rhinovirus hrv member picornaviridae family compose 100 different virus serotype record clinically effective antiviral chemotherapeutic agent treatment disease cause hrv previous study raoulic acid test serotype human rhinovirus anti-hrv2 specie -3 specie b activity study raoulic acid find possess broad-spectrum antiviral activity hrv 50 inhibition concentration 9.5 microg/ml inhibition cellular absorption hrv particle furthermore effect raoulic acid resistance hrv5 exhibit pleconaril pronounced effect hrv1b -6 -14 -15 -40 ribavirin possess weak antiviral activity hrv collectively result demonstrate raoulic acid novel therapeutic candidate different group human rhinovirus\",\"worldwide prevalence chronic hepatitis c virus hcv infection estimate approach 200 million people current therapy rely combination pegylated interferon-alpha ribavirin poorly tolerate regimen typically associate 50 sustain virological response rate infect 1 virus development direct-acting antiviral agent treat hcv focus predominantly inhibitor viral enzyme ns3 protease rna-dependent rna polymerase ns5b describe profile bms-790052 small molecule inhibitor hcv ns5a protein exhibit picomolar half-maximum effective concentration ec(50 replicon express broad range hcv jfh-1 2a infectious virus cell culture phase clinical trial patient chronically infect hcv administration single 100-mg dose bms-790052 associate 3.3 log(10 reduction mean viral load measure 24 h post-dose sustained additional 120 h patient infect 1b virus genotypic analysis sample baseline 24 144 h post-dose reveal major hcv variant observe substitution amino-acid position identify use vitro replicon system result provide clinical validation inhibitor hcv ns5a protein known enzymatic function approach suppression virus replication offer potential therapeutic regiman base combination hcv inhibitor\",\"passage pv foot-and-mouth disease virus fmdv presence ribavirin select virus decrease sensitivity r include different mutation polymerase 3d ): g64s located finger subdomain case pv m296i located loop beta9-alpha11 active site case fmdv investigate disparate substitution select closely related 3ds construct fmdvs 3d include g62s equivalent replacement fmdv pv g64s m296i substitution g62s m296i inflict fmdv strong selective disadvantage partially compensate substitution m296i corresponding mutant polymerase 3d(g62s 3d(m296i 3d(g62s-m296i analyze functionally structurally g62s 3d impair rna-binding polymerization r monophosphate incorporation activity x-ray structure 3d(g62s)-rna 3d(m296i)-rna 3d(g62s-m296i)-rna complex position separate 13.1 loop replacement reside tightly connect extensive network interaction reach polymerase active site particular g62s restrict flexibility loop beta9-alpha11 consequence flexibility active site ability bind rna template localized change finger subdomain 3d affect catalytic domain result provide structural interpretation different amino acid substitution select confer r resistance closely related virus reveal complex network intra-3d interaction affect recognition rna template incoming nucleotide\",\"dendritic cell dc dysfunction suggest play role weak antiviral t-cell responsiveness observe course chronic hepatitis c virus hcv infection study undertake evaluate change dc function related different therapeutic outcome hcv-infected patient\",\"assess hepatitis c virus (hcv)-rna level integral response-guided therapy rule early discontinuation determination treatment duration mainly establish hcv-rna assay detection limit 50iu/ml cobas amplicor hcv currently use real-time pcr-based cobas ampliprep/cobas-taqman hcv cap-ctm test detection limit approximately 10iu/ml unknown shortening treatment duration 16/24 week patient rapid virological response week 4 rvr viral load 10 50iu/ml possible\",\"50 hepatitis c virus (hcv)-infected patient respond classical pegylated interferon (peg-ifn)/ribavirin combination therapy fail respond course treatment synonymous therapy failure retreatment beneficial alternative retreatment strategy include repeat classical standard care optimized drug regiman adherence include ribavirin serum concentration adjustment correct possible comorbiditie addition new specific anti-hcv molecule backbone pegylated interferon/ribavirin option retreatment include consensus natural interferon patient advanced disease expose high risk lethal complication customize maintenance therapy effective option slow complication patient low-dose interferon monotherapy sufficient maintenance therapy remain verify clinical trial new possibility noninvasive assessment fibrosis use genetic test predict fibrosis progression responsiveness interferon major emerge opportunity run parallel revolution pharmacologic armentarium\",\"favipiravir t-705 previously potent antiviral effect influenza virus rna virus cell culture animal model currently favipiravir undergo clinical evaluation treatment influenza b virus infection study favipiravir evaluate vitro ability inhibit replication representative panel seasonal influenza virus 2009 a(h1n1 strain animal virus pandemic pdm potential swine triple reassortant h2n2 h4n2 avian h7n2 avian h5n1 include virus resistant currently licensed anti-influenza drug virus test plaque reduction assay mdck cell subset test yield reduction focus inhibition fi assay majority virus test favipiravir significantly inhibit plaque formation 3.2 mum 0.5 microg/ml 50 effective concentration ec(50)s 0.19 22.48 mum 0.03 3.53 microg/ml virus exception single dually resistant 2009 a(h1n1 virus complete inhibition plaque formation 3.2 mum 0.5 microg/ml 2009 pandemic increase drug resistance circulate seasonal influenza virus urgent need new drug target influenza study demonstrate favipiravir inhibit vitro replication wide range influenza virus include resistant currently available drug\",\"result post-transplant antiviral therapy recurrent hepatitis c virus hcv poor significant pre-transplant predictor sustained viral response svr identify\",\"recent advance development agent act specifically inhibit hepatitis c virus hcv set fundamentally change way patient treat new directly act anti-hcv agent protease polymerase inhibitor initially add standard care pegylated interferon-alpha ribavirin future therapy likely constitute combination agent act distinct stage viral replication differ resistance profile directly act anti-hcv agent undoubtedly improve treatment outcome introduction combination therapy complication patient group hiv-positive patient receive antiretroviral arv relatively highly represent hcv infection high risk drug-drug interaction ddi combination anti-hcv treatment gradually evolve resemble anti-hiv therapy essential consider increase potential ddi patient receive combination anti-hcv therapy particularly hcv/hiv-co-infected individual therapeutic drug monitoring likely play role clinical management interaction\",\"small-molecule hepatitis c virus hcv ns3 protease inhibitor boceprevir sch 503034 antiviral activity use monotherapy combination pegylated alpha interferon ribavirin clinical trial improvement inhibitor potency pharmacokinetic property offer opportunity increase drug exposure far increase sustained virological response exploration structure-activity relationship ketoamide inhibitor related boceprevir lead discovery sch 900518 novel ketoamide protease inhibitor form reversible covalent bond active-site serine overall inhibition constant k*(i 7 nm dissociation half-life 1 2 h. sch 900518 inhibit replicon rna 90 effective concentration ec(90 40 nm. biochemical assay sch 900518 active protease 1 3 2-week treatment 5x ec(90 inhibitor reduce replicon rna level 3 log unit selection replicon cell sch 900518 result outgrowth resistant mutant t54a/s a156s/t/v mutation cross-resistance study demonstrate majority mutation resistance boceprevir telaprevir cause similar fold loss activity inhibitor sch 900518 retain activity mutant higher intrinsic potency combination treatment alpha interferon enhance inhibition replicon rna suppress emergence resistant replicon colony support use sch 900518-pegylated alpha interferon combination therapy clinic summary result preclinical characterization antiviral activity sch 900518 support evaluation clinical study\",\"patient chronic hepatitis c chc 4 predictor rapid virologic response rvr determine adequately aim assess pretreatment variable predict rvr sustained virologic response svr\",\"present review discuss recent development drug discovery hepatitis c. verge new era introduction direct act oral agent transform treatment landscape healthcare provider patient need stay abreast change influence decision treat article discuss promising up-to-date hepatitis c virus antiviral therapy clinical investigation associate clinical trial result\",\"objective analysis identify predictor relapse 1 patient 48 week treatment peginterferon plus ribavirin\",\"insulin resistance predictive factor response treatment peginterferon ribavirin patient hepatitis c. insulin resistance impair sensitivity interferon block intracellular signalling insulin resistance induce development steatosis progression fibrosis proinflammatory cytokine release reduce bioavailability interferon suppressor cytokine signalling 3 protein tyrosine phosphatase involve block intracellular signalling interferon insulin insulin resistance treat diet physical exercise use insulin-sensitizing agent biguanide glitazone tric-1 study demonstrate add metformin routine treatment improve possibility cure woman patient insulin sensitivity return normal treatment\",\"association hepatitis c virus 4 hcv-4 hepatic steatosis clarify aim determine parameter associate steatosis hcv-4 patient assess effect steatosis treatment peginterferon ribavirin\",\"pegylated interferon peg-ifn alfa-2b plus ribavirin rbv standard care adult chronic hepatitis c approve treatment child time study aim study evaluate efficacy safety peg-ifn alfa-2b plus rbv child\",\"rapid emergence subsequent spread novel 2009 influenza a/h1n1 virus 2009 h1n1 prompt world health organization declare pandemic 21st century highlight threat influenza public health healthcare system widespread resistance class influenza antiviral adamantane neuraminidase inhibitor occur pandemic seasonal virus render drug marginal utility treatment modality worldwide 2009 h1n1 seasonal h3n2 strain resistant adamantane rimantadine amantadine majority seasonal h1n1 strain resistant oseltamivir widely prescribe neuraminidase inhibitor nai address need effective therapy evaluate vitro activity triple combination antiviral drug tcad regiman compose drug different mechanism action drug-resistant seasonal 2009 h1n1 influenza virus amantadine ribavirin oseltamivir combination test amantadine- oseltamivir-resistant influenza virus use vitro infection model mdck cell datum triple combination highly synergistic drug-resistant virus synergy triple combination significantly great synergy double combination test p<0.05 include combination nai surprisingly amantadine oseltamivir contribute antiviral activity tcad regiman amantadine- oseltamivir-resistant virus respectively concentration activity single agent concentration clinically achievable datum demonstrate tcad regiman compose amantadine ribavirin oseltamivir highly synergistic resistant virus include 2009 h1n1 tcad regimen overcome baseline drug resistance class approve influenza antiviral represent highly active antiviral therapy seasonal pandemic influenza\",\"current standard care hepatitis c virus hcv infection pegylated alpha interferon combination ribavirin limited response rate adverse effect drug target viral protein clinical development suffer development high viral resistance inhibition cellular protein essential viral amplification think high barrier emergence resistance cyclophilin inhibitor cyclosporine analog debio-025 scy635 nim811 promise result treatment hcv infection early clinical trial study investigate frequency mechanism resistance cyclosporine csa nim811 structurally unrelated cyclophilin inhibitor sfa-1 replicon-containing huh7 cell cross-resistance clone observe nim811-resistant clone select obtain initial resistance csa sfa-1 time require select resistance cyclophilin inhibitor significantly long require resistance selection viral protein inhibitor achievable resistance level substantially low resistance cyclophilin inhibitor mediate amino acid substitution ns3 ns5a ns5b ns5a mutation confer majority resistance mutation d320e ns5a mediate resistance confer ns5a result indicate low frequency level resistance cyclophilin-binding drug mediate amino acid substitution viral protein interaction cyclophilin ns5a critical ns5a mutation large impact resistance\",\"hepatitis c virus hcv infection associate increase prevalence diabete insulin resistance ir causal relationship establish\",\"compare 14 24 week treatment patient hcv 2 3 infection rapid virological response rvr\",\"hepatic steatosis commonly patient chronic hepatitis c infection great association chance hepatitis c virus closely associate lipid metabolism lifecycle hepatic steatosis common 3 infection direct viral effect include microsomal triglyceride transfer protein peroxisome proliferator activating receptor sterol regulatory element binding protein non-genotype 3 infection hepatic steatosis consider largely alteration host metabolism particularly insulin resistance clinical relevance association fully explore hepatic steatosis associate increase hepatic fibrosis reduce level sustained virological response pegylated interferon ribavirin small study triale adjuvant anti-diabetic therapy hmg-coa reductase inhibitor pegylated-interferon ribavirin improve sustained virological response reduce viral titer furthermore simple lifestyle alteration positive effect parameter disease activity insight raise possibility novel treatment option\",\"neuraminidase inhibitor oseltamivir zanamivi use treat h5n1 influenza oseltamivir-resistant h5n1 virus isolate oseltamivir-treated patient reassortment h5n1 virus oseltamvir-resistant human h1n1 virus currently circulate create oseltamivir-resistant h5n1 virus render oseltamivir stockpile obsolete need unique effective antiviral combat h5n1 influenza virus investigational drug t-705 favipiravir 6-fluoro-3-hydroxy-2-pyrazinecarboxamide antiviral activity seasonal influenza virus mouse-adapted h5n1 influenza virus derive benign duck virus efficacy highly pathogenic h5n1 virus substantially virulent remain unclear demonstrate t-705 effectively protect mouse lethal infection oseltamivir-sensitive -resistant highly pathogenic h5n1 virus furthermore biochemical analysis suggest t-705 ribofuranosyl triphosphate active form t-705 act like purine purine nucleoside human cell inhibit human dna synthesis conclude t-705 promise therapeutic agent treatment highly pathogenic h5n1 influenza patient\",\"investigate sustained virological response svr non-svr chronic hepatitis c patient pegylated interferon plus ribavirin peg-ifn/rbv combination therapy distinguishable viral factor ifn/rbv resistance-determining region irrdr on-treatment factor new index rebound index ri ri ri-1st viral load week 1 divide viral load 24 h second ri ri-2nd viral load week 2 divide viral load 24 h calculate subject patient divide 3 group base ri-1st ri-2nd ri-a group ri-1st 1.0 ri-b group ri-1st 1.0 ri-2nd 0.7 ri-c group ri-1st 1.0 ri-2nd 0.7 svr rate 71.4 10/14 ri-a group 46.2 6/13 ri-b group 20.0 3/15 ri-c group p 0.005 ri-a group ri-c group irrdr 6 irrdr 5 svr rate 81.3 13/16 23.1 6/26 p 0.0002 respectively combine ri irrdr predict factor svr rate 87.5 7/8 ri-a group 6 mutation irrdr 7.7 1/13 ri-c group 5 irrdr mutation p 0.0003\",\"ribavirin rbv nucleoside analogue use treatment hepatitis c virus hcv infection combination interferon potential mechanism rbv resistance hcv replication remain poorly understand serial passage cell harbor hcv 2a replicon presence rbv result reduce susceptibility replicon rbv transfection fresh cell rna rbv-resistant replicon cell demonstrate rbv resistance observe largely replicon-derived major amino acid substitution t1134s ns3 p1969s ns4b v2405a ns5a y2471h ns5b region identify site-directed mutagenesis mutation replicon indicate y2471h play role reduce susceptibility rbv lead decrease replication fitness result addition analysis sequence database suggest hcv variant reduce susceptibility rbv identify preferential 2a\",\"persistent hepatitis c virus hcv infection leading cause chronic hepatitis cirrhosis hepatocellular carcinoma major indication liver transplantation adult current standard care treatment soc pegylated-interferon-\\u03b1 2 ribavirin rbv limited efficacy associate significant effect frequently associate poor compliance treatment discontinuation require specialized frequent monitoring overcome limited efficacy soc 50 direct-acting antiviral agent daa design target viral-encoded protein essential hcv life cycle currently development rapid selection resistant mutant associate quasispecie nature hcv high mutation replication rate main challenge new hcv therapy predictive host viral factor combination daa ifn and/or rbv need accurately evaluate design effective individualized treatment strategy short time interval minimum effect\",\"abstract hepatitis c virus hcv 4 5 6 represent 20 hcv case worldwide hcv-4 mainly egypt represent 90 hcv case antischistosomal therapy main cause contamination follow procedure perform informal provider traditional healer dental care wound treatment circumcision delivery excision scarification highly prevalent sub-saharan africa middle east europe prevalence recently increase particularly intravenous drug user immigrant hcv-5 mainly find south africa represent 40 hcv pocket hcv-5 find france spain syria belgium sporadic case find mode transmission mainly iatrogenic transfusion hcv-6 find hong kong vietnam thailand myanmar american australian asian origin response treatment hcv-4 intermediate hcv-1 hcv-2 hcv-3 sustained viral response achieve 43 70 pegylated interferon ribavirin high egyptians europeans african negatively related insulin resistance severity fibrosis increase 80 24 week therapy rapid virological response achieve hcv-5 sustained virological response achieve 60 48 week therapy hcv-6 consider easy-to-treat lead response 60 85 case\",\"chronic hepatitis c virus hcv infection major cause cirrhosis hepatocellular carcinoma liver failure lead transplantation current standard treatment combination pegylated interferon alfa ribavirin eradicate virus 50 patient directly act antiviral daa agent inhibit hcv replication phase 1 2 3 trial include reagent target nonstructural (ns)3 protease ns5a protein rna-dependent rna-polymerase ns5b compound directly inhibit hcv replication interaction host cell protein high genetic heterogeneity hcv rapid replication monotherapy daa agent pose high risk selection resistant variant review parameter determine resistance genotypic phenotypic resistance profile daa agent strategy avoid selection resistant variant\",\"prevalence hepatitis c virus hcv infection vary world high number infection report egypt expression mxa gene find reliable sensitive marker induction endogenous type interferon ifn viral infection study examine correlation gene expression mxa response treatment pegylated-ifn-alfa2b ribavirin patient type 4 hcv 20 healthy volunteer control enrol prospective study design strict inclusion criterion nullify effect confound variable far minimize selection bias quantification hcv-rna mxa gene real-time pcr perform patient quantification mxa gene perform control statistically significant difference patient control group regard quantity mxa gene expression p 0.05 mann-whitney test p 0.004 statistically significant difference responder nonresponder p 0.05 ): responder high percentage case initial mxa 2(6 p 0.05 conclude mxa protein expression sensitive biological marker ongoing virus replication presence type 1 ifn result highlight importance detection mxa expression start therapy factor assess likelihood hcv 4 patient achieve sustained virological response treatment ifn-\\u03b12 combination ribavirin\",\"year interferon therapy inhibit hbv replication patient long-term administration oral nucleos(t)ide analogue efficient long early treatment adaptation patient partial virological response resistance provide follow demonstration potent antiviral effect term sustained virological response svr rate pegylated-ifn couple ribavirin standard treatment chronic hepatitis c nearly 65 treat patient achieve svr long-term suppression hbv eradication hcv halt progression chronic hepatitis cirrhosis hepatocellular carcinoma liver decompensation\",\"clinical course pandemic h1n1 2009 influenza severe particularly young patient comorbiditie pandemic h1n1 2009 sensitive antiviral agent oseltamivir zanamivir resistant m2 inhibitor clinical datum available treatment pandemic h1n1 2009 influenza hospital setting oseltamivir zanamivir appear beneficial hospitalize patient severe influenza treat oseltamivir mortality length stay significantly reduce viral load reduce quickly untreated patient patient high risk treat oseltamivir zanamivir reduction risk complication mortality treatment demonstrate oseltamivir zanamivir datum evidence antiviral agent effective severe pandemic h1n1 2009 influenza current world health organization guidance strongly recommend use oseltamivir severe progressive infection pandemic h1n1 2009 zanamivir alternative infect virus oseltamivir-resistant little resistance oseltamivir find date\",\"insulin resistance ir affect sustained virological response svr use insulin-sensitizing agent propose improve therapy outcome safety efficacy pioglitazone insulin sensitivity svr treatment-na\\u00efve patient chronic hepatitis c chc 4 ir receive standard antiviral therapy evaluate randomized-controlled study\",\"randomized multicenter trial evaluate individualization treatment duration peginterferon alfa-2a 180 microg/wk plus ribavirin 1000/1200 mg/day patient chronic hepatitis c 1/4 base rapidity virologic response vr\",\"promise result observe investigational drug class hepatitis c hcv specifically target antiviral therapy hepatitis c stat-cs combine peginterferon plus ribavirin peg-ifn/rbv class potential increase sustained virological response svr rate reduce therapy duration 1 chronic hcv patient compare peg-ifn/rbv remarkable sequence variation hcv result high viral replication rate intrinsically error-prone nature hcv polymerase variant reduce susceptibility stat-cs occur naturally treatment usually low level select patient respond potent stat-c treatment review describe resistance stat-c develop provide overview mutation confer vary level resistance stat-cs identify characterize use genotypic phenotypic tool discuss understanding selection variant reduce susceptibility treatment regiman important optimize use new class hcv therapy strategy optimize treatment regimen increase response rate minimize resistance discuss finally resistance consequence achieve svr initial regimen alternative treatment option patient achieve svr future future potential therapeutic strategy address patient develop resistance stat-cs discuss include combination therapy multiple stat-c non-overlapping resistance profile\",\"chronic hepatitis c virus chc infection treat interferon/ribavirin subset patient respond treatment nonresponder mark pretreatment up-regulation subset interferon stimulated gene isg liver include isg15 study nonresponder gene expression phenotype influence clinical factor uncover cellular basis phenotype isg15 protein expression\",\"study seek characterize relationship pharmacokinetic pharmacodynamic parameter virologic response hiv/hepatitis c virus genotype-1 co-infecte patient receive pegylated interferon-alpha-2b peg-ifn2b ribavirin try establish underlying mechanism lead poor sustained virologic responder rate observe african-americans caucasians compare result observe cohort hepatitis c virus mono-infected patient\",\"chronic hepatitis b virus hbv infection overall recognise 10 hiv+ person worldwide large difference accord geographical region chronic hepatitis c virus hcv infection affect 25 hiv+ individual great rate approximately 75 intravenous drug user person infect contaminate blood blood product hiv-hepatitis co-infecte individual accelerate course liver disease fast progression cirrhosis number anti-hbv drug increase year agent e.g. lamivudine emtricitabine tenofovir exert significant activity hiv emergence drug resistance challenge long-term benefit anti-hbv monotherapy mainly lamivudine result use new potent anti-hbv drug e.g. tenofovir promising prospect stopping revert hbv-related liver damage case respect chronic hepatitis c combination pegylated interferon plus ribavirin 1 year permit achieve sustained hcv clearance 40 hiv-hcv co-infecte patient new direct anti-hcv drug eagerly await population minority hiv+ patient delta hepatitis multiple hepatitis bad prognosis appropriate diagnosis monitoring chronic viral hepatitis include use non-invasive tool assess liver fibrosis measurement viral load allow confront adequately chronic viral hepatitis hiv+ patient prevent development end-stage liver disease option available liver transplantation article form special issue antiviral research mark 25th anniversary antiretroviral drug discovery development vol 85 issue 1 2010\",\"insulin resistance ir reduce response pegylated-interferon (peg-ifn)/ribavirin chronic hepatitis c chc mechanism undefined examine relationship baseline insulin level main component affect homeostasis model assessment insulin resistance homa-ir assessment ir non-diabetic patient acute virological response peg-ifn measure 24 h injection correlate intracellular interferon signalling 62 patient treat peg-ifn/ribavirin serum insulin homa-ir assess baseline hepatitis c virus (hcv)-rna measure baseline 24 h 1 2 4 12 week treatment initiation sustained virological response examine 24 week therapy discontinuation mean baseline insulin 11.52 /- 8.51 u/l mean homa-ir 2.65 /- 2.01 significantly high advanced liver fibrosis hepatitis c virus-rna decay observe 24 h injection peg-ifn significantly low 0.7 /- 0.8 log patient homa =3 compare homa <3 1.7 /- 0.8 p 0.001 highly significant r -0.42 inverse correlation observe baseline insulin level 24-h hcv-rna decay difference early viral kinetic patient homa =3 <3 result significant difference percentage patient achieve rapid week 4 sustained virological response multivariate analysis inclusive patient age hcv fibrosis stage identify baseline insulin level main independent variable affect 24-h response peg-ifn hyperinsulinaemia reduce cellular response pegylated-interferon chc ir strategy reduce insulin level initiation treatment pursue improve efficacy anti-viral treatment\",\"chronic hepatitis c virus hcv infection global health problem 170 million people infect worldwide current therapy pegylated interferon peg-ifn plus ribavirin rbv provide approximately 40 sustain virological response undetectable hcv rna great 24 week cessation therapy 1-infected individual addition limited sustained virological response peg-ifn/rbv treatment associate adverse effect nucleoside long cornerstone antiviral therapy prove efficacy high barrier resistance use surrogate virus hcv subgenomic replicon class nucleoside analog monophosphate prodrug identify inhibit hcv rna replication nucleoside analog possess 2\\u00b4-c-methyl modification vary ability phosphorylate act alternative substrate inhibitor hcv rna polymerase discuss class nucleoside inhibitor focus available structure-activity relationship mode action resistance profile\",\"killer immunoglobulin-like receptor kir express natural killer natural killer t cell involve activation cell influence antiviral immunity liver study investigate association kir genetic diversity sustained virologic response svr peginterferon ribavirin peg/rbv therapy liver transplant lt recipient hepatitis c virus hcv recurrence test kir 44 hcv-infected lt recipient treat peg/rbv 48 week patient categorize kir a/a b/x analyze association svr 44 34 patient svr 2 18 11 lack kir2ds2/kir2dl2 achieve svr compare 13 26 50 carry gene odd ratio 8.0 95 confidence interval 1.5 42.0 p 0.008 association lack kir2ds2/kir2dl2 svr remain significant exclusion 10 patient non-genotype 1 hcv correlation find activating inhibitory kir gene absence kir2ds2 and/or kir2dl2 associate failure peg/rbv therapy patient recurrent hcv lt finding support role natural killer natural killer t cell hcv clearance lt generalizable treatment hcv infection outside setting lt\",\"non-structural protein 5a ns5a hepatitis c virus hcv mutation interferon sensitivity-determining region isdr pkr-binding domain pkr-bd variable region 3 v3 interferon/ribavirin resistance-determining region irrdr correlate ifn-based therapy response tunisia high prevalence hcv-1b find datum regard implication ns5a treatment response available current study examine relationship pre-treatment mutation number isdr pkr-bd v3 irrdr entire isdr-v3 region ns5a aa 2209 2379 response 48-week course combined ifn plus ribavirin therapy 15 hcv-1b-infected tunisian patient refer hcv-j sequence significant high genetic variability observe pkr-bd sustained virological responder patient compare non-responder p 0.040 importantly consider entire region isdr v3 refer ns5a(isdr-v3 clear difference mutation number observe sustained virological responder 19.6 /- 3.16 non-responder 15.0 /- 1.41 p 0.002 additionally detailed analysis ns5a(isdr-v3 region reveal elevated degree mutation rate region located amino acid 2282 2308 p 0.0006 interestingly analysis specific amino acid variation define proline serine position 2300 signature pattern sensitive resistant strain respectively genetic variability ns5a region hcv-1b strain associate response combined ifn plus ribavirin therapy tunisian cohort\",\"patient chronic hepatitis c virus hcv infection frequently treat combination pegylated interferon peginterferon ribavirin study compare efficacy safety peginterferon alfa-2a peginterferon alfa-2b combination ribavirin\",\"insulin resistance affect sustained virological response svr chronic hepatitis c. know add metformin standard antiviral treatment improve svr conduct prospective multicentere randomize double-blinded placebo-controlled trial 19 spanish hospital include 123 consecutive patient 1 chronic hepatitis c insulin resistance patient randomize receive metformin arm n 59 placebo arm b n 64 addition peginterferon alfa-2a 180 microg/week ribavirin 1000 1200 mg/day primary end point svr secondary endpoint viral clearance week 12 24 48 change homeostasis model assessment homa index 24 week difference arm baseline intent-to-treat analysis svr observe 53 versus 42 arm arm b respectively p ns subgroup analysis svr high female n 54 receive metformin arm 58 15/26 versus 29 8/28 arm b p 0.03 protocol analysis ppa n 101 svr 67 arm 49 arm b p 0.06 viral decline 12 week great female receive metformin -4.88 1.18 versus -4.0 1.44 p 0.021 difference male triple therapy tolerated diarrhea arm 34 versus 11 p 0.05\",\"viral hepatitis pose important problem child preschooler hepatitis virus hav infection frequently cause acute liver failure vaccinate toddler hav country high endemicity expect decrease mortality hav vaccine demonstrate efficacy comparable immunoglobulin post-exposure prophylaxis recently develop vaccine hepatitis e virus hev benefit fetal health pregnant woman prone acute liver failure result hev hepatitis b vaccine continue demonstrate value versatility prevent liver disease chronic infection undetectable level serum hbv dna complement e-seroconversion preferred outcome measure suppress viral load correlate long-term complication hbeag status taiwanese child low pretreatment hbv dna 2 x 10(8 copies/ml strongly predict response interferon-alpha future paediatric study incorporate hbv dna level rationale routine treatment immunotolerant hepatitis b childhood remain uncertain treatment chronic hepatitis b childhood require consideration risk benefit childhood hepatitis c virus hcv infection result mainly mother-to-infant transmission baby hcv-infected woman test serum hcv rna 1 month age negative confirmatory anti-hcv antibody testing perform 12 15 month age child chronic hepatitis c develop progressive fibrosis/cirrhosis particularly setting obesity insulin resistance treatment child chronically infect 2 3 highly successful combination therapy pegylated interferon-alpha ribavirin tolerated superior pegylated interferon-alpha\",\"aim study assess effect insulin resistance ir response hepatitis c virus hcv therapy hiv-hcv-coinfected patient\",\"combination therapy chronic hepatitis c associate depression lead bad treatment outcome objective study determine association patient characteristic depression treatment evaluate relationship depression treatment outcome\",\"boceprevir hepatitis c virus hcv nonstructural protein ns 3/4a protease inhibitor currently evaluate combination peginterferon alfa-2b ribavirin phase 3 study clinical resistance profile boceprevir characterize detail far ns3 protease domain viral rna clone hcv 1-infected patient n 22 mean number 47 clone sequence end treatment 400 mg boceprevir twice time daily 14 day genotypic phenotypic viral fitness analysis end treatment wild-type ns3 protease sequence observe mean frequency 85.9 remain isolate previously observe resistance mutation v36m/a t54a/s r155k/t a156s v170a mutation v55a unknown resistance boceprevir detect combination phenotypic analysis hcv replicon assay low v36 g t54s r155l 3.8- 5.5-fold 50 inhibitory concentration ic(50 medium v55a r155 k v170a t54a a156s 6.8- 17.7-fold ic(50 high level a156 t 120-fold ic(50 resistance boceprevir overall frequency resistant mutation level resistance increase great decline mean maximum hcv rna level week end treatment frequency resistant variant decline number wild-type isolate increase 95.5 exception v36 v170 variant resistant mutation decline 50 mathematical modeling reveal impaired replicative fitness single mutation combined mutation relative increase replication efficiency suggest\",\"high serum total cholesterol low-density lipoprotein ldl level demonstrate increase probability sustained viral response svr chronic hepatitis c. conversely insulin resistance reduce svr rate investigate influence baseline glucose lipid value outcome hepatitis c virus hcv treatment hiv-1 infected subject\",\"individualized treatment combination peg-interferon ribavirin patient hepatitis c virus hcv infection validate randomized control clinical trial usefulness real world unknown aim present study assess feasibility individualized treatment hcv patient compare standard therapy real-life clinical setting\",\"ribavirin rbv combine pegylated interferon pegifn alpha2a pegifnalpha2b standard care chronic hepatitis c virus hcv infection lack head-to-head study 2 pegifn directly compare endpoint study safety antiviral efficacy 2 regimen\",\"dramatic progress development less-toxic simple alternative current standard-of-care therapy chronic hepatitis c involve combination pegylated interferon peg-ifn ribavirin rbv accessible viral target identify licensure advanced clinical compound anticipate year highly replicative nature hcv infection couple error-prone viral rna synthesis considerable genome diversity pose extraordinary challenge drug development peg-ifn likely remain mainstay therapy foreseeable future time multiple direct-acting antiviral stat-c inhibitor available provide sufficiently high barrier resistance use combination\",\"hepatitis c virus hcv infect 3 world population treatment chronic hcv consist combination pegylated interferon-alpha peg-ifn-alpha ribavirin rbv identify genetic variant associate hcv treatment response conduct genome-wide association study sustained virological response svr peg-ifn-alpha/rbv combination therapy 293 australian individual 1 chronic hepatitis c validation independent replication cohort consist 555 individual report association svr gene region encode interleukin 28b il28b ifnlambda3 rs8099917 combined p 9.25 x 10(-9 1.98 95 ci 1.57 2.52 il28b contribute viral resistance know upregulate interferon rna virus infection datum suggest host genetic useful prediction drug response support investigation role il28b treatment hcv disease treat ifn-alpha\",\"increasingly clear tailored therapeutic approach patient hepatitis c virus infection need success rate difficult treat low-responsive hepatitis c virus patient completely satisfactory need optimise treatment duration intensity patient high likelihood response addition management special patient category originally exclude phase iii registration trial need critically re-evaluate article report recommendation treatment hepatitis c virus infection individual basis draft expert scientific society\",\"hepatitis c virus hcv major cause chronic liver disease infect 170 million people worldwide hcv produce wide gamut manifestation vary mild self-limiting disease cirrhosis hepatocellular carcinoma variety viral environmental host genetic factor contribute clinical spectrum patient infect hcv influence response interferon ifn therapy predict probable outcome treatment patient hcv infection challenging task treatment hcv pegylated interferon peg-ifn plus ribavirin eradicate virus approximately 60 patient hcv 1 42 51 response rate 2 3 76 84 response rate significant number patient respond therapy relapse follow discontinuation treatment significant effect preclude treatment accurately predict patient respond therapy increasingly important point patient care respect healthcare cost clinician need continue treatment patient respond stop treatment patient unlikely respond viral rna measurement genotyping use optimize treatment low viral load nongenotype 1 likely associate sustained virological response svr rapid virological response rvr define undetectable hcv rna 4 week treatment increasingly recognize powerful tool predict treatment response variety host factor include single nuclear polymorphism snp ifn response gene insulin resistance obesity ethnicity human leukocyte antigen difference t-cell immune response find modulate response antiviral treatment presence severe fibrosis/cirrhosis pretreatment liver biopsy predict poor response treatment recent study gene expression profiling characterization liver serum proteome provide option accurately predict outcome patient infect hcv future future study factor predict treatment response tailor treatment base require conquer disease\",\"rapid decline hepatitis c virus rna crucial determine outcome therapy patient 1 chronic hepatitis c. variable influence early phase viral decay largely unexplored aim assess pre-treatment variable predict rapid virologic response rvr sustained virologic response svr\",\"hepatitis c virus hcv quasispecie diversity likely affect early viral decline treatment hepatitis c human immunodeficiency virus hiv infection evaluate influence hcv therapy change nonstructural 5a ns5a protein\",\"hepatitis c virus hcv 4 hcv-4 increase prevalence western country little know severity disease response treatment aim study assess predictor logistic regression severe fibrosis metavir score f3-f4 sustained virological response svr peginterferon ribavirin 226 consecutive hcv-4 patient egyptian 40 europeans 35 africans 24\",\"patient chronically infect hepatitis c virus hcv require significantly different duration therapy achieve substantially different sustained virologic response rate interferon-based therapy depend hcv infect currently exist systematic framework explain genotype-specific response rate human know natural host hcv-a virus year old-one possibility time frame relationship hcv accumulate adaptive mutation confer increase resistance human immune system interferon therapy function trigger immune response hypothesize clinical response rate reflection viral evolutionary adaptation immune system\",\"investigate evolution hepatitis c viral hcv genome small number patient experience viral breakthrough shed light problem resistance interferon therapy hcv genome sequence diversity viral nonstructural 5a protein-coding region ns5a link interferon responsiveness analyse temporal sequence change ns5a 1a patient 6 breakthrough bt 12 sustain virologic responder svr 12 non-responder nr receive dose peg-interferon ribavirin therapy entire ns5a region amplify reverse transcription (rt)-pcr follow direct sequencing serum sample baseline on-treatment time point group compare baseline sequence week 12 later time point bt patient resemble svr patient high number amino acid substitution week 12 nr patient number amino acid substitution group decrease bt substitution focus v3 flanking region bt patient svr patient high number substitution ns5a bt svr group suggest selective pressure associate viral response therapy result provide evidence amino acid substitution ns5a coding region reflect host response drive selective pressure viral adaptation\",\"report long-term followup cohort patient hepatitis c virus (hcv)-related vasculitis treat rituximab pegylated interferon alfa-2b peg-ifn alfa-2b plus ribavirin\",\"chronic hepatitis c virus hcv infection affect approximately 4 million person major indication liver transplantation united states current standard treatment hcv pegylated interferon combination ribavirin despite significant advance treatment approximately 50 patient treat patient clear hcv infection polymerase inhibitor potent antiviral effect represent major contribution future hcv treatment new drug role treatment difficult patient non-responder co-infecte hiv decompensated liver disease liver transplant recipient remain determine\",\"standard therapy pegylated interferon ribavirin chronic hepatitis c effective 40 50 individual 1 hepatitis c virus hcv infection associate significant treatment-related toxicity newly develop small molecule target key enzyme essential hcv replication development telaprevir peptidomimetic inhibitor hcv ns3/4a protease great promise early trial currently advanced stage clinical development treatment-na\\u00efve patient previous treatment failure addition telaprevir standard interferon ribavirin therapy tolerated enhance rate sustained virologic response shorten treatment duration report current experience use telaprevir treat chronic hcv infection monotherapy combination agent review\",\"hepatitis c virus hcv major cause chronic liver disease lead death liver failure hepatocellular carcinoma hepatitis c common indication liver transplantation worldwide major cause increase incidence hepatocellular cancer united states current paradigm hcv treatment rely pegylated interferon ribavirin agent enhance endogenous mechanism viral clearance dependent host factor patient 1 hcv infection sustained viral response svr rate remain suboptimal half 1-infected individual achieve svr lead shift investigational focus treatment hcv specifically target antiviral therapy hcv agent review focus boceprevir protease inhibitor discuss mechanism action effect hcv viral resistance\",\"current standard care treatment hepatitis c pegylated interferon ribavirin despite large number new oral agent development interferon likely remain backbone future therapy interferon unique antiviral immunomodulatory property critical limit resistance protease inhibitor improve efficacy optimize pharmacokinetic promote adherence interferon dosing regimen critical new regimen enter clinical arena review highlight novel interferon development offer therapeutic advantage formulation currently available\",\"suppressor cytokine signaling 3 socs3 suppress janus kinase (jak)-signal transducer activator transcription stat signaling block ifn-induced protein study relationship socs3 phosphorylation stat1 liver outcome interferon therapy examine\",\"recurring emergence influenza virus strain resistant available antiviral medication global health concern especially light potential new influenza virus pandemic currently circulate strain influenza virus united states resistant major class anti-influenza drug adamantane neuraminidase inhibitor new therapeutic approach rapidly deploy address issue recurring resistance develop test double triple combination approve anti-influenza drug oseltamivir amantadine ribavirin influenza virus strain use cytopathic effect inhibition assay mdck cell select a/new caledonia/20/99 h1n1 a/sydney/05/97 h3n2 representative wild-type version predominant circulate seasonal influenza virus strain a/duck/mn/1525/81 h5n1 representative avian influenza virus strain dose-response curve generate drug combination degree drug interaction quantify use model calculate synergy antagonism drug double triple combination report demonstrate triple combination antiviral highly synergistic influenza virus importantly synergy triple combination 2- 13-fold great synergy double combination depend influenza virus datum support investigation novel combination oseltamivir amantadine ribavirin effective treatment seasonal pandemic influenza virus allow efficient use exist drug supply\",\"study evaluate pharmacologic cost hepatitis c treatment consider recommendation duration therapy sustained virological response aim analyze relevant scientific article publish previous 10 year consider common present spain analysis estimate overall cost 1,636,524.58 1,761,365.73 euro 1,794.586.39 1,917,013.73 euro use pegylated interferon (pegifn)-alpha-2a pegifn-alpha-2b respectively sustained virological response 59.18 64.58 respectively significant difference formulation finally assess economic cost use high-dose pegifn-alpha-2a ribavirin patient 1 treatment resistance baseline hcv-rna value 800.000ui/ml early viral response 12 week weight 85 kg\",\"analysis hepatitis c virus hcv rna kinetic antiviral therapy allow estimation probability response\",\"despite improvement treatment hcv infection half patient cure standard combination therapy pegylated interferon alpha ribavirin hcv life cycle offer number potential target molecular therapy specifically target antiviral therapy hcv stat-cs preclinical clinical stage development evidence date suggest monotherapy antiviral drug unlikely eradicate hcv infection combination therapy interferon ribavirin necessary augmentation antiviral drug activity and/or prevention drug resistance result clinical trial carry past year stat-c agent combination standard therapy peginterferon ribavirin provide great promise high rate sustained virological response potentially short duration therapy standard therapy achieve pegylated interferon ribavirin likely remain cornerstone therapeutic regimen short term combination antiviral drug different class possibly novel agent target host factor modulate viral replication augment antiviral defense offer eventual possibility interferon-free regimen\",\"treatment chronic hepatitis c currently base combination pegylated interferon-o ribavirin drug exert direct selective pressure viral function mean interferon-a/ribavirin treatment failure selection interferon-a- ribavirin-resistant viral variant novel antiviral approach currently preclinical clinical development target viral enzyme function hepatitis c virus protease polymerase new drug potentially select resistant viral variant vitro vivo resistance likely important issue clinical practice\",\"hepatitis c virus hcv infection represent global health problem evolution hepatic cirrhosis hepatocellular carcinoma viral pathogenesis infectious process fully understand development natural viral resistance host immune system represent mayor challenge design alternative therapeutic intervention development viral vaccine molecular mechanism hepatic fibrosis describe new alternative treatment patient hcv infection hepatic cirrhosis intensive research new drug viral protease inhibitor assembly inhibitor immune modulator study clinical trial additional alternative include antifibrotic drug reverse hepatic cellular damage cause hcv infection review reference viral infective mechanism molecular pathway liver fibrosis overviews conventional new treatment hcv infection liver fibrosis\",\"discovery hepatitis b virus 1968 hepatitis virus 1973 year need identify hepatitis c virus hcv 1989 discovery hcv revolution hepatology magnitude global burden related hcv infection major cause cirrhosis hepatocellular carcinoma therapy hepatitis c rapidly evolve currently nearly 60 sustained virological response combination pegylated interferon plus ribavirin patient sustained virological response viral eradication correspond cure infection regression histological liver lesion demonstrate recently availability vitro culture system allow characterize viral enzyme potential therapeutic target novel therapeutic era open protease polymerase inhibitor use step association pegylated interferon ribavirin increase efficacy decrease risk resistance thank new molecule potent antiviral activity reasonably predict rapid improvement treatment efficient tolerate progressive replacement interferon ribavirin combination virus specific enzyme inhibitor\",\"recommend therapy chronic hepatitis c pegylated interferon ribavirin 24 48 week known adverse effect aim study evaluate impact antiviral therapy male sexual health\",\"chronic hepatitis c chc 1b patient high viral load resistant peginterferon peg-ifn ribavirin rbv combination therapy especially old female patient\",\"49-year-old white man present primary-care clinic fatigue poor concentration enlarge liver minimally tender edge subsequently refer liver clinic\",\"approximately 3 worldwide population i.e. 170 million people chronically infect hepatitis c virus hcv estimate 20 patient develop liver cirrhosis mean 20 year 2 5 cirrhotic patient die end-stage liver disease hepatocellular carcinoma currently approve antiviral therapy pegylated interferon pegifn ribavirin induce sustained virological response svr 40 50 patient infect 1 prevalent hcv type review focus development clinical application serine protease inhibitor anti-hcv agent highly active induce significant decline serum hcv rna rapid development resistance counteract combination antiviral agent currently pegifn-alpha ribavirin serine protease inhibitor reach clinical phase iii trial increase svr rate shortening treatment duration combine pegifn ribavirin trial interferon-free target combination therapy currently underway\",\"hepatitis c virus hcv major health problem worldwide infect estimate 170 million people study employ large datum set sequence 14,654 sequence 25 100 clone sequence analyze region patient 67 patient infect hcv 1 23 1a 44 1b patient sample prior combined therapy alpha interferon plus ribavirin available patient additional sample 6 12 month treatment available twenty-seven patient respond treatment 12 1a 15 1b patient respond treatment 11 1a vs. 29 1b region hcv genome analyze compress hypervariable region hvr1 hvr2 hvr3 envelope 2 glycoprotein include interferon sensitive determine region isdr v3 domain ns5a protein previously cuevas j.m. torres-puente m. jim\\u00e9nez-hern\\u00e1ndez n. bracho m.a. garc\\u00eda-robles i. wrobel b. carnicer f. del olmo j. ortega e. moya a. gonz\\u00e1lez-candelas f. 2008b genetic variability hepatitis c virus combined therapy interferon plus ribavirin plos 3 8) e3058 amino acid position region analyze detect positive selection compare amino acid composition positively select position responder non-responder patient exclude non-conclusive case clear difference detect case conclusion identify specific position completely discriminatory treatment response difficult task result concordance previous study suggest hcv evasion strategy likely base global increase variability yield combination mutation increase resistance fixation specific amino acid confer resistance antiviral treatment immune response sense particular systemic response patient play essential role determine outcome antiviral treatment\",\"cyclic periodic ifn treatment cpit consist induction treatment nifn-beta follow maintenance treatment ifn-alpha prevent viral breakthrough achieve rapid virological response rvr early virological response evr chronic hepatitis c chc efficacy immune response rbv+peg-ifn-alpha2b use induction approach cpit novel combination treatment nct 7 chc patient 1b high viral load evaluate biometric multiplex serum cytokine assay utilize characterize immunomodulatory effect rvr evr 7/7 7/7 respectively viral titer drop detectable level patient sustained virological response svr end cpit early virological responder eavr patient svr end cpit late virological responder lavr baseline eavr compare control il-6 il-15 cxcl-8 cxcl-10 level significantly high p 0.05 il-10 il-13 level significantly low p 0.05 il-12 level low lavr gm-csf cxcl-8 cxcl-10 ccl-4 level significantly high p 0.05 il-10 il-12 low control eavr lavr il-12 increase ccxl-8 decrease significantly p 0.05 conclusion nct-induced viral clearance lead improvement innate immune response result svr chc 1b high viral load\",\"lethal mutagenesis virus extinction promote mutagen-induced elevation mutation rate virus meet problem selection mutagen-resistant variant extensively document standard non-mutagenic antiviral inhibitor previously characterize mutant foot-and-mouth disease virus include rna-dependent rna polymerase replacement m296i decrease sensitivity virus mutagenic nucleoside analogue ribavirin\",\"inosine monophosphate dehydrogenase impdh pivotal enzyme biosynthesis guanosine tri-phosphate gtp frequently increase tumor cell anti-viral agent ribavirin immunosuppressant mycophenolic acid mpa potent inhibitor impdh recently impdh inhibition lead necrotic signal require activation cdc42\",\"half population 1 hcv resistant current pegylated-interferon-alpha peg-ifn-alpha ribavirin therapy resistance ifn therapy urgent problem especially patient 1 hcv infection sensitivity hcv strain anti-hcv reagent include ifn thoroughly address establish different subgenomic replicon 1b-4 1b-5 kah5 strain addition previously establish replicon o strain comparatively examine sensitivity replicon ifn-alpha ifn-gamma ifn-lambda cyclosporine fluvastatin replicon 1b-4 kah5 replicon sensitive resistant respectively ifn-lambda ec(50 ): 1.50 ng/ml vs. 8.50 ng/ml fluvastatin ec(50 ): 2.82 microm vs. 7.87 microm replicon possess similar feature term genetic distance o strain hcv rna expression level sensitivity ifn-alpha ec(50 ): 1.44 iu/ml vs. 1.37 iu/ml cyclosporine ec(50 ): 0.71 microg/ml vs. 0.96 microg/ml replicon useful tool examine mechanism anti-hcv activity especially ifn-lambda statin\",\"increase worldwide burden liver failure liver cancer chronic hepatitis c virus hcv infection discovery development effort new antiviral medicine hcv expand rapidly hcv protease inhibitor pi telaprevir vx950 boceprevir sch503034 furthest clinical development phase ii datum suggest potential treatment advance triple combination regimen comprise protease inhibitor pegylated interferon ribavirin current datum suggest regimen fail produce sustained virologic response 30 40 patient tolerance interferon/ribavirin treatment regimen problematic need continued development new anti-hcv agent far optimize treatment efficacy safety hcv polymerase hcv pol attractive target antiviral therapy gene sequence encode hcv pol relatively conserve main hcv emergence viral resistance expect relatively slow pharmaceutical agent nucleoside analogue target active catalytic site hcv pol\",\"treatment hepatitis c virus hcv infection pegylated interferon/ribavirin achieve sustained virological response 56 hcv mono-infected patient 40 hcv/human immunodeficiency virus (hiv)-co-infected patient relationship patient adherence outcome warrant study\",\"present review concise review recent development field viral hepatitis base publication december 2007 november 2008\",\"previous study provide direct experimental evidence contribution hcv core protein development insulin resistance ir clinical impact hcv core region ir clear present study evaluate impact amino acid aa substitution hcv-1b core region ir 123 japanese patient infect hcv-1b cirrhosis diabetes mellitus investigate treatment efficacy 48-week pegylated interferon peg-ifn plus ribavirin rbv accord homa-ir value patient ir homa-ir 2.5 severe ir homa-ir 3.5 present 51.2 27.6 respectively multivariate analysis identify body mass index 25 kg/m(2 hepatocyte steatosis 5 significant determinant ir furthermore multivariate analysis identify hepatocyte steatosis 5 aa substitution core region gln70 his70 and/or met91 age 55 year significant determinant severe ir especially significantly low proportion patient gln70 his70 and/or met91 note severe ir 59.6 severe ir 82.4 rate sustained virological response patient ir 50.0 significantly different ir 52.9 furthermore rate non-virological response patient ir 28.9 significantly different ir 20.6 conclusion present study indicate substitution hcv-1b core region important predictor severe ir patient cirrhosis diabetes mellitus homa-ir value useful predictor 48-week peg-ifn plus rbv therapy\",\"hepatitis c virus hcv infection major cause chronic liver disease lead hepatocellular carcinoma end-stage liver disease current fda-approved treatment hcv pegylated interferon-alpha ifnalpha ribavirin effective 50 patient epidemiological evidence suggest obesity alcohol smoking environmental pollutant contribute resistance ifnalpha therapy hcv acrolein ubiquitous environmental pollutant major component cigarette smoke generate endogenously cellular metabolism lipid peroxidation study examine effect acrolein ifnalpha-mediated signaling antiviral gene expression culture primary human hepatocyte ii hcv replication hcv-replicon system datum demonstrate nontoxic concentration acrolein significantly inhibit ifnalpha-induced tyrosine phosphorylation cytoplasmic nuclear stat1 stat2 alter total level acrolein down-regulate ifnalpha-stimulated gene transcription result reduce expression antiviral gene importantly acrolein abolish ifnalpha-mediated down-regulation hcv viral expression hcv-replicon system study define mechanism involve resistance ifnalpha identify pathogenic role acrolein potentially environmental pollutant suppress ifnalpha antiviral activity establish adverse impact hcv therapy\",\"albinterferon-alpha-2b albifn long-acting fusion polypeptide compose albumin ifn-alpha-2b phase 2 study albifn 1500 mug q2wk q4wk patient 2/3 chronic hepatitis c albifn demonstrate sustained virological response svr rate 62 77 intent-to-treat population\",\"early change hepatitis c virus hcv rna level assess large cohort african american white patient chronic hepatitis c hcv 1 undergo therapy peginterferon alfa-2a ribavirin study viral resistance antiviral therapy hepatitis c virahep-c analysis restricted 341 patient complete 28 day therapy dose modification hcv rna level decrease patient change vary markedly overall 28-day decrease hcv rna level predictive sustained virological response first- second-phase viral kinetic response factor associate small decrease hcv rna level baseline day 28 include african american race high initial hcv rna level severe hepatic fibrosis high body weight african american patient similar 28-day decrease viral level white patient likely achieve sustained virological response result suggest racial difference response antiviral therapy great unresponsiveness intracellular action interferon african american individual standard dose peginterferon ribavirin suboptimal patient high body weight trial registration clinicaltrials.gov identifier nct00038974\",\"amantadine-resistant influenza a/duck/mn/1525/81 h5n1 virus develop low-pathogenic north american wild-type amantadine-sensitive virus study treatment infection cell culture mouse double combination amantadine oseltamivir cell culture-active form oseltamivir carboxylate ribavirin use amantadine-oseltamivir carboxylate amantadine-ribavirin combination synergistic interaction range dose wild-type virus madin-darby canine kidney mdck cell culture oseltamivir carboxylate-ribavirin combination primarily additive interaction oseltamivir carboxylate-ribavirin combination amantadine-resistant virus presence amantadine drug combination resistant virus improve activity wild-type amantadine-resistant virus lethal mouse intranasal instillation resistant virus infection treat amantadine 100 mg/kg body weight/day wild-type virus infection treatable oral dose 10 weakly effective 100 mg/kg/day administer twice day 5 day start 4 h prior virus exposure drug combination study treatment amantadine-resistant virus infection amantadine-oseltamivir amantadine-ribavirin combination significantly use oseltamivir ribavirin contrast oseltamivir-ribavirin 25- 75-mg/kg/day combination treatment produce significant reduction mortality wild-type virus infection markedly reduce severity combination amantadine 10 mg/kg/day combine compound 20 40 mg/kg/day compare monotherapy compound result indicate lack benefit amantadine combination amantadine-resistant virus positive benefit combination amantadine-sensitive virus\",\"signal transducer activator transcription stat play critical role antiviral defense understand pegylated interferon (ifn)-alpha ribavirin combination therapy resistance examine stat expression liver\",\"treatment hepatitis c virus infection currently consist pegylated interferon ribavirin rbv nucleoside analog rbv clearly play role aid treatment response antiviral mechanism unclear regardless specific mechanism rbv hypothesize difference level cellular uptake rbv affect antiviral efficacy treatment success cell rbv resistant reduce uptake monitor rbv uptake cell line determine effect uptake capacity viral replication rbv-resistant cell demonstrate reduce rbv uptake increase growth model rna virus presence rbv overexpression equilibrative nucleoside transporter 1 ent1 concentrative nucleoside transporter 3 cnt3 increase rbv uptake rbv-sensitive cell line restore uptake defect rbv-resistant cell line cnt3 express huh-7 liver cell inhibition concentrative transport affect rbv uptake block equilibrative transport use inhibitor nitrobenzylmercaptopurine riboside recapitulate rbv-resistant phenotype rbv-sensitive cell line reduction rbv uptake increase growth result indicate rbv uptake restricted primarily ent1 cell line examine interestingly rbv-resistant cell line compensate reduce ent1-mediated nucleoside uptake increase activity alternative nucleoside transporter ent2 possible rbv uptake affect antiviral treatment response natural difference patient acquire resistance\",\"debio 025 cyclophilin cyp inhibitor calcineurin-binding property drug inhibit viral replication 1b 2a replicon nanomolar concentration additive synergistic antiviral effect interferon ribavirin specifically target antiviral therapy hepatitis c stat-c drug cross-resistance protease polymerase inhibitor human debio 025 activity 1 2 3 4 display additive antiviral effect pegylated interferon (peg-ifn)alpha2a 1 4 patient prominent effect reversible hyperbilirubinaemia cause inhibition biliary transporter debio 025 potent anti-hcv drug novel mechanism action efficacy profile attractive candidate combination current future hcv treatment\",\"hepatitis c virus hcv present region involve potentially evade antiviral treatment host immune system region know pkr-bd v3 domain propose involve resistance interferon additionally hypervariable region envelope e2 glycoprotein good candidate participate evasion immune system study use cohort 22 non-responder patient combined therapy interferon alpha-2a plus ribavirin sample obtain initiation therapy 6 or/and 12 month treatment available range 25 100 clone patient genome region time sample obtain predominant amino acid sequence time sample patient determine sequence pkr-bd v3 domain hypervariable region different time sample compare patient high level variability detect hypervariable region e2 protein low extent v3 domain ns5a protein clear pattern adaptation host immune system antiviral treatment detect summary high level variability correlate viral adaptive response antiviral treatment promote convergent adaptive change consequently region involve evasion strategy likely base combination multiple mechanism pool change hcv genome confer virus ability overcome strong selective pressure\",\"insulin resistance ir associate hepatitis c virus hcv infection study aim elucidate impact ir beta-cell function response peginterferon-alpha (peg-ifn)/ribavirin combination therapy chronic hepatitis c chc patient\",\"evaluate possible influence baseline insulin resistance sustained virological response\",\"natural history chronic hepatitis c define retrospective prospective study conduct 20 year study clearly demonstrate outcome chronic hepatitis c virus infection profoundly influence variety cofactor comorbiditie cofactor affect course liver disease hepatitis c significant influence result antiviral therapy unfortunately comorbiditie negatively influence course outcome liver disease reduce chance achieve sustained virological response pegylated interferon peg-ifn ribavirin treatment important frequent comorbidity influence course chronic hepatitis c response antiviral therapy represent metabolic syndrome associate state insulin resistance comorbiditie negative influence progression hepatitis c response antiviral therapy include excess alcohol intake human immunodeficiency virus hepatitis b virus co-infection number condition reduce benefit therapy affect negatively compliance and/or adherence adequate peg-ifn ribavirin dose\",\"hepatitis c virus hcv infection remain health problem worldwide current standard treatment hcv infection pegylated interferon-alpha plus ribavirin clearly sufficiently effective tolerable\",\"specifically target antiviral therapy hepatitis c virus stat-c stand new era treatment patient chronic hepatitis c. result recent trial protease polymerase inhibitor indicate therapy single hcv specific compound sufficient eradicate hepatitis c virus infection combination therapy necessary improve sustained virologic response rate search optimal combination stat-c compound peginterferon alfa ribavirin currently investigation clinical trial overall current study indicate peginterferon alfa ribavirin remain backbone antiviral therapy chronic hepatitis c era stat-c. anticipate combination stat-c compound non-overlapping resistance profile improve response antiviral therapy promise combination protease inhibitor plus nucleoside analogue non-nucleoside analogue polymerase inhibitor\",\"insulin resistance candidate predictive factor virological response peginterferon plus ribavirin peg/rbv therapy chronic hepatitis c patient examine index insulin resistance serve predictor sustained virological response svr fifty-one patient 1b high viral load receive peg/rbv therapy 48 week include homeostasis model assessment insulin resistance homa-ir whole-body insulin sensitivity index wbisi calculate 75-g oral glucose tolerance test serum level soluble tumor necrosis factor receptor 2 stfnr2 evaluate therapy patient achieve svr significantly low homa-ir stnfr2 level high wbisi compare non-svr patient positive predictive value svr 0.653 homa-ir 2 0.846 wbisi 6 high wbisi serve highly specific predictor svr peg/rbv therapy\",\"need effective treatment chronic hepatitis c infection drive development novel antiviral agent target specific step viral replication cycle\",\"hepatitis c virus hcv infection major grow global health problem affect 170 million people worldwide leading cause liver cirrhosis hepatocellular carcinoma currently treatment restricted interferon alfa ribavirin lead successful outcome 50 individual new effective treatment tolerable side-effect profile need urgently development hinder inability culture hcv scarcity animal model review progress hcv biology include cell culture new animal model contribution work understanding virus life-cycle pathogenesis development specifically target antiviral treatment discuss change understanding hcv epidemiology clinical manifestation diagnostic\",\"insulin resistance promote hepatic fibrosis chronic hepatitis c hcv emerge cofactor failure achieve sustained viral response svr\",\"influenza pneumonia cause high mortality year pandemic episode kill million people influenza-related mortality variously ascribe ineffective host response fail limit viral replication excessive host inflammatory response result lung injury impairment gas exchange bacterial superinfection seek determine lung inflammation promote impaired host survival influenza pneumonia\",\"chronic hepatitis c virus hcv infection remain global health threat approximately 175 million carrier worldwide currently treatment consist pegylated interferon alpha plus ribavirin 12 72 week depend hcv baseline viral load initial virological response therapy adverse effect limited sustained virological response therapy warrant need novel hcv therapy specifically target antiviral therapy design inhibit hcv serine protease rna-dependent rna polymerase recently enter clinical development main characteristic new antiviral agent important challenge arise use -- toxicity rapid selection resistance -- discuss\",\"hepatitis c virus hcv common rna virus cause hepatitis liver cancer infection treat ifn-alpha ribavirin expensive physically demand therapy fail half patient genomic sequence independent hcv isolate differ approximately 10 effect variation response therapy unknown address question analyze amino acid covariance viral coding region pretherapy hcv sequence 94 participant viral resistance antiviral therapy chronic hepatitis c virahep-c clinical study covarying position common link network differ response therapy 3-fold hydrophobic amino acid pair hcv nonresponde patient hydrophobic interaction predict contribute failure therapy stabilize viral protein complex use analysis detect pattern network predict outcome therapy great 95 coverage 100 accuracy raise possibility prognostic test reduce therapeutic failure furthermore hub position network attractive antiviral target genetic linkage position predict suppress evolution resistant variant finally covariance network analysis applicable virus sufficient genetic variation include human rna virus\",\"debio 025 potent inhibitor hepatitis c virus hcv replication j. paeshuyse hepatology 43:761 770 2006 phase clinical study monotherapy debio 025 dose 1,200 mg twice day result mean maximal decrease viral load 3.6 log(10 unit r. flisiak hepatology 47:817 826 2008 reduction 4.6 log(10 unit obtain phase ii study debio 025 combine interferon r. flisiak j. hepatol 48:s62 2008 report particular characteristic vitro anti-hcv activity debio 025 combination debio 025 ribavirin specifically target antiviral therapy hcv stat-c inhibitor ns3 protease ns5b nucleoside nonnucleoside polymerase inhibitor result additive antiviral activity short-term antiviral assay debio 025 unique ability clear hepatoma cell hcv replicon use combination interferon stat-c inhibitor debio 025 use concentration observe human plasma 0.1 0.5 mum able delay prevent development resistance hcv protease inhibitor nucleoside nonnucleoside polymerase inhibitor debio 025 form attractive drug candidate treatment hcv infection combination standard interferon-based treatment treatment directly target hcv polymerase and/or protease\",\"hypokalaemic thyrotoxic periodic paralysis enigmatic uncommon condition occur exclusively male asian descent underlying cause thyrotoxicosis well-recognized etiology include toxic multinodular goiter graves disease iodine excess thyrotoxicosis number hormonal factor hypothesize contribute hypokalaemic thyrotoxic periodic paralysis particularly postprandial hyperinsulinaemia testosterone present case 48-year-old hepatitis c positive gender-assigned man factor propose interact lend support hypothesis patient present interferon-induced thyroiditis cause acute generalize weakness whilst undergo combination interferon-alpha-2beta ribavirin therapy hepatitis c infection marked insulin resistance hyperinsulinaemia present exacerbate paresis initial treatment beta-blocker fail normalize serum potassium concentration require novel use spironolactone despite euthyroidism continue require testosterone supplement dissipate\",\"hepatitis c virus hcv evolve remarkable mechanism favor viral persistence interfere host innate adaptive immune response mechanism likely contribute resistance exogenously administer interferon use hcv treatment review host innate adaptive immune response context hcv infection strategy response subvert virus addition contribution host factor race insulin resistance interferon non-responsiveness discuss progress understand molecular underpinning interferon treatment failure hcv infection result promising novel treatment strategy hcv treatment non-responder\",\"antiviral agent treatment influenza urgently need circumvent limitation current drug critical area high frequency resistance m2 inhibitor currently circulate strain variable frequency resistance oseltamivir a(h1n1 strain limited efficacy treatment treatment-emergent antiviral resistance case avian influenza a(h5n1 illness human lack parenteral agent seriously ill patient neuraminidase inhibitor nai zanamivir peramivir undergo undergo clinical trial use intravenous intramuscular administration long-acting nai designate cs-8958 study use inhalation advance understand mechanism involve influenza virus replication reveal number potential target exploit development new agent agent t-705 polymerase inhibitor das181 attachment inhibitor combination therapy currently available agent support datum animal model receive limited clinical study date\",\"majority patient chronic hepatitis c fail respond antiviral therapy genetic basis resistance unknown quasispecie nature hcv important implication concern viral persistence response therapy hcv nonstructural 5a ns5a protein controversially implicate inherent resistance hcv interferon ifn antiviral therapy evaluate ns5a quasispecie pre-treatment composition hcv 1a/1b related responsiveness combined pegylated interferon peg-ifn ribavirin therapy detailed analysis complete ns5a perform full-length ns5a clone sequence 11 pre-treatment sample patient infect 1 hcv 3 virological sustain responder 4 non-responder 4 end-of-treatment responder study significant correlation mean number mutation hcv ns5a treatment treatment outcome phylogenetic construction complete ns5a sequence obtain patient fail clustering associate specific response pattern single amino acid position associate different response therapy ns5a region analyze mutation cluster downstream isdr primarily v3 region observe crs nls region ns5a protein conflict variable analyze significant difference find region antagonistic function viable present different mutation profile compare treatment response patient sample present low genetic distance value present small number variant heterogeneous pattern end-of-treatment patient result suggest detailed molecular analysis ns5a region large sample size necessary understand role therapy outcome hcv 1a/1b infection\",\"hepatitis b virus hbv hepatitis c virus hcv infection major threat worldwide combination therapy interferon-alpha ribavirin currently treatment choice hcv-infected patient regimen effective approximately 50 patient provoke severe side-effect numerous natural alternative treat hcv suggest deoxynojirimycin derivative iminosugar exert anti-hcv activity inhibit alpha-glucosidase non-immunosuppressive derivate cyclosporine nim811 exert anti-hcv activity bind cyclophilin natural product promise anti-hcv activity 2-arylbenzofuran derivative mellein pseudoguaianolide hbv treatment drug available specifically target virus polymerase lamivudine entecavir telbivudine adefovir dipivoxil efficacy drug hamper development resistance point mutation hbv polymerase drug resistance adverse side-effect search novel drug mandatory wogonin ellagic acid artemisinin artesunate chrysophanol 8-o-beta-d-glucoside saikosaponin c protostane triterpene active hbv natural product need investigate detail explore potential novel adjunct established hbv hcv therapy\",\"importance metabolic disorder pathophysiology human immunodeficiency virus hiv hepatitis c virus hcv infection increasingly apparent metabolic anomaly potential multiple-organ involvement expect chronic nature disease intracellular dysregulation associate endocrine cytokine metabolic anomaly hiv hcv infection link metabolic syndrome appear pathway common study difference similarity metabolic anomaly add understanding hiv hcv infection provide guidance treat chronic disease review highlight principal underlie factor metabolic disorder chronic viral diseases-namely insulin resistance liver damage chronic viral state host immune response rise glucose lipid metabolic disorder turn risk factor hepatic damage interaction hiv and/or hcv insulin resistance type 2 diabete steatosis fibrogenesis consider determine treatment long-term follow-up patient recent datum indicate hcv clearance improve insulin resistance hepatic function hcv-infected patient treat interferon ribavirin\",\"resistance mutation hepatitis c virus hcv nonstructural protein 3 ns3 protease inhibitor 1 viral quasispecie allow 1000-fold viral load reduction treatment consistent report reduce replicative fitness vitro recently r155 k protease mutation report dominant quasispecie treatment-na\\u00efve individual raise concern possible drug resistance investigate prevalence dominant resistance mutation specifically target antiviral therapy hcv stat-c population analyze hcv genome sequence 507 treatment-na\\u00efve patient infect hcv 1 united states germany switzerland phylogenetic sequence analysis viral load datum use identify possible spread replication-competent drug-resistant viral strain population infer consequence mutation viral replication vivo mutation describe confer resistance protease inhibitor telaprevir biln2061 itmn-191 sch6 boceprevir ns5b polymerase inhibitor ag-021541 ns4a antagonist ach-806 observe sporadic unrelated case frequency 0.3 2.8 population include patient possible multidrug resistance collectively 8.6 patient infect 1a 1.4 infect 1b carry dominant resistance mutation viral load high majority patient suggest drug-resistant viral strain achieve replication level comparable nonresistant virus vivo\",\"interferon-alpha induce 2'-5'-oligoadenylate synthetase activate rnase l. viral rna cleave rnase l uu/ua dinucleotide clinical relevance rnase l cleavage response interferon-alpha-based therapy chronic hepatitis c unknown\",\"overweight/obesity independent negative predictive factor steatosis chronic hepatitis c virus infection nonresponse combined peginterferon ribavirin treatment infection cause 1 associate waist circumference body mass index bmi diabete steatosis degree fibrosis obesity independent negative predictive factor inefficacy antiviral treatment\",\"dynamic viral decline immediately start therapy chronic hepatitis c virus hcv infection prognostic potential ultimate sustained virologic response considerable interindividual variability decline report include difference race human major histocompatability complex mhc gene encode human leukocyte antigen important immune response viral infection examine carriage specific human mhc allele associate rate early viral decline longitudinal viral level datum baseline day 1 2 7 14 28 treatment medium resolution mhc genotyping random coefficient model use examine association mhc class class ii allele carriage dynamic viral decline 180 african-american aa 194 caucasian americans genotype-1 hcv infection 28 day treatment peginterferon alpha2a plus ribavirin baseline viral level similar race irrespective allele carriage rate change viral decline associate allele race subgroup define race specific allele fast rate decline observe term estimate mean viral decline log(10 iu/ml week noncarrier a*03 2.75 p 0.018 carrier cw*03 2.99 p 0.046 noncarrier dqa1 04 2.66 p 0.018 dqb1 0402 2.65 p 0.018 mhc allele associate viral decline 28 day peginterferon therapy\",\"chronic hepatitis c virus hcv infection pressing medical problem worldwide current therapy pegylated interferon plus ribavirin peg-ifn/rbv associate poor risk benefit profile long treatment duration 48 week inadequate success rate approximately 40 50 svr sustained viral response patient infect 1 hcv review focus recent clinical trial result specifically target antiviral therapy hcv stat-c protease polymerase inhibitor past decade anti-hcv drug discovery focus target host factor require viral replication second multiple hcv antiviral agent owe large number hcv inhibitor currently pre-clinical clinical development today focus advanced compound hcv polymerase hcv protease inhibitor class class compound use illustrate property associate inhibitor bind active site hcv polymerase active site hcv protease macrocyclic linear ketoamide inhibitor allosteric polymerase inhibitor\",\"emergence influenza strain resistant commonly use antiviral highlight need develop new compound target viral gene product host mechanism essential effective virus replication exist assay identify potential antiviral compound use high throughput screening assay target specific viral replication step broaden search antiviral cell-based replication assay perform labor intensive limit throughput\",\"oral silibinin sil widely use treatment hepatitis c efficacy unclear substantially high dose administer intravenously iv\",\"treatment predictor important tool management therapy patient chronic hepatitis b c virus hbv hcv infection chronic hepatitis b pretreatment parameter identify prediction virologic response interferon alfa-based antiviral therapy treatment polymerase inhibitor interferon alfa pegylated interferon alfa-treated patient low baseline hbv dna concentration hbv b high baseline alt level significantly associate treatment response patient treat nucleos(t)ide analogue low baseline hbv dna viral positively associate virologic response treatment good predictor response hbv dna kinetic early viral suppression associate favourable virologic response reduce risk subsequent resistance mutation current standard treatment pegylated interferon alfa ribavirin patient chronic hepatitis c infection hcv 2 3 baseline viral load 400,000 800,000 iu/ml asian caucasian ethnicity young age low ggt level absence advanced fibrosis/cirrhosis absence steatosis liver identify independent pretreatment predictor sustained virologic response initiation treatment initial viral decline undetectable hcv-rna week 4 therapy rvr good predictor sustained virologic response independent hcv\",\"nitazoxanide primary metabolite tizoxanide inhibit hepatitis c virus hcv replication hcv replicon system study potential resistance subject huh7 cell harbor hcv replicon serial passage 250 mum g418 increase concentration nitazoxanide tizoxanide passage replicon-containing cell line compound result increase 50 effective concentration ec(50)s 7- 13-fold ec(90)s 14- 36-fold 50 cytotoxic concentration 2- 4-fold compound serial passage compound alter susceptibility hcv replicon ribavirin 2'-c-methylcytidine interestingly serial passage nitazoxanide tizoxanide result increase sensitivity alpha interferon 2b ec(50)s ec(90)s reduce three- eightfold respectively replicon isolate cell line great ability confer tizoxanide resistance increase susceptibility alpha interferon replicon isolate parental cell line previously expose nitazoxanide tizoxanide finding indicative cell-mediated activity differ anti-hcv drug complementary interferon consistent enhance response rate observe clinically nitazoxanide combine pegylated interferon therapy finally unlike datum compound advanced clinical development hcv datum consistent resistance hcv replicon-containing cell line confer change host mutation virus\",\"patient chronic hepatitis c risk develop type 2 diabetes mellitus dm impaired fast glucose ifg risk increase hepatitis c virus hcv patient respond antiviral therapy\",\"cross-sectional study suggest insulin resistance strongly associate hepatic steatosis fibrosis patient chronic hepatitis c chc affect efficacy antiviral therapy aim investigate retrospectively impact insulin resistance treatment response chinese 1 chc patient receive 24-week course therapy peginterferon alpha-2b/ribavirin\",\"treatment peginterferon alpha ribavirin percentage non response relapse approximatively 33 18 respectively treatment failure viral resistance insufficient treatment prevention treatment failure base good knowledge predictive factor failure treatment patient respond interferon alpha ribavirin new treatment peginterferon alpha-2b ribavirin possible obtain 45 sustained virological response svr relapser 17 svr non responder patient respond peginterferon alpha ribavirin new treatment peginterferon alpha-2b ribavirin possible obtain 36 svr relapser 4 svr non responder new therapeutic strategy necessary non responder new therapeutic strategy allow significant benefit term svr protease inhibitor currently test non responder concern risk selection multi-resistant strain\",\"prevalence clinical implication naturally occur variant resistant hepatitis c virus hcv protease inhibitor treatment-naive patient report report prevalence variant effect clinical response\",\"insulin resistance extremely common frequently associate comorbid condition cardiovascular disease hypertension obesity infertility neurodegeneration addition insulin resistance driving force type 2 diabete mellitus interestingly co-existence insulin resistance chronic hepatitis c occur predict chance recent estimate indicate 30 70 patient chronic hepatitis c display evidence insulin resistance recent research reveal molecule include tumor necrosis factor alpha suppressor cytokine signaling 1 3 protein insulin-receptor substrate 1 2 adipocytokine potentially involve development insulin resistance patient chronic hepatitis c. unfortunately baseline insulin resistance negative impact treatment outcome patient chronic hepatitis c. successfully manage insulin resistance diabetes mellitus patient improve patient likelihood successful outcome antiviral therapy likewise eradication hepatitis c virus patient insulin resistance diabetes mellitus appear improve glucose metabolism adjunctive therapy insulin sensitizer weight loss recommend ability improve antiviral treatment response patient chronic hepatitis c unproven study way determine improve insulin sensitivity result outcome patient receive pegylated interferon alfa plus ribavirin therapy chronic hepatitis c.\",\"r1626 prodrug hepatitis c virus hcv rna polymerase inhibitor r1479 time-dependent dose-dependent reduction hcv rna level previous study present study evaluate efficacy safety r1626 administer 4 week combination peginterferon alfa-2a /- ribavirin hcv 1-infected treatment-naive patient patient randomize dual 1500 1500 mg r1626 twice daily bid peginterferon alfa-2a n 21 dual 3000 3000 mg r1626 bid peginterferon alfa-2a n 32 triple 1500 1500 mg r1626 bid peginterferon alfa-2a ribavirin n 31 standard care soc peginterferon alfa-2a ribavirin n 20 4 week hcv rna undetectable 15 iu/ml 29 69 74 patient dual 1500 dual 3000 triple 1500 arm respectively compare 5 patient receive soc respective mean reduction hcv rna baseline week 4 3.6 4.5 5.2 2.4 log(10 iu/ml. synergy observe r1626 peginterferon alfa-2a r1626 ribavirin evidence development viral resistance adverse event ae mainly mild moderate seven patient ae include patient ae soc incidence grade 4 neutropenia 48 78 39 10 dual 1500 dual 3000 triple 1500 soc respectively main reason dose reduction\",\"hcv-796 selectively inhibit hepatitis c virus hcv ns5b rna-dependent rna polymerase hepatoma cell contain 1b hcv replicon hcv-796 reduce hcv rna level 3 4 log(10 hcv copies/mug total rna concentration compound inhibit 50 hcv rna level 9 nm cell bear replicon variant reduce susceptibility hcv-796 generate presence hcv-796 follow g418 selection sequence analysis ns5b gene derive replicon variant reveal amino acid change 5 drug-binding pocket specifically mutation observe leu314 cys316 ile363 ser365 met414 ns5b directly interact hcv-796 impact amino acid substitution viral fitness drug susceptibility examine recombinant replicon ns5b enzyme single-amino-acid mutation replicon variant 10- 1,000-fold efficient form colony cell wild-type replicon s365l variant fail establish stable cell line variant l314f i363v m414v four- ninefold-lower steady-state hcv rna level reduce binding affinity hcv-796 demonstrate enzyme harbor c316y mutation effect resistance mutation structurally rationalize use x-ray crystallography datum different level resistance hcv-796 observe replicon enzyme variant variant retain susceptibility pegylated interferon ribavirin hcv-specific inhibitor combined virological biochemical biophysical structural approach reveal mechanism resistance variant select potent polymerase inhibitor hcv-796\",\"insulin resistance reduce response interferon alfa-based therapy chronic hepatitis c patient speculate improvement insulin sensitivity increase chance respond treatment individual\",\"nucleoside analog r1479 potent highly selective inhibitor nonstructural protein 5b-directed hepatitis c virus hcv replication vitro r1626 tri-isobutyl ester prodrug r1479 develop increase bioavailability improve antiviral activity multicenter observer-blinded randomize placebo-controlled multiple ascend dose phase 1b study design evaluate safety pharmacokinetic antiviral activity potentially identify maximum tolerated dose r1626 patient chronic hepatitis c. forty-seven treatment-na\\u00efve patient infect hcv 1 treat r1626 orally dose 500 mg 1500 mg 3000 mg 4500 mg placebo twice daily 14 day 14 day follow-up safety tolerability pharmacokinetic antiviral activity assess dose include 3000 mg twice daily tolerate 14 day treatment increase frequency adverse event high dose 4500 mg reversible mild moderate hematological change observe increase dose r1626 efficiently convert r1479 dose-proportional pharmacokinetic observe entire dose range pharmacokinetic r1479 linear dose range evaluate dose-dependent time-dependent reduction hcv rna observe mean decrease median range viral load 14 day treatment dose 500 1500 3000 4500 mg 0.32 0.22 0.01 0.71 1.2 0.8 0.49 2.46 2.6 2.7 1.27 3.93 3.7 4.1 2.15 4.39 log(10 respectively resistance r1479 observe 14 day treatment r1626\",\"substantial proportion hepatitis c virus (hcv)-1b-infected patient respond interferon-based therapy study aim explore predictive marker ultimate virological response hcv-1b-infected patient treat pegylated interferon/ribavirin peg-ifn/rbv combination therapy nonstructural protein 5a ns5a sequence hcv pretreated sera 45 patient infect hcv-1b analyze mean number mutation variable region 3 v3 plus upstream flanking region ns5a amino acid 2334 2379 refer ifn/rbv resistance-determining region irrdr significantly high hcv isolate obtain patient later achieve sustained virological response svr peg-ifn/rbv patient undergo non-svr receiver operating characteristic curve analysis estimate mutation irrdr optimal threshold svr prediction 16 76 21 svr 2 8 24 non-svr hcv mutation irrdr irrdr 6 p 0.0001 18 patient infect hcv irrdr 6 great examine significant 1 log reduction disappearance serum hcv core antigen titer 24 hour initial dose peg-ifn/rbv 10 37 27 patient hcv irrdr 5 p 0.0001 positive predictive value irrdr 6 great svr 89 16/18 p 0.0007 negative predictive value non-svr 81 22/27 p 0.0008\",\"hepatitis c infection hcv remain global problem current anti-hcv therapy available clinic sustain virologic response rate svr 50 especially hcv 1-infected subject svr low hiv-hcv co-infecte patient estimate 30 40 exciting new research way find new anti-hcv therapy presently effort develop new anti-hcv agent hcv-infected person fail pegylated interferon ribavirin-based therapy focus inhibitor key hcv enzyme hcv ns3 protease ns5b polymerase protease inhibitor telaprevir vx-950 vertex boceprevir sch 503034 schering-plough polymerase inhibitor valopicitabine nm283 idenix r1626 roche hcv-796 viropharma advance late-stage clinical trial aforementioned agent telaprevir advanced clinical development early trial result efficacy safety hcv drug-resistance profile novel agent discuss review paper\",\"clinical significance molecule involve innate immunity treatment response remain unclear aim elucidate mechanism underlie resistance antiviral therapy predictive usefulness gene quantification chronic hepatitis c ch-c\",\"phase 2 randomize multicenter open-label study evaluate safety efficacy albinterferon alfa-2b interferon-alpha treatment-na\\u00efve patient 2/3 chronic hepatitis c virus infection\",\"hepatitis c virus hcv infect approximately 3 world population chronicity hepatitis c depend level genetic variability recently torres-puente j viral hepat 2008 15 188 report genetic variability estimate large-scale sequence analysis 67 patient infect hcv 1a 23 patient 1b 44 patient relate response lack alpha-interferon plus ribavirin treatment .. hcv genome region analyse sample prior antiviral therapy compress hypervariable region e2 glycoprotein include interferon sensitive determining region v3 domain ns5a protein haplotype nucleotide diversity measure clear tendency high genetic variability level nonresponder responder patient refine analysis genetic variability haplotype nucleotide diversity number haplotype mutation consider distribution biologically meaningful subregion mention surround intervene region variability level heterogeneous different subregion high nonresponder patient interestingly significant difference detect biologically relevant region surround region suggest level variability hcv genome exclusively hypervariable region main indicator treatment response finally number haplotype mutation discriminator haplotype nucleotide diversity especially ns5a region\",\"investigate association insulin resistance rapid virologic response\",\"concise review recent development field viral hepatitis base publication december 2006 november 2007\",\"ribavirin minor transient effect hepatitis c virus hcv replication suggest select novel mutation f415y rna-dependent rna polymerase 1a virus twenty-nine patient chronic hepatitis c inno lipa 1a 17 1b 11 1a/1b 1 nonresponder interferon-based therapy identify retrospectively screen baseline week 24 treatment 24 week post-treatment selection resistance mutation include amino acid position 415 polymerase investigate use clonal sequencing pyrosequencing ns5b gene screen f415y resistance mutation patient receive combination therapy ribavirin interferon \\u03b1 15 1a patient treat interferon plus ribavirin f415y change week 24 f/y mixture present 24 week therapy additional patient group f415y change 24 week post-therapy ns5b gene sequence order identify amino acid change associate ribavirin therapy evidence find ribavirin select particular amino acid rna-dependent rna polymerase ribavirin weak inhibitor hcv replication select resistance mutation sequence hcv rna polymerase\",\"chronic hepatitis c virus hcv infection remain global health threat approximately 200 million carrier worldwide current treatment consist use peginterferon (pegifn)/ribavirin rbv 24 48 week depend hcv effect fact half patient infect hcv 1 4 common accomplish sustained virological response medication warrant need novel anti-hcv therapy\",\"previously report relationship viral polymerase polymorphism initial decline viral load induce interferon-alpha ribavirin therapy 1b-related chronic hepatitis c patient presence e124 k i85v ns5b closely associate viral clearance 8 week treatment aim study investigate mechanism polymorphism ns5b protein affect early viral clearance use replicon system derive strain o 1b virus mutant v85i k124e v85i/k124e introduce replicon or6c derivative huh7 cell transfecte replicon include luciferase reporter gene luciferase activity measure 72 hr post-transfection mutant high luciferase activity wild type v85i mutant high activity result confirm neomycin gene-containing replicon mutation replicon down-regulate ribavirin level reduction v85i mutant low result suggest mutation partly contribute resistance early viral clearance interferon ribavirin combination therapy\",\"efficacy treatment hepatitis c virus improve far ideal new antihepatitis c virus therapy require\",\"newer neuraminidase inhibitor use recently treat influenza b virus infection emergence drug resistance pose potential problem previous ribavirin aerosol treatment influenza effective drug resistance observe ribavirin aerosol treatment quick process limited twice daily treatment megaribavirin formulation 100 mg ribavirin/ml develop use aerotech ii nebulizer effective prevent death lethal influenza virus mouse model aerosol generate use aerotech ii nebulizer flow 10 l air/min produce aerosol droplet contain 2.3 mg ribavirin/l mass median aerodynamic diameter 1.8 microm use system treatment single daily 30-min exposure day 1 4 produce survival rate great 90 delay start aerosol treatment 48 72 h treat daily 30 min day day 2 3 3 4 respectively significantly increase number survivor mean time death treatment influenza general pandemic avian influenza megaribavirin-aerotech ii method aerosol treatment allow short treatment period minimize environmental issue cost\",\"interferon-alpha ribavirin combined therapy mainstream treatment hepatitis c infection efficacy combined treatment 30 60 factor affect responsiveness poorly define study intend investigate genetic difference responder non-responder patient genome-wide linkage disequilibrium screening locus associate genetic difference patient group conduct use 382 autosomal short tandem repeat str marker involve 92 patient identify 19 str marker display different allele frequency patient group addition base genomic location biological function select cd81 il15 gene perform single nucleotide polymorphism genotyping conclusion study provide new approach identify associate polymorphism susceptible locus interferon-alpha ribavirin combined therapy patient chronic hepatitis c.\",\"peginterferon ribavirin therapy chronic hepatitis c lead sustained loss serum hepatitis c virus hcv rna half treat patient viral kinetic profile treatment responder shed light mechanism action interferon ribavirin minimal information available explain patient experience little virologic suppression\",\"novel small-molecule inhibitor refer r706 discover high-throughput screen chemical library huh-7-derived replicon cell carry autonomously replicate subgenomic rna hepatitis c virus hcv r706 highly potent block hcv rna replication measure real-time reverse transcription-pcr western blotting r706-treated replicon cell structure-activity iteration r706 series yield lead compound r803 potent highly specific hcv replication significant inhibitory activity panel hcv-related positive-stranded rna virus furthermore hcv 1 replicon display markedly high sensitivity r803 treatment 2a-derived replicon addition r803 test panel biochemical cell-based assay on-target off-target activity datum suggest compound therapeutic window close 100-fold exact mechanism action remain elusive find r803 effective alpha interferon ifn-alpha block hcv rna replication replicon model combination study r803 weak synergistic effect ifn-alpha/ribavirin additive effect protease inhibitor allosteric inhibitor rna-dependent rna polymerase 20 conclude r803 related heterocyclic compound constitute new class hcv-specific inhibitor potentially develop treatment hcv infection\",\"viral breakthrough vb define detectable hcv vl anti-hcv therapy achieve maximal suppression characterize use peg-ifn hiv/hcv-coinfected patient evaluate possible mechanism vb hiv/hcv-coinfected patient receive peg-ifn/rbv thirty hiv/hcv coinfected patient treat peg-ifn 1.5 mug/kg sc qwk rbv 1 1.2 g daily 48 week liver chemistry hcv vl genotyping dna microarray sequencing hcv e-2 envelope perform treatment vb low baseline hcv vl high alt ast relapser etr p 0.05 low cd4 t lymphocyte patient sustained virological response svr similar second phase hcv viral kinetic vs. etr svr p 0.05 hcv envelope sequence similar patient vb pretreatment break-through vb high level interferon-induced gene ifig expression pretreatment patient etr p 0.01 hiv/hcv-coinfected patient high rate vb peg-ifn/rbv therapy characterize high level ifig expression immunodeficiency hepatic inflammation novel strategy require treatment person vb\",\"rna virus exhibit extraordinarily high mutation rate genome replication nonnatural ribonucleoside increase mutation rate rna virus act ambiguous substrate replication explore antiviral agent act lethal mutagenesis synthesize novel n-6-substituted purine analogue ambiguous incorporation characteristic tautomerization nucleobase potent analogue reduce titer pv coxsackievirus cvb3 1,000-fold single passage hela cell culture increase transition mutation frequency 65-fold kinetic analysis incorporation pv polymerase indicate analogue template ambiguously increase efficiency compare known mutagenic nucleoside ribavirin notably nucleoside efficient substrate cellular ribonucleotide reductase vitro suggest conversion deoxyriboucleoside hinder potentially limit genetic damage host cell furthermore high-fidelity pv variant g64s display resistance antiviral effect mutagenic potential analogue purine nucleoside analogue represent promise lead compound development clinically useful antiviral therapy base strategy lethal mutagenesis\",\"new therapy approve treatment chronic hepatitis c 5 year usa approval pegylated interferon (ifn)-alpha(2a ribavirin multiple new drug currently development expect approve use usa and/or eu 2011 2013 mechanism action pegylated ifn ribavirin completely know likely continue use combination regimen number year direct antiviral likely new drug use combination pegylated ifn ribavirin viral resistance prove significant barrier require consolidation therapy 24 week pegylated ifn ribavirin use successfully prevent selection emergence resistant variant numerous compound ribavirin analog long-acting ifn hepatoprotectant immunomodulator development replace drug use currently combination direct antiviral protease polymerase inhibitor rapidly follow development occur hiv drug therapy\",\"liver transplantation indicate end-stage chronic viral liver disease adequate prophylaxis administer patient case develop recurrent hepatitis b hbv c hcv virus infection today patient receive prophylaxis use nucleoside analogue drug specific immune globulin drug connection orthotopic liver transplantation hbv related cirrhosis present low risk relapse high 5 10 year survival rate lamivudine drug use prophylactic treatment drug increasingly combine replace adefovir low genetic barrier cause viral resistance patient develop viral recurrence orthotopic liver transplantation hcv related cirrhosis elevated number case cirrhosis hepatic insufficiency set year prophylaxis transplantation pre-emptive treatment use interferon ribavirin present numerous effect result reduction dose suspension therapy consequently low sustained virological remission rate risk rejection treatment tolerate patient histologically confirm chronic disease patient virological remission rate low pathology require new therapeutic protocol and/or new drug order obtain compliance response\",\"quasispecie nature hepatitis c virus hcv important implication concern resistance antiviral agent determine hcv ns5a quasispecie composition dynamic related responsiveness combined interferon ifn ribavirin therapy extensive sequence analysis clone rt-pcr amplification product hcv-1b ns5a quasispecie sequential isolate 15 treat sustained responder non-responder untreated patient perform accumulation mutation ns5a therapy relatively frequent v3 domain unusual amino acid change result imposition minor variant present treatment occur week therapy treatment complexity diversity quasispecie low isolate responder non-responder particularly v3 domain difference nucleotide entropy 0.35 vs 0.64 p=0.003 genetic distance 0.0145 vs 0.0302 p=0.05 non-synonymous substitution 0.0102 vs 0.0203 p=0.036 statistically significant difference apparent treatment complexity diversity remain stable tend increase non-responder tend decrease responder observation suggest composition dynamic hcv ns5a quasispecie particularly v3 domain play role response combined ifn/ribavirin therapy\",\"hepatitis c virus hcv persist majority infected individual major cause chronic hepatitis liver cirrhosis hepatocellular carcinoma chronic hepatitis c currently treat interferon (ifn)-alpha combination ifn-alpha ribavirin availability hcv replicon system lohmann science 285 110 113 1999 allow investigation effect ifn genuine hcv replication culture cell ifn-alpha inhibit subgenomic hcv rna replication huh-7 human hepatoma cell immunofluorescence western blot northern blot analysis reveal level hcv protein replicon rna reduce treatment ifn-alpha dose-dependent manner experiment investigate mxa play role inhibition hcv human mxa protein ifn-induced gtpase antiviral activity rna virus hcv rna replication affect transfecte huh-7 cell transiently overexpresse mxa. dominant-negative mutant mxa interfere antiviral activity ifn-alpha hcv rna replication result demonstrate ifn-alpha inhibit hcv replicon mxa-independent pathway\"],\"title\":[\"Identification of NS5B Resistance-Associated Mutations in Hepatitis C Virus Circulating in Treatment Na\\u00efve Vietnamese Patients.\",\"Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of February 23, 2022.\",\"Genetic Diversity Does Not Contribute to Attenuation of HeLa Passaged Wild-Type Yellow Fever Virus Strain French Viscerotropic Virus.\",\"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.\",\"High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infection.\",\"Deciphering the significance of plasma chemokines as prognostic biomarkers in Pegylated IFN-\\u03b1-2a /ribavirin-treated chronic hepatitis C genotype 4 patients.\",\"Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.\",\"The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters.\",\"Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication.\",\"Spontaneous pneumothorax and pneumomediastinum in patients with COVID-19: A case series from Iran.\",\"Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.\",\"Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C.\",\"Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2.\",\"4'-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives.\",\"Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids.\",\"Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis.\",\"Antiviral susceptibilities of avian influenza A(H5), A(H7), and A(H9) viruses isolated in Japan.\",\"Road to elimination of HCV: Clinical challenges in HCV management.\",\"Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo.\",\"Influence of Ribavirin on Mumps Virus Population Diversity.\",\"Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance.\",\"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report.\",\"Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models.\",\"Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against RNA-Dependent RNA Polymerase Complex (nsp7/nsp8/nsp12) of SARS-CoV-2.\",\"Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19.\",\"Phytonutrient Inhibitors of SARS-CoV-2/NSP5-Encoded Main Protease (M[pro]) Autocleavage Enzyme Critical for COVID-19 Pathogenesis.\",\"Two phytocompounds from Schinopsis brasiliensis show promising antiviral activity with multiples targets in Influenza A virus.\",\"2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.\",\"Synthesis of novel N-(2-phenyl-3-pyridyl) thiadiazole/isothiazole carboxamide analogs as potent plant elicitors.\",\"Treatment progress and expansion in Japan: From interferon to direct-acting antiviral.\",\"Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.\",\"HCV RdRp, sofosbuvir and beyond.\",\"Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection.\",\"The Relationship Between HCV-NS5A Gene Mutations and Resistance to Combination Therapy in Patients with HCV- Genotype 1-B.\",\"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.\",\"Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.\",\"Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics.\",\"Mathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized?\",\"Structural Simplification of Marine Natural Products: Discovery of Hamacanthin Derivatives Containing Indole and Piperazinone as Novel Antiviral and Anti-phytopathogenic-fungus Agents.\",\"Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients.\",\"Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination.\",\"Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C.\",\"Comparison of Zaire and Bundibugyo Ebolavirus Polymerase Complexes and Susceptibility to Antivirals through a Newly Developed Bundibugyo Minigenome System.\",\"Targeting Some Enzymes with Repurposing Approved Pharmaceutical Drugs for Expeditious Antiviral Approaches Against Newer Strains of COVID-19.\",\"Structural Bioinformatics Used to Predict the Protein Targets of Remdesivir and Flavones in SARS-CoV-2 Infection.\",\"Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics.\",\"Prevention of CD8 T Cell Deletion during Chronic Viral Infection.\",\"Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort.\",\"Predictors of early and sustained virological response of viral hepatitis C.\",\"The isolation of high-affinity ssDNA aptamer for the detection of ribavirin in chicken.\",\"Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.\",\"Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer.\",\"Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance.\",\"Favipiravir-resistant influenza A virus shows potential for transmission.\",\"An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-\\u03b2-1a and hydroxychloroquine in hospitalized patients with COVID-19.\",\"Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.\",\"Marine algal antagonists targeting 3CL protease and spike glycoprotein of SARS-CoV-2: a computational approach for anti-COVID-19 drug discovery.\",\"Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.\",\"Population Disequilibrium as Promoter of Adaptive Explorations in Hepatitis C Virus.\",\"Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.\",\"Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2.\",\"A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.\",\"Naturally Occurring Resistance Associated Substitutions in Non-Cirrhotic, Treatment Naive HCV-HIV Co-Infected Patients Does Not Affect the Treatment Response for Anti-HCV Antiviral Therapy.\",\"Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.\",\"Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir.\",\"Development of a Genetically Stable Live Attenuated Influenza Vaccine Strain Using an Engineered High-Fidelity Viral Polymerase.\",\"Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.\",\"Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C.\",\"Whole-Genome Analysis Surveillance of Influenza A Virus Resistance to Polymerase Complex Inhibitors in Eastern Spain from 2016 to 2019.\",\"Structural basis for backtracking by the SARS-CoV-2 replication-transcription complex.\",\"New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals.\",\"Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.\",\"Treatment failure with DAA therapy: Importance of resistance.\",\"Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.\",\"Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.\",\"Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.\",\"Biostructural Models for the Binding of Nucleoside Analogs to SARS-CoV-2 RNA-Dependent RNA Polymerase.\",\"Predicted occurrence, ecotoxicological risk and environmentally acquired resistance of antiviral drugs associated with COVID-19 in environmental waters.\",\"Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit.\",\"A Hyper-Attenuated Variant of Rift Valley Fever Virus Generated by a Mutagenic Drug (Favipiravir) Unveils Potential Virulence Markers.\",\"Interferon-\\u03b3 inducible protein-10 and interleukin 28B gene polymorphism as predictive markers for genotype 4 hepatitis C virus treatment response.\",\"The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National Program Protocol In Patients With Midrange Ejection Fraction.\",\"Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir.\",\"Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.\",\"Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine.\",\"Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant.\",\"Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.\",\"High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance.\",\"Broad spectrum compounds targeting early stages of rabies virus (RABV) infection.\",\"A review on favipiravir: the properties, function, and usefulness to treat COVID-19.\",\"Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus.\",\"Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report.\",\"Molecular Characterization of Hepatitis C Virus for Developed Antiviral Agents Resistance Mutations and New Insights into in-silico Prediction Studies.\",\"Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.\",\"An effective drug against COVID-19: reality or dream?\",\"Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial.\",\"Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders.\",\"COVID-19 update: The race to therapeutic development.\",\"Most Promising Compounds for Treating COVID-19 and Recent Trends in Antimicrobial & Antifungal Agents.\",\"Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.\",\"Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response.\",\"Characterization of the Human Intestinal Drug Transport with Ussing Chamber System Incorporating Freshly Isolated Human Jejunum.\",\"Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).\",\"In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.\",\"Inhibitory Activity of Honeysuckle Extracts against Influenza A Virus In Vitro and In Vivo.\",\"Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases.\",\"CURING HEPATITIS C WITH THE NEW DIRECT ACTING ANTIVIRALS DID NOT IMPROVE INSULIN RESISTANCE AFTER ONE YEAR.\",\"Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.\",\"The Impacts of Antivirals on the Coronavirus Genome Structure and Subsequent Pathogenicity, Virus Fitness and Antiviral Design.\",\"Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action.\",\"Marine Natural Product for Pesticide Candidate: Pulmonarin Alkaloids as Novel Antiviral and Anti-Phytopathogenic-Fungus Agents.\",\"Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life.\",\"Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.\",\"Drug Resistance in Hepatitis C Virus: Future Prospects and Strategies to Combat It.\",\"Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?\",\"A living WHO guideline on drugs for covid-19\",\"In Vitro Characterization of Multidrug-Resistant Influenza A(H1N1)pdm09 Viruses Carrying a Dual Neuraminidase Mutation Isolated from Immunocompromised Patients.\",\"A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFN\\u03b1 + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress.\",\"Insulin resistance in children with chronic hepatitis C and its association with response to IFN-alpha and ribavirin.\",\"Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C.\",\"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.\",\"Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.\",\"Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy.\",\"Mutations on VEEV nsP1 relate RNA capping efficiency to ribavirin susceptibility.\",\"Diversity of the hepatitis C virus NS5B gene during HIV co-infection.\",\"Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients.\",\"Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.\",\"Streptindole and Its Derivatives as Novel Antiviral and Anti-Phytopathogenic Fungus Agents.\",\"Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials.\",\"In vitro inhibition of mumps virus replication by favipiravir (T-705).\",\"An Extended Primer Grip of Picornavirus Polymerase Facilitates Sexual RNA Replication Mechanisms.\",\"Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.\",\"The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?\",\"Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.\",\"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.\",\"Salvage therapy in cancer patients with hepatitis C without sustained virologic response after direct-acting antivirals-A prospective study.\",\"Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins.\",\"Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project.\",\"Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis.\",\"Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy.\",\"Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.\",\"Pharmaceutical Approaches for Treatment of Hepatitis C virus.\",\"Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-na\\u00efve, HCV GT1b-infected patients, with non-severe fibrosis.\",\"Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.\",\"Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.\",\"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.\",\"Antiviral therapeutics for chikungunya virus.\",\"Ombitasvir/paritaprevir/ritonavir & dasabuvir \\u00b1 ribavirin following protease inhibitors failure - a prospective multi-centre trial.\",\"Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the suppression of STING.\",\"Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice.\",\"Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance.\",\"Next-generation direct-acting influenza therapeutics.\",\"Influenza and antiviral resistance: an overview.\",\"Elevated serum levels of adiponectin and interlukin-28B after IFN/RIB therapy in hepatitis C virus-infected patients.\",\"Drug Resistance Assessment Following Administration of Respiratory Syncytial Virus (RSV) Fusion Inhibitor Presatovir to Participants Experimentally Infected With RSV.\",\"Interferon-Free Hepatitis C Virus Therapy.\",\"Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E.\",\"Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model.\",\"Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro.\",\"A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract.\",\"Recurrent Ebolavirus disease in the Democratic Republic of Congo: update and challenges.\",\"Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin.\",\"NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors.\",\"Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.\",\"Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent.\",\"Synthesis, Antiviral Activity, and Induction of Plant Resistance of Indole Analogues Bearing Dithioacetal Moiety.\",\"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia.\",\"Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters.\",\"Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study.\",\"Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-na\\u00efve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China.\",\"Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence.\",\"Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis.\",\"Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.\",\"Small-Molecule Antiviral \\u03b2-d-N [4]-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance.\",\"Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment.\",\"Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.\",\"New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials.\",\"Cellular Signaling Analysis shows antiviral, ribavirin-mediated ribosomal signaling modulation.\",\"Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.\",\"Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.\",\"Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway.\",\"Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.\",\"[Prospects For the Use of Peptides against Respiratory Syncytial Virus].\",\"Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report.\",\"Genetic variants in RIG-I-like receptor influences HCV clearance in Chinese Han population.\",\"Retreatment with elbasvir, grazoprevir, sofosbuvir \\u00b1 ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.\",\"Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study.\",\"High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.\",\"Follow-up Results of HCV GT2 Patients After Sofosbuvir/Ribavirin Therapy: Careful Attention to Occurrence of HCC.\",\"Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs.\",\"Antivirals targeting the polymerase complex of influenza viruses.\",\"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.\",\"Establishment of a Cell Culture Model of Persistent Flaviviral Infection: Usutu Virus Shows Sustained Replication during Passages and Resistance to Extinction by Antiviral Nucleosides.\",\"Atorvastatin in Combination with Pegylated Interferon and Ribavirin Provided High Rate of Sustained Virological Response in Patients with Genotype 3 Hepatitis C Virus.\",\"The association of hepatitis c virus infection status with serum glucose levels.\",\"HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma.\",\"Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients.\",\"Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients.\",\"Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature.\",\"Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir.\",\"Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure.\",\"Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.\",\"Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study.\",\"Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation.\",\"Senecavirus-Specific Recombination Assays Reveal the Intimate Link between Polymerase Fidelity and RNA Recombination.\",\"Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients.\",\"Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.\",\"Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters.\",\"Hepatitis C Genotype 4 Virus Nonstructural 3 and Nonstructural 5A Resistance-associated Substitutions in a 16-year-old Adolescent Failing Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin.\",\"Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice.\",\"GLI1-Inducible Glucuronidation Targets a Broad Spectrum of Drugs.\",\"Transport of ribavirin across the rat and human placental barrier: Roles of nucleoside and ATP-binding cassette drug efflux transporters.\",\"Hepatitis C - New drugs and treatment prospects.\",\"Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.\",\"All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C.\",\"Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir \\u00b1 Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.\",\"Intergenotypic 2k/1b hepatitis C virus recombinants in the East Macedonia and Thrace region of Greece.\",\"Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients.\",\"Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.\",\"Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan.\",\"Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.\",\"Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus.\",\"The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.\",\"Viral resistance in HCV infection.\",\"The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis.\",\"Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.\",\"Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus.\",\"Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse.\",\"Interferon-Free Regimen for Hepatitis C: Insight and Management.\",\"Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance.\",\"Treating Influenza Infection, From Now and Into the Future.\",\"Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients.\",\"Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.\",\"Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse.\",\"Sofosbuvir: Really Meets the Unmet Needs for Hepatitis C Treatment?\",\"High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.\",\"Resistance of high fitness hepatitis C virus to lethal mutagenesis.\",\"Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function.\",\"Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.\",\"Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.\",\"Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.\",\"DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS?\",\"Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection.\",\"Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.\",\"Genetic Polymorphisms within Interferon-\\u03bb Region and Interferon-\\u03bb3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses.\",\"Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment.\",\"Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.\",\"Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.\",\"Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.\",\"Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a.\",\"The Role of Biochemical Variations and Genotype Testing in Determining the Virological Response of Patients Infected with Hepatitis C Virus.\",\"A Simple and Robust Approach for Evaluation of Antivirals Using a Recombinant Influenza Virus Expressing Gaussia Luciferase.\",\"Druggability of the guanosine/adenosine/cytidine nucleoside hydrolase from Trichomonas vaginalis.\",\"Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease.\",\"[Potential application of sofosbuvir-based treatment for chronic hepatitis C in China].\",\"Exploration of (hetero)aryl Derived Thienylchalcones for Antiviral and Anticancer Activities.\",\"Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens.\",\"Long-term familial Mediterranean fever remission on successful hepatitis C virus treatment in a patient not responding to colchicine: a case report.\",\"Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy.\",\"Design, Synthesis, Antiviral Bioactivity, and Defense Mechanisms of Novel Dithioacetal Derivatives Bearing a Strobilurin Moiety.\",\"Identifying causal variants at the interferon lambda locus in case-control studies: Utilizing non-synonymous variant rs117648444 to probe the role of IFN-\\u03bb4.\",\"Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.\",\"[Chronic hepatitis C : Standard treatment and remaining challenges].\",\"Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection.\",\"Vitamin D deficiency in hepatitis C virus infection: what is old? what is new?\",\"Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).\",\"Daclatasvir plus asunaprevir in treatment-na\\u00efve patients with hepatitis C virus genotype 1b infection.\",\"Protease inhibitor therapy for hepatitis C virus-infection.\",\"Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling.\",\"Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model.\",\"The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.\",\"High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.\",\"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses.\",\"Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.\",\"Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study.\",\"Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen.\",\"HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era.\",\"12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis.\",\"Treatment of early stage chronic hepatitis C virus infection.\",\"Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017.\",\"Use of next-generation sequencing in the CHAT study (acute HCV in HIV): effect of baseline resistance-associated NS3 variants on treatment failure.\",\"Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.\",\"Prevalence and Clinical Correlates of Chronic Hepatitis E Infection in German Renal Transplant Recipients With Elevated Liver Enzymes.\",\"Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.\",\"Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.\",\"Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: a case series.\",\"A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan.\",\"Treatment of hepatitis C: Results in real life.\",\"Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.\",\"Mining a Kr\\u00f6hnke Pyridine Library for Anti-Arenavirus Activity.\",\"The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment.\",\"Effect of branched-chain amino acid supplementation on insulin resistance and quality of life in chronic hepatitis C patients.\",\"Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience.\",\"Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.\",\"A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-\\u03b1 and ribavirin for chronic hepatitis C virus infection.\",\"Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs.\",\"Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.\",\"Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.\",\"Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection.\",\"Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment.\",\"Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.\",\"Mechanism of Hepatitis C Virus-Induced Diabetes Mellitus.\",\"Pan-Genotype Hepatitis E Virus Replication in Stem Cell-Derived Hepatocellular Systems.\",\"Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population.\",\"Research progress in human infection with avian influenza H7N9 virus.\",\"Enhancing the antiviral potency of ER \\u03b1-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.\",\"Retreatment Options Following HCV Direct Acting Antiviral Failure.\",\"Experimental adaptation of human echovirus 11 to ultraviolet radiation leads to resistance to disinfection and ribavirin.\",\"Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.\",\"Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.\",\"Protease inhibitors for the treatment of hepatitis C virus infection.\",\"Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry.\",\"\\u03b2-d-N [4]-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome.\",\"In-Vitro Transcription analysis of NS5A from HCV-3a circulating in Pakistani patients with chronic hepatitis C and their differential response to antiviral therapy.\",\"Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.\",\"Proofreading-Deficient Coronaviruses Adapt for Increased Fitness over Long-Term Passage without Reversion of Exoribonuclease-Inactivating Mutations.\",\"Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.\",\"Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.\",\"Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.\",\"Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.\",\"Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals.\",\"Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.\",\"Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.\",\"In silico 3-D structure prediction and molecular docking studies of inosine monophosphate dehydrogenase from Plasmodium falciparum.\",\"Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C.\",\"Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients.\",\"Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.\",\"Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era.\",\"Direct-acting antiviral agents against hepatitis C virus and lipid metabolism.\",\"Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience.\",\"Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.\",\"Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Na\\u00efve or Treatment-Experienced.\",\"Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals.\",\"Interferon-\\u03b3-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.\",\"The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution.\",\"Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.\",\"Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).\",\"Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.\",\"Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.\",\"Epistatic Interactions within the Influenza A Virus Polymerase Complex Mediate Mutagen Resistance and Replication Fidelity.\",\"Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy.\",\"Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication.\",\"Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?\",\"Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.\",\"Genotype-specific acquisition, evolution and adaptation of characteristic mutations in hepatitis E virus.\",\"Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir.\",\"Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience.\",\"Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.\",\"Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.\",\"Nucleoside analogue 2'-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin.\",\"Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.\",\"Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.\",\"Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.\",\"Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.\",\"Real-world challenges for hepatitis C virus medications: a critical overview.\",\"Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.\",\"Attenuation of Foot-and-Mouth Disease Virus by Engineered Viral Polymerase Fidelity.\",\"Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.\",\"Efficacy and safety of telaprevir with natural human interferon-\\u03b2 and ribavirin in Japanese chronic hepatitis C patients with depression.\",\"Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.\",\"Assessment of the Relation Between SNP in MxA Gene and the Responsiveness of Egyptian HCV Genotype 4 Patients to Pegylated Interferon and Ribavirin Treatment.\",\"Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility.\",\"Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.\",\"Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-na\\u00efve, noncirrhotic HCV genotype 3-infected patients.\",\"Sofosbuvir and velpatasvir for the treatment of hepatitis C.\",\"Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.\",\"Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors.\",\"Direct-acting antivirals: the endgame for hepatitis C?\",\"Experience in real clinical practice with new direct acting antivirals in chronic hepatitis C.\",\"Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.\",\"Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life.\",\"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.\",\"Molecular analysis of amantadine-resistant influenza A (H1N1 pdm09) virus isolated from slum dwellers of Dhaka, Bangladesh.\",\"IL-10 and IL-28B gene variants as predictors of sustained response to peginterferon and ribavirin therapy in chronic HCV infection.\",\"Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase.\",\"Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.\",\"Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1.\",\"Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.\",\"Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long?\",\"Synthesis and anti-cancer activities of new sulfonamides 4-substituted-triazolyl nucleosides.\",\"Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.\",\"Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.\",\"Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.\",\"In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.\",\"Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection.\",\"Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.\",\"[Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016].\",\"Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.\",\"Relapse of HCV Genotype 1b Infection After Sofosbuvir/Ledipasvir Treatment Presenting as De Novo Cryoglobulinemic Vasculitis.\",\"[Favipiravir, a new concept of antiviral drug against influenza viruses].\",\"Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C.\",\"Treatment Options in Hepatitis C.\",\"Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.\",\"Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.\",\"Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256.\",\"Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.\",\"US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.\",\"Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs.\",\"HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy.\",\"Management of direct antiviral agent failures.\",\"Antiviral therapy for respiratory viral infections in immunocompromised patients.\",\"Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.\",\"Japanese Surveillance Systems and Treatment for Influenza.\",\"Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.\",\"Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.\",\"Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation.\",\"Ribavirin suppresses bacterial virulence by targeting LysR-type transcriptional regulators.\",\"Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.\",\"The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-na\\u00efve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.\",\"Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.\",\"Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors.\",\"Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.\",\"Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.\",\"Reinventing HCV Treatment: Past and Future Perspectives.\",\"An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy.\",\"Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.\",\"Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection.\",\"Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.\",\"The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design.\",\"Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.\",\"Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations.\",\"Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.\",\"Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents.\",\"Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.\",\"Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance.\",\"Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.\",\"Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.\",\"Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells.\",\"Future landscape of hepatitis C research - Basic, translational and clinical perspectives.\",\"Biomedical Mutation Analysis (BMA): A software tool for analyzing mutations associated with antiviral resistance.\",\"Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance.\",\"[Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure].\",\"Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.\",\"Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.\",\"NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.\",\"Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.\",\"New Therapies for Hepatitis C Virus.\",\"Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses.\",\"Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses.\",\"Management of HCV-Associated Liver Cirrhosis.\",\"From current status to optimization of HCV treatment: Recommendations from an expert panel.\",\"Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.\",\"Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.\",\"Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C.\",\"Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients.\",\"Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.\",\"Current and novel antiviral strategies for influenza infection.\",\"Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance.\",\"Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.\",\"Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach.\",\"Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.\",\"Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.\",\"Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-na\\u00efve patients with hepatitis C virus genotype 1 infection.\",\"Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation.\",\"Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India.\",\"Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.\",\"Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.\",\"Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.\",\"Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin.\",\"Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity.\",\"Prevention and management of treatment failure to new oral hepatitis C drugs.\",\"Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.\",\"Involvement of a joker mutation in a polymerase-independent lethal mutagenesis escape mechanism.\",\"Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort.\",\"1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.\",\"Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.\",\"Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.\",\"Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection.\",\"Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System.\",\"[Resistance to protease inhibitors and efficiency of antiviral therapy in patients with chronic hepatitis C].\",\"Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.\",\"Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life.\",\"Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry.\",\"All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.\",\"An update on the management of hepatitis C virus-infected patients with stage 4-5 chronic kidney disease while awaiting the revised KDIGO Guidelines.\",\"A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.\",\"[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].\",\"HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials.\",\"eIF4E-phosphorylation-mediated Sox2 upregulation promotes pancreatic tumor cell repopulation after irradiation.\",\"Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs.\",\"Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.\",\"A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment.\",\"The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.\",\"Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C.\",\"Direct anti-HCV agents.\",\"The Attenuation Phenotype of a Ribavirin-Resistant Porcine Reproductive and Respiratory Syndrome Virus Is Maintained during Sequential Passages in Pigs.\",\"Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.\",\"The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia.\",\"Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir:Daclatasvir combination therapy.\",\"Escape Mutations in NS4B Render Dengue Virus Insensitive to the Antiviral Activity of the Paracetamol Metabolite AM404.\",\"Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.\",\"Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.\",\"Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.\",\"Advances in hepatitis C therapy: What is the current state - what come's next?\",\"A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin.\",\"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).\",\"New approaches in the treatment of hepatitis C.\",\"Hepatitis C and insulin action: An intimate relationship.\",\"Ribavirin: Past, present and future.\",\"Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.\",\"Design, synthesis, and in vitro biological evaluation of novel 6-methyl-7-substituted-7-deaza purine nucleoside analogs as anti-influenza A agents.\",\"Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.\",\"High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.\",\"Targeting translation: eIF4E as an emerging anticancer drug target.\",\"Molecular characterization of hepatitis C virus core region in moroccan intravenous drug users.\",\"A Rapid Screening Assay Identifies Monotherapy with Interferon-\\u00df and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus.\",\"Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.\",\"Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.\",\"Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy.\",\"Artesunate, an anti-malarial drug, has a potential to inhibit HCV replication.\",\"Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.\",\"Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy.\",\"Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa.\",\"Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-\\u03b1 and ribavirin therapy.\",\"No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy.\",\"GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.\",\"Impact of Body Weight Reduction via Diet and Exercise on the Anti-Viral Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Insulin Resistance: A Randomized Controlled Pilot Trial.\",\"The role of HCV proteins on treatment outcomes.\",\"Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.\",\"Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?\",\"Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C.\",\"L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.\",\"Current Treatment Options in Patients with Hepatitis C Virus Genotype 6.\",\"Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.\",\"Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.\",\"Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches.\",\"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.\",\"Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.\",\"Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review.\",\"Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.\",\"Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients.\",\"The New Era of Interferon-Free Treatment of Chronic Hepatitis C.\",\"Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.\",\"Development and persistence of DAA resistance associated mutations in patients failing HCV treatment.\",\"Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.\",\"Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.\",\"Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b.\",\"The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease.\",\"Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance.\",\"Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance.\",\"[Novel methods of hepatitis C treatment and prevention].\",\"Clinical Implications of Antiviral Resistance in Influenza.\",\"Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.\",\"Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68.\",\"Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.\",\"Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.\",\"Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature.\",\"Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection.\",\"Extrahepatic morbidity and mortality of chronic hepatitis C.\",\"Viral Polymerase-Helicase Complexes Regulate Replication Fidelity To Overcome Intracellular Nucleotide Depletion.\",\"Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy.\",\"Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens.\",\"Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues.\",\"Management of direct-acting antiviral agent failures.\",\"Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies.\",\"Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.\",\"Steatosis and hepatitis C.\",\"Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.\",\"Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-na\\u00efve patients with chronic hepatitis: single-centre experience.\",\"Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.\",\"Resistance to direct-acting antiviral agents: clinical utility and significance.\",\"Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.\",\"Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-na\\u00efve patients with chronic HCV genotype 1 infection (ESSENTIAL II).\",\"Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.\",\"Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.\",\"Is hepatitis E virus an emerging problem in industrialized countries?\",\"Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.\",\"Hepatitis C in Children Co-infected With Human Immunodeficiency Virus.\",\"Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir.\",\"Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.\",\"The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C.\",\"Suramin inhibits chikungunya virus replication through multiple mechanisms.\",\"Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.\",\"Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.\",\"Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.\",\"Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.\",\"Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells.\",\"Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.\",\"Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.\",\"Natural interferon-beta treatment for patients with chronic hepatitis C in Japan.\",\"Hepatitis C virus: Virology, diagnosis and treatment.\",\"Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.\",\"Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases.\",\"[Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].\",\"Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution.\",\"In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance.\",\"Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells.\",\"2-Pyridinyl-4(3H)-quinazolinone: a scaffold for anti-influenza A virus compounds.\",\"Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.\",\"Changing the face of hepatitis C management - the design and development of sofosbuvir.\",\"E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient.\",\"Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy.\",\"Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.\",\"Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals.\",\"Effects of ribavirin on the replication and genetic stability of porcine reproductive and respiratory syndrome virus.\",\"Novel daidzein analogs and their in vitro anti-influenza activities.\",\"Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing.\",\"Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.\",\"Interferon-\\u03bb-related genes and therapeutic response in Chinese hepatitis C patients.\",\"Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.\",\"HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients.\",\"Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.\",\"Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.\",\"Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.\",\"Enhancing our understanding of current therapies for hepatitis C virus (HCV).\",\"Gene therapies for hepatitis C virus.\",\"Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin.\",\"Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection.\",\"Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.\",\"Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals.\",\"Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotype.\",\"Optimizing antiviral therapy for influenza: understanding the evidence.\",\"Retreatment with peginterferon and ribavirin in chronic hepatitis C.\",\"Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings.\",\"Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.\",\"Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma.\",\"Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.\",\"Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients.\",\"Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.\",\"Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy.\",\"Hepatitis C therapy: Looking toward interferon-sparing regimens.\",\"Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b.\",\"Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.\",\"Antivirals against enteroviruses: a critical review from a public-health perspective.\",\"Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.\",\"Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.\",\"Sofosbuvir, a New Nucleotide Analogue, for the Treatment of Chronic Hepatitis C Infection.\",\"Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations.\",\"Effective lethal mutagenesis of influenza virus by three nucleoside analogs.\",\"Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFN\\u03b1/RBV therapy.\",\"Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian patients.\",\"ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.\",\"Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy.\",\"Tricistronic hepatitis C virus subgenomic replicon expressing double transgenes.\",\"Sonic Hedgehog factor Gli1: As good as resistant.\",\"Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.\",\"Finally sofosbuvir: an oral anti-HCV drug with wide performance capability.\",\"The relationship between HLA-G and viral loads in non-responder HCV-infected patients after combined therapy with IFN-\\u03b12\\u03b1 and ribavirin.\",\"When will resistance be futile?\",\"New treatments for chronic hepatitis C: an overview for paediatricians.\",\"Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.\",\"[Treatment of hepatitis C: what is known?].\",\"Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs.\",\"Sofosbuvir as backbone of interferon free treatments.\",\"Anti-interferon-\\u03b1 neutralizing antibody induced telaprevir resistance under the interferon-\\u03b1 plus telaprevir treatment in vitro.\",\"Inhibitory effects of Pycnogenol\\u00ae on hepatitis C virus replication.\",\"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.\",\"Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy.\",\"Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.\",\"Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.\",\"Sofosbuvir: A novel treatment option for chronic hepatitis C infection.\",\"Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial.\",\"In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.\",\"Baseline sensitivity of T cells to alpha-IFN correlates with sustained virological response to IFN-based triple therapy in HCV infection.\",\"FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.\",\"Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study.\",\"Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.\",\"Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.\",\"Persistent hepatitis C virus infection impairs ribavirin antiviral activity through clathrin-mediated trafficking of equilibrative nucleoside transporter 1.\",\"Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.\",\"Update on the treatment of hepatitis C genotypes 2-6.\",\"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.\",\"Emerging treatments for chronic hepatitis C.\",\"Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.\",\"Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.\",\"Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.\",\"Gene polymorphisms of IL-10 and MxA in responders and non-responders to interferon therapy in HCV Egyptian patients genotype 4.\",\"Emerging therapies for hepatitis C.\",\"Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.\",\"Human small intestinal epithelial cells differentiated from adult intestinal stem cells as a novel system for predicting oral drug absorption in humans.\",\"A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients.\",\"Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.\",\"Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.\",\"An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials.\",\"Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.\",\"rs8099917 and viral genotyping as indications for living donor liver transplantation for hepatitis C: a case report.\",\"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.\",\"Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus.\",\"Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance.\",\"Treatment of HCV infection with the novel NS3/4A protease inhibitors.\",\"Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study.\",\"An interferon response gene signature is associated with the therapeutic response of hepatitis C patients.\",\"Modeling viral evolutionary dynamics after telaprevir-based treatment.\",\"GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection.\",\"Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.\",\"Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.\",\"Efficacy of daclatasvir in hepatitis C virus.\",\"Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.\",\"A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy.\",\"Interleukin 28B polymorphisms and therapy response in Egyptian hepatitis C genotype-4 patients.\",\"Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.\",\"Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.\",\"A pilot study of add-on oral hypoglycemic agents in treatment-na\\u00efve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.\",\"Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.\",\"Sofosbuvir: a review of its use in patients with chronic hepatitis C.\",\"[The value of genetics in the era of hepatitis C triple therapy].\",\"Update on hepatitis C virus resistance to direct-acting antiviral agents.\",\"Foot-and-mouth disease virus low-fidelity polymerase mutants are attenuated.\",\"Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir.\",\"microRNAs: novel players in hepatitis C virus infection.\",\"The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.\",\"\\u039canagement of patients with hepatitis B and C before and after liver and kidney transplantation.\",\"In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.\",\"Hepatitis C in HIV-infected patients: impact of direct-acting antivirals.\",\"Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance.\",\"Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.\",\"Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives.\",\"Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C.\",\"Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.\",\"Telaprevir-based treatment effects on hepatitis C virus in liver and blood.\",\"Activation of endogenous type I IFN signaling contributes to persistent HCV infection.\",\"Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b.\",\"Sofosbuvir and ribavirin in HCV genotypes 2 and 3.\",\"ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.\",\"Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential.\",\"Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients.\",\"Interferon-free strategies with a nucleoside/nucleotide analogue.\",\"New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development.\",\"Targets for antiviral therapy of hepatitis C.\",\"The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.\",\"Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.\",\"Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.\",\"The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.\",\"Identification of na\\u00efve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms.\",\"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.\",\"ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.\",\"Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever.\",\"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.\",\"Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms.\",\"MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.\",\"Hepatitis C virus NS5A inhibitors and drug resistance mutations.\",\"Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.\",\"Review article: genetic factors that modify the outcome of viral hepatitis.\",\"Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-\\u03b1 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group.\",\"New hepatitis C therapies: the toolbox, strategies, and challenges.\",\"Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.\",\"Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.\",\"Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure.\",\"Insulin resistance, steatosis and hepatitis C virus.\",\"The past, present and future of neutralizing antibodies for hepatitis C virus.\",\"Mycophenolic acid, mycophenolate mofetil, mizoribine, ribavirin, and 7-nitroindole inhibit propagation of Babesia parasites by targeting inosine 5'-monophosphate dehydrogenase.\",\"Emergence of genetically variant Hepatitis C virus population in response to increased antiviral drug pressure, Pakistan.\",\"Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.\",\"Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients.\",\"All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-na\\u00efve patients with genotype 1 HCV infection.\",\"Drug resistance of a viral population and its individual intrahost variants during the first 48 hours of therapy.\",\"Chronic hepatitis C: future treatment.\",\"Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.\",\"What is the future of ribavirin therapy for hepatitis C?\",\"Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013.\",\"Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.\",\"Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.\",\"Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling.\",\"IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort.\",\"Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.\",\"Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.\",\"Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.\",\"Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.\",\"HCV direct-acting antiviral agents: the best interferon-free combinations.\",\"Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.\",\"Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.\",\"Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.\",\"Interferon-\\u03b1/\\u03b2 for treatment of chronic hepatitis C infection in the era of direct-acting antiviral agents.\",\"Does telaprevir possess a direct antidiabetic effect?\",\"Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels.\",\"Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes.\",\"In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.\",\"All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses.\",\"Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.\",\"Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.\",\"Sofosbuvir for the treatment of hepatitis C virus.\",\"Hepatitis C virus NS3 inhibitors: current and future perspectives.\",\"Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy.\",\"Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load.\",\"Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance.\",\"Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011.\",\"An overview of emerging therapies for the treatment of chronic hepatitis C.\",\"Endogenous IFN\\u03b3 in chronic HCV genotype 4 patients treated with PEG-IFN\\u03b1 and ribavirin.\",\"Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?\",\"HCV infection selectively impairs type I but not type III IFN signaling.\",\"Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B.\",\"Daclatasvir: potential role in hepatitis C.\",\"Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective.\",\"Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.\",\"Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFN\\u03b1R2a.\",\"Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.\",\"In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.\",\"Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation.\",\"Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1.\",\"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.\",\"Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.\",\"Emerging treatments for hepatitis C.\",\"In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.\",\"Optimizing DAA management in daily practice.\",\"Antiviral activities of Indonesian medicinal plants in the East Java region against hepatitis C virus.\",\"Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region.\",\"[Telaprevir resistance].\",\"[Telaprevir in HCV-monoinfected patients with failure to prior treatment].\",\"[Telaprevir in treatment-na\\u00efve patients with HCV monoinfection].\",\"Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis.\",\"Viral breakthrough is associated with resistance using direct acting agents in patients treated for chronic hepatitis C infection.\",\"Sensitivity of a ribavirin resistant mutant of hepatitis C virus to other antiviral drugs.\",\"Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.\",\"Current and future therapies for hepatitis C virus infection: from viral proteins to host targets.\",\"Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance.\",\"Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics.\",\"Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir.\",\"Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.\",\"NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.\",\"Containing \\\"The Great Houdini\\\" of viruses: combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C.\",\"Nucleotide prodrugs for the treatment of HCV infection.\",\"Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.\",\"Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885.\",\"Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations.\",\"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.\",\"Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.\",\"Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C.\",\"Screening and evaluation of anti-respiratory syncytial virus compounds in cultured cells.\",\"Selecting and characterizing drug-resistant hepatitis C virus replicon.\",\"Randomized study of asunaprevir plus pegylated interferon-\\u03b1 and ribavirin for previously untreated genotype 1 chronic hepatitis C.\",\"Mutations in the STAT1\\u2011interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy.\",\"Evolution of cell culture systems for HCV.\",\"A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.\",\"Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin.\",\"Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.\",\"Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.\",\"Durability of SVR in chronic hepatitis C patients treated with peginterferon-\\u03b12a/ribavirin in combination with a direct-acting anti-viral.\",\"SOCS-1 promoter methylation and treatment response in chronic hepatitis C patients receiving pegylated-interferon/ribavirin.\",\"Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy.\",\"Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C.\",\"The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon \\u03b1 treatment.\",\"Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals.\",\"Amiodarone inhibits the entry and assembly steps of hepatitis C virus life cycle.\",\"The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese.\",\"Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.\",\"Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir.\",\"Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.\",\"Hepatitis C therapy with HCV NS5B polymerase inhibitors.\",\"Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.\",\"Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming.\",\"Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.\",\"Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.\",\"Repeated exposure to 5D9, an inhibitor of 3D polymerase, effectively limits the replication of foot-and-mouth disease virus in host cells.\",\"Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.\",\"Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions.\",\"Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.\",\"Proteomic characterization of hepatitis C eradication: enzyme switch in the healing liver.\",\"Sustained virological response following chronic hepatitis C treatment is associated with improvement in insulin resistance.\",\"Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.\",\"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.\",\"[The molecular biology of hepatitis C virus].\",\"[Update on hepatitis C therapy. New drugs, treatment response monitoring and emergence of resistance].\",\"New horizons in hepatitis C antiviral therapy with direct-acting antivirals.\",\"Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.\",\"Profile of alisporivir and its potential in the treatment of hepatitis C.\",\"Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors.\",\"IDX184 in combination with pegylated interferon-\\u03b12a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.\",\"Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.\",\"A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy.\",\"Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study.\",\"Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-\\u03b12b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.\",\"Antiviral resistance and the future landscape of hepatitis C virus infection therapy.\",\"Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.\",\"High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C.\",\"JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-na\\u00efve HCV genotype 1/4 patients.\",\"Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.\",\"PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-na\\u00efve HCV genotype 1/4 patients.\",\"Glucose abnormalities in hepatitis C virus infection.\",\"Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.\",\"Epistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance.\",\"Interferon free therapy with direct acting antivirals for HCV.\",\"New therapeutic strategies in HCV: second-generation protease inhibitors.\",\"How to optimize HCV therapy in genotype 4 patients.\",\"RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs.\",\"Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma.\",\"Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C.\",\"Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.\",\"Association of \\u03b3-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV).\",\"Cytokines genes polymorphisms in chronic hepatitis C: impact on susceptibility to infection and response to therapy.\",\"Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy.\",\"Numerical detection, measuring and analysis of differential interferon resistance for individual HCV intra-host variants and its influence on the therapy response.\",\"Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon.\",\"Liver transplantation in the setting of chronic HCV.\",\"The role of resistance in HCV treatment.\",\"The role of viral and host genetics in natural history and treatment of chronic HCV infection.\",\"HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents.\",\"Future perspectives: towards interferon-free regimens for HCV.\",\"Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?\",\"Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.\",\"Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.\",\"HCV NS5A inhibitors in development.\",\"Nucleoside/nucleotide analogue polymerase inhibitors in development.\",\"Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR.\",\"Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C.\",\"Current progress in the treatment of chronic hepatitis C.\",\"Interferon stimulated genes and hepatitis C virus infection.\",\"Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment.\",\"Current prospects for interferon-free treatment of hepatitis C in 2012.\",\"The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance.\",\"Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.\",\"Association of insulin resistance, viral load, and adipokine levels with liver histology in patients with chronic hepatitis C: an observational, multicenter study in Turkey.\",\"Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.\",\"Host factors determining the efficacy of hepatitis C treatment.\",\"Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver.\",\"Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.\",\"Inhibition of norovirus replication by the nucleoside analogue 2'-C-methylcytidine.\",\"Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?\",\"Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus.\",\"Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection.\",\"Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.\",\"Enhanced inhibition of foot-and-mouth disease virus by combinations of porcine interferon-\\u03b1 and antiviral agents.\",\"Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.\",\"NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients.\",\"Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro.\",\"Telaprevir: a hepatitis C NS3/4A protease inhibitor.\",\"A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.\",\"Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.\",\"New developments in the management of hepatitis C virus infection: focus on boceprevir.\",\"Mutations in non-structural 5A and rapid viral response to pegylated interferon-\\u03b1-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.\",\"Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.\",\"Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy.\",\"Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients.\",\"Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers.\",\"Application of fractional factorial designs to study drug combinations.\",\"Hepatitis C variability, patterns of resistance, and impact on therapy.\",\"Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir.\",\"Amantadine in non-responder patients with chronic hepatitis C: a randomized prospective study.\",\"Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.\",\"Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.\",\"Different impact of IL28B polymorphisms on response to peginterferon-\\u03b1 plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b.\",\"Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.\",\"Interferon-\\u03b3-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.\",\"Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon-alpha and ribavirin therapy, and efficacy of retreatment.\",\"Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.\",\"Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection.\",\"Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C.\",\"Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.\",\"Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.\",\"TMC435 for the treatment of chronic hepatitis C.\",\"MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.\",\"Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.\",\"Interleukin-4 polymorphisms and response to combination therapy in Egyptian chronic hepatitis C patients.\",\"Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.\",\"Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.\",\"Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection.\",\"New virologic tools for management of chronic hepatitis B and C.\",\"New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.\",\"New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.\",\"Hepatitis C viral evolution in genotype 1 treatment-na\\u00efve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.\",\"A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.\",\"Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.\",\"Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-\\u03b1-2a plus ribavirin and RVR.\",\"Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice.\",\"Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting.\",\"Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-na\\u00efve and experienced subjects.\",\"25-Hydroxyvitamin D3 suppresses hepatitis C virus production.\",\"The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance.\",\"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-na\\u00efve patients with chronic hepatitis C: a randomized phase II study.\",\"Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.\",\"Anti-HCV drugs in the pipeline.\",\"Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.\",\"Pioglitazone decreases hepatitis C viral load in overweight, treatment na\\u00efve, genotype 4 infected-patients: a pilot study.\",\"Lymphotropic hepatitis C virus has an interferon-resistant phenotype.\",\"Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase.\",\"Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action.\",\"Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.\",\"Insulin resistance and response to telaprevir plus peginterferon \\u03b1 and ribavirin in treatment-naive patients infected with HCV genotype 1.\",\"[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].\",\"Differences in virological response to peginterferon-\\u03b1 plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.\",\"Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.\",\"Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.\",\"Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.\",\"Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner.\",\"Update on alisporivir in treatment of viral hepatitis C.\",\"Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.\",\"[Current options for predicting therapeutic response in chronically infected patients with hepatitis C virus genotype 1].\",\"Insulin resistance impairs viral dynamics independently of ethnicity or genotypes.\",\"Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.\",\"Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.\",\"Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.\",\"Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome.\",\"Chronic hepatitis C: treatments of the future.\",\"Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients.\",\"Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance.\",\"Preliminary study of two antiviral agents for hepatitis C genotype 1.\",\"New developments in HCV therapy.\",\"Treatment failure with new hepatitis C drugs.\",\"Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients.\",\"Hepatic expression of MxA and OAS1 in an ex vivo liver slice assay independently predicts treatment outcomes in chronic hepatitis C.\",\"Serum PAI-1 is a novel predictor for response to pegylated interferon-\\u03b1-2b plus ribavirin therapy in chronic hepatitis C virus infection.\",\"Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.\",\"The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.\",\"Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.\",\"Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.\",\"Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.\",\"Telaprevir user's guide.\",\"New targets for antiviral therapy of chronic hepatitis C.\",\"Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus.\",\"Mutations around interferon sensitivity-determining region: a pilot resistance report of hepatitis C virus 1b in a Hong Kong population.\",\"The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors.\",\"Double-Filtration Plasmapheresis plus Interferon-\\u03b2 for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy.\",\"Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.\",\"Tailor-made therapy for viral hepatitis: recent advances.\",\"Telaprevir: an oral protease inhibitor for hepatitis C virus infection.\",\"Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b.\",\"Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents.\",\"Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.\",\"Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.\",\"Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.\",\"Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C.\",\"Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy.\",\"Telaprevir for the treatment of chronic hepatitis C infection.\",\"Ribavirin enhances IFN-\\u03b1 signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV.\",\"Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals.\",\"Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-\\u03b12b plus ribavirin.\",\"Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients.\",\"Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.\",\"Drugs in development for chronic hepatitis C: a promising future.\",\"Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.\",\"Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C.\",\"[Human immunodeficiency virus infection and viral hepatitis].\",\"Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing.\",\"Antiviral drugs for viruses other than human immunodeficiency virus.\",\"IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.\",\"Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy.\",\"Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.\",\"The role of insulin resistance in HIV/hepatitis C virus-coinfected patients.\",\"Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.\",\"Lethal mutagenesis of foot-and-mouth disease virus involves shifts in sequence space.\",\"Use of HOMA-IR in hepatitis C.\",\"Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.\",\"Tempo and mode of inhibitor-mutagen antiviral therapies: a multidisciplinary approach.\",\"Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.\",\"Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.\",\"Metabolic alterations and chronic hepatitis C: treatment strategies.\",\"Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations.\",\"Boceprevir: a user's guide.\",\"Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.\",\"Selection of hepatitis C virus resistant to ribavirin.\",\"Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.\",\"New treatments for chronic hepatitis C virus infection.\",\"Mechanisms of non-response to antiviral treatment in chronic hepatitis C.\",\"Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.\",\"Pegylated interferon plus ribavirin therapy improves pancreatic \\u03b2-cell function in chronic hepatitis C patients.\",\"Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.\",\"Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.\",\"TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.\",\"Directly acting antivirals against hepatitis C virus.\",\"Meta-analysis: insulin resistance and sustained virological response in hepatitis C.\",\"Antiviral therapy: why does it fail in HCV-related chronic hepatitis?\",\"Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.\",\"[New therapeutic options in chronic hepatitis C virus infection].\",\"Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C.\",\"Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.\",\"High baseline interleukine-8 level is an independent risk factor for the achievement of sustained virological response in chronic HCV patients.\",\"Host-based ribavirin resistance influences hepatitis C virus replication and treatment response.\",\"Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: a vicious circle of clinical significance?\",\"Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients.\",\"Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.\",\"Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).\",\"Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.\",\"Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of \\u03b2-D-2'-deoxy-2'-\\u03b1-fluoro-2'-\\u03b2-C-methylguanosine.\",\"IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.\",\"Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy.\",\"High-dose pegylated interferon-\\u03b1 and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).\",\"Inhibition of bovine viral diarrhea virus RNA synthesis by thiosemicarbazone derived from 5,6-dimethoxy-1-indanone.\",\"Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients.\",\"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.\",\"Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.\",\"INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.\",\"Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN \\u03b1-2a/RBV in hepatitis C patients.\",\"Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.\",\"'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field?\",\"Envelope 2 protein phosphorylation sites S75 & 277 of hepatitis C virus genotype 1a and interferon resistance: a sequence alignment approach.\",\"Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease.\",\"Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy.\",\"Sequence variability of HCV Core region: important predictors of HCV induced pathogenesis and viral production.\",\"Quantitation of pretreatment serum interferon-\\u03b3-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response.\",\"Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy.\",\"New direct-acting antivirals' combination for the treatment of chronic hepatitis C.\",\"Future hepatitis C virus treatment: interferon-sparing combinations.\",\"The role of triple therapy in HCV genotype 1-experienced patients.\",\"The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 na\\u00efve patients.\",\"Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C.\",\"How to use virological tools for the optimal management of chronic hepatitis C.\",\"Hepatic steatosis and hepatitis C: Still unhappy bedfellows?\",\"Hepatitis C virus: How genetic variability affects pathobiology of disease.\",\"Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy.\",\"Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.\",\"Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.\",\"Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice.\",\"Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.\",\"IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.\",\"Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.\",\"Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.\",\"New HCV therapies on the horizon.\",\"Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.\",\"Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C.\",\"Neutralizing antibodies to interferon-\\u03b1 and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-\\u03b1-2a and ribavirin (ANRS HC16 GAMMATRI substudy).\",\"Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-\\u03b1-2a and ribavirin in HIV/HCV co-infected patients.\",\"Gene expression signature-based screening identifies new broadly effective influenza a antivirals.\",\"IL28B and the control of hepatitis C virus infection.\",\"RG7128 alone or in combination with pegylated interferon-\\u03b12a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.\",\"Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis.\",\"A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape.\",\"Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.\",\"S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.\",\"The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients.\",\"A novel small molecule inhibitor of hepatitis C virus entry.\",\"Detection of HCV RNA in the peripheral blood mononuclear cells of serum HCV RNA-negative Egyptian patients under interferon treatment.\",\"Differential interferon signaling in liver lobule and portal area cells under treatment for chronic hepatitis C.\",\"A perspective on modelling hepatitis C virus infection.\",\"Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.\",\"Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.\",\"Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.\",\"The Hepatitis C Virus Nonstructural Protein 2 (NS2): An Up-and-Coming Antiviral Drug Target.\",\"Combination chemotherapy for influenza.\",\"Study of nitric oxide in patients with chronic hepatitis C genotype 4: relationship to viremia and response to antiviral therapy.\",\"An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1.\",\"Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.\",\"Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 h.\",\"New NS5B polymerase inhibitors for hepatitis C.\",\"Management of HIV and hepatitis virus coinfection.\",\"Sequence diversity of hepatitis C virus 6a within the extended interferon sensitivity-determining region correlates with interferon-alpha/ribavirin treatment outcomes.\",\"[Mutations within the interferon sensitivity determining region in Korean patients infected with hepatitis C virus genotype 1b].\",\"Individualisation of antiviral therapy for chronic hepatitis C.\",\"Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.\",\"Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin.\",\"Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus.\",\"5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.\",\"The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C.\",\"Safety of small molecules in combination with interferon-based therapy for hepatitis C virus.\",\"Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.\",\"Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment.\",\"The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors.\",\"Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management.\",\"Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders.\",\"Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance.\",\"Anti-human rhinovirus activity of raoulic acid from Raoulia australis.\",\"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.\",\"Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin.\",\"Impairment of TLR7-dependent signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders to interferon/ribavirin therapy.\",\"Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.\",\"Management of nonresponsive hepatitis C.\",\"In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.\",\"Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation.\",\"New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.\",\"Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.\",\"Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.\",\"New therapies in the management of hepatitis C virus.\",\"Identifying HCV genotype 1 patients at risk of relapse.\",\"[Hepatitis C and metabolic syndrome].\",\"Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.\",\"High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.\",\"Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.\",\"Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.\",\"Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial.\",\"In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials.\",\"Hepatitis C and hepatic steatosis.\",\"T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.\",\"Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b.\",\"Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin.\",\"New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents.\",\"The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.\",\"Resistance to direct antiviral agents in patients with hepatitis C virus infection.\",\"MxA expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients.\",\"HBV and HCV therapy.\",\"The use of antiviral agents for the management of severe influenza.\",\"Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.\",\"Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.\",\"Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).\",\"Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection.\",\"Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.\",\"Viral hepatitis and HIV co-infection.\",\"Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance.\",\"Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.\",\"Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients.\",\"NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.\",\"Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.\",\"Treatment of insulin resistance with metformin in na\\u00efve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.\",\"Current issues in the management of paediatric viral hepatitis.\",\"Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study.\",\"Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study.\",\"Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.\",\"Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients.\",\"Feasibility of individualized treatment for hepatitis C patients in the real world.\",\"Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.\",\"Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities.\",\"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.\",\"Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.\",\"Predicting the probable outcome of treatment in HCV patients.\",\"Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin.\",\"Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.\",\"Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.\",\"The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy.\",\"Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.\",\"Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.\",\"HCV NS5B polymerase inhibitors.\",\"Telaprevir: hope on the horizon, getting closer.\",\"Boceprevir, an NS3 protease inhibitor of HCV.\",\"Novel interferons for treatment of hepatitis C virus.\",\"Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C.\",\"Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.\",\"[Cost-effectiveness of chronic hepatitis C treatment in Spain].\",\"Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment.\",\"New and experimental therapies for HCV.\",\"Therapeutic implications of hepatitis C virus resistance to antiviral drugs.\",\"[Novel treatments for hepatitis C viral infection and the hepatic fibrosis].\",\"[Hepatitis C: the recovery].\",\"Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C.\",\"Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.\",\"Treatment of chronic hepatitis C in a slow responder: a case for extended therapy.\",\"Serine protease inhibitors as anti-hepatitis C virus agents.\",\"The role of positive selection in hepatitis C virus.\",\"Multiple cytokine profiling of the therapeutic responses to ribavirin and pegylated interferon-alpha2b using an \\\"induction\\\" approach with natural interferon-beta in difficult-to-treat chronic hepatitis C.\",\"Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment.\",\"The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells.\",\"Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents.\",\"Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues.\",\"Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.\",\"Update on viral hepatitis: 2008.\",\"Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.\",\"Acrolein, a ubiquitous pollutant and lipid hydroperoxide product, inhibits antiviral activity of interferon-alpha: relevance to hepatitis C.\",\"Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.\",\"Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection.\",\"Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.\",\"Predictive value of the phosphorylation of signal transducers and activators of transcription in the outcome of interferon therapy for chronic hepatitis C.\",\"Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance.\",\"An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C.\",\"Combined therapy of interferon plus ribavirin promotes multiple adaptive solutions in hepatitis C virus.\",\"Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.\",\"Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients.\",\"What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C?\",\"A review of current anti-HCV treatment regimens and possible future strategies.\",\"Future treatment options for HCV: double, triple, what is the optimal combination?\",\"Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load.\",\"Review article: investigational agents for chronic hepatitis C.\",\"Development of novel treatments for hepatitis C.\",\"Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection.\",\"Augmented lung inflammation protects against influenza A pneumonia.\",\"New therapies for hepatitis C virus infection.\",\"Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans.\",\"Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.\",\"Hepatitis C infection and thyrotoxic periodic paralysis--a novel use of an old drug.\",\"Treatment failure in hepatitis C: mechanisms of non-response.\",\"Developing new antiviral agents for influenza treatment: what does the future hold?\",\"Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.\",\"Natural products as promising drug candidates for the treatment of hepatitis B and C.\",\"Metabolic disorders and chronic viral disease: the case of HIV and HCV.\",\"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-na\\u00efve patients.\",\"Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C.\",\"[Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis].\",\"Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C.\",\"Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.\",\"Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay.\",\"Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.\",\"Treatment predictors of a sustained virologic response in hepatitis B and C.\",\"Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.\",\"Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.\",\"Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.\",\"[Hepatitis C: which strategy in case of treatment failure ?].\",\"Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.\",\"Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment.\",\"R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.\",\"Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.\",\"Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.\",\"Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.\",\"Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.\",\"Hepatitis C protease and polymerase inhibitors in development.\",\"Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response.\",\"Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.\",\"Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response.\",\"Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a.\",\"Update on viral hepatitis: 2007.\",\"Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.\",\"Emerging drugs for hepatitis C.\",\"Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment.\",\"Review article: novel therapeutic options for chronic hepatitis C.\",\"MegaRibavirin aerosol for the treatment of influenza A virus infections in mice.\",\"The genetic differences with whole genome linkage disequilibrium mapping between responder and non-responder in interferon-alpha and ribavirin combined therapy for chronic hepatitis C patients.\",\"Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.\",\"Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.\",\"Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients.\",\"Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues.\",\"New drugs for hepatitis C virus.\",\"Clinical management of patients with recurrent viral hepatitis after liver transplantation.\",\"Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.\",\"Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway.\"],\"x_tsne\":{\"__ndarray__\":\"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\",\"dtype\":\"float32\",\"order\":\"little\",\"shape\":[1288]},\"y\":[\"5\",\"0\",\"8\",\"6\",\"15\",\"9\",\"0\",\"6\",\"6\",\"0\",\"0\",\"4\",\"3\",\"3\",\"8\",\"6\",\"18\",\"11\",\"6\",\"8\",\"6\",\"6\",\"6\",\"6\",\"3\",\"6\",\"18\",\"6\",\"3\",\"5\",\"7\",\"6\",\"0\",\"1\",\"0\",\"8\",\"0\",\"6\",\"3\",\"6\",\"6\",\"14\",\"8\",\"0\",\"6\",\"0\",\"3\",\"6\",\"16\",\"3\",\"11\",\"8\",\"6\",\"18\",\"0\",\"11\",\"6\",\"13\",\"8\",\"11\",\"6\",\"6\",\"13\",\"19\",\"6\",\"8\",\"0\",\"11\",\"18\",\"6\",\"0\",\"6\",\"11\",\"11\",\"0\",\"5\",\"6\",\"0\",\"0\",\"8\",\"7\",\"10\",\"6\",\"0\",\"10\",\"6\",\"11\",\"6\",\"8\",\"0\",\"18\",\"0\",\"10\",\"15\",\"0\",\"0\",\"5\",\"0\",\"3\",\"6\",\"3\",\"8\",\"0\",\"18\",\"18\",\"6\",\"16\",\"6\",\"6\",\"6\",\"3\",\"11\",\"19\",\"10\",\"0\",\"10\",\"8\",\"15\",\"16\",\"11\",\"0\",\"16\",\"14\",\"8\",\"13\",\"9\",\"11\",\"3\",\"15\",\"8\",\"8\",\"6\",\"5\",\"0\",\"0\",\"5\",\"6\",\"5\",\"14\",\"9\",\"5\",\"5\",\"14\",\"14\",\"6\",\"6\",\"3\",\"14\",\"12\",\"18\",\"18\",\"18\",\"18\",\"7\",\"3\",\"10\",\"8\",\"18\",\"8\",\"3\",\"8\",\"11\",\"11\",\"11\",\"19\",\"3\",\"18\",\"12\",\"10\",\"14\",\"8\",\"16\",\"17\",\"8\",\"11\",\"17\",\"5\",\"3\",\"11\",\"15\",\"15\",\"14\",\"3\",\"15\",\"7\",\"15\",\"3\",\"11\",\"14\",\"5\",\"18\",\"6\",\"8\",\"10\",\"12\",\"10\",\"16\",\"19\",\"15\",\"4\",\"15\",\"5\",\"14\",\"3\",\"8\",\"11\",\"3\",\"14\",\"11\",\"10\",\"3\",\"8\",\"19\",\"5\",\"5\",\"14\",\"10\",\"11\",\"17\",\"14\",\"3\",\"11\",\"14\",\"5\",\"14\",\"5\",\"18\",\"8\",\"19\",\"11\",\"8\",\"9\",\"15\",\"11\",\"4\",\"11\",\"8\",\"5\",\"14\",\"17\",\"14\",\"16\",\"11\",\"5\",\"7\",\"16\",\"10\",\"3\",\"14\",\"9\",\"9\",\"8\",\"8\",\"5\",\"15\",\"3\",\"12\",\"10\",\"14\",\"3\",\"9\",\"7\",\"4\",\"15\",\"10\",\"19\",\"17\",\"5\",\"11\",\"9\",\"11\",\"11\",\"18\",\"6\",\"7\",\"15\",\"4\",\"14\",\"10\",\"10\",\"2\",\"14\",\"10\",\"14\",\"11\",\"11\",\"10\",\"4\",\"11\",\"3\",\"15\",\"16\",\"5\",\"14\",\"10\",\"10\",\"4\",\"5\",\"14\",\"12\",\"5\",\"16\",\"8\",\"7\",\"8\",\"8\",\"5\",\"8\",\"11\",\"4\",\"5\",\"19\",\"8\",\"1\",\"15\",\"8\",\"3\",\"3\",\"11\",\"13\",\"5\",\"15\",\"7\",\"3\",\"14\",\"11\",\"14\",\"12\",\"12\",\"17\",\"11\",\"10\",\"1\",\"16\",\"18\",\"14\",\"15\",\"11\",\"17\",\"8\",\"11\",\"8\",\"7\",\"1\",\"8\",\"18\",\"12\",\"14\",\"5\",\"8\",\"5\",\"17\",\"10\",\"11\",\"5\",\"4\",\"8\",\"14\",\"9\",\"11\",\"7\",\"10\",\"18\",\"14\",\"4\",\"11\",\"14\",\"5\",\"5\",\"14\",\"11\",\"14\",\"18\",\"7\",\"8\",\"5\",\"17\",\"14\",\"11\",\"3\",\"4\",\"17\",\"11\",\"4\",\"2\",\"10\",\"10\",\"10\",\"14\",\"18\",\"7\",\"4\",\"14\",\"14\",\"19\",\"11\",\"14\",\"10\",\"5\",\"11\",\"10\",\"7\",\"18\",\"19\",\"15\",\"17\",\"3\",\"4\",\"14\",\"5\",\"15\",\"10\",\"11\",\"10\",\"8\",\"2\",\"2\",\"14\",\"18\",\"4\",\"8\",\"5\",\"19\",\"19\",\"5\",\"15\",\"5\",\"10\",\"10\",\"5\",\"5\",\"2\",\"19\",\"5\",\"13\",\"10\",\"5\",\"5\",\"7\",\"5\",\"10\",\"13\",\"17\",\"4\",\"5\",\"14\",\"18\",\"2\",\"18\",\"19\",\"10\",\"11\",\"14\",\"14\",\"16\",\"14\",\"18\",\"15\",\"2\",\"10\",\"5\",\"19\",\"8\",\"15\",\"18\",\"7\",\"5\",\"14\",\"1\",\"19\",\"2\",\"4\",\"10\",\"17\",\"5\",\"17\",\"5\",\"14\",\"3\",\"5\",\"5\",\"10\",\"19\",\"16\",\"5\",\"8\",\"10\",\"1\",\"1\",\"8\",\"14\",\"10\",\"5\",\"5\",\"8\",\"14\",\"5\",\"16\",\"5\",\"18\",\"18\",\"5\",\"19\",\"3\",\"1\",\"8\",\"14\",\"17\",\"10\",\"9\",\"19\",\"2\",\"1\",\"1\",\"2\",\"3\",\"16\",\"9\",\"14\",\"12\",\"1\",\"15\",\"5\",\"4\",\"4\",\"19\",\"4\",\"10\",\"5\",\"4\",\"10\",\"5\",\"10\",\"5\",\"14\",\"19\",\"17\",\"15\",\"19\",\"9\",\"4\",\"18\",\"14\",\"19\",\"11\",\"14\",\"2\",\"13\",\"10\",\"8\",\"16\",\"3\",\"5\",\"2\",\"2\",\"19\",\"12\",\"18\",\"13\",\"2\",\"10\",\"17\",\"19\",\"2\",\"2\",\"8\",\"4\",\"13\",\"19\",\"9\",\"7\",\"8\",\"14\",\"13\",\"10\",\"4\",\"8\",\"7\",\"4\",\"10\",\"10\",\"5\",\"3\",\"19\",\"8\",\"19\",\"18\",\"18\",\"10\",\"4\",\"18\",\"10\",\"9\",\"2\",\"8\",\"18\",\"17\",\"10\",\"7\",\"14\",\"16\",\"1\",\"3\",\"15\",\"4\",\"10\",\"2\",\"4\",\"13\",\"9\",\"9\",\"18\",\"2\",\"10\",\"14\",\"17\",\"5\",\"7\",\"13\",\"2\",\"10\",\"2\",\"4\",\"8\",\"19\",\"2\",\"4\",\"19\",\"18\",\"1\",\"16\",\"10\",\"11\",\"19\",\"3\",\"2\",\"15\",\"7\",\"3\",\"19\",\"13\",\"5\",\"13\",\"4\",\"9\",\"19\",\"2\",\"9\",\"19\",\"2\",\"4\",\"3\",\"19\",\"7\",\"12\",\"14\",\"18\",\"10\",\"9\",\"14\",\"10\",\"4\",\"5\",\"2\",\"9\",\"2\",\"7\",\"4\",\"12\",\"8\",\"8\",\"4\",\"9\",\"4\",\"19\",\"10\",\"15\",\"8\",\"12\",\"5\",\"2\",\"9\",\"2\",\"4\",\"4\",\"4\",\"17\",\"13\",\"2\",\"7\",\"18\",\"1\",\"16\",\"12\",\"4\",\"9\",\"5\",\"8\",\"2\",\"10\",\"3\",\"10\",\"19\",\"13\",\"8\",\"2\",\"15\",\"7\",\"14\",\"10\",\"9\",\"2\",\"4\",\"4\",\"4\",\"7\",\"4\",\"4\",\"19\",\"16\",\"4\",\"19\",\"19\",\"7\",\"4\",\"4\",\"18\",\"14\",\"10\",\"10\",\"19\",\"10\",\"10\",\"2\",\"4\",\"2\",\"2\",\"2\",\"12\",\"10\",\"8\",\"1\",\"14\",\"16\",\"14\",\"9\",\"4\",\"17\",\"5\",\"18\",\"17\",\"14\",\"9\",\"7\",\"10\",\"16\",\"9\",\"5\",\"4\",\"4\",\"2\",\"2\",\"5\",\"2\",\"12\",\"7\",\"18\",\"10\",\"16\",\"14\",\"19\",\"19\",\"9\",\"9\",\"9\",\"18\",\"19\",\"9\",\"4\",\"9\",\"7\",\"10\",\"5\",\"10\",\"7\",\"2\",\"19\",\"10\",\"13\",\"7\",\"2\",\"5\",\"2\",\"2\",\"10\",\"5\",\"2\",\"2\",\"10\",\"16\",\"2\",\"4\",\"10\",\"19\",\"10\",\"6\",\"18\",\"19\",\"2\",\"5\",\"19\",\"2\",\"19\",\"2\",\"10\",\"9\",\"19\",\"3\",\"19\",\"19\",\"1\",\"9\",\"19\",\"8\",\"2\",\"14\",\"5\",\"9\",\"2\",\"12\",\"9\",\"3\",\"10\",\"7\",\"2\",\"2\",\"9\",\"19\",\"1\",\"3\",\"19\",\"2\",\"8\",\"9\",\"2\",\"9\",\"12\",\"16\",\"14\",\"4\",\"10\",\"5\",\"19\",\"10\",\"19\",\"19\",\"19\",\"10\",\"2\",\"19\",\"5\",\"19\",\"17\",\"12\",\"14\",\"10\",\"14\",\"12\",\"10\",\"9\",\"5\",\"4\",\"10\",\"19\",\"1\",\"5\",\"18\",\"7\",\"7\",\"7\",\"9\",\"9\",\"2\",\"5\",\"10\",\"10\",\"9\",\"10\",\"2\",\"19\",\"17\",\"4\",\"2\",\"10\",\"9\",\"10\",\"7\",\"4\",\"16\",\"16\",\"16\",\"8\",\"7\",\"4\",\"2\",\"8\",\"9\",\"2\",\"18\",\"5\",\"8\",\"1\",\"1\",\"19\",\"2\",\"9\",\"1\",\"2\",\"1\",\"2\",\"2\",\"19\",\"2\",\"3\",\"10\",\"2\",\"10\",\"18\",\"2\",\"2\",\"9\",\"7\",\"1\",\"2\",\"7\",\"16\",\"16\",\"14\",\"5\",\"19\",\"16\",\"7\",\"9\",\"1\",\"2\",\"10\",\"5\",\"10\",\"2\",\"2\",\"7\",\"12\",\"16\",\"5\",\"14\",\"3\",\"16\",\"14\",\"9\",\"19\",\"19\",\"16\",\"9\",\"19\",\"16\",\"13\",\"16\",\"2\",\"13\",\"9\",\"14\",\"1\",\"12\",\"5\",\"13\",\"10\",\"16\",\"18\",\"17\",\"19\",\"16\",\"4\",\"2\",\"2\",\"5\",\"2\",\"5\",\"1\",\"7\",\"7\",\"2\",\"9\",\"5\",\"9\",\"9\",\"2\",\"9\",\"18\",\"1\",\"19\",\"9\",\"16\",\"9\",\"2\",\"10\",\"19\",\"2\",\"5\",\"2\",\"5\",\"7\",\"2\",\"9\",\"8\",\"7\",\"19\",\"14\",\"5\",\"5\",\"7\",\"13\",\"8\",\"18\",\"7\",\"12\",\"13\",\"13\",\"2\",\"8\",\"16\",\"2\",\"8\",\"9\",\"7\",\"12\",\"10\",\"19\",\"13\",\"4\",\"19\",\"5\",\"10\",\"1\",\"16\",\"7\",\"16\",\"12\",\"5\",\"16\",\"10\",\"7\",\"5\",\"2\",\"2\",\"7\",\"9\",\"16\",\"7\",\"1\",\"19\",\"19\",\"19\",\"10\",\"7\",\"5\",\"8\",\"12\",\"5\",\"1\",\"8\",\"19\",\"7\",\"2\",\"10\",\"10\",\"1\",\"1\",\"7\",\"9\",\"5\",\"5\",\"9\",\"5\",\"12\",\"10\",\"12\",\"1\",\"7\",\"19\",\"19\",\"9\",\"7\",\"7\",\"9\",\"7\",\"19\",\"16\",\"10\",\"9\",\"13\",\"18\",\"7\",\"14\",\"9\",\"8\",\"16\",\"10\",\"16\",\"19\",\"10\",\"10\",\"10\",\"9\",\"5\",\"13\",\"3\",\"18\",\"10\",\"9\",\"9\",\"9\",\"10\",\"13\",\"1\",\"1\",\"14\",\"1\",\"9\",\"16\",\"3\",\"10\",\"10\",\"10\",\"14\",\"19\",\"16\",\"7\",\"16\",\"8\",\"19\",\"8\",\"10\",\"14\",\"10\",\"18\",\"10\",\"13\",\"19\",\"7\",\"10\",\"14\",\"16\",\"12\",\"9\",\"18\",\"19\",\"16\",\"14\",\"12\",\"18\",\"8\",\"9\",\"5\",\"10\",\"5\",\"7\",\"10\",\"18\",\"16\",\"14\",\"9\",\"7\",\"13\",\"13\",\"16\",\"9\",\"7\",\"1\",\"2\",\"14\",\"10\",\"16\",\"10\",\"2\",\"12\",\"10\",\"10\",\"9\",\"7\",\"10\",\"7\",\"7\",\"13\",\"7\",\"10\",\"1\",\"9\",\"10\",\"2\",\"10\",\"10\",\"9\",\"18\",\"14\",\"10\",\"5\",\"2\",\"10\",\"10\",\"14\",\"9\",\"10\",\"10\",\"1\",\"7\",\"8\",\"8\",\"9\",\"19\",\"13\",\"10\",\"16\",\"10\",\"7\",\"10\",\"18\",\"9\",\"9\",\"19\",\"1\",\"16\",\"16\",\"10\",\"10\",\"2\",\"16\",\"3\",\"10\",\"16\",\"18\",\"10\",\"1\",\"19\",\"10\",\"10\",\"18\",\"1\",\"10\",\"12\",\"19\",\"10\",\"12\",\"7\",\"19\",\"3\",\"10\",\"10\",\"19\",\"12\",\"16\",\"2\",\"2\",\"16\",\"14\",\"19\",\"16\",\"14\",\"1\",\"19\",\"10\",\"14\",\"1\",\"16\",\"10\",\"1\",\"10\",\"8\",\"10\",\"18\",\"7\",\"10\",\"19\",\"13\",\"8\",\"9\",\"10\",\"1\",\"9\"],\"y_tsne\":{\"__ndarray__\":\"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\",\"dtype\":\"float32\",\"order\":\"little\",\"shape\":[1288]}},\"selected\":{\"id\":\"1340\"},\"selection_policy\":{\"id\":\"1339\"}},\"id\":\"1296\",\"type\":\"ColumnDataSource\"},{\"attributes\":{\"source\":{\"id\":\"1302\"}},\"id\":\"1307\",\"type\":\"CDSView\"},{\"attributes\":{},\"id\":\"1335\",\"type\":\"BasicTickFormatter\"},{\"attributes\":{},\"id\":\"1277\",\"type\":\"BasicTicker\"},{\"attributes\":{},\"id\":\"1270\",\"type\":\"LinearScale\"},{\"attributes\":{},\"id\":\"1285\",\"type\":\"HelpTool\"},{\"attributes\":{},\"id\":\"1342\",\"type\":\"Selection\"},{\"attributes\":{\"factors\":[\"5\",\"0\",\"8\",\"6\",\"15\",\"9\",\"4\",\"3\",\"18\",\"11\",\"7\",\"1\",\"14\",\"16\",\"13\",\"19\",\"10\",\"12\",\"17\",\"2\"],\"palette\":[\"#1f77b4\",\"#aec7e8\",\"#ff7f0e\",\"#ffbb78\",\"#2ca02c\",\"#98df8a\",\"#d62728\",\"#ff9896\",\"#9467bd\",\"#c5b0d5\",\"#8c564b\",\"#c49c94\",\"#e377c2\",\"#f7b6d2\",\"#7f7f7f\",\"#c7c7c7\",\"#bcbd22\",\"#dbdb8d\",\"#17becf\",\"#9edae5\"]},\"id\":\"1260\",\"type\":\"CategoricalColorMapper\"},{\"attributes\":{},\"id\":\"1339\",\"type\":\"UnionRenderers\"},{\"attributes\":{\"text\":\"Mouse over the dots\"},\"id\":\"1262\",\"type\":\"Title\"},{\"attributes\":{\"fill_color\":{\"field\":\"y\",\"transform\":{\"id\":\"1260\"}},\"line_color\":{\"field\":\"y\",\"transform\":{\"id\":\"1260\"}},\"size\":{\"value\":5},\"x\":{\"field\":\"x_tsne\"},\"y\":{\"field\":\"y_tsne\"}},\"id\":\"1298\",\"type\":\"Scatter\"},{\"attributes\":{},\"id\":\"1284\",\"type\":\"ResetTool\"},{\"attributes\":{\"fill_color\":{\"value\":\"black\"},\"marker\":{\"value\":\"square\"},\"size\":{\"value\":8},\"x\":{\"field\":\"x_tsne\"},\"y\":{\"field\":\"y_tsne\"}},\"id\":\"1304\",\"type\":\"Scatter\"},{\"attributes\":{},\"id\":\"1281\",\"type\":\"WheelZoomTool\"},{\"attributes\":{\"formatter\":{\"id\":\"1335\"},\"major_label_policy\":{\"id\":\"1333\"},\"ticker\":{\"id\":\"1273\"}},\"id\":\"1272\",\"type\":\"LinearAxis\"},{\"attributes\":{},\"id\":\"1336\",\"type\":\"AllLabels\"},{\"attributes\":{\"fill_alpha\":{\"value\":0.1},\"fill_color\":{\"value\":\"black\"},\"line_alpha\":{\"value\":0.1},\"marker\":{\"value\":\"square\"},\"size\":{\"value\":8},\"x\":{\"field\":\"x_tsne\"},\"y\":{\"field\":\"y_tsne\"}},\"id\":\"1305\",\"type\":\"Scatter\"},{\"attributes\":{},\"id\":\"1283\",\"type\":\"SaveTool\"},{\"attributes\":{},\"id\":\"1341\",\"type\":\"UnionRenderers\"},{\"attributes\":{\"fill_alpha\":{\"value\":0.1},\"fill_color\":{\"field\":\"y\",\"transform\":{\"id\":\"1260\"}},\"line_alpha\":{\"value\":0.1},\"line_color\":{\"field\":\"y\",\"transform\":{\"id\":\"1260\"}},\"size\":{\"value\":5},\"x\":{\"field\":\"x_tsne\"},\"y\":{\"field\":\"y_tsne\"}},\"id\":\"1299\",\"type\":\"Scatter\"},{\"attributes\":{\"axis\":{\"id\":\"1272\"},\"ticker\":null},\"id\":\"1275\",\"type\":\"Grid\"},{\"attributes\":{},\"id\":\"1280\",\"type\":\"PanTool\"},{\"attributes\":{},\"id\":\"1338\",\"type\":\"BasicTickFormatter\"},{\"attributes\":{\"axis\":{\"id\":\"1276\"},\"dimension\":1,\"ticker\":null},\"id\":\"1279\",\"type\":\"Grid\"},{\"attributes\":{\"callback\":null,\"tooltips\":[[\"index\",\"$index\"],[\"(x,y)\",\"($x, $y)\"],[\"doi\",\"@doi\"],[\"title\",\"@title\"]]},\"id\":\"1287\",\"type\":\"HoverTool\"},{\"attributes\":{\"data_source\":{\"id\":\"1302\"},\"glyph\":{\"id\":\"1304\"},\"hover_glyph\":null,\"muted_glyph\":null,\"nonselection_glyph\":{\"id\":\"1305\"},\"view\":{\"id\":\"1307\"}},\"id\":\"1306\",\"type\":\"GlyphRenderer\"},{\"attributes\":{\"bottom_units\":\"screen\",\"fill_alpha\":0.5,\"fill_color\":\"lightgrey\",\"left_units\":\"screen\",\"level\":\"overlay\",\"line_alpha\":1.0,\"line_color\":\"black\",\"line_dash\":[4,4],\"line_width\":2,\"right_units\":\"screen\",\"syncable\":false,\"top_units\":\"screen\"},\"id\":\"1286\",\"type\":\"BoxAnnotation\"},{\"attributes\":{\"data_source\":{\"id\":\"1296\"},\"glyph\":{\"id\":\"1298\"},\"hover_glyph\":null,\"muted_glyph\":null,\"nonselection_glyph\":{\"id\":\"1299\"},\"view\":{\"id\":\"1301\"}},\"id\":\"1300\",\"type\":\"GlyphRenderer\"}],\"root_ids\":[\"1261\"]},\"title\":\"Bokeh Application\",\"version\":\"2.3.3\"}};\n",
              "  var render_items = [{\"docid\":\"bca35dff-5df1-469f-a99f-210fee959c98\",\"root_ids\":[\"1261\"],\"roots\":{\"1261\":\"068d5fcc-7369-453e-ae06-ad9afba151fd\"}}];\n",
              "  root.Bokeh.embed.embed_items_notebook(docs_json, render_items);\n",
              "\n",
              "  }\n",
              "  if (root.Bokeh !== undefined) {\n",
              "    embed_document(root);\n",
              "  } else {\n",
              "    var attempts = 0;\n",
              "    var timer = setInterval(function(root) {\n",
              "      if (root.Bokeh !== undefined) {\n",
              "        clearInterval(timer);\n",
              "        embed_document(root);\n",
              "      } else {\n",
              "        attempts++;\n",
              "        if (attempts > 100) {\n",
              "          clearInterval(timer);\n",
              "          console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
              "        }\n",
              "      }\n",
              "    }, 10, root)\n",
              "  }\n",
              "})(window);"
            ],
            "application/vnd.bokehjs_exec.v0+json": ""
          },
          "metadata": {
            "application/vnd.bokehjs_exec.v0+json": {
              "id": "1261"
            }
          }
        }
      ]
    }
  ]
}